doc_id,term,association
uuid-beb7826582ba40e187ad48f702cab450,requested,0.302104
uuid-beb7826582ba40e187ad48f702cab450,trial,0.317502
uuid-45dbb9b3d6c6406b8b3c982098f40f40,requested,0.410804
uuid-45dbb9b3d6c6406b8b3c982098f40f40,clinical,0.46545
uuid-45dbb9b3d6c6406b8b3c982098f40f40,trial,0.495699
uuid-d58f2ec48c784ddf9495b7b63bf7bf90,melanoma,0.410364
uuid-cf51bdea49aa4165aa76aabb511f658e,N Engl J Med,0.346227
uuid-cf51bdea49aa4165aa76aabb511f658e,ASCO,0.692361
uuid-cf51bdea49aa4165aa76aabb511f658e,McDermott DF,0.328126
uuid-cf51bdea49aa4165aa76aabb511f658e,ESMO,0.340084
uuid-cf51bdea49aa4165aa76aabb511f658e,Escudier B,0.303787
uuid-cf51bdea49aa4165aa76aabb511f658e,et al.,0.431418
uuid-cf51bdea49aa4165aa76aabb511f658e,phase 2 study,0.305142
uuid-cf51bdea49aa4165aa76aabb511f658e,Horn L,0.306752
uuid-974b5938cb3f4b598ccd147089c8f2d5,ASCO,0.814469
uuid-7fdb61bcb2db4aa7bb36aa2ecd6b4b86,nivolumab,0.811201
uuid-fadfd1d69612471e8b3fe6fc157f317e,use of nivolumab for the treatment,0.409821
uuid-fadfd1d69612471e8b3fe6fc157f317e,patients with advanced or metastatic,0.645244
uuid-fadfd1d69612471e8b3fe6fc157f317e,nivolumab combined with ipilimumab,0.676339
uuid-fadfd1d69612471e8b3fe6fc157f317e,not approved,0.453534
uuid-fadfd1d69612471e8b3fe6fc157f317e,clinical trials investigating the safety,0.548799
uuid-fadfd1d69612471e8b3fe6fc157f317e,phase 1/2 study CA209-032,0.34114
uuid-fadfd1d69612471e8b3fe6fc157f317e,bladder cancer,0.749142
uuid-fadfd1d69612471e8b3fe6fc157f317e,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-30e4a50d7e644e97b262a94fe98f9b0b,use of nivolumab for the treatment,0.303526
uuid-30e4a50d7e644e97b262a94fe98f9b0b,efficacy,0.312449
uuid-30e4a50d7e644e97b262a94fe98f9b0b,not approved,0.313271
uuid-30e4a50d7e644e97b262a94fe98f9b0b,CA209-003,0.322962
uuid-30e4a50d7e644e97b262a94fe98f9b0b,investigating,0.548388
uuid-e9fc7f48ca7f436188ac84c7436d1295,95% CI,0.419478
uuid-e9fc7f48ca7f436188ac84c7436d1295,respectively,0.497608
uuid-e9fc7f48ca7f436188ac84c7436d1295,Objective response rate,0.403649
uuid-e9fc7f48ca7f436188ac84c7436d1295,ORR,0.578109
uuid-e9fc7f48ca7f436188ac84c7436d1295,patients with advanced or metastatic,0.306625
uuid-e9fc7f48ca7f436188ac84c7436d1295,Median overall survival,0.498783
uuid-e9fc7f48ca7f436188ac84c7436d1295,nivolumab combined with ipilimumab,0.300486
uuid-e9fc7f48ca7f436188ac84c7436d1295,tumors,0.323334
uuid-e9fc7f48ca7f436188ac84c7436d1295,ESMO,0.534361
uuid-e9fc7f48ca7f436188ac84c7436d1295,Median OS,0.394058
uuid-e9fc7f48ca7f436188ac84c7436d1295,small cell lung cancer,0.380999
uuid-e9fc7f48ca7f436188ac84c7436d1295,SCLC,0.365686
uuid-e9fc7f48ca7f436188ac84c7436d1295,hazard ratio,0.419392
uuid-e9fc7f48ca7f436188ac84c7436d1295,grade 3 to 4 AEs,0.414535
uuid-e9fc7f48ca7f436188ac84c7436d1295,phase 1/2 study CA209-032,0.398283
uuid-e9fc7f48ca7f436188ac84c7436d1295,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-9b5a527871ce4569864360a4bf957ea4,nivolumab,0.370699
uuid-90a5d1cf0c3648bdb14a8c228ed95233,OS,0.391605
uuid-90a5d1cf0c3648bdb14a8c228ed95233,95% CI,0.622436
uuid-90a5d1cf0c3648bdb14a8c228ed95233,patients,0.318755
uuid-90a5d1cf0c3648bdb14a8c228ed95233,considered investigational,0.560783
uuid-90a5d1cf0c3648bdb14a8c228ed95233,Objective response rate,0.517231
uuid-90a5d1cf0c3648bdb14a8c228ed95233,ORR,0.59836
uuid-90a5d1cf0c3648bdb14a8c228ed95233,patients with advanced or metastatic,0.51624
uuid-90a5d1cf0c3648bdb14a8c228ed95233,PFS,0.327599
uuid-90a5d1cf0c3648bdb14a8c228ed95233,Median overall survival,0.643385
uuid-90a5d1cf0c3648bdb14a8c228ed95233,nivolumab combined with ipilimumab,0.503559
uuid-90a5d1cf0c3648bdb14a8c228ed95233,tumors,0.502936
uuid-90a5d1cf0c3648bdb14a8c228ed95233,Median OS,0.527355
uuid-90a5d1cf0c3648bdb14a8c228ed95233,small cell lung cancer,0.613602
uuid-90a5d1cf0c3648bdb14a8c228ed95233,SCLC,0.596242
uuid-90a5d1cf0c3648bdb14a8c228ed95233,hazard ratio,0.614822
uuid-90a5d1cf0c3648bdb14a8c228ed95233,phase 1/2 study CA209-032,0.637888
uuid-90a5d1cf0c3648bdb14a8c228ed95233,evaluates the efficacy of nivolumab monotherapy,0.621648
uuid-3f88a02954284ca489ef3d0813627916,nivolumab,0.530487
uuid-3f88a02954284ca489ef3d0813627916,Bristol-Myers Squibb,0.459328
uuid-3f88a02954284ca489ef3d0813627916,evaluating,0.629817
uuid-3f88a02954284ca489ef3d0813627916,not conducted any controlled clinical trials/studies,0.686218
uuid-3f88a02954284ca489ef3d0813627916,Pubmed literature search,0.839314
uuid-3f88a02954284ca489ef3d0813627916,purposes other than its labeled indication must be considered investigational,0.907421
uuid-3f88a02954284ca489ef3d0813627916,not identify any citations relevant to your inquiry,0.797696
uuid-3f88a02954284ca489ef3d0813627916,using the following search terms,0.783191
uuid-3f88a02954284ca489ef3d0813627916,efficacy and safety of nivolumab,0.474312
uuid-7e8e438816af4fa7847c8d801e631d01,N Engl J Med,0.47446
uuid-7e8e438816af4fa7847c8d801e631d01,protocol,0.775143
uuid-7e8e438816af4fa7847c8d801e631d01,McDermott DF,0.756118
uuid-7e8e438816af4fa7847c8d801e631d01,Motzer RJ,0.827454
uuid-7e8e438816af4fa7847c8d801e631d01,phase 3 study,0.422813
uuid-7e8e438816af4fa7847c8d801e631d01,Escudier B,0.764532
uuid-7e8e438816af4fa7847c8d801e631d01,NEJM,0.403986
uuid-7e8e438816af4fa7847c8d801e631d01,et al.,0.688347
uuid-7e8e438816af4fa7847c8d801e631d01,J Clin Oncol,0.796776
uuid-7e8e438816af4fa7847c8d801e631d01,Topalian,0.391537
uuid-7e8e438816af4fa7847c8d801e631d01,phase 1 study,0.491683
uuid-7e8e438816af4fa7847c8d801e631d01,CA209-003,0.556088
uuid-7e8e438816af4fa7847c8d801e631d01,phase 2 study,0.690687
uuid-7e8e438816af4fa7847c8d801e631d01,present using the following search terms,0.310671
uuid-7e8e438816af4fa7847c8d801e631d01,investigating,0.600457
uuid-eaf12c19dae8451d8d82944c404485b9,OS,0.503429
uuid-eaf12c19dae8451d8d82944c404485b9,95% CI,0.826181
uuid-eaf12c19dae8451d8d82944c404485b9,respectively,0.586221
uuid-eaf12c19dae8451d8d82944c404485b9,Objective response rate,0.520699
uuid-eaf12c19dae8451d8d82944c404485b9,ORR,0.697806
uuid-eaf12c19dae8451d8d82944c404485b9,PFS,0.378731
uuid-eaf12c19dae8451d8d82944c404485b9,Median overall survival,0.765191
uuid-eaf12c19dae8451d8d82944c404485b9,monotherapy,0.385148
uuid-eaf12c19dae8451d8d82944c404485b9,Median OS,0.790845
uuid-eaf12c19dae8451d8d82944c404485b9,docetaxel,0.427315
uuid-eaf12c19dae8451d8d82944c404485b9,hazard ratio,0.7827
uuid-eaf12c19dae8451d8d82944c404485b9,Median duration of response,0.326686
uuid-9ce020d374644730bdd1d70c470227fe,OS,0.304645
uuid-9ce020d374644730bdd1d70c470227fe,95% CI,0.408622
uuid-9ce020d374644730bdd1d70c470227fe,NSCLC,0.33588
uuid-9ce020d374644730bdd1d70c470227fe,respectively,0.499027
uuid-9ce020d374644730bdd1d70c470227fe,Objective response rate,0.688609
uuid-9ce020d374644730bdd1d70c470227fe,ORR,0.678791
uuid-9ce020d374644730bdd1d70c470227fe,Median overall survival,0.445394
uuid-9ce020d374644730bdd1d70c470227fe,monotherapy,0.519987
uuid-9ce020d374644730bdd1d70c470227fe,Median OS,0.375881
uuid-9ce020d374644730bdd1d70c470227fe,docetaxel,0.378462
uuid-9ce020d374644730bdd1d70c470227fe,Antonia SJ,0.333337
uuid-9ce020d374644730bdd1d70c470227fe,hazard ratio,0.41425
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,N Engl J Med,0.766032
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,protocol,0.874182
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,McDermott DF,0.960227
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Motzer RJ,0.937306
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,phase 3 study,0.460393
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Escudier B,0.963515
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,NEJM,0.474086
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,et al.,0.949387
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,J Clin Oncol,0.883564
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Topalian,0.418815
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Rizvi NA,0.471055
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Brahmer J,0.406289
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,Weber JS,0.328759
uuid-a0c63e673a9d44b0a0d98ec5d91045c3,phase 2 study,0.812219
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,N Engl J Med,0.415351
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,protocol,0.620592
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,McDermott DF,0.642003
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,Motzer RJ,0.631887
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,phase 3 study,0.443395
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,Escudier B,0.642353
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,NEJM,0.306014
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,et al.,0.59736
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,J Clin Oncol,0.591597
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,Rizvi NA,0.301009
uuid-ad7c7bde4cf444e3964ee80fd3dfd440,phase 2 study,0.553139
uuid-01d11bbf5a4f4658a480d705eb627b33,Bristol-Myers Squibb,0.720091
uuid-01d11bbf5a4f4658a480d705eb627b33,evaluating,0.526233
uuid-01d11bbf5a4f4658a480d705eb627b33,not conducted any controlled clinical trials/studies,0.600585
uuid-01d11bbf5a4f4658a480d705eb627b33,requested,0.33863
uuid-01d11bbf5a4f4658a480d705eb627b33,efficacy and safety of nivolumab,0.463601
uuid-050ac6b74b114ff59ed75591b8bdad93,Opdivo,0.454295
uuid-050ac6b74b114ff59ed75591b8bdad93,RCC,0.770004
uuid-de493b34cbf54efc96d823e4ae13ddc4,search of published literature,0.394524
uuid-de493b34cbf54efc96d823e4ae13ddc4,Additionally,0.413583
uuid-de493b34cbf54efc96d823e4ae13ddc4,ongoing,0.322117
uuid-de493b34cbf54efc96d823e4ae13ddc4,PubMed and EMBASE,0.391671
uuid-de493b34cbf54efc96d823e4ae13ddc4,detailed search of www.clinicaltrials.gov,0.375936
uuid-de493b34cbf54efc96d823e4ae13ddc4,efficacy and safety of nivolumab,0.370699
uuid-de493b34cbf54efc96d823e4ae13ddc4,not identify any planned,0.34283
uuid-de493b34cbf54efc96d823e4ae13ddc4,Weber JS,0.319229
uuid-de493b34cbf54efc96d823e4ae13ddc4,not identify any citations relevant to your request,0.447813
uuid-de493b34cbf54efc96d823e4ae13ddc4,present using the following search terms,0.408199
uuid-f84c5e256fab44cba64a95e5059ae55e,requested,0.304654
uuid-ed0cbc9ba8be4d99bd98ef0ecdd2901b,patients with advanced or metastatic,0.478326
uuid-ed0cbc9ba8be4d99bd98ef0ecdd2901b,nivolumab combined with ipilimumab,0.498766
uuid-ed0cbc9ba8be4d99bd98ef0ecdd2901b,not approved,0.34724
uuid-ed0cbc9ba8be4d99bd98ef0ecdd2901b,clinical trials investigating the safety,0.426729
uuid-ed0cbc9ba8be4d99bd98ef0ecdd2901b,bladder cancer,0.6548
uuid-296c5590fae24931b052789fa31a603a,nivolumab,0.356017
uuid-296c5590fae24931b052789fa31a603a,evaluating,0.317183
uuid-296c5590fae24931b052789fa31a603a,not conducted any controlled clinical trials/studies,0.350654
uuid-296c5590fae24931b052789fa31a603a,Pubmed literature search,0.554789
uuid-296c5590fae24931b052789fa31a603a,purposes other than its labeled indication must be considered investigational,0.585644
uuid-296c5590fae24931b052789fa31a603a,not identify any citations relevant to your inquiry,0.552002
uuid-296c5590fae24931b052789fa31a603a,open-label,0.426008
uuid-296c5590fae24931b052789fa31a603a,using the following search terms,0.527471
uuid-423d606539784bcbbee4559ee4f03e5c,use of nivolumab for the treatment,0.435597
uuid-423d606539784bcbbee4559ee4f03e5c,efficacy,0.459317
uuid-423d606539784bcbbee4559ee4f03e5c,not approved,0.558926
uuid-423d606539784bcbbee4559ee4f03e5c,clinical trials investigating the safety,0.598064
uuid-423d606539784bcbbee4559ee4f03e5c,clinicaltrials.gov,0.437497
uuid-423d606539784bcbbee4559ee4f03e5c,safety of nivolumab monotherapy,0.303846
uuid-423d606539784bcbbee4559ee4f03e5c,bladder cancer,0.44905
uuid-ae76dae5fbab4e038115a1b302c513df,search of published literature,0.327212
uuid-ae76dae5fbab4e038115a1b302c513df,phase 3 study,0.646794
uuid-ae76dae5fbab4e038115a1b302c513df,PubMed and EMBASE,0.320345
uuid-ae76dae5fbab4e038115a1b302c513df,Rizvi NA,0.305008
uuid-ae76dae5fbab4e038115a1b302c513df,Weber JS,0.511477
uuid-c7efe9eafd5041999dcb5e9bce52726b,Bristol-Myers Squibb,0.489316
uuid-c7efe9eafd5041999dcb5e9bce52726b,evaluating,0.310446
uuid-c7efe9eafd5041999dcb5e9bce52726b,not conducted any controlled clinical trials/studies,0.358395
uuid-c7efe9eafd5041999dcb5e9bce52726b,adverse,0.415073
uuid-c7efe9eafd5041999dcb5e9bce52726b,reported,0.403638
uuid-fd3267206ba046a184167588bab13ed7,N Engl J Med,0.766032
uuid-fd3267206ba046a184167588bab13ed7,protocol,0.874182
uuid-fd3267206ba046a184167588bab13ed7,McDermott DF,0.960227
uuid-fd3267206ba046a184167588bab13ed7,Motzer RJ,0.937306
uuid-fd3267206ba046a184167588bab13ed7,phase 3 study,0.460393
uuid-fd3267206ba046a184167588bab13ed7,Escudier B,0.963515
uuid-fd3267206ba046a184167588bab13ed7,NEJM,0.474086
uuid-fd3267206ba046a184167588bab13ed7,et al.,0.949387
uuid-fd3267206ba046a184167588bab13ed7,J Clin Oncol,0.883564
uuid-fd3267206ba046a184167588bab13ed7,Topalian,0.418815
uuid-fd3267206ba046a184167588bab13ed7,Rizvi NA,0.471055
uuid-fd3267206ba046a184167588bab13ed7,Brahmer J,0.406289
uuid-fd3267206ba046a184167588bab13ed7,Weber JS,0.328759
uuid-fd3267206ba046a184167588bab13ed7,phase 2 study,0.812219
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,95% CI,0.484623
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,Median overall survival,0.37775
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,Median OS,0.407419
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,BMS,0.431223
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,hazard ratio,0.418626
uuid-b7f19ea40b8d4a07ac403d1bf2c780cf,Median duration of response,0.469779
uuid-a073e132282e43149dad3a89da1b3d57,N Engl J Med,0.415351
uuid-a073e132282e43149dad3a89da1b3d57,protocol,0.620592
uuid-a073e132282e43149dad3a89da1b3d57,McDermott DF,0.642003
uuid-a073e132282e43149dad3a89da1b3d57,Motzer RJ,0.631887
uuid-a073e132282e43149dad3a89da1b3d57,phase 3 study,0.443395
uuid-a073e132282e43149dad3a89da1b3d57,Escudier B,0.642353
uuid-a073e132282e43149dad3a89da1b3d57,NEJM,0.306014
uuid-a073e132282e43149dad3a89da1b3d57,et al.,0.59736
uuid-a073e132282e43149dad3a89da1b3d57,J Clin Oncol,0.591597
uuid-a073e132282e43149dad3a89da1b3d57,Rizvi NA,0.301009
uuid-a073e132282e43149dad3a89da1b3d57,phase 2 study,0.553139
uuid-fbc08e30d2d74952a808591e04fe1bcb,OS,0.517683
uuid-fbc08e30d2d74952a808591e04fe1bcb,95% CI,0.887029
uuid-fbc08e30d2d74952a808591e04fe1bcb,respectively,0.541932
uuid-fbc08e30d2d74952a808591e04fe1bcb,Objective response rate,0.732884
uuid-fbc08e30d2d74952a808591e04fe1bcb,ORR,0.826341
uuid-fbc08e30d2d74952a808591e04fe1bcb,PFS,0.416378
uuid-fbc08e30d2d74952a808591e04fe1bcb,Median overall survival,0.810566
uuid-fbc08e30d2d74952a808591e04fe1bcb,monotherapy,0.504664
uuid-fbc08e30d2d74952a808591e04fe1bcb,Median OS,0.783041
uuid-fbc08e30d2d74952a808591e04fe1bcb,hazard ratio,0.851803
uuid-fbc08e30d2d74952a808591e04fe1bcb,Median duration of response,0.350254
uuid-35480dd33a4340ffa7c36f8a098a3d3c,95% CI,0.419478
uuid-35480dd33a4340ffa7c36f8a098a3d3c,respectively,0.497608
uuid-35480dd33a4340ffa7c36f8a098a3d3c,Objective response rate,0.403649
uuid-35480dd33a4340ffa7c36f8a098a3d3c,ORR,0.578109
uuid-35480dd33a4340ffa7c36f8a098a3d3c,patients with advanced or metastatic,0.306625
uuid-35480dd33a4340ffa7c36f8a098a3d3c,Median overall survival,0.498783
uuid-35480dd33a4340ffa7c36f8a098a3d3c,nivolumab combined with ipilimumab,0.300486
uuid-35480dd33a4340ffa7c36f8a098a3d3c,tumors,0.323334
uuid-35480dd33a4340ffa7c36f8a098a3d3c,ESMO,0.534361
uuid-35480dd33a4340ffa7c36f8a098a3d3c,Median OS,0.394058
uuid-35480dd33a4340ffa7c36f8a098a3d3c,small cell lung cancer,0.380999
uuid-35480dd33a4340ffa7c36f8a098a3d3c,SCLC,0.365686
uuid-35480dd33a4340ffa7c36f8a098a3d3c,hazard ratio,0.419392
uuid-35480dd33a4340ffa7c36f8a098a3d3c,grade 3 to 4 AEs,0.414535
uuid-35480dd33a4340ffa7c36f8a098a3d3c,phase 1/2 study CA209-032,0.398283
uuid-35480dd33a4340ffa7c36f8a098a3d3c,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-511d97af416244b5b08da29a14245860,Opdivo,0.423037
uuid-511d97af416244b5b08da29a14245860,grade,0.451734
uuid-656a5a08c0fe4edda692cab657e14f16,nivolumab,0.481374
uuid-656a5a08c0fe4edda692cab657e14f16,Bristol-Myers Squibb,0.496213
uuid-656a5a08c0fe4edda692cab657e14f16,evaluating,0.607089
uuid-656a5a08c0fe4edda692cab657e14f16,not conducted any controlled clinical trials/studies,0.665444
uuid-656a5a08c0fe4edda692cab657e14f16,Pubmed literature search,0.657952
uuid-656a5a08c0fe4edda692cab657e14f16,purposes other than its labeled indication must be considered investigational,0.729602
uuid-656a5a08c0fe4edda692cab657e14f16,not identify any citations relevant to your inquiry,0.620519
uuid-656a5a08c0fe4edda692cab657e14f16,search of published literature,0.30277
uuid-656a5a08c0fe4edda692cab657e14f16,using the following search terms,0.607037
uuid-656a5a08c0fe4edda692cab657e14f16,efficacy and safety of nivolumab,0.517951
uuid-cb5648b56d754655b0b0ac093fdb80e2,search of published literature,0.421795
uuid-cb5648b56d754655b0b0ac093fdb80e2,phase 3 study,0.588208
uuid-cb5648b56d754655b0b0ac093fdb80e2,PubMed and EMBASE,0.419018
uuid-cb5648b56d754655b0b0ac093fdb80e2,Weber JS,0.507878
uuid-cb5648b56d754655b0b0ac093fdb80e2,present using the following search terms,0.379124
uuid-fdd108e13a1142fc9c4be28ce650684f,N Engl J Med,0.415351
uuid-fdd108e13a1142fc9c4be28ce650684f,protocol,0.620592
uuid-fdd108e13a1142fc9c4be28ce650684f,McDermott DF,0.642003
uuid-fdd108e13a1142fc9c4be28ce650684f,Motzer RJ,0.631887
uuid-fdd108e13a1142fc9c4be28ce650684f,phase 3 study,0.443395
uuid-fdd108e13a1142fc9c4be28ce650684f,Escudier B,0.642353
uuid-fdd108e13a1142fc9c4be28ce650684f,NEJM,0.306014
uuid-fdd108e13a1142fc9c4be28ce650684f,et al.,0.59736
uuid-fdd108e13a1142fc9c4be28ce650684f,J Clin Oncol,0.591597
uuid-fdd108e13a1142fc9c4be28ce650684f,Rizvi NA,0.301009
uuid-fdd108e13a1142fc9c4be28ce650684f,phase 2 study,0.553139
uuid-31d08e51601e400ba2a4bbe7502845a6,N Engl J Med,0.304989
uuid-31d08e51601e400ba2a4bbe7502845a6,AEs,0.337832
uuid-31d08e51601e400ba2a4bbe7502845a6,patients,0.387033
uuid-31d08e51601e400ba2a4bbe7502845a6,provided in the Detailed Information,0.370845
uuid-31d08e51601e400ba2a4bbe7502845a6,ESMO,0.421367
uuid-31d08e51601e400ba2a4bbe7502845a6,NEJM,0.709799
uuid-31d08e51601e400ba2a4bbe7502845a6,Topalian,0.735417
uuid-31d08e51601e400ba2a4bbe7502845a6,grade 3 to 4 AEs,0.538198
uuid-c91bef9a885c48599c01f9d2db26a2ec,fatigue,0.323475
uuid-248615fff22b4c5c96436bac2e0f54cc,N Engl J Med,0.786038
uuid-248615fff22b4c5c96436bac2e0f54cc,Lancet Oncol,0.557089
uuid-248615fff22b4c5c96436bac2e0f54cc,protocol,0.811248
uuid-248615fff22b4c5c96436bac2e0f54cc,McDermott DF,0.868318
uuid-248615fff22b4c5c96436bac2e0f54cc,Motzer RJ,0.83863
uuid-248615fff22b4c5c96436bac2e0f54cc,phase 3 study,0.584895
uuid-248615fff22b4c5c96436bac2e0f54cc,Escudier B,0.872681
uuid-248615fff22b4c5c96436bac2e0f54cc,NEJM,0.472956
uuid-248615fff22b4c5c96436bac2e0f54cc,et al.,0.847814
uuid-248615fff22b4c5c96436bac2e0f54cc,J Clin Oncol,0.781502
uuid-248615fff22b4c5c96436bac2e0f54cc,Topalian,0.430076
uuid-248615fff22b4c5c96436bac2e0f54cc,Rizvi NA,0.716598
uuid-248615fff22b4c5c96436bac2e0f54cc,Brahmer J,0.46213
uuid-248615fff22b4c5c96436bac2e0f54cc,Weber JS,0.606253
uuid-248615fff22b4c5c96436bac2e0f54cc,phase 2 study,0.83125
uuid-401b46ce90fd471c99de88e9843c2750,melanoma,0.410364
uuid-270db85af3704e76a5c49085b97acf57,nivolumab,0.513451
uuid-270db85af3704e76a5c49085b97acf57,Bristol-Myers Squibb,0.452802
uuid-270db85af3704e76a5c49085b97acf57,evaluating,0.606083
uuid-270db85af3704e76a5c49085b97acf57,not conducted any controlled clinical trials/studies,0.668407
uuid-270db85af3704e76a5c49085b97acf57,Pubmed literature search,0.878595
uuid-270db85af3704e76a5c49085b97acf57,purposes other than its labeled indication must be considered investigational,0.93946
uuid-270db85af3704e76a5c49085b97acf57,not identify any citations relevant to your inquiry,0.838852
uuid-270db85af3704e76a5c49085b97acf57,using the following search terms,0.825654
uuid-270db85af3704e76a5c49085b97acf57,efficacy and safety of nivolumab,0.443462
uuid-75921ee562ad41d99bff8e3d03600fb0,fatigue,0.323475
uuid-402394bfeeb948dcab9cc1f3f13c2876,use of nivolumab for the treatment,0.409821
uuid-402394bfeeb948dcab9cc1f3f13c2876,patients with advanced or metastatic,0.645244
uuid-402394bfeeb948dcab9cc1f3f13c2876,nivolumab combined with ipilimumab,0.676339
uuid-402394bfeeb948dcab9cc1f3f13c2876,not approved,0.453534
uuid-402394bfeeb948dcab9cc1f3f13c2876,clinical trials investigating the safety,0.548799
uuid-402394bfeeb948dcab9cc1f3f13c2876,phase 1/2 study CA209-032,0.34114
uuid-402394bfeeb948dcab9cc1f3f13c2876,bladder cancer,0.749142
uuid-402394bfeeb948dcab9cc1f3f13c2876,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-7e67490255b74efab342f2f1995c0abc,nivolumab,0.570144
uuid-7e67490255b74efab342f2f1995c0abc,Bristol-Myers Squibb,0.458604
uuid-7e67490255b74efab342f2f1995c0abc,evaluating,0.612067
uuid-7e67490255b74efab342f2f1995c0abc,not conducted any controlled clinical trials/studies,0.673571
uuid-7e67490255b74efab342f2f1995c0abc,Pubmed literature search,0.866707
uuid-7e67490255b74efab342f2f1995c0abc,purposes other than its labeled indication must be considered investigational,0.933028
uuid-7e67490255b74efab342f2f1995c0abc,not identify any citations relevant to your inquiry,0.82415
uuid-7e67490255b74efab342f2f1995c0abc,using the following search terms,0.811825
uuid-7e67490255b74efab342f2f1995c0abc,efficacy and safety of nivolumab,0.451633
uuid-fa1a0d0d3fe04c80a608969296bdc27b,phase 3 study,0.382788
uuid-fa1a0d0d3fe04c80a608969296bdc27b,NEJM,0.335542
uuid-fa1a0d0d3fe04c80a608969296bdc27b,Topalian,0.348658
uuid-fa1a0d0d3fe04c80a608969296bdc27b,phase 1 study,0.399014
uuid-fa1a0d0d3fe04c80a608969296bdc27b,Rizvi NA,0.394965
uuid-fa1a0d0d3fe04c80a608969296bdc27b,mg,0.439851
uuid-fa1a0d0d3fe04c80a608969296bdc27b,CA209-003,0.360127
uuid-fa1a0d0d3fe04c80a608969296bdc27b,Weber JS,0.34591
uuid-fa1a0d0d3fe04c80a608969296bdc27b,phase 2 study,0.432741
uuid-fa1a0d0d3fe04c80a608969296bdc27b,kg,0.373405
uuid-4ed32112c28d4119bbfec29e6dc2502f,Bristol-Myers Squibb,0.494637
uuid-718e61a180fb4d498146a600ac7819a5,provided in the Detailed Information,0.349112
uuid-718e61a180fb4d498146a600ac7819a5,Weber JS,0.321343
uuid-abbf9ac4ac374b3c8a40f4d933263879,phase 3 study,0.414515
uuid-abbf9ac4ac374b3c8a40f4d933263879,phase 1 study,0.318812
uuid-abbf9ac4ac374b3c8a40f4d933263879,Rizvi NA,0.41501
uuid-abbf9ac4ac374b3c8a40f4d933263879,mg,0.400456
uuid-abbf9ac4ac374b3c8a40f4d933263879,Weber JS,0.341287
uuid-abbf9ac4ac374b3c8a40f4d933263879,phase 2 study,0.402162
uuid-abbf9ac4ac374b3c8a40f4d933263879,kg,0.334413
uuid-2a96f6e83d4b47f990f3233439356acd,not conducted any controlled clinical trials/studies,0.308294
uuid-d5da0430cbed475383ec319b7d58ef1e,ipilimumab,0.385692
uuid-d5da0430cbed475383ec319b7d58ef1e,ASCO 2015,0.417944
uuid-d5da0430cbed475383ec319b7d58ef1e,partial response,0.382425
uuid-d5da0430cbed475383ec319b7d58ef1e,Stable disease,0.586335
uuid-d5da0430cbed475383ec319b7d58ef1e,cohort,0.307748
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,protocol,0.43173
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,RCC,0.387857
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,McDermott DF,0.347146
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,search of published literature,0.514294
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,Additionally,0.643121
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,ongoing,0.552009
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,Motzer RJ,0.377032
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,PubMed and EMBASE,0.516498
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,Escudier B,0.359065
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,et al.,0.303557
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,J Clin Oncol,0.342049
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,detailed search of www.clinicaltrials.gov,0.5979
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,efficacy and safety of nivolumab,0.444178
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,not identify any planned,0.571731
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,combination,0.320909
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,phase 2 study,0.305831
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,not identify any citations relevant to your request,0.64452
uuid-f03c4ff8f2be44f3834c4d95a9f5c670,present using the following search terms,0.511841
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,N Engl J Med,0.5218
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,protocol,0.822129
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,RCC,0.351265
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,McDermott DF,0.805326
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,search of published literature,0.328584
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,Motzer RJ,0.830191
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,phase 3 study,0.375845
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,PubMed and EMBASE,0.327895
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,Escudier B,0.815105
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,NEJM,0.388967
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,et al.,0.745528
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,J Clin Oncol,0.787871
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,Topalian,0.347249
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,Rizvi NA,0.308297
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,phase 2 study,0.670697
uuid-efd5ba9f8df84b6a9e73d5c79b8450de,present using the following search terms,0.304579
uuid-8b82a58b85884868ab3e741664feae2e,use of nivolumab for the treatment,0.409821
uuid-8b82a58b85884868ab3e741664feae2e,patients with advanced or metastatic,0.645244
uuid-8b82a58b85884868ab3e741664feae2e,nivolumab combined with ipilimumab,0.676339
uuid-8b82a58b85884868ab3e741664feae2e,not approved,0.453534
uuid-8b82a58b85884868ab3e741664feae2e,clinical trials investigating the safety,0.548799
uuid-8b82a58b85884868ab3e741664feae2e,phase 1/2 study CA209-032,0.34114
uuid-8b82a58b85884868ab3e741664feae2e,bladder cancer,0.749142
uuid-8b82a58b85884868ab3e741664feae2e,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,use of nivolumab for the treatment,0.409821
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,patients with advanced or metastatic,0.645244
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,nivolumab combined with ipilimumab,0.676339
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,not approved,0.453534
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,clinical trials investigating the safety,0.548799
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,phase 1/2 study CA209-032,0.34114
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,bladder cancer,0.749142
uuid-5a49c5a7dcea4227b0ae3ffa6f55ee5e,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-f0bcb71d45b240da9eb4268952fb3817,N Engl J Med,0.440681
uuid-f0bcb71d45b240da9eb4268952fb3817,protocol,0.698878
uuid-f0bcb71d45b240da9eb4268952fb3817,McDermott DF,0.633917
uuid-f0bcb71d45b240da9eb4268952fb3817,Motzer RJ,0.658509
uuid-f0bcb71d45b240da9eb4268952fb3817,phase 3 study,0.36503
uuid-f0bcb71d45b240da9eb4268952fb3817,Escudier B,0.643885
uuid-f0bcb71d45b240da9eb4268952fb3817,NEJM,0.331905
uuid-f0bcb71d45b240da9eb4268952fb3817,et al.,0.585914
uuid-f0bcb71d45b240da9eb4268952fb3817,J Clin Oncol,0.62062
uuid-f0bcb71d45b240da9eb4268952fb3817,Topalian,0.305543
uuid-f0bcb71d45b240da9eb4268952fb3817,Rizvi NA,0.310971
uuid-f0bcb71d45b240da9eb4268952fb3817,phase 2 study,0.535083
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,search of published literature,0.851133
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,PubMed and EMBASE,0.851162
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,trial,0.357918
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,efficacy and safety of nivolumab,0.545404
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,not identify any citations relevant to your request,0.324216
uuid-ca55cbb4d6584c79ac3b9e76ead5d526,present using the following search terms,0.805392
uuid-66838893a53e42af84efc3eea4d4cc43,N Engl J Med,0.304989
uuid-66838893a53e42af84efc3eea4d4cc43,AEs,0.337832
uuid-66838893a53e42af84efc3eea4d4cc43,patients,0.387033
uuid-66838893a53e42af84efc3eea4d4cc43,provided in the Detailed Information,0.370845
uuid-66838893a53e42af84efc3eea4d4cc43,ESMO,0.421367
uuid-66838893a53e42af84efc3eea4d4cc43,NEJM,0.709799
uuid-66838893a53e42af84efc3eea4d4cc43,Topalian,0.735417
uuid-66838893a53e42af84efc3eea4d4cc43,grade 3 to 4 AEs,0.538198
uuid-df9428c7e1df43c3a15fc5bb22203538,N Engl J Med,0.304989
uuid-df9428c7e1df43c3a15fc5bb22203538,AEs,0.337832
uuid-df9428c7e1df43c3a15fc5bb22203538,patients,0.387033
uuid-df9428c7e1df43c3a15fc5bb22203538,provided in the Detailed Information,0.370845
uuid-df9428c7e1df43c3a15fc5bb22203538,ESMO,0.421367
uuid-df9428c7e1df43c3a15fc5bb22203538,NEJM,0.709799
uuid-df9428c7e1df43c3a15fc5bb22203538,Topalian,0.735417
uuid-df9428c7e1df43c3a15fc5bb22203538,grade 3 to 4 AEs,0.538198
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,N Engl J Med,0.312806
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,requested,0.451355
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,McDermott DF,0.461399
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,Motzer RJ,0.376424
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,phase 3 study,0.314861
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,Escudier B,0.446763
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,et al.,0.540953
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,J Clin Oncol,0.350881
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,Weber JS,0.330462
uuid-0a0e8bae2ad442dfb7db8f680dc0ab3c,phase 2 study,0.469394
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,N Engl J Med,0.632818
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,provided in the Detailed Information,0.334159
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,protocol,0.381212
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,McDermott DF,0.462692
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,Motzer RJ,0.447862
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,ESMO,0.795915
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,Escudier B,0.47011
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,et al.,0.479154
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,J Clin Oncol,0.372465
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,Brahmer J,0.3223
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,phase 2 study,0.38699
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,Horn L,0.510095
uuid-b5e4a8a0fc1341d0a3e86a320bbe9acc,grade 3 to 4 AEs,0.335467
uuid-e7c3276bef424794afdc45da81bc210a,use of nivolumab for the treatment,0.671228
uuid-e7c3276bef424794afdc45da81bc210a,efficacy,0.737477
uuid-e7c3276bef424794afdc45da81bc210a,not approved,0.805794
uuid-e7c3276bef424794afdc45da81bc210a,clinical trials investigating the safety,0.78466
uuid-e7c3276bef424794afdc45da81bc210a,safety of nivolumab monotherapy,0.578099
uuid-e7c3276bef424794afdc45da81bc210a,phase,0.428461
uuid-653a4596db354b9290e70111a2437150,nivolumab,0.603111
uuid-653a4596db354b9290e70111a2437150,Bristol-Myers Squibb,0.449516
uuid-653a4596db354b9290e70111a2437150,evaluating,0.605225
uuid-653a4596db354b9290e70111a2437150,not conducted any controlled clinical trials/studies,0.651997
uuid-653a4596db354b9290e70111a2437150,Pubmed literature search,0.774688
uuid-653a4596db354b9290e70111a2437150,purposes other than its labeled indication must be considered investigational,0.847803
uuid-653a4596db354b9290e70111a2437150,not identify any citations relevant to your inquiry,0.736269
uuid-653a4596db354b9290e70111a2437150,using the following search terms,0.717628
uuid-653a4596db354b9290e70111a2437150,efficacy and safety of nivolumab,0.446765
uuid-cbc121dd54de4491a2b88320dfb54d32,Bristol-Myers Squibb,0.342439
uuid-cbc121dd54de4491a2b88320dfb54d32,Opdivo,0.49028
uuid-cbc121dd54de4491a2b88320dfb54d32,Pubmed literature search,0.593556
uuid-cbc121dd54de4491a2b88320dfb54d32,purposes other than its labeled indication must be considered investigational,0.562964
uuid-cbc121dd54de4491a2b88320dfb54d32,not identify any citations relevant to your inquiry,0.587515
uuid-cbc121dd54de4491a2b88320dfb54d32,adverse,0.316871
uuid-cbc121dd54de4491a2b88320dfb54d32,using the following search terms,0.625843
uuid-cbc121dd54de4491a2b88320dfb54d32,reported,0.583695
uuid-b4da96df315a47e28e6ba3ff947a3c1a,NSCLC,0.339686
uuid-b4da96df315a47e28e6ba3ff947a3c1a,non-small cell lung cancer,0.325596
uuid-b4da96df315a47e28e6ba3ff947a3c1a,platinum-based doublet chemotherapy,0.322639
uuid-eb7a1879637a4e27890a9cb223a540e4,fatigue,0.323475
uuid-f6582772a39745cb843bcc482643100e,N Engl J Med,0.507479
uuid-f6582772a39745cb843bcc482643100e,protocol,0.776111
uuid-f6582772a39745cb843bcc482643100e,McDermott DF,0.806392
uuid-f6582772a39745cb843bcc482643100e,Motzer RJ,0.810264
uuid-f6582772a39745cb843bcc482643100e,Escudier B,0.803548
uuid-f6582772a39745cb843bcc482643100e,NEJM,0.330705
uuid-f6582772a39745cb843bcc482643100e,et al.,0.746575
uuid-f6582772a39745cb843bcc482643100e,J Clin Oncol,0.80227
uuid-f6582772a39745cb843bcc482643100e,Rizvi NA,0.322715
uuid-f6582772a39745cb843bcc482643100e,phase 2 study,0.63006
uuid-033be96af7b045e5acab316e64ada9ac,use of nivolumab for the treatment,0.435597
uuid-033be96af7b045e5acab316e64ada9ac,efficacy,0.459317
uuid-033be96af7b045e5acab316e64ada9ac,not approved,0.558926
uuid-033be96af7b045e5acab316e64ada9ac,clinical trials investigating the safety,0.598064
uuid-033be96af7b045e5acab316e64ada9ac,clinicaltrials.gov,0.437497
uuid-033be96af7b045e5acab316e64ada9ac,safety of nivolumab monotherapy,0.303846
uuid-033be96af7b045e5acab316e64ada9ac,bladder cancer,0.44905
uuid-9aa5bde2da95475bb2e2aabe372458e8,OS,0.62262
uuid-9aa5bde2da95475bb2e2aabe372458e8,PFS,0.65903
uuid-9aa5bde2da95475bb2e2aabe372458e8,Overall survival,0.644151
uuid-1153a41f636c4efdb6bf6c63171083af,use of nivolumab for the treatment,0.435597
uuid-1153a41f636c4efdb6bf6c63171083af,efficacy,0.459317
uuid-1153a41f636c4efdb6bf6c63171083af,not approved,0.558926
uuid-1153a41f636c4efdb6bf6c63171083af,clinical trials investigating the safety,0.598064
uuid-1153a41f636c4efdb6bf6c63171083af,clinicaltrials.gov,0.437497
uuid-1153a41f636c4efdb6bf6c63171083af,safety of nivolumab monotherapy,0.303846
uuid-1153a41f636c4efdb6bf6c63171083af,bladder cancer,0.44905
uuid-0899a557cb334912bc01ffed40cc7725,use of nivolumab for the treatment,0.305739
uuid-0899a557cb334912bc01ffed40cc7725,patients with advanced or metastatic,0.509457
uuid-0899a557cb334912bc01ffed40cc7725,nivolumab combined with ipilimumab,0.496885
uuid-0899a557cb334912bc01ffed40cc7725,not approved,0.397631
uuid-0899a557cb334912bc01ffed40cc7725,clinical trials investigating the safety,0.478965
uuid-0899a557cb334912bc01ffed40cc7725,bladder cancer,0.940126
uuid-2b24c3a3c2464f568997660ae19f2f57,Lancet Oncol,0.324455
uuid-2b24c3a3c2464f568997660ae19f2f57,adverse,0.305067
uuid-2b24c3a3c2464f568997660ae19f2f57,phase 3 study,0.424495
uuid-2b24c3a3c2464f568997660ae19f2f57,NEJM,0.30875
uuid-2b24c3a3c2464f568997660ae19f2f57,melanoma,0.411465
uuid-2b24c3a3c2464f568997660ae19f2f57,phase 1 study,0.349471
uuid-2b24c3a3c2464f568997660ae19f2f57,Rizvi NA,0.397514
uuid-2b24c3a3c2464f568997660ae19f2f57,mg,0.316849
uuid-2b24c3a3c2464f568997660ae19f2f57,CA209-003,0.348788
uuid-2b24c3a3c2464f568997660ae19f2f57,Weber JS,0.444748
uuid-2b24c3a3c2464f568997660ae19f2f57,phase 2 study,0.418915
uuid-071abeae067b4217a9431f9b3657c44b,use of nivolumab for the treatment,0.435597
uuid-071abeae067b4217a9431f9b3657c44b,efficacy,0.459317
uuid-071abeae067b4217a9431f9b3657c44b,not approved,0.558926
uuid-071abeae067b4217a9431f9b3657c44b,clinical trials investigating the safety,0.598064
uuid-071abeae067b4217a9431f9b3657c44b,clinicaltrials.gov,0.437497
uuid-071abeae067b4217a9431f9b3657c44b,safety of nivolumab monotherapy,0.303846
uuid-071abeae067b4217a9431f9b3657c44b,bladder cancer,0.44905
uuid-fd03e050c7f245c4a4eb5680a47afb61,use of nivolumab for the treatment,0.435597
uuid-fd03e050c7f245c4a4eb5680a47afb61,efficacy,0.459317
uuid-fd03e050c7f245c4a4eb5680a47afb61,not approved,0.558926
uuid-fd03e050c7f245c4a4eb5680a47afb61,clinical trials investigating the safety,0.598064
uuid-fd03e050c7f245c4a4eb5680a47afb61,clinicaltrials.gov,0.437497
uuid-fd03e050c7f245c4a4eb5680a47afb61,safety of nivolumab monotherapy,0.303846
uuid-fd03e050c7f245c4a4eb5680a47afb61,bladder cancer,0.44905
uuid-e01d0c0717e6409e898d8c87c6ee1ced,OS,0.484059
uuid-e01d0c0717e6409e898d8c87c6ee1ced,95% CI,0.789908
uuid-e01d0c0717e6409e898d8c87c6ee1ced,respectively,0.56815
uuid-e01d0c0717e6409e898d8c87c6ee1ced,Objective response rate,0.496697
uuid-e01d0c0717e6409e898d8c87c6ee1ced,ORR,0.662838
uuid-e01d0c0717e6409e898d8c87c6ee1ced,PFS,0.365454
uuid-e01d0c0717e6409e898d8c87c6ee1ced,Median overall survival,0.725875
uuid-e01d0c0717e6409e898d8c87c6ee1ced,monotherapy,0.374461
uuid-e01d0c0717e6409e898d8c87c6ee1ced,Median OS,0.765952
uuid-e01d0c0717e6409e898d8c87c6ee1ced,Brahmer J,0.304922
uuid-e01d0c0717e6409e898d8c87c6ee1ced,docetaxel,0.44742
uuid-e01d0c0717e6409e898d8c87c6ee1ced,hazard ratio,0.745791
uuid-e01d0c0717e6409e898d8c87c6ee1ced,Median duration of response,0.306815
uuid-6813bb11a2d642a29f384366b2ad11e4,ipilimumab,0.385692
uuid-6813bb11a2d642a29f384366b2ad11e4,ASCO 2015,0.417944
uuid-6813bb11a2d642a29f384366b2ad11e4,partial response,0.382425
uuid-6813bb11a2d642a29f384366b2ad11e4,Stable disease,0.586335
uuid-6813bb11a2d642a29f384366b2ad11e4,cohort,0.307748
uuid-971bfe03b07140098d90785421a00158,N Engl J Med,0.626658
uuid-971bfe03b07140098d90785421a00158,Lancet Oncol,0.362586
uuid-971bfe03b07140098d90785421a00158,protocol,0.764297
uuid-971bfe03b07140098d90785421a00158,McDermott DF,0.781192
uuid-971bfe03b07140098d90785421a00158,search of published literature,0.313745
uuid-971bfe03b07140098d90785421a00158,Motzer RJ,0.801581
uuid-971bfe03b07140098d90785421a00158,phase 3 study,0.618861
uuid-971bfe03b07140098d90785421a00158,PubMed and EMBASE,0.311444
uuid-971bfe03b07140098d90785421a00158,Escudier B,0.789821
uuid-971bfe03b07140098d90785421a00158,NEJM,0.384166
uuid-971bfe03b07140098d90785421a00158,et al.,0.735574
uuid-971bfe03b07140098d90785421a00158,J Clin Oncol,0.736946
uuid-971bfe03b07140098d90785421a00158,Topalian,0.361115
uuid-971bfe03b07140098d90785421a00158,phase 1 study,0.442926
uuid-971bfe03b07140098d90785421a00158,Rizvi NA,0.527796
uuid-971bfe03b07140098d90785421a00158,Brahmer J,0.345221
uuid-971bfe03b07140098d90785421a00158,efficacy and safety of nivolumab,0.313715
uuid-971bfe03b07140098d90785421a00158,CA209-003,0.425441
uuid-971bfe03b07140098d90785421a00158,Weber JS,0.417488
uuid-971bfe03b07140098d90785421a00158,phase 2 study,0.807167
uuid-971bfe03b07140098d90785421a00158,present using the following search terms,0.309627
uuid-971bfe03b07140098d90785421a00158,investigating,0.353322
uuid-4cfde24952764f48a0878e32a4793adc,Bristol-Myers Squibb,0.6842
uuid-4cfde24952764f48a0878e32a4793adc,evaluating,0.500704
uuid-4cfde24952764f48a0878e32a4793adc,not conducted any controlled clinical trials/studies,0.573708
uuid-4cfde24952764f48a0878e32a4793adc,adverse,0.72874
uuid-4cfde24952764f48a0878e32a4793adc,efficacy and safety of nivolumab,0.4675
uuid-4cfde24952764f48a0878e32a4793adc,reported,0.507353
uuid-9fc3408038774b05aa4abf119baa32bb,nivolumab,0.361138
uuid-af602e6d49e44c6f9659f85920ea6906,Bristol-Myers Squibb,0.351139
uuid-af602e6d49e44c6f9659f85920ea6906,evaluating,0.393781
uuid-af602e6d49e44c6f9659f85920ea6906,not conducted any controlled clinical trials/studies,0.401959
uuid-af602e6d49e44c6f9659f85920ea6906,NSCLC,0.316818
uuid-af602e6d49e44c6f9659f85920ea6906,efficacy and safety of nivolumab,0.448974
uuid-08c64714d2414fbfbe72d277231c6907,requested,0.731617
uuid-8a46bfa97e37409aae836c97ced572d5,requested,0.703219
uuid-b86a8de1b8df422f845271213bd9b950,requested,0.790158
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,protocol,0.410746
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,McDermott DF,0.470854
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,Motzer RJ,0.445478
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,tumors,0.3896
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,phase 3 study,0.49027
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,Escudier B,0.461229
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,et al.,0.489934
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,J Clin Oncol,0.438112
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,phase 1 study,0.3997
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,Rizvi NA,0.387303
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,CA209-003,0.332234
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,Weber JS,0.30627
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,phase 2 study,0.551277
uuid-720242ab8dc64ec4bab2ed79bf8d5b2f,partial response,0.304583
uuid-d6fde80e89524858a2ea4cd274765d70,melanoma,0.410364
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,Bristol-Myers Squibb,0.341822
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,not conducted any controlled clinical trials/studies,0.304507
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,Opdivo,0.461382
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,Pubmed literature search,0.614325
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,not identify any citations relevant to your inquiry,0.606087
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,adverse,0.304183
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,using the following search terms,0.642331
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,databases,0.315039
uuid-f73fb1363d2c4a4e8096ebe06126d0b9,reported,0.556704
uuid-b815440708e7450689a9b8e8145a5354,search of published literature,0.394524
uuid-b815440708e7450689a9b8e8145a5354,Additionally,0.413583
uuid-b815440708e7450689a9b8e8145a5354,ongoing,0.322117
uuid-b815440708e7450689a9b8e8145a5354,PubMed and EMBASE,0.391671
uuid-b815440708e7450689a9b8e8145a5354,detailed search of www.clinicaltrials.gov,0.375936
uuid-b815440708e7450689a9b8e8145a5354,efficacy and safety of nivolumab,0.370699
uuid-b815440708e7450689a9b8e8145a5354,not identify any planned,0.34283
uuid-b815440708e7450689a9b8e8145a5354,Weber JS,0.319229
uuid-b815440708e7450689a9b8e8145a5354,not identify any citations relevant to your request,0.447813
uuid-b815440708e7450689a9b8e8145a5354,present using the following search terms,0.408199
uuid-51978ea6d110422b87faf21550d8b43b,use of nivolumab for the treatment,0.690264
uuid-51978ea6d110422b87faf21550d8b43b,efficacy,0.615419
uuid-51978ea6d110422b87faf21550d8b43b,patients,0.525457
uuid-51978ea6d110422b87faf21550d8b43b,not approved,0.783484
uuid-51978ea6d110422b87faf21550d8b43b,clinical trials investigating the safety,0.815457
uuid-51978ea6d110422b87faf21550d8b43b,safety of nivolumab monotherapy,0.413458
uuid-51978ea6d110422b87faf21550d8b43b,bladder cancer,0.324783
uuid-6c1d45aeec7f478f8c95de889b960230,evaluating,0.366546
uuid-6c1d45aeec7f478f8c95de889b960230,not conducted any controlled clinical trials/studies,0.360172
uuid-6c1d45aeec7f478f8c95de889b960230,search of published literature,0.403755
uuid-6c1d45aeec7f478f8c95de889b960230,Additionally,0.418906
uuid-6c1d45aeec7f478f8c95de889b960230,ongoing,0.467576
uuid-6c1d45aeec7f478f8c95de889b960230,PubMed and EMBASE,0.39617
uuid-6c1d45aeec7f478f8c95de889b960230,detailed search of www.clinicaltrials.gov,0.437393
uuid-6c1d45aeec7f478f8c95de889b960230,efficacy and safety of nivolumab,0.42836
uuid-6c1d45aeec7f478f8c95de889b960230,not identify any planned,0.454065
uuid-6c1d45aeec7f478f8c95de889b960230,combination,0.397925
uuid-6c1d45aeec7f478f8c95de889b960230,BMS,0.30879
uuid-6c1d45aeec7f478f8c95de889b960230,not identify any citations relevant to your request,0.449603
uuid-6c1d45aeec7f478f8c95de889b960230,present using the following search terms,0.394376
uuid-31f8a587a0154b4d8354ebe565def71e,search of published literature,0.394524
uuid-31f8a587a0154b4d8354ebe565def71e,Additionally,0.413583
uuid-31f8a587a0154b4d8354ebe565def71e,ongoing,0.322117
uuid-31f8a587a0154b4d8354ebe565def71e,PubMed and EMBASE,0.391671
uuid-31f8a587a0154b4d8354ebe565def71e,detailed search of www.clinicaltrials.gov,0.375936
uuid-31f8a587a0154b4d8354ebe565def71e,efficacy and safety of nivolumab,0.370699
uuid-31f8a587a0154b4d8354ebe565def71e,not identify any planned,0.34283
uuid-31f8a587a0154b4d8354ebe565def71e,Weber JS,0.319229
uuid-31f8a587a0154b4d8354ebe565def71e,not identify any citations relevant to your request,0.447813
uuid-31f8a587a0154b4d8354ebe565def71e,present using the following search terms,0.408199
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,nivolumab,0.588555
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,Bristol-Myers Squibb,0.422134
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,evaluating,0.587635
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,not conducted any controlled clinical trials/studies,0.640274
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,Pubmed literature search,0.865944
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,purposes other than its labeled indication must be considered investigational,0.930668
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,not identify any citations relevant to your inquiry,0.827941
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,using the following search terms,0.813233
uuid-2bd6c96ed1b44f30bc370a5899c91d4b,efficacy and safety of nivolumab,0.421272
uuid-9fdc2048d2ca45b989281a2d89a28cae,requested,0.44769
uuid-9fdc2048d2ca45b989281a2d89a28cae,trial,0.309472
uuid-24fe1d4aca5949d6bf47726267c78d72,nivolumab,0.404875
uuid-24fe1d4aca5949d6bf47726267c78d72,Bristol-Myers Squibb,0.415447
uuid-24fe1d4aca5949d6bf47726267c78d72,evaluating,0.567054
uuid-24fe1d4aca5949d6bf47726267c78d72,not conducted any controlled clinical trials/studies,0.625819
uuid-24fe1d4aca5949d6bf47726267c78d72,Pubmed literature search,0.914429
uuid-24fe1d4aca5949d6bf47726267c78d72,purposes other than its labeled indication must be considered investigational,0.956856
uuid-24fe1d4aca5949d6bf47726267c78d72,not identify any citations relevant to your inquiry,0.87904
uuid-24fe1d4aca5949d6bf47726267c78d72,using the following search terms,0.870641
uuid-24fe1d4aca5949d6bf47726267c78d72,efficacy and safety of nivolumab,0.385572
uuid-bd251e954ad54bb78622b80d58a66180,nivolumab,0.588555
uuid-bd251e954ad54bb78622b80d58a66180,Bristol-Myers Squibb,0.422134
uuid-bd251e954ad54bb78622b80d58a66180,evaluating,0.587635
uuid-bd251e954ad54bb78622b80d58a66180,not conducted any controlled clinical trials/studies,0.640274
uuid-bd251e954ad54bb78622b80d58a66180,Pubmed literature search,0.865944
uuid-bd251e954ad54bb78622b80d58a66180,purposes other than its labeled indication must be considered investigational,0.930668
uuid-bd251e954ad54bb78622b80d58a66180,not identify any citations relevant to your inquiry,0.827941
uuid-bd251e954ad54bb78622b80d58a66180,using the following search terms,0.813233
uuid-bd251e954ad54bb78622b80d58a66180,efficacy and safety of nivolumab,0.421272
uuid-74a548436a2a42de8b84fde67d78b24d,N Engl J Med,0.535286
uuid-74a548436a2a42de8b84fde67d78b24d,Lancet Oncol,0.364361
uuid-74a548436a2a42de8b84fde67d78b24d,protocol,0.50442
uuid-74a548436a2a42de8b84fde67d78b24d,McDermott DF,0.548182
uuid-74a548436a2a42de8b84fde67d78b24d,Motzer RJ,0.532741
uuid-74a548436a2a42de8b84fde67d78b24d,phase 3 study,0.493197
uuid-74a548436a2a42de8b84fde67d78b24d,Escudier B,0.547344
uuid-74a548436a2a42de8b84fde67d78b24d,et al.,0.519366
uuid-74a548436a2a42de8b84fde67d78b24d,J Clin Oncol,0.509597
uuid-74a548436a2a42de8b84fde67d78b24d,Rizvi NA,0.478602
uuid-74a548436a2a42de8b84fde67d78b24d,Brahmer J,0.338223
uuid-74a548436a2a42de8b84fde67d78b24d,Weber JS,0.370952
uuid-74a548436a2a42de8b84fde67d78b24d,phase 2 study,0.591434
uuid-e3c077595c274466a7cdf7e9b4466237,phase 3 study,0.411479
uuid-e3c077595c274466a7cdf7e9b4466237,open-label,0.407638
uuid-e3c077595c274466a7cdf7e9b4466237,phase 1 study,0.336258
uuid-e3c077595c274466a7cdf7e9b4466237,phase 2 study,0.348851
uuid-e3c077595c274466a7cdf7e9b4466237,phase,0.446608
uuid-c067d257e1c14ecf9bac8fac5f809741,respectively,0.723094
uuid-c067d257e1c14ecf9bac8fac5f809741,Objective response rate,0.613675
uuid-c067d257e1c14ecf9bac8fac5f809741,ORR,0.550635
uuid-c067d257e1c14ecf9bac8fac5f809741,monotherapy,0.501003
uuid-c067d257e1c14ecf9bac8fac5f809741,docetaxel,0.426809
uuid-c067d257e1c14ecf9bac8fac5f809741,Antonia SJ,0.358408
uuid-28431214fe484aa08436d7b6f53723e2,Bristol-Myers Squibb,0.351139
uuid-28431214fe484aa08436d7b6f53723e2,evaluating,0.393781
uuid-28431214fe484aa08436d7b6f53723e2,not conducted any controlled clinical trials/studies,0.401959
uuid-28431214fe484aa08436d7b6f53723e2,NSCLC,0.316818
uuid-28431214fe484aa08436d7b6f53723e2,efficacy and safety of nivolumab,0.448974
uuid-570bed28b06e4afbb46ed75881592dad,Bristol-Myers Squibb,0.453576
uuid-570bed28b06e4afbb46ed75881592dad,evaluating,0.57188
uuid-570bed28b06e4afbb46ed75881592dad,not conducted any controlled clinical trials/studies,0.523316
uuid-570bed28b06e4afbb46ed75881592dad,efficacy,0.30015
uuid-570bed28b06e4afbb46ed75881592dad,NSCLC,0.748072
uuid-570bed28b06e4afbb46ed75881592dad,non-small cell lung cancer,0.766403
uuid-570bed28b06e4afbb46ed75881592dad,considered investigational,0.326263
uuid-570bed28b06e4afbb46ed75881592dad,phase 3 study,0.386351
uuid-570bed28b06e4afbb46ed75881592dad,phase 1 study,0.387895
uuid-570bed28b06e4afbb46ed75881592dad,Rizvi NA,0.306173
uuid-570bed28b06e4afbb46ed75881592dad,efficacy and safety of nivolumab,0.514479
uuid-570bed28b06e4afbb46ed75881592dad,safety of nivolumab monotherapy,0.443947
uuid-570bed28b06e4afbb46ed75881592dad,platinum-based doublet chemotherapy,0.487131
uuid-37bc2b4681ae48b8a17c863cb9d5438d,evaluating,0.366546
uuid-37bc2b4681ae48b8a17c863cb9d5438d,not conducted any controlled clinical trials/studies,0.360172
uuid-37bc2b4681ae48b8a17c863cb9d5438d,search of published literature,0.403755
uuid-37bc2b4681ae48b8a17c863cb9d5438d,Additionally,0.418906
uuid-37bc2b4681ae48b8a17c863cb9d5438d,ongoing,0.467576
uuid-37bc2b4681ae48b8a17c863cb9d5438d,PubMed and EMBASE,0.39617
uuid-37bc2b4681ae48b8a17c863cb9d5438d,detailed search of www.clinicaltrials.gov,0.437393
uuid-37bc2b4681ae48b8a17c863cb9d5438d,efficacy and safety of nivolumab,0.42836
uuid-37bc2b4681ae48b8a17c863cb9d5438d,not identify any planned,0.454065
uuid-37bc2b4681ae48b8a17c863cb9d5438d,combination,0.397925
uuid-37bc2b4681ae48b8a17c863cb9d5438d,BMS,0.30879
uuid-37bc2b4681ae48b8a17c863cb9d5438d,not identify any citations relevant to your request,0.449603
uuid-37bc2b4681ae48b8a17c863cb9d5438d,present using the following search terms,0.394376
uuid-640fe9ecc63e40799596a25e464f3291,Bristol-Myers Squibb,0.453576
uuid-640fe9ecc63e40799596a25e464f3291,evaluating,0.57188
uuid-640fe9ecc63e40799596a25e464f3291,not conducted any controlled clinical trials/studies,0.523316
uuid-640fe9ecc63e40799596a25e464f3291,efficacy,0.30015
uuid-640fe9ecc63e40799596a25e464f3291,NSCLC,0.748072
uuid-640fe9ecc63e40799596a25e464f3291,non-small cell lung cancer,0.766403
uuid-640fe9ecc63e40799596a25e464f3291,considered investigational,0.326263
uuid-640fe9ecc63e40799596a25e464f3291,phase 3 study,0.386351
uuid-640fe9ecc63e40799596a25e464f3291,phase 1 study,0.387895
uuid-640fe9ecc63e40799596a25e464f3291,Rizvi NA,0.306173
uuid-640fe9ecc63e40799596a25e464f3291,efficacy and safety of nivolumab,0.514479
uuid-640fe9ecc63e40799596a25e464f3291,safety of nivolumab monotherapy,0.443947
uuid-640fe9ecc63e40799596a25e464f3291,platinum-based doublet chemotherapy,0.487131
uuid-7c09a4c77d674a09ac182f6ab149aacf,ASCO,0.666061
uuid-7c09a4c77d674a09ac182f6ab149aacf,ESMO,0.423414
uuid-7c09a4c77d674a09ac182f6ab149aacf,Brahmer J,0.323166
uuid-7c09a4c77d674a09ac182f6ab149aacf,Horn L,0.506905
uuid-a52f733a6edd4849b4da60f9ef9f67ea,OS,0.62262
uuid-a52f733a6edd4849b4da60f9ef9f67ea,PFS,0.65903
uuid-a52f733a6edd4849b4da60f9ef9f67ea,Overall survival,0.644151
uuid-63be02a6e6f24fc59f0e4b14ebdcd7cf,fatigue,0.323475
uuid-e82b1ae67ec84d81b2090d92148878a2,adverse,0.416199
uuid-1f1daede43d7493c938799631a2f16ca,Bristol-Myers Squibb,0.341822
uuid-1f1daede43d7493c938799631a2f16ca,not conducted any controlled clinical trials/studies,0.304507
uuid-1f1daede43d7493c938799631a2f16ca,Opdivo,0.461382
uuid-1f1daede43d7493c938799631a2f16ca,Pubmed literature search,0.614325
uuid-1f1daede43d7493c938799631a2f16ca,purposes other than its labeled indication must be considered investigational,0.586645
uuid-1f1daede43d7493c938799631a2f16ca,not identify any citations relevant to your inquiry,0.606087
uuid-1f1daede43d7493c938799631a2f16ca,adverse,0.304183
uuid-1f1daede43d7493c938799631a2f16ca,using the following search terms,0.642331
uuid-1f1daede43d7493c938799631a2f16ca,databases,0.315039
uuid-1f1daede43d7493c938799631a2f16ca,reported,0.556704
uuid-821b556e3ad44313b16505aff732a4ae,nivolumab,0.368052
uuid-aa21c5b603644dc1aab2b513d70fb4ae,Bristol-Myers Squibb,0.494637
uuid-5a33b2e729034bba9c688c8074599488,OS,0.493645
uuid-5a33b2e729034bba9c688c8074599488,95% CI,0.855936
uuid-5a33b2e729034bba9c688c8074599488,respectively,0.645107
uuid-5a33b2e729034bba9c688c8074599488,Objective response rate,0.625246
uuid-5a33b2e729034bba9c688c8074599488,ORR,0.786651
uuid-5a33b2e729034bba9c688c8074599488,PFS,0.347896
uuid-5a33b2e729034bba9c688c8074599488,Median overall survival,0.810365
uuid-5a33b2e729034bba9c688c8074599488,monotherapy,0.48658
uuid-5a33b2e729034bba9c688c8074599488,Median OS,0.80248
uuid-5a33b2e729034bba9c688c8074599488,docetaxel,0.378001
uuid-5a33b2e729034bba9c688c8074599488,hazard ratio,0.823604
uuid-5a33b2e729034bba9c688c8074599488,Median duration of response,0.338212
uuid-41022c9153de49e99f8121d988519bb6,adverse,0.489809
uuid-41022c9153de49e99f8121d988519bb6,reported,0.316138
uuid-972a08a053904757877a17ccc229a5e6,Bristol-Myers Squibb,0.840451
uuid-972a08a053904757877a17ccc229a5e6,evaluating,0.718784
uuid-972a08a053904757877a17ccc229a5e6,not conducted any controlled clinical trials/studies,0.798502
uuid-972a08a053904757877a17ccc229a5e6,adverse,0.316881
uuid-972a08a053904757877a17ccc229a5e6,efficacy and safety of nivolumab,0.640661
uuid-972a08a053904757877a17ccc229a5e6,reported,0.342563
uuid-2f8b3cb1c96e439c849bc35a0b066c3a,Bristol-Myers Squibb,0.494637
uuid-46abe6323c104d58982c68b080d0b0df,patients,0.395956
uuid-46abe6323c104d58982c68b080d0b0df,phase 1 study,0.457468
uuid-46abe6323c104d58982c68b080d0b0df,efficacy and safety of nivolumab,0.303882
uuid-46abe6323c104d58982c68b080d0b0df,mg,0.434942
uuid-46abe6323c104d58982c68b080d0b0df,CA209-003,0.447389
uuid-46abe6323c104d58982c68b080d0b0df,kg,0.406757
uuid-46abe6323c104d58982c68b080d0b0df,investigating,0.337579
uuid-406cee62818a445caf9c0ea4bbbfc36d,Bristol-Myers Squibb,0.494637
uuid-cc17468b34b345d7966042996578fcf1,Bristol-Myers Squibb,0.344205
uuid-cc17468b34b345d7966042996578fcf1,patients,0.378339
uuid-cc17468b34b345d7966042996578fcf1,adverse,0.739229
uuid-cc17468b34b345d7966042996578fcf1,reported,0.643575
uuid-c9a4e905b4a4406caef4cb54d67db61f,Bristol-Myers Squibb,0.527629
uuid-c9a4e905b4a4406caef4cb54d67db61f,evaluating,0.358225
uuid-c9a4e905b4a4406caef4cb54d67db61f,not conducted any controlled clinical trials/studies,0.427177
uuid-c9a4e905b4a4406caef4cb54d67db61f,efficacy and safety of nivolumab,0.326774
uuid-483646cac4564bfb8aab6c45fc4330f3,use of nivolumab for the treatment,0.435597
uuid-483646cac4564bfb8aab6c45fc4330f3,efficacy,0.459317
uuid-483646cac4564bfb8aab6c45fc4330f3,not approved,0.558926
uuid-483646cac4564bfb8aab6c45fc4330f3,clinical trials investigating the safety,0.598064
uuid-483646cac4564bfb8aab6c45fc4330f3,clinicaltrials.gov,0.437497
uuid-483646cac4564bfb8aab6c45fc4330f3,safety of nivolumab monotherapy,0.303846
uuid-483646cac4564bfb8aab6c45fc4330f3,bladder cancer,0.44905
uuid-df24836b5555437bb2724934a507801c,nivolumab,0.333749
uuid-df24836b5555437bb2724934a507801c,patients,0.39326
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,N Engl J Med,0.47446
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,protocol,0.775143
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,McDermott DF,0.756118
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,Motzer RJ,0.827454
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,phase 3 study,0.422813
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,Escudier B,0.764532
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,NEJM,0.403986
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,et al.,0.688347
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,J Clin Oncol,0.796776
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,Topalian,0.391537
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,phase 1 study,0.491683
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,CA209-003,0.556088
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,phase 2 study,0.690687
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,present using the following search terms,0.310671
uuid-4d4e3dacd8a94af788ad6bc7df3bf8fe,investigating,0.600457
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,N Engl J Med,0.304989
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,AEs,0.337832
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,patients,0.387033
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,provided in the Detailed Information,0.370845
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,ESMO,0.421367
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,NEJM,0.709799
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,Topalian,0.735417
uuid-92ab29e4957f4bb0aa519b0f95f08ea1,grade 3 to 4 AEs,0.538198
uuid-e127231756ff4a48934d17cbdfe786d6,trial,0.41505
uuid-79358cca1d2d47d0abd9bc1962510704,melanoma,0.375771
uuid-fd1ab428c7c64213a580f4ef7f826f9a,use of nivolumab for the treatment,0.32305
uuid-fd1ab428c7c64213a580f4ef7f826f9a,efficacy,0.300968
uuid-fd1ab428c7c64213a580f4ef7f826f9a,search of published literature,0.353774
uuid-fd1ab428c7c64213a580f4ef7f826f9a,PubMed and EMBASE,0.360867
uuid-fd1ab428c7c64213a580f4ef7f826f9a,not approved,0.439754
uuid-fd1ab428c7c64213a580f4ef7f826f9a,clinical trials investigating the safety,0.535828
uuid-fd1ab428c7c64213a580f4ef7f826f9a,trial,0.49328
uuid-fd1ab428c7c64213a580f4ef7f826f9a,present using the following search terms,0.378905
uuid-9dd6fd5e888b4014a7f2801f6ce642fd,nivolumab,0.359772
uuid-cc91ed9700de4d38ae3c892b65e10c5e,requested,0.435523
uuid-691447e7dbd64c858b8153d2bd1b8801,Bristol-Myers Squibb,0.396137
uuid-691447e7dbd64c858b8153d2bd1b8801,requested,0.827977
uuid-a981119fb22b469a8cd33a200d5925bc,nivolumab,0.515365
uuid-a981119fb22b469a8cd33a200d5925bc,Bristol-Myers Squibb,0.443787
uuid-a981119fb22b469a8cd33a200d5925bc,evaluating,0.591523
uuid-a981119fb22b469a8cd33a200d5925bc,not conducted any controlled clinical trials/studies,0.654469
uuid-a981119fb22b469a8cd33a200d5925bc,Pubmed literature search,0.871714
uuid-a981119fb22b469a8cd33a200d5925bc,purposes other than its labeled indication must be considered investigational,0.932881
uuid-a981119fb22b469a8cd33a200d5925bc,not identify any citations relevant to your inquiry,0.83429
uuid-a981119fb22b469a8cd33a200d5925bc,using the following search terms,0.818083
uuid-a981119fb22b469a8cd33a200d5925bc,efficacy and safety of nivolumab,0.418418
uuid-7bee8fd2b6ef4f58b3600e776730102a,nivolumab,0.523959
uuid-7bee8fd2b6ef4f58b3600e776730102a,Bristol-Myers Squibb,0.421442
uuid-7bee8fd2b6ef4f58b3600e776730102a,evaluating,0.574159
uuid-7bee8fd2b6ef4f58b3600e776730102a,not conducted any controlled clinical trials/studies,0.62808
uuid-7bee8fd2b6ef4f58b3600e776730102a,Pubmed literature search,0.860622
uuid-7bee8fd2b6ef4f58b3600e776730102a,purposes other than its labeled indication must be considered investigational,0.921091
uuid-7bee8fd2b6ef4f58b3600e776730102a,not identify any citations relevant to your inquiry,0.827125
uuid-7bee8fd2b6ef4f58b3600e776730102a,using the following search terms,0.809064
uuid-7bee8fd2b6ef4f58b3600e776730102a,efficacy and safety of nivolumab,0.394521
uuid-18285c3f6b2c41eda511c59d50cfaaad,N Engl J Med,0.5218
uuid-18285c3f6b2c41eda511c59d50cfaaad,protocol,0.822129
uuid-18285c3f6b2c41eda511c59d50cfaaad,RCC,0.351265
uuid-18285c3f6b2c41eda511c59d50cfaaad,McDermott DF,0.805326
uuid-18285c3f6b2c41eda511c59d50cfaaad,search of published literature,0.328584
uuid-18285c3f6b2c41eda511c59d50cfaaad,Motzer RJ,0.830191
uuid-18285c3f6b2c41eda511c59d50cfaaad,phase 3 study,0.375845
uuid-18285c3f6b2c41eda511c59d50cfaaad,PubMed and EMBASE,0.327895
uuid-18285c3f6b2c41eda511c59d50cfaaad,Escudier B,0.815105
uuid-18285c3f6b2c41eda511c59d50cfaaad,NEJM,0.388967
uuid-18285c3f6b2c41eda511c59d50cfaaad,et al.,0.745528
uuid-18285c3f6b2c41eda511c59d50cfaaad,J Clin Oncol,0.787871
uuid-18285c3f6b2c41eda511c59d50cfaaad,Topalian,0.347249
uuid-18285c3f6b2c41eda511c59d50cfaaad,Rizvi NA,0.308297
uuid-18285c3f6b2c41eda511c59d50cfaaad,phase 2 study,0.670697
uuid-18285c3f6b2c41eda511c59d50cfaaad,present using the following search terms,0.304579
uuid-aba204c802fb412fa3e83e776b168715,nivolumab,0.53306
uuid-aba204c802fb412fa3e83e776b168715,Bristol-Myers Squibb,0.438995
uuid-aba204c802fb412fa3e83e776b168715,evaluating,0.613925
uuid-aba204c802fb412fa3e83e776b168715,not conducted any controlled clinical trials/studies,0.665227
uuid-aba204c802fb412fa3e83e776b168715,Pubmed literature search,0.859215
uuid-aba204c802fb412fa3e83e776b168715,purposes other than its labeled indication must be considered investigational,0.922294
uuid-aba204c802fb412fa3e83e776b168715,not identify any citations relevant to your inquiry,0.824251
uuid-aba204c802fb412fa3e83e776b168715,using the following search terms,0.808119
uuid-aba204c802fb412fa3e83e776b168715,efficacy and safety of nivolumab,0.467407
uuid-0216ec2085794fcbb3def6dfc61969dd,patients,0.538518
uuid-0216ec2085794fcbb3def6dfc61969dd,Opdivo,0.663525
uuid-0216ec2085794fcbb3def6dfc61969dd,trial,0.3927
uuid-ab4db1922f4f42f99eed5f578619d0f9,safety,0.981862
uuid-ab4db1922f4f42f99eed5f578619d0f9,databases,0.875208
uuid-27f595f40146481f833720fb387a0295,Opdivo,0.822137
uuid-27f595f40146481f833720fb387a0295,trial,0.464755
uuid-de983b742c734c5eb7c26a051a5da115,N Engl J Med,0.616113
uuid-de983b742c734c5eb7c26a051a5da115,protocol,0.97724
uuid-de983b742c734c5eb7c26a051a5da115,McDermott DF,0.883388
uuid-de983b742c734c5eb7c26a051a5da115,Motzer RJ,0.925001
uuid-de983b742c734c5eb7c26a051a5da115,phase 3 study,0.419481
uuid-de983b742c734c5eb7c26a051a5da115,Escudier B,0.901881
uuid-de983b742c734c5eb7c26a051a5da115,NEJM,0.473283
uuid-de983b742c734c5eb7c26a051a5da115,et al.,0.82621
uuid-de983b742c734c5eb7c26a051a5da115,J Clin Oncol,0.871247
uuid-de983b742c734c5eb7c26a051a5da115,Topalian,0.420752
uuid-de983b742c734c5eb7c26a051a5da115,Rizvi NA,0.413835
uuid-de983b742c734c5eb7c26a051a5da115,Brahmer J,0.340634
uuid-de983b742c734c5eb7c26a051a5da115,phase 2 study,0.718589
uuid-2afaee71b9e44260bdbea429e5d0f949,Bristol-Myers Squibb,0.587381
uuid-2afaee71b9e44260bdbea429e5d0f949,evaluating,0.426254
uuid-2afaee71b9e44260bdbea429e5d0f949,not conducted any controlled clinical trials/studies,0.490195
uuid-2afaee71b9e44260bdbea429e5d0f949,efficacy and safety of nivolumab,0.405714
uuid-2afaee71b9e44260bdbea429e5d0f949,investigating,0.33363
uuid-1610130567e946fb93d2eb7d6e506a99,Bristol-Myers Squibb,0.48796
uuid-1610130567e946fb93d2eb7d6e506a99,not conducted any controlled clinical trials/studies,0.312448
uuid-202136e27e8d45c393dec984a2eb5523,Opdivo,0.335824
uuid-202136e27e8d45c393dec984a2eb5523,adverse,0.352606
uuid-202136e27e8d45c393dec984a2eb5523,reported,0.490155
uuid-73beee49072a46e885c3db568f2a63bc,OS,0.521365
uuid-73beee49072a46e885c3db568f2a63bc,95% CI,0.919678
uuid-73beee49072a46e885c3db568f2a63bc,respectively,0.467176
uuid-73beee49072a46e885c3db568f2a63bc,Objective response rate,0.59328
uuid-73beee49072a46e885c3db568f2a63bc,ORR,0.741808
uuid-73beee49072a46e885c3db568f2a63bc,PFS,0.393216
uuid-73beee49072a46e885c3db568f2a63bc,Median overall survival,0.883951
uuid-73beee49072a46e885c3db568f2a63bc,monotherapy,0.348005
uuid-73beee49072a46e885c3db568f2a63bc,Median OS,0.858361
uuid-73beee49072a46e885c3db568f2a63bc,hazard ratio,0.902487
uuid-73beee49072a46e885c3db568f2a63bc,Median duration of response,0.411448
uuid-380181b45d404a9c8e6dc281ac67f8ed,nivolumab,0.338201
uuid-380181b45d404a9c8e6dc281ac67f8ed,clinical,0.37246
uuid-380181b45d404a9c8e6dc281ac67f8ed,trial,0.411216
uuid-f063299e0c2d4e429f72e7831f7e7120,respectively,0.620512
uuid-f063299e0c2d4e429f72e7831f7e7120,Objective response rate,0.576635
uuid-f063299e0c2d4e429f72e7831f7e7120,ORR,0.49411
uuid-f063299e0c2d4e429f72e7831f7e7120,monotherapy,0.415747
uuid-f063299e0c2d4e429f72e7831f7e7120,docetaxel,0.39867
uuid-f2f1cd65f5d04f67a43d338e4406184f,nivolumab,0.332928
uuid-318c2921b7954e2ab0da992da8b65600,melanoma,0.410364
uuid-6eb11da688e844938e33c8c4926a8ff8,nivolumab,0.751926
uuid-6eb11da688e844938e33c8c4926a8ff8,Bristol-Myers Squibb,0.512364
uuid-6eb11da688e844938e33c8c4926a8ff8,evaluating,0.641688
uuid-6eb11da688e844938e33c8c4926a8ff8,not conducted any controlled clinical trials/studies,0.653538
uuid-6eb11da688e844938e33c8c4926a8ff8,purposes other than its labeled indication must be considered investigational,0.417449
uuid-6eb11da688e844938e33c8c4926a8ff8,search of published literature,0.345132
uuid-6eb11da688e844938e33c8c4926a8ff8,PubMed and EMBASE,0.313635
uuid-6eb11da688e844938e33c8c4926a8ff8,efficacy and safety of nivolumab,0.581398
uuid-6eb11da688e844938e33c8c4926a8ff8,present using the following search terms,0.344108
uuid-783d6710d7044fe89f6029e671f8d02b,provided in the Detailed Information,0.349112
uuid-783d6710d7044fe89f6029e671f8d02b,Weber JS,0.321343
uuid-2c0a0677746f4949a57c808a87b236e7,OS,0.397065
uuid-2c0a0677746f4949a57c808a87b236e7,95% CI,0.637173
uuid-2c0a0677746f4949a57c808a87b236e7,respectively,0.582587
uuid-2c0a0677746f4949a57c808a87b236e7,Objective response rate,0.480294
uuid-2c0a0677746f4949a57c808a87b236e7,ORR,0.659618
uuid-2c0a0677746f4949a57c808a87b236e7,Median overall survival,0.643226
uuid-2c0a0677746f4949a57c808a87b236e7,monotherapy,0.314607
uuid-2c0a0677746f4949a57c808a87b236e7,ESMO,0.344149
uuid-2c0a0677746f4949a57c808a87b236e7,Median OS,0.624209
uuid-2c0a0677746f4949a57c808a87b236e7,docetaxel,0.378986
uuid-2c0a0677746f4949a57c808a87b236e7,hazard ratio,0.611629
uuid-174c2c2347c14ab49d503362b260475b,efficacy,0.339275
uuid-174c2c2347c14ab49d503362b260475b,not approved,0.432879
uuid-174c2c2347c14ab49d503362b260475b,clinical trials investigating the safety,0.520254
uuid-9c2672d2d0254fe9bc833bf9639c1cad,requested,0.356419
uuid-83ebdec67bcd47358672d2829a0e036c,provided in the Detailed Information,0.400287
uuid-83ebdec67bcd47358672d2829a0e036c,Weber JS,0.400318
uuid-451bf5f1818b4e479106390e452f48db,Bristol-Myers Squibb,0.341822
uuid-451bf5f1818b4e479106390e452f48db,not conducted any controlled clinical trials/studies,0.304507
uuid-451bf5f1818b4e479106390e452f48db,Opdivo,0.461382
uuid-451bf5f1818b4e479106390e452f48db,Pubmed literature search,0.614325
uuid-451bf5f1818b4e479106390e452f48db,purposes other than its labeled indication must be considered investigational,0.586645
uuid-451bf5f1818b4e479106390e452f48db,not identify any citations relevant to your inquiry,0.606087
uuid-451bf5f1818b4e479106390e452f48db,adverse,0.304183
uuid-451bf5f1818b4e479106390e452f48db,using the following search terms,0.642331
uuid-451bf5f1818b4e479106390e452f48db,databases,0.315039
uuid-451bf5f1818b4e479106390e452f48db,reported,0.556704
uuid-6fee17ab56bf44d19fd0abbbe623ad26,evaluating,0.331463
uuid-6fee17ab56bf44d19fd0abbbe623ad26,not conducted any controlled clinical trials/studies,0.327968
uuid-6fee17ab56bf44d19fd0abbbe623ad26,protocol,0.532972
uuid-6fee17ab56bf44d19fd0abbbe623ad26,RCC,0.386451
uuid-6fee17ab56bf44d19fd0abbbe623ad26,McDermott DF,0.444329
uuid-6fee17ab56bf44d19fd0abbbe623ad26,search of published literature,0.50452
uuid-6fee17ab56bf44d19fd0abbbe623ad26,Additionally,0.555299
uuid-6fee17ab56bf44d19fd0abbbe623ad26,ongoing,0.478674
uuid-6fee17ab56bf44d19fd0abbbe623ad26,Motzer RJ,0.475488
uuid-6fee17ab56bf44d19fd0abbbe623ad26,PubMed and EMBASE,0.501909
uuid-6fee17ab56bf44d19fd0abbbe623ad26,Escudier B,0.459186
uuid-6fee17ab56bf44d19fd0abbbe623ad26,et al.,0.397016
uuid-6fee17ab56bf44d19fd0abbbe623ad26,J Clin Oncol,0.428996
uuid-6fee17ab56bf44d19fd0abbbe623ad26,detailed search of www.clinicaltrials.gov,0.514934
uuid-6fee17ab56bf44d19fd0abbbe623ad26,efficacy and safety of nivolumab,0.47512
uuid-6fee17ab56bf44d19fd0abbbe623ad26,not identify any planned,0.493147
uuid-6fee17ab56bf44d19fd0abbbe623ad26,phase 2 study,0.384586
uuid-6fee17ab56bf44d19fd0abbbe623ad26,not identify any citations relevant to your request,0.565812
uuid-6fee17ab56bf44d19fd0abbbe623ad26,present using the following search terms,0.490802
uuid-bc68e9af5ede475a835ff1c96e22d278,N Engl J Med,0.673548
uuid-bc68e9af5ede475a835ff1c96e22d278,Lancet Oncol,0.350563
uuid-bc68e9af5ede475a835ff1c96e22d278,protocol,0.837793
uuid-bc68e9af5ede475a835ff1c96e22d278,McDermott DF,0.912384
uuid-bc68e9af5ede475a835ff1c96e22d278,Motzer RJ,0.895454
uuid-bc68e9af5ede475a835ff1c96e22d278,phase 3 study,0.484739
uuid-bc68e9af5ede475a835ff1c96e22d278,Escudier B,0.908217
uuid-bc68e9af5ede475a835ff1c96e22d278,NEJM,0.491067
uuid-bc68e9af5ede475a835ff1c96e22d278,et al.,0.901246
uuid-bc68e9af5ede475a835ff1c96e22d278,J Clin Oncol,0.862956
uuid-bc68e9af5ede475a835ff1c96e22d278,Topalian,0.429989
uuid-bc68e9af5ede475a835ff1c96e22d278,phase 1 study,0.302978
uuid-bc68e9af5ede475a835ff1c96e22d278,Rizvi NA,0.485777
uuid-bc68e9af5ede475a835ff1c96e22d278,Brahmer J,0.342618
uuid-bc68e9af5ede475a835ff1c96e22d278,Weber JS,0.307765
uuid-bc68e9af5ede475a835ff1c96e22d278,phase 2 study,0.81115
uuid-f7752f116a884e83847fc2739f937ee4,nivolumab,0.359772
uuid-70e5468376944c99b91de1287bc55fef,use of nivolumab for the treatment,0.409821
uuid-70e5468376944c99b91de1287bc55fef,patients with advanced or metastatic,0.645244
uuid-70e5468376944c99b91de1287bc55fef,nivolumab combined with ipilimumab,0.676339
uuid-70e5468376944c99b91de1287bc55fef,not approved,0.453534
uuid-70e5468376944c99b91de1287bc55fef,clinical trials investigating the safety,0.548799
uuid-70e5468376944c99b91de1287bc55fef,phase 1/2 study CA209-032,0.34114
uuid-70e5468376944c99b91de1287bc55fef,bladder cancer,0.749142
uuid-70e5468376944c99b91de1287bc55fef,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-c5e4d7d08bea4f41b09948102849fae0,95% CI,0.419478
uuid-c5e4d7d08bea4f41b09948102849fae0,respectively,0.497608
uuid-c5e4d7d08bea4f41b09948102849fae0,Objective response rate,0.403649
uuid-c5e4d7d08bea4f41b09948102849fae0,ORR,0.578109
uuid-c5e4d7d08bea4f41b09948102849fae0,patients with advanced or metastatic,0.306625
uuid-c5e4d7d08bea4f41b09948102849fae0,Median overall survival,0.498783
uuid-c5e4d7d08bea4f41b09948102849fae0,nivolumab combined with ipilimumab,0.300486
uuid-c5e4d7d08bea4f41b09948102849fae0,tumors,0.323334
uuid-c5e4d7d08bea4f41b09948102849fae0,ESMO,0.534361
uuid-c5e4d7d08bea4f41b09948102849fae0,Median OS,0.394058
uuid-c5e4d7d08bea4f41b09948102849fae0,small cell lung cancer,0.380999
uuid-c5e4d7d08bea4f41b09948102849fae0,SCLC,0.365686
uuid-c5e4d7d08bea4f41b09948102849fae0,hazard ratio,0.419392
uuid-c5e4d7d08bea4f41b09948102849fae0,grade 3 to 4 AEs,0.414535
uuid-c5e4d7d08bea4f41b09948102849fae0,phase 1/2 study CA209-032,0.398283
uuid-c5e4d7d08bea4f41b09948102849fae0,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-bc0373c6e13d4ca3ab2f7cd792caeafb,Objective response rate,0.451139
uuid-bc0373c6e13d4ca3ab2f7cd792caeafb,clinicaltrials.gov,0.503706
uuid-46f981fb1cd44242949e5fe7c395bd91,requested,0.702613
uuid-117f0562f0284eda9ae9d8750eb491c0,95% CI,0.419478
uuid-117f0562f0284eda9ae9d8750eb491c0,respectively,0.497608
uuid-117f0562f0284eda9ae9d8750eb491c0,Objective response rate,0.403649
uuid-117f0562f0284eda9ae9d8750eb491c0,ORR,0.578109
uuid-117f0562f0284eda9ae9d8750eb491c0,patients with advanced or metastatic,0.306625
uuid-117f0562f0284eda9ae9d8750eb491c0,Median overall survival,0.498783
uuid-117f0562f0284eda9ae9d8750eb491c0,nivolumab combined with ipilimumab,0.300486
uuid-117f0562f0284eda9ae9d8750eb491c0,tumors,0.323334
uuid-117f0562f0284eda9ae9d8750eb491c0,ESMO,0.534361
uuid-117f0562f0284eda9ae9d8750eb491c0,Median OS,0.394058
uuid-117f0562f0284eda9ae9d8750eb491c0,small cell lung cancer,0.380999
uuid-117f0562f0284eda9ae9d8750eb491c0,SCLC,0.365686
uuid-117f0562f0284eda9ae9d8750eb491c0,hazard ratio,0.419392
uuid-117f0562f0284eda9ae9d8750eb491c0,grade 3 to 4 AEs,0.414535
uuid-117f0562f0284eda9ae9d8750eb491c0,phase 1/2 study CA209-032,0.398283
uuid-117f0562f0284eda9ae9d8750eb491c0,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-ebcdee1bce63452cbf8896d3a2aff49b,use of nivolumab for the treatment,0.369098
uuid-ebcdee1bce63452cbf8896d3a2aff49b,efficacy,0.37457
uuid-ebcdee1bce63452cbf8896d3a2aff49b,Opdivo,0.449594
uuid-ebcdee1bce63452cbf8896d3a2aff49b,not approved,0.424233
uuid-ebcdee1bce63452cbf8896d3a2aff49b,clinical trials investigating the safety,0.417409
uuid-cf47837e2e0c44bd8ce478f6885b9db8,requested,0.591997
uuid-9ef09a0ebf3b4f708e6fc5fcbdaa2d07,Objective response rate,0.441907
uuid-9ef09a0ebf3b4f708e6fc5fcbdaa2d07,clinicaltrials.gov,0.508609
uuid-89fbc1be11d14cc4a172f0e1eb60321b,95% CI,0.419478
uuid-89fbc1be11d14cc4a172f0e1eb60321b,respectively,0.497608
uuid-89fbc1be11d14cc4a172f0e1eb60321b,Objective response rate,0.403649
uuid-89fbc1be11d14cc4a172f0e1eb60321b,ORR,0.578109
uuid-89fbc1be11d14cc4a172f0e1eb60321b,patients with advanced or metastatic,0.306625
uuid-89fbc1be11d14cc4a172f0e1eb60321b,Median overall survival,0.498783
uuid-89fbc1be11d14cc4a172f0e1eb60321b,nivolumab combined with ipilimumab,0.300486
uuid-89fbc1be11d14cc4a172f0e1eb60321b,tumors,0.323334
uuid-89fbc1be11d14cc4a172f0e1eb60321b,ESMO,0.534361
uuid-89fbc1be11d14cc4a172f0e1eb60321b,Median OS,0.394058
uuid-89fbc1be11d14cc4a172f0e1eb60321b,small cell lung cancer,0.380999
uuid-89fbc1be11d14cc4a172f0e1eb60321b,SCLC,0.365686
uuid-89fbc1be11d14cc4a172f0e1eb60321b,hazard ratio,0.419392
uuid-89fbc1be11d14cc4a172f0e1eb60321b,grade 3 to 4 AEs,0.414535
uuid-89fbc1be11d14cc4a172f0e1eb60321b,phase 1/2 study CA209-032,0.398283
uuid-89fbc1be11d14cc4a172f0e1eb60321b,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-4aa58ae1d0284a058e8fc85331639fbe,N Engl J Med,0.736537
uuid-4aa58ae1d0284a058e8fc85331639fbe,Lancet Oncol,0.412554
uuid-4aa58ae1d0284a058e8fc85331639fbe,protocol,0.498467
uuid-4aa58ae1d0284a058e8fc85331639fbe,McDermott DF,0.527343
uuid-4aa58ae1d0284a058e8fc85331639fbe,Motzer RJ,0.486874
uuid-4aa58ae1d0284a058e8fc85331639fbe,phase 3 study,0.539239
uuid-4aa58ae1d0284a058e8fc85331639fbe,Escudier B,0.522059
uuid-4aa58ae1d0284a058e8fc85331639fbe,et al.,0.50848
uuid-4aa58ae1d0284a058e8fc85331639fbe,J Clin Oncol,0.444735
uuid-4aa58ae1d0284a058e8fc85331639fbe,Rizvi NA,0.663369
uuid-4aa58ae1d0284a058e8fc85331639fbe,Brahmer J,0.697776
uuid-4aa58ae1d0284a058e8fc85331639fbe,Weber JS,0.406207
uuid-4aa58ae1d0284a058e8fc85331639fbe,BMS,0.495407
uuid-4aa58ae1d0284a058e8fc85331639fbe,phase 2 study,0.655158
uuid-14de41a85a724f7a8dcdba8b70e82d47,Bristol-Myers Squibb,0.398191
uuid-14de41a85a724f7a8dcdba8b70e82d47,requested,0.827269
uuid-df2d26223ed94080a570a5f731f4c1fc,nivolumab,0.360563
uuid-5597528ae99840bb970bc4f30856502f,provided in the Detailed Information,0.349112
uuid-5597528ae99840bb970bc4f30856502f,Weber JS,0.321343
uuid-8fbd3c16268b484aaa63c8777463dfd1,nivolumab,0.356017
uuid-8fbd3c16268b484aaa63c8777463dfd1,evaluating,0.317183
uuid-8fbd3c16268b484aaa63c8777463dfd1,not conducted any controlled clinical trials/studies,0.350654
uuid-8fbd3c16268b484aaa63c8777463dfd1,Pubmed literature search,0.554789
uuid-8fbd3c16268b484aaa63c8777463dfd1,purposes other than its labeled indication must be considered investigational,0.585644
uuid-8fbd3c16268b484aaa63c8777463dfd1,not identify any citations relevant to your inquiry,0.552002
uuid-8fbd3c16268b484aaa63c8777463dfd1,open-label,0.426008
uuid-8fbd3c16268b484aaa63c8777463dfd1,using the following search terms,0.527471
uuid-9df1828671aa4fc59388c85b066af1bf,N Engl J Med,0.47446
uuid-9df1828671aa4fc59388c85b066af1bf,protocol,0.775143
uuid-9df1828671aa4fc59388c85b066af1bf,McDermott DF,0.756118
uuid-9df1828671aa4fc59388c85b066af1bf,Motzer RJ,0.827454
uuid-9df1828671aa4fc59388c85b066af1bf,phase 3 study,0.422813
uuid-9df1828671aa4fc59388c85b066af1bf,Escudier B,0.764532
uuid-9df1828671aa4fc59388c85b066af1bf,NEJM,0.403986
uuid-9df1828671aa4fc59388c85b066af1bf,et al.,0.688347
uuid-9df1828671aa4fc59388c85b066af1bf,J Clin Oncol,0.796776
uuid-9df1828671aa4fc59388c85b066af1bf,Topalian,0.391537
uuid-9df1828671aa4fc59388c85b066af1bf,phase 1 study,0.491683
uuid-9df1828671aa4fc59388c85b066af1bf,CA209-003,0.556088
uuid-9df1828671aa4fc59388c85b066af1bf,phase 2 study,0.690687
uuid-9df1828671aa4fc59388c85b066af1bf,present using the following search terms,0.310671
uuid-9df1828671aa4fc59388c85b066af1bf,investigating,0.600457
uuid-999d7047350e49cfb990f3be60dc5cef,Bristol-Myers Squibb,0.341822
uuid-999d7047350e49cfb990f3be60dc5cef,not conducted any controlled clinical trials/studies,0.304507
uuid-999d7047350e49cfb990f3be60dc5cef,Opdivo,0.461382
uuid-999d7047350e49cfb990f3be60dc5cef,Pubmed literature search,0.614325
uuid-999d7047350e49cfb990f3be60dc5cef,purposes other than its labeled indication must be considered investigational,0.586645
uuid-999d7047350e49cfb990f3be60dc5cef,not identify any citations relevant to your inquiry,0.606087
uuid-999d7047350e49cfb990f3be60dc5cef,adverse,0.304183
uuid-999d7047350e49cfb990f3be60dc5cef,using the following search terms,0.642331
uuid-999d7047350e49cfb990f3be60dc5cef,databases,0.315039
uuid-999d7047350e49cfb990f3be60dc5cef,reported,0.556704
uuid-4401c200dc77455fb566d7bbf5310806,nivolumab,0.516632
uuid-4401c200dc77455fb566d7bbf5310806,Bristol-Myers Squibb,0.355189
uuid-4401c200dc77455fb566d7bbf5310806,evaluating,0.455247
uuid-4401c200dc77455fb566d7bbf5310806,not conducted any controlled clinical trials/studies,0.432479
uuid-4401c200dc77455fb566d7bbf5310806,not approved,0.34439
uuid-4401c200dc77455fb566d7bbf5310806,clinical trials investigating the safety,0.389627
uuid-4401c200dc77455fb566d7bbf5310806,efficacy and safety of nivolumab,0.400287
uuid-2f56bfd27ca74aa598b95896a7261b4f,Objective response rate,0.451139
uuid-2f56bfd27ca74aa598b95896a7261b4f,clinicaltrials.gov,0.503706
uuid-ede91b3174454d1fa8cfabb9734a2e20,N Engl J Med,0.714946
uuid-ede91b3174454d1fa8cfabb9734a2e20,Lancet Oncol,0.448679
uuid-ede91b3174454d1fa8cfabb9734a2e20,patients,0.309769
uuid-ede91b3174454d1fa8cfabb9734a2e20,protocol,0.700662
uuid-ede91b3174454d1fa8cfabb9734a2e20,McDermott DF,0.68799
uuid-ede91b3174454d1fa8cfabb9734a2e20,Motzer RJ,0.689932
uuid-ede91b3174454d1fa8cfabb9734a2e20,phase 3 study,0.545628
uuid-ede91b3174454d1fa8cfabb9734a2e20,Escudier B,0.698812
uuid-ede91b3174454d1fa8cfabb9734a2e20,NEJM,0.402095
uuid-ede91b3174454d1fa8cfabb9734a2e20,et al.,0.640511
uuid-ede91b3174454d1fa8cfabb9734a2e20,J Clin Oncol,0.626106
uuid-ede91b3174454d1fa8cfabb9734a2e20,Topalian,0.37979
uuid-ede91b3174454d1fa8cfabb9734a2e20,phase 1 study,0.381282
uuid-ede91b3174454d1fa8cfabb9734a2e20,Rizvi NA,0.636006
uuid-ede91b3174454d1fa8cfabb9734a2e20,Brahmer J,0.517174
uuid-ede91b3174454d1fa8cfabb9734a2e20,efficacy and safety of nivolumab,0.368444
uuid-ede91b3174454d1fa8cfabb9734a2e20,Weber JS,0.406071
uuid-ede91b3174454d1fa8cfabb9734a2e20,phase 2 study,0.692115
uuid-69649cbee1644e9b94e1741834eac5ae,use of nivolumab for the treatment,0.305739
uuid-69649cbee1644e9b94e1741834eac5ae,patients with advanced or metastatic,0.509457
uuid-69649cbee1644e9b94e1741834eac5ae,nivolumab combined with ipilimumab,0.496885
uuid-69649cbee1644e9b94e1741834eac5ae,not approved,0.397631
uuid-69649cbee1644e9b94e1741834eac5ae,clinical trials investigating the safety,0.478965
uuid-69649cbee1644e9b94e1741834eac5ae,bladder cancer,0.940126
uuid-947cd4ba821245149727e90af793ef86,N Engl J Med,0.302601
uuid-947cd4ba821245149727e90af793ef86,AEs,0.348167
uuid-947cd4ba821245149727e90af793ef86,patients,0.536884
uuid-947cd4ba821245149727e90af793ef86,provided in the Detailed Information,0.387544
uuid-947cd4ba821245149727e90af793ef86,ESMO,0.462801
uuid-947cd4ba821245149727e90af793ef86,NEJM,0.66427
uuid-947cd4ba821245149727e90af793ef86,Topalian,0.692873
uuid-947cd4ba821245149727e90af793ef86,grade 3 to 4 AEs,0.626596
uuid-44fbc5d7a19e4b6dbb8f06b961d18e0e,melanoma,0.410364
uuid-a1db01ff1c8b4683b15d35bcdea4828a,Bristol-Myers Squibb,0.625349
uuid-a1db01ff1c8b4683b15d35bcdea4828a,evaluating,0.495994
uuid-a1db01ff1c8b4683b15d35bcdea4828a,not conducted any controlled clinical trials/studies,0.535789
uuid-a1db01ff1c8b4683b15d35bcdea4828a,patients,0.33529
uuid-a1db01ff1c8b4683b15d35bcdea4828a,efficacy and safety of nivolumab,0.445551
uuid-df80fbe0c0ba42398051c0709e421119,N Engl J Med,0.311332
uuid-df80fbe0c0ba42398051c0709e421119,AEs,0.376275
uuid-df80fbe0c0ba42398051c0709e421119,protocol,0.453335
uuid-df80fbe0c0ba42398051c0709e421119,adverse,0.478404
uuid-df80fbe0c0ba42398051c0709e421119,McDermott DF,0.515164
uuid-df80fbe0c0ba42398051c0709e421119,Motzer RJ,0.508371
uuid-df80fbe0c0ba42398051c0709e421119,phase 3 study,0.506039
uuid-df80fbe0c0ba42398051c0709e421119,Escudier B,0.503703
uuid-df80fbe0c0ba42398051c0709e421119,et al.,0.46378
uuid-df80fbe0c0ba42398051c0709e421119,J Clin Oncol,0.495836
uuid-df80fbe0c0ba42398051c0709e421119,CA209-003,0.308672
uuid-df80fbe0c0ba42398051c0709e421119,phase 2 study,0.555271
uuid-df80fbe0c0ba42398051c0709e421119,fatigue,0.456504
uuid-df80fbe0c0ba42398051c0709e421119,reported,0.50733
uuid-3034ba0968044ccb8ce4c024d9bfa752,nivolumab,0.422279
uuid-3034ba0968044ccb8ce4c024d9bfa752,Bristol-Myers Squibb,0.66893
uuid-3034ba0968044ccb8ce4c024d9bfa752,evaluating,0.671029
uuid-3034ba0968044ccb8ce4c024d9bfa752,not conducted any controlled clinical trials/studies,0.760072
uuid-3034ba0968044ccb8ce4c024d9bfa752,Pubmed literature search,0.627676
uuid-3034ba0968044ccb8ce4c024d9bfa752,purposes other than its labeled indication must be considered investigational,0.720345
uuid-3034ba0968044ccb8ce4c024d9bfa752,not identify any citations relevant to your inquiry,0.580218
uuid-3034ba0968044ccb8ce4c024d9bfa752,adverse,0.435412
uuid-3034ba0968044ccb8ce4c024d9bfa752,using the following search terms,0.560926
uuid-3034ba0968044ccb8ce4c024d9bfa752,efficacy and safety of nivolumab,0.515448
uuid-8fbee452e9e84c6fba106bf3541fea98,mg,0.300211
uuid-9569de620d3b488bbf4a6aba4b8f61eb,Bristol-Myers Squibb,0.396793
uuid-9569de620d3b488bbf4a6aba4b8f61eb,requested,0.743312
uuid-9569de620d3b488bbf4a6aba4b8f61eb,Opdivo,0.385736
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,Bristol-Myers Squibb,0.341822
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,not conducted any controlled clinical trials/studies,0.304507
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,Opdivo,0.461382
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,Pubmed literature search,0.614325
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,not identify any citations relevant to your inquiry,0.606087
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,adverse,0.304183
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,using the following search terms,0.642331
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,databases,0.315039
uuid-2fd3ca3737fb4a808db0aaadca01ea4c,reported,0.556704
uuid-a0e0576389ae4914b28c9df4e97fbc7a,N Engl J Med,0.458338
uuid-a0e0576389ae4914b28c9df4e97fbc7a,Lancet Oncol,0.362096
uuid-a0e0576389ae4914b28c9df4e97fbc7a,protocol,0.479296
uuid-a0e0576389ae4914b28c9df4e97fbc7a,McDermott DF,0.517778
uuid-a0e0576389ae4914b28c9df4e97fbc7a,search of published literature,0.340772
uuid-a0e0576389ae4914b28c9df4e97fbc7a,Motzer RJ,0.516084
uuid-a0e0576389ae4914b28c9df4e97fbc7a,phase 3 study,0.757276
uuid-a0e0576389ae4914b28c9df4e97fbc7a,PubMed and EMBASE,0.33824
uuid-a0e0576389ae4914b28c9df4e97fbc7a,Escudier B,0.53257
uuid-a0e0576389ae4914b28c9df4e97fbc7a,et al.,0.497508
uuid-a0e0576389ae4914b28c9df4e97fbc7a,J Clin Oncol,0.429024
uuid-a0e0576389ae4914b28c9df4e97fbc7a,Rizvi NA,0.478676
uuid-a0e0576389ae4914b28c9df4e97fbc7a,Weber JS,0.589818
uuid-a0e0576389ae4914b28c9df4e97fbc7a,phase 2 study,0.616255
uuid-b0a8e900af384f88acd945b28c97a6f7,et al.,0.301352
uuid-9b118d288b014f37b552ae5a7dccb388,patients,0.461004
uuid-9b118d288b014f37b552ae5a7dccb388,PD-L1,0.511425
uuid-08f79e39ff01433aa7fc32d4e7a49209,N Engl J Med,0.372319
uuid-08f79e39ff01433aa7fc32d4e7a49209,protocol,0.393064
uuid-08f79e39ff01433aa7fc32d4e7a49209,McDermott DF,0.411706
uuid-08f79e39ff01433aa7fc32d4e7a49209,Motzer RJ,0.39656
uuid-08f79e39ff01433aa7fc32d4e7a49209,Escudier B,0.416497
uuid-08f79e39ff01433aa7fc32d4e7a49209,et al.,0.414948
uuid-08f79e39ff01433aa7fc32d4e7a49209,J Clin Oncol,0.346208
uuid-08f79e39ff01433aa7fc32d4e7a49209,phase 2 study,0.324391
uuid-060754b7145347299031fe3ebd7b334b,provided in the Detailed Information,0.388544
uuid-060754b7145347299031fe3ebd7b334b,adverse,0.570374
uuid-060754b7145347299031fe3ebd7b334b,Weber JS,0.323481
uuid-e812505c620744fbb35397737ada3246,nivolumab,0.496662
uuid-e812505c620744fbb35397737ada3246,Bristol-Myers Squibb,0.656671
uuid-e812505c620744fbb35397737ada3246,evaluating,0.706633
uuid-e812505c620744fbb35397737ada3246,not conducted any controlled clinical trials/studies,0.755116
uuid-e812505c620744fbb35397737ada3246,Pubmed literature search,0.498746
uuid-e812505c620744fbb35397737ada3246,purposes other than its labeled indication must be considered investigational,0.598636
uuid-e812505c620744fbb35397737ada3246,not identify any citations relevant to your inquiry,0.45886
uuid-e812505c620744fbb35397737ada3246,using the following search terms,0.434411
uuid-e812505c620744fbb35397737ada3246,efficacy and safety of nivolumab,0.582848
uuid-7e389089a4f44b05b6079214afea35fb,Opdivo,0.31248
uuid-7e389089a4f44b05b6079214afea35fb,Pubmed literature search,0.358899
uuid-7e389089a4f44b05b6079214afea35fb,purposes other than its labeled indication must be considered investigational,0.321554
uuid-7e389089a4f44b05b6079214afea35fb,not identify any citations relevant to your inquiry,0.372479
uuid-7e389089a4f44b05b6079214afea35fb,using the following search terms,0.387533
uuid-7e389089a4f44b05b6079214afea35fb,safety,0.574765
uuid-7e389089a4f44b05b6079214afea35fb,databases,0.505386
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,OS,0.520925
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,95% CI,0.873434
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,respectively,0.59658
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,Objective response rate,0.557167
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,ORR,0.753596
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,PFS,0.385476
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,Median overall survival,0.82519
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,monotherapy,0.399269
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,Median OS,0.81215
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,docetaxel,0.364122
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,hazard ratio,0.838351
uuid-9602c0dd57bc4012b9561cb6a3a2bcc8,Median duration of response,0.353132
uuid-8c1df3494fdb4547988d9b45a222a183,adverse,0.339013
uuid-8c1df3494fdb4547988d9b45a222a183,phase 3 study,0.319839
uuid-8c1df3494fdb4547988d9b45a222a183,Rizvi NA,0.364772
uuid-8c1df3494fdb4547988d9b45a222a183,Brahmer J,0.4414
uuid-8c1df3494fdb4547988d9b45a222a183,BMS,0.743077
uuid-8c1df3494fdb4547988d9b45a222a183,reported,0.507787
uuid-e9f94b9393114079b8e0d7d787eac894,nivolumab,0.515891
uuid-e9f94b9393114079b8e0d7d787eac894,Bristol-Myers Squibb,0.336963
uuid-e9f94b9393114079b8e0d7d787eac894,evaluating,0.46824
uuid-e9f94b9393114079b8e0d7d787eac894,not conducted any controlled clinical trials/studies,0.517322
uuid-e9f94b9393114079b8e0d7d787eac894,Pubmed literature search,0.647663
uuid-e9f94b9393114079b8e0d7d787eac894,purposes other than its labeled indication must be considered investigational,0.703515
uuid-e9f94b9393114079b8e0d7d787eac894,not identify any citations relevant to your inquiry,0.631369
uuid-e9f94b9393114079b8e0d7d787eac894,using the following search terms,0.606545
uuid-e9f94b9393114079b8e0d7d787eac894,efficacy and safety of nivolumab,0.382706
uuid-f51f45bd2ee34517ae024f08500a92b5,nivolumab,0.344939
uuid-f51f45bd2ee34517ae024f08500a92b5,Bristol-Myers Squibb,0.363004
uuid-f51f45bd2ee34517ae024f08500a92b5,evaluating,0.564404
uuid-f51f45bd2ee34517ae024f08500a92b5,not conducted any controlled clinical trials/studies,0.538169
uuid-f51f45bd2ee34517ae024f08500a92b5,RCC,0.336118
uuid-f51f45bd2ee34517ae024f08500a92b5,search of published literature,0.750115
uuid-f51f45bd2ee34517ae024f08500a92b5,Additionally,0.766378
uuid-f51f45bd2ee34517ae024f08500a92b5,ongoing,0.629393
uuid-f51f45bd2ee34517ae024f08500a92b5,PubMed and EMBASE,0.745288
uuid-f51f45bd2ee34517ae024f08500a92b5,detailed search of www.clinicaltrials.gov,0.729251
uuid-f51f45bd2ee34517ae024f08500a92b5,efficacy and safety of nivolumab,0.716075
uuid-f51f45bd2ee34517ae024f08500a92b5,not identify any planned,0.665705
uuid-f51f45bd2ee34517ae024f08500a92b5,not identify any citations relevant to your request,0.849476
uuid-f51f45bd2ee34517ae024f08500a92b5,present using the following search terms,0.773092
uuid-413a5305e93c41ba8063ef286b70b3aa,Objective response rate,0.451139
uuid-413a5305e93c41ba8063ef286b70b3aa,clinicaltrials.gov,0.503706
uuid-48051a6d8b204d34a74b6dcd62ff1140,N Engl J Med,0.597594
uuid-48051a6d8b204d34a74b6dcd62ff1140,requested,0.511873
uuid-48051a6d8b204d34a74b6dcd62ff1140,protocol,0.729022
uuid-48051a6d8b204d34a74b6dcd62ff1140,McDermott DF,0.776074
uuid-48051a6d8b204d34a74b6dcd62ff1140,Motzer RJ,0.765196
uuid-48051a6d8b204d34a74b6dcd62ff1140,phase 3 study,0.32548
uuid-48051a6d8b204d34a74b6dcd62ff1140,Escudier B,0.784951
uuid-48051a6d8b204d34a74b6dcd62ff1140,NEJM,0.409396
uuid-48051a6d8b204d34a74b6dcd62ff1140,et al.,0.771066
uuid-48051a6d8b204d34a74b6dcd62ff1140,J Clin Oncol,0.707271
uuid-48051a6d8b204d34a74b6dcd62ff1140,Topalian,0.352286
uuid-48051a6d8b204d34a74b6dcd62ff1140,Rizvi NA,0.343156
uuid-48051a6d8b204d34a74b6dcd62ff1140,phase 2 study,0.624359
uuid-51d025be484741429b1c096b4bc734f1,adverse,0.713454
uuid-51d025be484741429b1c096b4bc734f1,BMS,0.365419
uuid-51d025be484741429b1c096b4bc734f1,reported,0.661447
uuid-8ba2b44fdd0a45279da8eacef9875319,requested,0.703219
uuid-24d31f9078c54952b2b2cdd92c2d2699,Opdivo,0.561272
uuid-8c48b98b28244190b0750a1d561b58a4,evaluating,0.331463
uuid-8c48b98b28244190b0750a1d561b58a4,not conducted any controlled clinical trials/studies,0.327968
uuid-8c48b98b28244190b0750a1d561b58a4,protocol,0.532972
uuid-8c48b98b28244190b0750a1d561b58a4,RCC,0.38645
uuid-8c48b98b28244190b0750a1d561b58a4,McDermott DF,0.44433
uuid-8c48b98b28244190b0750a1d561b58a4,search of published literature,0.504519
uuid-8c48b98b28244190b0750a1d561b58a4,Additionally,0.555298
uuid-8c48b98b28244190b0750a1d561b58a4,ongoing,0.478673
uuid-8c48b98b28244190b0750a1d561b58a4,Motzer RJ,0.475489
uuid-8c48b98b28244190b0750a1d561b58a4,PubMed and EMBASE,0.501909
uuid-8c48b98b28244190b0750a1d561b58a4,Escudier B,0.459187
uuid-8c48b98b28244190b0750a1d561b58a4,et al.,0.397017
uuid-8c48b98b28244190b0750a1d561b58a4,J Clin Oncol,0.428997
uuid-8c48b98b28244190b0750a1d561b58a4,detailed search of www.clinicaltrials.gov,0.514933
uuid-8c48b98b28244190b0750a1d561b58a4,efficacy and safety of nivolumab,0.47512
uuid-8c48b98b28244190b0750a1d561b58a4,not identify any planned,0.493147
uuid-8c48b98b28244190b0750a1d561b58a4,phase 2 study,0.384586
uuid-8c48b98b28244190b0750a1d561b58a4,not identify any citations relevant to your request,0.565811
uuid-8c48b98b28244190b0750a1d561b58a4,present using the following search terms,0.490801
uuid-d3e63046423e4f6584b92ecaf2c061a9,nivolumab,0.576789
uuid-d3e63046423e4f6584b92ecaf2c061a9,Bristol-Myers Squibb,0.475882
uuid-d3e63046423e4f6584b92ecaf2c061a9,evaluating,0.62034
uuid-d3e63046423e4f6584b92ecaf2c061a9,not conducted any controlled clinical trials/studies,0.681164
uuid-d3e63046423e4f6584b92ecaf2c061a9,Pubmed literature search,0.82009
uuid-d3e63046423e4f6584b92ecaf2c061a9,purposes other than its labeled indication must be considered investigational,0.89247
uuid-d3e63046423e4f6584b92ecaf2c061a9,not identify any citations relevant to your inquiry,0.781812
uuid-d3e63046423e4f6584b92ecaf2c061a9,using the following search terms,0.763059
uuid-d3e63046423e4f6584b92ecaf2c061a9,efficacy and safety of nivolumab,0.4681
uuid-0d61e2151d44438cba84b99991750a82,patients with advanced or metastatic,0.478326
uuid-0d61e2151d44438cba84b99991750a82,nivolumab combined with ipilimumab,0.498766
uuid-0d61e2151d44438cba84b99991750a82,not approved,0.34724
uuid-0d61e2151d44438cba84b99991750a82,clinical trials investigating the safety,0.426729
uuid-0d61e2151d44438cba84b99991750a82,bladder cancer,0.6548
uuid-7ca2309bb9c44f52a6fb930b6ec9281d,requested,0.703219
uuid-d7bb2622e42d4149a0584888ae7d0d5d,requested,0.703219
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,N Engl J Med,0.778072
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Lancet Oncol,0.395426
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,protocol,0.833474
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,McDermott DF,0.848872
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Motzer RJ,0.849806
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,phase 3 study,0.543472
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Escudier B,0.859122
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,NEJM,0.465171
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,et al.,0.806509
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,J Clin Oncol,0.785725
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Topalian,0.431311
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,phase 1 study,0.325442
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Rizvi NA,0.583157
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Brahmer J,0.486914
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,Weber JS,0.385764
uuid-4a8f30fb20ba4fa4a234deb2f36d88fd,phase 2 study,0.781016
uuid-33a9a64890404d26a707248b6c0a34fc,nivolumab,0.428082
uuid-33a9a64890404d26a707248b6c0a34fc,Bristol-Myers Squibb,0.485387
uuid-33a9a64890404d26a707248b6c0a34fc,evaluating,0.701565
uuid-33a9a64890404d26a707248b6c0a34fc,not conducted any controlled clinical trials/studies,0.706363
uuid-33a9a64890404d26a707248b6c0a34fc,NSCLC,0.484276
uuid-33a9a64890404d26a707248b6c0a34fc,non-small cell lung cancer,0.531914
uuid-33a9a64890404d26a707248b6c0a34fc,Pubmed literature search,0.594398
uuid-33a9a64890404d26a707248b6c0a34fc,purposes other than its labeled indication must be considered investigational,0.674533
uuid-33a9a64890404d26a707248b6c0a34fc,not identify any citations relevant to your inquiry,0.56824
uuid-33a9a64890404d26a707248b6c0a34fc,Additionally,0.32031
uuid-33a9a64890404d26a707248b6c0a34fc,ongoing,0.325946
uuid-33a9a64890404d26a707248b6c0a34fc,using the following search terms,0.53812
uuid-33a9a64890404d26a707248b6c0a34fc,detailed search of www.clinicaltrials.gov,0.337508
uuid-33a9a64890404d26a707248b6c0a34fc,efficacy and safety of nivolumab,0.589869
uuid-33a9a64890404d26a707248b6c0a34fc,not identify any planned,0.325185
uuid-33a9a64890404d26a707248b6c0a34fc,not identify any citations relevant to your request,0.339847
uuid-33a9a64890404d26a707248b6c0a34fc,safety of nivolumab monotherapy,0.309453
uuid-adaa3babbefd4af299bac7434f3ef07d,safety of nivolumab monotherapy,0.329148
uuid-158f37a1e4424cc78ba2532c8bba1ede,ASCO,0.638895
uuid-158f37a1e4424cc78ba2532c8bba1ede,requested,0.634116
uuid-158f37a1e4424cc78ba2532c8bba1ede,Horn L,0.429909
uuid-158f37a1e4424cc78ba2532c8bba1ede,platinum-based doublet chemotherapy,0.377611
uuid-dcb95188deb24eae93de86e29cd37030,use of nivolumab for the treatment,0.305739
uuid-dcb95188deb24eae93de86e29cd37030,patients with advanced or metastatic,0.509457
uuid-dcb95188deb24eae93de86e29cd37030,nivolumab combined with ipilimumab,0.496885
uuid-dcb95188deb24eae93de86e29cd37030,not approved,0.397631
uuid-dcb95188deb24eae93de86e29cd37030,clinical trials investigating the safety,0.478965
uuid-dcb95188deb24eae93de86e29cd37030,bladder cancer,0.940126
uuid-512e947a4a21432b89bfa9c6c651c56e,Additionally,0.318085
uuid-512e947a4a21432b89bfa9c6c651c56e,not identify any citations relevant to your request,0.337749
uuid-c408fb9f3eee465a83b4ac276458a52a,nivolumab,0.999168
uuid-c408fb9f3eee465a83b4ac276458a52a,Pubmed literature search,0.395314
uuid-c408fb9f3eee465a83b4ac276458a52a,purposes other than its labeled indication must be considered investigational,0.464236
uuid-c408fb9f3eee465a83b4ac276458a52a,not identify any citations relevant to your inquiry,0.368569
uuid-c408fb9f3eee465a83b4ac276458a52a,using the following search terms,0.364279
uuid-c408fb9f3eee465a83b4ac276458a52a,present using the following search terms,0.329876
uuid-47ef8ff037be4b47aebc9078a311290f,requested,0.703219
uuid-475ca447e7d3491a8b260e840f99afa2,requested,0.44769
uuid-475ca447e7d3491a8b260e840f99afa2,trial,0.309472
uuid-698381b5ce324c029ac3edc03ca0cad5,protocol,0.379546
uuid-698381b5ce324c029ac3edc03ca0cad5,McDermott DF,0.454493
uuid-698381b5ce324c029ac3edc03ca0cad5,Motzer RJ,0.426201
uuid-698381b5ce324c029ac3edc03ca0cad5,phase 3 study,0.568103
uuid-698381b5ce324c029ac3edc03ca0cad5,Escudier B,0.440449
uuid-698381b5ce324c029ac3edc03ca0cad5,et al.,0.467342
uuid-698381b5ce324c029ac3edc03ca0cad5,J Clin Oncol,0.411165
uuid-698381b5ce324c029ac3edc03ca0cad5,phase 1 study,0.406428
uuid-698381b5ce324c029ac3edc03ca0cad5,Rizvi NA,0.346877
uuid-698381b5ce324c029ac3edc03ca0cad5,CA209-003,0.360622
uuid-698381b5ce324c029ac3edc03ca0cad5,phase 2 study,0.570436
uuid-698381b5ce324c029ac3edc03ca0cad5,partial response,0.315617
uuid-57e897d6a9af48f4bccec01d9ad7f3db,RCC,0.702523
uuid-57e897d6a9af48f4bccec01d9ad7f3db,phase 1 study,0.330744
uuid-57e897d6a9af48f4bccec01d9ad7f3db,CA209-003,0.408607
uuid-57e897d6a9af48f4bccec01d9ad7f3db,investigating,0.645293
uuid-11eb4e786369409ea071d7d9634d14b8,respectively,0.483806
uuid-11eb4e786369409ea071d7d9634d14b8,Objective response rate,0.573619
uuid-11eb4e786369409ea071d7d9634d14b8,ORR,0.430378
uuid-11eb4e786369409ea071d7d9634d14b8,monotherapy,0.327181
uuid-11eb4e786369409ea071d7d9634d14b8,clinicaltrials.gov,0.391121
uuid-11eb4e786369409ea071d7d9634d14b8,docetaxel,0.312578
uuid-5f42114370bd4f47876c3af3a9d89832,N Engl J Med,0.304989
uuid-5f42114370bd4f47876c3af3a9d89832,AEs,0.337832
uuid-5f42114370bd4f47876c3af3a9d89832,patients,0.387033
uuid-5f42114370bd4f47876c3af3a9d89832,provided in the Detailed Information,0.370845
uuid-5f42114370bd4f47876c3af3a9d89832,ESMO,0.421367
uuid-5f42114370bd4f47876c3af3a9d89832,NEJM,0.709799
uuid-5f42114370bd4f47876c3af3a9d89832,Topalian,0.735417
uuid-5f42114370bd4f47876c3af3a9d89832,grade 3 to 4 AEs,0.538198
uuid-02836f524f4046c59c8b4b5917c00378,N Engl J Med,0.47446
uuid-02836f524f4046c59c8b4b5917c00378,protocol,0.775143
uuid-02836f524f4046c59c8b4b5917c00378,McDermott DF,0.756118
uuid-02836f524f4046c59c8b4b5917c00378,Motzer RJ,0.827454
uuid-02836f524f4046c59c8b4b5917c00378,phase 3 study,0.422813
uuid-02836f524f4046c59c8b4b5917c00378,Escudier B,0.764532
uuid-02836f524f4046c59c8b4b5917c00378,NEJM,0.403986
uuid-02836f524f4046c59c8b4b5917c00378,et al.,0.688347
uuid-02836f524f4046c59c8b4b5917c00378,J Clin Oncol,0.796776
uuid-02836f524f4046c59c8b4b5917c00378,Topalian,0.391537
uuid-02836f524f4046c59c8b4b5917c00378,phase 1 study,0.491683
uuid-02836f524f4046c59c8b4b5917c00378,CA209-003,0.556088
uuid-02836f524f4046c59c8b4b5917c00378,phase 2 study,0.690687
uuid-02836f524f4046c59c8b4b5917c00378,present using the following search terms,0.310671
uuid-02836f524f4046c59c8b4b5917c00378,investigating,0.600457
uuid-4beec79b6a614d939f007edf6c2d0bee,AEs,0.350409
uuid-4beec79b6a614d939f007edf6c2d0bee,patients,0.482932
uuid-4beec79b6a614d939f007edf6c2d0bee,grade,0.545815
uuid-4beec79b6a614d939f007edf6c2d0bee,grade 3 to 4 AEs,0.530209
uuid-3e1370c5d3c34f729848c4539b304d3a,N Engl J Med,0.302886
uuid-3e1370c5d3c34f729848c4539b304d3a,protocol,0.301657
uuid-3e1370c5d3c34f729848c4539b304d3a,McDermott DF,0.322568
uuid-3e1370c5d3c34f729848c4539b304d3a,Motzer RJ,0.300458
uuid-3e1370c5d3c34f729848c4539b304d3a,Escudier B,0.321938
uuid-3e1370c5d3c34f729848c4539b304d3a,et al.,0.322796
uuid-3e1370c5d3c34f729848c4539b304d3a,Rizvi NA,0.309559
uuid-3e1370c5d3c34f729848c4539b304d3a,Weber JS,0.416741
uuid-3e1370c5d3c34f729848c4539b304d3a,phase 2 study,0.31108
uuid-ec8528aca1b4430d9789986f2956f40b,requested,0.703219
uuid-38715dec3cde43cd85ceb9ef21d89514,requested,0.703219
uuid-7a4ca59a948648d181498859eda9b1ee,Bristol-Myers Squibb,0.494637
uuid-0f465005b69446d79538bf1fe499e651,Bristol-Myers Squibb,0.485985
uuid-0f465005b69446d79538bf1fe499e651,reported,0.336202
uuid-7a4ee63daa5843d6a64fef1000ac77f5,patients with advanced or metastatic,0.409376
uuid-7a4ee63daa5843d6a64fef1000ac77f5,nivolumab combined with ipilimumab,0.427428
uuid-7a4ee63daa5843d6a64fef1000ac77f5,open-label,0.303635
uuid-7a4ee63daa5843d6a64fef1000ac77f5,trial,0.374144
uuid-7a4ee63daa5843d6a64fef1000ac77f5,bladder cancer,0.402854
uuid-fa3a5c6db0d7437eaffc24612bd85d99,McDermott DF,0.320244
uuid-fa3a5c6db0d7437eaffc24612bd85d99,Motzer RJ,0.324695
uuid-fa3a5c6db0d7437eaffc24612bd85d99,phase 3 study,0.379138
uuid-fa3a5c6db0d7437eaffc24612bd85d99,Escudier B,0.323424
uuid-fa3a5c6db0d7437eaffc24612bd85d99,Rizvi NA,0.312209
uuid-fa3a5c6db0d7437eaffc24612bd85d99,Weber JS,0.336333
uuid-fa3a5c6db0d7437eaffc24612bd85d99,phase 2 study,0.36125
uuid-0c7214dbead3490aa8aa50e69e465a0a,nivolumab,0.331661
uuid-0c7214dbead3490aa8aa50e69e465a0a,Bristol-Myers Squibb,0.538032
uuid-0c7214dbead3490aa8aa50e69e465a0a,evaluating,0.467204
uuid-0c7214dbead3490aa8aa50e69e465a0a,not conducted any controlled clinical trials/studies,0.520489
uuid-0c7214dbead3490aa8aa50e69e465a0a,efficacy and safety of nivolumab,0.396223
uuid-b11601747a77478b88b0874d994cc6a6,use of nivolumab for the treatment,0.444013
uuid-b11601747a77478b88b0874d994cc6a6,patients,0.948654
uuid-b11601747a77478b88b0874d994cc6a6,considered investigational,0.404388
uuid-b11601747a77478b88b0874d994cc6a6,tumors,0.309747
uuid-b11601747a77478b88b0874d994cc6a6,small cell lung cancer,0.479485
uuid-b11601747a77478b88b0874d994cc6a6,SCLC,0.4335
uuid-b11601747a77478b88b0874d994cc6a6,grade 3 to 4 AEs,0.476561
uuid-b11601747a77478b88b0874d994cc6a6,phase 1/2 study CA209-032,0.313604
uuid-799d6157589f43ff880371866f05c3eb,nivolumab,0.349596
uuid-799d6157589f43ff880371866f05c3eb,trial,0.368763
uuid-69b9a3ce08774b0eaa975a00b3c60d53,requested,0.509987
uuid-69b9a3ce08774b0eaa975a00b3c60d53,trial,0.435748
uuid-61669ac0a1264b8abdab2f956531ef98,N Engl J Med,0.414636
uuid-61669ac0a1264b8abdab2f956531ef98,Lancet Oncol,0.403123
uuid-61669ac0a1264b8abdab2f956531ef98,provided in the Detailed Information,0.444411
uuid-61669ac0a1264b8abdab2f956531ef98,protocol,0.414004
uuid-61669ac0a1264b8abdab2f956531ef98,McDermott DF,0.446337
uuid-61669ac0a1264b8abdab2f956531ef98,Motzer RJ,0.425467
uuid-61669ac0a1264b8abdab2f956531ef98,Escudier B,0.447738
uuid-61669ac0a1264b8abdab2f956531ef98,et al.,0.434685
uuid-61669ac0a1264b8abdab2f956531ef98,J Clin Oncol,0.397451
uuid-61669ac0a1264b8abdab2f956531ef98,Rizvi NA,0.449949
uuid-61669ac0a1264b8abdab2f956531ef98,Weber JS,0.597072
uuid-61669ac0a1264b8abdab2f956531ef98,phase 2 study,0.42712
uuid-06c329a3937e4e3f9b38ffd5e1f5d481,Bristol-Myers Squibb,0.332628
uuid-06c329a3937e4e3f9b38ffd5e1f5d481,evaluating,0.340996
uuid-06c329a3937e4e3f9b38ffd5e1f5d481,not conducted any controlled clinical trials/studies,0.34546
uuid-06c329a3937e4e3f9b38ffd5e1f5d481,NSCLC,0.309728
uuid-06c329a3937e4e3f9b38ffd5e1f5d481,efficacy and safety of nivolumab,0.385415
uuid-6b44da31dba4448a8a46006aac2ad38a,N Engl J Med,0.302601
uuid-6b44da31dba4448a8a46006aac2ad38a,AEs,0.348167
uuid-6b44da31dba4448a8a46006aac2ad38a,patients,0.536884
uuid-6b44da31dba4448a8a46006aac2ad38a,provided in the Detailed Information,0.387544
uuid-6b44da31dba4448a8a46006aac2ad38a,ESMO,0.462801
uuid-6b44da31dba4448a8a46006aac2ad38a,NEJM,0.66427
uuid-6b44da31dba4448a8a46006aac2ad38a,Topalian,0.692873
uuid-6b44da31dba4448a8a46006aac2ad38a,grade 3 to 4 AEs,0.626596
uuid-c1346c9a0426427d86618e45066e4e68,Bristol-Myers Squibb,0.341822
uuid-c1346c9a0426427d86618e45066e4e68,not conducted any controlled clinical trials/studies,0.304507
uuid-c1346c9a0426427d86618e45066e4e68,Opdivo,0.461382
uuid-c1346c9a0426427d86618e45066e4e68,Pubmed literature search,0.614325
uuid-c1346c9a0426427d86618e45066e4e68,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c1346c9a0426427d86618e45066e4e68,not identify any citations relevant to your inquiry,0.606087
uuid-c1346c9a0426427d86618e45066e4e68,adverse,0.304183
uuid-c1346c9a0426427d86618e45066e4e68,using the following search terms,0.642331
uuid-c1346c9a0426427d86618e45066e4e68,databases,0.315039
uuid-c1346c9a0426427d86618e45066e4e68,reported,0.556704
uuid-eb771edff81e4c469886e0e03316128c,evaluating,0.366546
uuid-eb771edff81e4c469886e0e03316128c,not conducted any controlled clinical trials/studies,0.360172
uuid-eb771edff81e4c469886e0e03316128c,search of published literature,0.403755
uuid-eb771edff81e4c469886e0e03316128c,Additionally,0.418906
uuid-eb771edff81e4c469886e0e03316128c,ongoing,0.467576
uuid-eb771edff81e4c469886e0e03316128c,PubMed and EMBASE,0.39617
uuid-eb771edff81e4c469886e0e03316128c,detailed search of www.clinicaltrials.gov,0.437393
uuid-eb771edff81e4c469886e0e03316128c,efficacy and safety of nivolumab,0.42836
uuid-eb771edff81e4c469886e0e03316128c,not identify any planned,0.454065
uuid-eb771edff81e4c469886e0e03316128c,combination,0.397925
uuid-eb771edff81e4c469886e0e03316128c,BMS,0.30879
uuid-eb771edff81e4c469886e0e03316128c,not identify any citations relevant to your request,0.449603
uuid-eb771edff81e4c469886e0e03316128c,present using the following search terms,0.394376
uuid-9ab5cb8709e34f25a6e861938a2457b5,nivolumab,0.629743
uuid-9ab5cb8709e34f25a6e861938a2457b5,Bristol-Myers Squibb,0.405746
uuid-9ab5cb8709e34f25a6e861938a2457b5,evaluating,0.589133
uuid-9ab5cb8709e34f25a6e861938a2457b5,not conducted any controlled clinical trials/studies,0.632433
uuid-9ab5cb8709e34f25a6e861938a2457b5,Pubmed literature search,0.832691
uuid-9ab5cb8709e34f25a6e861938a2457b5,purposes other than its labeled indication must be considered investigational,0.901345
uuid-9ab5cb8709e34f25a6e861938a2457b5,not identify any citations relevant to your inquiry,0.793885
uuid-9ab5cb8709e34f25a6e861938a2457b5,using the following search terms,0.778529
uuid-9ab5cb8709e34f25a6e861938a2457b5,efficacy and safety of nivolumab,0.437229
uuid-632fa7a2b22943e98cca1f27c2c7aad9,McDermott DF,0.320244
uuid-632fa7a2b22943e98cca1f27c2c7aad9,Motzer RJ,0.324695
uuid-632fa7a2b22943e98cca1f27c2c7aad9,phase 3 study,0.379138
uuid-632fa7a2b22943e98cca1f27c2c7aad9,Escudier B,0.323424
uuid-632fa7a2b22943e98cca1f27c2c7aad9,Rizvi NA,0.312209
uuid-632fa7a2b22943e98cca1f27c2c7aad9,Weber JS,0.336333
uuid-632fa7a2b22943e98cca1f27c2c7aad9,phase 2 study,0.36125
uuid-30c03f94069849a5914462fea52af4f2,requested,0.748269
uuid-dbaf04fe5da54729b752178911ef9dab,N Engl J Med,0.689907
uuid-dbaf04fe5da54729b752178911ef9dab,Lancet Oncol,0.584216
uuid-dbaf04fe5da54729b752178911ef9dab,protocol,0.72528
uuid-dbaf04fe5da54729b752178911ef9dab,McDermott DF,0.794444
uuid-dbaf04fe5da54729b752178911ef9dab,Motzer RJ,0.755383
uuid-dbaf04fe5da54729b752178911ef9dab,phase 3 study,0.521307
uuid-dbaf04fe5da54729b752178911ef9dab,Escudier B,0.794743
uuid-dbaf04fe5da54729b752178911ef9dab,NEJM,0.434762
uuid-dbaf04fe5da54729b752178911ef9dab,et al.,0.777092
uuid-dbaf04fe5da54729b752178911ef9dab,J Clin Oncol,0.708338
uuid-dbaf04fe5da54729b752178911ef9dab,Topalian,0.401719
uuid-dbaf04fe5da54729b752178911ef9dab,Rizvi NA,0.731383
uuid-dbaf04fe5da54729b752178911ef9dab,Brahmer J,0.378658
uuid-dbaf04fe5da54729b752178911ef9dab,Weber JS,0.614831
uuid-dbaf04fe5da54729b752178911ef9dab,phase 2 study,0.769458
uuid-a182e21044b149e7a47f5593367fa85a,95% CI,0.419478
uuid-a182e21044b149e7a47f5593367fa85a,respectively,0.497608
uuid-a182e21044b149e7a47f5593367fa85a,Objective response rate,0.403649
uuid-a182e21044b149e7a47f5593367fa85a,ORR,0.578109
uuid-a182e21044b149e7a47f5593367fa85a,patients with advanced or metastatic,0.306625
uuid-a182e21044b149e7a47f5593367fa85a,Median overall survival,0.498783
uuid-a182e21044b149e7a47f5593367fa85a,nivolumab combined with ipilimumab,0.300486
uuid-a182e21044b149e7a47f5593367fa85a,tumors,0.323334
uuid-a182e21044b149e7a47f5593367fa85a,ESMO,0.534361
uuid-a182e21044b149e7a47f5593367fa85a,Median OS,0.394058
uuid-a182e21044b149e7a47f5593367fa85a,small cell lung cancer,0.380999
uuid-a182e21044b149e7a47f5593367fa85a,SCLC,0.365686
uuid-a182e21044b149e7a47f5593367fa85a,hazard ratio,0.419392
uuid-a182e21044b149e7a47f5593367fa85a,grade 3 to 4 AEs,0.414535
uuid-a182e21044b149e7a47f5593367fa85a,phase 1/2 study CA209-032,0.398283
uuid-a182e21044b149e7a47f5593367fa85a,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,Bristol-Myers Squibb,0.341822
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,not conducted any controlled clinical trials/studies,0.304507
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,Opdivo,0.461382
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,Pubmed literature search,0.614325
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,purposes other than its labeled indication must be considered investigational,0.586645
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,not identify any citations relevant to your inquiry,0.606087
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,adverse,0.304183
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,using the following search terms,0.642331
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,databases,0.315039
uuid-dd56b7e6f5d14be8bab1fa9eb5e8c407,reported,0.556704
uuid-b2921fea300245628b84e75f6ef9b8d6,nivolumab,0.474286
uuid-b2921fea300245628b84e75f6ef9b8d6,Bristol-Myers Squibb,0.593218
uuid-b2921fea300245628b84e75f6ef9b8d6,evaluating,0.675932
uuid-b2921fea300245628b84e75f6ef9b8d6,not conducted any controlled clinical trials/studies,0.749993
uuid-b2921fea300245628b84e75f6ef9b8d6,Pubmed literature search,0.730174
uuid-b2921fea300245628b84e75f6ef9b8d6,purposes other than its labeled indication must be considered investigational,0.813502
uuid-b2921fea300245628b84e75f6ef9b8d6,not identify any citations relevant to your inquiry,0.684299
uuid-b2921fea300245628b84e75f6ef9b8d6,using the following search terms,0.666248
uuid-b2921fea300245628b84e75f6ef9b8d6,efficacy and safety of nivolumab,0.516497
uuid-8a23203e52dc4bdcbcac37c1e7b9b331,melanoma,0.410364
uuid-921495b44ed748af85d162b680a6c5d5,N Engl J Med,0.427636
uuid-921495b44ed748af85d162b680a6c5d5,protocol,0.429136
uuid-921495b44ed748af85d162b680a6c5d5,McDermott DF,0.44782
uuid-921495b44ed748af85d162b680a6c5d5,Motzer RJ,0.430476
uuid-921495b44ed748af85d162b680a6c5d5,Escudier B,0.450887
uuid-921495b44ed748af85d162b680a6c5d5,et al.,0.456026
uuid-921495b44ed748af85d162b680a6c5d5,J Clin Oncol,0.384624
uuid-921495b44ed748af85d162b680a6c5d5,Rizvi NA,0.305616
uuid-921495b44ed748af85d162b680a6c5d5,phase 2 study,0.351446
uuid-ae81396e41c64b43b70bd94421287ab5,nivolumab,0.359772
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,N Engl J Med,0.535286
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Lancet Oncol,0.364361
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,protocol,0.50442
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,McDermott DF,0.548182
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Motzer RJ,0.532741
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,phase 3 study,0.493197
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Escudier B,0.547344
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,et al.,0.519366
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,J Clin Oncol,0.509597
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Rizvi NA,0.478602
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Brahmer J,0.338223
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,Weber JS,0.370952
uuid-8eefea7f068d43ccb0935a4b7fb58ed1,phase 2 study,0.591434
uuid-7c1469c3307a4350a7bce9ef0f41c022,Bristol-Myers Squibb,0.834378
uuid-7c1469c3307a4350a7bce9ef0f41c022,use of nivolumab for the treatment,0.446777
uuid-7c1469c3307a4350a7bce9ef0f41c022,evaluating,0.930191
uuid-7c1469c3307a4350a7bce9ef0f41c022,not conducted any controlled clinical trials/studies,0.940875
uuid-7c1469c3307a4350a7bce9ef0f41c022,efficacy,0.386092
uuid-7c1469c3307a4350a7bce9ef0f41c022,non-small cell lung cancer,0.310518
uuid-7c1469c3307a4350a7bce9ef0f41c022,patients,0.316454
uuid-7c1469c3307a4350a7bce9ef0f41c022,considered investigational,0.357584
uuid-7c1469c3307a4350a7bce9ef0f41c022,purposes other than its labeled indication must be considered investigational,0.306027
uuid-7c1469c3307a4350a7bce9ef0f41c022,search of published literature,0.38276
uuid-7c1469c3307a4350a7bce9ef0f41c022,PubMed and EMBASE,0.328653
uuid-7c1469c3307a4350a7bce9ef0f41c022,not approved,0.37092
uuid-7c1469c3307a4350a7bce9ef0f41c022,efficacy and safety of nivolumab,0.826713
uuid-7c1469c3307a4350a7bce9ef0f41c022,present using the following search terms,0.32397
uuid-7c1469c3307a4350a7bce9ef0f41c022,safety of nivolumab monotherapy,0.512091
uuid-c9ac47ab0da44285aaa61ee8247087a9,Bristol-Myers Squibb,0.341822
uuid-c9ac47ab0da44285aaa61ee8247087a9,not conducted any controlled clinical trials/studies,0.304507
uuid-c9ac47ab0da44285aaa61ee8247087a9,Opdivo,0.461382
uuid-c9ac47ab0da44285aaa61ee8247087a9,Pubmed literature search,0.614325
uuid-c9ac47ab0da44285aaa61ee8247087a9,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c9ac47ab0da44285aaa61ee8247087a9,not identify any citations relevant to your inquiry,0.606087
uuid-c9ac47ab0da44285aaa61ee8247087a9,adverse,0.304183
uuid-c9ac47ab0da44285aaa61ee8247087a9,using the following search terms,0.642331
uuid-c9ac47ab0da44285aaa61ee8247087a9,databases,0.315039
uuid-c9ac47ab0da44285aaa61ee8247087a9,reported,0.556704
uuid-09e1fadd188c462cbe39d5657c0afb12,provided in the Detailed Information,0.349112
uuid-09e1fadd188c462cbe39d5657c0afb12,Weber JS,0.321343
uuid-8793ab4d647849ddb95e127af85d9200,Bristol-Myers Squibb,0.341822
uuid-8793ab4d647849ddb95e127af85d9200,not conducted any controlled clinical trials/studies,0.304507
uuid-8793ab4d647849ddb95e127af85d9200,Opdivo,0.461382
uuid-8793ab4d647849ddb95e127af85d9200,Pubmed literature search,0.614325
uuid-8793ab4d647849ddb95e127af85d9200,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8793ab4d647849ddb95e127af85d9200,not identify any citations relevant to your inquiry,0.606087
uuid-8793ab4d647849ddb95e127af85d9200,adverse,0.304183
uuid-8793ab4d647849ddb95e127af85d9200,using the following search terms,0.642331
uuid-8793ab4d647849ddb95e127af85d9200,databases,0.315039
uuid-8793ab4d647849ddb95e127af85d9200,reported,0.556704
uuid-663d8ec37e7a4d7a92e020378e2d7f11,requested,0.342199
uuid-a7799af5bf724acd845f5e4b7eebd7b6,nivolumab,0.511776
uuid-a7799af5bf724acd845f5e4b7eebd7b6,Bristol-Myers Squibb,0.45146
uuid-a7799af5bf724acd845f5e4b7eebd7b6,evaluating,0.59849
uuid-a7799af5bf724acd845f5e4b7eebd7b6,not conducted any controlled clinical trials/studies,0.663407
uuid-a7799af5bf724acd845f5e4b7eebd7b6,Pubmed literature search,0.882292
uuid-a7799af5bf724acd845f5e4b7eebd7b6,purposes other than its labeled indication must be considered investigational,0.943473
uuid-a7799af5bf724acd845f5e4b7eebd7b6,not identify any citations relevant to your inquiry,0.842165
uuid-a7799af5bf724acd845f5e4b7eebd7b6,using the following search terms,0.828578
uuid-a7799af5bf724acd845f5e4b7eebd7b6,efficacy and safety of nivolumab,0.427656
uuid-9846676b22284700aa66e39d45ecbebc,requested,0.334635
uuid-fb21c1f9e3b845c0a76f6899ddf2265e,Objective response rate,0.334237
uuid-fb21c1f9e3b845c0a76f6899ddf2265e,mg,0.521078
uuid-fb21c1f9e3b845c0a76f6899ddf2265e,kg,0.481207
uuid-5303ebec5a634c549f3a6b57927e1b99,Opdivo,0.948626
uuid-5303ebec5a634c549f3a6b57927e1b99,using the following search terms,0.325687
uuid-5303ebec5a634c549f3a6b57927e1b99,trial,0.446207
uuid-5303ebec5a634c549f3a6b57927e1b99,reported,0.370612
uuid-7ee19370f7f4453da68340c937679d16,95% CI,0.419478
uuid-7ee19370f7f4453da68340c937679d16,respectively,0.497608
uuid-7ee19370f7f4453da68340c937679d16,Objective response rate,0.403649
uuid-7ee19370f7f4453da68340c937679d16,ORR,0.578109
uuid-7ee19370f7f4453da68340c937679d16,patients with advanced or metastatic,0.306625
uuid-7ee19370f7f4453da68340c937679d16,Median overall survival,0.498783
uuid-7ee19370f7f4453da68340c937679d16,nivolumab combined with ipilimumab,0.300486
uuid-7ee19370f7f4453da68340c937679d16,tumors,0.323334
uuid-7ee19370f7f4453da68340c937679d16,ESMO,0.534361
uuid-7ee19370f7f4453da68340c937679d16,Median OS,0.394058
uuid-7ee19370f7f4453da68340c937679d16,small cell lung cancer,0.380999
uuid-7ee19370f7f4453da68340c937679d16,SCLC,0.365686
uuid-7ee19370f7f4453da68340c937679d16,hazard ratio,0.419392
uuid-7ee19370f7f4453da68340c937679d16,grade 3 to 4 AEs,0.414535
uuid-7ee19370f7f4453da68340c937679d16,phase 1/2 study CA209-032,0.398283
uuid-7ee19370f7f4453da68340c937679d16,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-709e03426e78464495b54f9294c00b5b,patients with advanced or metastatic,0.478326
uuid-709e03426e78464495b54f9294c00b5b,nivolumab combined with ipilimumab,0.498766
uuid-709e03426e78464495b54f9294c00b5b,not approved,0.34724
uuid-709e03426e78464495b54f9294c00b5b,clinical trials investigating the safety,0.426729
uuid-709e03426e78464495b54f9294c00b5b,bladder cancer,0.6548
uuid-de671d7636cf402584d0379a5be1ad12,N Engl J Med,0.766032
uuid-de671d7636cf402584d0379a5be1ad12,protocol,0.874182
uuid-de671d7636cf402584d0379a5be1ad12,McDermott DF,0.960227
uuid-de671d7636cf402584d0379a5be1ad12,Motzer RJ,0.937306
uuid-de671d7636cf402584d0379a5be1ad12,phase 3 study,0.460393
uuid-de671d7636cf402584d0379a5be1ad12,Escudier B,0.963515
uuid-de671d7636cf402584d0379a5be1ad12,NEJM,0.474086
uuid-de671d7636cf402584d0379a5be1ad12,et al.,0.949387
uuid-de671d7636cf402584d0379a5be1ad12,J Clin Oncol,0.883564
uuid-de671d7636cf402584d0379a5be1ad12,Topalian,0.418815
uuid-de671d7636cf402584d0379a5be1ad12,Rizvi NA,0.471055
uuid-de671d7636cf402584d0379a5be1ad12,Brahmer J,0.406289
uuid-de671d7636cf402584d0379a5be1ad12,Weber JS,0.328759
uuid-de671d7636cf402584d0379a5be1ad12,phase 2 study,0.812219
uuid-e04ffc7c3fb742f09e14f41e320b1515,requested,0.790158
uuid-172f5eb5492d441bbc14294b977b9959,nivolumab,0.45858
uuid-172f5eb5492d441bbc14294b977b9959,Bristol-Myers Squibb,0.32162
uuid-172f5eb5492d441bbc14294b977b9959,evaluating,0.476582
uuid-172f5eb5492d441bbc14294b977b9959,not conducted any controlled clinical trials/studies,0.52797
uuid-172f5eb5492d441bbc14294b977b9959,Pubmed literature search,0.935487
uuid-172f5eb5492d441bbc14294b977b9959,purposes other than its labeled indication must be considered investigational,0.961255
uuid-172f5eb5492d441bbc14294b977b9959,not identify any citations relevant to your inquiry,0.913496
uuid-172f5eb5492d441bbc14294b977b9959,using the following search terms,0.904835
uuid-172f5eb5492d441bbc14294b977b9959,efficacy and safety of nivolumab,0.3113
uuid-ce279032594146d68ba399b04d688d62,use of nivolumab for the treatment,0.305739
uuid-ce279032594146d68ba399b04d688d62,patients with advanced or metastatic,0.509457
uuid-ce279032594146d68ba399b04d688d62,nivolumab combined with ipilimumab,0.496885
uuid-ce279032594146d68ba399b04d688d62,not approved,0.397631
uuid-ce279032594146d68ba399b04d688d62,clinical trials investigating the safety,0.478965
uuid-ce279032594146d68ba399b04d688d62,bladder cancer,0.940126
uuid-461ed461136542b4974cbca8bae99702,requested,0.703219
uuid-9186bdbe853146f3b49a46ea2f5220ed,not approved,0.304735
uuid-9186bdbe853146f3b49a46ea2f5220ed,clinical trials investigating the safety,0.315246
uuid-9186bdbe853146f3b49a46ea2f5220ed,safety of nivolumab monotherapy,0.346032
uuid-9186bdbe853146f3b49a46ea2f5220ed,phase,0.345956
uuid-32dae564f94b40edaefa4b0976ca6a63,Bristol-Myers Squibb,0.341822
uuid-32dae564f94b40edaefa4b0976ca6a63,not conducted any controlled clinical trials/studies,0.304507
uuid-32dae564f94b40edaefa4b0976ca6a63,Opdivo,0.461382
uuid-32dae564f94b40edaefa4b0976ca6a63,Pubmed literature search,0.614325
uuid-32dae564f94b40edaefa4b0976ca6a63,purposes other than its labeled indication must be considered investigational,0.586645
uuid-32dae564f94b40edaefa4b0976ca6a63,not identify any citations relevant to your inquiry,0.606087
uuid-32dae564f94b40edaefa4b0976ca6a63,adverse,0.304183
uuid-32dae564f94b40edaefa4b0976ca6a63,using the following search terms,0.642331
uuid-32dae564f94b40edaefa4b0976ca6a63,databases,0.315039
uuid-32dae564f94b40edaefa4b0976ca6a63,reported,0.556704
uuid-320de93b8d2149a2932615205b171dd3,patients with advanced or metastatic,0.51319
uuid-320de93b8d2149a2932615205b171dd3,nivolumab combined with ipilimumab,0.516305
uuid-320de93b8d2149a2932615205b171dd3,open-label,0.393956
uuid-320de93b8d2149a2932615205b171dd3,clinical trials investigating the safety,0.379928
uuid-320de93b8d2149a2932615205b171dd3,clinicaltrials.gov,0.301653
uuid-320de93b8d2149a2932615205b171dd3,bladder cancer,0.822117
uuid-358d7bca38184da393abfe6392c20a10,Bristol-Myers Squibb,0.341822
uuid-358d7bca38184da393abfe6392c20a10,not conducted any controlled clinical trials/studies,0.304507
uuid-358d7bca38184da393abfe6392c20a10,Opdivo,0.461382
uuid-358d7bca38184da393abfe6392c20a10,Pubmed literature search,0.614325
uuid-358d7bca38184da393abfe6392c20a10,purposes other than its labeled indication must be considered investigational,0.586645
uuid-358d7bca38184da393abfe6392c20a10,not identify any citations relevant to your inquiry,0.606087
uuid-358d7bca38184da393abfe6392c20a10,adverse,0.304183
uuid-358d7bca38184da393abfe6392c20a10,using the following search terms,0.642331
uuid-358d7bca38184da393abfe6392c20a10,databases,0.315039
uuid-358d7bca38184da393abfe6392c20a10,reported,0.556704
uuid-0fc20435d0884b33b6736004f84fcc15,nivolumab,0.33847
uuid-0fc20435d0884b33b6736004f84fcc15,Bristol-Myers Squibb,0.389477
uuid-0fc20435d0884b33b6736004f84fcc15,use of nivolumab for the treatment,0.302261
uuid-0fc20435d0884b33b6736004f84fcc15,evaluating,0.521922
uuid-0fc20435d0884b33b6736004f84fcc15,not conducted any controlled clinical trials/studies,0.498032
uuid-0fc20435d0884b33b6736004f84fcc15,patients,0.321904
uuid-0fc20435d0884b33b6736004f84fcc15,search of published literature,0.456015
uuid-0fc20435d0884b33b6736004f84fcc15,clinical,0.34956
uuid-0fc20435d0884b33b6736004f84fcc15,PubMed and EMBASE,0.435274
uuid-0fc20435d0884b33b6736004f84fcc15,trial,0.351399
uuid-0fc20435d0884b33b6736004f84fcc15,efficacy and safety of nivolumab,0.563289
uuid-0fc20435d0884b33b6736004f84fcc15,present using the following search terms,0.436327
uuid-3190c49b761f4fb6b8c75ed2be72f455,Bristol-Myers Squibb,0.336054
uuid-9ae563ce88ab434ea19fc25308f20255,fatigue,0.585465
uuid-9ae563ce88ab434ea19fc25308f20255,bladder cancer,0.332858
uuid-d192410e8e774e23b9bf3ae3e437ee24,OS,0.62262
uuid-d192410e8e774e23b9bf3ae3e437ee24,PFS,0.65903
uuid-d192410e8e774e23b9bf3ae3e437ee24,Overall survival,0.644151
uuid-8341db6b7b894ae8ab2ccd2caee2fe5b,Objective response rate,0.451139
uuid-8341db6b7b894ae8ab2ccd2caee2fe5b,clinicaltrials.gov,0.503706
uuid-96c7159aa4c64754947d290c26c03f83,evaluating,0.40973
uuid-96c7159aa4c64754947d290c26c03f83,not conducted any controlled clinical trials/studies,0.336623
uuid-96c7159aa4c64754947d290c26c03f83,95% CI,0.453068
uuid-96c7159aa4c64754947d290c26c03f83,efficacy,0.35969
uuid-96c7159aa4c64754947d290c26c03f83,NSCLC,0.462874
uuid-96c7159aa4c64754947d290c26c03f83,non-small cell lung cancer,0.463115
uuid-96c7159aa4c64754947d290c26c03f83,Median overall survival,0.358272
uuid-96c7159aa4c64754947d290c26c03f83,Median OS,0.380576
uuid-96c7159aa4c64754947d290c26c03f83,docetaxel,0.30425
uuid-96c7159aa4c64754947d290c26c03f83,hazard ratio,0.410455
uuid-96c7159aa4c64754947d290c26c03f83,safety of nivolumab monotherapy,0.522179
uuid-96c7159aa4c64754947d290c26c03f83,Median duration of response,0.383062
uuid-96c7159aa4c64754947d290c26c03f83,platinum-based doublet chemotherapy,0.378048
uuid-4c05c0e65d4541bca5c939a3560df00e,NSCLC,0.50004
uuid-4c05c0e65d4541bca5c939a3560df00e,non-small cell lung cancer,0.47514
uuid-4c05c0e65d4541bca5c939a3560df00e,patients,0.361282
uuid-4c05c0e65d4541bca5c939a3560df00e,considered investigational,0.322817
uuid-4c05c0e65d4541bca5c939a3560df00e,phase 3 study,0.460021
uuid-4c05c0e65d4541bca5c939a3560df00e,melanoma,0.317214
uuid-4c05c0e65d4541bca5c939a3560df00e,phase 1 study,0.363092
uuid-4c05c0e65d4541bca5c939a3560df00e,Rizvi NA,0.416947
uuid-4c05c0e65d4541bca5c939a3560df00e,small cell lung cancer,0.351371
uuid-4c05c0e65d4541bca5c939a3560df00e,efficacy and safety of nivolumab,0.31134
uuid-4c05c0e65d4541bca5c939a3560df00e,SCLC,0.388855
uuid-4c05c0e65d4541bca5c939a3560df00e,therapy,0.555977
uuid-88ee30abd62c45578577a7dfb56e3bda,PD-L1,0.592565
uuid-a1894a42959249ceaa0355c4ad19ee95,PD-L1,0.677095
uuid-a6696004b92a4708a5f8be8b6e6f5390,evaluating,0.331463
uuid-a6696004b92a4708a5f8be8b6e6f5390,not conducted any controlled clinical trials/studies,0.327968
uuid-a6696004b92a4708a5f8be8b6e6f5390,protocol,0.532972
uuid-a6696004b92a4708a5f8be8b6e6f5390,RCC,0.386451
uuid-a6696004b92a4708a5f8be8b6e6f5390,McDermott DF,0.444329
uuid-a6696004b92a4708a5f8be8b6e6f5390,search of published literature,0.50452
uuid-a6696004b92a4708a5f8be8b6e6f5390,Additionally,0.555299
uuid-a6696004b92a4708a5f8be8b6e6f5390,ongoing,0.478674
uuid-a6696004b92a4708a5f8be8b6e6f5390,Motzer RJ,0.475488
uuid-a6696004b92a4708a5f8be8b6e6f5390,PubMed and EMBASE,0.501909
uuid-a6696004b92a4708a5f8be8b6e6f5390,Escudier B,0.459186
uuid-a6696004b92a4708a5f8be8b6e6f5390,et al.,0.397016
uuid-a6696004b92a4708a5f8be8b6e6f5390,J Clin Oncol,0.428996
uuid-a6696004b92a4708a5f8be8b6e6f5390,detailed search of www.clinicaltrials.gov,0.514934
uuid-a6696004b92a4708a5f8be8b6e6f5390,efficacy and safety of nivolumab,0.47512
uuid-a6696004b92a4708a5f8be8b6e6f5390,not identify any planned,0.493147
uuid-a6696004b92a4708a5f8be8b6e6f5390,phase 2 study,0.384586
uuid-a6696004b92a4708a5f8be8b6e6f5390,not identify any citations relevant to your request,0.565812
uuid-a6696004b92a4708a5f8be8b6e6f5390,present using the following search terms,0.490802
uuid-a08c451cfefc4bfabb7cef6ff636b781,melanoma,0.410364
uuid-6858c90f9397484284fe5457f5b6d766,Bristol-Myers Squibb,0.840451
uuid-6858c90f9397484284fe5457f5b6d766,evaluating,0.718784
uuid-6858c90f9397484284fe5457f5b6d766,not conducted any controlled clinical trials/studies,0.798502
uuid-6858c90f9397484284fe5457f5b6d766,adverse,0.316881
uuid-6858c90f9397484284fe5457f5b6d766,efficacy and safety of nivolumab,0.640661
uuid-6858c90f9397484284fe5457f5b6d766,reported,0.342563
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,N Engl J Med,0.47446
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,protocol,0.775143
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,McDermott DF,0.756118
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,Motzer RJ,0.827454
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,phase 3 study,0.422813
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,Escudier B,0.764532
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,NEJM,0.403986
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,et al.,0.688347
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,J Clin Oncol,0.796776
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,Topalian,0.391537
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,phase 1 study,0.491683
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,CA209-003,0.556088
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,phase 2 study,0.690687
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,present using the following search terms,0.310671
uuid-d0cf33488bc74f15bd7e55f9c3f03a37,investigating,0.600457
uuid-fe022a7107354e989ded7a2e6637a032,requested,0.358038
uuid-b248e48447644cb0822ce8568a3a0d7d,patients,0.315236
uuid-b248e48447644cb0822ce8568a3a0d7d,trial,0.572987
uuid-b248e48447644cb0822ce8568a3a0d7d,safety,0.317677
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,evaluating,0.331463
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,not conducted any controlled clinical trials/studies,0.327968
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,protocol,0.532972
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,RCC,0.386451
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,McDermott DF,0.444329
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,search of published literature,0.50452
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,Additionally,0.555299
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,ongoing,0.478674
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,Motzer RJ,0.475488
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,PubMed and EMBASE,0.501909
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,Escudier B,0.459186
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,et al.,0.397016
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,J Clin Oncol,0.428996
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,detailed search of www.clinicaltrials.gov,0.514934
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,efficacy and safety of nivolumab,0.47512
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,not identify any planned,0.493147
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,phase 2 study,0.384586
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,not identify any citations relevant to your request,0.565812
uuid-ac35745d8ef14c0b9b1ee601d276d7e7,present using the following search terms,0.490802
uuid-7efaa3716b7c4786936cfad617d6fc91,95% CI,0.419478
uuid-7efaa3716b7c4786936cfad617d6fc91,respectively,0.497608
uuid-7efaa3716b7c4786936cfad617d6fc91,Objective response rate,0.403649
uuid-7efaa3716b7c4786936cfad617d6fc91,ORR,0.578109
uuid-7efaa3716b7c4786936cfad617d6fc91,patients with advanced or metastatic,0.306625
uuid-7efaa3716b7c4786936cfad617d6fc91,Median overall survival,0.498783
uuid-7efaa3716b7c4786936cfad617d6fc91,nivolumab combined with ipilimumab,0.300486
uuid-7efaa3716b7c4786936cfad617d6fc91,tumors,0.323334
uuid-7efaa3716b7c4786936cfad617d6fc91,ESMO,0.534361
uuid-7efaa3716b7c4786936cfad617d6fc91,Median OS,0.394058
uuid-7efaa3716b7c4786936cfad617d6fc91,small cell lung cancer,0.380999
uuid-7efaa3716b7c4786936cfad617d6fc91,SCLC,0.365686
uuid-7efaa3716b7c4786936cfad617d6fc91,hazard ratio,0.419392
uuid-7efaa3716b7c4786936cfad617d6fc91,grade 3 to 4 AEs,0.414535
uuid-7efaa3716b7c4786936cfad617d6fc91,phase 1/2 study CA209-032,0.398283
uuid-7efaa3716b7c4786936cfad617d6fc91,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-467e474dc6cc4ba5a04c67a73874ad53,use of nivolumab for the treatment,0.435597
uuid-467e474dc6cc4ba5a04c67a73874ad53,efficacy,0.459317
uuid-467e474dc6cc4ba5a04c67a73874ad53,not approved,0.558926
uuid-467e474dc6cc4ba5a04c67a73874ad53,clinical trials investigating the safety,0.598064
uuid-467e474dc6cc4ba5a04c67a73874ad53,clinicaltrials.gov,0.437497
uuid-467e474dc6cc4ba5a04c67a73874ad53,safety of nivolumab monotherapy,0.303846
uuid-467e474dc6cc4ba5a04c67a73874ad53,bladder cancer,0.44905
uuid-8d6d44ee24564e7ab0364c44b05a113a,use of nivolumab for the treatment,0.435597
uuid-8d6d44ee24564e7ab0364c44b05a113a,efficacy,0.459317
uuid-8d6d44ee24564e7ab0364c44b05a113a,not approved,0.558926
uuid-8d6d44ee24564e7ab0364c44b05a113a,clinical trials investigating the safety,0.598064
uuid-8d6d44ee24564e7ab0364c44b05a113a,clinicaltrials.gov,0.437497
uuid-8d6d44ee24564e7ab0364c44b05a113a,safety of nivolumab monotherapy,0.303846
uuid-8d6d44ee24564e7ab0364c44b05a113a,bladder cancer,0.44905
uuid-3b9983c494e04da7a77967a269ee8ac9,Objective response rate,0.451139
uuid-3b9983c494e04da7a77967a269ee8ac9,clinicaltrials.gov,0.503706
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,evaluating,0.341444
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,not conducted any controlled clinical trials/studies,0.341168
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,patients,0.414865
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,Pubmed literature search,0.402748
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,purposes other than its labeled indication must be considered investigational,0.441458
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,not identify any citations relevant to your inquiry,0.390475
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,NEJM,0.428464
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,Topalian,0.471541
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,using the following search terms,0.374417
uuid-3a7e3bc3278a417cbf2cb9a618f59a5a,grade 3 to 4 AEs,0.378881
uuid-29a3b42bef1d479baeaafe2f01523483,evaluating,0.341078
uuid-29a3b42bef1d479baeaafe2f01523483,not conducted any controlled clinical trials/studies,0.34083
uuid-29a3b42bef1d479baeaafe2f01523483,patients,0.415055
uuid-29a3b42bef1d479baeaafe2f01523483,Pubmed literature search,0.400733
uuid-29a3b42bef1d479baeaafe2f01523483,purposes other than its labeled indication must be considered investigational,0.439423
uuid-29a3b42bef1d479baeaafe2f01523483,not identify any citations relevant to your inquiry,0.388476
uuid-29a3b42bef1d479baeaafe2f01523483,NEJM,0.430148
uuid-29a3b42bef1d479baeaafe2f01523483,Topalian,0.473146
uuid-29a3b42bef1d479baeaafe2f01523483,using the following search terms,0.372438
uuid-29a3b42bef1d479baeaafe2f01523483,grade 3 to 4 AEs,0.379752
uuid-716dbb6450a54774804f84b9f28e8263,mg,0.477032
uuid-716dbb6450a54774804f84b9f28e8263,kg,0.401951
uuid-d2da0585fe08472a9d92990c2a1dd3d6,AEs,0.358987
uuid-d2da0585fe08472a9d92990c2a1dd3d6,respectively,0.659336
uuid-d2da0585fe08472a9d92990c2a1dd3d6,Objective response rate,0.389065
uuid-d2da0585fe08472a9d92990c2a1dd3d6,ORR,0.473818
uuid-d2da0585fe08472a9d92990c2a1dd3d6,monotherapy,0.348324
uuid-d2da0585fe08472a9d92990c2a1dd3d6,docetaxel,0.374957
uuid-d2da0585fe08472a9d92990c2a1dd3d6,grade,0.328554
uuid-c7c2070861374f69a5596d578edb32be,use of nivolumab for the treatment,0.305739
uuid-c7c2070861374f69a5596d578edb32be,patients with advanced or metastatic,0.509457
uuid-c7c2070861374f69a5596d578edb32be,nivolumab combined with ipilimumab,0.496885
uuid-c7c2070861374f69a5596d578edb32be,not approved,0.397631
uuid-c7c2070861374f69a5596d578edb32be,clinical trials investigating the safety,0.478965
uuid-c7c2070861374f69a5596d578edb32be,bladder cancer,0.940126
uuid-175d2fd05fb949d0a11ce403edb42e57,nivolumab,0.610472
uuid-175d2fd05fb949d0a11ce403edb42e57,Bristol-Myers Squibb,0.599325
uuid-175d2fd05fb949d0a11ce403edb42e57,evaluating,0.728523
uuid-175d2fd05fb949d0a11ce403edb42e57,not conducted any controlled clinical trials/studies,0.785334
uuid-175d2fd05fb949d0a11ce403edb42e57,Pubmed literature search,0.724563
uuid-175d2fd05fb949d0a11ce403edb42e57,purposes other than its labeled indication must be considered investigational,0.821767
uuid-175d2fd05fb949d0a11ce403edb42e57,not identify any citations relevant to your inquiry,0.67333
uuid-175d2fd05fb949d0a11ce403edb42e57,using the following search terms,0.656342
uuid-175d2fd05fb949d0a11ce403edb42e57,efficacy and safety of nivolumab,0.582207
uuid-08f1182bd7a1462c8adf1a52b3129b94,N Engl J Med,0.304989
uuid-08f1182bd7a1462c8adf1a52b3129b94,AEs,0.337832
uuid-08f1182bd7a1462c8adf1a52b3129b94,patients,0.387033
uuid-08f1182bd7a1462c8adf1a52b3129b94,provided in the Detailed Information,0.370845
uuid-08f1182bd7a1462c8adf1a52b3129b94,ESMO,0.421367
uuid-08f1182bd7a1462c8adf1a52b3129b94,NEJM,0.709799
uuid-08f1182bd7a1462c8adf1a52b3129b94,Topalian,0.735417
uuid-08f1182bd7a1462c8adf1a52b3129b94,grade 3 to 4 AEs,0.538198
uuid-2b4ad49387864affaf1732fb94cacd9f,therapy,0.406846
uuid-c0d4972cfeaf458e99522afcf023ddeb,Bristol-Myers Squibb,0.322957
uuid-c0d4972cfeaf458e99522afcf023ddeb,evaluating,0.327644
uuid-c0d4972cfeaf458e99522afcf023ddeb,not conducted any controlled clinical trials/studies,0.356128
uuid-c0d4972cfeaf458e99522afcf023ddeb,NSCLC,0.576708
uuid-c0d4972cfeaf458e99522afcf023ddeb,non-small cell lung cancer,0.551899
uuid-c0d4972cfeaf458e99522afcf023ddeb,considered investigational,0.41322
uuid-c0d4972cfeaf458e99522afcf023ddeb,melanoma,0.301402
uuid-c0d4972cfeaf458e99522afcf023ddeb,small cell lung cancer,0.398596
uuid-c0d4972cfeaf458e99522afcf023ddeb,efficacy and safety of nivolumab,0.336842
uuid-c0d4972cfeaf458e99522afcf023ddeb,SCLC,0.444834
uuid-c0d4972cfeaf458e99522afcf023ddeb,therapy,0.645299
uuid-d8973be97d39499ab3644d8226dc082a,patients with advanced or metastatic,0.478326
uuid-d8973be97d39499ab3644d8226dc082a,nivolumab combined with ipilimumab,0.498766
uuid-d8973be97d39499ab3644d8226dc082a,not approved,0.34724
uuid-d8973be97d39499ab3644d8226dc082a,clinical trials investigating the safety,0.426729
uuid-d8973be97d39499ab3644d8226dc082a,bladder cancer,0.6548
uuid-0873f290db2b4e4c805d6ab4a5a91f49,use of nivolumab for the treatment,0.409821
uuid-0873f290db2b4e4c805d6ab4a5a91f49,patients with advanced or metastatic,0.645244
uuid-0873f290db2b4e4c805d6ab4a5a91f49,nivolumab combined with ipilimumab,0.676339
uuid-0873f290db2b4e4c805d6ab4a5a91f49,not approved,0.453534
uuid-0873f290db2b4e4c805d6ab4a5a91f49,clinical trials investigating the safety,0.548799
uuid-0873f290db2b4e4c805d6ab4a5a91f49,phase 1/2 study CA209-032,0.34114
uuid-0873f290db2b4e4c805d6ab4a5a91f49,bladder cancer,0.749142
uuid-0873f290db2b4e4c805d6ab4a5a91f49,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-a33911a2b8ba4198ab0963f5c0454cff,use of nivolumab for the treatment,0.369634
uuid-a33911a2b8ba4198ab0963f5c0454cff,efficacy,0.438911
uuid-a33911a2b8ba4198ab0963f5c0454cff,Opdivo,0.380863
uuid-a33911a2b8ba4198ab0963f5c0454cff,not approved,0.477871
uuid-a33911a2b8ba4198ab0963f5c0454cff,open-label,0.302536
uuid-a33911a2b8ba4198ab0963f5c0454cff,clinical trials investigating the safety,0.479748
uuid-a33911a2b8ba4198ab0963f5c0454cff,trial,0.468319
uuid-a33911a2b8ba4198ab0963f5c0454cff,safety of nivolumab monotherapy,0.460304
uuid-a33911a2b8ba4198ab0963f5c0454cff,phase,0.376398
uuid-34cb885644344932ae0a8a64bf013dd2,N Engl J Med,0.463615
uuid-34cb885644344932ae0a8a64bf013dd2,NSCLC,0.411904
uuid-34cb885644344932ae0a8a64bf013dd2,Lancet Oncol,0.356346
uuid-34cb885644344932ae0a8a64bf013dd2,non-small cell lung cancer,0.479924
uuid-34cb885644344932ae0a8a64bf013dd2,phase 3 study,0.353194
uuid-34cb885644344932ae0a8a64bf013dd2,Rizvi NA,0.55688
uuid-34cb885644344932ae0a8a64bf013dd2,Brahmer J,0.571788
uuid-34cb885644344932ae0a8a64bf013dd2,PD-L1,0.439281
uuid-34cb885644344932ae0a8a64bf013dd2,phase 2 study,0.304107
uuid-f98cd651e3d940d4a9c95d137f83fae7,patients with advanced or metastatic,0.478326
uuid-f98cd651e3d940d4a9c95d137f83fae7,nivolumab combined with ipilimumab,0.498766
uuid-f98cd651e3d940d4a9c95d137f83fae7,not approved,0.34724
uuid-f98cd651e3d940d4a9c95d137f83fae7,clinical trials investigating the safety,0.426729
uuid-f98cd651e3d940d4a9c95d137f83fae7,bladder cancer,0.6548
uuid-64abb719ebc64045aad2e81a2fcadd19,Bristol-Myers Squibb,0.341822
uuid-64abb719ebc64045aad2e81a2fcadd19,not conducted any controlled clinical trials/studies,0.304507
uuid-64abb719ebc64045aad2e81a2fcadd19,Opdivo,0.461382
uuid-64abb719ebc64045aad2e81a2fcadd19,Pubmed literature search,0.614325
uuid-64abb719ebc64045aad2e81a2fcadd19,purposes other than its labeled indication must be considered investigational,0.586645
uuid-64abb719ebc64045aad2e81a2fcadd19,not identify any citations relevant to your inquiry,0.606087
uuid-64abb719ebc64045aad2e81a2fcadd19,adverse,0.304183
uuid-64abb719ebc64045aad2e81a2fcadd19,using the following search terms,0.642331
uuid-64abb719ebc64045aad2e81a2fcadd19,databases,0.315039
uuid-64abb719ebc64045aad2e81a2fcadd19,reported,0.556704
uuid-d016854a3885469eaa52b93cbda3ce17,use of nivolumab for the treatment,0.435597
uuid-d016854a3885469eaa52b93cbda3ce17,efficacy,0.459317
uuid-d016854a3885469eaa52b93cbda3ce17,not approved,0.558926
uuid-d016854a3885469eaa52b93cbda3ce17,clinical trials investigating the safety,0.598064
uuid-d016854a3885469eaa52b93cbda3ce17,clinicaltrials.gov,0.437497
uuid-d016854a3885469eaa52b93cbda3ce17,safety of nivolumab monotherapy,0.303846
uuid-d016854a3885469eaa52b93cbda3ce17,bladder cancer,0.44905
uuid-2efd38e6654947c384c5f24544fdb7c6,use of nivolumab for the treatment,0.435597
uuid-2efd38e6654947c384c5f24544fdb7c6,efficacy,0.459317
uuid-2efd38e6654947c384c5f24544fdb7c6,not approved,0.558926
uuid-2efd38e6654947c384c5f24544fdb7c6,clinical trials investigating the safety,0.598064
uuid-2efd38e6654947c384c5f24544fdb7c6,clinicaltrials.gov,0.437497
uuid-2efd38e6654947c384c5f24544fdb7c6,safety of nivolumab monotherapy,0.303846
uuid-2efd38e6654947c384c5f24544fdb7c6,bladder cancer,0.44905
uuid-1d7e78c512e04556a06f31fdcc0ddf5f,melanoma,0.410364
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,patients,0.350185
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,protocol,0.364313
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,McDermott DF,0.39108
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,Motzer RJ,0.394397
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,phase 3 study,0.461915
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,Escudier B,0.393278
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,et al.,0.363785
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,J Clin Oncol,0.3454
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,Rizvi NA,0.387522
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,Weber JS,0.414993
uuid-a3cfbe89c8914f95b626e9e9e59e50cd,phase 2 study,0.445652
uuid-ba0fce73c27b4fb8ab6916b569c50f23,nivolumab,0.453128
uuid-871d607b57e147cb857589980809f546,clinical,0.482647
uuid-871d607b57e147cb857589980809f546,trial,0.305347
uuid-871d607b57e147cb857589980809f546,BMS,0.391495
uuid-5c6548c357a249ff95685b4e69f2a2a7,trial,0.310479
uuid-79288563f637452c880cb858b1428f19,use of nivolumab for the treatment,0.516044
uuid-79288563f637452c880cb858b1428f19,efficacy,0.61569
uuid-79288563f637452c880cb858b1428f19,not approved,0.613956
uuid-79288563f637452c880cb858b1428f19,clinical trials investigating the safety,0.580376
uuid-79288563f637452c880cb858b1428f19,trial,0.561914
uuid-79288563f637452c880cb858b1428f19,safety of nivolumab monotherapy,0.504587
uuid-f957d0f6181546a1b6620e83fb82c5b6,fatigue,0.411608
uuid-4fb60e4de7b9474fac66cb756dc8abe4,Bristol-Myers Squibb,0.341822
uuid-4fb60e4de7b9474fac66cb756dc8abe4,not conducted any controlled clinical trials/studies,0.304507
uuid-4fb60e4de7b9474fac66cb756dc8abe4,Opdivo,0.461382
uuid-4fb60e4de7b9474fac66cb756dc8abe4,Pubmed literature search,0.614325
uuid-4fb60e4de7b9474fac66cb756dc8abe4,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4fb60e4de7b9474fac66cb756dc8abe4,not identify any citations relevant to your inquiry,0.606087
uuid-4fb60e4de7b9474fac66cb756dc8abe4,adverse,0.304183
uuid-4fb60e4de7b9474fac66cb756dc8abe4,using the following search terms,0.642331
uuid-4fb60e4de7b9474fac66cb756dc8abe4,databases,0.315039
uuid-4fb60e4de7b9474fac66cb756dc8abe4,reported,0.556704
uuid-87a814510a8d48e599bb546fe1af02fe,N Engl J Med,0.369198
uuid-87a814510a8d48e599bb546fe1af02fe,protocol,0.521104
uuid-87a814510a8d48e599bb546fe1af02fe,McDermott DF,0.58641
uuid-87a814510a8d48e599bb546fe1af02fe,Motzer RJ,0.585786
uuid-87a814510a8d48e599bb546fe1af02fe,phase 3 study,0.559297
uuid-87a814510a8d48e599bb546fe1af02fe,Escudier B,0.573796
uuid-87a814510a8d48e599bb546fe1af02fe,et al.,0.544779
uuid-87a814510a8d48e599bb546fe1af02fe,J Clin Oncol,0.575934
uuid-87a814510a8d48e599bb546fe1af02fe,phase 1 study,0.430165
uuid-87a814510a8d48e599bb546fe1af02fe,Rizvi NA,0.315564
uuid-87a814510a8d48e599bb546fe1af02fe,CA209-003,0.468729
uuid-87a814510a8d48e599bb546fe1af02fe,phase 2 study,0.646463
uuid-87a814510a8d48e599bb546fe1af02fe,investigating,0.353621
uuid-0fca0701a2194757a95527d4aad0de48,patients with advanced or metastatic,0.478326
uuid-0fca0701a2194757a95527d4aad0de48,nivolumab combined with ipilimumab,0.498766
uuid-0fca0701a2194757a95527d4aad0de48,not approved,0.34724
uuid-0fca0701a2194757a95527d4aad0de48,clinical trials investigating the safety,0.426729
uuid-0fca0701a2194757a95527d4aad0de48,bladder cancer,0.6548
uuid-1621d657e45e488bae8de1602043e77b,95% CI,0.368332
uuid-1621d657e45e488bae8de1602043e77b,NSCLC,0.498467
uuid-1621d657e45e488bae8de1602043e77b,non-small cell lung cancer,0.430459
uuid-1621d657e45e488bae8de1602043e77b,Objective response rate,0.480097
uuid-1621d657e45e488bae8de1602043e77b,ORR,0.476446
uuid-1621d657e45e488bae8de1602043e77b,Median overall survival,0.366656
uuid-1621d657e45e488bae8de1602043e77b,monotherapy,0.355726
uuid-1621d657e45e488bae8de1602043e77b,Median OS,0.348153
uuid-1621d657e45e488bae8de1602043e77b,phase 1 study,0.35881
uuid-1621d657e45e488bae8de1602043e77b,hazard ratio,0.370178
uuid-bac27efa9aa64242bbaee603b82e411f,95% CI,0.419478
uuid-bac27efa9aa64242bbaee603b82e411f,respectively,0.497608
uuid-bac27efa9aa64242bbaee603b82e411f,Objective response rate,0.403649
uuid-bac27efa9aa64242bbaee603b82e411f,ORR,0.578109
uuid-bac27efa9aa64242bbaee603b82e411f,patients with advanced or metastatic,0.306625
uuid-bac27efa9aa64242bbaee603b82e411f,Median overall survival,0.498783
uuid-bac27efa9aa64242bbaee603b82e411f,nivolumab combined with ipilimumab,0.300486
uuid-bac27efa9aa64242bbaee603b82e411f,tumors,0.323334
uuid-bac27efa9aa64242bbaee603b82e411f,ESMO,0.534361
uuid-bac27efa9aa64242bbaee603b82e411f,Median OS,0.394058
uuid-bac27efa9aa64242bbaee603b82e411f,small cell lung cancer,0.380999
uuid-bac27efa9aa64242bbaee603b82e411f,SCLC,0.365686
uuid-bac27efa9aa64242bbaee603b82e411f,hazard ratio,0.419392
uuid-bac27efa9aa64242bbaee603b82e411f,grade 3 to 4 AEs,0.414535
uuid-bac27efa9aa64242bbaee603b82e411f,phase 1/2 study CA209-032,0.398283
uuid-bac27efa9aa64242bbaee603b82e411f,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-e437c2dbfb5c4cb38efaff9930bf6716,Objective response rate,0.451139
uuid-e437c2dbfb5c4cb38efaff9930bf6716,clinicaltrials.gov,0.503706
uuid-e56c4f058ed14100865a0cb40d55ee51,nivolumab,0.543381
uuid-e56c4f058ed14100865a0cb40d55ee51,Bristol-Myers Squibb,0.642855
uuid-e56c4f058ed14100865a0cb40d55ee51,evaluating,0.707142
uuid-e56c4f058ed14100865a0cb40d55ee51,not conducted any controlled clinical trials/studies,0.772852
uuid-e56c4f058ed14100865a0cb40d55ee51,Pubmed literature search,0.641054
uuid-e56c4f058ed14100865a0cb40d55ee51,purposes other than its labeled indication must be considered investigational,0.738757
uuid-e56c4f058ed14100865a0cb40d55ee51,not identify any citations relevant to your inquiry,0.592121
uuid-e56c4f058ed14100865a0cb40d55ee51,using the following search terms,0.572878
uuid-e56c4f058ed14100865a0cb40d55ee51,efficacy and safety of nivolumab,0.561244
uuid-2f4867eafd64452584c7d8fcf1d01f67,trial,0.445315
uuid-60066fe2a82b459e8f2a8c89ec2d7425,ASCO,0.550403
uuid-60066fe2a82b459e8f2a8c89ec2d7425,requested,0.477352
uuid-4d2e3bfd8d014d899a4a7671522ba672,ESMO,0.337344
uuid-4d2e3bfd8d014d899a4a7671522ba672,fatigue,0.660242
uuid-f637fb3693e442dfa63d4aa8af27dd06,Bristol-Myers Squibb,0.341822
uuid-f637fb3693e442dfa63d4aa8af27dd06,not conducted any controlled clinical trials/studies,0.304507
uuid-f637fb3693e442dfa63d4aa8af27dd06,Opdivo,0.461382
uuid-f637fb3693e442dfa63d4aa8af27dd06,Pubmed literature search,0.614325
uuid-f637fb3693e442dfa63d4aa8af27dd06,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f637fb3693e442dfa63d4aa8af27dd06,not identify any citations relevant to your inquiry,0.606087
uuid-f637fb3693e442dfa63d4aa8af27dd06,adverse,0.304183
uuid-f637fb3693e442dfa63d4aa8af27dd06,using the following search terms,0.642331
uuid-f637fb3693e442dfa63d4aa8af27dd06,databases,0.315039
uuid-f637fb3693e442dfa63d4aa8af27dd06,reported,0.556704
uuid-27619f33365f4b32aa65ba3908a22dc1,nivolumab,0.51741
uuid-27619f33365f4b32aa65ba3908a22dc1,Bristol-Myers Squibb,0.334305
uuid-27619f33365f4b32aa65ba3908a22dc1,evaluating,0.464508
uuid-27619f33365f4b32aa65ba3908a22dc1,not conducted any controlled clinical trials/studies,0.513215
uuid-27619f33365f4b32aa65ba3908a22dc1,Pubmed literature search,0.662622
uuid-27619f33365f4b32aa65ba3908a22dc1,purposes other than its labeled indication must be considered investigational,0.716197
uuid-27619f33365f4b32aa65ba3908a22dc1,not identify any citations relevant to your inquiry,0.647491
uuid-27619f33365f4b32aa65ba3908a22dc1,using the following search terms,0.622084
uuid-27619f33365f4b32aa65ba3908a22dc1,efficacy and safety of nivolumab,0.373761
uuid-839ea3b02cca41b58fa3d7a285c83a11,95% CI,0.419478
uuid-839ea3b02cca41b58fa3d7a285c83a11,respectively,0.497608
uuid-839ea3b02cca41b58fa3d7a285c83a11,Objective response rate,0.403649
uuid-839ea3b02cca41b58fa3d7a285c83a11,ORR,0.578109
uuid-839ea3b02cca41b58fa3d7a285c83a11,patients with advanced or metastatic,0.306625
uuid-839ea3b02cca41b58fa3d7a285c83a11,Median overall survival,0.498783
uuid-839ea3b02cca41b58fa3d7a285c83a11,nivolumab combined with ipilimumab,0.300486
uuid-839ea3b02cca41b58fa3d7a285c83a11,tumors,0.323334
uuid-839ea3b02cca41b58fa3d7a285c83a11,ESMO,0.534361
uuid-839ea3b02cca41b58fa3d7a285c83a11,Median OS,0.394058
uuid-839ea3b02cca41b58fa3d7a285c83a11,small cell lung cancer,0.380999
uuid-839ea3b02cca41b58fa3d7a285c83a11,SCLC,0.365686
uuid-839ea3b02cca41b58fa3d7a285c83a11,hazard ratio,0.419392
uuid-839ea3b02cca41b58fa3d7a285c83a11,grade 3 to 4 AEs,0.414535
uuid-839ea3b02cca41b58fa3d7a285c83a11,phase 1/2 study CA209-032,0.398283
uuid-839ea3b02cca41b58fa3d7a285c83a11,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-8009f257ee874a43bd04233628b0b47e,requested,0.706913
uuid-feb7e641f5b947f7b5304a4952c7a187,nivolumab,0.304992
uuid-feb7e641f5b947f7b5304a4952c7a187,NEJM,0.351437
uuid-feb7e641f5b947f7b5304a4952c7a187,Topalian,0.37131
uuid-5c13728c48264b9badd8781c2e6cf5d7,phase 3 study,0.499604
uuid-5c13728c48264b9badd8781c2e6cf5d7,phase 2 study,0.437962
uuid-5c13728c48264b9badd8781c2e6cf5d7,phase,0.339118
uuid-5c13728c48264b9badd8781c2e6cf5d7,Overall survival,0.311788
uuid-30e180f93da246afad5f21d76ac3c6a3,nivolumab,0.344939
uuid-30e180f93da246afad5f21d76ac3c6a3,Bristol-Myers Squibb,0.363004
uuid-30e180f93da246afad5f21d76ac3c6a3,evaluating,0.564404
uuid-30e180f93da246afad5f21d76ac3c6a3,not conducted any controlled clinical trials/studies,0.538169
uuid-30e180f93da246afad5f21d76ac3c6a3,RCC,0.336118
uuid-30e180f93da246afad5f21d76ac3c6a3,search of published literature,0.750115
uuid-30e180f93da246afad5f21d76ac3c6a3,Additionally,0.766378
uuid-30e180f93da246afad5f21d76ac3c6a3,ongoing,0.629393
uuid-30e180f93da246afad5f21d76ac3c6a3,PubMed and EMBASE,0.745288
uuid-30e180f93da246afad5f21d76ac3c6a3,detailed search of www.clinicaltrials.gov,0.729251
uuid-30e180f93da246afad5f21d76ac3c6a3,efficacy and safety of nivolumab,0.716075
uuid-30e180f93da246afad5f21d76ac3c6a3,not identify any planned,0.665705
uuid-30e180f93da246afad5f21d76ac3c6a3,not identify any citations relevant to your request,0.849476
uuid-30e180f93da246afad5f21d76ac3c6a3,present using the following search terms,0.773092
uuid-2f5da9fb171c410abba0b4025cd7b1ad,nivolumab,0.484045
uuid-2f5da9fb171c410abba0b4025cd7b1ad,Bristol-Myers Squibb,0.579051
uuid-2f5da9fb171c410abba0b4025cd7b1ad,evaluating,0.718507
uuid-2f5da9fb171c410abba0b4025cd7b1ad,not conducted any controlled clinical trials/studies,0.776738
uuid-2f5da9fb171c410abba0b4025cd7b1ad,Pubmed literature search,0.767158
uuid-2f5da9fb171c410abba0b4025cd7b1ad,purposes other than its labeled indication must be considered investigational,0.854615
uuid-2f5da9fb171c410abba0b4025cd7b1ad,not identify any citations relevant to your inquiry,0.719422
uuid-2f5da9fb171c410abba0b4025cd7b1ad,using the following search terms,0.699287
uuid-2f5da9fb171c410abba0b4025cd7b1ad,efficacy and safety of nivolumab,0.546309
uuid-d2e4d260cd3c4bd68a335fa074a05da9,nivolumab,0.587848
uuid-d2e4d260cd3c4bd68a335fa074a05da9,Bristol-Myers Squibb,0.499963
uuid-d2e4d260cd3c4bd68a335fa074a05da9,evaluating,0.710235
uuid-d2e4d260cd3c4bd68a335fa074a05da9,not conducted any controlled clinical trials/studies,0.750243
uuid-d2e4d260cd3c4bd68a335fa074a05da9,Pubmed literature search,0.766041
uuid-d2e4d260cd3c4bd68a335fa074a05da9,purposes other than its labeled indication must be considered investigational,0.855336
uuid-d2e4d260cd3c4bd68a335fa074a05da9,not identify any citations relevant to your inquiry,0.716872
uuid-d2e4d260cd3c4bd68a335fa074a05da9,using the following search terms,0.701591
uuid-d2e4d260cd3c4bd68a335fa074a05da9,efficacy and safety of nivolumab,0.565337
uuid-7264c28bd1054464a533075501709928,N Engl J Med,0.304989
uuid-7264c28bd1054464a533075501709928,AEs,0.337832
uuid-7264c28bd1054464a533075501709928,patients,0.387033
uuid-7264c28bd1054464a533075501709928,provided in the Detailed Information,0.370845
uuid-7264c28bd1054464a533075501709928,ESMO,0.421367
uuid-7264c28bd1054464a533075501709928,NEJM,0.709799
uuid-7264c28bd1054464a533075501709928,Topalian,0.735417
uuid-7264c28bd1054464a533075501709928,grade 3 to 4 AEs,0.538198
uuid-f52f5a1450bb4076b9b80971d5de3888,clinical,0.657764
uuid-f52f5a1450bb4076b9b80971d5de3888,trial,0.670432
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,N Engl J Med,0.316536
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,adverse,0.337201
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,McDermott DF,0.307467
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,phase 3 study,0.480684
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,Escudier B,0.302495
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,Rizvi NA,0.373034
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,Weber JS,0.325773
uuid-a70e20a1ef3c4a35ad56ef661844c6a5,phase 2 study,0.417776
uuid-32101b6a226c424bb17f7b8a99eac82b,NEJM,0.426934
uuid-32101b6a226c424bb17f7b8a99eac82b,Topalian,0.423821
uuid-32101b6a226c424bb17f7b8a99eac82b,mg,0.525266
uuid-32101b6a226c424bb17f7b8a99eac82b,kg,0.432984
uuid-92b6b138f92a4a17be0c43963dde5c8d,mg,0.300211
uuid-cef9ca49af7e41c2973c4658bf7ac1f9,PD-L1,0.619775
uuid-7662996e677f440da82760a31a40cdd6,evaluating,0.331463
uuid-7662996e677f440da82760a31a40cdd6,not conducted any controlled clinical trials/studies,0.327968
uuid-7662996e677f440da82760a31a40cdd6,protocol,0.532972
uuid-7662996e677f440da82760a31a40cdd6,RCC,0.386451
uuid-7662996e677f440da82760a31a40cdd6,McDermott DF,0.444329
uuid-7662996e677f440da82760a31a40cdd6,search of published literature,0.50452
uuid-7662996e677f440da82760a31a40cdd6,Additionally,0.555299
uuid-7662996e677f440da82760a31a40cdd6,ongoing,0.478674
uuid-7662996e677f440da82760a31a40cdd6,Motzer RJ,0.475488
uuid-7662996e677f440da82760a31a40cdd6,PubMed and EMBASE,0.501909
uuid-7662996e677f440da82760a31a40cdd6,Escudier B,0.459186
uuid-7662996e677f440da82760a31a40cdd6,et al.,0.397016
uuid-7662996e677f440da82760a31a40cdd6,J Clin Oncol,0.428996
uuid-7662996e677f440da82760a31a40cdd6,detailed search of www.clinicaltrials.gov,0.514934
uuid-7662996e677f440da82760a31a40cdd6,efficacy and safety of nivolumab,0.47512
uuid-7662996e677f440da82760a31a40cdd6,not identify any planned,0.493147
uuid-7662996e677f440da82760a31a40cdd6,phase 2 study,0.384586
uuid-7662996e677f440da82760a31a40cdd6,not identify any citations relevant to your request,0.565812
uuid-7662996e677f440da82760a31a40cdd6,present using the following search terms,0.490802
uuid-fabc0958f6a6488885442981f928c460,OS,0.62262
uuid-fabc0958f6a6488885442981f928c460,PFS,0.65903
uuid-fabc0958f6a6488885442981f928c460,Overall survival,0.644151
uuid-2a0b3a0643424640b66cad458c229b9b,OS,0.521365
uuid-2a0b3a0643424640b66cad458c229b9b,95% CI,0.919678
uuid-2a0b3a0643424640b66cad458c229b9b,respectively,0.467176
uuid-2a0b3a0643424640b66cad458c229b9b,Objective response rate,0.59328
uuid-2a0b3a0643424640b66cad458c229b9b,ORR,0.741808
uuid-2a0b3a0643424640b66cad458c229b9b,PFS,0.393216
uuid-2a0b3a0643424640b66cad458c229b9b,Median overall survival,0.883951
uuid-2a0b3a0643424640b66cad458c229b9b,monotherapy,0.348005
uuid-2a0b3a0643424640b66cad458c229b9b,Median OS,0.858361
uuid-2a0b3a0643424640b66cad458c229b9b,hazard ratio,0.902487
uuid-2a0b3a0643424640b66cad458c229b9b,Median duration of response,0.411448
uuid-daa1c00d73444c5b84dc05c9b413d9d1,nivolumab,0.581463
uuid-daa1c00d73444c5b84dc05c9b413d9d1,Bristol-Myers Squibb,0.391262
uuid-daa1c00d73444c5b84dc05c9b413d9d1,evaluating,0.546808
uuid-daa1c00d73444c5b84dc05c9b413d9d1,not conducted any controlled clinical trials/studies,0.595748
uuid-daa1c00d73444c5b84dc05c9b413d9d1,Pubmed literature search,0.841073
uuid-daa1c00d73444c5b84dc05c9b413d9d1,purposes other than its labeled indication must be considered investigational,0.901121
uuid-daa1c00d73444c5b84dc05c9b413d9d1,not identify any citations relevant to your inquiry,0.810837
uuid-daa1c00d73444c5b84dc05c9b413d9d1,using the following search terms,0.792777
uuid-daa1c00d73444c5b84dc05c9b413d9d1,efficacy and safety of nivolumab,0.381513
uuid-f3253fd1a9834e43a040362d55a6a6bb,requested,0.44769
uuid-f3253fd1a9834e43a040362d55a6a6bb,trial,0.309472
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,95% CI,0.419478
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,respectively,0.497608
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,Objective response rate,0.403649
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,ORR,0.578109
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,patients with advanced or metastatic,0.306625
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,Median overall survival,0.498783
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,nivolumab combined with ipilimumab,0.300486
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,tumors,0.323334
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,ESMO,0.534361
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,Median OS,0.394058
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,small cell lung cancer,0.380999
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,SCLC,0.365686
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,hazard ratio,0.419392
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,grade 3 to 4 AEs,0.414535
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,phase 1/2 study CA209-032,0.398283
uuid-0f54a5fe09344cfbbcdf334f89a2d81d,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,Bristol-Myers Squibb,0.341822
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,not conducted any controlled clinical trials/studies,0.304507
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,Opdivo,0.461382
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,Pubmed literature search,0.614325
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,not identify any citations relevant to your inquiry,0.606087
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,adverse,0.304183
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,using the following search terms,0.642331
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,databases,0.315039
uuid-4daf8bcb7f204d1b9933fe123c8d85f4,reported,0.556704
uuid-3f6696a3f58a46ad97ef2c0f125204e9,RCC,0.949689
uuid-3f6696a3f58a46ad97ef2c0f125204e9,Additionally,0.536589
uuid-3f6696a3f58a46ad97ef2c0f125204e9,ongoing,0.538295
uuid-3f6696a3f58a46ad97ef2c0f125204e9,detailed search of www.clinicaltrials.gov,0.552452
uuid-3f6696a3f58a46ad97ef2c0f125204e9,not identify any planned,0.549914
uuid-3f6696a3f58a46ad97ef2c0f125204e9,not identify any citations relevant to your request,0.497898
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,Opdivo,0.50165
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,open-label,0.304253
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,trial,0.521827
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,docetaxel,0.30238
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,safety of nivolumab monotherapy,0.432481
uuid-a72bd144763f4f48bcd57e3f9b3f2fa9,phase,0.378496
uuid-14b780099d284054bf63e2d0af4caaf8,Objective response rate,0.451139
uuid-14b780099d284054bf63e2d0af4caaf8,clinicaltrials.gov,0.503706
uuid-cbce3bb1f5694e60a57fea03b885b8e0,N Engl J Med,0.766032
uuid-cbce3bb1f5694e60a57fea03b885b8e0,protocol,0.874182
uuid-cbce3bb1f5694e60a57fea03b885b8e0,McDermott DF,0.960227
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Motzer RJ,0.937306
uuid-cbce3bb1f5694e60a57fea03b885b8e0,phase 3 study,0.460393
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Escudier B,0.963515
uuid-cbce3bb1f5694e60a57fea03b885b8e0,NEJM,0.474086
uuid-cbce3bb1f5694e60a57fea03b885b8e0,et al.,0.949387
uuid-cbce3bb1f5694e60a57fea03b885b8e0,J Clin Oncol,0.883564
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Topalian,0.418815
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Rizvi NA,0.471055
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Brahmer J,0.406289
uuid-cbce3bb1f5694e60a57fea03b885b8e0,Weber JS,0.328759
uuid-cbce3bb1f5694e60a57fea03b885b8e0,phase 2 study,0.812219
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,nivolumab,0.344939
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,Bristol-Myers Squibb,0.363004
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,evaluating,0.564404
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,not conducted any controlled clinical trials/studies,0.538169
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,RCC,0.336118
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,search of published literature,0.750115
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,Additionally,0.766378
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,ongoing,0.629393
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,PubMed and EMBASE,0.745288
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,detailed search of www.clinicaltrials.gov,0.729251
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,efficacy and safety of nivolumab,0.716075
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,not identify any planned,0.665705
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,not identify any citations relevant to your request,0.849476
uuid-4aca60a6f66f4a43b9d1c51a06dc1c88,present using the following search terms,0.773092
uuid-4f04aa666ef447ab9b672e7bf30c72fa,patients with advanced or metastatic,0.478326
uuid-4f04aa666ef447ab9b672e7bf30c72fa,nivolumab combined with ipilimumab,0.498766
uuid-4f04aa666ef447ab9b672e7bf30c72fa,not approved,0.34724
uuid-4f04aa666ef447ab9b672e7bf30c72fa,clinical trials investigating the safety,0.426729
uuid-4f04aa666ef447ab9b672e7bf30c72fa,bladder cancer,0.6548
uuid-d1e17e1471a44dd691b8878993a0bcf3,Opdivo,0.50165
uuid-d1e17e1471a44dd691b8878993a0bcf3,open-label,0.304253
uuid-d1e17e1471a44dd691b8878993a0bcf3,trial,0.521827
uuid-d1e17e1471a44dd691b8878993a0bcf3,docetaxel,0.30238
uuid-d1e17e1471a44dd691b8878993a0bcf3,safety of nivolumab monotherapy,0.432481
uuid-d1e17e1471a44dd691b8878993a0bcf3,phase,0.378496
uuid-24c765c7ae8a43c8ae83d54744fcb608,requested,0.44769
uuid-24c765c7ae8a43c8ae83d54744fcb608,trial,0.309472
uuid-60b3fdad1da94b138cf3bb5c40344f6c,nivolumab,0.360392
uuid-60b3fdad1da94b138cf3bb5c40344f6c,trial,0.433746
uuid-adce48c5ff2044a9aff695e3e3e25ebd,trial,0.336342
uuid-03c8215255c844eeae62a0dd2e837e23,Opdivo,0.50165
uuid-03c8215255c844eeae62a0dd2e837e23,open-label,0.304253
uuid-03c8215255c844eeae62a0dd2e837e23,trial,0.521827
uuid-03c8215255c844eeae62a0dd2e837e23,docetaxel,0.30238
uuid-03c8215255c844eeae62a0dd2e837e23,safety of nivolumab monotherapy,0.432481
uuid-03c8215255c844eeae62a0dd2e837e23,phase,0.378496
uuid-635b4cea95d74428a83f2cb6e7a3b91d,95% CI,0.419478
uuid-635b4cea95d74428a83f2cb6e7a3b91d,respectively,0.497608
uuid-635b4cea95d74428a83f2cb6e7a3b91d,Objective response rate,0.403649
uuid-635b4cea95d74428a83f2cb6e7a3b91d,ORR,0.578109
uuid-635b4cea95d74428a83f2cb6e7a3b91d,patients with advanced or metastatic,0.306625
uuid-635b4cea95d74428a83f2cb6e7a3b91d,Median overall survival,0.498783
uuid-635b4cea95d74428a83f2cb6e7a3b91d,nivolumab combined with ipilimumab,0.300486
uuid-635b4cea95d74428a83f2cb6e7a3b91d,tumors,0.323334
uuid-635b4cea95d74428a83f2cb6e7a3b91d,ESMO,0.534361
uuid-635b4cea95d74428a83f2cb6e7a3b91d,Median OS,0.394058
uuid-635b4cea95d74428a83f2cb6e7a3b91d,small cell lung cancer,0.380999
uuid-635b4cea95d74428a83f2cb6e7a3b91d,SCLC,0.365686
uuid-635b4cea95d74428a83f2cb6e7a3b91d,hazard ratio,0.419392
uuid-635b4cea95d74428a83f2cb6e7a3b91d,grade 3 to 4 AEs,0.414535
uuid-635b4cea95d74428a83f2cb6e7a3b91d,phase 1/2 study CA209-032,0.398283
uuid-635b4cea95d74428a83f2cb6e7a3b91d,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-644db38542004cdeb627b3148ba198b7,Lancet Oncol,0.693877
uuid-644db38542004cdeb627b3148ba198b7,patients,0.405972
uuid-644db38542004cdeb627b3148ba198b7,ipilimumab,0.370825
uuid-644db38542004cdeb627b3148ba198b7,phase 3 study,0.623784
uuid-644db38542004cdeb627b3148ba198b7,ASCO 2015,0.343144
uuid-644db38542004cdeb627b3148ba198b7,melanoma,0.311721
uuid-644db38542004cdeb627b3148ba198b7,phase 1 study,0.381973
uuid-644db38542004cdeb627b3148ba198b7,Rizvi NA,0.651494
uuid-644db38542004cdeb627b3148ba198b7,CA209-003,0.307938
uuid-644db38542004cdeb627b3148ba198b7,Weber JS,0.728839
uuid-644db38542004cdeb627b3148ba198b7,phase 2 study,0.401293
uuid-644db38542004cdeb627b3148ba198b7,Antonia SJ,0.482552
uuid-f321593e8194419e920e97daf08494cf,fatigue,0.323475
uuid-8235f66706d34ab7b9b8b01af37eeefa,melanoma,0.410364
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,Bristol-Myers Squibb,0.378281
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,evaluating,0.527641
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,not conducted any controlled clinical trials/studies,0.508829
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,search of published literature,0.571933
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,Additionally,0.503465
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,ongoing,0.393538
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,PubMed and EMBASE,0.559873
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,detailed search of www.clinicaltrials.gov,0.473296
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,phase 1 study,0.439311
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,efficacy and safety of nivolumab,0.650378
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,not identify any planned,0.420793
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,CA209-003,0.479478
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,not identify any citations relevant to your request,0.588931
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,present using the following search terms,0.599566
uuid-3f1feb96c15947cc821ab3ef9bfc0e9d,investigating,0.57643
uuid-a9e2c136520e4eb38ef5d899b6001797,patients with advanced or metastatic,0.478326
uuid-a9e2c136520e4eb38ef5d899b6001797,nivolumab combined with ipilimumab,0.498766
uuid-a9e2c136520e4eb38ef5d899b6001797,not approved,0.34724
uuid-a9e2c136520e4eb38ef5d899b6001797,clinical trials investigating the safety,0.426729
uuid-a9e2c136520e4eb38ef5d899b6001797,bladder cancer,0.6548
uuid-a77eb14f02ab409d821d36ced398b362,95% CI,0.419478
uuid-a77eb14f02ab409d821d36ced398b362,respectively,0.497608
uuid-a77eb14f02ab409d821d36ced398b362,Objective response rate,0.403649
uuid-a77eb14f02ab409d821d36ced398b362,ORR,0.578109
uuid-a77eb14f02ab409d821d36ced398b362,patients with advanced or metastatic,0.306625
uuid-a77eb14f02ab409d821d36ced398b362,Median overall survival,0.498783
uuid-a77eb14f02ab409d821d36ced398b362,nivolumab combined with ipilimumab,0.300486
uuid-a77eb14f02ab409d821d36ced398b362,tumors,0.323334
uuid-a77eb14f02ab409d821d36ced398b362,ESMO,0.534361
uuid-a77eb14f02ab409d821d36ced398b362,Median OS,0.394058
uuid-a77eb14f02ab409d821d36ced398b362,small cell lung cancer,0.380999
uuid-a77eb14f02ab409d821d36ced398b362,SCLC,0.365686
uuid-a77eb14f02ab409d821d36ced398b362,hazard ratio,0.419392
uuid-a77eb14f02ab409d821d36ced398b362,grade 3 to 4 AEs,0.414535
uuid-a77eb14f02ab409d821d36ced398b362,phase 1/2 study CA209-032,0.398283
uuid-a77eb14f02ab409d821d36ced398b362,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-665f9cf3617e4d3692ae9998f443e5d7,nivolumab,0.624377
uuid-665f9cf3617e4d3692ae9998f443e5d7,Bristol-Myers Squibb,0.452527
uuid-665f9cf3617e4d3692ae9998f443e5d7,evaluating,0.630657
uuid-665f9cf3617e4d3692ae9998f443e5d7,not conducted any controlled clinical trials/studies,0.677902
uuid-665f9cf3617e4d3692ae9998f443e5d7,Pubmed literature search,0.825349
uuid-665f9cf3617e4d3692ae9998f443e5d7,purposes other than its labeled indication must be considered investigational,0.899831
uuid-665f9cf3617e4d3692ae9998f443e5d7,not identify any citations relevant to your inquiry,0.781156
uuid-665f9cf3617e4d3692ae9998f443e5d7,using the following search terms,0.76766
uuid-665f9cf3617e4d3692ae9998f443e5d7,efficacy and safety of nivolumab,0.468322
uuid-5d0ef2f79f5846a9811fa6bf00bdb0fb,nivolumab,0.310213
uuid-5d0ef2f79f5846a9811fa6bf00bdb0fb,clinicaltrials.gov,0.602918
uuid-03cf6261768e4a328fb26915d9fbd68d,nivolumab,0.411722
uuid-03cf6261768e4a328fb26915d9fbd68d,use of nivolumab for the treatment,0.305733
uuid-03cf6261768e4a328fb26915d9fbd68d,patients,0.448107
uuid-03cf6261768e4a328fb26915d9fbd68d,RCC,0.491365
uuid-b361037cf8044b53846e582cd6b8fb60,N Engl J Med,0.714946
uuid-b361037cf8044b53846e582cd6b8fb60,Lancet Oncol,0.448679
uuid-b361037cf8044b53846e582cd6b8fb60,patients,0.309769
uuid-b361037cf8044b53846e582cd6b8fb60,protocol,0.700662
uuid-b361037cf8044b53846e582cd6b8fb60,McDermott DF,0.68799
uuid-b361037cf8044b53846e582cd6b8fb60,Motzer RJ,0.689932
uuid-b361037cf8044b53846e582cd6b8fb60,phase 3 study,0.545628
uuid-b361037cf8044b53846e582cd6b8fb60,Escudier B,0.698812
uuid-b361037cf8044b53846e582cd6b8fb60,NEJM,0.402095
uuid-b361037cf8044b53846e582cd6b8fb60,et al.,0.640511
uuid-b361037cf8044b53846e582cd6b8fb60,J Clin Oncol,0.626106
uuid-b361037cf8044b53846e582cd6b8fb60,Topalian,0.37979
uuid-b361037cf8044b53846e582cd6b8fb60,phase 1 study,0.381282
uuid-b361037cf8044b53846e582cd6b8fb60,Rizvi NA,0.636006
uuid-b361037cf8044b53846e582cd6b8fb60,Brahmer J,0.517174
uuid-b361037cf8044b53846e582cd6b8fb60,efficacy and safety of nivolumab,0.368444
uuid-b361037cf8044b53846e582cd6b8fb60,Weber JS,0.406071
uuid-b361037cf8044b53846e582cd6b8fb60,phase 2 study,0.692115
uuid-f1bdfebd4b244c549f78245dfa8143df,OS,0.53535
uuid-f1bdfebd4b244c549f78245dfa8143df,95% CI,0.887962
uuid-f1bdfebd4b244c549f78245dfa8143df,respectively,0.334956
uuid-f1bdfebd4b244c549f78245dfa8143df,Objective response rate,0.479472
uuid-f1bdfebd4b244c549f78245dfa8143df,ORR,0.615143
uuid-f1bdfebd4b244c549f78245dfa8143df,PFS,0.402279
uuid-f1bdfebd4b244c549f78245dfa8143df,Median overall survival,0.852892
uuid-f1bdfebd4b244c549f78245dfa8143df,Median OS,0.858212
uuid-f1bdfebd4b244c549f78245dfa8143df,hazard ratio,0.868078
uuid-f1bdfebd4b244c549f78245dfa8143df,Median duration of response,0.442563
uuid-0785213e0f084e4d8c268a3aa4f3ab38,requested,0.44769
uuid-0785213e0f084e4d8c268a3aa4f3ab38,trial,0.309472
uuid-6d50d06fddf748eda8a20931e012291a,purposes other than its labeled indication must be considered investigational,0.316355
uuid-8e19b1d4b65f40c89280de6efc76f7bb,Opdivo,0.50165
uuid-8e19b1d4b65f40c89280de6efc76f7bb,open-label,0.304253
uuid-8e19b1d4b65f40c89280de6efc76f7bb,trial,0.521827
uuid-8e19b1d4b65f40c89280de6efc76f7bb,docetaxel,0.30238
uuid-8e19b1d4b65f40c89280de6efc76f7bb,safety of nivolumab monotherapy,0.432481
uuid-8e19b1d4b65f40c89280de6efc76f7bb,phase,0.378496
uuid-6ea64379ecac48f0a6146167d4117a7b,requested,0.703219
uuid-58095592996943a989fefada98f10704,AEs,0.539214
uuid-58095592996943a989fefada98f10704,patients,0.60863
uuid-58095592996943a989fefada98f10704,NEJM,0.315571
uuid-58095592996943a989fefada98f10704,phase 1 study,0.301964
uuid-58095592996943a989fefada98f10704,grade,0.421143
uuid-58095592996943a989fefada98f10704,grade 3 to 4 AEs,0.679602
uuid-3fcdcce0a097499293b72f87cd5aef5f,Bristol-Myers Squibb,0.341822
uuid-3fcdcce0a097499293b72f87cd5aef5f,not conducted any controlled clinical trials/studies,0.304507
uuid-3fcdcce0a097499293b72f87cd5aef5f,Opdivo,0.461382
uuid-3fcdcce0a097499293b72f87cd5aef5f,Pubmed literature search,0.614325
uuid-3fcdcce0a097499293b72f87cd5aef5f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-3fcdcce0a097499293b72f87cd5aef5f,not identify any citations relevant to your inquiry,0.606087
uuid-3fcdcce0a097499293b72f87cd5aef5f,adverse,0.304183
uuid-3fcdcce0a097499293b72f87cd5aef5f,using the following search terms,0.642331
uuid-3fcdcce0a097499293b72f87cd5aef5f,databases,0.315039
uuid-3fcdcce0a097499293b72f87cd5aef5f,reported,0.556704
uuid-ea0c848a028349f9b232a4c79b820cc4,search of published literature,0.394524
uuid-ea0c848a028349f9b232a4c79b820cc4,Additionally,0.413583
uuid-ea0c848a028349f9b232a4c79b820cc4,ongoing,0.322117
uuid-ea0c848a028349f9b232a4c79b820cc4,PubMed and EMBASE,0.391671
uuid-ea0c848a028349f9b232a4c79b820cc4,detailed search of www.clinicaltrials.gov,0.375936
uuid-ea0c848a028349f9b232a4c79b820cc4,efficacy and safety of nivolumab,0.370699
uuid-ea0c848a028349f9b232a4c79b820cc4,not identify any planned,0.34283
uuid-ea0c848a028349f9b232a4c79b820cc4,Weber JS,0.319229
uuid-ea0c848a028349f9b232a4c79b820cc4,not identify any citations relevant to your request,0.447813
uuid-ea0c848a028349f9b232a4c79b820cc4,present using the following search terms,0.408199
uuid-8dd29a643b3a4a909c3ee48880ebe083,requested,0.602053
uuid-8832a3d1c0c8455abdc368761510063b,requested,0.540431
uuid-931624c800364eee8baa7f8367b98bf4,requested,0.594234
uuid-0a94f19f2d5e424193767de46f7168f6,trial,0.310289
uuid-756347da9d0a49388faad724f05196f3,nivolumab,0.51071
uuid-756347da9d0a49388faad724f05196f3,Bristol-Myers Squibb,0.407485
uuid-756347da9d0a49388faad724f05196f3,evaluating,0.543733
uuid-756347da9d0a49388faad724f05196f3,not conducted any controlled clinical trials/studies,0.593872
uuid-756347da9d0a49388faad724f05196f3,Pubmed literature search,0.731932
uuid-756347da9d0a49388faad724f05196f3,purposes other than its labeled indication must be considered investigational,0.792756
uuid-756347da9d0a49388faad724f05196f3,not identify any citations relevant to your inquiry,0.704085
uuid-756347da9d0a49388faad724f05196f3,using the following search terms,0.682402
uuid-756347da9d0a49388faad724f05196f3,efficacy and safety of nivolumab,0.381055
uuid-756347da9d0a49388faad724f05196f3,combination,0.317167
uuid-dce61eb0358c4afb8d5516e9f999e998,requested,0.467034
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,nivolumab,0.561065
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,Bristol-Myers Squibb,0.442981
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,evaluating,0.613858
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,not conducted any controlled clinical trials/studies,0.665843
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,Pubmed literature search,0.828734
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,purposes other than its labeled indication must be considered investigational,0.897795
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,not identify any citations relevant to your inquiry,0.78679
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,using the following search terms,0.773307
uuid-e6b0c0a25f244437ad5f8ca2796f8f40,efficacy and safety of nivolumab,0.458
uuid-a17696c354384210b71aacc944753f7e,provided in the Detailed Information,0.349112
uuid-a17696c354384210b71aacc944753f7e,Weber JS,0.321343
uuid-a325b3a9d34443069b8e0bda1219d5de,nivolumab,0.441653
uuid-95c1d3f723f5463ca030b24e3fbe98bb,use of nivolumab for the treatment,0.54561
uuid-95c1d3f723f5463ca030b24e3fbe98bb,evaluating,0.316615
uuid-95c1d3f723f5463ca030b24e3fbe98bb,patients,0.348855
uuid-95c1d3f723f5463ca030b24e3fbe98bb,considered investigational,0.558905
uuid-95c1d3f723f5463ca030b24e3fbe98bb,not approved,0.335711
uuid-95c1d3f723f5463ca030b24e3fbe98bb,small cell lung cancer,0.389223
uuid-95c1d3f723f5463ca030b24e3fbe98bb,clinicaltrials.gov,0.48685
uuid-95c1d3f723f5463ca030b24e3fbe98bb,SCLC,0.362884
uuid-95c1d3f723f5463ca030b24e3fbe98bb,phase 1/2 study CA209-032,0.375072
uuid-95c1d3f723f5463ca030b24e3fbe98bb,evaluates the efficacy of nivolumab monotherapy,0.337938
uuid-cadcb1e12daa40078a2977c7392fb9bf,evaluating,0.318124
uuid-cadcb1e12daa40078a2977c7392fb9bf,not conducted any controlled clinical trials/studies,0.303299
uuid-cadcb1e12daa40078a2977c7392fb9bf,search of published literature,0.310472
uuid-cadcb1e12daa40078a2977c7392fb9bf,Additionally,0.309508
uuid-cadcb1e12daa40078a2977c7392fb9bf,PubMed and EMBASE,0.300877
uuid-cadcb1e12daa40078a2977c7392fb9bf,efficacy and safety of nivolumab,0.367857
uuid-cadcb1e12daa40078a2977c7392fb9bf,not identify any citations relevant to your request,0.338438
uuid-cadcb1e12daa40078a2977c7392fb9bf,present using the following search terms,0.320919
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,nivolumab,0.593327
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,Bristol-Myers Squibb,0.405681
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,evaluating,0.564731
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,not conducted any controlled clinical trials/studies,0.619666
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,Pubmed literature search,0.790161
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,purposes other than its labeled indication must be considered investigational,0.864163
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,not identify any citations relevant to your inquiry,0.752083
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,using the following search terms,0.734682
uuid-f0fcd8b88db94a6fb0f51e862b3d04c1,efficacy and safety of nivolumab,0.413113
uuid-e6b5f7f370b64630b898af81daeee1cd,Opdivo,0.480714
uuid-e6b5f7f370b64630b898af81daeee1cd,trial,0.301151
uuid-e6b5f7f370b64630b898af81daeee1cd,BMS,0.346922
uuid-2dba21d7339c4187850499d5ce8d24ba,requested,0.314741
uuid-2dba21d7339c4187850499d5ce8d24ba,McDermott DF,0.42332
uuid-2dba21d7339c4187850499d5ce8d24ba,Motzer RJ,0.350496
uuid-2dba21d7339c4187850499d5ce8d24ba,phase 3 study,0.329806
uuid-2dba21d7339c4187850499d5ce8d24ba,Escudier B,0.408483
uuid-2dba21d7339c4187850499d5ce8d24ba,et al.,0.501287
uuid-2dba21d7339c4187850499d5ce8d24ba,J Clin Oncol,0.330566
uuid-2dba21d7339c4187850499d5ce8d24ba,phase 2 study,0.463552
uuid-ff19c82d65114c6e8924ff200b1cec9a,evaluating,0.326511
uuid-ff19c82d65114c6e8924ff200b1cec9a,not conducted any controlled clinical trials/studies,0.308229
uuid-ff19c82d65114c6e8924ff200b1cec9a,RCC,0.316062
uuid-ff19c82d65114c6e8924ff200b1cec9a,search of published literature,0.510987
uuid-ff19c82d65114c6e8924ff200b1cec9a,Additionally,0.720971
uuid-ff19c82d65114c6e8924ff200b1cec9a,ongoing,0.587023
uuid-ff19c82d65114c6e8924ff200b1cec9a,PubMed and EMBASE,0.513581
uuid-ff19c82d65114c6e8924ff200b1cec9a,detailed search of www.clinicaltrials.gov,0.662734
uuid-ff19c82d65114c6e8924ff200b1cec9a,efficacy and safety of nivolumab,0.444016
uuid-ff19c82d65114c6e8924ff200b1cec9a,not identify any planned,0.619369
uuid-ff19c82d65114c6e8924ff200b1cec9a,not identify any citations relevant to your request,0.711349
uuid-ff19c82d65114c6e8924ff200b1cec9a,present using the following search terms,0.521206
uuid-057b3b15bd8d476f97dfa522f277bddb,evaluating,0.366546
uuid-057b3b15bd8d476f97dfa522f277bddb,not conducted any controlled clinical trials/studies,0.360172
uuid-057b3b15bd8d476f97dfa522f277bddb,search of published literature,0.403755
uuid-057b3b15bd8d476f97dfa522f277bddb,Additionally,0.418906
uuid-057b3b15bd8d476f97dfa522f277bddb,ongoing,0.467576
uuid-057b3b15bd8d476f97dfa522f277bddb,PubMed and EMBASE,0.39617
uuid-057b3b15bd8d476f97dfa522f277bddb,detailed search of www.clinicaltrials.gov,0.437393
uuid-057b3b15bd8d476f97dfa522f277bddb,efficacy and safety of nivolumab,0.42836
uuid-057b3b15bd8d476f97dfa522f277bddb,not identify any planned,0.454065
uuid-057b3b15bd8d476f97dfa522f277bddb,combination,0.397925
uuid-057b3b15bd8d476f97dfa522f277bddb,BMS,0.30879
uuid-057b3b15bd8d476f97dfa522f277bddb,not identify any citations relevant to your request,0.449603
uuid-057b3b15bd8d476f97dfa522f277bddb,present using the following search terms,0.394376
uuid-c85e24184c9e4932a5a60eea3d4c3315,ipilimumab,0.385692
uuid-c85e24184c9e4932a5a60eea3d4c3315,ASCO 2015,0.417944
uuid-c85e24184c9e4932a5a60eea3d4c3315,partial response,0.382425
uuid-c85e24184c9e4932a5a60eea3d4c3315,Stable disease,0.586335
uuid-c85e24184c9e4932a5a60eea3d4c3315,cohort,0.307748
uuid-867b2748abb34c57b4b3df6fa1f9b963,fatigue,0.323475
uuid-eb88cee77e314b6494ac8572c0a62a3b,fatigue,0.323475
uuid-14e7c841970a4770bfb5197874b227e1,nivolumab,0.376003
uuid-14e7c841970a4770bfb5197874b227e1,evaluating,0.332515
uuid-14e7c841970a4770bfb5197874b227e1,not conducted any controlled clinical trials/studies,0.364983
uuid-14e7c841970a4770bfb5197874b227e1,Pubmed literature search,0.567292
uuid-14e7c841970a4770bfb5197874b227e1,purposes other than its labeled indication must be considered investigational,0.600521
uuid-14e7c841970a4770bfb5197874b227e1,not identify any citations relevant to your inquiry,0.564115
uuid-14e7c841970a4770bfb5197874b227e1,open-label,0.417278
uuid-14e7c841970a4770bfb5197874b227e1,using the following search terms,0.538694
uuid-f6ff74f84ad846e0b0a0a26360190fa2,Opdivo,0.50165
uuid-f6ff74f84ad846e0b0a0a26360190fa2,open-label,0.304253
uuid-f6ff74f84ad846e0b0a0a26360190fa2,trial,0.521827
uuid-f6ff74f84ad846e0b0a0a26360190fa2,docetaxel,0.30238
uuid-f6ff74f84ad846e0b0a0a26360190fa2,safety of nivolumab monotherapy,0.432481
uuid-f6ff74f84ad846e0b0a0a26360190fa2,phase,0.378496
uuid-ece34979f07a49cf811ae4d66bf17be2,nivolumab,0.520664
uuid-8d3b8f3916cb42788914233ea5f9e429,Bristol-Myers Squibb,0.341822
uuid-8d3b8f3916cb42788914233ea5f9e429,not conducted any controlled clinical trials/studies,0.304507
uuid-8d3b8f3916cb42788914233ea5f9e429,Opdivo,0.461382
uuid-8d3b8f3916cb42788914233ea5f9e429,Pubmed literature search,0.614325
uuid-8d3b8f3916cb42788914233ea5f9e429,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8d3b8f3916cb42788914233ea5f9e429,not identify any citations relevant to your inquiry,0.606087
uuid-8d3b8f3916cb42788914233ea5f9e429,adverse,0.304183
uuid-8d3b8f3916cb42788914233ea5f9e429,using the following search terms,0.642331
uuid-8d3b8f3916cb42788914233ea5f9e429,databases,0.315039
uuid-8d3b8f3916cb42788914233ea5f9e429,reported,0.556704
uuid-95a62a7edd4644669509f28a65f81f20,grade,0.371372
uuid-bad60012e9864407bdadc27705394291,95% CI,0.419478
uuid-bad60012e9864407bdadc27705394291,respectively,0.497608
uuid-bad60012e9864407bdadc27705394291,Objective response rate,0.403649
uuid-bad60012e9864407bdadc27705394291,ORR,0.578109
uuid-bad60012e9864407bdadc27705394291,patients with advanced or metastatic,0.306625
uuid-bad60012e9864407bdadc27705394291,Median overall survival,0.498783
uuid-bad60012e9864407bdadc27705394291,nivolumab combined with ipilimumab,0.300486
uuid-bad60012e9864407bdadc27705394291,tumors,0.323334
uuid-bad60012e9864407bdadc27705394291,ESMO,0.534361
uuid-bad60012e9864407bdadc27705394291,Median OS,0.394058
uuid-bad60012e9864407bdadc27705394291,small cell lung cancer,0.380999
uuid-bad60012e9864407bdadc27705394291,SCLC,0.365686
uuid-bad60012e9864407bdadc27705394291,hazard ratio,0.419392
uuid-bad60012e9864407bdadc27705394291,grade 3 to 4 AEs,0.414535
uuid-bad60012e9864407bdadc27705394291,phase 1/2 study CA209-032,0.398283
uuid-bad60012e9864407bdadc27705394291,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,N Engl J Med,0.47446
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,protocol,0.775143
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,McDermott DF,0.756118
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,Motzer RJ,0.827454
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,phase 3 study,0.422813
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,Escudier B,0.764532
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,NEJM,0.403986
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,et al.,0.688347
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,J Clin Oncol,0.796776
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,Topalian,0.391537
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,phase 1 study,0.491683
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,CA209-003,0.556088
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,phase 2 study,0.690687
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,present using the following search terms,0.310671
uuid-6e5ba7f7c5d845d5b7b7d014321fae52,investigating,0.600457
uuid-603cb24d5eb0455c93bc4985db2826a7,nivolumab,0.359409
uuid-603cb24d5eb0455c93bc4985db2826a7,Bristol-Myers Squibb,0.309852
uuid-603cb24d5eb0455c93bc4985db2826a7,evaluating,0.398002
uuid-603cb24d5eb0455c93bc4985db2826a7,not conducted any controlled clinical trials/studies,0.440952
uuid-603cb24d5eb0455c93bc4985db2826a7,Pubmed literature search,0.479365
uuid-603cb24d5eb0455c93bc4985db2826a7,purposes other than its labeled indication must be considered investigational,0.525269
uuid-603cb24d5eb0455c93bc4985db2826a7,not identify any citations relevant to your inquiry,0.472127
uuid-603cb24d5eb0455c93bc4985db2826a7,open-label,0.372153
uuid-603cb24d5eb0455c93bc4985db2826a7,using the following search terms,0.445361
uuid-603cb24d5eb0455c93bc4985db2826a7,efficacy and safety of nivolumab,0.359775
uuid-6bd236d322e04b29b551033f53b418b7,melanoma,0.410364
uuid-a626654d21ff42ec9bda368c9293b0c5,provided in the Detailed Information,0.339144
uuid-a626654d21ff42ec9bda368c9293b0c5,clinical,0.351176
uuid-97ed80427f7648c8930056fe058b7417,Opdivo,0.919349
uuid-97ed80427f7648c8930056fe058b7417,using the following search terms,0.329047
uuid-97ed80427f7648c8930056fe058b7417,trial,0.383341
uuid-97ed80427f7648c8930056fe058b7417,reported,0.326044
uuid-fbe2a76039714eeda8b77db14b8b47e7,patients,0.316329
uuid-fbe2a76039714eeda8b77db14b8b47e7,provided in the Detailed Information,0.339319
uuid-fbe2a76039714eeda8b77db14b8b47e7,RCC,0.381587
uuid-fbe2a76039714eeda8b77db14b8b47e7,melanoma,0.313847
uuid-098eacf98af6432ebdefa0b76b629f93,partial response,0.5133
uuid-098eacf98af6432ebdefa0b76b629f93,therapy,0.56936
uuid-098eacf98af6432ebdefa0b76b629f93,Stable disease,0.41151
uuid-4dcd199139a04c10b2e3b3dc9956b931,Bristol-Myers Squibb,0.375981
uuid-4dcd199139a04c10b2e3b3dc9956b931,requested,0.302735
uuid-45881a6e6cb44e7fa5de3068677baaa7,Bristol-Myers Squibb,0.350861
uuid-45881a6e6cb44e7fa5de3068677baaa7,ESMO,0.436429
uuid-cbe04b4276b646bdb86af8387638fbc7,nivolumab,0.507896
uuid-cbe04b4276b646bdb86af8387638fbc7,Bristol-Myers Squibb,0.456751
uuid-cbe04b4276b646bdb86af8387638fbc7,evaluating,0.609793
uuid-cbe04b4276b646bdb86af8387638fbc7,not conducted any controlled clinical trials/studies,0.673333
uuid-cbe04b4276b646bdb86af8387638fbc7,Pubmed literature search,0.87737
uuid-cbe04b4276b646bdb86af8387638fbc7,purposes other than its labeled indication must be considered investigational,0.939194
uuid-cbe04b4276b646bdb86af8387638fbc7,not identify any citations relevant to your inquiry,0.83745
uuid-cbe04b4276b646bdb86af8387638fbc7,using the following search terms,0.823412
uuid-cbe04b4276b646bdb86af8387638fbc7,efficacy and safety of nivolumab,0.444793
uuid-c0777a32a5594bae8adf0e9bb408cc84,nivolumab,0.999168
uuid-c0777a32a5594bae8adf0e9bb408cc84,Pubmed literature search,0.395314
uuid-c0777a32a5594bae8adf0e9bb408cc84,purposes other than its labeled indication must be considered investigational,0.464236
uuid-c0777a32a5594bae8adf0e9bb408cc84,not identify any citations relevant to your inquiry,0.368569
uuid-c0777a32a5594bae8adf0e9bb408cc84,using the following search terms,0.364279
uuid-c0777a32a5594bae8adf0e9bb408cc84,present using the following search terms,0.329876
uuid-2c89850b24644295bf6f8527f3669540,nivolumab,0.378297
uuid-2c89850b24644295bf6f8527f3669540,evaluating,0.369868
uuid-2c89850b24644295bf6f8527f3669540,not conducted any controlled clinical trials/studies,0.416751
uuid-2c89850b24644295bf6f8527f3669540,Pubmed literature search,0.590866
uuid-2c89850b24644295bf6f8527f3669540,purposes other than its labeled indication must be considered investigational,0.626996
uuid-2c89850b24644295bf6f8527f3669540,not identify any citations relevant to your inquiry,0.583699
uuid-2c89850b24644295bf6f8527f3669540,open-label,0.326738
uuid-2c89850b24644295bf6f8527f3669540,using the following search terms,0.559195
uuid-727cc8ac95d547b3abb45353fcd4dda8,use of nivolumab for the treatment,0.305739
uuid-727cc8ac95d547b3abb45353fcd4dda8,patients with advanced or metastatic,0.509457
uuid-727cc8ac95d547b3abb45353fcd4dda8,nivolumab combined with ipilimumab,0.496885
uuid-727cc8ac95d547b3abb45353fcd4dda8,not approved,0.397631
uuid-727cc8ac95d547b3abb45353fcd4dda8,clinical trials investigating the safety,0.478965
uuid-727cc8ac95d547b3abb45353fcd4dda8,bladder cancer,0.940126
uuid-023ad11348b244abbbdea39cbc38de63,N Engl J Med,0.302601
uuid-023ad11348b244abbbdea39cbc38de63,AEs,0.348167
uuid-023ad11348b244abbbdea39cbc38de63,patients,0.536884
uuid-023ad11348b244abbbdea39cbc38de63,provided in the Detailed Information,0.387544
uuid-023ad11348b244abbbdea39cbc38de63,ESMO,0.462801
uuid-023ad11348b244abbbdea39cbc38de63,NEJM,0.66427
uuid-023ad11348b244abbbdea39cbc38de63,Topalian,0.692873
uuid-023ad11348b244abbbdea39cbc38de63,grade 3 to 4 AEs,0.626596
uuid-8c052ce985ed4592ab2cc258eb400ec4,Opdivo,0.50165
uuid-8c052ce985ed4592ab2cc258eb400ec4,open-label,0.304253
uuid-8c052ce985ed4592ab2cc258eb400ec4,trial,0.521827
uuid-8c052ce985ed4592ab2cc258eb400ec4,docetaxel,0.30238
uuid-8c052ce985ed4592ab2cc258eb400ec4,safety of nivolumab monotherapy,0.432481
uuid-8c052ce985ed4592ab2cc258eb400ec4,phase,0.378496
uuid-03a7f2c5abf649c78b46e689a543c749,N Engl J Med,0.322506
uuid-03a7f2c5abf649c78b46e689a543c749,requested,0.654492
uuid-0373060d0cb84a07b57d712fe430fefe,mg,0.300211
uuid-ca68ef3190be4b36a58494edb5d5cc29,95% CI,0.419478
uuid-ca68ef3190be4b36a58494edb5d5cc29,respectively,0.497608
uuid-ca68ef3190be4b36a58494edb5d5cc29,Objective response rate,0.403649
uuid-ca68ef3190be4b36a58494edb5d5cc29,ORR,0.578109
uuid-ca68ef3190be4b36a58494edb5d5cc29,patients with advanced or metastatic,0.306625
uuid-ca68ef3190be4b36a58494edb5d5cc29,Median overall survival,0.498783
uuid-ca68ef3190be4b36a58494edb5d5cc29,nivolumab combined with ipilimumab,0.300486
uuid-ca68ef3190be4b36a58494edb5d5cc29,tumors,0.323334
uuid-ca68ef3190be4b36a58494edb5d5cc29,ESMO,0.534361
uuid-ca68ef3190be4b36a58494edb5d5cc29,Median OS,0.394058
uuid-ca68ef3190be4b36a58494edb5d5cc29,small cell lung cancer,0.380999
uuid-ca68ef3190be4b36a58494edb5d5cc29,SCLC,0.365686
uuid-ca68ef3190be4b36a58494edb5d5cc29,hazard ratio,0.419392
uuid-ca68ef3190be4b36a58494edb5d5cc29,grade 3 to 4 AEs,0.414535
uuid-ca68ef3190be4b36a58494edb5d5cc29,phase 1/2 study CA209-032,0.398283
uuid-ca68ef3190be4b36a58494edb5d5cc29,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-0882b09de2354413b15619d7427f8ee1,nivolumab,0.454173
uuid-0882b09de2354413b15619d7427f8ee1,Bristol-Myers Squibb,0.576657
uuid-0882b09de2354413b15619d7427f8ee1,evaluating,0.538914
uuid-0882b09de2354413b15619d7427f8ee1,not conducted any controlled clinical trials/studies,0.568059
uuid-0882b09de2354413b15619d7427f8ee1,efficacy and safety of nivolumab,0.475891
uuid-9f8b4729eace45208cc9b973666e8a5b,95% CI,0.419478
uuid-9f8b4729eace45208cc9b973666e8a5b,respectively,0.497608
uuid-9f8b4729eace45208cc9b973666e8a5b,Objective response rate,0.403649
uuid-9f8b4729eace45208cc9b973666e8a5b,ORR,0.578109
uuid-9f8b4729eace45208cc9b973666e8a5b,patients with advanced or metastatic,0.306625
uuid-9f8b4729eace45208cc9b973666e8a5b,Median overall survival,0.498783
uuid-9f8b4729eace45208cc9b973666e8a5b,nivolumab combined with ipilimumab,0.300486
uuid-9f8b4729eace45208cc9b973666e8a5b,tumors,0.323334
uuid-9f8b4729eace45208cc9b973666e8a5b,ESMO,0.534361
uuid-9f8b4729eace45208cc9b973666e8a5b,Median OS,0.394058
uuid-9f8b4729eace45208cc9b973666e8a5b,small cell lung cancer,0.380999
uuid-9f8b4729eace45208cc9b973666e8a5b,SCLC,0.365686
uuid-9f8b4729eace45208cc9b973666e8a5b,hazard ratio,0.419392
uuid-9f8b4729eace45208cc9b973666e8a5b,grade 3 to 4 AEs,0.414535
uuid-9f8b4729eace45208cc9b973666e8a5b,phase 1/2 study CA209-032,0.398283
uuid-9f8b4729eace45208cc9b973666e8a5b,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-10c30b22510747cea2a5942b9bab0f0b,trial,0.395617
uuid-18699c7f1bf34d9cb6ef787ed1374b79,patients,0.556054
uuid-18699c7f1bf34d9cb6ef787ed1374b79,provided in the Detailed Information,0.329929
uuid-18699c7f1bf34d9cb6ef787ed1374b79,adverse,0.32982
uuid-18699c7f1bf34d9cb6ef787ed1374b79,phase 3 study,0.523726
uuid-18699c7f1bf34d9cb6ef787ed1374b79,melanoma,0.382071
uuid-18699c7f1bf34d9cb6ef787ed1374b79,Weber JS,0.428777
uuid-18699c7f1bf34d9cb6ef787ed1374b79,phase 2 study,0.307314
uuid-18699c7f1bf34d9cb6ef787ed1374b79,grade 3 to 4 AEs,0.466022
uuid-63ec4ff6ca804701baa47000710a4689,N Engl J Med,0.51723
uuid-63ec4ff6ca804701baa47000710a4689,requested,0.625061
uuid-63ec4ff6ca804701baa47000710a4689,et al.,0.302041
uuid-63ec4ff6ca804701baa47000710a4689,Brahmer J,0.439461
uuid-63ec4ff6ca804701baa47000710a4689,Horn L,0.67064
uuid-63ec4ff6ca804701baa47000710a4689,platinum-based doublet chemotherapy,0.466664
uuid-e4c0d88aaf80451e9c3ec112526aee8c,use of nivolumab for the treatment,0.409821
uuid-e4c0d88aaf80451e9c3ec112526aee8c,patients with advanced or metastatic,0.645244
uuid-e4c0d88aaf80451e9c3ec112526aee8c,nivolumab combined with ipilimumab,0.676339
uuid-e4c0d88aaf80451e9c3ec112526aee8c,not approved,0.453534
uuid-e4c0d88aaf80451e9c3ec112526aee8c,clinical trials investigating the safety,0.548799
uuid-e4c0d88aaf80451e9c3ec112526aee8c,phase 1/2 study CA209-032,0.34114
uuid-e4c0d88aaf80451e9c3ec112526aee8c,bladder cancer,0.749142
uuid-e4c0d88aaf80451e9c3ec112526aee8c,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-dcdb04a652ea4171a11d5402ea1fa94e,Objective response rate,0.451139
uuid-dcdb04a652ea4171a11d5402ea1fa94e,clinicaltrials.gov,0.503706
uuid-f89829aa0e29458d871b4e2af08f63d3,evaluating,0.331463
uuid-f89829aa0e29458d871b4e2af08f63d3,not conducted any controlled clinical trials/studies,0.327968
uuid-f89829aa0e29458d871b4e2af08f63d3,protocol,0.532972
uuid-f89829aa0e29458d871b4e2af08f63d3,RCC,0.386451
uuid-f89829aa0e29458d871b4e2af08f63d3,McDermott DF,0.444329
uuid-f89829aa0e29458d871b4e2af08f63d3,search of published literature,0.50452
uuid-f89829aa0e29458d871b4e2af08f63d3,Additionally,0.555299
uuid-f89829aa0e29458d871b4e2af08f63d3,ongoing,0.478674
uuid-f89829aa0e29458d871b4e2af08f63d3,Motzer RJ,0.475488
uuid-f89829aa0e29458d871b4e2af08f63d3,PubMed and EMBASE,0.501909
uuid-f89829aa0e29458d871b4e2af08f63d3,Escudier B,0.459186
uuid-f89829aa0e29458d871b4e2af08f63d3,et al.,0.397016
uuid-f89829aa0e29458d871b4e2af08f63d3,J Clin Oncol,0.428996
uuid-f89829aa0e29458d871b4e2af08f63d3,detailed search of www.clinicaltrials.gov,0.514934
uuid-f89829aa0e29458d871b4e2af08f63d3,efficacy and safety of nivolumab,0.47512
uuid-f89829aa0e29458d871b4e2af08f63d3,not identify any planned,0.493147
uuid-f89829aa0e29458d871b4e2af08f63d3,phase 2 study,0.384586
uuid-f89829aa0e29458d871b4e2af08f63d3,not identify any citations relevant to your request,0.565812
uuid-f89829aa0e29458d871b4e2af08f63d3,present using the following search terms,0.490802
uuid-c7b33826f36a404a936e675c13b6d230,requested,0.568004
uuid-6e4a8b5854d9495a8be714c0b467818b,respectively,0.661351
uuid-6e4a8b5854d9495a8be714c0b467818b,Objective response rate,0.619462
uuid-6e4a8b5854d9495a8be714c0b467818b,ORR,0.537232
uuid-6e4a8b5854d9495a8be714c0b467818b,monotherapy,0.421967
uuid-6e4a8b5854d9495a8be714c0b467818b,docetaxel,0.426453
uuid-05c78bf3d041419fac4874764e3b3068,nivolumab,0.571195
uuid-05c78bf3d041419fac4874764e3b3068,Bristol-Myers Squibb,0.443417
uuid-05c78bf3d041419fac4874764e3b3068,evaluating,0.627985
uuid-05c78bf3d041419fac4874764e3b3068,not conducted any controlled clinical trials/studies,0.665815
uuid-05c78bf3d041419fac4874764e3b3068,Pubmed literature search,0.855932
uuid-05c78bf3d041419fac4874764e3b3068,purposes other than its labeled indication must be considered investigational,0.922817
uuid-05c78bf3d041419fac4874764e3b3068,not identify any citations relevant to your inquiry,0.813013
uuid-05c78bf3d041419fac4874764e3b3068,using the following search terms,0.801578
uuid-05c78bf3d041419fac4874764e3b3068,efficacy and safety of nivolumab,0.442757
uuid-139f22bf9478476ea760b6e72f1f1f0d,nivolumab,0.557995
uuid-139f22bf9478476ea760b6e72f1f1f0d,evaluating,0.460622
uuid-139f22bf9478476ea760b6e72f1f1f0d,not conducted any controlled clinical trials/studies,0.467885
uuid-139f22bf9478476ea760b6e72f1f1f0d,Pubmed literature search,0.575178
uuid-139f22bf9478476ea760b6e72f1f1f0d,purposes other than its labeled indication must be considered investigational,0.631098
uuid-139f22bf9478476ea760b6e72f1f1f0d,not identify any citations relevant to your inquiry,0.565516
uuid-139f22bf9478476ea760b6e72f1f1f0d,using the following search terms,0.536057
uuid-139f22bf9478476ea760b6e72f1f1f0d,efficacy and safety of nivolumab,0.339265
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,Opdivo,0.50165
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,open-label,0.304253
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,trial,0.521827
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,docetaxel,0.30238
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,safety of nivolumab monotherapy,0.432481
uuid-42614a9bd1234ff3b0b961d77f1e5d5c,phase,0.378496
uuid-d694171792324e289bb9fb0cf12ff256,use of nivolumab for the treatment,0.305739
uuid-d694171792324e289bb9fb0cf12ff256,patients with advanced or metastatic,0.509457
uuid-d694171792324e289bb9fb0cf12ff256,nivolumab combined with ipilimumab,0.496885
uuid-d694171792324e289bb9fb0cf12ff256,not approved,0.397631
uuid-d694171792324e289bb9fb0cf12ff256,clinical trials investigating the safety,0.478965
uuid-d694171792324e289bb9fb0cf12ff256,bladder cancer,0.940126
uuid-7c4813c4ee544adbabba66eae8398f8d,nivolumab,0.413583
uuid-6436175d53254872b4c2c8ab5a6b350e,ipilimumab,0.385692
uuid-6436175d53254872b4c2c8ab5a6b350e,ASCO 2015,0.417944
uuid-6436175d53254872b4c2c8ab5a6b350e,partial response,0.382425
uuid-6436175d53254872b4c2c8ab5a6b350e,Stable disease,0.586335
uuid-6436175d53254872b4c2c8ab5a6b350e,cohort,0.307748
uuid-128f90dd9d6d4020804a3a8aa3b1bd51,fatigue,0.323475
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,nivolumab,0.63431
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,Bristol-Myers Squibb,0.447514
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,evaluating,0.636878
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,not conducted any controlled clinical trials/studies,0.675018
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,Pubmed literature search,0.818877
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,purposes other than its labeled indication must be considered investigational,0.894717
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,not identify any citations relevant to your inquiry,0.777381
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,using the following search terms,0.762975
uuid-5fa4c94e51a34f6c91ba06f7d2e38353,efficacy and safety of nivolumab,0.482925
uuid-2b8c5df3db1f45c9bb2cfa53c08e6ca6,open-label,0.353833
uuid-2b8c5df3db1f45c9bb2cfa53c08e6ca6,trial,0.476706
uuid-2b8c5df3db1f45c9bb2cfa53c08e6ca6,phase,0.340384
uuid-1409224ee70c4cd18e5495c971278919,Opdivo,0.50165
uuid-1409224ee70c4cd18e5495c971278919,open-label,0.304253
uuid-1409224ee70c4cd18e5495c971278919,trial,0.521827
uuid-1409224ee70c4cd18e5495c971278919,docetaxel,0.30238
uuid-1409224ee70c4cd18e5495c971278919,safety of nivolumab monotherapy,0.432481
uuid-1409224ee70c4cd18e5495c971278919,phase,0.378496
uuid-05803d15832542d88c853de39161405f,nivolumab,0.567445
uuid-05803d15832542d88c853de39161405f,Bristol-Myers Squibb,0.439784
uuid-05803d15832542d88c853de39161405f,evaluating,0.594796
uuid-05803d15832542d88c853de39161405f,not conducted any controlled clinical trials/studies,0.656647
uuid-05803d15832542d88c853de39161405f,Pubmed literature search,0.878652
uuid-05803d15832542d88c853de39161405f,purposes other than its labeled indication must be considered investigational,0.941484
uuid-05803d15832542d88c853de39161405f,not identify any citations relevant to your inquiry,0.837621
uuid-05803d15832542d88c853de39161405f,using the following search terms,0.825277
uuid-05803d15832542d88c853de39161405f,efficacy and safety of nivolumab,0.433238
uuid-59a4ce6cf22a4e32a05672660c32f2cf,N Engl J Med,0.304989
uuid-59a4ce6cf22a4e32a05672660c32f2cf,AEs,0.337832
uuid-59a4ce6cf22a4e32a05672660c32f2cf,patients,0.387033
uuid-59a4ce6cf22a4e32a05672660c32f2cf,provided in the Detailed Information,0.370845
uuid-59a4ce6cf22a4e32a05672660c32f2cf,ESMO,0.421367
uuid-59a4ce6cf22a4e32a05672660c32f2cf,NEJM,0.709799
uuid-59a4ce6cf22a4e32a05672660c32f2cf,Topalian,0.735417
uuid-59a4ce6cf22a4e32a05672660c32f2cf,grade 3 to 4 AEs,0.538198
uuid-c19715f791c245c4945c24f02b565235,nivolumab,0.547875
uuid-c19715f791c245c4945c24f02b565235,Bristol-Myers Squibb,0.443313
uuid-c19715f791c245c4945c24f02b565235,evaluating,0.622461
uuid-c19715f791c245c4945c24f02b565235,not conducted any controlled clinical trials/studies,0.670631
uuid-c19715f791c245c4945c24f02b565235,Pubmed literature search,0.87285
uuid-c19715f791c245c4945c24f02b565235,purposes other than its labeled indication must be considered investigational,0.936454
uuid-c19715f791c245c4945c24f02b565235,not identify any citations relevant to your inquiry,0.831874
uuid-c19715f791c245c4945c24f02b565235,using the following search terms,0.81989
uuid-c19715f791c245c4945c24f02b565235,efficacy and safety of nivolumab,0.453079
uuid-b45a58d1f6f04726a211f3201ccd8095,N Engl J Med,0.304989
uuid-b45a58d1f6f04726a211f3201ccd8095,AEs,0.337832
uuid-b45a58d1f6f04726a211f3201ccd8095,patients,0.387033
uuid-b45a58d1f6f04726a211f3201ccd8095,provided in the Detailed Information,0.370845
uuid-b45a58d1f6f04726a211f3201ccd8095,ESMO,0.421367
uuid-b45a58d1f6f04726a211f3201ccd8095,NEJM,0.709799
uuid-b45a58d1f6f04726a211f3201ccd8095,Topalian,0.735417
uuid-b45a58d1f6f04726a211f3201ccd8095,grade 3 to 4 AEs,0.538198
uuid-fd38176f277a4a6fb5cbf48a64fab577,nivolumab,0.593641
uuid-fd38176f277a4a6fb5cbf48a64fab577,Bristol-Myers Squibb,0.414112
uuid-fd38176f277a4a6fb5cbf48a64fab577,evaluating,0.591149
uuid-fd38176f277a4a6fb5cbf48a64fab577,not conducted any controlled clinical trials/studies,0.62805
uuid-fd38176f277a4a6fb5cbf48a64fab577,Pubmed literature search,0.778121
uuid-fd38176f277a4a6fb5cbf48a64fab577,purposes other than its labeled indication must be considered investigational,0.853358
uuid-fd38176f277a4a6fb5cbf48a64fab577,not identify any citations relevant to your inquiry,0.741839
uuid-fd38176f277a4a6fb5cbf48a64fab577,using the following search terms,0.723298
uuid-fd38176f277a4a6fb5cbf48a64fab577,efficacy and safety of nivolumab,0.421368
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,use of nivolumab for the treatment,0.305739
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,patients with advanced or metastatic,0.509457
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,nivolumab combined with ipilimumab,0.496885
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,not approved,0.397631
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,clinical trials investigating the safety,0.478965
uuid-09d7ddfd78bf4cbb96e6ad0af4b2aa74,bladder cancer,0.940126
uuid-eae0e77c60034b6e8898d2373fdc4e6c,95% CI,0.419478
uuid-eae0e77c60034b6e8898d2373fdc4e6c,respectively,0.497608
uuid-eae0e77c60034b6e8898d2373fdc4e6c,Objective response rate,0.403649
uuid-eae0e77c60034b6e8898d2373fdc4e6c,ORR,0.578109
uuid-eae0e77c60034b6e8898d2373fdc4e6c,patients with advanced or metastatic,0.306625
uuid-eae0e77c60034b6e8898d2373fdc4e6c,Median overall survival,0.498783
uuid-eae0e77c60034b6e8898d2373fdc4e6c,nivolumab combined with ipilimumab,0.300486
uuid-eae0e77c60034b6e8898d2373fdc4e6c,tumors,0.323334
uuid-eae0e77c60034b6e8898d2373fdc4e6c,ESMO,0.534361
uuid-eae0e77c60034b6e8898d2373fdc4e6c,Median OS,0.394058
uuid-eae0e77c60034b6e8898d2373fdc4e6c,small cell lung cancer,0.380999
uuid-eae0e77c60034b6e8898d2373fdc4e6c,SCLC,0.365686
uuid-eae0e77c60034b6e8898d2373fdc4e6c,hazard ratio,0.419392
uuid-eae0e77c60034b6e8898d2373fdc4e6c,grade 3 to 4 AEs,0.414535
uuid-eae0e77c60034b6e8898d2373fdc4e6c,phase 1/2 study CA209-032,0.398283
uuid-eae0e77c60034b6e8898d2373fdc4e6c,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-b3f871d3de5448e283363391ad208551,Bristol-Myers Squibb,0.494637
uuid-78a0ccb461684b54b03be22caba7bec4,Weber JS,0.374144
uuid-062fe46e6dda49039df82142d7a78f1d,nivolumab,0.394662
uuid-062fe46e6dda49039df82142d7a78f1d,Bristol-Myers Squibb,0.316062
uuid-062fe46e6dda49039df82142d7a78f1d,evaluating,0.541564
uuid-062fe46e6dda49039df82142d7a78f1d,not conducted any controlled clinical trials/studies,0.506362
uuid-062fe46e6dda49039df82142d7a78f1d,RCC,0.307611
uuid-062fe46e6dda49039df82142d7a78f1d,search of published literature,0.780634
uuid-062fe46e6dda49039df82142d7a78f1d,Additionally,0.726874
uuid-062fe46e6dda49039df82142d7a78f1d,ongoing,0.562906
uuid-062fe46e6dda49039df82142d7a78f1d,PubMed and EMBASE,0.779832
uuid-062fe46e6dda49039df82142d7a78f1d,detailed search of www.clinicaltrials.gov,0.679837
uuid-062fe46e6dda49039df82142d7a78f1d,efficacy and safety of nivolumab,0.711581
uuid-062fe46e6dda49039df82142d7a78f1d,not identify any planned,0.604685
uuid-062fe46e6dda49039df82142d7a78f1d,not identify any citations relevant to your request,0.842672
uuid-062fe46e6dda49039df82142d7a78f1d,present using the following search terms,0.824883
uuid-638864c5852149a283bee79e84df8d47,ongoing,0.323996
uuid-638864c5852149a283bee79e84df8d47,efficacy and safety of nivolumab,0.329856
uuid-638864c5852149a283bee79e84df8d47,not identify any planned,0.303776
uuid-638864c5852149a283bee79e84df8d47,combination,0.313026
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,Opdivo,0.50165
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,open-label,0.304253
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,trial,0.521827
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,docetaxel,0.30238
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,safety of nivolumab monotherapy,0.432481
uuid-42bc54e0f9ef40cbb12cbc3d263cb38c,phase,0.378496
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,use of nivolumab for the treatment,0.305739
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,patients with advanced or metastatic,0.509457
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,nivolumab combined with ipilimumab,0.496885
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,not approved,0.397631
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,clinical trials investigating the safety,0.478965
uuid-8d0b62b6fb2d4629a758d8c25adbeae9,bladder cancer,0.940126
uuid-df68b3bafe714f6eb72f3ead28e50d40,ASCO,0.511602
uuid-df68b3bafe714f6eb72f3ead28e50d40,Objective response rate,0.455586
uuid-df68b3bafe714f6eb72f3ead28e50d40,ORR,0.372206
uuid-df68b3bafe714f6eb72f3ead28e50d40,Median OS,0.337583
uuid-df68b3bafe714f6eb72f3ead28e50d40,ASCO 2015,0.420641
uuid-df68b3bafe714f6eb72f3ead28e50d40,phase 1 study,0.343132
uuid-df68b3bafe714f6eb72f3ead28e50d40,Antonia SJ,0.31238
uuid-fc500d4f562f4cefaa38dc79f99973a9,nivolumab,0.570076
uuid-fc500d4f562f4cefaa38dc79f99973a9,Bristol-Myers Squibb,0.438095
uuid-fc500d4f562f4cefaa38dc79f99973a9,evaluating,0.596485
uuid-fc500d4f562f4cefaa38dc79f99973a9,not conducted any controlled clinical trials/studies,0.655487
uuid-fc500d4f562f4cefaa38dc79f99973a9,Pubmed literature search,0.878157
uuid-fc500d4f562f4cefaa38dc79f99973a9,purposes other than its labeled indication must be considered investigational,0.940834
uuid-fc500d4f562f4cefaa38dc79f99973a9,not identify any citations relevant to your inquiry,0.837413
uuid-fc500d4f562f4cefaa38dc79f99973a9,using the following search terms,0.825151
uuid-fc500d4f562f4cefaa38dc79f99973a9,efficacy and safety of nivolumab,0.43254
uuid-b99b9d2accc84604b01d6293acf4897e,ESMO,0.337344
uuid-b99b9d2accc84604b01d6293acf4897e,fatigue,0.660242
uuid-cec0dec44d234c398e5807aee653e037,nivolumab,0.344939
uuid-cec0dec44d234c398e5807aee653e037,Bristol-Myers Squibb,0.363004
uuid-cec0dec44d234c398e5807aee653e037,evaluating,0.564404
uuid-cec0dec44d234c398e5807aee653e037,not conducted any controlled clinical trials/studies,0.538169
uuid-cec0dec44d234c398e5807aee653e037,RCC,0.336118
uuid-cec0dec44d234c398e5807aee653e037,search of published literature,0.750115
uuid-cec0dec44d234c398e5807aee653e037,Additionally,0.766378
uuid-cec0dec44d234c398e5807aee653e037,ongoing,0.629393
uuid-cec0dec44d234c398e5807aee653e037,PubMed and EMBASE,0.745288
uuid-cec0dec44d234c398e5807aee653e037,detailed search of www.clinicaltrials.gov,0.729251
uuid-cec0dec44d234c398e5807aee653e037,efficacy and safety of nivolumab,0.716075
uuid-cec0dec44d234c398e5807aee653e037,not identify any planned,0.665705
uuid-cec0dec44d234c398e5807aee653e037,not identify any citations relevant to your request,0.849476
uuid-cec0dec44d234c398e5807aee653e037,present using the following search terms,0.773092
uuid-5b8a9f1f757141a290cc5165e1751062,nivolumab,0.595944
uuid-5b8a9f1f757141a290cc5165e1751062,Bristol-Myers Squibb,0.409275
uuid-5b8a9f1f757141a290cc5165e1751062,evaluating,0.554713
uuid-5b8a9f1f757141a290cc5165e1751062,not conducted any controlled clinical trials/studies,0.615983
uuid-5b8a9f1f757141a290cc5165e1751062,Pubmed literature search,0.827198
uuid-5b8a9f1f757141a290cc5165e1751062,purposes other than its labeled indication must be considered investigational,0.894487
uuid-5b8a9f1f757141a290cc5165e1751062,not identify any citations relevant to your inquiry,0.789484
uuid-5b8a9f1f757141a290cc5165e1751062,using the following search terms,0.774998
uuid-5b8a9f1f757141a290cc5165e1751062,efficacy and safety of nivolumab,0.400541
uuid-0a23a77658e54879a5eb87779fe7f3e7,provided in the Detailed Information,0.349112
uuid-0a23a77658e54879a5eb87779fe7f3e7,Weber JS,0.321343
uuid-1884deb93dc943878bbad1b4b9b54a59,NSCLC,0.487564
uuid-1884deb93dc943878bbad1b4b9b54a59,Lancet Oncol,0.408285
uuid-1884deb93dc943878bbad1b4b9b54a59,non-small cell lung cancer,0.425216
uuid-1884deb93dc943878bbad1b4b9b54a59,phase 3 study,0.406253
uuid-1884deb93dc943878bbad1b4b9b54a59,phase 1 study,0.591752
uuid-1884deb93dc943878bbad1b4b9b54a59,Rizvi NA,0.511912
uuid-1884deb93dc943878bbad1b4b9b54a59,CA209-003,0.456298
uuid-1884deb93dc943878bbad1b4b9b54a59,Weber JS,0.339277
uuid-1884deb93dc943878bbad1b4b9b54a59,phase 2 study,0.340247
uuid-1884deb93dc943878bbad1b4b9b54a59,SCLC,0.30471
uuid-1884deb93dc943878bbad1b4b9b54a59,Antonia SJ,0.337097
uuid-a27454e75bfe4d439d9e31f505b6a2ad,Opdivo,0.50165
uuid-a27454e75bfe4d439d9e31f505b6a2ad,open-label,0.304253
uuid-a27454e75bfe4d439d9e31f505b6a2ad,trial,0.521827
uuid-a27454e75bfe4d439d9e31f505b6a2ad,docetaxel,0.30238
uuid-a27454e75bfe4d439d9e31f505b6a2ad,safety of nivolumab monotherapy,0.432481
uuid-a27454e75bfe4d439d9e31f505b6a2ad,phase,0.378496
uuid-c95d58d72bda48d3b31579950c465357,95% CI,0.419478
uuid-c95d58d72bda48d3b31579950c465357,respectively,0.497608
uuid-c95d58d72bda48d3b31579950c465357,Objective response rate,0.403649
uuid-c95d58d72bda48d3b31579950c465357,ORR,0.578109
uuid-c95d58d72bda48d3b31579950c465357,patients with advanced or metastatic,0.306625
uuid-c95d58d72bda48d3b31579950c465357,Median overall survival,0.498783
uuid-c95d58d72bda48d3b31579950c465357,nivolumab combined with ipilimumab,0.300486
uuid-c95d58d72bda48d3b31579950c465357,tumors,0.323334
uuid-c95d58d72bda48d3b31579950c465357,ESMO,0.534361
uuid-c95d58d72bda48d3b31579950c465357,Median OS,0.394058
uuid-c95d58d72bda48d3b31579950c465357,small cell lung cancer,0.380999
uuid-c95d58d72bda48d3b31579950c465357,SCLC,0.365686
uuid-c95d58d72bda48d3b31579950c465357,hazard ratio,0.419392
uuid-c95d58d72bda48d3b31579950c465357,grade 3 to 4 AEs,0.414535
uuid-c95d58d72bda48d3b31579950c465357,phase 1/2 study CA209-032,0.398283
uuid-c95d58d72bda48d3b31579950c465357,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-d3654776db1b42c1910c8dc445f8da9a,melanoma,0.410364
uuid-b555d305064e432093a8bcdb5bbce306,nivolumab,0.543393
uuid-b555d305064e432093a8bcdb5bbce306,Bristol-Myers Squibb,0.458581
uuid-b555d305064e432093a8bcdb5bbce306,evaluating,0.627127
uuid-b555d305064e432093a8bcdb5bbce306,not conducted any controlled clinical trials/studies,0.674468
uuid-b555d305064e432093a8bcdb5bbce306,Pubmed literature search,0.83387
uuid-b555d305064e432093a8bcdb5bbce306,purposes other than its labeled indication must be considered investigational,0.900914
uuid-b555d305064e432093a8bcdb5bbce306,not identify any citations relevant to your inquiry,0.791951
uuid-b555d305064e432093a8bcdb5bbce306,using the following search terms,0.779466
uuid-b555d305064e432093a8bcdb5bbce306,efficacy and safety of nivolumab,0.464468
uuid-d212a94bc4c54043b372412a7e297d44,Lancet Oncol,0.406401
uuid-d212a94bc4c54043b372412a7e297d44,phase 3 study,0.803344
uuid-d212a94bc4c54043b372412a7e297d44,melanoma,0.355296
uuid-d212a94bc4c54043b372412a7e297d44,phase 1 study,0.44682
uuid-d212a94bc4c54043b372412a7e297d44,Rizvi NA,0.53134
uuid-d212a94bc4c54043b372412a7e297d44,CA209-003,0.385648
uuid-d212a94bc4c54043b372412a7e297d44,Weber JS,0.533741
uuid-d212a94bc4c54043b372412a7e297d44,BMS,0.342861
uuid-d212a94bc4c54043b372412a7e297d44,phase 2 study,0.513385
uuid-eb1a2b2b9f67494790e20d6d898a81e0,Bristol-Myers Squibb,0.396088
uuid-eb1a2b2b9f67494790e20d6d898a81e0,95% CI,0.416844
uuid-eb1a2b2b9f67494790e20d6d898a81e0,patients,0.349645
uuid-eb1a2b2b9f67494790e20d6d898a81e0,Median overall survival,0.37953
uuid-eb1a2b2b9f67494790e20d6d898a81e0,adverse,0.360039
uuid-eb1a2b2b9f67494790e20d6d898a81e0,Median OS,0.365925
uuid-eb1a2b2b9f67494790e20d6d898a81e0,hazard ratio,0.381192
uuid-eb1a2b2b9f67494790e20d6d898a81e0,Median duration of response,0.39407
uuid-0f3adae499c740ef829b7cc771f87728,adverse,0.416199
uuid-2e6d0bc3cc694a80890144b8696a0be7,nivolumab,0.359772
uuid-fec3920538f44b148137a6fa72ed7ce3,efficacy,0.354465
uuid-fec3920538f44b148137a6fa72ed7ce3,RCC,0.314785
uuid-fec3920538f44b148137a6fa72ed7ce3,Topalian,0.332318
uuid-fec3920538f44b148137a6fa72ed7ce3,phase 1 study,0.458647
uuid-fec3920538f44b148137a6fa72ed7ce3,CA209-003,0.473563
uuid-fec3920538f44b148137a6fa72ed7ce3,safety,0.382032
uuid-fec3920538f44b148137a6fa72ed7ce3,investigating,0.393338
uuid-fec3920538f44b148137a6fa72ed7ce3,Overall survival,0.323114
uuid-86bb495451d54e3ca423cd5bbb46dd1b,provided in the Detailed Information,0.309309
uuid-acd1fb8044c24038813a239b41403a21,adverse,0.419275
uuid-04bd34db048442cfbcf6ff9878bf1a5e,95% CI,0.419478
uuid-04bd34db048442cfbcf6ff9878bf1a5e,respectively,0.497608
uuid-04bd34db048442cfbcf6ff9878bf1a5e,Objective response rate,0.403649
uuid-04bd34db048442cfbcf6ff9878bf1a5e,ORR,0.578109
uuid-04bd34db048442cfbcf6ff9878bf1a5e,patients with advanced or metastatic,0.306625
uuid-04bd34db048442cfbcf6ff9878bf1a5e,Median overall survival,0.498783
uuid-04bd34db048442cfbcf6ff9878bf1a5e,nivolumab combined with ipilimumab,0.300486
uuid-04bd34db048442cfbcf6ff9878bf1a5e,tumors,0.323334
uuid-04bd34db048442cfbcf6ff9878bf1a5e,ESMO,0.534361
uuid-04bd34db048442cfbcf6ff9878bf1a5e,Median OS,0.394058
uuid-04bd34db048442cfbcf6ff9878bf1a5e,small cell lung cancer,0.380999
uuid-04bd34db048442cfbcf6ff9878bf1a5e,SCLC,0.365686
uuid-04bd34db048442cfbcf6ff9878bf1a5e,hazard ratio,0.419392
uuid-04bd34db048442cfbcf6ff9878bf1a5e,grade 3 to 4 AEs,0.414535
uuid-04bd34db048442cfbcf6ff9878bf1a5e,phase 1/2 study CA209-032,0.398283
uuid-04bd34db048442cfbcf6ff9878bf1a5e,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-777e607efa7545d894575c58e46be1ac,nivolumab,0.344939
uuid-777e607efa7545d894575c58e46be1ac,Bristol-Myers Squibb,0.363004
uuid-777e607efa7545d894575c58e46be1ac,evaluating,0.564404
uuid-777e607efa7545d894575c58e46be1ac,not conducted any controlled clinical trials/studies,0.538169
uuid-777e607efa7545d894575c58e46be1ac,RCC,0.336118
uuid-777e607efa7545d894575c58e46be1ac,search of published literature,0.750115
uuid-777e607efa7545d894575c58e46be1ac,Additionally,0.766378
uuid-777e607efa7545d894575c58e46be1ac,ongoing,0.629393
uuid-777e607efa7545d894575c58e46be1ac,PubMed and EMBASE,0.745288
uuid-777e607efa7545d894575c58e46be1ac,detailed search of www.clinicaltrials.gov,0.729251
uuid-777e607efa7545d894575c58e46be1ac,efficacy and safety of nivolumab,0.716075
uuid-777e607efa7545d894575c58e46be1ac,not identify any planned,0.665705
uuid-777e607efa7545d894575c58e46be1ac,not identify any citations relevant to your request,0.849476
uuid-777e607efa7545d894575c58e46be1ac,present using the following search terms,0.773092
uuid-e59eab5834d9488183cd1f5a090bcdf7,use of nivolumab for the treatment,0.305739
uuid-e59eab5834d9488183cd1f5a090bcdf7,patients with advanced or metastatic,0.509457
uuid-e59eab5834d9488183cd1f5a090bcdf7,nivolumab combined with ipilimumab,0.496885
uuid-e59eab5834d9488183cd1f5a090bcdf7,not approved,0.397631
uuid-e59eab5834d9488183cd1f5a090bcdf7,clinical trials investigating the safety,0.478965
uuid-e59eab5834d9488183cd1f5a090bcdf7,bladder cancer,0.940126
uuid-5dc267e4e793400ab30b6005de598680,provided in the Detailed Information,0.349112
uuid-5dc267e4e793400ab30b6005de598680,Weber JS,0.321343
uuid-c8b8a55423e74fcea2fd99629cb67d98,N Engl J Med,0.736537
uuid-c8b8a55423e74fcea2fd99629cb67d98,Lancet Oncol,0.412554
uuid-c8b8a55423e74fcea2fd99629cb67d98,protocol,0.498467
uuid-c8b8a55423e74fcea2fd99629cb67d98,McDermott DF,0.527343
uuid-c8b8a55423e74fcea2fd99629cb67d98,Motzer RJ,0.486874
uuid-c8b8a55423e74fcea2fd99629cb67d98,phase 3 study,0.539239
uuid-c8b8a55423e74fcea2fd99629cb67d98,Escudier B,0.522059
uuid-c8b8a55423e74fcea2fd99629cb67d98,et al.,0.50848
uuid-c8b8a55423e74fcea2fd99629cb67d98,J Clin Oncol,0.444735
uuid-c8b8a55423e74fcea2fd99629cb67d98,Rizvi NA,0.663369
uuid-c8b8a55423e74fcea2fd99629cb67d98,Brahmer J,0.697776
uuid-c8b8a55423e74fcea2fd99629cb67d98,Weber JS,0.406207
uuid-c8b8a55423e74fcea2fd99629cb67d98,BMS,0.495407
uuid-c8b8a55423e74fcea2fd99629cb67d98,phase 2 study,0.655158
uuid-c10eb31c326249ac81cd451a40b6b8de,OS,0.62262
uuid-c10eb31c326249ac81cd451a40b6b8de,PFS,0.65903
uuid-c10eb31c326249ac81cd451a40b6b8de,Overall survival,0.644151
uuid-1c35e1e6d3b049e798f4e406e59c46f5,use of nivolumab for the treatment,0.409821
uuid-1c35e1e6d3b049e798f4e406e59c46f5,patients with advanced or metastatic,0.645244
uuid-1c35e1e6d3b049e798f4e406e59c46f5,nivolumab combined with ipilimumab,0.676339
uuid-1c35e1e6d3b049e798f4e406e59c46f5,not approved,0.453534
uuid-1c35e1e6d3b049e798f4e406e59c46f5,clinical trials investigating the safety,0.548799
uuid-1c35e1e6d3b049e798f4e406e59c46f5,phase 1/2 study CA209-032,0.34114
uuid-1c35e1e6d3b049e798f4e406e59c46f5,bladder cancer,0.749142
uuid-1c35e1e6d3b049e798f4e406e59c46f5,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-235761bca62b4bf38387f5777089e98e,use of nivolumab for the treatment,0.305739
uuid-235761bca62b4bf38387f5777089e98e,patients with advanced or metastatic,0.509457
uuid-235761bca62b4bf38387f5777089e98e,nivolumab combined with ipilimumab,0.496885
uuid-235761bca62b4bf38387f5777089e98e,not approved,0.397631
uuid-235761bca62b4bf38387f5777089e98e,clinical trials investigating the safety,0.478965
uuid-235761bca62b4bf38387f5777089e98e,bladder cancer,0.940126
uuid-80407ce8079943deaa484e91f86ff5eb,N Engl J Med,0.47446
uuid-80407ce8079943deaa484e91f86ff5eb,protocol,0.775143
uuid-80407ce8079943deaa484e91f86ff5eb,McDermott DF,0.756118
uuid-80407ce8079943deaa484e91f86ff5eb,Motzer RJ,0.827454
uuid-80407ce8079943deaa484e91f86ff5eb,phase 3 study,0.422813
uuid-80407ce8079943deaa484e91f86ff5eb,Escudier B,0.764532
uuid-80407ce8079943deaa484e91f86ff5eb,NEJM,0.403986
uuid-80407ce8079943deaa484e91f86ff5eb,et al.,0.688347
uuid-80407ce8079943deaa484e91f86ff5eb,J Clin Oncol,0.796776
uuid-80407ce8079943deaa484e91f86ff5eb,Topalian,0.391537
uuid-80407ce8079943deaa484e91f86ff5eb,phase 1 study,0.491683
uuid-80407ce8079943deaa484e91f86ff5eb,CA209-003,0.556088
uuid-80407ce8079943deaa484e91f86ff5eb,phase 2 study,0.690687
uuid-80407ce8079943deaa484e91f86ff5eb,present using the following search terms,0.310671
uuid-80407ce8079943deaa484e91f86ff5eb,investigating,0.600457
uuid-ef0cde59afa44c04bca6144f388dca89,nivolumab,0.574074
uuid-ef0cde59afa44c04bca6144f388dca89,Bristol-Myers Squibb,0.429238
uuid-ef0cde59afa44c04bca6144f388dca89,evaluating,0.587732
uuid-ef0cde59afa44c04bca6144f388dca89,not conducted any controlled clinical trials/studies,0.645965
uuid-ef0cde59afa44c04bca6144f388dca89,Pubmed literature search,0.877103
uuid-ef0cde59afa44c04bca6144f388dca89,purposes other than its labeled indication must be considered investigational,0.93987
uuid-ef0cde59afa44c04bca6144f388dca89,not identify any citations relevant to your inquiry,0.838127
uuid-ef0cde59afa44c04bca6144f388dca89,using the following search terms,0.82441
uuid-ef0cde59afa44c04bca6144f388dca89,efficacy and safety of nivolumab,0.42376
uuid-401bf9e252e840bf96c78ed1322d82be,OS,0.62262
uuid-401bf9e252e840bf96c78ed1322d82be,PFS,0.65903
uuid-401bf9e252e840bf96c78ed1322d82be,Overall survival,0.644151
uuid-d33fac54e1d242deaed72da9c3e4e041,requested,0.748269
uuid-ecb6d04fec1d487b98618ac26c0f567d,N Engl J Med,0.673548
uuid-ecb6d04fec1d487b98618ac26c0f567d,Lancet Oncol,0.350563
uuid-ecb6d04fec1d487b98618ac26c0f567d,protocol,0.837793
uuid-ecb6d04fec1d487b98618ac26c0f567d,McDermott DF,0.912384
uuid-ecb6d04fec1d487b98618ac26c0f567d,Motzer RJ,0.895454
uuid-ecb6d04fec1d487b98618ac26c0f567d,phase 3 study,0.484739
uuid-ecb6d04fec1d487b98618ac26c0f567d,Escudier B,0.908217
uuid-ecb6d04fec1d487b98618ac26c0f567d,NEJM,0.491067
uuid-ecb6d04fec1d487b98618ac26c0f567d,et al.,0.901246
uuid-ecb6d04fec1d487b98618ac26c0f567d,J Clin Oncol,0.862956
uuid-ecb6d04fec1d487b98618ac26c0f567d,Topalian,0.429989
uuid-ecb6d04fec1d487b98618ac26c0f567d,phase 1 study,0.302978
uuid-ecb6d04fec1d487b98618ac26c0f567d,Rizvi NA,0.485777
uuid-ecb6d04fec1d487b98618ac26c0f567d,Brahmer J,0.342618
uuid-ecb6d04fec1d487b98618ac26c0f567d,Weber JS,0.307765
uuid-ecb6d04fec1d487b98618ac26c0f567d,phase 2 study,0.81115
uuid-8b389fdba9cf4c66b20691e7a8b80fe2,OS,0.62262
uuid-8b389fdba9cf4c66b20691e7a8b80fe2,PFS,0.65903
uuid-8b389fdba9cf4c66b20691e7a8b80fe2,Overall survival,0.644151
uuid-9d849bfd4294408fb8653afa66d33285,use of nivolumab for the treatment,0.305739
uuid-9d849bfd4294408fb8653afa66d33285,patients with advanced or metastatic,0.509457
uuid-9d849bfd4294408fb8653afa66d33285,nivolumab combined with ipilimumab,0.496885
uuid-9d849bfd4294408fb8653afa66d33285,not approved,0.397631
uuid-9d849bfd4294408fb8653afa66d33285,clinical trials investigating the safety,0.478965
uuid-9d849bfd4294408fb8653afa66d33285,bladder cancer,0.940126
uuid-d7ad8b44ae1c4b03bce4c90844841724,requested,0.540431
uuid-f5426f3485e44521ab82b67f09f4cc3f,requested,0.703219
uuid-8044e9f502a34572831f5a95b6e7fa40,requested,0.596876
uuid-5dc1cea143e54bfb9f5a2994a20ea661,requested,0.703219
uuid-0dfdf7098cdc42448cf701495e432cf7,95% CI,0.419478
uuid-0dfdf7098cdc42448cf701495e432cf7,respectively,0.497608
uuid-0dfdf7098cdc42448cf701495e432cf7,Objective response rate,0.403649
uuid-0dfdf7098cdc42448cf701495e432cf7,ORR,0.578109
uuid-0dfdf7098cdc42448cf701495e432cf7,patients with advanced or metastatic,0.306625
uuid-0dfdf7098cdc42448cf701495e432cf7,Median overall survival,0.498783
uuid-0dfdf7098cdc42448cf701495e432cf7,nivolumab combined with ipilimumab,0.300486
uuid-0dfdf7098cdc42448cf701495e432cf7,tumors,0.323334
uuid-0dfdf7098cdc42448cf701495e432cf7,ESMO,0.534361
uuid-0dfdf7098cdc42448cf701495e432cf7,Median OS,0.394058
uuid-0dfdf7098cdc42448cf701495e432cf7,small cell lung cancer,0.380999
uuid-0dfdf7098cdc42448cf701495e432cf7,SCLC,0.365686
uuid-0dfdf7098cdc42448cf701495e432cf7,hazard ratio,0.419392
uuid-0dfdf7098cdc42448cf701495e432cf7,grade 3 to 4 AEs,0.414535
uuid-0dfdf7098cdc42448cf701495e432cf7,phase 1/2 study CA209-032,0.398283
uuid-0dfdf7098cdc42448cf701495e432cf7,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-af8096ba1c6d4a729528a2ea767d5fa4,Opdivo,0.50165
uuid-af8096ba1c6d4a729528a2ea767d5fa4,open-label,0.304253
uuid-af8096ba1c6d4a729528a2ea767d5fa4,trial,0.521827
uuid-af8096ba1c6d4a729528a2ea767d5fa4,docetaxel,0.30238
uuid-af8096ba1c6d4a729528a2ea767d5fa4,safety of nivolumab monotherapy,0.432481
uuid-af8096ba1c6d4a729528a2ea767d5fa4,phase,0.378496
uuid-5af347fdc0ad4961b4195012caebbf46,Opdivo,0.50165
uuid-5af347fdc0ad4961b4195012caebbf46,open-label,0.304253
uuid-5af347fdc0ad4961b4195012caebbf46,trial,0.521827
uuid-5af347fdc0ad4961b4195012caebbf46,docetaxel,0.30238
uuid-5af347fdc0ad4961b4195012caebbf46,safety of nivolumab monotherapy,0.432481
uuid-5af347fdc0ad4961b4195012caebbf46,phase,0.378496
uuid-8f20bb41e53f4260a153ac118d78b031,Opdivo,0.50165
uuid-8f20bb41e53f4260a153ac118d78b031,open-label,0.304253
uuid-8f20bb41e53f4260a153ac118d78b031,trial,0.521827
uuid-8f20bb41e53f4260a153ac118d78b031,docetaxel,0.30238
uuid-8f20bb41e53f4260a153ac118d78b031,safety of nivolumab monotherapy,0.432481
uuid-8f20bb41e53f4260a153ac118d78b031,phase,0.378496
uuid-5c90f152f7a940cdb1394ba1ddd8d6a6,requested,0.568004
uuid-f46aaa0e78fd40d0a226fde6134aa832,open-label,0.39841
uuid-f46aaa0e78fd40d0a226fde6134aa832,trial,0.441894
uuid-f46aaa0e78fd40d0a226fde6134aa832,phase,0.507232
uuid-dfbec954b83a4755a5844b76e28dc0d7,Bristol-Myers Squibb,0.330517
uuid-dfbec954b83a4755a5844b76e28dc0d7,Opdivo,0.430944
uuid-dfbec954b83a4755a5844b76e28dc0d7,Pubmed literature search,0.52271
uuid-dfbec954b83a4755a5844b76e28dc0d7,purposes other than its labeled indication must be considered investigational,0.494514
uuid-dfbec954b83a4755a5844b76e28dc0d7,not identify any citations relevant to your inquiry,0.522608
uuid-dfbec954b83a4755a5844b76e28dc0d7,adverse,0.354466
uuid-dfbec954b83a4755a5844b76e28dc0d7,using the following search terms,0.553475
uuid-dfbec954b83a4755a5844b76e28dc0d7,reported,0.584702
uuid-70a8dc4749914429a1bc2ad09df54e04,Bristol-Myers Squibb,0.474956
uuid-70a8dc4749914429a1bc2ad09df54e04,evaluating,0.573107
uuid-70a8dc4749914429a1bc2ad09df54e04,not conducted any controlled clinical trials/studies,0.571917
uuid-70a8dc4749914429a1bc2ad09df54e04,search of published literature,0.358275
uuid-70a8dc4749914429a1bc2ad09df54e04,PubMed and EMBASE,0.327029
uuid-70a8dc4749914429a1bc2ad09df54e04,phase 1 study,0.471364
uuid-70a8dc4749914429a1bc2ad09df54e04,efficacy and safety of nivolumab,0.609107
uuid-70a8dc4749914429a1bc2ad09df54e04,CA209-003,0.512918
uuid-70a8dc4749914429a1bc2ad09df54e04,present using the following search terms,0.344632
uuid-70a8dc4749914429a1bc2ad09df54e04,investigating,0.669765
uuid-3cf31be3c7db405a883226dd1366227b,evaluating,0.333942
uuid-3cf31be3c7db405a883226dd1366227b,search of published literature,0.394781
uuid-3cf31be3c7db405a883226dd1366227b,Additionally,0.325161
uuid-3cf31be3c7db405a883226dd1366227b,PubMed and EMBASE,0.401513
uuid-3cf31be3c7db405a883226dd1366227b,efficacy and safety of nivolumab,0.375572
uuid-3cf31be3c7db405a883226dd1366227b,not identify any citations relevant to your request,0.423798
uuid-3cf31be3c7db405a883226dd1366227b,present using the following search terms,0.484697
uuid-38b849741bf546fdb743f3f0aa6d4eb8,Median OS,0.30556
uuid-38b849741bf546fdb743f3f0aa6d4eb8,not approved,0.392456
uuid-38b849741bf546fdb743f3f0aa6d4eb8,clinical trials investigating the safety,0.467974
uuid-38b849741bf546fdb743f3f0aa6d4eb8,fatigue,0.399896
uuid-38b849741bf546fdb743f3f0aa6d4eb8,hazard ratio,0.308509
uuid-2a38d79428f24a4f987876f4c1c77b8d,nivolumab,0.533409
uuid-2a38d79428f24a4f987876f4c1c77b8d,Bristol-Myers Squibb,0.426975
uuid-2a38d79428f24a4f987876f4c1c77b8d,evaluating,0.621736
uuid-2a38d79428f24a4f987876f4c1c77b8d,not conducted any controlled clinical trials/studies,0.644209
uuid-2a38d79428f24a4f987876f4c1c77b8d,Pubmed literature search,0.684954
uuid-2a38d79428f24a4f987876f4c1c77b8d,purposes other than its labeled indication must be considered investigational,0.753114
uuid-2a38d79428f24a4f987876f4c1c77b8d,not identify any citations relevant to your inquiry,0.668251
uuid-2a38d79428f24a4f987876f4c1c77b8d,search of published literature,0.323773
uuid-2a38d79428f24a4f987876f4c1c77b8d,Additionally,0.339673
uuid-2a38d79428f24a4f987876f4c1c77b8d,ongoing,0.307883
uuid-2a38d79428f24a4f987876f4c1c77b8d,PubMed and EMBASE,0.308601
uuid-2a38d79428f24a4f987876f4c1c77b8d,using the following search terms,0.635284
uuid-2a38d79428f24a4f987876f4c1c77b8d,detailed search of www.clinicaltrials.gov,0.344149
uuid-2a38d79428f24a4f987876f4c1c77b8d,efficacy and safety of nivolumab,0.521983
uuid-2a38d79428f24a4f987876f4c1c77b8d,not identify any planned,0.316934
uuid-2a38d79428f24a4f987876f4c1c77b8d,not identify any citations relevant to your request,0.395096
uuid-2a38d79428f24a4f987876f4c1c77b8d,present using the following search terms,0.365522
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,NSCLC,0.480337
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,respectively,0.400584
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,non-small cell lung cancer,0.395662
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,patients,0.382838
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,considered investigational,0.378457
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,Objective response rate,0.446233
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,ORR,0.488323
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,monotherapy,0.419452
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,small cell lung cancer,0.328277
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,docetaxel,0.370754
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,SCLC,0.328412
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,grade 3 to 4 AEs,0.337672
uuid-74d7eb70e42e4dc6890fa3ce4588ab4c,platinum-based doublet chemotherapy,0.355492
uuid-4e26db87b16a49629db7133f3423636f,nivolumab,0.533409
uuid-4e26db87b16a49629db7133f3423636f,Bristol-Myers Squibb,0.426975
uuid-4e26db87b16a49629db7133f3423636f,evaluating,0.621736
uuid-4e26db87b16a49629db7133f3423636f,not conducted any controlled clinical trials/studies,0.644209
uuid-4e26db87b16a49629db7133f3423636f,Pubmed literature search,0.684954
uuid-4e26db87b16a49629db7133f3423636f,purposes other than its labeled indication must be considered investigational,0.753114
uuid-4e26db87b16a49629db7133f3423636f,not identify any citations relevant to your inquiry,0.668251
uuid-4e26db87b16a49629db7133f3423636f,search of published literature,0.323773
uuid-4e26db87b16a49629db7133f3423636f,Additionally,0.339673
uuid-4e26db87b16a49629db7133f3423636f,ongoing,0.307883
uuid-4e26db87b16a49629db7133f3423636f,PubMed and EMBASE,0.308601
uuid-4e26db87b16a49629db7133f3423636f,using the following search terms,0.635284
uuid-4e26db87b16a49629db7133f3423636f,detailed search of www.clinicaltrials.gov,0.344149
uuid-4e26db87b16a49629db7133f3423636f,efficacy and safety of nivolumab,0.521983
uuid-4e26db87b16a49629db7133f3423636f,not identify any planned,0.316934
uuid-4e26db87b16a49629db7133f3423636f,not identify any citations relevant to your request,0.395096
uuid-4e26db87b16a49629db7133f3423636f,present using the following search terms,0.365522
uuid-a41b8b9a1a7a4a8eae51bb69de058395,respectively,0.661351
uuid-a41b8b9a1a7a4a8eae51bb69de058395,Objective response rate,0.619462
uuid-a41b8b9a1a7a4a8eae51bb69de058395,ORR,0.537232
uuid-a41b8b9a1a7a4a8eae51bb69de058395,monotherapy,0.421967
uuid-a41b8b9a1a7a4a8eae51bb69de058395,docetaxel,0.426453
uuid-11020c4462434e588a722a46f9b1a318,Bristol-Myers Squibb,0.363619
uuid-11020c4462434e588a722a46f9b1a318,not conducted any controlled clinical trials/studies,0.324604
uuid-11020c4462434e588a722a46f9b1a318,Opdivo,0.460341
uuid-11020c4462434e588a722a46f9b1a318,Pubmed literature search,0.608058
uuid-11020c4462434e588a722a46f9b1a318,purposes other than its labeled indication must be considered investigational,0.586106
uuid-11020c4462434e588a722a46f9b1a318,not identify any citations relevant to your inquiry,0.599868
uuid-11020c4462434e588a722a46f9b1a318,adverse,0.3044
uuid-11020c4462434e588a722a46f9b1a318,using the following search terms,0.633262
uuid-11020c4462434e588a722a46f9b1a318,databases,0.307465
uuid-11020c4462434e588a722a46f9b1a318,reported,0.545836
uuid-f3ac2f469f884966be72c4c5104a26e3,patients with advanced or metastatic,0.478326
uuid-f3ac2f469f884966be72c4c5104a26e3,nivolumab combined with ipilimumab,0.498766
uuid-f3ac2f469f884966be72c4c5104a26e3,not approved,0.34724
uuid-f3ac2f469f884966be72c4c5104a26e3,clinical trials investigating the safety,0.426729
uuid-f3ac2f469f884966be72c4c5104a26e3,bladder cancer,0.6548
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,evaluating,0.331463
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,not conducted any controlled clinical trials/studies,0.327968
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,protocol,0.532972
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,RCC,0.386451
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,McDermott DF,0.444329
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,search of published literature,0.50452
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,Additionally,0.555299
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,ongoing,0.478674
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,Motzer RJ,0.475488
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,PubMed and EMBASE,0.501909
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,Escudier B,0.459186
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,et al.,0.397016
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,J Clin Oncol,0.428996
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,detailed search of www.clinicaltrials.gov,0.514934
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,efficacy and safety of nivolumab,0.47512
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,not identify any planned,0.493147
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,phase 2 study,0.384586
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,not identify any citations relevant to your request,0.565812
uuid-5ea40561dcc3435bb9a46c3bd6b6c722,present using the following search terms,0.490802
uuid-a5f8debb749945038dca0308a4925424,nivolumab,0.375158
uuid-a5f8debb749945038dca0308a4925424,Bristol-Myers Squibb,0.31235
uuid-a5f8debb749945038dca0308a4925424,evaluating,0.511438
uuid-a5f8debb749945038dca0308a4925424,not conducted any controlled clinical trials/studies,0.477531
uuid-a5f8debb749945038dca0308a4925424,RCC,0.307428
uuid-a5f8debb749945038dca0308a4925424,search of published literature,0.710733
uuid-a5f8debb749945038dca0308a4925424,Additionally,0.711466
uuid-a5f8debb749945038dca0308a4925424,ongoing,0.566565
uuid-a5f8debb749945038dca0308a4925424,PubMed and EMBASE,0.709046
uuid-a5f8debb749945038dca0308a4925424,detailed search of www.clinicaltrials.gov,0.673505
uuid-a5f8debb749945038dca0308a4925424,phase 1 study,0.319262
uuid-a5f8debb749945038dca0308a4925424,efficacy and safety of nivolumab,0.667003
uuid-a5f8debb749945038dca0308a4925424,not identify any planned,0.605032
uuid-a5f8debb749945038dca0308a4925424,CA209-003,0.324544
uuid-a5f8debb749945038dca0308a4925424,not identify any citations relevant to your request,0.807219
uuid-a5f8debb749945038dca0308a4925424,present using the following search terms,0.755771
uuid-a5f8debb749945038dca0308a4925424,investigating,0.325171
uuid-459f07ff157347408e0e7b277727e51a,phase 3 study,0.411479
uuid-459f07ff157347408e0e7b277727e51a,open-label,0.407638
uuid-459f07ff157347408e0e7b277727e51a,phase 1 study,0.336258
uuid-459f07ff157347408e0e7b277727e51a,phase 2 study,0.348851
uuid-459f07ff157347408e0e7b277727e51a,phase,0.446608
uuid-c864fd9bace946edbed81d9ecddf3bf8,95% CI,0.419478
uuid-c864fd9bace946edbed81d9ecddf3bf8,respectively,0.497608
uuid-c864fd9bace946edbed81d9ecddf3bf8,Objective response rate,0.403649
uuid-c864fd9bace946edbed81d9ecddf3bf8,ORR,0.578109
uuid-c864fd9bace946edbed81d9ecddf3bf8,patients with advanced or metastatic,0.306625
uuid-c864fd9bace946edbed81d9ecddf3bf8,Median overall survival,0.498783
uuid-c864fd9bace946edbed81d9ecddf3bf8,nivolumab combined with ipilimumab,0.300486
uuid-c864fd9bace946edbed81d9ecddf3bf8,tumors,0.323334
uuid-c864fd9bace946edbed81d9ecddf3bf8,ESMO,0.534361
uuid-c864fd9bace946edbed81d9ecddf3bf8,Median OS,0.394058
uuid-c864fd9bace946edbed81d9ecddf3bf8,small cell lung cancer,0.380999
uuid-c864fd9bace946edbed81d9ecddf3bf8,SCLC,0.365686
uuid-c864fd9bace946edbed81d9ecddf3bf8,hazard ratio,0.419392
uuid-c864fd9bace946edbed81d9ecddf3bf8,grade 3 to 4 AEs,0.414535
uuid-c864fd9bace946edbed81d9ecddf3bf8,phase 1/2 study CA209-032,0.398283
uuid-c864fd9bace946edbed81d9ecddf3bf8,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-4c940aca24ce4ec197156498abd4851c,OS,0.62262
uuid-4c940aca24ce4ec197156498abd4851c,PFS,0.65903
uuid-4c940aca24ce4ec197156498abd4851c,Overall survival,0.644151
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,N Engl J Med,0.302601
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,AEs,0.348167
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,patients,0.536884
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,provided in the Detailed Information,0.387544
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,ESMO,0.462801
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,NEJM,0.66427
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,Topalian,0.692873
uuid-4552ceba91c94ebd840f7c5f49e5ae9e,grade 3 to 4 AEs,0.626596
uuid-6405180ed2d84a46a15e832feaa7b0f1,N Engl J Med,0.338899
uuid-6405180ed2d84a46a15e832feaa7b0f1,provided in the Detailed Information,0.436968
uuid-6405180ed2d84a46a15e832feaa7b0f1,protocol,0.453585
uuid-6405180ed2d84a46a15e832feaa7b0f1,adverse,0.324832
uuid-6405180ed2d84a46a15e832feaa7b0f1,McDermott DF,0.542191
uuid-6405180ed2d84a46a15e832feaa7b0f1,Motzer RJ,0.522108
uuid-6405180ed2d84a46a15e832feaa7b0f1,phase 3 study,0.460884
uuid-6405180ed2d84a46a15e832feaa7b0f1,Escudier B,0.529511
uuid-6405180ed2d84a46a15e832feaa7b0f1,et al.,0.503626
uuid-6405180ed2d84a46a15e832feaa7b0f1,J Clin Oncol,0.5023
uuid-6405180ed2d84a46a15e832feaa7b0f1,Weber JS,0.34061
uuid-6405180ed2d84a46a15e832feaa7b0f1,phase 2 study,0.545721
uuid-3a239302b129481aba04991515205e6c,nivolumab,0.324218
uuid-3a239302b129481aba04991515205e6c,evaluating,0.310249
uuid-3a239302b129481aba04991515205e6c,not conducted any controlled clinical trials/studies,0.322652
uuid-3a239302b129481aba04991515205e6c,Pubmed literature search,0.416435
uuid-3a239302b129481aba04991515205e6c,purposes other than its labeled indication must be considered investigational,0.451854
uuid-3a239302b129481aba04991515205e6c,not identify any citations relevant to your inquiry,0.404364
uuid-3a239302b129481aba04991515205e6c,using the following search terms,0.388538
uuid-104e225c7f1e4d22a078aa42a1381bae,requested,0.595565
uuid-8c474ec5514242058925fbe0242e1d87,requested,0.553831
uuid-8c474ec5514242058925fbe0242e1d87,Horn L,0.582928
uuid-8c474ec5514242058925fbe0242e1d87,platinum-based doublet chemotherapy,0.625968
uuid-55748449fb9541dcbd3354bc4b57e55c,use of nivolumab for the treatment,0.311704
uuid-55748449fb9541dcbd3354bc4b57e55c,efficacy,0.35863
uuid-55748449fb9541dcbd3354bc4b57e55c,patients,0.311205
uuid-55748449fb9541dcbd3354bc4b57e55c,RCC,0.421812
uuid-55748449fb9541dcbd3354bc4b57e55c,phase 1 study,0.468818
uuid-55748449fb9541dcbd3354bc4b57e55c,CA209-003,0.413937
uuid-55748449fb9541dcbd3354bc4b57e55c,safety,0.345481
uuid-55748449fb9541dcbd3354bc4b57e55c,investigating,0.338069
uuid-d450cf1073714e179f676bfc883b4da2,Bristol-Myers Squibb,0.341822
uuid-d450cf1073714e179f676bfc883b4da2,not conducted any controlled clinical trials/studies,0.304507
uuid-d450cf1073714e179f676bfc883b4da2,Opdivo,0.461382
uuid-d450cf1073714e179f676bfc883b4da2,Pubmed literature search,0.614325
uuid-d450cf1073714e179f676bfc883b4da2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d450cf1073714e179f676bfc883b4da2,not identify any citations relevant to your inquiry,0.606087
uuid-d450cf1073714e179f676bfc883b4da2,adverse,0.304183
uuid-d450cf1073714e179f676bfc883b4da2,using the following search terms,0.642331
uuid-d450cf1073714e179f676bfc883b4da2,databases,0.315039
uuid-d450cf1073714e179f676bfc883b4da2,reported,0.556704
uuid-6e61b5505615437f89dd993445e1a82a,N Engl J Med,0.400046
uuid-6e61b5505615437f89dd993445e1a82a,protocol,0.583735
uuid-6e61b5505615437f89dd993445e1a82a,McDermott DF,0.603371
uuid-6e61b5505615437f89dd993445e1a82a,Motzer RJ,0.593137
uuid-6e61b5505615437f89dd993445e1a82a,phase 3 study,0.401882
uuid-6e61b5505615437f89dd993445e1a82a,Escudier B,0.603955
uuid-6e61b5505615437f89dd993445e1a82a,et al.,0.576351
uuid-6e61b5505615437f89dd993445e1a82a,J Clin Oncol,0.547598
uuid-6e61b5505615437f89dd993445e1a82a,phase 2 study,0.528273
uuid-4fdc746712b141be979f326830b55761,OS,0.62262
uuid-4fdc746712b141be979f326830b55761,PFS,0.65903
uuid-4fdc746712b141be979f326830b55761,Overall survival,0.644151
uuid-dc68805dac5e4d42bf59e8e1899df6fd,nivolumab,0.599968
uuid-dc68805dac5e4d42bf59e8e1899df6fd,Bristol-Myers Squibb,0.465989
uuid-dc68805dac5e4d42bf59e8e1899df6fd,evaluating,0.636107
uuid-dc68805dac5e4d42bf59e8e1899df6fd,not conducted any controlled clinical trials/studies,0.681201
uuid-dc68805dac5e4d42bf59e8e1899df6fd,Pubmed literature search,0.802059
uuid-dc68805dac5e4d42bf59e8e1899df6fd,purposes other than its labeled indication must be considered investigational,0.877075
uuid-dc68805dac5e4d42bf59e8e1899df6fd,not identify any citations relevant to your inquiry,0.760546
uuid-dc68805dac5e4d42bf59e8e1899df6fd,using the following search terms,0.744837
uuid-dc68805dac5e4d42bf59e8e1899df6fd,efficacy and safety of nivolumab,0.484888
uuid-abc469ee963f4c2f8496ea596f16a6a4,provided in the Detailed Information,0.375874
uuid-9a55a51690f841ab86dac86c13c0f8e5,requested,0.343939
uuid-508db00ca94e40a09915f4d11d303166,patients,0.505109
uuid-508db00ca94e40a09915f4d11d303166,safety,0.450586
uuid-508db00ca94e40a09915f4d11d303166,databases,0.505843
uuid-983782a0473c4942b2fba6db720f16b7,requested,0.851316
uuid-983782a0473c4942b2fba6db720f16b7,Horn L,0.326727
uuid-31eeafdd36a540fdb4354e19b590d44b,N Engl J Med,0.689907
uuid-31eeafdd36a540fdb4354e19b590d44b,Lancet Oncol,0.584216
uuid-31eeafdd36a540fdb4354e19b590d44b,protocol,0.72528
uuid-31eeafdd36a540fdb4354e19b590d44b,McDermott DF,0.794444
uuid-31eeafdd36a540fdb4354e19b590d44b,Motzer RJ,0.755383
uuid-31eeafdd36a540fdb4354e19b590d44b,phase 3 study,0.521307
uuid-31eeafdd36a540fdb4354e19b590d44b,Escudier B,0.794743
uuid-31eeafdd36a540fdb4354e19b590d44b,NEJM,0.434762
uuid-31eeafdd36a540fdb4354e19b590d44b,et al.,0.777092
uuid-31eeafdd36a540fdb4354e19b590d44b,J Clin Oncol,0.708338
uuid-31eeafdd36a540fdb4354e19b590d44b,Topalian,0.401719
uuid-31eeafdd36a540fdb4354e19b590d44b,Rizvi NA,0.731383
uuid-31eeafdd36a540fdb4354e19b590d44b,Brahmer J,0.378658
uuid-31eeafdd36a540fdb4354e19b590d44b,Weber JS,0.614831
uuid-31eeafdd36a540fdb4354e19b590d44b,phase 2 study,0.769458
uuid-2e8fb63b03bc4570a8d9094948116741,requested,0.366547
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,Bristol-Myers Squibb,0.341822
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,not conducted any controlled clinical trials/studies,0.304507
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,Opdivo,0.461382
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,Pubmed literature search,0.614325
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,purposes other than its labeled indication must be considered investigational,0.586645
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,not identify any citations relevant to your inquiry,0.606087
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,adverse,0.304183
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,using the following search terms,0.642331
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,databases,0.315039
uuid-1f0152c5bb724ce19a6b8bad0fcc9775,reported,0.556704
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,use of nivolumab for the treatment,0.409821
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,patients with advanced or metastatic,0.645244
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,nivolumab combined with ipilimumab,0.676339
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,not approved,0.453534
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,clinical trials investigating the safety,0.548799
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,phase 1/2 study CA209-032,0.34114
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,bladder cancer,0.749142
uuid-0de3b38a6f8f4ab8817c9e518ff2cd97,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,Bristol-Myers Squibb,0.341822
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,not conducted any controlled clinical trials/studies,0.304507
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,Opdivo,0.461382
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,Pubmed literature search,0.614325
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,purposes other than its labeled indication must be considered investigational,0.586645
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,not identify any citations relevant to your inquiry,0.606087
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,adverse,0.304183
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,using the following search terms,0.642331
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,databases,0.315039
uuid-58dd2c37e1a94a1f8b8ccc1f197ad999,reported,0.556704
uuid-367f503b4b66459b9ac9fb7e871ee8b4,search of published literature,0.394524
uuid-367f503b4b66459b9ac9fb7e871ee8b4,Additionally,0.413583
uuid-367f503b4b66459b9ac9fb7e871ee8b4,ongoing,0.322117
uuid-367f503b4b66459b9ac9fb7e871ee8b4,PubMed and EMBASE,0.391671
uuid-367f503b4b66459b9ac9fb7e871ee8b4,detailed search of www.clinicaltrials.gov,0.375936
uuid-367f503b4b66459b9ac9fb7e871ee8b4,efficacy and safety of nivolumab,0.370699
uuid-367f503b4b66459b9ac9fb7e871ee8b4,not identify any planned,0.34283
uuid-367f503b4b66459b9ac9fb7e871ee8b4,Weber JS,0.319229
uuid-367f503b4b66459b9ac9fb7e871ee8b4,not identify any citations relevant to your request,0.447813
uuid-367f503b4b66459b9ac9fb7e871ee8b4,present using the following search terms,0.408199
uuid-50ef1535f6754791baac7f832605bfc8,nivolumab,0.41757
uuid-50ef1535f6754791baac7f832605bfc8,Bristol-Myers Squibb,0.561084
uuid-50ef1535f6754791baac7f832605bfc8,evaluating,0.701107
uuid-50ef1535f6754791baac7f832605bfc8,not conducted any controlled clinical trials/studies,0.752437
uuid-50ef1535f6754791baac7f832605bfc8,Pubmed literature search,0.811215
uuid-50ef1535f6754791baac7f832605bfc8,purposes other than its labeled indication must be considered investigational,0.879129
uuid-50ef1535f6754791baac7f832605bfc8,not identify any citations relevant to your inquiry,0.767127
uuid-50ef1535f6754791baac7f832605bfc8,using the following search terms,0.759291
uuid-50ef1535f6754791baac7f832605bfc8,efficacy and safety of nivolumab,0.526702
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,Bristol-Myers Squibb,0.341822
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,not conducted any controlled clinical trials/studies,0.304507
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,Opdivo,0.461382
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,Pubmed literature search,0.614325
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,not identify any citations relevant to your inquiry,0.606087
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,adverse,0.304183
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,using the following search terms,0.642331
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,databases,0.315039
uuid-dfea8fd85dfa4fc68e39ae33d40a36e2,reported,0.556704
uuid-b19c8be5d930436281abacb0946c3d82,Objective response rate,0.451139
uuid-b19c8be5d930436281abacb0946c3d82,clinicaltrials.gov,0.503706
uuid-2641ee21fb8a4ff8b18a99fc12169910,trial,0.319152
uuid-69b2352799b74f9fac54b8dc4bd97f1c,search of published literature,0.394524
uuid-69b2352799b74f9fac54b8dc4bd97f1c,Additionally,0.413583
uuid-69b2352799b74f9fac54b8dc4bd97f1c,ongoing,0.322117
uuid-69b2352799b74f9fac54b8dc4bd97f1c,PubMed and EMBASE,0.391671
uuid-69b2352799b74f9fac54b8dc4bd97f1c,detailed search of www.clinicaltrials.gov,0.375936
uuid-69b2352799b74f9fac54b8dc4bd97f1c,efficacy and safety of nivolumab,0.370699
uuid-69b2352799b74f9fac54b8dc4bd97f1c,not identify any planned,0.34283
uuid-69b2352799b74f9fac54b8dc4bd97f1c,Weber JS,0.319229
uuid-69b2352799b74f9fac54b8dc4bd97f1c,not identify any citations relevant to your request,0.447813
uuid-69b2352799b74f9fac54b8dc4bd97f1c,present using the following search terms,0.408199
uuid-c9b825d43b6d40ff985df6a694a8f0ad,Bristol-Myers Squibb,0.494637
uuid-43491d809801441aaf47d1ba94dc16d1,nivolumab,0.572007
uuid-43491d809801441aaf47d1ba94dc16d1,Bristol-Myers Squibb,0.454551
uuid-43491d809801441aaf47d1ba94dc16d1,evaluating,0.606948
uuid-43491d809801441aaf47d1ba94dc16d1,not conducted any controlled clinical trials/studies,0.6694
uuid-43491d809801441aaf47d1ba94dc16d1,Pubmed literature search,0.868273
uuid-43491d809801441aaf47d1ba94dc16d1,purposes other than its labeled indication must be considered investigational,0.934369
uuid-43491d809801441aaf47d1ba94dc16d1,not identify any citations relevant to your inquiry,0.826029
uuid-43491d809801441aaf47d1ba94dc16d1,using the following search terms,0.813469
uuid-43491d809801441aaf47d1ba94dc16d1,efficacy and safety of nivolumab,0.446264
uuid-bf58e4f3297145eaa0b27968fa908511,Bristol-Myers Squibb,0.396793
uuid-bf58e4f3297145eaa0b27968fa908511,requested,0.743312
uuid-bf58e4f3297145eaa0b27968fa908511,Opdivo,0.385736
uuid-af709d5b1879428f9a2b919e3e34a8f3,nivolumab,0.359772
uuid-aaba35ff7019485baf8c68289fa4e2d5,OS,0.328439
uuid-aaba35ff7019485baf8c68289fa4e2d5,docetaxel,0.340031
uuid-ef8ba097b1a6482f9a399e097fc63c09,OS,0.328439
uuid-ef8ba097b1a6482f9a399e097fc63c09,docetaxel,0.340031
uuid-bad99f48ef794ecfbd03b42a34101d6b,grade,0.309792
uuid-427683e8784e416180a0e8e47c0d1eeb,patients with advanced or metastatic,0.478326
uuid-427683e8784e416180a0e8e47c0d1eeb,nivolumab combined with ipilimumab,0.498766
uuid-427683e8784e416180a0e8e47c0d1eeb,not approved,0.34724
uuid-427683e8784e416180a0e8e47c0d1eeb,clinical trials investigating the safety,0.426729
uuid-427683e8784e416180a0e8e47c0d1eeb,bladder cancer,0.6548
uuid-7dee92a54c1743658458ff1453302d8c,respectively,0.661351
uuid-7dee92a54c1743658458ff1453302d8c,Objective response rate,0.619462
uuid-7dee92a54c1743658458ff1453302d8c,ORR,0.537232
uuid-7dee92a54c1743658458ff1453302d8c,monotherapy,0.421967
uuid-7dee92a54c1743658458ff1453302d8c,docetaxel,0.426453
uuid-7c3088f2211840fcb2f520ec99122d49,Bristol-Myers Squibb,0.840451
uuid-7c3088f2211840fcb2f520ec99122d49,evaluating,0.718784
uuid-7c3088f2211840fcb2f520ec99122d49,not conducted any controlled clinical trials/studies,0.798502
uuid-7c3088f2211840fcb2f520ec99122d49,adverse,0.316881
uuid-7c3088f2211840fcb2f520ec99122d49,efficacy and safety of nivolumab,0.640661
uuid-7c3088f2211840fcb2f520ec99122d49,reported,0.342563
uuid-41e4a2e4920745a3aaa982107b893e5e,N Engl J Med,0.730936
uuid-41e4a2e4920745a3aaa982107b893e5e,requested,0.300519
uuid-41e4a2e4920745a3aaa982107b893e5e,protocol,0.841438
uuid-41e4a2e4920745a3aaa982107b893e5e,McDermott DF,0.915579
uuid-41e4a2e4920745a3aaa982107b893e5e,Motzer RJ,0.894839
uuid-41e4a2e4920745a3aaa982107b893e5e,phase 3 study,0.422473
uuid-41e4a2e4920745a3aaa982107b893e5e,Escudier B,0.918427
uuid-41e4a2e4920745a3aaa982107b893e5e,NEJM,0.446862
uuid-41e4a2e4920745a3aaa982107b893e5e,et al.,0.903265
uuid-41e4a2e4920745a3aaa982107b893e5e,J Clin Oncol,0.848583
uuid-41e4a2e4920745a3aaa982107b893e5e,Topalian,0.396385
uuid-41e4a2e4920745a3aaa982107b893e5e,Rizvi NA,0.44308
uuid-41e4a2e4920745a3aaa982107b893e5e,Brahmer J,0.392049
uuid-41e4a2e4920745a3aaa982107b893e5e,Weber JS,0.30098
uuid-41e4a2e4920745a3aaa982107b893e5e,phase 2 study,0.773132
uuid-b0b1ec61768648a18eca108e442f70e0,Bristol-Myers Squibb,0.341822
uuid-b0b1ec61768648a18eca108e442f70e0,not conducted any controlled clinical trials/studies,0.304507
uuid-b0b1ec61768648a18eca108e442f70e0,Opdivo,0.461382
uuid-b0b1ec61768648a18eca108e442f70e0,Pubmed literature search,0.614325
uuid-b0b1ec61768648a18eca108e442f70e0,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b0b1ec61768648a18eca108e442f70e0,not identify any citations relevant to your inquiry,0.606087
uuid-b0b1ec61768648a18eca108e442f70e0,adverse,0.304183
uuid-b0b1ec61768648a18eca108e442f70e0,using the following search terms,0.642331
uuid-b0b1ec61768648a18eca108e442f70e0,databases,0.315039
uuid-b0b1ec61768648a18eca108e442f70e0,reported,0.556704
uuid-60336ba5eb2b4db9b9e7a1aad693e343,Objective response rate,0.451139
uuid-60336ba5eb2b4db9b9e7a1aad693e343,clinicaltrials.gov,0.503706
uuid-2380a27b8b3b44289a2f377980b62ce5,use of nivolumab for the treatment,0.409821
uuid-2380a27b8b3b44289a2f377980b62ce5,patients with advanced or metastatic,0.645244
uuid-2380a27b8b3b44289a2f377980b62ce5,nivolumab combined with ipilimumab,0.676339
uuid-2380a27b8b3b44289a2f377980b62ce5,not approved,0.453534
uuid-2380a27b8b3b44289a2f377980b62ce5,clinical trials investigating the safety,0.548799
uuid-2380a27b8b3b44289a2f377980b62ce5,phase 1/2 study CA209-032,0.34114
uuid-2380a27b8b3b44289a2f377980b62ce5,bladder cancer,0.749142
uuid-2380a27b8b3b44289a2f377980b62ce5,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-6df9dbf3823749cca4f50c41dc83f1cf,N Engl J Med,0.426245
uuid-6df9dbf3823749cca4f50c41dc83f1cf,protocol,0.427777
uuid-6df9dbf3823749cca4f50c41dc83f1cf,McDermott DF,0.446254
uuid-6df9dbf3823749cca4f50c41dc83f1cf,Motzer RJ,0.428813
uuid-6df9dbf3823749cca4f50c41dc83f1cf,Escudier B,0.449235
uuid-6df9dbf3823749cca4f50c41dc83f1cf,et al.,0.454619
uuid-6df9dbf3823749cca4f50c41dc83f1cf,J Clin Oncol,0.383083
uuid-6df9dbf3823749cca4f50c41dc83f1cf,Rizvi NA,0.305537
uuid-6df9dbf3823749cca4f50c41dc83f1cf,phase 2 study,0.349742
uuid-aa986b1ae5414521a7776da8bb555662,requested,0.569902
uuid-2022cd36bb944d2f894f6324a93b7fe1,ipilimumab,0.385692
uuid-2022cd36bb944d2f894f6324a93b7fe1,ASCO 2015,0.417944
uuid-2022cd36bb944d2f894f6324a93b7fe1,partial response,0.382425
uuid-2022cd36bb944d2f894f6324a93b7fe1,Stable disease,0.586335
uuid-2022cd36bb944d2f894f6324a93b7fe1,cohort,0.307748
uuid-0cadad73375a4d288e1f0b1bc418fcfd,nivolumab,0.499161
uuid-0cadad73375a4d288e1f0b1bc418fcfd,evaluating,0.445182
uuid-0cadad73375a4d288e1f0b1bc418fcfd,not conducted any controlled clinical trials/studies,0.421963
uuid-0cadad73375a4d288e1f0b1bc418fcfd,Pubmed literature search,0.376415
uuid-0cadad73375a4d288e1f0b1bc418fcfd,purposes other than its labeled indication must be considered investigational,0.437684
uuid-0cadad73375a4d288e1f0b1bc418fcfd,not identify any citations relevant to your inquiry,0.365654
uuid-0cadad73375a4d288e1f0b1bc418fcfd,using the following search terms,0.338601
uuid-0cadad73375a4d288e1f0b1bc418fcfd,efficacy and safety of nivolumab,0.358911
uuid-29053833e9f64073a624d00b9e5c2490,provided in the Detailed Information,0.316089
uuid-48e9c9e090c041b0b11769806239bdb2,provided in the Detailed Information,0.377993
uuid-48e9c9e090c041b0b11769806239bdb2,Weber JS,0.339634
uuid-78285391df4247ae861c89bce4da98ef,N Engl J Med,0.530939
uuid-78285391df4247ae861c89bce4da98ef,ASCO,0.316082
uuid-78285391df4247ae861c89bce4da98ef,Lancet Oncol,0.459805
uuid-78285391df4247ae861c89bce4da98ef,protocol,0.496501
uuid-78285391df4247ae861c89bce4da98ef,monotherapy,0.363567
uuid-78285391df4247ae861c89bce4da98ef,McDermott DF,0.521777
uuid-78285391df4247ae861c89bce4da98ef,Motzer RJ,0.515049
uuid-78285391df4247ae861c89bce4da98ef,phase 3 study,0.460208
uuid-78285391df4247ae861c89bce4da98ef,Escudier B,0.52876
uuid-78285391df4247ae861c89bce4da98ef,ASCO 2015,0.344359
uuid-78285391df4247ae861c89bce4da98ef,et al.,0.525402
uuid-78285391df4247ae861c89bce4da98ef,J Clin Oncol,0.452436
uuid-78285391df4247ae861c89bce4da98ef,Rizvi NA,0.572737
uuid-78285391df4247ae861c89bce4da98ef,Brahmer J,0.391299
uuid-78285391df4247ae861c89bce4da98ef,PD-L1,0.37273
uuid-78285391df4247ae861c89bce4da98ef,Weber JS,0.314431
uuid-78285391df4247ae861c89bce4da98ef,phase 2 study,0.574769
uuid-78285391df4247ae861c89bce4da98ef,Antonia SJ,0.317937
uuid-d7917ff503ec420eb1c3c71a112f1e3a,nivolumab,0.999168
uuid-d7917ff503ec420eb1c3c71a112f1e3a,Pubmed literature search,0.395314
uuid-d7917ff503ec420eb1c3c71a112f1e3a,purposes other than its labeled indication must be considered investigational,0.464236
uuid-d7917ff503ec420eb1c3c71a112f1e3a,not identify any citations relevant to your inquiry,0.368569
uuid-d7917ff503ec420eb1c3c71a112f1e3a,using the following search terms,0.364279
uuid-d7917ff503ec420eb1c3c71a112f1e3a,present using the following search terms,0.329876
uuid-027502a2fdba463aae83eb2f4b1f2741,N Engl J Med,0.786688
uuid-027502a2fdba463aae83eb2f4b1f2741,Lancet Oncol,0.550311
uuid-027502a2fdba463aae83eb2f4b1f2741,protocol,0.818393
uuid-027502a2fdba463aae83eb2f4b1f2741,McDermott DF,0.878889
uuid-027502a2fdba463aae83eb2f4b1f2741,Motzer RJ,0.848659
uuid-027502a2fdba463aae83eb2f4b1f2741,phase 3 study,0.541592
uuid-027502a2fdba463aae83eb2f4b1f2741,Escudier B,0.882863
uuid-027502a2fdba463aae83eb2f4b1f2741,NEJM,0.488076
uuid-027502a2fdba463aae83eb2f4b1f2741,et al.,0.85679
uuid-027502a2fdba463aae83eb2f4b1f2741,J Clin Oncol,0.797469
uuid-027502a2fdba463aae83eb2f4b1f2741,Topalian,0.446701
uuid-027502a2fdba463aae83eb2f4b1f2741,Rizvi NA,0.696394
uuid-027502a2fdba463aae83eb2f4b1f2741,Brahmer J,0.451471
uuid-027502a2fdba463aae83eb2f4b1f2741,Weber JS,0.58732
uuid-027502a2fdba463aae83eb2f4b1f2741,phase 2 study,0.815662
uuid-e99287fb42244425b1a7779bdc745b3e,fatigue,0.411608
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,nivolumab,0.570998
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,Bristol-Myers Squibb,0.456082
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,evaluating,0.607967
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,not conducted any controlled clinical trials/studies,0.670372
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,Pubmed literature search,0.868183
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,purposes other than its labeled indication must be considered investigational,0.934084
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,not identify any citations relevant to your inquiry,0.825903
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,using the following search terms,0.813507
uuid-14a0c641de6d49c3b4610d8ff5a79bf8,efficacy and safety of nivolumab,0.447527
uuid-f7fdfd21cf244fb0a93ee19397e4f372,N Engl J Med,0.304989
uuid-f7fdfd21cf244fb0a93ee19397e4f372,AEs,0.337832
uuid-f7fdfd21cf244fb0a93ee19397e4f372,patients,0.387033
uuid-f7fdfd21cf244fb0a93ee19397e4f372,provided in the Detailed Information,0.370845
uuid-f7fdfd21cf244fb0a93ee19397e4f372,ESMO,0.421367
uuid-f7fdfd21cf244fb0a93ee19397e4f372,NEJM,0.709799
uuid-f7fdfd21cf244fb0a93ee19397e4f372,Topalian,0.735417
uuid-f7fdfd21cf244fb0a93ee19397e4f372,grade 3 to 4 AEs,0.538198
uuid-5197c488c3574e56a41746ea650328ef,patients with advanced or metastatic,0.648508
uuid-5197c488c3574e56a41746ea650328ef,nivolumab combined with ipilimumab,0.659448
uuid-5197c488c3574e56a41746ea650328ef,tumors,0.38955
uuid-5197c488c3574e56a41746ea650328ef,small cell lung cancer,0.304902
uuid-5197c488c3574e56a41746ea650328ef,phase 1/2 study CA209-032,0.392866
uuid-5197c488c3574e56a41746ea650328ef,bladder cancer,0.753247
uuid-5197c488c3574e56a41746ea650328ef,evaluates the efficacy of nivolumab monotherapy,0.44078
uuid-cedc2b50f11c4c0bbecdbf91a1e3acd6,Bristol-Myers Squibb,0.398191
uuid-cedc2b50f11c4c0bbecdbf91a1e3acd6,requested,0.827269
uuid-c82122498e2d4e0c96812f513c4db1ae,use of nivolumab for the treatment,0.305739
uuid-c82122498e2d4e0c96812f513c4db1ae,patients with advanced or metastatic,0.509457
uuid-c82122498e2d4e0c96812f513c4db1ae,nivolumab combined with ipilimumab,0.496885
uuid-c82122498e2d4e0c96812f513c4db1ae,not approved,0.397631
uuid-c82122498e2d4e0c96812f513c4db1ae,clinical trials investigating the safety,0.478965
uuid-c82122498e2d4e0c96812f513c4db1ae,bladder cancer,0.940126
uuid-47b685db536b4178b9e79b136366abe4,respectively,0.540595
uuid-47b685db536b4178b9e79b136366abe4,ORR,0.30739
uuid-47b685db536b4178b9e79b136366abe4,monotherapy,0.380341
uuid-47b685db536b4178b9e79b136366abe4,docetaxel,0.467818
uuid-47b685db536b4178b9e79b136366abe4,Overall survival,0.324376
uuid-5a7754160ee142dd88a06427fe780970,95% CI,0.419478
uuid-5a7754160ee142dd88a06427fe780970,respectively,0.497608
uuid-5a7754160ee142dd88a06427fe780970,Objective response rate,0.403649
uuid-5a7754160ee142dd88a06427fe780970,ORR,0.578109
uuid-5a7754160ee142dd88a06427fe780970,patients with advanced or metastatic,0.306625
uuid-5a7754160ee142dd88a06427fe780970,Median overall survival,0.498783
uuid-5a7754160ee142dd88a06427fe780970,nivolumab combined with ipilimumab,0.300486
uuid-5a7754160ee142dd88a06427fe780970,tumors,0.323334
uuid-5a7754160ee142dd88a06427fe780970,ESMO,0.534361
uuid-5a7754160ee142dd88a06427fe780970,Median OS,0.394058
uuid-5a7754160ee142dd88a06427fe780970,small cell lung cancer,0.380999
uuid-5a7754160ee142dd88a06427fe780970,SCLC,0.365686
uuid-5a7754160ee142dd88a06427fe780970,hazard ratio,0.419392
uuid-5a7754160ee142dd88a06427fe780970,grade 3 to 4 AEs,0.414535
uuid-5a7754160ee142dd88a06427fe780970,phase 1/2 study CA209-032,0.398283
uuid-5a7754160ee142dd88a06427fe780970,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-f3c05b3477d5468bb9039518f668bd4f,nivolumab,0.355009
uuid-f3c05b3477d5468bb9039518f668bd4f,Bristol-Myers Squibb,0.421475
uuid-f3c05b3477d5468bb9039518f668bd4f,use of nivolumab for the treatment,0.378777
uuid-f3c05b3477d5468bb9039518f668bd4f,evaluating,0.657233
uuid-f3c05b3477d5468bb9039518f668bd4f,not conducted any controlled clinical trials/studies,0.600833
uuid-f3c05b3477d5468bb9039518f668bd4f,patients,0.356688
uuid-f3c05b3477d5468bb9039518f668bd4f,search of published literature,0.587073
uuid-f3c05b3477d5468bb9039518f668bd4f,Additionally,0.510159
uuid-f3c05b3477d5468bb9039518f668bd4f,ongoing,0.427204
uuid-f3c05b3477d5468bb9039518f668bd4f,PubMed and EMBASE,0.566005
uuid-f3c05b3477d5468bb9039518f668bd4f,detailed search of www.clinicaltrials.gov,0.477333
uuid-f3c05b3477d5468bb9039518f668bd4f,melanoma,0.398173
uuid-f3c05b3477d5468bb9039518f668bd4f,efficacy and safety of nivolumab,0.711577
uuid-f3c05b3477d5468bb9039518f668bd4f,not identify any planned,0.434398
uuid-f3c05b3477d5468bb9039518f668bd4f,not identify any citations relevant to your request,0.579646
uuid-f3c05b3477d5468bb9039518f668bd4f,therapy,0.328008
uuid-f3c05b3477d5468bb9039518f668bd4f,present using the following search terms,0.589023
uuid-f3c05b3477d5468bb9039518f668bd4f,safety of nivolumab monotherapy,0.326079
uuid-bcba1d1f578d413393414f3ec3bc8af9,Bristol-Myers Squibb,0.36472
uuid-618ac63f492d4bb4918bcb41a0cda691,Bristol-Myers Squibb,0.398191
uuid-618ac63f492d4bb4918bcb41a0cda691,requested,0.827269
uuid-ec3346d5a77b487cbd3e4e9fafb07abe,Bristol-Myers Squibb,0.398191
uuid-ec3346d5a77b487cbd3e4e9fafb07abe,requested,0.827269
uuid-48d9e4ae92cd42c6819d9141908155c0,PD-L1,0.637706
uuid-f778d009008b4b4c82b33a236320cded,patients,0.331953
uuid-f778d009008b4b4c82b33a236320cded,NEJM,0.331379
uuid-f778d009008b4b4c82b33a236320cded,Topalian,0.403728
uuid-f778d009008b4b4c82b33a236320cded,clinical trials investigating the safety,0.342569
uuid-230624ad9e694be2af9835d1d705e27b,fatigue,0.323475
uuid-bfc077aeda894d9d932d65b75241df54,use of nivolumab for the treatment,0.305739
uuid-bfc077aeda894d9d932d65b75241df54,patients with advanced or metastatic,0.509457
uuid-bfc077aeda894d9d932d65b75241df54,nivolumab combined with ipilimumab,0.496885
uuid-bfc077aeda894d9d932d65b75241df54,not approved,0.397631
uuid-bfc077aeda894d9d932d65b75241df54,clinical trials investigating the safety,0.478965
uuid-bfc077aeda894d9d932d65b75241df54,bladder cancer,0.940126
uuid-966c445424f64df3ba6831bff490ef5b,N Engl J Med,0.517364
uuid-966c445424f64df3ba6831bff490ef5b,requested,0.621687
uuid-966c445424f64df3ba6831bff490ef5b,Brahmer J,0.441718
uuid-966c445424f64df3ba6831bff490ef5b,Horn L,0.671333
uuid-966c445424f64df3ba6831bff490ef5b,platinum-based doublet chemotherapy,0.466033
uuid-ce4e05872234430cb43d503be1044b29,nivolumab,0.359772
uuid-46c426d2146544c58929270ee5260015,Bristol-Myers Squibb,0.389424
uuid-46c426d2146544c58929270ee5260015,requested,0.820468
uuid-46ab5066ea584e33818691509f33047a,patients with advanced or metastatic,0.478326
uuid-46ab5066ea584e33818691509f33047a,nivolumab combined with ipilimumab,0.498766
uuid-46ab5066ea584e33818691509f33047a,not approved,0.34724
uuid-46ab5066ea584e33818691509f33047a,clinical trials investigating the safety,0.426729
uuid-46ab5066ea584e33818691509f33047a,bladder cancer,0.6548
uuid-73c66370513c4ba5a200e2d6006dd7fa,Bristol-Myers Squibb,0.396793
uuid-73c66370513c4ba5a200e2d6006dd7fa,requested,0.743312
uuid-73c66370513c4ba5a200e2d6006dd7fa,Opdivo,0.385736
uuid-0316ee28c8be415884df0f08477431b8,nivolumab,0.359772
uuid-52c205d1965942bdb6bf1b28231b007f,search of published literature,0.394524
uuid-52c205d1965942bdb6bf1b28231b007f,Additionally,0.413583
uuid-52c205d1965942bdb6bf1b28231b007f,ongoing,0.322117
uuid-52c205d1965942bdb6bf1b28231b007f,PubMed and EMBASE,0.391671
uuid-52c205d1965942bdb6bf1b28231b007f,detailed search of www.clinicaltrials.gov,0.375936
uuid-52c205d1965942bdb6bf1b28231b007f,efficacy and safety of nivolumab,0.370699
uuid-52c205d1965942bdb6bf1b28231b007f,not identify any planned,0.34283
uuid-52c205d1965942bdb6bf1b28231b007f,Weber JS,0.319229
uuid-52c205d1965942bdb6bf1b28231b007f,not identify any citations relevant to your request,0.447813
uuid-52c205d1965942bdb6bf1b28231b007f,present using the following search terms,0.408199
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,OS,0.517683
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,95% CI,0.887029
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,respectively,0.541932
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,Objective response rate,0.732884
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,ORR,0.826341
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,PFS,0.416378
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,Median overall survival,0.810566
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,monotherapy,0.504664
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,Median OS,0.783041
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,hazard ratio,0.851803
uuid-e52c611ab6f343aa8c93f2ef94b3a38a,Median duration of response,0.350254
uuid-2383f133742b4128a7c472409ebf4145,nivolumab,0.585313
uuid-2383f133742b4128a7c472409ebf4145,Bristol-Myers Squibb,0.437052
uuid-2383f133742b4128a7c472409ebf4145,evaluating,0.574799
uuid-2383f133742b4128a7c472409ebf4145,not conducted any controlled clinical trials/studies,0.608746
uuid-2383f133742b4128a7c472409ebf4145,Pubmed literature search,0.565955
uuid-2383f133742b4128a7c472409ebf4145,purposes other than its labeled indication must be considered investigational,0.642716
uuid-2383f133742b4128a7c472409ebf4145,not identify any citations relevant to your inquiry,0.535666
uuid-2383f133742b4128a7c472409ebf4145,search of published literature,0.341628
uuid-2383f133742b4128a7c472409ebf4145,PubMed and EMBASE,0.320709
uuid-2383f133742b4128a7c472409ebf4145,using the following search terms,0.52211
uuid-2383f133742b4128a7c472409ebf4145,efficacy and safety of nivolumab,0.506372
uuid-2383f133742b4128a7c472409ebf4145,present using the following search terms,0.34303
uuid-a37a507300214efb9e08f9dfbb033396,N Engl J Med,0.655749
uuid-a37a507300214efb9e08f9dfbb033396,protocol,0.836967
uuid-a37a507300214efb9e08f9dfbb033396,McDermott DF,0.921427
uuid-a37a507300214efb9e08f9dfbb033396,Motzer RJ,0.90831
uuid-a37a507300214efb9e08f9dfbb033396,phase 3 study,0.537275
uuid-a37a507300214efb9e08f9dfbb033396,Escudier B,0.919304
uuid-a37a507300214efb9e08f9dfbb033396,NEJM,0.454873
uuid-a37a507300214efb9e08f9dfbb033396,et al.,0.877698
uuid-a37a507300214efb9e08f9dfbb033396,J Clin Oncol,0.866701
uuid-a37a507300214efb9e08f9dfbb033396,Topalian,0.413823
uuid-a37a507300214efb9e08f9dfbb033396,Rizvi NA,0.42527
uuid-a37a507300214efb9e08f9dfbb033396,Weber JS,0.306371
uuid-a37a507300214efb9e08f9dfbb033396,phase 2 study,0.824788
uuid-1037a656831d401796921e4a6db3e4c4,provided in the Detailed Information,0.349112
uuid-1037a656831d401796921e4a6db3e4c4,Weber JS,0.321343
uuid-20038d0effa349c796df236e8fb7dcb4,nivolumab,0.344939
uuid-20038d0effa349c796df236e8fb7dcb4,Bristol-Myers Squibb,0.363004
uuid-20038d0effa349c796df236e8fb7dcb4,evaluating,0.564404
uuid-20038d0effa349c796df236e8fb7dcb4,not conducted any controlled clinical trials/studies,0.538169
uuid-20038d0effa349c796df236e8fb7dcb4,RCC,0.336118
uuid-20038d0effa349c796df236e8fb7dcb4,search of published literature,0.750115
uuid-20038d0effa349c796df236e8fb7dcb4,Additionally,0.766378
uuid-20038d0effa349c796df236e8fb7dcb4,ongoing,0.629393
uuid-20038d0effa349c796df236e8fb7dcb4,PubMed and EMBASE,0.745288
uuid-20038d0effa349c796df236e8fb7dcb4,detailed search of www.clinicaltrials.gov,0.729251
uuid-20038d0effa349c796df236e8fb7dcb4,efficacy and safety of nivolumab,0.716075
uuid-20038d0effa349c796df236e8fb7dcb4,not identify any planned,0.665705
uuid-20038d0effa349c796df236e8fb7dcb4,not identify any citations relevant to your request,0.849476
uuid-20038d0effa349c796df236e8fb7dcb4,present using the following search terms,0.773092
uuid-a43522c34a894f7c84a4c54268aef758,Pubmed literature search,0.301881
uuid-a43522c34a894f7c84a4c54268aef758,purposes other than its labeled indication must be considered investigational,0.321011
uuid-a43522c34a894f7c84a4c54268aef758,not identify any citations relevant to your inquiry,0.302155
uuid-11db49dafa564f8e99ae2482ae887de9,N Engl J Med,0.302601
uuid-11db49dafa564f8e99ae2482ae887de9,AEs,0.348167
uuid-11db49dafa564f8e99ae2482ae887de9,patients,0.536884
uuid-11db49dafa564f8e99ae2482ae887de9,provided in the Detailed Information,0.387544
uuid-11db49dafa564f8e99ae2482ae887de9,ESMO,0.462801
uuid-11db49dafa564f8e99ae2482ae887de9,NEJM,0.66427
uuid-11db49dafa564f8e99ae2482ae887de9,Topalian,0.692873
uuid-11db49dafa564f8e99ae2482ae887de9,grade 3 to 4 AEs,0.626596
uuid-e5fc46ef1a004f04be86d5203e0fd428,use of nivolumab for the treatment,0.305739
uuid-e5fc46ef1a004f04be86d5203e0fd428,patients with advanced or metastatic,0.509457
uuid-e5fc46ef1a004f04be86d5203e0fd428,nivolumab combined with ipilimumab,0.496885
uuid-e5fc46ef1a004f04be86d5203e0fd428,not approved,0.397631
uuid-e5fc46ef1a004f04be86d5203e0fd428,clinical trials investigating the safety,0.478965
uuid-e5fc46ef1a004f04be86d5203e0fd428,bladder cancer,0.940126
uuid-3ff1240cefca4b549af368333ad68d66,evaluating,0.310004
uuid-3ff1240cefca4b549af368333ad68d66,AEs,0.347891
uuid-3ff1240cefca4b549af368333ad68d66,efficacy,0.36294
uuid-3ff1240cefca4b549af368333ad68d66,NSCLC,0.452254
uuid-3ff1240cefca4b549af368333ad68d66,respectively,0.394163
uuid-3ff1240cefca4b549af368333ad68d66,non-small cell lung cancer,0.44875
uuid-3ff1240cefca4b549af368333ad68d66,docetaxel,0.537623
uuid-3ff1240cefca4b549af368333ad68d66,safety of nivolumab monotherapy,0.522238
uuid-3ff1240cefca4b549af368333ad68d66,platinum-based doublet chemotherapy,0.471572
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,N Engl J Med,0.463615
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,NSCLC,0.411904
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,Lancet Oncol,0.356346
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,non-small cell lung cancer,0.479924
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,phase 3 study,0.353194
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,Rizvi NA,0.55688
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,Brahmer J,0.571788
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,PD-L1,0.439281
uuid-fe2527642f6a4e7e8c4c0b39de11f0ca,phase 2 study,0.304107
uuid-ad8a343f67cf42fabb65a04b37f9496f,use of nivolumab for the treatment,0.409821
uuid-ad8a343f67cf42fabb65a04b37f9496f,patients with advanced or metastatic,0.645244
uuid-ad8a343f67cf42fabb65a04b37f9496f,nivolumab combined with ipilimumab,0.676339
uuid-ad8a343f67cf42fabb65a04b37f9496f,not approved,0.453534
uuid-ad8a343f67cf42fabb65a04b37f9496f,clinical trials investigating the safety,0.548799
uuid-ad8a343f67cf42fabb65a04b37f9496f,phase 1/2 study CA209-032,0.34114
uuid-ad8a343f67cf42fabb65a04b37f9496f,bladder cancer,0.749142
uuid-ad8a343f67cf42fabb65a04b37f9496f,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-c98cd10107b24206bbf35bed6ab4697b,use of nivolumab for the treatment,0.305739
uuid-c98cd10107b24206bbf35bed6ab4697b,patients with advanced or metastatic,0.509457
uuid-c98cd10107b24206bbf35bed6ab4697b,nivolumab combined with ipilimumab,0.496885
uuid-c98cd10107b24206bbf35bed6ab4697b,not approved,0.397631
uuid-c98cd10107b24206bbf35bed6ab4697b,clinical trials investigating the safety,0.478965
uuid-c98cd10107b24206bbf35bed6ab4697b,bladder cancer,0.940126
uuid-6214feb1b7c040e7a28a2533bad4aa94,N Engl J Med,0.689907
uuid-6214feb1b7c040e7a28a2533bad4aa94,Lancet Oncol,0.584216
uuid-6214feb1b7c040e7a28a2533bad4aa94,protocol,0.72528
uuid-6214feb1b7c040e7a28a2533bad4aa94,McDermott DF,0.794444
uuid-6214feb1b7c040e7a28a2533bad4aa94,Motzer RJ,0.755383
uuid-6214feb1b7c040e7a28a2533bad4aa94,phase 3 study,0.521307
uuid-6214feb1b7c040e7a28a2533bad4aa94,Escudier B,0.794743
uuid-6214feb1b7c040e7a28a2533bad4aa94,NEJM,0.434762
uuid-6214feb1b7c040e7a28a2533bad4aa94,et al.,0.777092
uuid-6214feb1b7c040e7a28a2533bad4aa94,J Clin Oncol,0.708338
uuid-6214feb1b7c040e7a28a2533bad4aa94,Topalian,0.401719
uuid-6214feb1b7c040e7a28a2533bad4aa94,Rizvi NA,0.731383
uuid-6214feb1b7c040e7a28a2533bad4aa94,Brahmer J,0.378658
uuid-6214feb1b7c040e7a28a2533bad4aa94,Weber JS,0.614831
uuid-6214feb1b7c040e7a28a2533bad4aa94,phase 2 study,0.769458
uuid-abf69e27fba04ecb812fc16d903edb7d,N Engl J Med,0.660733
uuid-abf69e27fba04ecb812fc16d903edb7d,Lancet Oncol,0.482314
uuid-abf69e27fba04ecb812fc16d903edb7d,protocol,0.627395
uuid-abf69e27fba04ecb812fc16d903edb7d,McDermott DF,0.654379
uuid-abf69e27fba04ecb812fc16d903edb7d,Motzer RJ,0.626994
uuid-abf69e27fba04ecb812fc16d903edb7d,phase 3 study,0.598375
uuid-abf69e27fba04ecb812fc16d903edb7d,Escudier B,0.646338
uuid-abf69e27fba04ecb812fc16d903edb7d,NEJM,0.554572
uuid-abf69e27fba04ecb812fc16d903edb7d,et al.,0.61546
uuid-abf69e27fba04ecb812fc16d903edb7d,J Clin Oncol,0.604667
uuid-abf69e27fba04ecb812fc16d903edb7d,Topalian,0.536322
uuid-abf69e27fba04ecb812fc16d903edb7d,phase 1 study,0.37104
uuid-abf69e27fba04ecb812fc16d903edb7d,Rizvi NA,0.670839
uuid-abf69e27fba04ecb812fc16d903edb7d,Brahmer J,0.417566
uuid-abf69e27fba04ecb812fc16d903edb7d,CA209-003,0.360239
uuid-abf69e27fba04ecb812fc16d903edb7d,Weber JS,0.570024
uuid-abf69e27fba04ecb812fc16d903edb7d,phase 2 study,0.715588
uuid-31c8bc1be6874a299c9bff750a532c46,N Engl J Med,0.689907
uuid-31c8bc1be6874a299c9bff750a532c46,Lancet Oncol,0.584216
uuid-31c8bc1be6874a299c9bff750a532c46,protocol,0.72528
uuid-31c8bc1be6874a299c9bff750a532c46,McDermott DF,0.794444
uuid-31c8bc1be6874a299c9bff750a532c46,Motzer RJ,0.755383
uuid-31c8bc1be6874a299c9bff750a532c46,phase 3 study,0.521307
uuid-31c8bc1be6874a299c9bff750a532c46,Escudier B,0.794743
uuid-31c8bc1be6874a299c9bff750a532c46,NEJM,0.434762
uuid-31c8bc1be6874a299c9bff750a532c46,et al.,0.777092
uuid-31c8bc1be6874a299c9bff750a532c46,J Clin Oncol,0.708338
uuid-31c8bc1be6874a299c9bff750a532c46,Topalian,0.401719
uuid-31c8bc1be6874a299c9bff750a532c46,Rizvi NA,0.731383
uuid-31c8bc1be6874a299c9bff750a532c46,Brahmer J,0.378658
uuid-31c8bc1be6874a299c9bff750a532c46,Weber JS,0.614831
uuid-31c8bc1be6874a299c9bff750a532c46,phase 2 study,0.769458
uuid-6b0187cf87d64c2d82c28d15fc45662e,N Engl J Med,0.305662
uuid-6b0187cf87d64c2d82c28d15fc45662e,provided in the Detailed Information,0.353678
uuid-6b0187cf87d64c2d82c28d15fc45662e,clinical,0.39832
uuid-d5ebc2832ab34947a6567931c752edd6,nivolumab,0.341449
uuid-673c0802372f4cd49de08252ce1f1750,nivolumab,0.341449
uuid-deec193098e640a4847b1d27af36a463,N Engl J Med,0.448483
uuid-deec193098e640a4847b1d27af36a463,protocol,0.770446
uuid-deec193098e640a4847b1d27af36a463,McDermott DF,0.741196
uuid-deec193098e640a4847b1d27af36a463,Motzer RJ,0.818144
uuid-deec193098e640a4847b1d27af36a463,phase 3 study,0.417055
uuid-deec193098e640a4847b1d27af36a463,Escudier B,0.749917
uuid-deec193098e640a4847b1d27af36a463,NEJM,0.400698
uuid-deec193098e640a4847b1d27af36a463,et al.,0.668641
uuid-deec193098e640a4847b1d27af36a463,J Clin Oncol,0.792018
uuid-deec193098e640a4847b1d27af36a463,Topalian,0.388894
uuid-deec193098e640a4847b1d27af36a463,phase 1 study,0.500686
uuid-deec193098e640a4847b1d27af36a463,CA209-003,0.567381
uuid-deec193098e640a4847b1d27af36a463,phase 2 study,0.677985
uuid-deec193098e640a4847b1d27af36a463,present using the following search terms,0.310558
uuid-deec193098e640a4847b1d27af36a463,investigating,0.615835
uuid-b67e84996c4546309dff815f011b4aa9,Objective response rate,0.451139
uuid-b67e84996c4546309dff815f011b4aa9,clinicaltrials.gov,0.503706
uuid-172f09c3e2da4fbdb3263a0babacfae5,Objective response rate,0.451139
uuid-172f09c3e2da4fbdb3263a0babacfae5,clinicaltrials.gov,0.503706
uuid-75a9c1a24ea6446197d76527572e727e,nivolumab,0.999168
uuid-75a9c1a24ea6446197d76527572e727e,Pubmed literature search,0.395314
uuid-75a9c1a24ea6446197d76527572e727e,purposes other than its labeled indication must be considered investigational,0.464236
uuid-75a9c1a24ea6446197d76527572e727e,not identify any citations relevant to your inquiry,0.368569
uuid-75a9c1a24ea6446197d76527572e727e,using the following search terms,0.364279
uuid-75a9c1a24ea6446197d76527572e727e,present using the following search terms,0.329876
uuid-eded102e57484316b496244dd6b60140,requested,0.596741
uuid-c973618f9f234a18a0267494b61d730e,OS,0.500083
uuid-c973618f9f234a18a0267494b61d730e,95% CI,0.843312
uuid-c973618f9f234a18a0267494b61d730e,respectively,0.497716
uuid-c973618f9f234a18a0267494b61d730e,Objective response rate,0.578541
uuid-c973618f9f234a18a0267494b61d730e,ORR,0.695906
uuid-c973618f9f234a18a0267494b61d730e,PFS,0.354585
uuid-c973618f9f234a18a0267494b61d730e,Median overall survival,0.766624
uuid-c973618f9f234a18a0267494b61d730e,monotherapy,0.531225
uuid-c973618f9f234a18a0267494b61d730e,Median OS,0.772989
uuid-c973618f9f234a18a0267494b61d730e,PD-L1,0.331158
uuid-c973618f9f234a18a0267494b61d730e,docetaxel,0.454892
uuid-c973618f9f234a18a0267494b61d730e,hazard ratio,0.829458
uuid-76994c4b15714966a97ec2fc9351c114,use of nivolumab for the treatment,0.409821
uuid-76994c4b15714966a97ec2fc9351c114,patients with advanced or metastatic,0.645244
uuid-76994c4b15714966a97ec2fc9351c114,nivolumab combined with ipilimumab,0.676339
uuid-76994c4b15714966a97ec2fc9351c114,not approved,0.453534
uuid-76994c4b15714966a97ec2fc9351c114,clinical trials investigating the safety,0.548799
uuid-76994c4b15714966a97ec2fc9351c114,phase 1/2 study CA209-032,0.34114
uuid-76994c4b15714966a97ec2fc9351c114,bladder cancer,0.749142
uuid-76994c4b15714966a97ec2fc9351c114,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-9fcf4f3b135c47f09c779f5ac698c849,OS,0.333033
uuid-9fcf4f3b135c47f09c779f5ac698c849,95% CI,0.797066
uuid-9fcf4f3b135c47f09c779f5ac698c849,respectively,0.415294
uuid-9fcf4f3b135c47f09c779f5ac698c849,Objective response rate,0.548173
uuid-9fcf4f3b135c47f09c779f5ac698c849,ORR,0.691584
uuid-9fcf4f3b135c47f09c779f5ac698c849,Median overall survival,0.751756
uuid-9fcf4f3b135c47f09c779f5ac698c849,monotherapy,0.363134
uuid-9fcf4f3b135c47f09c779f5ac698c849,Median OS,0.706468
uuid-9fcf4f3b135c47f09c779f5ac698c849,hazard ratio,0.774036
uuid-9fcf4f3b135c47f09c779f5ac698c849,Median duration of response,0.431875
uuid-f828939612a54f589dc3486191ce4bb3,Bristol-Myers Squibb,0.321218
uuid-f828939612a54f589dc3486191ce4bb3,use of nivolumab for the treatment,0.358365
uuid-f828939612a54f589dc3486191ce4bb3,evaluating,0.336943
uuid-f828939612a54f589dc3486191ce4bb3,not conducted any controlled clinical trials/studies,0.312219
uuid-f828939612a54f589dc3486191ce4bb3,efficacy,0.411634
uuid-f828939612a54f589dc3486191ce4bb3,not approved,0.516692
uuid-f828939612a54f589dc3486191ce4bb3,clinical trials investigating the safety,0.6245
uuid-f42a0386f822484696573800d126b48c,evaluating,0.434159
uuid-f42a0386f822484696573800d126b48c,not conducted any controlled clinical trials/studies,0.429128
uuid-f42a0386f822484696573800d126b48c,search of published literature,0.527837
uuid-f42a0386f822484696573800d126b48c,PubMed and EMBASE,0.514324
uuid-f42a0386f822484696573800d126b48c,Rizvi NA,0.339686
uuid-f42a0386f822484696573800d126b48c,efficacy and safety of nivolumab,0.561063
uuid-f42a0386f822484696573800d126b48c,Weber JS,0.301304
uuid-f42a0386f822484696573800d126b48c,not identify any citations relevant to your request,0.360911
uuid-f42a0386f822484696573800d126b48c,present using the following search terms,0.52381
uuid-645d581875eb4032b3a1d21442fb225f,OS,0.62262
uuid-645d581875eb4032b3a1d21442fb225f,PFS,0.65903
uuid-645d581875eb4032b3a1d21442fb225f,Overall survival,0.644151
uuid-e56a3f4b091e44c29ae8e8713eed20d2,95% CI,0.419478
uuid-e56a3f4b091e44c29ae8e8713eed20d2,respectively,0.497608
uuid-e56a3f4b091e44c29ae8e8713eed20d2,Objective response rate,0.403649
uuid-e56a3f4b091e44c29ae8e8713eed20d2,ORR,0.578109
uuid-e56a3f4b091e44c29ae8e8713eed20d2,patients with advanced or metastatic,0.306625
uuid-e56a3f4b091e44c29ae8e8713eed20d2,Median overall survival,0.498783
uuid-e56a3f4b091e44c29ae8e8713eed20d2,nivolumab combined with ipilimumab,0.300486
uuid-e56a3f4b091e44c29ae8e8713eed20d2,tumors,0.323334
uuid-e56a3f4b091e44c29ae8e8713eed20d2,ESMO,0.534361
uuid-e56a3f4b091e44c29ae8e8713eed20d2,Median OS,0.394058
uuid-e56a3f4b091e44c29ae8e8713eed20d2,small cell lung cancer,0.380999
uuid-e56a3f4b091e44c29ae8e8713eed20d2,SCLC,0.365686
uuid-e56a3f4b091e44c29ae8e8713eed20d2,hazard ratio,0.419392
uuid-e56a3f4b091e44c29ae8e8713eed20d2,grade 3 to 4 AEs,0.414535
uuid-e56a3f4b091e44c29ae8e8713eed20d2,phase 1/2 study CA209-032,0.398283
uuid-e56a3f4b091e44c29ae8e8713eed20d2,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-665472753dc74812a2d9ec996be9a43a,nivolumab,0.580265
uuid-665472753dc74812a2d9ec996be9a43a,Bristol-Myers Squibb,0.438595
uuid-665472753dc74812a2d9ec996be9a43a,evaluating,0.596992
uuid-665472753dc74812a2d9ec996be9a43a,not conducted any controlled clinical trials/studies,0.650874
uuid-665472753dc74812a2d9ec996be9a43a,Pubmed literature search,0.85789
uuid-665472753dc74812a2d9ec996be9a43a,purposes other than its labeled indication must be considered investigational,0.924057
uuid-665472753dc74812a2d9ec996be9a43a,not identify any citations relevant to your inquiry,0.819302
uuid-665472753dc74812a2d9ec996be9a43a,using the following search terms,0.804463
uuid-665472753dc74812a2d9ec996be9a43a,efficacy and safety of nivolumab,0.4315
uuid-24e1072ea3df4cb49b80f73f49f8f93c,95% CI,0.419478
uuid-24e1072ea3df4cb49b80f73f49f8f93c,respectively,0.497608
uuid-24e1072ea3df4cb49b80f73f49f8f93c,Objective response rate,0.403649
uuid-24e1072ea3df4cb49b80f73f49f8f93c,ORR,0.578109
uuid-24e1072ea3df4cb49b80f73f49f8f93c,patients with advanced or metastatic,0.306625
uuid-24e1072ea3df4cb49b80f73f49f8f93c,Median overall survival,0.498783
uuid-24e1072ea3df4cb49b80f73f49f8f93c,nivolumab combined with ipilimumab,0.300486
uuid-24e1072ea3df4cb49b80f73f49f8f93c,tumors,0.323334
uuid-24e1072ea3df4cb49b80f73f49f8f93c,ESMO,0.534361
uuid-24e1072ea3df4cb49b80f73f49f8f93c,Median OS,0.394058
uuid-24e1072ea3df4cb49b80f73f49f8f93c,small cell lung cancer,0.380999
uuid-24e1072ea3df4cb49b80f73f49f8f93c,SCLC,0.365686
uuid-24e1072ea3df4cb49b80f73f49f8f93c,hazard ratio,0.419392
uuid-24e1072ea3df4cb49b80f73f49f8f93c,grade 3 to 4 AEs,0.414535
uuid-24e1072ea3df4cb49b80f73f49f8f93c,phase 1/2 study CA209-032,0.398283
uuid-24e1072ea3df4cb49b80f73f49f8f93c,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-5c03dd575ab14c7ab67fa4feb6606e33,requested,0.323513
uuid-1e5964171413442c93829a76ec4eaf75,use of nivolumab for the treatment,0.443648
uuid-1e5964171413442c93829a76ec4eaf75,patients,0.952999
uuid-1e5964171413442c93829a76ec4eaf75,considered investigational,0.39172
uuid-1e5964171413442c93829a76ec4eaf75,tumors,0.312155
uuid-1e5964171413442c93829a76ec4eaf75,small cell lung cancer,0.465717
uuid-1e5964171413442c93829a76ec4eaf75,SCLC,0.419503
uuid-1e5964171413442c93829a76ec4eaf75,grade 3 to 4 AEs,0.469189
uuid-1e5964171413442c93829a76ec4eaf75,phase 1/2 study CA209-032,0.304454
uuid-7b0db57d1fc14b9e82edcb50a74a293f,Rizvi NA,0.309032
uuid-7b0db57d1fc14b9e82edcb50a74a293f,Brahmer J,0.486483
uuid-7b0db57d1fc14b9e82edcb50a74a293f,BMS,0.898594
uuid-715b750604164a90a9b1d58d139853f6,OS,0.62262
uuid-715b750604164a90a9b1d58d139853f6,PFS,0.65903
uuid-715b750604164a90a9b1d58d139853f6,Overall survival,0.644151
uuid-e06cc523fd8641c58eedf4022bb674d4,nivolumab,0.359772
uuid-1234e776d1bb4359b9136a1500694784,trial,0.334959
uuid-1ed799dd57e24312a54acd0da5ffed4d,95% CI,0.419478
uuid-1ed799dd57e24312a54acd0da5ffed4d,respectively,0.497608
uuid-1ed799dd57e24312a54acd0da5ffed4d,Objective response rate,0.403649
uuid-1ed799dd57e24312a54acd0da5ffed4d,ORR,0.578109
uuid-1ed799dd57e24312a54acd0da5ffed4d,patients with advanced or metastatic,0.306625
uuid-1ed799dd57e24312a54acd0da5ffed4d,Median overall survival,0.498783
uuid-1ed799dd57e24312a54acd0da5ffed4d,nivolumab combined with ipilimumab,0.300486
uuid-1ed799dd57e24312a54acd0da5ffed4d,tumors,0.323334
uuid-1ed799dd57e24312a54acd0da5ffed4d,ESMO,0.534361
uuid-1ed799dd57e24312a54acd0da5ffed4d,Median OS,0.394058
uuid-1ed799dd57e24312a54acd0da5ffed4d,small cell lung cancer,0.380999
uuid-1ed799dd57e24312a54acd0da5ffed4d,SCLC,0.365686
uuid-1ed799dd57e24312a54acd0da5ffed4d,hazard ratio,0.419392
uuid-1ed799dd57e24312a54acd0da5ffed4d,grade 3 to 4 AEs,0.414535
uuid-1ed799dd57e24312a54acd0da5ffed4d,phase 1/2 study CA209-032,0.398283
uuid-1ed799dd57e24312a54acd0da5ffed4d,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-610a60ff11e34d099736f0128fec752b,nivolumab,0.431656
uuid-610a60ff11e34d099736f0128fec752b,Bristol-Myers Squibb,0.519884
uuid-610a60ff11e34d099736f0128fec752b,evaluating,0.736755
uuid-610a60ff11e34d099736f0128fec752b,not conducted any controlled clinical trials/studies,0.70305
uuid-610a60ff11e34d099736f0128fec752b,NSCLC,0.321528
uuid-610a60ff11e34d099736f0128fec752b,non-small cell lung cancer,0.349535
uuid-610a60ff11e34d099736f0128fec752b,considered investigational,0.30152
uuid-610a60ff11e34d099736f0128fec752b,search of published literature,0.512583
uuid-610a60ff11e34d099736f0128fec752b,Additionally,0.334901
uuid-610a60ff11e34d099736f0128fec752b,PubMed and EMBASE,0.483441
uuid-610a60ff11e34d099736f0128fec752b,efficacy and safety of nivolumab,0.737548
uuid-610a60ff11e34d099736f0128fec752b,not identify any citations relevant to your request,0.408861
uuid-610a60ff11e34d099736f0128fec752b,present using the following search terms,0.504523
uuid-610a60ff11e34d099736f0128fec752b,safety of nivolumab monotherapy,0.370742
uuid-7a429dac42c043358a5651b4b2bb8169,adverse,0.359679
uuid-7a429dac42c043358a5651b4b2bb8169,safety,0.683054
uuid-7a429dac42c043358a5651b4b2bb8169,databases,0.613463
uuid-7a429dac42c043358a5651b4b2bb8169,reported,0.527144
uuid-00cf803b6d5a4f4d8115e764542dbf39,fatigue,0.411608
uuid-3672346cbc394b1e860d7ddadc49ff0d,OS,0.62262
uuid-3672346cbc394b1e860d7ddadc49ff0d,PFS,0.65903
uuid-3672346cbc394b1e860d7ddadc49ff0d,Overall survival,0.644151
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,nivolumab,0.431656
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,Bristol-Myers Squibb,0.519884
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,evaluating,0.736755
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,not conducted any controlled clinical trials/studies,0.70305
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,NSCLC,0.321528
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,non-small cell lung cancer,0.349535
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,considered investigational,0.30152
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,search of published literature,0.512583
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,Additionally,0.334901
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,PubMed and EMBASE,0.483441
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,efficacy and safety of nivolumab,0.737548
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,not identify any citations relevant to your request,0.408861
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,present using the following search terms,0.504523
uuid-a6c31b1cb4c04eeeae9f1f3def1e7be8,safety of nivolumab monotherapy,0.370742
uuid-0ff083bc7dc64201897fa55f4fa56933,ipilimumab,0.385692
uuid-0ff083bc7dc64201897fa55f4fa56933,ASCO 2015,0.417944
uuid-0ff083bc7dc64201897fa55f4fa56933,partial response,0.382425
uuid-0ff083bc7dc64201897fa55f4fa56933,Stable disease,0.586335
uuid-0ff083bc7dc64201897fa55f4fa56933,cohort,0.307748
uuid-aa2a250fd7184c888f8b0c2e7cf12dd6,trial,0.318349
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,nivolumab,0.567301
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,Bristol-Myers Squibb,0.617614
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,evaluating,0.7431
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,not conducted any controlled clinical trials/studies,0.797264
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,Pubmed literature search,0.693076
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,purposes other than its labeled indication must be considered investigational,0.795817
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,not identify any citations relevant to your inquiry,0.641821
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,using the following search terms,0.622159
uuid-2e3f02fca2d54432b9c0dacf2d73a05c,efficacy and safety of nivolumab,0.584738
uuid-15ed01c48be848b1b23e25e234b450fd,Bristol-Myers Squibb,0.341822
uuid-15ed01c48be848b1b23e25e234b450fd,not conducted any controlled clinical trials/studies,0.304507
uuid-15ed01c48be848b1b23e25e234b450fd,Opdivo,0.461382
uuid-15ed01c48be848b1b23e25e234b450fd,Pubmed literature search,0.614325
uuid-15ed01c48be848b1b23e25e234b450fd,purposes other than its labeled indication must be considered investigational,0.586645
uuid-15ed01c48be848b1b23e25e234b450fd,not identify any citations relevant to your inquiry,0.606087
uuid-15ed01c48be848b1b23e25e234b450fd,adverse,0.304183
uuid-15ed01c48be848b1b23e25e234b450fd,using the following search terms,0.642331
uuid-15ed01c48be848b1b23e25e234b450fd,databases,0.315039
uuid-15ed01c48be848b1b23e25e234b450fd,reported,0.556704
uuid-63783f113b9b46318cb47aa350052880,use of nivolumab for the treatment,0.409821
uuid-63783f113b9b46318cb47aa350052880,patients with advanced or metastatic,0.645244
uuid-63783f113b9b46318cb47aa350052880,nivolumab combined with ipilimumab,0.676339
uuid-63783f113b9b46318cb47aa350052880,not approved,0.453534
uuid-63783f113b9b46318cb47aa350052880,clinical trials investigating the safety,0.548799
uuid-63783f113b9b46318cb47aa350052880,phase 1/2 study CA209-032,0.34114
uuid-63783f113b9b46318cb47aa350052880,bladder cancer,0.749142
uuid-63783f113b9b46318cb47aa350052880,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-edbccdb9065a44dfb67b88bf8072929c,nivolumab,0.568841
uuid-edbccdb9065a44dfb67b88bf8072929c,Bristol-Myers Squibb,0.456898
uuid-edbccdb9065a44dfb67b88bf8072929c,evaluating,0.608873
uuid-edbccdb9065a44dfb67b88bf8072929c,not conducted any controlled clinical trials/studies,0.67129
uuid-edbccdb9065a44dfb67b88bf8072929c,Pubmed literature search,0.868391
uuid-edbccdb9065a44dfb67b88bf8072929c,purposes other than its labeled indication must be considered investigational,0.934227
uuid-edbccdb9065a44dfb67b88bf8072929c,not identify any citations relevant to your inquiry,0.826079
uuid-edbccdb9065a44dfb67b88bf8072929c,using the following search terms,0.813628
uuid-edbccdb9065a44dfb67b88bf8072929c,efficacy and safety of nivolumab,0.448396
uuid-f68737c253e949168d04dd92469db909,N Engl J Med,0.304989
uuid-f68737c253e949168d04dd92469db909,AEs,0.337832
uuid-f68737c253e949168d04dd92469db909,patients,0.387033
uuid-f68737c253e949168d04dd92469db909,provided in the Detailed Information,0.370845
uuid-f68737c253e949168d04dd92469db909,ESMO,0.421367
uuid-f68737c253e949168d04dd92469db909,NEJM,0.709799
uuid-f68737c253e949168d04dd92469db909,Topalian,0.735417
uuid-f68737c253e949168d04dd92469db909,grade 3 to 4 AEs,0.538198
uuid-1b4b1fc0c729412baab173f4bd35cc95,Opdivo,0.50165
uuid-1b4b1fc0c729412baab173f4bd35cc95,open-label,0.304253
uuid-1b4b1fc0c729412baab173f4bd35cc95,trial,0.521827
uuid-1b4b1fc0c729412baab173f4bd35cc95,docetaxel,0.30238
uuid-1b4b1fc0c729412baab173f4bd35cc95,safety of nivolumab monotherapy,0.432481
uuid-1b4b1fc0c729412baab173f4bd35cc95,phase,0.378496
uuid-a85c58d78b6c4964bead77ee4838c8d6,Opdivo,0.50165
uuid-a85c58d78b6c4964bead77ee4838c8d6,open-label,0.304253
uuid-a85c58d78b6c4964bead77ee4838c8d6,trial,0.521827
uuid-a85c58d78b6c4964bead77ee4838c8d6,docetaxel,0.30238
uuid-a85c58d78b6c4964bead77ee4838c8d6,safety of nivolumab monotherapy,0.432481
uuid-a85c58d78b6c4964bead77ee4838c8d6,phase,0.378496
uuid-d65ad93e5b324ccbac3de4cc5942c564,evaluating,0.331463
uuid-d65ad93e5b324ccbac3de4cc5942c564,not conducted any controlled clinical trials/studies,0.327968
uuid-d65ad93e5b324ccbac3de4cc5942c564,protocol,0.532972
uuid-d65ad93e5b324ccbac3de4cc5942c564,RCC,0.386451
uuid-d65ad93e5b324ccbac3de4cc5942c564,McDermott DF,0.444329
uuid-d65ad93e5b324ccbac3de4cc5942c564,search of published literature,0.50452
uuid-d65ad93e5b324ccbac3de4cc5942c564,Additionally,0.555299
uuid-d65ad93e5b324ccbac3de4cc5942c564,ongoing,0.478674
uuid-d65ad93e5b324ccbac3de4cc5942c564,Motzer RJ,0.475488
uuid-d65ad93e5b324ccbac3de4cc5942c564,PubMed and EMBASE,0.501909
uuid-d65ad93e5b324ccbac3de4cc5942c564,Escudier B,0.459186
uuid-d65ad93e5b324ccbac3de4cc5942c564,et al.,0.397016
uuid-d65ad93e5b324ccbac3de4cc5942c564,J Clin Oncol,0.428996
uuid-d65ad93e5b324ccbac3de4cc5942c564,detailed search of www.clinicaltrials.gov,0.514934
uuid-d65ad93e5b324ccbac3de4cc5942c564,efficacy and safety of nivolumab,0.47512
uuid-d65ad93e5b324ccbac3de4cc5942c564,not identify any planned,0.493147
uuid-d65ad93e5b324ccbac3de4cc5942c564,phase 2 study,0.384586
uuid-d65ad93e5b324ccbac3de4cc5942c564,not identify any citations relevant to your request,0.565812
uuid-d65ad93e5b324ccbac3de4cc5942c564,present using the following search terms,0.490802
uuid-da9ca572dd4d4704b1afcabbd1083884,nivolumab,0.441653
uuid-22f808bb9e064888b795f9f0ab056c3e,nivolumab,0.569621
uuid-22f808bb9e064888b795f9f0ab056c3e,Bristol-Myers Squibb,0.45893
uuid-22f808bb9e064888b795f9f0ab056c3e,evaluating,0.610388
uuid-22f808bb9e064888b795f9f0ab056c3e,not conducted any controlled clinical trials/studies,0.6727
uuid-22f808bb9e064888b795f9f0ab056c3e,Pubmed literature search,0.867189
uuid-22f808bb9e064888b795f9f0ab056c3e,purposes other than its labeled indication must be considered investigational,0.933194
uuid-22f808bb9e064888b795f9f0ab056c3e,not identify any citations relevant to your inquiry,0.824732
uuid-22f808bb9e064888b795f9f0ab056c3e,using the following search terms,0.81245
uuid-22f808bb9e064888b795f9f0ab056c3e,efficacy and safety of nivolumab,0.450062
uuid-e3a95aab8c5f44a88f1fe307dd7b53db,Opdivo,0.34283
uuid-e3a95aab8c5f44a88f1fe307dd7b53db,adverse,0.515433
uuid-e3a95aab8c5f44a88f1fe307dd7b53db,reported,0.681616
uuid-89bf948934f04bae942d88f478ffdd40,Opdivo,0.50165
uuid-89bf948934f04bae942d88f478ffdd40,open-label,0.304253
uuid-89bf948934f04bae942d88f478ffdd40,trial,0.521827
uuid-89bf948934f04bae942d88f478ffdd40,docetaxel,0.30238
uuid-89bf948934f04bae942d88f478ffdd40,safety of nivolumab monotherapy,0.432481
uuid-89bf948934f04bae942d88f478ffdd40,phase,0.378496
uuid-b5897254d2c4481faba1ddb951d1663f,ipilimumab,0.385692
uuid-b5897254d2c4481faba1ddb951d1663f,ASCO 2015,0.417944
uuid-b5897254d2c4481faba1ddb951d1663f,partial response,0.382425
uuid-b5897254d2c4481faba1ddb951d1663f,Stable disease,0.586335
uuid-b5897254d2c4481faba1ddb951d1663f,cohort,0.307748
uuid-2fde80015074418f95e8cb67ce770b7a,Opdivo,0.50165
uuid-2fde80015074418f95e8cb67ce770b7a,open-label,0.304253
uuid-2fde80015074418f95e8cb67ce770b7a,trial,0.521827
uuid-2fde80015074418f95e8cb67ce770b7a,docetaxel,0.30238
uuid-2fde80015074418f95e8cb67ce770b7a,safety of nivolumab monotherapy,0.432481
uuid-2fde80015074418f95e8cb67ce770b7a,phase,0.378496
uuid-920dddccdd374bd99693bfd2ae7e9252,N Engl J Med,0.535286
uuid-920dddccdd374bd99693bfd2ae7e9252,Lancet Oncol,0.364361
uuid-920dddccdd374bd99693bfd2ae7e9252,protocol,0.50442
uuid-920dddccdd374bd99693bfd2ae7e9252,McDermott DF,0.548182
uuid-920dddccdd374bd99693bfd2ae7e9252,Motzer RJ,0.532741
uuid-920dddccdd374bd99693bfd2ae7e9252,phase 3 study,0.493197
uuid-920dddccdd374bd99693bfd2ae7e9252,Escudier B,0.547344
uuid-920dddccdd374bd99693bfd2ae7e9252,et al.,0.519366
uuid-920dddccdd374bd99693bfd2ae7e9252,J Clin Oncol,0.509597
uuid-920dddccdd374bd99693bfd2ae7e9252,Rizvi NA,0.478602
uuid-920dddccdd374bd99693bfd2ae7e9252,Brahmer J,0.338223
uuid-920dddccdd374bd99693bfd2ae7e9252,Weber JS,0.370952
uuid-920dddccdd374bd99693bfd2ae7e9252,phase 2 study,0.591434
uuid-f3456687245e4a66b85d50134b1eadbb,nivolumab,0.534749
uuid-f3456687245e4a66b85d50134b1eadbb,Bristol-Myers Squibb,0.486619
uuid-f3456687245e4a66b85d50134b1eadbb,evaluating,0.683166
uuid-f3456687245e4a66b85d50134b1eadbb,not conducted any controlled clinical trials/studies,0.723627
uuid-f3456687245e4a66b85d50134b1eadbb,Pubmed literature search,0.798611
uuid-f3456687245e4a66b85d50134b1eadbb,purposes other than its labeled indication must be considered investigational,0.878785
uuid-f3456687245e4a66b85d50134b1eadbb,not identify any citations relevant to your inquiry,0.754174
uuid-f3456687245e4a66b85d50134b1eadbb,using the following search terms,0.736374
uuid-f3456687245e4a66b85d50134b1eadbb,efficacy and safety of nivolumab,0.519123
uuid-dadc2d2589864e8094d429555a42c50d,evaluating,0.331463
uuid-dadc2d2589864e8094d429555a42c50d,not conducted any controlled clinical trials/studies,0.327968
uuid-dadc2d2589864e8094d429555a42c50d,protocol,0.532972
uuid-dadc2d2589864e8094d429555a42c50d,RCC,0.386451
uuid-dadc2d2589864e8094d429555a42c50d,McDermott DF,0.444329
uuid-dadc2d2589864e8094d429555a42c50d,search of published literature,0.50452
uuid-dadc2d2589864e8094d429555a42c50d,Additionally,0.555299
uuid-dadc2d2589864e8094d429555a42c50d,ongoing,0.478674
uuid-dadc2d2589864e8094d429555a42c50d,Motzer RJ,0.475488
uuid-dadc2d2589864e8094d429555a42c50d,PubMed and EMBASE,0.501909
uuid-dadc2d2589864e8094d429555a42c50d,Escudier B,0.459186
uuid-dadc2d2589864e8094d429555a42c50d,et al.,0.397016
uuid-dadc2d2589864e8094d429555a42c50d,J Clin Oncol,0.428996
uuid-dadc2d2589864e8094d429555a42c50d,detailed search of www.clinicaltrials.gov,0.514934
uuid-dadc2d2589864e8094d429555a42c50d,efficacy and safety of nivolumab,0.47512
uuid-dadc2d2589864e8094d429555a42c50d,not identify any planned,0.493147
uuid-dadc2d2589864e8094d429555a42c50d,phase 2 study,0.384586
uuid-dadc2d2589864e8094d429555a42c50d,not identify any citations relevant to your request,0.565812
uuid-dadc2d2589864e8094d429555a42c50d,present using the following search terms,0.490802
uuid-936566b80e8f4092967558af6cd4a070,N Engl J Med,0.400046
uuid-936566b80e8f4092967558af6cd4a070,protocol,0.583735
uuid-936566b80e8f4092967558af6cd4a070,McDermott DF,0.603371
uuid-936566b80e8f4092967558af6cd4a070,Motzer RJ,0.593137
uuid-936566b80e8f4092967558af6cd4a070,phase 3 study,0.401882
uuid-936566b80e8f4092967558af6cd4a070,Escudier B,0.603955
uuid-936566b80e8f4092967558af6cd4a070,et al.,0.576351
uuid-936566b80e8f4092967558af6cd4a070,J Clin Oncol,0.547598
uuid-936566b80e8f4092967558af6cd4a070,phase 2 study,0.528273
uuid-ccbba0a282b94db8958f74b0e47db4cc,nivolumab,0.999168
uuid-ccbba0a282b94db8958f74b0e47db4cc,Pubmed literature search,0.395314
uuid-ccbba0a282b94db8958f74b0e47db4cc,purposes other than its labeled indication must be considered investigational,0.464236
uuid-ccbba0a282b94db8958f74b0e47db4cc,not identify any citations relevant to your inquiry,0.368569
uuid-ccbba0a282b94db8958f74b0e47db4cc,using the following search terms,0.364279
uuid-ccbba0a282b94db8958f74b0e47db4cc,present using the following search terms,0.329876
uuid-1954fe11fc3f4f18bf762fc501318683,nivolumab,0.344939
uuid-1954fe11fc3f4f18bf762fc501318683,Bristol-Myers Squibb,0.363004
uuid-1954fe11fc3f4f18bf762fc501318683,evaluating,0.564404
uuid-1954fe11fc3f4f18bf762fc501318683,not conducted any controlled clinical trials/studies,0.538169
uuid-1954fe11fc3f4f18bf762fc501318683,RCC,0.336118
uuid-1954fe11fc3f4f18bf762fc501318683,search of published literature,0.750115
uuid-1954fe11fc3f4f18bf762fc501318683,Additionally,0.766378
uuid-1954fe11fc3f4f18bf762fc501318683,ongoing,0.629393
uuid-1954fe11fc3f4f18bf762fc501318683,PubMed and EMBASE,0.745288
uuid-1954fe11fc3f4f18bf762fc501318683,detailed search of www.clinicaltrials.gov,0.729251
uuid-1954fe11fc3f4f18bf762fc501318683,efficacy and safety of nivolumab,0.716075
uuid-1954fe11fc3f4f18bf762fc501318683,not identify any planned,0.665705
uuid-1954fe11fc3f4f18bf762fc501318683,not identify any citations relevant to your request,0.849476
uuid-1954fe11fc3f4f18bf762fc501318683,present using the following search terms,0.773092
uuid-bf8a9222953446379ee5c92c291f82dc,requested,0.314741
uuid-bf8a9222953446379ee5c92c291f82dc,McDermott DF,0.42332
uuid-bf8a9222953446379ee5c92c291f82dc,Motzer RJ,0.350496
uuid-bf8a9222953446379ee5c92c291f82dc,phase 3 study,0.329806
uuid-bf8a9222953446379ee5c92c291f82dc,Escudier B,0.408483
uuid-bf8a9222953446379ee5c92c291f82dc,et al.,0.501287
uuid-bf8a9222953446379ee5c92c291f82dc,J Clin Oncol,0.330566
uuid-bf8a9222953446379ee5c92c291f82dc,phase 2 study,0.463552
uuid-ddc6339dfa8943c8b6a50f00360fd016,fatigue,0.323475
uuid-7c4f5d92cce449c184a21590075cda20,Opdivo,0.305146
uuid-7c4f5d92cce449c184a21590075cda20,adverse,0.553218
uuid-7c4f5d92cce449c184a21590075cda20,ongoing,0.301113
uuid-7c4f5d92cce449c184a21590075cda20,safety,0.582014
uuid-7c4f5d92cce449c184a21590075cda20,databases,0.521727
uuid-7c4f5d92cce449c184a21590075cda20,reported,0.607145
uuid-89d761dd1d994c57b285f0ea2a460c27,Bristol-Myers Squibb,0.494484
uuid-89d761dd1d994c57b285f0ea2a460c27,adverse,0.399468
uuid-89d761dd1d994c57b285f0ea2a460c27,reported,0.470007
uuid-64d33ca91eb74087a983aed3db7ad82a,95% CI,0.419478
uuid-64d33ca91eb74087a983aed3db7ad82a,respectively,0.497608
uuid-64d33ca91eb74087a983aed3db7ad82a,Objective response rate,0.403649
uuid-64d33ca91eb74087a983aed3db7ad82a,ORR,0.578109
uuid-64d33ca91eb74087a983aed3db7ad82a,patients with advanced or metastatic,0.306625
uuid-64d33ca91eb74087a983aed3db7ad82a,Median overall survival,0.498783
uuid-64d33ca91eb74087a983aed3db7ad82a,nivolumab combined with ipilimumab,0.300486
uuid-64d33ca91eb74087a983aed3db7ad82a,tumors,0.323334
uuid-64d33ca91eb74087a983aed3db7ad82a,ESMO,0.534361
uuid-64d33ca91eb74087a983aed3db7ad82a,Median OS,0.394058
uuid-64d33ca91eb74087a983aed3db7ad82a,small cell lung cancer,0.380999
uuid-64d33ca91eb74087a983aed3db7ad82a,SCLC,0.365686
uuid-64d33ca91eb74087a983aed3db7ad82a,hazard ratio,0.419392
uuid-64d33ca91eb74087a983aed3db7ad82a,grade 3 to 4 AEs,0.414535
uuid-64d33ca91eb74087a983aed3db7ad82a,phase 1/2 study CA209-032,0.398283
uuid-64d33ca91eb74087a983aed3db7ad82a,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-99630624cf694a888f4c7f7ffbca7f5c,evaluating,0.331463
uuid-99630624cf694a888f4c7f7ffbca7f5c,not conducted any controlled clinical trials/studies,0.327968
uuid-99630624cf694a888f4c7f7ffbca7f5c,protocol,0.532972
uuid-99630624cf694a888f4c7f7ffbca7f5c,RCC,0.386451
uuid-99630624cf694a888f4c7f7ffbca7f5c,McDermott DF,0.444329
uuid-99630624cf694a888f4c7f7ffbca7f5c,search of published literature,0.50452
uuid-99630624cf694a888f4c7f7ffbca7f5c,Additionally,0.555299
uuid-99630624cf694a888f4c7f7ffbca7f5c,ongoing,0.478674
uuid-99630624cf694a888f4c7f7ffbca7f5c,Motzer RJ,0.475488
uuid-99630624cf694a888f4c7f7ffbca7f5c,PubMed and EMBASE,0.501909
uuid-99630624cf694a888f4c7f7ffbca7f5c,Escudier B,0.459186
uuid-99630624cf694a888f4c7f7ffbca7f5c,et al.,0.397016
uuid-99630624cf694a888f4c7f7ffbca7f5c,J Clin Oncol,0.428996
uuid-99630624cf694a888f4c7f7ffbca7f5c,detailed search of www.clinicaltrials.gov,0.514934
uuid-99630624cf694a888f4c7f7ffbca7f5c,efficacy and safety of nivolumab,0.47512
uuid-99630624cf694a888f4c7f7ffbca7f5c,not identify any planned,0.493147
uuid-99630624cf694a888f4c7f7ffbca7f5c,phase 2 study,0.384586
uuid-99630624cf694a888f4c7f7ffbca7f5c,not identify any citations relevant to your request,0.565812
uuid-99630624cf694a888f4c7f7ffbca7f5c,present using the following search terms,0.490802
uuid-53e91a9f800f469094b92617dee38303,requested,0.595565
uuid-a0f4bc4f8727418f82932ef0c3618c51,requested,0.594234
uuid-8011b495807f4acdbc12e334a9baa438,Opdivo,0.50165
uuid-8011b495807f4acdbc12e334a9baa438,open-label,0.304253
uuid-8011b495807f4acdbc12e334a9baa438,trial,0.521827
uuid-8011b495807f4acdbc12e334a9baa438,docetaxel,0.30238
uuid-8011b495807f4acdbc12e334a9baa438,safety of nivolumab monotherapy,0.432481
uuid-8011b495807f4acdbc12e334a9baa438,phase,0.378496
uuid-ab062eca3030417bb0a7e154a8813edb,N Engl J Med,0.535286
uuid-ab062eca3030417bb0a7e154a8813edb,Lancet Oncol,0.364361
uuid-ab062eca3030417bb0a7e154a8813edb,protocol,0.50442
uuid-ab062eca3030417bb0a7e154a8813edb,McDermott DF,0.548182
uuid-ab062eca3030417bb0a7e154a8813edb,Motzer RJ,0.532741
uuid-ab062eca3030417bb0a7e154a8813edb,phase 3 study,0.493197
uuid-ab062eca3030417bb0a7e154a8813edb,Escudier B,0.547344
uuid-ab062eca3030417bb0a7e154a8813edb,et al.,0.519366
uuid-ab062eca3030417bb0a7e154a8813edb,J Clin Oncol,0.509597
uuid-ab062eca3030417bb0a7e154a8813edb,Rizvi NA,0.478602
uuid-ab062eca3030417bb0a7e154a8813edb,Brahmer J,0.338223
uuid-ab062eca3030417bb0a7e154a8813edb,Weber JS,0.370952
uuid-ab062eca3030417bb0a7e154a8813edb,phase 2 study,0.591434
uuid-3a447b3407ba43188b22d001618b7335,OS,0.62262
uuid-3a447b3407ba43188b22d001618b7335,PFS,0.65903
uuid-3a447b3407ba43188b22d001618b7335,Overall survival,0.644151
uuid-d93191dbfbf64f4a91799daba0abb4d3,95% CI,0.419478
uuid-d93191dbfbf64f4a91799daba0abb4d3,respectively,0.497608
uuid-d93191dbfbf64f4a91799daba0abb4d3,Objective response rate,0.403649
uuid-d93191dbfbf64f4a91799daba0abb4d3,ORR,0.578109
uuid-d93191dbfbf64f4a91799daba0abb4d3,patients with advanced or metastatic,0.306625
uuid-d93191dbfbf64f4a91799daba0abb4d3,Median overall survival,0.498783
uuid-d93191dbfbf64f4a91799daba0abb4d3,nivolumab combined with ipilimumab,0.300486
uuid-d93191dbfbf64f4a91799daba0abb4d3,tumors,0.323334
uuid-d93191dbfbf64f4a91799daba0abb4d3,ESMO,0.534361
uuid-d93191dbfbf64f4a91799daba0abb4d3,Median OS,0.394058
uuid-d93191dbfbf64f4a91799daba0abb4d3,small cell lung cancer,0.380999
uuid-d93191dbfbf64f4a91799daba0abb4d3,SCLC,0.365686
uuid-d93191dbfbf64f4a91799daba0abb4d3,hazard ratio,0.419392
uuid-d93191dbfbf64f4a91799daba0abb4d3,grade 3 to 4 AEs,0.414535
uuid-d93191dbfbf64f4a91799daba0abb4d3,phase 1/2 study CA209-032,0.398283
uuid-d93191dbfbf64f4a91799daba0abb4d3,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,OS,0.304645
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,95% CI,0.408622
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,NSCLC,0.33588
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,respectively,0.499027
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,Objective response rate,0.688609
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,ORR,0.678791
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,Median overall survival,0.445394
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,monotherapy,0.519987
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,Median OS,0.375881
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,docetaxel,0.378462
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,Antonia SJ,0.333337
uuid-4bcd6027ecfa4005ba810bb0e7cbe57b,hazard ratio,0.41425
uuid-27408301e09742f7a3fea747f7509dd4,Opdivo,0.50165
uuid-27408301e09742f7a3fea747f7509dd4,open-label,0.304253
uuid-27408301e09742f7a3fea747f7509dd4,trial,0.521827
uuid-27408301e09742f7a3fea747f7509dd4,docetaxel,0.30238
uuid-27408301e09742f7a3fea747f7509dd4,safety of nivolumab monotherapy,0.432481
uuid-27408301e09742f7a3fea747f7509dd4,phase,0.378496
uuid-1ea7b20d565147f592486ac858420d54,Bristol-Myers Squibb,0.341822
uuid-1ea7b20d565147f592486ac858420d54,not conducted any controlled clinical trials/studies,0.304507
uuid-1ea7b20d565147f592486ac858420d54,Opdivo,0.461382
uuid-1ea7b20d565147f592486ac858420d54,Pubmed literature search,0.614325
uuid-1ea7b20d565147f592486ac858420d54,purposes other than its labeled indication must be considered investigational,0.586645
uuid-1ea7b20d565147f592486ac858420d54,not identify any citations relevant to your inquiry,0.606087
uuid-1ea7b20d565147f592486ac858420d54,adverse,0.304183
uuid-1ea7b20d565147f592486ac858420d54,using the following search terms,0.642331
uuid-1ea7b20d565147f592486ac858420d54,databases,0.315039
uuid-1ea7b20d565147f592486ac858420d54,reported,0.556704
uuid-abd471b0988d428a98d15c72c0d6dfa6,nivolumab,0.999168
uuid-abd471b0988d428a98d15c72c0d6dfa6,Pubmed literature search,0.395314
uuid-abd471b0988d428a98d15c72c0d6dfa6,purposes other than its labeled indication must be considered investigational,0.464236
uuid-abd471b0988d428a98d15c72c0d6dfa6,not identify any citations relevant to your inquiry,0.368569
uuid-abd471b0988d428a98d15c72c0d6dfa6,using the following search terms,0.364279
uuid-abd471b0988d428a98d15c72c0d6dfa6,present using the following search terms,0.329876
uuid-96b1112554ea451bb6471067490cd434,Opdivo,0.50165
uuid-96b1112554ea451bb6471067490cd434,open-label,0.304253
uuid-96b1112554ea451bb6471067490cd434,trial,0.521827
uuid-96b1112554ea451bb6471067490cd434,docetaxel,0.30238
uuid-96b1112554ea451bb6471067490cd434,safety of nivolumab monotherapy,0.432481
uuid-96b1112554ea451bb6471067490cd434,phase,0.378496
uuid-9ad32a91d1d14ab5972ce7b2756a044d,use of nivolumab for the treatment,0.305739
uuid-9ad32a91d1d14ab5972ce7b2756a044d,patients with advanced or metastatic,0.509457
uuid-9ad32a91d1d14ab5972ce7b2756a044d,nivolumab combined with ipilimumab,0.496885
uuid-9ad32a91d1d14ab5972ce7b2756a044d,not approved,0.397631
uuid-9ad32a91d1d14ab5972ce7b2756a044d,clinical trials investigating the safety,0.478965
uuid-9ad32a91d1d14ab5972ce7b2756a044d,bladder cancer,0.940126
uuid-0f19584b65414abe830588fc576044d7,nivolumab,0.580265
uuid-0f19584b65414abe830588fc576044d7,Bristol-Myers Squibb,0.438595
uuid-0f19584b65414abe830588fc576044d7,evaluating,0.596992
uuid-0f19584b65414abe830588fc576044d7,not conducted any controlled clinical trials/studies,0.650874
uuid-0f19584b65414abe830588fc576044d7,Pubmed literature search,0.85789
uuid-0f19584b65414abe830588fc576044d7,purposes other than its labeled indication must be considered investigational,0.924057
uuid-0f19584b65414abe830588fc576044d7,not identify any citations relevant to your inquiry,0.819302
uuid-0f19584b65414abe830588fc576044d7,using the following search terms,0.804463
uuid-0f19584b65414abe830588fc576044d7,efficacy and safety of nivolumab,0.4315
uuid-995155659cd444a3b93528066cd58cc5,use of nivolumab for the treatment,0.305739
uuid-995155659cd444a3b93528066cd58cc5,patients with advanced or metastatic,0.509457
uuid-995155659cd444a3b93528066cd58cc5,nivolumab combined with ipilimumab,0.496885
uuid-995155659cd444a3b93528066cd58cc5,not approved,0.397631
uuid-995155659cd444a3b93528066cd58cc5,clinical trials investigating the safety,0.478965
uuid-995155659cd444a3b93528066cd58cc5,bladder cancer,0.940126
uuid-51fa3eb371be462ea7cff057da57b367,melanoma,0.410364
uuid-b59a9ba879dc4f1f834f77370300197b,ASCO,0.572408
uuid-b59a9ba879dc4f1f834f77370300197b,requested,0.60375
uuid-2d49d264ac644735946dcd38aa1691ce,small cell lung cancer,0.408252
uuid-2d49d264ac644735946dcd38aa1691ce,SCLC,0.478167
uuid-2d49d264ac644735946dcd38aa1691ce,therapy,0.765211
uuid-2d49d264ac644735946dcd38aa1691ce,relapsed,0.515693
uuid-76bfe343fb454fb0a8b63b15c43daf26,ASCO,0.596104
uuid-76bfe343fb454fb0a8b63b15c43daf26,Objective response rate,0.344723
uuid-76bfe343fb454fb0a8b63b15c43daf26,ASCO 2015,0.313517
uuid-76bfe343fb454fb0a8b63b15c43daf26,phase 1 study,0.375646
uuid-a8654c2845fd413284435344ec441ae1,nivolumab,0.575969
uuid-a8654c2845fd413284435344ec441ae1,Bristol-Myers Squibb,0.461877
uuid-a8654c2845fd413284435344ec441ae1,evaluating,0.625709
uuid-a8654c2845fd413284435344ec441ae1,not conducted any controlled clinical trials/studies,0.682324
uuid-a8654c2845fd413284435344ec441ae1,Pubmed literature search,0.859223
uuid-a8654c2845fd413284435344ec441ae1,purposes other than its labeled indication must be considered investigational,0.928059
uuid-a8654c2845fd413284435344ec441ae1,not identify any citations relevant to your inquiry,0.815907
uuid-a8654c2845fd413284435344ec441ae1,using the following search terms,0.803621
uuid-a8654c2845fd413284435344ec441ae1,efficacy and safety of nivolumab,0.466758
uuid-74b2471759de4637b76fa16294638181,Opdivo,0.50165
uuid-74b2471759de4637b76fa16294638181,open-label,0.304253
uuid-74b2471759de4637b76fa16294638181,trial,0.521827
uuid-74b2471759de4637b76fa16294638181,docetaxel,0.30238
uuid-74b2471759de4637b76fa16294638181,safety of nivolumab monotherapy,0.432481
uuid-74b2471759de4637b76fa16294638181,phase,0.378496
uuid-6fd74f0d93d242c4b213b799316f9ec7,trial,0.395617
uuid-3849030a2743480daaf85936defcc28a,Bristol-Myers Squibb,0.494637
uuid-83040020debb40fe90ecca3adbbc5f90,NSCLC,0.480337
uuid-83040020debb40fe90ecca3adbbc5f90,respectively,0.400584
uuid-83040020debb40fe90ecca3adbbc5f90,non-small cell lung cancer,0.395662
uuid-83040020debb40fe90ecca3adbbc5f90,patients,0.382838
uuid-83040020debb40fe90ecca3adbbc5f90,considered investigational,0.378457
uuid-83040020debb40fe90ecca3adbbc5f90,Objective response rate,0.446233
uuid-83040020debb40fe90ecca3adbbc5f90,ORR,0.488323
uuid-83040020debb40fe90ecca3adbbc5f90,monotherapy,0.419452
uuid-83040020debb40fe90ecca3adbbc5f90,small cell lung cancer,0.328277
uuid-83040020debb40fe90ecca3adbbc5f90,docetaxel,0.370754
uuid-83040020debb40fe90ecca3adbbc5f90,SCLC,0.328412
uuid-83040020debb40fe90ecca3adbbc5f90,grade 3 to 4 AEs,0.337672
uuid-83040020debb40fe90ecca3adbbc5f90,platinum-based doublet chemotherapy,0.355492
uuid-3379f6c00f604dcdb08d7f99f24a539d,N Engl J Med,0.322506
uuid-3379f6c00f604dcdb08d7f99f24a539d,requested,0.654492
uuid-6e9dcf2fb91a49af9c4454873763899b,Bristol-Myers Squibb,0.633142
uuid-6e9dcf2fb91a49af9c4454873763899b,use of nivolumab for the treatment,0.303479
uuid-6e9dcf2fb91a49af9c4454873763899b,evaluating,0.743108
uuid-6e9dcf2fb91a49af9c4454873763899b,not conducted any controlled clinical trials/studies,0.720303
uuid-6e9dcf2fb91a49af9c4454873763899b,efficacy,0.342045
uuid-6e9dcf2fb91a49af9c4454873763899b,NSCLC,0.588844
uuid-6e9dcf2fb91a49af9c4454873763899b,non-small cell lung cancer,0.612068
uuid-6e9dcf2fb91a49af9c4454873763899b,patients,0.422477
uuid-6e9dcf2fb91a49af9c4454873763899b,considered investigational,0.370111
uuid-6e9dcf2fb91a49af9c4454873763899b,efficacy and safety of nivolumab,0.638364
uuid-6e9dcf2fb91a49af9c4454873763899b,safety of nivolumab monotherapy,0.543855
uuid-6e9dcf2fb91a49af9c4454873763899b,platinum-based doublet chemotherapy,0.378954
uuid-dce5204e8fc345ec9851994528799ca3,provided in the Detailed Information,0.349112
uuid-dce5204e8fc345ec9851994528799ca3,Weber JS,0.321343
uuid-77a67e3f05d747a1952a9186ac4acaab,patients,0.410361
uuid-77a67e3f05d747a1952a9186ac4acaab,clinical,0.426878
uuid-77a67e3f05d747a1952a9186ac4acaab,trial,0.57188
uuid-96148f00ade44ca5a24158863c807c91,Lancet Oncol,0.354363
uuid-96148f00ade44ca5a24158863c807c91,phase 3 study,0.432565
uuid-96148f00ade44ca5a24158863c807c91,Rizvi NA,0.408564
uuid-96148f00ade44ca5a24158863c807c91,trial,0.363052
uuid-96148f00ade44ca5a24158863c807c91,Weber JS,0.459799
uuid-101276219f534b24a4e1e8c3ddd3e2f9,adverse,0.339013
uuid-101276219f534b24a4e1e8c3ddd3e2f9,phase 3 study,0.319839
uuid-101276219f534b24a4e1e8c3ddd3e2f9,Rizvi NA,0.364772
uuid-101276219f534b24a4e1e8c3ddd3e2f9,Brahmer J,0.4414
uuid-101276219f534b24a4e1e8c3ddd3e2f9,BMS,0.743077
uuid-101276219f534b24a4e1e8c3ddd3e2f9,reported,0.507787
uuid-9a445a86a0254a4ab233fcd4bdf379ae,nivolumab,0.561462
uuid-9a445a86a0254a4ab233fcd4bdf379ae,Bristol-Myers Squibb,0.472343
uuid-9a445a86a0254a4ab233fcd4bdf379ae,evaluating,0.648021
uuid-9a445a86a0254a4ab233fcd4bdf379ae,not conducted any controlled clinical trials/studies,0.698087
uuid-9a445a86a0254a4ab233fcd4bdf379ae,Pubmed literature search,0.841906
uuid-9a445a86a0254a4ab233fcd4bdf379ae,purposes other than its labeled indication must be considered investigational,0.914026
uuid-9a445a86a0254a4ab233fcd4bdf379ae,not identify any citations relevant to your inquiry,0.800198
uuid-9a445a86a0254a4ab233fcd4bdf379ae,using the following search terms,0.784059
uuid-9a445a86a0254a4ab233fcd4bdf379ae,efficacy and safety of nivolumab,0.483604
uuid-dba9f2c6f1e34c2e82481a9580861c04,NSCLC,0.472141
uuid-dba9f2c6f1e34c2e82481a9580861c04,Lancet Oncol,0.35789
uuid-dba9f2c6f1e34c2e82481a9580861c04,non-small cell lung cancer,0.442751
uuid-dba9f2c6f1e34c2e82481a9580861c04,patients,0.409704
uuid-dba9f2c6f1e34c2e82481a9580861c04,considered investigational,0.309223
uuid-dba9f2c6f1e34c2e82481a9580861c04,phase 3 study,0.510287
uuid-dba9f2c6f1e34c2e82481a9580861c04,melanoma,0.367308
uuid-dba9f2c6f1e34c2e82481a9580861c04,phase 1 study,0.398247
uuid-dba9f2c6f1e34c2e82481a9580861c04,Rizvi NA,0.436664
uuid-dba9f2c6f1e34c2e82481a9580861c04,small cell lung cancer,0.355806
uuid-dba9f2c6f1e34c2e82481a9580861c04,efficacy and safety of nivolumab,0.313048
uuid-dba9f2c6f1e34c2e82481a9580861c04,Weber JS,0.357821
uuid-dba9f2c6f1e34c2e82481a9580861c04,SCLC,0.390602
uuid-dba9f2c6f1e34c2e82481a9580861c04,therapy,0.524681
uuid-9abba2b46aee43018ad3b4e09b8a6a13,trial,0.306565
uuid-ae28046b29d140b5a8148ef30935c9c6,search of published literature,0.392478
uuid-ae28046b29d140b5a8148ef30935c9c6,Additionally,0.453425
uuid-ae28046b29d140b5a8148ef30935c9c6,ongoing,0.374816
uuid-ae28046b29d140b5a8148ef30935c9c6,PubMed and EMBASE,0.390047
uuid-ae28046b29d140b5a8148ef30935c9c6,detailed search of www.clinicaltrials.gov,0.430932
uuid-ae28046b29d140b5a8148ef30935c9c6,efficacy and safety of nivolumab,0.376176
uuid-ae28046b29d140b5a8148ef30935c9c6,not identify any planned,0.394611
uuid-ae28046b29d140b5a8148ef30935c9c6,not identify any citations relevant to your request,0.497579
uuid-ae28046b29d140b5a8148ef30935c9c6,present using the following search terms,0.418121
uuid-03203b09c7dc42ba9f49070d8c51d0bc,use of nivolumab for the treatment,0.305739
uuid-03203b09c7dc42ba9f49070d8c51d0bc,patients with advanced or metastatic,0.509457
uuid-03203b09c7dc42ba9f49070d8c51d0bc,nivolumab combined with ipilimumab,0.496885
uuid-03203b09c7dc42ba9f49070d8c51d0bc,not approved,0.397631
uuid-03203b09c7dc42ba9f49070d8c51d0bc,clinical trials investigating the safety,0.478965
uuid-03203b09c7dc42ba9f49070d8c51d0bc,bladder cancer,0.940126
uuid-4017012418b94606a071118ca168c823,requested,0.321067
uuid-4017012418b94606a071118ca168c823,bladder cancer,0.32509
uuid-e6c316d508fd4aa9bdf427f7ea796c84,nivolumab,0.322544
uuid-e6c316d508fd4aa9bdf427f7ea796c84,Bristol-Myers Squibb,0.538606
uuid-e6c316d508fd4aa9bdf427f7ea796c84,evaluating,0.623596
uuid-e6c316d508fd4aa9bdf427f7ea796c84,not conducted any controlled clinical trials/studies,0.630163
uuid-e6c316d508fd4aa9bdf427f7ea796c84,search of published literature,0.574458
uuid-e6c316d508fd4aa9bdf427f7ea796c84,Additionally,0.579336
uuid-e6c316d508fd4aa9bdf427f7ea796c84,ongoing,0.479553
uuid-e6c316d508fd4aa9bdf427f7ea796c84,PubMed and EMBASE,0.557737
uuid-e6c316d508fd4aa9bdf427f7ea796c84,detailed search of www.clinicaltrials.gov,0.549869
uuid-e6c316d508fd4aa9bdf427f7ea796c84,efficacy and safety of nivolumab,0.689885
uuid-e6c316d508fd4aa9bdf427f7ea796c84,not identify any planned,0.501929
uuid-e6c316d508fd4aa9bdf427f7ea796c84,not identify any citations relevant to your request,0.631655
uuid-e6c316d508fd4aa9bdf427f7ea796c84,present using the following search terms,0.579758
uuid-28c7bfc8a56843ed922fb6573d3b78ae,requested,0.44769
uuid-28c7bfc8a56843ed922fb6573d3b78ae,trial,0.309472
uuid-1a82cb94d4d04da68b32a46fa90441be,Opdivo,0.50165
uuid-1a82cb94d4d04da68b32a46fa90441be,open-label,0.304253
uuid-1a82cb94d4d04da68b32a46fa90441be,trial,0.521827
uuid-1a82cb94d4d04da68b32a46fa90441be,docetaxel,0.30238
uuid-1a82cb94d4d04da68b32a46fa90441be,safety of nivolumab monotherapy,0.432481
uuid-1a82cb94d4d04da68b32a46fa90441be,phase,0.378496
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,Opdivo,0.50165
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,open-label,0.304253
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,trial,0.521827
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,docetaxel,0.30238
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,safety of nivolumab monotherapy,0.432481
uuid-bda9af8ec08f4e9cbfac39c1a7fcfe33,phase,0.378496
uuid-992af53d185f448fa4c9bb66b5e21428,fatigue,0.411608
uuid-b5e7458a48ae4f5e8047e9d21c95e802,Opdivo,0.50165
uuid-b5e7458a48ae4f5e8047e9d21c95e802,open-label,0.304253
uuid-b5e7458a48ae4f5e8047e9d21c95e802,trial,0.521827
uuid-b5e7458a48ae4f5e8047e9d21c95e802,docetaxel,0.30238
uuid-b5e7458a48ae4f5e8047e9d21c95e802,safety of nivolumab monotherapy,0.432481
uuid-b5e7458a48ae4f5e8047e9d21c95e802,phase,0.378496
uuid-ce415bfdcc514745a14f8fb41f148e5c,provided in the Detailed Information,0.420423
uuid-fa51ea9916b9475db121cd34825a7eb9,nivolumab,0.503241
uuid-fa51ea9916b9475db121cd34825a7eb9,Bristol-Myers Squibb,0.625406
uuid-fa51ea9916b9475db121cd34825a7eb9,evaluating,0.74113
uuid-fa51ea9916b9475db121cd34825a7eb9,not conducted any controlled clinical trials/studies,0.803707
uuid-fa51ea9916b9475db121cd34825a7eb9,Pubmed literature search,0.727523
uuid-fa51ea9916b9475db121cd34825a7eb9,purposes other than its labeled indication must be considered investigational,0.821319
uuid-fa51ea9916b9475db121cd34825a7eb9,not identify any citations relevant to your inquiry,0.677181
uuid-fa51ea9916b9475db121cd34825a7eb9,using the following search terms,0.658606
uuid-fa51ea9916b9475db121cd34825a7eb9,efficacy and safety of nivolumab,0.582236
uuid-7e85c6440f834116ae37b29c8c5b8c57,OS,0.517683
uuid-7e85c6440f834116ae37b29c8c5b8c57,95% CI,0.887029
uuid-7e85c6440f834116ae37b29c8c5b8c57,respectively,0.541932
uuid-7e85c6440f834116ae37b29c8c5b8c57,Objective response rate,0.732884
uuid-7e85c6440f834116ae37b29c8c5b8c57,ORR,0.826341
uuid-7e85c6440f834116ae37b29c8c5b8c57,PFS,0.416378
uuid-7e85c6440f834116ae37b29c8c5b8c57,Median overall survival,0.810566
uuid-7e85c6440f834116ae37b29c8c5b8c57,monotherapy,0.504664
uuid-7e85c6440f834116ae37b29c8c5b8c57,Median OS,0.783041
uuid-7e85c6440f834116ae37b29c8c5b8c57,hazard ratio,0.851803
uuid-7e85c6440f834116ae37b29c8c5b8c57,Median duration of response,0.350254
uuid-f8159c7c5153447da37281849140b793,requested,0.44769
uuid-f8159c7c5153447da37281849140b793,trial,0.309472
uuid-0089c1dcb1084d3fb984df4e65006cf4,patients,0.556054
uuid-0089c1dcb1084d3fb984df4e65006cf4,provided in the Detailed Information,0.329929
uuid-0089c1dcb1084d3fb984df4e65006cf4,adverse,0.32982
uuid-0089c1dcb1084d3fb984df4e65006cf4,phase 3 study,0.523726
uuid-0089c1dcb1084d3fb984df4e65006cf4,melanoma,0.382071
uuid-0089c1dcb1084d3fb984df4e65006cf4,Weber JS,0.428777
uuid-0089c1dcb1084d3fb984df4e65006cf4,phase 2 study,0.307314
uuid-0089c1dcb1084d3fb984df4e65006cf4,grade 3 to 4 AEs,0.466022
uuid-c14d1affd16d4638ae07bca363620b79,use of nivolumab for the treatment,0.409821
uuid-c14d1affd16d4638ae07bca363620b79,patients with advanced or metastatic,0.645244
uuid-c14d1affd16d4638ae07bca363620b79,nivolumab combined with ipilimumab,0.676339
uuid-c14d1affd16d4638ae07bca363620b79,not approved,0.453534
uuid-c14d1affd16d4638ae07bca363620b79,clinical trials investigating the safety,0.548799
uuid-c14d1affd16d4638ae07bca363620b79,phase 1/2 study CA209-032,0.34114
uuid-c14d1affd16d4638ae07bca363620b79,bladder cancer,0.749142
uuid-c14d1affd16d4638ae07bca363620b79,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-9b6c59662f1743cd9ed7c09910c9e924,patients,0.579047
uuid-9b6c59662f1743cd9ed7c09910c9e924,adverse,0.55213
uuid-9b6c59662f1743cd9ed7c09910c9e924,grade 3 to 4 AEs,0.368023
uuid-9b6c59662f1743cd9ed7c09910c9e924,reported,0.725107
uuid-71d2a1689f544016bd2813f7cbc20bcc,use of nivolumab for the treatment,0.445924
uuid-71d2a1689f544016bd2813f7cbc20bcc,efficacy,0.424179
uuid-71d2a1689f544016bd2813f7cbc20bcc,RCC,0.445456
uuid-71d2a1689f544016bd2813f7cbc20bcc,not approved,0.498022
uuid-71d2a1689f544016bd2813f7cbc20bcc,clinical trials investigating the safety,0.501478
uuid-71d2a1689f544016bd2813f7cbc20bcc,safety of nivolumab monotherapy,0.30786
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,Bristol-Myers Squibb,0.341822
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,not conducted any controlled clinical trials/studies,0.304507
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,Opdivo,0.461382
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,Pubmed literature search,0.614325
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,not identify any citations relevant to your inquiry,0.606087
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,adverse,0.304183
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,using the following search terms,0.642331
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,databases,0.315039
uuid-4cfdc4d32c8244f1bb0ad0f5c90d0969,reported,0.556704
uuid-a8de7ba3c4934bb98361ba7562897e7d,Bristol-Myers Squibb,0.341822
uuid-a8de7ba3c4934bb98361ba7562897e7d,not conducted any controlled clinical trials/studies,0.304507
uuid-a8de7ba3c4934bb98361ba7562897e7d,Opdivo,0.461382
uuid-a8de7ba3c4934bb98361ba7562897e7d,Pubmed literature search,0.614325
uuid-a8de7ba3c4934bb98361ba7562897e7d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a8de7ba3c4934bb98361ba7562897e7d,not identify any citations relevant to your inquiry,0.606087
uuid-a8de7ba3c4934bb98361ba7562897e7d,adverse,0.304183
uuid-a8de7ba3c4934bb98361ba7562897e7d,using the following search terms,0.642331
uuid-a8de7ba3c4934bb98361ba7562897e7d,databases,0.315039
uuid-a8de7ba3c4934bb98361ba7562897e7d,reported,0.556704
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,nivolumab,0.328574
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,Bristol-Myers Squibb,0.380092
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,use of nivolumab for the treatment,0.356382
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,evaluating,0.63485
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,not conducted any controlled clinical trials/studies,0.577107
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,patients,0.354852
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,search of published literature,0.648516
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,Additionally,0.520805
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,ongoing,0.407977
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,PubMed and EMBASE,0.629647
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,detailed search of www.clinicaltrials.gov,0.474105
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,melanoma,0.37374
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,efficacy and safety of nivolumab,0.728573
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,not identify any planned,0.422677
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,not identify any citations relevant to your request,0.601968
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,therapy,0.32913
uuid-9ee1b676f3cc465ebe15f1b5ebb22681,present using the following search terms,0.64772
uuid-f9946da76c67426483d8d7d882f049f7,use of nivolumab for the treatment,0.305739
uuid-f9946da76c67426483d8d7d882f049f7,patients with advanced or metastatic,0.509457
uuid-f9946da76c67426483d8d7d882f049f7,nivolumab combined with ipilimumab,0.496885
uuid-f9946da76c67426483d8d7d882f049f7,not approved,0.397631
uuid-f9946da76c67426483d8d7d882f049f7,clinical trials investigating the safety,0.478965
uuid-f9946da76c67426483d8d7d882f049f7,bladder cancer,0.940126
uuid-1bd9750daf5748b28a620d7412619e82,NSCLC,0.327373
uuid-1bd9750daf5748b28a620d7412619e82,respectively,0.32989
uuid-1bd9750daf5748b28a620d7412619e82,Objective response rate,0.414926
uuid-1bd9750daf5748b28a620d7412619e82,ORR,0.46431
uuid-1bd9750daf5748b28a620d7412619e82,Median overall survival,0.358033
uuid-291fa959a2fd46578d8c9bc0a5c4736d,small cell lung cancer,0.393135
uuid-291fa959a2fd46578d8c9bc0a5c4736d,SCLC,0.441325
uuid-291fa959a2fd46578d8c9bc0a5c4736d,therapy,0.512398
uuid-6b29f46d3116438ea89d910fcd2b41df,Bristol-Myers Squibb,0.494637
uuid-46471042ec864666b8db02648baa9c5c,Bristol-Myers Squibb,0.876817
uuid-46471042ec864666b8db02648baa9c5c,use of nivolumab for the treatment,0.300612
uuid-46471042ec864666b8db02648baa9c5c,evaluating,0.941561
uuid-46471042ec864666b8db02648baa9c5c,not conducted any controlled clinical trials/studies,0.985336
uuid-46471042ec864666b8db02648baa9c5c,non-small cell lung cancer,0.309536
uuid-46471042ec864666b8db02648baa9c5c,considered investigational,0.313986
uuid-46471042ec864666b8db02648baa9c5c,purposes other than its labeled indication must be considered investigational,0.319531
uuid-46471042ec864666b8db02648baa9c5c,search of published literature,0.478815
uuid-46471042ec864666b8db02648baa9c5c,PubMed and EMBASE,0.425557
uuid-46471042ec864666b8db02648baa9c5c,efficacy and safety of nivolumab,0.900773
uuid-46471042ec864666b8db02648baa9c5c,present using the following search terms,0.413048
uuid-46471042ec864666b8db02648baa9c5c,safety of nivolumab monotherapy,0.403726
uuid-769c9b379c8f40249963e2de52f85d63,requested,0.415594
uuid-f1265a5732f049b7a526d6b91c1b52b8,open-label,0.3753
uuid-f1265a5732f049b7a526d6b91c1b52b8,trial,0.445017
uuid-1991af4f858944edb9c7fc56a1ea74b3,N Engl J Med,0.427636
uuid-1991af4f858944edb9c7fc56a1ea74b3,protocol,0.429136
uuid-1991af4f858944edb9c7fc56a1ea74b3,McDermott DF,0.44782
uuid-1991af4f858944edb9c7fc56a1ea74b3,Motzer RJ,0.430476
uuid-1991af4f858944edb9c7fc56a1ea74b3,Escudier B,0.450887
uuid-1991af4f858944edb9c7fc56a1ea74b3,et al.,0.456026
uuid-1991af4f858944edb9c7fc56a1ea74b3,J Clin Oncol,0.384624
uuid-1991af4f858944edb9c7fc56a1ea74b3,Rizvi NA,0.305616
uuid-1991af4f858944edb9c7fc56a1ea74b3,phase 2 study,0.351446
uuid-07aad9eebfe24b478929439278aa6f7a,evaluating,0.340268
uuid-07aad9eebfe24b478929439278aa6f7a,not conducted any controlled clinical trials/studies,0.326834
uuid-07aad9eebfe24b478929439278aa6f7a,search of published literature,0.428843
uuid-07aad9eebfe24b478929439278aa6f7a,Additionally,0.421938
uuid-07aad9eebfe24b478929439278aa6f7a,ongoing,0.338718
uuid-07aad9eebfe24b478929439278aa6f7a,PubMed and EMBASE,0.421635
uuid-07aad9eebfe24b478929439278aa6f7a,detailed search of www.clinicaltrials.gov,0.395128
uuid-07aad9eebfe24b478929439278aa6f7a,efficacy and safety of nivolumab,0.449164
uuid-07aad9eebfe24b478929439278aa6f7a,not identify any planned,0.357684
uuid-07aad9eebfe24b478929439278aa6f7a,not identify any citations relevant to your request,0.4725
uuid-07aad9eebfe24b478929439278aa6f7a,present using the following search terms,0.442701
uuid-3daec091b56e40e4ba8af0938659a935,melanoma,0.410364
uuid-19870d8b1e584f06b06bd29b66e55b3a,nivolumab,0.590995
uuid-e416cee7e25f4fea98a48f3e8835e7da,requested,0.596876
uuid-8a48f2b0685b42009f278860380272e7,Bristol-Myers Squibb,0.37879
uuid-8a48f2b0685b42009f278860380272e7,evaluating,0.551968
uuid-8a48f2b0685b42009f278860380272e7,N Engl J Med,0.47935
uuid-8a48f2b0685b42009f278860380272e7,not conducted any controlled clinical trials/studies,0.557186
uuid-8a48f2b0685b42009f278860380272e7,NSCLC,0.395346
uuid-8a48f2b0685b42009f278860380272e7,non-small cell lung cancer,0.396064
uuid-8a48f2b0685b42009f278860380272e7,considered investigational,0.30933
uuid-8a48f2b0685b42009f278860380272e7,purposes other than its labeled indication must be considered investigational,0.361184
uuid-8a48f2b0685b42009f278860380272e7,phase 3 study,0.356156
uuid-8a48f2b0685b42009f278860380272e7,Rizvi NA,0.325774
uuid-8a48f2b0685b42009f278860380272e7,Brahmer J,0.526068
uuid-8a48f2b0685b42009f278860380272e7,efficacy and safety of nivolumab,0.524488
uuid-8a48f2b0685b42009f278860380272e7,phase 2 study,0.342606
uuid-1e257dd9b0d540d39be64922f83fe0ec,ipilimumab,0.385692
uuid-1e257dd9b0d540d39be64922f83fe0ec,ASCO 2015,0.417944
uuid-1e257dd9b0d540d39be64922f83fe0ec,partial response,0.382425
uuid-1e257dd9b0d540d39be64922f83fe0ec,Stable disease,0.586335
uuid-1e257dd9b0d540d39be64922f83fe0ec,cohort,0.307748
uuid-1af946144e53423c8e91e6a6fa55ae8d,use of nivolumab for the treatment,0.305739
uuid-1af946144e53423c8e91e6a6fa55ae8d,patients with advanced or metastatic,0.509457
uuid-1af946144e53423c8e91e6a6fa55ae8d,nivolumab combined with ipilimumab,0.496885
uuid-1af946144e53423c8e91e6a6fa55ae8d,not approved,0.397631
uuid-1af946144e53423c8e91e6a6fa55ae8d,clinical trials investigating the safety,0.478965
uuid-1af946144e53423c8e91e6a6fa55ae8d,bladder cancer,0.940126
uuid-05798990749541e1b1996b2140858ef8,search of published literature,0.394524
uuid-05798990749541e1b1996b2140858ef8,Additionally,0.413583
uuid-05798990749541e1b1996b2140858ef8,ongoing,0.322117
uuid-05798990749541e1b1996b2140858ef8,PubMed and EMBASE,0.391671
uuid-05798990749541e1b1996b2140858ef8,detailed search of www.clinicaltrials.gov,0.375936
uuid-05798990749541e1b1996b2140858ef8,efficacy and safety of nivolumab,0.370699
uuid-05798990749541e1b1996b2140858ef8,not identify any planned,0.34283
uuid-05798990749541e1b1996b2140858ef8,Weber JS,0.319229
uuid-05798990749541e1b1996b2140858ef8,not identify any citations relevant to your request,0.447813
uuid-05798990749541e1b1996b2140858ef8,present using the following search terms,0.408199
uuid-a34f75fc9c614a29a0b59f80b97ee33a,OS,0.62262
uuid-a34f75fc9c614a29a0b59f80b97ee33a,PFS,0.65903
uuid-a34f75fc9c614a29a0b59f80b97ee33a,Overall survival,0.644151
uuid-353030a7a940432889adc9cd1a679491,nivolumab,0.549798
uuid-353030a7a940432889adc9cd1a679491,Bristol-Myers Squibb,0.451358
uuid-353030a7a940432889adc9cd1a679491,evaluating,0.59509
uuid-353030a7a940432889adc9cd1a679491,not conducted any controlled clinical trials/studies,0.653411
uuid-353030a7a940432889adc9cd1a679491,Pubmed literature search,0.789145
uuid-353030a7a940432889adc9cd1a679491,purposes other than its labeled indication must be considered investigational,0.858013
uuid-353030a7a940432889adc9cd1a679491,not identify any citations relevant to your inquiry,0.749757
uuid-353030a7a940432889adc9cd1a679491,using the following search terms,0.734613
uuid-353030a7a940432889adc9cd1a679491,efficacy and safety of nivolumab,0.46291
uuid-6dd466e6f4764181a860fea2e54ed4c8,OS,0.304645
uuid-6dd466e6f4764181a860fea2e54ed4c8,95% CI,0.408622
uuid-6dd466e6f4764181a860fea2e54ed4c8,NSCLC,0.33588
uuid-6dd466e6f4764181a860fea2e54ed4c8,respectively,0.499027
uuid-6dd466e6f4764181a860fea2e54ed4c8,Objective response rate,0.688609
uuid-6dd466e6f4764181a860fea2e54ed4c8,ORR,0.678791
uuid-6dd466e6f4764181a860fea2e54ed4c8,Median overall survival,0.445394
uuid-6dd466e6f4764181a860fea2e54ed4c8,monotherapy,0.519987
uuid-6dd466e6f4764181a860fea2e54ed4c8,Median OS,0.375881
uuid-6dd466e6f4764181a860fea2e54ed4c8,docetaxel,0.378462
uuid-6dd466e6f4764181a860fea2e54ed4c8,Antonia SJ,0.333337
uuid-6dd466e6f4764181a860fea2e54ed4c8,hazard ratio,0.41425
uuid-3446968c4a8d4fce9601fca722f48d45,use of nivolumab for the treatment,0.409821
uuid-3446968c4a8d4fce9601fca722f48d45,patients with advanced or metastatic,0.645244
uuid-3446968c4a8d4fce9601fca722f48d45,nivolumab combined with ipilimumab,0.676339
uuid-3446968c4a8d4fce9601fca722f48d45,not approved,0.453534
uuid-3446968c4a8d4fce9601fca722f48d45,clinical trials investigating the safety,0.548799
uuid-3446968c4a8d4fce9601fca722f48d45,phase 1/2 study CA209-032,0.34114
uuid-3446968c4a8d4fce9601fca722f48d45,bladder cancer,0.749142
uuid-3446968c4a8d4fce9601fca722f48d45,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-125852abd9c4478f90515ae013be4db4,requested,0.596876
uuid-84f20dd7a2104e348ae66dc21f4bbb7e,adverse,0.371332
uuid-84f20dd7a2104e348ae66dc21f4bbb7e,fatigue,0.355858
uuid-42c044ab19da473eb6d181cdfe17fe87,Bristol-Myers Squibb,0.437313
uuid-42c044ab19da473eb6d181cdfe17fe87,evaluating,0.381769
uuid-42c044ab19da473eb6d181cdfe17fe87,not conducted any controlled clinical trials/studies,0.449643
uuid-42c044ab19da473eb6d181cdfe17fe87,Opdivo,0.384678
uuid-42c044ab19da473eb6d181cdfe17fe87,Pubmed literature search,0.707704
uuid-42c044ab19da473eb6d181cdfe17fe87,purposes other than its labeled indication must be considered investigational,0.707531
uuid-42c044ab19da473eb6d181cdfe17fe87,not identify any citations relevant to your inquiry,0.689469
uuid-42c044ab19da473eb6d181cdfe17fe87,using the following search terms,0.713981
uuid-42c044ab19da473eb6d181cdfe17fe87,reported,0.460743
uuid-1f4eaedbea5843edb4c25e1a9df365f4,Bristol-Myers Squibb,0.396793
uuid-1f4eaedbea5843edb4c25e1a9df365f4,requested,0.743312
uuid-1f4eaedbea5843edb4c25e1a9df365f4,Opdivo,0.385736
uuid-dbde5168bc0940dcb2fcb6b359df25f3,ASCO,0.56076
uuid-dbde5168bc0940dcb2fcb6b359df25f3,Objective response rate,0.448218
uuid-dbde5168bc0940dcb2fcb6b359df25f3,ORR,0.335807
uuid-dbde5168bc0940dcb2fcb6b359df25f3,ASCO 2015,0.432074
uuid-dbde5168bc0940dcb2fcb6b359df25f3,phase 1 study,0.353524
uuid-dbde5168bc0940dcb2fcb6b359df25f3,Antonia SJ,0.340757
uuid-7c174b11276942f48ab34a66e3bde842,requested,0.540431
uuid-aff749bc5a044b85b020f57389948574,fatigue,0.411608
uuid-6257a819dd594cbe86377eabf4df964d,nivolumab,0.601734
uuid-6257a819dd594cbe86377eabf4df964d,melanoma,0.44657
uuid-bf296b56958b42d3ad55a5b7226349a3,fatigue,0.411608
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,N Engl J Med,0.475841
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,respectively,0.361581
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,ASCO,0.502974
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,Objective response rate,0.372883
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,ORR,0.391005
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,Median OS,0.366685
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,Rizvi NA,0.350225
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,Brahmer J,0.578988
uuid-5a0065f3258f4bd6b9bca2ef487c40d5,docetaxel,0.378592
uuid-c37bb9e235d343e6b3419270f5e1759e,requested,0.651776
uuid-ce17015eeb4d4822bd597866781c3cb7,Bristol-Myers Squibb,0.358381
uuid-ce17015eeb4d4822bd597866781c3cb7,reported,0.309202
uuid-70840ba72ca84047be8b593b1e051244,Bristol-Myers Squibb,0.494637
uuid-92384e426c9647d39f64bfe6eaeb0771,nivolumab,0.655488
uuid-92384e426c9647d39f64bfe6eaeb0771,Pubmed literature search,0.717239
uuid-92384e426c9647d39f64bfe6eaeb0771,purposes other than its labeled indication must be considered investigational,0.74151
uuid-92384e426c9647d39f64bfe6eaeb0771,not identify any citations relevant to your inquiry,0.700271
uuid-92384e426c9647d39f64bfe6eaeb0771,using the following search terms,0.697692
uuid-2caa62d562b74990afc6b3c5816c4e72,nivolumab,0.580451
uuid-2caa62d562b74990afc6b3c5816c4e72,Bristol-Myers Squibb,0.439837
uuid-2caa62d562b74990afc6b3c5816c4e72,evaluating,0.597856
uuid-2caa62d562b74990afc6b3c5816c4e72,not conducted any controlled clinical trials/studies,0.651818
uuid-2caa62d562b74990afc6b3c5816c4e72,Pubmed literature search,0.857229
uuid-2caa62d562b74990afc6b3c5816c4e72,purposes other than its labeled indication must be considered investigational,0.923564
uuid-2caa62d562b74990afc6b3c5816c4e72,not identify any citations relevant to your inquiry,0.81856
uuid-2caa62d562b74990afc6b3c5816c4e72,using the following search terms,0.803741
uuid-2caa62d562b74990afc6b3c5816c4e72,efficacy and safety of nivolumab,0.43247
uuid-4d997c84099d44bea07c55dc94472ea8,nivolumab,0.375168
uuid-4d997c84099d44bea07c55dc94472ea8,evaluating,0.330914
uuid-4d997c84099d44bea07c55dc94472ea8,not conducted any controlled clinical trials/studies,0.365499
uuid-4d997c84099d44bea07c55dc94472ea8,Pubmed literature search,0.571879
uuid-4d997c84099d44bea07c55dc94472ea8,purposes other than its labeled indication must be considered investigational,0.604485
uuid-4d997c84099d44bea07c55dc94472ea8,not identify any citations relevant to your inquiry,0.568685
uuid-4d997c84099d44bea07c55dc94472ea8,open-label,0.403618
uuid-4d997c84099d44bea07c55dc94472ea8,using the following search terms,0.543398
uuid-74d913077a78480e84a09a1eb83e47a9,nivolumab,0.569479
uuid-74d913077a78480e84a09a1eb83e47a9,Bristol-Myers Squibb,0.458408
uuid-74d913077a78480e84a09a1eb83e47a9,evaluating,0.609916
uuid-74d913077a78480e84a09a1eb83e47a9,not conducted any controlled clinical trials/studies,0.672053
uuid-74d913077a78480e84a09a1eb83e47a9,Pubmed literature search,0.867611
uuid-74d913077a78480e84a09a1eb83e47a9,purposes other than its labeled indication must be considered investigational,0.933386
uuid-74d913077a78480e84a09a1eb83e47a9,not identify any citations relevant to your inquiry,0.825256
uuid-74d913077a78480e84a09a1eb83e47a9,using the following search terms,0.813093
uuid-74d913077a78480e84a09a1eb83e47a9,efficacy and safety of nivolumab,0.449392
uuid-448495429b8c4dd2935dd2403823e1b8,Opdivo,0.50165
uuid-448495429b8c4dd2935dd2403823e1b8,open-label,0.304253
uuid-448495429b8c4dd2935dd2403823e1b8,trial,0.521827
uuid-448495429b8c4dd2935dd2403823e1b8,docetaxel,0.30238
uuid-448495429b8c4dd2935dd2403823e1b8,safety of nivolumab monotherapy,0.432481
uuid-448495429b8c4dd2935dd2403823e1b8,phase,0.378496
uuid-9bde8793626e4fee8c4a504336706e40,use of nivolumab for the treatment,0.305739
uuid-9bde8793626e4fee8c4a504336706e40,patients with advanced or metastatic,0.509457
uuid-9bde8793626e4fee8c4a504336706e40,nivolumab combined with ipilimumab,0.496885
uuid-9bde8793626e4fee8c4a504336706e40,not approved,0.397631
uuid-9bde8793626e4fee8c4a504336706e40,clinical trials investigating the safety,0.478965
uuid-9bde8793626e4fee8c4a504336706e40,bladder cancer,0.940126
uuid-81e1180ed74e4a5b9b6efa77440717c3,95% CI,0.384282
uuid-81e1180ed74e4a5b9b6efa77440717c3,ASCO,0.40687
uuid-81e1180ed74e4a5b9b6efa77440717c3,Objective response rate,0.409634
uuid-81e1180ed74e4a5b9b6efa77440717c3,Median overall survival,0.319094
uuid-81e1180ed74e4a5b9b6efa77440717c3,Median OS,0.403026
uuid-81e1180ed74e4a5b9b6efa77440717c3,ASCO 2015,0.386899
uuid-81e1180ed74e4a5b9b6efa77440717c3,hazard ratio,0.403406
uuid-f760d15e7fed471083cc633efcb54390,nivolumab,0.330431
uuid-f760d15e7fed471083cc633efcb54390,evaluating,0.325437
uuid-f760d15e7fed471083cc633efcb54390,not conducted any controlled clinical trials/studies,0.364217
uuid-f760d15e7fed471083cc633efcb54390,Pubmed literature search,0.49351
uuid-f760d15e7fed471083cc633efcb54390,purposes other than its labeled indication must be considered investigational,0.52728
uuid-f760d15e7fed471083cc633efcb54390,not identify any citations relevant to your inquiry,0.492897
uuid-f760d15e7fed471083cc633efcb54390,open-label,0.410079
uuid-f760d15e7fed471083cc633efcb54390,using the following search terms,0.465094
uuid-107ce78266dd4c77a86ea49209077d85,ASCO,0.572408
uuid-107ce78266dd4c77a86ea49209077d85,requested,0.60375
uuid-eb2e791523bc49e0ba60a961fab75100,NSCLC,0.487564
uuid-eb2e791523bc49e0ba60a961fab75100,Lancet Oncol,0.408285
uuid-eb2e791523bc49e0ba60a961fab75100,non-small cell lung cancer,0.425216
uuid-eb2e791523bc49e0ba60a961fab75100,phase 3 study,0.406253
uuid-eb2e791523bc49e0ba60a961fab75100,phase 1 study,0.591752
uuid-eb2e791523bc49e0ba60a961fab75100,Rizvi NA,0.511912
uuid-eb2e791523bc49e0ba60a961fab75100,CA209-003,0.456298
uuid-eb2e791523bc49e0ba60a961fab75100,Weber JS,0.339277
uuid-eb2e791523bc49e0ba60a961fab75100,phase 2 study,0.340247
uuid-eb2e791523bc49e0ba60a961fab75100,SCLC,0.30471
uuid-eb2e791523bc49e0ba60a961fab75100,Antonia SJ,0.337097
uuid-026de24cc217463c9778906a411734da,AEs,0.574214
uuid-026de24cc217463c9778906a411734da,respectively,0.364886
uuid-026de24cc217463c9778906a411734da,patients,0.369621
uuid-026de24cc217463c9778906a411734da,grade,0.642744
uuid-026de24cc217463c9778906a411734da,grade 3 to 4 AEs,0.565283
uuid-c790196ae00a4f4780e7c67baa57ab9f,use of nivolumab for the treatment,0.305739
uuid-c790196ae00a4f4780e7c67baa57ab9f,patients with advanced or metastatic,0.509457
uuid-c790196ae00a4f4780e7c67baa57ab9f,nivolumab combined with ipilimumab,0.496885
uuid-c790196ae00a4f4780e7c67baa57ab9f,not approved,0.397631
uuid-c790196ae00a4f4780e7c67baa57ab9f,clinical trials investigating the safety,0.478965
uuid-c790196ae00a4f4780e7c67baa57ab9f,bladder cancer,0.940126
uuid-e5438f7b86ce47529860862416390281,AEs,0.36786
uuid-e5438f7b86ce47529860862416390281,NEJM,0.316923
uuid-e5438f7b86ce47529860862416390281,Topalian,0.334
uuid-e5438f7b86ce47529860862416390281,fatigue,0.322169
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,nivolumab,0.55782
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,Bristol-Myers Squibb,0.452945
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,evaluating,0.619769
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,not conducted any controlled clinical trials/studies,0.67649
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,Pubmed literature search,0.859556
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,purposes other than its labeled indication must be considered investigational,0.927734
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,not identify any citations relevant to your inquiry,0.816015
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,using the following search terms,0.803182
uuid-bd8a868ee92a4a05b6b9a4c5866adcc9,efficacy and safety of nivolumab,0.456812
uuid-05a75b519e444017bb960dc2c6f72bd9,melanoma,0.540824
uuid-fd63ff105c724ec680b34614786bfb7f,search of published literature,0.394524
uuid-fd63ff105c724ec680b34614786bfb7f,Additionally,0.413583
uuid-fd63ff105c724ec680b34614786bfb7f,ongoing,0.322117
uuid-fd63ff105c724ec680b34614786bfb7f,PubMed and EMBASE,0.391671
uuid-fd63ff105c724ec680b34614786bfb7f,detailed search of www.clinicaltrials.gov,0.375936
uuid-fd63ff105c724ec680b34614786bfb7f,efficacy and safety of nivolumab,0.370699
uuid-fd63ff105c724ec680b34614786bfb7f,not identify any planned,0.34283
uuid-fd63ff105c724ec680b34614786bfb7f,Weber JS,0.319229
uuid-fd63ff105c724ec680b34614786bfb7f,not identify any citations relevant to your request,0.447813
uuid-fd63ff105c724ec680b34614786bfb7f,present using the following search terms,0.408199
uuid-2d1638462c4f4db5ba7b61879c25953f,Bristol-Myers Squibb,0.351139
uuid-2d1638462c4f4db5ba7b61879c25953f,evaluating,0.393781
uuid-2d1638462c4f4db5ba7b61879c25953f,not conducted any controlled clinical trials/studies,0.401959
uuid-2d1638462c4f4db5ba7b61879c25953f,NSCLC,0.316818
uuid-2d1638462c4f4db5ba7b61879c25953f,efficacy and safety of nivolumab,0.448974
uuid-be3c8577714c48ec84579dbd6e6f179a,NSCLC,0.480337
uuid-be3c8577714c48ec84579dbd6e6f179a,respectively,0.400584
uuid-be3c8577714c48ec84579dbd6e6f179a,non-small cell lung cancer,0.395662
uuid-be3c8577714c48ec84579dbd6e6f179a,patients,0.382838
uuid-be3c8577714c48ec84579dbd6e6f179a,considered investigational,0.378457
uuid-be3c8577714c48ec84579dbd6e6f179a,Objective response rate,0.446233
uuid-be3c8577714c48ec84579dbd6e6f179a,ORR,0.488323
uuid-be3c8577714c48ec84579dbd6e6f179a,monotherapy,0.419452
uuid-be3c8577714c48ec84579dbd6e6f179a,small cell lung cancer,0.328277
uuid-be3c8577714c48ec84579dbd6e6f179a,docetaxel,0.370754
uuid-be3c8577714c48ec84579dbd6e6f179a,SCLC,0.328412
uuid-be3c8577714c48ec84579dbd6e6f179a,grade 3 to 4 AEs,0.337672
uuid-be3c8577714c48ec84579dbd6e6f179a,platinum-based doublet chemotherapy,0.355492
uuid-6c88107cc4dd409c988d11e91ebef384,requested,0.460281
uuid-78ba3e0fa132466cbe9b1388bb9c00ce,fatigue,0.323475
uuid-491f806e1fd84ccfa54a89cc7a6b7e66,requested,0.596876
uuid-f68af44f41ff4b9793fc66908bf46fd8,patients with advanced or metastatic,0.663854
uuid-f68af44f41ff4b9793fc66908bf46fd8,nivolumab combined with ipilimumab,0.651138
uuid-f68af44f41ff4b9793fc66908bf46fd8,phase 1/2 study CA209-032,0.332197
uuid-f68af44f41ff4b9793fc66908bf46fd8,bladder cancer,0.942932
uuid-f68af44f41ff4b9793fc66908bf46fd8,evaluates the efficacy of nivolumab monotherapy,0.380394
uuid-32a401998c0343758743b7d74899f9a1,nivolumab,0.343098
uuid-32a401998c0343758743b7d74899f9a1,Bristol-Myers Squibb,0.351759
uuid-32a401998c0343758743b7d74899f9a1,evaluating,0.532241
uuid-32a401998c0343758743b7d74899f9a1,not conducted any controlled clinical trials/studies,0.512822
uuid-32a401998c0343758743b7d74899f9a1,RCC,0.318064
uuid-32a401998c0343758743b7d74899f9a1,search of published literature,0.722027
uuid-32a401998c0343758743b7d74899f9a1,Additionally,0.756669
uuid-32a401998c0343758743b7d74899f9a1,ongoing,0.620938
uuid-32a401998c0343758743b7d74899f9a1,PubMed and EMBASE,0.716641
uuid-32a401998c0343758743b7d74899f9a1,detailed search of www.clinicaltrials.gov,0.716874
uuid-32a401998c0343758743b7d74899f9a1,efficacy and safety of nivolumab,0.698792
uuid-32a401998c0343758743b7d74899f9a1,not identify any planned,0.655092
uuid-32a401998c0343758743b7d74899f9a1,not identify any citations relevant to your request,0.830665
uuid-32a401998c0343758743b7d74899f9a1,present using the following search terms,0.744432
uuid-44b74f355b2a436391d37529ae514c0f,requested,0.596876
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,use of nivolumab for the treatment,0.305739
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,patients with advanced or metastatic,0.509457
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,nivolumab combined with ipilimumab,0.496885
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,not approved,0.397631
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,clinical trials investigating the safety,0.478965
uuid-e12c72519e724f369d7bd5cc8a6d0ad9,bladder cancer,0.940126
uuid-356ed8820c884524b3d9dfca404f2111,patients with advanced or metastatic,0.590005
uuid-356ed8820c884524b3d9dfca404f2111,nivolumab combined with ipilimumab,0.574352
uuid-356ed8820c884524b3d9dfca404f2111,clinicaltrials.gov,0.309101
uuid-356ed8820c884524b3d9dfca404f2111,bladder cancer,0.914251
uuid-356ed8820c884524b3d9dfca404f2111,evaluates the efficacy of nivolumab monotherapy,0.311256
uuid-4b219c8b2fed4cc1824af5db768087c5,nivolumab,0.360392
uuid-4b219c8b2fed4cc1824af5db768087c5,trial,0.433746
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,N Engl J Med,0.714946
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Lancet Oncol,0.448679
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,patients,0.309769
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,protocol,0.700662
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,McDermott DF,0.68799
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Motzer RJ,0.689932
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,phase 3 study,0.545628
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Escudier B,0.698812
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,NEJM,0.402095
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,et al.,0.640511
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,J Clin Oncol,0.626106
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Topalian,0.37979
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,phase 1 study,0.381282
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Rizvi NA,0.636006
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Brahmer J,0.517174
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,efficacy and safety of nivolumab,0.368444
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,Weber JS,0.406071
uuid-8d8a75f5aaad4e79a19a823b5024d7cd,phase 2 study,0.692115
uuid-1401ef5b40d845448ab5f72b7ac7dad0,use of nivolumab for the treatment,0.305739
uuid-1401ef5b40d845448ab5f72b7ac7dad0,patients with advanced or metastatic,0.509457
uuid-1401ef5b40d845448ab5f72b7ac7dad0,nivolumab combined with ipilimumab,0.496885
uuid-1401ef5b40d845448ab5f72b7ac7dad0,not approved,0.397631
uuid-1401ef5b40d845448ab5f72b7ac7dad0,clinical trials investigating the safety,0.478965
uuid-1401ef5b40d845448ab5f72b7ac7dad0,bladder cancer,0.940126
uuid-ab89db63d5a846ab8ee55354e4a5c912,patients with advanced or metastatic,0.478326
uuid-ab89db63d5a846ab8ee55354e4a5c912,nivolumab combined with ipilimumab,0.498766
uuid-ab89db63d5a846ab8ee55354e4a5c912,not approved,0.34724
uuid-ab89db63d5a846ab8ee55354e4a5c912,clinical trials investigating the safety,0.426729
uuid-ab89db63d5a846ab8ee55354e4a5c912,bladder cancer,0.6548
uuid-861c267f396a427c8f634d473d604928,use of nivolumab for the treatment,0.389407
uuid-861c267f396a427c8f634d473d604928,patients with advanced or metastatic,0.616496
uuid-861c267f396a427c8f634d473d604928,nivolumab combined with ipilimumab,0.64124
uuid-861c267f396a427c8f634d473d604928,tumors,0.321518
uuid-861c267f396a427c8f634d473d604928,not approved,0.429497
uuid-861c267f396a427c8f634d473d604928,clinical trials investigating the safety,0.524767
uuid-861c267f396a427c8f634d473d604928,phase 1/2 study CA209-032,0.327827
uuid-861c267f396a427c8f634d473d604928,bladder cancer,0.721399
uuid-861c267f396a427c8f634d473d604928,evaluates the efficacy of nivolumab monotherapy,0.369514
uuid-a7cd545a24024d04963ac506f78563a7,Opdivo,0.50165
uuid-a7cd545a24024d04963ac506f78563a7,open-label,0.304253
uuid-a7cd545a24024d04963ac506f78563a7,trial,0.521827
uuid-a7cd545a24024d04963ac506f78563a7,docetaxel,0.30238
uuid-a7cd545a24024d04963ac506f78563a7,safety of nivolumab monotherapy,0.432481
uuid-a7cd545a24024d04963ac506f78563a7,phase,0.378496
uuid-95ec1835d6e54334b5a13706ad9ff674,PD-L1,0.419529
uuid-477bd314fadf45a28871a5609c68f4f6,Bristol-Myers Squibb,0.555163
uuid-477bd314fadf45a28871a5609c68f4f6,not conducted any controlled clinical trials/studies,0.303087
uuid-477bd314fadf45a28871a5609c68f4f6,adverse,0.387223
uuid-477bd314fadf45a28871a5609c68f4f6,reported,0.506043
uuid-34e2fb79fbce4036ba9fca01d197e494,mg,0.300211
uuid-19b2f395e0fc4ba685c30dcae71c044d,Opdivo,0.50165
uuid-19b2f395e0fc4ba685c30dcae71c044d,open-label,0.304253
uuid-19b2f395e0fc4ba685c30dcae71c044d,trial,0.521827
uuid-19b2f395e0fc4ba685c30dcae71c044d,docetaxel,0.30238
uuid-19b2f395e0fc4ba685c30dcae71c044d,safety of nivolumab monotherapy,0.432481
uuid-19b2f395e0fc4ba685c30dcae71c044d,phase,0.378496
uuid-aef56aa7c9734f318461a364ab52d72a,requested,0.596876
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,Bristol-Myers Squibb,0.341822
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,not conducted any controlled clinical trials/studies,0.304507
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,Opdivo,0.461382
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,Pubmed literature search,0.614325
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,not identify any citations relevant to your inquiry,0.606087
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,adverse,0.304183
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,using the following search terms,0.642331
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,databases,0.315039
uuid-baf4cb84d8d24dd0a0d335d9905b75b6,reported,0.556704
uuid-9f58872ffe4f411498f88ee43296ce57,OS,0.470034
uuid-9f58872ffe4f411498f88ee43296ce57,95% CI,0.797076
uuid-9f58872ffe4f411498f88ee43296ce57,respectively,0.660998
uuid-9f58872ffe4f411498f88ee43296ce57,Objective response rate,0.578857
uuid-9f58872ffe4f411498f88ee43296ce57,ORR,0.752855
uuid-9f58872ffe4f411498f88ee43296ce57,PFS,0.333603
uuid-9f58872ffe4f411498f88ee43296ce57,Median overall survival,0.740105
uuid-9f58872ffe4f411498f88ee43296ce57,monotherapy,0.434052
uuid-9f58872ffe4f411498f88ee43296ce57,Median OS,0.759031
uuid-9f58872ffe4f411498f88ee43296ce57,docetaxel,0.464917
uuid-9f58872ffe4f411498f88ee43296ce57,hazard ratio,0.756801
uuid-19b5b432c3514efca6431bc715199613,ASCO,0.572408
uuid-19b5b432c3514efca6431bc715199613,requested,0.60375
uuid-fac0921612304e01a214eb606c2104b9,nivolumab,0.522354
uuid-fac0921612304e01a214eb606c2104b9,Bristol-Myers Squibb,0.455639
uuid-fac0921612304e01a214eb606c2104b9,evaluating,0.605005
uuid-fac0921612304e01a214eb606c2104b9,not conducted any controlled clinical trials/studies,0.667233
uuid-fac0921612304e01a214eb606c2104b9,Pubmed literature search,0.857138
uuid-fac0921612304e01a214eb606c2104b9,purposes other than its labeled indication must be considered investigational,0.924088
uuid-fac0921612304e01a214eb606c2104b9,not identify any citations relevant to your inquiry,0.815669
uuid-fac0921612304e01a214eb606c2104b9,using the following search terms,0.800708
uuid-fac0921612304e01a214eb606c2104b9,efficacy and safety of nivolumab,0.432343
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,use of nivolumab for the treatment,0.305739
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,patients with advanced or metastatic,0.509457
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,nivolumab combined with ipilimumab,0.496885
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,not approved,0.397631
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,clinical trials investigating the safety,0.478965
uuid-c8d18e5874cf4f0e99ab15a32c2b8017,bladder cancer,0.940126
uuid-fe560735a537425aa51a2302373f579e,Bristol-Myers Squibb,0.341822
uuid-fe560735a537425aa51a2302373f579e,not conducted any controlled clinical trials/studies,0.304507
uuid-fe560735a537425aa51a2302373f579e,Opdivo,0.461382
uuid-fe560735a537425aa51a2302373f579e,Pubmed literature search,0.614325
uuid-fe560735a537425aa51a2302373f579e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-fe560735a537425aa51a2302373f579e,not identify any citations relevant to your inquiry,0.606087
uuid-fe560735a537425aa51a2302373f579e,adverse,0.304183
uuid-fe560735a537425aa51a2302373f579e,using the following search terms,0.642331
uuid-fe560735a537425aa51a2302373f579e,databases,0.315039
uuid-fe560735a537425aa51a2302373f579e,reported,0.556704
uuid-654e8dfda99349cfbec95f7bfe8421ea,patients,0.3492
uuid-654e8dfda99349cfbec95f7bfe8421ea,protocol,0.363205
uuid-654e8dfda99349cfbec95f7bfe8421ea,McDermott DF,0.390473
uuid-654e8dfda99349cfbec95f7bfe8421ea,Motzer RJ,0.393375
uuid-654e8dfda99349cfbec95f7bfe8421ea,phase 3 study,0.463524
uuid-654e8dfda99349cfbec95f7bfe8421ea,Escudier B,0.392411
uuid-654e8dfda99349cfbec95f7bfe8421ea,et al.,0.363169
uuid-654e8dfda99349cfbec95f7bfe8421ea,J Clin Oncol,0.3447
uuid-654e8dfda99349cfbec95f7bfe8421ea,Rizvi NA,0.387742
uuid-654e8dfda99349cfbec95f7bfe8421ea,Weber JS,0.415578
uuid-654e8dfda99349cfbec95f7bfe8421ea,phase 2 study,0.44646
uuid-64933fb4263e476a86416ebebdab03df,fatigue,0.323475
uuid-a5833c1916aa4608bbea4c401f0173ea,use of nivolumab for the treatment,0.409821
uuid-a5833c1916aa4608bbea4c401f0173ea,patients with advanced or metastatic,0.645244
uuid-a5833c1916aa4608bbea4c401f0173ea,nivolumab combined with ipilimumab,0.676339
uuid-a5833c1916aa4608bbea4c401f0173ea,not approved,0.453534
uuid-a5833c1916aa4608bbea4c401f0173ea,clinical trials investigating the safety,0.548799
uuid-a5833c1916aa4608bbea4c401f0173ea,phase 1/2 study CA209-032,0.34114
uuid-a5833c1916aa4608bbea4c401f0173ea,bladder cancer,0.749142
uuid-a5833c1916aa4608bbea4c401f0173ea,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-3be9f9c46e804f279df5568fe211c733,Bristol-Myers Squibb,0.341822
uuid-3be9f9c46e804f279df5568fe211c733,not conducted any controlled clinical trials/studies,0.304507
uuid-3be9f9c46e804f279df5568fe211c733,Opdivo,0.461382
uuid-3be9f9c46e804f279df5568fe211c733,Pubmed literature search,0.614325
uuid-3be9f9c46e804f279df5568fe211c733,purposes other than its labeled indication must be considered investigational,0.586645
uuid-3be9f9c46e804f279df5568fe211c733,not identify any citations relevant to your inquiry,0.606087
uuid-3be9f9c46e804f279df5568fe211c733,adverse,0.304183
uuid-3be9f9c46e804f279df5568fe211c733,using the following search terms,0.642331
uuid-3be9f9c46e804f279df5568fe211c733,databases,0.315039
uuid-3be9f9c46e804f279df5568fe211c733,reported,0.556704
uuid-dd0b3d5e6992422daf3657742bd8ae85,evaluating,0.362576
uuid-dd0b3d5e6992422daf3657742bd8ae85,RCC,0.321803
uuid-dd0b3d5e6992422daf3657742bd8ae85,search of published literature,0.593963
uuid-dd0b3d5e6992422daf3657742bd8ae85,Additionally,0.700931
uuid-dd0b3d5e6992422daf3657742bd8ae85,ongoing,0.599101
uuid-dd0b3d5e6992422daf3657742bd8ae85,PubMed and EMBASE,0.600039
uuid-dd0b3d5e6992422daf3657742bd8ae85,detailed search of www.clinicaltrials.gov,0.671757
uuid-dd0b3d5e6992422daf3657742bd8ae85,PD-L1,0.346792
uuid-dd0b3d5e6992422daf3657742bd8ae85,efficacy and safety of nivolumab,0.468108
uuid-dd0b3d5e6992422daf3657742bd8ae85,not identify any planned,0.62192
uuid-dd0b3d5e6992422daf3657742bd8ae85,not identify any citations relevant to your request,0.756572
uuid-dd0b3d5e6992422daf3657742bd8ae85,present using the following search terms,0.625575
uuid-99042268346c406db971134a5ca15f53,N Engl J Med,0.463615
uuid-99042268346c406db971134a5ca15f53,NSCLC,0.411904
uuid-99042268346c406db971134a5ca15f53,Lancet Oncol,0.356346
uuid-99042268346c406db971134a5ca15f53,non-small cell lung cancer,0.479924
uuid-99042268346c406db971134a5ca15f53,phase 3 study,0.353194
uuid-99042268346c406db971134a5ca15f53,Rizvi NA,0.55688
uuid-99042268346c406db971134a5ca15f53,Brahmer J,0.571788
uuid-99042268346c406db971134a5ca15f53,PD-L1,0.439281
uuid-99042268346c406db971134a5ca15f53,phase 2 study,0.304107
uuid-006aa23445cd4a1b8de1929c47495740,N Engl J Med,0.453413
uuid-006aa23445cd4a1b8de1929c47495740,ASCO,0.45824
uuid-006aa23445cd4a1b8de1929c47495740,Lancet Oncol,0.455656
uuid-006aa23445cd4a1b8de1929c47495740,protocol,0.34668
uuid-006aa23445cd4a1b8de1929c47495740,McDermott DF,0.434407
uuid-006aa23445cd4a1b8de1929c47495740,Motzer RJ,0.355494
uuid-006aa23445cd4a1b8de1929c47495740,phase 3 study,0.346338
uuid-006aa23445cd4a1b8de1929c47495740,Escudier B,0.39706
uuid-006aa23445cd4a1b8de1929c47495740,NEJM,0.52059
uuid-006aa23445cd4a1b8de1929c47495740,et al.,0.435911
uuid-006aa23445cd4a1b8de1929c47495740,J Clin Oncol,0.411988
uuid-006aa23445cd4a1b8de1929c47495740,Topalian,0.519124
uuid-006aa23445cd4a1b8de1929c47495740,phase 1 study,0.384853
uuid-006aa23445cd4a1b8de1929c47495740,Rizvi NA,0.522573
uuid-006aa23445cd4a1b8de1929c47495740,mg,0.318458
uuid-006aa23445cd4a1b8de1929c47495740,CA209-003,0.341395
uuid-006aa23445cd4a1b8de1929c47495740,Weber JS,0.441137
uuid-006aa23445cd4a1b8de1929c47495740,phase 2 study,0.50022
uuid-3281696f209b49039fa721404134dfe3,Opdivo,0.819089
uuid-3281696f209b49039fa721404134dfe3,ipilimumab,0.326421
uuid-3281696f209b49039fa721404134dfe3,trial,0.604796
uuid-dfeb3b71df7d4b2d9de30a965c467364,clinical,0.580313
uuid-dfeb3b71df7d4b2d9de30a965c467364,trial,0.397483
uuid-8e860e2e463e4d6d887f041b588cfa6d,patients,0.379981
uuid-8e860e2e463e4d6d887f041b588cfa6d,phase 3 study,0.492229
uuid-8e860e2e463e4d6d887f041b588cfa6d,phase 2 study,0.326752
uuid-4b2f3ddfa1d54f3f99f80977b9cfc5fe,ipilimumab,0.385692
uuid-4b2f3ddfa1d54f3f99f80977b9cfc5fe,ASCO 2015,0.417944
uuid-4b2f3ddfa1d54f3f99f80977b9cfc5fe,partial response,0.382425
uuid-4b2f3ddfa1d54f3f99f80977b9cfc5fe,Stable disease,0.586335
uuid-4b2f3ddfa1d54f3f99f80977b9cfc5fe,cohort,0.307748
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,patients,0.357568
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,provided in the Detailed Information,0.35265
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,adverse,0.322505
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,phase 3 study,0.356962
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,Rizvi NA,0.320888
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,Brahmer J,0.338826
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,BMS,0.670096
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,grade 3 to 4 AEs,0.354546
uuid-fa78bc9e6cbc4b849ebfc5e33ff9fd0a,reported,0.368488
uuid-5ead9fd28b9a43d4b9bae674e29af621,N Engl J Med,0.5051
uuid-5ead9fd28b9a43d4b9bae674e29af621,ASCO,0.451177
uuid-5ead9fd28b9a43d4b9bae674e29af621,Lancet Oncol,0.406108
uuid-5ead9fd28b9a43d4b9bae674e29af621,phase 3 study,0.314684
uuid-5ead9fd28b9a43d4b9bae674e29af621,Rizvi NA,0.573428
uuid-5ead9fd28b9a43d4b9bae674e29af621,Brahmer J,0.625869
uuid-a13ae56598304525a8b950e45dcf8359,adverse,0.399647
uuid-10f2004bf9a24b3994196ac4db88907f,N Engl J Med,0.535286
uuid-10f2004bf9a24b3994196ac4db88907f,Lancet Oncol,0.364361
uuid-10f2004bf9a24b3994196ac4db88907f,protocol,0.50442
uuid-10f2004bf9a24b3994196ac4db88907f,McDermott DF,0.548182
uuid-10f2004bf9a24b3994196ac4db88907f,Motzer RJ,0.532741
uuid-10f2004bf9a24b3994196ac4db88907f,phase 3 study,0.493197
uuid-10f2004bf9a24b3994196ac4db88907f,Escudier B,0.547344
uuid-10f2004bf9a24b3994196ac4db88907f,et al.,0.519366
uuid-10f2004bf9a24b3994196ac4db88907f,J Clin Oncol,0.509597
uuid-10f2004bf9a24b3994196ac4db88907f,Rizvi NA,0.478602
uuid-10f2004bf9a24b3994196ac4db88907f,Brahmer J,0.338223
uuid-10f2004bf9a24b3994196ac4db88907f,Weber JS,0.370952
uuid-10f2004bf9a24b3994196ac4db88907f,phase 2 study,0.591434
uuid-2e055f0e9bed4f0f911fbecaabdff423,et al.,0.305446
uuid-2e055f0e9bed4f0f911fbecaabdff423,phase 2 study,0.318842
uuid-015c09478aaf4cf89105088bc287115b,Bristol-Myers Squibb,0.361443
uuid-015c09478aaf4cf89105088bc287115b,evaluating,0.591075
uuid-015c09478aaf4cf89105088bc287115b,not conducted any controlled clinical trials/studies,0.544189
uuid-015c09478aaf4cf89105088bc287115b,search of published literature,0.624938
uuid-015c09478aaf4cf89105088bc287115b,Additionally,0.45805
uuid-015c09478aaf4cf89105088bc287115b,ipilimumab,0.377476
uuid-015c09478aaf4cf89105088bc287115b,ongoing,0.348279
uuid-015c09478aaf4cf89105088bc287115b,PubMed and EMBASE,0.607881
uuid-015c09478aaf4cf89105088bc287115b,detailed search of www.clinicaltrials.gov,0.407663
uuid-015c09478aaf4cf89105088bc287115b,efficacy and safety of nivolumab,0.6883
uuid-015c09478aaf4cf89105088bc287115b,not identify any planned,0.365722
uuid-015c09478aaf4cf89105088bc287115b,combination,0.339909
uuid-015c09478aaf4cf89105088bc287115b,not identify any citations relevant to your request,0.5315
uuid-015c09478aaf4cf89105088bc287115b,present using the following search terms,0.608749
uuid-dcd86d6541224d5fa7b68849414afb9a,nivolumab,0.785557
uuid-dcd86d6541224d5fa7b68849414afb9a,purposes other than its labeled indication must be considered investigational,0.317505
uuid-dcd86d6541224d5fa7b68849414afb9a,clinical trials investigating the safety,0.309946
uuid-4943e642804f4a55b3491fe3f14c953e,requested,0.595565
uuid-197425dfac0349378f1566da4f351834,Bristol-Myers Squibb,0.877696
uuid-197425dfac0349378f1566da4f351834,use of nivolumab for the treatment,0.302636
uuid-197425dfac0349378f1566da4f351834,evaluating,0.942445
uuid-197425dfac0349378f1566da4f351834,not conducted any controlled clinical trials/studies,0.984128
uuid-197425dfac0349378f1566da4f351834,non-small cell lung cancer,0.303486
uuid-197425dfac0349378f1566da4f351834,considered investigational,0.313004
uuid-197425dfac0349378f1566da4f351834,purposes other than its labeled indication must be considered investigational,0.32104
uuid-197425dfac0349378f1566da4f351834,search of published literature,0.471902
uuid-197425dfac0349378f1566da4f351834,PubMed and EMBASE,0.419099
uuid-197425dfac0349378f1566da4f351834,efficacy and safety of nivolumab,0.890496
uuid-197425dfac0349378f1566da4f351834,present using the following search terms,0.406776
uuid-197425dfac0349378f1566da4f351834,safety of nivolumab monotherapy,0.404865
uuid-f98d5228c03b4b978343f971bb14e62b,OS,0.62262
uuid-f98d5228c03b4b978343f971bb14e62b,PFS,0.65903
uuid-f98d5228c03b4b978343f971bb14e62b,Overall survival,0.644151
uuid-4e63261de40241f3ba087d382344965d,Bristol-Myers Squibb,0.341822
uuid-4e63261de40241f3ba087d382344965d,not conducted any controlled clinical trials/studies,0.304507
uuid-4e63261de40241f3ba087d382344965d,Opdivo,0.461382
uuid-4e63261de40241f3ba087d382344965d,Pubmed literature search,0.614325
uuid-4e63261de40241f3ba087d382344965d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4e63261de40241f3ba087d382344965d,not identify any citations relevant to your inquiry,0.606087
uuid-4e63261de40241f3ba087d382344965d,adverse,0.304183
uuid-4e63261de40241f3ba087d382344965d,using the following search terms,0.642331
uuid-4e63261de40241f3ba087d382344965d,databases,0.315039
uuid-4e63261de40241f3ba087d382344965d,reported,0.556704
uuid-bc92f49b6b724947ace0694376efe632,Bristol-Myers Squibb,0.840451
uuid-bc92f49b6b724947ace0694376efe632,evaluating,0.718784
uuid-bc92f49b6b724947ace0694376efe632,not conducted any controlled clinical trials/studies,0.798502
uuid-bc92f49b6b724947ace0694376efe632,adverse,0.316881
uuid-bc92f49b6b724947ace0694376efe632,efficacy and safety of nivolumab,0.640661
uuid-bc92f49b6b724947ace0694376efe632,reported,0.342563
uuid-c4e6f96982c34063bda3b985cb23aec5,small cell lung cancer,0.393135
uuid-c4e6f96982c34063bda3b985cb23aec5,SCLC,0.441325
uuid-c4e6f96982c34063bda3b985cb23aec5,therapy,0.512398
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,nivolumab,0.567944
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,Bristol-Myers Squibb,0.441056
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,evaluating,0.597834
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,not conducted any controlled clinical trials/studies,0.658405
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,Pubmed literature search,0.877055
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,purposes other than its labeled indication must be considered investigational,0.940341
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,not identify any citations relevant to your inquiry,0.836065
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,using the following search terms,0.823473
uuid-1336e3e0b1a7489ab3c6a8f0f4e6a716,efficacy and safety of nivolumab,0.4355
uuid-58153aee2be94a23afea6147fd1dcab1,Opdivo,0.50165
uuid-58153aee2be94a23afea6147fd1dcab1,open-label,0.304253
uuid-58153aee2be94a23afea6147fd1dcab1,trial,0.521827
uuid-58153aee2be94a23afea6147fd1dcab1,docetaxel,0.30238
uuid-58153aee2be94a23afea6147fd1dcab1,safety of nivolumab monotherapy,0.432481
uuid-58153aee2be94a23afea6147fd1dcab1,phase,0.378496
uuid-967c72d825e749c4864c00eaaa95d20b,patients,0.350185
uuid-967c72d825e749c4864c00eaaa95d20b,protocol,0.364313
uuid-967c72d825e749c4864c00eaaa95d20b,McDermott DF,0.39108
uuid-967c72d825e749c4864c00eaaa95d20b,Motzer RJ,0.394397
uuid-967c72d825e749c4864c00eaaa95d20b,phase 3 study,0.461915
uuid-967c72d825e749c4864c00eaaa95d20b,Escudier B,0.393278
uuid-967c72d825e749c4864c00eaaa95d20b,et al.,0.363785
uuid-967c72d825e749c4864c00eaaa95d20b,J Clin Oncol,0.3454
uuid-967c72d825e749c4864c00eaaa95d20b,Rizvi NA,0.387522
uuid-967c72d825e749c4864c00eaaa95d20b,Weber JS,0.414993
uuid-967c72d825e749c4864c00eaaa95d20b,phase 2 study,0.445652
uuid-ad073df129984ec09ce90198465caca0,NSCLC,0.373344
uuid-ad073df129984ec09ce90198465caca0,non-small cell lung cancer,0.327146
uuid-ad073df129984ec09ce90198465caca0,patients,0.349328
uuid-ad073df129984ec09ce90198465caca0,considered investigational,0.303512
uuid-ad073df129984ec09ce90198465caca0,Objective response rate,0.345748
uuid-ad073df129984ec09ce90198465caca0,ORR,0.379366
uuid-ad073df129984ec09ce90198465caca0,platinum-based doublet chemotherapy,0.328425
uuid-7f1c060c34bf4d17b7074e98ce157b10,use of nivolumab for the treatment,0.409821
uuid-7f1c060c34bf4d17b7074e98ce157b10,patients with advanced or metastatic,0.645244
uuid-7f1c060c34bf4d17b7074e98ce157b10,nivolumab combined with ipilimumab,0.676339
uuid-7f1c060c34bf4d17b7074e98ce157b10,not approved,0.453534
uuid-7f1c060c34bf4d17b7074e98ce157b10,clinical trials investigating the safety,0.548799
uuid-7f1c060c34bf4d17b7074e98ce157b10,phase 1/2 study CA209-032,0.34114
uuid-7f1c060c34bf4d17b7074e98ce157b10,bladder cancer,0.749142
uuid-7f1c060c34bf4d17b7074e98ce157b10,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-09f24a63d3d448ad92e2352bd32ab0f9,nivolumab,0.677487
uuid-09f24a63d3d448ad92e2352bd32ab0f9,not approved,0.383079
uuid-09f24a63d3d448ad92e2352bd32ab0f9,clinical trials investigating the safety,0.502002
uuid-97cb69ff65294bb4ae523cbebcba2229,evaluating,0.331463
uuid-97cb69ff65294bb4ae523cbebcba2229,not conducted any controlled clinical trials/studies,0.327968
uuid-97cb69ff65294bb4ae523cbebcba2229,protocol,0.532972
uuid-97cb69ff65294bb4ae523cbebcba2229,RCC,0.386451
uuid-97cb69ff65294bb4ae523cbebcba2229,McDermott DF,0.444329
uuid-97cb69ff65294bb4ae523cbebcba2229,search of published literature,0.50452
uuid-97cb69ff65294bb4ae523cbebcba2229,Additionally,0.555299
uuid-97cb69ff65294bb4ae523cbebcba2229,ongoing,0.478674
uuid-97cb69ff65294bb4ae523cbebcba2229,Motzer RJ,0.475488
uuid-97cb69ff65294bb4ae523cbebcba2229,PubMed and EMBASE,0.501909
uuid-97cb69ff65294bb4ae523cbebcba2229,Escudier B,0.459186
uuid-97cb69ff65294bb4ae523cbebcba2229,et al.,0.397016
uuid-97cb69ff65294bb4ae523cbebcba2229,J Clin Oncol,0.428996
uuid-97cb69ff65294bb4ae523cbebcba2229,detailed search of www.clinicaltrials.gov,0.514934
uuid-97cb69ff65294bb4ae523cbebcba2229,efficacy and safety of nivolumab,0.47512
uuid-97cb69ff65294bb4ae523cbebcba2229,not identify any planned,0.493147
uuid-97cb69ff65294bb4ae523cbebcba2229,phase 2 study,0.384586
uuid-97cb69ff65294bb4ae523cbebcba2229,not identify any citations relevant to your request,0.565812
uuid-97cb69ff65294bb4ae523cbebcba2229,present using the following search terms,0.490802
uuid-c4601b0da5b843edbdd08cfff80a5921,N Engl J Med,0.463615
uuid-c4601b0da5b843edbdd08cfff80a5921,NSCLC,0.411904
uuid-c4601b0da5b843edbdd08cfff80a5921,Lancet Oncol,0.356346
uuid-c4601b0da5b843edbdd08cfff80a5921,non-small cell lung cancer,0.479924
uuid-c4601b0da5b843edbdd08cfff80a5921,phase 3 study,0.353194
uuid-c4601b0da5b843edbdd08cfff80a5921,Rizvi NA,0.55688
uuid-c4601b0da5b843edbdd08cfff80a5921,Brahmer J,0.571788
uuid-c4601b0da5b843edbdd08cfff80a5921,PD-L1,0.439281
uuid-c4601b0da5b843edbdd08cfff80a5921,phase 2 study,0.304107
uuid-69ede39c126548b8b3a4813c860978cf,N Engl J Med,0.448483
uuid-69ede39c126548b8b3a4813c860978cf,protocol,0.770446
uuid-69ede39c126548b8b3a4813c860978cf,McDermott DF,0.741196
uuid-69ede39c126548b8b3a4813c860978cf,Motzer RJ,0.818144
uuid-69ede39c126548b8b3a4813c860978cf,phase 3 study,0.417055
uuid-69ede39c126548b8b3a4813c860978cf,Escudier B,0.749917
uuid-69ede39c126548b8b3a4813c860978cf,NEJM,0.400698
uuid-69ede39c126548b8b3a4813c860978cf,et al.,0.668641
uuid-69ede39c126548b8b3a4813c860978cf,J Clin Oncol,0.792018
uuid-69ede39c126548b8b3a4813c860978cf,Topalian,0.388894
uuid-69ede39c126548b8b3a4813c860978cf,phase 1 study,0.500686
uuid-69ede39c126548b8b3a4813c860978cf,CA209-003,0.567381
uuid-69ede39c126548b8b3a4813c860978cf,phase 2 study,0.677985
uuid-69ede39c126548b8b3a4813c860978cf,present using the following search terms,0.310558
uuid-69ede39c126548b8b3a4813c860978cf,investigating,0.615835
uuid-9ec2bb2c250f4c94821190507bf20782,evaluating,0.331463
uuid-9ec2bb2c250f4c94821190507bf20782,not conducted any controlled clinical trials/studies,0.327968
uuid-9ec2bb2c250f4c94821190507bf20782,protocol,0.532972
uuid-9ec2bb2c250f4c94821190507bf20782,RCC,0.386451
uuid-9ec2bb2c250f4c94821190507bf20782,McDermott DF,0.444329
uuid-9ec2bb2c250f4c94821190507bf20782,search of published literature,0.50452
uuid-9ec2bb2c250f4c94821190507bf20782,Additionally,0.555299
uuid-9ec2bb2c250f4c94821190507bf20782,ongoing,0.478674
uuid-9ec2bb2c250f4c94821190507bf20782,Motzer RJ,0.475488
uuid-9ec2bb2c250f4c94821190507bf20782,PubMed and EMBASE,0.501909
uuid-9ec2bb2c250f4c94821190507bf20782,Escudier B,0.459186
uuid-9ec2bb2c250f4c94821190507bf20782,et al.,0.397016
uuid-9ec2bb2c250f4c94821190507bf20782,J Clin Oncol,0.428996
uuid-9ec2bb2c250f4c94821190507bf20782,detailed search of www.clinicaltrials.gov,0.514934
uuid-9ec2bb2c250f4c94821190507bf20782,efficacy and safety of nivolumab,0.47512
uuid-9ec2bb2c250f4c94821190507bf20782,not identify any planned,0.493147
uuid-9ec2bb2c250f4c94821190507bf20782,phase 2 study,0.384586
uuid-9ec2bb2c250f4c94821190507bf20782,not identify any citations relevant to your request,0.565812
uuid-9ec2bb2c250f4c94821190507bf20782,present using the following search terms,0.490802
uuid-a6a27e79428240508e6786063d579f8e,Bristol-Myers Squibb,0.341822
uuid-a6a27e79428240508e6786063d579f8e,not conducted any controlled clinical trials/studies,0.304507
uuid-a6a27e79428240508e6786063d579f8e,Opdivo,0.461382
uuid-a6a27e79428240508e6786063d579f8e,Pubmed literature search,0.614325
uuid-a6a27e79428240508e6786063d579f8e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a6a27e79428240508e6786063d579f8e,not identify any citations relevant to your inquiry,0.606087
uuid-a6a27e79428240508e6786063d579f8e,adverse,0.304183
uuid-a6a27e79428240508e6786063d579f8e,using the following search terms,0.642331
uuid-a6a27e79428240508e6786063d579f8e,databases,0.315039
uuid-a6a27e79428240508e6786063d579f8e,reported,0.556704
uuid-ec011f476a3747bdb29690a04477c0aa,N Engl J Med,0.456474
uuid-ec011f476a3747bdb29690a04477c0aa,Lancet Oncol,0.357873
uuid-ec011f476a3747bdb29690a04477c0aa,protocol,0.480893
uuid-ec011f476a3747bdb29690a04477c0aa,McDermott DF,0.51746
uuid-ec011f476a3747bdb29690a04477c0aa,search of published literature,0.343051
uuid-ec011f476a3747bdb29690a04477c0aa,Motzer RJ,0.516788
uuid-ec011f476a3747bdb29690a04477c0aa,phase 3 study,0.754973
uuid-ec011f476a3747bdb29690a04477c0aa,PubMed and EMBASE,0.340792
uuid-ec011f476a3747bdb29690a04477c0aa,Escudier B,0.532534
uuid-ec011f476a3747bdb29690a04477c0aa,et al.,0.496867
uuid-ec011f476a3747bdb29690a04477c0aa,J Clin Oncol,0.430616
uuid-ec011f476a3747bdb29690a04477c0aa,Rizvi NA,0.473891
uuid-ec011f476a3747bdb29690a04477c0aa,Weber JS,0.580854
uuid-ec011f476a3747bdb29690a04477c0aa,phase 2 study,0.6143
uuid-fd1a5b95f7ee42698d8a1f605c7684c5,requested,0.596876
uuid-638c7f18f9d242a2af5dc26f74dcbd68,Bristol-Myers Squibb,0.341822
uuid-638c7f18f9d242a2af5dc26f74dcbd68,not conducted any controlled clinical trials/studies,0.304507
uuid-638c7f18f9d242a2af5dc26f74dcbd68,Opdivo,0.461382
uuid-638c7f18f9d242a2af5dc26f74dcbd68,Pubmed literature search,0.614325
uuid-638c7f18f9d242a2af5dc26f74dcbd68,purposes other than its labeled indication must be considered investigational,0.586645
uuid-638c7f18f9d242a2af5dc26f74dcbd68,not identify any citations relevant to your inquiry,0.606087
uuid-638c7f18f9d242a2af5dc26f74dcbd68,adverse,0.304183
uuid-638c7f18f9d242a2af5dc26f74dcbd68,using the following search terms,0.642331
uuid-638c7f18f9d242a2af5dc26f74dcbd68,databases,0.315039
uuid-638c7f18f9d242a2af5dc26f74dcbd68,reported,0.556704
uuid-f7e483aefcef460693dadaed0e1f2160,Bristol-Myers Squibb,0.306864
uuid-4581d4a9463c40e7a72c5789d2fc0f54,nivolumab,0.480134
uuid-4581d4a9463c40e7a72c5789d2fc0f54,Bristol-Myers Squibb,0.550957
uuid-4581d4a9463c40e7a72c5789d2fc0f54,evaluating,0.688383
uuid-4581d4a9463c40e7a72c5789d2fc0f54,not conducted any controlled clinical trials/studies,0.722339
uuid-4581d4a9463c40e7a72c5789d2fc0f54,Pubmed literature search,0.58447
uuid-4581d4a9463c40e7a72c5789d2fc0f54,purposes other than its labeled indication must be considered investigational,0.678818
uuid-4581d4a9463c40e7a72c5789d2fc0f54,not identify any citations relevant to your inquiry,0.547896
uuid-4581d4a9463c40e7a72c5789d2fc0f54,using the following search terms,0.519313
uuid-4581d4a9463c40e7a72c5789d2fc0f54,efficacy and safety of nivolumab,0.557464
uuid-0ec2f697e1ff4f64a3971d1a905c14c3,trial,0.457788
uuid-bb8020224f2a48c2930ad292e96228aa,Bristol-Myers Squibb,0.527337
uuid-bb8020224f2a48c2930ad292e96228aa,evaluating,0.379283
uuid-bb8020224f2a48c2930ad292e96228aa,not conducted any controlled clinical trials/studies,0.4276
uuid-bb8020224f2a48c2930ad292e96228aa,adverse,0.756164
uuid-bb8020224f2a48c2930ad292e96228aa,phase 3 study,0.357841
uuid-bb8020224f2a48c2930ad292e96228aa,melanoma,0.41228
uuid-bb8020224f2a48c2930ad292e96228aa,efficacy and safety of nivolumab,0.352888
uuid-bb8020224f2a48c2930ad292e96228aa,reported,0.420672
uuid-e1c25998c2b04b2a8356820304973ea1,Opdivo,0.50165
uuid-e1c25998c2b04b2a8356820304973ea1,open-label,0.304253
uuid-e1c25998c2b04b2a8356820304973ea1,trial,0.521827
uuid-e1c25998c2b04b2a8356820304973ea1,docetaxel,0.30238
uuid-e1c25998c2b04b2a8356820304973ea1,safety of nivolumab monotherapy,0.432481
uuid-e1c25998c2b04b2a8356820304973ea1,phase,0.378496
uuid-db57e5d62bf048bebb390a636fa7801c,N Engl J Med,0.448483
uuid-db57e5d62bf048bebb390a636fa7801c,protocol,0.770446
uuid-db57e5d62bf048bebb390a636fa7801c,McDermott DF,0.741196
uuid-db57e5d62bf048bebb390a636fa7801c,Motzer RJ,0.818144
uuid-db57e5d62bf048bebb390a636fa7801c,phase 3 study,0.417055
uuid-db57e5d62bf048bebb390a636fa7801c,Escudier B,0.749917
uuid-db57e5d62bf048bebb390a636fa7801c,NEJM,0.400698
uuid-db57e5d62bf048bebb390a636fa7801c,et al.,0.668641
uuid-db57e5d62bf048bebb390a636fa7801c,J Clin Oncol,0.792018
uuid-db57e5d62bf048bebb390a636fa7801c,Topalian,0.388894
uuid-db57e5d62bf048bebb390a636fa7801c,phase 1 study,0.500686
uuid-db57e5d62bf048bebb390a636fa7801c,CA209-003,0.567381
uuid-db57e5d62bf048bebb390a636fa7801c,phase 2 study,0.677985
uuid-db57e5d62bf048bebb390a636fa7801c,present using the following search terms,0.310558
uuid-db57e5d62bf048bebb390a636fa7801c,investigating,0.615835
uuid-451123d895054fed8c7cbe2efd6fe62e,N Engl J Med,0.427636
uuid-451123d895054fed8c7cbe2efd6fe62e,protocol,0.429136
uuid-451123d895054fed8c7cbe2efd6fe62e,McDermott DF,0.44782
uuid-451123d895054fed8c7cbe2efd6fe62e,Motzer RJ,0.430476
uuid-451123d895054fed8c7cbe2efd6fe62e,Escudier B,0.450887
uuid-451123d895054fed8c7cbe2efd6fe62e,et al.,0.456026
uuid-451123d895054fed8c7cbe2efd6fe62e,J Clin Oncol,0.384624
uuid-451123d895054fed8c7cbe2efd6fe62e,Rizvi NA,0.305616
uuid-451123d895054fed8c7cbe2efd6fe62e,phase 2 study,0.351446
uuid-cad316b768114e798599eca93d21fe23,N Engl J Med,0.432549
uuid-cad316b768114e798599eca93d21fe23,McDermott DF,0.412676
uuid-cad316b768114e798599eca93d21fe23,Motzer RJ,0.367349
uuid-cad316b768114e798599eca93d21fe23,ESMO,0.477338
uuid-cad316b768114e798599eca93d21fe23,Escudier B,0.406032
uuid-cad316b768114e798599eca93d21fe23,et al.,0.475724
uuid-cad316b768114e798599eca93d21fe23,J Clin Oncol,0.332459
uuid-cad316b768114e798599eca93d21fe23,phase 2 study,0.349951
uuid-cad316b768114e798599eca93d21fe23,Horn L,0.328249
uuid-c719e0d76a524d1b8fede44353f049bd,N Engl J Med,0.518987
uuid-c719e0d76a524d1b8fede44353f049bd,protocol,0.718241
uuid-c719e0d76a524d1b8fede44353f049bd,McDermott DF,0.740638
uuid-c719e0d76a524d1b8fede44353f049bd,Motzer RJ,0.751286
uuid-c719e0d76a524d1b8fede44353f049bd,phase 3 study,0.471877
uuid-c719e0d76a524d1b8fede44353f049bd,Escudier B,0.751669
uuid-c719e0d76a524d1b8fede44353f049bd,NEJM,0.316136
uuid-c719e0d76a524d1b8fede44353f049bd,et al.,0.706109
uuid-c719e0d76a524d1b8fede44353f049bd,J Clin Oncol,0.688831
uuid-c719e0d76a524d1b8fede44353f049bd,Rizvi NA,0.365672
uuid-c719e0d76a524d1b8fede44353f049bd,phase 2 study,0.682511
uuid-cb8f5388cd23475597d3b22a6cd86de1,NEJM,0.335802
uuid-cb8f5388cd23475597d3b22a6cd86de1,Topalian,0.36183
uuid-cb8f5388cd23475597d3b22a6cd86de1,Weber JS,0.30401
uuid-277ca8928b554e03a827da3a540d01f4,nivolumab,0.330431
uuid-277ca8928b554e03a827da3a540d01f4,evaluating,0.325437
uuid-277ca8928b554e03a827da3a540d01f4,not conducted any controlled clinical trials/studies,0.364217
uuid-277ca8928b554e03a827da3a540d01f4,Pubmed literature search,0.49351
uuid-277ca8928b554e03a827da3a540d01f4,purposes other than its labeled indication must be considered investigational,0.52728
uuid-277ca8928b554e03a827da3a540d01f4,not identify any citations relevant to your inquiry,0.492897
uuid-277ca8928b554e03a827da3a540d01f4,open-label,0.410079
uuid-277ca8928b554e03a827da3a540d01f4,using the following search terms,0.465094
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,use of nivolumab for the treatment,0.409821
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,patients with advanced or metastatic,0.645244
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,nivolumab combined with ipilimumab,0.676339
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,not approved,0.453534
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,clinical trials investigating the safety,0.548799
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,phase 1/2 study CA209-032,0.34114
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,bladder cancer,0.749142
uuid-c061980f6bcd4f84bbfca8fd613a9c1b,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-9ccabe713f5e4fdc9bd98fa482c9cada,nivolumab,0.434123
uuid-9ccabe713f5e4fdc9bd98fa482c9cada,melanoma,0.464756
uuid-1a85c3fc34704559892e0c701c68d44c,adverse,0.62407
uuid-1a85c3fc34704559892e0c701c68d44c,RCC,0.485524
uuid-1a85c3fc34704559892e0c701c68d44c,reported,0.369666
uuid-1a10b5b2020e4cde8adb6c4a6ea36925,adverse,0.806921
uuid-1a10b5b2020e4cde8adb6c4a6ea36925,phase 3 study,0.417854
uuid-1a10b5b2020e4cde8adb6c4a6ea36925,melanoma,0.490547
uuid-1a10b5b2020e4cde8adb6c4a6ea36925,reported,0.442882
uuid-5ba217281cee4788a9df860ce1f582d6,NSCLC,0.531113
uuid-5ba217281cee4788a9df860ce1f582d6,non-small cell lung cancer,0.619176
uuid-5ba217281cee4788a9df860ce1f582d6,phase 3 study,0.375516
uuid-5ba217281cee4788a9df860ce1f582d6,phase 1 study,0.321118
uuid-5ba217281cee4788a9df860ce1f582d6,PD-L1,0.648585
uuid-51b314e7093e477581447009eee6b9c8,Opdivo,0.714033
uuid-51b314e7093e477581447009eee6b9c8,clinical trials investigating the safety,0.364597
uuid-51b314e7093e477581447009eee6b9c8,trial,0.36301
uuid-45aa118efd644784b7dca4901f5f3e59,nivolumab,0.35245
uuid-45aa118efd644784b7dca4901f5f3e59,Bristol-Myers Squibb,0.57792
uuid-45aa118efd644784b7dca4901f5f3e59,evaluating,0.780862
uuid-45aa118efd644784b7dca4901f5f3e59,not conducted any controlled clinical trials/studies,0.763243
uuid-45aa118efd644784b7dca4901f5f3e59,search of published literature,0.759497
uuid-45aa118efd644784b7dca4901f5f3e59,PubMed and EMBASE,0.732482
uuid-45aa118efd644784b7dca4901f5f3e59,phase 1 study,0.316902
uuid-45aa118efd644784b7dca4901f5f3e59,efficacy and safety of nivolumab,0.888137
uuid-45aa118efd644784b7dca4901f5f3e59,not identify any citations relevant to your request,0.428859
uuid-45aa118efd644784b7dca4901f5f3e59,present using the following search terms,0.748703
uuid-a34606950e5b44b0ade9f46b8fab823f,N Engl J Med,0.689907
uuid-a34606950e5b44b0ade9f46b8fab823f,Lancet Oncol,0.584216
uuid-a34606950e5b44b0ade9f46b8fab823f,protocol,0.72528
uuid-a34606950e5b44b0ade9f46b8fab823f,McDermott DF,0.794444
uuid-a34606950e5b44b0ade9f46b8fab823f,Motzer RJ,0.755383
uuid-a34606950e5b44b0ade9f46b8fab823f,phase 3 study,0.521307
uuid-a34606950e5b44b0ade9f46b8fab823f,Escudier B,0.794743
uuid-a34606950e5b44b0ade9f46b8fab823f,NEJM,0.434762
uuid-a34606950e5b44b0ade9f46b8fab823f,et al.,0.777092
uuid-a34606950e5b44b0ade9f46b8fab823f,J Clin Oncol,0.708338
uuid-a34606950e5b44b0ade9f46b8fab823f,Topalian,0.401719
uuid-a34606950e5b44b0ade9f46b8fab823f,Rizvi NA,0.731383
uuid-a34606950e5b44b0ade9f46b8fab823f,Brahmer J,0.378658
uuid-a34606950e5b44b0ade9f46b8fab823f,Weber JS,0.614831
uuid-a34606950e5b44b0ade9f46b8fab823f,phase 2 study,0.769458
uuid-b8902e183f314754a05f8bfd502ddc0b,Opdivo,0.50165
uuid-b8902e183f314754a05f8bfd502ddc0b,open-label,0.304253
uuid-b8902e183f314754a05f8bfd502ddc0b,trial,0.521827
uuid-b8902e183f314754a05f8bfd502ddc0b,docetaxel,0.30238
uuid-b8902e183f314754a05f8bfd502ddc0b,safety of nivolumab monotherapy,0.432481
uuid-b8902e183f314754a05f8bfd502ddc0b,phase,0.378496
uuid-9b559f95d4d04dc3b90eeb7d57fb50bf,OS,0.62262
uuid-9b559f95d4d04dc3b90eeb7d57fb50bf,PFS,0.65903
uuid-9b559f95d4d04dc3b90eeb7d57fb50bf,Overall survival,0.644151
uuid-9c6ff20a7f2b4dfebaa7bafdd85ecbe2,nivolumab,0.316537
uuid-7a1824d8d7964ceaabb1dd227ebd117e,Opdivo,0.50165
uuid-7a1824d8d7964ceaabb1dd227ebd117e,open-label,0.304253
uuid-7a1824d8d7964ceaabb1dd227ebd117e,trial,0.521827
uuid-7a1824d8d7964ceaabb1dd227ebd117e,docetaxel,0.30238
uuid-7a1824d8d7964ceaabb1dd227ebd117e,safety of nivolumab monotherapy,0.432481
uuid-7a1824d8d7964ceaabb1dd227ebd117e,phase,0.378496
uuid-65459a0015e84275887a93b5b80f2f7e,N Engl J Med,0.304989
uuid-65459a0015e84275887a93b5b80f2f7e,AEs,0.337832
uuid-65459a0015e84275887a93b5b80f2f7e,patients,0.387033
uuid-65459a0015e84275887a93b5b80f2f7e,provided in the Detailed Information,0.370845
uuid-65459a0015e84275887a93b5b80f2f7e,ESMO,0.421367
uuid-65459a0015e84275887a93b5b80f2f7e,NEJM,0.709799
uuid-65459a0015e84275887a93b5b80f2f7e,Topalian,0.735417
uuid-65459a0015e84275887a93b5b80f2f7e,grade 3 to 4 AEs,0.538198
uuid-f47039c8918245b69fe76d6c98369011,phase 1 study,0.317962
uuid-f47039c8918245b69fe76d6c98369011,CA209-003,0.485064
uuid-f47039c8918245b69fe76d6c98369011,investigating,0.737342
uuid-8f4004433a2f460aba4e488fe9228d00,nivolumab,0.501509
uuid-8f4004433a2f460aba4e488fe9228d00,Bristol-Myers Squibb,0.380898
uuid-8f4004433a2f460aba4e488fe9228d00,evaluating,0.534888
uuid-8f4004433a2f460aba4e488fe9228d00,not conducted any controlled clinical trials/studies,0.582549
uuid-8f4004433a2f460aba4e488fe9228d00,Pubmed literature search,0.791297
uuid-8f4004433a2f460aba4e488fe9228d00,purposes other than its labeled indication must be considered investigational,0.835802
uuid-8f4004433a2f460aba4e488fe9228d00,not identify any citations relevant to your inquiry,0.782132
uuid-8f4004433a2f460aba4e488fe9228d00,Additionally,0.377289
uuid-8f4004433a2f460aba4e488fe9228d00,ongoing,0.380387
uuid-8f4004433a2f460aba4e488fe9228d00,using the following search terms,0.75184
uuid-8f4004433a2f460aba4e488fe9228d00,detailed search of www.clinicaltrials.gov,0.398969
uuid-8f4004433a2f460aba4e488fe9228d00,efficacy and safety of nivolumab,0.423641
uuid-8f4004433a2f460aba4e488fe9228d00,not identify any planned,0.386537
uuid-8f4004433a2f460aba4e488fe9228d00,not identify any citations relevant to your request,0.382577
uuid-0b60e734f64f40a9a10f179542161301,requested,0.44769
uuid-0b60e734f64f40a9a10f179542161301,trial,0.309472
uuid-fad586b5340943928d34fb2a0a1fb9aa,fatigue,0.704358
uuid-83189a3dd2354899b17817d0cb5db8e9,provided in the Detailed Information,0.512861
uuid-83189a3dd2354899b17817d0cb5db8e9,clinical,0.425442
uuid-fac42505b7994670902813a2792d8503,N Engl J Med,0.463615
uuid-fac42505b7994670902813a2792d8503,NSCLC,0.411904
uuid-fac42505b7994670902813a2792d8503,Lancet Oncol,0.356346
uuid-fac42505b7994670902813a2792d8503,non-small cell lung cancer,0.479924
uuid-fac42505b7994670902813a2792d8503,phase 3 study,0.353194
uuid-fac42505b7994670902813a2792d8503,Rizvi NA,0.55688
uuid-fac42505b7994670902813a2792d8503,Brahmer J,0.571788
uuid-fac42505b7994670902813a2792d8503,PD-L1,0.439281
uuid-fac42505b7994670902813a2792d8503,phase 2 study,0.304107
uuid-c112730cf2984417aefcbb76610b68ea,search of published literature,0.394524
uuid-c112730cf2984417aefcbb76610b68ea,Additionally,0.413583
uuid-c112730cf2984417aefcbb76610b68ea,ongoing,0.322117
uuid-c112730cf2984417aefcbb76610b68ea,PubMed and EMBASE,0.391671
uuid-c112730cf2984417aefcbb76610b68ea,detailed search of www.clinicaltrials.gov,0.375936
uuid-c112730cf2984417aefcbb76610b68ea,efficacy and safety of nivolumab,0.370699
uuid-c112730cf2984417aefcbb76610b68ea,not identify any planned,0.34283
uuid-c112730cf2984417aefcbb76610b68ea,Weber JS,0.319229
uuid-c112730cf2984417aefcbb76610b68ea,not identify any citations relevant to your request,0.447813
uuid-c112730cf2984417aefcbb76610b68ea,present using the following search terms,0.408199
uuid-3e2998decc5240c59edcfbee4ee60663,Opdivo,0.50165
uuid-3e2998decc5240c59edcfbee4ee60663,open-label,0.304253
uuid-3e2998decc5240c59edcfbee4ee60663,trial,0.521827
uuid-3e2998decc5240c59edcfbee4ee60663,docetaxel,0.30238
uuid-3e2998decc5240c59edcfbee4ee60663,safety of nivolumab monotherapy,0.432481
uuid-3e2998decc5240c59edcfbee4ee60663,phase,0.378496
uuid-923cd5e23e244a69a92c46722c9d2f11,evaluating,0.331463
uuid-923cd5e23e244a69a92c46722c9d2f11,not conducted any controlled clinical trials/studies,0.327968
uuid-923cd5e23e244a69a92c46722c9d2f11,protocol,0.532972
uuid-923cd5e23e244a69a92c46722c9d2f11,RCC,0.386451
uuid-923cd5e23e244a69a92c46722c9d2f11,McDermott DF,0.444329
uuid-923cd5e23e244a69a92c46722c9d2f11,search of published literature,0.50452
uuid-923cd5e23e244a69a92c46722c9d2f11,Additionally,0.555299
uuid-923cd5e23e244a69a92c46722c9d2f11,ongoing,0.478674
uuid-923cd5e23e244a69a92c46722c9d2f11,Motzer RJ,0.475488
uuid-923cd5e23e244a69a92c46722c9d2f11,PubMed and EMBASE,0.501909
uuid-923cd5e23e244a69a92c46722c9d2f11,Escudier B,0.459186
uuid-923cd5e23e244a69a92c46722c9d2f11,et al.,0.397016
uuid-923cd5e23e244a69a92c46722c9d2f11,J Clin Oncol,0.428996
uuid-923cd5e23e244a69a92c46722c9d2f11,detailed search of www.clinicaltrials.gov,0.514934
uuid-923cd5e23e244a69a92c46722c9d2f11,efficacy and safety of nivolumab,0.47512
uuid-923cd5e23e244a69a92c46722c9d2f11,not identify any planned,0.493147
uuid-923cd5e23e244a69a92c46722c9d2f11,phase 2 study,0.384586
uuid-923cd5e23e244a69a92c46722c9d2f11,not identify any citations relevant to your request,0.565812
uuid-923cd5e23e244a69a92c46722c9d2f11,present using the following search terms,0.490802
uuid-d09ee103b886438b801a5f5d78c91e37,95% CI,0.419478
uuid-d09ee103b886438b801a5f5d78c91e37,respectively,0.497608
uuid-d09ee103b886438b801a5f5d78c91e37,Objective response rate,0.403649
uuid-d09ee103b886438b801a5f5d78c91e37,ORR,0.578109
uuid-d09ee103b886438b801a5f5d78c91e37,patients with advanced or metastatic,0.306625
uuid-d09ee103b886438b801a5f5d78c91e37,Median overall survival,0.498783
uuid-d09ee103b886438b801a5f5d78c91e37,nivolumab combined with ipilimumab,0.300486
uuid-d09ee103b886438b801a5f5d78c91e37,tumors,0.323334
uuid-d09ee103b886438b801a5f5d78c91e37,ESMO,0.534361
uuid-d09ee103b886438b801a5f5d78c91e37,Median OS,0.394058
uuid-d09ee103b886438b801a5f5d78c91e37,small cell lung cancer,0.380999
uuid-d09ee103b886438b801a5f5d78c91e37,SCLC,0.365686
uuid-d09ee103b886438b801a5f5d78c91e37,hazard ratio,0.419392
uuid-d09ee103b886438b801a5f5d78c91e37,grade 3 to 4 AEs,0.414535
uuid-d09ee103b886438b801a5f5d78c91e37,phase 1/2 study CA209-032,0.398283
uuid-d09ee103b886438b801a5f5d78c91e37,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-227e53ec3d624672977e90eaf61d9a39,nivolumab,0.585144
uuid-227e53ec3d624672977e90eaf61d9a39,Bristol-Myers Squibb,0.429117
uuid-227e53ec3d624672977e90eaf61d9a39,evaluating,0.59349
uuid-227e53ec3d624672977e90eaf61d9a39,not conducted any controlled clinical trials/studies,0.649052
uuid-227e53ec3d624672977e90eaf61d9a39,Pubmed literature search,0.864064
uuid-227e53ec3d624672977e90eaf61d9a39,purposes other than its labeled indication must be considered investigational,0.930682
uuid-227e53ec3d624672977e90eaf61d9a39,not identify any citations relevant to your inquiry,0.823605
uuid-227e53ec3d624672977e90eaf61d9a39,using the following search terms,0.809419
uuid-227e53ec3d624672977e90eaf61d9a39,efficacy and safety of nivolumab,0.426249
uuid-23bd29d695434c4388d8f9f53c831be6,nivolumab,0.361138
uuid-c76d2dfba60e4970a259fa7480737089,use of nivolumab for the treatment,0.440423
uuid-c76d2dfba60e4970a259fa7480737089,search of published literature,0.311531
uuid-c76d2dfba60e4970a259fa7480737089,PubMed and EMBASE,0.312811
uuid-c76d2dfba60e4970a259fa7480737089,not approved,0.404782
uuid-c76d2dfba60e4970a259fa7480737089,open-label,0.578291
uuid-c76d2dfba60e4970a259fa7480737089,clinical trials investigating the safety,0.440014
uuid-c76d2dfba60e4970a259fa7480737089,present using the following search terms,0.328669
uuid-c76d2dfba60e4970a259fa7480737089,phase,0.41185
uuid-08f05dec855a4b7b9a2009cd9dfee89b,Bristol-Myers Squibb,0.35257
uuid-08f05dec855a4b7b9a2009cd9dfee89b,evaluating,0.398134
uuid-08f05dec855a4b7b9a2009cd9dfee89b,not conducted any controlled clinical trials/studies,0.407287
uuid-08f05dec855a4b7b9a2009cd9dfee89b,efficacy and safety of nivolumab,0.466723
uuid-933ed50197854c928e4633a1c7506213,Opdivo,0.50165
uuid-933ed50197854c928e4633a1c7506213,open-label,0.304253
uuid-933ed50197854c928e4633a1c7506213,trial,0.521827
uuid-933ed50197854c928e4633a1c7506213,docetaxel,0.30238
uuid-933ed50197854c928e4633a1c7506213,safety of nivolumab monotherapy,0.432481
uuid-933ed50197854c928e4633a1c7506213,phase,0.378496
uuid-f4a237862ae64e4ca79896dc01d67560,95% CI,0.419478
uuid-f4a237862ae64e4ca79896dc01d67560,respectively,0.497608
uuid-f4a237862ae64e4ca79896dc01d67560,Objective response rate,0.403649
uuid-f4a237862ae64e4ca79896dc01d67560,ORR,0.578109
uuid-f4a237862ae64e4ca79896dc01d67560,patients with advanced or metastatic,0.306625
uuid-f4a237862ae64e4ca79896dc01d67560,Median overall survival,0.498783
uuid-f4a237862ae64e4ca79896dc01d67560,nivolumab combined with ipilimumab,0.300486
uuid-f4a237862ae64e4ca79896dc01d67560,tumors,0.323334
uuid-f4a237862ae64e4ca79896dc01d67560,ESMO,0.534361
uuid-f4a237862ae64e4ca79896dc01d67560,Median OS,0.394058
uuid-f4a237862ae64e4ca79896dc01d67560,small cell lung cancer,0.380999
uuid-f4a237862ae64e4ca79896dc01d67560,SCLC,0.365686
uuid-f4a237862ae64e4ca79896dc01d67560,hazard ratio,0.419392
uuid-f4a237862ae64e4ca79896dc01d67560,grade 3 to 4 AEs,0.414535
uuid-f4a237862ae64e4ca79896dc01d67560,phase 1/2 study CA209-032,0.398283
uuid-f4a237862ae64e4ca79896dc01d67560,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-3b08b45073a5411890c3628114fb4c5c,Brahmer J,0.398149
uuid-3b08b45073a5411890c3628114fb4c5c,BMS,0.544631
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,N Engl J Med,0.535286
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Lancet Oncol,0.364361
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,protocol,0.50442
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,McDermott DF,0.548182
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Motzer RJ,0.532741
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,phase 3 study,0.493197
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Escudier B,0.547344
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,et al.,0.519366
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,J Clin Oncol,0.509597
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Rizvi NA,0.478602
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Brahmer J,0.338223
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,Weber JS,0.370952
uuid-8a5a9fff796d4fe18b15c876c36a1dfe,phase 2 study,0.591434
uuid-945d6ebad33e49c39d12c784efae6f97,Opdivo,0.377895
uuid-945d6ebad33e49c39d12c784efae6f97,clinical,0.355294
uuid-945d6ebad33e49c39d12c784efae6f97,trial,0.920889
uuid-ab4ee7997f9944da8108c4b14ebdcad6,use of nivolumab for the treatment,0.30404
uuid-ab4ee7997f9944da8108c4b14ebdcad6,patients,0.411801
uuid-ab4ee7997f9944da8108c4b14ebdcad6,mg,0.604727
uuid-ab4ee7997f9944da8108c4b14ebdcad6,kg,0.65861
uuid-ab4ee7997f9944da8108c4b14ebdcad6,relapsed,0.437733
uuid-ab4ee7997f9944da8108c4b14ebdcad6,Overall survival,0.3418
uuid-ab4ee7997f9944da8108c4b14ebdcad6,cohort,0.531316
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,N Engl J Med,0.620843
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,ASCO,0.553901
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,Lancet Oncol,0.475981
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,Rizvi NA,0.624137
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,Brahmer J,0.698322
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,phase 2 study,0.363212
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,Antonia SJ,0.326997
uuid-aa8f0e77b09b4861a51b4d6a8a6b1abc,Horn L,0.338933
uuid-d60aa1314e1145c29d411f5df429107f,95% CI,0.419478
uuid-d60aa1314e1145c29d411f5df429107f,respectively,0.497608
uuid-d60aa1314e1145c29d411f5df429107f,Objective response rate,0.403649
uuid-d60aa1314e1145c29d411f5df429107f,ORR,0.578109
uuid-d60aa1314e1145c29d411f5df429107f,patients with advanced or metastatic,0.306625
uuid-d60aa1314e1145c29d411f5df429107f,Median overall survival,0.498783
uuid-d60aa1314e1145c29d411f5df429107f,nivolumab combined with ipilimumab,0.300486
uuid-d60aa1314e1145c29d411f5df429107f,tumors,0.323334
uuid-d60aa1314e1145c29d411f5df429107f,ESMO,0.534361
uuid-d60aa1314e1145c29d411f5df429107f,Median OS,0.394058
uuid-d60aa1314e1145c29d411f5df429107f,small cell lung cancer,0.380999
uuid-d60aa1314e1145c29d411f5df429107f,SCLC,0.365686
uuid-d60aa1314e1145c29d411f5df429107f,hazard ratio,0.419392
uuid-d60aa1314e1145c29d411f5df429107f,grade 3 to 4 AEs,0.414535
uuid-d60aa1314e1145c29d411f5df429107f,phase 1/2 study CA209-032,0.398283
uuid-d60aa1314e1145c29d411f5df429107f,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-278ef7af016744c592f979f18690b5c4,95% CI,0.49664
uuid-278ef7af016744c592f979f18690b5c4,respectively,0.777958
uuid-278ef7af016744c592f979f18690b5c4,Objective response rate,0.494099
uuid-278ef7af016744c592f979f18690b5c4,ORR,0.591635
uuid-278ef7af016744c592f979f18690b5c4,Median overall survival,0.404982
uuid-278ef7af016744c592f979f18690b5c4,monotherapy,0.411095
uuid-278ef7af016744c592f979f18690b5c4,Median OS,0.446085
uuid-278ef7af016744c592f979f18690b5c4,docetaxel,0.557428
uuid-278ef7af016744c592f979f18690b5c4,hazard ratio,0.463594
uuid-76e2012cade143abaae5d46550c3a3c1,N Engl J Med,0.666673
uuid-76e2012cade143abaae5d46550c3a3c1,protocol,0.784297
uuid-76e2012cade143abaae5d46550c3a3c1,McDermott DF,0.863473
uuid-76e2012cade143abaae5d46550c3a3c1,Motzer RJ,0.839535
uuid-76e2012cade143abaae5d46550c3a3c1,phase 3 study,0.445361
uuid-76e2012cade143abaae5d46550c3a3c1,Escudier B,0.862895
uuid-76e2012cade143abaae5d46550c3a3c1,NEJM,0.429443
uuid-76e2012cade143abaae5d46550c3a3c1,et al.,0.845549
uuid-76e2012cade143abaae5d46550c3a3c1,J Clin Oncol,0.786791
uuid-76e2012cade143abaae5d46550c3a3c1,Topalian,0.389875
uuid-76e2012cade143abaae5d46550c3a3c1,Rizvi NA,0.366362
uuid-76e2012cade143abaae5d46550c3a3c1,Brahmer J,0.346515
uuid-76e2012cade143abaae5d46550c3a3c1,phase 2 study,0.725511
uuid-0b87acccc06945abacebceb7c6ad5e4d,search of published literature,0.394524
uuid-0b87acccc06945abacebceb7c6ad5e4d,Additionally,0.413583
uuid-0b87acccc06945abacebceb7c6ad5e4d,ongoing,0.322117
uuid-0b87acccc06945abacebceb7c6ad5e4d,PubMed and EMBASE,0.391671
uuid-0b87acccc06945abacebceb7c6ad5e4d,detailed search of www.clinicaltrials.gov,0.375936
uuid-0b87acccc06945abacebceb7c6ad5e4d,efficacy and safety of nivolumab,0.370699
uuid-0b87acccc06945abacebceb7c6ad5e4d,not identify any planned,0.34283
uuid-0b87acccc06945abacebceb7c6ad5e4d,Weber JS,0.319229
uuid-0b87acccc06945abacebceb7c6ad5e4d,not identify any citations relevant to your request,0.447813
uuid-0b87acccc06945abacebceb7c6ad5e4d,present using the following search terms,0.408199
uuid-accfbd3836db4b34bab11b6337433ad7,nivolumab,0.364813
uuid-accfbd3836db4b34bab11b6337433ad7,RCC,0.341827
uuid-e3ddd7cacaea463a982c4e9bbd24404a,ASCO,0.47553
uuid-e3ddd7cacaea463a982c4e9bbd24404a,Topalian,0.312775
uuid-e3ddd7cacaea463a982c4e9bbd24404a,phase 1 study,0.325983
uuid-e3ddd7cacaea463a982c4e9bbd24404a,mg,0.433781
uuid-e3ddd7cacaea463a982c4e9bbd24404a,kg,0.393194
uuid-c0c0910dec0e413a968dec8f5797b08f,adverse,0.530938
uuid-c0c0910dec0e413a968dec8f5797b08f,reported,0.394505
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,nivolumab,0.339646
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,Bristol-Myers Squibb,0.546345
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,evaluating,0.692374
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,not conducted any controlled clinical trials/studies,0.68924
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,RCC,0.335713
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,search of published literature,0.705337
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,Additionally,0.632838
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,ongoing,0.507851
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,PubMed and EMBASE,0.688715
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,detailed search of www.clinicaltrials.gov,0.596466
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,efficacy and safety of nivolumab,0.789246
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,not identify any planned,0.537254
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,not identify any citations relevant to your request,0.715951
uuid-bf3aca369f1d43d78cbdba1fb8eff00f,present using the following search terms,0.706539
uuid-2c2b5aea6c7840ee8a501d8719f17793,adverse,0.419275
uuid-4c5765b026df48bb80abffdc6cbdd594,grade,0.359729
uuid-87496368cafa4f4f8660ef3f5a66bd51,nivolumab,0.503688
uuid-87496368cafa4f4f8660ef3f5a66bd51,Bristol-Myers Squibb,0.647751
uuid-87496368cafa4f4f8660ef3f5a66bd51,evaluating,0.741181
uuid-87496368cafa4f4f8660ef3f5a66bd51,not conducted any controlled clinical trials/studies,0.810158
uuid-87496368cafa4f4f8660ef3f5a66bd51,Pubmed literature search,0.730321
uuid-87496368cafa4f4f8660ef3f5a66bd51,purposes other than its labeled indication must be considered investigational,0.822861
uuid-87496368cafa4f4f8660ef3f5a66bd51,not identify any citations relevant to your inquiry,0.679867
uuid-87496368cafa4f4f8660ef3f5a66bd51,using the following search terms,0.66172
uuid-87496368cafa4f4f8660ef3f5a66bd51,efficacy and safety of nivolumab,0.579664
uuid-587d56244b374baaa84c08a8574a3682,OS,0.62262
uuid-587d56244b374baaa84c08a8574a3682,PFS,0.65903
uuid-587d56244b374baaa84c08a8574a3682,Overall survival,0.644151
uuid-d46c88f625ec4199b4e3f321c9229147,N Engl J Med,0.448483
uuid-d46c88f625ec4199b4e3f321c9229147,protocol,0.770446
uuid-d46c88f625ec4199b4e3f321c9229147,McDermott DF,0.741196
uuid-d46c88f625ec4199b4e3f321c9229147,Motzer RJ,0.818144
uuid-d46c88f625ec4199b4e3f321c9229147,phase 3 study,0.417055
uuid-d46c88f625ec4199b4e3f321c9229147,Escudier B,0.749917
uuid-d46c88f625ec4199b4e3f321c9229147,NEJM,0.400698
uuid-d46c88f625ec4199b4e3f321c9229147,et al.,0.668641
uuid-d46c88f625ec4199b4e3f321c9229147,J Clin Oncol,0.792018
uuid-d46c88f625ec4199b4e3f321c9229147,Topalian,0.388894
uuid-d46c88f625ec4199b4e3f321c9229147,phase 1 study,0.500686
uuid-d46c88f625ec4199b4e3f321c9229147,CA209-003,0.567381
uuid-d46c88f625ec4199b4e3f321c9229147,phase 2 study,0.677985
uuid-d46c88f625ec4199b4e3f321c9229147,present using the following search terms,0.310558
uuid-d46c88f625ec4199b4e3f321c9229147,investigating,0.615835
uuid-748d7bc64e914b378aeda9f45330b516,95% CI,0.419478
uuid-748d7bc64e914b378aeda9f45330b516,respectively,0.497608
uuid-748d7bc64e914b378aeda9f45330b516,Objective response rate,0.403649
uuid-748d7bc64e914b378aeda9f45330b516,ORR,0.578109
uuid-748d7bc64e914b378aeda9f45330b516,patients with advanced or metastatic,0.306625
uuid-748d7bc64e914b378aeda9f45330b516,Median overall survival,0.498783
uuid-748d7bc64e914b378aeda9f45330b516,nivolumab combined with ipilimumab,0.300486
uuid-748d7bc64e914b378aeda9f45330b516,tumors,0.323334
uuid-748d7bc64e914b378aeda9f45330b516,ESMO,0.534361
uuid-748d7bc64e914b378aeda9f45330b516,Median OS,0.394058
uuid-748d7bc64e914b378aeda9f45330b516,small cell lung cancer,0.380999
uuid-748d7bc64e914b378aeda9f45330b516,SCLC,0.365686
uuid-748d7bc64e914b378aeda9f45330b516,hazard ratio,0.419392
uuid-748d7bc64e914b378aeda9f45330b516,grade 3 to 4 AEs,0.414535
uuid-748d7bc64e914b378aeda9f45330b516,phase 1/2 study CA209-032,0.398283
uuid-748d7bc64e914b378aeda9f45330b516,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-6748d6f8b6374ee1976f5e30d4c518ef,requested,0.594234
uuid-76260c362b3545bca6c9e1b90b06de97,requested,0.594234
uuid-2a0dd60777694adfbd11fad8a50d80eb,AEs,0.574214
uuid-2a0dd60777694adfbd11fad8a50d80eb,respectively,0.364886
uuid-2a0dd60777694adfbd11fad8a50d80eb,patients,0.369621
uuid-2a0dd60777694adfbd11fad8a50d80eb,grade,0.642744
uuid-2a0dd60777694adfbd11fad8a50d80eb,grade 3 to 4 AEs,0.565283
uuid-c6f990a6671541d986bd91aa8f8e1893,nivolumab,0.359772
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,patients,0.539448
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,considered investigational,0.867485
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,patients with advanced or metastatic,0.811488
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,nivolumab combined with ipilimumab,0.790864
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,tumors,0.78735
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,small cell lung cancer,0.931289
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,SCLC,0.888482
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,therapy,0.354857
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,grade 3 to 4 AEs,0.314546
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,phase 1/2 study CA209-032,0.962815
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,bladder cancer,0.372632
uuid-f31e7c900a2c41fb8f5e5b885cee87d5,evaluates the efficacy of nivolumab monotherapy,0.942618
uuid-44037395b34841ae809199d4e8c1ab0b,trial,0.432663
uuid-44037395b34841ae809199d4e8c1ab0b,clinicaltrials.gov,0.419153
uuid-500090530e57404aaa72add9f35551da,provided in the Detailed Information,0.344414
uuid-500090530e57404aaa72add9f35551da,Weber JS,0.315772
uuid-70f2208298fe44ee8c5b32a8841ad67c,use of nivolumab for the treatment,0.305739
uuid-70f2208298fe44ee8c5b32a8841ad67c,patients with advanced or metastatic,0.509457
uuid-70f2208298fe44ee8c5b32a8841ad67c,nivolumab combined with ipilimumab,0.496885
uuid-70f2208298fe44ee8c5b32a8841ad67c,not approved,0.397631
uuid-70f2208298fe44ee8c5b32a8841ad67c,clinical trials investigating the safety,0.478965
uuid-70f2208298fe44ee8c5b32a8841ad67c,bladder cancer,0.940126
uuid-375aef72380244578b5a6473a2233c95,nivolumab,0.465762
uuid-375aef72380244578b5a6473a2233c95,use of nivolumab for the treatment,0.575974
uuid-375aef72380244578b5a6473a2233c95,evaluating,0.362987
uuid-375aef72380244578b5a6473a2233c95,efficacy,0.681156
uuid-375aef72380244578b5a6473a2233c95,clinical,0.45665
uuid-375aef72380244578b5a6473a2233c95,not approved,0.684611
uuid-375aef72380244578b5a6473a2233c95,clinical trials investigating the safety,0.66825
uuid-375aef72380244578b5a6473a2233c95,safety of nivolumab monotherapy,0.465734
uuid-05d7872e0e434a78b57f4e61c35d48ee,respectively,0.660241
uuid-05d7872e0e434a78b57f4e61c35d48ee,Objective response rate,0.618542
uuid-05d7872e0e434a78b57f4e61c35d48ee,ORR,0.535955
uuid-05d7872e0e434a78b57f4e61c35d48ee,monotherapy,0.423253
uuid-05d7872e0e434a78b57f4e61c35d48ee,docetaxel,0.428587
uuid-64fb2565ae4246a2b814f3edccd4f315,Opdivo,0.597693
uuid-64fb2565ae4246a2b814f3edccd4f315,trial,0.315472
uuid-289ead00a2794ddc9ec67a16a2b55a6e,Bristol-Myers Squibb,0.410873
uuid-289ead00a2794ddc9ec67a16a2b55a6e,evaluating,0.426653
uuid-289ead00a2794ddc9ec67a16a2b55a6e,not conducted any controlled clinical trials/studies,0.459216
uuid-289ead00a2794ddc9ec67a16a2b55a6e,purposes other than its labeled indication must be considered investigational,0.344466
uuid-1c57818c6c7b430d9fc977f0ea6e20b4,nivolumab,0.367083
uuid-1c57818c6c7b430d9fc977f0ea6e20b4,fatigue,0.463134
uuid-1529811017214bcc98266d06e68cb96c,nivolumab,0.573368
uuid-1529811017214bcc98266d06e68cb96c,Bristol-Myers Squibb,0.437862
uuid-1529811017214bcc98266d06e68cb96c,evaluating,0.5945
uuid-1529811017214bcc98266d06e68cb96c,not conducted any controlled clinical trials/studies,0.655121
uuid-1529811017214bcc98266d06e68cb96c,Pubmed literature search,0.876447
uuid-1529811017214bcc98266d06e68cb96c,purposes other than its labeled indication must be considered investigational,0.939959
uuid-1529811017214bcc98266d06e68cb96c,not identify any citations relevant to your inquiry,0.835959
uuid-1529811017214bcc98266d06e68cb96c,using the following search terms,0.823015
uuid-1529811017214bcc98266d06e68cb96c,efficacy and safety of nivolumab,0.432466
uuid-f8fe649602684108942e88285be318c0,N Engl J Med,0.310202
uuid-f8fe649602684108942e88285be318c0,non-small cell lung cancer,0.345951
uuid-f8fe649602684108942e88285be318c0,phase 3 study,0.310436
uuid-f8fe649602684108942e88285be318c0,Rizvi NA,0.382632
uuid-f8fe649602684108942e88285be318c0,Brahmer J,0.358724
uuid-f8fe649602684108942e88285be318c0,PD-L1,0.34051
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,Bristol-Myers Squibb,0.85141
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,use of nivolumab for the treatment,0.308112
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,evaluating,0.840301
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,not conducted any controlled clinical trials/studies,0.872069
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,patients,0.344626
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,considered investigational,0.307634
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,adverse,0.334018
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,search of published literature,0.363337
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,PubMed and EMBASE,0.314101
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,efficacy and safety of nivolumab,0.774483
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,present using the following search terms,0.303796
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,safety of nivolumab monotherapy,0.361317
uuid-d6e25fd42b1c45008bc4130b1af9b0ca,reported,0.341592
uuid-ab194bb123ef4a5fad98af30a708240d,trial,0.325942
uuid-33ca5c825fac47aeb2c828d827456e7b,N Engl J Med,0.448483
uuid-33ca5c825fac47aeb2c828d827456e7b,protocol,0.770446
uuid-33ca5c825fac47aeb2c828d827456e7b,McDermott DF,0.741196
uuid-33ca5c825fac47aeb2c828d827456e7b,Motzer RJ,0.818144
uuid-33ca5c825fac47aeb2c828d827456e7b,phase 3 study,0.417055
uuid-33ca5c825fac47aeb2c828d827456e7b,Escudier B,0.749917
uuid-33ca5c825fac47aeb2c828d827456e7b,NEJM,0.400698
uuid-33ca5c825fac47aeb2c828d827456e7b,et al.,0.668641
uuid-33ca5c825fac47aeb2c828d827456e7b,J Clin Oncol,0.792018
uuid-33ca5c825fac47aeb2c828d827456e7b,Topalian,0.388894
uuid-33ca5c825fac47aeb2c828d827456e7b,phase 1 study,0.500686
uuid-33ca5c825fac47aeb2c828d827456e7b,CA209-003,0.567381
uuid-33ca5c825fac47aeb2c828d827456e7b,phase 2 study,0.677985
uuid-33ca5c825fac47aeb2c828d827456e7b,present using the following search terms,0.310558
uuid-33ca5c825fac47aeb2c828d827456e7b,investigating,0.615835
uuid-997047552fee4dc288043fd7d0f9f434,nivolumab,0.563269
uuid-997047552fee4dc288043fd7d0f9f434,Bristol-Myers Squibb,0.478927
uuid-997047552fee4dc288043fd7d0f9f434,evaluating,0.67695
uuid-997047552fee4dc288043fd7d0f9f434,not conducted any controlled clinical trials/studies,0.715728
uuid-997047552fee4dc288043fd7d0f9f434,Pubmed literature search,0.835428
uuid-997047552fee4dc288043fd7d0f9f434,purposes other than its labeled indication must be considered investigational,0.911717
uuid-997047552fee4dc288043fd7d0f9f434,not identify any citations relevant to your inquiry,0.78843
uuid-997047552fee4dc288043fd7d0f9f434,using the following search terms,0.775736
uuid-997047552fee4dc288043fd7d0f9f434,efficacy and safety of nivolumab,0.505016
uuid-c09e07fc90f74867a28038ab1768cabb,respectively,0.661351
uuid-c09e07fc90f74867a28038ab1768cabb,Objective response rate,0.619462
uuid-c09e07fc90f74867a28038ab1768cabb,ORR,0.537232
uuid-c09e07fc90f74867a28038ab1768cabb,monotherapy,0.421967
uuid-c09e07fc90f74867a28038ab1768cabb,docetaxel,0.426453
uuid-046ee515fd474abbb9a807566bd0c283,Opdivo,0.50165
uuid-046ee515fd474abbb9a807566bd0c283,open-label,0.304253
uuid-046ee515fd474abbb9a807566bd0c283,trial,0.521827
uuid-046ee515fd474abbb9a807566bd0c283,docetaxel,0.30238
uuid-046ee515fd474abbb9a807566bd0c283,safety of nivolumab monotherapy,0.432481
uuid-046ee515fd474abbb9a807566bd0c283,phase,0.378496
uuid-37cba303cca647478d0d49bcb55e8cd7,N Engl J Med,0.463615
uuid-37cba303cca647478d0d49bcb55e8cd7,NSCLC,0.411904
uuid-37cba303cca647478d0d49bcb55e8cd7,Lancet Oncol,0.356346
uuid-37cba303cca647478d0d49bcb55e8cd7,non-small cell lung cancer,0.479924
uuid-37cba303cca647478d0d49bcb55e8cd7,phase 3 study,0.353194
uuid-37cba303cca647478d0d49bcb55e8cd7,Rizvi NA,0.55688
uuid-37cba303cca647478d0d49bcb55e8cd7,Brahmer J,0.571788
uuid-37cba303cca647478d0d49bcb55e8cd7,PD-L1,0.439281
uuid-37cba303cca647478d0d49bcb55e8cd7,phase 2 study,0.304107
uuid-d4b6a096429e472ca3ed8d3213253471,evaluating,0.435499
uuid-d4b6a096429e472ca3ed8d3213253471,not conducted any controlled clinical trials/studies,0.382472
uuid-d4b6a096429e472ca3ed8d3213253471,RCC,0.620753
uuid-d4b6a096429e472ca3ed8d3213253471,search of published literature,0.637933
uuid-d4b6a096429e472ca3ed8d3213253471,Additionally,0.654041
uuid-d4b6a096429e472ca3ed8d3213253471,ongoing,0.540519
uuid-d4b6a096429e472ca3ed8d3213253471,PubMed and EMBASE,0.635096
uuid-d4b6a096429e472ca3ed8d3213253471,detailed search of www.clinicaltrials.gov,0.611125
uuid-d4b6a096429e472ca3ed8d3213253471,phase 1 study,0.326182
uuid-d4b6a096429e472ca3ed8d3213253471,efficacy and safety of nivolumab,0.585228
uuid-d4b6a096429e472ca3ed8d3213253471,not identify any planned,0.556501
uuid-d4b6a096429e472ca3ed8d3213253471,not identify any citations relevant to your request,0.706086
uuid-d4b6a096429e472ca3ed8d3213253471,therapy,0.300094
uuid-d4b6a096429e472ca3ed8d3213253471,present using the following search terms,0.632831
uuid-b59220c573694f09950eee0b80f4b0ee,Opdivo,0.50165
uuid-b59220c573694f09950eee0b80f4b0ee,open-label,0.304253
uuid-b59220c573694f09950eee0b80f4b0ee,trial,0.521827
uuid-b59220c573694f09950eee0b80f4b0ee,docetaxel,0.30238
uuid-b59220c573694f09950eee0b80f4b0ee,safety of nivolumab monotherapy,0.432481
uuid-b59220c573694f09950eee0b80f4b0ee,phase,0.378496
uuid-2eb1bc27b73343a4a52514a371ebed76,nivolumab,0.566204
uuid-2eb1bc27b73343a4a52514a371ebed76,Bristol-Myers Squibb,0.485455
uuid-2eb1bc27b73343a4a52514a371ebed76,evaluating,0.668324
uuid-2eb1bc27b73343a4a52514a371ebed76,not conducted any controlled clinical trials/studies,0.719265
uuid-2eb1bc27b73343a4a52514a371ebed76,Pubmed literature search,0.836776
uuid-2eb1bc27b73343a4a52514a371ebed76,purposes other than its labeled indication must be considered investigational,0.913148
uuid-2eb1bc27b73343a4a52514a371ebed76,not identify any citations relevant to your inquiry,0.790829
uuid-2eb1bc27b73343a4a52514a371ebed76,using the following search terms,0.776589
uuid-2eb1bc27b73343a4a52514a371ebed76,efficacy and safety of nivolumab,0.511947
uuid-eb8f948f4ad046a1975171a29951d08f,evaluating,0.350194
uuid-eb8f948f4ad046a1975171a29951d08f,not conducted any controlled clinical trials/studies,0.314999
uuid-eb8f948f4ad046a1975171a29951d08f,search of published literature,0.485036
uuid-eb8f948f4ad046a1975171a29951d08f,Additionally,0.48317
uuid-eb8f948f4ad046a1975171a29951d08f,ongoing,0.377032
uuid-eb8f948f4ad046a1975171a29951d08f,PubMed and EMBASE,0.481761
uuid-eb8f948f4ad046a1975171a29951d08f,detailed search of www.clinicaltrials.gov,0.458049
uuid-eb8f948f4ad046a1975171a29951d08f,phase 1 study,0.567121
uuid-eb8f948f4ad046a1975171a29951d08f,efficacy and safety of nivolumab,0.49174
uuid-eb8f948f4ad046a1975171a29951d08f,not identify any planned,0.407189
uuid-eb8f948f4ad046a1975171a29951d08f,CA209-003,0.651076
uuid-eb8f948f4ad046a1975171a29951d08f,not identify any citations relevant to your request,0.558133
uuid-eb8f948f4ad046a1975171a29951d08f,present using the following search terms,0.526365
uuid-eb8f948f4ad046a1975171a29951d08f,investigating,0.744208
uuid-2bf5f6f712394f8fb422b2264fda8da2,nivolumab,0.522333
uuid-2bf5f6f712394f8fb422b2264fda8da2,Bristol-Myers Squibb,0.488143
uuid-2bf5f6f712394f8fb422b2264fda8da2,evaluating,0.65769
uuid-2bf5f6f712394f8fb422b2264fda8da2,not conducted any controlled clinical trials/studies,0.709817
uuid-2bf5f6f712394f8fb422b2264fda8da2,Pubmed literature search,0.79372
uuid-2bf5f6f712394f8fb422b2264fda8da2,purposes other than its labeled indication must be considered investigational,0.871549
uuid-2bf5f6f712394f8fb422b2264fda8da2,not identify any citations relevant to your inquiry,0.749073
uuid-2bf5f6f712394f8fb422b2264fda8da2,using the following search terms,0.732109
uuid-2bf5f6f712394f8fb422b2264fda8da2,efficacy and safety of nivolumab,0.498795
uuid-e4784dfc24f14d94a8ade7ae74503020,use of nivolumab for the treatment,0.305739
uuid-e4784dfc24f14d94a8ade7ae74503020,patients with advanced or metastatic,0.509457
uuid-e4784dfc24f14d94a8ade7ae74503020,nivolumab combined with ipilimumab,0.496885
uuid-e4784dfc24f14d94a8ade7ae74503020,not approved,0.397631
uuid-e4784dfc24f14d94a8ade7ae74503020,clinical trials investigating the safety,0.478965
uuid-e4784dfc24f14d94a8ade7ae74503020,bladder cancer,0.940126
uuid-e0de445a6fd949ba855d224c478cb473,N Engl J Med,0.730936
uuid-e0de445a6fd949ba855d224c478cb473,requested,0.300519
uuid-e0de445a6fd949ba855d224c478cb473,protocol,0.841438
uuid-e0de445a6fd949ba855d224c478cb473,McDermott DF,0.915579
uuid-e0de445a6fd949ba855d224c478cb473,Motzer RJ,0.894839
uuid-e0de445a6fd949ba855d224c478cb473,phase 3 study,0.422473
uuid-e0de445a6fd949ba855d224c478cb473,Escudier B,0.918427
uuid-e0de445a6fd949ba855d224c478cb473,NEJM,0.446862
uuid-e0de445a6fd949ba855d224c478cb473,et al.,0.903265
uuid-e0de445a6fd949ba855d224c478cb473,J Clin Oncol,0.848583
uuid-e0de445a6fd949ba855d224c478cb473,Topalian,0.396385
uuid-e0de445a6fd949ba855d224c478cb473,Rizvi NA,0.44308
uuid-e0de445a6fd949ba855d224c478cb473,Brahmer J,0.392049
uuid-e0de445a6fd949ba855d224c478cb473,Weber JS,0.30098
uuid-e0de445a6fd949ba855d224c478cb473,phase 2 study,0.773132
uuid-ce90bca9d71d48d6ac1a47f6e8dfad47,AEs,0.319815
uuid-ce90bca9d71d48d6ac1a47f6e8dfad47,adverse,0.601941
uuid-ce90bca9d71d48d6ac1a47f6e8dfad47,grade,0.45746
uuid-4783b1da5f6c4043a82e440e24ff84b3,AEs,0.380824
uuid-4783b1da5f6c4043a82e440e24ff84b3,95% CI,0.498907
uuid-4783b1da5f6c4043a82e440e24ff84b3,Median overall survival,0.364118
uuid-4783b1da5f6c4043a82e440e24ff84b3,Median OS,0.340314
uuid-4783b1da5f6c4043a82e440e24ff84b3,grade,0.43022
uuid-4783b1da5f6c4043a82e440e24ff84b3,Median duration of response,0.7967
uuid-46e9654c9eb842b4acb1e77e07376cbc,N Engl J Med,0.6472
uuid-46e9654c9eb842b4acb1e77e07376cbc,protocol,0.814012
uuid-46e9654c9eb842b4acb1e77e07376cbc,McDermott DF,0.921172
uuid-46e9654c9eb842b4acb1e77e07376cbc,Motzer RJ,0.888764
uuid-46e9654c9eb842b4acb1e77e07376cbc,phase 3 study,0.494055
uuid-46e9654c9eb842b4acb1e77e07376cbc,Escudier B,0.901344
uuid-46e9654c9eb842b4acb1e77e07376cbc,NEJM,0.510566
uuid-46e9654c9eb842b4acb1e77e07376cbc,et al.,0.894032
uuid-46e9654c9eb842b4acb1e77e07376cbc,J Clin Oncol,0.895493
uuid-46e9654c9eb842b4acb1e77e07376cbc,Topalian,0.469757
uuid-46e9654c9eb842b4acb1e77e07376cbc,phase 1 study,0.354534
uuid-46e9654c9eb842b4acb1e77e07376cbc,Rizvi NA,0.407551
uuid-46e9654c9eb842b4acb1e77e07376cbc,Brahmer J,0.304432
uuid-46e9654c9eb842b4acb1e77e07376cbc,CA209-003,0.362765
uuid-46e9654c9eb842b4acb1e77e07376cbc,phase 2 study,0.83206
uuid-a2eb0383637e483283381afdde90dae3,Opdivo,0.50165
uuid-a2eb0383637e483283381afdde90dae3,open-label,0.304253
uuid-a2eb0383637e483283381afdde90dae3,trial,0.521827
uuid-a2eb0383637e483283381afdde90dae3,docetaxel,0.30238
uuid-a2eb0383637e483283381afdde90dae3,safety of nivolumab monotherapy,0.432481
uuid-a2eb0383637e483283381afdde90dae3,phase,0.378496
uuid-62bfbd6d68d9479aa42cd315331958b2,use of nivolumab for the treatment,0.305739
uuid-62bfbd6d68d9479aa42cd315331958b2,patients with advanced or metastatic,0.509457
uuid-62bfbd6d68d9479aa42cd315331958b2,nivolumab combined with ipilimumab,0.496885
uuid-62bfbd6d68d9479aa42cd315331958b2,not approved,0.397631
uuid-62bfbd6d68d9479aa42cd315331958b2,clinical trials investigating the safety,0.478965
uuid-62bfbd6d68d9479aa42cd315331958b2,bladder cancer,0.940126
uuid-1c2b21294b864a2fb2544a9827d4d2e7,requested,0.596876
uuid-26ea9788423a4e70bcdd43bf71a52ea0,requested,0.596876
uuid-37b5137181184dd89e21a9da361048cc,requested,0.596876
uuid-6a8d2628627247c4b3e463bd660f9d06,requested,0.596876
uuid-8773ac11099e41fcb28c2352f0ffc347,N Engl J Med,0.402295
uuid-8773ac11099e41fcb28c2352f0ffc347,protocol,0.614514
uuid-8773ac11099e41fcb28c2352f0ffc347,McDermott DF,0.685488
uuid-8773ac11099e41fcb28c2352f0ffc347,Motzer RJ,0.666845
uuid-8773ac11099e41fcb28c2352f0ffc347,phase 3 study,0.396759
uuid-8773ac11099e41fcb28c2352f0ffc347,Escudier B,0.683776
uuid-8773ac11099e41fcb28c2352f0ffc347,et al.,0.701371
uuid-8773ac11099e41fcb28c2352f0ffc347,J Clin Oncol,0.643396
uuid-8773ac11099e41fcb28c2352f0ffc347,phase 2 study,0.617451
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,Bristol-Myers Squibb,0.453576
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,evaluating,0.57188
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,not conducted any controlled clinical trials/studies,0.523316
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,efficacy,0.30015
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,NSCLC,0.748072
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,non-small cell lung cancer,0.766403
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,considered investigational,0.326263
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,phase 3 study,0.386351
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,phase 1 study,0.387895
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,Rizvi NA,0.306173
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,efficacy and safety of nivolumab,0.514479
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,safety of nivolumab monotherapy,0.443947
uuid-a8c3ca8a8a0f41d9a874d16f010cc78f,platinum-based doublet chemotherapy,0.487131
uuid-eeb0578c32174ce8ad107a31fe00f5da,evaluating,0.366546
uuid-eeb0578c32174ce8ad107a31fe00f5da,not conducted any controlled clinical trials/studies,0.360172
uuid-eeb0578c32174ce8ad107a31fe00f5da,search of published literature,0.403755
uuid-eeb0578c32174ce8ad107a31fe00f5da,Additionally,0.418906
uuid-eeb0578c32174ce8ad107a31fe00f5da,ongoing,0.467576
uuid-eeb0578c32174ce8ad107a31fe00f5da,PubMed and EMBASE,0.39617
uuid-eeb0578c32174ce8ad107a31fe00f5da,detailed search of www.clinicaltrials.gov,0.437393
uuid-eeb0578c32174ce8ad107a31fe00f5da,efficacy and safety of nivolumab,0.42836
uuid-eeb0578c32174ce8ad107a31fe00f5da,not identify any planned,0.454065
uuid-eeb0578c32174ce8ad107a31fe00f5da,combination,0.397925
uuid-eeb0578c32174ce8ad107a31fe00f5da,BMS,0.30879
uuid-eeb0578c32174ce8ad107a31fe00f5da,not identify any citations relevant to your request,0.449603
uuid-eeb0578c32174ce8ad107a31fe00f5da,present using the following search terms,0.394376
uuid-b5654a5e21794273be7f176428ed77ec,95% CI,0.419478
uuid-b5654a5e21794273be7f176428ed77ec,respectively,0.497608
uuid-b5654a5e21794273be7f176428ed77ec,Objective response rate,0.403649
uuid-b5654a5e21794273be7f176428ed77ec,ORR,0.578109
uuid-b5654a5e21794273be7f176428ed77ec,patients with advanced or metastatic,0.306625
uuid-b5654a5e21794273be7f176428ed77ec,Median overall survival,0.498783
uuid-b5654a5e21794273be7f176428ed77ec,nivolumab combined with ipilimumab,0.300486
uuid-b5654a5e21794273be7f176428ed77ec,tumors,0.323334
uuid-b5654a5e21794273be7f176428ed77ec,ESMO,0.534361
uuid-b5654a5e21794273be7f176428ed77ec,Median OS,0.394058
uuid-b5654a5e21794273be7f176428ed77ec,small cell lung cancer,0.380999
uuid-b5654a5e21794273be7f176428ed77ec,SCLC,0.365686
uuid-b5654a5e21794273be7f176428ed77ec,hazard ratio,0.419392
uuid-b5654a5e21794273be7f176428ed77ec,grade 3 to 4 AEs,0.414535
uuid-b5654a5e21794273be7f176428ed77ec,phase 1/2 study CA209-032,0.398283
uuid-b5654a5e21794273be7f176428ed77ec,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-633d27f6586d4069ac76369109882e68,provided in the Detailed Information,0.349491
uuid-633d27f6586d4069ac76369109882e68,Weber JS,0.322104
uuid-5a8d6ef47ded4f4fbfa3a08b9ed56ef0,fatigue,0.323475
uuid-a0d76a73878a4e58937558ca4c041e16,nivolumab,0.346162
uuid-a0d76a73878a4e58937558ca4c041e16,Bristol-Myers Squibb,0.449751
uuid-a0d76a73878a4e58937558ca4c041e16,evaluating,0.513404
uuid-a0d76a73878a4e58937558ca4c041e16,not conducted any controlled clinical trials/studies,0.570674
uuid-a0d76a73878a4e58937558ca4c041e16,Pubmed literature search,0.511789
uuid-a0d76a73878a4e58937558ca4c041e16,purposes other than its labeled indication must be considered investigational,0.584136
uuid-a0d76a73878a4e58937558ca4c041e16,not identify any citations relevant to your inquiry,0.481419
uuid-a0d76a73878a4e58937558ca4c041e16,adverse,0.380236
uuid-a0d76a73878a4e58937558ca4c041e16,using the following search terms,0.456209
uuid-a0d76a73878a4e58937558ca4c041e16,efficacy and safety of nivolumab,0.415204
uuid-12c6e6e7119940768badb693417f7df7,nivolumab,0.330431
uuid-12c6e6e7119940768badb693417f7df7,evaluating,0.325437
uuid-12c6e6e7119940768badb693417f7df7,not conducted any controlled clinical trials/studies,0.364217
uuid-12c6e6e7119940768badb693417f7df7,Pubmed literature search,0.49351
uuid-12c6e6e7119940768badb693417f7df7,purposes other than its labeled indication must be considered investigational,0.52728
uuid-12c6e6e7119940768badb693417f7df7,not identify any citations relevant to your inquiry,0.492897
uuid-12c6e6e7119940768badb693417f7df7,open-label,0.410079
uuid-12c6e6e7119940768badb693417f7df7,using the following search terms,0.465094
uuid-6f25af4c888540b4ba3679197265329f,ipilimumab,0.385692
uuid-6f25af4c888540b4ba3679197265329f,ASCO 2015,0.417944
uuid-6f25af4c888540b4ba3679197265329f,partial response,0.382425
uuid-6f25af4c888540b4ba3679197265329f,Stable disease,0.586335
uuid-6f25af4c888540b4ba3679197265329f,cohort,0.307748
uuid-d301b61274384fe19f21107ff83e629c,ASCO,0.810467
uuid-bec2f42bd5594c61b04386762d79c719,95% CI,0.419478
uuid-bec2f42bd5594c61b04386762d79c719,respectively,0.497608
uuid-bec2f42bd5594c61b04386762d79c719,Objective response rate,0.403649
uuid-bec2f42bd5594c61b04386762d79c719,ORR,0.578109
uuid-bec2f42bd5594c61b04386762d79c719,patients with advanced or metastatic,0.306625
uuid-bec2f42bd5594c61b04386762d79c719,Median overall survival,0.498783
uuid-bec2f42bd5594c61b04386762d79c719,nivolumab combined with ipilimumab,0.300486
uuid-bec2f42bd5594c61b04386762d79c719,tumors,0.323334
uuid-bec2f42bd5594c61b04386762d79c719,ESMO,0.534361
uuid-bec2f42bd5594c61b04386762d79c719,Median OS,0.394058
uuid-bec2f42bd5594c61b04386762d79c719,small cell lung cancer,0.380999
uuid-bec2f42bd5594c61b04386762d79c719,SCLC,0.365686
uuid-bec2f42bd5594c61b04386762d79c719,hazard ratio,0.419392
uuid-bec2f42bd5594c61b04386762d79c719,grade 3 to 4 AEs,0.414535
uuid-bec2f42bd5594c61b04386762d79c719,phase 1/2 study CA209-032,0.398283
uuid-bec2f42bd5594c61b04386762d79c719,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-60fa20fa44a44645a3e8a8e846792f97,ipilimumab,0.385692
uuid-60fa20fa44a44645a3e8a8e846792f97,ASCO 2015,0.417944
uuid-60fa20fa44a44645a3e8a8e846792f97,partial response,0.382425
uuid-60fa20fa44a44645a3e8a8e846792f97,Stable disease,0.586335
uuid-60fa20fa44a44645a3e8a8e846792f97,cohort,0.307748
uuid-f77f656478db45a68c8e32b707bbb35c,Bristol-Myers Squibb,0.341822
uuid-f77f656478db45a68c8e32b707bbb35c,not conducted any controlled clinical trials/studies,0.304507
uuid-f77f656478db45a68c8e32b707bbb35c,Opdivo,0.461382
uuid-f77f656478db45a68c8e32b707bbb35c,Pubmed literature search,0.614325
uuid-f77f656478db45a68c8e32b707bbb35c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f77f656478db45a68c8e32b707bbb35c,not identify any citations relevant to your inquiry,0.606087
uuid-f77f656478db45a68c8e32b707bbb35c,adverse,0.304183
uuid-f77f656478db45a68c8e32b707bbb35c,using the following search terms,0.642331
uuid-f77f656478db45a68c8e32b707bbb35c,databases,0.315039
uuid-f77f656478db45a68c8e32b707bbb35c,reported,0.556704
uuid-88c7b917a7544bf8901dbfcfcf5def9e,OS,0.62262
uuid-88c7b917a7544bf8901dbfcfcf5def9e,PFS,0.65903
uuid-88c7b917a7544bf8901dbfcfcf5def9e,Overall survival,0.644151
uuid-8a76b4a7b5374edf925f15b061cea9a5,nivolumab,0.970186
uuid-8a76b4a7b5374edf925f15b061cea9a5,Pubmed literature search,0.36892
uuid-8a76b4a7b5374edf925f15b061cea9a5,purposes other than its labeled indication must be considered investigational,0.433479
uuid-8a76b4a7b5374edf925f15b061cea9a5,not identify any citations relevant to your inquiry,0.347679
uuid-8a76b4a7b5374edf925f15b061cea9a5,using the following search terms,0.34114
uuid-68d1d528b4b8469c87ff48c995090dd6,N Engl J Med,0.448483
uuid-68d1d528b4b8469c87ff48c995090dd6,protocol,0.770446
uuid-68d1d528b4b8469c87ff48c995090dd6,McDermott DF,0.741196
uuid-68d1d528b4b8469c87ff48c995090dd6,Motzer RJ,0.818144
uuid-68d1d528b4b8469c87ff48c995090dd6,phase 3 study,0.417055
uuid-68d1d528b4b8469c87ff48c995090dd6,Escudier B,0.749917
uuid-68d1d528b4b8469c87ff48c995090dd6,NEJM,0.400698
uuid-68d1d528b4b8469c87ff48c995090dd6,et al.,0.668641
uuid-68d1d528b4b8469c87ff48c995090dd6,J Clin Oncol,0.792018
uuid-68d1d528b4b8469c87ff48c995090dd6,Topalian,0.388894
uuid-68d1d528b4b8469c87ff48c995090dd6,phase 1 study,0.500686
uuid-68d1d528b4b8469c87ff48c995090dd6,CA209-003,0.567381
uuid-68d1d528b4b8469c87ff48c995090dd6,phase 2 study,0.677985
uuid-68d1d528b4b8469c87ff48c995090dd6,present using the following search terms,0.310558
uuid-68d1d528b4b8469c87ff48c995090dd6,investigating,0.615835
uuid-33d183d7295842309e6811727d31eb78,RCC,0.981079
uuid-46438b3e6e714182b46145b201f78d5e,Bristol-Myers Squibb,0.692321
uuid-46438b3e6e714182b46145b201f78d5e,evaluating,0.742434
uuid-46438b3e6e714182b46145b201f78d5e,not conducted any controlled clinical trials/studies,0.74597
uuid-46438b3e6e714182b46145b201f78d5e,patients,0.471714
uuid-46438b3e6e714182b46145b201f78d5e,considered investigational,0.318269
uuid-46438b3e6e714182b46145b201f78d5e,adverse,0.373627
uuid-46438b3e6e714182b46145b201f78d5e,search of published literature,0.36734
uuid-46438b3e6e714182b46145b201f78d5e,ipilimumab,0.318051
uuid-46438b3e6e714182b46145b201f78d5e,PubMed and EMBASE,0.327607
uuid-46438b3e6e714182b46145b201f78d5e,efficacy and safety of nivolumab,0.705583
uuid-46438b3e6e714182b46145b201f78d5e,present using the following search terms,0.325119
uuid-46438b3e6e714182b46145b201f78d5e,safety of nivolumab monotherapy,0.306232
uuid-521abd73caa34cf08b793bbcc76c56c6,N Engl J Med,0.422636
uuid-521abd73caa34cf08b793bbcc76c56c6,protocol,0.748554
uuid-521abd73caa34cf08b793bbcc76c56c6,McDermott DF,0.714859
uuid-521abd73caa34cf08b793bbcc76c56c6,search of published literature,0.321945
uuid-521abd73caa34cf08b793bbcc76c56c6,Motzer RJ,0.793788
uuid-521abd73caa34cf08b793bbcc76c56c6,phase 3 study,0.417156
uuid-521abd73caa34cf08b793bbcc76c56c6,PubMed and EMBASE,0.317317
uuid-521abd73caa34cf08b793bbcc76c56c6,Escudier B,0.724387
uuid-521abd73caa34cf08b793bbcc76c56c6,NEJM,0.381834
uuid-521abd73caa34cf08b793bbcc76c56c6,et al.,0.641141
uuid-521abd73caa34cf08b793bbcc76c56c6,J Clin Oncol,0.764795
uuid-521abd73caa34cf08b793bbcc76c56c6,Topalian,0.374132
uuid-521abd73caa34cf08b793bbcc76c56c6,phase 1 study,0.508313
uuid-521abd73caa34cf08b793bbcc76c56c6,efficacy and safety of nivolumab,0.350129
uuid-521abd73caa34cf08b793bbcc76c56c6,CA209-003,0.566084
uuid-521abd73caa34cf08b793bbcc76c56c6,phase 2 study,0.656373
uuid-521abd73caa34cf08b793bbcc76c56c6,present using the following search terms,0.3326
uuid-521abd73caa34cf08b793bbcc76c56c6,investigating,0.617357
uuid-7c13c8d04b254ad480685e010532cd58,Bristol-Myers Squibb,0.364104
uuid-7c13c8d04b254ad480685e010532cd58,not conducted any controlled clinical trials/studies,0.301364
uuid-7c13c8d04b254ad480685e010532cd58,Opdivo,0.468773
uuid-7c13c8d04b254ad480685e010532cd58,Pubmed literature search,0.577451
uuid-7c13c8d04b254ad480685e010532cd58,purposes other than its labeled indication must be considered investigational,0.549864
uuid-7c13c8d04b254ad480685e010532cd58,not identify any citations relevant to your inquiry,0.57029
uuid-7c13c8d04b254ad480685e010532cd58,adverse,0.373725
uuid-7c13c8d04b254ad480685e010532cd58,using the following search terms,0.607532
uuid-7c13c8d04b254ad480685e010532cd58,reported,0.618037
uuid-a603135912d14d32a31c1e7f82276207,Opdivo,0.50165
uuid-a603135912d14d32a31c1e7f82276207,open-label,0.304253
uuid-a603135912d14d32a31c1e7f82276207,trial,0.521827
uuid-a603135912d14d32a31c1e7f82276207,docetaxel,0.30238
uuid-a603135912d14d32a31c1e7f82276207,safety of nivolumab monotherapy,0.432481
uuid-a603135912d14d32a31c1e7f82276207,phase,0.378496
uuid-282fc6addc874d7aa0b171510ce3a94a,95% CI,0.38846
uuid-282fc6addc874d7aa0b171510ce3a94a,respectively,0.46226
uuid-282fc6addc874d7aa0b171510ce3a94a,considered investigational,0.352275
uuid-282fc6addc874d7aa0b171510ce3a94a,Objective response rate,0.384337
uuid-282fc6addc874d7aa0b171510ce3a94a,ORR,0.553614
uuid-282fc6addc874d7aa0b171510ce3a94a,patients with advanced or metastatic,0.317036
uuid-282fc6addc874d7aa0b171510ce3a94a,Median overall survival,0.470774
uuid-282fc6addc874d7aa0b171510ce3a94a,nivolumab combined with ipilimumab,0.30748
uuid-282fc6addc874d7aa0b171510ce3a94a,tumors,0.3494
uuid-282fc6addc874d7aa0b171510ce3a94a,ESMO,0.525552
uuid-282fc6addc874d7aa0b171510ce3a94a,Median OS,0.363258
uuid-282fc6addc874d7aa0b171510ce3a94a,small cell lung cancer,0.427558
uuid-282fc6addc874d7aa0b171510ce3a94a,SCLC,0.409434
uuid-282fc6addc874d7aa0b171510ce3a94a,hazard ratio,0.394536
uuid-282fc6addc874d7aa0b171510ce3a94a,grade 3 to 4 AEs,0.434635
uuid-282fc6addc874d7aa0b171510ce3a94a,phase 1/2 study CA209-032,0.432313
uuid-282fc6addc874d7aa0b171510ce3a94a,evaluates the efficacy of nivolumab monotherapy,0.418511
uuid-e3887252c44841919e168aa5c5cedf00,Bristol-Myers Squibb,0.406833
uuid-e3887252c44841919e168aa5c5cedf00,requested,0.807064
uuid-f15d9e0aaca04218a855971f6e577f2a,Opdivo,0.50165
uuid-f15d9e0aaca04218a855971f6e577f2a,open-label,0.304253
uuid-f15d9e0aaca04218a855971f6e577f2a,trial,0.521827
uuid-f15d9e0aaca04218a855971f6e577f2a,docetaxel,0.30238
uuid-f15d9e0aaca04218a855971f6e577f2a,safety of nivolumab monotherapy,0.432481
uuid-f15d9e0aaca04218a855971f6e577f2a,phase,0.378496
uuid-25653e82b974433282bedd6ba1a18adb,N Engl J Med,0.420899
uuid-25653e82b974433282bedd6ba1a18adb,requested,0.697007
uuid-25653e82b974433282bedd6ba1a18adb,et al.,0.317012
uuid-25653e82b974433282bedd6ba1a18adb,Brahmer J,0.361892
uuid-25653e82b974433282bedd6ba1a18adb,Horn L,0.443002
uuid-25653e82b974433282bedd6ba1a18adb,platinum-based doublet chemotherapy,0.311951
uuid-361c4961192c464782a7838cbdca66d0,Bristol-Myers Squibb,0.341822
uuid-361c4961192c464782a7838cbdca66d0,not conducted any controlled clinical trials/studies,0.304507
uuid-361c4961192c464782a7838cbdca66d0,Opdivo,0.461382
uuid-361c4961192c464782a7838cbdca66d0,Pubmed literature search,0.614325
uuid-361c4961192c464782a7838cbdca66d0,purposes other than its labeled indication must be considered investigational,0.586645
uuid-361c4961192c464782a7838cbdca66d0,not identify any citations relevant to your inquiry,0.606087
uuid-361c4961192c464782a7838cbdca66d0,adverse,0.304183
uuid-361c4961192c464782a7838cbdca66d0,using the following search terms,0.642331
uuid-361c4961192c464782a7838cbdca66d0,databases,0.315039
uuid-361c4961192c464782a7838cbdca66d0,reported,0.556704
uuid-9feaf5e3a58449a9a833684702902b1c,nivolumab,0.558115
uuid-9feaf5e3a58449a9a833684702902b1c,Bristol-Myers Squibb,0.431652
uuid-9feaf5e3a58449a9a833684702902b1c,evaluating,0.577531
uuid-9feaf5e3a58449a9a833684702902b1c,not conducted any controlled clinical trials/studies,0.629086
uuid-9feaf5e3a58449a9a833684702902b1c,Pubmed literature search,0.771092
uuid-9feaf5e3a58449a9a833684702902b1c,purposes other than its labeled indication must be considered investigational,0.841072
uuid-9feaf5e3a58449a9a833684702902b1c,not identify any citations relevant to your inquiry,0.73376
uuid-9feaf5e3a58449a9a833684702902b1c,using the following search terms,0.717325
uuid-9feaf5e3a58449a9a833684702902b1c,efficacy and safety of nivolumab,0.439922
uuid-67d8c1ebcd0a4a9ca030f46efa8b50a8,adverse,0.896802
uuid-67d8c1ebcd0a4a9ca030f46efa8b50a8,reported,0.534438
uuid-ffda2b1c9a4642f1bb6311da65fe31a1,Opdivo,0.668716
uuid-ffda2b1c9a4642f1bb6311da65fe31a1,clinical,0.679757
uuid-ffda2b1c9a4642f1bb6311da65fe31a1,trial,0.764196
uuid-054e28453aad48feb721c49d6f6c298f,grade,0.322776
uuid-726d55b169c743d2800b69d0fc5347bf,OS,0.62262
uuid-726d55b169c743d2800b69d0fc5347bf,PFS,0.65903
uuid-726d55b169c743d2800b69d0fc5347bf,Overall survival,0.644151
uuid-796fba470e5149afb59c44c82e039672,adverse,0.878104
uuid-796fba470e5149afb59c44c82e039672,reported,0.456488
uuid-8d494574358346418639fef0e82b40c9,N Engl J Med,0.304989
uuid-8d494574358346418639fef0e82b40c9,AEs,0.337832
uuid-8d494574358346418639fef0e82b40c9,patients,0.387033
uuid-8d494574358346418639fef0e82b40c9,provided in the Detailed Information,0.370845
uuid-8d494574358346418639fef0e82b40c9,ESMO,0.421367
uuid-8d494574358346418639fef0e82b40c9,NEJM,0.709799
uuid-8d494574358346418639fef0e82b40c9,Topalian,0.735417
uuid-8d494574358346418639fef0e82b40c9,grade 3 to 4 AEs,0.538198
uuid-07731a2e18e64f1784cf30f7e09323ba,Objective response rate,0.451139
uuid-07731a2e18e64f1784cf30f7e09323ba,clinicaltrials.gov,0.503706
uuid-9cf09356053048b89168275dd347dcb4,OS,0.325492
uuid-9cf09356053048b89168275dd347dcb4,95% CI,0.65992
uuid-9cf09356053048b89168275dd347dcb4,respectively,0.733721
uuid-9cf09356053048b89168275dd347dcb4,Objective response rate,0.646233
uuid-9cf09356053048b89168275dd347dcb4,ORR,0.746588
uuid-9cf09356053048b89168275dd347dcb4,Median overall survival,0.637504
uuid-9cf09356053048b89168275dd347dcb4,monotherapy,0.619352
uuid-9cf09356053048b89168275dd347dcb4,Median OS,0.608244
uuid-9cf09356053048b89168275dd347dcb4,mg,0.353517
uuid-9cf09356053048b89168275dd347dcb4,docetaxel,0.332503
uuid-9cf09356053048b89168275dd347dcb4,kg,0.319776
uuid-9cf09356053048b89168275dd347dcb4,hazard ratio,0.634547
uuid-3b5fb76a2ed64de3ae2be3020853b82b,nivolumab,0.560223
uuid-3b5fb76a2ed64de3ae2be3020853b82b,Bristol-Myers Squibb,0.467587
uuid-3b5fb76a2ed64de3ae2be3020853b82b,evaluating,0.641472
uuid-3b5fb76a2ed64de3ae2be3020853b82b,not conducted any controlled clinical trials/studies,0.688544
uuid-3b5fb76a2ed64de3ae2be3020853b82b,Pubmed literature search,0.820102
uuid-3b5fb76a2ed64de3ae2be3020853b82b,purposes other than its labeled indication must be considered investigational,0.894735
uuid-3b5fb76a2ed64de3ae2be3020853b82b,not identify any citations relevant to your inquiry,0.776012
uuid-3b5fb76a2ed64de3ae2be3020853b82b,using the following search terms,0.761485
uuid-3b5fb76a2ed64de3ae2be3020853b82b,efficacy and safety of nivolumab,0.472312
uuid-7a66fd872cf34879bacd5533ca415f1e,use of nivolumab for the treatment,0.305739
uuid-7a66fd872cf34879bacd5533ca415f1e,patients with advanced or metastatic,0.509457
uuid-7a66fd872cf34879bacd5533ca415f1e,nivolumab combined with ipilimumab,0.496885
uuid-7a66fd872cf34879bacd5533ca415f1e,not approved,0.397631
uuid-7a66fd872cf34879bacd5533ca415f1e,clinical trials investigating the safety,0.478965
uuid-7a66fd872cf34879bacd5533ca415f1e,bladder cancer,0.940126
uuid-cb7848b2255a4213906e869ade0f4ad4,fatigue,0.411608
uuid-7a09cecf622f4466b64a7556ef2b2f6e,respectively,0.483806
uuid-7a09cecf622f4466b64a7556ef2b2f6e,Objective response rate,0.573619
uuid-7a09cecf622f4466b64a7556ef2b2f6e,ORR,0.430378
uuid-7a09cecf622f4466b64a7556ef2b2f6e,monotherapy,0.327181
uuid-7a09cecf622f4466b64a7556ef2b2f6e,clinicaltrials.gov,0.391121
uuid-7a09cecf622f4466b64a7556ef2b2f6e,docetaxel,0.312578
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,use of nivolumab for the treatment,0.409821
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,patients with advanced or metastatic,0.645244
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,nivolumab combined with ipilimumab,0.676339
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,not approved,0.453534
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,clinical trials investigating the safety,0.548799
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,phase 1/2 study CA209-032,0.34114
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,bladder cancer,0.749142
uuid-3f790fcda62e4d56bdc3b4fc6ff1aeaf,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-e3270482fc3442ed99349bcea7922ba5,95% CI,0.419478
uuid-e3270482fc3442ed99349bcea7922ba5,respectively,0.497608
uuid-e3270482fc3442ed99349bcea7922ba5,Objective response rate,0.403649
uuid-e3270482fc3442ed99349bcea7922ba5,ORR,0.578109
uuid-e3270482fc3442ed99349bcea7922ba5,patients with advanced or metastatic,0.306625
uuid-e3270482fc3442ed99349bcea7922ba5,Median overall survival,0.498783
uuid-e3270482fc3442ed99349bcea7922ba5,nivolumab combined with ipilimumab,0.300486
uuid-e3270482fc3442ed99349bcea7922ba5,tumors,0.323334
uuid-e3270482fc3442ed99349bcea7922ba5,ESMO,0.534361
uuid-e3270482fc3442ed99349bcea7922ba5,Median OS,0.394058
uuid-e3270482fc3442ed99349bcea7922ba5,small cell lung cancer,0.380999
uuid-e3270482fc3442ed99349bcea7922ba5,SCLC,0.365686
uuid-e3270482fc3442ed99349bcea7922ba5,hazard ratio,0.419392
uuid-e3270482fc3442ed99349bcea7922ba5,grade 3 to 4 AEs,0.414535
uuid-e3270482fc3442ed99349bcea7922ba5,phase 1/2 study CA209-032,0.398283
uuid-e3270482fc3442ed99349bcea7922ba5,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-d04318c590724f7d870b4fd63ef65d47,nivolumab,0.999168
uuid-d04318c590724f7d870b4fd63ef65d47,Pubmed literature search,0.395314
uuid-d04318c590724f7d870b4fd63ef65d47,purposes other than its labeled indication must be considered investigational,0.464236
uuid-d04318c590724f7d870b4fd63ef65d47,not identify any citations relevant to your inquiry,0.368569
uuid-d04318c590724f7d870b4fd63ef65d47,using the following search terms,0.364279
uuid-d04318c590724f7d870b4fd63ef65d47,present using the following search terms,0.329876
uuid-ba4848cc365941509458b479d3d5a858,95% CI,0.419478
uuid-ba4848cc365941509458b479d3d5a858,respectively,0.497608
uuid-ba4848cc365941509458b479d3d5a858,Objective response rate,0.403649
uuid-ba4848cc365941509458b479d3d5a858,ORR,0.578109
uuid-ba4848cc365941509458b479d3d5a858,patients with advanced or metastatic,0.306625
uuid-ba4848cc365941509458b479d3d5a858,Median overall survival,0.498783
uuid-ba4848cc365941509458b479d3d5a858,nivolumab combined with ipilimumab,0.300486
uuid-ba4848cc365941509458b479d3d5a858,tumors,0.323334
uuid-ba4848cc365941509458b479d3d5a858,ESMO,0.534361
uuid-ba4848cc365941509458b479d3d5a858,Median OS,0.394058
uuid-ba4848cc365941509458b479d3d5a858,small cell lung cancer,0.380999
uuid-ba4848cc365941509458b479d3d5a858,SCLC,0.365686
uuid-ba4848cc365941509458b479d3d5a858,hazard ratio,0.419392
uuid-ba4848cc365941509458b479d3d5a858,grade 3 to 4 AEs,0.414535
uuid-ba4848cc365941509458b479d3d5a858,phase 1/2 study CA209-032,0.398283
uuid-ba4848cc365941509458b479d3d5a858,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-38bcce41d6a0427fba2b179c74ab454c,Opdivo,0.50165
uuid-38bcce41d6a0427fba2b179c74ab454c,open-label,0.304253
uuid-38bcce41d6a0427fba2b179c74ab454c,trial,0.521827
uuid-38bcce41d6a0427fba2b179c74ab454c,docetaxel,0.30238
uuid-38bcce41d6a0427fba2b179c74ab454c,safety of nivolumab monotherapy,0.432481
uuid-38bcce41d6a0427fba2b179c74ab454c,phase,0.378496
uuid-1940c0e835aa4a589fc7b297e39c91a0,use of nivolumab for the treatment,0.407594
uuid-1940c0e835aa4a589fc7b297e39c91a0,patients with advanced or metastatic,0.644977
uuid-1940c0e835aa4a589fc7b297e39c91a0,nivolumab combined with ipilimumab,0.666385
uuid-1940c0e835aa4a589fc7b297e39c91a0,tumors,0.315644
uuid-1940c0e835aa4a589fc7b297e39c91a0,not approved,0.439945
uuid-1940c0e835aa4a589fc7b297e39c91a0,clinical trials investigating the safety,0.528418
uuid-1940c0e835aa4a589fc7b297e39c91a0,phase 1/2 study CA209-032,0.354255
uuid-1940c0e835aa4a589fc7b297e39c91a0,bladder cancer,0.753191
uuid-1940c0e835aa4a589fc7b297e39c91a0,evaluates the efficacy of nivolumab monotherapy,0.393726
uuid-bd66fdee80d3441b921df41b9447679c,use of nivolumab for the treatment,0.305739
uuid-bd66fdee80d3441b921df41b9447679c,patients with advanced or metastatic,0.509457
uuid-bd66fdee80d3441b921df41b9447679c,nivolumab combined with ipilimumab,0.496885
uuid-bd66fdee80d3441b921df41b9447679c,not approved,0.397631
uuid-bd66fdee80d3441b921df41b9447679c,clinical trials investigating the safety,0.478965
uuid-bd66fdee80d3441b921df41b9447679c,bladder cancer,0.940126
uuid-54c0d22746d0423e8d484307ef70b2e3,nivolumab,0.418131
uuid-54c0d22746d0423e8d484307ef70b2e3,Bristol-Myers Squibb,0.313729
uuid-54c0d22746d0423e8d484307ef70b2e3,evaluating,0.459198
uuid-54c0d22746d0423e8d484307ef70b2e3,not conducted any controlled clinical trials/studies,0.47542
uuid-54c0d22746d0423e8d484307ef70b2e3,Pubmed literature search,0.630161
uuid-54c0d22746d0423e8d484307ef70b2e3,purposes other than its labeled indication must be considered investigational,0.67367
uuid-54c0d22746d0423e8d484307ef70b2e3,not identify any citations relevant to your inquiry,0.621821
uuid-54c0d22746d0423e8d484307ef70b2e3,using the following search terms,0.596905
uuid-54c0d22746d0423e8d484307ef70b2e3,efficacy and safety of nivolumab,0.333759
uuid-d0d084d65dbf4f54a76f7ea9310d19f4,fatigue,0.323475
uuid-c857a1e87f4648f48bb94bc42253ec8e,Opdivo,0.50165
uuid-c857a1e87f4648f48bb94bc42253ec8e,open-label,0.304253
uuid-c857a1e87f4648f48bb94bc42253ec8e,trial,0.521827
uuid-c857a1e87f4648f48bb94bc42253ec8e,docetaxel,0.30238
uuid-c857a1e87f4648f48bb94bc42253ec8e,safety of nivolumab monotherapy,0.432481
uuid-c857a1e87f4648f48bb94bc42253ec8e,phase,0.378496
uuid-5adf32722a2f464c9cfc2a0593fa08db,trial,0.306565
uuid-f91517a8a0e24f7db92cfeb80605c957,nivolumab,0.458307
uuid-f91517a8a0e24f7db92cfeb80605c957,Bristol-Myers Squibb,0.550882
uuid-f91517a8a0e24f7db92cfeb80605c957,evaluating,0.70097
uuid-f91517a8a0e24f7db92cfeb80605c957,not conducted any controlled clinical trials/studies,0.719262
uuid-f91517a8a0e24f7db92cfeb80605c957,Pubmed literature search,0.567238
uuid-f91517a8a0e24f7db92cfeb80605c957,purposes other than its labeled indication must be considered investigational,0.658087
uuid-f91517a8a0e24f7db92cfeb80605c957,not identify any citations relevant to your inquiry,0.533059
uuid-f91517a8a0e24f7db92cfeb80605c957,using the following search terms,0.506739
uuid-f91517a8a0e24f7db92cfeb80605c957,efficacy and safety of nivolumab,0.57863
uuid-c957eb4c6a0b4cc1860a1e5c7fc89618,respectively,0.661351
uuid-c957eb4c6a0b4cc1860a1e5c7fc89618,Objective response rate,0.619462
uuid-c957eb4c6a0b4cc1860a1e5c7fc89618,ORR,0.537232
uuid-c957eb4c6a0b4cc1860a1e5c7fc89618,monotherapy,0.421967
uuid-c957eb4c6a0b4cc1860a1e5c7fc89618,docetaxel,0.426453
uuid-487836d1152e400084f8078d555fff31,N Engl J Med,0.307908
uuid-487836d1152e400084f8078d555fff31,NSCLC,0.389868
uuid-487836d1152e400084f8078d555fff31,Lancet Oncol,0.360456
uuid-487836d1152e400084f8078d555fff31,non-small cell lung cancer,0.387715
uuid-487836d1152e400084f8078d555fff31,patients,0.336186
uuid-487836d1152e400084f8078d555fff31,phase 3 study,0.507178
uuid-487836d1152e400084f8078d555fff31,phase 1 study,0.327973
uuid-487836d1152e400084f8078d555fff31,Rizvi NA,0.512501
uuid-487836d1152e400084f8078d555fff31,Weber JS,0.476719
uuid-487836d1152e400084f8078d555fff31,phase 2 study,0.373782
uuid-487836d1152e400084f8078d555fff31,therapy,0.315477
uuid-9d7088c488b14efa855405e6cdff8a3b,Bristol-Myers Squibb,0.386303
uuid-9d7088c488b14efa855405e6cdff8a3b,protocol,0.505624
uuid-9d7088c488b14efa855405e6cdff8a3b,McDermott DF,0.463854
uuid-9d7088c488b14efa855405e6cdff8a3b,Motzer RJ,0.5728
uuid-9d7088c488b14efa855405e6cdff8a3b,phase 3 study,0.403834
uuid-9d7088c488b14efa855405e6cdff8a3b,Escudier B,0.480925
uuid-9d7088c488b14efa855405e6cdff8a3b,et al.,0.389201
uuid-9d7088c488b14efa855405e6cdff8a3b,J Clin Oncol,0.511105
uuid-9d7088c488b14efa855405e6cdff8a3b,phase 1 study,0.427751
uuid-9d7088c488b14efa855405e6cdff8a3b,CA209-003,0.508667
uuid-9d7088c488b14efa855405e6cdff8a3b,phase 2 study,0.435177
uuid-9d7088c488b14efa855405e6cdff8a3b,investigating,0.64858
uuid-6b7c3803531e4017b12f0c1d0364b411,efficacy,0.32951
uuid-6b7c3803531e4017b12f0c1d0364b411,Opdivo,0.392049
uuid-6b7c3803531e4017b12f0c1d0364b411,not approved,0.31157
uuid-6b7c3803531e4017b12f0c1d0364b411,open-label,0.333379
uuid-6b7c3803531e4017b12f0c1d0364b411,trial,0.457974
uuid-6b7c3803531e4017b12f0c1d0364b411,docetaxel,0.419301
uuid-6b7c3803531e4017b12f0c1d0364b411,safety of nivolumab monotherapy,0.430098
uuid-6b7c3803531e4017b12f0c1d0364b411,phase,0.484755
uuid-5e8eeb6f57664a32b1c53917d127efb2,nivolumab,0.392227
uuid-6414e89fa0854423b5a69d3e9bdc5f73,nivolumab,0.325294
uuid-6414e89fa0854423b5a69d3e9bdc5f73,Bristol-Myers Squibb,0.763834
uuid-6414e89fa0854423b5a69d3e9bdc5f73,use of nivolumab for the treatment,0.337109
uuid-6414e89fa0854423b5a69d3e9bdc5f73,evaluating,0.875974
uuid-6414e89fa0854423b5a69d3e9bdc5f73,not conducted any controlled clinical trials/studies,0.883056
uuid-6414e89fa0854423b5a69d3e9bdc5f73,efficacy,0.314486
uuid-6414e89fa0854423b5a69d3e9bdc5f73,NSCLC,0.484028
uuid-6414e89fa0854423b5a69d3e9bdc5f73,non-small cell lung cancer,0.503747
uuid-6414e89fa0854423b5a69d3e9bdc5f73,patients,0.374757
uuid-6414e89fa0854423b5a69d3e9bdc5f73,considered investigational,0.429499
uuid-6414e89fa0854423b5a69d3e9bdc5f73,purposes other than its labeled indication must be considered investigational,0.31467
uuid-6414e89fa0854423b5a69d3e9bdc5f73,search of published literature,0.302475
uuid-6414e89fa0854423b5a69d3e9bdc5f73,efficacy and safety of nivolumab,0.771049
uuid-6414e89fa0854423b5a69d3e9bdc5f73,safety of nivolumab monotherapy,0.493944
uuid-dea62264543640bb8d46cafa57264303,mg,0.40574
uuid-dea62264543640bb8d46cafa57264303,kg,0.321401
uuid-9bfd38e065214456a124b878f3a3adb1,nivolumab,0.42969
uuid-beeda6ca4edc4fc2bed6ec8b162ed9c0,trial,0.33931
uuid-39d9730bf2c145a49dedb9efee35dffe,N Engl J Med,0.302601
uuid-39d9730bf2c145a49dedb9efee35dffe,AEs,0.348167
uuid-39d9730bf2c145a49dedb9efee35dffe,patients,0.536884
uuid-39d9730bf2c145a49dedb9efee35dffe,provided in the Detailed Information,0.387544
uuid-39d9730bf2c145a49dedb9efee35dffe,ESMO,0.462801
uuid-39d9730bf2c145a49dedb9efee35dffe,NEJM,0.66427
uuid-39d9730bf2c145a49dedb9efee35dffe,Topalian,0.692873
uuid-39d9730bf2c145a49dedb9efee35dffe,grade 3 to 4 AEs,0.626596
uuid-6b9ee69a83834f719fefa79086a41c65,evaluating,0.366546
uuid-6b9ee69a83834f719fefa79086a41c65,not conducted any controlled clinical trials/studies,0.360172
uuid-6b9ee69a83834f719fefa79086a41c65,search of published literature,0.403755
uuid-6b9ee69a83834f719fefa79086a41c65,Additionally,0.418906
uuid-6b9ee69a83834f719fefa79086a41c65,ongoing,0.467576
uuid-6b9ee69a83834f719fefa79086a41c65,PubMed and EMBASE,0.39617
uuid-6b9ee69a83834f719fefa79086a41c65,detailed search of www.clinicaltrials.gov,0.437393
uuid-6b9ee69a83834f719fefa79086a41c65,efficacy and safety of nivolumab,0.42836
uuid-6b9ee69a83834f719fefa79086a41c65,not identify any planned,0.454065
uuid-6b9ee69a83834f719fefa79086a41c65,combination,0.397925
uuid-6b9ee69a83834f719fefa79086a41c65,BMS,0.30879
uuid-6b9ee69a83834f719fefa79086a41c65,not identify any citations relevant to your request,0.449603
uuid-6b9ee69a83834f719fefa79086a41c65,present using the following search terms,0.394376
uuid-e2f7f4289efa4f708c7d0c2025b11e7a,melanoma,0.387987
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,Opdivo,0.50165
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,open-label,0.304253
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,trial,0.521827
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,docetaxel,0.30238
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,safety of nivolumab monotherapy,0.432481
uuid-d714fdbdc06f4fd0be64a0ca7d8a942f,phase,0.378496
uuid-5ff4440503734572beb8a23cfff9e0ef,use of nivolumab for the treatment,0.409821
uuid-5ff4440503734572beb8a23cfff9e0ef,patients with advanced or metastatic,0.645244
uuid-5ff4440503734572beb8a23cfff9e0ef,nivolumab combined with ipilimumab,0.676339
uuid-5ff4440503734572beb8a23cfff9e0ef,not approved,0.453534
uuid-5ff4440503734572beb8a23cfff9e0ef,clinical trials investigating the safety,0.548799
uuid-5ff4440503734572beb8a23cfff9e0ef,phase 1/2 study CA209-032,0.34114
uuid-5ff4440503734572beb8a23cfff9e0ef,bladder cancer,0.749142
uuid-5ff4440503734572beb8a23cfff9e0ef,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-28c07d9087e947a08513523ea6027b36,use of nivolumab for the treatment,0.305739
uuid-28c07d9087e947a08513523ea6027b36,patients with advanced or metastatic,0.509457
uuid-28c07d9087e947a08513523ea6027b36,nivolumab combined with ipilimumab,0.496885
uuid-28c07d9087e947a08513523ea6027b36,not approved,0.397631
uuid-28c07d9087e947a08513523ea6027b36,clinical trials investigating the safety,0.478965
uuid-28c07d9087e947a08513523ea6027b36,bladder cancer,0.940126
uuid-cbd85588e4f04d0e93b1631869d0efdc,95% CI,0.419478
uuid-cbd85588e4f04d0e93b1631869d0efdc,respectively,0.497608
uuid-cbd85588e4f04d0e93b1631869d0efdc,Objective response rate,0.403649
uuid-cbd85588e4f04d0e93b1631869d0efdc,ORR,0.578109
uuid-cbd85588e4f04d0e93b1631869d0efdc,patients with advanced or metastatic,0.306625
uuid-cbd85588e4f04d0e93b1631869d0efdc,Median overall survival,0.498783
uuid-cbd85588e4f04d0e93b1631869d0efdc,nivolumab combined with ipilimumab,0.300486
uuid-cbd85588e4f04d0e93b1631869d0efdc,tumors,0.323334
uuid-cbd85588e4f04d0e93b1631869d0efdc,ESMO,0.534361
uuid-cbd85588e4f04d0e93b1631869d0efdc,Median OS,0.394058
uuid-cbd85588e4f04d0e93b1631869d0efdc,small cell lung cancer,0.380999
uuid-cbd85588e4f04d0e93b1631869d0efdc,SCLC,0.365686
uuid-cbd85588e4f04d0e93b1631869d0efdc,hazard ratio,0.419392
uuid-cbd85588e4f04d0e93b1631869d0efdc,grade 3 to 4 AEs,0.414535
uuid-cbd85588e4f04d0e93b1631869d0efdc,phase 1/2 study CA209-032,0.398283
uuid-cbd85588e4f04d0e93b1631869d0efdc,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-30cadb2d766741fea29026fbc0672ea8,N Engl J Med,0.304989
uuid-30cadb2d766741fea29026fbc0672ea8,AEs,0.337832
uuid-30cadb2d766741fea29026fbc0672ea8,patients,0.387033
uuid-30cadb2d766741fea29026fbc0672ea8,provided in the Detailed Information,0.370845
uuid-30cadb2d766741fea29026fbc0672ea8,ESMO,0.421367
uuid-30cadb2d766741fea29026fbc0672ea8,NEJM,0.709799
uuid-30cadb2d766741fea29026fbc0672ea8,Topalian,0.735417
uuid-30cadb2d766741fea29026fbc0672ea8,grade 3 to 4 AEs,0.538198
uuid-4a70c19b2809446bb4351c4f222382dd,Bristol-Myers Squibb,0.553156
uuid-4a70c19b2809446bb4351c4f222382dd,evaluating,0.47983
uuid-4a70c19b2809446bb4351c4f222382dd,not conducted any controlled clinical trials/studies,0.52349
uuid-4a70c19b2809446bb4351c4f222382dd,NSCLC,0.442085
uuid-4a70c19b2809446bb4351c4f222382dd,non-small cell lung cancer,0.455828
uuid-4a70c19b2809446bb4351c4f222382dd,efficacy and safety of nivolumab,0.395464
uuid-6daeb7be690843ce8f85d7c0bc578f75,nivolumab,0.38638
uuid-6daeb7be690843ce8f85d7c0bc578f75,open-label,0.399109
uuid-6daeb7be690843ce8f85d7c0bc578f75,phase,0.50136
uuid-7d86e721ae244e60993d0e9dd7d1dfba,nivolumab,0.390668
uuid-7d86e721ae244e60993d0e9dd7d1dfba,Bristol-Myers Squibb,0.475067
uuid-7d86e721ae244e60993d0e9dd7d1dfba,evaluating,0.546892
uuid-7d86e721ae244e60993d0e9dd7d1dfba,not conducted any controlled clinical trials/studies,0.543583
uuid-7d86e721ae244e60993d0e9dd7d1dfba,search of published literature,0.367523
uuid-7d86e721ae244e60993d0e9dd7d1dfba,PubMed and EMBASE,0.34714
uuid-7d86e721ae244e60993d0e9dd7d1dfba,not approved,0.3355
uuid-7d86e721ae244e60993d0e9dd7d1dfba,clinical trials investigating the safety,0.399465
uuid-7d86e721ae244e60993d0e9dd7d1dfba,efficacy and safety of nivolumab,0.513988
uuid-7d86e721ae244e60993d0e9dd7d1dfba,present using the following search terms,0.363263
uuid-4dc49f62a0c54186ba76f839f326c0e2,OS,0.62262
uuid-4dc49f62a0c54186ba76f839f326c0e2,PFS,0.65903
uuid-4dc49f62a0c54186ba76f839f326c0e2,Overall survival,0.644151
uuid-b2ccd80f503a430dba3c6ed0c1ec9ec8,respectively,0.661351
uuid-b2ccd80f503a430dba3c6ed0c1ec9ec8,Objective response rate,0.619462
uuid-b2ccd80f503a430dba3c6ed0c1ec9ec8,ORR,0.537232
uuid-b2ccd80f503a430dba3c6ed0c1ec9ec8,monotherapy,0.421967
uuid-b2ccd80f503a430dba3c6ed0c1ec9ec8,docetaxel,0.426453
uuid-bfc9e3f4befd46a685a82c5187821c19,trial,0.342742
uuid-d824d213671d47209d62c2571e67e648,N Engl J Med,0.672096
uuid-d824d213671d47209d62c2571e67e648,ESMO,0.436384
uuid-d824d213671d47209d62c2571e67e648,Rizvi NA,0.472296
uuid-d824d213671d47209d62c2571e67e648,Brahmer J,0.720441
uuid-d824d213671d47209d62c2571e67e648,Horn L,0.608589
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,Bristol-Myers Squibb,0.667947
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,evaluating,0.731176
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,not conducted any controlled clinical trials/studies,0.768278
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,search of published literature,0.338268
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,efficacy and safety of nivolumab,0.683512
uuid-7295586eddca4b4a9d7bf3a9bd5e32e5,safety of nivolumab monotherapy,0.301739
uuid-b07f6d37f4f743c6882c232a992a7933,nivolumab,0.690441
uuid-b07f6d37f4f743c6882c232a992a7933,Bristol-Myers Squibb,0.337248
uuid-b07f6d37f4f743c6882c232a992a7933,evaluating,0.51312
uuid-b07f6d37f4f743c6882c232a992a7933,not conducted any controlled clinical trials/studies,0.556895
uuid-b07f6d37f4f743c6882c232a992a7933,Pubmed literature search,0.858502
uuid-b07f6d37f4f743c6882c232a992a7933,purposes other than its labeled indication must be considered investigational,0.91428
uuid-b07f6d37f4f743c6882c232a992a7933,not identify any citations relevant to your inquiry,0.824198
uuid-b07f6d37f4f743c6882c232a992a7933,using the following search terms,0.81373
uuid-b07f6d37f4f743c6882c232a992a7933,efficacy and safety of nivolumab,0.377478
uuid-b14f2a9c022d472ea58ec79757524719,Objective response rate,0.451139
uuid-b14f2a9c022d472ea58ec79757524719,clinicaltrials.gov,0.503706
uuid-810b4ff394844186bad7be3078fc55b0,adverse,0.339013
uuid-810b4ff394844186bad7be3078fc55b0,phase 3 study,0.319839
uuid-810b4ff394844186bad7be3078fc55b0,Rizvi NA,0.364772
uuid-810b4ff394844186bad7be3078fc55b0,Brahmer J,0.4414
uuid-810b4ff394844186bad7be3078fc55b0,BMS,0.743077
uuid-810b4ff394844186bad7be3078fc55b0,reported,0.507787
uuid-07ff88f4c58f400f989bfd2fc832aa2d,use of nivolumab for the treatment,0.305739
uuid-07ff88f4c58f400f989bfd2fc832aa2d,patients with advanced or metastatic,0.509457
uuid-07ff88f4c58f400f989bfd2fc832aa2d,nivolumab combined with ipilimumab,0.496885
uuid-07ff88f4c58f400f989bfd2fc832aa2d,not approved,0.397631
uuid-07ff88f4c58f400f989bfd2fc832aa2d,clinical trials investigating the safety,0.478965
uuid-07ff88f4c58f400f989bfd2fc832aa2d,bladder cancer,0.940126
uuid-9767f07683034e9fb8ad0e539716175f,fatigue,0.704358
uuid-14a81afd4fa34a6481103e999d1345f4,evaluating,0.331463
uuid-14a81afd4fa34a6481103e999d1345f4,not conducted any controlled clinical trials/studies,0.327968
uuid-14a81afd4fa34a6481103e999d1345f4,protocol,0.532972
uuid-14a81afd4fa34a6481103e999d1345f4,RCC,0.386451
uuid-14a81afd4fa34a6481103e999d1345f4,McDermott DF,0.444329
uuid-14a81afd4fa34a6481103e999d1345f4,search of published literature,0.50452
uuid-14a81afd4fa34a6481103e999d1345f4,Additionally,0.555299
uuid-14a81afd4fa34a6481103e999d1345f4,ongoing,0.478674
uuid-14a81afd4fa34a6481103e999d1345f4,Motzer RJ,0.475488
uuid-14a81afd4fa34a6481103e999d1345f4,PubMed and EMBASE,0.501909
uuid-14a81afd4fa34a6481103e999d1345f4,Escudier B,0.459186
uuid-14a81afd4fa34a6481103e999d1345f4,et al.,0.397016
uuid-14a81afd4fa34a6481103e999d1345f4,J Clin Oncol,0.428996
uuid-14a81afd4fa34a6481103e999d1345f4,detailed search of www.clinicaltrials.gov,0.514934
uuid-14a81afd4fa34a6481103e999d1345f4,efficacy and safety of nivolumab,0.47512
uuid-14a81afd4fa34a6481103e999d1345f4,not identify any planned,0.493147
uuid-14a81afd4fa34a6481103e999d1345f4,phase 2 study,0.384586
uuid-14a81afd4fa34a6481103e999d1345f4,not identify any citations relevant to your request,0.565812
uuid-14a81afd4fa34a6481103e999d1345f4,present using the following search terms,0.490802
uuid-0035c49faeaf40508e6412f48acd8c27,use of nivolumab for the treatment,0.305739
uuid-0035c49faeaf40508e6412f48acd8c27,patients with advanced or metastatic,0.509457
uuid-0035c49faeaf40508e6412f48acd8c27,nivolumab combined with ipilimumab,0.496885
uuid-0035c49faeaf40508e6412f48acd8c27,not approved,0.397631
uuid-0035c49faeaf40508e6412f48acd8c27,clinical trials investigating the safety,0.478965
uuid-0035c49faeaf40508e6412f48acd8c27,bladder cancer,0.940126
uuid-d4f7a350f4914e419155420c4f79644e,provided in the Detailed Information,0.349112
uuid-d4f7a350f4914e419155420c4f79644e,Weber JS,0.321343
uuid-7ecb9bc814984712b7defe3e86a52b83,Opdivo,0.50165
uuid-7ecb9bc814984712b7defe3e86a52b83,open-label,0.304253
uuid-7ecb9bc814984712b7defe3e86a52b83,trial,0.521827
uuid-7ecb9bc814984712b7defe3e86a52b83,docetaxel,0.30238
uuid-7ecb9bc814984712b7defe3e86a52b83,safety of nivolumab monotherapy,0.432481
uuid-7ecb9bc814984712b7defe3e86a52b83,phase,0.378496
uuid-881c9462fd9c4aa5894f89219df62649,nivolumab,0.573368
uuid-881c9462fd9c4aa5894f89219df62649,Bristol-Myers Squibb,0.437862
uuid-881c9462fd9c4aa5894f89219df62649,evaluating,0.5945
uuid-881c9462fd9c4aa5894f89219df62649,not conducted any controlled clinical trials/studies,0.655121
uuid-881c9462fd9c4aa5894f89219df62649,Pubmed literature search,0.876447
uuid-881c9462fd9c4aa5894f89219df62649,purposes other than its labeled indication must be considered investigational,0.939959
uuid-881c9462fd9c4aa5894f89219df62649,not identify any citations relevant to your inquiry,0.835959
uuid-881c9462fd9c4aa5894f89219df62649,using the following search terms,0.823015
uuid-881c9462fd9c4aa5894f89219df62649,efficacy and safety of nivolumab,0.432466
uuid-3d5e399306ab433580fecfca60725661,95% CI,0.419478
uuid-3d5e399306ab433580fecfca60725661,respectively,0.497608
uuid-3d5e399306ab433580fecfca60725661,Objective response rate,0.403649
uuid-3d5e399306ab433580fecfca60725661,ORR,0.578109
uuid-3d5e399306ab433580fecfca60725661,patients with advanced or metastatic,0.306625
uuid-3d5e399306ab433580fecfca60725661,Median overall survival,0.498783
uuid-3d5e399306ab433580fecfca60725661,nivolumab combined with ipilimumab,0.300486
uuid-3d5e399306ab433580fecfca60725661,tumors,0.323334
uuid-3d5e399306ab433580fecfca60725661,ESMO,0.534361
uuid-3d5e399306ab433580fecfca60725661,Median OS,0.394058
uuid-3d5e399306ab433580fecfca60725661,small cell lung cancer,0.380999
uuid-3d5e399306ab433580fecfca60725661,SCLC,0.365686
uuid-3d5e399306ab433580fecfca60725661,hazard ratio,0.419392
uuid-3d5e399306ab433580fecfca60725661,grade 3 to 4 AEs,0.414535
uuid-3d5e399306ab433580fecfca60725661,phase 1/2 study CA209-032,0.398283
uuid-3d5e399306ab433580fecfca60725661,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-4d07e5c90dc74fbd893646f66b967da5,nivolumab,0.553131
uuid-4d07e5c90dc74fbd893646f66b967da5,Bristol-Myers Squibb,0.459799
uuid-4d07e5c90dc74fbd893646f66b967da5,evaluating,0.609548
uuid-4d07e5c90dc74fbd893646f66b967da5,not conducted any controlled clinical trials/studies,0.666063
uuid-4d07e5c90dc74fbd893646f66b967da5,Pubmed literature search,0.778567
uuid-4d07e5c90dc74fbd893646f66b967da5,purposes other than its labeled indication must be considered investigational,0.851191
uuid-4d07e5c90dc74fbd893646f66b967da5,not identify any citations relevant to your inquiry,0.73564
uuid-4d07e5c90dc74fbd893646f66b967da5,using the following search terms,0.722174
uuid-4d07e5c90dc74fbd893646f66b967da5,efficacy and safety of nivolumab,0.478103
uuid-5f1fb52012884d7d82b89011ce6ec387,requested,0.595565
uuid-0105e34505cf4e1cb00c2eacbd664689,AEs,0.36786
uuid-0105e34505cf4e1cb00c2eacbd664689,NEJM,0.316923
uuid-0105e34505cf4e1cb00c2eacbd664689,Topalian,0.334
uuid-0105e34505cf4e1cb00c2eacbd664689,fatigue,0.322169
uuid-9457ccd16c7b47f1965bce00a39b735d,trial,0.405437
uuid-723a794fb3dd466e845351deca74a61c,Bristol-Myers Squibb,0.398191
uuid-723a794fb3dd466e845351deca74a61c,requested,0.827269
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,N Engl J Med,0.304989
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,AEs,0.337832
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,patients,0.387033
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,provided in the Detailed Information,0.370845
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,ESMO,0.421367
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,NEJM,0.709799
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,Topalian,0.735417
uuid-1490b54c0c9248b4b6c2bfad4cf3a817,grade 3 to 4 AEs,0.538198
uuid-d670d9e83a134de39ed0ed063b060b6b,Bristol-Myers Squibb,0.398191
uuid-d670d9e83a134de39ed0ed063b060b6b,requested,0.827269
uuid-ae83e9e1ee8d42908472965ab904dbde,Bristol-Myers Squibb,0.429216
uuid-0383d0a4c3ed492dab09df4e38f72517,requested,0.595565
uuid-76c3d01be4224bcf8cf8025168d6b1c2,evaluating,0.439461
uuid-76c3d01be4224bcf8cf8025168d6b1c2,not conducted any controlled clinical trials/studies,0.431506
uuid-76c3d01be4224bcf8cf8025168d6b1c2,search of published literature,0.657775
uuid-76c3d01be4224bcf8cf8025168d6b1c2,Additionally,0.629271
uuid-76c3d01be4224bcf8cf8025168d6b1c2,ongoing,0.490203
uuid-76c3d01be4224bcf8cf8025168d6b1c2,PubMed and EMBASE,0.654377
uuid-76c3d01be4224bcf8cf8025168d6b1c2,detailed search of www.clinicaltrials.gov,0.581655
uuid-76c3d01be4224bcf8cf8025168d6b1c2,efficacy and safety of nivolumab,0.604991
uuid-76c3d01be4224bcf8cf8025168d6b1c2,not identify any planned,0.523312
uuid-76c3d01be4224bcf8cf8025168d6b1c2,not identify any citations relevant to your request,0.702799
uuid-76c3d01be4224bcf8cf8025168d6b1c2,present using the following search terms,0.670227
uuid-7670952985a2437bbc2332f1d3d4378b,trial,0.39642
uuid-9d7332fb3e8b41a1b0861ac627f94f8b,fatigue,0.323475
uuid-30053ac8455446d691536671072be641,95% CI,0.419478
uuid-30053ac8455446d691536671072be641,respectively,0.497608
uuid-30053ac8455446d691536671072be641,Objective response rate,0.403649
uuid-30053ac8455446d691536671072be641,ORR,0.578109
uuid-30053ac8455446d691536671072be641,patients with advanced or metastatic,0.306625
uuid-30053ac8455446d691536671072be641,Median overall survival,0.498783
uuid-30053ac8455446d691536671072be641,nivolumab combined with ipilimumab,0.300486
uuid-30053ac8455446d691536671072be641,tumors,0.323334
uuid-30053ac8455446d691536671072be641,ESMO,0.534361
uuid-30053ac8455446d691536671072be641,Median OS,0.394058
uuid-30053ac8455446d691536671072be641,small cell lung cancer,0.380999
uuid-30053ac8455446d691536671072be641,SCLC,0.365686
uuid-30053ac8455446d691536671072be641,hazard ratio,0.419392
uuid-30053ac8455446d691536671072be641,grade 3 to 4 AEs,0.414535
uuid-30053ac8455446d691536671072be641,phase 1/2 study CA209-032,0.398283
uuid-30053ac8455446d691536671072be641,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,95% CI,0.419478
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,respectively,0.497608
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,Objective response rate,0.403649
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,ORR,0.578109
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,patients with advanced or metastatic,0.306625
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,Median overall survival,0.498783
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,nivolumab combined with ipilimumab,0.300486
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,tumors,0.323334
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,ESMO,0.534361
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,Median OS,0.394058
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,small cell lung cancer,0.380999
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,SCLC,0.365686
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,hazard ratio,0.419392
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,grade 3 to 4 AEs,0.414535
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,phase 1/2 study CA209-032,0.398283
uuid-00ebfb9f482f4f7db0a240ad99d7ee1c,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-5b5a89e826a64bae8834537f575cc08f,N Engl J Med,0.304989
uuid-5b5a89e826a64bae8834537f575cc08f,AEs,0.337832
uuid-5b5a89e826a64bae8834537f575cc08f,patients,0.387033
uuid-5b5a89e826a64bae8834537f575cc08f,provided in the Detailed Information,0.370845
uuid-5b5a89e826a64bae8834537f575cc08f,ESMO,0.421367
uuid-5b5a89e826a64bae8834537f575cc08f,NEJM,0.709799
uuid-5b5a89e826a64bae8834537f575cc08f,Topalian,0.735417
uuid-5b5a89e826a64bae8834537f575cc08f,grade 3 to 4 AEs,0.538198
uuid-89a6f9330b3b478c9937e9799cae2e4f,Objective response rate,0.451139
uuid-89a6f9330b3b478c9937e9799cae2e4f,clinicaltrials.gov,0.503706
uuid-d74f8bb760ae414b8614ad16f679e1da,respectively,0.661351
uuid-d74f8bb760ae414b8614ad16f679e1da,Objective response rate,0.619462
uuid-d74f8bb760ae414b8614ad16f679e1da,ORR,0.537232
uuid-d74f8bb760ae414b8614ad16f679e1da,monotherapy,0.421967
uuid-d74f8bb760ae414b8614ad16f679e1da,docetaxel,0.426453
uuid-e386780905b041a282e1074b6c35d4f1,95% CI,0.419478
uuid-e386780905b041a282e1074b6c35d4f1,respectively,0.497608
uuid-e386780905b041a282e1074b6c35d4f1,Objective response rate,0.403649
uuid-e386780905b041a282e1074b6c35d4f1,ORR,0.578109
uuid-e386780905b041a282e1074b6c35d4f1,patients with advanced or metastatic,0.306625
uuid-e386780905b041a282e1074b6c35d4f1,Median overall survival,0.498783
uuid-e386780905b041a282e1074b6c35d4f1,nivolumab combined with ipilimumab,0.300486
uuid-e386780905b041a282e1074b6c35d4f1,tumors,0.323334
uuid-e386780905b041a282e1074b6c35d4f1,ESMO,0.534361
uuid-e386780905b041a282e1074b6c35d4f1,Median OS,0.394058
uuid-e386780905b041a282e1074b6c35d4f1,small cell lung cancer,0.380999
uuid-e386780905b041a282e1074b6c35d4f1,SCLC,0.365686
uuid-e386780905b041a282e1074b6c35d4f1,hazard ratio,0.419392
uuid-e386780905b041a282e1074b6c35d4f1,grade 3 to 4 AEs,0.414535
uuid-e386780905b041a282e1074b6c35d4f1,phase 1/2 study CA209-032,0.398283
uuid-e386780905b041a282e1074b6c35d4f1,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-97a4658358074dfb980669c12f04b64d,nivolumab,0.570095
uuid-97a4658358074dfb980669c12f04b64d,Bristol-Myers Squibb,0.451367
uuid-97a4658358074dfb980669c12f04b64d,evaluating,0.637702
uuid-97a4658358074dfb980669c12f04b64d,not conducted any controlled clinical trials/studies,0.677002
uuid-97a4658358074dfb980669c12f04b64d,Pubmed literature search,0.842826
uuid-97a4658358074dfb980669c12f04b64d,purposes other than its labeled indication must be considered investigational,0.913464
uuid-97a4658358074dfb980669c12f04b64d,not identify any citations relevant to your inquiry,0.798284
uuid-97a4658358074dfb980669c12f04b64d,using the following search terms,0.78621
uuid-97a4658358074dfb980669c12f04b64d,efficacy and safety of nivolumab,0.447493
uuid-ac763659e60047bbb27c8194336c9213,nivolumab,0.664623
uuid-ac763659e60047bbb27c8194336c9213,purposes other than its labeled indication must be considered investigational,0.334429
uuid-ac763659e60047bbb27c8194336c9213,RCC,0.386924
uuid-8d4ec8bb6c9e44de8f75d4a0d7cd9679,adverse,0.556725
uuid-28879ee72797443ea60969305874ec07,OS,0.62262
uuid-28879ee72797443ea60969305874ec07,PFS,0.65903
uuid-28879ee72797443ea60969305874ec07,Overall survival,0.644151
uuid-50ef456878da435a838cadeb836c1027,Opdivo,0.964631
uuid-50ef456878da435a838cadeb836c1027,using the following search terms,0.334914
uuid-50ef456878da435a838cadeb836c1027,trial,0.457102
uuid-50ef456878da435a838cadeb836c1027,reported,0.350606
uuid-2928ac4088054aa7955f36df5f6f2d20,Opdivo,0.50165
uuid-2928ac4088054aa7955f36df5f6f2d20,open-label,0.304253
uuid-2928ac4088054aa7955f36df5f6f2d20,trial,0.521827
uuid-2928ac4088054aa7955f36df5f6f2d20,docetaxel,0.30238
uuid-2928ac4088054aa7955f36df5f6f2d20,safety of nivolumab monotherapy,0.432481
uuid-2928ac4088054aa7955f36df5f6f2d20,phase,0.378496
uuid-d9a95dcb45ee4186b3f346a380718cdc,ASCO,0.572408
uuid-d9a95dcb45ee4186b3f346a380718cdc,requested,0.60375
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,nivolumab,0.511776
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,Bristol-Myers Squibb,0.45146
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,evaluating,0.59849
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,not conducted any controlled clinical trials/studies,0.663407
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,Pubmed literature search,0.882292
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,purposes other than its labeled indication must be considered investigational,0.943473
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,not identify any citations relevant to your inquiry,0.842165
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,using the following search terms,0.828578
uuid-d5ea74b1aee94b8d96ec539abb2ac20a,efficacy and safety of nivolumab,0.427656
uuid-40c095d7b23b4f1095cf69d2b00c6435,mg,0.300211
uuid-8797463b3268410ea96a66d9cc781ea7,not conducted any controlled clinical trials/studies,0.303422
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,N Engl J Med,0.495649
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,protocol,0.736971
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,McDermott DF,0.762108
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,Motzer RJ,0.773565
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,phase 3 study,0.454434
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,Escudier B,0.763658
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,NEJM,0.4325
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,et al.,0.712875
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,J Clin Oncol,0.738632
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,Topalian,0.412144
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,Rizvi NA,0.375979
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,Weber JS,0.324917
uuid-4bdfb1b9dad64a9d884b5d86d35678d0,phase 2 study,0.660323
uuid-d72a8c761ce847a4a1bb8216c0b40374,OS,0.435429
uuid-d72a8c761ce847a4a1bb8216c0b40374,PFS,0.417576
uuid-d72a8c761ce847a4a1bb8216c0b40374,Median overall survival,0.314902
uuid-d72a8c761ce847a4a1bb8216c0b40374,fatigue,0.694715
uuid-d72a8c761ce847a4a1bb8216c0b40374,Overall survival,0.406685
uuid-470e122f29bc4ecc937fe8a7afbec075,N Engl J Med,0.655749
uuid-470e122f29bc4ecc937fe8a7afbec075,protocol,0.836967
uuid-470e122f29bc4ecc937fe8a7afbec075,McDermott DF,0.921427
uuid-470e122f29bc4ecc937fe8a7afbec075,Motzer RJ,0.90831
uuid-470e122f29bc4ecc937fe8a7afbec075,phase 3 study,0.537275
uuid-470e122f29bc4ecc937fe8a7afbec075,Escudier B,0.919304
uuid-470e122f29bc4ecc937fe8a7afbec075,NEJM,0.454873
uuid-470e122f29bc4ecc937fe8a7afbec075,et al.,0.877698
uuid-470e122f29bc4ecc937fe8a7afbec075,J Clin Oncol,0.866701
uuid-470e122f29bc4ecc937fe8a7afbec075,Topalian,0.413823
uuid-470e122f29bc4ecc937fe8a7afbec075,Rizvi NA,0.42527
uuid-470e122f29bc4ecc937fe8a7afbec075,Weber JS,0.306371
uuid-470e122f29bc4ecc937fe8a7afbec075,phase 2 study,0.824788
uuid-11c70082dccb496798e9b2d075c3aeb9,open-label,0.417714
uuid-11c70082dccb496798e9b2d075c3aeb9,trial,0.439817
uuid-11c70082dccb496798e9b2d075c3aeb9,phase,0.338437
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,N Engl J Med,0.585592
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,protocol,0.703048
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,McDermott DF,0.808613
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,Motzer RJ,0.783017
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,phase 3 study,0.465459
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,Escudier B,0.804268
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,NEJM,0.338631
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,et al.,0.770371
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,J Clin Oncol,0.754974
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,Rizvi NA,0.374947
uuid-6ca4a8bfc99d431ba7cb8fc2206f4b21,phase 2 study,0.717397
uuid-746cb9d0531d4be3804c379c0aef8008,provided in the Detailed Information,0.349112
uuid-746cb9d0531d4be3804c379c0aef8008,Weber JS,0.321343
uuid-8014f7af629749869c3f71d7001b6050,OS,0.62262
uuid-8014f7af629749869c3f71d7001b6050,PFS,0.65903
uuid-8014f7af629749869c3f71d7001b6050,Overall survival,0.644151
uuid-33b4bea5bf6b408e87a164c03535f6df,provided in the Detailed Information,0.365483
uuid-680739499f3f4d2ba4cf6dc06aa65837,trial,0.395559
uuid-71164c534bfd48ecb44a6c11a692b276,requested,0.999534
uuid-71164c534bfd48ecb44a6c11a692b276,Horn L,0.429605
uuid-71164c534bfd48ecb44a6c11a692b276,platinum-based doublet chemotherapy,0.390386
uuid-aeb03898f74b40ee88738eb40ac0b8fa,OS,0.453898
uuid-aeb03898f74b40ee88738eb40ac0b8fa,95% CI,0.705798
uuid-aeb03898f74b40ee88738eb40ac0b8fa,Objective response rate,0.404173
uuid-aeb03898f74b40ee88738eb40ac0b8fa,ORR,0.493927
uuid-aeb03898f74b40ee88738eb40ac0b8fa,PFS,0.311003
uuid-aeb03898f74b40ee88738eb40ac0b8fa,Median overall survival,0.664453
uuid-aeb03898f74b40ee88738eb40ac0b8fa,Median OS,0.680328
uuid-aeb03898f74b40ee88738eb40ac0b8fa,hazard ratio,0.690678
uuid-aeb03898f74b40ee88738eb40ac0b8fa,Overall survival,0.368412
uuid-aeb03898f74b40ee88738eb40ac0b8fa,Median duration of response,0.322423
uuid-791ae67ba61e442ab694bddac9b7623b,N Engl J Med,0.304989
uuid-791ae67ba61e442ab694bddac9b7623b,AEs,0.337832
uuid-791ae67ba61e442ab694bddac9b7623b,patients,0.387033
uuid-791ae67ba61e442ab694bddac9b7623b,provided in the Detailed Information,0.370845
uuid-791ae67ba61e442ab694bddac9b7623b,ESMO,0.421367
uuid-791ae67ba61e442ab694bddac9b7623b,NEJM,0.709799
uuid-791ae67ba61e442ab694bddac9b7623b,Topalian,0.735417
uuid-791ae67ba61e442ab694bddac9b7623b,grade 3 to 4 AEs,0.538198
uuid-a1f34ea7d82c422d94cda33035d76cd6,OS,0.62262
uuid-a1f34ea7d82c422d94cda33035d76cd6,PFS,0.65903
uuid-a1f34ea7d82c422d94cda33035d76cd6,Overall survival,0.644151
uuid-6153321595e54f32a2aac8f7a5532d59,BMS,0.449215
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,use of nivolumab for the treatment,0.305739
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,patients with advanced or metastatic,0.509457
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,nivolumab combined with ipilimumab,0.496885
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,not approved,0.397631
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,clinical trials investigating the safety,0.478965
uuid-4b0bc2d8f2a94ad1bb346c41c0e7cf1d,bladder cancer,0.940126
uuid-cbc3eab1b1974afaab3b529f172d6789,OS,0.62262
uuid-cbc3eab1b1974afaab3b529f172d6789,PFS,0.65903
uuid-cbc3eab1b1974afaab3b529f172d6789,Overall survival,0.644151
uuid-9a2158e43ad6430f8fb02919a472cdcf,Bristol-Myers Squibb,0.650384
uuid-9a2158e43ad6430f8fb02919a472cdcf,evaluating,0.542365
uuid-9a2158e43ad6430f8fb02919a472cdcf,not conducted any controlled clinical trials/studies,0.600219
uuid-9a2158e43ad6430f8fb02919a472cdcf,adverse,0.315348
uuid-9a2158e43ad6430f8fb02919a472cdcf,efficacy and safety of nivolumab,0.467273
uuid-9a2158e43ad6430f8fb02919a472cdcf,reported,0.352879
uuid-8c547d4408174704977efe37c89136a5,nivolumab,0.653127
uuid-8c547d4408174704977efe37c89136a5,clinical trials investigating the safety,0.332666
uuid-8c547d4408174704977efe37c89136a5,clinicaltrials.gov,0.359682
uuid-f887e206da2f49a897af30d1d60a2966,use of nivolumab for the treatment,0.305739
uuid-f887e206da2f49a897af30d1d60a2966,patients with advanced or metastatic,0.509457
uuid-f887e206da2f49a897af30d1d60a2966,nivolumab combined with ipilimumab,0.496885
uuid-f887e206da2f49a897af30d1d60a2966,not approved,0.397631
uuid-f887e206da2f49a897af30d1d60a2966,clinical trials investigating the safety,0.478965
uuid-f887e206da2f49a897af30d1d60a2966,bladder cancer,0.940126
uuid-2e3089ef066345ba8733405a8d6c815c,use of nivolumab for the treatment,0.409821
uuid-2e3089ef066345ba8733405a8d6c815c,patients with advanced or metastatic,0.645244
uuid-2e3089ef066345ba8733405a8d6c815c,nivolumab combined with ipilimumab,0.676339
uuid-2e3089ef066345ba8733405a8d6c815c,not approved,0.453534
uuid-2e3089ef066345ba8733405a8d6c815c,clinical trials investigating the safety,0.548799
uuid-2e3089ef066345ba8733405a8d6c815c,phase 1/2 study CA209-032,0.34114
uuid-2e3089ef066345ba8733405a8d6c815c,bladder cancer,0.749142
uuid-2e3089ef066345ba8733405a8d6c815c,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-a176d83a46e04072a2eb5af5ff523300,nivolumab,0.564851
uuid-a176d83a46e04072a2eb5af5ff523300,RCC,0.667636
uuid-10fc95214c014ba3b50ad745a962fc7e,nivolumab,0.568125
uuid-10fc95214c014ba3b50ad745a962fc7e,Bristol-Myers Squibb,0.45003
uuid-10fc95214c014ba3b50ad745a962fc7e,evaluating,0.591255
uuid-10fc95214c014ba3b50ad745a962fc7e,not conducted any controlled clinical trials/studies,0.652649
uuid-10fc95214c014ba3b50ad745a962fc7e,Pubmed literature search,0.857452
uuid-10fc95214c014ba3b50ad745a962fc7e,purposes other than its labeled indication must be considered investigational,0.919989
uuid-10fc95214c014ba3b50ad745a962fc7e,not identify any citations relevant to your inquiry,0.817413
uuid-10fc95214c014ba3b50ad745a962fc7e,using the following search terms,0.805754
uuid-10fc95214c014ba3b50ad745a962fc7e,efficacy and safety of nivolumab,0.432456
uuid-b3329c16c54446aebc8e2c7c0b3f7480,respectively,0.483806
uuid-b3329c16c54446aebc8e2c7c0b3f7480,Objective response rate,0.573619
uuid-b3329c16c54446aebc8e2c7c0b3f7480,ORR,0.430378
uuid-b3329c16c54446aebc8e2c7c0b3f7480,monotherapy,0.327181
uuid-b3329c16c54446aebc8e2c7c0b3f7480,clinicaltrials.gov,0.391121
uuid-b3329c16c54446aebc8e2c7c0b3f7480,docetaxel,0.312578
uuid-b52559817e074480ba6200b49d4f3605,nivolumab,0.543297
uuid-b52559817e074480ba6200b49d4f3605,Bristol-Myers Squibb,0.483073
uuid-b52559817e074480ba6200b49d4f3605,evaluating,0.658374
uuid-b52559817e074480ba6200b49d4f3605,not conducted any controlled clinical trials/studies,0.703131
uuid-b52559817e074480ba6200b49d4f3605,Pubmed literature search,0.812911
uuid-b52559817e074480ba6200b49d4f3605,purposes other than its labeled indication must be considered investigational,0.887025
uuid-b52559817e074480ba6200b49d4f3605,not identify any citations relevant to your inquiry,0.771862
uuid-b52559817e074480ba6200b49d4f3605,using the following search terms,0.754251
uuid-b52559817e074480ba6200b49d4f3605,efficacy and safety of nivolumab,0.496892
uuid-c42c743dadc54f8eaf6d7fc54d8939ad,OS,0.62262
uuid-c42c743dadc54f8eaf6d7fc54d8939ad,PFS,0.65903
uuid-c42c743dadc54f8eaf6d7fc54d8939ad,Overall survival,0.644151
uuid-9b66b062b0ca4677954b442cb5551889,OS,0.62262
uuid-9b66b062b0ca4677954b442cb5551889,PFS,0.65903
uuid-9b66b062b0ca4677954b442cb5551889,Overall survival,0.644151
uuid-f94a8444720e4f75a5f51a51e10e7e08,95% CI,0.368332
uuid-f94a8444720e4f75a5f51a51e10e7e08,NSCLC,0.498467
uuid-f94a8444720e4f75a5f51a51e10e7e08,non-small cell lung cancer,0.430459
uuid-f94a8444720e4f75a5f51a51e10e7e08,Objective response rate,0.480097
uuid-f94a8444720e4f75a5f51a51e10e7e08,ORR,0.476446
uuid-f94a8444720e4f75a5f51a51e10e7e08,Median overall survival,0.366656
uuid-f94a8444720e4f75a5f51a51e10e7e08,monotherapy,0.355726
uuid-f94a8444720e4f75a5f51a51e10e7e08,Median OS,0.348153
uuid-f94a8444720e4f75a5f51a51e10e7e08,phase 1 study,0.35881
uuid-f94a8444720e4f75a5f51a51e10e7e08,hazard ratio,0.370178
uuid-094328d781694f6d88f91ff2e14e3c5d,ipilimumab,0.385692
uuid-094328d781694f6d88f91ff2e14e3c5d,ASCO 2015,0.417944
uuid-094328d781694f6d88f91ff2e14e3c5d,partial response,0.382425
uuid-094328d781694f6d88f91ff2e14e3c5d,Stable disease,0.586335
uuid-094328d781694f6d88f91ff2e14e3c5d,cohort,0.307748
uuid-9525cb8cf1d9432aae869e104abcdab2,use of nivolumab for the treatment,0.440423
uuid-9525cb8cf1d9432aae869e104abcdab2,search of published literature,0.311531
uuid-9525cb8cf1d9432aae869e104abcdab2,PubMed and EMBASE,0.312811
uuid-9525cb8cf1d9432aae869e104abcdab2,not approved,0.404782
uuid-9525cb8cf1d9432aae869e104abcdab2,open-label,0.578291
uuid-9525cb8cf1d9432aae869e104abcdab2,clinical trials investigating the safety,0.440014
uuid-9525cb8cf1d9432aae869e104abcdab2,present using the following search terms,0.328669
uuid-9525cb8cf1d9432aae869e104abcdab2,phase,0.41185
uuid-c80afd84c5024f2db045edf7c39fe8a6,N Engl J Med,0.666673
uuid-c80afd84c5024f2db045edf7c39fe8a6,protocol,0.784297
uuid-c80afd84c5024f2db045edf7c39fe8a6,McDermott DF,0.863473
uuid-c80afd84c5024f2db045edf7c39fe8a6,Motzer RJ,0.839535
uuid-c80afd84c5024f2db045edf7c39fe8a6,phase 3 study,0.445361
uuid-c80afd84c5024f2db045edf7c39fe8a6,Escudier B,0.862895
uuid-c80afd84c5024f2db045edf7c39fe8a6,NEJM,0.429443
uuid-c80afd84c5024f2db045edf7c39fe8a6,et al.,0.845549
uuid-c80afd84c5024f2db045edf7c39fe8a6,J Clin Oncol,0.786791
uuid-c80afd84c5024f2db045edf7c39fe8a6,Topalian,0.389875
uuid-c80afd84c5024f2db045edf7c39fe8a6,Rizvi NA,0.366362
uuid-c80afd84c5024f2db045edf7c39fe8a6,Brahmer J,0.346515
uuid-c80afd84c5024f2db045edf7c39fe8a6,phase 2 study,0.725511
uuid-b5a95c514fb34890b0ad01a5aa3dfe57,open-label,0.539462
uuid-b5a95c514fb34890b0ad01a5aa3dfe57,phase,0.350616
uuid-8934c1ddf882402a8e63a39202f98d16,fatigue,0.323475
uuid-6c1fcca5641e494988fa9ec6caa48d7b,fatigue,0.323475
uuid-171ad69e810c43958ed0bac64d0a65fa,requested,0.596876
uuid-57daf1c3decf4c13b52b443a3e8d0144,requested,0.596876
uuid-d7c483149c074ae4b20161641ed3aedb,nivolumab,0.359772
uuid-24f07eedc6cb4adf98f27d8efc1ff48c,ipilimumab,0.385692
uuid-24f07eedc6cb4adf98f27d8efc1ff48c,ASCO 2015,0.417944
uuid-24f07eedc6cb4adf98f27d8efc1ff48c,partial response,0.382425
uuid-24f07eedc6cb4adf98f27d8efc1ff48c,Stable disease,0.586335
uuid-24f07eedc6cb4adf98f27d8efc1ff48c,cohort,0.307748
uuid-9ae7d89737a44044b349053b5702af45,Bristol-Myers Squibb,0.405577
uuid-9ae7d89737a44044b349053b5702af45,evaluating,0.460537
uuid-9ae7d89737a44044b349053b5702af45,not conducted any controlled clinical trials/studies,0.465268
uuid-9ae7d89737a44044b349053b5702af45,phase 1 study,0.435574
uuid-9ae7d89737a44044b349053b5702af45,efficacy and safety of nivolumab,0.487261
uuid-9ae7d89737a44044b349053b5702af45,CA209-003,0.515297
uuid-9ae7d89737a44044b349053b5702af45,investigating,0.721188
uuid-4eb9cc60dae84a948405d17f49791f73,95% CI,0.384282
uuid-4eb9cc60dae84a948405d17f49791f73,ASCO,0.40687
uuid-4eb9cc60dae84a948405d17f49791f73,Objective response rate,0.409634
uuid-4eb9cc60dae84a948405d17f49791f73,Median overall survival,0.319094
uuid-4eb9cc60dae84a948405d17f49791f73,Median OS,0.403026
uuid-4eb9cc60dae84a948405d17f49791f73,ASCO 2015,0.386899
uuid-4eb9cc60dae84a948405d17f49791f73,hazard ratio,0.403406
uuid-9746341beb2d4d70a1091ad73fcc07f4,Opdivo,0.50165
uuid-9746341beb2d4d70a1091ad73fcc07f4,open-label,0.304253
uuid-9746341beb2d4d70a1091ad73fcc07f4,trial,0.521827
uuid-9746341beb2d4d70a1091ad73fcc07f4,docetaxel,0.30238
uuid-9746341beb2d4d70a1091ad73fcc07f4,safety of nivolumab monotherapy,0.432481
uuid-9746341beb2d4d70a1091ad73fcc07f4,phase,0.378496
uuid-3960d95e1e0f44beb9bf189da370a521,mg,0.648432
uuid-3960d95e1e0f44beb9bf189da370a521,kg,0.623652
uuid-648946ed527c4743a9b8a36047c103f0,patients,0.349201
uuid-648946ed527c4743a9b8a36047c103f0,protocol,0.363204
uuid-648946ed527c4743a9b8a36047c103f0,McDermott DF,0.390473
uuid-648946ed527c4743a9b8a36047c103f0,Motzer RJ,0.393374
uuid-648946ed527c4743a9b8a36047c103f0,phase 3 study,0.463524
uuid-648946ed527c4743a9b8a36047c103f0,Escudier B,0.39241
uuid-648946ed527c4743a9b8a36047c103f0,et al.,0.363168
uuid-648946ed527c4743a9b8a36047c103f0,J Clin Oncol,0.3447
uuid-648946ed527c4743a9b8a36047c103f0,Rizvi NA,0.387741
uuid-648946ed527c4743a9b8a36047c103f0,Weber JS,0.415578
uuid-648946ed527c4743a9b8a36047c103f0,phase 2 study,0.44646
uuid-9c713155e8834167b70fa1b6974494f0,nivolumab,0.359772
uuid-d0c20da033d0439c8c8930bd733e5ad4,nivolumab,0.304992
uuid-d0c20da033d0439c8c8930bd733e5ad4,NEJM,0.351437
uuid-d0c20da033d0439c8c8930bd733e5ad4,Topalian,0.37131
uuid-1e174a31ba4841baa8c6013ad9bd77bf,N Engl J Med,0.8724
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Lancet Oncol,0.471317
uuid-1e174a31ba4841baa8c6013ad9bd77bf,protocol,0.769475
uuid-1e174a31ba4841baa8c6013ad9bd77bf,McDermott DF,0.794457
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Motzer RJ,0.776663
uuid-1e174a31ba4841baa8c6013ad9bd77bf,phase 3 study,0.528563
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Escudier B,0.803087
uuid-1e174a31ba4841baa8c6013ad9bd77bf,NEJM,0.474423
uuid-1e174a31ba4841baa8c6013ad9bd77bf,et al.,0.764592
uuid-1e174a31ba4841baa8c6013ad9bd77bf,J Clin Oncol,0.709582
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Topalian,0.446007
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Rizvi NA,0.665226
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Brahmer J,0.615908
uuid-1e174a31ba4841baa8c6013ad9bd77bf,Weber JS,0.463244
uuid-1e174a31ba4841baa8c6013ad9bd77bf,phase 2 study,0.74722
uuid-dd4ff346681940fcaa38a409dd44c399,NSCLC,0.327373
uuid-dd4ff346681940fcaa38a409dd44c399,respectively,0.32989
uuid-dd4ff346681940fcaa38a409dd44c399,Objective response rate,0.414926
uuid-dd4ff346681940fcaa38a409dd44c399,ORR,0.46431
uuid-dd4ff346681940fcaa38a409dd44c399,Median overall survival,0.358033
uuid-17ad54a575604babb5ddf1468a4b4cec,95% CI,0.384282
uuid-17ad54a575604babb5ddf1468a4b4cec,ASCO,0.40687
uuid-17ad54a575604babb5ddf1468a4b4cec,Objective response rate,0.409634
uuid-17ad54a575604babb5ddf1468a4b4cec,Median overall survival,0.319094
uuid-17ad54a575604babb5ddf1468a4b4cec,Median OS,0.403026
uuid-17ad54a575604babb5ddf1468a4b4cec,ASCO 2015,0.386899
uuid-17ad54a575604babb5ddf1468a4b4cec,hazard ratio,0.403406
uuid-3720159ffd0c4d10a651a5a02b19794b,Opdivo,0.93671
uuid-3720159ffd0c4d10a651a5a02b19794b,trial,0.54768
uuid-3720159ffd0c4d10a651a5a02b19794b,reported,0.336785
uuid-06166458a597408399203801db506770,OS,0.62262
uuid-06166458a597408399203801db506770,PFS,0.65903
uuid-06166458a597408399203801db506770,Overall survival,0.644151
uuid-1879923563f14c7fb8500df9473feec5,N Engl J Med,0.666673
uuid-1879923563f14c7fb8500df9473feec5,protocol,0.784297
uuid-1879923563f14c7fb8500df9473feec5,McDermott DF,0.863473
uuid-1879923563f14c7fb8500df9473feec5,Motzer RJ,0.839535
uuid-1879923563f14c7fb8500df9473feec5,phase 3 study,0.445361
uuid-1879923563f14c7fb8500df9473feec5,Escudier B,0.862895
uuid-1879923563f14c7fb8500df9473feec5,NEJM,0.429443
uuid-1879923563f14c7fb8500df9473feec5,et al.,0.845549
uuid-1879923563f14c7fb8500df9473feec5,J Clin Oncol,0.786791
uuid-1879923563f14c7fb8500df9473feec5,Topalian,0.389875
uuid-1879923563f14c7fb8500df9473feec5,Rizvi NA,0.366362
uuid-1879923563f14c7fb8500df9473feec5,Brahmer J,0.346515
uuid-1879923563f14c7fb8500df9473feec5,phase 2 study,0.725511
uuid-e52f3ad4cce242fa8a82084bc9349b14,N Engl J Med,0.304989
uuid-e52f3ad4cce242fa8a82084bc9349b14,AEs,0.337832
uuid-e52f3ad4cce242fa8a82084bc9349b14,patients,0.387033
uuid-e52f3ad4cce242fa8a82084bc9349b14,provided in the Detailed Information,0.370845
uuid-e52f3ad4cce242fa8a82084bc9349b14,ESMO,0.421367
uuid-e52f3ad4cce242fa8a82084bc9349b14,NEJM,0.709799
uuid-e52f3ad4cce242fa8a82084bc9349b14,Topalian,0.735417
uuid-e52f3ad4cce242fa8a82084bc9349b14,grade 3 to 4 AEs,0.538198
uuid-4bd60517648644d09346e914e423795b,evaluating,0.366546
uuid-4bd60517648644d09346e914e423795b,not conducted any controlled clinical trials/studies,0.360172
uuid-4bd60517648644d09346e914e423795b,search of published literature,0.403755
uuid-4bd60517648644d09346e914e423795b,Additionally,0.418906
uuid-4bd60517648644d09346e914e423795b,ongoing,0.467576
uuid-4bd60517648644d09346e914e423795b,PubMed and EMBASE,0.39617
uuid-4bd60517648644d09346e914e423795b,detailed search of www.clinicaltrials.gov,0.437393
uuid-4bd60517648644d09346e914e423795b,efficacy and safety of nivolumab,0.42836
uuid-4bd60517648644d09346e914e423795b,not identify any planned,0.454065
uuid-4bd60517648644d09346e914e423795b,combination,0.397925
uuid-4bd60517648644d09346e914e423795b,BMS,0.30879
uuid-4bd60517648644d09346e914e423795b,not identify any citations relevant to your request,0.449603
uuid-4bd60517648644d09346e914e423795b,present using the following search terms,0.394376
uuid-27fd3629c44b4d38a7a758727b235f68,requested,0.744471
uuid-7a34fa29e756475484fe4f9aa68a2d8f,requested,0.790753
uuid-a8c33f9af0244a55ad321ca41f2f0d96,nivolumab,0.359772
uuid-215d59516eb7406390b6032ded279e5f,N Engl J Med,0.304989
uuid-215d59516eb7406390b6032ded279e5f,AEs,0.337832
uuid-215d59516eb7406390b6032ded279e5f,patients,0.387033
uuid-215d59516eb7406390b6032ded279e5f,provided in the Detailed Information,0.370845
uuid-215d59516eb7406390b6032ded279e5f,ESMO,0.421367
uuid-215d59516eb7406390b6032ded279e5f,NEJM,0.709799
uuid-215d59516eb7406390b6032ded279e5f,Topalian,0.735417
uuid-215d59516eb7406390b6032ded279e5f,grade 3 to 4 AEs,0.538198
uuid-fb547e1f2ee64c3ca2f498e1540106c7,NSCLC,0.480337
uuid-fb547e1f2ee64c3ca2f498e1540106c7,respectively,0.400584
uuid-fb547e1f2ee64c3ca2f498e1540106c7,non-small cell lung cancer,0.395662
uuid-fb547e1f2ee64c3ca2f498e1540106c7,patients,0.382838
uuid-fb547e1f2ee64c3ca2f498e1540106c7,considered investigational,0.378457
uuid-fb547e1f2ee64c3ca2f498e1540106c7,Objective response rate,0.446233
uuid-fb547e1f2ee64c3ca2f498e1540106c7,ORR,0.488323
uuid-fb547e1f2ee64c3ca2f498e1540106c7,monotherapy,0.419452
uuid-fb547e1f2ee64c3ca2f498e1540106c7,small cell lung cancer,0.328277
uuid-fb547e1f2ee64c3ca2f498e1540106c7,docetaxel,0.370754
uuid-fb547e1f2ee64c3ca2f498e1540106c7,SCLC,0.328412
uuid-fb547e1f2ee64c3ca2f498e1540106c7,grade 3 to 4 AEs,0.337672
uuid-fb547e1f2ee64c3ca2f498e1540106c7,platinum-based doublet chemotherapy,0.355492
uuid-eb280ff10b8c44c8aceefd926e468fba,use of nivolumab for the treatment,0.305739
uuid-eb280ff10b8c44c8aceefd926e468fba,patients with advanced or metastatic,0.509457
uuid-eb280ff10b8c44c8aceefd926e468fba,nivolumab combined with ipilimumab,0.496885
uuid-eb280ff10b8c44c8aceefd926e468fba,not approved,0.397631
uuid-eb280ff10b8c44c8aceefd926e468fba,clinical trials investigating the safety,0.478965
uuid-eb280ff10b8c44c8aceefd926e468fba,bladder cancer,0.940126
uuid-6feff5994d544fa9bedf6d3c2dbbe446,nivolumab,0.510392
uuid-6feff5994d544fa9bedf6d3c2dbbe446,Bristol-Myers Squibb,0.464176
uuid-6feff5994d544fa9bedf6d3c2dbbe446,evaluating,0.683286
uuid-6feff5994d544fa9bedf6d3c2dbbe446,not conducted any controlled clinical trials/studies,0.682483
uuid-6feff5994d544fa9bedf6d3c2dbbe446,RCC,0.308694
uuid-6feff5994d544fa9bedf6d3c2dbbe446,search of published literature,0.839602
uuid-6feff5994d544fa9bedf6d3c2dbbe446,Additionally,0.446384
uuid-6feff5994d544fa9bedf6d3c2dbbe446,PubMed and EMBASE,0.823429
uuid-6feff5994d544fa9bedf6d3c2dbbe446,detailed search of www.clinicaltrials.gov,0.366719
uuid-6feff5994d544fa9bedf6d3c2dbbe446,efficacy and safety of nivolumab,0.841
uuid-6feff5994d544fa9bedf6d3c2dbbe446,not identify any citations relevant to your request,0.605656
uuid-6feff5994d544fa9bedf6d3c2dbbe446,present using the following search terms,0.832619
uuid-fc41e21bb997455f954ab2a9ebe6c52b,patients,0.573851
uuid-fc41e21bb997455f954ab2a9ebe6c52b,Opdivo,0.41506
uuid-fc41e21bb997455f954ab2a9ebe6c52b,adverse,0.617329
uuid-fc41e21bb997455f954ab2a9ebe6c52b,grade 3 to 4 AEs,0.351389
uuid-fc41e21bb997455f954ab2a9ebe6c52b,reported,0.749189
uuid-a882ed8f16124b1484f0ef95dfb567b5,fatigue,0.411608
uuid-6e760dab4ef24f049c540fc938540ad4,fatigue,0.704358
uuid-b11e256ae3014aad89458d2b112dfebc,patients with advanced or metastatic,0.392873
uuid-b11e256ae3014aad89458d2b112dfebc,nivolumab combined with ipilimumab,0.4509
uuid-b11e256ae3014aad89458d2b112dfebc,open-label,0.526693
uuid-b11e256ae3014aad89458d2b112dfebc,phase,0.34837
uuid-b11e256ae3014aad89458d2b112dfebc,bladder cancer,0.351263
uuid-6b27a41728254e40953413b5ceaff707,nivolumab,0.359772
uuid-21806c3cbb7746fa9a032fcfe0346aea,use of nivolumab for the treatment,0.409821
uuid-21806c3cbb7746fa9a032fcfe0346aea,patients with advanced or metastatic,0.645244
uuid-21806c3cbb7746fa9a032fcfe0346aea,nivolumab combined with ipilimumab,0.676339
uuid-21806c3cbb7746fa9a032fcfe0346aea,not approved,0.453534
uuid-21806c3cbb7746fa9a032fcfe0346aea,clinical trials investigating the safety,0.548799
uuid-21806c3cbb7746fa9a032fcfe0346aea,phase 1/2 study CA209-032,0.34114
uuid-21806c3cbb7746fa9a032fcfe0346aea,bladder cancer,0.749142
uuid-21806c3cbb7746fa9a032fcfe0346aea,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-418421e6350b4050b85f9e7c3d3b9754,requested,0.362694
uuid-418421e6350b4050b85f9e7c3d3b9754,open-label,0.431233
uuid-418421e6350b4050b85f9e7c3d3b9754,trial,0.455193
uuid-418421e6350b4050b85f9e7c3d3b9754,phase,0.325863
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,N Engl J Med,0.5218
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,protocol,0.822129
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,RCC,0.351265
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,McDermott DF,0.805326
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,search of published literature,0.328584
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,Motzer RJ,0.830191
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,phase 3 study,0.375845
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,PubMed and EMBASE,0.327895
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,Escudier B,0.815105
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,NEJM,0.388967
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,et al.,0.745528
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,J Clin Oncol,0.787871
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,Topalian,0.347249
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,Rizvi NA,0.308297
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,phase 2 study,0.670697
uuid-09bc3dc5fbb54fa6bab08c13c84550e3,present using the following search terms,0.304579
uuid-40a0ec1ca67d470bac261f44e40f29f1,nivolumab,0.33361
uuid-40a0ec1ca67d470bac261f44e40f29f1,clinicaltrials.gov,0.645643
uuid-181f0f6402cf4c75b96381531184de63,nivolumab,0.426112
uuid-181f0f6402cf4c75b96381531184de63,Bristol-Myers Squibb,0.414683
uuid-181f0f6402cf4c75b96381531184de63,evaluating,0.618441
uuid-181f0f6402cf4c75b96381531184de63,not conducted any controlled clinical trials/studies,0.59781
uuid-181f0f6402cf4c75b96381531184de63,search of published literature,0.714235
uuid-181f0f6402cf4c75b96381531184de63,Additionally,0.677808
uuid-181f0f6402cf4c75b96381531184de63,ongoing,0.561965
uuid-181f0f6402cf4c75b96381531184de63,PubMed and EMBASE,0.703738
uuid-181f0f6402cf4c75b96381531184de63,detailed search of www.clinicaltrials.gov,0.645679
uuid-181f0f6402cf4c75b96381531184de63,efficacy and safety of nivolumab,0.739441
uuid-181f0f6402cf4c75b96381531184de63,not identify any planned,0.590181
uuid-181f0f6402cf4c75b96381531184de63,not identify any citations relevant to your request,0.76779
uuid-181f0f6402cf4c75b96381531184de63,present using the following search terms,0.732321
uuid-d08bf11ca787481a9a41fbc05facb294,Bristol-Myers Squibb,0.32824
uuid-d08bf11ca787481a9a41fbc05facb294,evaluating,0.386378
uuid-d08bf11ca787481a9a41fbc05facb294,not conducted any controlled clinical trials/studies,0.388158
uuid-d08bf11ca787481a9a41fbc05facb294,protocol,0.407734
uuid-d08bf11ca787481a9a41fbc05facb294,McDermott DF,0.3069
uuid-d08bf11ca787481a9a41fbc05facb294,Motzer RJ,0.46282
uuid-d08bf11ca787481a9a41fbc05facb294,Escudier B,0.336783
uuid-d08bf11ca787481a9a41fbc05facb294,J Clin Oncol,0.405787
uuid-d08bf11ca787481a9a41fbc05facb294,phase 1 study,0.474232
uuid-d08bf11ca787481a9a41fbc05facb294,efficacy and safety of nivolumab,0.43278
uuid-d08bf11ca787481a9a41fbc05facb294,CA209-003,0.571323
uuid-d08bf11ca787481a9a41fbc05facb294,phase 2 study,0.303628
uuid-d08bf11ca787481a9a41fbc05facb294,investigating,0.77075
uuid-c69b7e5b11514803876390081c6d67c8,search of published literature,0.394524
uuid-c69b7e5b11514803876390081c6d67c8,Additionally,0.413583
uuid-c69b7e5b11514803876390081c6d67c8,ongoing,0.322117
uuid-c69b7e5b11514803876390081c6d67c8,PubMed and EMBASE,0.391671
uuid-c69b7e5b11514803876390081c6d67c8,detailed search of www.clinicaltrials.gov,0.375936
uuid-c69b7e5b11514803876390081c6d67c8,efficacy and safety of nivolumab,0.370699
uuid-c69b7e5b11514803876390081c6d67c8,not identify any planned,0.34283
uuid-c69b7e5b11514803876390081c6d67c8,Weber JS,0.319229
uuid-c69b7e5b11514803876390081c6d67c8,not identify any citations relevant to your request,0.447813
uuid-c69b7e5b11514803876390081c6d67c8,present using the following search terms,0.408199
uuid-a3dfe91698b44e1987878b517a84506e,use of nivolumab for the treatment,0.305739
uuid-a3dfe91698b44e1987878b517a84506e,patients with advanced or metastatic,0.509457
uuid-a3dfe91698b44e1987878b517a84506e,nivolumab combined with ipilimumab,0.496885
uuid-a3dfe91698b44e1987878b517a84506e,not approved,0.397631
uuid-a3dfe91698b44e1987878b517a84506e,clinical trials investigating the safety,0.478965
uuid-a3dfe91698b44e1987878b517a84506e,bladder cancer,0.940126
uuid-ce4adaa986304253958cf73faf595858,evaluating,0.328997
uuid-ce4adaa986304253958cf73faf595858,not conducted any controlled clinical trials/studies,0.325444
uuid-ce4adaa986304253958cf73faf595858,protocol,0.534557
uuid-ce4adaa986304253958cf73faf595858,RCC,0.387518
uuid-ce4adaa986304253958cf73faf595858,McDermott DF,0.446693
uuid-ce4adaa986304253958cf73faf595858,search of published literature,0.507554
uuid-ce4adaa986304253958cf73faf595858,Additionally,0.557318
uuid-ce4adaa986304253958cf73faf595858,ongoing,0.480759
uuid-ce4adaa986304253958cf73faf595858,Motzer RJ,0.477516
uuid-ce4adaa986304253958cf73faf595858,PubMed and EMBASE,0.5052
uuid-ce4adaa986304253958cf73faf595858,Escudier B,0.461714
uuid-ce4adaa986304253958cf73faf595858,et al.,0.400032
uuid-ce4adaa986304253958cf73faf595858,J Clin Oncol,0.430273
uuid-ce4adaa986304253958cf73faf595858,detailed search of www.clinicaltrials.gov,0.517366
uuid-ce4adaa986304253958cf73faf595858,efficacy and safety of nivolumab,0.474802
uuid-ce4adaa986304253958cf73faf595858,not identify any planned,0.495387
uuid-ce4adaa986304253958cf73faf595858,phase 2 study,0.386789
uuid-ce4adaa986304253958cf73faf595858,not identify any citations relevant to your request,0.568753
uuid-ce4adaa986304253958cf73faf595858,present using the following search terms,0.493883
uuid-4a2743d8466b41a190e11d0a0968d707,95% CI,0.419478
uuid-4a2743d8466b41a190e11d0a0968d707,respectively,0.497608
uuid-4a2743d8466b41a190e11d0a0968d707,Objective response rate,0.403649
uuid-4a2743d8466b41a190e11d0a0968d707,ORR,0.578109
uuid-4a2743d8466b41a190e11d0a0968d707,patients with advanced or metastatic,0.306625
uuid-4a2743d8466b41a190e11d0a0968d707,Median overall survival,0.498783
uuid-4a2743d8466b41a190e11d0a0968d707,nivolumab combined with ipilimumab,0.300486
uuid-4a2743d8466b41a190e11d0a0968d707,tumors,0.323334
uuid-4a2743d8466b41a190e11d0a0968d707,ESMO,0.534361
uuid-4a2743d8466b41a190e11d0a0968d707,Median OS,0.394058
uuid-4a2743d8466b41a190e11d0a0968d707,small cell lung cancer,0.380999
uuid-4a2743d8466b41a190e11d0a0968d707,SCLC,0.365686
uuid-4a2743d8466b41a190e11d0a0968d707,hazard ratio,0.419392
uuid-4a2743d8466b41a190e11d0a0968d707,grade 3 to 4 AEs,0.414535
uuid-4a2743d8466b41a190e11d0a0968d707,phase 1/2 study CA209-032,0.398283
uuid-4a2743d8466b41a190e11d0a0968d707,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-8717e7e0f73c491b93468d50f7f3b53b,use of nivolumab for the treatment,0.305739
uuid-8717e7e0f73c491b93468d50f7f3b53b,patients with advanced or metastatic,0.509457
uuid-8717e7e0f73c491b93468d50f7f3b53b,nivolumab combined with ipilimumab,0.496885
uuid-8717e7e0f73c491b93468d50f7f3b53b,not approved,0.397631
uuid-8717e7e0f73c491b93468d50f7f3b53b,clinical trials investigating the safety,0.478965
uuid-8717e7e0f73c491b93468d50f7f3b53b,bladder cancer,0.940126
uuid-b756e4dc57e54399850093c6f2ea4b0a,ipilimumab,0.385692
uuid-b756e4dc57e54399850093c6f2ea4b0a,ASCO 2015,0.417944
uuid-b756e4dc57e54399850093c6f2ea4b0a,partial response,0.382425
uuid-b756e4dc57e54399850093c6f2ea4b0a,Stable disease,0.586335
uuid-b756e4dc57e54399850093c6f2ea4b0a,cohort,0.307748
uuid-053388fc51d3461fa2c0984888a19c5d,N Engl J Med,0.448483
uuid-053388fc51d3461fa2c0984888a19c5d,protocol,0.770446
uuid-053388fc51d3461fa2c0984888a19c5d,McDermott DF,0.741196
uuid-053388fc51d3461fa2c0984888a19c5d,Motzer RJ,0.818144
uuid-053388fc51d3461fa2c0984888a19c5d,phase 3 study,0.417055
uuid-053388fc51d3461fa2c0984888a19c5d,Escudier B,0.749917
uuid-053388fc51d3461fa2c0984888a19c5d,NEJM,0.400698
uuid-053388fc51d3461fa2c0984888a19c5d,et al.,0.668641
uuid-053388fc51d3461fa2c0984888a19c5d,J Clin Oncol,0.792018
uuid-053388fc51d3461fa2c0984888a19c5d,Topalian,0.388894
uuid-053388fc51d3461fa2c0984888a19c5d,phase 1 study,0.500686
uuid-053388fc51d3461fa2c0984888a19c5d,CA209-003,0.567381
uuid-053388fc51d3461fa2c0984888a19c5d,phase 2 study,0.677985
uuid-053388fc51d3461fa2c0984888a19c5d,present using the following search terms,0.310558
uuid-053388fc51d3461fa2c0984888a19c5d,investigating,0.615835
uuid-37dbfcf28c11488ea4aced3790b01833,patients with advanced or metastatic,0.478326
uuid-37dbfcf28c11488ea4aced3790b01833,nivolumab combined with ipilimumab,0.498766
uuid-37dbfcf28c11488ea4aced3790b01833,not approved,0.34724
uuid-37dbfcf28c11488ea4aced3790b01833,clinical trials investigating the safety,0.426729
uuid-37dbfcf28c11488ea4aced3790b01833,bladder cancer,0.6548
uuid-48ca927b2504474a9beef6422592eaca,nivolumab,0.568949
uuid-48ca927b2504474a9beef6422592eaca,Bristol-Myers Squibb,0.441767
uuid-48ca927b2504474a9beef6422592eaca,evaluating,0.597547
uuid-48ca927b2504474a9beef6422592eaca,not conducted any controlled clinical trials/studies,0.659101
uuid-48ca927b2504474a9beef6422592eaca,Pubmed literature search,0.876667
uuid-48ca927b2504474a9beef6422592eaca,purposes other than its labeled indication must be considered investigational,0.940059
uuid-48ca927b2504474a9beef6422592eaca,not identify any citations relevant to your inquiry,0.835655
uuid-48ca927b2504474a9beef6422592eaca,using the following search terms,0.823045
uuid-48ca927b2504474a9beef6422592eaca,efficacy and safety of nivolumab,0.437107
uuid-7e02fea549094f73afc95787e941a27b,provided in the Detailed Information,0.511879
uuid-7e02fea549094f73afc95787e941a27b,Overall survival,0.410247
uuid-5df16a46593840799ff24bb8b61e94b5,OS,0.62262
uuid-5df16a46593840799ff24bb8b61e94b5,PFS,0.65903
uuid-5df16a46593840799ff24bb8b61e94b5,Overall survival,0.644151
uuid-d75144df6f0a47d5b77a7c6c488f7a59,Opdivo,0.50165
uuid-d75144df6f0a47d5b77a7c6c488f7a59,open-label,0.304253
uuid-d75144df6f0a47d5b77a7c6c488f7a59,trial,0.521827
uuid-d75144df6f0a47d5b77a7c6c488f7a59,docetaxel,0.30238
uuid-d75144df6f0a47d5b77a7c6c488f7a59,safety of nivolumab monotherapy,0.432481
uuid-d75144df6f0a47d5b77a7c6c488f7a59,phase,0.378496
uuid-de31eb66a2fa449db66c7faebec5fd6e,nivolumab,0.573065
uuid-de31eb66a2fa449db66c7faebec5fd6e,Bristol-Myers Squibb,0.468911
uuid-de31eb66a2fa449db66c7faebec5fd6e,evaluating,0.667083
uuid-de31eb66a2fa449db66c7faebec5fd6e,not conducted any controlled clinical trials/studies,0.700034
uuid-de31eb66a2fa449db66c7faebec5fd6e,Pubmed literature search,0.789478
uuid-de31eb66a2fa449db66c7faebec5fd6e,purposes other than its labeled indication must be considered investigational,0.871588
uuid-de31eb66a2fa449db66c7faebec5fd6e,not identify any citations relevant to your inquiry,0.744753
uuid-de31eb66a2fa449db66c7faebec5fd6e,using the following search terms,0.72785
uuid-de31eb66a2fa449db66c7faebec5fd6e,efficacy and safety of nivolumab,0.494603
uuid-67897426def94b06a970becdec6b6b22,nivolumab,0.527963
uuid-67897426def94b06a970becdec6b6b22,Bristol-Myers Squibb,0.722473
uuid-67897426def94b06a970becdec6b6b22,evaluating,0.675792
uuid-67897426def94b06a970becdec6b6b22,not conducted any controlled clinical trials/studies,0.732864
uuid-67897426def94b06a970becdec6b6b22,purposes other than its labeled indication must be considered investigational,0.351124
uuid-67897426def94b06a970becdec6b6b22,efficacy and safety of nivolumab,0.596152
uuid-266f1905ce18448fbb68e68f8a28b115,search of published literature,0.394524
uuid-266f1905ce18448fbb68e68f8a28b115,Additionally,0.413583
uuid-266f1905ce18448fbb68e68f8a28b115,ongoing,0.322117
uuid-266f1905ce18448fbb68e68f8a28b115,PubMed and EMBASE,0.391671
uuid-266f1905ce18448fbb68e68f8a28b115,detailed search of www.clinicaltrials.gov,0.375936
uuid-266f1905ce18448fbb68e68f8a28b115,efficacy and safety of nivolumab,0.370699
uuid-266f1905ce18448fbb68e68f8a28b115,not identify any planned,0.34283
uuid-266f1905ce18448fbb68e68f8a28b115,Weber JS,0.319229
uuid-266f1905ce18448fbb68e68f8a28b115,not identify any citations relevant to your request,0.447813
uuid-266f1905ce18448fbb68e68f8a28b115,present using the following search terms,0.408199
uuid-4d7e09321ef446639990fb1e1ebc3af3,nivolumab,0.557964
uuid-4d7e09321ef446639990fb1e1ebc3af3,RCC,0.714062
uuid-2c0c07210f04403d8b20c472eafaba71,fatigue,0.704358
uuid-c78600aa60664345ad492ef8c4f8ffbc,95% CI,0.419478
uuid-c78600aa60664345ad492ef8c4f8ffbc,respectively,0.497608
uuid-c78600aa60664345ad492ef8c4f8ffbc,Objective response rate,0.403649
uuid-c78600aa60664345ad492ef8c4f8ffbc,ORR,0.578109
uuid-c78600aa60664345ad492ef8c4f8ffbc,patients with advanced or metastatic,0.306625
uuid-c78600aa60664345ad492ef8c4f8ffbc,Median overall survival,0.498783
uuid-c78600aa60664345ad492ef8c4f8ffbc,nivolumab combined with ipilimumab,0.300486
uuid-c78600aa60664345ad492ef8c4f8ffbc,tumors,0.323334
uuid-c78600aa60664345ad492ef8c4f8ffbc,ESMO,0.534361
uuid-c78600aa60664345ad492ef8c4f8ffbc,Median OS,0.394058
uuid-c78600aa60664345ad492ef8c4f8ffbc,small cell lung cancer,0.380999
uuid-c78600aa60664345ad492ef8c4f8ffbc,SCLC,0.365686
uuid-c78600aa60664345ad492ef8c4f8ffbc,hazard ratio,0.419392
uuid-c78600aa60664345ad492ef8c4f8ffbc,grade 3 to 4 AEs,0.414535
uuid-c78600aa60664345ad492ef8c4f8ffbc,phase 1/2 study CA209-032,0.398283
uuid-c78600aa60664345ad492ef8c4f8ffbc,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-40ef1b0dec174c339bba4f723f9929b1,nivolumab,0.436193
uuid-40ef1b0dec174c339bba4f723f9929b1,Bristol-Myers Squibb,0.451013
uuid-40ef1b0dec174c339bba4f723f9929b1,evaluating,0.607351
uuid-40ef1b0dec174c339bba4f723f9929b1,not conducted any controlled clinical trials/studies,0.634755
uuid-40ef1b0dec174c339bba4f723f9929b1,Pubmed literature search,0.67046
uuid-40ef1b0dec174c339bba4f723f9929b1,purposes other than its labeled indication must be considered investigational,0.734775
uuid-40ef1b0dec174c339bba4f723f9929b1,not identify any citations relevant to your inquiry,0.639311
uuid-40ef1b0dec174c339bba4f723f9929b1,using the following search terms,0.623521
uuid-40ef1b0dec174c339bba4f723f9929b1,efficacy and safety of nivolumab,0.467302
uuid-214d54bc3609423bb1a6f45f09538a60,open-label,0.539462
uuid-214d54bc3609423bb1a6f45f09538a60,phase,0.350616
uuid-1286f02caf354963855dc2dd48ba7d0c,Opdivo,0.50165
uuid-1286f02caf354963855dc2dd48ba7d0c,open-label,0.304253
uuid-1286f02caf354963855dc2dd48ba7d0c,trial,0.521827
uuid-1286f02caf354963855dc2dd48ba7d0c,docetaxel,0.30238
uuid-1286f02caf354963855dc2dd48ba7d0c,safety of nivolumab monotherapy,0.432481
uuid-1286f02caf354963855dc2dd48ba7d0c,phase,0.378496
uuid-a8a028740bab4ff69471c6b49d409d5d,requested,0.596876
uuid-17e82ee91da949c68b5c452710de5efc,Bristol-Myers Squibb,0.444935
uuid-17e82ee91da949c68b5c452710de5efc,evaluating,0.412107
uuid-17e82ee91da949c68b5c452710de5efc,not conducted any controlled clinical trials/studies,0.470139
uuid-17e82ee91da949c68b5c452710de5efc,Opdivo,0.399143
uuid-17e82ee91da949c68b5c452710de5efc,Pubmed literature search,0.604504
uuid-17e82ee91da949c68b5c452710de5efc,purposes other than its labeled indication must be considered investigational,0.609782
uuid-17e82ee91da949c68b5c452710de5efc,not identify any citations relevant to your inquiry,0.588223
uuid-17e82ee91da949c68b5c452710de5efc,using the following search terms,0.615845
uuid-17e82ee91da949c68b5c452710de5efc,efficacy and safety of nivolumab,0.34611
uuid-17e82ee91da949c68b5c452710de5efc,reported,0.510377
uuid-23900a2e9783486493294f8f2ace6bc1,Bristol-Myers Squibb,0.7893
uuid-23900a2e9783486493294f8f2ace6bc1,evaluating,0.677611
uuid-23900a2e9783486493294f8f2ace6bc1,not conducted any controlled clinical trials/studies,0.747775
uuid-23900a2e9783486493294f8f2ace6bc1,adverse,0.307448
uuid-23900a2e9783486493294f8f2ace6bc1,efficacy and safety of nivolumab,0.591222
uuid-23900a2e9783486493294f8f2ace6bc1,reported,0.332064
uuid-ef4ea0702e3445a5875407efb82efbfd,requested,0.44769
uuid-ef4ea0702e3445a5875407efb82efbfd,trial,0.309472
uuid-a143a6e8eef14905adabe4832956d8ea,nivolumab,0.635048
uuid-a143a6e8eef14905adabe4832956d8ea,Bristol-Myers Squibb,0.455651
uuid-a143a6e8eef14905adabe4832956d8ea,evaluating,0.67589
uuid-a143a6e8eef14905adabe4832956d8ea,not conducted any controlled clinical trials/studies,0.713812
uuid-a143a6e8eef14905adabe4832956d8ea,Pubmed literature search,0.787611
uuid-a143a6e8eef14905adabe4832956d8ea,purposes other than its labeled indication must be considered investigational,0.867666
uuid-a143a6e8eef14905adabe4832956d8ea,not identify any citations relevant to your inquiry,0.745483
uuid-a143a6e8eef14905adabe4832956d8ea,search of published literature,0.36203
uuid-a143a6e8eef14905adabe4832956d8ea,PubMed and EMBASE,0.335021
uuid-a143a6e8eef14905adabe4832956d8ea,using the following search terms,0.730789
uuid-a143a6e8eef14905adabe4832956d8ea,efficacy and safety of nivolumab,0.565497
uuid-a143a6e8eef14905adabe4832956d8ea,present using the following search terms,0.347393
uuid-129a805fc4ee412fadd8248971c75d14,protocol,0.308387
uuid-129a805fc4ee412fadd8248971c75d14,Motzer RJ,0.313363
uuid-129a805fc4ee412fadd8248971c75d14,Escudier B,0.301941
uuid-129a805fc4ee412fadd8248971c75d14,phase 2 study,0.307461
uuid-dd6710f5aaf8471d87f2621e96030532,Bristol-Myers Squibb,0.356985
uuid-dd6710f5aaf8471d87f2621e96030532,evaluating,0.439074
uuid-dd6710f5aaf8471d87f2621e96030532,not conducted any controlled clinical trials/studies,0.456974
uuid-dd6710f5aaf8471d87f2621e96030532,non-small cell lung cancer,0.305541
uuid-dd6710f5aaf8471d87f2621e96030532,Brahmer J,0.483529
uuid-dd6710f5aaf8471d87f2621e96030532,efficacy and safety of nivolumab,0.405605
uuid-dd6710f5aaf8471d87f2621e96030532,BMS,0.704113
uuid-72a5e183c4ed499aab86feee3d4311f6,nivolumab,0.811201
uuid-98b94a4b392c4627936690131e17a14d,search of published literature,0.660461
uuid-98b94a4b392c4627936690131e17a14d,clinical,0.495888
uuid-98b94a4b392c4627936690131e17a14d,phase 3 study,0.331361
uuid-98b94a4b392c4627936690131e17a14d,PubMed and EMBASE,0.658815
uuid-98b94a4b392c4627936690131e17a14d,trial,0.535061
uuid-98b94a4b392c4627936690131e17a14d,efficacy and safety of nivolumab,0.406604
uuid-98b94a4b392c4627936690131e17a14d,present using the following search terms,0.610357
uuid-62510c49eb0c4788ac0db334894a1ea3,adverse,0.60559
uuid-62510c49eb0c4788ac0db334894a1ea3,grade,0.30469
uuid-62510c49eb0c4788ac0db334894a1ea3,reported,0.535271
uuid-6965cdf64bd64914bec6c6e7fb7363da,N Engl J Med,0.448483
uuid-6965cdf64bd64914bec6c6e7fb7363da,protocol,0.770446
uuid-6965cdf64bd64914bec6c6e7fb7363da,McDermott DF,0.741196
uuid-6965cdf64bd64914bec6c6e7fb7363da,Motzer RJ,0.818144
uuid-6965cdf64bd64914bec6c6e7fb7363da,phase 3 study,0.417055
uuid-6965cdf64bd64914bec6c6e7fb7363da,Escudier B,0.749917
uuid-6965cdf64bd64914bec6c6e7fb7363da,NEJM,0.400698
uuid-6965cdf64bd64914bec6c6e7fb7363da,et al.,0.668641
uuid-6965cdf64bd64914bec6c6e7fb7363da,J Clin Oncol,0.792018
uuid-6965cdf64bd64914bec6c6e7fb7363da,Topalian,0.388894
uuid-6965cdf64bd64914bec6c6e7fb7363da,phase 1 study,0.500686
uuid-6965cdf64bd64914bec6c6e7fb7363da,CA209-003,0.567381
uuid-6965cdf64bd64914bec6c6e7fb7363da,phase 2 study,0.677985
uuid-6965cdf64bd64914bec6c6e7fb7363da,present using the following search terms,0.310558
uuid-6965cdf64bd64914bec6c6e7fb7363da,investigating,0.615835
uuid-00b32976a9ef49b483cedbd6525c9302,nivolumab,0.359772
uuid-8ebffa5bd5624ddaa3971a7ea20f7064,trial,0.415633
uuid-fe4912d4447a49018d887e0c6e9056b1,requested,0.596715
uuid-fe4912d4447a49018d887e0c6e9056b1,therapy,0.355745
uuid-f1914a4ffa8a49a091cea061a004ba49,clinical,0.317816
uuid-f1914a4ffa8a49a091cea061a004ba49,therapy,0.379163
uuid-08721a717da640469b9a7e40672547c4,patients,0.350185
uuid-08721a717da640469b9a7e40672547c4,protocol,0.364313
uuid-08721a717da640469b9a7e40672547c4,McDermott DF,0.39108
uuid-08721a717da640469b9a7e40672547c4,Motzer RJ,0.394397
uuid-08721a717da640469b9a7e40672547c4,phase 3 study,0.461915
uuid-08721a717da640469b9a7e40672547c4,Escudier B,0.393278
uuid-08721a717da640469b9a7e40672547c4,et al.,0.363785
uuid-08721a717da640469b9a7e40672547c4,J Clin Oncol,0.3454
uuid-08721a717da640469b9a7e40672547c4,Rizvi NA,0.387522
uuid-08721a717da640469b9a7e40672547c4,Weber JS,0.414993
uuid-08721a717da640469b9a7e40672547c4,phase 2 study,0.445652
uuid-19c16a941ce24effbd10ab2aed906108,N Engl J Med,0.448483
uuid-19c16a941ce24effbd10ab2aed906108,protocol,0.770446
uuid-19c16a941ce24effbd10ab2aed906108,McDermott DF,0.741196
uuid-19c16a941ce24effbd10ab2aed906108,Motzer RJ,0.818144
uuid-19c16a941ce24effbd10ab2aed906108,phase 3 study,0.417055
uuid-19c16a941ce24effbd10ab2aed906108,Escudier B,0.749917
uuid-19c16a941ce24effbd10ab2aed906108,NEJM,0.400698
uuid-19c16a941ce24effbd10ab2aed906108,et al.,0.668641
uuid-19c16a941ce24effbd10ab2aed906108,J Clin Oncol,0.792018
uuid-19c16a941ce24effbd10ab2aed906108,Topalian,0.388894
uuid-19c16a941ce24effbd10ab2aed906108,phase 1 study,0.500686
uuid-19c16a941ce24effbd10ab2aed906108,CA209-003,0.567381
uuid-19c16a941ce24effbd10ab2aed906108,phase 2 study,0.677985
uuid-19c16a941ce24effbd10ab2aed906108,present using the following search terms,0.310558
uuid-19c16a941ce24effbd10ab2aed906108,investigating,0.615835
uuid-cd490d431af04c0ea1eba8157774026b,nivolumab,0.574182
uuid-cd490d431af04c0ea1eba8157774026b,Bristol-Myers Squibb,0.357574
uuid-cd490d431af04c0ea1eba8157774026b,evaluating,0.526908
uuid-cd490d431af04c0ea1eba8157774026b,not conducted any controlled clinical trials/studies,0.560727
uuid-cd490d431af04c0ea1eba8157774026b,Pubmed literature search,0.759837
uuid-cd490d431af04c0ea1eba8157774026b,purposes other than its labeled indication must be considered investigational,0.811573
uuid-cd490d431af04c0ea1eba8157774026b,not identify any citations relevant to your inquiry,0.752396
uuid-cd490d431af04c0ea1eba8157774026b,Additionally,0.360985
uuid-cd490d431af04c0ea1eba8157774026b,ongoing,0.366867
uuid-cd490d431af04c0ea1eba8157774026b,using the following search terms,0.719791
uuid-cd490d431af04c0ea1eba8157774026b,detailed search of www.clinicaltrials.gov,0.382629
uuid-cd490d431af04c0ea1eba8157774026b,efficacy and safety of nivolumab,0.41591
uuid-cd490d431af04c0ea1eba8157774026b,not identify any planned,0.370776
uuid-cd490d431af04c0ea1eba8157774026b,not identify any citations relevant to your request,0.378244
uuid-704ec3e3b93848bfa385fbcc5793da47,Bristol-Myers Squibb,0.341822
uuid-704ec3e3b93848bfa385fbcc5793da47,not conducted any controlled clinical trials/studies,0.304507
uuid-704ec3e3b93848bfa385fbcc5793da47,Opdivo,0.461382
uuid-704ec3e3b93848bfa385fbcc5793da47,Pubmed literature search,0.614325
uuid-704ec3e3b93848bfa385fbcc5793da47,purposes other than its labeled indication must be considered investigational,0.586645
uuid-704ec3e3b93848bfa385fbcc5793da47,not identify any citations relevant to your inquiry,0.606087
uuid-704ec3e3b93848bfa385fbcc5793da47,adverse,0.304183
uuid-704ec3e3b93848bfa385fbcc5793da47,using the following search terms,0.642331
uuid-704ec3e3b93848bfa385fbcc5793da47,databases,0.315039
uuid-704ec3e3b93848bfa385fbcc5793da47,reported,0.556704
uuid-1c59e605d1bd477dad807727fdef394c,evaluating,0.327649
uuid-1c59e605d1bd477dad807727fdef394c,95% CI,0.523102
uuid-1c59e605d1bd477dad807727fdef394c,patients,0.304107
uuid-1c59e605d1bd477dad807727fdef394c,Objective response rate,0.356133
uuid-1c59e605d1bd477dad807727fdef394c,ORR,0.404161
uuid-1c59e605d1bd477dad807727fdef394c,Median overall survival,0.440135
uuid-1c59e605d1bd477dad807727fdef394c,monotherapy,0.316329
uuid-1c59e605d1bd477dad807727fdef394c,phase 3 study,0.327459
uuid-1c59e605d1bd477dad807727fdef394c,Median OS,0.437626
uuid-1c59e605d1bd477dad807727fdef394c,efficacy and safety of nivolumab,0.331863
uuid-1c59e605d1bd477dad807727fdef394c,hazard ratio,0.529032
uuid-8d3c77ca08b649d09f76c9f501455d5e,efficacy,0.309807
uuid-8d3c77ca08b649d09f76c9f501455d5e,safety,0.413595
uuid-d40bc28df57a4209b1329a41ef34063f,OS,0.62262
uuid-d40bc28df57a4209b1329a41ef34063f,PFS,0.65903
uuid-d40bc28df57a4209b1329a41ef34063f,Overall survival,0.644151
uuid-3c3332b88944432a8330127a6f8675ea,nivolumab,0.395254
uuid-3c3332b88944432a8330127a6f8675ea,Bristol-Myers Squibb,0.357076
uuid-3c3332b88944432a8330127a6f8675ea,evaluating,0.521004
uuid-3c3332b88944432a8330127a6f8675ea,not conducted any controlled clinical trials/studies,0.513109
uuid-3c3332b88944432a8330127a6f8675ea,purposes other than its labeled indication must be considered investigational,0.332144
uuid-3c3332b88944432a8330127a6f8675ea,search of published literature,0.439582
uuid-3c3332b88944432a8330127a6f8675ea,Additionally,0.338663
uuid-3c3332b88944432a8330127a6f8675ea,PubMed and EMBASE,0.423322
uuid-3c3332b88944432a8330127a6f8675ea,detailed search of www.clinicaltrials.gov,0.316109
uuid-3c3332b88944432a8330127a6f8675ea,phase 1 study,0.510471
uuid-3c3332b88944432a8330127a6f8675ea,efficacy and safety of nivolumab,0.577583
uuid-3c3332b88944432a8330127a6f8675ea,CA209-003,0.57104
uuid-3c3332b88944432a8330127a6f8675ea,not identify any citations relevant to your request,0.418312
uuid-3c3332b88944432a8330127a6f8675ea,present using the following search terms,0.467146
uuid-3c3332b88944432a8330127a6f8675ea,investigating,0.686657
uuid-4dacec2303994c36bb270c7b88537e27,Opdivo,0.50165
uuid-4dacec2303994c36bb270c7b88537e27,open-label,0.304253
uuid-4dacec2303994c36bb270c7b88537e27,trial,0.521827
uuid-4dacec2303994c36bb270c7b88537e27,docetaxel,0.30238
uuid-4dacec2303994c36bb270c7b88537e27,safety of nivolumab monotherapy,0.432481
uuid-4dacec2303994c36bb270c7b88537e27,phase,0.378496
uuid-37b8bc18526d46fda2b5cf29a0363372,nivolumab,0.520431
uuid-37b8bc18526d46fda2b5cf29a0363372,Bristol-Myers Squibb,0.445924
uuid-37b8bc18526d46fda2b5cf29a0363372,evaluating,0.569205
uuid-37b8bc18526d46fda2b5cf29a0363372,not conducted any controlled clinical trials/studies,0.637929
uuid-37b8bc18526d46fda2b5cf29a0363372,Pubmed literature search,0.750852
uuid-37b8bc18526d46fda2b5cf29a0363372,purposes other than its labeled indication must be considered investigational,0.823465
uuid-37b8bc18526d46fda2b5cf29a0363372,not identify any citations relevant to your inquiry,0.70978
uuid-37b8bc18526d46fda2b5cf29a0363372,using the following search terms,0.695032
uuid-37b8bc18526d46fda2b5cf29a0363372,efficacy and safety of nivolumab,0.428097
uuid-57abc4d36b0d401c99e88dcbd2e91ec4,AEs,0.605338
uuid-57abc4d36b0d401c99e88dcbd2e91ec4,grade,0.874091
uuid-57abc4d36b0d401c99e88dcbd2e91ec4,grade 3 to 4 AEs,0.485247
uuid-5b98d26e9fc74c3694f37688753c3acb,Objective response rate,0.451139
uuid-5b98d26e9fc74c3694f37688753c3acb,clinicaltrials.gov,0.503706
uuid-d0465d2932894fdcb0a9806a91c841b7,NSCLC,0.327373
uuid-d0465d2932894fdcb0a9806a91c841b7,respectively,0.32989
uuid-d0465d2932894fdcb0a9806a91c841b7,Objective response rate,0.414926
uuid-d0465d2932894fdcb0a9806a91c841b7,ORR,0.46431
uuid-d0465d2932894fdcb0a9806a91c841b7,Median overall survival,0.358033
uuid-5148ff122f634d5189c8c3f89f9e7ab1,patients with advanced or metastatic,0.489046
uuid-5148ff122f634d5189c8c3f89f9e7ab1,nivolumab combined with ipilimumab,0.471544
uuid-5148ff122f634d5189c8c3f89f9e7ab1,not approved,0.37469
uuid-5148ff122f634d5189c8c3f89f9e7ab1,clinical trials investigating the safety,0.453858
uuid-5148ff122f634d5189c8c3f89f9e7ab1,bladder cancer,0.947249
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,N Engl J Med,0.689907
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Lancet Oncol,0.584216
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,protocol,0.72528
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,McDermott DF,0.794444
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Motzer RJ,0.755383
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,phase 3 study,0.521307
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Escudier B,0.794743
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,NEJM,0.434762
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,et al.,0.777092
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,J Clin Oncol,0.708338
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Topalian,0.401719
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Rizvi NA,0.731383
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Brahmer J,0.378658
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,Weber JS,0.614831
uuid-3a8ba6fde3f344e6a7c76aebd32ba99c,phase 2 study,0.769458
uuid-72cb78616e7b4b868459d8d55e04afb5,95% CI,0.419478
uuid-72cb78616e7b4b868459d8d55e04afb5,respectively,0.497608
uuid-72cb78616e7b4b868459d8d55e04afb5,Objective response rate,0.403649
uuid-72cb78616e7b4b868459d8d55e04afb5,ORR,0.578109
uuid-72cb78616e7b4b868459d8d55e04afb5,patients with advanced or metastatic,0.306625
uuid-72cb78616e7b4b868459d8d55e04afb5,Median overall survival,0.498783
uuid-72cb78616e7b4b868459d8d55e04afb5,nivolumab combined with ipilimumab,0.300486
uuid-72cb78616e7b4b868459d8d55e04afb5,tumors,0.323334
uuid-72cb78616e7b4b868459d8d55e04afb5,ESMO,0.534361
uuid-72cb78616e7b4b868459d8d55e04afb5,Median OS,0.394058
uuid-72cb78616e7b4b868459d8d55e04afb5,small cell lung cancer,0.380999
uuid-72cb78616e7b4b868459d8d55e04afb5,SCLC,0.365686
uuid-72cb78616e7b4b868459d8d55e04afb5,hazard ratio,0.419392
uuid-72cb78616e7b4b868459d8d55e04afb5,grade 3 to 4 AEs,0.414535
uuid-72cb78616e7b4b868459d8d55e04afb5,phase 1/2 study CA209-032,0.398283
uuid-72cb78616e7b4b868459d8d55e04afb5,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-23e2f05769b54a85ab6966b24ba4dd98,evaluating,0.430293
uuid-23e2f05769b54a85ab6966b24ba4dd98,not conducted any controlled clinical trials/studies,0.38775
uuid-23e2f05769b54a85ab6966b24ba4dd98,95% CI,0.512404
uuid-23e2f05769b54a85ab6966b24ba4dd98,patients,0.376958
uuid-23e2f05769b54a85ab6966b24ba4dd98,Objective response rate,0.303518
uuid-23e2f05769b54a85ab6966b24ba4dd98,ORR,0.405144
uuid-23e2f05769b54a85ab6966b24ba4dd98,Median overall survival,0.462907
uuid-23e2f05769b54a85ab6966b24ba4dd98,search of published literature,0.428819
uuid-23e2f05769b54a85ab6966b24ba4dd98,PubMed and EMBASE,0.41128
uuid-23e2f05769b54a85ab6966b24ba4dd98,Median OS,0.437957
uuid-23e2f05769b54a85ab6966b24ba4dd98,melanoma,0.300184
uuid-23e2f05769b54a85ab6966b24ba4dd98,efficacy and safety of nivolumab,0.484442
uuid-23e2f05769b54a85ab6966b24ba4dd98,present using the following search terms,0.410715
uuid-23e2f05769b54a85ab6966b24ba4dd98,hazard ratio,0.519224
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,patients,0.556054
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,provided in the Detailed Information,0.329929
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,adverse,0.32982
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,phase 3 study,0.523726
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,melanoma,0.382071
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,Weber JS,0.428777
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,phase 2 study,0.307314
uuid-034f9ecf67b04cc09dbb813a8cdec9dc,grade 3 to 4 AEs,0.466022
uuid-28c8a2a99056406d99d9120cbb15cb5c,nivolumab,0.530519
uuid-28c8a2a99056406d99d9120cbb15cb5c,Bristol-Myers Squibb,0.454062
uuid-28c8a2a99056406d99d9120cbb15cb5c,evaluating,0.564939
uuid-28c8a2a99056406d99d9120cbb15cb5c,not conducted any controlled clinical trials/studies,0.615545
uuid-28c8a2a99056406d99d9120cbb15cb5c,Pubmed literature search,0.72524
uuid-28c8a2a99056406d99d9120cbb15cb5c,purposes other than its labeled indication must be considered investigational,0.776897
uuid-28c8a2a99056406d99d9120cbb15cb5c,not identify any citations relevant to your inquiry,0.71431
uuid-28c8a2a99056406d99d9120cbb15cb5c,using the following search terms,0.689812
uuid-28c8a2a99056406d99d9120cbb15cb5c,efficacy and safety of nivolumab,0.475505
uuid-28c8a2a99056406d99d9120cbb15cb5c,not identify any citations relevant to your request,0.323074
uuid-28c8a2a99056406d99d9120cbb15cb5c,present using the following search terms,0.305541
uuid-8855394d781d4d2bac95696576332bdb,requested,0.691974
uuid-8855394d781d4d2bac95696576332bdb,RCC,0.374973
uuid-3b03bba520614a25ad238990d5e77621,Objective response rate,0.451139
uuid-3b03bba520614a25ad238990d5e77621,clinicaltrials.gov,0.503706
uuid-99c98ef14a584259aace5ae4c6ba077d,Bristol-Myers Squibb,0.494637
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,use of nivolumab for the treatment,0.409821
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,patients with advanced or metastatic,0.645244
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,nivolumab combined with ipilimumab,0.676339
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,not approved,0.453534
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,clinical trials investigating the safety,0.548799
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,phase 1/2 study CA209-032,0.34114
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,bladder cancer,0.749142
uuid-a162f13cfdfe4715a4fc61d2a5b1a743,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-f3e565a184fc412ba723b028602c160a,trial,0.353912
uuid-5295cad5a2c345b3b0435c3619075be1,nivolumab,0.325654
uuid-5295cad5a2c345b3b0435c3619075be1,clinical,0.455
uuid-5295cad5a2c345b3b0435c3619075be1,therapy,0.326015
uuid-1524f0789b5e4de5842c4f5f1253966b,Opdivo,0.50165
uuid-1524f0789b5e4de5842c4f5f1253966b,open-label,0.304253
uuid-1524f0789b5e4de5842c4f5f1253966b,trial,0.521827
uuid-1524f0789b5e4de5842c4f5f1253966b,docetaxel,0.30238
uuid-1524f0789b5e4de5842c4f5f1253966b,safety of nivolumab monotherapy,0.432481
uuid-1524f0789b5e4de5842c4f5f1253966b,phase,0.378496
uuid-c7cd1ffb7a18483cb3793796dc620bf5,nivolumab,0.343098
uuid-c7cd1ffb7a18483cb3793796dc620bf5,Bristol-Myers Squibb,0.351759
uuid-c7cd1ffb7a18483cb3793796dc620bf5,evaluating,0.532241
uuid-c7cd1ffb7a18483cb3793796dc620bf5,not conducted any controlled clinical trials/studies,0.512822
uuid-c7cd1ffb7a18483cb3793796dc620bf5,RCC,0.318064
uuid-c7cd1ffb7a18483cb3793796dc620bf5,search of published literature,0.722027
uuid-c7cd1ffb7a18483cb3793796dc620bf5,Additionally,0.756669
uuid-c7cd1ffb7a18483cb3793796dc620bf5,ongoing,0.620938
uuid-c7cd1ffb7a18483cb3793796dc620bf5,PubMed and EMBASE,0.716641
uuid-c7cd1ffb7a18483cb3793796dc620bf5,detailed search of www.clinicaltrials.gov,0.716874
uuid-c7cd1ffb7a18483cb3793796dc620bf5,efficacy and safety of nivolumab,0.698792
uuid-c7cd1ffb7a18483cb3793796dc620bf5,not identify any planned,0.655092
uuid-c7cd1ffb7a18483cb3793796dc620bf5,not identify any citations relevant to your request,0.830665
uuid-c7cd1ffb7a18483cb3793796dc620bf5,present using the following search terms,0.744432
uuid-c18c9b1348664a43988121fb41ed90a9,N Engl J Med,0.373043
uuid-c18c9b1348664a43988121fb41ed90a9,protocol,0.46881
uuid-c18c9b1348664a43988121fb41ed90a9,McDermott DF,0.576976
uuid-c18c9b1348664a43988121fb41ed90a9,Motzer RJ,0.550553
uuid-c18c9b1348664a43988121fb41ed90a9,phase 3 study,0.466524
uuid-c18c9b1348664a43988121fb41ed90a9,Escudier B,0.56633
uuid-c18c9b1348664a43988121fb41ed90a9,et al.,0.5383
uuid-c18c9b1348664a43988121fb41ed90a9,J Clin Oncol,0.527144
uuid-c18c9b1348664a43988121fb41ed90a9,phase 2 study,0.569024
uuid-df9fba101dba47a19c272e43348ed149,use of nivolumab for the treatment,0.409821
uuid-df9fba101dba47a19c272e43348ed149,patients with advanced or metastatic,0.645244
uuid-df9fba101dba47a19c272e43348ed149,nivolumab combined with ipilimumab,0.676339
uuid-df9fba101dba47a19c272e43348ed149,not approved,0.453534
uuid-df9fba101dba47a19c272e43348ed149,clinical trials investigating the safety,0.548799
uuid-df9fba101dba47a19c272e43348ed149,phase 1/2 study CA209-032,0.34114
uuid-df9fba101dba47a19c272e43348ed149,bladder cancer,0.749142
uuid-df9fba101dba47a19c272e43348ed149,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-c649857981d04948b51969801caa699d,N Engl J Med,0.689907
uuid-c649857981d04948b51969801caa699d,Lancet Oncol,0.584216
uuid-c649857981d04948b51969801caa699d,protocol,0.72528
uuid-c649857981d04948b51969801caa699d,McDermott DF,0.794444
uuid-c649857981d04948b51969801caa699d,Motzer RJ,0.755383
uuid-c649857981d04948b51969801caa699d,phase 3 study,0.521307
uuid-c649857981d04948b51969801caa699d,Escudier B,0.794743
uuid-c649857981d04948b51969801caa699d,NEJM,0.434762
uuid-c649857981d04948b51969801caa699d,et al.,0.777092
uuid-c649857981d04948b51969801caa699d,J Clin Oncol,0.708338
uuid-c649857981d04948b51969801caa699d,Topalian,0.401719
uuid-c649857981d04948b51969801caa699d,Rizvi NA,0.731383
uuid-c649857981d04948b51969801caa699d,Brahmer J,0.378658
uuid-c649857981d04948b51969801caa699d,Weber JS,0.614831
uuid-c649857981d04948b51969801caa699d,phase 2 study,0.769458
uuid-e0a56af9f0a14cbc94f6418465868772,nivolumab,0.583463
uuid-e0a56af9f0a14cbc94f6418465868772,Bristol-Myers Squibb,0.439221
uuid-e0a56af9f0a14cbc94f6418465868772,evaluating,0.609367
uuid-e0a56af9f0a14cbc94f6418465868772,not conducted any controlled clinical trials/studies,0.660183
uuid-e0a56af9f0a14cbc94f6418465868772,Pubmed literature search,0.833752
uuid-e0a56af9f0a14cbc94f6418465868772,purposes other than its labeled indication must be considered investigational,0.906393
uuid-e0a56af9f0a14cbc94f6418465868772,not identify any citations relevant to your inquiry,0.790878
uuid-e0a56af9f0a14cbc94f6418465868772,using the following search terms,0.776939
uuid-e0a56af9f0a14cbc94f6418465868772,efficacy and safety of nivolumab,0.437175
uuid-f315b77fadca48b3aed6ed106a12ad5b,N Engl J Med,0.689907
uuid-f315b77fadca48b3aed6ed106a12ad5b,Lancet Oncol,0.584216
uuid-f315b77fadca48b3aed6ed106a12ad5b,protocol,0.72528
uuid-f315b77fadca48b3aed6ed106a12ad5b,McDermott DF,0.794444
uuid-f315b77fadca48b3aed6ed106a12ad5b,Motzer RJ,0.755383
uuid-f315b77fadca48b3aed6ed106a12ad5b,phase 3 study,0.521307
uuid-f315b77fadca48b3aed6ed106a12ad5b,Escudier B,0.794743
uuid-f315b77fadca48b3aed6ed106a12ad5b,NEJM,0.434762
uuid-f315b77fadca48b3aed6ed106a12ad5b,et al.,0.777092
uuid-f315b77fadca48b3aed6ed106a12ad5b,J Clin Oncol,0.708338
uuid-f315b77fadca48b3aed6ed106a12ad5b,Topalian,0.401719
uuid-f315b77fadca48b3aed6ed106a12ad5b,Rizvi NA,0.731383
uuid-f315b77fadca48b3aed6ed106a12ad5b,Brahmer J,0.378658
uuid-f315b77fadca48b3aed6ed106a12ad5b,Weber JS,0.614831
uuid-f315b77fadca48b3aed6ed106a12ad5b,phase 2 study,0.769458
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,N Engl J Med,0.302601
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,AEs,0.348167
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,patients,0.536884
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,provided in the Detailed Information,0.387544
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,ESMO,0.462801
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,NEJM,0.66427
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,Topalian,0.692873
uuid-3ab0e5c418e64f0eb80e44d2c2653ffe,grade 3 to 4 AEs,0.626596
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,N Engl J Med,0.321308
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,protocol,0.353939
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,McDermott DF,0.35843
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,Motzer RJ,0.345777
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,Escudier B,0.361696
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,et al.,0.364897
uuid-c18b5a6b6a644221acf5c5ec1b5f1959,J Clin Oncol,0.305637
uuid-74d82b8cc6204241b4350263c78d846e,requested,0.596876
uuid-983fce1ceb18447c9db6ba122ad9b97e,requested,0.596876
uuid-58972845d55e441fa762fc5dc9f585a0,Bristol-Myers Squibb,0.353476
uuid-58972845d55e441fa762fc5dc9f585a0,N Engl J Med,0.390731
uuid-58972845d55e441fa762fc5dc9f585a0,protocol,0.639185
uuid-58972845d55e441fa762fc5dc9f585a0,McDermott DF,0.654805
uuid-58972845d55e441fa762fc5dc9f585a0,Motzer RJ,0.714531
uuid-58972845d55e441fa762fc5dc9f585a0,phase 3 study,0.481465
uuid-58972845d55e441fa762fc5dc9f585a0,Escudier B,0.658723
uuid-58972845d55e441fa762fc5dc9f585a0,NEJM,0.306698
uuid-58972845d55e441fa762fc5dc9f585a0,et al.,0.588613
uuid-58972845d55e441fa762fc5dc9f585a0,J Clin Oncol,0.675658
uuid-58972845d55e441fa762fc5dc9f585a0,Topalian,0.306189
uuid-58972845d55e441fa762fc5dc9f585a0,phase 1 study,0.435154
uuid-58972845d55e441fa762fc5dc9f585a0,CA209-003,0.482874
uuid-58972845d55e441fa762fc5dc9f585a0,phase 2 study,0.601549
uuid-58972845d55e441fa762fc5dc9f585a0,investigating,0.526991
uuid-4620b4e373f24b6bb42e8845dddfb47c,nivolumab,0.575565
uuid-4620b4e373f24b6bb42e8845dddfb47c,Bristol-Myers Squibb,0.457373
uuid-4620b4e373f24b6bb42e8845dddfb47c,evaluating,0.618387
uuid-4620b4e373f24b6bb42e8845dddfb47c,not conducted any controlled clinical trials/studies,0.673391
uuid-4620b4e373f24b6bb42e8845dddfb47c,Pubmed literature search,0.856544
uuid-4620b4e373f24b6bb42e8845dddfb47c,purposes other than its labeled indication must be considered investigational,0.924886
uuid-4620b4e373f24b6bb42e8845dddfb47c,not identify any citations relevant to your inquiry,0.814424
uuid-4620b4e373f24b6bb42e8845dddfb47c,using the following search terms,0.801208
uuid-4620b4e373f24b6bb42e8845dddfb47c,efficacy and safety of nivolumab,0.452836
uuid-b36d5cffff4c4b92ba35238036cd79a8,95% CI,0.419478
uuid-b36d5cffff4c4b92ba35238036cd79a8,respectively,0.497608
uuid-b36d5cffff4c4b92ba35238036cd79a8,Objective response rate,0.403649
uuid-b36d5cffff4c4b92ba35238036cd79a8,ORR,0.578109
uuid-b36d5cffff4c4b92ba35238036cd79a8,patients with advanced or metastatic,0.306625
uuid-b36d5cffff4c4b92ba35238036cd79a8,Median overall survival,0.498783
uuid-b36d5cffff4c4b92ba35238036cd79a8,nivolumab combined with ipilimumab,0.300486
uuid-b36d5cffff4c4b92ba35238036cd79a8,tumors,0.323334
uuid-b36d5cffff4c4b92ba35238036cd79a8,ESMO,0.534361
uuid-b36d5cffff4c4b92ba35238036cd79a8,Median OS,0.394058
uuid-b36d5cffff4c4b92ba35238036cd79a8,small cell lung cancer,0.380999
uuid-b36d5cffff4c4b92ba35238036cd79a8,SCLC,0.365686
uuid-b36d5cffff4c4b92ba35238036cd79a8,hazard ratio,0.419392
uuid-b36d5cffff4c4b92ba35238036cd79a8,grade 3 to 4 AEs,0.414535
uuid-b36d5cffff4c4b92ba35238036cd79a8,phase 1/2 study CA209-032,0.398283
uuid-b36d5cffff4c4b92ba35238036cd79a8,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-d46bf21dc0f749e893fd62c30acd4fae,nivolumab,0.520431
uuid-d46bf21dc0f749e893fd62c30acd4fae,Bristol-Myers Squibb,0.445924
uuid-d46bf21dc0f749e893fd62c30acd4fae,evaluating,0.569205
uuid-d46bf21dc0f749e893fd62c30acd4fae,not conducted any controlled clinical trials/studies,0.637929
uuid-d46bf21dc0f749e893fd62c30acd4fae,Pubmed literature search,0.750852
uuid-d46bf21dc0f749e893fd62c30acd4fae,purposes other than its labeled indication must be considered investigational,0.823465
uuid-d46bf21dc0f749e893fd62c30acd4fae,not identify any citations relevant to your inquiry,0.70978
uuid-d46bf21dc0f749e893fd62c30acd4fae,using the following search terms,0.695032
uuid-d46bf21dc0f749e893fd62c30acd4fae,efficacy and safety of nivolumab,0.428097
uuid-fb1d2e6f433e42699f2a5b04a99343c7,Bristol-Myers Squibb,0.341822
uuid-fb1d2e6f433e42699f2a5b04a99343c7,not conducted any controlled clinical trials/studies,0.304507
uuid-fb1d2e6f433e42699f2a5b04a99343c7,Opdivo,0.461382
uuid-fb1d2e6f433e42699f2a5b04a99343c7,Pubmed literature search,0.614325
uuid-fb1d2e6f433e42699f2a5b04a99343c7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-fb1d2e6f433e42699f2a5b04a99343c7,not identify any citations relevant to your inquiry,0.606087
uuid-fb1d2e6f433e42699f2a5b04a99343c7,adverse,0.304183
uuid-fb1d2e6f433e42699f2a5b04a99343c7,using the following search terms,0.642331
uuid-fb1d2e6f433e42699f2a5b04a99343c7,databases,0.315039
uuid-fb1d2e6f433e42699f2a5b04a99343c7,reported,0.556704
uuid-7d32be4edd2a4d639afcebd26e89fae2,search of published literature,0.394524
uuid-7d32be4edd2a4d639afcebd26e89fae2,Additionally,0.413583
uuid-7d32be4edd2a4d639afcebd26e89fae2,ongoing,0.322117
uuid-7d32be4edd2a4d639afcebd26e89fae2,PubMed and EMBASE,0.391671
uuid-7d32be4edd2a4d639afcebd26e89fae2,detailed search of www.clinicaltrials.gov,0.375936
uuid-7d32be4edd2a4d639afcebd26e89fae2,efficacy and safety of nivolumab,0.370699
uuid-7d32be4edd2a4d639afcebd26e89fae2,not identify any planned,0.34283
uuid-7d32be4edd2a4d639afcebd26e89fae2,Weber JS,0.319229
uuid-7d32be4edd2a4d639afcebd26e89fae2,not identify any citations relevant to your request,0.447813
uuid-7d32be4edd2a4d639afcebd26e89fae2,present using the following search terms,0.408199
uuid-f397cb98a5594f4a9d1a4008abea19c7,patients with advanced or metastatic,0.478326
uuid-f397cb98a5594f4a9d1a4008abea19c7,nivolumab combined with ipilimumab,0.498766
uuid-f397cb98a5594f4a9d1a4008abea19c7,not approved,0.34724
uuid-f397cb98a5594f4a9d1a4008abea19c7,clinical trials investigating the safety,0.426729
uuid-f397cb98a5594f4a9d1a4008abea19c7,bladder cancer,0.6548
uuid-226a10af43504d44b1d29ff74b5a010a,N Engl J Med,0.689907
uuid-226a10af43504d44b1d29ff74b5a010a,Lancet Oncol,0.584216
uuid-226a10af43504d44b1d29ff74b5a010a,protocol,0.72528
uuid-226a10af43504d44b1d29ff74b5a010a,McDermott DF,0.794444
uuid-226a10af43504d44b1d29ff74b5a010a,Motzer RJ,0.755383
uuid-226a10af43504d44b1d29ff74b5a010a,phase 3 study,0.521307
uuid-226a10af43504d44b1d29ff74b5a010a,Escudier B,0.794743
uuid-226a10af43504d44b1d29ff74b5a010a,NEJM,0.434762
uuid-226a10af43504d44b1d29ff74b5a010a,et al.,0.777092
uuid-226a10af43504d44b1d29ff74b5a010a,J Clin Oncol,0.708338
uuid-226a10af43504d44b1d29ff74b5a010a,Topalian,0.401719
uuid-226a10af43504d44b1d29ff74b5a010a,Rizvi NA,0.731383
uuid-226a10af43504d44b1d29ff74b5a010a,Brahmer J,0.378658
uuid-226a10af43504d44b1d29ff74b5a010a,Weber JS,0.614831
uuid-226a10af43504d44b1d29ff74b5a010a,phase 2 study,0.769458
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,OS,0.386958
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,95% CI,0.821802
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,ORR,0.350294
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,PFS,0.34735
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,Median overall survival,0.706527
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,Median OS,0.73574
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,hazard ratio,0.699087
uuid-f2374cbb24ec4edd99cfd3f09a94fc2f,Median duration of response,0.755434
uuid-a95c8b3de3a64d6b91da2ff4a1b7d2de,requested,0.311179
uuid-a95c8b3de3a64d6b91da2ff4a1b7d2de,adverse,0.326146
uuid-149192ce927e46d691a8e46a8cd31c74,patients,0.357038
uuid-149192ce927e46d691a8e46a8cd31c74,adverse,0.730822
uuid-149192ce927e46d691a8e46a8cd31c74,efficacy and safety of nivolumab,0.302836
uuid-149192ce927e46d691a8e46a8cd31c74,safety,0.347325
uuid-149192ce927e46d691a8e46a8cd31c74,reported,0.455156
uuid-431a52b2beae48d0a966079ca64dc75f,Opdivo,0.472989
uuid-7775db507d204651883ee7739551f11c,Opdivo,0.804564
uuid-7775db507d204651883ee7739551f11c,trial,0.519328
uuid-879a8c77d8cb42c69e8b80b1d1e515c5,nivolumab,0.441653
uuid-4fb04a53c3444829ba630a67ecd35aee,N Engl J Med,0.448483
uuid-4fb04a53c3444829ba630a67ecd35aee,protocol,0.770446
uuid-4fb04a53c3444829ba630a67ecd35aee,McDermott DF,0.741196
uuid-4fb04a53c3444829ba630a67ecd35aee,Motzer RJ,0.818144
uuid-4fb04a53c3444829ba630a67ecd35aee,phase 3 study,0.417055
uuid-4fb04a53c3444829ba630a67ecd35aee,Escudier B,0.749917
uuid-4fb04a53c3444829ba630a67ecd35aee,NEJM,0.400698
uuid-4fb04a53c3444829ba630a67ecd35aee,et al.,0.668641
uuid-4fb04a53c3444829ba630a67ecd35aee,J Clin Oncol,0.792018
uuid-4fb04a53c3444829ba630a67ecd35aee,Topalian,0.388894
uuid-4fb04a53c3444829ba630a67ecd35aee,phase 1 study,0.500686
uuid-4fb04a53c3444829ba630a67ecd35aee,CA209-003,0.567381
uuid-4fb04a53c3444829ba630a67ecd35aee,phase 2 study,0.677985
uuid-4fb04a53c3444829ba630a67ecd35aee,present using the following search terms,0.310558
uuid-4fb04a53c3444829ba630a67ecd35aee,investigating,0.615835
uuid-73b3ead06cdf41f4ac027c2acd1976d3,NSCLC,0.480337
uuid-73b3ead06cdf41f4ac027c2acd1976d3,respectively,0.400584
uuid-73b3ead06cdf41f4ac027c2acd1976d3,non-small cell lung cancer,0.395662
uuid-73b3ead06cdf41f4ac027c2acd1976d3,patients,0.382838
uuid-73b3ead06cdf41f4ac027c2acd1976d3,considered investigational,0.378457
uuid-73b3ead06cdf41f4ac027c2acd1976d3,Objective response rate,0.446233
uuid-73b3ead06cdf41f4ac027c2acd1976d3,ORR,0.488323
uuid-73b3ead06cdf41f4ac027c2acd1976d3,monotherapy,0.419452
uuid-73b3ead06cdf41f4ac027c2acd1976d3,small cell lung cancer,0.328277
uuid-73b3ead06cdf41f4ac027c2acd1976d3,docetaxel,0.370754
uuid-73b3ead06cdf41f4ac027c2acd1976d3,SCLC,0.328412
uuid-73b3ead06cdf41f4ac027c2acd1976d3,grade 3 to 4 AEs,0.337672
uuid-73b3ead06cdf41f4ac027c2acd1976d3,platinum-based doublet chemotherapy,0.355492
uuid-f14e23496b7f4fcc9ed285afa23ec6f6,requested,0.422859
uuid-f14e23496b7f4fcc9ed285afa23ec6f6,trial,0.318196
uuid-ebc0f6bb41be4f6dadb96cefba078181,N Engl J Med,0.448483
uuid-ebc0f6bb41be4f6dadb96cefba078181,protocol,0.770446
uuid-ebc0f6bb41be4f6dadb96cefba078181,McDermott DF,0.741196
uuid-ebc0f6bb41be4f6dadb96cefba078181,Motzer RJ,0.818144
uuid-ebc0f6bb41be4f6dadb96cefba078181,phase 3 study,0.417055
uuid-ebc0f6bb41be4f6dadb96cefba078181,Escudier B,0.749917
uuid-ebc0f6bb41be4f6dadb96cefba078181,NEJM,0.400698
uuid-ebc0f6bb41be4f6dadb96cefba078181,et al.,0.668641
uuid-ebc0f6bb41be4f6dadb96cefba078181,J Clin Oncol,0.792018
uuid-ebc0f6bb41be4f6dadb96cefba078181,Topalian,0.388894
uuid-ebc0f6bb41be4f6dadb96cefba078181,phase 1 study,0.500686
uuid-ebc0f6bb41be4f6dadb96cefba078181,CA209-003,0.567381
uuid-ebc0f6bb41be4f6dadb96cefba078181,phase 2 study,0.677985
uuid-ebc0f6bb41be4f6dadb96cefba078181,present using the following search terms,0.310558
uuid-ebc0f6bb41be4f6dadb96cefba078181,investigating,0.615835
uuid-1c21058f2c554afa94102c148f3afdba,N Engl J Med,0.304989
uuid-1c21058f2c554afa94102c148f3afdba,AEs,0.337832
uuid-1c21058f2c554afa94102c148f3afdba,patients,0.387033
uuid-1c21058f2c554afa94102c148f3afdba,provided in the Detailed Information,0.370845
uuid-1c21058f2c554afa94102c148f3afdba,ESMO,0.421367
uuid-1c21058f2c554afa94102c148f3afdba,NEJM,0.709799
uuid-1c21058f2c554afa94102c148f3afdba,Topalian,0.735417
uuid-1c21058f2c554afa94102c148f3afdba,grade 3 to 4 AEs,0.538198
uuid-d576ea414a9f45d6b9c33cda8e1c72d7,requested,0.613399
uuid-4a8cd79b2c284bba9bb43903ab4aba23,N Engl J Med,0.448483
uuid-4a8cd79b2c284bba9bb43903ab4aba23,protocol,0.770446
uuid-4a8cd79b2c284bba9bb43903ab4aba23,McDermott DF,0.741196
uuid-4a8cd79b2c284bba9bb43903ab4aba23,Motzer RJ,0.818144
uuid-4a8cd79b2c284bba9bb43903ab4aba23,phase 3 study,0.417055
uuid-4a8cd79b2c284bba9bb43903ab4aba23,Escudier B,0.749917
uuid-4a8cd79b2c284bba9bb43903ab4aba23,NEJM,0.400698
uuid-4a8cd79b2c284bba9bb43903ab4aba23,et al.,0.668641
uuid-4a8cd79b2c284bba9bb43903ab4aba23,J Clin Oncol,0.792018
uuid-4a8cd79b2c284bba9bb43903ab4aba23,Topalian,0.388894
uuid-4a8cd79b2c284bba9bb43903ab4aba23,phase 1 study,0.500686
uuid-4a8cd79b2c284bba9bb43903ab4aba23,CA209-003,0.567381
uuid-4a8cd79b2c284bba9bb43903ab4aba23,phase 2 study,0.677985
uuid-4a8cd79b2c284bba9bb43903ab4aba23,present using the following search terms,0.310558
uuid-4a8cd79b2c284bba9bb43903ab4aba23,investigating,0.615835
uuid-3cf6f42594904280bd127f951bc04229,N Engl J Med,0.304989
uuid-3cf6f42594904280bd127f951bc04229,AEs,0.337832
uuid-3cf6f42594904280bd127f951bc04229,patients,0.387033
uuid-3cf6f42594904280bd127f951bc04229,provided in the Detailed Information,0.370845
uuid-3cf6f42594904280bd127f951bc04229,ESMO,0.421367
uuid-3cf6f42594904280bd127f951bc04229,NEJM,0.709799
uuid-3cf6f42594904280bd127f951bc04229,Topalian,0.735417
uuid-3cf6f42594904280bd127f951bc04229,grade 3 to 4 AEs,0.538198
uuid-39ca9693854648c3b14ef23b0b32e639,use of nivolumab for the treatment,0.409821
uuid-39ca9693854648c3b14ef23b0b32e639,patients with advanced or metastatic,0.645244
uuid-39ca9693854648c3b14ef23b0b32e639,nivolumab combined with ipilimumab,0.676339
uuid-39ca9693854648c3b14ef23b0b32e639,not approved,0.453534
uuid-39ca9693854648c3b14ef23b0b32e639,clinical trials investigating the safety,0.548799
uuid-39ca9693854648c3b14ef23b0b32e639,phase 1/2 study CA209-032,0.34114
uuid-39ca9693854648c3b14ef23b0b32e639,bladder cancer,0.749142
uuid-39ca9693854648c3b14ef23b0b32e639,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-c32ab2ba9b05408c910b47ca890b525a,Opdivo,0.50165
uuid-c32ab2ba9b05408c910b47ca890b525a,open-label,0.304253
uuid-c32ab2ba9b05408c910b47ca890b525a,trial,0.521827
uuid-c32ab2ba9b05408c910b47ca890b525a,docetaxel,0.30238
uuid-c32ab2ba9b05408c910b47ca890b525a,safety of nivolumab monotherapy,0.432481
uuid-c32ab2ba9b05408c910b47ca890b525a,phase,0.378496
uuid-f99f1cd57e6f4b5c82906478359fcd13,use of nivolumab for the treatment,0.440423
uuid-f99f1cd57e6f4b5c82906478359fcd13,search of published literature,0.311531
uuid-f99f1cd57e6f4b5c82906478359fcd13,PubMed and EMBASE,0.312811
uuid-f99f1cd57e6f4b5c82906478359fcd13,not approved,0.404782
uuid-f99f1cd57e6f4b5c82906478359fcd13,open-label,0.578291
uuid-f99f1cd57e6f4b5c82906478359fcd13,clinical trials investigating the safety,0.440014
uuid-f99f1cd57e6f4b5c82906478359fcd13,present using the following search terms,0.328669
uuid-f99f1cd57e6f4b5c82906478359fcd13,phase,0.41185
uuid-70dd993b010940fcb7bfc44eb86e57c2,Additionally,0.483288
uuid-70dd993b010940fcb7bfc44eb86e57c2,ongoing,0.500649
uuid-70dd993b010940fcb7bfc44eb86e57c2,open-label,0.357781
uuid-70dd993b010940fcb7bfc44eb86e57c2,detailed search of www.clinicaltrials.gov,0.465481
uuid-70dd993b010940fcb7bfc44eb86e57c2,not identify any planned,0.477736
uuid-70dd993b010940fcb7bfc44eb86e57c2,clinicaltrials.gov,0.372778
uuid-70dd993b010940fcb7bfc44eb86e57c2,not identify any citations relevant to your request,0.396005
uuid-70dd993b010940fcb7bfc44eb86e57c2,phase,0.381401
uuid-d40f286b96ec4e0bb6fca224c7f4ad13,OS,0.62262
uuid-d40f286b96ec4e0bb6fca224c7f4ad13,PFS,0.65903
uuid-d40f286b96ec4e0bb6fca224c7f4ad13,Overall survival,0.644151
uuid-c30acb33c71e4f36842d8bd75c1be8e7,Bristol-Myers Squibb,0.341822
uuid-c30acb33c71e4f36842d8bd75c1be8e7,not conducted any controlled clinical trials/studies,0.304507
uuid-c30acb33c71e4f36842d8bd75c1be8e7,Opdivo,0.461382
uuid-c30acb33c71e4f36842d8bd75c1be8e7,Pubmed literature search,0.614325
uuid-c30acb33c71e4f36842d8bd75c1be8e7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c30acb33c71e4f36842d8bd75c1be8e7,not identify any citations relevant to your inquiry,0.606087
uuid-c30acb33c71e4f36842d8bd75c1be8e7,adverse,0.304183
uuid-c30acb33c71e4f36842d8bd75c1be8e7,using the following search terms,0.642331
uuid-c30acb33c71e4f36842d8bd75c1be8e7,databases,0.315039
uuid-c30acb33c71e4f36842d8bd75c1be8e7,reported,0.556704
uuid-5614faa752cc44f49f8a540bae8ed412,provided in the Detailed Information,0.392816
uuid-5614faa752cc44f49f8a540bae8ed412,Overall survival,0.43418
uuid-87ffbd064d7147a4ba7623d509dd8237,nivolumab,0.510392
uuid-87ffbd064d7147a4ba7623d509dd8237,Bristol-Myers Squibb,0.464176
uuid-87ffbd064d7147a4ba7623d509dd8237,evaluating,0.683286
uuid-87ffbd064d7147a4ba7623d509dd8237,not conducted any controlled clinical trials/studies,0.682483
uuid-87ffbd064d7147a4ba7623d509dd8237,RCC,0.308694
uuid-87ffbd064d7147a4ba7623d509dd8237,search of published literature,0.839602
uuid-87ffbd064d7147a4ba7623d509dd8237,Additionally,0.446384
uuid-87ffbd064d7147a4ba7623d509dd8237,PubMed and EMBASE,0.823429
uuid-87ffbd064d7147a4ba7623d509dd8237,detailed search of www.clinicaltrials.gov,0.366719
uuid-87ffbd064d7147a4ba7623d509dd8237,efficacy and safety of nivolumab,0.841
uuid-87ffbd064d7147a4ba7623d509dd8237,not identify any citations relevant to your request,0.605656
uuid-87ffbd064d7147a4ba7623d509dd8237,present using the following search terms,0.832619
uuid-1295277078a54772b20daad39a37e245,nivolumab,0.426112
uuid-1295277078a54772b20daad39a37e245,Bristol-Myers Squibb,0.414683
uuid-1295277078a54772b20daad39a37e245,evaluating,0.618441
uuid-1295277078a54772b20daad39a37e245,not conducted any controlled clinical trials/studies,0.59781
uuid-1295277078a54772b20daad39a37e245,search of published literature,0.714235
uuid-1295277078a54772b20daad39a37e245,Additionally,0.677808
uuid-1295277078a54772b20daad39a37e245,ongoing,0.561965
uuid-1295277078a54772b20daad39a37e245,PubMed and EMBASE,0.703738
uuid-1295277078a54772b20daad39a37e245,detailed search of www.clinicaltrials.gov,0.645679
uuid-1295277078a54772b20daad39a37e245,efficacy and safety of nivolumab,0.739441
uuid-1295277078a54772b20daad39a37e245,not identify any planned,0.590181
uuid-1295277078a54772b20daad39a37e245,not identify any citations relevant to your request,0.76779
uuid-1295277078a54772b20daad39a37e245,present using the following search terms,0.732321
uuid-f751cec09b324242b229ea02260f2c53,nivolumab,0.629838
uuid-f751cec09b324242b229ea02260f2c53,Bristol-Myers Squibb,0.397203
uuid-f751cec09b324242b229ea02260f2c53,evaluating,0.58461
uuid-f751cec09b324242b229ea02260f2c53,not conducted any controlled clinical trials/studies,0.61931
uuid-f751cec09b324242b229ea02260f2c53,Pubmed literature search,0.767019
uuid-f751cec09b324242b229ea02260f2c53,purposes other than its labeled indication must be considered investigational,0.841133
uuid-f751cec09b324242b229ea02260f2c53,not identify any citations relevant to your inquiry,0.731528
uuid-f751cec09b324242b229ea02260f2c53,using the following search terms,0.712736
uuid-f751cec09b324242b229ea02260f2c53,efficacy and safety of nivolumab,0.431415
uuid-6f859da91efe4a7f804fee8093a3edfe,nivolumab,0.33361
uuid-6f859da91efe4a7f804fee8093a3edfe,clinicaltrials.gov,0.645643
uuid-9f2f34a2602a4395aefe1619680eca45,N Engl J Med,0.427636
uuid-9f2f34a2602a4395aefe1619680eca45,protocol,0.429136
uuid-9f2f34a2602a4395aefe1619680eca45,McDermott DF,0.44782
uuid-9f2f34a2602a4395aefe1619680eca45,Motzer RJ,0.430476
uuid-9f2f34a2602a4395aefe1619680eca45,Escudier B,0.450887
uuid-9f2f34a2602a4395aefe1619680eca45,et al.,0.456026
uuid-9f2f34a2602a4395aefe1619680eca45,J Clin Oncol,0.384624
uuid-9f2f34a2602a4395aefe1619680eca45,Rizvi NA,0.305616
uuid-9f2f34a2602a4395aefe1619680eca45,phase 2 study,0.351446
uuid-2301a43a6d804477a8f81b5d707a9410,use of nivolumab for the treatment,0.409821
uuid-2301a43a6d804477a8f81b5d707a9410,patients with advanced or metastatic,0.645244
uuid-2301a43a6d804477a8f81b5d707a9410,nivolumab combined with ipilimumab,0.676339
uuid-2301a43a6d804477a8f81b5d707a9410,not approved,0.453534
uuid-2301a43a6d804477a8f81b5d707a9410,clinical trials investigating the safety,0.548799
uuid-2301a43a6d804477a8f81b5d707a9410,phase 1/2 study CA209-032,0.34114
uuid-2301a43a6d804477a8f81b5d707a9410,bladder cancer,0.749142
uuid-2301a43a6d804477a8f81b5d707a9410,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-84a628e63f22498fbca356fb61a931af,OS,0.62262
uuid-84a628e63f22498fbca356fb61a931af,PFS,0.65903
uuid-84a628e63f22498fbca356fb61a931af,Overall survival,0.644151
uuid-2d2db4cdf70245d2bf7d32684e468866,clinicaltrials.gov,0.340701
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,95% CI,0.419478
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,respectively,0.497608
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,Objective response rate,0.403649
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,ORR,0.578109
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,patients with advanced or metastatic,0.306625
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,Median overall survival,0.498783
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,nivolumab combined with ipilimumab,0.300486
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,tumors,0.323334
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,ESMO,0.534361
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,Median OS,0.394058
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,small cell lung cancer,0.380999
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,SCLC,0.365686
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,hazard ratio,0.419392
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,grade 3 to 4 AEs,0.414535
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,phase 1/2 study CA209-032,0.398283
uuid-a14c1fdef55f4d00af7ae6d751d1da4a,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-a866ddaa06f14fcaa8212b6bb72fe808,N Engl J Med,0.666673
uuid-a866ddaa06f14fcaa8212b6bb72fe808,protocol,0.784297
uuid-a866ddaa06f14fcaa8212b6bb72fe808,McDermott DF,0.863473
uuid-a866ddaa06f14fcaa8212b6bb72fe808,Motzer RJ,0.839535
uuid-a866ddaa06f14fcaa8212b6bb72fe808,phase 3 study,0.445361
uuid-a866ddaa06f14fcaa8212b6bb72fe808,Escudier B,0.862895
uuid-a866ddaa06f14fcaa8212b6bb72fe808,NEJM,0.429443
uuid-a866ddaa06f14fcaa8212b6bb72fe808,et al.,0.845549
uuid-a866ddaa06f14fcaa8212b6bb72fe808,J Clin Oncol,0.786791
uuid-a866ddaa06f14fcaa8212b6bb72fe808,Topalian,0.389875
uuid-a866ddaa06f14fcaa8212b6bb72fe808,Rizvi NA,0.366362
uuid-a866ddaa06f14fcaa8212b6bb72fe808,Brahmer J,0.346515
uuid-a866ddaa06f14fcaa8212b6bb72fe808,phase 2 study,0.725511
uuid-9d66d9962b2f434daf5896034ad1997e,nivolumab,0.427206
uuid-9d66d9962b2f434daf5896034ad1997e,Bristol-Myers Squibb,0.300245
uuid-9d66d9962b2f434daf5896034ad1997e,evaluating,0.502705
uuid-9d66d9962b2f434daf5896034ad1997e,not conducted any controlled clinical trials/studies,0.477006
uuid-9d66d9962b2f434daf5896034ad1997e,NSCLC,0.301603
uuid-9d66d9962b2f434daf5896034ad1997e,non-small cell lung cancer,0.311879
uuid-9d66d9962b2f434daf5896034ad1997e,patients,0.417564
uuid-9d66d9962b2f434daf5896034ad1997e,Pubmed literature search,0.314799
uuid-9d66d9962b2f434daf5896034ad1997e,purposes other than its labeled indication must be considered investigational,0.388687
uuid-9d66d9962b2f434daf5896034ad1997e,phase 3 study,0.369066
uuid-9d66d9962b2f434daf5896034ad1997e,phase 1 study,0.453109
uuid-9d66d9962b2f434daf5896034ad1997e,efficacy and safety of nivolumab,0.486089
uuid-9d66d9962b2f434daf5896034ad1997e,mg,0.30831
uuid-9d66d9962b2f434daf5896034ad1997e,CA209-003,0.370265
uuid-9d66d9962b2f434daf5896034ad1997e,therapy,0.30981
uuid-cbb07e2df39f4c9db061d58ec033240d,N Engl J Med,0.672096
uuid-cbb07e2df39f4c9db061d58ec033240d,ESMO,0.436384
uuid-cbb07e2df39f4c9db061d58ec033240d,Rizvi NA,0.472296
uuid-cbb07e2df39f4c9db061d58ec033240d,Brahmer J,0.720441
uuid-cbb07e2df39f4c9db061d58ec033240d,Horn L,0.608589
uuid-64be0d7194e449f080e4987fd7a94eb7,search of published literature,0.315764
uuid-64be0d7194e449f080e4987fd7a94eb7,phase 3 study,0.504988
uuid-64be0d7194e449f080e4987fd7a94eb7,PubMed and EMBASE,0.313977
uuid-64be0d7194e449f080e4987fd7a94eb7,Weber JS,0.513675
uuid-b33ef90c58474397beac812c36016a5d,95% CI,0.419478
uuid-b33ef90c58474397beac812c36016a5d,respectively,0.497608
uuid-b33ef90c58474397beac812c36016a5d,Objective response rate,0.403649
uuid-b33ef90c58474397beac812c36016a5d,ORR,0.578109
uuid-b33ef90c58474397beac812c36016a5d,patients with advanced or metastatic,0.306625
uuid-b33ef90c58474397beac812c36016a5d,Median overall survival,0.498783
uuid-b33ef90c58474397beac812c36016a5d,nivolumab combined with ipilimumab,0.300486
uuid-b33ef90c58474397beac812c36016a5d,tumors,0.323334
uuid-b33ef90c58474397beac812c36016a5d,ESMO,0.534361
uuid-b33ef90c58474397beac812c36016a5d,Median OS,0.394058
uuid-b33ef90c58474397beac812c36016a5d,small cell lung cancer,0.380999
uuid-b33ef90c58474397beac812c36016a5d,SCLC,0.365686
uuid-b33ef90c58474397beac812c36016a5d,hazard ratio,0.419392
uuid-b33ef90c58474397beac812c36016a5d,grade 3 to 4 AEs,0.414535
uuid-b33ef90c58474397beac812c36016a5d,phase 1/2 study CA209-032,0.398283
uuid-b33ef90c58474397beac812c36016a5d,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-ed23fbd99ef64d2c8b4be47735166b76,OS,0.30588
uuid-ed23fbd99ef64d2c8b4be47735166b76,95% CI,0.768716
uuid-ed23fbd99ef64d2c8b4be47735166b76,respectively,0.58691
uuid-ed23fbd99ef64d2c8b4be47735166b76,Objective response rate,0.516939
uuid-ed23fbd99ef64d2c8b4be47735166b76,ORR,0.607137
uuid-ed23fbd99ef64d2c8b4be47735166b76,Median overall survival,0.625688
uuid-ed23fbd99ef64d2c8b4be47735166b76,monotherapy,0.415492
uuid-ed23fbd99ef64d2c8b4be47735166b76,Median OS,0.67223
uuid-ed23fbd99ef64d2c8b4be47735166b76,docetaxel,0.486882
uuid-ed23fbd99ef64d2c8b4be47735166b76,hazard ratio,0.668285
uuid-ed23fbd99ef64d2c8b4be47735166b76,Median duration of response,0.499297
uuid-5bd7dd556bd24a75a9829d67568d75ce,use of nivolumab for the treatment,0.409821
uuid-5bd7dd556bd24a75a9829d67568d75ce,patients with advanced or metastatic,0.645244
uuid-5bd7dd556bd24a75a9829d67568d75ce,nivolumab combined with ipilimumab,0.676339
uuid-5bd7dd556bd24a75a9829d67568d75ce,not approved,0.453534
uuid-5bd7dd556bd24a75a9829d67568d75ce,clinical trials investigating the safety,0.548799
uuid-5bd7dd556bd24a75a9829d67568d75ce,phase 1/2 study CA209-032,0.34114
uuid-5bd7dd556bd24a75a9829d67568d75ce,bladder cancer,0.749142
uuid-5bd7dd556bd24a75a9829d67568d75ce,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-8edfd44399d84d1bac94e1483db125fa,AEs,0.323667
uuid-8edfd44399d84d1bac94e1483db125fa,grade 3 to 4 AEs,0.40682
uuid-35350e2e9c5d47d5be97ea461ab96a88,investigating,0.333883
uuid-a2e998d0190e49f4a26010b375a3d43a,nivolumab,0.42541
uuid-a2e998d0190e49f4a26010b375a3d43a,Bristol-Myers Squibb,0.445144
uuid-a2e998d0190e49f4a26010b375a3d43a,evaluating,0.593008
uuid-a2e998d0190e49f4a26010b375a3d43a,not conducted any controlled clinical trials/studies,0.624237
uuid-a2e998d0190e49f4a26010b375a3d43a,NSCLC,0.478806
uuid-a2e998d0190e49f4a26010b375a3d43a,non-small cell lung cancer,0.528164
uuid-a2e998d0190e49f4a26010b375a3d43a,Pubmed literature search,0.62415
uuid-a2e998d0190e49f4a26010b375a3d43a,purposes other than its labeled indication must be considered investigational,0.693614
uuid-a2e998d0190e49f4a26010b375a3d43a,not identify any citations relevant to your inquiry,0.591421
uuid-a2e998d0190e49f4a26010b375a3d43a,using the following search terms,0.575974
uuid-a2e998d0190e49f4a26010b375a3d43a,efficacy and safety of nivolumab,0.473721
uuid-ff4765fdc40a4cc39e947ec4c7638597,ipilimumab,0.385692
uuid-ff4765fdc40a4cc39e947ec4c7638597,ASCO 2015,0.417944
uuid-ff4765fdc40a4cc39e947ec4c7638597,partial response,0.382425
uuid-ff4765fdc40a4cc39e947ec4c7638597,Stable disease,0.586335
uuid-ff4765fdc40a4cc39e947ec4c7638597,cohort,0.307748
uuid-ca7805a7195c49a38ff72df726cd9933,patients with advanced or metastatic,0.478326
uuid-ca7805a7195c49a38ff72df726cd9933,nivolumab combined with ipilimumab,0.498766
uuid-ca7805a7195c49a38ff72df726cd9933,not approved,0.34724
uuid-ca7805a7195c49a38ff72df726cd9933,clinical trials investigating the safety,0.426729
uuid-ca7805a7195c49a38ff72df726cd9933,bladder cancer,0.6548
uuid-e16b09a209c24ac6a8ad5986cdc75566,use of nivolumab for the treatment,0.440423
uuid-e16b09a209c24ac6a8ad5986cdc75566,search of published literature,0.311531
uuid-e16b09a209c24ac6a8ad5986cdc75566,PubMed and EMBASE,0.312811
uuid-e16b09a209c24ac6a8ad5986cdc75566,not approved,0.404782
uuid-e16b09a209c24ac6a8ad5986cdc75566,open-label,0.578291
uuid-e16b09a209c24ac6a8ad5986cdc75566,clinical trials investigating the safety,0.440014
uuid-e16b09a209c24ac6a8ad5986cdc75566,present using the following search terms,0.328669
uuid-e16b09a209c24ac6a8ad5986cdc75566,phase,0.41185
uuid-d1274d7754a94b97b7730b876d1cda7b,N Engl J Med,0.359883
uuid-d1274d7754a94b97b7730b876d1cda7b,respectively,0.637142
uuid-d1274d7754a94b97b7730b876d1cda7b,ASCO,0.362108
uuid-d1274d7754a94b97b7730b876d1cda7b,ORR,0.386698
uuid-d1274d7754a94b97b7730b876d1cda7b,Median OS,0.315141
uuid-d1274d7754a94b97b7730b876d1cda7b,Brahmer J,0.52754
uuid-d1274d7754a94b97b7730b876d1cda7b,docetaxel,0.451722
uuid-d1274d7754a94b97b7730b876d1cda7b,Horn L,0.316361
uuid-3fd3642b82a846908ce95a6262082fcf,N Engl J Med,0.304989
uuid-3fd3642b82a846908ce95a6262082fcf,AEs,0.337832
uuid-3fd3642b82a846908ce95a6262082fcf,patients,0.387033
uuid-3fd3642b82a846908ce95a6262082fcf,provided in the Detailed Information,0.370845
uuid-3fd3642b82a846908ce95a6262082fcf,ESMO,0.421367
uuid-3fd3642b82a846908ce95a6262082fcf,NEJM,0.709799
uuid-3fd3642b82a846908ce95a6262082fcf,Topalian,0.735417
uuid-3fd3642b82a846908ce95a6262082fcf,grade 3 to 4 AEs,0.538198
uuid-c036d709cd4149c19896b79adc14e98b,patients,0.345143
uuid-c036d709cd4149c19896b79adc14e98b,provided in the Detailed Information,0.330334
uuid-c036d709cd4149c19896b79adc14e98b,ESMO,0.322733
uuid-c036d709cd4149c19896b79adc14e98b,NEJM,0.573497
uuid-c036d709cd4149c19896b79adc14e98b,Topalian,0.612411
uuid-c036d709cd4149c19896b79adc14e98b,grade 3 to 4 AEs,0.416191
uuid-38e53beacd1f4f8f86b7d6ba9796506b,AEs,0.587153
uuid-38e53beacd1f4f8f86b7d6ba9796506b,patients,0.507767
uuid-38e53beacd1f4f8f86b7d6ba9796506b,phase 1 study,0.306846
uuid-38e53beacd1f4f8f86b7d6ba9796506b,grade,0.402597
uuid-38e53beacd1f4f8f86b7d6ba9796506b,grade 3 to 4 AEs,0.59806
uuid-13ca1efaf175494896324fa1b6fc069c,fatigue,0.323475
uuid-c8f6ef8484cb4233adb330a2779a3bbe,ipilimumab,0.385692
uuid-c8f6ef8484cb4233adb330a2779a3bbe,ASCO 2015,0.417944
uuid-c8f6ef8484cb4233adb330a2779a3bbe,partial response,0.382425
uuid-c8f6ef8484cb4233adb330a2779a3bbe,Stable disease,0.586335
uuid-c8f6ef8484cb4233adb330a2779a3bbe,cohort,0.307748
uuid-eff17334ae504bc8996ffdc76b4084a3,ASCO,0.430306
uuid-eff17334ae504bc8996ffdc76b4084a3,requested,0.333132
uuid-657036bf5a5f4d669c72607332a889ca,nivolumab,0.357039
uuid-ce0ffd1fd2364c78996f06029105e55a,Bristol-Myers Squibb,0.729308
uuid-ce0ffd1fd2364c78996f06029105e55a,evaluating,0.547333
uuid-ce0ffd1fd2364c78996f06029105e55a,not conducted any controlled clinical trials/studies,0.623026
uuid-ce0ffd1fd2364c78996f06029105e55a,efficacy and safety of nivolumab,0.519685
uuid-8a0911ed344e4533a2e1a5e72a30f94d,95% CI,0.419478
uuid-8a0911ed344e4533a2e1a5e72a30f94d,respectively,0.497608
uuid-8a0911ed344e4533a2e1a5e72a30f94d,Objective response rate,0.403649
uuid-8a0911ed344e4533a2e1a5e72a30f94d,ORR,0.578109
uuid-8a0911ed344e4533a2e1a5e72a30f94d,patients with advanced or metastatic,0.306625
uuid-8a0911ed344e4533a2e1a5e72a30f94d,Median overall survival,0.498783
uuid-8a0911ed344e4533a2e1a5e72a30f94d,nivolumab combined with ipilimumab,0.300486
uuid-8a0911ed344e4533a2e1a5e72a30f94d,tumors,0.323334
uuid-8a0911ed344e4533a2e1a5e72a30f94d,ESMO,0.534361
uuid-8a0911ed344e4533a2e1a5e72a30f94d,Median OS,0.394058
uuid-8a0911ed344e4533a2e1a5e72a30f94d,small cell lung cancer,0.380999
uuid-8a0911ed344e4533a2e1a5e72a30f94d,SCLC,0.365686
uuid-8a0911ed344e4533a2e1a5e72a30f94d,hazard ratio,0.419392
uuid-8a0911ed344e4533a2e1a5e72a30f94d,grade 3 to 4 AEs,0.414535
uuid-8a0911ed344e4533a2e1a5e72a30f94d,phase 1/2 study CA209-032,0.398283
uuid-8a0911ed344e4533a2e1a5e72a30f94d,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,use of nivolumab for the treatment,0.409821
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,patients with advanced or metastatic,0.645244
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,nivolumab combined with ipilimumab,0.676339
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,not approved,0.453534
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,clinical trials investigating the safety,0.548799
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,phase 1/2 study CA209-032,0.34114
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,bladder cancer,0.749142
uuid-8f5d6555fe1b499a9b0d43f9c70412a1,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-dad3f3485da6486781fd2ac18376ce39,patients with advanced or metastatic,0.468858
uuid-dad3f3485da6486781fd2ac18376ce39,nivolumab combined with ipilimumab,0.446918
uuid-dad3f3485da6486781fd2ac18376ce39,not approved,0.352562
uuid-dad3f3485da6486781fd2ac18376ce39,clinical trials investigating the safety,0.429501
uuid-dad3f3485da6486781fd2ac18376ce39,bladder cancer,0.950698
uuid-b5f7545d0b264252b38bf5ebfa5f4392,N Engl J Med,0.304989
uuid-b5f7545d0b264252b38bf5ebfa5f4392,AEs,0.337832
uuid-b5f7545d0b264252b38bf5ebfa5f4392,patients,0.387033
uuid-b5f7545d0b264252b38bf5ebfa5f4392,provided in the Detailed Information,0.370845
uuid-b5f7545d0b264252b38bf5ebfa5f4392,ESMO,0.421367
uuid-b5f7545d0b264252b38bf5ebfa5f4392,NEJM,0.709799
uuid-b5f7545d0b264252b38bf5ebfa5f4392,Topalian,0.735417
uuid-b5f7545d0b264252b38bf5ebfa5f4392,grade 3 to 4 AEs,0.538198
uuid-f51d107cab794187a8f29e1df3246217,Opdivo,0.50165
uuid-f51d107cab794187a8f29e1df3246217,open-label,0.304253
uuid-f51d107cab794187a8f29e1df3246217,trial,0.521827
uuid-f51d107cab794187a8f29e1df3246217,docetaxel,0.30238
uuid-f51d107cab794187a8f29e1df3246217,safety of nivolumab monotherapy,0.432481
uuid-f51d107cab794187a8f29e1df3246217,phase,0.378496
uuid-09c9dac2d20b4e41801a698fb8a3b722,N Engl J Med,0.778072
uuid-09c9dac2d20b4e41801a698fb8a3b722,Lancet Oncol,0.395426
uuid-09c9dac2d20b4e41801a698fb8a3b722,protocol,0.833474
uuid-09c9dac2d20b4e41801a698fb8a3b722,McDermott DF,0.848872
uuid-09c9dac2d20b4e41801a698fb8a3b722,Motzer RJ,0.849806
uuid-09c9dac2d20b4e41801a698fb8a3b722,phase 3 study,0.543472
uuid-09c9dac2d20b4e41801a698fb8a3b722,Escudier B,0.859122
uuid-09c9dac2d20b4e41801a698fb8a3b722,NEJM,0.465171
uuid-09c9dac2d20b4e41801a698fb8a3b722,et al.,0.806509
uuid-09c9dac2d20b4e41801a698fb8a3b722,J Clin Oncol,0.785725
uuid-09c9dac2d20b4e41801a698fb8a3b722,Topalian,0.431311
uuid-09c9dac2d20b4e41801a698fb8a3b722,phase 1 study,0.325443
uuid-09c9dac2d20b4e41801a698fb8a3b722,Rizvi NA,0.583157
uuid-09c9dac2d20b4e41801a698fb8a3b722,Brahmer J,0.486914
uuid-09c9dac2d20b4e41801a698fb8a3b722,Weber JS,0.385764
uuid-09c9dac2d20b4e41801a698fb8a3b722,phase 2 study,0.781016
uuid-963a048193e44c219bc817da172afba4,considered investigational,0.304675
uuid-963a048193e44c219bc817da172afba4,melanoma,0.390708
uuid-963a048193e44c219bc817da172afba4,small cell lung cancer,0.516081
uuid-963a048193e44c219bc817da172afba4,partial response,0.321143
uuid-963a048193e44c219bc817da172afba4,SCLC,0.591083
uuid-963a048193e44c219bc817da172afba4,therapy,0.861777
uuid-963a048193e44c219bc817da172afba4,relapsed,0.388255
uuid-01ef09bda90c4bce988e773d21a936af,OS,0.62262
uuid-01ef09bda90c4bce988e773d21a936af,PFS,0.65903
uuid-01ef09bda90c4bce988e773d21a936af,Overall survival,0.644151
uuid-0c139bfcafc34836a536eb2f8d23542b,use of nivolumab for the treatment,0.409821
uuid-0c139bfcafc34836a536eb2f8d23542b,patients with advanced or metastatic,0.645244
uuid-0c139bfcafc34836a536eb2f8d23542b,nivolumab combined with ipilimumab,0.676339
uuid-0c139bfcafc34836a536eb2f8d23542b,not approved,0.453534
uuid-0c139bfcafc34836a536eb2f8d23542b,clinical trials investigating the safety,0.548799
uuid-0c139bfcafc34836a536eb2f8d23542b,phase 1/2 study CA209-032,0.34114
uuid-0c139bfcafc34836a536eb2f8d23542b,bladder cancer,0.749142
uuid-0c139bfcafc34836a536eb2f8d23542b,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-0a3d3a042d604d51a2ac864ca0a46861,nivolumab,0.606276
uuid-0a3d3a042d604d51a2ac864ca0a46861,Weber JS,0.346532
uuid-8a1d5cfe04b149408189f7133dc858a4,OS,0.358678
uuid-8a1d5cfe04b149408189f7133dc858a4,95% CI,0.709672
uuid-8a1d5cfe04b149408189f7133dc858a4,respectively,0.644018
uuid-8a1d5cfe04b149408189f7133dc858a4,Objective response rate,0.626634
uuid-8a1d5cfe04b149408189f7133dc858a4,ORR,0.747489
uuid-8a1d5cfe04b149408189f7133dc858a4,Median overall survival,0.683752
uuid-8a1d5cfe04b149408189f7133dc858a4,monotherapy,0.481381
uuid-8a1d5cfe04b149408189f7133dc858a4,Median OS,0.66175
uuid-8a1d5cfe04b149408189f7133dc858a4,docetaxel,0.319157
uuid-8a1d5cfe04b149408189f7133dc858a4,hazard ratio,0.698894
uuid-7c3185e147e24e8fae96ddc3fc299dac,nivolumab,0.548731
uuid-7c3185e147e24e8fae96ddc3fc299dac,Bristol-Myers Squibb,0.423614
uuid-7c3185e147e24e8fae96ddc3fc299dac,evaluating,0.577414
uuid-7c3185e147e24e8fae96ddc3fc299dac,not conducted any controlled clinical trials/studies,0.638398
uuid-7c3185e147e24e8fae96ddc3fc299dac,Pubmed literature search,0.863604
uuid-7c3185e147e24e8fae96ddc3fc299dac,purposes other than its labeled indication must be considered investigational,0.924489
uuid-7c3185e147e24e8fae96ddc3fc299dac,not identify any citations relevant to your inquiry,0.823348
uuid-7c3185e147e24e8fae96ddc3fc299dac,using the following search terms,0.811555
uuid-7c3185e147e24e8fae96ddc3fc299dac,efficacy and safety of nivolumab,0.4183
uuid-afe18c161423480c9b597d218d9c5193,requested,0.596876
uuid-cfd10a59aec243da9f6cde9f088e18b2,patients with advanced or metastatic,0.468858
uuid-cfd10a59aec243da9f6cde9f088e18b2,nivolumab combined with ipilimumab,0.446918
uuid-cfd10a59aec243da9f6cde9f088e18b2,not approved,0.352562
uuid-cfd10a59aec243da9f6cde9f088e18b2,clinical trials investigating the safety,0.429501
uuid-cfd10a59aec243da9f6cde9f088e18b2,bladder cancer,0.950698
uuid-71323edc24f8477a9ef9a76247e291c5,nivolumab,0.429246
uuid-71323edc24f8477a9ef9a76247e291c5,Bristol-Myers Squibb,0.310609
uuid-71323edc24f8477a9ef9a76247e291c5,evaluating,0.460406
uuid-71323edc24f8477a9ef9a76247e291c5,not conducted any controlled clinical trials/studies,0.478289
uuid-71323edc24f8477a9ef9a76247e291c5,Pubmed literature search,0.655635
uuid-71323edc24f8477a9ef9a76247e291c5,purposes other than its labeled indication must be considered investigational,0.698669
uuid-71323edc24f8477a9ef9a76247e291c5,not identify any citations relevant to your inquiry,0.646207
uuid-71323edc24f8477a9ef9a76247e291c5,using the following search terms,0.621941
uuid-71323edc24f8477a9ef9a76247e291c5,efficacy and safety of nivolumab,0.329915
uuid-e06da23346924d03a9e0bda1ad43e3cc,mg,0.300211
uuid-86af7d3622204cecb72392b5dbf79156,melanoma,0.628566
uuid-6af0e4625300473baa8401a78ab920b3,ipilimumab,0.397493
uuid-6af0e4625300473baa8401a78ab920b3,ASCO 2015,0.391446
uuid-6af0e4625300473baa8401a78ab920b3,partial response,0.334408
uuid-6af0e4625300473baa8401a78ab920b3,Stable disease,0.516519
uuid-6af0e4625300473baa8401a78ab920b3,cohort,0.321347
uuid-66b24072aed04d2cb4c16296661f0a66,nivolumab,0.462537
uuid-66b24072aed04d2cb4c16296661f0a66,requested,0.312235
uuid-66b24072aed04d2cb4c16296661f0a66,melanoma,0.405069
uuid-6732c5c5394a45fdbabab814500ae993,melanoma,0.628566
uuid-787e8859709045a79db034d3b6053a9c,evaluating,0.366546
uuid-787e8859709045a79db034d3b6053a9c,not conducted any controlled clinical trials/studies,0.360172
uuid-787e8859709045a79db034d3b6053a9c,search of published literature,0.403755
uuid-787e8859709045a79db034d3b6053a9c,Additionally,0.418906
uuid-787e8859709045a79db034d3b6053a9c,ongoing,0.467576
uuid-787e8859709045a79db034d3b6053a9c,PubMed and EMBASE,0.39617
uuid-787e8859709045a79db034d3b6053a9c,detailed search of www.clinicaltrials.gov,0.437393
uuid-787e8859709045a79db034d3b6053a9c,efficacy and safety of nivolumab,0.42836
uuid-787e8859709045a79db034d3b6053a9c,not identify any planned,0.454065
uuid-787e8859709045a79db034d3b6053a9c,combination,0.397925
uuid-787e8859709045a79db034d3b6053a9c,BMS,0.30879
uuid-787e8859709045a79db034d3b6053a9c,not identify any citations relevant to your request,0.449603
uuid-787e8859709045a79db034d3b6053a9c,present using the following search terms,0.394376
uuid-f40f9225fbc348069da07376f790535e,N Engl J Med,0.304989
uuid-f40f9225fbc348069da07376f790535e,AEs,0.337832
uuid-f40f9225fbc348069da07376f790535e,patients,0.387033
uuid-f40f9225fbc348069da07376f790535e,provided in the Detailed Information,0.370845
uuid-f40f9225fbc348069da07376f790535e,ESMO,0.421367
uuid-f40f9225fbc348069da07376f790535e,NEJM,0.709799
uuid-f40f9225fbc348069da07376f790535e,Topalian,0.735417
uuid-f40f9225fbc348069da07376f790535e,grade 3 to 4 AEs,0.538198
uuid-17eb052102424571b16f5537b02aff0d,NEJM,0.426934
uuid-17eb052102424571b16f5537b02aff0d,Topalian,0.423821
uuid-17eb052102424571b16f5537b02aff0d,mg,0.525266
uuid-17eb052102424571b16f5537b02aff0d,kg,0.432984
uuid-cbce46b3c9cc484b9f810146729558ae,provided in the Detailed Information,0.447582
uuid-cbce46b3c9cc484b9f810146729558ae,Additionally,0.365182
uuid-cbce46b3c9cc484b9f810146729558ae,clinical,0.520763
uuid-cbce46b3c9cc484b9f810146729558ae,detailed search of www.clinicaltrials.gov,0.303041
uuid-451fcca84e624395a41adfacb9c56e00,nivolumab,0.999168
uuid-451fcca84e624395a41adfacb9c56e00,Pubmed literature search,0.395314
uuid-451fcca84e624395a41adfacb9c56e00,purposes other than its labeled indication must be considered investigational,0.464236
uuid-451fcca84e624395a41adfacb9c56e00,not identify any citations relevant to your inquiry,0.368569
uuid-451fcca84e624395a41adfacb9c56e00,using the following search terms,0.364279
uuid-451fcca84e624395a41adfacb9c56e00,present using the following search terms,0.329876
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,OS,0.53535
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,95% CI,0.887962
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,respectively,0.334956
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,Objective response rate,0.479472
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,ORR,0.615143
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,PFS,0.402279
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,Median overall survival,0.852892
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,Median OS,0.858212
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,hazard ratio,0.868078
uuid-68e6c3b7ad2e49b8a7539d0c4e05362f,Median duration of response,0.442563
uuid-6f7c02129d1742fab27e1be6e6e1a6eb,requested,0.444771
uuid-676c66407bb245c492f19975355b2084,Bristol-Myers Squibb,0.334367
uuid-676c66407bb245c492f19975355b2084,requested,0.379258
uuid-676c66407bb245c492f19975355b2084,Opdivo,0.572868
uuid-676c66407bb245c492f19975355b2084,trial,0.321877
uuid-676c66407bb245c492f19975355b2084,reported,0.328312
uuid-e711832b885f4d2c8da109b5326f896b,use of nivolumab for the treatment,0.415084
uuid-e711832b885f4d2c8da109b5326f896b,efficacy,0.475124
uuid-e711832b885f4d2c8da109b5326f896b,not approved,0.624887
uuid-e711832b885f4d2c8da109b5326f896b,clinical trials investigating the safety,0.741408
uuid-13826be136104877896932101e7d93e2,N Engl J Med,0.304989
uuid-13826be136104877896932101e7d93e2,AEs,0.337832
uuid-13826be136104877896932101e7d93e2,patients,0.387033
uuid-13826be136104877896932101e7d93e2,provided in the Detailed Information,0.370845
uuid-13826be136104877896932101e7d93e2,ESMO,0.421367
uuid-13826be136104877896932101e7d93e2,NEJM,0.709799
uuid-13826be136104877896932101e7d93e2,Topalian,0.735417
uuid-13826be136104877896932101e7d93e2,grade 3 to 4 AEs,0.538198
uuid-bcea55760ec04414bc43fa7f83cbc5a3,N Engl J Med,0.672096
uuid-bcea55760ec04414bc43fa7f83cbc5a3,ESMO,0.436384
uuid-bcea55760ec04414bc43fa7f83cbc5a3,Rizvi NA,0.472296
uuid-bcea55760ec04414bc43fa7f83cbc5a3,Brahmer J,0.720441
uuid-bcea55760ec04414bc43fa7f83cbc5a3,Horn L,0.608589
uuid-6e56b182e0694be8a6b79e217bda95b7,mg,0.36216
uuid-6e56b182e0694be8a6b79e217bda95b7,kg,0.348096
uuid-1169bf03c18847b48d75198f0fdfa744,nivolumab,0.428647
uuid-1169bf03c18847b48d75198f0fdfa744,evaluating,0.482154
uuid-1169bf03c18847b48d75198f0fdfa744,not conducted any controlled clinical trials/studies,0.425277
uuid-1169bf03c18847b48d75198f0fdfa744,search of published literature,0.682075
uuid-1169bf03c18847b48d75198f0fdfa744,Additionally,0.344335
uuid-1169bf03c18847b48d75198f0fdfa744,PubMed and EMBASE,0.674516
uuid-1169bf03c18847b48d75198f0fdfa744,efficacy and safety of nivolumab,0.619894
uuid-1169bf03c18847b48d75198f0fdfa744,not identify any citations relevant to your request,0.481469
uuid-1169bf03c18847b48d75198f0fdfa744,therapy,0.343114
uuid-1169bf03c18847b48d75198f0fdfa744,present using the following search terms,0.680118
uuid-b871cb887b874e6ca821f880a1f99f0a,Objective response rate,0.451139
uuid-b871cb887b874e6ca821f880a1f99f0a,clinicaltrials.gov,0.503706
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,N Engl J Med,0.620843
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,ASCO,0.553901
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,Lancet Oncol,0.475981
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,Rizvi NA,0.624137
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,Brahmer J,0.698322
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,phase 2 study,0.363212
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,Antonia SJ,0.326997
uuid-d5d2f1f4d2e146d680fd13029e21ddfd,Horn L,0.338933
uuid-905769c95bd143a080a66716035a4d51,respectively,0.661351
uuid-905769c95bd143a080a66716035a4d51,Objective response rate,0.619462
uuid-905769c95bd143a080a66716035a4d51,ORR,0.537232
uuid-905769c95bd143a080a66716035a4d51,monotherapy,0.421967
uuid-905769c95bd143a080a66716035a4d51,docetaxel,0.426453
uuid-547823d55b9748d4b942255d52790ee4,OS,0.62262
uuid-547823d55b9748d4b942255d52790ee4,PFS,0.65903
uuid-547823d55b9748d4b942255d52790ee4,Overall survival,0.644151
uuid-1682590315fd46929d209dbbefd67f17,requested,0.44769
uuid-1682590315fd46929d209dbbefd67f17,trial,0.309472
uuid-54586e73ee1d422f9f7e48def9944b96,N Engl J Med,0.714946
uuid-54586e73ee1d422f9f7e48def9944b96,Lancet Oncol,0.448679
uuid-54586e73ee1d422f9f7e48def9944b96,patients,0.309769
uuid-54586e73ee1d422f9f7e48def9944b96,protocol,0.700662
uuid-54586e73ee1d422f9f7e48def9944b96,McDermott DF,0.68799
uuid-54586e73ee1d422f9f7e48def9944b96,Motzer RJ,0.689932
uuid-54586e73ee1d422f9f7e48def9944b96,phase 3 study,0.545628
uuid-54586e73ee1d422f9f7e48def9944b96,Escudier B,0.698812
uuid-54586e73ee1d422f9f7e48def9944b96,NEJM,0.402095
uuid-54586e73ee1d422f9f7e48def9944b96,et al.,0.640511
uuid-54586e73ee1d422f9f7e48def9944b96,J Clin Oncol,0.626106
uuid-54586e73ee1d422f9f7e48def9944b96,Topalian,0.37979
uuid-54586e73ee1d422f9f7e48def9944b96,phase 1 study,0.381282
uuid-54586e73ee1d422f9f7e48def9944b96,Rizvi NA,0.636006
uuid-54586e73ee1d422f9f7e48def9944b96,Brahmer J,0.517174
uuid-54586e73ee1d422f9f7e48def9944b96,efficacy and safety of nivolumab,0.368444
uuid-54586e73ee1d422f9f7e48def9944b96,Weber JS,0.406071
uuid-54586e73ee1d422f9f7e48def9944b96,phase 2 study,0.692115
uuid-90ca48ac7ba14fd4a8f50e94a0de10b6,Bristol-Myers Squibb,0.303166
uuid-90ca48ac7ba14fd4a8f50e94a0de10b6,requested,0.65
uuid-6bd27a2ef050433ab633bb444c51b805,N Engl J Med,0.302601
uuid-6bd27a2ef050433ab633bb444c51b805,AEs,0.348167
uuid-6bd27a2ef050433ab633bb444c51b805,patients,0.536884
uuid-6bd27a2ef050433ab633bb444c51b805,provided in the Detailed Information,0.387544
uuid-6bd27a2ef050433ab633bb444c51b805,ESMO,0.462801
uuid-6bd27a2ef050433ab633bb444c51b805,NEJM,0.66427
uuid-6bd27a2ef050433ab633bb444c51b805,Topalian,0.692873
uuid-6bd27a2ef050433ab633bb444c51b805,grade 3 to 4 AEs,0.626596
uuid-187a7a75119e4721b089c8665bf468c1,N Engl J Med,0.448483
uuid-187a7a75119e4721b089c8665bf468c1,protocol,0.770446
uuid-187a7a75119e4721b089c8665bf468c1,McDermott DF,0.741196
uuid-187a7a75119e4721b089c8665bf468c1,Motzer RJ,0.818144
uuid-187a7a75119e4721b089c8665bf468c1,phase 3 study,0.417055
uuid-187a7a75119e4721b089c8665bf468c1,Escudier B,0.749917
uuid-187a7a75119e4721b089c8665bf468c1,NEJM,0.400698
uuid-187a7a75119e4721b089c8665bf468c1,et al.,0.668641
uuid-187a7a75119e4721b089c8665bf468c1,J Clin Oncol,0.792018
uuid-187a7a75119e4721b089c8665bf468c1,Topalian,0.388894
uuid-187a7a75119e4721b089c8665bf468c1,phase 1 study,0.500686
uuid-187a7a75119e4721b089c8665bf468c1,CA209-003,0.567381
uuid-187a7a75119e4721b089c8665bf468c1,phase 2 study,0.677985
uuid-187a7a75119e4721b089c8665bf468c1,present using the following search terms,0.310558
uuid-187a7a75119e4721b089c8665bf468c1,investigating,0.615835
uuid-4149298eae7646e68ebd56d5b5c0ca06,Bristol-Myers Squibb,0.354436
uuid-4149298eae7646e68ebd56d5b5c0ca06,evaluating,0.408245
uuid-4149298eae7646e68ebd56d5b5c0ca06,not conducted any controlled clinical trials/studies,0.446291
uuid-4149298eae7646e68ebd56d5b5c0ca06,NSCLC,0.491921
uuid-4149298eae7646e68ebd56d5b5c0ca06,non-small cell lung cancer,0.482151
uuid-4149298eae7646e68ebd56d5b5c0ca06,patients,0.360763
uuid-4149298eae7646e68ebd56d5b5c0ca06,considered investigational,0.34224
uuid-4149298eae7646e68ebd56d5b5c0ca06,phase 3 study,0.408512
uuid-4149298eae7646e68ebd56d5b5c0ca06,melanoma,0.310343
uuid-4149298eae7646e68ebd56d5b5c0ca06,phase 1 study,0.338324
uuid-4149298eae7646e68ebd56d5b5c0ca06,Rizvi NA,0.355955
uuid-4149298eae7646e68ebd56d5b5c0ca06,small cell lung cancer,0.328482
uuid-4149298eae7646e68ebd56d5b5c0ca06,efficacy and safety of nivolumab,0.410717
uuid-4149298eae7646e68ebd56d5b5c0ca06,SCLC,0.362791
uuid-4149298eae7646e68ebd56d5b5c0ca06,therapy,0.540986
uuid-4865c595499e4be6898bd7831e7f4642,N Engl J Med,0.456313
uuid-4865c595499e4be6898bd7831e7f4642,Lancet Oncol,0.35792
uuid-4865c595499e4be6898bd7831e7f4642,protocol,0.480703
uuid-4865c595499e4be6898bd7831e7f4642,McDermott DF,0.517282
uuid-4865c595499e4be6898bd7831e7f4642,search of published literature,0.343168
uuid-4865c595499e4be6898bd7831e7f4642,Motzer RJ,0.516572
uuid-4865c595499e4be6898bd7831e7f4642,phase 3 study,0.754961
uuid-4865c595499e4be6898bd7831e7f4642,PubMed and EMBASE,0.340904
uuid-4865c595499e4be6898bd7831e7f4642,Escudier B,0.532358
uuid-4865c595499e4be6898bd7831e7f4642,et al.,0.49669
uuid-4865c595499e4be6898bd7831e7f4642,J Clin Oncol,0.430347
uuid-4865c595499e4be6898bd7831e7f4642,Rizvi NA,0.474087
uuid-4865c595499e4be6898bd7831e7f4642,Weber JS,0.58101
uuid-4865c595499e4be6898bd7831e7f4642,phase 2 study,0.614106
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,N Engl J Med,0.456474
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,Lancet Oncol,0.357873
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,protocol,0.480893
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,McDermott DF,0.51746
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,search of published literature,0.343051
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,Motzer RJ,0.516788
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,phase 3 study,0.754973
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,PubMed and EMBASE,0.340792
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,Escudier B,0.532534
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,et al.,0.496867
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,J Clin Oncol,0.430616
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,Rizvi NA,0.473891
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,Weber JS,0.580854
uuid-e01d6cc7bfa34e5cbe0520b3d5376160,phase 2 study,0.6143
uuid-644b5eaa7a6e4feb8ef27c02d0fe51c9,nivolumab,0.460202
uuid-644b5eaa7a6e4feb8ef27c02d0fe51c9,melanoma,0.49119
uuid-e5d8a75a59654bf8ac618fbddaff2078,not identify any citations relevant to your inquiry,0.311701
uuid-e5d8a75a59654bf8ac618fbddaff2078,using the following search terms,0.322506
uuid-e5d8a75a59654bf8ac618fbddaff2078,safety,0.529003
uuid-e5d8a75a59654bf8ac618fbddaff2078,databases,0.473147
uuid-9feeb77fd7cc4efa90d0a6b4bc1eee3d,requested,0.596876
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,N Engl J Med,0.38657
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,protocol,0.500728
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,McDermott DF,0.512333
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,Motzer RJ,0.515611
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,Escudier B,0.515456
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,et al.,0.483027
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,J Clin Oncol,0.495423
uuid-98da1d00b3cd4e85a4d4a60bc479b90d,phase 2 study,0.433673
uuid-0dbdf99fc84a448c82bfa8bc076228ef,use of nivolumab for the treatment,0.409821
uuid-0dbdf99fc84a448c82bfa8bc076228ef,patients with advanced or metastatic,0.645244
uuid-0dbdf99fc84a448c82bfa8bc076228ef,nivolumab combined with ipilimumab,0.676339
uuid-0dbdf99fc84a448c82bfa8bc076228ef,not approved,0.453534
uuid-0dbdf99fc84a448c82bfa8bc076228ef,clinical trials investigating the safety,0.548799
uuid-0dbdf99fc84a448c82bfa8bc076228ef,phase 1/2 study CA209-032,0.34114
uuid-0dbdf99fc84a448c82bfa8bc076228ef,bladder cancer,0.749142
uuid-0dbdf99fc84a448c82bfa8bc076228ef,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-0411d76bb8e3495a8ac38be04b3008fb,requested,0.407944
uuid-7d75c223175e4d1484ab911a0150e273,evaluating,0.422111
uuid-7d75c223175e4d1484ab911a0150e273,not conducted any controlled clinical trials/studies,0.424277
uuid-7d75c223175e4d1484ab911a0150e273,protocol,0.485143
uuid-7d75c223175e4d1484ab911a0150e273,RCC,0.386834
uuid-7d75c223175e4d1484ab911a0150e273,McDermott DF,0.400802
uuid-7d75c223175e4d1484ab911a0150e273,search of published literature,0.541937
uuid-7d75c223175e4d1484ab911a0150e273,Additionally,0.53624
uuid-7d75c223175e4d1484ab911a0150e273,ongoing,0.451384
uuid-7d75c223175e4d1484ab911a0150e273,Motzer RJ,0.431317
uuid-7d75c223175e4d1484ab911a0150e273,PubMed and EMBASE,0.535304
uuid-7d75c223175e4d1484ab911a0150e273,Escudier B,0.416307
uuid-7d75c223175e4d1484ab911a0150e273,et al.,0.354361
uuid-7d75c223175e4d1484ab911a0150e273,J Clin Oncol,0.383708
uuid-7d75c223175e4d1484ab911a0150e273,detailed search of www.clinicaltrials.gov,0.495014
uuid-7d75c223175e4d1484ab911a0150e273,efficacy and safety of nivolumab,0.542707
uuid-7d75c223175e4d1484ab911a0150e273,not identify any planned,0.46752
uuid-7d75c223175e4d1484ab911a0150e273,phase 2 study,0.348055
uuid-7d75c223175e4d1484ab911a0150e273,not identify any citations relevant to your request,0.562311
uuid-7d75c223175e4d1484ab911a0150e273,present using the following search terms,0.526556
uuid-c09423fc247b4046b39f12cea6385deb,AEs,0.310608
uuid-c09423fc247b4046b39f12cea6385deb,patients,0.471661
uuid-c09423fc247b4046b39f12cea6385deb,fatigue,0.36265
uuid-c09423fc247b4046b39f12cea6385deb,grade,0.381374
uuid-c09423fc247b4046b39f12cea6385deb,grade 3 to 4 AEs,0.420077
uuid-6b6d0064ffeb479794f1da55d5bd454e,nivolumab,0.999168
uuid-6b6d0064ffeb479794f1da55d5bd454e,Pubmed literature search,0.395314
uuid-6b6d0064ffeb479794f1da55d5bd454e,purposes other than its labeled indication must be considered investigational,0.464236
uuid-6b6d0064ffeb479794f1da55d5bd454e,not identify any citations relevant to your inquiry,0.368569
uuid-6b6d0064ffeb479794f1da55d5bd454e,using the following search terms,0.364279
uuid-6b6d0064ffeb479794f1da55d5bd454e,present using the following search terms,0.329876
uuid-dd36a0b9864541acac79a75725a27d08,NSCLC,0.487564
uuid-dd36a0b9864541acac79a75725a27d08,Lancet Oncol,0.408285
uuid-dd36a0b9864541acac79a75725a27d08,non-small cell lung cancer,0.425216
uuid-dd36a0b9864541acac79a75725a27d08,phase 3 study,0.406253
uuid-dd36a0b9864541acac79a75725a27d08,phase 1 study,0.591752
uuid-dd36a0b9864541acac79a75725a27d08,Rizvi NA,0.511912
uuid-dd36a0b9864541acac79a75725a27d08,CA209-003,0.456298
uuid-dd36a0b9864541acac79a75725a27d08,Weber JS,0.339277
uuid-dd36a0b9864541acac79a75725a27d08,phase 2 study,0.340247
uuid-dd36a0b9864541acac79a75725a27d08,SCLC,0.30471
uuid-dd36a0b9864541acac79a75725a27d08,Antonia SJ,0.337097
uuid-aeb5f5f8d81a4f92b6bc237bcedd2d30,requested,0.559679
uuid-0145f24ecc0246b6993edd03726e5016,nivolumab,0.520431
uuid-0145f24ecc0246b6993edd03726e5016,Bristol-Myers Squibb,0.445924
uuid-0145f24ecc0246b6993edd03726e5016,evaluating,0.569205
uuid-0145f24ecc0246b6993edd03726e5016,not conducted any controlled clinical trials/studies,0.637929
uuid-0145f24ecc0246b6993edd03726e5016,Pubmed literature search,0.750852
uuid-0145f24ecc0246b6993edd03726e5016,purposes other than its labeled indication must be considered investigational,0.823465
uuid-0145f24ecc0246b6993edd03726e5016,not identify any citations relevant to your inquiry,0.70978
uuid-0145f24ecc0246b6993edd03726e5016,using the following search terms,0.695032
uuid-0145f24ecc0246b6993edd03726e5016,efficacy and safety of nivolumab,0.428097
uuid-056d8b1c84284baa8c36e425306d6611,fatigue,0.323475
uuid-88e9d0631dee4b4f9fd96d1384d4cd8a,Bristol-Myers Squibb,0.351139
uuid-88e9d0631dee4b4f9fd96d1384d4cd8a,evaluating,0.393781
uuid-88e9d0631dee4b4f9fd96d1384d4cd8a,not conducted any controlled clinical trials/studies,0.401959
uuid-88e9d0631dee4b4f9fd96d1384d4cd8a,NSCLC,0.316818
uuid-88e9d0631dee4b4f9fd96d1384d4cd8a,efficacy and safety of nivolumab,0.448974
uuid-0b6b7a0bd3d94fd88c81c433f604f756,provided in the Detailed Information,0.366597
uuid-c90e9d9dffbb4e29a8da56c9f128f29a,melanoma,0.410364
uuid-9566a4826e11413c93bd70eb5a193252,patients,0.742515
uuid-9566a4826e11413c93bd70eb5a193252,small cell lung cancer,0.323351
uuid-9566a4826e11413c93bd70eb5a193252,grade 3 to 4 AEs,0.328442
uuid-5ff429660f41476081248d72df4f01be,requested,0.594234
uuid-c296e951575843d08af99982e711adf1,Bristol-Myers Squibb,0.398097
uuid-c296e951575843d08af99982e711adf1,requested,0.825692
uuid-505d2b2d448542e59f97bae33ab8b98c,therapy,0.313979
uuid-505d2b2d448542e59f97bae33ab8b98c,reported,0.322639
uuid-42dc3c97a2104357b5c90e221553c3d2,evaluating,0.366546
uuid-42dc3c97a2104357b5c90e221553c3d2,not conducted any controlled clinical trials/studies,0.360172
uuid-42dc3c97a2104357b5c90e221553c3d2,search of published literature,0.403755
uuid-42dc3c97a2104357b5c90e221553c3d2,Additionally,0.418906
uuid-42dc3c97a2104357b5c90e221553c3d2,ongoing,0.467576
uuid-42dc3c97a2104357b5c90e221553c3d2,PubMed and EMBASE,0.39617
uuid-42dc3c97a2104357b5c90e221553c3d2,detailed search of www.clinicaltrials.gov,0.437393
uuid-42dc3c97a2104357b5c90e221553c3d2,efficacy and safety of nivolumab,0.42836
uuid-42dc3c97a2104357b5c90e221553c3d2,not identify any planned,0.454065
uuid-42dc3c97a2104357b5c90e221553c3d2,combination,0.397925
uuid-42dc3c97a2104357b5c90e221553c3d2,BMS,0.30879
uuid-42dc3c97a2104357b5c90e221553c3d2,not identify any citations relevant to your request,0.449603
uuid-42dc3c97a2104357b5c90e221553c3d2,present using the following search terms,0.394376
uuid-40334360984440b88af7891a401b5d48,requested,0.317267
uuid-40334360984440b88af7891a401b5d48,trial,0.332562
uuid-40334360984440b88af7891a401b5d48,phase,0.375972
uuid-fa8bcdb6fafb445ba193c20571c75f57,Opdivo,0.471301
uuid-fa8bcdb6fafb445ba193c20571c75f57,Pubmed literature search,0.600911
uuid-fa8bcdb6fafb445ba193c20571c75f57,purposes other than its labeled indication must be considered investigational,0.566183
uuid-fa8bcdb6fafb445ba193c20571c75f57,not identify any citations relevant to your inquiry,0.598372
uuid-fa8bcdb6fafb445ba193c20571c75f57,using the following search terms,0.633329
uuid-fa8bcdb6fafb445ba193c20571c75f57,safety,0.439514
uuid-fa8bcdb6fafb445ba193c20571c75f57,databases,0.430798
uuid-fa8bcdb6fafb445ba193c20571c75f57,reported,0.458786
uuid-c392081a9233437da4b97a0d1c312cde,RCC,0.315708
uuid-c392081a9233437da4b97a0d1c312cde,phase 3 study,0.39056
uuid-c392081a9233437da4b97a0d1c312cde,Weber JS,0.379347
uuid-c392081a9233437da4b97a0d1c312cde,therapy,0.526244
uuid-c32aa46acb13438bb15c1f2a4ced976b,Opdivo,0.50165
uuid-c32aa46acb13438bb15c1f2a4ced976b,open-label,0.304253
uuid-c32aa46acb13438bb15c1f2a4ced976b,trial,0.521827
uuid-c32aa46acb13438bb15c1f2a4ced976b,docetaxel,0.30238
uuid-c32aa46acb13438bb15c1f2a4ced976b,safety of nivolumab monotherapy,0.432481
uuid-c32aa46acb13438bb15c1f2a4ced976b,phase,0.378496
uuid-3d5557073bd64b819b9e574581380e40,patients with advanced or metastatic,0.468858
uuid-3d5557073bd64b819b9e574581380e40,nivolumab combined with ipilimumab,0.446918
uuid-3d5557073bd64b819b9e574581380e40,not approved,0.352562
uuid-3d5557073bd64b819b9e574581380e40,clinical trials investigating the safety,0.429501
uuid-3d5557073bd64b819b9e574581380e40,bladder cancer,0.950698
uuid-3011decf8f9b466ea663295de0b001e9,N Engl J Med,0.373043
uuid-3011decf8f9b466ea663295de0b001e9,protocol,0.46881
uuid-3011decf8f9b466ea663295de0b001e9,McDermott DF,0.576976
uuid-3011decf8f9b466ea663295de0b001e9,Motzer RJ,0.550553
uuid-3011decf8f9b466ea663295de0b001e9,phase 3 study,0.466524
uuid-3011decf8f9b466ea663295de0b001e9,Escudier B,0.56633
uuid-3011decf8f9b466ea663295de0b001e9,et al.,0.5383
uuid-3011decf8f9b466ea663295de0b001e9,J Clin Oncol,0.527144
uuid-3011decf8f9b466ea663295de0b001e9,phase 2 study,0.569024
uuid-debc88fc656142ddb8c6ffd55917d679,nivolumab combined with ipilimumab,0.302198
uuid-debc88fc656142ddb8c6ffd55917d679,trial,0.409605
uuid-ec14f32cd05d4cc99199e92732e0e6c3,mg,0.300211
uuid-f70e505efe584a42afe68bb15974f827,Opdivo,0.50165
uuid-f70e505efe584a42afe68bb15974f827,open-label,0.304253
uuid-f70e505efe584a42afe68bb15974f827,trial,0.521827
uuid-f70e505efe584a42afe68bb15974f827,docetaxel,0.30238
uuid-f70e505efe584a42afe68bb15974f827,safety of nivolumab monotherapy,0.432481
uuid-f70e505efe584a42afe68bb15974f827,phase,0.378496
uuid-36ee1239a6da41a2bada1500330a2999,grade,0.348963
uuid-68b85fdc7bf7429e8630fd3700144c96,nivolumab,0.510392
uuid-68b85fdc7bf7429e8630fd3700144c96,Bristol-Myers Squibb,0.464176
uuid-68b85fdc7bf7429e8630fd3700144c96,evaluating,0.683286
uuid-68b85fdc7bf7429e8630fd3700144c96,not conducted any controlled clinical trials/studies,0.682483
uuid-68b85fdc7bf7429e8630fd3700144c96,RCC,0.308694
uuid-68b85fdc7bf7429e8630fd3700144c96,search of published literature,0.839602
uuid-68b85fdc7bf7429e8630fd3700144c96,Additionally,0.446384
uuid-68b85fdc7bf7429e8630fd3700144c96,PubMed and EMBASE,0.823429
uuid-68b85fdc7bf7429e8630fd3700144c96,detailed search of www.clinicaltrials.gov,0.366719
uuid-68b85fdc7bf7429e8630fd3700144c96,efficacy and safety of nivolumab,0.841
uuid-68b85fdc7bf7429e8630fd3700144c96,not identify any citations relevant to your request,0.605656
uuid-68b85fdc7bf7429e8630fd3700144c96,present using the following search terms,0.832619
uuid-8b98a76e9e7d4142a498253f6cb11098,patients,0.679527
uuid-8b98a76e9e7d4142a498253f6cb11098,small cell lung cancer,0.30151
uuid-8b98a76e9e7d4142a498253f6cb11098,grade 3 to 4 AEs,0.39094
uuid-0137e293d61640f2b6441769b05d81d8,nivolumab,0.304992
uuid-0137e293d61640f2b6441769b05d81d8,NEJM,0.351437
uuid-0137e293d61640f2b6441769b05d81d8,Topalian,0.37131
uuid-1a29c74a5b234eeca3300a8fac4fd40c,N Engl J Med,0.448483
uuid-1a29c74a5b234eeca3300a8fac4fd40c,protocol,0.770446
uuid-1a29c74a5b234eeca3300a8fac4fd40c,McDermott DF,0.741196
uuid-1a29c74a5b234eeca3300a8fac4fd40c,Motzer RJ,0.818144
uuid-1a29c74a5b234eeca3300a8fac4fd40c,phase 3 study,0.417055
uuid-1a29c74a5b234eeca3300a8fac4fd40c,Escudier B,0.749917
uuid-1a29c74a5b234eeca3300a8fac4fd40c,NEJM,0.400698
uuid-1a29c74a5b234eeca3300a8fac4fd40c,et al.,0.668641
uuid-1a29c74a5b234eeca3300a8fac4fd40c,J Clin Oncol,0.792018
uuid-1a29c74a5b234eeca3300a8fac4fd40c,Topalian,0.388894
uuid-1a29c74a5b234eeca3300a8fac4fd40c,phase 1 study,0.500686
uuid-1a29c74a5b234eeca3300a8fac4fd40c,CA209-003,0.567381
uuid-1a29c74a5b234eeca3300a8fac4fd40c,phase 2 study,0.677985
uuid-1a29c74a5b234eeca3300a8fac4fd40c,present using the following search terms,0.310558
uuid-1a29c74a5b234eeca3300a8fac4fd40c,investigating,0.615835
uuid-969d164fbe4c406eac1c413c438fa8a0,patients with advanced or metastatic,0.478326
uuid-969d164fbe4c406eac1c413c438fa8a0,nivolumab combined with ipilimumab,0.498766
uuid-969d164fbe4c406eac1c413c438fa8a0,not approved,0.34724
uuid-969d164fbe4c406eac1c413c438fa8a0,clinical trials investigating the safety,0.426729
uuid-969d164fbe4c406eac1c413c438fa8a0,bladder cancer,0.6548
uuid-c7596eb08716406ab3bf5550a95cf11b,N Engl J Med,0.302601
uuid-c7596eb08716406ab3bf5550a95cf11b,AEs,0.348167
uuid-c7596eb08716406ab3bf5550a95cf11b,patients,0.536884
uuid-c7596eb08716406ab3bf5550a95cf11b,provided in the Detailed Information,0.387544
uuid-c7596eb08716406ab3bf5550a95cf11b,ESMO,0.462801
uuid-c7596eb08716406ab3bf5550a95cf11b,NEJM,0.66427
uuid-c7596eb08716406ab3bf5550a95cf11b,Topalian,0.692873
uuid-c7596eb08716406ab3bf5550a95cf11b,grade 3 to 4 AEs,0.626596
uuid-b605476cbcf84a108823b6fe1e79b806,N Engl J Med,0.304989
uuid-b605476cbcf84a108823b6fe1e79b806,AEs,0.337832
uuid-b605476cbcf84a108823b6fe1e79b806,patients,0.387033
uuid-b605476cbcf84a108823b6fe1e79b806,provided in the Detailed Information,0.370845
uuid-b605476cbcf84a108823b6fe1e79b806,ESMO,0.421367
uuid-b605476cbcf84a108823b6fe1e79b806,NEJM,0.709799
uuid-b605476cbcf84a108823b6fe1e79b806,Topalian,0.735417
uuid-b605476cbcf84a108823b6fe1e79b806,grade 3 to 4 AEs,0.538198
uuid-efc43fa75ff34b9e93c5110ecceefcc0,nivolumab,0.324658
uuid-efc43fa75ff34b9e93c5110ecceefcc0,use of nivolumab for the treatment,0.543355
uuid-efc43fa75ff34b9e93c5110ecceefcc0,evaluating,0.348676
uuid-efc43fa75ff34b9e93c5110ecceefcc0,efficacy,0.388907
uuid-efc43fa75ff34b9e93c5110ecceefcc0,patients,0.419915
uuid-efc43fa75ff34b9e93c5110ecceefcc0,search of published literature,0.449959
uuid-efc43fa75ff34b9e93c5110ecceefcc0,PubMed and EMBASE,0.444573
uuid-efc43fa75ff34b9e93c5110ecceefcc0,not approved,0.582429
uuid-efc43fa75ff34b9e93c5110ecceefcc0,clinical trials investigating the safety,0.64854
uuid-efc43fa75ff34b9e93c5110ecceefcc0,efficacy and safety of nivolumab,0.399101
uuid-efc43fa75ff34b9e93c5110ecceefcc0,present using the following search terms,0.465296
uuid-8084ed9c41654f6c8798b8d7b7bdac9a,NSCLC,0.35614
uuid-8084ed9c41654f6c8798b8d7b7bdac9a,non-small cell lung cancer,0.303269
uuid-8084ed9c41654f6c8798b8d7b7bdac9a,phase 3 study,0.45311
uuid-dcf2e01c0d59451790a111528099e485,ASCO,0.602931
uuid-dcf2e01c0d59451790a111528099e485,requested,0.635059
uuid-dcf2e01c0d59451790a111528099e485,Horn L,0.466094
uuid-dcf2e01c0d59451790a111528099e485,platinum-based doublet chemotherapy,0.372235
uuid-a49dec80a8f446ad97f9447e2bfeb647,OS,0.517683
uuid-a49dec80a8f446ad97f9447e2bfeb647,95% CI,0.887029
uuid-a49dec80a8f446ad97f9447e2bfeb647,respectively,0.541932
uuid-a49dec80a8f446ad97f9447e2bfeb647,Objective response rate,0.732884
uuid-a49dec80a8f446ad97f9447e2bfeb647,ORR,0.826341
uuid-a49dec80a8f446ad97f9447e2bfeb647,PFS,0.416378
uuid-a49dec80a8f446ad97f9447e2bfeb647,Median overall survival,0.810566
uuid-a49dec80a8f446ad97f9447e2bfeb647,monotherapy,0.504664
uuid-a49dec80a8f446ad97f9447e2bfeb647,Median OS,0.783041
uuid-a49dec80a8f446ad97f9447e2bfeb647,hazard ratio,0.851803
uuid-a49dec80a8f446ad97f9447e2bfeb647,Median duration of response,0.350254
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,OS,0.517683
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,95% CI,0.887029
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,respectively,0.541932
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,Objective response rate,0.732884
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,ORR,0.826341
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,PFS,0.416378
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,Median overall survival,0.810566
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,monotherapy,0.504664
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,Median OS,0.783041
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,hazard ratio,0.851803
uuid-44c583b4ca7c4ad49d4fe99e1278a13d,Median duration of response,0.350254
uuid-21372341f8924fca971efa8b428ae5f2,nivolumab,0.617032
uuid-21372341f8924fca971efa8b428ae5f2,Bristol-Myers Squibb,0.46045
uuid-21372341f8924fca971efa8b428ae5f2,evaluating,0.642074
uuid-21372341f8924fca971efa8b428ae5f2,not conducted any controlled clinical trials/studies,0.685803
uuid-21372341f8924fca971efa8b428ae5f2,Pubmed literature search,0.837463
uuid-21372341f8924fca971efa8b428ae5f2,purposes other than its labeled indication must be considered investigational,0.910738
uuid-21372341f8924fca971efa8b428ae5f2,not identify any citations relevant to your inquiry,0.79394
uuid-21372341f8924fca971efa8b428ae5f2,using the following search terms,0.780565
uuid-21372341f8924fca971efa8b428ae5f2,efficacy and safety of nivolumab,0.483724
uuid-06647da6ce0a474bb382f9e9324d08fa,provided in the Detailed Information,0.34899
uuid-06647da6ce0a474bb382f9e9324d08fa,Weber JS,0.355509
uuid-6515c6043f47460f8497059d2c5094cd,nivolumab,0.338545
uuid-ca5f2822936942fd9f6701b1d69fb0b1,Bristol-Myers Squibb,0.36472
uuid-b696ce4af1b84b9ba518d25e734dbe8a,Rizvi NA,0.365648
uuid-b696ce4af1b84b9ba518d25e734dbe8a,trial,0.324432
uuid-b696ce4af1b84b9ba518d25e734dbe8a,mg,0.33443
uuid-b696ce4af1b84b9ba518d25e734dbe8a,Weber JS,0.364988
uuid-b696ce4af1b84b9ba518d25e734dbe8a,kg,0.317545
uuid-b170cf8397a545019dd185c01a1e6ff2,Bristol-Myers Squibb,0.341822
uuid-b170cf8397a545019dd185c01a1e6ff2,not conducted any controlled clinical trials/studies,0.304507
uuid-b170cf8397a545019dd185c01a1e6ff2,Opdivo,0.461382
uuid-b170cf8397a545019dd185c01a1e6ff2,Pubmed literature search,0.614325
uuid-b170cf8397a545019dd185c01a1e6ff2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b170cf8397a545019dd185c01a1e6ff2,not identify any citations relevant to your inquiry,0.606087
uuid-b170cf8397a545019dd185c01a1e6ff2,adverse,0.304183
uuid-b170cf8397a545019dd185c01a1e6ff2,using the following search terms,0.642331
uuid-b170cf8397a545019dd185c01a1e6ff2,databases,0.315039
uuid-b170cf8397a545019dd185c01a1e6ff2,reported,0.556704
uuid-1e4920170d5b4bb0a327181a31626178,nivolumab,0.568715
uuid-1e4920170d5b4bb0a327181a31626178,Bristol-Myers Squibb,0.441262
uuid-1e4920170d5b4bb0a327181a31626178,evaluating,0.597739
uuid-1e4920170d5b4bb0a327181a31626178,not conducted any controlled clinical trials/studies,0.658717
uuid-1e4920170d5b4bb0a327181a31626178,Pubmed literature search,0.877216
uuid-1e4920170d5b4bb0a327181a31626178,purposes other than its labeled indication must be considered investigational,0.940484
uuid-1e4920170d5b4bb0a327181a31626178,not identify any citations relevant to your inquiry,0.835962
uuid-1e4920170d5b4bb0a327181a31626178,using the following search terms,0.823738
uuid-1e4920170d5b4bb0a327181a31626178,efficacy and safety of nivolumab,0.436199
uuid-c956656093e84578ba670a19abcee9e0,use of nivolumab for the treatment,0.440423
uuid-c956656093e84578ba670a19abcee9e0,search of published literature,0.311531
uuid-c956656093e84578ba670a19abcee9e0,PubMed and EMBASE,0.312811
uuid-c956656093e84578ba670a19abcee9e0,not approved,0.404782
uuid-c956656093e84578ba670a19abcee9e0,open-label,0.578291
uuid-c956656093e84578ba670a19abcee9e0,clinical trials investigating the safety,0.440014
uuid-c956656093e84578ba670a19abcee9e0,present using the following search terms,0.328669
uuid-c956656093e84578ba670a19abcee9e0,phase,0.41185
uuid-b25604f0fc5d45658958979267c70848,provided in the Detailed Information,0.336018
uuid-b25604f0fc5d45658958979267c70848,Weber JS,0.324053
uuid-4f4705c9ddd84119868631e88768bb94,use of nivolumab for the treatment,0.582062
uuid-4f4705c9ddd84119868631e88768bb94,efficacy,0.563967
uuid-4f4705c9ddd84119868631e88768bb94,not approved,0.741861
uuid-4f4705c9ddd84119868631e88768bb94,clinical trials investigating the safety,0.813562
uuid-4f4705c9ddd84119868631e88768bb94,clinicaltrials.gov,0.41835
uuid-4f4705c9ddd84119868631e88768bb94,safety of nivolumab monotherapy,0.315483
uuid-4f4705c9ddd84119868631e88768bb94,bladder cancer,0.384568
uuid-a041b227028e44929ea4ac3f848b6ee9,nivolumab,0.527985
uuid-a041b227028e44929ea4ac3f848b6ee9,Bristol-Myers Squibb,0.481105
uuid-a041b227028e44929ea4ac3f848b6ee9,evaluating,0.677683
uuid-a041b227028e44929ea4ac3f848b6ee9,not conducted any controlled clinical trials/studies,0.721773
uuid-a041b227028e44929ea4ac3f848b6ee9,Pubmed literature search,0.812241
uuid-a041b227028e44929ea4ac3f848b6ee9,purposes other than its labeled indication must be considered investigational,0.890518
uuid-a041b227028e44929ea4ac3f848b6ee9,not identify any citations relevant to your inquiry,0.76614
uuid-a041b227028e44929ea4ac3f848b6ee9,using the following search terms,0.750292
uuid-a041b227028e44929ea4ac3f848b6ee9,efficacy and safety of nivolumab,0.518565
uuid-b8e793996a6641e08743391ec4a2d946,not identify any citations relevant to your request,0.317214
uuid-b8e793996a6641e08743391ec4a2d946,present using the following search terms,0.362029
uuid-9ec3809212a14468af5723c1e77c1e2e,adverse,0.308733
uuid-ae2ded56d6654ece91b1df6b370c6979,adverse,0.444677
uuid-ae2ded56d6654ece91b1df6b370c6979,reported,0.612982
uuid-af1d86d7f6ba4998aab7e1579ecc4cd5,Bristol-Myers Squibb,0.307009
uuid-af1d86d7f6ba4998aab7e1579ecc4cd5,requested,0.323839
uuid-4a71b7636ed64492ab7b18f4651f3010,95% CI,0.419478
uuid-4a71b7636ed64492ab7b18f4651f3010,respectively,0.497608
uuid-4a71b7636ed64492ab7b18f4651f3010,Objective response rate,0.403649
uuid-4a71b7636ed64492ab7b18f4651f3010,ORR,0.578109
uuid-4a71b7636ed64492ab7b18f4651f3010,patients with advanced or metastatic,0.306625
uuid-4a71b7636ed64492ab7b18f4651f3010,Median overall survival,0.498783
uuid-4a71b7636ed64492ab7b18f4651f3010,nivolumab combined with ipilimumab,0.300486
uuid-4a71b7636ed64492ab7b18f4651f3010,tumors,0.323334
uuid-4a71b7636ed64492ab7b18f4651f3010,ESMO,0.534361
uuid-4a71b7636ed64492ab7b18f4651f3010,Median OS,0.394058
uuid-4a71b7636ed64492ab7b18f4651f3010,small cell lung cancer,0.380999
uuid-4a71b7636ed64492ab7b18f4651f3010,SCLC,0.365686
uuid-4a71b7636ed64492ab7b18f4651f3010,hazard ratio,0.419392
uuid-4a71b7636ed64492ab7b18f4651f3010,grade 3 to 4 AEs,0.414535
uuid-4a71b7636ed64492ab7b18f4651f3010,phase 1/2 study CA209-032,0.398283
uuid-4a71b7636ed64492ab7b18f4651f3010,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-d1946f0ca27943dd9bf95b834b9de838,requested,0.509424
uuid-cf060910277b4c87b91ade73b95e4bf9,Opdivo,0.50165
uuid-cf060910277b4c87b91ade73b95e4bf9,open-label,0.304253
uuid-cf060910277b4c87b91ade73b95e4bf9,trial,0.521827
uuid-cf060910277b4c87b91ade73b95e4bf9,docetaxel,0.30238
uuid-cf060910277b4c87b91ade73b95e4bf9,safety of nivolumab monotherapy,0.432481
uuid-cf060910277b4c87b91ade73b95e4bf9,phase,0.378496
uuid-b09e1f25544443e2ae83ef95906395a5,use of nivolumab for the treatment,0.409821
uuid-b09e1f25544443e2ae83ef95906395a5,patients with advanced or metastatic,0.645244
uuid-b09e1f25544443e2ae83ef95906395a5,nivolumab combined with ipilimumab,0.676339
uuid-b09e1f25544443e2ae83ef95906395a5,not approved,0.453534
uuid-b09e1f25544443e2ae83ef95906395a5,clinical trials investigating the safety,0.548799
uuid-b09e1f25544443e2ae83ef95906395a5,phase 1/2 study CA209-032,0.34114
uuid-b09e1f25544443e2ae83ef95906395a5,bladder cancer,0.749142
uuid-b09e1f25544443e2ae83ef95906395a5,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-eaf6ad664ba24cb19acc77392ea34abf,NSCLC,0.753703
uuid-eaf6ad664ba24cb19acc77392ea34abf,non-small cell lung cancer,0.729984
uuid-eaf6ad664ba24cb19acc77392ea34abf,considered investigational,0.474697
uuid-eaf6ad664ba24cb19acc77392ea34abf,small cell lung cancer,0.414774
uuid-eaf6ad664ba24cb19acc77392ea34abf,SCLC,0.468566
uuid-eaf6ad664ba24cb19acc77392ea34abf,therapy,0.59938
uuid-eaf6ad664ba24cb19acc77392ea34abf,safety of nivolumab monotherapy,0.329401
uuid-eaf6ad664ba24cb19acc77392ea34abf,platinum-based doublet chemotherapy,0.391363
uuid-ee7057b116604070a2a1a8d30f23a8e7,clinical,0.358272
uuid-ee7057b116604070a2a1a8d30f23a8e7,phase 3 study,0.548155
uuid-ee7057b116604070a2a1a8d30f23a8e7,phase 1 study,0.42036
uuid-ee7057b116604070a2a1a8d30f23a8e7,Rizvi NA,0.378742
uuid-ee7057b116604070a2a1a8d30f23a8e7,CA209-003,0.39539
uuid-ee7057b116604070a2a1a8d30f23a8e7,Weber JS,0.406904
uuid-ee7057b116604070a2a1a8d30f23a8e7,phase 2 study,0.42634
uuid-ee7057b116604070a2a1a8d30f23a8e7,partial response,0.431172
uuid-ee7057b116604070a2a1a8d30f23a8e7,Stable disease,0.44003
uuid-bc7d8610d00d47618f742468400fa7e8,NSCLC,0.487564
uuid-bc7d8610d00d47618f742468400fa7e8,Lancet Oncol,0.408285
uuid-bc7d8610d00d47618f742468400fa7e8,non-small cell lung cancer,0.425216
uuid-bc7d8610d00d47618f742468400fa7e8,phase 3 study,0.406253
uuid-bc7d8610d00d47618f742468400fa7e8,phase 1 study,0.591752
uuid-bc7d8610d00d47618f742468400fa7e8,Rizvi NA,0.511912
uuid-bc7d8610d00d47618f742468400fa7e8,CA209-003,0.456298
uuid-bc7d8610d00d47618f742468400fa7e8,Weber JS,0.339277
uuid-bc7d8610d00d47618f742468400fa7e8,phase 2 study,0.340247
uuid-bc7d8610d00d47618f742468400fa7e8,SCLC,0.30471
uuid-bc7d8610d00d47618f742468400fa7e8,Antonia SJ,0.337097
uuid-eb49e336ac9f457a8e87e7cff70554a1,patients,0.556054
uuid-eb49e336ac9f457a8e87e7cff70554a1,provided in the Detailed Information,0.329929
uuid-eb49e336ac9f457a8e87e7cff70554a1,adverse,0.32982
uuid-eb49e336ac9f457a8e87e7cff70554a1,phase 3 study,0.523726
uuid-eb49e336ac9f457a8e87e7cff70554a1,melanoma,0.382071
uuid-eb49e336ac9f457a8e87e7cff70554a1,Weber JS,0.428777
uuid-eb49e336ac9f457a8e87e7cff70554a1,phase 2 study,0.307314
uuid-eb49e336ac9f457a8e87e7cff70554a1,grade 3 to 4 AEs,0.466022
uuid-af7af07764554bc6ab48508ea6986eaa,trial,0.480962
uuid-af7af07764554bc6ab48508ea6986eaa,BMS,0.352893
uuid-91fbab6e797b4fd89dce209616245850,N Engl J Med,0.448483
uuid-91fbab6e797b4fd89dce209616245850,protocol,0.770446
uuid-91fbab6e797b4fd89dce209616245850,McDermott DF,0.741196
uuid-91fbab6e797b4fd89dce209616245850,Motzer RJ,0.818144
uuid-91fbab6e797b4fd89dce209616245850,phase 3 study,0.417055
uuid-91fbab6e797b4fd89dce209616245850,Escudier B,0.749917
uuid-91fbab6e797b4fd89dce209616245850,NEJM,0.400698
uuid-91fbab6e797b4fd89dce209616245850,et al.,0.668641
uuid-91fbab6e797b4fd89dce209616245850,J Clin Oncol,0.792018
uuid-91fbab6e797b4fd89dce209616245850,Topalian,0.388894
uuid-91fbab6e797b4fd89dce209616245850,phase 1 study,0.500686
uuid-91fbab6e797b4fd89dce209616245850,CA209-003,0.567381
uuid-91fbab6e797b4fd89dce209616245850,phase 2 study,0.677985
uuid-91fbab6e797b4fd89dce209616245850,present using the following search terms,0.310558
uuid-91fbab6e797b4fd89dce209616245850,investigating,0.615835
uuid-1281b83c7a9d48c8a292c1e4b00f052d,Pubmed literature search,0.349305
uuid-1281b83c7a9d48c8a292c1e4b00f052d,purposes other than its labeled indication must be considered investigational,0.320673
uuid-1281b83c7a9d48c8a292c1e4b00f052d,not identify any citations relevant to your inquiry,0.361341
uuid-1281b83c7a9d48c8a292c1e4b00f052d,using the following search terms,0.373179
uuid-1281b83c7a9d48c8a292c1e4b00f052d,safety,0.57921
uuid-1281b83c7a9d48c8a292c1e4b00f052d,databases,0.513723
uuid-1dd31959369449b3b8e6776e28e932b9,Bristol-Myers Squibb,0.345444
uuid-1dd31959369449b3b8e6776e28e932b9,Opdivo,0.501449
uuid-1dd31959369449b3b8e6776e28e932b9,Pubmed literature search,0.585917
uuid-1dd31959369449b3b8e6776e28e932b9,purposes other than its labeled indication must be considered investigational,0.557437
uuid-1dd31959369449b3b8e6776e28e932b9,not identify any citations relevant to your inquiry,0.580072
uuid-1dd31959369449b3b8e6776e28e932b9,adverse,0.323288
uuid-1dd31959369449b3b8e6776e28e932b9,using the following search terms,0.617266
uuid-1dd31959369449b3b8e6776e28e932b9,databases,0.301333
uuid-1dd31959369449b3b8e6776e28e932b9,reported,0.581813
uuid-79fed997b51148b5ba7e0ade183dfa67,nivolumab,0.999168
uuid-79fed997b51148b5ba7e0ade183dfa67,Pubmed literature search,0.395314
uuid-79fed997b51148b5ba7e0ade183dfa67,purposes other than its labeled indication must be considered investigational,0.464236
uuid-79fed997b51148b5ba7e0ade183dfa67,not identify any citations relevant to your inquiry,0.368569
uuid-79fed997b51148b5ba7e0ade183dfa67,using the following search terms,0.364279
uuid-79fed997b51148b5ba7e0ade183dfa67,present using the following search terms,0.329876
uuid-6f98a6942be646a786d0309bd91d096c,N Engl J Med,0.766032
uuid-6f98a6942be646a786d0309bd91d096c,protocol,0.874182
uuid-6f98a6942be646a786d0309bd91d096c,McDermott DF,0.960227
uuid-6f98a6942be646a786d0309bd91d096c,Motzer RJ,0.937306
uuid-6f98a6942be646a786d0309bd91d096c,phase 3 study,0.460393
uuid-6f98a6942be646a786d0309bd91d096c,Escudier B,0.963515
uuid-6f98a6942be646a786d0309bd91d096c,NEJM,0.474086
uuid-6f98a6942be646a786d0309bd91d096c,et al.,0.949387
uuid-6f98a6942be646a786d0309bd91d096c,J Clin Oncol,0.883564
uuid-6f98a6942be646a786d0309bd91d096c,Topalian,0.418815
uuid-6f98a6942be646a786d0309bd91d096c,Rizvi NA,0.471055
uuid-6f98a6942be646a786d0309bd91d096c,Brahmer J,0.406289
uuid-6f98a6942be646a786d0309bd91d096c,Weber JS,0.328759
uuid-6f98a6942be646a786d0309bd91d096c,phase 2 study,0.812219
uuid-16182258eeea444aa558b5643d5f696b,adverse,0.339013
uuid-16182258eeea444aa558b5643d5f696b,phase 3 study,0.319839
uuid-16182258eeea444aa558b5643d5f696b,Rizvi NA,0.364772
uuid-16182258eeea444aa558b5643d5f696b,Brahmer J,0.4414
uuid-16182258eeea444aa558b5643d5f696b,BMS,0.743077
uuid-16182258eeea444aa558b5643d5f696b,reported,0.507787
uuid-23faa7466b4a44f48c3624a2f2b7a532,nivolumab,0.519309
uuid-23faa7466b4a44f48c3624a2f2b7a532,Bristol-Myers Squibb,0.495781
uuid-23faa7466b4a44f48c3624a2f2b7a532,evaluating,0.599806
uuid-23faa7466b4a44f48c3624a2f2b7a532,not conducted any controlled clinical trials/studies,0.656273
uuid-23faa7466b4a44f48c3624a2f2b7a532,Pubmed literature search,0.696787
uuid-23faa7466b4a44f48c3624a2f2b7a532,purposes other than its labeled indication must be considered investigational,0.772725
uuid-23faa7466b4a44f48c3624a2f2b7a532,not identify any citations relevant to your inquiry,0.655995
uuid-23faa7466b4a44f48c3624a2f2b7a532,using the following search terms,0.639319
uuid-23faa7466b4a44f48c3624a2f2b7a532,efficacy and safety of nivolumab,0.458917
uuid-83911234c93a41c49d566f92e23519f0,nivolumab,0.321332
uuid-83911234c93a41c49d566f92e23519f0,Bristol-Myers Squibb,0.312259
uuid-83911234c93a41c49d566f92e23519f0,evaluating,0.458799
uuid-83911234c93a41c49d566f92e23519f0,not conducted any controlled clinical trials/studies,0.464088
uuid-83911234c93a41c49d566f92e23519f0,Pubmed literature search,0.315359
uuid-83911234c93a41c49d566f92e23519f0,purposes other than its labeled indication must be considered investigational,0.390924
uuid-83911234c93a41c49d566f92e23519f0,efficacy and safety of nivolumab,0.342742
uuid-2c7f4155522346d58af95ed5cad8a2f2,Bristol-Myers Squibb,0.361662
uuid-c0c0464b38464342886a5ee60d75443e,Opdivo,0.462089
uuid-c0c0464b38464342886a5ee60d75443e,RCC,0.566811
uuid-c0c0464b38464342886a5ee60d75443e,melanoma,0.371536
uuid-c0c0464b38464342886a5ee60d75443e,safety,0.547571
uuid-c0c0464b38464342886a5ee60d75443e,databases,0.480774
uuid-f000a036413847148379acfe1adc9ec1,nivolumab,0.50323
uuid-f000a036413847148379acfe1adc9ec1,Bristol-Myers Squibb,0.497001
uuid-f000a036413847148379acfe1adc9ec1,evaluating,0.691247
uuid-f000a036413847148379acfe1adc9ec1,not conducted any controlled clinical trials/studies,0.732925
uuid-f000a036413847148379acfe1adc9ec1,Pubmed literature search,0.836285
uuid-f000a036413847148379acfe1adc9ec1,purposes other than its labeled indication must be considered investigational,0.911096
uuid-f000a036413847148379acfe1adc9ec1,not identify any citations relevant to your inquiry,0.789465
uuid-f000a036413847148379acfe1adc9ec1,using the following search terms,0.776234
uuid-f000a036413847148379acfe1adc9ec1,efficacy and safety of nivolumab,0.518748
uuid-cefdef8ed0b34fe28395bf06a742a62f,requested,0.596876
uuid-31e352c383324c0ebcf7032f07c47c95,requested,0.596876
uuid-a24fa6126873487892f4469929bdbbaf,N Engl J Med,0.802402
uuid-a24fa6126873487892f4469929bdbbaf,Lancet Oncol,0.56115
uuid-a24fa6126873487892f4469929bdbbaf,protocol,0.825455
uuid-a24fa6126873487892f4469929bdbbaf,McDermott DF,0.885167
uuid-a24fa6126873487892f4469929bdbbaf,Motzer RJ,0.855335
uuid-a24fa6126873487892f4469929bdbbaf,phase 3 study,0.542754
uuid-a24fa6126873487892f4469929bdbbaf,Escudier B,0.889228
uuid-a24fa6126873487892f4469929bdbbaf,NEJM,0.49481
uuid-a24fa6126873487892f4469929bdbbaf,et al.,0.863613
uuid-a24fa6126873487892f4469929bdbbaf,J Clin Oncol,0.80113
uuid-a24fa6126873487892f4469929bdbbaf,Topalian,0.450909
uuid-a24fa6126873487892f4469929bdbbaf,Rizvi NA,0.701925
uuid-a24fa6126873487892f4469929bdbbaf,Brahmer J,0.469271
uuid-a24fa6126873487892f4469929bdbbaf,Weber JS,0.595586
uuid-a24fa6126873487892f4469929bdbbaf,phase 2 study,0.814538
uuid-0959ff7443ca4c35ae79c14c1273c8c1,N Engl J Med,0.304989
uuid-0959ff7443ca4c35ae79c14c1273c8c1,AEs,0.337832
uuid-0959ff7443ca4c35ae79c14c1273c8c1,patients,0.387033
uuid-0959ff7443ca4c35ae79c14c1273c8c1,provided in the Detailed Information,0.370845
uuid-0959ff7443ca4c35ae79c14c1273c8c1,ESMO,0.421367
uuid-0959ff7443ca4c35ae79c14c1273c8c1,NEJM,0.709799
uuid-0959ff7443ca4c35ae79c14c1273c8c1,Topalian,0.735417
uuid-0959ff7443ca4c35ae79c14c1273c8c1,grade 3 to 4 AEs,0.538198
uuid-b446c8571ded4ffcbdecf88a4d66e605,search of published literature,0.394524
uuid-b446c8571ded4ffcbdecf88a4d66e605,Additionally,0.413583
uuid-b446c8571ded4ffcbdecf88a4d66e605,ongoing,0.322117
uuid-b446c8571ded4ffcbdecf88a4d66e605,PubMed and EMBASE,0.391671
uuid-b446c8571ded4ffcbdecf88a4d66e605,detailed search of www.clinicaltrials.gov,0.375936
uuid-b446c8571ded4ffcbdecf88a4d66e605,efficacy and safety of nivolumab,0.370699
uuid-b446c8571ded4ffcbdecf88a4d66e605,not identify any planned,0.34283
uuid-b446c8571ded4ffcbdecf88a4d66e605,Weber JS,0.319229
uuid-b446c8571ded4ffcbdecf88a4d66e605,not identify any citations relevant to your request,0.447813
uuid-b446c8571ded4ffcbdecf88a4d66e605,present using the following search terms,0.408199
uuid-424e6276a02d42c995c1f69900ccf840,provided in the Detailed Information,0.349112
uuid-424e6276a02d42c995c1f69900ccf840,Weber JS,0.321343
uuid-ca922dda71094f13b02600d3a708e035,nivolumab,0.597722
uuid-ca922dda71094f13b02600d3a708e035,Bristol-Myers Squibb,0.407066
uuid-ca922dda71094f13b02600d3a708e035,evaluating,0.552322
uuid-ca922dda71094f13b02600d3a708e035,not conducted any controlled clinical trials/studies,0.614006
uuid-ca922dda71094f13b02600d3a708e035,Pubmed literature search,0.827563
uuid-ca922dda71094f13b02600d3a708e035,purposes other than its labeled indication must be considered investigational,0.894644
uuid-ca922dda71094f13b02600d3a708e035,not identify any citations relevant to your inquiry,0.789627
uuid-ca922dda71094f13b02600d3a708e035,using the following search terms,0.775499
uuid-ca922dda71094f13b02600d3a708e035,efficacy and safety of nivolumab,0.399478
uuid-cc81917845fd4170a4d2abf144c686d1,clinical,0.459138
uuid-cc81917845fd4170a4d2abf144c686d1,trial,0.485342
uuid-81f08a16572b403694b6e692a340bf50,OS,0.62262
uuid-81f08a16572b403694b6e692a340bf50,PFS,0.65903
uuid-81f08a16572b403694b6e692a340bf50,Overall survival,0.644151
uuid-395636676c564f9e8b6faf103a7c1104,requested,0.540431
uuid-97ac9972e66a44a3805ba63c129b5c0b,adverse,0.320944
uuid-97ac9972e66a44a3805ba63c129b5c0b,grade,0.36209
uuid-e32e3f7ce137413c951fe64cce622bba,Bristol-Myers Squibb,0.341822
uuid-e32e3f7ce137413c951fe64cce622bba,not conducted any controlled clinical trials/studies,0.304507
uuid-e32e3f7ce137413c951fe64cce622bba,Opdivo,0.461382
uuid-e32e3f7ce137413c951fe64cce622bba,Pubmed literature search,0.614325
uuid-e32e3f7ce137413c951fe64cce622bba,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e32e3f7ce137413c951fe64cce622bba,not identify any citations relevant to your inquiry,0.606087
uuid-e32e3f7ce137413c951fe64cce622bba,adverse,0.304183
uuid-e32e3f7ce137413c951fe64cce622bba,using the following search terms,0.642331
uuid-e32e3f7ce137413c951fe64cce622bba,databases,0.315039
uuid-e32e3f7ce137413c951fe64cce622bba,reported,0.556704
uuid-6c919addca2b445ca9457cd2c984c3a3,requested,0.646489
uuid-e76a641989424d2fb411f0263709cbb4,N Engl J Med,0.302601
uuid-e76a641989424d2fb411f0263709cbb4,AEs,0.348167
uuid-e76a641989424d2fb411f0263709cbb4,patients,0.536884
uuid-e76a641989424d2fb411f0263709cbb4,provided in the Detailed Information,0.387544
uuid-e76a641989424d2fb411f0263709cbb4,ESMO,0.462801
uuid-e76a641989424d2fb411f0263709cbb4,NEJM,0.66427
uuid-e76a641989424d2fb411f0263709cbb4,Topalian,0.692873
uuid-e76a641989424d2fb411f0263709cbb4,grade 3 to 4 AEs,0.626596
uuid-e31c015946154ccdba0f3fcf038a2a2b,N Engl J Med,0.302601
uuid-e31c015946154ccdba0f3fcf038a2a2b,AEs,0.348167
uuid-e31c015946154ccdba0f3fcf038a2a2b,patients,0.536884
uuid-e31c015946154ccdba0f3fcf038a2a2b,provided in the Detailed Information,0.387544
uuid-e31c015946154ccdba0f3fcf038a2a2b,ESMO,0.462801
uuid-e31c015946154ccdba0f3fcf038a2a2b,NEJM,0.66427
uuid-e31c015946154ccdba0f3fcf038a2a2b,Topalian,0.692873
uuid-e31c015946154ccdba0f3fcf038a2a2b,grade 3 to 4 AEs,0.626596
uuid-5864754ec08948b4aaf3c0ac489334d0,N Engl J Med,0.302601
uuid-5864754ec08948b4aaf3c0ac489334d0,AEs,0.348167
uuid-5864754ec08948b4aaf3c0ac489334d0,patients,0.536884
uuid-5864754ec08948b4aaf3c0ac489334d0,provided in the Detailed Information,0.387544
uuid-5864754ec08948b4aaf3c0ac489334d0,ESMO,0.462801
uuid-5864754ec08948b4aaf3c0ac489334d0,NEJM,0.66427
uuid-5864754ec08948b4aaf3c0ac489334d0,Topalian,0.692873
uuid-5864754ec08948b4aaf3c0ac489334d0,grade 3 to 4 AEs,0.626596
uuid-1cffce72fb744085ba3a1d71581d1f4e,N Engl J Med,0.304989
uuid-1cffce72fb744085ba3a1d71581d1f4e,AEs,0.337832
uuid-1cffce72fb744085ba3a1d71581d1f4e,patients,0.387033
uuid-1cffce72fb744085ba3a1d71581d1f4e,provided in the Detailed Information,0.370845
uuid-1cffce72fb744085ba3a1d71581d1f4e,ESMO,0.421367
uuid-1cffce72fb744085ba3a1d71581d1f4e,NEJM,0.709799
uuid-1cffce72fb744085ba3a1d71581d1f4e,Topalian,0.735417
uuid-1cffce72fb744085ba3a1d71581d1f4e,grade 3 to 4 AEs,0.538198
uuid-08150cb12427416c90bf8562e7e5f545,use of nivolumab for the treatment,0.440423
uuid-08150cb12427416c90bf8562e7e5f545,search of published literature,0.311531
uuid-08150cb12427416c90bf8562e7e5f545,PubMed and EMBASE,0.312811
uuid-08150cb12427416c90bf8562e7e5f545,not approved,0.404782
uuid-08150cb12427416c90bf8562e7e5f545,open-label,0.578291
uuid-08150cb12427416c90bf8562e7e5f545,clinical trials investigating the safety,0.440014
uuid-08150cb12427416c90bf8562e7e5f545,present using the following search terms,0.328669
uuid-08150cb12427416c90bf8562e7e5f545,phase,0.41185
uuid-153c16e9fffa4d26bd7260afc8974c76,OS,0.62262
uuid-153c16e9fffa4d26bd7260afc8974c76,PFS,0.65903
uuid-153c16e9fffa4d26bd7260afc8974c76,Overall survival,0.644151
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,nivolumab,0.505807
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,Bristol-Myers Squibb,0.368558
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,evaluating,0.528387
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,not conducted any controlled clinical trials/studies,0.551127
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,Pubmed literature search,0.67476
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,purposes other than its labeled indication must be considered investigational,0.728558
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,not identify any citations relevant to your inquiry,0.660502
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,using the following search terms,0.632571
uuid-6ef4f8cf48b74d19a8e6957b8bc03338,efficacy and safety of nivolumab,0.396503
uuid-e13a5b6c4d85414196a355e7ea39f3f1,fatigue,0.323475
uuid-2830213bbb2743e48bd7400164fcae2a,nivolumab,0.532522
uuid-2830213bbb2743e48bd7400164fcae2a,Bristol-Myers Squibb,0.394225
uuid-2830213bbb2743e48bd7400164fcae2a,evaluating,0.573883
uuid-2830213bbb2743e48bd7400164fcae2a,not conducted any controlled clinical trials/studies,0.595208
uuid-2830213bbb2743e48bd7400164fcae2a,non-small cell lung cancer,0.320465
uuid-2830213bbb2743e48bd7400164fcae2a,Pubmed literature search,0.643979
uuid-2830213bbb2743e48bd7400164fcae2a,purposes other than its labeled indication must be considered investigational,0.714029
uuid-2830213bbb2743e48bd7400164fcae2a,not identify any citations relevant to your inquiry,0.622013
uuid-2830213bbb2743e48bd7400164fcae2a,using the following search terms,0.593406
uuid-2830213bbb2743e48bd7400164fcae2a,efficacy and safety of nivolumab,0.450282
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,nivolumab,0.562954
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,Bristol-Myers Squibb,0.478318
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,evaluating,0.676176
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,not conducted any controlled clinical trials/studies,0.715201
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,Pubmed literature search,0.836085
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,purposes other than its labeled indication must be considered investigational,0.912286
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,not identify any citations relevant to your inquiry,0.78914
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,using the following search terms,0.776373
uuid-beb0b9b0f4df4e8a8d7c58f2facccafe,efficacy and safety of nivolumab,0.504139
uuid-7648105eb4d7493b8fb4974fa745e1e0,N Engl J Med,0.448483
uuid-7648105eb4d7493b8fb4974fa745e1e0,protocol,0.770446
uuid-7648105eb4d7493b8fb4974fa745e1e0,McDermott DF,0.741196
uuid-7648105eb4d7493b8fb4974fa745e1e0,Motzer RJ,0.818144
uuid-7648105eb4d7493b8fb4974fa745e1e0,phase 3 study,0.417055
uuid-7648105eb4d7493b8fb4974fa745e1e0,Escudier B,0.749917
uuid-7648105eb4d7493b8fb4974fa745e1e0,NEJM,0.400698
uuid-7648105eb4d7493b8fb4974fa745e1e0,et al.,0.668641
uuid-7648105eb4d7493b8fb4974fa745e1e0,J Clin Oncol,0.792018
uuid-7648105eb4d7493b8fb4974fa745e1e0,Topalian,0.388894
uuid-7648105eb4d7493b8fb4974fa745e1e0,phase 1 study,0.500686
uuid-7648105eb4d7493b8fb4974fa745e1e0,CA209-003,0.567381
uuid-7648105eb4d7493b8fb4974fa745e1e0,phase 2 study,0.677985
uuid-7648105eb4d7493b8fb4974fa745e1e0,present using the following search terms,0.310558
uuid-7648105eb4d7493b8fb4974fa745e1e0,investigating,0.615835
uuid-16cce1125b0741539d89dd9c03139fc9,Opdivo,0.50165
uuid-16cce1125b0741539d89dd9c03139fc9,open-label,0.304253
uuid-16cce1125b0741539d89dd9c03139fc9,trial,0.521827
uuid-16cce1125b0741539d89dd9c03139fc9,docetaxel,0.30238
uuid-16cce1125b0741539d89dd9c03139fc9,safety of nivolumab monotherapy,0.432481
uuid-16cce1125b0741539d89dd9c03139fc9,phase,0.378496
uuid-895168d692454ad9b648fa46c3df55fc,Objective response rate,0.451139
uuid-895168d692454ad9b648fa46c3df55fc,clinicaltrials.gov,0.503706
uuid-178a7f812b094831b0bb8aacd3584271,nivolumab,0.571366
uuid-178a7f812b094831b0bb8aacd3584271,Bristol-Myers Squibb,0.643909
uuid-178a7f812b094831b0bb8aacd3584271,evaluating,0.644775
uuid-178a7f812b094831b0bb8aacd3584271,not conducted any controlled clinical trials/studies,0.677001
uuid-178a7f812b094831b0bb8aacd3584271,purposes other than its labeled indication must be considered investigational,0.325413
uuid-178a7f812b094831b0bb8aacd3584271,efficacy and safety of nivolumab,0.561732
uuid-3369798c16d4492e988a3c0f4d8696be,search of published literature,0.394524
uuid-3369798c16d4492e988a3c0f4d8696be,Additionally,0.413583
uuid-3369798c16d4492e988a3c0f4d8696be,ongoing,0.322117
uuid-3369798c16d4492e988a3c0f4d8696be,PubMed and EMBASE,0.391671
uuid-3369798c16d4492e988a3c0f4d8696be,detailed search of www.clinicaltrials.gov,0.375936
uuid-3369798c16d4492e988a3c0f4d8696be,efficacy and safety of nivolumab,0.370699
uuid-3369798c16d4492e988a3c0f4d8696be,not identify any planned,0.34283
uuid-3369798c16d4492e988a3c0f4d8696be,Weber JS,0.319229
uuid-3369798c16d4492e988a3c0f4d8696be,not identify any citations relevant to your request,0.447813
uuid-3369798c16d4492e988a3c0f4d8696be,present using the following search terms,0.408199
uuid-07c47fc81b83402e884ab86104b29a1d,Objective response rate,0.451139
uuid-07c47fc81b83402e884ab86104b29a1d,clinicaltrials.gov,0.503706
uuid-3edc1175dc6941a78bf0695573b7187c,fatigue,0.411608
uuid-8328602cbc8446ff9dfaff417cec350c,nivolumab,0.999168
uuid-8328602cbc8446ff9dfaff417cec350c,Pubmed literature search,0.395314
uuid-8328602cbc8446ff9dfaff417cec350c,purposes other than its labeled indication must be considered investigational,0.464236
uuid-8328602cbc8446ff9dfaff417cec350c,not identify any citations relevant to your inquiry,0.368569
uuid-8328602cbc8446ff9dfaff417cec350c,using the following search terms,0.364279
uuid-8328602cbc8446ff9dfaff417cec350c,present using the following search terms,0.329876
uuid-6e319ede615743f486c15172943d2a62,nivolumab,0.411518
uuid-6e319ede615743f486c15172943d2a62,combination,0.313591
uuid-ab7bf96d632a439db55e1284ffb90619,Bristol-Myers Squibb,0.470863
uuid-ab7bf96d632a439db55e1284ffb90619,evaluating,0.32135
uuid-ab7bf96d632a439db55e1284ffb90619,not conducted any controlled clinical trials/studies,0.3731
uuid-ab7bf96d632a439db55e1284ffb90619,adverse,0.321157
uuid-ab7bf96d632a439db55e1284ffb90619,therapy,0.383231
uuid-ab7bf96d632a439db55e1284ffb90619,reported,0.356526
uuid-9b8039cb76a64d4db69d4412eb5b05b0,mg,0.464316
uuid-9b8039cb76a64d4db69d4412eb5b05b0,kg,0.365492
uuid-e85c84ade923478fba2bd69cfc6e4e02,N Engl J Med,0.304989
uuid-e85c84ade923478fba2bd69cfc6e4e02,AEs,0.337832
uuid-e85c84ade923478fba2bd69cfc6e4e02,patients,0.387033
uuid-e85c84ade923478fba2bd69cfc6e4e02,provided in the Detailed Information,0.370845
uuid-e85c84ade923478fba2bd69cfc6e4e02,ESMO,0.421367
uuid-e85c84ade923478fba2bd69cfc6e4e02,NEJM,0.709799
uuid-e85c84ade923478fba2bd69cfc6e4e02,Topalian,0.735417
uuid-e85c84ade923478fba2bd69cfc6e4e02,grade 3 to 4 AEs,0.538198
uuid-3956864c2f5d45e7851de413e9affc15,fatigue,0.323475
uuid-c5b0554fe9ea464bb4bdcf2754bb58bd,patients,0.480124
uuid-c5b0554fe9ea464bb4bdcf2754bb58bd,RCC,0.318067
uuid-c5b0554fe9ea464bb4bdcf2754bb58bd,grade,0.454983
uuid-c5b0554fe9ea464bb4bdcf2754bb58bd,grade 3 to 4 AEs,0.360173
uuid-f86cf90036aa4fe5aaa8828592a9c4d7,Objective response rate,0.451139
uuid-f86cf90036aa4fe5aaa8828592a9c4d7,clinicaltrials.gov,0.503706
uuid-76c0deb1db8b4f7ca14c347d1cb4851d,fatigue,0.316905
uuid-46bbe38a3aed40568c9907432c3de901,N Engl J Med,0.448483
uuid-46bbe38a3aed40568c9907432c3de901,protocol,0.770446
uuid-46bbe38a3aed40568c9907432c3de901,McDermott DF,0.741196
uuid-46bbe38a3aed40568c9907432c3de901,Motzer RJ,0.818144
uuid-46bbe38a3aed40568c9907432c3de901,phase 3 study,0.417055
uuid-46bbe38a3aed40568c9907432c3de901,Escudier B,0.749917
uuid-46bbe38a3aed40568c9907432c3de901,NEJM,0.400698
uuid-46bbe38a3aed40568c9907432c3de901,et al.,0.668641
uuid-46bbe38a3aed40568c9907432c3de901,J Clin Oncol,0.792018
uuid-46bbe38a3aed40568c9907432c3de901,Topalian,0.388894
uuid-46bbe38a3aed40568c9907432c3de901,phase 1 study,0.500686
uuid-46bbe38a3aed40568c9907432c3de901,CA209-003,0.567381
uuid-46bbe38a3aed40568c9907432c3de901,phase 2 study,0.677985
uuid-46bbe38a3aed40568c9907432c3de901,present using the following search terms,0.310558
uuid-46bbe38a3aed40568c9907432c3de901,investigating,0.615835
uuid-5662a567dd034ec7bf00a41a804f3d04,nivolumab,0.609847
uuid-5662a567dd034ec7bf00a41a804f3d04,Bristol-Myers Squibb,0.42725
uuid-5662a567dd034ec7bf00a41a804f3d04,evaluating,0.628812
uuid-5662a567dd034ec7bf00a41a804f3d04,not conducted any controlled clinical trials/studies,0.668837
uuid-5662a567dd034ec7bf00a41a804f3d04,Pubmed literature search,0.761611
uuid-5662a567dd034ec7bf00a41a804f3d04,purposes other than its labeled indication must be considered investigational,0.842226
uuid-5662a567dd034ec7bf00a41a804f3d04,not identify any citations relevant to your inquiry,0.719452
uuid-5662a567dd034ec7bf00a41a804f3d04,using the following search terms,0.70089
uuid-5662a567dd034ec7bf00a41a804f3d04,efficacy and safety of nivolumab,0.480563
uuid-85fa8924c77b426d856bd7d6916810cb,use of nivolumab for the treatment,0.409821
uuid-85fa8924c77b426d856bd7d6916810cb,patients with advanced or metastatic,0.645244
uuid-85fa8924c77b426d856bd7d6916810cb,nivolumab combined with ipilimumab,0.676339
uuid-85fa8924c77b426d856bd7d6916810cb,not approved,0.453534
uuid-85fa8924c77b426d856bd7d6916810cb,clinical trials investigating the safety,0.548799
uuid-85fa8924c77b426d856bd7d6916810cb,phase 1/2 study CA209-032,0.34114
uuid-85fa8924c77b426d856bd7d6916810cb,bladder cancer,0.749142
uuid-85fa8924c77b426d856bd7d6916810cb,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-f322a33db2404ec0a63f7ab94809c598,AEs,0.308621
uuid-f322a33db2404ec0a63f7ab94809c598,95% CI,0.430169
uuid-f322a33db2404ec0a63f7ab94809c598,respectively,0.511803
uuid-f322a33db2404ec0a63f7ab94809c598,patients,0.300332
uuid-f322a33db2404ec0a63f7ab94809c598,considered investigational,0.306232
uuid-f322a33db2404ec0a63f7ab94809c598,Objective response rate,0.460068
uuid-f322a33db2404ec0a63f7ab94809c598,ORR,0.617508
uuid-f322a33db2404ec0a63f7ab94809c598,Median overall survival,0.512511
uuid-f322a33db2404ec0a63f7ab94809c598,ESMO,0.486388
uuid-f322a33db2404ec0a63f7ab94809c598,Median OS,0.412839
uuid-f322a33db2404ec0a63f7ab94809c598,small cell lung cancer,0.37978
uuid-f322a33db2404ec0a63f7ab94809c598,SCLC,0.363862
uuid-f322a33db2404ec0a63f7ab94809c598,hazard ratio,0.441976
uuid-f322a33db2404ec0a63f7ab94809c598,grade 3 to 4 AEs,0.461557
uuid-f322a33db2404ec0a63f7ab94809c598,phase 1/2 study CA209-032,0.367152
uuid-f322a33db2404ec0a63f7ab94809c598,evaluates the efficacy of nivolumab monotherapy,0.350081
uuid-ec79ffa3e0b941ecbb5dc645537f468f,patients,0.524625
uuid-ec79ffa3e0b941ecbb5dc645537f468f,RCC,0.603499
uuid-39973ae4ddfe43d5b4986b7aa026113a,nivolumab,0.324658
uuid-39973ae4ddfe43d5b4986b7aa026113a,use of nivolumab for the treatment,0.543355
uuid-39973ae4ddfe43d5b4986b7aa026113a,evaluating,0.348676
uuid-39973ae4ddfe43d5b4986b7aa026113a,efficacy,0.388907
uuid-39973ae4ddfe43d5b4986b7aa026113a,patients,0.419915
uuid-39973ae4ddfe43d5b4986b7aa026113a,search of published literature,0.449959
uuid-39973ae4ddfe43d5b4986b7aa026113a,PubMed and EMBASE,0.444573
uuid-39973ae4ddfe43d5b4986b7aa026113a,not approved,0.582429
uuid-39973ae4ddfe43d5b4986b7aa026113a,clinical trials investigating the safety,0.64854
uuid-39973ae4ddfe43d5b4986b7aa026113a,efficacy and safety of nivolumab,0.399101
uuid-39973ae4ddfe43d5b4986b7aa026113a,present using the following search terms,0.465296
uuid-4863db5b2809426aba94f6bcb07f1b6f,Bristol-Myers Squibb,0.307009
uuid-4863db5b2809426aba94f6bcb07f1b6f,requested,0.323839
uuid-82d94049dec34d949b641bf4aa03539c,N Engl J Med,0.5218
uuid-82d94049dec34d949b641bf4aa03539c,protocol,0.822129
uuid-82d94049dec34d949b641bf4aa03539c,RCC,0.351265
uuid-82d94049dec34d949b641bf4aa03539c,McDermott DF,0.805326
uuid-82d94049dec34d949b641bf4aa03539c,search of published literature,0.328584
uuid-82d94049dec34d949b641bf4aa03539c,Motzer RJ,0.830191
uuid-82d94049dec34d949b641bf4aa03539c,phase 3 study,0.375845
uuid-82d94049dec34d949b641bf4aa03539c,PubMed and EMBASE,0.327895
uuid-82d94049dec34d949b641bf4aa03539c,Escudier B,0.815105
uuid-82d94049dec34d949b641bf4aa03539c,NEJM,0.388967
uuid-82d94049dec34d949b641bf4aa03539c,et al.,0.745528
uuid-82d94049dec34d949b641bf4aa03539c,J Clin Oncol,0.787871
uuid-82d94049dec34d949b641bf4aa03539c,Topalian,0.347249
uuid-82d94049dec34d949b641bf4aa03539c,Rizvi NA,0.308297
uuid-82d94049dec34d949b641bf4aa03539c,phase 2 study,0.670697
uuid-82d94049dec34d949b641bf4aa03539c,present using the following search terms,0.304579
uuid-035f8ec735e0423c964a82df1b67123d,Opdivo,0.848928
uuid-035f8ec735e0423c964a82df1b67123d,trial,0.438989
uuid-035f8ec735e0423c964a82df1b67123d,reported,0.335514
uuid-16ddc86a7bd24c8e9108557a09c28794,N Engl J Med,0.304989
uuid-16ddc86a7bd24c8e9108557a09c28794,AEs,0.337832
uuid-16ddc86a7bd24c8e9108557a09c28794,patients,0.387033
uuid-16ddc86a7bd24c8e9108557a09c28794,provided in the Detailed Information,0.370845
uuid-16ddc86a7bd24c8e9108557a09c28794,ESMO,0.421367
uuid-16ddc86a7bd24c8e9108557a09c28794,NEJM,0.709799
uuid-16ddc86a7bd24c8e9108557a09c28794,Topalian,0.735417
uuid-16ddc86a7bd24c8e9108557a09c28794,grade 3 to 4 AEs,0.538198
uuid-906166df9aac4e2894f852207463a58b,nivolumab,0.496973
uuid-906166df9aac4e2894f852207463a58b,Bristol-Myers Squibb,0.441034
uuid-906166df9aac4e2894f852207463a58b,evaluating,0.591175
uuid-906166df9aac4e2894f852207463a58b,not conducted any controlled clinical trials/studies,0.651523
uuid-906166df9aac4e2894f852207463a58b,Pubmed literature search,0.880255
uuid-906166df9aac4e2894f852207463a58b,purposes other than its labeled indication must be considered investigational,0.936359
uuid-906166df9aac4e2894f852207463a58b,not identify any citations relevant to your inquiry,0.841448
uuid-906166df9aac4e2894f852207463a58b,using the following search terms,0.830894
uuid-906166df9aac4e2894f852207463a58b,efficacy and safety of nivolumab,0.419352
uuid-e9eb4419be684b1fb6d742d7adda907b,OS,0.62262
uuid-e9eb4419be684b1fb6d742d7adda907b,PFS,0.65903
uuid-e9eb4419be684b1fb6d742d7adda907b,Overall survival,0.644151
uuid-6231091aef9241569a69d610a8ebb914,nivolumab,0.520431
uuid-6231091aef9241569a69d610a8ebb914,Bristol-Myers Squibb,0.445924
uuid-6231091aef9241569a69d610a8ebb914,evaluating,0.569205
uuid-6231091aef9241569a69d610a8ebb914,not conducted any controlled clinical trials/studies,0.637929
uuid-6231091aef9241569a69d610a8ebb914,Pubmed literature search,0.750852
uuid-6231091aef9241569a69d610a8ebb914,purposes other than its labeled indication must be considered investigational,0.823465
uuid-6231091aef9241569a69d610a8ebb914,not identify any citations relevant to your inquiry,0.70978
uuid-6231091aef9241569a69d610a8ebb914,using the following search terms,0.695032
uuid-6231091aef9241569a69d610a8ebb914,efficacy and safety of nivolumab,0.428097
uuid-146607642abd44299bf39d72910b7f32,nivolumab,0.359772
uuid-9f569eb666f042ed8d0a906fab31611e,patients,0.350185
uuid-9f569eb666f042ed8d0a906fab31611e,protocol,0.364313
uuid-9f569eb666f042ed8d0a906fab31611e,McDermott DF,0.39108
uuid-9f569eb666f042ed8d0a906fab31611e,Motzer RJ,0.394397
uuid-9f569eb666f042ed8d0a906fab31611e,phase 3 study,0.461915
uuid-9f569eb666f042ed8d0a906fab31611e,Escudier B,0.393278
uuid-9f569eb666f042ed8d0a906fab31611e,et al.,0.363785
uuid-9f569eb666f042ed8d0a906fab31611e,J Clin Oncol,0.3454
uuid-9f569eb666f042ed8d0a906fab31611e,Rizvi NA,0.387522
uuid-9f569eb666f042ed8d0a906fab31611e,Weber JS,0.414993
uuid-9f569eb666f042ed8d0a906fab31611e,phase 2 study,0.445652
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,N Engl J Med,0.689907
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Lancet Oncol,0.584216
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,protocol,0.72528
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,McDermott DF,0.794444
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Motzer RJ,0.755383
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,phase 3 study,0.521307
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Escudier B,0.794743
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,NEJM,0.434762
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,et al.,0.777092
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,J Clin Oncol,0.708338
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Topalian,0.401719
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Rizvi NA,0.731383
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Brahmer J,0.378658
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,Weber JS,0.614831
uuid-d433875fdc8d47499a2f7bab3b7dbf2f,phase 2 study,0.769458
uuid-c05f261f97bb45ffa330d3e212eb4f8c,patients,0.32677
uuid-c05f261f97bb45ffa330d3e212eb4f8c,trial,0.350512
uuid-ed40ec08b5894a018822a9b5d861b732,AEs,0.318518
uuid-ed40ec08b5894a018822a9b5d861b732,patients,0.490534
uuid-ed40ec08b5894a018822a9b5d861b732,provided in the Detailed Information,0.314996
uuid-ed40ec08b5894a018822a9b5d861b732,NEJM,0.548224
uuid-ed40ec08b5894a018822a9b5d861b732,Topalian,0.581891
uuid-ed40ec08b5894a018822a9b5d861b732,grade 3 to 4 AEs,0.495761
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,Opdivo,0.50165
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,open-label,0.304253
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,trial,0.521827
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,docetaxel,0.30238
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,safety of nivolumab monotherapy,0.432481
uuid-a509aae8b5394ae78d2a9b8f2c5edb89,phase,0.378496
uuid-84607731a1c24517bed56b0729a2e838,Opdivo,0.548355
uuid-670dc09ab5774841af3b69f61eb5981a,ipilimumab,0.37894
uuid-670dc09ab5774841af3b69f61eb5981a,ASCO 2015,0.347733
uuid-ab2ac3de25384d3d887e527bed054eb5,Opdivo,0.423061
uuid-ab2ac3de25384d3d887e527bed054eb5,PD-L1,0.538506
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,Opdivo,0.50165
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,open-label,0.304253
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,trial,0.521827
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,docetaxel,0.30238
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,safety of nivolumab monotherapy,0.432481
uuid-5374b36f8c7c41c4936f0f0e9cc414b4,phase,0.378496
uuid-d64b743a1bde414ca30e939b5c9d2cba,nivolumab,0.507362
uuid-d64b743a1bde414ca30e939b5c9d2cba,Bristol-Myers Squibb,0.574155
uuid-d64b743a1bde414ca30e939b5c9d2cba,evaluating,0.753674
uuid-d64b743a1bde414ca30e939b5c9d2cba,not conducted any controlled clinical trials/studies,0.772481
uuid-d64b743a1bde414ca30e939b5c9d2cba,NSCLC,0.392401
uuid-d64b743a1bde414ca30e939b5c9d2cba,non-small cell lung cancer,0.438392
uuid-d64b743a1bde414ca30e939b5c9d2cba,Pubmed literature search,0.619377
uuid-d64b743a1bde414ca30e939b5c9d2cba,purposes other than its labeled indication must be considered investigational,0.720396
uuid-d64b743a1bde414ca30e939b5c9d2cba,not identify any citations relevant to your inquiry,0.572614
uuid-d64b743a1bde414ca30e939b5c9d2cba,using the following search terms,0.550002
uuid-d64b743a1bde414ca30e939b5c9d2cba,efficacy and safety of nivolumab,0.5958
uuid-d64b743a1bde414ca30e939b5c9d2cba,safety of nivolumab monotherapy,0.350568
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,95% CI,0.419478
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,respectively,0.497608
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,Objective response rate,0.403649
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,ORR,0.578109
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,patients with advanced or metastatic,0.306625
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,Median overall survival,0.498783
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,nivolumab combined with ipilimumab,0.300486
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,tumors,0.323334
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,ESMO,0.534361
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,Median OS,0.394058
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,small cell lung cancer,0.380999
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,SCLC,0.365686
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,hazard ratio,0.419392
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,grade 3 to 4 AEs,0.414535
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,phase 1/2 study CA209-032,0.398283
uuid-6e8ff3d4fa884b4ea4a5859e854b9083,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-565f53f3121d4d7caa030b38e9ec5b39,requested,0.551003
uuid-635ef27a2d414cc3b92c65e9372e483c,nivolumab,0.672104
uuid-635ef27a2d414cc3b92c65e9372e483c,Bristol-Myers Squibb,0.432328
uuid-635ef27a2d414cc3b92c65e9372e483c,evaluating,0.645148
uuid-635ef27a2d414cc3b92c65e9372e483c,not conducted any controlled clinical trials/studies,0.675299
uuid-635ef27a2d414cc3b92c65e9372e483c,Pubmed literature search,0.813278
uuid-635ef27a2d414cc3b92c65e9372e483c,purposes other than its labeled indication must be considered investigational,0.893002
uuid-635ef27a2d414cc3b92c65e9372e483c,not identify any citations relevant to your inquiry,0.768382
uuid-635ef27a2d414cc3b92c65e9372e483c,using the following search terms,0.755025
uuid-635ef27a2d414cc3b92c65e9372e483c,efficacy and safety of nivolumab,0.487339
uuid-100220ce7c2c49de8070c67b97fc94f5,fatigue,0.411608
uuid-21a663393daf44a39023eee17561c702,use of nivolumab for the treatment,0.321321
uuid-21a663393daf44a39023eee17561c702,patients,0.825104
uuid-21a663393daf44a39023eee17561c702,considered investigational,0.313551
uuid-21a663393daf44a39023eee17561c702,small cell lung cancer,0.449827
uuid-21a663393daf44a39023eee17561c702,grade,0.467409
uuid-21a663393daf44a39023eee17561c702,SCLC,0.419737
uuid-21a663393daf44a39023eee17561c702,therapy,0.427204
uuid-21a663393daf44a39023eee17561c702,grade 3 to 4 AEs,0.545366
uuid-48269e78d948442ea4142f317bb70b18,trial,0.309644
uuid-eb2fd1e0f1ba43e5afeb3f9691f8f266,Opdivo,0.679397
uuid-eb2fd1e0f1ba43e5afeb3f9691f8f266,trial,0.438973
uuid-f36af19d30ab4c14a27bd79f0a286cca,safety,0.778307
uuid-f36af19d30ab4c14a27bd79f0a286cca,databases,0.798802
uuid-eff7477ef930409684022ddafee8b66e,melanoma,0.410364
uuid-436d71dc890f4550bb0ca4e4e85d4b6a,fatigue,0.323475
uuid-76b6467bcbe64f30a1a51ebd34e1e208,Opdivo,0.50165
uuid-76b6467bcbe64f30a1a51ebd34e1e208,open-label,0.304253
uuid-76b6467bcbe64f30a1a51ebd34e1e208,trial,0.521827
uuid-76b6467bcbe64f30a1a51ebd34e1e208,docetaxel,0.30238
uuid-76b6467bcbe64f30a1a51ebd34e1e208,safety of nivolumab monotherapy,0.432481
uuid-76b6467bcbe64f30a1a51ebd34e1e208,phase,0.378496
uuid-758c2d3663d3440fae8d099b08f10adb,Opdivo,0.50165
uuid-758c2d3663d3440fae8d099b08f10adb,open-label,0.304253
uuid-758c2d3663d3440fae8d099b08f10adb,trial,0.521827
uuid-758c2d3663d3440fae8d099b08f10adb,docetaxel,0.30238
uuid-758c2d3663d3440fae8d099b08f10adb,safety of nivolumab monotherapy,0.432481
uuid-758c2d3663d3440fae8d099b08f10adb,phase,0.378496
uuid-98f276cbdfa64988a834de8fbb1ad327,Bristol-Myers Squibb,0.353707
uuid-e5fcb52896a442f1905bd46e4de1352f,nivolumab,0.359772
uuid-0355c2c58327454e84476f3eda7c4231,N Engl J Med,0.463615
uuid-0355c2c58327454e84476f3eda7c4231,NSCLC,0.411904
uuid-0355c2c58327454e84476f3eda7c4231,Lancet Oncol,0.356346
uuid-0355c2c58327454e84476f3eda7c4231,non-small cell lung cancer,0.479924
uuid-0355c2c58327454e84476f3eda7c4231,phase 3 study,0.353194
uuid-0355c2c58327454e84476f3eda7c4231,Rizvi NA,0.55688
uuid-0355c2c58327454e84476f3eda7c4231,Brahmer J,0.571788
uuid-0355c2c58327454e84476f3eda7c4231,PD-L1,0.439281
uuid-0355c2c58327454e84476f3eda7c4231,phase 2 study,0.304107
uuid-bb79dd1d7fb54c70ab953646e662ff26,N Engl J Med,0.336827
uuid-bb79dd1d7fb54c70ab953646e662ff26,ASCO,0.698854
uuid-bb79dd1d7fb54c70ab953646e662ff26,et al.,0.386994
uuid-bb79dd1d7fb54c70ab953646e662ff26,phase 2 study,0.328355
uuid-bb79dd1d7fb54c70ab953646e662ff26,Horn L,0.336874
uuid-342bf3d8bd084cb48264c62a620d3e2a,AEs,0.349137
uuid-342bf3d8bd084cb48264c62a620d3e2a,respectively,0.682073
uuid-342bf3d8bd084cb48264c62a620d3e2a,ASCO,0.363164
uuid-342bf3d8bd084cb48264c62a620d3e2a,Objective response rate,0.555115
uuid-342bf3d8bd084cb48264c62a620d3e2a,ORR,0.580944
uuid-342bf3d8bd084cb48264c62a620d3e2a,monotherapy,0.373693
uuid-342bf3d8bd084cb48264c62a620d3e2a,docetaxel,0.383382
uuid-342bf3d8bd084cb48264c62a620d3e2a,grade,0.321955
uuid-342bf3d8bd084cb48264c62a620d3e2a,Antonia SJ,0.413063
uuid-fef29747e50743499fb116d769ab4fda,nivolumab,0.47916
uuid-fef29747e50743499fb116d769ab4fda,Bristol-Myers Squibb,0.371626
uuid-fef29747e50743499fb116d769ab4fda,evaluating,0.505197
uuid-fef29747e50743499fb116d769ab4fda,not conducted any controlled clinical trials/studies,0.479345
uuid-fef29747e50743499fb116d769ab4fda,efficacy and safety of nivolumab,0.446516
uuid-6042bc66e81e43c993f07fb54407eb10,N Engl J Med,0.585592
uuid-6042bc66e81e43c993f07fb54407eb10,protocol,0.703048
uuid-6042bc66e81e43c993f07fb54407eb10,McDermott DF,0.808613
uuid-6042bc66e81e43c993f07fb54407eb10,Motzer RJ,0.783017
uuid-6042bc66e81e43c993f07fb54407eb10,phase 3 study,0.465459
uuid-6042bc66e81e43c993f07fb54407eb10,Escudier B,0.804268
uuid-6042bc66e81e43c993f07fb54407eb10,NEJM,0.338631
uuid-6042bc66e81e43c993f07fb54407eb10,et al.,0.770371
uuid-6042bc66e81e43c993f07fb54407eb10,J Clin Oncol,0.754974
uuid-6042bc66e81e43c993f07fb54407eb10,Rizvi NA,0.374947
uuid-6042bc66e81e43c993f07fb54407eb10,phase 2 study,0.717397
uuid-80506593ee7047f6a245d2bc3b6a7e0a,AEs,0.349137
uuid-80506593ee7047f6a245d2bc3b6a7e0a,respectively,0.682073
uuid-80506593ee7047f6a245d2bc3b6a7e0a,ASCO,0.363164
uuid-80506593ee7047f6a245d2bc3b6a7e0a,Objective response rate,0.555115
uuid-80506593ee7047f6a245d2bc3b6a7e0a,ORR,0.580944
uuid-80506593ee7047f6a245d2bc3b6a7e0a,monotherapy,0.373693
uuid-80506593ee7047f6a245d2bc3b6a7e0a,docetaxel,0.383382
uuid-80506593ee7047f6a245d2bc3b6a7e0a,grade,0.321955
uuid-80506593ee7047f6a245d2bc3b6a7e0a,Antonia SJ,0.413063
uuid-f6ce6f23aa9e41438231833785bfcecd,95% CI,0.384282
uuid-f6ce6f23aa9e41438231833785bfcecd,ASCO,0.40687
uuid-f6ce6f23aa9e41438231833785bfcecd,Objective response rate,0.409634
uuid-f6ce6f23aa9e41438231833785bfcecd,Median overall survival,0.319094
uuid-f6ce6f23aa9e41438231833785bfcecd,Median OS,0.403026
uuid-f6ce6f23aa9e41438231833785bfcecd,ASCO 2015,0.386899
uuid-f6ce6f23aa9e41438231833785bfcecd,hazard ratio,0.403406
uuid-c88424fa0cff4e139640879efe373830,evaluating,0.317808
uuid-c88424fa0cff4e139640879efe373830,not conducted any controlled clinical trials/studies,0.341176
uuid-c88424fa0cff4e139640879efe373830,Pubmed literature search,0.309063
uuid-c88424fa0cff4e139640879efe373830,purposes other than its labeled indication must be considered investigational,0.349412
uuid-c5a6109cef0f4915a1e0086ecfea400f,Opdivo,0.50165
uuid-c5a6109cef0f4915a1e0086ecfea400f,open-label,0.304253
uuid-c5a6109cef0f4915a1e0086ecfea400f,trial,0.521827
uuid-c5a6109cef0f4915a1e0086ecfea400f,docetaxel,0.30238
uuid-c5a6109cef0f4915a1e0086ecfea400f,safety of nivolumab monotherapy,0.432481
uuid-c5a6109cef0f4915a1e0086ecfea400f,phase,0.378496
uuid-3175afe04a32458bad56e0d23ac6d4f3,Opdivo,0.50165
uuid-3175afe04a32458bad56e0d23ac6d4f3,open-label,0.304253
uuid-3175afe04a32458bad56e0d23ac6d4f3,trial,0.521827
uuid-3175afe04a32458bad56e0d23ac6d4f3,docetaxel,0.30238
uuid-3175afe04a32458bad56e0d23ac6d4f3,safety of nivolumab monotherapy,0.432481
uuid-3175afe04a32458bad56e0d23ac6d4f3,phase,0.378496
uuid-7f5a17720d5248659c782d7bdee18d17,monotherapy,0.444089
uuid-7f5a17720d5248659c782d7bdee18d17,mg,0.853025
uuid-7f5a17720d5248659c782d7bdee18d17,kg,0.853742
uuid-7f5a17720d5248659c782d7bdee18d17,phase,0.318256
uuid-7f5a17720d5248659c782d7bdee18d17,cohort,0.461371
uuid-25b515551e2b47b1a3e93c616a5b6341,OS,0.393878
uuid-25b515551e2b47b1a3e93c616a5b6341,95% CI,0.592551
uuid-25b515551e2b47b1a3e93c616a5b6341,respectively,0.364053
uuid-25b515551e2b47b1a3e93c616a5b6341,Objective response rate,0.455984
uuid-25b515551e2b47b1a3e93c616a5b6341,ORR,0.608976
uuid-25b515551e2b47b1a3e93c616a5b6341,PFS,0.307137
uuid-25b515551e2b47b1a3e93c616a5b6341,Median overall survival,0.646189
uuid-25b515551e2b47b1a3e93c616a5b6341,Median OS,0.53887
uuid-25b515551e2b47b1a3e93c616a5b6341,fatigue,0.418926
uuid-25b515551e2b47b1a3e93c616a5b6341,hazard ratio,0.556176
uuid-241c2da3b8854e869ee7153b3f648430,Bristol-Myers Squibb,0.436422
uuid-efc6a056fa784aeaade21b2ee45bf330,Opdivo,0.542053
uuid-efc6a056fa784aeaade21b2ee45bf330,trial,0.555466
uuid-134ca43cb0da41e592d7fde2b77bae1a,Bristol-Myers Squibb,0.453985
uuid-ed2d37197d024ab18f806643914d5036,open-label,0.39841
uuid-ed2d37197d024ab18f806643914d5036,trial,0.441894
uuid-ed2d37197d024ab18f806643914d5036,phase,0.507232
uuid-8bafad5c0e164d90b3482f11faa953e2,Objective response rate,0.451139
uuid-8bafad5c0e164d90b3482f11faa953e2,clinicaltrials.gov,0.503706
uuid-bf821d47b5c0420bb7dda2b8168e470b,clinical,0.408933
uuid-bf821d47b5c0420bb7dda2b8168e470b,trial,0.42305
uuid-3762b980610f49b49f9a9fcde08d6949,provided in the Detailed Information,0.349112
uuid-3762b980610f49b49f9a9fcde08d6949,Weber JS,0.321343
uuid-8d0950361f7f4a368214902802116b7d,nivolumab,0.56154
uuid-8d0950361f7f4a368214902802116b7d,Bristol-Myers Squibb,0.404293
uuid-8d0950361f7f4a368214902802116b7d,evaluating,0.545132
uuid-8d0950361f7f4a368214902802116b7d,not conducted any controlled clinical trials/studies,0.606638
uuid-8d0950361f7f4a368214902802116b7d,Pubmed literature search,0.851584
uuid-8d0950361f7f4a368214902802116b7d,purposes other than its labeled indication must be considered investigational,0.909339
uuid-8d0950361f7f4a368214902802116b7d,not identify any citations relevant to your inquiry,0.817966
uuid-8d0950361f7f4a368214902802116b7d,using the following search terms,0.803614
uuid-8d0950361f7f4a368214902802116b7d,efficacy and safety of nivolumab,0.398137
uuid-c86ffcd215ff4077917e6fb6ad5aa685,fatigue,0.323475
uuid-0b336e8a20ff481782b41fc555b1759c,fatigue,0.323475
uuid-4f5d6433ee6a4d2ebfb0ea4c040bef43,NSCLC,0.327373
uuid-4f5d6433ee6a4d2ebfb0ea4c040bef43,respectively,0.32989
uuid-4f5d6433ee6a4d2ebfb0ea4c040bef43,Objective response rate,0.414926
uuid-4f5d6433ee6a4d2ebfb0ea4c040bef43,ORR,0.46431
uuid-4f5d6433ee6a4d2ebfb0ea4c040bef43,Median overall survival,0.358033
uuid-2eee6265c1d744758cabb823c9cd4fd7,trial,0.32776
uuid-155a3bfc321e488c952a314d0e9132f1,Bristol-Myers Squibb,0.341822
uuid-155a3bfc321e488c952a314d0e9132f1,not conducted any controlled clinical trials/studies,0.304507
uuid-155a3bfc321e488c952a314d0e9132f1,Opdivo,0.461382
uuid-155a3bfc321e488c952a314d0e9132f1,Pubmed literature search,0.614325
uuid-155a3bfc321e488c952a314d0e9132f1,purposes other than its labeled indication must be considered investigational,0.586645
uuid-155a3bfc321e488c952a314d0e9132f1,not identify any citations relevant to your inquiry,0.606087
uuid-155a3bfc321e488c952a314d0e9132f1,adverse,0.304183
uuid-155a3bfc321e488c952a314d0e9132f1,using the following search terms,0.642331
uuid-155a3bfc321e488c952a314d0e9132f1,databases,0.315039
uuid-155a3bfc321e488c952a314d0e9132f1,reported,0.556704
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,AEs,0.349137
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,respectively,0.682073
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,ASCO,0.363164
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,Objective response rate,0.555115
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,ORR,0.580944
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,monotherapy,0.373693
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,docetaxel,0.383382
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,grade,0.321955
uuid-20d50c16c1444ff4a3b2f9535ed0ef2b,Antonia SJ,0.413063
uuid-75f4d64a875d4b22a9c8f1c4c6e55948,Objective response rate,0.451139
uuid-75f4d64a875d4b22a9c8f1c4c6e55948,clinicaltrials.gov,0.503706
uuid-9c52c5e700144288b0d508c887aef39b,mg,0.300211
uuid-42041b812681484f814c06a1eb330b22,Opdivo,0.50165
uuid-42041b812681484f814c06a1eb330b22,open-label,0.304253
uuid-42041b812681484f814c06a1eb330b22,trial,0.521827
uuid-42041b812681484f814c06a1eb330b22,docetaxel,0.30238
uuid-42041b812681484f814c06a1eb330b22,safety of nivolumab monotherapy,0.432481
uuid-42041b812681484f814c06a1eb330b22,phase,0.378496
uuid-4856adcd4272484c93e753a94578d59b,patients,0.350087
uuid-4856adcd4272484c93e753a94578d59b,trial,0.460167
uuid-14b386ab2de645ba9492ede76037feb7,N Engl J Med,0.535286
uuid-14b386ab2de645ba9492ede76037feb7,Lancet Oncol,0.364361
uuid-14b386ab2de645ba9492ede76037feb7,protocol,0.50442
uuid-14b386ab2de645ba9492ede76037feb7,McDermott DF,0.548182
uuid-14b386ab2de645ba9492ede76037feb7,Motzer RJ,0.532741
uuid-14b386ab2de645ba9492ede76037feb7,phase 3 study,0.493197
uuid-14b386ab2de645ba9492ede76037feb7,Escudier B,0.547344
uuid-14b386ab2de645ba9492ede76037feb7,et al.,0.519366
uuid-14b386ab2de645ba9492ede76037feb7,J Clin Oncol,0.509597
uuid-14b386ab2de645ba9492ede76037feb7,Rizvi NA,0.478602
uuid-14b386ab2de645ba9492ede76037feb7,Brahmer J,0.338223
uuid-14b386ab2de645ba9492ede76037feb7,Weber JS,0.370952
uuid-14b386ab2de645ba9492ede76037feb7,phase 2 study,0.591434
uuid-1ea1708e887c439e890b8833715eff35,NSCLC,0.359085
uuid-1ea1708e887c439e890b8833715eff35,non-small cell lung cancer,0.438777
uuid-1ea1708e887c439e890b8833715eff35,phase 3 study,0.314799
uuid-1ea1708e887c439e890b8833715eff35,phase 1 study,0.323434
uuid-1ea1708e887c439e890b8833715eff35,PD-L1,0.532537
uuid-1ea1708e887c439e890b8833715eff35,CA209-003,0.318113
uuid-79701bb5d92e46bb8676d73d8acbb813,NEJM,0.317555
uuid-f7c3fe93086f45a986a3d45cdcaefc22,OS,0.62262
uuid-f7c3fe93086f45a986a3d45cdcaefc22,PFS,0.65903
uuid-f7c3fe93086f45a986a3d45cdcaefc22,Overall survival,0.644151
uuid-01f8a7ded0264204b7db310da5a7a601,nivolumab,0.576982
uuid-01f8a7ded0264204b7db310da5a7a601,Bristol-Myers Squibb,0.431049
uuid-01f8a7ded0264204b7db310da5a7a601,evaluating,0.593548
uuid-01f8a7ded0264204b7db310da5a7a601,not conducted any controlled clinical trials/studies,0.649532
uuid-01f8a7ded0264204b7db310da5a7a601,Pubmed literature search,0.874999
uuid-01f8a7ded0264204b7db310da5a7a601,purposes other than its labeled indication must be considered investigational,0.938553
uuid-01f8a7ded0264204b7db310da5a7a601,not identify any citations relevant to your inquiry,0.835774
uuid-01f8a7ded0264204b7db310da5a7a601,using the following search terms,0.822172
uuid-01f8a7ded0264204b7db310da5a7a601,efficacy and safety of nivolumab,0.429258
uuid-e195567c53124ec49f63e73942281565,patients with advanced or metastatic,0.468858
uuid-e195567c53124ec49f63e73942281565,nivolumab combined with ipilimumab,0.446918
uuid-e195567c53124ec49f63e73942281565,not approved,0.352562
uuid-e195567c53124ec49f63e73942281565,clinical trials investigating the safety,0.429501
uuid-e195567c53124ec49f63e73942281565,bladder cancer,0.950698
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,Bristol-Myers Squibb,0.574336
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,evaluating,0.629186
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,OS,0.409933
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,not conducted any controlled clinical trials/studies,0.648555
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,patients,0.320335
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,PFS,0.331642
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,adverse,0.362798
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,RCC,0.317172
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,search of published literature,0.307121
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,efficacy and safety of nivolumab,0.599219
uuid-dfb8549b7b2d43f5bb91f581d3dfb549,safety of nivolumab monotherapy,0.337091
uuid-5588eef9a1354333a0bc954a13883897,provided in the Detailed Information,0.349112
uuid-5588eef9a1354333a0bc954a13883897,Weber JS,0.321343
uuid-7a8125c1fd874caabcfe5e2cf480f60a,Bristol-Myers Squibb,0.326895
uuid-7a8125c1fd874caabcfe5e2cf480f60a,Opdivo,0.325015
uuid-7a8125c1fd874caabcfe5e2cf480f60a,adverse,0.554225
uuid-7a8125c1fd874caabcfe5e2cf480f60a,reported,0.782933
uuid-0769da3ed9674c3aa9c8f777483aa1f6,nivolumab,0.479405
uuid-0769da3ed9674c3aa9c8f777483aa1f6,Bristol-Myers Squibb,0.490774
uuid-0769da3ed9674c3aa9c8f777483aa1f6,evaluating,0.668328
uuid-0769da3ed9674c3aa9c8f777483aa1f6,not conducted any controlled clinical trials/studies,0.718644
uuid-0769da3ed9674c3aa9c8f777483aa1f6,Pubmed literature search,0.827224
uuid-0769da3ed9674c3aa9c8f777483aa1f6,purposes other than its labeled indication must be considered investigational,0.8998
uuid-0769da3ed9674c3aa9c8f777483aa1f6,not identify any citations relevant to your inquiry,0.783573
uuid-0769da3ed9674c3aa9c8f777483aa1f6,using the following search terms,0.767619
uuid-0769da3ed9674c3aa9c8f777483aa1f6,efficacy and safety of nivolumab,0.499178
uuid-1e39ca9a67b34be184f87cd67a872451,N Engl J Med,0.564757
uuid-1e39ca9a67b34be184f87cd67a872451,protocol,0.417674
uuid-1e39ca9a67b34be184f87cd67a872451,McDermott DF,0.498928
uuid-1e39ca9a67b34be184f87cd67a872451,Motzer RJ,0.463181
uuid-1e39ca9a67b34be184f87cd67a872451,phase 3 study,0.570662
uuid-1e39ca9a67b34be184f87cd67a872451,Escudier B,0.488086
uuid-1e39ca9a67b34be184f87cd67a872451,et al.,0.512667
uuid-1e39ca9a67b34be184f87cd67a872451,J Clin Oncol,0.428791
uuid-1e39ca9a67b34be184f87cd67a872451,phase 1 study,0.408991
uuid-1e39ca9a67b34be184f87cd67a872451,Rizvi NA,0.449917
uuid-1e39ca9a67b34be184f87cd67a872451,Brahmer J,0.40548
uuid-1e39ca9a67b34be184f87cd67a872451,CA209-003,0.300622
uuid-1e39ca9a67b34be184f87cd67a872451,phase 2 study,0.660756
uuid-4b73dc39f9784573b408afc0d534f260,nivolumab,0.567837
uuid-4b73dc39f9784573b408afc0d534f260,Bristol-Myers Squibb,0.444777
uuid-4b73dc39f9784573b408afc0d534f260,evaluating,0.601715
uuid-4b73dc39f9784573b408afc0d534f260,not conducted any controlled clinical trials/studies,0.661992
uuid-4b73dc39f9784573b408afc0d534f260,Pubmed literature search,0.874841
uuid-4b73dc39f9784573b408afc0d534f260,purposes other than its labeled indication must be considered investigational,0.938998
uuid-4b73dc39f9784573b408afc0d534f260,not identify any citations relevant to your inquiry,0.833358
uuid-4b73dc39f9784573b408afc0d534f260,using the following search terms,0.820812
uuid-4b73dc39f9784573b408afc0d534f260,efficacy and safety of nivolumab,0.438068
uuid-f9337d5a7101455cb3c2b2828b5a578b,requested,0.594234
uuid-6412781ce8ec43fea3d4cd49b5818214,provided in the Detailed Information,0.349112
uuid-6412781ce8ec43fea3d4cd49b5818214,Weber JS,0.321343
uuid-881cebd770ea47979ec4ce648742a2e8,Pubmed literature search,0.395461
uuid-881cebd770ea47979ec4ce648742a2e8,purposes other than its labeled indication must be considered investigational,0.37511
uuid-881cebd770ea47979ec4ce648742a2e8,not identify any citations relevant to your inquiry,0.392461
uuid-881cebd770ea47979ec4ce648742a2e8,using the following search terms,0.413282
uuid-881cebd770ea47979ec4ce648742a2e8,reported,0.340659
uuid-40ec3e1ee653496497a75108606bd286,Opdivo,0.50165
uuid-40ec3e1ee653496497a75108606bd286,open-label,0.304253
uuid-40ec3e1ee653496497a75108606bd286,trial,0.521827
uuid-40ec3e1ee653496497a75108606bd286,docetaxel,0.30238
uuid-40ec3e1ee653496497a75108606bd286,safety of nivolumab monotherapy,0.432481
uuid-40ec3e1ee653496497a75108606bd286,phase,0.378496
uuid-149cf90f65f54ec29308bb4896f0b441,patients with advanced or metastatic,0.478326
uuid-149cf90f65f54ec29308bb4896f0b441,nivolumab combined with ipilimumab,0.498766
uuid-149cf90f65f54ec29308bb4896f0b441,not approved,0.34724
uuid-149cf90f65f54ec29308bb4896f0b441,clinical trials investigating the safety,0.426729
uuid-149cf90f65f54ec29308bb4896f0b441,bladder cancer,0.6548
uuid-1ecfd3156faa48f3a259840a97372cc4,nivolumab,0.495499
uuid-1ecfd3156faa48f3a259840a97372cc4,Bristol-Myers Squibb,0.495021
uuid-1ecfd3156faa48f3a259840a97372cc4,evaluating,0.572225
uuid-1ecfd3156faa48f3a259840a97372cc4,not conducted any controlled clinical trials/studies,0.637891
uuid-1ecfd3156faa48f3a259840a97372cc4,Pubmed literature search,0.747378
uuid-1ecfd3156faa48f3a259840a97372cc4,purposes other than its labeled indication must be considered investigational,0.813438
uuid-1ecfd3156faa48f3a259840a97372cc4,not identify any citations relevant to your inquiry,0.710157
uuid-1ecfd3156faa48f3a259840a97372cc4,using the following search terms,0.694219
uuid-1ecfd3156faa48f3a259840a97372cc4,efficacy and safety of nivolumab,0.411135
uuid-c53dd3f1b35444f180d0660b00694c0f,Bristol-Myers Squibb,0.307009
uuid-c53dd3f1b35444f180d0660b00694c0f,requested,0.323839
uuid-dfacc92c85224364a817e34dc74142f0,patients with advanced or metastatic,0.468858
uuid-dfacc92c85224364a817e34dc74142f0,nivolumab combined with ipilimumab,0.446918
uuid-dfacc92c85224364a817e34dc74142f0,not approved,0.352562
uuid-dfacc92c85224364a817e34dc74142f0,clinical trials investigating the safety,0.429501
uuid-dfacc92c85224364a817e34dc74142f0,bladder cancer,0.950698
uuid-40b1da1227f1405d8ef85aed85eb7222,Bristol-Myers Squibb,0.453985
uuid-3846003550ce42fabf7fdcf4c8c01195,N Engl J Med,0.325809
uuid-3846003550ce42fabf7fdcf4c8c01195,protocol,0.354341
uuid-3846003550ce42fabf7fdcf4c8c01195,McDermott DF,0.361653
uuid-3846003550ce42fabf7fdcf4c8c01195,Motzer RJ,0.350876
uuid-3846003550ce42fabf7fdcf4c8c01195,Escudier B,0.367593
uuid-3846003550ce42fabf7fdcf4c8c01195,et al.,0.367382
uuid-3846003550ce42fabf7fdcf4c8c01195,J Clin Oncol,0.306851
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,95% CI,0.539708
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,respectively,0.725277
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,Objective response rate,0.585108
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,ORR,0.670371
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,Median overall survival,0.523901
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,monotherapy,0.681146
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,Median OS,0.506544
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,mg,0.4257
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,docetaxel,0.318893
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,kg,0.39269
uuid-e020dd59e7804bf2ac233ffe2e57eeb9,hazard ratio,0.525264
uuid-eecf18fe9bb749f4bf5fe64d66fa5519,provided in the Detailed Information,0.39304
uuid-33c2fc38db4048ce94d3f3c6f1d57174,search of published literature,0.394524
uuid-33c2fc38db4048ce94d3f3c6f1d57174,Additionally,0.413583
uuid-33c2fc38db4048ce94d3f3c6f1d57174,ongoing,0.322117
uuid-33c2fc38db4048ce94d3f3c6f1d57174,PubMed and EMBASE,0.391671
uuid-33c2fc38db4048ce94d3f3c6f1d57174,detailed search of www.clinicaltrials.gov,0.375936
uuid-33c2fc38db4048ce94d3f3c6f1d57174,efficacy and safety of nivolumab,0.370699
uuid-33c2fc38db4048ce94d3f3c6f1d57174,not identify any planned,0.34283
uuid-33c2fc38db4048ce94d3f3c6f1d57174,Weber JS,0.319229
uuid-33c2fc38db4048ce94d3f3c6f1d57174,not identify any citations relevant to your request,0.447813
uuid-33c2fc38db4048ce94d3f3c6f1d57174,present using the following search terms,0.408199
uuid-1ac7d107449c4dca830d3e186639810b,AEs,0.318533
uuid-1ac7d107449c4dca830d3e186639810b,patients,0.488039
uuid-1ac7d107449c4dca830d3e186639810b,provided in the Detailed Information,0.314621
uuid-1ac7d107449c4dca830d3e186639810b,NEJM,0.550837
uuid-1ac7d107449c4dca830d3e186639810b,Topalian,0.584663
uuid-1ac7d107449c4dca830d3e186639810b,grade 3 to 4 AEs,0.492266
uuid-36090729b8b7487da801cbddfcd03d0e,use of nivolumab for the treatment,0.355742
uuid-36090729b8b7487da801cbddfcd03d0e,patients,0.813246
uuid-36090729b8b7487da801cbddfcd03d0e,considered investigational,0.338948
uuid-36090729b8b7487da801cbddfcd03d0e,small cell lung cancer,0.391114
uuid-36090729b8b7487da801cbddfcd03d0e,SCLC,0.343182
uuid-36090729b8b7487da801cbddfcd03d0e,grade 3 to 4 AEs,0.401718
uuid-10e7e438a1874dbcb280d65b46bc4550,search of published literature,0.394524
uuid-10e7e438a1874dbcb280d65b46bc4550,Additionally,0.413583
uuid-10e7e438a1874dbcb280d65b46bc4550,ongoing,0.322117
uuid-10e7e438a1874dbcb280d65b46bc4550,PubMed and EMBASE,0.391671
uuid-10e7e438a1874dbcb280d65b46bc4550,detailed search of www.clinicaltrials.gov,0.375936
uuid-10e7e438a1874dbcb280d65b46bc4550,efficacy and safety of nivolumab,0.370699
uuid-10e7e438a1874dbcb280d65b46bc4550,not identify any planned,0.34283
uuid-10e7e438a1874dbcb280d65b46bc4550,Weber JS,0.319229
uuid-10e7e438a1874dbcb280d65b46bc4550,not identify any citations relevant to your request,0.447813
uuid-10e7e438a1874dbcb280d65b46bc4550,present using the following search terms,0.408199
uuid-e3e2d5f5750b44289e4cdb48d4d43d5f,OS,0.62262
uuid-e3e2d5f5750b44289e4cdb48d4d43d5f,PFS,0.65903
uuid-e3e2d5f5750b44289e4cdb48d4d43d5f,Overall survival,0.644151
uuid-e688f5f00e8744dbaec866fcc074cbfb,nivolumab,0.316171
uuid-e688f5f00e8744dbaec866fcc074cbfb,use of nivolumab for the treatment,0.55099
uuid-e688f5f00e8744dbaec866fcc074cbfb,evaluating,0.322329
uuid-e688f5f00e8744dbaec866fcc074cbfb,efficacy,0.40271
uuid-e688f5f00e8744dbaec866fcc074cbfb,patients,0.441227
uuid-e688f5f00e8744dbaec866fcc074cbfb,search of published literature,0.369214
uuid-e688f5f00e8744dbaec866fcc074cbfb,PubMed and EMBASE,0.363082
uuid-e688f5f00e8744dbaec866fcc074cbfb,not approved,0.592496
uuid-e688f5f00e8744dbaec866fcc074cbfb,clinical trials investigating the safety,0.653371
uuid-e688f5f00e8744dbaec866fcc074cbfb,efficacy and safety of nivolumab,0.344775
uuid-e688f5f00e8744dbaec866fcc074cbfb,present using the following search terms,0.385746
uuid-673a33120a6341efa5de170a90ddc886,use of nivolumab for the treatment,0.440423
uuid-673a33120a6341efa5de170a90ddc886,search of published literature,0.311531
uuid-673a33120a6341efa5de170a90ddc886,PubMed and EMBASE,0.312811
uuid-673a33120a6341efa5de170a90ddc886,not approved,0.404782
uuid-673a33120a6341efa5de170a90ddc886,open-label,0.578291
uuid-673a33120a6341efa5de170a90ddc886,clinical trials investigating the safety,0.440014
uuid-673a33120a6341efa5de170a90ddc886,present using the following search terms,0.328669
uuid-673a33120a6341efa5de170a90ddc886,phase,0.41185
uuid-8c8f00d368774ccf9f0d489deee42473,patients,0.324046
uuid-8c8f00d368774ccf9f0d489deee42473,patients with advanced or metastatic,0.410904
uuid-8c8f00d368774ccf9f0d489deee42473,nivolumab combined with ipilimumab,0.380227
uuid-8c8f00d368774ccf9f0d489deee42473,clinical trials investigating the safety,0.341508
uuid-8c8f00d368774ccf9f0d489deee42473,bladder cancer,0.786845
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,patients,0.356336
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,considered investigational,0.410874
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,patients with advanced or metastatic,0.352925
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,nivolumab combined with ipilimumab,0.331045
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,tumors,0.740394
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,small cell lung cancer,0.425236
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,SCLC,0.387548
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,phase 1/2 study CA209-032,0.436981
uuid-b5b9e156e6a34ec7a2816405d1d5aa1e,evaluates the efficacy of nivolumab monotherapy,0.451868
uuid-d77db5e66840429589654fdbaf1595d5,Bristol-Myers Squibb,0.341822
uuid-d77db5e66840429589654fdbaf1595d5,not conducted any controlled clinical trials/studies,0.304507
uuid-d77db5e66840429589654fdbaf1595d5,Opdivo,0.461382
uuid-d77db5e66840429589654fdbaf1595d5,Pubmed literature search,0.614325
uuid-d77db5e66840429589654fdbaf1595d5,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d77db5e66840429589654fdbaf1595d5,not identify any citations relevant to your inquiry,0.606087
uuid-d77db5e66840429589654fdbaf1595d5,adverse,0.304183
uuid-d77db5e66840429589654fdbaf1595d5,using the following search terms,0.642331
uuid-d77db5e66840429589654fdbaf1595d5,databases,0.315039
uuid-d77db5e66840429589654fdbaf1595d5,reported,0.556704
uuid-a2fd9a166073482ea18b6bcf059991e2,Objective response rate,0.451139
uuid-a2fd9a166073482ea18b6bcf059991e2,clinicaltrials.gov,0.503706
uuid-11e8c83d3870422ab34744d968ee0e89,respectively,0.661351
uuid-11e8c83d3870422ab34744d968ee0e89,Objective response rate,0.619462
uuid-11e8c83d3870422ab34744d968ee0e89,ORR,0.537232
uuid-11e8c83d3870422ab34744d968ee0e89,monotherapy,0.421967
uuid-11e8c83d3870422ab34744d968ee0e89,docetaxel,0.426453
uuid-2489627596f64e729808aa425265e06e,Bristol-Myers Squibb,0.307009
uuid-2489627596f64e729808aa425265e06e,requested,0.323839
uuid-5a731021fa1c4cb08dc4f7f4280398ae,nivolumab,0.359772
uuid-bc72f5f8ffa34569a81c4a997a0d5adb,PD-L1,0.730911
uuid-be2245ce03044dcb875bfec5cb111753,trial,0.445315
uuid-2ebdc014057f43cc826b9a236e9f8389,ipilimumab,0.385692
uuid-2ebdc014057f43cc826b9a236e9f8389,ASCO 2015,0.417944
uuid-2ebdc014057f43cc826b9a236e9f8389,partial response,0.382425
uuid-2ebdc014057f43cc826b9a236e9f8389,Stable disease,0.586335
uuid-2ebdc014057f43cc826b9a236e9f8389,cohort,0.307748
uuid-387d24a037674e07aae7828a88e0f88a,requested,0.44769
uuid-387d24a037674e07aae7828a88e0f88a,trial,0.309472
uuid-24575e383dcf4409adc44d51978413e3,use of nivolumab for the treatment,0.440423
uuid-24575e383dcf4409adc44d51978413e3,search of published literature,0.311531
uuid-24575e383dcf4409adc44d51978413e3,PubMed and EMBASE,0.312811
uuid-24575e383dcf4409adc44d51978413e3,not approved,0.404782
uuid-24575e383dcf4409adc44d51978413e3,open-label,0.578291
uuid-24575e383dcf4409adc44d51978413e3,clinical trials investigating the safety,0.440014
uuid-24575e383dcf4409adc44d51978413e3,present using the following search terms,0.328669
uuid-24575e383dcf4409adc44d51978413e3,phase,0.41185
uuid-826c8ab4c99a413faee7bc06fde335e8,OS,0.517683
uuid-826c8ab4c99a413faee7bc06fde335e8,95% CI,0.887029
uuid-826c8ab4c99a413faee7bc06fde335e8,respectively,0.541932
uuid-826c8ab4c99a413faee7bc06fde335e8,Objective response rate,0.732884
uuid-826c8ab4c99a413faee7bc06fde335e8,ORR,0.826341
uuid-826c8ab4c99a413faee7bc06fde335e8,PFS,0.416378
uuid-826c8ab4c99a413faee7bc06fde335e8,Median overall survival,0.810566
uuid-826c8ab4c99a413faee7bc06fde335e8,monotherapy,0.504664
uuid-826c8ab4c99a413faee7bc06fde335e8,Median OS,0.783041
uuid-826c8ab4c99a413faee7bc06fde335e8,hazard ratio,0.851803
uuid-826c8ab4c99a413faee7bc06fde335e8,Median duration of response,0.350254
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,OS,0.387982
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,95% CI,0.745043
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,respectively,0.729294
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,Objective response rate,0.590876
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,ORR,0.722442
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,Median overall survival,0.659043
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,monotherapy,0.514468
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,Median OS,0.696688
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,PD-L1,0.300997
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,docetaxel,0.635065
uuid-7e0bc213ca3f4c0884a0bec2d03dd503,hazard ratio,0.729977
uuid-19eec274928f4db09d75a5b4bbac036d,95% CI,0.482283
uuid-19eec274928f4db09d75a5b4bbac036d,respectively,0.319895
uuid-19eec274928f4db09d75a5b4bbac036d,ASCO,0.389676
uuid-19eec274928f4db09d75a5b4bbac036d,Objective response rate,0.357341
uuid-19eec274928f4db09d75a5b4bbac036d,ORR,0.358789
uuid-19eec274928f4db09d75a5b4bbac036d,Median overall survival,0.421434
uuid-19eec274928f4db09d75a5b4bbac036d,Median OS,0.603017
uuid-19eec274928f4db09d75a5b4bbac036d,docetaxel,0.351836
uuid-19eec274928f4db09d75a5b4bbac036d,hazard ratio,0.51871
uuid-f8b59e4da398465a91d5ce74bb9855f5,ipilimumab,0.385692
uuid-f8b59e4da398465a91d5ce74bb9855f5,ASCO 2015,0.417944
uuid-f8b59e4da398465a91d5ce74bb9855f5,partial response,0.382425
uuid-f8b59e4da398465a91d5ce74bb9855f5,Stable disease,0.586335
uuid-f8b59e4da398465a91d5ce74bb9855f5,cohort,0.307748
uuid-a250b12b3fa64fa59b6630a453917684,Objective response rate,0.451139
uuid-a250b12b3fa64fa59b6630a453917684,clinicaltrials.gov,0.503706
uuid-e2d5248c386a445c90774dde72d3a753,melanoma,0.40889
uuid-ccc90509866d4d22ad361f32a21f5532,requested,0.551003
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,Opdivo,0.50165
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,open-label,0.304253
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,trial,0.521827
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,docetaxel,0.30238
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,safety of nivolumab monotherapy,0.432481
uuid-e710cd6b22d74e0ea4ebb7218cfea0fb,phase,0.378496
uuid-f1f74994b4d84c6596e2c11678e4ec3e,mg,0.318479
uuid-5849a134850d4d9396a15d2b1727a54a,nivolumab,0.403342
uuid-5849a134850d4d9396a15d2b1727a54a,Bristol-Myers Squibb,0.455453
uuid-5849a134850d4d9396a15d2b1727a54a,evaluating,0.601648
uuid-5849a134850d4d9396a15d2b1727a54a,not conducted any controlled clinical trials/studies,0.616533
uuid-5849a134850d4d9396a15d2b1727a54a,Pubmed literature search,0.394076
uuid-5849a134850d4d9396a15d2b1727a54a,purposes other than its labeled indication must be considered investigational,0.465771
uuid-5849a134850d4d9396a15d2b1727a54a,not identify any citations relevant to your inquiry,0.382126
uuid-5849a134850d4d9396a15d2b1727a54a,search of published literature,0.444041
uuid-5849a134850d4d9396a15d2b1727a54a,Additionally,0.343065
uuid-5849a134850d4d9396a15d2b1727a54a,clinical,0.317867
uuid-5849a134850d4d9396a15d2b1727a54a,PubMed and EMBASE,0.420808
uuid-5849a134850d4d9396a15d2b1727a54a,using the following search terms,0.350086
uuid-5849a134850d4d9396a15d2b1727a54a,detailed search of www.clinicaltrials.gov,0.309466
uuid-5849a134850d4d9396a15d2b1727a54a,efficacy and safety of nivolumab,0.620842
uuid-5849a134850d4d9396a15d2b1727a54a,not identify any citations relevant to your request,0.389628
uuid-5849a134850d4d9396a15d2b1727a54a,present using the following search terms,0.433694
uuid-5744dbda421f40769faa9476fbb4ed32,Bristol-Myers Squibb,0.344149
uuid-5744dbda421f40769faa9476fbb4ed32,requested,0.32002
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,N Engl J Med,0.448483
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,protocol,0.770446
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,McDermott DF,0.741196
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,Motzer RJ,0.818144
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,phase 3 study,0.417055
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,Escudier B,0.749917
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,NEJM,0.400698
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,et al.,0.668641
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,J Clin Oncol,0.792018
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,Topalian,0.388894
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,phase 1 study,0.500686
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,CA209-003,0.567381
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,phase 2 study,0.677985
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,present using the following search terms,0.310558
uuid-c3a5e3ddf9ab4607b4368e8ebee0dbc4,investigating,0.615835
uuid-ae76d14fc46c4e3981301ea617de9a50,Opdivo,0.50165
uuid-ae76d14fc46c4e3981301ea617de9a50,open-label,0.304253
uuid-ae76d14fc46c4e3981301ea617de9a50,trial,0.521827
uuid-ae76d14fc46c4e3981301ea617de9a50,docetaxel,0.30238
uuid-ae76d14fc46c4e3981301ea617de9a50,safety of nivolumab monotherapy,0.432481
uuid-ae76d14fc46c4e3981301ea617de9a50,phase,0.378496
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,95% CI,0.482283
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,respectively,0.319895
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,ASCO,0.389676
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,Objective response rate,0.357341
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,ORR,0.358789
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,Median overall survival,0.421434
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,Median OS,0.603017
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,docetaxel,0.351836
uuid-22ff598a8a0e4bdf8a5f766bb70834fc,hazard ratio,0.51871
uuid-c31571d6374f4c68b8974a2b56cac8fe,NSCLC,0.690469
uuid-c31571d6374f4c68b8974a2b56cac8fe,non-small cell lung cancer,0.713175
uuid-c31571d6374f4c68b8974a2b56cac8fe,considered investigational,0.341357
uuid-c31571d6374f4c68b8974a2b56cac8fe,PD-L1,0.383909
uuid-c31571d6374f4c68b8974a2b56cac8fe,SCLC,0.322417
uuid-c31571d6374f4c68b8974a2b56cac8fe,therapy,0.440939
uuid-c31571d6374f4c68b8974a2b56cac8fe,safety of nivolumab monotherapy,0.361989
uuid-c31571d6374f4c68b8974a2b56cac8fe,platinum-based doublet chemotherapy,0.423853
uuid-4536b0463a194399bd60b448282bf8fa,OS,0.304645
uuid-4536b0463a194399bd60b448282bf8fa,95% CI,0.408622
uuid-4536b0463a194399bd60b448282bf8fa,NSCLC,0.33588
uuid-4536b0463a194399bd60b448282bf8fa,respectively,0.499027
uuid-4536b0463a194399bd60b448282bf8fa,Objective response rate,0.688609
uuid-4536b0463a194399bd60b448282bf8fa,ORR,0.678791
uuid-4536b0463a194399bd60b448282bf8fa,Median overall survival,0.445394
uuid-4536b0463a194399bd60b448282bf8fa,monotherapy,0.519987
uuid-4536b0463a194399bd60b448282bf8fa,Median OS,0.375881
uuid-4536b0463a194399bd60b448282bf8fa,docetaxel,0.378462
uuid-4536b0463a194399bd60b448282bf8fa,Antonia SJ,0.333337
uuid-4536b0463a194399bd60b448282bf8fa,hazard ratio,0.41425
uuid-f81498988873489a8bff8be8e57889ba,melanoma,0.410364
uuid-658fe45a2ede49f5ac991d981993f53f,N Engl J Med,0.448483
uuid-658fe45a2ede49f5ac991d981993f53f,protocol,0.770446
uuid-658fe45a2ede49f5ac991d981993f53f,McDermott DF,0.741196
uuid-658fe45a2ede49f5ac991d981993f53f,Motzer RJ,0.818144
uuid-658fe45a2ede49f5ac991d981993f53f,phase 3 study,0.417055
uuid-658fe45a2ede49f5ac991d981993f53f,Escudier B,0.749917
uuid-658fe45a2ede49f5ac991d981993f53f,NEJM,0.400698
uuid-658fe45a2ede49f5ac991d981993f53f,et al.,0.668641
uuid-658fe45a2ede49f5ac991d981993f53f,J Clin Oncol,0.792018
uuid-658fe45a2ede49f5ac991d981993f53f,Topalian,0.388894
uuid-658fe45a2ede49f5ac991d981993f53f,phase 1 study,0.500686
uuid-658fe45a2ede49f5ac991d981993f53f,CA209-003,0.567381
uuid-658fe45a2ede49f5ac991d981993f53f,phase 2 study,0.677985
uuid-658fe45a2ede49f5ac991d981993f53f,present using the following search terms,0.310558
uuid-658fe45a2ede49f5ac991d981993f53f,investigating,0.615835
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,search of published literature,0.394524
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,Additionally,0.413583
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,ongoing,0.322117
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,PubMed and EMBASE,0.391671
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,detailed search of www.clinicaltrials.gov,0.375936
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,efficacy and safety of nivolumab,0.370699
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,not identify any planned,0.34283
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,Weber JS,0.319229
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,not identify any citations relevant to your request,0.447813
uuid-7d12c1e941e940ddabe4aa3267b7d2ba,present using the following search terms,0.408199
uuid-0334f0d02f2e446a80e428052ddc13e9,Opdivo,0.355719
uuid-0334f0d02f2e446a80e428052ddc13e9,adverse,0.379366
uuid-0334f0d02f2e446a80e428052ddc13e9,safety,0.564993
uuid-0334f0d02f2e446a80e428052ddc13e9,databases,0.507914
uuid-0334f0d02f2e446a80e428052ddc13e9,reported,0.635283
uuid-46092ed0a7e2468cb45e7e025b22fcba,N Engl J Med,0.748233
uuid-46092ed0a7e2468cb45e7e025b22fcba,Lancet Oncol,0.365736
uuid-46092ed0a7e2468cb45e7e025b22fcba,protocol,0.540443
uuid-46092ed0a7e2468cb45e7e025b22fcba,McDermott DF,0.561234
uuid-46092ed0a7e2468cb45e7e025b22fcba,Motzer RJ,0.520728
uuid-46092ed0a7e2468cb45e7e025b22fcba,phase 3 study,0.465914
uuid-46092ed0a7e2468cb45e7e025b22fcba,Escudier B,0.56657
uuid-46092ed0a7e2468cb45e7e025b22fcba,NEJM,0.359088
uuid-46092ed0a7e2468cb45e7e025b22fcba,et al.,0.556677
uuid-46092ed0a7e2468cb45e7e025b22fcba,J Clin Oncol,0.460965
uuid-46092ed0a7e2468cb45e7e025b22fcba,Topalian,0.34678
uuid-46092ed0a7e2468cb45e7e025b22fcba,Rizvi NA,0.623654
uuid-46092ed0a7e2468cb45e7e025b22fcba,Brahmer J,0.572238
uuid-46092ed0a7e2468cb45e7e025b22fcba,Weber JS,0.375984
uuid-46092ed0a7e2468cb45e7e025b22fcba,phase 2 study,0.599599
uuid-eb4b440645374869b0a7450de0157ec2,grade,0.445335
uuid-88dd9359d837412bbac472b66b32ff41,search of published literature,0.394524
uuid-88dd9359d837412bbac472b66b32ff41,Additionally,0.413583
uuid-88dd9359d837412bbac472b66b32ff41,ongoing,0.322117
uuid-88dd9359d837412bbac472b66b32ff41,PubMed and EMBASE,0.391671
uuid-88dd9359d837412bbac472b66b32ff41,detailed search of www.clinicaltrials.gov,0.375936
uuid-88dd9359d837412bbac472b66b32ff41,efficacy and safety of nivolumab,0.370699
uuid-88dd9359d837412bbac472b66b32ff41,not identify any planned,0.34283
uuid-88dd9359d837412bbac472b66b32ff41,Weber JS,0.319229
uuid-88dd9359d837412bbac472b66b32ff41,not identify any citations relevant to your request,0.447813
uuid-88dd9359d837412bbac472b66b32ff41,present using the following search terms,0.408199
uuid-d44cac1a98934d07a4553dc562a730d6,nivolumab,0.426112
uuid-d44cac1a98934d07a4553dc562a730d6,Bristol-Myers Squibb,0.414683
uuid-d44cac1a98934d07a4553dc562a730d6,evaluating,0.618441
uuid-d44cac1a98934d07a4553dc562a730d6,not conducted any controlled clinical trials/studies,0.59781
uuid-d44cac1a98934d07a4553dc562a730d6,search of published literature,0.714235
uuid-d44cac1a98934d07a4553dc562a730d6,Additionally,0.677808
uuid-d44cac1a98934d07a4553dc562a730d6,ongoing,0.561965
uuid-d44cac1a98934d07a4553dc562a730d6,PubMed and EMBASE,0.703738
uuid-d44cac1a98934d07a4553dc562a730d6,detailed search of www.clinicaltrials.gov,0.645679
uuid-d44cac1a98934d07a4553dc562a730d6,efficacy and safety of nivolumab,0.739441
uuid-d44cac1a98934d07a4553dc562a730d6,not identify any planned,0.590181
uuid-d44cac1a98934d07a4553dc562a730d6,not identify any citations relevant to your request,0.76779
uuid-d44cac1a98934d07a4553dc562a730d6,present using the following search terms,0.732321
uuid-22948f36ebdd4894a040a5dae17a5ade,Brahmer J,0.423425
uuid-22948f36ebdd4894a040a5dae17a5ade,BMS,0.819282
uuid-060afd0d223541fbbc1f85864540161f,nivolumab,0.614166
uuid-060afd0d223541fbbc1f85864540161f,Bristol-Myers Squibb,0.43886
uuid-060afd0d223541fbbc1f85864540161f,evaluating,0.615605
uuid-060afd0d223541fbbc1f85864540161f,not conducted any controlled clinical trials/studies,0.661844
uuid-060afd0d223541fbbc1f85864540161f,Pubmed literature search,0.820381
uuid-060afd0d223541fbbc1f85864540161f,purposes other than its labeled indication must be considered investigational,0.891613
uuid-060afd0d223541fbbc1f85864540161f,not identify any citations relevant to your inquiry,0.778203
uuid-060afd0d223541fbbc1f85864540161f,using the following search terms,0.764876
uuid-060afd0d223541fbbc1f85864540161f,efficacy and safety of nivolumab,0.461735
uuid-4f7667d6b7dc480fa42a76361a4717f6,Bristol-Myers Squibb,0.341822
uuid-4f7667d6b7dc480fa42a76361a4717f6,not conducted any controlled clinical trials/studies,0.304507
uuid-4f7667d6b7dc480fa42a76361a4717f6,Opdivo,0.461382
uuid-4f7667d6b7dc480fa42a76361a4717f6,Pubmed literature search,0.614325
uuid-4f7667d6b7dc480fa42a76361a4717f6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4f7667d6b7dc480fa42a76361a4717f6,not identify any citations relevant to your inquiry,0.606087
uuid-4f7667d6b7dc480fa42a76361a4717f6,adverse,0.304183
uuid-4f7667d6b7dc480fa42a76361a4717f6,using the following search terms,0.642331
uuid-4f7667d6b7dc480fa42a76361a4717f6,databases,0.315039
uuid-4f7667d6b7dc480fa42a76361a4717f6,reported,0.556704
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,use of nivolumab for the treatment,0.409821
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,patients with advanced or metastatic,0.645244
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,nivolumab combined with ipilimumab,0.676339
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,not approved,0.453534
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,clinical trials investigating the safety,0.548799
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,phase 1/2 study CA209-032,0.34114
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,bladder cancer,0.749142
uuid-baed74a5e81c4a7ab1060ed4ed2b3c82,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-aedd2ed36f754b278537f1ede1d17a01,nivolumab,0.811201
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,N Engl J Med,0.302601
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,AEs,0.348167
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,patients,0.536884
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,provided in the Detailed Information,0.387544
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,ESMO,0.462801
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,NEJM,0.66427
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,Topalian,0.692873
uuid-2cfe80c4dd7e4f899a5b7ed489548b67,grade 3 to 4 AEs,0.626596
uuid-7506d01035f748159da3a4c056302b1a,Bristol-Myers Squibb,0.307009
uuid-7506d01035f748159da3a4c056302b1a,requested,0.323839
uuid-e97a8138e1d64fd2a5d30f96f6a423a1,OS,0.62262
uuid-e97a8138e1d64fd2a5d30f96f6a423a1,PFS,0.65903
uuid-e97a8138e1d64fd2a5d30f96f6a423a1,Overall survival,0.644151
uuid-6f018033c1e34e7f8de8a72905560e7c,OS,0.509239
uuid-6f018033c1e34e7f8de8a72905560e7c,95% CI,0.914257
uuid-6f018033c1e34e7f8de8a72905560e7c,respectively,0.451371
uuid-6f018033c1e34e7f8de8a72905560e7c,Objective response rate,0.581191
uuid-6f018033c1e34e7f8de8a72905560e7c,ORR,0.730322
uuid-6f018033c1e34e7f8de8a72905560e7c,PFS,0.386284
uuid-6f018033c1e34e7f8de8a72905560e7c,Median overall survival,0.876328
uuid-6f018033c1e34e7f8de8a72905560e7c,monotherapy,0.345837
uuid-6f018033c1e34e7f8de8a72905560e7c,Median OS,0.851966
uuid-6f018033c1e34e7f8de8a72905560e7c,hazard ratio,0.900897
uuid-6f018033c1e34e7f8de8a72905560e7c,Median duration of response,0.409196
uuid-e0027356f6a84a9784380bb9a74fc9b0,nivolumab,0.548568
uuid-e0027356f6a84a9784380bb9a74fc9b0,Bristol-Myers Squibb,0.427745
uuid-e0027356f6a84a9784380bb9a74fc9b0,evaluating,0.57344
uuid-e0027356f6a84a9784380bb9a74fc9b0,not conducted any controlled clinical trials/studies,0.641832
uuid-e0027356f6a84a9784380bb9a74fc9b0,Pubmed literature search,0.858064
uuid-e0027356f6a84a9784380bb9a74fc9b0,purposes other than its labeled indication must be considered investigational,0.918744
uuid-e0027356f6a84a9784380bb9a74fc9b0,not identify any citations relevant to your inquiry,0.818368
uuid-e0027356f6a84a9784380bb9a74fc9b0,using the following search terms,0.806152
uuid-e0027356f6a84a9784380bb9a74fc9b0,efficacy and safety of nivolumab,0.423223
uuid-51fa0fa2ef08445c91f75fff2700a131,nivolumab,0.346978
uuid-51fa0fa2ef08445c91f75fff2700a131,Bristol-Myers Squibb,0.434936
uuid-51fa0fa2ef08445c91f75fff2700a131,evaluating,0.602489
uuid-51fa0fa2ef08445c91f75fff2700a131,not conducted any controlled clinical trials/studies,0.582057
uuid-51fa0fa2ef08445c91f75fff2700a131,search of published literature,0.656298
uuid-51fa0fa2ef08445c91f75fff2700a131,Additionally,0.579969
uuid-51fa0fa2ef08445c91f75fff2700a131,ongoing,0.45281
uuid-51fa0fa2ef08445c91f75fff2700a131,PubMed and EMBASE,0.643298
uuid-51fa0fa2ef08445c91f75fff2700a131,detailed search of www.clinicaltrials.gov,0.542198
uuid-51fa0fa2ef08445c91f75fff2700a131,phase 1 study,0.378501
uuid-51fa0fa2ef08445c91f75fff2700a131,efficacy and safety of nivolumab,0.7287
uuid-51fa0fa2ef08445c91f75fff2700a131,not identify any planned,0.482577
uuid-51fa0fa2ef08445c91f75fff2700a131,CA209-003,0.381665
uuid-51fa0fa2ef08445c91f75fff2700a131,not identify any citations relevant to your request,0.674308
uuid-51fa0fa2ef08445c91f75fff2700a131,present using the following search terms,0.684503
uuid-51fa0fa2ef08445c91f75fff2700a131,investigating,0.433271
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,N Engl J Med,0.448483
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,protocol,0.770446
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,McDermott DF,0.741196
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,Motzer RJ,0.818144
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,phase 3 study,0.417055
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,Escudier B,0.749917
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,NEJM,0.400698
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,et al.,0.668641
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,J Clin Oncol,0.792018
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,Topalian,0.388894
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,phase 1 study,0.500686
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,CA209-003,0.567381
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,phase 2 study,0.677985
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,present using the following search terms,0.310558
uuid-44a03c6d1a5f4a528dbc12cc0ee8693d,investigating,0.615835
uuid-18aa4fefb865415ea68bff85c6914808,Bristol-Myers Squibb,0.307009
uuid-18aa4fefb865415ea68bff85c6914808,requested,0.323839
uuid-43da351c3b6c4a23be003269400ccd00,melanoma,0.628566
uuid-0fa8397654754fbface444be7bde7445,requested,0.551003
uuid-337533222f7b4189b1e1c8d4d910e5cf,Topalian,0.300075
uuid-337533222f7b4189b1e1c8d4d910e5cf,Weber JS,0.319567
uuid-77814c7d14d84926823b0a967a0b789c,clinical trials investigating the safety,0.419282
uuid-eca7e7201a1342749c79e13056657c11,safety,0.388318
uuid-bcb7a6d91c474f47864385d599828b67,Bristol-Myers Squibb,0.935058
uuid-bcb7a6d91c474f47864385d599828b67,evaluating,0.739131
uuid-bcb7a6d91c474f47864385d599828b67,not conducted any controlled clinical trials/studies,0.840976
uuid-bcb7a6d91c474f47864385d599828b67,efficacy and safety of nivolumab,0.648711
uuid-d75b8a1de26949d3937e0115a33c63fd,nivolumab,0.368869
uuid-b826daab0d8342edb1854ebd21648464,Bristol-Myers Squibb,0.341822
uuid-b826daab0d8342edb1854ebd21648464,not conducted any controlled clinical trials/studies,0.304507
uuid-b826daab0d8342edb1854ebd21648464,Opdivo,0.461382
uuid-b826daab0d8342edb1854ebd21648464,Pubmed literature search,0.614325
uuid-b826daab0d8342edb1854ebd21648464,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b826daab0d8342edb1854ebd21648464,not identify any citations relevant to your inquiry,0.606087
uuid-b826daab0d8342edb1854ebd21648464,adverse,0.304183
uuid-b826daab0d8342edb1854ebd21648464,using the following search terms,0.642331
uuid-b826daab0d8342edb1854ebd21648464,databases,0.315039
uuid-b826daab0d8342edb1854ebd21648464,reported,0.556704
uuid-4b73c740a5f749aba6c77ccc98b86bdb,patients with advanced or metastatic,0.478326
uuid-4b73c740a5f749aba6c77ccc98b86bdb,nivolumab combined with ipilimumab,0.498766
uuid-4b73c740a5f749aba6c77ccc98b86bdb,not approved,0.34724
uuid-4b73c740a5f749aba6c77ccc98b86bdb,clinical trials investigating the safety,0.426729
uuid-4b73c740a5f749aba6c77ccc98b86bdb,bladder cancer,0.6548
uuid-a9d11b63456d40a5bef5881e40b97afc,OS,0.62262
uuid-a9d11b63456d40a5bef5881e40b97afc,PFS,0.65903
uuid-a9d11b63456d40a5bef5881e40b97afc,Overall survival,0.644151
uuid-e606c92006494e0db8ef4a01320c0f28,fatigue,0.323475
uuid-07a71535ac504b9aa7fd6ee479846822,patients with advanced or metastatic,0.468858
uuid-07a71535ac504b9aa7fd6ee479846822,nivolumab combined with ipilimumab,0.446918
uuid-07a71535ac504b9aa7fd6ee479846822,not approved,0.352562
uuid-07a71535ac504b9aa7fd6ee479846822,clinical trials investigating the safety,0.429501
uuid-07a71535ac504b9aa7fd6ee479846822,bladder cancer,0.950698
uuid-ec455a2b69d94bf58f6511a463a44afd,N Engl J Med,0.448483
uuid-ec455a2b69d94bf58f6511a463a44afd,protocol,0.770446
uuid-ec455a2b69d94bf58f6511a463a44afd,McDermott DF,0.741196
uuid-ec455a2b69d94bf58f6511a463a44afd,Motzer RJ,0.818144
uuid-ec455a2b69d94bf58f6511a463a44afd,phase 3 study,0.417055
uuid-ec455a2b69d94bf58f6511a463a44afd,Escudier B,0.749917
uuid-ec455a2b69d94bf58f6511a463a44afd,NEJM,0.400698
uuid-ec455a2b69d94bf58f6511a463a44afd,et al.,0.668641
uuid-ec455a2b69d94bf58f6511a463a44afd,J Clin Oncol,0.792018
uuid-ec455a2b69d94bf58f6511a463a44afd,Topalian,0.388894
uuid-ec455a2b69d94bf58f6511a463a44afd,phase 1 study,0.500686
uuid-ec455a2b69d94bf58f6511a463a44afd,CA209-003,0.567381
uuid-ec455a2b69d94bf58f6511a463a44afd,phase 2 study,0.677985
uuid-ec455a2b69d94bf58f6511a463a44afd,present using the following search terms,0.310558
uuid-ec455a2b69d94bf58f6511a463a44afd,investigating,0.615835
uuid-71fd459b76f54600a97da7dfa18942bc,nivolumab,0.344939
uuid-71fd459b76f54600a97da7dfa18942bc,Bristol-Myers Squibb,0.363004
uuid-71fd459b76f54600a97da7dfa18942bc,evaluating,0.564404
uuid-71fd459b76f54600a97da7dfa18942bc,not conducted any controlled clinical trials/studies,0.538169
uuid-71fd459b76f54600a97da7dfa18942bc,RCC,0.336118
uuid-71fd459b76f54600a97da7dfa18942bc,search of published literature,0.750115
uuid-71fd459b76f54600a97da7dfa18942bc,Additionally,0.766378
uuid-71fd459b76f54600a97da7dfa18942bc,ongoing,0.629393
uuid-71fd459b76f54600a97da7dfa18942bc,PubMed and EMBASE,0.745288
uuid-71fd459b76f54600a97da7dfa18942bc,detailed search of www.clinicaltrials.gov,0.729251
uuid-71fd459b76f54600a97da7dfa18942bc,efficacy and safety of nivolumab,0.716075
uuid-71fd459b76f54600a97da7dfa18942bc,not identify any planned,0.665705
uuid-71fd459b76f54600a97da7dfa18942bc,not identify any citations relevant to your request,0.849476
uuid-71fd459b76f54600a97da7dfa18942bc,present using the following search terms,0.773092
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,Opdivo,0.50165
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,open-label,0.304253
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,trial,0.521827
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,docetaxel,0.30238
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,safety of nivolumab monotherapy,0.432481
uuid-e2a09b3d66f84affb2e8b03bc3d3eec2,phase,0.378496
uuid-f991617d659f48f19cdc64c3a6551057,Bristol-Myers Squibb,0.433931
uuid-f991617d659f48f19cdc64c3a6551057,use of nivolumab for the treatment,0.472436
uuid-f991617d659f48f19cdc64c3a6551057,evaluating,0.554532
uuid-f991617d659f48f19cdc64c3a6551057,not conducted any controlled clinical trials/studies,0.551259
uuid-f991617d659f48f19cdc64c3a6551057,patients,0.686337
uuid-f991617d659f48f19cdc64c3a6551057,considered investigational,0.629036
uuid-f991617d659f48f19cdc64c3a6551057,patients with advanced or metastatic,0.33932
uuid-f991617d659f48f19cdc64c3a6551057,tumors,0.58282
uuid-f991617d659f48f19cdc64c3a6551057,small cell lung cancer,0.547612
uuid-f991617d659f48f19cdc64c3a6551057,efficacy and safety of nivolumab,0.50381
uuid-f991617d659f48f19cdc64c3a6551057,SCLC,0.49415
uuid-f991617d659f48f19cdc64c3a6551057,safety of nivolumab monotherapy,0.346244
uuid-f991617d659f48f19cdc64c3a6551057,grade 3 to 4 AEs,0.305027
uuid-f991617d659f48f19cdc64c3a6551057,phase 1/2 study CA209-032,0.507715
uuid-f991617d659f48f19cdc64c3a6551057,evaluates the efficacy of nivolumab monotherapy,0.476409
uuid-937b331ead634c14a5fe060613f9b9f4,phase 1 study,0.39736
uuid-937b331ead634c14a5fe060613f9b9f4,Rizvi NA,0.357524
uuid-937b331ead634c14a5fe060613f9b9f4,mg,0.498872
uuid-937b331ead634c14a5fe060613f9b9f4,CA209-003,0.329078
uuid-937b331ead634c14a5fe060613f9b9f4,kg,0.428667
uuid-e5fc5983261b46699dd6ca6b0d945105,melanoma,0.410364
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,OS,0.423127
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,AEs,0.340094
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,95% CI,0.331028
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,Median overall survival,0.38427
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,fatigue,0.752007
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,hazard ratio,0.337278
uuid-76b6fb8fa4dd40acaab5a349c06e04f9,Overall survival,0.565578
uuid-bfc4939c81634a1d8cc7f831b06f7e04,nivolumab,0.541626
uuid-bfc4939c81634a1d8cc7f831b06f7e04,Bristol-Myers Squibb,0.460612
uuid-bfc4939c81634a1d8cc7f831b06f7e04,evaluating,0.655014
uuid-bfc4939c81634a1d8cc7f831b06f7e04,not conducted any controlled clinical trials/studies,0.694223
uuid-bfc4939c81634a1d8cc7f831b06f7e04,Pubmed literature search,0.8052
uuid-bfc4939c81634a1d8cc7f831b06f7e04,purposes other than its labeled indication must be considered investigational,0.87833
uuid-bfc4939c81634a1d8cc7f831b06f7e04,not identify any citations relevant to your inquiry,0.764343
uuid-bfc4939c81634a1d8cc7f831b06f7e04,using the following search terms,0.749015
uuid-bfc4939c81634a1d8cc7f831b06f7e04,efficacy and safety of nivolumab,0.504398
uuid-1d8d2aeb8abf4e79b166d4a093f2a856,requested,0.599827
uuid-ba68ab4c471d473289bb9c71bd556180,requested,0.599827
uuid-73c784128ed64e89bd9ece913a05aa88,requested,0.601886
uuid-83a955dbb92f48aca431a01c2f53d007,nivolumab,0.519374
uuid-83a955dbb92f48aca431a01c2f53d007,Bristol-Myers Squibb,0.448252
uuid-83a955dbb92f48aca431a01c2f53d007,evaluating,0.573102
uuid-83a955dbb92f48aca431a01c2f53d007,not conducted any controlled clinical trials/studies,0.641454
uuid-83a955dbb92f48aca431a01c2f53d007,Pubmed literature search,0.754589
uuid-83a955dbb92f48aca431a01c2f53d007,purposes other than its labeled indication must be considered investigational,0.82742
uuid-83a955dbb92f48aca431a01c2f53d007,not identify any citations relevant to your inquiry,0.712595
uuid-83a955dbb92f48aca431a01c2f53d007,using the following search terms,0.698383
uuid-83a955dbb92f48aca431a01c2f53d007,efficacy and safety of nivolumab,0.428387
uuid-35c20131af8f44cf87f6a5c25a10e0b8,evaluating,0.300662
uuid-35c20131af8f44cf87f6a5c25a10e0b8,NSCLC,0.329831
uuid-35c20131af8f44cf87f6a5c25a10e0b8,non-small cell lung cancer,0.328689
uuid-35c20131af8f44cf87f6a5c25a10e0b8,patients,0.502916
uuid-35c20131af8f44cf87f6a5c25a10e0b8,melanoma,0.345087
uuid-35c20131af8f44cf87f6a5c25a10e0b8,phase 1 study,0.329607
uuid-35c20131af8f44cf87f6a5c25a10e0b8,mg,0.489915
uuid-35c20131af8f44cf87f6a5c25a10e0b8,kg,0.435144
uuid-bda958e8d3fd40aa849906dca3ae88ac,Bristol-Myers Squibb,0.398191
uuid-bda958e8d3fd40aa849906dca3ae88ac,requested,0.827269
uuid-8d8066b9b6924e67a4daec3065bc2210,N Engl J Med,0.475537
uuid-8d8066b9b6924e67a4daec3065bc2210,protocol,0.670678
uuid-8d8066b9b6924e67a4daec3065bc2210,McDermott DF,0.746868
uuid-8d8066b9b6924e67a4daec3065bc2210,Motzer RJ,0.728393
uuid-8d8066b9b6924e67a4daec3065bc2210,phase 3 study,0.420109
uuid-8d8066b9b6924e67a4daec3065bc2210,Escudier B,0.744749
uuid-8d8066b9b6924e67a4daec3065bc2210,NEJM,0.331914
uuid-8d8066b9b6924e67a4daec3065bc2210,et al.,0.755106
uuid-8d8066b9b6924e67a4daec3065bc2210,J Clin Oncol,0.706193
uuid-8d8066b9b6924e67a4daec3065bc2210,Topalian,0.303513
uuid-8d8066b9b6924e67a4daec3065bc2210,phase 2 study,0.658205
uuid-637ecf5c5723437999d9100da4bb0bc0,nivolumab,0.510706
uuid-637ecf5c5723437999d9100da4bb0bc0,Bristol-Myers Squibb,0.463774
uuid-637ecf5c5723437999d9100da4bb0bc0,evaluating,0.652445
uuid-637ecf5c5723437999d9100da4bb0bc0,not conducted any controlled clinical trials/studies,0.690297
uuid-637ecf5c5723437999d9100da4bb0bc0,Pubmed literature search,0.853835
uuid-637ecf5c5723437999d9100da4bb0bc0,purposes other than its labeled indication must be considered investigational,0.922784
uuid-637ecf5c5723437999d9100da4bb0bc0,not identify any citations relevant to your inquiry,0.809731
uuid-637ecf5c5723437999d9100da4bb0bc0,using the following search terms,0.797325
uuid-637ecf5c5723437999d9100da4bb0bc0,efficacy and safety of nivolumab,0.461287
uuid-70c07acf4b3446f9a770768574fa928a,N Engl J Med,0.495649
uuid-70c07acf4b3446f9a770768574fa928a,protocol,0.736971
uuid-70c07acf4b3446f9a770768574fa928a,McDermott DF,0.762108
uuid-70c07acf4b3446f9a770768574fa928a,Motzer RJ,0.773565
uuid-70c07acf4b3446f9a770768574fa928a,phase 3 study,0.454434
uuid-70c07acf4b3446f9a770768574fa928a,Escudier B,0.763658
uuid-70c07acf4b3446f9a770768574fa928a,NEJM,0.4325
uuid-70c07acf4b3446f9a770768574fa928a,et al.,0.712875
uuid-70c07acf4b3446f9a770768574fa928a,J Clin Oncol,0.738632
uuid-70c07acf4b3446f9a770768574fa928a,Topalian,0.412144
uuid-70c07acf4b3446f9a770768574fa928a,Rizvi NA,0.375979
uuid-70c07acf4b3446f9a770768574fa928a,Weber JS,0.324917
uuid-70c07acf4b3446f9a770768574fa928a,phase 2 study,0.660323
uuid-c6be4e8145a24281a48f4187c9124cfd,evaluating,0.331463
uuid-c6be4e8145a24281a48f4187c9124cfd,not conducted any controlled clinical trials/studies,0.327968
uuid-c6be4e8145a24281a48f4187c9124cfd,protocol,0.532972
uuid-c6be4e8145a24281a48f4187c9124cfd,RCC,0.386451
uuid-c6be4e8145a24281a48f4187c9124cfd,McDermott DF,0.444329
uuid-c6be4e8145a24281a48f4187c9124cfd,search of published literature,0.50452
uuid-c6be4e8145a24281a48f4187c9124cfd,Additionally,0.555299
uuid-c6be4e8145a24281a48f4187c9124cfd,ongoing,0.478674
uuid-c6be4e8145a24281a48f4187c9124cfd,Motzer RJ,0.475488
uuid-c6be4e8145a24281a48f4187c9124cfd,PubMed and EMBASE,0.501909
uuid-c6be4e8145a24281a48f4187c9124cfd,Escudier B,0.459186
uuid-c6be4e8145a24281a48f4187c9124cfd,et al.,0.397016
uuid-c6be4e8145a24281a48f4187c9124cfd,J Clin Oncol,0.428996
uuid-c6be4e8145a24281a48f4187c9124cfd,detailed search of www.clinicaltrials.gov,0.514934
uuid-c6be4e8145a24281a48f4187c9124cfd,efficacy and safety of nivolumab,0.47512
uuid-c6be4e8145a24281a48f4187c9124cfd,not identify any planned,0.493147
uuid-c6be4e8145a24281a48f4187c9124cfd,phase 2 study,0.384586
uuid-c6be4e8145a24281a48f4187c9124cfd,not identify any citations relevant to your request,0.565812
uuid-c6be4e8145a24281a48f4187c9124cfd,present using the following search terms,0.490802
uuid-6061a8fe803543d7bde45e868212ccde,N Engl J Med,0.918937
uuid-6061a8fe803543d7bde45e868212ccde,Lancet Oncol,0.359136
uuid-6061a8fe803543d7bde45e868212ccde,protocol,0.702537
uuid-6061a8fe803543d7bde45e868212ccde,McDermott DF,0.732818
uuid-6061a8fe803543d7bde45e868212ccde,Motzer RJ,0.716918
uuid-6061a8fe803543d7bde45e868212ccde,phase 3 study,0.547427
uuid-6061a8fe803543d7bde45e868212ccde,Escudier B,0.739293
uuid-6061a8fe803543d7bde45e868212ccde,NEJM,0.426168
uuid-6061a8fe803543d7bde45e868212ccde,et al.,0.711446
uuid-6061a8fe803543d7bde45e868212ccde,J Clin Oncol,0.646774
uuid-6061a8fe803543d7bde45e868212ccde,Topalian,0.404623
uuid-6061a8fe803543d7bde45e868212ccde,Rizvi NA,0.634491
uuid-6061a8fe803543d7bde45e868212ccde,Brahmer J,0.710067
uuid-6061a8fe803543d7bde45e868212ccde,Weber JS,0.361313
uuid-6061a8fe803543d7bde45e868212ccde,phase 2 study,0.761269
uuid-6061a8fe803543d7bde45e868212ccde,Horn L,0.343787
uuid-19b6c56761044d50b215854a6334f0fb,nivolumab,0.999168
uuid-19b6c56761044d50b215854a6334f0fb,Pubmed literature search,0.395314
uuid-19b6c56761044d50b215854a6334f0fb,purposes other than its labeled indication must be considered investigational,0.464236
uuid-19b6c56761044d50b215854a6334f0fb,not identify any citations relevant to your inquiry,0.368569
uuid-19b6c56761044d50b215854a6334f0fb,using the following search terms,0.364279
uuid-19b6c56761044d50b215854a6334f0fb,present using the following search terms,0.329876
uuid-e3bea3fb56434612bd5628add696219a,open-label,0.39841
uuid-e3bea3fb56434612bd5628add696219a,trial,0.441894
uuid-e3bea3fb56434612bd5628add696219a,phase,0.507232
uuid-752f32997c0a4db2bc6563a7fcb4d38a,NSCLC,0.483901
uuid-752f32997c0a4db2bc6563a7fcb4d38a,non-small cell lung cancer,0.439647
uuid-752f32997c0a4db2bc6563a7fcb4d38a,Brahmer J,0.31981
uuid-752f32997c0a4db2bc6563a7fcb4d38a,platinum-based doublet chemotherapy,0.390425
uuid-510d47233be2431193bfdd2b760e058b,NSCLC,0.362732
uuid-510d47233be2431193bfdd2b760e058b,non-small cell lung cancer,0.373882
uuid-510d47233be2431193bfdd2b760e058b,open-label,0.530765
uuid-510d47233be2431193bfdd2b760e058b,trial,0.359621
uuid-510d47233be2431193bfdd2b760e058b,phase,0.525089
uuid-72a47386c1eb462780d8eeba3d7fc117,N Engl J Med,0.302601
uuid-72a47386c1eb462780d8eeba3d7fc117,AEs,0.348167
uuid-72a47386c1eb462780d8eeba3d7fc117,patients,0.536884
uuid-72a47386c1eb462780d8eeba3d7fc117,provided in the Detailed Information,0.387544
uuid-72a47386c1eb462780d8eeba3d7fc117,ESMO,0.462801
uuid-72a47386c1eb462780d8eeba3d7fc117,NEJM,0.66427
uuid-72a47386c1eb462780d8eeba3d7fc117,Topalian,0.692873
uuid-72a47386c1eb462780d8eeba3d7fc117,grade 3 to 4 AEs,0.626596
uuid-f5e3c65a28d3416690ed9524d81639df,Objective response rate,0.451139
uuid-f5e3c65a28d3416690ed9524d81639df,clinicaltrials.gov,0.503706
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,N Engl J Med,0.448483
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,protocol,0.770446
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,McDermott DF,0.741196
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,Motzer RJ,0.818144
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,phase 3 study,0.417055
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,Escudier B,0.749917
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,NEJM,0.400698
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,et al.,0.668641
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,J Clin Oncol,0.792018
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,Topalian,0.388894
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,phase 1 study,0.500686
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,CA209-003,0.567381
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,phase 2 study,0.677985
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,present using the following search terms,0.310558
uuid-92ac98fae79a4c90ae4f28f8a00ba79f,investigating,0.615835
uuid-a0e0af43c4df4d2aa32c0d66ff98f73e,requested,0.44769
uuid-a0e0af43c4df4d2aa32c0d66ff98f73e,trial,0.309472
uuid-967e05e9d6a149da992c20098bc91ac4,use of nivolumab for the treatment,0.336887
uuid-967e05e9d6a149da992c20098bc91ac4,patients,0.318093
uuid-967e05e9d6a149da992c20098bc91ac4,patients with advanced or metastatic,0.397137
uuid-967e05e9d6a149da992c20098bc91ac4,nivolumab combined with ipilimumab,0.415918
uuid-967e05e9d6a149da992c20098bc91ac4,not approved,0.36374
uuid-967e05e9d6a149da992c20098bc91ac4,clinical trials investigating the safety,0.418488
uuid-967e05e9d6a149da992c20098bc91ac4,bladder cancer,0.391173
uuid-ff8c2e37599140ea8d4780a627747a7e,N Engl J Med,0.304989
uuid-ff8c2e37599140ea8d4780a627747a7e,AEs,0.337832
uuid-ff8c2e37599140ea8d4780a627747a7e,patients,0.387033
uuid-ff8c2e37599140ea8d4780a627747a7e,provided in the Detailed Information,0.370845
uuid-ff8c2e37599140ea8d4780a627747a7e,ESMO,0.421367
uuid-ff8c2e37599140ea8d4780a627747a7e,NEJM,0.709799
uuid-ff8c2e37599140ea8d4780a627747a7e,Topalian,0.735417
uuid-ff8c2e37599140ea8d4780a627747a7e,grade 3 to 4 AEs,0.538198
uuid-d61733e775544545837b7605b483dcdf,fatigue,0.704358
uuid-dc12e78c748c4d71a63ac33c797e8756,requested,0.389528
uuid-dc12e78c748c4d71a63ac33c797e8756,clinicaltrials.gov,0.382584
uuid-4f5681eb8902402c85a04009f133875b,Bristol-Myers Squibb,0.341822
uuid-4f5681eb8902402c85a04009f133875b,not conducted any controlled clinical trials/studies,0.304507
uuid-4f5681eb8902402c85a04009f133875b,Opdivo,0.461382
uuid-4f5681eb8902402c85a04009f133875b,Pubmed literature search,0.614325
uuid-4f5681eb8902402c85a04009f133875b,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4f5681eb8902402c85a04009f133875b,not identify any citations relevant to your inquiry,0.606087
uuid-4f5681eb8902402c85a04009f133875b,adverse,0.304183
uuid-4f5681eb8902402c85a04009f133875b,using the following search terms,0.642331
uuid-4f5681eb8902402c85a04009f133875b,databases,0.315039
uuid-4f5681eb8902402c85a04009f133875b,reported,0.556704
uuid-997aea168a10403fbd04b1d4fc2c3cc3,N Engl J Med,0.302601
uuid-997aea168a10403fbd04b1d4fc2c3cc3,AEs,0.348167
uuid-997aea168a10403fbd04b1d4fc2c3cc3,patients,0.536884
uuid-997aea168a10403fbd04b1d4fc2c3cc3,provided in the Detailed Information,0.387544
uuid-997aea168a10403fbd04b1d4fc2c3cc3,ESMO,0.462801
uuid-997aea168a10403fbd04b1d4fc2c3cc3,NEJM,0.66427
uuid-997aea168a10403fbd04b1d4fc2c3cc3,Topalian,0.692873
uuid-997aea168a10403fbd04b1d4fc2c3cc3,grade 3 to 4 AEs,0.626596
uuid-25fc60c999a441e3a9f7769c062052ca,N Engl J Med,0.448483
uuid-25fc60c999a441e3a9f7769c062052ca,protocol,0.770446
uuid-25fc60c999a441e3a9f7769c062052ca,McDermott DF,0.741196
uuid-25fc60c999a441e3a9f7769c062052ca,Motzer RJ,0.818144
uuid-25fc60c999a441e3a9f7769c062052ca,phase 3 study,0.417055
uuid-25fc60c999a441e3a9f7769c062052ca,Escudier B,0.749917
uuid-25fc60c999a441e3a9f7769c062052ca,NEJM,0.400698
uuid-25fc60c999a441e3a9f7769c062052ca,et al.,0.668641
uuid-25fc60c999a441e3a9f7769c062052ca,J Clin Oncol,0.792018
uuid-25fc60c999a441e3a9f7769c062052ca,Topalian,0.388894
uuid-25fc60c999a441e3a9f7769c062052ca,phase 1 study,0.500686
uuid-25fc60c999a441e3a9f7769c062052ca,CA209-003,0.567381
uuid-25fc60c999a441e3a9f7769c062052ca,phase 2 study,0.677985
uuid-25fc60c999a441e3a9f7769c062052ca,present using the following search terms,0.310558
uuid-25fc60c999a441e3a9f7769c062052ca,investigating,0.615835
uuid-aa8d6f1cd4294b41828d691a2606a941,AEs,0.318033
uuid-aa8d6f1cd4294b41828d691a2606a941,patients,0.329115
uuid-aa8d6f1cd4294b41828d691a2606a941,adverse,0.325637
uuid-aa8d6f1cd4294b41828d691a2606a941,grade,0.474994
uuid-aa8d6f1cd4294b41828d691a2606a941,phase,0.331735
uuid-aa8d6f1cd4294b41828d691a2606a941,grade 3 to 4 AEs,0.396532
uuid-aa8d6f1cd4294b41828d691a2606a941,reported,0.343158
uuid-a4c25e2eb8ee4512bebf0fb644331c19,OS,0.387982
uuid-a4c25e2eb8ee4512bebf0fb644331c19,95% CI,0.745043
uuid-a4c25e2eb8ee4512bebf0fb644331c19,respectively,0.729294
uuid-a4c25e2eb8ee4512bebf0fb644331c19,Objective response rate,0.590876
uuid-a4c25e2eb8ee4512bebf0fb644331c19,ORR,0.722442
uuid-a4c25e2eb8ee4512bebf0fb644331c19,Median overall survival,0.659043
uuid-a4c25e2eb8ee4512bebf0fb644331c19,monotherapy,0.514468
uuid-a4c25e2eb8ee4512bebf0fb644331c19,Median OS,0.696688
uuid-a4c25e2eb8ee4512bebf0fb644331c19,PD-L1,0.300997
uuid-a4c25e2eb8ee4512bebf0fb644331c19,docetaxel,0.635065
uuid-a4c25e2eb8ee4512bebf0fb644331c19,hazard ratio,0.729977
uuid-2158244e9f2048e8a5522105846b6b41,fatigue,0.318151
uuid-ddd3eb6a9c484c6d87b3511a53d062d1,fatigue,0.411608
uuid-8a184034b95f41edb301285b31ef4c9b,nivolumab,0.343268
uuid-8a184034b95f41edb301285b31ef4c9b,evaluating,0.382597
uuid-8a184034b95f41edb301285b31ef4c9b,not conducted any controlled clinical trials/studies,0.398191
uuid-8a184034b95f41edb301285b31ef4c9b,purposes other than its labeled indication must be considered investigational,0.331112
uuid-8a184034b95f41edb301285b31ef4c9b,protocol,0.344583
uuid-8a184034b95f41edb301285b31ef4c9b,McDermott DF,0.356146
uuid-8a184034b95f41edb301285b31ef4c9b,search of published literature,0.414782
uuid-8a184034b95f41edb301285b31ef4c9b,Motzer RJ,0.363713
uuid-8a184034b95f41edb301285b31ef4c9b,phase 3 study,0.635987
uuid-8a184034b95f41edb301285b31ef4c9b,PubMed and EMBASE,0.396143
uuid-8a184034b95f41edb301285b31ef4c9b,Escudier B,0.37493
uuid-8a184034b95f41edb301285b31ef4c9b,et al.,0.332991
uuid-8a184034b95f41edb301285b31ef4c9b,Rizvi NA,0.349397
uuid-8a184034b95f41edb301285b31ef4c9b,efficacy and safety of nivolumab,0.463476
uuid-8a184034b95f41edb301285b31ef4c9b,Weber JS,0.465702
uuid-8a184034b95f41edb301285b31ef4c9b,phase 2 study,0.455614
uuid-8a184034b95f41edb301285b31ef4c9b,present using the following search terms,0.367425
uuid-0d30cbd39c60449283145451d7d2ee80,OS,0.387982
uuid-0d30cbd39c60449283145451d7d2ee80,95% CI,0.745043
uuid-0d30cbd39c60449283145451d7d2ee80,respectively,0.729294
uuid-0d30cbd39c60449283145451d7d2ee80,Objective response rate,0.590876
uuid-0d30cbd39c60449283145451d7d2ee80,ORR,0.722442
uuid-0d30cbd39c60449283145451d7d2ee80,Median overall survival,0.659043
uuid-0d30cbd39c60449283145451d7d2ee80,monotherapy,0.514468
uuid-0d30cbd39c60449283145451d7d2ee80,Median OS,0.696688
uuid-0d30cbd39c60449283145451d7d2ee80,PD-L1,0.300997
uuid-0d30cbd39c60449283145451d7d2ee80,docetaxel,0.635065
uuid-0d30cbd39c60449283145451d7d2ee80,hazard ratio,0.729977
uuid-533b818cff1542b88b10b031ca70a89b,Bristol-Myers Squibb,0.371627
uuid-533b818cff1542b88b10b031ca70a89b,adverse,0.3117
uuid-533b818cff1542b88b10b031ca70a89b,phase 3 study,0.358741
uuid-533b818cff1542b88b10b031ca70a89b,phase 1 study,0.378891
uuid-533b818cff1542b88b10b031ca70a89b,CA209-003,0.42214
uuid-533b818cff1542b88b10b031ca70a89b,grade,0.336817
uuid-533b818cff1542b88b10b031ca70a89b,investigating,0.345396
uuid-03e7ce2dd9844601824e7d4e7ff0d711,mg,0.300211
uuid-90fcd50c389243639b657ab160def53c,evaluating,0.434159
uuid-90fcd50c389243639b657ab160def53c,not conducted any controlled clinical trials/studies,0.429128
uuid-90fcd50c389243639b657ab160def53c,search of published literature,0.527837
uuid-90fcd50c389243639b657ab160def53c,PubMed and EMBASE,0.514324
uuid-90fcd50c389243639b657ab160def53c,Rizvi NA,0.339686
uuid-90fcd50c389243639b657ab160def53c,efficacy and safety of nivolumab,0.561063
uuid-90fcd50c389243639b657ab160def53c,Weber JS,0.301304
uuid-90fcd50c389243639b657ab160def53c,not identify any citations relevant to your request,0.360911
uuid-90fcd50c389243639b657ab160def53c,present using the following search terms,0.52381
uuid-b9521edf28804e8689d4bb73585ff09b,provided in the Detailed Information,0.349112
uuid-b9521edf28804e8689d4bb73585ff09b,Weber JS,0.321343
uuid-93c1667e54a443368219a713cde31702,OS,0.62262
uuid-93c1667e54a443368219a713cde31702,PFS,0.65903
uuid-93c1667e54a443368219a713cde31702,Overall survival,0.644151
uuid-48856968c6644897a0181873a7c34707,nivolumab,0.595619
uuid-48856968c6644897a0181873a7c34707,Bristol-Myers Squibb,0.477957
uuid-48856968c6644897a0181873a7c34707,evaluating,0.590452
uuid-48856968c6644897a0181873a7c34707,not conducted any controlled clinical trials/studies,0.627513
uuid-48856968c6644897a0181873a7c34707,non-small cell lung cancer,0.304264
uuid-48856968c6644897a0181873a7c34707,Pubmed literature search,0.717519
uuid-48856968c6644897a0181873a7c34707,purposes other than its labeled indication must be considered investigational,0.784539
uuid-48856968c6644897a0181873a7c34707,not identify any citations relevant to your inquiry,0.686714
uuid-48856968c6644897a0181873a7c34707,using the following search terms,0.67576
uuid-48856968c6644897a0181873a7c34707,efficacy and safety of nivolumab,0.451934
uuid-bfd7f9e1ef9049789eed115f11283b05,nivolumab,0.616989
uuid-bfd7f9e1ef9049789eed115f11283b05,Bristol-Myers Squibb,0.453377
uuid-bfd7f9e1ef9049789eed115f11283b05,evaluating,0.636769
uuid-bfd7f9e1ef9049789eed115f11283b05,not conducted any controlled clinical trials/studies,0.682611
uuid-bfd7f9e1ef9049789eed115f11283b05,Pubmed literature search,0.843325
uuid-bfd7f9e1ef9049789eed115f11283b05,purposes other than its labeled indication must be considered investigational,0.915946
uuid-bfd7f9e1ef9049789eed115f11283b05,not identify any citations relevant to your inquiry,0.799673
uuid-bfd7f9e1ef9049789eed115f11283b05,using the following search terms,0.786568
uuid-bfd7f9e1ef9049789eed115f11283b05,efficacy and safety of nivolumab,0.480412
uuid-75d96eee303f47b4826ee45efd17bab6,AEs,0.417679
uuid-75d96eee303f47b4826ee45efd17bab6,95% CI,0.500725
uuid-75d96eee303f47b4826ee45efd17bab6,respectively,0.561059
uuid-75d96eee303f47b4826ee45efd17bab6,Objective response rate,0.451898
uuid-75d96eee303f47b4826ee45efd17bab6,ORR,0.563006
uuid-75d96eee303f47b4826ee45efd17bab6,Median overall survival,0.479998
uuid-75d96eee303f47b4826ee45efd17bab6,Median OS,0.465392
uuid-75d96eee303f47b4826ee45efd17bab6,grade,0.518585
uuid-75d96eee303f47b4826ee45efd17bab6,hazard ratio,0.458409
uuid-75d96eee303f47b4826ee45efd17bab6,grade 3 to 4 AEs,0.335546
uuid-d9bea3cf7ace4ec49d40a278088c5b31,Opdivo,0.465909
uuid-d9bea3cf7ace4ec49d40a278088c5b31,cohort,0.340655
uuid-99e4c45302924d9682e202c84fbd2dae,NSCLC,0.346111
uuid-99e4c45302924d9682e202c84fbd2dae,ASCO,0.377656
uuid-99e4c45302924d9682e202c84fbd2dae,non-small cell lung cancer,0.333579
uuid-99e4c45302924d9682e202c84fbd2dae,Brahmer J,0.426959
uuid-323771f8bfb940579688697f41376ea1,provided in the Detailed Information,0.484728
uuid-323771f8bfb940579688697f41376ea1,clinical,0.684488
uuid-d88563f97d7c4df7bd712bf08b708d46,N Engl J Med,0.336409
uuid-d88563f97d7c4df7bd712bf08b708d46,provided in the Detailed Information,0.371381
uuid-d88563f97d7c4df7bd712bf08b708d46,clinical,0.404261
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,nivolumab,0.510392
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,Bristol-Myers Squibb,0.464176
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,evaluating,0.683286
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,not conducted any controlled clinical trials/studies,0.682483
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,RCC,0.308694
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,search of published literature,0.839602
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,Additionally,0.446384
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,PubMed and EMBASE,0.823429
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,detailed search of www.clinicaltrials.gov,0.366719
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,efficacy and safety of nivolumab,0.841
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,not identify any citations relevant to your request,0.605656
uuid-ed0d2feb28b24f3eb78c9ae9c1cbfb7f,present using the following search terms,0.832619
uuid-6c23db60f62c4ee3bc6e19c7fea599af,Bristol-Myers Squibb,0.307009
uuid-6c23db60f62c4ee3bc6e19c7fea599af,requested,0.323839
uuid-9f4efa6ca54347b7a5d0887cb7164664,search of published literature,0.394524
uuid-9f4efa6ca54347b7a5d0887cb7164664,Additionally,0.413583
uuid-9f4efa6ca54347b7a5d0887cb7164664,ongoing,0.322117
uuid-9f4efa6ca54347b7a5d0887cb7164664,PubMed and EMBASE,0.391671
uuid-9f4efa6ca54347b7a5d0887cb7164664,detailed search of www.clinicaltrials.gov,0.375936
uuid-9f4efa6ca54347b7a5d0887cb7164664,efficacy and safety of nivolumab,0.370699
uuid-9f4efa6ca54347b7a5d0887cb7164664,not identify any planned,0.34283
uuid-9f4efa6ca54347b7a5d0887cb7164664,Weber JS,0.319229
uuid-9f4efa6ca54347b7a5d0887cb7164664,not identify any citations relevant to your request,0.447813
uuid-9f4efa6ca54347b7a5d0887cb7164664,present using the following search terms,0.408199
uuid-aab580d47b694a0cb0a23bdb56fc5850,ongoing,0.323996
uuid-aab580d47b694a0cb0a23bdb56fc5850,efficacy and safety of nivolumab,0.329856
uuid-aab580d47b694a0cb0a23bdb56fc5850,not identify any planned,0.303776
uuid-aab580d47b694a0cb0a23bdb56fc5850,combination,0.313026
uuid-5936d61d65644b5ea2316d468e482694,Bristol-Myers Squibb,0.36472
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,N Engl J Med,0.448483
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,protocol,0.770446
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,McDermott DF,0.741196
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,Motzer RJ,0.818144
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,phase 3 study,0.417055
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,Escudier B,0.749917
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,NEJM,0.400698
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,et al.,0.668641
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,J Clin Oncol,0.792018
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,Topalian,0.388894
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,phase 1 study,0.500686
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,CA209-003,0.567381
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,phase 2 study,0.677985
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,present using the following search terms,0.310558
uuid-a61ef21ccb574dc2a04907a0c2a15bb9,investigating,0.615835
uuid-5891495de1ef4d17a5c80516f32fdf96,OS,0.52847
uuid-5891495de1ef4d17a5c80516f32fdf96,PFS,0.551796
uuid-5891495de1ef4d17a5c80516f32fdf96,Overall survival,0.54781
uuid-69a7488229604acbb0dcff7b2d789cab,AEs,0.406265
uuid-69a7488229604acbb0dcff7b2d789cab,95% CI,0.4154
uuid-69a7488229604acbb0dcff7b2d789cab,respectively,0.41253
uuid-69a7488229604acbb0dcff7b2d789cab,ORR,0.383446
uuid-69a7488229604acbb0dcff7b2d789cab,Median overall survival,0.423269
uuid-69a7488229604acbb0dcff7b2d789cab,Median OS,0.4056
uuid-69a7488229604acbb0dcff7b2d789cab,grade,0.571873
uuid-69a7488229604acbb0dcff7b2d789cab,hazard ratio,0.379498
uuid-69a7488229604acbb0dcff7b2d789cab,grade 3 to 4 AEs,0.336553
uuid-aa732ce0df5a49dcb39f82043db32048,nivolumab,0.510392
uuid-aa732ce0df5a49dcb39f82043db32048,Bristol-Myers Squibb,0.464176
uuid-aa732ce0df5a49dcb39f82043db32048,evaluating,0.683286
uuid-aa732ce0df5a49dcb39f82043db32048,not conducted any controlled clinical trials/studies,0.682483
uuid-aa732ce0df5a49dcb39f82043db32048,RCC,0.308694
uuid-aa732ce0df5a49dcb39f82043db32048,search of published literature,0.839602
uuid-aa732ce0df5a49dcb39f82043db32048,Additionally,0.446384
uuid-aa732ce0df5a49dcb39f82043db32048,PubMed and EMBASE,0.823429
uuid-aa732ce0df5a49dcb39f82043db32048,detailed search of www.clinicaltrials.gov,0.366719
uuid-aa732ce0df5a49dcb39f82043db32048,efficacy and safety of nivolumab,0.841
uuid-aa732ce0df5a49dcb39f82043db32048,not identify any citations relevant to your request,0.605656
uuid-aa732ce0df5a49dcb39f82043db32048,present using the following search terms,0.832619
uuid-ebf045ee78374218a81a4650968d61d8,nivolumab,0.435164
uuid-ebf045ee78374218a81a4650968d61d8,clinical,0.353961
uuid-ebf045ee78374218a81a4650968d61d8,clinical trials investigating the safety,0.385629
uuid-23bb26b40752418ba1d4bd6542c76b5e,nivolumab,0.359772
uuid-c37c8c9dd6e74c10ad79fa7d47c46c7f,patients with advanced or metastatic,0.468858
uuid-c37c8c9dd6e74c10ad79fa7d47c46c7f,nivolumab combined with ipilimumab,0.446918
uuid-c37c8c9dd6e74c10ad79fa7d47c46c7f,not approved,0.352562
uuid-c37c8c9dd6e74c10ad79fa7d47c46c7f,clinical trials investigating the safety,0.429501
uuid-c37c8c9dd6e74c10ad79fa7d47c46c7f,bladder cancer,0.950698
uuid-7592dc3a44e94148b57fa7bd00b4b1f3,requested,0.594234
uuid-32271c155afb4f25b9bc4f980b47152e,mg,0.300211
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,respectively,0.399488
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,monotherapy,0.425356
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,mg,0.306077
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,grade,0.314178
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,Antonia SJ,0.333679
uuid-7f77f9e9d9324a02a3db3ebed70c7bea,reported,0.385916
uuid-bdc155c99fc54df4b54ba9771c9e96f8,N Engl J Med,0.892438
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Lancet Oncol,0.369114
uuid-bdc155c99fc54df4b54ba9771c9e96f8,provided in the Detailed Information,0.302862
uuid-bdc155c99fc54df4b54ba9771c9e96f8,protocol,0.755063
uuid-bdc155c99fc54df4b54ba9771c9e96f8,McDermott DF,0.82995
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Motzer RJ,0.803103
uuid-bdc155c99fc54df4b54ba9771c9e96f8,ESMO,0.341635
uuid-bdc155c99fc54df4b54ba9771c9e96f8,phase 3 study,0.507488
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Escudier B,0.832421
uuid-bdc155c99fc54df4b54ba9771c9e96f8,NEJM,0.452995
uuid-bdc155c99fc54df4b54ba9771c9e96f8,et al.,0.8085
uuid-bdc155c99fc54df4b54ba9771c9e96f8,J Clin Oncol,0.737251
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Topalian,0.42081
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Rizvi NA,0.588152
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Brahmer J,0.577339
uuid-bdc155c99fc54df4b54ba9771c9e96f8,Weber JS,0.403598
uuid-bdc155c99fc54df4b54ba9771c9e96f8,phase 2 study,0.770524
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,Bristol-Myers Squibb,0.341822
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,not conducted any controlled clinical trials/studies,0.304507
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,Opdivo,0.461382
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,Pubmed literature search,0.614325
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,purposes other than its labeled indication must be considered investigational,0.586645
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,not identify any citations relevant to your inquiry,0.606087
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,adverse,0.304183
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,using the following search terms,0.642331
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,databases,0.315039
uuid-99d4167df52d40b2ad83fb84ccf1e9f3,reported,0.556704
uuid-46593370744043c1a06a67a0d902417a,N Engl J Med,0.44479
uuid-46593370744043c1a06a67a0d902417a,protocol,0.582401
uuid-46593370744043c1a06a67a0d902417a,McDermott DF,0.553715
uuid-46593370744043c1a06a67a0d902417a,Motzer RJ,0.63436
uuid-46593370744043c1a06a67a0d902417a,Escudier B,0.565624
uuid-46593370744043c1a06a67a0d902417a,NEJM,0.361548
uuid-46593370744043c1a06a67a0d902417a,et al.,0.470542
uuid-46593370744043c1a06a67a0d902417a,J Clin Oncol,0.602367
uuid-46593370744043c1a06a67a0d902417a,Topalian,0.333531
uuid-46593370744043c1a06a67a0d902417a,phase 1 study,0.321617
uuid-46593370744043c1a06a67a0d902417a,CA209-003,0.392428
uuid-46593370744043c1a06a67a0d902417a,phase 2 study,0.451126
uuid-46593370744043c1a06a67a0d902417a,investigating,0.478417
uuid-84491a5dadb9453ab69750abc5d664d5,ASCO,0.3849
uuid-84491a5dadb9453ab69750abc5d664d5,requested,0.529205
uuid-84491a5dadb9453ab69750abc5d664d5,Overall survival,0.343924
uuid-fffc2b33d71e4cf2bab4a67d467474f7,requested,0.543494
uuid-fffc2b33d71e4cf2bab4a67d467474f7,BMS,0.371478
uuid-c059277e262c4d38bae820c1ca41bf18,nivolumab,0.353502
uuid-c059277e262c4d38bae820c1ca41bf18,evaluating,0.329044
uuid-c059277e262c4d38bae820c1ca41bf18,RCC,0.365155
uuid-c059277e262c4d38bae820c1ca41bf18,search of published literature,0.679412
uuid-c059277e262c4d38bae820c1ca41bf18,Additionally,0.858609
uuid-c059277e262c4d38bae820c1ca41bf18,ongoing,0.763562
uuid-c059277e262c4d38bae820c1ca41bf18,PubMed and EMBASE,0.691194
uuid-c059277e262c4d38bae820c1ca41bf18,detailed search of www.clinicaltrials.gov,0.840282
uuid-c059277e262c4d38bae820c1ca41bf18,efficacy and safety of nivolumab,0.494869
uuid-c059277e262c4d38bae820c1ca41bf18,not identify any planned,0.791027
uuid-c059277e262c4d38bae820c1ca41bf18,not identify any citations relevant to your request,0.923258
uuid-c059277e262c4d38bae820c1ca41bf18,present using the following search terms,0.727915
uuid-75d2ef6f62084881985ca29766782e11,requested,0.594234
uuid-809f2e94bdfe42498d2414243335ffaf,evaluating,0.30533
uuid-809f2e94bdfe42498d2414243335ffaf,search of published literature,0.345572
uuid-809f2e94bdfe42498d2414243335ffaf,Additionally,0.399622
uuid-809f2e94bdfe42498d2414243335ffaf,ongoing,0.337756
uuid-809f2e94bdfe42498d2414243335ffaf,PubMed and EMBASE,0.337744
uuid-809f2e94bdfe42498d2414243335ffaf,detailed search of www.clinicaltrials.gov,0.379
uuid-809f2e94bdfe42498d2414243335ffaf,efficacy and safety of nivolumab,0.392576
uuid-809f2e94bdfe42498d2414243335ffaf,not identify any planned,0.35123
uuid-809f2e94bdfe42498d2414243335ffaf,not identify any citations relevant to your request,0.424652
uuid-809f2e94bdfe42498d2414243335ffaf,present using the following search terms,0.356725
uuid-765dab349ce248de8fe04a43be07fc44,evaluating,0.366546
uuid-765dab349ce248de8fe04a43be07fc44,not conducted any controlled clinical trials/studies,0.360172
uuid-765dab349ce248de8fe04a43be07fc44,search of published literature,0.403755
uuid-765dab349ce248de8fe04a43be07fc44,Additionally,0.418906
uuid-765dab349ce248de8fe04a43be07fc44,ongoing,0.467576
uuid-765dab349ce248de8fe04a43be07fc44,PubMed and EMBASE,0.39617
uuid-765dab349ce248de8fe04a43be07fc44,detailed search of www.clinicaltrials.gov,0.437393
uuid-765dab349ce248de8fe04a43be07fc44,efficacy and safety of nivolumab,0.42836
uuid-765dab349ce248de8fe04a43be07fc44,not identify any planned,0.454065
uuid-765dab349ce248de8fe04a43be07fc44,combination,0.397925
uuid-765dab349ce248de8fe04a43be07fc44,BMS,0.30879
uuid-765dab349ce248de8fe04a43be07fc44,not identify any citations relevant to your request,0.449603
uuid-765dab349ce248de8fe04a43be07fc44,present using the following search terms,0.394376
uuid-f52a7722006b46db9815f644818131a1,OS,0.62262
uuid-f52a7722006b46db9815f644818131a1,PFS,0.65903
uuid-f52a7722006b46db9815f644818131a1,Overall survival,0.644151
uuid-361ada5ccd5f461597527e169f09cec5,nivolumab,0.524934
uuid-361ada5ccd5f461597527e169f09cec5,Bristol-Myers Squibb,0.397018
uuid-361ada5ccd5f461597527e169f09cec5,evaluating,0.577993
uuid-361ada5ccd5f461597527e169f09cec5,not conducted any controlled clinical trials/studies,0.598442
uuid-361ada5ccd5f461597527e169f09cec5,Pubmed literature search,0.748573
uuid-361ada5ccd5f461597527e169f09cec5,purposes other than its labeled indication must be considered investigational,0.815396
uuid-361ada5ccd5f461597527e169f09cec5,not identify any citations relevant to your inquiry,0.714029
uuid-361ada5ccd5f461597527e169f09cec5,using the following search terms,0.696827
uuid-361ada5ccd5f461597527e169f09cec5,efficacy and safety of nivolumab,0.424034
uuid-46f301dab3a54cdb869290e0d66bf3e2,respectively,0.661351
uuid-46f301dab3a54cdb869290e0d66bf3e2,Objective response rate,0.619462
uuid-46f301dab3a54cdb869290e0d66bf3e2,ORR,0.537232
uuid-46f301dab3a54cdb869290e0d66bf3e2,monotherapy,0.421967
uuid-46f301dab3a54cdb869290e0d66bf3e2,docetaxel,0.426453
uuid-5c6bdc410a66413290d48e1cdd2e3711,nivolumab,0.5688
uuid-5c6bdc410a66413290d48e1cdd2e3711,Bristol-Myers Squibb,0.466268
uuid-5c6bdc410a66413290d48e1cdd2e3711,evaluating,0.654825
uuid-5c6bdc410a66413290d48e1cdd2e3711,not conducted any controlled clinical trials/studies,0.697765
uuid-5c6bdc410a66413290d48e1cdd2e3711,Pubmed literature search,0.837292
uuid-5c6bdc410a66413290d48e1cdd2e3711,purposes other than its labeled indication must be considered investigational,0.91077
uuid-5c6bdc410a66413290d48e1cdd2e3711,not identify any citations relevant to your inquiry,0.79255
uuid-5c6bdc410a66413290d48e1cdd2e3711,using the following search terms,0.779496
uuid-5c6bdc410a66413290d48e1cdd2e3711,efficacy and safety of nivolumab,0.4896
uuid-55b843d366324f43be06ef2f74b3a1f4,use of nivolumab for the treatment,0.440423
uuid-55b843d366324f43be06ef2f74b3a1f4,search of published literature,0.311531
uuid-55b843d366324f43be06ef2f74b3a1f4,PubMed and EMBASE,0.312811
uuid-55b843d366324f43be06ef2f74b3a1f4,not approved,0.404782
uuid-55b843d366324f43be06ef2f74b3a1f4,open-label,0.578291
uuid-55b843d366324f43be06ef2f74b3a1f4,clinical trials investigating the safety,0.440014
uuid-55b843d366324f43be06ef2f74b3a1f4,present using the following search terms,0.328669
uuid-55b843d366324f43be06ef2f74b3a1f4,phase,0.41185
uuid-4b82742b3910426e89badf2db72f0231,Bristol-Myers Squibb,0.398191
uuid-4b82742b3910426e89badf2db72f0231,requested,0.827269
uuid-8930b055cee24d1e8a836b43d7ad51e8,requested,0.805973
uuid-d339a258b4584b36aa909a8a42ac03db,requested,0.540431
uuid-6feccfc37b464607b88df501f3f9a346,requested,0.594234
uuid-fcb5a5a6e08a4199819677f6bff2e3a1,monotherapy,0.444089
uuid-fcb5a5a6e08a4199819677f6bff2e3a1,mg,0.853025
uuid-fcb5a5a6e08a4199819677f6bff2e3a1,kg,0.853742
uuid-fcb5a5a6e08a4199819677f6bff2e3a1,phase,0.318256
uuid-fcb5a5a6e08a4199819677f6bff2e3a1,cohort,0.461371
uuid-ef38e76ad71f45bdbda4463d46f9072d,N Engl J Med,0.5218
uuid-ef38e76ad71f45bdbda4463d46f9072d,protocol,0.822129
uuid-ef38e76ad71f45bdbda4463d46f9072d,RCC,0.351265
uuid-ef38e76ad71f45bdbda4463d46f9072d,McDermott DF,0.805326
uuid-ef38e76ad71f45bdbda4463d46f9072d,search of published literature,0.328584
uuid-ef38e76ad71f45bdbda4463d46f9072d,Motzer RJ,0.830191
uuid-ef38e76ad71f45bdbda4463d46f9072d,phase 3 study,0.375845
uuid-ef38e76ad71f45bdbda4463d46f9072d,PubMed and EMBASE,0.327895
uuid-ef38e76ad71f45bdbda4463d46f9072d,Escudier B,0.815105
uuid-ef38e76ad71f45bdbda4463d46f9072d,NEJM,0.388967
uuid-ef38e76ad71f45bdbda4463d46f9072d,et al.,0.745528
uuid-ef38e76ad71f45bdbda4463d46f9072d,J Clin Oncol,0.787871
uuid-ef38e76ad71f45bdbda4463d46f9072d,Topalian,0.347249
uuid-ef38e76ad71f45bdbda4463d46f9072d,Rizvi NA,0.308297
uuid-ef38e76ad71f45bdbda4463d46f9072d,phase 2 study,0.670697
uuid-ef38e76ad71f45bdbda4463d46f9072d,present using the following search terms,0.304579
uuid-96fef3675ead4f2faf2a10494ac97812,Bristol-Myers Squibb,0.396485
uuid-a0ead39614db4f968b78d5a8fa22e9e9,provided in the Detailed Information,0.353516
uuid-a0ead39614db4f968b78d5a8fa22e9e9,adverse,0.308788
uuid-484fb76e5f374bb5b7efdb2f32405cea,Bristol-Myers Squibb,0.334579
uuid-484fb76e5f374bb5b7efdb2f32405cea,use of nivolumab for the treatment,0.31105
uuid-484fb76e5f374bb5b7efdb2f32405cea,evaluating,0.369591
uuid-484fb76e5f374bb5b7efdb2f32405cea,not conducted any controlled clinical trials/studies,0.352896
uuid-484fb76e5f374bb5b7efdb2f32405cea,efficacy,0.358292
uuid-484fb76e5f374bb5b7efdb2f32405cea,not approved,0.45395
uuid-484fb76e5f374bb5b7efdb2f32405cea,clinical trials investigating the safety,0.561782
uuid-484fb76e5f374bb5b7efdb2f32405cea,efficacy and safety of nivolumab,0.310897
uuid-484fb76e5f374bb5b7efdb2f32405cea,safety,0.302766
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,N Engl J Med,0.359883
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,respectively,0.637142
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,ASCO,0.362108
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,ORR,0.386698
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,Median OS,0.315141
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,Brahmer J,0.52754
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,docetaxel,0.451722
uuid-445b74c4ed2d4891bf8cd4bc53e2436c,Horn L,0.316361
uuid-5f11e5ea93cf422fb24725b059054e11,requested,0.631687
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,N Engl J Med,0.714946
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Lancet Oncol,0.448679
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,patients,0.309769
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,protocol,0.700662
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,McDermott DF,0.68799
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Motzer RJ,0.689932
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,phase 3 study,0.545628
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Escudier B,0.698812
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,NEJM,0.402095
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,et al.,0.640511
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,J Clin Oncol,0.626106
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Topalian,0.37979
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,phase 1 study,0.381282
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Rizvi NA,0.636006
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Brahmer J,0.517174
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,efficacy and safety of nivolumab,0.368444
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,Weber JS,0.406071
uuid-1aaf386f6e0a4cc7a260bd96b5b11e90,phase 2 study,0.692115
uuid-bac5059524db43789a0c0e09be3f8071,requested,0.594234
uuid-16a6a6c2635a4a8e95af17e0be005391,requested,0.594234
uuid-c8b1ab296ee04c1e830195b857e97a65,N Engl J Med,0.448483
uuid-c8b1ab296ee04c1e830195b857e97a65,protocol,0.770446
uuid-c8b1ab296ee04c1e830195b857e97a65,McDermott DF,0.741196
uuid-c8b1ab296ee04c1e830195b857e97a65,Motzer RJ,0.818144
uuid-c8b1ab296ee04c1e830195b857e97a65,phase 3 study,0.417055
uuid-c8b1ab296ee04c1e830195b857e97a65,Escudier B,0.749917
uuid-c8b1ab296ee04c1e830195b857e97a65,NEJM,0.400698
uuid-c8b1ab296ee04c1e830195b857e97a65,et al.,0.668641
uuid-c8b1ab296ee04c1e830195b857e97a65,J Clin Oncol,0.792018
uuid-c8b1ab296ee04c1e830195b857e97a65,Topalian,0.388894
uuid-c8b1ab296ee04c1e830195b857e97a65,phase 1 study,0.500686
uuid-c8b1ab296ee04c1e830195b857e97a65,CA209-003,0.567381
uuid-c8b1ab296ee04c1e830195b857e97a65,phase 2 study,0.677985
uuid-c8b1ab296ee04c1e830195b857e97a65,present using the following search terms,0.310558
uuid-c8b1ab296ee04c1e830195b857e97a65,investigating,0.615835
uuid-d406f0811c6d42f9af7368ec25804cf8,provided in the Detailed Information,0.349112
uuid-d406f0811c6d42f9af7368ec25804cf8,Weber JS,0.321343
uuid-7eb136ef434049b29ad0fde35b2259aa,patients,0.321169
uuid-7eb136ef434049b29ad0fde35b2259aa,Median duration of response,0.305682
uuid-03bccdb0103940cb9b575c1fcdd94e84,OS,0.387982
uuid-03bccdb0103940cb9b575c1fcdd94e84,95% CI,0.745043
uuid-03bccdb0103940cb9b575c1fcdd94e84,respectively,0.729294
uuid-03bccdb0103940cb9b575c1fcdd94e84,Objective response rate,0.590876
uuid-03bccdb0103940cb9b575c1fcdd94e84,ORR,0.722442
uuid-03bccdb0103940cb9b575c1fcdd94e84,Median overall survival,0.659043
uuid-03bccdb0103940cb9b575c1fcdd94e84,monotherapy,0.514468
uuid-03bccdb0103940cb9b575c1fcdd94e84,Median OS,0.696688
uuid-03bccdb0103940cb9b575c1fcdd94e84,PD-L1,0.300997
uuid-03bccdb0103940cb9b575c1fcdd94e84,docetaxel,0.635065
uuid-03bccdb0103940cb9b575c1fcdd94e84,hazard ratio,0.729977
uuid-27fc3c7bbe3747a193b3b2794a77db14,adverse,0.419275
uuid-c96f13982299450998fd48d25a4e7e32,nivolumab,0.350587
uuid-c96f13982299450998fd48d25a4e7e32,safety,0.549863
uuid-c96f13982299450998fd48d25a4e7e32,databases,0.585329
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,Bristol-Myers Squibb,0.333356
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,evaluating,0.311712
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,not conducted any controlled clinical trials/studies,0.370119
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,Pubmed literature search,0.346956
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,purposes other than its labeled indication must be considered investigational,0.389646
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,not identify any citations relevant to your inquiry,0.322754
uuid-8513a3c08d0641a9bf5d13d8a4b859e9,using the following search terms,0.311271
uuid-1502b7162814413ca3c5f4f6c95d2981,OS,0.62262
uuid-1502b7162814413ca3c5f4f6c95d2981,PFS,0.65903
uuid-1502b7162814413ca3c5f4f6c95d2981,Overall survival,0.644151
uuid-67030c09fa334f1ca8a874e17c2a9294,OS,0.529612
uuid-67030c09fa334f1ca8a874e17c2a9294,95% CI,0.876681
uuid-67030c09fa334f1ca8a874e17c2a9294,respectively,0.522647
uuid-67030c09fa334f1ca8a874e17c2a9294,Objective response rate,0.726401
uuid-67030c09fa334f1ca8a874e17c2a9294,ORR,0.81829
uuid-67030c09fa334f1ca8a874e17c2a9294,PFS,0.435864
uuid-67030c09fa334f1ca8a874e17c2a9294,Median overall survival,0.807124
uuid-67030c09fa334f1ca8a874e17c2a9294,monotherapy,0.50198
uuid-67030c09fa334f1ca8a874e17c2a9294,Median OS,0.76892
uuid-67030c09fa334f1ca8a874e17c2a9294,hazard ratio,0.843022
uuid-67030c09fa334f1ca8a874e17c2a9294,Median duration of response,0.339264
uuid-aed9093615f94a28857bd702417bb12f,OS,0.41173
uuid-aed9093615f94a28857bd702417bb12f,AEs,0.393795
uuid-aed9093615f94a28857bd702417bb12f,95% CI,0.637793
uuid-aed9093615f94a28857bd702417bb12f,respectively,0.418126
uuid-aed9093615f94a28857bd702417bb12f,Objective response rate,0.37305
uuid-aed9093615f94a28857bd702417bb12f,ORR,0.501375
uuid-aed9093615f94a28857bd702417bb12f,Median overall survival,0.630271
uuid-aed9093615f94a28857bd702417bb12f,Median OS,0.619957
uuid-aed9093615f94a28857bd702417bb12f,grade,0.450199
uuid-aed9093615f94a28857bd702417bb12f,hazard ratio,0.620293
uuid-aed9093615f94a28857bd702417bb12f,grade 3 to 4 AEs,0.307987
uuid-f73e05c0feca41c493e9c06e9edc7bb2,nivolumab,0.486697
uuid-f73e05c0feca41c493e9c06e9edc7bb2,use of nivolumab for the treatment,0.324482
uuid-f73e05c0feca41c493e9c06e9edc7bb2,evaluating,0.499451
uuid-f73e05c0feca41c493e9c06e9edc7bb2,not conducted any controlled clinical trials/studies,0.433127
uuid-f73e05c0feca41c493e9c06e9edc7bb2,search of published literature,0.902175
uuid-f73e05c0feca41c493e9c06e9edc7bb2,Additionally,0.372857
uuid-f73e05c0feca41c493e9c06e9edc7bb2,PubMed and EMBASE,0.900783
uuid-f73e05c0feca41c493e9c06e9edc7bb2,efficacy and safety of nivolumab,0.698274
uuid-f73e05c0feca41c493e9c06e9edc7bb2,not identify any citations relevant to your request,0.575738
uuid-f73e05c0feca41c493e9c06e9edc7bb2,present using the following search terms,0.911094
uuid-2ab59e90fb8442468cd77c4151f919f5,requested,0.599397
uuid-6188464441704ff2ba131c01a63acc57,AEs,0.410654
uuid-6188464441704ff2ba131c01a63acc57,95% CI,0.404013
uuid-6188464441704ff2ba131c01a63acc57,respectively,0.358628
uuid-6188464441704ff2ba131c01a63acc57,ORR,0.351471
uuid-6188464441704ff2ba131c01a63acc57,Median overall survival,0.412868
uuid-6188464441704ff2ba131c01a63acc57,Median OS,0.390601
uuid-6188464441704ff2ba131c01a63acc57,grade,0.574159
uuid-6188464441704ff2ba131c01a63acc57,hazard ratio,0.366489
uuid-6188464441704ff2ba131c01a63acc57,grade 3 to 4 AEs,0.331306
uuid-e80b3b863bac4768ab81d552a9d05493,AEs,0.392567
uuid-e80b3b863bac4768ab81d552a9d05493,grade,0.641278
uuid-e80b3b863bac4768ab81d552a9d05493,grade 3 to 4 AEs,0.360102
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,OS,0.387982
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,95% CI,0.745043
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,respectively,0.729294
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,Objective response rate,0.590876
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,ORR,0.722442
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,Median overall survival,0.659043
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,monotherapy,0.514468
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,Median OS,0.696688
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,PD-L1,0.300997
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,docetaxel,0.635065
uuid-0bedec3952dc4a2d9b5f20907f36c7b4,hazard ratio,0.729977
uuid-fd9cc259eff64a5985c6e102282bb02f,OS,0.387982
uuid-fd9cc259eff64a5985c6e102282bb02f,95% CI,0.745043
uuid-fd9cc259eff64a5985c6e102282bb02f,respectively,0.729294
uuid-fd9cc259eff64a5985c6e102282bb02f,Objective response rate,0.590876
uuid-fd9cc259eff64a5985c6e102282bb02f,ORR,0.722442
uuid-fd9cc259eff64a5985c6e102282bb02f,Median overall survival,0.659043
uuid-fd9cc259eff64a5985c6e102282bb02f,monotherapy,0.514468
uuid-fd9cc259eff64a5985c6e102282bb02f,Median OS,0.696688
uuid-fd9cc259eff64a5985c6e102282bb02f,PD-L1,0.300997
uuid-fd9cc259eff64a5985c6e102282bb02f,docetaxel,0.635065
uuid-fd9cc259eff64a5985c6e102282bb02f,hazard ratio,0.729977
uuid-8d2d7ca4450b48bb8bc8f88227b90061,use of nivolumab for the treatment,0.409821
uuid-8d2d7ca4450b48bb8bc8f88227b90061,patients with advanced or metastatic,0.645244
uuid-8d2d7ca4450b48bb8bc8f88227b90061,nivolumab combined with ipilimumab,0.676339
uuid-8d2d7ca4450b48bb8bc8f88227b90061,not approved,0.453534
uuid-8d2d7ca4450b48bb8bc8f88227b90061,clinical trials investigating the safety,0.548799
uuid-8d2d7ca4450b48bb8bc8f88227b90061,phase 1/2 study CA209-032,0.34114
uuid-8d2d7ca4450b48bb8bc8f88227b90061,bladder cancer,0.749142
uuid-8d2d7ca4450b48bb8bc8f88227b90061,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-915ffe3e79914fbfbd4583259af39465,nivolumab,0.999168
uuid-915ffe3e79914fbfbd4583259af39465,Pubmed literature search,0.395314
uuid-915ffe3e79914fbfbd4583259af39465,purposes other than its labeled indication must be considered investigational,0.464236
uuid-915ffe3e79914fbfbd4583259af39465,not identify any citations relevant to your inquiry,0.368569
uuid-915ffe3e79914fbfbd4583259af39465,using the following search terms,0.364279
uuid-915ffe3e79914fbfbd4583259af39465,present using the following search terms,0.329876
uuid-0ad5b2bfcdf14d39a5418f05dbd331cd,Bristol-Myers Squibb,0.307009
uuid-0ad5b2bfcdf14d39a5418f05dbd331cd,requested,0.323839
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,N Engl J Med,0.467135
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,provided in the Detailed Information,0.370939
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,protocol,0.566242
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,McDermott DF,0.648889
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,Motzer RJ,0.627872
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,clinical,0.324377
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,phase 3 study,0.515262
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,Escudier B,0.634045
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,NEJM,0.339295
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,et al.,0.612656
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,J Clin Oncol,0.621181
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,Topalian,0.320504
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,phase 1 study,0.330011
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,Rizvi NA,0.380851
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,CA209-003,0.34084
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,Weber JS,0.316744
uuid-a7552f57aa0d4f86b7cdd828bbac7cd9,phase 2 study,0.653884
uuid-44e90e4bac4c438b8882915e996e7df2,nivolumab,0.999168
uuid-44e90e4bac4c438b8882915e996e7df2,Pubmed literature search,0.395314
uuid-44e90e4bac4c438b8882915e996e7df2,purposes other than its labeled indication must be considered investigational,0.464236
uuid-44e90e4bac4c438b8882915e996e7df2,not identify any citations relevant to your inquiry,0.368569
uuid-44e90e4bac4c438b8882915e996e7df2,using the following search terms,0.364279
uuid-44e90e4bac4c438b8882915e996e7df2,present using the following search terms,0.329876
uuid-efff6c0ef6654b7ba4683a5a92e20eb5,Bristol-Myers Squibb,0.335185
uuid-efff6c0ef6654b7ba4683a5a92e20eb5,phase 3 study,0.317589
uuid-efff6c0ef6654b7ba4683a5a92e20eb5,investigating,0.336623
uuid-67eb81dd31f14d9e8cd9e9e89fa406a6,Bristol-Myers Squibb,0.307009
uuid-67eb81dd31f14d9e8cd9e9e89fa406a6,requested,0.323839
uuid-82c96f215304499f9aac63f5fe270637,requested,0.599827
uuid-d1e19e87f4424302bfdd397c2e1660ea,nivolumab,0.54991
uuid-6b81092d66eb4fc0aad02913103673d5,nivolumab,0.325371
uuid-9ca34c2c5f494305afcda91f930f1c77,trial,0.306565
uuid-ef87828b24764a8d8be0e80ebc32e621,trial,0.306565
uuid-d0b2c7c0848346bf92058a10cb6e2fb0,nivolumab,0.356111
uuid-d0b2c7c0848346bf92058a10cb6e2fb0,open-label,0.344657
uuid-d0b2c7c0848346bf92058a10cb6e2fb0,trial,0.382016
uuid-d0b2c7c0848346bf92058a10cb6e2fb0,phase,0.428364
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,evaluating,0.366546
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,not conducted any controlled clinical trials/studies,0.360172
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,search of published literature,0.403755
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,Additionally,0.418906
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,ongoing,0.467576
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,PubMed and EMBASE,0.39617
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,detailed search of www.clinicaltrials.gov,0.437393
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,efficacy and safety of nivolumab,0.42836
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,not identify any planned,0.454065
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,combination,0.397925
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,BMS,0.30879
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,not identify any citations relevant to your request,0.449603
uuid-856a2bd9ce8647b887b7ce3e741a0fe3,present using the following search terms,0.394376
uuid-e713f62a1e8d41a1994534b2033a1413,search of published literature,0.394524
uuid-e713f62a1e8d41a1994534b2033a1413,Additionally,0.413583
uuid-e713f62a1e8d41a1994534b2033a1413,ongoing,0.322117
uuid-e713f62a1e8d41a1994534b2033a1413,PubMed and EMBASE,0.391671
uuid-e713f62a1e8d41a1994534b2033a1413,detailed search of www.clinicaltrials.gov,0.375936
uuid-e713f62a1e8d41a1994534b2033a1413,efficacy and safety of nivolumab,0.370699
uuid-e713f62a1e8d41a1994534b2033a1413,not identify any planned,0.34283
uuid-e713f62a1e8d41a1994534b2033a1413,Weber JS,0.319229
uuid-e713f62a1e8d41a1994534b2033a1413,not identify any citations relevant to your request,0.447813
uuid-e713f62a1e8d41a1994534b2033a1413,present using the following search terms,0.408199
uuid-e0557f9c99cd4740bc76e317853eaca2,OS,0.387982
uuid-e0557f9c99cd4740bc76e317853eaca2,95% CI,0.745043
uuid-e0557f9c99cd4740bc76e317853eaca2,respectively,0.729294
uuid-e0557f9c99cd4740bc76e317853eaca2,Objective response rate,0.590876
uuid-e0557f9c99cd4740bc76e317853eaca2,ORR,0.722442
uuid-e0557f9c99cd4740bc76e317853eaca2,Median overall survival,0.659043
uuid-e0557f9c99cd4740bc76e317853eaca2,monotherapy,0.514468
uuid-e0557f9c99cd4740bc76e317853eaca2,Median OS,0.696688
uuid-e0557f9c99cd4740bc76e317853eaca2,PD-L1,0.300997
uuid-e0557f9c99cd4740bc76e317853eaca2,docetaxel,0.635065
uuid-e0557f9c99cd4740bc76e317853eaca2,hazard ratio,0.729977
uuid-c179595375274261936ef52421701605,Bristol-Myers Squibb,0.341822
uuid-c179595375274261936ef52421701605,not conducted any controlled clinical trials/studies,0.304507
uuid-c179595375274261936ef52421701605,Opdivo,0.461382
uuid-c179595375274261936ef52421701605,Pubmed literature search,0.614325
uuid-c179595375274261936ef52421701605,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c179595375274261936ef52421701605,not identify any citations relevant to your inquiry,0.606087
uuid-c179595375274261936ef52421701605,adverse,0.304183
uuid-c179595375274261936ef52421701605,using the following search terms,0.642331
uuid-c179595375274261936ef52421701605,databases,0.315039
uuid-c179595375274261936ef52421701605,reported,0.556704
uuid-edce5b4d91f1494bb66e99058339f4b9,use of nivolumab for the treatment,0.383211
uuid-edce5b4d91f1494bb66e99058339f4b9,patients,0.81918
uuid-edce5b4d91f1494bb66e99058339f4b9,considered investigational,0.3142
uuid-edce5b4d91f1494bb66e99058339f4b9,small cell lung cancer,0.38416
uuid-edce5b4d91f1494bb66e99058339f4b9,SCLC,0.339548
uuid-edce5b4d91f1494bb66e99058339f4b9,grade 3 to 4 AEs,0.398018
uuid-7e0f240cdd22448a97bf9002b06c227d,ipilimumab,0.385692
uuid-7e0f240cdd22448a97bf9002b06c227d,ASCO 2015,0.417944
uuid-7e0f240cdd22448a97bf9002b06c227d,partial response,0.382425
uuid-7e0f240cdd22448a97bf9002b06c227d,Stable disease,0.586335
uuid-7e0f240cdd22448a97bf9002b06c227d,cohort,0.307748
uuid-03ea1db82a9c49d981319c1523a9906f,requested,0.596741
uuid-58b0b4a758c4408597347e84bb881af7,OS,0.390672
uuid-58b0b4a758c4408597347e84bb881af7,95% CI,0.734555
uuid-58b0b4a758c4408597347e84bb881af7,respectively,0.731714
uuid-58b0b4a758c4408597347e84bb881af7,Objective response rate,0.584329
uuid-58b0b4a758c4408597347e84bb881af7,ORR,0.714462
uuid-58b0b4a758c4408597347e84bb881af7,Median overall survival,0.655969
uuid-58b0b4a758c4408597347e84bb881af7,monotherapy,0.495641
uuid-58b0b4a758c4408597347e84bb881af7,Median OS,0.694284
uuid-58b0b4a758c4408597347e84bb881af7,docetaxel,0.640463
uuid-58b0b4a758c4408597347e84bb881af7,hazard ratio,0.7217
uuid-9bff8b99bd754260a722efe18a7d0c0c,OS,0.387982
uuid-9bff8b99bd754260a722efe18a7d0c0c,95% CI,0.745043
uuid-9bff8b99bd754260a722efe18a7d0c0c,respectively,0.729294
uuid-9bff8b99bd754260a722efe18a7d0c0c,Objective response rate,0.590876
uuid-9bff8b99bd754260a722efe18a7d0c0c,ORR,0.722442
uuid-9bff8b99bd754260a722efe18a7d0c0c,Median overall survival,0.659043
uuid-9bff8b99bd754260a722efe18a7d0c0c,monotherapy,0.514468
uuid-9bff8b99bd754260a722efe18a7d0c0c,Median OS,0.696688
uuid-9bff8b99bd754260a722efe18a7d0c0c,PD-L1,0.300997
uuid-9bff8b99bd754260a722efe18a7d0c0c,docetaxel,0.635065
uuid-9bff8b99bd754260a722efe18a7d0c0c,hazard ratio,0.729977
uuid-8b17e06cb63940eb87d11b9d12a57fca,AEs,0.36786
uuid-8b17e06cb63940eb87d11b9d12a57fca,NEJM,0.316923
uuid-8b17e06cb63940eb87d11b9d12a57fca,Topalian,0.334
uuid-8b17e06cb63940eb87d11b9d12a57fca,fatigue,0.322169
uuid-b38e8c50dffb402d93871024ce357a6e,Bristol-Myers Squibb,0.307009
uuid-b38e8c50dffb402d93871024ce357a6e,requested,0.323839
uuid-4def3eb63bde481fa2b67c39333849aa,provided in the Detailed Information,0.349112
uuid-4def3eb63bde481fa2b67c39333849aa,Weber JS,0.321343
uuid-a6274a540d1642dea5c0ad1e3df468e9,Objective response rate,0.451139
uuid-a6274a540d1642dea5c0ad1e3df468e9,clinicaltrials.gov,0.503706
uuid-e6939668eacc4e56b281bd781e549361,N Engl J Med,0.304989
uuid-e6939668eacc4e56b281bd781e549361,AEs,0.337832
uuid-e6939668eacc4e56b281bd781e549361,patients,0.387033
uuid-e6939668eacc4e56b281bd781e549361,provided in the Detailed Information,0.370845
uuid-e6939668eacc4e56b281bd781e549361,ESMO,0.421367
uuid-e6939668eacc4e56b281bd781e549361,NEJM,0.709799
uuid-e6939668eacc4e56b281bd781e549361,Topalian,0.735417
uuid-e6939668eacc4e56b281bd781e549361,grade 3 to 4 AEs,0.538198
uuid-9ff36dccdf724212afd47f5d2cf34016,Objective response rate,0.451139
uuid-9ff36dccdf724212afd47f5d2cf34016,clinicaltrials.gov,0.503706
uuid-787e0819c8114fc2a7bdd624689d02bb,Objective response rate,0.451139
uuid-787e0819c8114fc2a7bdd624689d02bb,clinicaltrials.gov,0.503706
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,N Engl J Med,0.802402
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Lancet Oncol,0.56115
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,protocol,0.825455
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,McDermott DF,0.885167
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Motzer RJ,0.855335
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,phase 3 study,0.542754
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Escudier B,0.889228
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,NEJM,0.49481
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,et al.,0.863613
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,J Clin Oncol,0.80113
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Topalian,0.450909
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Rizvi NA,0.701925
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Brahmer J,0.469271
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,Weber JS,0.595586
uuid-74bfc5119e8b4f0c8f3e698ad09741ea,phase 2 study,0.814538
uuid-3fc06751ee1446ffa08a73cf2cb631ba,nivolumab,0.359772
uuid-5373e3854b4942aca9985b3c6c7effe7,95% CI,0.384282
uuid-5373e3854b4942aca9985b3c6c7effe7,ASCO,0.40687
uuid-5373e3854b4942aca9985b3c6c7effe7,Objective response rate,0.409634
uuid-5373e3854b4942aca9985b3c6c7effe7,Median overall survival,0.319094
uuid-5373e3854b4942aca9985b3c6c7effe7,Median OS,0.403026
uuid-5373e3854b4942aca9985b3c6c7effe7,ASCO 2015,0.386899
uuid-5373e3854b4942aca9985b3c6c7effe7,hazard ratio,0.403406
uuid-e7ba3eb02bce496282a4b845a9f9db66,evaluating,0.331981
uuid-e7ba3eb02bce496282a4b845a9f9db66,search of published literature,0.448344
uuid-e7ba3eb02bce496282a4b845a9f9db66,Additionally,0.480679
uuid-e7ba3eb02bce496282a4b845a9f9db66,ongoing,0.382544
uuid-e7ba3eb02bce496282a4b845a9f9db66,PubMed and EMBASE,0.446202
uuid-e7ba3eb02bce496282a4b845a9f9db66,detailed search of www.clinicaltrials.gov,0.458627
uuid-e7ba3eb02bce496282a4b845a9f9db66,phase 1 study,0.566756
uuid-e7ba3eb02bce496282a4b845a9f9db66,efficacy and safety of nivolumab,0.463346
uuid-e7ba3eb02bce496282a4b845a9f9db66,not identify any planned,0.411005
uuid-e7ba3eb02bce496282a4b845a9f9db66,CA209-003,0.655106
uuid-e7ba3eb02bce496282a4b845a9f9db66,not identify any citations relevant to your request,0.549312
uuid-e7ba3eb02bce496282a4b845a9f9db66,present using the following search terms,0.496677
uuid-e7ba3eb02bce496282a4b845a9f9db66,investigating,0.752886
uuid-8dd8a515f9ef4801b28b219e445b8078,95% CI,0.487208
uuid-8dd8a515f9ef4801b28b219e445b8078,respectively,0.367004
uuid-8dd8a515f9ef4801b28b219e445b8078,considered investigational,0.419153
uuid-8dd8a515f9ef4801b28b219e445b8078,Objective response rate,0.498353
uuid-8dd8a515f9ef4801b28b219e445b8078,ORR,0.570072
uuid-8dd8a515f9ef4801b28b219e445b8078,patients with advanced or metastatic,0.40511
uuid-8dd8a515f9ef4801b28b219e445b8078,Median overall survival,0.500919
uuid-8dd8a515f9ef4801b28b219e445b8078,monotherapy,0.313111
uuid-8dd8a515f9ef4801b28b219e445b8078,nivolumab combined with ipilimumab,0.398959
uuid-8dd8a515f9ef4801b28b219e445b8078,tumors,0.438134
uuid-8dd8a515f9ef4801b28b219e445b8078,Median OS,0.416006
uuid-8dd8a515f9ef4801b28b219e445b8078,small cell lung cancer,0.51429
uuid-8dd8a515f9ef4801b28b219e445b8078,SCLC,0.505933
uuid-8dd8a515f9ef4801b28b219e445b8078,hazard ratio,0.505086
uuid-8dd8a515f9ef4801b28b219e445b8078,phase 1/2 study CA209-032,0.5105
uuid-8dd8a515f9ef4801b28b219e445b8078,evaluates the efficacy of nivolumab monotherapy,0.499668
uuid-8a3f8d2ff7104767a305a4a2a654a838,evaluating,0.331463
uuid-8a3f8d2ff7104767a305a4a2a654a838,not conducted any controlled clinical trials/studies,0.327968
uuid-8a3f8d2ff7104767a305a4a2a654a838,protocol,0.532972
uuid-8a3f8d2ff7104767a305a4a2a654a838,RCC,0.386451
uuid-8a3f8d2ff7104767a305a4a2a654a838,McDermott DF,0.444329
uuid-8a3f8d2ff7104767a305a4a2a654a838,search of published literature,0.50452
uuid-8a3f8d2ff7104767a305a4a2a654a838,Additionally,0.555299
uuid-8a3f8d2ff7104767a305a4a2a654a838,ongoing,0.478674
uuid-8a3f8d2ff7104767a305a4a2a654a838,Motzer RJ,0.475488
uuid-8a3f8d2ff7104767a305a4a2a654a838,PubMed and EMBASE,0.501909
uuid-8a3f8d2ff7104767a305a4a2a654a838,Escudier B,0.459186
uuid-8a3f8d2ff7104767a305a4a2a654a838,et al.,0.397016
uuid-8a3f8d2ff7104767a305a4a2a654a838,J Clin Oncol,0.428996
uuid-8a3f8d2ff7104767a305a4a2a654a838,detailed search of www.clinicaltrials.gov,0.514934
uuid-8a3f8d2ff7104767a305a4a2a654a838,efficacy and safety of nivolumab,0.47512
uuid-8a3f8d2ff7104767a305a4a2a654a838,not identify any planned,0.493147
uuid-8a3f8d2ff7104767a305a4a2a654a838,phase 2 study,0.384586
uuid-8a3f8d2ff7104767a305a4a2a654a838,not identify any citations relevant to your request,0.565812
uuid-8a3f8d2ff7104767a305a4a2a654a838,present using the following search terms,0.490802
uuid-6332b3061f2d42a59e0b1a1482e59a5d,nivolumab,0.329591
uuid-d3283de9459b40dd8f895167fcb8ee0e,clinical,0.317288
uuid-95c02f9ea13c4da0bd5712750f7fb03e,OS,0.387982
uuid-95c02f9ea13c4da0bd5712750f7fb03e,95% CI,0.745043
uuid-95c02f9ea13c4da0bd5712750f7fb03e,respectively,0.729294
uuid-95c02f9ea13c4da0bd5712750f7fb03e,Objective response rate,0.590876
uuid-95c02f9ea13c4da0bd5712750f7fb03e,ORR,0.722442
uuid-95c02f9ea13c4da0bd5712750f7fb03e,Median overall survival,0.659043
uuid-95c02f9ea13c4da0bd5712750f7fb03e,monotherapy,0.514468
uuid-95c02f9ea13c4da0bd5712750f7fb03e,Median OS,0.696688
uuid-95c02f9ea13c4da0bd5712750f7fb03e,PD-L1,0.300997
uuid-95c02f9ea13c4da0bd5712750f7fb03e,docetaxel,0.635065
uuid-95c02f9ea13c4da0bd5712750f7fb03e,hazard ratio,0.729977
uuid-ca0656d1cdc34542ad4f82c41942ab03,OS,0.549501
uuid-ca0656d1cdc34542ad4f82c41942ab03,95% CI,0.834015
uuid-ca0656d1cdc34542ad4f82c41942ab03,Objective response rate,0.410279
uuid-ca0656d1cdc34542ad4f82c41942ab03,ORR,0.558479
uuid-ca0656d1cdc34542ad4f82c41942ab03,PFS,0.402671
uuid-ca0656d1cdc34542ad4f82c41942ab03,Median overall survival,0.796907
uuid-ca0656d1cdc34542ad4f82c41942ab03,Median OS,0.760988
uuid-ca0656d1cdc34542ad4f82c41942ab03,fatigue,0.350344
uuid-ca0656d1cdc34542ad4f82c41942ab03,hazard ratio,0.809755
uuid-ca0656d1cdc34542ad4f82c41942ab03,Overall survival,0.406731
uuid-ca0656d1cdc34542ad4f82c41942ab03,Median duration of response,0.414368
uuid-f08ef1525cd64a818fbea2442b51c31a,fatigue,0.411608
uuid-bdba5ca6bdf54852b4b860d429678b81,nivolumab,0.387926
uuid-c23e0f1c05cf4be49d3dd10ed5503ab0,N Engl J Med,0.332054
uuid-c23e0f1c05cf4be49d3dd10ed5503ab0,ASCO,0.456596
uuid-c23e0f1c05cf4be49d3dd10ed5503ab0,Brahmer J,0.507449
uuid-c23e0f1c05cf4be49d3dd10ed5503ab0,Horn L,0.340008
uuid-809e5f0490eb4b5da88b945781fcd246,requested,0.342361
uuid-228fc539b1d14283984d934965a0f768,nivolumab,0.304992
uuid-228fc539b1d14283984d934965a0f768,NEJM,0.351437
uuid-228fc539b1d14283984d934965a0f768,Topalian,0.37131
uuid-8f49e31c2eba416bb80aebed46b022aa,Bristol-Myers Squibb,0.344149
uuid-8f49e31c2eba416bb80aebed46b022aa,requested,0.32002
uuid-8605961e3cd84f739d49451675370d9c,Bristol-Myers Squibb,0.341822
uuid-8605961e3cd84f739d49451675370d9c,not conducted any controlled clinical trials/studies,0.304507
uuid-8605961e3cd84f739d49451675370d9c,Opdivo,0.461382
uuid-8605961e3cd84f739d49451675370d9c,Pubmed literature search,0.614325
uuid-8605961e3cd84f739d49451675370d9c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8605961e3cd84f739d49451675370d9c,not identify any citations relevant to your inquiry,0.606087
uuid-8605961e3cd84f739d49451675370d9c,adverse,0.304183
uuid-8605961e3cd84f739d49451675370d9c,using the following search terms,0.642331
uuid-8605961e3cd84f739d49451675370d9c,databases,0.315039
uuid-8605961e3cd84f739d49451675370d9c,reported,0.556704
uuid-77895ddef70b44e4be7741c44761cf94,requested,0.596876
uuid-f0c7c6b6761c4ab7a1c9d8b208face69,requested,0.594234
uuid-655699265fa04d0faa835790f072e9fc,patients,0.432857
uuid-655699265fa04d0faa835790f072e9fc,Opdivo,0.31463
uuid-655699265fa04d0faa835790f072e9fc,small cell lung cancer,0.338018
uuid-655699265fa04d0faa835790f072e9fc,SCLC,0.339697
uuid-655699265fa04d0faa835790f072e9fc,therapy,0.445993
uuid-655699265fa04d0faa835790f072e9fc,investigating,0.371872
uuid-6ac6b4a68aee4455af2e5f66ccd184a9,Bristol-Myers Squibb,0.344149
uuid-6ac6b4a68aee4455af2e5f66ccd184a9,requested,0.32002
uuid-8261e7035d204dde904718e10819c340,Bristol-Myers Squibb,0.36121
uuid-8261e7035d204dde904718e10819c340,requested,0.360003
uuid-4335d773c31d4225b3cc9338eb0a8788,ipilimumab,0.385692
uuid-4335d773c31d4225b3cc9338eb0a8788,ASCO 2015,0.417944
uuid-4335d773c31d4225b3cc9338eb0a8788,partial response,0.382425
uuid-4335d773c31d4225b3cc9338eb0a8788,Stable disease,0.586335
uuid-4335d773c31d4225b3cc9338eb0a8788,cohort,0.307748
uuid-23de1ab9a28f4b0dbe604690b29c120d,Objective response rate,0.451139
uuid-23de1ab9a28f4b0dbe604690b29c120d,clinicaltrials.gov,0.503706
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,Bristol-Myers Squibb,0.341822
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,not conducted any controlled clinical trials/studies,0.304507
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,Opdivo,0.461382
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,Pubmed literature search,0.614325
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,not identify any citations relevant to your inquiry,0.606087
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,adverse,0.304183
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,using the following search terms,0.642331
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,databases,0.315039
uuid-6d5eb567f2904ef2b288b7eeb5cb038e,reported,0.556704
uuid-93b0a43fa4794185b4686f3ba7693434,N Engl J Med,0.304989
uuid-93b0a43fa4794185b4686f3ba7693434,AEs,0.337832
uuid-93b0a43fa4794185b4686f3ba7693434,patients,0.387033
uuid-93b0a43fa4794185b4686f3ba7693434,provided in the Detailed Information,0.370845
uuid-93b0a43fa4794185b4686f3ba7693434,ESMO,0.421367
uuid-93b0a43fa4794185b4686f3ba7693434,NEJM,0.709799
uuid-93b0a43fa4794185b4686f3ba7693434,Topalian,0.735417
uuid-93b0a43fa4794185b4686f3ba7693434,grade 3 to 4 AEs,0.538198
uuid-310e8a22d2a74295b1decdeee7a1d163,nivolumab,0.498867
uuid-310e8a22d2a74295b1decdeee7a1d163,Bristol-Myers Squibb,0.464173
uuid-310e8a22d2a74295b1decdeee7a1d163,evaluating,0.630283
uuid-310e8a22d2a74295b1decdeee7a1d163,not conducted any controlled clinical trials/studies,0.686191
uuid-310e8a22d2a74295b1decdeee7a1d163,Pubmed literature search,0.856666
uuid-310e8a22d2a74295b1decdeee7a1d163,purposes other than its labeled indication must be considered investigational,0.922616
uuid-310e8a22d2a74295b1decdeee7a1d163,not identify any citations relevant to your inquiry,0.816673
uuid-310e8a22d2a74295b1decdeee7a1d163,using the following search terms,0.800782
uuid-310e8a22d2a74295b1decdeee7a1d163,efficacy and safety of nivolumab,0.460711
uuid-1a229c031cf247b4b4a3a1b321a52f34,Bristol-Myers Squibb,0.364129
uuid-1a229c031cf247b4b4a3a1b321a52f34,requested,0.331201
uuid-3b57f26edd9a4f519bdfdd2837b853d7,Bristol-Myers Squibb,0.344149
uuid-3b57f26edd9a4f519bdfdd2837b853d7,requested,0.32002
uuid-56f0ceef7d3e4bea912cb1ac5c4c0294,Bristol-Myers Squibb,0.307009
uuid-56f0ceef7d3e4bea912cb1ac5c4c0294,requested,0.323839
uuid-202a0c68ea6f401b9afbe8cdadc831ad,evaluating,0.301438
uuid-202a0c68ea6f401b9afbe8cdadc831ad,OS,0.437291
uuid-202a0c68ea6f401b9afbe8cdadc831ad,95% CI,0.766941
uuid-202a0c68ea6f401b9afbe8cdadc831ad,Objective response rate,0.417614
uuid-202a0c68ea6f401b9afbe8cdadc831ad,ORR,0.542379
uuid-202a0c68ea6f401b9afbe8cdadc831ad,PFS,0.337471
uuid-202a0c68ea6f401b9afbe8cdadc831ad,Pubmed literature search,0.308084
uuid-202a0c68ea6f401b9afbe8cdadc831ad,Median overall survival,0.71528
uuid-202a0c68ea6f401b9afbe8cdadc831ad,purposes other than its labeled indication must be considered investigational,0.349362
uuid-202a0c68ea6f401b9afbe8cdadc831ad,monotherapy,0.355302
uuid-202a0c68ea6f401b9afbe8cdadc831ad,Median OS,0.68397
uuid-202a0c68ea6f401b9afbe8cdadc831ad,hazard ratio,0.778643
uuid-202a0c68ea6f401b9afbe8cdadc831ad,Median duration of response,0.318965
uuid-58781f87da174f99b29ae9c7729438f8,NSCLC,0.480337
uuid-58781f87da174f99b29ae9c7729438f8,respectively,0.400584
uuid-58781f87da174f99b29ae9c7729438f8,non-small cell lung cancer,0.395662
uuid-58781f87da174f99b29ae9c7729438f8,patients,0.382838
uuid-58781f87da174f99b29ae9c7729438f8,considered investigational,0.378457
uuid-58781f87da174f99b29ae9c7729438f8,Objective response rate,0.446233
uuid-58781f87da174f99b29ae9c7729438f8,ORR,0.488323
uuid-58781f87da174f99b29ae9c7729438f8,monotherapy,0.419452
uuid-58781f87da174f99b29ae9c7729438f8,small cell lung cancer,0.328277
uuid-58781f87da174f99b29ae9c7729438f8,docetaxel,0.370754
uuid-58781f87da174f99b29ae9c7729438f8,SCLC,0.328412
uuid-58781f87da174f99b29ae9c7729438f8,grade 3 to 4 AEs,0.337672
uuid-58781f87da174f99b29ae9c7729438f8,platinum-based doublet chemotherapy,0.355492
uuid-3482b1f882dc47adacabdb7c61970af9,use of nivolumab for the treatment,0.708582
uuid-3482b1f882dc47adacabdb7c61970af9,evaluating,0.30636
uuid-3482b1f882dc47adacabdb7c61970af9,efficacy,0.737446
uuid-3482b1f882dc47adacabdb7c61970af9,not approved,0.859102
uuid-3482b1f882dc47adacabdb7c61970af9,clinical trials investigating the safety,0.870093
uuid-3482b1f882dc47adacabdb7c61970af9,safety of nivolumab monotherapy,0.538449
uuid-959e8b1f23f1417392ad02af610c1035,N Engl J Med,0.448483
uuid-959e8b1f23f1417392ad02af610c1035,protocol,0.770446
uuid-959e8b1f23f1417392ad02af610c1035,McDermott DF,0.741196
uuid-959e8b1f23f1417392ad02af610c1035,Motzer RJ,0.818144
uuid-959e8b1f23f1417392ad02af610c1035,phase 3 study,0.417055
uuid-959e8b1f23f1417392ad02af610c1035,Escudier B,0.749917
uuid-959e8b1f23f1417392ad02af610c1035,NEJM,0.400698
uuid-959e8b1f23f1417392ad02af610c1035,et al.,0.668641
uuid-959e8b1f23f1417392ad02af610c1035,J Clin Oncol,0.792018
uuid-959e8b1f23f1417392ad02af610c1035,Topalian,0.388894
uuid-959e8b1f23f1417392ad02af610c1035,phase 1 study,0.500686
uuid-959e8b1f23f1417392ad02af610c1035,CA209-003,0.567381
uuid-959e8b1f23f1417392ad02af610c1035,phase 2 study,0.677985
uuid-959e8b1f23f1417392ad02af610c1035,present using the following search terms,0.310558
uuid-959e8b1f23f1417392ad02af610c1035,investigating,0.615835
uuid-c9d4bdac95154230a48a79cd2a1eebb5,OS,0.387982
uuid-c9d4bdac95154230a48a79cd2a1eebb5,95% CI,0.745043
uuid-c9d4bdac95154230a48a79cd2a1eebb5,respectively,0.729294
uuid-c9d4bdac95154230a48a79cd2a1eebb5,Objective response rate,0.590876
uuid-c9d4bdac95154230a48a79cd2a1eebb5,ORR,0.722442
uuid-c9d4bdac95154230a48a79cd2a1eebb5,Median overall survival,0.659043
uuid-c9d4bdac95154230a48a79cd2a1eebb5,monotherapy,0.514468
uuid-c9d4bdac95154230a48a79cd2a1eebb5,Median OS,0.696688
uuid-c9d4bdac95154230a48a79cd2a1eebb5,PD-L1,0.300997
uuid-c9d4bdac95154230a48a79cd2a1eebb5,docetaxel,0.635065
uuid-c9d4bdac95154230a48a79cd2a1eebb5,hazard ratio,0.729977
uuid-e943316d555f4270a93a58c24e8a045d,OS,0.387982
uuid-e943316d555f4270a93a58c24e8a045d,95% CI,0.745043
uuid-e943316d555f4270a93a58c24e8a045d,respectively,0.729294
uuid-e943316d555f4270a93a58c24e8a045d,Objective response rate,0.590876
uuid-e943316d555f4270a93a58c24e8a045d,ORR,0.722442
uuid-e943316d555f4270a93a58c24e8a045d,Median overall survival,0.659043
uuid-e943316d555f4270a93a58c24e8a045d,monotherapy,0.514468
uuid-e943316d555f4270a93a58c24e8a045d,Median OS,0.696688
uuid-e943316d555f4270a93a58c24e8a045d,PD-L1,0.300997
uuid-e943316d555f4270a93a58c24e8a045d,docetaxel,0.635065
uuid-e943316d555f4270a93a58c24e8a045d,hazard ratio,0.729977
uuid-f01b560fa9c0469d98c4f6d199db98cd,OS,0.387982
uuid-f01b560fa9c0469d98c4f6d199db98cd,95% CI,0.745043
uuid-f01b560fa9c0469d98c4f6d199db98cd,respectively,0.729294
uuid-f01b560fa9c0469d98c4f6d199db98cd,Objective response rate,0.590876
uuid-f01b560fa9c0469d98c4f6d199db98cd,ORR,0.722442
uuid-f01b560fa9c0469d98c4f6d199db98cd,Median overall survival,0.659043
uuid-f01b560fa9c0469d98c4f6d199db98cd,monotherapy,0.514468
uuid-f01b560fa9c0469d98c4f6d199db98cd,Median OS,0.696688
uuid-f01b560fa9c0469d98c4f6d199db98cd,PD-L1,0.300997
uuid-f01b560fa9c0469d98c4f6d199db98cd,docetaxel,0.635065
uuid-f01b560fa9c0469d98c4f6d199db98cd,hazard ratio,0.729977
uuid-45f23299402d43088982e39111da03fd,provided in the Detailed Information,0.349112
uuid-45f23299402d43088982e39111da03fd,Weber JS,0.321343
uuid-32665cc0c7d349b38d2fb9acafbfbe44,Objective response rate,0.451139
uuid-32665cc0c7d349b38d2fb9acafbfbe44,clinicaltrials.gov,0.503706
uuid-6ebbb8b12d334a278abada5447221756,nivolumab,0.361138
uuid-6ea5a2c9a771448b907111772a7a3377,Objective response rate,0.451139
uuid-6ea5a2c9a771448b907111772a7a3377,clinicaltrials.gov,0.503706
uuid-1312438acb3e44fe9c670348860289d3,evaluating,0.328997
uuid-1312438acb3e44fe9c670348860289d3,not conducted any controlled clinical trials/studies,0.325444
uuid-1312438acb3e44fe9c670348860289d3,protocol,0.534557
uuid-1312438acb3e44fe9c670348860289d3,RCC,0.387518
uuid-1312438acb3e44fe9c670348860289d3,McDermott DF,0.446693
uuid-1312438acb3e44fe9c670348860289d3,search of published literature,0.507554
uuid-1312438acb3e44fe9c670348860289d3,Additionally,0.557318
uuid-1312438acb3e44fe9c670348860289d3,ongoing,0.480759
uuid-1312438acb3e44fe9c670348860289d3,Motzer RJ,0.477516
uuid-1312438acb3e44fe9c670348860289d3,PubMed and EMBASE,0.5052
uuid-1312438acb3e44fe9c670348860289d3,Escudier B,0.461714
uuid-1312438acb3e44fe9c670348860289d3,et al.,0.400032
uuid-1312438acb3e44fe9c670348860289d3,J Clin Oncol,0.430273
uuid-1312438acb3e44fe9c670348860289d3,detailed search of www.clinicaltrials.gov,0.517366
uuid-1312438acb3e44fe9c670348860289d3,efficacy and safety of nivolumab,0.474802
uuid-1312438acb3e44fe9c670348860289d3,not identify any planned,0.495387
uuid-1312438acb3e44fe9c670348860289d3,phase 2 study,0.386789
uuid-1312438acb3e44fe9c670348860289d3,not identify any citations relevant to your request,0.568753
uuid-1312438acb3e44fe9c670348860289d3,present using the following search terms,0.493883
uuid-e0e0151b293d4089bd6b24c99ba1ef11,patients,0.593924
uuid-098d045c799f43e2adc000e2fc44ba7a,patients,0.556054
uuid-098d045c799f43e2adc000e2fc44ba7a,provided in the Detailed Information,0.329929
uuid-098d045c799f43e2adc000e2fc44ba7a,adverse,0.32982
uuid-098d045c799f43e2adc000e2fc44ba7a,phase 3 study,0.523726
uuid-098d045c799f43e2adc000e2fc44ba7a,melanoma,0.382071
uuid-098d045c799f43e2adc000e2fc44ba7a,Weber JS,0.428777
uuid-098d045c799f43e2adc000e2fc44ba7a,phase 2 study,0.307314
uuid-098d045c799f43e2adc000e2fc44ba7a,grade 3 to 4 AEs,0.466022
uuid-656a2c7c3371424fbb69a04462513006,nivolumab,0.577352
uuid-656a2c7c3371424fbb69a04462513006,Bristol-Myers Squibb,0.348458
uuid-656a2c7c3371424fbb69a04462513006,evaluating,0.533156
uuid-656a2c7c3371424fbb69a04462513006,not conducted any controlled clinical trials/studies,0.533215
uuid-656a2c7c3371424fbb69a04462513006,Pubmed literature search,0.66463
uuid-656a2c7c3371424fbb69a04462513006,purposes other than its labeled indication must be considered investigational,0.726589
uuid-656a2c7c3371424fbb69a04462513006,not identify any citations relevant to your inquiry,0.63356
uuid-656a2c7c3371424fbb69a04462513006,using the following search terms,0.619188
uuid-656a2c7c3371424fbb69a04462513006,efficacy and safety of nivolumab,0.379623
uuid-656a2c7c3371424fbb69a04462513006,mg,0.465679
uuid-656a2c7c3371424fbb69a04462513006,kg,0.451324
uuid-0031c3f086bb4d8389f050b2fdba8407,search of published literature,0.394524
uuid-0031c3f086bb4d8389f050b2fdba8407,Additionally,0.413583
uuid-0031c3f086bb4d8389f050b2fdba8407,ongoing,0.322117
uuid-0031c3f086bb4d8389f050b2fdba8407,PubMed and EMBASE,0.391671
uuid-0031c3f086bb4d8389f050b2fdba8407,detailed search of www.clinicaltrials.gov,0.375936
uuid-0031c3f086bb4d8389f050b2fdba8407,efficacy and safety of nivolumab,0.370699
uuid-0031c3f086bb4d8389f050b2fdba8407,not identify any planned,0.34283
uuid-0031c3f086bb4d8389f050b2fdba8407,Weber JS,0.319229
uuid-0031c3f086bb4d8389f050b2fdba8407,not identify any citations relevant to your request,0.447813
uuid-0031c3f086bb4d8389f050b2fdba8407,present using the following search terms,0.408199
uuid-e59d345fce914c2b81392865bd04fd6e,Bristol-Myers Squibb,0.307009
uuid-e59d345fce914c2b81392865bd04fd6e,requested,0.323839
uuid-2318cb4a535043f48c5d02e716ad4093,OS,0.387982
uuid-2318cb4a535043f48c5d02e716ad4093,95% CI,0.745043
uuid-2318cb4a535043f48c5d02e716ad4093,respectively,0.729294
uuid-2318cb4a535043f48c5d02e716ad4093,Objective response rate,0.590876
uuid-2318cb4a535043f48c5d02e716ad4093,ORR,0.722442
uuid-2318cb4a535043f48c5d02e716ad4093,Median overall survival,0.659043
uuid-2318cb4a535043f48c5d02e716ad4093,monotherapy,0.514468
uuid-2318cb4a535043f48c5d02e716ad4093,Median OS,0.696688
uuid-2318cb4a535043f48c5d02e716ad4093,PD-L1,0.300997
uuid-2318cb4a535043f48c5d02e716ad4093,docetaxel,0.635065
uuid-2318cb4a535043f48c5d02e716ad4093,hazard ratio,0.729977
uuid-dd69ff0220f44250958a9d65c9f9cfac,OS,0.387982
uuid-dd69ff0220f44250958a9d65c9f9cfac,95% CI,0.745043
uuid-dd69ff0220f44250958a9d65c9f9cfac,respectively,0.729294
uuid-dd69ff0220f44250958a9d65c9f9cfac,Objective response rate,0.590876
uuid-dd69ff0220f44250958a9d65c9f9cfac,ORR,0.722442
uuid-dd69ff0220f44250958a9d65c9f9cfac,Median overall survival,0.659043
uuid-dd69ff0220f44250958a9d65c9f9cfac,monotherapy,0.514468
uuid-dd69ff0220f44250958a9d65c9f9cfac,Median OS,0.696688
uuid-dd69ff0220f44250958a9d65c9f9cfac,PD-L1,0.300997
uuid-dd69ff0220f44250958a9d65c9f9cfac,docetaxel,0.635065
uuid-dd69ff0220f44250958a9d65c9f9cfac,hazard ratio,0.729977
uuid-2a69f2622db34cbfa07cd0a08dd2e0cc,patients,0.347996
uuid-2a69f2622db34cbfa07cd0a08dd2e0cc,adverse,0.426519
uuid-2a69f2622db34cbfa07cd0a08dd2e0cc,safety,0.396587
uuid-2a69f2622db34cbfa07cd0a08dd2e0cc,reported,0.54473
uuid-4112a3b3cf854832b546c191e7aae232,95% CI,0.419478
uuid-4112a3b3cf854832b546c191e7aae232,respectively,0.497608
uuid-4112a3b3cf854832b546c191e7aae232,Objective response rate,0.403649
uuid-4112a3b3cf854832b546c191e7aae232,ORR,0.578109
uuid-4112a3b3cf854832b546c191e7aae232,patients with advanced or metastatic,0.306625
uuid-4112a3b3cf854832b546c191e7aae232,Median overall survival,0.498783
uuid-4112a3b3cf854832b546c191e7aae232,nivolumab combined with ipilimumab,0.300486
uuid-4112a3b3cf854832b546c191e7aae232,tumors,0.323334
uuid-4112a3b3cf854832b546c191e7aae232,ESMO,0.534361
uuid-4112a3b3cf854832b546c191e7aae232,Median OS,0.394058
uuid-4112a3b3cf854832b546c191e7aae232,small cell lung cancer,0.380999
uuid-4112a3b3cf854832b546c191e7aae232,SCLC,0.365686
uuid-4112a3b3cf854832b546c191e7aae232,hazard ratio,0.419392
uuid-4112a3b3cf854832b546c191e7aae232,grade 3 to 4 AEs,0.414535
uuid-4112a3b3cf854832b546c191e7aae232,phase 1/2 study CA209-032,0.398283
uuid-4112a3b3cf854832b546c191e7aae232,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-9e594160c9784992a47525072c537a8d,OS,0.387982
uuid-9e594160c9784992a47525072c537a8d,95% CI,0.745043
uuid-9e594160c9784992a47525072c537a8d,respectively,0.729294
uuid-9e594160c9784992a47525072c537a8d,Objective response rate,0.590876
uuid-9e594160c9784992a47525072c537a8d,ORR,0.722442
uuid-9e594160c9784992a47525072c537a8d,Median overall survival,0.659043
uuid-9e594160c9784992a47525072c537a8d,monotherapy,0.514468
uuid-9e594160c9784992a47525072c537a8d,Median OS,0.696688
uuid-9e594160c9784992a47525072c537a8d,PD-L1,0.300997
uuid-9e594160c9784992a47525072c537a8d,docetaxel,0.635065
uuid-9e594160c9784992a47525072c537a8d,hazard ratio,0.729977
uuid-512c9ba823f143ae848241c8efd3ffa6,ASCO,0.572408
uuid-512c9ba823f143ae848241c8efd3ffa6,requested,0.60375
uuid-2864709a0e614bd6bd59be160b73e229,requested,0.443116
uuid-2864709a0e614bd6bd59be160b73e229,trial,0.453781
uuid-2864709a0e614bd6bd59be160b73e229,clinicaltrials.gov,0.301906
uuid-259f422aa41e492a90fac2d2573958d7,use of nivolumab for the treatment,0.312769
uuid-259f422aa41e492a90fac2d2573958d7,patients,0.675518
uuid-259f422aa41e492a90fac2d2573958d7,considered investigational,0.321765
uuid-259f422aa41e492a90fac2d2573958d7,small cell lung cancer,0.301003
uuid-e6e1be4014e548c4b4f135ee54839b7a,OS,0.387982
uuid-e6e1be4014e548c4b4f135ee54839b7a,95% CI,0.745043
uuid-e6e1be4014e548c4b4f135ee54839b7a,respectively,0.729294
uuid-e6e1be4014e548c4b4f135ee54839b7a,Objective response rate,0.590876
uuid-e6e1be4014e548c4b4f135ee54839b7a,ORR,0.722442
uuid-e6e1be4014e548c4b4f135ee54839b7a,Median overall survival,0.659043
uuid-e6e1be4014e548c4b4f135ee54839b7a,monotherapy,0.514468
uuid-e6e1be4014e548c4b4f135ee54839b7a,Median OS,0.696688
uuid-e6e1be4014e548c4b4f135ee54839b7a,PD-L1,0.300997
uuid-e6e1be4014e548c4b4f135ee54839b7a,docetaxel,0.635065
uuid-e6e1be4014e548c4b4f135ee54839b7a,hazard ratio,0.729977
uuid-839bca3193fc45bc9dde82802d19e8c8,nivolumab,0.482011
uuid-e8e793b0043b48a097790a7caf89f32c,adverse,0.419275
uuid-53a7319bc412448eb70d1e7e514441e8,requested,0.596876
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,N Engl J Med,0.427636
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,protocol,0.429136
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,McDermott DF,0.44782
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,Motzer RJ,0.430476
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,Escudier B,0.450887
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,et al.,0.456026
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,J Clin Oncol,0.384624
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,Rizvi NA,0.305616
uuid-65eebf0c2cb140ce9da1fee7ec0276a2,phase 2 study,0.351446
uuid-9d8683f051fc4d3782c26e3eb57e6d49,Objective response rate,0.435546
uuid-9d8683f051fc4d3782c26e3eb57e6d49,clinicaltrials.gov,0.510094
uuid-81732251244f4d8b9abc4cef5b8e45bd,nivolumab,0.324191
uuid-81732251244f4d8b9abc4cef5b8e45bd,Bristol-Myers Squibb,0.451027
uuid-81732251244f4d8b9abc4cef5b8e45bd,evaluating,0.499557
uuid-81732251244f4d8b9abc4cef5b8e45bd,not conducted any controlled clinical trials/studies,0.530484
uuid-81732251244f4d8b9abc4cef5b8e45bd,Pubmed literature search,0.491292
uuid-81732251244f4d8b9abc4cef5b8e45bd,purposes other than its labeled indication must be considered investigational,0.515791
uuid-81732251244f4d8b9abc4cef5b8e45bd,not identify any citations relevant to your inquiry,0.485735
uuid-81732251244f4d8b9abc4cef5b8e45bd,search of published literature,0.444358
uuid-81732251244f4d8b9abc4cef5b8e45bd,Additionally,0.370937
uuid-81732251244f4d8b9abc4cef5b8e45bd,PubMed and EMBASE,0.433019
uuid-81732251244f4d8b9abc4cef5b8e45bd,using the following search terms,0.492321
uuid-81732251244f4d8b9abc4cef5b8e45bd,detailed search of www.clinicaltrials.gov,0.356473
uuid-81732251244f4d8b9abc4cef5b8e45bd,efficacy and safety of nivolumab,0.517327
uuid-81732251244f4d8b9abc4cef5b8e45bd,not identify any planned,0.314448
uuid-81732251244f4d8b9abc4cef5b8e45bd,safety,0.321006
uuid-81732251244f4d8b9abc4cef5b8e45bd,not identify any citations relevant to your request,0.434794
uuid-81732251244f4d8b9abc4cef5b8e45bd,present using the following search terms,0.452094
uuid-81732251244f4d8b9abc4cef5b8e45bd,reported,0.393211
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,OS,0.314628
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,AEs,0.341171
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,95% CI,0.492202
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,respectively,0.343276
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,ORR,0.354976
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,Median overall survival,0.463338
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,Median OS,0.490759
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,grade,0.494896
uuid-540aa3c6f6fa40acaa8ea0d52b74ecd1,hazard ratio,0.447546
uuid-2e7ed38b035c4334ba3e09966c42423a,not conducted any controlled clinical trials/studies,0.324772
uuid-2e7ed38b035c4334ba3e09966c42423a,purposes other than its labeled indication must be considered investigational,0.331503
uuid-ab00f8c52cbd42ffa4af0efb970d6905,not conducted any controlled clinical trials/studies,0.323378
uuid-ab00f8c52cbd42ffa4af0efb970d6905,NSCLC,0.557022
uuid-ab00f8c52cbd42ffa4af0efb970d6905,non-small cell lung cancer,0.534527
uuid-ab00f8c52cbd42ffa4af0efb970d6905,considered investigational,0.378249
uuid-ab00f8c52cbd42ffa4af0efb970d6905,phase 3 study,0.333109
uuid-ab00f8c52cbd42ffa4af0efb970d6905,phase 1 study,0.304417
uuid-ab00f8c52cbd42ffa4af0efb970d6905,small cell lung cancer,0.371969
uuid-ab00f8c52cbd42ffa4af0efb970d6905,efficacy and safety of nivolumab,0.317247
uuid-ab00f8c52cbd42ffa4af0efb970d6905,SCLC,0.416288
uuid-ab00f8c52cbd42ffa4af0efb970d6905,therapy,0.620258
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,N Engl J Med,0.495306
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,phase 3 study,0.465971
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,phase 1 study,0.322054
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,Rizvi NA,0.404017
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,Brahmer J,0.459458
uuid-b79c91e07d0c4f0fbe3a423b4b284e74,phase 2 study,0.468266
uuid-1c837d44941843debe77cc4705c3359a,patients with advanced or metastatic,0.468858
uuid-1c837d44941843debe77cc4705c3359a,nivolumab combined with ipilimumab,0.446918
uuid-1c837d44941843debe77cc4705c3359a,not approved,0.352562
uuid-1c837d44941843debe77cc4705c3359a,clinical trials investigating the safety,0.429501
uuid-1c837d44941843debe77cc4705c3359a,bladder cancer,0.950698
uuid-f870394e6f714682b6f53394d78cb74e,Opdivo,0.35123
uuid-f870394e6f714682b6f53394d78cb74e,adverse,0.399925
uuid-f870394e6f714682b6f53394d78cb74e,safety,0.550534
uuid-f870394e6f714682b6f53394d78cb74e,databases,0.492328
uuid-f870394e6f714682b6f53394d78cb74e,reported,0.657668
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,OS,0.517683
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,95% CI,0.887029
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,respectively,0.541932
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,Objective response rate,0.732884
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,ORR,0.826341
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,PFS,0.416378
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,Median overall survival,0.810566
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,monotherapy,0.504664
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,Median OS,0.783041
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,hazard ratio,0.851803
uuid-4b991f9bc56f4d209a14e2a21c09e3b3,Median duration of response,0.350254
uuid-d098181712444ded8c89cc8737556a8c,trial,0.367291
uuid-0d080cefceaf45bfa7bda406e4ba4eb2,ipilimumab,0.385692
uuid-0d080cefceaf45bfa7bda406e4ba4eb2,ASCO 2015,0.417944
uuid-0d080cefceaf45bfa7bda406e4ba4eb2,partial response,0.382425
uuid-0d080cefceaf45bfa7bda406e4ba4eb2,Stable disease,0.586335
uuid-0d080cefceaf45bfa7bda406e4ba4eb2,cohort,0.307748
uuid-b400407396cc4d6faf22d93c12c7324d,ipilimumab,0.385692
uuid-b400407396cc4d6faf22d93c12c7324d,ASCO 2015,0.417944
uuid-b400407396cc4d6faf22d93c12c7324d,partial response,0.382425
uuid-b400407396cc4d6faf22d93c12c7324d,Stable disease,0.586335
uuid-b400407396cc4d6faf22d93c12c7324d,cohort,0.307748
uuid-ab246e842ed346ebbba7e8fc2cff4215,N Engl J Med,0.302601
uuid-ab246e842ed346ebbba7e8fc2cff4215,AEs,0.348167
uuid-ab246e842ed346ebbba7e8fc2cff4215,patients,0.536884
uuid-ab246e842ed346ebbba7e8fc2cff4215,provided in the Detailed Information,0.387544
uuid-ab246e842ed346ebbba7e8fc2cff4215,ESMO,0.462801
uuid-ab246e842ed346ebbba7e8fc2cff4215,NEJM,0.66427
uuid-ab246e842ed346ebbba7e8fc2cff4215,Topalian,0.692873
uuid-ab246e842ed346ebbba7e8fc2cff4215,grade 3 to 4 AEs,0.626596
uuid-d28177c4e59946f7b3524b2e1f2cc40d,N Engl J Med,0.54825
uuid-d28177c4e59946f7b3524b2e1f2cc40d,NSCLC,0.358785
uuid-d28177c4e59946f7b3524b2e1f2cc40d,non-small cell lung cancer,0.308706
uuid-d28177c4e59946f7b3524b2e1f2cc40d,ESMO,0.396697
uuid-d28177c4e59946f7b3524b2e1f2cc40d,phase 3 study,0.368632
uuid-d28177c4e59946f7b3524b2e1f2cc40d,phase 1 study,0.306384
uuid-d28177c4e59946f7b3524b2e1f2cc40d,Rizvi NA,0.47921
uuid-d28177c4e59946f7b3524b2e1f2cc40d,Brahmer J,0.605319
uuid-d28177c4e59946f7b3524b2e1f2cc40d,phase 2 study,0.362302
uuid-d28177c4e59946f7b3524b2e1f2cc40d,Horn L,0.443225
uuid-428df8a968ad4d0e97a0dac2872fc7e3,nivolumab,0.628319
uuid-428df8a968ad4d0e97a0dac2872fc7e3,evaluating,0.463239
uuid-428df8a968ad4d0e97a0dac2872fc7e3,not conducted any controlled clinical trials/studies,0.423403
uuid-428df8a968ad4d0e97a0dac2872fc7e3,RCC,0.369007
uuid-428df8a968ad4d0e97a0dac2872fc7e3,search of published literature,0.741732
uuid-428df8a968ad4d0e97a0dac2872fc7e3,Additionally,0.405045
uuid-428df8a968ad4d0e97a0dac2872fc7e3,PubMed and EMBASE,0.738823
uuid-428df8a968ad4d0e97a0dac2872fc7e3,detailed search of www.clinicaltrials.gov,0.340951
uuid-428df8a968ad4d0e97a0dac2872fc7e3,efficacy and safety of nivolumab,0.605792
uuid-428df8a968ad4d0e97a0dac2872fc7e3,not identify any citations relevant to your request,0.557229
uuid-428df8a968ad4d0e97a0dac2872fc7e3,therapy,0.453453
uuid-428df8a968ad4d0e97a0dac2872fc7e3,present using the following search terms,0.749872
uuid-1ca4adedca3c47649a6f4ca308f51bd9,OS,0.387982
uuid-1ca4adedca3c47649a6f4ca308f51bd9,95% CI,0.745043
uuid-1ca4adedca3c47649a6f4ca308f51bd9,respectively,0.729294
uuid-1ca4adedca3c47649a6f4ca308f51bd9,Objective response rate,0.590876
uuid-1ca4adedca3c47649a6f4ca308f51bd9,ORR,0.722442
uuid-1ca4adedca3c47649a6f4ca308f51bd9,Median overall survival,0.659043
uuid-1ca4adedca3c47649a6f4ca308f51bd9,monotherapy,0.514468
uuid-1ca4adedca3c47649a6f4ca308f51bd9,Median OS,0.696688
uuid-1ca4adedca3c47649a6f4ca308f51bd9,PD-L1,0.300997
uuid-1ca4adedca3c47649a6f4ca308f51bd9,docetaxel,0.635065
uuid-1ca4adedca3c47649a6f4ca308f51bd9,hazard ratio,0.729977
uuid-21e16ac7f677434eb4ac2225bdd263b4,ASCO,0.397725
uuid-9a98578d1e694e769998845ea647c7b2,Bristol-Myers Squibb,0.341822
uuid-9a98578d1e694e769998845ea647c7b2,not conducted any controlled clinical trials/studies,0.304507
uuid-9a98578d1e694e769998845ea647c7b2,Opdivo,0.461382
uuid-9a98578d1e694e769998845ea647c7b2,Pubmed literature search,0.614325
uuid-9a98578d1e694e769998845ea647c7b2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9a98578d1e694e769998845ea647c7b2,not identify any citations relevant to your inquiry,0.606087
uuid-9a98578d1e694e769998845ea647c7b2,adverse,0.304183
uuid-9a98578d1e694e769998845ea647c7b2,using the following search terms,0.642331
uuid-9a98578d1e694e769998845ea647c7b2,databases,0.315039
uuid-9a98578d1e694e769998845ea647c7b2,reported,0.556704
uuid-f70fbe1f911e43a19aeec9e5c029413d,Objective response rate,0.451139
uuid-f70fbe1f911e43a19aeec9e5c029413d,clinicaltrials.gov,0.503706
uuid-3e6210ab4fcc415dbb090e14e825a831,N Engl J Med,0.448483
uuid-3e6210ab4fcc415dbb090e14e825a831,protocol,0.770446
uuid-3e6210ab4fcc415dbb090e14e825a831,McDermott DF,0.741196
uuid-3e6210ab4fcc415dbb090e14e825a831,Motzer RJ,0.818144
uuid-3e6210ab4fcc415dbb090e14e825a831,phase 3 study,0.417055
uuid-3e6210ab4fcc415dbb090e14e825a831,Escudier B,0.749917
uuid-3e6210ab4fcc415dbb090e14e825a831,NEJM,0.400698
uuid-3e6210ab4fcc415dbb090e14e825a831,et al.,0.668641
uuid-3e6210ab4fcc415dbb090e14e825a831,J Clin Oncol,0.792018
uuid-3e6210ab4fcc415dbb090e14e825a831,Topalian,0.388894
uuid-3e6210ab4fcc415dbb090e14e825a831,phase 1 study,0.500686
uuid-3e6210ab4fcc415dbb090e14e825a831,CA209-003,0.567381
uuid-3e6210ab4fcc415dbb090e14e825a831,phase 2 study,0.677985
uuid-3e6210ab4fcc415dbb090e14e825a831,present using the following search terms,0.310558
uuid-3e6210ab4fcc415dbb090e14e825a831,investigating,0.615835
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,OS,0.387982
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,95% CI,0.745043
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,respectively,0.729294
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,Objective response rate,0.590876
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,ORR,0.722442
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,Median overall survival,0.659043
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,monotherapy,0.514468
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,Median OS,0.696688
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,PD-L1,0.300997
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,docetaxel,0.635065
uuid-810d1a9f787b4dd5b44d9bf3ed034b3e,hazard ratio,0.729977
uuid-506b1cfdb05f4aa4a8f0eebccc2c2a1c,ipilimumab,0.385692
uuid-506b1cfdb05f4aa4a8f0eebccc2c2a1c,ASCO 2015,0.417944
uuid-506b1cfdb05f4aa4a8f0eebccc2c2a1c,partial response,0.382425
uuid-506b1cfdb05f4aa4a8f0eebccc2c2a1c,Stable disease,0.586335
uuid-506b1cfdb05f4aa4a8f0eebccc2c2a1c,cohort,0.307748
uuid-0fd363f742b540f0a6130cbf1c332894,N Engl J Med,0.304989
uuid-0fd363f742b540f0a6130cbf1c332894,AEs,0.337832
uuid-0fd363f742b540f0a6130cbf1c332894,patients,0.387033
uuid-0fd363f742b540f0a6130cbf1c332894,provided in the Detailed Information,0.370845
uuid-0fd363f742b540f0a6130cbf1c332894,ESMO,0.421367
uuid-0fd363f742b540f0a6130cbf1c332894,NEJM,0.709799
uuid-0fd363f742b540f0a6130cbf1c332894,Topalian,0.735417
uuid-0fd363f742b540f0a6130cbf1c332894,grade 3 to 4 AEs,0.538198
uuid-4ae4543c2f814fcea7375354281ae05b,use of nivolumab for the treatment,0.409821
uuid-4ae4543c2f814fcea7375354281ae05b,patients with advanced or metastatic,0.645244
uuid-4ae4543c2f814fcea7375354281ae05b,nivolumab combined with ipilimumab,0.676339
uuid-4ae4543c2f814fcea7375354281ae05b,not approved,0.453534
uuid-4ae4543c2f814fcea7375354281ae05b,clinical trials investigating the safety,0.548799
uuid-4ae4543c2f814fcea7375354281ae05b,phase 1/2 study CA209-032,0.34114
uuid-4ae4543c2f814fcea7375354281ae05b,bladder cancer,0.749142
uuid-4ae4543c2f814fcea7375354281ae05b,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-27b12e5f12164264963106d9cef57a38,N Engl J Med,0.370003
uuid-27b12e5f12164264963106d9cef57a38,Lancet Oncol,0.325661
uuid-27b12e5f12164264963106d9cef57a38,protocol,0.370152
uuid-27b12e5f12164264963106d9cef57a38,McDermott DF,0.383667
uuid-27b12e5f12164264963106d9cef57a38,Motzer RJ,0.364039
uuid-27b12e5f12164264963106d9cef57a38,Escudier B,0.384855
uuid-27b12e5f12164264963106d9cef57a38,et al.,0.383921
uuid-27b12e5f12164264963106d9cef57a38,J Clin Oncol,0.3242
uuid-27b12e5f12164264963106d9cef57a38,Topalian,0.310455
uuid-27b12e5f12164264963106d9cef57a38,Rizvi NA,0.357753
uuid-27b12e5f12164264963106d9cef57a38,Weber JS,0.364738
uuid-27b12e5f12164264963106d9cef57a38,phase 2 study,0.380303
uuid-18067503d4174db294a58ee9babbf735,N Engl J Med,0.351111
uuid-18067503d4174db294a58ee9babbf735,protocol,0.35804
uuid-18067503d4174db294a58ee9babbf735,McDermott DF,0.384209
uuid-18067503d4174db294a58ee9babbf735,Motzer RJ,0.363703
uuid-18067503d4174db294a58ee9babbf735,Escudier B,0.384663
uuid-18067503d4174db294a58ee9babbf735,et al.,0.391576
uuid-18067503d4174db294a58ee9babbf735,J Clin Oncol,0.325264
uuid-a2ab129b7df0494d9b88179d8ff9a08d,nivolumab,0.450955
uuid-75551a79a7d244ff86bfff597ade631e,requested,0.553831
uuid-75551a79a7d244ff86bfff597ade631e,Horn L,0.582928
uuid-75551a79a7d244ff86bfff597ade631e,platinum-based doublet chemotherapy,0.625968
uuid-56f4153ef0064910a90af0c23a4d14bc,nivolumab,0.324658
uuid-56f4153ef0064910a90af0c23a4d14bc,use of nivolumab for the treatment,0.543355
uuid-56f4153ef0064910a90af0c23a4d14bc,evaluating,0.348676
uuid-56f4153ef0064910a90af0c23a4d14bc,efficacy,0.388907
uuid-56f4153ef0064910a90af0c23a4d14bc,patients,0.419915
uuid-56f4153ef0064910a90af0c23a4d14bc,search of published literature,0.449959
uuid-56f4153ef0064910a90af0c23a4d14bc,PubMed and EMBASE,0.444573
uuid-56f4153ef0064910a90af0c23a4d14bc,not approved,0.582429
uuid-56f4153ef0064910a90af0c23a4d14bc,clinical trials investigating the safety,0.64854
uuid-56f4153ef0064910a90af0c23a4d14bc,efficacy and safety of nivolumab,0.399101
uuid-56f4153ef0064910a90af0c23a4d14bc,present using the following search terms,0.465296
uuid-0cf4b0f9378d41cbb18162830984b416,OS,0.387982
uuid-0cf4b0f9378d41cbb18162830984b416,95% CI,0.745043
uuid-0cf4b0f9378d41cbb18162830984b416,respectively,0.729294
uuid-0cf4b0f9378d41cbb18162830984b416,Objective response rate,0.590876
uuid-0cf4b0f9378d41cbb18162830984b416,ORR,0.722442
uuid-0cf4b0f9378d41cbb18162830984b416,Median overall survival,0.659043
uuid-0cf4b0f9378d41cbb18162830984b416,monotherapy,0.514468
uuid-0cf4b0f9378d41cbb18162830984b416,Median OS,0.696688
uuid-0cf4b0f9378d41cbb18162830984b416,PD-L1,0.300997
uuid-0cf4b0f9378d41cbb18162830984b416,docetaxel,0.635065
uuid-0cf4b0f9378d41cbb18162830984b416,hazard ratio,0.729977
uuid-c851c3a43d6446288037374eabb78de4,Bristol-Myers Squibb,0.399725
uuid-c851c3a43d6446288037374eabb78de4,not conducted any controlled clinical trials/studies,0.346115
uuid-c851c3a43d6446288037374eabb78de4,provided in the Detailed Information,0.332115
uuid-c851c3a43d6446288037374eabb78de4,adverse,0.444392
uuid-c851c3a43d6446288037374eabb78de4,McDermott DF,0.330426
uuid-c851c3a43d6446288037374eabb78de4,Motzer RJ,0.327213
uuid-c851c3a43d6446288037374eabb78de4,phase 3 study,0.361824
uuid-c851c3a43d6446288037374eabb78de4,Escudier B,0.324604
uuid-c851c3a43d6446288037374eabb78de4,J Clin Oncol,0.312083
uuid-c851c3a43d6446288037374eabb78de4,phase 2 study,0.352337
uuid-c851c3a43d6446288037374eabb78de4,fatigue,0.5152
uuid-c851c3a43d6446288037374eabb78de4,reported,0.43118
uuid-8b0782f18a4b489ab2cd6b066e8d44e2,requested,0.687399
uuid-646a6d91072a468fad543397485b24f8,mg,0.300211
uuid-300f6f3ab7c4419f9b9da6439a3994de,nivolumab,0.486697
uuid-300f6f3ab7c4419f9b9da6439a3994de,use of nivolumab for the treatment,0.324482
uuid-300f6f3ab7c4419f9b9da6439a3994de,evaluating,0.499451
uuid-300f6f3ab7c4419f9b9da6439a3994de,not conducted any controlled clinical trials/studies,0.433127
uuid-300f6f3ab7c4419f9b9da6439a3994de,search of published literature,0.902175
uuid-300f6f3ab7c4419f9b9da6439a3994de,Additionally,0.372857
uuid-300f6f3ab7c4419f9b9da6439a3994de,PubMed and EMBASE,0.900783
uuid-300f6f3ab7c4419f9b9da6439a3994de,efficacy and safety of nivolumab,0.698274
uuid-300f6f3ab7c4419f9b9da6439a3994de,not identify any citations relevant to your request,0.575738
uuid-300f6f3ab7c4419f9b9da6439a3994de,present using the following search terms,0.911094
uuid-7fe953e1eac44f4782d61c6cdb103702,N Engl J Med,0.427636
uuid-7fe953e1eac44f4782d61c6cdb103702,protocol,0.429136
uuid-7fe953e1eac44f4782d61c6cdb103702,McDermott DF,0.44782
uuid-7fe953e1eac44f4782d61c6cdb103702,Motzer RJ,0.430476
uuid-7fe953e1eac44f4782d61c6cdb103702,Escudier B,0.450887
uuid-7fe953e1eac44f4782d61c6cdb103702,et al.,0.456026
uuid-7fe953e1eac44f4782d61c6cdb103702,J Clin Oncol,0.384624
uuid-7fe953e1eac44f4782d61c6cdb103702,Rizvi NA,0.305616
uuid-7fe953e1eac44f4782d61c6cdb103702,phase 2 study,0.351446
uuid-5f069327b2bf4742835b082eca949b72,ipilimumab,0.385692
uuid-5f069327b2bf4742835b082eca949b72,ASCO 2015,0.417944
uuid-5f069327b2bf4742835b082eca949b72,partial response,0.382425
uuid-5f069327b2bf4742835b082eca949b72,Stable disease,0.586335
uuid-5f069327b2bf4742835b082eca949b72,cohort,0.307748
uuid-38f8e24a03964a7080564296c23cd470,PD-L1,0.708176
uuid-84ec0dc3b464457ca4c9f6f2f40927e3,investigating,0.43154
uuid-a7a20a7adfad40328a7ab7e397d1830e,Bristol-Myers Squibb,0.36472
uuid-f0591acace46405bafb064a7f79a5f7b,Opdivo,0.448997
uuid-f0591acace46405bafb064a7f79a5f7b,adverse,0.47055
uuid-f0591acace46405bafb064a7f79a5f7b,reported,0.722822
uuid-3891075b9c044d87bfcd38a8bcc5d23e,mg,0.300211
uuid-f5ca91b95c45460f903564b058d69318,requested,0.559441
uuid-e79f23eaa842417c85e2c810f7c0b762,nivolumab,0.476778
uuid-e79f23eaa842417c85e2c810f7c0b762,Bristol-Myers Squibb,0.416854
uuid-e79f23eaa842417c85e2c810f7c0b762,evaluating,0.617875
uuid-e79f23eaa842417c85e2c810f7c0b762,not conducted any controlled clinical trials/studies,0.643716
uuid-e79f23eaa842417c85e2c810f7c0b762,non-small cell lung cancer,0.328252
uuid-e79f23eaa842417c85e2c810f7c0b762,Pubmed literature search,0.691208
uuid-e79f23eaa842417c85e2c810f7c0b762,purposes other than its labeled indication must be considered investigational,0.763269
uuid-e79f23eaa842417c85e2c810f7c0b762,not identify any citations relevant to your inquiry,0.656932
uuid-e79f23eaa842417c85e2c810f7c0b762,using the following search terms,0.638352
uuid-e79f23eaa842417c85e2c810f7c0b762,efficacy and safety of nivolumab,0.490333
uuid-03f08a13692948a1bdf872c92b7b77f1,Bristol-Myers Squibb,0.457498
uuid-03f08a13692948a1bdf872c92b7b77f1,evaluating,0.47698
uuid-03f08a13692948a1bdf872c92b7b77f1,not conducted any controlled clinical trials/studies,0.495184
uuid-03f08a13692948a1bdf872c92b7b77f1,NSCLC,0.32078
uuid-03f08a13692948a1bdf872c92b7b77f1,efficacy and safety of nivolumab,0.508093
uuid-eb3ceaace2c04b8b8f1561bff2b16982,not approved,0.389731
uuid-eb3ceaace2c04b8b8f1561bff2b16982,clinical trials investigating the safety,0.464336
uuid-eb3ceaace2c04b8b8f1561bff2b16982,fatigue,0.389752
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,nivolumab,0.403905
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,Bristol-Myers Squibb,0.330206
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,evaluating,0.557645
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,not conducted any controlled clinical trials/studies,0.524177
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,RCC,0.30703
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,search of published literature,0.792387
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,Additionally,0.730768
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,ongoing,0.568388
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,PubMed and EMBASE,0.7901
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,detailed search of www.clinicaltrials.gov,0.683837
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,efficacy and safety of nivolumab,0.725412
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,not identify any planned,0.609549
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,not identify any citations relevant to your request,0.844297
uuid-fb4a2cf2e04c4c65b77500dea1f2463e,present using the following search terms,0.828935
uuid-c2d4b1ada6da47eda2d53115f4d752ac,Opdivo,0.476741
uuid-c2d4b1ada6da47eda2d53115f4d752ac,trial,0.393134
uuid-c2d4b1ada6da47eda2d53115f4d752ac,docetaxel,0.437864
uuid-c2d4b1ada6da47eda2d53115f4d752ac,safety of nivolumab monotherapy,0.350737
uuid-c2d4b1ada6da47eda2d53115f4d752ac,phase,0.406186
uuid-e8320ca48b4841569c4aad7b7d84e889,N Engl J Med,0.392644
uuid-e8320ca48b4841569c4aad7b7d84e889,protocol,0.415504
uuid-e8320ca48b4841569c4aad7b7d84e889,McDermott DF,0.528516
uuid-e8320ca48b4841569c4aad7b7d84e889,Motzer RJ,0.490536
uuid-e8320ca48b4841569c4aad7b7d84e889,phase 3 study,0.490123
uuid-e8320ca48b4841569c4aad7b7d84e889,Escudier B,0.511152
uuid-e8320ca48b4841569c4aad7b7d84e889,et al.,0.489178
uuid-e8320ca48b4841569c4aad7b7d84e889,J Clin Oncol,0.474995
uuid-e8320ca48b4841569c4aad7b7d84e889,Rizvi NA,0.311157
uuid-e8320ca48b4841569c4aad7b7d84e889,phase 2 study,0.57543
uuid-147ebdcadb7c4e8eb190f156a6b57d16,provided in the Detailed Information,0.34899
uuid-147ebdcadb7c4e8eb190f156a6b57d16,Weber JS,0.355509
uuid-3450e397506842aeb60d4b1c087b4e8e,nivolumab,0.622461
uuid-3450e397506842aeb60d4b1c087b4e8e,Bristol-Myers Squibb,0.507624
uuid-3450e397506842aeb60d4b1c087b4e8e,evaluating,0.689529
uuid-3450e397506842aeb60d4b1c087b4e8e,not conducted any controlled clinical trials/studies,0.73333
uuid-3450e397506842aeb60d4b1c087b4e8e,Pubmed literature search,0.765664
uuid-3450e397506842aeb60d4b1c087b4e8e,purposes other than its labeled indication must be considered investigational,0.854619
uuid-3450e397506842aeb60d4b1c087b4e8e,not identify any citations relevant to your inquiry,0.719279
uuid-3450e397506842aeb60d4b1c087b4e8e,using the following search terms,0.700386
uuid-3450e397506842aeb60d4b1c087b4e8e,efficacy and safety of nivolumab,0.543083
uuid-ffe7dad189e342b7a32e6f833b94e361,requested,0.54928
uuid-1a9e85d1fef64af2b067d3f183b7455f,fatigue,0.411608
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,evaluating,0.350845
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,not conducted any controlled clinical trials/studies,0.345107
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,search of published literature,0.385331
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,Additionally,0.40981
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,ongoing,0.457998
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,PubMed and EMBASE,0.378285
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,detailed search of www.clinicaltrials.gov,0.428522
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,efficacy and safety of nivolumab,0.407868
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,not identify any planned,0.444729
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,combination,0.388252
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,BMS,0.316104
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,not identify any citations relevant to your request,0.438151
uuid-574e3bdca5f34cf1a67ab4f02bc8af9f,present using the following search terms,0.377101
uuid-edad47a750424d9f984b9918594acf0c,Bristol-Myers Squibb,0.647951
uuid-edad47a750424d9f984b9918594acf0c,evaluating,0.535772
uuid-edad47a750424d9f984b9918594acf0c,not conducted any controlled clinical trials/studies,0.596265
uuid-edad47a750424d9f984b9918594acf0c,patients,0.461311
uuid-edad47a750424d9f984b9918594acf0c,efficacy and safety of nivolumab,0.458155
uuid-090fe9281e01495fa4bba3fbe7f726fd,OS,0.313805
uuid-090fe9281e01495fa4bba3fbe7f726fd,95% CI,0.609295
uuid-090fe9281e01495fa4bba3fbe7f726fd,respectively,0.616176
uuid-090fe9281e01495fa4bba3fbe7f726fd,Objective response rate,0.452394
uuid-090fe9281e01495fa4bba3fbe7f726fd,ORR,0.57096
uuid-090fe9281e01495fa4bba3fbe7f726fd,Median overall survival,0.532292
uuid-090fe9281e01495fa4bba3fbe7f726fd,monotherapy,0.450833
uuid-090fe9281e01495fa4bba3fbe7f726fd,Median OS,0.581775
uuid-090fe9281e01495fa4bba3fbe7f726fd,docetaxel,0.650345
uuid-090fe9281e01495fa4bba3fbe7f726fd,hazard ratio,0.60843
uuid-5bb82f6ca9df425299c1970a49bcdde9,evaluating,0.328997
uuid-5bb82f6ca9df425299c1970a49bcdde9,not conducted any controlled clinical trials/studies,0.325444
uuid-5bb82f6ca9df425299c1970a49bcdde9,protocol,0.534557
uuid-5bb82f6ca9df425299c1970a49bcdde9,RCC,0.387518
uuid-5bb82f6ca9df425299c1970a49bcdde9,McDermott DF,0.446693
uuid-5bb82f6ca9df425299c1970a49bcdde9,search of published literature,0.507554
uuid-5bb82f6ca9df425299c1970a49bcdde9,Additionally,0.557318
uuid-5bb82f6ca9df425299c1970a49bcdde9,ongoing,0.480759
uuid-5bb82f6ca9df425299c1970a49bcdde9,Motzer RJ,0.477516
uuid-5bb82f6ca9df425299c1970a49bcdde9,PubMed and EMBASE,0.5052
uuid-5bb82f6ca9df425299c1970a49bcdde9,Escudier B,0.461714
uuid-5bb82f6ca9df425299c1970a49bcdde9,et al.,0.400032
uuid-5bb82f6ca9df425299c1970a49bcdde9,J Clin Oncol,0.430273
uuid-5bb82f6ca9df425299c1970a49bcdde9,detailed search of www.clinicaltrials.gov,0.517366
uuid-5bb82f6ca9df425299c1970a49bcdde9,efficacy and safety of nivolumab,0.474802
uuid-5bb82f6ca9df425299c1970a49bcdde9,not identify any planned,0.495387
uuid-5bb82f6ca9df425299c1970a49bcdde9,phase 2 study,0.386789
uuid-5bb82f6ca9df425299c1970a49bcdde9,not identify any citations relevant to your request,0.568753
uuid-5bb82f6ca9df425299c1970a49bcdde9,present using the following search terms,0.493883
uuid-989a3f7244d847d6b572717824666cd7,nivolumab,0.451468
uuid-989a3f7244d847d6b572717824666cd7,Bristol-Myers Squibb,0.538918
uuid-989a3f7244d847d6b572717824666cd7,evaluating,0.660915
uuid-989a3f7244d847d6b572717824666cd7,not conducted any controlled clinical trials/studies,0.692357
uuid-989a3f7244d847d6b572717824666cd7,Pubmed literature search,0.542625
uuid-989a3f7244d847d6b572717824666cd7,purposes other than its labeled indication must be considered investigational,0.633555
uuid-989a3f7244d847d6b572717824666cd7,not identify any citations relevant to your inquiry,0.511275
uuid-989a3f7244d847d6b572717824666cd7,using the following search terms,0.479601
uuid-989a3f7244d847d6b572717824666cd7,melanoma,0.378426
uuid-989a3f7244d847d6b572717824666cd7,efficacy and safety of nivolumab,0.519562
uuid-5e74dd2f40ea49de9ef9848026582064,OS,0.347231
uuid-5e74dd2f40ea49de9ef9848026582064,AEs,0.309925
uuid-5e74dd2f40ea49de9ef9848026582064,95% CI,0.62346
uuid-5e74dd2f40ea49de9ef9848026582064,respectively,0.62457
uuid-5e74dd2f40ea49de9ef9848026582064,Objective response rate,0.497036
uuid-5e74dd2f40ea49de9ef9848026582064,ORR,0.612289
uuid-5e74dd2f40ea49de9ef9848026582064,Median overall survival,0.601352
uuid-5e74dd2f40ea49de9ef9848026582064,monotherapy,0.40429
uuid-5e74dd2f40ea49de9ef9848026582064,Median OS,0.586347
uuid-5e74dd2f40ea49de9ef9848026582064,grade,0.363655
uuid-5e74dd2f40ea49de9ef9848026582064,hazard ratio,0.579733
uuid-468a4c856a044fa8a156bfc4ef742c3e,NSCLC,0.874494
uuid-468a4c856a044fa8a156bfc4ef742c3e,non-small cell lung cancer,0.848286
uuid-468a4c856a044fa8a156bfc4ef742c3e,considered investigational,0.3536
uuid-468a4c856a044fa8a156bfc4ef742c3e,phase 3 study,0.314143
uuid-468a4c856a044fa8a156bfc4ef742c3e,phase 1 study,0.429266
uuid-468a4c856a044fa8a156bfc4ef742c3e,safety of nivolumab monotherapy,0.307284
uuid-468a4c856a044fa8a156bfc4ef742c3e,platinum-based doublet chemotherapy,0.354992
uuid-eed065ed39f540068faac627bc7f9536,nivolumab,0.621606
uuid-eed065ed39f540068faac627bc7f9536,Bristol-Myers Squibb,0.410246
uuid-eed065ed39f540068faac627bc7f9536,evaluating,0.593257
uuid-eed065ed39f540068faac627bc7f9536,not conducted any controlled clinical trials/studies,0.63323
uuid-eed065ed39f540068faac627bc7f9536,Pubmed literature search,0.772203
uuid-eed065ed39f540068faac627bc7f9536,purposes other than its labeled indication must be considered investigational,0.85068
uuid-eed065ed39f540068faac627bc7f9536,not identify any citations relevant to your inquiry,0.733173
uuid-eed065ed39f540068faac627bc7f9536,using the following search terms,0.715727
uuid-eed065ed39f540068faac627bc7f9536,efficacy and safety of nivolumab,0.441525
uuid-59b77d4d26684f6baf42945553f69967,evaluating,0.331463
uuid-59b77d4d26684f6baf42945553f69967,not conducted any controlled clinical trials/studies,0.327968
uuid-59b77d4d26684f6baf42945553f69967,protocol,0.532972
uuid-59b77d4d26684f6baf42945553f69967,RCC,0.386451
uuid-59b77d4d26684f6baf42945553f69967,McDermott DF,0.444329
uuid-59b77d4d26684f6baf42945553f69967,search of published literature,0.50452
uuid-59b77d4d26684f6baf42945553f69967,Additionally,0.555299
uuid-59b77d4d26684f6baf42945553f69967,ongoing,0.478674
uuid-59b77d4d26684f6baf42945553f69967,Motzer RJ,0.475488
uuid-59b77d4d26684f6baf42945553f69967,PubMed and EMBASE,0.501909
uuid-59b77d4d26684f6baf42945553f69967,Escudier B,0.459186
uuid-59b77d4d26684f6baf42945553f69967,et al.,0.397016
uuid-59b77d4d26684f6baf42945553f69967,J Clin Oncol,0.428996
uuid-59b77d4d26684f6baf42945553f69967,detailed search of www.clinicaltrials.gov,0.514934
uuid-59b77d4d26684f6baf42945553f69967,efficacy and safety of nivolumab,0.47512
uuid-59b77d4d26684f6baf42945553f69967,not identify any planned,0.493147
uuid-59b77d4d26684f6baf42945553f69967,phase 2 study,0.384586
uuid-59b77d4d26684f6baf42945553f69967,not identify any citations relevant to your request,0.565812
uuid-59b77d4d26684f6baf42945553f69967,present using the following search terms,0.490802
uuid-4a885862132e4a2f939026eb1ee5be4f,patients with advanced or metastatic,0.468858
uuid-4a885862132e4a2f939026eb1ee5be4f,nivolumab combined with ipilimumab,0.446918
uuid-4a885862132e4a2f939026eb1ee5be4f,not approved,0.352562
uuid-4a885862132e4a2f939026eb1ee5be4f,clinical trials investigating the safety,0.429501
uuid-4a885862132e4a2f939026eb1ee5be4f,bladder cancer,0.950698
uuid-db20c372a2174077a29f60faa387f488,not conducted any controlled clinical trials/studies,0.323287
uuid-db20c372a2174077a29f60faa387f488,NSCLC,0.557108
uuid-db20c372a2174077a29f60faa387f488,non-small cell lung cancer,0.534716
uuid-db20c372a2174077a29f60faa387f488,considered investigational,0.378666
uuid-db20c372a2174077a29f60faa387f488,phase 3 study,0.332492
uuid-db20c372a2174077a29f60faa387f488,phase 1 study,0.304388
uuid-db20c372a2174077a29f60faa387f488,small cell lung cancer,0.372641
uuid-db20c372a2174077a29f60faa387f488,efficacy and safety of nivolumab,0.317198
uuid-db20c372a2174077a29f60faa387f488,SCLC,0.417011
uuid-db20c372a2174077a29f60faa387f488,therapy,0.620924
uuid-2ab1976af23c4fed89fbf03746c0381d,OS,0.387982
uuid-2ab1976af23c4fed89fbf03746c0381d,95% CI,0.745043
uuid-2ab1976af23c4fed89fbf03746c0381d,respectively,0.729294
uuid-2ab1976af23c4fed89fbf03746c0381d,Objective response rate,0.590876
uuid-2ab1976af23c4fed89fbf03746c0381d,ORR,0.722442
uuid-2ab1976af23c4fed89fbf03746c0381d,Median overall survival,0.659043
uuid-2ab1976af23c4fed89fbf03746c0381d,monotherapy,0.514468
uuid-2ab1976af23c4fed89fbf03746c0381d,Median OS,0.696688
uuid-2ab1976af23c4fed89fbf03746c0381d,PD-L1,0.300997
uuid-2ab1976af23c4fed89fbf03746c0381d,docetaxel,0.635065
uuid-2ab1976af23c4fed89fbf03746c0381d,hazard ratio,0.729977
uuid-476a5db15b5a4108b85ad2d8efacafd7,clinicaltrials.gov,0.388287
uuid-476a5db15b5a4108b85ad2d8efacafd7,BMS,0.353151
uuid-de6f6dda6bde4e2cacd296977da621d3,evaluating,0.326511
uuid-de6f6dda6bde4e2cacd296977da621d3,not conducted any controlled clinical trials/studies,0.308229
uuid-de6f6dda6bde4e2cacd296977da621d3,RCC,0.316062
uuid-de6f6dda6bde4e2cacd296977da621d3,search of published literature,0.510987
uuid-de6f6dda6bde4e2cacd296977da621d3,Additionally,0.720971
uuid-de6f6dda6bde4e2cacd296977da621d3,ongoing,0.587023
uuid-de6f6dda6bde4e2cacd296977da621d3,PubMed and EMBASE,0.513581
uuid-de6f6dda6bde4e2cacd296977da621d3,detailed search of www.clinicaltrials.gov,0.662734
uuid-de6f6dda6bde4e2cacd296977da621d3,efficacy and safety of nivolumab,0.444016
uuid-de6f6dda6bde4e2cacd296977da621d3,not identify any planned,0.619369
uuid-de6f6dda6bde4e2cacd296977da621d3,not identify any citations relevant to your request,0.711349
uuid-de6f6dda6bde4e2cacd296977da621d3,present using the following search terms,0.521206
uuid-dbe91e090e5e4e55be7897f8185bef73,N Engl J Med,0.520402
uuid-dbe91e090e5e4e55be7897f8185bef73,provided in the Detailed Information,0.434998
uuid-dbe91e090e5e4e55be7897f8185bef73,protocol,0.658119
uuid-dbe91e090e5e4e55be7897f8185bef73,McDermott DF,0.726713
uuid-dbe91e090e5e4e55be7897f8185bef73,Motzer RJ,0.711974
uuid-dbe91e090e5e4e55be7897f8185bef73,clinical,0.502249
uuid-dbe91e090e5e4e55be7897f8185bef73,phase 3 study,0.415967
uuid-dbe91e090e5e4e55be7897f8185bef73,Escudier B,0.724005
uuid-dbe91e090e5e4e55be7897f8185bef73,NEJM,0.358371
uuid-dbe91e090e5e4e55be7897f8185bef73,et al.,0.689006
uuid-dbe91e090e5e4e55be7897f8185bef73,J Clin Oncol,0.683657
uuid-dbe91e090e5e4e55be7897f8185bef73,Topalian,0.331782
uuid-dbe91e090e5e4e55be7897f8185bef73,Rizvi NA,0.344561
uuid-dbe91e090e5e4e55be7897f8185bef73,phase 2 study,0.635209
uuid-1f358394e6914c92a02bbb6a077eb5d2,Lancet Oncol,0.693877
uuid-1f358394e6914c92a02bbb6a077eb5d2,patients,0.405972
uuid-1f358394e6914c92a02bbb6a077eb5d2,ipilimumab,0.370825
uuid-1f358394e6914c92a02bbb6a077eb5d2,phase 3 study,0.623784
uuid-1f358394e6914c92a02bbb6a077eb5d2,ASCO 2015,0.343144
uuid-1f358394e6914c92a02bbb6a077eb5d2,melanoma,0.311721
uuid-1f358394e6914c92a02bbb6a077eb5d2,phase 1 study,0.381973
uuid-1f358394e6914c92a02bbb6a077eb5d2,Rizvi NA,0.651494
uuid-1f358394e6914c92a02bbb6a077eb5d2,CA209-003,0.307938
uuid-1f358394e6914c92a02bbb6a077eb5d2,Weber JS,0.728839
uuid-1f358394e6914c92a02bbb6a077eb5d2,phase 2 study,0.401293
uuid-1f358394e6914c92a02bbb6a077eb5d2,Antonia SJ,0.482552
uuid-41dce6149ef442569120769fafe25a7e,Opdivo,0.460218
uuid-41dce6149ef442569120769fafe25a7e,trial,0.434759
uuid-41dce6149ef442569120769fafe25a7e,docetaxel,0.483842
uuid-e826584da90f4280bb06299322c27503,OS,0.503938
uuid-e826584da90f4280bb06299322c27503,95% CI,0.918353
uuid-e826584da90f4280bb06299322c27503,respectively,0.337717
uuid-e826584da90f4280bb06299322c27503,Objective response rate,0.46992
uuid-e826584da90f4280bb06299322c27503,ORR,0.617632
uuid-e826584da90f4280bb06299322c27503,PFS,0.376033
uuid-e826584da90f4280bb06299322c27503,Median overall survival,0.862581
uuid-e826584da90f4280bb06299322c27503,Median OS,0.876177
uuid-e826584da90f4280bb06299322c27503,hazard ratio,0.900168
uuid-e826584da90f4280bb06299322c27503,Median duration of response,0.475836
uuid-3faa390b7a5f4e66be6ecfe2955c6b46,mg,0.300211
uuid-16e17a203e4a4d67a943daa1d6a4dca6,AEs,0.454113
uuid-16e17a203e4a4d67a943daa1d6a4dca6,NSCLC,0.37953
uuid-16e17a203e4a4d67a943daa1d6a4dca6,non-small cell lung cancer,0.380904
uuid-16e17a203e4a4d67a943daa1d6a4dca6,patients,0.47897
uuid-16e17a203e4a4d67a943daa1d6a4dca6,considered investigational,0.306544
uuid-16e17a203e4a4d67a943daa1d6a4dca6,small cell lung cancer,0.382079
uuid-16e17a203e4a4d67a943daa1d6a4dca6,grade,0.475906
uuid-16e17a203e4a4d67a943daa1d6a4dca6,SCLC,0.393164
uuid-16e17a203e4a4d67a943daa1d6a4dca6,therapy,0.465223
uuid-16e17a203e4a4d67a943daa1d6a4dca6,grade 3 to 4 AEs,0.522826
uuid-680b28759042433c9ff4d2d1e80222b0,requested,0.399688
uuid-cb6afecac2c248e5b650e1cbda232ec1,OS,0.470416
uuid-cb6afecac2c248e5b650e1cbda232ec1,AEs,0.312249
uuid-cb6afecac2c248e5b650e1cbda232ec1,95% CI,0.820361
uuid-cb6afecac2c248e5b650e1cbda232ec1,respectively,0.399825
uuid-cb6afecac2c248e5b650e1cbda232ec1,Objective response rate,0.434178
uuid-cb6afecac2c248e5b650e1cbda232ec1,ORR,0.578964
uuid-cb6afecac2c248e5b650e1cbda232ec1,PFS,0.364226
uuid-cb6afecac2c248e5b650e1cbda232ec1,Median overall survival,0.776144
uuid-cb6afecac2c248e5b650e1cbda232ec1,Median OS,0.779339
uuid-cb6afecac2c248e5b650e1cbda232ec1,hazard ratio,0.780416
uuid-cb6afecac2c248e5b650e1cbda232ec1,Median duration of response,0.450064
uuid-dbc7e75dc89042b29019545fb74179cb,N Engl J Med,0.532669
uuid-dbc7e75dc89042b29019545fb74179cb,requested,0.453629
uuid-dbc7e75dc89042b29019545fb74179cb,protocol,0.474917
uuid-dbc7e75dc89042b29019545fb74179cb,McDermott DF,0.585118
uuid-dbc7e75dc89042b29019545fb74179cb,Motzer RJ,0.54582
uuid-dbc7e75dc89042b29019545fb74179cb,ESMO,0.364183
uuid-dbc7e75dc89042b29019545fb74179cb,Escudier B,0.582784
uuid-dbc7e75dc89042b29019545fb74179cb,NEJM,0.303942
uuid-dbc7e75dc89042b29019545fb74179cb,et al.,0.636186
uuid-dbc7e75dc89042b29019545fb74179cb,J Clin Oncol,0.498669
uuid-dbc7e75dc89042b29019545fb74179cb,phase 2 study,0.483987
uuid-dbc7e75dc89042b29019545fb74179cb,Horn L,0.310731
uuid-62f82a9b7d2d46e19ba7d4ed6c7d4b4d,melanoma,0.410364
uuid-bb411ba358d4407c9a3489af66e543ea,fatigue,0.323475
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,OS,0.387982
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,95% CI,0.745043
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,respectively,0.729294
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,Objective response rate,0.590876
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,ORR,0.722442
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,Median overall survival,0.659043
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,monotherapy,0.514468
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,Median OS,0.696688
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,PD-L1,0.300997
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,docetaxel,0.635065
uuid-da1066181bf64b598b4e3ecdcaf7a4a0,hazard ratio,0.729977
uuid-e1f82212641e489cbbcf131c490a0edc,requested,0.488582
uuid-e1f82212641e489cbbcf131c490a0edc,trial,0.361556
uuid-4deba8598961470daafc523c889510f2,Objective response rate,0.451139
uuid-4deba8598961470daafc523c889510f2,clinicaltrials.gov,0.503706
uuid-7b84dde3663e41458df8f90c90c88e0e,Bristol-Myers Squibb,0.341822
uuid-7b84dde3663e41458df8f90c90c88e0e,not conducted any controlled clinical trials/studies,0.304507
uuid-7b84dde3663e41458df8f90c90c88e0e,Opdivo,0.461382
uuid-7b84dde3663e41458df8f90c90c88e0e,Pubmed literature search,0.614325
uuid-7b84dde3663e41458df8f90c90c88e0e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-7b84dde3663e41458df8f90c90c88e0e,not identify any citations relevant to your inquiry,0.606087
uuid-7b84dde3663e41458df8f90c90c88e0e,adverse,0.304183
uuid-7b84dde3663e41458df8f90c90c88e0e,using the following search terms,0.642331
uuid-7b84dde3663e41458df8f90c90c88e0e,databases,0.315039
uuid-7b84dde3663e41458df8f90c90c88e0e,reported,0.556704
uuid-599d7fdd59d247f9a9532e048f621ab6,nivolumab,0.577128
uuid-599d7fdd59d247f9a9532e048f621ab6,Bristol-Myers Squibb,0.441599
uuid-599d7fdd59d247f9a9532e048f621ab6,evaluating,0.60154
uuid-599d7fdd59d247f9a9532e048f621ab6,not conducted any controlled clinical trials/studies,0.661327
uuid-599d7fdd59d247f9a9532e048f621ab6,Pubmed literature search,0.870882
uuid-599d7fdd59d247f9a9532e048f621ab6,purposes other than its labeled indication must be considered investigational,0.936253
uuid-599d7fdd59d247f9a9532e048f621ab6,not identify any citations relevant to your inquiry,0.829618
uuid-599d7fdd59d247f9a9532e048f621ab6,using the following search terms,0.816807
uuid-599d7fdd59d247f9a9532e048f621ab6,efficacy and safety of nivolumab,0.442439
uuid-9d856e59af594cef8825eed873726767,N Engl J Med,0.427636
uuid-9d856e59af594cef8825eed873726767,protocol,0.429136
uuid-9d856e59af594cef8825eed873726767,McDermott DF,0.44782
uuid-9d856e59af594cef8825eed873726767,Motzer RJ,0.430476
uuid-9d856e59af594cef8825eed873726767,Escudier B,0.450887
uuid-9d856e59af594cef8825eed873726767,et al.,0.456026
uuid-9d856e59af594cef8825eed873726767,J Clin Oncol,0.384624
uuid-9d856e59af594cef8825eed873726767,Rizvi NA,0.305616
uuid-9d856e59af594cef8825eed873726767,phase 2 study,0.351446
uuid-95fdb83e91fe473ebb605315af914359,nivolumab,0.999168
uuid-95fdb83e91fe473ebb605315af914359,Pubmed literature search,0.395314
uuid-95fdb83e91fe473ebb605315af914359,purposes other than its labeled indication must be considered investigational,0.464236
uuid-95fdb83e91fe473ebb605315af914359,not identify any citations relevant to your inquiry,0.368569
uuid-95fdb83e91fe473ebb605315af914359,using the following search terms,0.364279
uuid-95fdb83e91fe473ebb605315af914359,present using the following search terms,0.329876
uuid-a16791ff01744dc2ab6ae3dbcd592c35,patients,0.556054
uuid-a16791ff01744dc2ab6ae3dbcd592c35,provided in the Detailed Information,0.329929
uuid-a16791ff01744dc2ab6ae3dbcd592c35,adverse,0.32982
uuid-a16791ff01744dc2ab6ae3dbcd592c35,phase 3 study,0.523726
uuid-a16791ff01744dc2ab6ae3dbcd592c35,melanoma,0.382071
uuid-a16791ff01744dc2ab6ae3dbcd592c35,Weber JS,0.428777
uuid-a16791ff01744dc2ab6ae3dbcd592c35,phase 2 study,0.307314
uuid-a16791ff01744dc2ab6ae3dbcd592c35,grade 3 to 4 AEs,0.466022
uuid-6792182f0eb3457890bc6f463acf9e17,nivolumab,0.567915
uuid-6792182f0eb3457890bc6f463acf9e17,Bristol-Myers Squibb,0.440616
uuid-6792182f0eb3457890bc6f463acf9e17,evaluating,0.595756
uuid-6792182f0eb3457890bc6f463acf9e17,not conducted any controlled clinical trials/studies,0.65735
uuid-6792182f0eb3457890bc6f463acf9e17,Pubmed literature search,0.878124
uuid-6792182f0eb3457890bc6f463acf9e17,purposes other than its labeled indication must be considered investigational,0.941032
uuid-6792182f0eb3457890bc6f463acf9e17,not identify any citations relevant to your inquiry,0.837002
uuid-6792182f0eb3457890bc6f463acf9e17,using the following search terms,0.824766
uuid-6792182f0eb3457890bc6f463acf9e17,efficacy and safety of nivolumab,0.434019
uuid-5e183d7f5b5e4eeebbb3f43986593346,95% CI,0.419478
uuid-5e183d7f5b5e4eeebbb3f43986593346,respectively,0.497608
uuid-5e183d7f5b5e4eeebbb3f43986593346,Objective response rate,0.403649
uuid-5e183d7f5b5e4eeebbb3f43986593346,ORR,0.578109
uuid-5e183d7f5b5e4eeebbb3f43986593346,patients with advanced or metastatic,0.306625
uuid-5e183d7f5b5e4eeebbb3f43986593346,Median overall survival,0.498783
uuid-5e183d7f5b5e4eeebbb3f43986593346,nivolumab combined with ipilimumab,0.300486
uuid-5e183d7f5b5e4eeebbb3f43986593346,tumors,0.323334
uuid-5e183d7f5b5e4eeebbb3f43986593346,ESMO,0.534361
uuid-5e183d7f5b5e4eeebbb3f43986593346,Median OS,0.394058
uuid-5e183d7f5b5e4eeebbb3f43986593346,small cell lung cancer,0.380999
uuid-5e183d7f5b5e4eeebbb3f43986593346,SCLC,0.365686
uuid-5e183d7f5b5e4eeebbb3f43986593346,hazard ratio,0.419392
uuid-5e183d7f5b5e4eeebbb3f43986593346,grade 3 to 4 AEs,0.414535
uuid-5e183d7f5b5e4eeebbb3f43986593346,phase 1/2 study CA209-032,0.398283
uuid-5e183d7f5b5e4eeebbb3f43986593346,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,OS,0.387982
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,95% CI,0.745043
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,respectively,0.729294
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,Objective response rate,0.590876
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,ORR,0.722442
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,Median overall survival,0.659043
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,monotherapy,0.514468
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,Median OS,0.696688
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,PD-L1,0.300997
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,docetaxel,0.635065
uuid-21160e3b610240d4ab6b0cb1fb5dc81d,hazard ratio,0.729977
uuid-89551482262e444aa7dcf2fde08bd914,melanoma,0.410364
uuid-e4a946a133f245729f9c9a2c562c84a0,patients with advanced or metastatic,0.468858
uuid-e4a946a133f245729f9c9a2c562c84a0,nivolumab combined with ipilimumab,0.446918
uuid-e4a946a133f245729f9c9a2c562c84a0,not approved,0.352562
uuid-e4a946a133f245729f9c9a2c562c84a0,clinical trials investigating the safety,0.429501
uuid-e4a946a133f245729f9c9a2c562c84a0,bladder cancer,0.950698
uuid-e8eb87ea4caf4170993ee2325a34432d,use of nivolumab for the treatment,0.440423
uuid-e8eb87ea4caf4170993ee2325a34432d,search of published literature,0.311531
uuid-e8eb87ea4caf4170993ee2325a34432d,PubMed and EMBASE,0.312811
uuid-e8eb87ea4caf4170993ee2325a34432d,not approved,0.404782
uuid-e8eb87ea4caf4170993ee2325a34432d,open-label,0.578291
uuid-e8eb87ea4caf4170993ee2325a34432d,clinical trials investigating the safety,0.440014
uuid-e8eb87ea4caf4170993ee2325a34432d,present using the following search terms,0.328669
uuid-e8eb87ea4caf4170993ee2325a34432d,phase,0.41185
uuid-878253b8e04841cd8c6951728adbd6ef,95% CI,0.680103
uuid-878253b8e04841cd8c6951728adbd6ef,Objective response rate,0.462337
uuid-878253b8e04841cd8c6951728adbd6ef,ORR,0.537672
uuid-878253b8e04841cd8c6951728adbd6ef,Median overall survival,0.601596
uuid-878253b8e04841cd8c6951728adbd6ef,monotherapy,0.378267
uuid-878253b8e04841cd8c6951728adbd6ef,Median OS,0.580333
uuid-878253b8e04841cd8c6951728adbd6ef,hazard ratio,0.658747
uuid-878253b8e04841cd8c6951728adbd6ef,Median duration of response,0.421068
uuid-e70c7834a78643bbbcd9f8a3ffc71440,OS,0.387982
uuid-e70c7834a78643bbbcd9f8a3ffc71440,95% CI,0.745043
uuid-e70c7834a78643bbbcd9f8a3ffc71440,respectively,0.729294
uuid-e70c7834a78643bbbcd9f8a3ffc71440,Objective response rate,0.590876
uuid-e70c7834a78643bbbcd9f8a3ffc71440,ORR,0.722442
uuid-e70c7834a78643bbbcd9f8a3ffc71440,Median overall survival,0.659043
uuid-e70c7834a78643bbbcd9f8a3ffc71440,monotherapy,0.514468
uuid-e70c7834a78643bbbcd9f8a3ffc71440,Median OS,0.696688
uuid-e70c7834a78643bbbcd9f8a3ffc71440,PD-L1,0.300997
uuid-e70c7834a78643bbbcd9f8a3ffc71440,docetaxel,0.635065
uuid-e70c7834a78643bbbcd9f8a3ffc71440,hazard ratio,0.729977
uuid-7236b2bb9b114f238e8fc365407d5d7e,OS,0.504018
uuid-7236b2bb9b114f238e8fc365407d5d7e,95% CI,0.91849
uuid-7236b2bb9b114f238e8fc365407d5d7e,respectively,0.337474
uuid-7236b2bb9b114f238e8fc365407d5d7e,Objective response rate,0.470012
uuid-7236b2bb9b114f238e8fc365407d5d7e,ORR,0.617999
uuid-7236b2bb9b114f238e8fc365407d5d7e,PFS,0.376169
uuid-7236b2bb9b114f238e8fc365407d5d7e,Median overall survival,0.86272
uuid-7236b2bb9b114f238e8fc365407d5d7e,Median OS,0.876273
uuid-7236b2bb9b114f238e8fc365407d5d7e,hazard ratio,0.90025
uuid-7236b2bb9b114f238e8fc365407d5d7e,Median duration of response,0.475928
uuid-2f71eaa5955a443d9468fd0209fe0bd5,ASCO,0.816943
uuid-2f71eaa5955a443d9468fd0209fe0bd5,Antonia SJ,0.350157
uuid-86299790546b4791b5c0beb18d0e1aeb,fatigue,0.411608
uuid-ba09550d9dd24aa5858370e65d794613,N Engl J Med,0.636726
uuid-ba09550d9dd24aa5858370e65d794613,non-small cell lung cancer,0.351489
uuid-ba09550d9dd24aa5858370e65d794613,ESMO,0.419331
uuid-ba09550d9dd24aa5858370e65d794613,Rizvi NA,0.470388
uuid-ba09550d9dd24aa5858370e65d794613,Brahmer J,0.676477
uuid-ba09550d9dd24aa5858370e65d794613,PD-L1,0.354847
uuid-ba09550d9dd24aa5858370e65d794613,Horn L,0.512976
uuid-ba09550d9dd24aa5858370e65d794613,platinum-based doublet chemotherapy,0.312066
uuid-86bcda90705a45219539c84bb42051e1,Opdivo,0.313775
uuid-86bcda90705a45219539c84bb42051e1,adverse,0.40954
uuid-86bcda90705a45219539c84bb42051e1,safety,0.558348
uuid-86bcda90705a45219539c84bb42051e1,databases,0.497042
uuid-86bcda90705a45219539c84bb42051e1,reported,0.646787
uuid-cedf874094be43adaed7e0ef91183828,Bristol-Myers Squibb,0.510666
uuid-cedf874094be43adaed7e0ef91183828,evaluating,0.362743
uuid-cedf874094be43adaed7e0ef91183828,not conducted any controlled clinical trials/studies,0.411912
uuid-cedf874094be43adaed7e0ef91183828,adverse,0.743658
uuid-cedf874094be43adaed7e0ef91183828,phase 3 study,0.345761
uuid-cedf874094be43adaed7e0ef91183828,melanoma,0.408652
uuid-cedf874094be43adaed7e0ef91183828,efficacy and safety of nivolumab,0.338674
uuid-cedf874094be43adaed7e0ef91183828,reported,0.416366
uuid-07eef32420ca408f914c6b806e6110d3,nivolumab,0.497077
uuid-07eef32420ca408f914c6b806e6110d3,Bristol-Myers Squibb,0.469384
uuid-07eef32420ca408f914c6b806e6110d3,evaluating,0.63453
uuid-07eef32420ca408f914c6b806e6110d3,not conducted any controlled clinical trials/studies,0.694547
uuid-07eef32420ca408f914c6b806e6110d3,Pubmed literature search,0.861707
uuid-07eef32420ca408f914c6b806e6110d3,purposes other than its labeled indication must be considered investigational,0.928224
uuid-07eef32420ca408f914c6b806e6110d3,not identify any citations relevant to your inquiry,0.819485
uuid-07eef32420ca408f914c6b806e6110d3,using the following search terms,0.805108
uuid-07eef32420ca408f914c6b806e6110d3,efficacy and safety of nivolumab,0.474554
uuid-f657676ecc8c421ca05656ee420111fc,OS,0.387982
uuid-f657676ecc8c421ca05656ee420111fc,95% CI,0.745043
uuid-f657676ecc8c421ca05656ee420111fc,respectively,0.729294
uuid-f657676ecc8c421ca05656ee420111fc,Objective response rate,0.590876
uuid-f657676ecc8c421ca05656ee420111fc,ORR,0.722442
uuid-f657676ecc8c421ca05656ee420111fc,Median overall survival,0.659043
uuid-f657676ecc8c421ca05656ee420111fc,monotherapy,0.514468
uuid-f657676ecc8c421ca05656ee420111fc,Median OS,0.696688
uuid-f657676ecc8c421ca05656ee420111fc,PD-L1,0.300997
uuid-f657676ecc8c421ca05656ee420111fc,docetaxel,0.635065
uuid-f657676ecc8c421ca05656ee420111fc,hazard ratio,0.729977
uuid-3e5f552adc01479cb8bbcb934ad779aa,OS,0.340526
uuid-3e5f552adc01479cb8bbcb934ad779aa,N Engl J Med,0.520756
uuid-3e5f552adc01479cb8bbcb934ad779aa,95% CI,0.498493
uuid-3e5f552adc01479cb8bbcb934ad779aa,respectively,0.355262
uuid-3e5f552adc01479cb8bbcb934ad779aa,ASCO,0.364214
uuid-3e5f552adc01479cb8bbcb934ad779aa,Objective response rate,0.373486
uuid-3e5f552adc01479cb8bbcb934ad779aa,ORR,0.473864
uuid-3e5f552adc01479cb8bbcb934ad779aa,Median overall survival,0.505259
uuid-3e5f552adc01479cb8bbcb934ad779aa,ESMO,0.325009
uuid-3e5f552adc01479cb8bbcb934ad779aa,Median OS,0.57479
uuid-3e5f552adc01479cb8bbcb934ad779aa,Rizvi NA,0.322081
uuid-3e5f552adc01479cb8bbcb934ad779aa,Brahmer J,0.538521
uuid-3e5f552adc01479cb8bbcb934ad779aa,Horn L,0.32559
uuid-3e5f552adc01479cb8bbcb934ad779aa,hazard ratio,0.475188
uuid-85ef37070920496abda7e83b462c22b3,nivolumab,0.344939
uuid-85ef37070920496abda7e83b462c22b3,Bristol-Myers Squibb,0.363004
uuid-85ef37070920496abda7e83b462c22b3,evaluating,0.564404
uuid-85ef37070920496abda7e83b462c22b3,not conducted any controlled clinical trials/studies,0.538169
uuid-85ef37070920496abda7e83b462c22b3,RCC,0.336118
uuid-85ef37070920496abda7e83b462c22b3,search of published literature,0.750115
uuid-85ef37070920496abda7e83b462c22b3,Additionally,0.766378
uuid-85ef37070920496abda7e83b462c22b3,ongoing,0.629393
uuid-85ef37070920496abda7e83b462c22b3,PubMed and EMBASE,0.745288
uuid-85ef37070920496abda7e83b462c22b3,detailed search of www.clinicaltrials.gov,0.729251
uuid-85ef37070920496abda7e83b462c22b3,efficacy and safety of nivolumab,0.716075
uuid-85ef37070920496abda7e83b462c22b3,not identify any planned,0.665705
uuid-85ef37070920496abda7e83b462c22b3,not identify any citations relevant to your request,0.849476
uuid-85ef37070920496abda7e83b462c22b3,present using the following search terms,0.773092
uuid-787dbdc8269743c3b558b329c68c0444,open-label,0.539462
uuid-787dbdc8269743c3b558b329c68c0444,phase,0.350616
uuid-0ae88b65b40540c79092ee6d9813b9f0,requested,0.594234
uuid-4137221fedba4f798f0d24d0b1d9f22e,melanoma,0.410364
uuid-ea10935f35414ce0b59ba470b8a84146,N Engl J Med,0.448483
uuid-ea10935f35414ce0b59ba470b8a84146,protocol,0.770446
uuid-ea10935f35414ce0b59ba470b8a84146,McDermott DF,0.741196
uuid-ea10935f35414ce0b59ba470b8a84146,Motzer RJ,0.818144
uuid-ea10935f35414ce0b59ba470b8a84146,phase 3 study,0.417055
uuid-ea10935f35414ce0b59ba470b8a84146,Escudier B,0.749917
uuid-ea10935f35414ce0b59ba470b8a84146,NEJM,0.400698
uuid-ea10935f35414ce0b59ba470b8a84146,et al.,0.668641
uuid-ea10935f35414ce0b59ba470b8a84146,J Clin Oncol,0.792018
uuid-ea10935f35414ce0b59ba470b8a84146,Topalian,0.388894
uuid-ea10935f35414ce0b59ba470b8a84146,phase 1 study,0.500686
uuid-ea10935f35414ce0b59ba470b8a84146,CA209-003,0.567381
uuid-ea10935f35414ce0b59ba470b8a84146,phase 2 study,0.677985
uuid-ea10935f35414ce0b59ba470b8a84146,present using the following search terms,0.310558
uuid-ea10935f35414ce0b59ba470b8a84146,investigating,0.615835
uuid-87a72d256ec34920a0a472ed40b96a39,N Engl J Med,0.529292
uuid-87a72d256ec34920a0a472ed40b96a39,protocol,0.692402
uuid-87a72d256ec34920a0a472ed40b96a39,McDermott DF,0.72358
uuid-87a72d256ec34920a0a472ed40b96a39,Motzer RJ,0.726538
uuid-87a72d256ec34920a0a472ed40b96a39,phase 3 study,0.512726
uuid-87a72d256ec34920a0a472ed40b96a39,Escudier B,0.727083
uuid-87a72d256ec34920a0a472ed40b96a39,NEJM,0.405551
uuid-87a72d256ec34920a0a472ed40b96a39,et al.,0.692152
uuid-87a72d256ec34920a0a472ed40b96a39,J Clin Oncol,0.686619
uuid-87a72d256ec34920a0a472ed40b96a39,Topalian,0.329268
uuid-87a72d256ec34920a0a472ed40b96a39,Rizvi NA,0.410902
uuid-87a72d256ec34920a0a472ed40b96a39,CA209-003,0.30444
uuid-87a72d256ec34920a0a472ed40b96a39,Weber JS,0.307005
uuid-87a72d256ec34920a0a472ed40b96a39,phase 2 study,0.726313
uuid-db14999fcee249cc9a66b182e8f50efb,NSCLC,0.874494
uuid-db14999fcee249cc9a66b182e8f50efb,non-small cell lung cancer,0.848286
uuid-db14999fcee249cc9a66b182e8f50efb,considered investigational,0.3536
uuid-db14999fcee249cc9a66b182e8f50efb,phase 3 study,0.314143
uuid-db14999fcee249cc9a66b182e8f50efb,phase 1 study,0.429266
uuid-db14999fcee249cc9a66b182e8f50efb,safety of nivolumab monotherapy,0.307284
uuid-db14999fcee249cc9a66b182e8f50efb,platinum-based doublet chemotherapy,0.354992
uuid-b7a22a67788041dbbce4966f7d3da8da,nivolumab,0.429052
uuid-b7a22a67788041dbbce4966f7d3da8da,melanoma,0.450874
uuid-55354ce9304e456eb59cf6df12a1207b,phase 3 study,0.577701
uuid-55354ce9304e456eb59cf6df12a1207b,Weber JS,0.507934
uuid-d1b81d97feb54cde84cf6a196c8c8c14,OS,0.387982
uuid-d1b81d97feb54cde84cf6a196c8c8c14,95% CI,0.745043
uuid-d1b81d97feb54cde84cf6a196c8c8c14,respectively,0.729294
uuid-d1b81d97feb54cde84cf6a196c8c8c14,Objective response rate,0.590876
uuid-d1b81d97feb54cde84cf6a196c8c8c14,ORR,0.722442
uuid-d1b81d97feb54cde84cf6a196c8c8c14,Median overall survival,0.659043
uuid-d1b81d97feb54cde84cf6a196c8c8c14,monotherapy,0.514468
uuid-d1b81d97feb54cde84cf6a196c8c8c14,Median OS,0.696688
uuid-d1b81d97feb54cde84cf6a196c8c8c14,PD-L1,0.300997
uuid-d1b81d97feb54cde84cf6a196c8c8c14,docetaxel,0.635065
uuid-d1b81d97feb54cde84cf6a196c8c8c14,hazard ratio,0.729977
uuid-a7001f2f63c741459b35fbcec325e3a7,OS,0.387982
uuid-a7001f2f63c741459b35fbcec325e3a7,95% CI,0.745043
uuid-a7001f2f63c741459b35fbcec325e3a7,respectively,0.729294
uuid-a7001f2f63c741459b35fbcec325e3a7,Objective response rate,0.590876
uuid-a7001f2f63c741459b35fbcec325e3a7,ORR,0.722442
uuid-a7001f2f63c741459b35fbcec325e3a7,Median overall survival,0.659043
uuid-a7001f2f63c741459b35fbcec325e3a7,monotherapy,0.514468
uuid-a7001f2f63c741459b35fbcec325e3a7,Median OS,0.696688
uuid-a7001f2f63c741459b35fbcec325e3a7,PD-L1,0.300997
uuid-a7001f2f63c741459b35fbcec325e3a7,docetaxel,0.635065
uuid-a7001f2f63c741459b35fbcec325e3a7,hazard ratio,0.729977
uuid-9820296a055e48e4a54cb6fba3155101,fatigue,0.411608
uuid-d8f7e850b762489f952098053a852147,nivolumab,0.56248
uuid-d8f7e850b762489f952098053a852147,Bristol-Myers Squibb,0.445027
uuid-d8f7e850b762489f952098053a852147,evaluating,0.618564
uuid-d8f7e850b762489f952098053a852147,not conducted any controlled clinical trials/studies,0.672365
uuid-d8f7e850b762489f952098053a852147,Pubmed literature search,0.860734
uuid-d8f7e850b762489f952098053a852147,purposes other than its labeled indication must be considered investigational,0.928642
uuid-d8f7e850b762489f952098053a852147,not identify any citations relevant to your inquiry,0.81869
uuid-d8f7e850b762489f952098053a852147,using the following search terms,0.804801
uuid-d8f7e850b762489f952098053a852147,efficacy and safety of nivolumab,0.45604
uuid-c5288b33b39b4178b7c102a4859b04f7,nivolumab,0.575668
uuid-c5288b33b39b4178b7c102a4859b04f7,Bristol-Myers Squibb,0.458941
uuid-c5288b33b39b4178b7c102a4859b04f7,evaluating,0.615075
uuid-c5288b33b39b4178b7c102a4859b04f7,not conducted any controlled clinical trials/studies,0.675687
uuid-c5288b33b39b4178b7c102a4859b04f7,Pubmed literature search,0.859779
uuid-c5288b33b39b4178b7c102a4859b04f7,purposes other than its labeled indication must be considered investigational,0.92847
uuid-c5288b33b39b4178b7c102a4859b04f7,not identify any citations relevant to your inquiry,0.816213
uuid-c5288b33b39b4178b7c102a4859b04f7,using the following search terms,0.80356
uuid-c5288b33b39b4178b7c102a4859b04f7,efficacy and safety of nivolumab,0.452829
uuid-19bbc37778824b538fd8b4c03b1fd318,nivolumab,0.359772
uuid-63dddfeeeaa04a3a8e5ec18ba1d70fb8,requested,0.44769
uuid-63dddfeeeaa04a3a8e5ec18ba1d70fb8,trial,0.309472
uuid-8892becb0180444c93ea7aa1dfd9cc48,Objective response rate,0.451139
uuid-8892becb0180444c93ea7aa1dfd9cc48,clinicaltrials.gov,0.503706
uuid-226ef96a0c9b4ad584c99f817eca856c,provided in the Detailed Information,0.308455
uuid-2717ef22a2064d4abc729b51ed31c39f,clinical,0.679078
uuid-2717ef22a2064d4abc729b51ed31c39f,trial,0.645769
uuid-509834c8b9754a20ae2d637f46fb7d3c,nivolumab,0.359772
uuid-0ea680be686548a2a43eb5ea1e80f5cf,provided in the Detailed Information,0.372135
uuid-ea464f75adca48f3bf6e283dd4b44085,search of published literature,0.478492
uuid-ea464f75adca48f3bf6e283dd4b44085,clinical,0.440179
uuid-ea464f75adca48f3bf6e283dd4b44085,phase 3 study,0.420985
uuid-ea464f75adca48f3bf6e283dd4b44085,PubMed and EMBASE,0.468083
uuid-ea464f75adca48f3bf6e283dd4b44085,trial,0.46145
uuid-ea464f75adca48f3bf6e283dd4b44085,efficacy and safety of nivolumab,0.35969
uuid-ea464f75adca48f3bf6e283dd4b44085,present using the following search terms,0.408058
uuid-135b643736a1484b9efbff0e8cb268e0,patients,0.379852
uuid-135b643736a1484b9efbff0e8cb268e0,clinical,0.593971
uuid-135b643736a1484b9efbff0e8cb268e0,trial,0.613157
uuid-fac3127d5e3142efbcf6afa54c48a3e4,nivolumab,0.616057
uuid-fac3127d5e3142efbcf6afa54c48a3e4,Bristol-Myers Squibb,0.458477
uuid-fac3127d5e3142efbcf6afa54c48a3e4,evaluating,0.698375
uuid-fac3127d5e3142efbcf6afa54c48a3e4,not conducted any controlled clinical trials/studies,0.704066
uuid-fac3127d5e3142efbcf6afa54c48a3e4,efficacy,0.306021
uuid-fac3127d5e3142efbcf6afa54c48a3e4,Pubmed literature search,0.794211
uuid-fac3127d5e3142efbcf6afa54c48a3e4,purposes other than its labeled indication must be considered investigational,0.876448
uuid-fac3127d5e3142efbcf6afa54c48a3e4,not identify any citations relevant to your inquiry,0.746813
uuid-fac3127d5e3142efbcf6afa54c48a3e4,using the following search terms,0.734201
uuid-fac3127d5e3142efbcf6afa54c48a3e4,efficacy and safety of nivolumab,0.50562
uuid-fac3127d5e3142efbcf6afa54c48a3e4,safety of nivolumab monotherapy,0.323529
uuid-318a1fb1ed3a417580f7cdf6616b7d78,Objective response rate,0.451139
uuid-318a1fb1ed3a417580f7cdf6616b7d78,clinicaltrials.gov,0.503706
uuid-5457133daccd402f858d407575cb8d43,clinical,0.534386
uuid-5457133daccd402f858d407575cb8d43,trial,0.554522
uuid-5457133daccd402f858d407575cb8d43,clinicaltrials.gov,0.323356
uuid-4c19cdacf19d418fb00b6cdff9e75380,OS,0.387982
uuid-4c19cdacf19d418fb00b6cdff9e75380,95% CI,0.745043
uuid-4c19cdacf19d418fb00b6cdff9e75380,respectively,0.729294
uuid-4c19cdacf19d418fb00b6cdff9e75380,Objective response rate,0.590876
uuid-4c19cdacf19d418fb00b6cdff9e75380,ORR,0.722442
uuid-4c19cdacf19d418fb00b6cdff9e75380,Median overall survival,0.659043
uuid-4c19cdacf19d418fb00b6cdff9e75380,monotherapy,0.514468
uuid-4c19cdacf19d418fb00b6cdff9e75380,Median OS,0.696688
uuid-4c19cdacf19d418fb00b6cdff9e75380,PD-L1,0.300997
uuid-4c19cdacf19d418fb00b6cdff9e75380,docetaxel,0.635065
uuid-4c19cdacf19d418fb00b6cdff9e75380,hazard ratio,0.729977
uuid-0da441d5247649de91f49a6c662e9285,nivolumab,0.350452
uuid-0da441d5247649de91f49a6c662e9285,Bristol-Myers Squibb,0.411729
uuid-0da441d5247649de91f49a6c662e9285,use of nivolumab for the treatment,0.3845
uuid-0da441d5247649de91f49a6c662e9285,evaluating,0.65428
uuid-0da441d5247649de91f49a6c662e9285,not conducted any controlled clinical trials/studies,0.594921
uuid-0da441d5247649de91f49a6c662e9285,patients,0.353742
uuid-0da441d5247649de91f49a6c662e9285,search of published literature,0.594784
uuid-0da441d5247649de91f49a6c662e9285,Additionally,0.504991
uuid-0da441d5247649de91f49a6c662e9285,ongoing,0.419432
uuid-0da441d5247649de91f49a6c662e9285,PubMed and EMBASE,0.574103
uuid-0da441d5247649de91f49a6c662e9285,detailed search of www.clinicaltrials.gov,0.470354
uuid-0da441d5247649de91f49a6c662e9285,melanoma,0.402175
uuid-0da441d5247649de91f49a6c662e9285,efficacy and safety of nivolumab,0.709875
uuid-0da441d5247649de91f49a6c662e9285,not identify any planned,0.427196
uuid-0da441d5247649de91f49a6c662e9285,not identify any citations relevant to your request,0.577055
uuid-0da441d5247649de91f49a6c662e9285,therapy,0.326263
uuid-0da441d5247649de91f49a6c662e9285,present using the following search terms,0.595801
uuid-0da441d5247649de91f49a6c662e9285,safety of nivolumab monotherapy,0.329127
uuid-b0119494800c469fb13ec68dd101924f,Bristol-Myers Squibb,0.53554
uuid-b0119494800c469fb13ec68dd101924f,not conducted any controlled clinical trials/studies,0.311086
uuid-b0119494800c469fb13ec68dd101924f,reported,0.336252
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,95% CI,0.419478
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,respectively,0.497608
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,Objective response rate,0.403649
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,ORR,0.578109
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,patients with advanced or metastatic,0.306625
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,Median overall survival,0.498783
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,nivolumab combined with ipilimumab,0.300486
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,tumors,0.323334
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,ESMO,0.534361
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,Median OS,0.394058
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,small cell lung cancer,0.380999
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,SCLC,0.365686
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,hazard ratio,0.419392
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,grade 3 to 4 AEs,0.414535
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,phase 1/2 study CA209-032,0.398283
uuid-1c8a0407a2ce4f2f8e7f0073d361bf74,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-5afba77aa405440280b9324b858bb421,N Engl J Med,0.375006
uuid-5afba77aa405440280b9324b858bb421,provided in the Detailed Information,0.330032
uuid-5afba77aa405440280b9324b858bb421,ESMO,0.920687
uuid-5afba77aa405440280b9324b858bb421,Horn L,0.615115
uuid-5afba77aa405440280b9324b858bb421,grade 3 to 4 AEs,0.425072
uuid-6950265e996b4f349c87cc810db02adb,provided in the Detailed Information,0.520966
uuid-6950265e996b4f349c87cc810db02adb,clinical,0.412225
uuid-002cdf09c86e4db1b33aeffe360520ad,patients,0.325778
uuid-002cdf09c86e4db1b33aeffe360520ad,considered investigational,0.318469
uuid-002cdf09c86e4db1b33aeffe360520ad,patients with advanced or metastatic,0.340133
uuid-002cdf09c86e4db1b33aeffe360520ad,nivolumab combined with ipilimumab,0.310297
uuid-002cdf09c86e4db1b33aeffe360520ad,tumors,0.530586
uuid-002cdf09c86e4db1b33aeffe360520ad,phase 3 study,0.382846
uuid-002cdf09c86e4db1b33aeffe360520ad,small cell lung cancer,0.334365
uuid-002cdf09c86e4db1b33aeffe360520ad,phase 2 study,0.341472
uuid-002cdf09c86e4db1b33aeffe360520ad,phase 1/2 study CA209-032,0.384926
uuid-002cdf09c86e4db1b33aeffe360520ad,evaluates the efficacy of nivolumab monotherapy,0.402587
uuid-824387b7629440beafd4f489e8a83e08,Objective response rate,0.451139
uuid-824387b7629440beafd4f489e8a83e08,clinicaltrials.gov,0.503706
uuid-9de876acb23242feb9500371076ec601,nivolumab,0.359772
uuid-604294bd5cc7402babda181b7ba5b5af,Objective response rate,0.451139
uuid-604294bd5cc7402babda181b7ba5b5af,clinicaltrials.gov,0.503706
uuid-860d71a1025746d192d94f8669de08e6,patients,0.61303
uuid-860d71a1025746d192d94f8669de08e6,requested,0.372759
uuid-860d71a1025746d192d94f8669de08e6,small cell lung cancer,0.325128
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,NSCLC,0.518033
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,non-small cell lung cancer,0.506908
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,patients,0.506255
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,phase 3 study,0.353379
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,phase 1 study,0.355073
uuid-b63290f0b3814e2997e9c3fccdc1cb9d,reported,0.308198
uuid-c3e8c54c421944458936bb25c4e6704f,protocol,0.335748
uuid-a8139ecdaec84f889d0d9d2d43804014,OS,0.387982
uuid-a8139ecdaec84f889d0d9d2d43804014,95% CI,0.745043
uuid-a8139ecdaec84f889d0d9d2d43804014,respectively,0.729294
uuid-a8139ecdaec84f889d0d9d2d43804014,Objective response rate,0.590876
uuid-a8139ecdaec84f889d0d9d2d43804014,ORR,0.722442
uuid-a8139ecdaec84f889d0d9d2d43804014,Median overall survival,0.659043
uuid-a8139ecdaec84f889d0d9d2d43804014,monotherapy,0.514468
uuid-a8139ecdaec84f889d0d9d2d43804014,Median OS,0.696688
uuid-a8139ecdaec84f889d0d9d2d43804014,PD-L1,0.300997
uuid-a8139ecdaec84f889d0d9d2d43804014,docetaxel,0.635065
uuid-a8139ecdaec84f889d0d9d2d43804014,hazard ratio,0.729977
uuid-fad1d9c6ac8e4ab7b273d83d94974595,N Engl J Med,0.636726
uuid-fad1d9c6ac8e4ab7b273d83d94974595,non-small cell lung cancer,0.351489
uuid-fad1d9c6ac8e4ab7b273d83d94974595,ESMO,0.419331
uuid-fad1d9c6ac8e4ab7b273d83d94974595,Rizvi NA,0.470388
uuid-fad1d9c6ac8e4ab7b273d83d94974595,Brahmer J,0.676477
uuid-fad1d9c6ac8e4ab7b273d83d94974595,PD-L1,0.354847
uuid-fad1d9c6ac8e4ab7b273d83d94974595,Horn L,0.512976
uuid-fad1d9c6ac8e4ab7b273d83d94974595,platinum-based doublet chemotherapy,0.312066
uuid-7471ed0d558a41299787719ef1dcf820,ASCO,0.458799
uuid-7471ed0d558a41299787719ef1dcf820,patients,0.350124
uuid-7471ed0d558a41299787719ef1dcf820,Objective response rate,0.337455
uuid-7471ed0d558a41299787719ef1dcf820,ASCO 2015,0.36516
uuid-7471ed0d558a41299787719ef1dcf820,NEJM,0.328145
uuid-7471ed0d558a41299787719ef1dcf820,Topalian,0.34655
uuid-7471ed0d558a41299787719ef1dcf820,phase 1 study,0.31794
uuid-4c155c9fc9df49c78942c080794fb806,Opdivo,0.435201
uuid-4c155c9fc9df49c78942c080794fb806,open-label,0.303472
uuid-4c155c9fc9df49c78942c080794fb806,trial,0.451008
uuid-4c155c9fc9df49c78942c080794fb806,docetaxel,0.396981
uuid-4c155c9fc9df49c78942c080794fb806,safety of nivolumab monotherapy,0.364021
uuid-4c155c9fc9df49c78942c080794fb806,phase,0.417045
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,N Engl J Med,0.466497
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,ASCO,0.491786
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,Lancet Oncol,0.34677
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,protocol,0.608956
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,McDermott DF,0.714024
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,Motzer RJ,0.665237
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,phase 3 study,0.390315
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,Escudier B,0.683678
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,NEJM,0.444843
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,et al.,0.725231
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,J Clin Oncol,0.701894
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,Topalian,0.420717
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,phase 1 study,0.445517
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,Rizvi NA,0.400269
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,CA209-003,0.399706
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,phase 2 study,0.658621
uuid-cfbdecc2030b453eb8ccbdbc6d9b4f2b,investigating,0.330817
uuid-b6e9b7490e134ec9be564dfc73103fcc,N Engl J Med,0.722032
uuid-b6e9b7490e134ec9be564dfc73103fcc,Lancet Oncol,0.607444
uuid-b6e9b7490e134ec9be564dfc73103fcc,protocol,0.760342
uuid-b6e9b7490e134ec9be564dfc73103fcc,McDermott DF,0.823986
uuid-b6e9b7490e134ec9be564dfc73103fcc,Motzer RJ,0.78757
uuid-b6e9b7490e134ec9be564dfc73103fcc,phase 3 study,0.569897
uuid-b6e9b7490e134ec9be564dfc73103fcc,Escudier B,0.824215
uuid-b6e9b7490e134ec9be564dfc73103fcc,NEJM,0.463736
uuid-b6e9b7490e134ec9be564dfc73103fcc,et al.,0.808472
uuid-b6e9b7490e134ec9be564dfc73103fcc,J Clin Oncol,0.742462
uuid-b6e9b7490e134ec9be564dfc73103fcc,Topalian,0.423327
uuid-b6e9b7490e134ec9be564dfc73103fcc,Rizvi NA,0.765921
uuid-b6e9b7490e134ec9be564dfc73103fcc,Brahmer J,0.421801
uuid-b6e9b7490e134ec9be564dfc73103fcc,Weber JS,0.634557
uuid-b6e9b7490e134ec9be564dfc73103fcc,phase 2 study,0.819184
uuid-0a25e3fa8e6d4a67ae755b5d5f60c60a,provided in the Detailed Information,0.349112
uuid-0a25e3fa8e6d4a67ae755b5d5f60c60a,Weber JS,0.321343
uuid-88a8638ef0cd4232843a5fc3ac70ffeb,use of nivolumab for the treatment,0.384879
uuid-88a8638ef0cd4232843a5fc3ac70ffeb,efficacy,0.460164
uuid-88a8638ef0cd4232843a5fc3ac70ffeb,not approved,0.599477
uuid-88a8638ef0cd4232843a5fc3ac70ffeb,clinical trials investigating the safety,0.73197
uuid-4b740b1cbbd1407ebee70e31144ac948,trial,0.303974
uuid-887b3ca8b0744ebfb28c2809a04de72b,OS,0.387982
uuid-887b3ca8b0744ebfb28c2809a04de72b,95% CI,0.745043
uuid-887b3ca8b0744ebfb28c2809a04de72b,respectively,0.729294
uuid-887b3ca8b0744ebfb28c2809a04de72b,Objective response rate,0.590876
uuid-887b3ca8b0744ebfb28c2809a04de72b,ORR,0.722442
uuid-887b3ca8b0744ebfb28c2809a04de72b,Median overall survival,0.659043
uuid-887b3ca8b0744ebfb28c2809a04de72b,monotherapy,0.514468
uuid-887b3ca8b0744ebfb28c2809a04de72b,Median OS,0.696688
uuid-887b3ca8b0744ebfb28c2809a04de72b,PD-L1,0.300997
uuid-887b3ca8b0744ebfb28c2809a04de72b,docetaxel,0.635065
uuid-887b3ca8b0744ebfb28c2809a04de72b,hazard ratio,0.729977
uuid-bf88b67cfb9d49c7a16a942ba7046248,Opdivo,0.336834
uuid-bf88b67cfb9d49c7a16a942ba7046248,adverse,0.403833
uuid-bf88b67cfb9d49c7a16a942ba7046248,safety,0.555858
uuid-bf88b67cfb9d49c7a16a942ba7046248,databases,0.493488
uuid-bf88b67cfb9d49c7a16a942ba7046248,reported,0.660262
uuid-4b18670037da40e5bf15ea0dd211d932,patients with advanced or metastatic,0.468858
uuid-4b18670037da40e5bf15ea0dd211d932,nivolumab combined with ipilimumab,0.446918
uuid-4b18670037da40e5bf15ea0dd211d932,not approved,0.352562
uuid-4b18670037da40e5bf15ea0dd211d932,clinical trials investigating the safety,0.429501
uuid-4b18670037da40e5bf15ea0dd211d932,bladder cancer,0.950698
uuid-5cd3c49145924ef6a80eaacf23d6d819,N Engl J Med,0.636726
uuid-5cd3c49145924ef6a80eaacf23d6d819,non-small cell lung cancer,0.351489
uuid-5cd3c49145924ef6a80eaacf23d6d819,ESMO,0.419331
uuid-5cd3c49145924ef6a80eaacf23d6d819,Rizvi NA,0.470388
uuid-5cd3c49145924ef6a80eaacf23d6d819,Brahmer J,0.676477
uuid-5cd3c49145924ef6a80eaacf23d6d819,PD-L1,0.354847
uuid-5cd3c49145924ef6a80eaacf23d6d819,Horn L,0.512976
uuid-5cd3c49145924ef6a80eaacf23d6d819,platinum-based doublet chemotherapy,0.312066
uuid-908693fb56194149bf0ef14eb9f73475,NSCLC,0.327373
uuid-908693fb56194149bf0ef14eb9f73475,respectively,0.32989
uuid-908693fb56194149bf0ef14eb9f73475,Objective response rate,0.414926
uuid-908693fb56194149bf0ef14eb9f73475,ORR,0.46431
uuid-908693fb56194149bf0ef14eb9f73475,Median overall survival,0.358033
uuid-24c15d99962d4d9ea2cf122fa5592799,nivolumab,0.562548
uuid-24c15d99962d4d9ea2cf122fa5592799,Bristol-Myers Squibb,0.473328
uuid-24c15d99962d4d9ea2cf122fa5592799,evaluating,0.648752
uuid-24c15d99962d4d9ea2cf122fa5592799,not conducted any controlled clinical trials/studies,0.698265
uuid-24c15d99962d4d9ea2cf122fa5592799,Pubmed literature search,0.850054
uuid-24c15d99962d4d9ea2cf122fa5592799,purposes other than its labeled indication must be considered investigational,0.92138
uuid-24c15d99962d4d9ea2cf122fa5592799,not identify any citations relevant to your inquiry,0.806499
uuid-24c15d99962d4d9ea2cf122fa5592799,using the following search terms,0.792495
uuid-24c15d99962d4d9ea2cf122fa5592799,efficacy and safety of nivolumab,0.482823
uuid-b72f0e4f5e254c8fbc19a21614554308,Objective response rate,0.429879
uuid-b72f0e4f5e254c8fbc19a21614554308,clinicaltrials.gov,0.51304
uuid-f510a46d854640188c8ab6b3b366929e,Objective response rate,0.436042
uuid-f510a46d854640188c8ab6b3b366929e,clinicaltrials.gov,0.492318
uuid-a05baf9a85b740eeb46a8a59e10d9130,patients with advanced or metastatic,0.468858
uuid-a05baf9a85b740eeb46a8a59e10d9130,nivolumab combined with ipilimumab,0.446918
uuid-a05baf9a85b740eeb46a8a59e10d9130,not approved,0.352562
uuid-a05baf9a85b740eeb46a8a59e10d9130,clinical trials investigating the safety,0.429501
uuid-a05baf9a85b740eeb46a8a59e10d9130,bladder cancer,0.950698
uuid-fbbe748017db4bcf831987f996840b30,requested,0.594234
uuid-6eb2023160664aa6b06f2486cc85cd10,requested,0.594234
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,OS,0.387982
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,95% CI,0.745043
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,respectively,0.729294
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,Objective response rate,0.590876
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,ORR,0.722442
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,Median overall survival,0.659043
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,monotherapy,0.514468
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,Median OS,0.696688
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,PD-L1,0.300997
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,docetaxel,0.635065
uuid-94bfae661b8d4af5b616d82f0fd6fdc3,hazard ratio,0.729977
uuid-ed292e9f2dc0432ea7deaeba6669e778,fatigue,0.704358
uuid-8c4f02efa5214051b8b37aa6494ab858,95% CI,0.419478
uuid-8c4f02efa5214051b8b37aa6494ab858,respectively,0.497608
uuid-8c4f02efa5214051b8b37aa6494ab858,Objective response rate,0.403649
uuid-8c4f02efa5214051b8b37aa6494ab858,ORR,0.578109
uuid-8c4f02efa5214051b8b37aa6494ab858,patients with advanced or metastatic,0.306625
uuid-8c4f02efa5214051b8b37aa6494ab858,Median overall survival,0.498783
uuid-8c4f02efa5214051b8b37aa6494ab858,nivolumab combined with ipilimumab,0.300486
uuid-8c4f02efa5214051b8b37aa6494ab858,tumors,0.323334
uuid-8c4f02efa5214051b8b37aa6494ab858,ESMO,0.534361
uuid-8c4f02efa5214051b8b37aa6494ab858,Median OS,0.394058
uuid-8c4f02efa5214051b8b37aa6494ab858,small cell lung cancer,0.380999
uuid-8c4f02efa5214051b8b37aa6494ab858,SCLC,0.365686
uuid-8c4f02efa5214051b8b37aa6494ab858,hazard ratio,0.419392
uuid-8c4f02efa5214051b8b37aa6494ab858,grade 3 to 4 AEs,0.414535
uuid-8c4f02efa5214051b8b37aa6494ab858,phase 1/2 study CA209-032,0.398283
uuid-8c4f02efa5214051b8b37aa6494ab858,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-c5f17a656931482998dcecb8e30a7c07,ipilimumab,0.385692
uuid-c5f17a656931482998dcecb8e30a7c07,ASCO 2015,0.417944
uuid-c5f17a656931482998dcecb8e30a7c07,partial response,0.382425
uuid-c5f17a656931482998dcecb8e30a7c07,Stable disease,0.586335
uuid-c5f17a656931482998dcecb8e30a7c07,cohort,0.307748
uuid-be1a3299e74f4d03a8ba7f7a45fe8e2b,nivolumab,0.437266
uuid-be1a3299e74f4d03a8ba7f7a45fe8e2b,open-label,0.369621
uuid-be1a3299e74f4d03a8ba7f7a45fe8e2b,trial,0.339223
uuid-be1a3299e74f4d03a8ba7f7a45fe8e2b,phase,0.503047
uuid-24ec1919587a447da6d5cf4fc642feb0,Objective response rate,0.427051
uuid-24ec1919587a447da6d5cf4fc642feb0,clinicaltrials.gov,0.524603
uuid-24ec1919587a447da6d5cf4fc642feb0,relapsed,0.306689
uuid-1b15cdcd22154acb8b81d5cf03717f81,N Engl J Med,0.448483
uuid-1b15cdcd22154acb8b81d5cf03717f81,protocol,0.770446
uuid-1b15cdcd22154acb8b81d5cf03717f81,McDermott DF,0.741196
uuid-1b15cdcd22154acb8b81d5cf03717f81,Motzer RJ,0.818144
uuid-1b15cdcd22154acb8b81d5cf03717f81,phase 3 study,0.417055
uuid-1b15cdcd22154acb8b81d5cf03717f81,Escudier B,0.749917
uuid-1b15cdcd22154acb8b81d5cf03717f81,NEJM,0.400698
uuid-1b15cdcd22154acb8b81d5cf03717f81,et al.,0.668641
uuid-1b15cdcd22154acb8b81d5cf03717f81,J Clin Oncol,0.792018
uuid-1b15cdcd22154acb8b81d5cf03717f81,Topalian,0.388894
uuid-1b15cdcd22154acb8b81d5cf03717f81,phase 1 study,0.500686
uuid-1b15cdcd22154acb8b81d5cf03717f81,CA209-003,0.567381
uuid-1b15cdcd22154acb8b81d5cf03717f81,phase 2 study,0.677985
uuid-1b15cdcd22154acb8b81d5cf03717f81,present using the following search terms,0.310558
uuid-1b15cdcd22154acb8b81d5cf03717f81,investigating,0.615835
uuid-12d5978c7a9a48a7ad514785b0198bff,use of nivolumab for the treatment,0.443916
uuid-12d5978c7a9a48a7ad514785b0198bff,patients,0.984798
uuid-12d5978c7a9a48a7ad514785b0198bff,considered investigational,0.403812
uuid-12d5978c7a9a48a7ad514785b0198bff,tumors,0.320539
uuid-12d5978c7a9a48a7ad514785b0198bff,small cell lung cancer,0.483574
uuid-12d5978c7a9a48a7ad514785b0198bff,SCLC,0.435122
uuid-12d5978c7a9a48a7ad514785b0198bff,grade 3 to 4 AEs,0.546336
uuid-12d5978c7a9a48a7ad514785b0198bff,phase 1/2 study CA209-032,0.320698
uuid-43c855462984431890631785476477db,Opdivo,0.317324
uuid-43c855462984431890631785476477db,adverse,0.417301
uuid-43c855462984431890631785476477db,safety,0.56208
uuid-43c855462984431890631785476477db,databases,0.497079
uuid-43c855462984431890631785476477db,reported,0.664282
uuid-8d503123611343aa8245a251881233ea,patients,0.409624
uuid-8d503123611343aa8245a251881233ea,considered investigational,0.385214
uuid-8d503123611343aa8245a251881233ea,clinical,0.375098
uuid-8d503123611343aa8245a251881233ea,small cell lung cancer,0.403148
uuid-8d503123611343aa8245a251881233ea,trial,0.410299
uuid-8d503123611343aa8245a251881233ea,SCLC,0.3873
uuid-8d503123611343aa8245a251881233ea,therapy,0.394955
uuid-8d503123611343aa8245a251881233ea,phase 1/2 study CA209-032,0.336989
uuid-8d503123611343aa8245a251881233ea,evaluates the efficacy of nivolumab monotherapy,0.303817
uuid-646e6f9013504b7eaf91615f834c0a16,respectively,0.661351
uuid-646e6f9013504b7eaf91615f834c0a16,Objective response rate,0.619462
uuid-646e6f9013504b7eaf91615f834c0a16,ORR,0.537232
uuid-646e6f9013504b7eaf91615f834c0a16,monotherapy,0.421967
uuid-646e6f9013504b7eaf91615f834c0a16,docetaxel,0.426453
uuid-55cf8aabab6b4750a23561f03e2a6d65,mg,0.952001
uuid-55cf8aabab6b4750a23561f03e2a6d65,kg,0.930993
uuid-55cf8aabab6b4750a23561f03e2a6d65,cohort,0.317287
uuid-1c13be4c5d4a4c04b0cc32e1882f272a,nivolumab,0.802334
uuid-373b39b260b24bef891e32abc34758b9,nivolumab,0.502339
uuid-373b39b260b24bef891e32abc34758b9,Bristol-Myers Squibb,0.500722
uuid-373b39b260b24bef891e32abc34758b9,evaluating,0.675045
uuid-373b39b260b24bef891e32abc34758b9,not conducted any controlled clinical trials/studies,0.729348
uuid-373b39b260b24bef891e32abc34758b9,Pubmed literature search,0.844417
uuid-373b39b260b24bef891e32abc34758b9,purposes other than its labeled indication must be considered investigational,0.916929
uuid-373b39b260b24bef891e32abc34758b9,not identify any citations relevant to your inquiry,0.799155
uuid-373b39b260b24bef891e32abc34758b9,using the following search terms,0.785143
uuid-373b39b260b24bef891e32abc34758b9,efficacy and safety of nivolumab,0.516377
uuid-3f5a423b16d24f8ba34e4f912bfc343e,nivolumab,0.544892
uuid-3f5a423b16d24f8ba34e4f912bfc343e,Bristol-Myers Squibb,0.470438
uuid-3f5a423b16d24f8ba34e4f912bfc343e,evaluating,0.640446
uuid-3f5a423b16d24f8ba34e4f912bfc343e,not conducted any controlled clinical trials/studies,0.698202
uuid-3f5a423b16d24f8ba34e4f912bfc343e,Pubmed literature search,0.826964
uuid-3f5a423b16d24f8ba34e4f912bfc343e,purposes other than its labeled indication must be considered investigational,0.898917
uuid-3f5a423b16d24f8ba34e4f912bfc343e,not identify any citations relevant to your inquiry,0.782799
uuid-3f5a423b16d24f8ba34e4f912bfc343e,using the following search terms,0.769283
uuid-3f5a423b16d24f8ba34e4f912bfc343e,efficacy and safety of nivolumab,0.492203
uuid-08eaa1618f0e48eba1201e692776cf20,requested,0.525918
uuid-df1bc8b6b103484187d562b8a859f93d,N Engl J Med,0.448483
uuid-df1bc8b6b103484187d562b8a859f93d,protocol,0.770446
uuid-df1bc8b6b103484187d562b8a859f93d,McDermott DF,0.741196
uuid-df1bc8b6b103484187d562b8a859f93d,Motzer RJ,0.818144
uuid-df1bc8b6b103484187d562b8a859f93d,phase 3 study,0.417055
uuid-df1bc8b6b103484187d562b8a859f93d,Escudier B,0.749917
uuid-df1bc8b6b103484187d562b8a859f93d,NEJM,0.400698
uuid-df1bc8b6b103484187d562b8a859f93d,et al.,0.668641
uuid-df1bc8b6b103484187d562b8a859f93d,J Clin Oncol,0.792018
uuid-df1bc8b6b103484187d562b8a859f93d,Topalian,0.388894
uuid-df1bc8b6b103484187d562b8a859f93d,phase 1 study,0.500686
uuid-df1bc8b6b103484187d562b8a859f93d,CA209-003,0.567381
uuid-df1bc8b6b103484187d562b8a859f93d,phase 2 study,0.677985
uuid-df1bc8b6b103484187d562b8a859f93d,present using the following search terms,0.310558
uuid-df1bc8b6b103484187d562b8a859f93d,investigating,0.615835
uuid-518db0a29b5745908bd8700b760efb6c,evaluating,0.336092
uuid-518db0a29b5745908bd8700b760efb6c,not conducted any controlled clinical trials/studies,0.333487
uuid-518db0a29b5745908bd8700b760efb6c,protocol,0.521043
uuid-518db0a29b5745908bd8700b760efb6c,RCC,0.397968
uuid-518db0a29b5745908bd8700b760efb6c,McDermott DF,0.428228
uuid-518db0a29b5745908bd8700b760efb6c,search of published literature,0.502033
uuid-518db0a29b5745908bd8700b760efb6c,Additionally,0.550508
uuid-518db0a29b5745908bd8700b760efb6c,ongoing,0.475889
uuid-518db0a29b5745908bd8700b760efb6c,Motzer RJ,0.461263
uuid-518db0a29b5745908bd8700b760efb6c,PubMed and EMBASE,0.499083
uuid-518db0a29b5745908bd8700b760efb6c,Escudier B,0.443869
uuid-518db0a29b5745908bd8700b760efb6c,et al.,0.38164
uuid-518db0a29b5745908bd8700b760efb6c,J Clin Oncol,0.413822
uuid-518db0a29b5745908bd8700b760efb6c,detailed search of www.clinicaltrials.gov,0.511089
uuid-518db0a29b5745908bd8700b760efb6c,efficacy and safety of nivolumab,0.476367
uuid-518db0a29b5745908bd8700b760efb6c,not identify any planned,0.489623
uuid-518db0a29b5745908bd8700b760efb6c,phase 2 study,0.368495
uuid-518db0a29b5745908bd8700b760efb6c,not identify any citations relevant to your request,0.561521
uuid-518db0a29b5745908bd8700b760efb6c,present using the following search terms,0.487377
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,use of nivolumab for the treatment,0.461595
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,evaluating,0.345466
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,efficacy,0.585253
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,not approved,0.437932
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,clinical trials investigating the safety,0.342145
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,therapy,0.35945
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,relapsed,0.771971
uuid-d65e0cc39fbe421f9a7e5e28b0fa40e1,safety of nivolumab monotherapy,0.358725
uuid-71468d2902fd4c9fbb27119deb588508,use of nivolumab for the treatment,0.444892
uuid-71468d2902fd4c9fbb27119deb588508,evaluating,0.30558
uuid-71468d2902fd4c9fbb27119deb588508,patients,0.440855
uuid-71468d2902fd4c9fbb27119deb588508,not approved,0.378002
uuid-71468d2902fd4c9fbb27119deb588508,clinical trials investigating the safety,0.352423
uuid-7ddab04555a84a05a615bdf75e40d68a,nivolumab,0.55743
uuid-7ddab04555a84a05a615bdf75e40d68a,Bristol-Myers Squibb,0.473631
uuid-7ddab04555a84a05a615bdf75e40d68a,evaluating,0.647676
uuid-7ddab04555a84a05a615bdf75e40d68a,not conducted any controlled clinical trials/studies,0.693043
uuid-7ddab04555a84a05a615bdf75e40d68a,Pubmed literature search,0.842989
uuid-7ddab04555a84a05a615bdf75e40d68a,purposes other than its labeled indication must be considered investigational,0.912445
uuid-7ddab04555a84a05a615bdf75e40d68a,not identify any citations relevant to your inquiry,0.801019
uuid-7ddab04555a84a05a615bdf75e40d68a,using the following search terms,0.786839
uuid-7ddab04555a84a05a615bdf75e40d68a,efficacy and safety of nivolumab,0.487338
uuid-b873c794865144f99cce52451dd20d00,requested,0.594234
uuid-5070c3c69d4f4296afa87a9cd4373ba9,Bristol-Myers Squibb,0.341822
uuid-5070c3c69d4f4296afa87a9cd4373ba9,not conducted any controlled clinical trials/studies,0.304507
uuid-5070c3c69d4f4296afa87a9cd4373ba9,Opdivo,0.461382
uuid-5070c3c69d4f4296afa87a9cd4373ba9,Pubmed literature search,0.614325
uuid-5070c3c69d4f4296afa87a9cd4373ba9,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5070c3c69d4f4296afa87a9cd4373ba9,not identify any citations relevant to your inquiry,0.606087
uuid-5070c3c69d4f4296afa87a9cd4373ba9,adverse,0.304183
uuid-5070c3c69d4f4296afa87a9cd4373ba9,using the following search terms,0.642331
uuid-5070c3c69d4f4296afa87a9cd4373ba9,databases,0.315039
uuid-5070c3c69d4f4296afa87a9cd4373ba9,reported,0.556704
uuid-8517952c6a9d4e0a86dfdc0424adc464,patients with advanced or metastatic,0.468858
uuid-8517952c6a9d4e0a86dfdc0424adc464,nivolumab combined with ipilimumab,0.446918
uuid-8517952c6a9d4e0a86dfdc0424adc464,not approved,0.352562
uuid-8517952c6a9d4e0a86dfdc0424adc464,clinical trials investigating the safety,0.429501
uuid-8517952c6a9d4e0a86dfdc0424adc464,bladder cancer,0.950698
uuid-588e5faccc244796a54437cb501c17dd,nivolumab,0.472091
uuid-588e5faccc244796a54437cb501c17dd,Bristol-Myers Squibb,0.474723
uuid-588e5faccc244796a54437cb501c17dd,evaluating,0.662462
uuid-588e5faccc244796a54437cb501c17dd,not conducted any controlled clinical trials/studies,0.699194
uuid-588e5faccc244796a54437cb501c17dd,NSCLC,0.322419
uuid-588e5faccc244796a54437cb501c17dd,non-small cell lung cancer,0.392572
uuid-588e5faccc244796a54437cb501c17dd,Pubmed literature search,0.785289
uuid-588e5faccc244796a54437cb501c17dd,purposes other than its labeled indication must be considered investigational,0.858842
uuid-588e5faccc244796a54437cb501c17dd,not identify any citations relevant to your inquiry,0.739941
uuid-588e5faccc244796a54437cb501c17dd,using the following search terms,0.726515
uuid-588e5faccc244796a54437cb501c17dd,efficacy and safety of nivolumab,0.492278
uuid-65e3353b900d40eabe9428a29c29e728,patients with advanced or metastatic,0.468858
uuid-65e3353b900d40eabe9428a29c29e728,nivolumab combined with ipilimumab,0.446918
uuid-65e3353b900d40eabe9428a29c29e728,not approved,0.352562
uuid-65e3353b900d40eabe9428a29c29e728,clinical trials investigating the safety,0.429501
uuid-65e3353b900d40eabe9428a29c29e728,bladder cancer,0.950698
uuid-6a34f6e28d1243b5b96a58075eb278c2,N Engl J Med,0.302601
uuid-6a34f6e28d1243b5b96a58075eb278c2,AEs,0.348167
uuid-6a34f6e28d1243b5b96a58075eb278c2,patients,0.536884
uuid-6a34f6e28d1243b5b96a58075eb278c2,provided in the Detailed Information,0.387544
uuid-6a34f6e28d1243b5b96a58075eb278c2,ESMO,0.462801
uuid-6a34f6e28d1243b5b96a58075eb278c2,NEJM,0.66427
uuid-6a34f6e28d1243b5b96a58075eb278c2,Topalian,0.692873
uuid-6a34f6e28d1243b5b96a58075eb278c2,grade 3 to 4 AEs,0.626596
uuid-a72f9f9368214be980b9e76bad766665,nivolumab,0.609104
uuid-a72f9f9368214be980b9e76bad766665,Bristol-Myers Squibb,0.433977
uuid-a72f9f9368214be980b9e76bad766665,evaluating,0.602773
uuid-a72f9f9368214be980b9e76bad766665,not conducted any controlled clinical trials/studies,0.646924
uuid-a72f9f9368214be980b9e76bad766665,Pubmed literature search,0.805381
uuid-a72f9f9368214be980b9e76bad766665,purposes other than its labeled indication must be considered investigational,0.87765
uuid-a72f9f9368214be980b9e76bad766665,not identify any citations relevant to your inquiry,0.766662
uuid-a72f9f9368214be980b9e76bad766665,using the following search terms,0.749321
uuid-a72f9f9368214be980b9e76bad766665,efficacy and safety of nivolumab,0.436133
uuid-5e57e1050ece43a6bad3753329c42052,Bristol-Myers Squibb,0.341822
uuid-5e57e1050ece43a6bad3753329c42052,not conducted any controlled clinical trials/studies,0.304507
uuid-5e57e1050ece43a6bad3753329c42052,Opdivo,0.461382
uuid-5e57e1050ece43a6bad3753329c42052,Pubmed literature search,0.614325
uuid-5e57e1050ece43a6bad3753329c42052,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5e57e1050ece43a6bad3753329c42052,not identify any citations relevant to your inquiry,0.606087
uuid-5e57e1050ece43a6bad3753329c42052,adverse,0.304183
uuid-5e57e1050ece43a6bad3753329c42052,using the following search terms,0.642331
uuid-5e57e1050ece43a6bad3753329c42052,databases,0.315039
uuid-5e57e1050ece43a6bad3753329c42052,reported,0.556704
uuid-ffd71cc7085e4951a2baaecd2162c65c,ipilimumab,0.385692
uuid-ffd71cc7085e4951a2baaecd2162c65c,ASCO 2015,0.417944
uuid-ffd71cc7085e4951a2baaecd2162c65c,partial response,0.382425
uuid-ffd71cc7085e4951a2baaecd2162c65c,Stable disease,0.586335
uuid-ffd71cc7085e4951a2baaecd2162c65c,cohort,0.307748
uuid-e4d7ec780e8142a4985772d1452d9937,trial,0.579203
uuid-e4d7ec780e8142a4985772d1452d9937,clinicaltrials.gov,0.511315
uuid-e4d7ec780e8142a4985772d1452d9937,BMS,0.458899
uuid-9e0eff5f52ba4139972cbb50d4c5bc3b,requested,0.336586
uuid-9e0eff5f52ba4139972cbb50d4c5bc3b,trial,0.344706
uuid-9e0eff5f52ba4139972cbb50d4c5bc3b,reported,0.331863
uuid-553089f5691e4459a7a64c29cf3b8731,adverse,0.806921
uuid-553089f5691e4459a7a64c29cf3b8731,phase 3 study,0.417854
uuid-553089f5691e4459a7a64c29cf3b8731,melanoma,0.490547
uuid-553089f5691e4459a7a64c29cf3b8731,reported,0.442882
uuid-b1d72b49bfba411a82df8a5b4565d05c,NSCLC,0.480337
uuid-b1d72b49bfba411a82df8a5b4565d05c,respectively,0.400584
uuid-b1d72b49bfba411a82df8a5b4565d05c,non-small cell lung cancer,0.395662
uuid-b1d72b49bfba411a82df8a5b4565d05c,patients,0.382838
uuid-b1d72b49bfba411a82df8a5b4565d05c,considered investigational,0.378457
uuid-b1d72b49bfba411a82df8a5b4565d05c,Objective response rate,0.446233
uuid-b1d72b49bfba411a82df8a5b4565d05c,ORR,0.488323
uuid-b1d72b49bfba411a82df8a5b4565d05c,monotherapy,0.419452
uuid-b1d72b49bfba411a82df8a5b4565d05c,small cell lung cancer,0.328277
uuid-b1d72b49bfba411a82df8a5b4565d05c,docetaxel,0.370754
uuid-b1d72b49bfba411a82df8a5b4565d05c,SCLC,0.328412
uuid-b1d72b49bfba411a82df8a5b4565d05c,grade 3 to 4 AEs,0.337672
uuid-b1d72b49bfba411a82df8a5b4565d05c,platinum-based doublet chemotherapy,0.355492
uuid-5ca5edd0cb5f40ba866015dd0e6dce94,respectively,0.661351
uuid-5ca5edd0cb5f40ba866015dd0e6dce94,Objective response rate,0.619462
uuid-5ca5edd0cb5f40ba866015dd0e6dce94,ORR,0.537232
uuid-5ca5edd0cb5f40ba866015dd0e6dce94,monotherapy,0.421967
uuid-5ca5edd0cb5f40ba866015dd0e6dce94,docetaxel,0.426453
uuid-ccbd0afe0bb04fb6a5d1ebedc5215365,trial,0.331898
uuid-cfc8c5aef4b44450896c92ac4134ff2e,patients with advanced or metastatic,0.478326
uuid-cfc8c5aef4b44450896c92ac4134ff2e,nivolumab combined with ipilimumab,0.498766
uuid-cfc8c5aef4b44450896c92ac4134ff2e,not approved,0.34724
uuid-cfc8c5aef4b44450896c92ac4134ff2e,clinical trials investigating the safety,0.426729
uuid-cfc8c5aef4b44450896c92ac4134ff2e,bladder cancer,0.6548
uuid-732e0efd62704b639948947afa978567,N Engl J Med,0.636726
uuid-732e0efd62704b639948947afa978567,non-small cell lung cancer,0.351489
uuid-732e0efd62704b639948947afa978567,ESMO,0.419331
uuid-732e0efd62704b639948947afa978567,Rizvi NA,0.470388
uuid-732e0efd62704b639948947afa978567,Brahmer J,0.676477
uuid-732e0efd62704b639948947afa978567,PD-L1,0.354847
uuid-732e0efd62704b639948947afa978567,Horn L,0.512976
uuid-732e0efd62704b639948947afa978567,platinum-based doublet chemotherapy,0.312066
uuid-6d30302015b34ce48503d62c3e9dc3ab,fatigue,0.411608
uuid-33ac836fff8c46a7873ec60e26c6fa40,evaluating,0.350845
uuid-33ac836fff8c46a7873ec60e26c6fa40,not conducted any controlled clinical trials/studies,0.345107
uuid-33ac836fff8c46a7873ec60e26c6fa40,search of published literature,0.385331
uuid-33ac836fff8c46a7873ec60e26c6fa40,Additionally,0.40981
uuid-33ac836fff8c46a7873ec60e26c6fa40,ongoing,0.457998
uuid-33ac836fff8c46a7873ec60e26c6fa40,PubMed and EMBASE,0.378285
uuid-33ac836fff8c46a7873ec60e26c6fa40,detailed search of www.clinicaltrials.gov,0.428522
uuid-33ac836fff8c46a7873ec60e26c6fa40,efficacy and safety of nivolumab,0.407868
uuid-33ac836fff8c46a7873ec60e26c6fa40,not identify any planned,0.444729
uuid-33ac836fff8c46a7873ec60e26c6fa40,combination,0.388252
uuid-33ac836fff8c46a7873ec60e26c6fa40,BMS,0.316104
uuid-33ac836fff8c46a7873ec60e26c6fa40,not identify any citations relevant to your request,0.438151
uuid-33ac836fff8c46a7873ec60e26c6fa40,present using the following search terms,0.377101
uuid-3c2ca1d6f0de4aaeb2cc2c10f2212dd8,NSCLC,0.52306
uuid-3c2ca1d6f0de4aaeb2cc2c10f2212dd8,non-small cell lung cancer,0.632232
uuid-3c2ca1d6f0de4aaeb2cc2c10f2212dd8,PD-L1,0.624113
uuid-c2dd49aaffb14a82864e300c2d96b50b,OS,0.62262
uuid-c2dd49aaffb14a82864e300c2d96b50b,PFS,0.65903
uuid-c2dd49aaffb14a82864e300c2d96b50b,Overall survival,0.644151
uuid-798cde7d9d304fbeb96f0daba896a415,nivolumab,0.556635
uuid-798cde7d9d304fbeb96f0daba896a415,Bristol-Myers Squibb,0.47997
uuid-798cde7d9d304fbeb96f0daba896a415,evaluating,0.677096
uuid-798cde7d9d304fbeb96f0daba896a415,not conducted any controlled clinical trials/studies,0.716154
uuid-798cde7d9d304fbeb96f0daba896a415,non-small cell lung cancer,0.335849
uuid-798cde7d9d304fbeb96f0daba896a415,Pubmed literature search,0.806862
uuid-798cde7d9d304fbeb96f0daba896a415,purposes other than its labeled indication must be considered investigational,0.887229
uuid-798cde7d9d304fbeb96f0daba896a415,not identify any citations relevant to your inquiry,0.759342
uuid-798cde7d9d304fbeb96f0daba896a415,using the following search terms,0.745362
uuid-798cde7d9d304fbeb96f0daba896a415,efficacy and safety of nivolumab,0.513489
uuid-53250775346c4d3790aec4fb677a3137,Bristol-Myers Squibb,0.341822
uuid-53250775346c4d3790aec4fb677a3137,not conducted any controlled clinical trials/studies,0.304507
uuid-53250775346c4d3790aec4fb677a3137,Opdivo,0.461382
uuid-53250775346c4d3790aec4fb677a3137,Pubmed literature search,0.614325
uuid-53250775346c4d3790aec4fb677a3137,purposes other than its labeled indication must be considered investigational,0.586645
uuid-53250775346c4d3790aec4fb677a3137,not identify any citations relevant to your inquiry,0.606087
uuid-53250775346c4d3790aec4fb677a3137,adverse,0.304183
uuid-53250775346c4d3790aec4fb677a3137,using the following search terms,0.642331
uuid-53250775346c4d3790aec4fb677a3137,databases,0.315039
uuid-53250775346c4d3790aec4fb677a3137,reported,0.556704
uuid-6e0641e577444cecbb9954b444f4226f,requested,0.385747
uuid-6e0641e577444cecbb9954b444f4226f,trial,0.369379
uuid-fa69c840d08c4e76bf5951b350ab8b6c,evaluating,0.450507
uuid-fa69c840d08c4e76bf5951b350ab8b6c,not conducted any controlled clinical trials/studies,0.425505
uuid-fa69c840d08c4e76bf5951b350ab8b6c,RCC,0.364653
uuid-fa69c840d08c4e76bf5951b350ab8b6c,search of published literature,0.621339
uuid-fa69c840d08c4e76bf5951b350ab8b6c,Additionally,0.81476
uuid-fa69c840d08c4e76bf5951b350ab8b6c,ongoing,0.757788
uuid-fa69c840d08c4e76bf5951b350ab8b6c,PubMed and EMBASE,0.62008
uuid-fa69c840d08c4e76bf5951b350ab8b6c,detailed search of www.clinicaltrials.gov,0.807675
uuid-fa69c840d08c4e76bf5951b350ab8b6c,efficacy and safety of nivolumab,0.590704
uuid-fa69c840d08c4e76bf5951b350ab8b6c,not identify any planned,0.77783
uuid-fa69c840d08c4e76bf5951b350ab8b6c,combination,0.424502
uuid-fa69c840d08c4e76bf5951b350ab8b6c,not identify any citations relevant to your request,0.848273
uuid-fa69c840d08c4e76bf5951b350ab8b6c,present using the following search terms,0.638562
uuid-f48ba03cebef4e76b9d4f1be695d6151,nivolumab,0.359772
uuid-57a3e67478404e3296fb7b70059f9c73,nivolumab,0.719072
uuid-8adeeacb954849c2876480664d5e8c0a,requested,0.594234
uuid-29f441a22a0c48d680c182d16e1ddb26,nivolumab,0.361138
uuid-51ec6f9e97244d11bb441cae7175b808,fatigue,0.411608
uuid-ddbf8d3598ad4e7f8115fee5b50b0669,Opdivo,0.476741
uuid-ddbf8d3598ad4e7f8115fee5b50b0669,trial,0.393134
uuid-ddbf8d3598ad4e7f8115fee5b50b0669,docetaxel,0.437864
uuid-ddbf8d3598ad4e7f8115fee5b50b0669,safety of nivolumab monotherapy,0.350737
uuid-ddbf8d3598ad4e7f8115fee5b50b0669,phase,0.406186
uuid-cfb89f7554e545ed892fa36bbfa61fb9,Bristol-Myers Squibb,0.398786
uuid-cfb89f7554e545ed892fa36bbfa61fb9,evaluating,0.418607
uuid-cfb89f7554e545ed892fa36bbfa61fb9,not conducted any controlled clinical trials/studies,0.424995
uuid-cfb89f7554e545ed892fa36bbfa61fb9,patients,0.499819
uuid-cfb89f7554e545ed892fa36bbfa61fb9,provided in the Detailed Information,0.301419
uuid-cfb89f7554e545ed892fa36bbfa61fb9,RCC,0.360788
uuid-cfb89f7554e545ed892fa36bbfa61fb9,phase 3 study,0.311862
uuid-cfb89f7554e545ed892fa36bbfa61fb9,efficacy and safety of nivolumab,0.42015
uuid-cfb89f7554e545ed892fa36bbfa61fb9,phase,0.343482
uuid-7caae353164b41b7a20893cd0686f9f9,Bristol-Myers Squibb,0.379229
uuid-bcb2eca12da4476d919b6a9b2fe9b9f1,BMS,0.527417
uuid-590bfeba77b045ac973cc894805750b7,fatigue,0.704358
uuid-57ad736f18324fa4980566da6139ca6e,nivolumab,0.57793
uuid-57ad736f18324fa4980566da6139ca6e,Bristol-Myers Squibb,0.354113
uuid-57ad736f18324fa4980566da6139ca6e,evaluating,0.505509
uuid-57ad736f18324fa4980566da6139ca6e,not conducted any controlled clinical trials/studies,0.566193
uuid-57ad736f18324fa4980566da6139ca6e,Pubmed literature search,0.909397
uuid-57ad736f18324fa4980566da6139ca6e,purposes other than its labeled indication must be considered investigational,0.956251
uuid-57ad736f18324fa4980566da6139ca6e,not identify any citations relevant to your inquiry,0.876117
uuid-57ad736f18324fa4980566da6139ca6e,using the following search terms,0.865054
uuid-57ad736f18324fa4980566da6139ca6e,efficacy and safety of nivolumab,0.343005
uuid-84f67dba58ad43b0a503e928dec52950,OS,0.387982
uuid-84f67dba58ad43b0a503e928dec52950,95% CI,0.745043
uuid-84f67dba58ad43b0a503e928dec52950,respectively,0.729294
uuid-84f67dba58ad43b0a503e928dec52950,Objective response rate,0.590876
uuid-84f67dba58ad43b0a503e928dec52950,ORR,0.722442
uuid-84f67dba58ad43b0a503e928dec52950,Median overall survival,0.659043
uuid-84f67dba58ad43b0a503e928dec52950,monotherapy,0.514468
uuid-84f67dba58ad43b0a503e928dec52950,Median OS,0.696688
uuid-84f67dba58ad43b0a503e928dec52950,PD-L1,0.300997
uuid-84f67dba58ad43b0a503e928dec52950,docetaxel,0.635065
uuid-84f67dba58ad43b0a503e928dec52950,hazard ratio,0.729977
uuid-d3ed897eb40b464395092906829766c3,open-label,0.625744
uuid-d3ed897eb40b464395092906829766c3,phase,0.50513
uuid-1c75f872eb90407b9262eff8d3aa908f,Bristol-Myers Squibb,0.341822
uuid-1c75f872eb90407b9262eff8d3aa908f,not conducted any controlled clinical trials/studies,0.304507
uuid-1c75f872eb90407b9262eff8d3aa908f,Opdivo,0.461382
uuid-1c75f872eb90407b9262eff8d3aa908f,Pubmed literature search,0.614325
uuid-1c75f872eb90407b9262eff8d3aa908f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-1c75f872eb90407b9262eff8d3aa908f,not identify any citations relevant to your inquiry,0.606087
uuid-1c75f872eb90407b9262eff8d3aa908f,adverse,0.304183
uuid-1c75f872eb90407b9262eff8d3aa908f,using the following search terms,0.642331
uuid-1c75f872eb90407b9262eff8d3aa908f,databases,0.315039
uuid-1c75f872eb90407b9262eff8d3aa908f,reported,0.556704
uuid-9d18e506a5e6407c9f01c3cf93e47138,N Engl J Med,0.721371
uuid-9d18e506a5e6407c9f01c3cf93e47138,protocol,0.905978
uuid-9d18e506a5e6407c9f01c3cf93e47138,McDermott DF,0.966058
uuid-9d18e506a5e6407c9f01c3cf93e47138,Motzer RJ,0.959839
uuid-9d18e506a5e6407c9f01c3cf93e47138,phase 3 study,0.537777
uuid-9d18e506a5e6407c9f01c3cf93e47138,Escudier B,0.969806
uuid-9d18e506a5e6407c9f01c3cf93e47138,NEJM,0.46017
uuid-9d18e506a5e6407c9f01c3cf93e47138,et al.,0.931887
uuid-9d18e506a5e6407c9f01c3cf93e47138,J Clin Oncol,0.906603
uuid-9d18e506a5e6407c9f01c3cf93e47138,Topalian,0.411939
uuid-9d18e506a5e6407c9f01c3cf93e47138,Rizvi NA,0.471091
uuid-9d18e506a5e6407c9f01c3cf93e47138,Brahmer J,0.363599
uuid-9d18e506a5e6407c9f01c3cf93e47138,Weber JS,0.315419
uuid-9d18e506a5e6407c9f01c3cf93e47138,phase 2 study,0.857017
uuid-1545c0eb54714e9490057c5926cb115f,nivolumab,0.368579
uuid-1545c0eb54714e9490057c5926cb115f,melanoma,0.397203
uuid-f8942a2821024f369a36bd08e3f1652c,Opdivo,0.659858
uuid-f8942a2821024f369a36bd08e3f1652c,trial,0.339507
uuid-3b2d5b845e5a41128ddc1ade5cbe792e,ipilimumab,0.385692
uuid-3b2d5b845e5a41128ddc1ade5cbe792e,ASCO 2015,0.417944
uuid-3b2d5b845e5a41128ddc1ade5cbe792e,partial response,0.382425
uuid-3b2d5b845e5a41128ddc1ade5cbe792e,Stable disease,0.586335
uuid-3b2d5b845e5a41128ddc1ade5cbe792e,cohort,0.307748
uuid-258de94d4115405fb028aa0ea472585f,fatigue,0.704358
uuid-4287e314e7154c888ca0d115309fe11d,OS,0.62262
uuid-4287e314e7154c888ca0d115309fe11d,PFS,0.65903
uuid-4287e314e7154c888ca0d115309fe11d,Overall survival,0.644151
uuid-326e5d269f9942a2bd0190b80f1c5c5c,Bristol-Myers Squibb,0.341822
uuid-326e5d269f9942a2bd0190b80f1c5c5c,not conducted any controlled clinical trials/studies,0.304507
uuid-326e5d269f9942a2bd0190b80f1c5c5c,Opdivo,0.461382
uuid-326e5d269f9942a2bd0190b80f1c5c5c,Pubmed literature search,0.614325
uuid-326e5d269f9942a2bd0190b80f1c5c5c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-326e5d269f9942a2bd0190b80f1c5c5c,not identify any citations relevant to your inquiry,0.606087
uuid-326e5d269f9942a2bd0190b80f1c5c5c,adverse,0.304183
uuid-326e5d269f9942a2bd0190b80f1c5c5c,using the following search terms,0.642331
uuid-326e5d269f9942a2bd0190b80f1c5c5c,databases,0.315039
uuid-326e5d269f9942a2bd0190b80f1c5c5c,reported,0.556704
uuid-92d8893eba07453dba8c18bc8e0e725c,95% CI,0.419478
uuid-92d8893eba07453dba8c18bc8e0e725c,respectively,0.497608
uuid-92d8893eba07453dba8c18bc8e0e725c,Objective response rate,0.403649
uuid-92d8893eba07453dba8c18bc8e0e725c,ORR,0.578109
uuid-92d8893eba07453dba8c18bc8e0e725c,patients with advanced or metastatic,0.306625
uuid-92d8893eba07453dba8c18bc8e0e725c,Median overall survival,0.498783
uuid-92d8893eba07453dba8c18bc8e0e725c,nivolumab combined with ipilimumab,0.300486
uuid-92d8893eba07453dba8c18bc8e0e725c,tumors,0.323334
uuid-92d8893eba07453dba8c18bc8e0e725c,ESMO,0.534361
uuid-92d8893eba07453dba8c18bc8e0e725c,Median OS,0.394058
uuid-92d8893eba07453dba8c18bc8e0e725c,small cell lung cancer,0.380999
uuid-92d8893eba07453dba8c18bc8e0e725c,SCLC,0.365686
uuid-92d8893eba07453dba8c18bc8e0e725c,hazard ratio,0.419392
uuid-92d8893eba07453dba8c18bc8e0e725c,grade 3 to 4 AEs,0.414535
uuid-92d8893eba07453dba8c18bc8e0e725c,phase 1/2 study CA209-032,0.398283
uuid-92d8893eba07453dba8c18bc8e0e725c,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-7c156d4ddf7d4fb5a023409fed0f8293,OS,0.518169
uuid-7c156d4ddf7d4fb5a023409fed0f8293,95% CI,0.795716
uuid-7c156d4ddf7d4fb5a023409fed0f8293,Objective response rate,0.42268
uuid-7c156d4ddf7d4fb5a023409fed0f8293,ORR,0.544519
uuid-7c156d4ddf7d4fb5a023409fed0f8293,PFS,0.36786
uuid-7c156d4ddf7d4fb5a023409fed0f8293,Median overall survival,0.754861
uuid-7c156d4ddf7d4fb5a023409fed0f8293,Median OS,0.745967
uuid-7c156d4ddf7d4fb5a023409fed0f8293,fatigue,0.322903
uuid-7c156d4ddf7d4fb5a023409fed0f8293,hazard ratio,0.775538
uuid-7c156d4ddf7d4fb5a023409fed0f8293,Overall survival,0.401329
uuid-7c156d4ddf7d4fb5a023409fed0f8293,Median duration of response,0.379851
uuid-c4555e71380447f8977fa6489a5e12fc,Bristol-Myers Squibb,0.341822
uuid-c4555e71380447f8977fa6489a5e12fc,not conducted any controlled clinical trials/studies,0.304507
uuid-c4555e71380447f8977fa6489a5e12fc,Opdivo,0.461382
uuid-c4555e71380447f8977fa6489a5e12fc,Pubmed literature search,0.614325
uuid-c4555e71380447f8977fa6489a5e12fc,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c4555e71380447f8977fa6489a5e12fc,not identify any citations relevant to your inquiry,0.606087
uuid-c4555e71380447f8977fa6489a5e12fc,adverse,0.304183
uuid-c4555e71380447f8977fa6489a5e12fc,using the following search terms,0.642331
uuid-c4555e71380447f8977fa6489a5e12fc,databases,0.315039
uuid-c4555e71380447f8977fa6489a5e12fc,reported,0.556704
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,OS,0.385886
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,95% CI,0.695439
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,respectively,0.717675
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,Objective response rate,0.55669
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,ORR,0.680718
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,Median overall survival,0.633227
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,monotherapy,0.446489
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,Median OS,0.671854
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,docetaxel,0.634528
uuid-401eb3fe7cde4aa08bbe2aedcac4dc23,hazard ratio,0.687194
uuid-50a33115c53b4e4aa843c897c854bbcb,trial,0.357514
uuid-2e8f969701364ecf837310bc902c2795,OS,0.35085
uuid-2e8f969701364ecf837310bc902c2795,95% CI,0.645425
uuid-2e8f969701364ecf837310bc902c2795,respectively,0.712033
uuid-2e8f969701364ecf837310bc902c2795,Objective response rate,0.573707
uuid-2e8f969701364ecf837310bc902c2795,ORR,0.680826
uuid-2e8f969701364ecf837310bc902c2795,Median overall survival,0.598263
uuid-2e8f969701364ecf837310bc902c2795,monotherapy,0.449347
uuid-2e8f969701364ecf837310bc902c2795,Median OS,0.620171
uuid-2e8f969701364ecf837310bc902c2795,docetaxel,0.613684
uuid-2e8f969701364ecf837310bc902c2795,hazard ratio,0.642159
uuid-58dbc1ddfaca4ae59d4fb645c0934687,nivolumab,0.378834
uuid-b520243b0a6f4045bd3ac03562481119,requested,0.608769
uuid-3318ef1aa89e4485ad3941764e78e9f7,NSCLC,0.480337
uuid-3318ef1aa89e4485ad3941764e78e9f7,respectively,0.400584
uuid-3318ef1aa89e4485ad3941764e78e9f7,non-small cell lung cancer,0.395662
uuid-3318ef1aa89e4485ad3941764e78e9f7,patients,0.382838
uuid-3318ef1aa89e4485ad3941764e78e9f7,considered investigational,0.378457
uuid-3318ef1aa89e4485ad3941764e78e9f7,Objective response rate,0.446233
uuid-3318ef1aa89e4485ad3941764e78e9f7,ORR,0.488323
uuid-3318ef1aa89e4485ad3941764e78e9f7,monotherapy,0.419452
uuid-3318ef1aa89e4485ad3941764e78e9f7,small cell lung cancer,0.328277
uuid-3318ef1aa89e4485ad3941764e78e9f7,docetaxel,0.370754
uuid-3318ef1aa89e4485ad3941764e78e9f7,SCLC,0.328412
uuid-3318ef1aa89e4485ad3941764e78e9f7,grade 3 to 4 AEs,0.337672
uuid-3318ef1aa89e4485ad3941764e78e9f7,platinum-based doublet chemotherapy,0.355492
uuid-0394ffc1a20e421aa79c677aadfa6fc9,NSCLC,0.480337
uuid-0394ffc1a20e421aa79c677aadfa6fc9,respectively,0.400584
uuid-0394ffc1a20e421aa79c677aadfa6fc9,non-small cell lung cancer,0.395662
uuid-0394ffc1a20e421aa79c677aadfa6fc9,patients,0.382838
uuid-0394ffc1a20e421aa79c677aadfa6fc9,considered investigational,0.378457
uuid-0394ffc1a20e421aa79c677aadfa6fc9,Objective response rate,0.446233
uuid-0394ffc1a20e421aa79c677aadfa6fc9,ORR,0.488323
uuid-0394ffc1a20e421aa79c677aadfa6fc9,monotherapy,0.419452
uuid-0394ffc1a20e421aa79c677aadfa6fc9,small cell lung cancer,0.328277
uuid-0394ffc1a20e421aa79c677aadfa6fc9,docetaxel,0.370754
uuid-0394ffc1a20e421aa79c677aadfa6fc9,SCLC,0.328412
uuid-0394ffc1a20e421aa79c677aadfa6fc9,grade 3 to 4 AEs,0.337672
uuid-0394ffc1a20e421aa79c677aadfa6fc9,platinum-based doublet chemotherapy,0.355492
uuid-293675f57f0b44c88db361d9a1aee87f,use of nivolumab for the treatment,0.59185
uuid-293675f57f0b44c88db361d9a1aee87f,efficacy,0.560048
uuid-293675f57f0b44c88db361d9a1aee87f,patients,0.422932
uuid-293675f57f0b44c88db361d9a1aee87f,not approved,0.618789
uuid-293675f57f0b44c88db361d9a1aee87f,clinical trials investigating the safety,0.58327
uuid-293675f57f0b44c88db361d9a1aee87f,safety of nivolumab monotherapy,0.425979
uuid-54d1c700d13445e5a9a1c821f223aefb,melanoma,0.628566
uuid-34cf8e3217c543ca9fd88a6157416bbc,nivolumab,0.568603
uuid-34cf8e3217c543ca9fd88a6157416bbc,Bristol-Myers Squibb,0.477035
uuid-34cf8e3217c543ca9fd88a6157416bbc,evaluating,0.64787
uuid-34cf8e3217c543ca9fd88a6157416bbc,not conducted any controlled clinical trials/studies,0.700763
uuid-34cf8e3217c543ca9fd88a6157416bbc,Pubmed literature search,0.832834
uuid-34cf8e3217c543ca9fd88a6157416bbc,purposes other than its labeled indication must be considered investigational,0.907323
uuid-34cf8e3217c543ca9fd88a6157416bbc,not identify any citations relevant to your inquiry,0.788923
uuid-34cf8e3217c543ca9fd88a6157416bbc,using the following search terms,0.773822
uuid-34cf8e3217c543ca9fd88a6157416bbc,efficacy and safety of nivolumab,0.482112
uuid-c6ba5c9ad9fa4c328dab78cba80e0339,patients with advanced or metastatic,0.468858
uuid-c6ba5c9ad9fa4c328dab78cba80e0339,nivolumab combined with ipilimumab,0.446918
uuid-c6ba5c9ad9fa4c328dab78cba80e0339,not approved,0.352562
uuid-c6ba5c9ad9fa4c328dab78cba80e0339,clinical trials investigating the safety,0.429501
uuid-c6ba5c9ad9fa4c328dab78cba80e0339,bladder cancer,0.950698
uuid-83dd251d61d343d39ba53fddd242a2c9,OS,0.393578
uuid-83dd251d61d343d39ba53fddd242a2c9,95% CI,0.604059
uuid-83dd251d61d343d39ba53fddd242a2c9,ORR,0.333266
uuid-83dd251d61d343d39ba53fddd242a2c9,PFS,0.359117
uuid-83dd251d61d343d39ba53fddd242a2c9,Median overall survival,0.583717
uuid-83dd251d61d343d39ba53fddd242a2c9,Median OS,0.556804
uuid-83dd251d61d343d39ba53fddd242a2c9,hazard ratio,0.557495
uuid-83dd251d61d343d39ba53fddd242a2c9,Median duration of response,0.42348
uuid-8e7beaadb6de4a198a3668dfc6f28c94,Opdivo,0.327163
uuid-8e7beaadb6de4a198a3668dfc6f28c94,adverse,0.405698
uuid-8e7beaadb6de4a198a3668dfc6f28c94,safety,0.559331
uuid-8e7beaadb6de4a198a3668dfc6f28c94,databases,0.496084
uuid-8e7beaadb6de4a198a3668dfc6f28c94,reported,0.65799
uuid-9fadf4d0698d41a6bea63c724ef19fc7,OS,0.387982
uuid-9fadf4d0698d41a6bea63c724ef19fc7,95% CI,0.745043
uuid-9fadf4d0698d41a6bea63c724ef19fc7,respectively,0.729294
uuid-9fadf4d0698d41a6bea63c724ef19fc7,Objective response rate,0.590876
uuid-9fadf4d0698d41a6bea63c724ef19fc7,ORR,0.722442
uuid-9fadf4d0698d41a6bea63c724ef19fc7,Median overall survival,0.659043
uuid-9fadf4d0698d41a6bea63c724ef19fc7,monotherapy,0.514468
uuid-9fadf4d0698d41a6bea63c724ef19fc7,Median OS,0.696688
uuid-9fadf4d0698d41a6bea63c724ef19fc7,PD-L1,0.300997
uuid-9fadf4d0698d41a6bea63c724ef19fc7,docetaxel,0.635065
uuid-9fadf4d0698d41a6bea63c724ef19fc7,hazard ratio,0.729977
uuid-c05c5c312a9343b5b6e0560bd6682a5e,fatigue,0.411608
uuid-77b5fc865c4c43ddbdcc06c523499583,requested,0.316524
uuid-77b5fc865c4c43ddbdcc06c523499583,trial,0.339072
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,OS,0.387982
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,95% CI,0.745043
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,respectively,0.729294
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,Objective response rate,0.590876
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,ORR,0.722442
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,Median overall survival,0.659043
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,monotherapy,0.514468
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,Median OS,0.696688
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,PD-L1,0.300997
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,docetaxel,0.635065
uuid-7d9c236dcc184a5ca5ad0f508f296cc0,hazard ratio,0.729977
uuid-d1d25741c21d4d6ca29b17f6d6c313fc,nivolumab,0.353805
uuid-90056ff9ae5842879814a778307672d4,N Engl J Med,0.448483
uuid-90056ff9ae5842879814a778307672d4,protocol,0.770446
uuid-90056ff9ae5842879814a778307672d4,McDermott DF,0.741196
uuid-90056ff9ae5842879814a778307672d4,Motzer RJ,0.818144
uuid-90056ff9ae5842879814a778307672d4,phase 3 study,0.417055
uuid-90056ff9ae5842879814a778307672d4,Escudier B,0.749917
uuid-90056ff9ae5842879814a778307672d4,NEJM,0.400698
uuid-90056ff9ae5842879814a778307672d4,et al.,0.668641
uuid-90056ff9ae5842879814a778307672d4,J Clin Oncol,0.792018
uuid-90056ff9ae5842879814a778307672d4,Topalian,0.388894
uuid-90056ff9ae5842879814a778307672d4,phase 1 study,0.500686
uuid-90056ff9ae5842879814a778307672d4,CA209-003,0.567381
uuid-90056ff9ae5842879814a778307672d4,phase 2 study,0.677985
uuid-90056ff9ae5842879814a778307672d4,present using the following search terms,0.310558
uuid-90056ff9ae5842879814a778307672d4,investigating,0.615835
uuid-0292fe6dbffa4b21bff3763ca653bcda,nivolumab,0.416876
uuid-0292fe6dbffa4b21bff3763ca653bcda,Bristol-Myers Squibb,0.627981
uuid-0292fe6dbffa4b21bff3763ca653bcda,evaluating,0.633313
uuid-0292fe6dbffa4b21bff3763ca653bcda,not conducted any controlled clinical trials/studies,0.664235
uuid-0292fe6dbffa4b21bff3763ca653bcda,considered investigational,0.364801
uuid-0292fe6dbffa4b21bff3763ca653bcda,Opdivo,0.309836
uuid-0292fe6dbffa4b21bff3763ca653bcda,Pubmed literature search,0.420587
uuid-0292fe6dbffa4b21bff3763ca653bcda,purposes other than its labeled indication must be considered investigational,0.491467
uuid-0292fe6dbffa4b21bff3763ca653bcda,not identify any citations relevant to your inquiry,0.376181
uuid-0292fe6dbffa4b21bff3763ca653bcda,using the following search terms,0.394317
uuid-0292fe6dbffa4b21bff3763ca653bcda,efficacy and safety of nivolumab,0.488932
uuid-0292fe6dbffa4b21bff3763ca653bcda,safety of nivolumab monotherapy,0.310449
uuid-c41dbb2c71e249f883cb2d62d6e77372,nivolumab,0.503071
uuid-c41dbb2c71e249f883cb2d62d6e77372,Bristol-Myers Squibb,0.610005
uuid-c41dbb2c71e249f883cb2d62d6e77372,use of nivolumab for the treatment,0.339897
uuid-c41dbb2c71e249f883cb2d62d6e77372,evaluating,0.77241
uuid-c41dbb2c71e249f883cb2d62d6e77372,not conducted any controlled clinical trials/studies,0.806308
uuid-c41dbb2c71e249f883cb2d62d6e77372,Pubmed literature search,0.67443
uuid-c41dbb2c71e249f883cb2d62d6e77372,purposes other than its labeled indication must be considered investigational,0.776764
uuid-c41dbb2c71e249f883cb2d62d6e77372,not identify any citations relevant to your inquiry,0.62158
uuid-c41dbb2c71e249f883cb2d62d6e77372,not approved,0.314794
uuid-c41dbb2c71e249f883cb2d62d6e77372,using the following search terms,0.60302
uuid-c41dbb2c71e249f883cb2d62d6e77372,efficacy and safety of nivolumab,0.596182
uuid-c41dbb2c71e249f883cb2d62d6e77372,safety of nivolumab monotherapy,0.331858
uuid-36ce27ea964d434fa7435cdd2c4e56d9,N Engl J Med,0.660733
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Lancet Oncol,0.482314
uuid-36ce27ea964d434fa7435cdd2c4e56d9,protocol,0.627395
uuid-36ce27ea964d434fa7435cdd2c4e56d9,McDermott DF,0.654379
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Motzer RJ,0.626994
uuid-36ce27ea964d434fa7435cdd2c4e56d9,phase 3 study,0.598375
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Escudier B,0.646338
uuid-36ce27ea964d434fa7435cdd2c4e56d9,NEJM,0.554572
uuid-36ce27ea964d434fa7435cdd2c4e56d9,et al.,0.61546
uuid-36ce27ea964d434fa7435cdd2c4e56d9,J Clin Oncol,0.604667
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Topalian,0.536322
uuid-36ce27ea964d434fa7435cdd2c4e56d9,phase 1 study,0.37104
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Rizvi NA,0.670839
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Brahmer J,0.417566
uuid-36ce27ea964d434fa7435cdd2c4e56d9,CA209-003,0.360239
uuid-36ce27ea964d434fa7435cdd2c4e56d9,Weber JS,0.570024
uuid-36ce27ea964d434fa7435cdd2c4e56d9,phase 2 study,0.715588
uuid-d82a589cd21f4d5ebf1f35f10a4c2cf5,nivolumab,0.359772
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,nivolumab,0.568283
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,Bristol-Myers Squibb,0.47155
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,evaluating,0.693143
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,not conducted any controlled clinical trials/studies,0.731897
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,Pubmed literature search,0.795319
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,purposes other than its labeled indication must be considered investigational,0.874358
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,not identify any citations relevant to your inquiry,0.753816
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,search of published literature,0.351973
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,PubMed and EMBASE,0.322626
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,using the following search terms,0.737097
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,efficacy and safety of nivolumab,0.57879
uuid-f2f076ad7cd94315ba5f9b0847eb7e30,present using the following search terms,0.333701
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,nivolumab,0.487327
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,use of nivolumab for the treatment,0.33631
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,clinical,0.348225
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,not approved,0.352291
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,clinical trials investigating the safety,0.346816
uuid-2d3e0d1b01b34e5aa51e7ae283baed3a,trial,0.381055
uuid-a43ff5f288fd42d9b017d981b83fd70d,nivolumab,0.361138
uuid-c440062c8a5047fba8a07520f740494f,Bristol-Myers Squibb,0.33211
uuid-c440062c8a5047fba8a07520f740494f,evaluating,0.305761
uuid-c440062c8a5047fba8a07520f740494f,N Engl J Med,0.436113
uuid-c440062c8a5047fba8a07520f740494f,not conducted any controlled clinical trials/studies,0.361649
uuid-c440062c8a5047fba8a07520f740494f,Pubmed literature search,0.446404
uuid-c440062c8a5047fba8a07520f740494f,purposes other than its labeled indication must be considered investigational,0.451051
uuid-c440062c8a5047fba8a07520f740494f,protocol,0.518234
uuid-c440062c8a5047fba8a07520f740494f,not identify any citations relevant to your inquiry,0.417518
uuid-c440062c8a5047fba8a07520f740494f,McDermott DF,0.529613
uuid-c440062c8a5047fba8a07520f740494f,Motzer RJ,0.533394
uuid-c440062c8a5047fba8a07520f740494f,phase 3 study,0.310043
uuid-c440062c8a5047fba8a07520f740494f,Escudier B,0.54038
uuid-c440062c8a5047fba8a07520f740494f,et al.,0.486524
uuid-c440062c8a5047fba8a07520f740494f,J Clin Oncol,0.477636
uuid-c440062c8a5047fba8a07520f740494f,using the following search terms,0.447608
uuid-c440062c8a5047fba8a07520f740494f,Rizvi NA,0.302056
uuid-c440062c8a5047fba8a07520f740494f,phase 2 study,0.455362
uuid-c440062c8a5047fba8a07520f740494f,reported,0.404456
uuid-278274031d584577b87120e4e9dcf200,requested,0.594234
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,OS,0.387982
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,95% CI,0.745043
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,respectively,0.729294
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,Objective response rate,0.590876
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,ORR,0.722442
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,Median overall survival,0.659043
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,monotherapy,0.514468
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,Median OS,0.696688
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,PD-L1,0.300997
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,docetaxel,0.635065
uuid-6e72bb7927cf4110ac3b0c9db8e3e0d1,hazard ratio,0.729977
uuid-68125850ee894beab4ed1627426a9029,nivolumab,0.516575
uuid-68125850ee894beab4ed1627426a9029,Bristol-Myers Squibb,0.433644
uuid-68125850ee894beab4ed1627426a9029,evaluating,0.584399
uuid-68125850ee894beab4ed1627426a9029,not conducted any controlled clinical trials/studies,0.642733
uuid-68125850ee894beab4ed1627426a9029,Pubmed literature search,0.875004
uuid-68125850ee894beab4ed1627426a9029,purposes other than its labeled indication must be considered investigational,0.934937
uuid-68125850ee894beab4ed1627426a9029,not identify any citations relevant to your inquiry,0.839034
uuid-68125850ee894beab4ed1627426a9029,using the following search terms,0.823263
uuid-68125850ee894beab4ed1627426a9029,efficacy and safety of nivolumab,0.414441
uuid-942d793e927b4d28aac09418b34017e0,requested,0.662269
uuid-58ed0aa325174ed28c99ed3e760b03f5,evaluating,0.434221
uuid-58ed0aa325174ed28c99ed3e760b03f5,not conducted any controlled clinical trials/studies,0.402654
uuid-58ed0aa325174ed28c99ed3e760b03f5,search of published literature,0.605476
uuid-58ed0aa325174ed28c99ed3e760b03f5,Additionally,0.556486
uuid-58ed0aa325174ed28c99ed3e760b03f5,ongoing,0.430965
uuid-58ed0aa325174ed28c99ed3e760b03f5,PubMed and EMBASE,0.60164
uuid-58ed0aa325174ed28c99ed3e760b03f5,detailed search of www.clinicaltrials.gov,0.523702
uuid-58ed0aa325174ed28c99ed3e760b03f5,phase 1 study,0.457338
uuid-58ed0aa325174ed28c99ed3e760b03f5,efficacy and safety of nivolumab,0.593264
uuid-58ed0aa325174ed28c99ed3e760b03f5,not identify any planned,0.464669
uuid-58ed0aa325174ed28c99ed3e760b03f5,CA209-003,0.510635
uuid-58ed0aa325174ed28c99ed3e760b03f5,not identify any citations relevant to your request,0.649954
uuid-58ed0aa325174ed28c99ed3e760b03f5,present using the following search terms,0.641912
uuid-58ed0aa325174ed28c99ed3e760b03f5,investigating,0.590817
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,N Engl J Med,0.302601
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,AEs,0.348167
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,patients,0.536884
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,provided in the Detailed Information,0.387544
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,ESMO,0.462801
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,NEJM,0.66427
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,Topalian,0.692873
uuid-41836c68f1ad464a9c0d7b8b4bf8b04c,grade 3 to 4 AEs,0.626596
uuid-27e4e6c1b79a471390059a3d18391d50,AEs,0.372608
uuid-27e4e6c1b79a471390059a3d18391d50,adverse,0.485846
uuid-27e4e6c1b79a471390059a3d18391d50,grade,0.418566
uuid-27e4e6c1b79a471390059a3d18391d50,reported,0.698978
uuid-d4008a5b55ae49c89005d0e0a509fe29,use of nivolumab for the treatment,0.31265
uuid-d4008a5b55ae49c89005d0e0a509fe29,patients,0.688136
uuid-d4008a5b55ae49c89005d0e0a509fe29,small cell lung cancer,0.421332
uuid-d4008a5b55ae49c89005d0e0a509fe29,SCLC,0.415285
uuid-d4008a5b55ae49c89005d0e0a509fe29,therapy,0.504814
uuid-f909e95284d14ec893cca7b98a7af225,evaluating,0.300402
uuid-f909e95284d14ec893cca7b98a7af225,not conducted any controlled clinical trials/studies,0.327498
uuid-f909e95284d14ec893cca7b98a7af225,Pubmed literature search,0.326809
uuid-f909e95284d14ec893cca7b98a7af225,purposes other than its labeled indication must be considered investigational,0.369307
uuid-f909e95284d14ec893cca7b98a7af225,not identify any citations relevant to your inquiry,0.317673
uuid-36c643fced69441a8604c6f9a702cbe8,fatigue,0.704358
uuid-08cc5151da964760bc9733ff1d6193b0,nivolumab,0.58472
uuid-08cc5151da964760bc9733ff1d6193b0,Bristol-Myers Squibb,0.447729
uuid-08cc5151da964760bc9733ff1d6193b0,evaluating,0.617845
uuid-08cc5151da964760bc9733ff1d6193b0,not conducted any controlled clinical trials/studies,0.666153
uuid-08cc5151da964760bc9733ff1d6193b0,Pubmed literature search,0.800901
uuid-08cc5151da964760bc9733ff1d6193b0,purposes other than its labeled indication must be considered investigational,0.873783
uuid-08cc5151da964760bc9733ff1d6193b0,not identify any citations relevant to your inquiry,0.758285
uuid-08cc5151da964760bc9733ff1d6193b0,using the following search terms,0.743939
uuid-08cc5151da964760bc9733ff1d6193b0,efficacy and safety of nivolumab,0.465326
uuid-4b355695cd634508a61086aef10edeff,nivolumab,0.502183
uuid-4b355695cd634508a61086aef10edeff,RCC,0.756598
uuid-bc117cd5d153413b903cc6bf9a05ee08,nivolumab,0.502183
uuid-bc117cd5d153413b903cc6bf9a05ee08,RCC,0.756598
uuid-ce8d0cde178f47769d95eab56db09af8,fatigue,0.411608
uuid-53d03570674d4879874afd9ca2cb6346,requested,0.594234
uuid-a21ce167175148f4a9d3d61f4bed84ea,patients with advanced or metastatic,0.468858
uuid-a21ce167175148f4a9d3d61f4bed84ea,nivolumab combined with ipilimumab,0.446918
uuid-a21ce167175148f4a9d3d61f4bed84ea,not approved,0.352562
uuid-a21ce167175148f4a9d3d61f4bed84ea,clinical trials investigating the safety,0.429501
uuid-a21ce167175148f4a9d3d61f4bed84ea,bladder cancer,0.950698
uuid-d82ca58bd09c449792efa38ee8d03016,requested,0.594234
uuid-62197042feaf4e5fb1f976e754a2c23f,patients with advanced or metastatic,0.478326
uuid-62197042feaf4e5fb1f976e754a2c23f,nivolumab combined with ipilimumab,0.498766
uuid-62197042feaf4e5fb1f976e754a2c23f,not approved,0.34724
uuid-62197042feaf4e5fb1f976e754a2c23f,clinical trials investigating the safety,0.426729
uuid-62197042feaf4e5fb1f976e754a2c23f,bladder cancer,0.6548
uuid-76e2c7ee197b41e1846d8f7819aebedd,fatigue,0.323475
uuid-0456bc7bb1284b149e999ca43a0e7365,CA209-003,0.3669
uuid-0456bc7bb1284b149e999ca43a0e7365,investigating,0.301611
uuid-7316998b3e91482d8606ec3d15eba1c4,Bristol-Myers Squibb,0.305663
uuid-7316998b3e91482d8606ec3d15eba1c4,evaluating,0.370522
uuid-7316998b3e91482d8606ec3d15eba1c4,not conducted any controlled clinical trials/studies,0.357492
uuid-7316998b3e91482d8606ec3d15eba1c4,phase 1 study,0.593791
uuid-7316998b3e91482d8606ec3d15eba1c4,efficacy and safety of nivolumab,0.403425
uuid-7316998b3e91482d8606ec3d15eba1c4,CA209-003,0.696383
uuid-7316998b3e91482d8606ec3d15eba1c4,investigating,0.869325
uuid-f1dd9d4738bd483086d897bfa7ca4da8,Opdivo,0.310957
uuid-f1dd9d4738bd483086d897bfa7ca4da8,adverse,0.49714
uuid-f1dd9d4738bd483086d897bfa7ca4da8,reported,0.712768
uuid-97d16a41eade494e9b61cd4a868d9fd8,Opdivo,0.303756
uuid-97d16a41eade494e9b61cd4a868d9fd8,Pubmed literature search,0.332345
uuid-97d16a41eade494e9b61cd4a868d9fd8,not identify any citations relevant to your inquiry,0.343653
uuid-97d16a41eade494e9b61cd4a868d9fd8,using the following search terms,0.361292
uuid-97d16a41eade494e9b61cd4a868d9fd8,safety,0.606158
uuid-97d16a41eade494e9b61cd4a868d9fd8,databases,0.531491
uuid-26f29fe2baf9484692c36fda95fa6c84,provided in the Detailed Information,0.309309
uuid-9824aae767bd42088a4b78d6d884a736,Bristol-Myers Squibb,0.806159
uuid-9824aae767bd42088a4b78d6d884a736,evaluating,0.930862
uuid-9824aae767bd42088a4b78d6d884a736,not conducted any controlled clinical trials/studies,0.95287
uuid-9824aae767bd42088a4b78d6d884a736,search of published literature,0.610335
uuid-9824aae767bd42088a4b78d6d884a736,PubMed and EMBASE,0.56399
uuid-9824aae767bd42088a4b78d6d884a736,efficacy and safety of nivolumab,0.945237
uuid-9824aae767bd42088a4b78d6d884a736,present using the following search terms,0.561961
uuid-9824aae767bd42088a4b78d6d884a736,safety of nivolumab monotherapy,0.366435
uuid-db0ae339f77b4051a6b8e80b62451f24,N Engl J Med,0.336159
uuid-db0ae339f77b4051a6b8e80b62451f24,protocol,0.5795
uuid-db0ae339f77b4051a6b8e80b62451f24,McDermott DF,0.498398
uuid-db0ae339f77b4051a6b8e80b62451f24,Motzer RJ,0.514367
uuid-db0ae339f77b4051a6b8e80b62451f24,phase 3 study,0.302243
uuid-db0ae339f77b4051a6b8e80b62451f24,Escudier B,0.501468
uuid-db0ae339f77b4051a6b8e80b62451f24,NEJM,0.33045
uuid-db0ae339f77b4051a6b8e80b62451f24,et al.,0.461442
uuid-db0ae339f77b4051a6b8e80b62451f24,J Clin Oncol,0.492072
uuid-db0ae339f77b4051a6b8e80b62451f24,Topalian,0.32231
uuid-db0ae339f77b4051a6b8e80b62451f24,phase 2 study,0.447587
uuid-e12cb5a9410a4104b04223a97d8b2f98,nivolumab,0.441653
uuid-3936cc5972164028bef26dbea884bfb9,use of nivolumab for the treatment,0.409821
uuid-3936cc5972164028bef26dbea884bfb9,patients with advanced or metastatic,0.645244
uuid-3936cc5972164028bef26dbea884bfb9,nivolumab combined with ipilimumab,0.676339
uuid-3936cc5972164028bef26dbea884bfb9,not approved,0.453534
uuid-3936cc5972164028bef26dbea884bfb9,clinical trials investigating the safety,0.548799
uuid-3936cc5972164028bef26dbea884bfb9,phase 1/2 study CA209-032,0.34114
uuid-3936cc5972164028bef26dbea884bfb9,bladder cancer,0.749142
uuid-3936cc5972164028bef26dbea884bfb9,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-e1a8577bd46e440ebc0e784fb4443fa7,patients,0.60717
uuid-e1a8577bd46e440ebc0e784fb4443fa7,grade 3 to 4 AEs,0.413471
uuid-337a9ee698914875a14912ae0e8a3bd0,Opdivo,0.453932
uuid-337a9ee698914875a14912ae0e8a3bd0,open-label,0.33512
uuid-337a9ee698914875a14912ae0e8a3bd0,trial,0.398214
uuid-337a9ee698914875a14912ae0e8a3bd0,docetaxel,0.463781
uuid-337a9ee698914875a14912ae0e8a3bd0,safety of nivolumab monotherapy,0.382086
uuid-337a9ee698914875a14912ae0e8a3bd0,phase,0.439445
uuid-61bf8917f20e45e88b7e1224d2021b0c,nivolumab,0.605778
uuid-05b061db3034407d9d9905288942767c,fatigue,0.704358
uuid-14472e282cff452fb90c63fef29e98bf,fatigue,0.704358
uuid-153906dba75442aaacf80c9c2ad8b067,Bristol-Myers Squibb,0.398191
uuid-153906dba75442aaacf80c9c2ad8b067,requested,0.827269
uuid-3bae04dbb58c4ecdb42701fa71186263,nivolumab,0.563862
uuid-3bae04dbb58c4ecdb42701fa71186263,Bristol-Myers Squibb,0.510315
uuid-3bae04dbb58c4ecdb42701fa71186263,evaluating,0.686709
uuid-3bae04dbb58c4ecdb42701fa71186263,not conducted any controlled clinical trials/studies,0.733731
uuid-3bae04dbb58c4ecdb42701fa71186263,Pubmed literature search,0.799162
uuid-3bae04dbb58c4ecdb42701fa71186263,purposes other than its labeled indication must be considered investigational,0.880069
uuid-3bae04dbb58c4ecdb42701fa71186263,not identify any citations relevant to your inquiry,0.751364
uuid-3bae04dbb58c4ecdb42701fa71186263,using the following search terms,0.737446
uuid-3bae04dbb58c4ecdb42701fa71186263,efficacy and safety of nivolumab,0.521904
uuid-5dd2d27b9a8c447d84d607d3a8dd8ae8,fatigue,0.704358
uuid-566c0f50953b4b58960789eceb5fd8e4,OS,0.387982
uuid-566c0f50953b4b58960789eceb5fd8e4,95% CI,0.745043
uuid-566c0f50953b4b58960789eceb5fd8e4,respectively,0.729294
uuid-566c0f50953b4b58960789eceb5fd8e4,Objective response rate,0.590876
uuid-566c0f50953b4b58960789eceb5fd8e4,ORR,0.722442
uuid-566c0f50953b4b58960789eceb5fd8e4,Median overall survival,0.659043
uuid-566c0f50953b4b58960789eceb5fd8e4,monotherapy,0.514468
uuid-566c0f50953b4b58960789eceb5fd8e4,Median OS,0.696688
uuid-566c0f50953b4b58960789eceb5fd8e4,PD-L1,0.300997
uuid-566c0f50953b4b58960789eceb5fd8e4,docetaxel,0.635065
uuid-566c0f50953b4b58960789eceb5fd8e4,hazard ratio,0.729977
uuid-5fb843ad2a894a01ae0211e677237345,provided in the Detailed Information,0.349112
uuid-5fb843ad2a894a01ae0211e677237345,Weber JS,0.321343
uuid-1178a075b8434506801b89579aa52876,search of published literature,0.394524
uuid-1178a075b8434506801b89579aa52876,Additionally,0.413583
uuid-1178a075b8434506801b89579aa52876,ongoing,0.322117
uuid-1178a075b8434506801b89579aa52876,PubMed and EMBASE,0.391671
uuid-1178a075b8434506801b89579aa52876,detailed search of www.clinicaltrials.gov,0.375936
uuid-1178a075b8434506801b89579aa52876,efficacy and safety of nivolumab,0.370699
uuid-1178a075b8434506801b89579aa52876,not identify any planned,0.34283
uuid-1178a075b8434506801b89579aa52876,Weber JS,0.319229
uuid-1178a075b8434506801b89579aa52876,not identify any citations relevant to your request,0.447813
uuid-1178a075b8434506801b89579aa52876,present using the following search terms,0.408199
uuid-4039c112c77643a7b81f606b6c829b36,evaluating,0.33595
uuid-4039c112c77643a7b81f606b6c829b36,not conducted any controlled clinical trials/studies,0.333389
uuid-4039c112c77643a7b81f606b6c829b36,protocol,0.519575
uuid-4039c112c77643a7b81f606b6c829b36,RCC,0.396552
uuid-4039c112c77643a7b81f606b6c829b36,McDermott DF,0.425884
uuid-4039c112c77643a7b81f606b6c829b36,search of published literature,0.498677
uuid-4039c112c77643a7b81f606b6c829b36,Additionally,0.549804
uuid-4039c112c77643a7b81f606b6c829b36,ongoing,0.474606
uuid-4039c112c77643a7b81f606b6c829b36,Motzer RJ,0.459308
uuid-4039c112c77643a7b81f606b6c829b36,PubMed and EMBASE,0.495663
uuid-4039c112c77643a7b81f606b6c829b36,Escudier B,0.441262
uuid-4039c112c77643a7b81f606b6c829b36,et al.,0.378311
uuid-4039c112c77643a7b81f606b6c829b36,J Clin Oncol,0.413083
uuid-4039c112c77643a7b81f606b6c829b36,detailed search of www.clinicaltrials.gov,0.509888
uuid-4039c112c77643a7b81f606b6c829b36,efficacy and safety of nivolumab,0.474675
uuid-4039c112c77643a7b81f606b6c829b36,not identify any planned,0.488523
uuid-4039c112c77643a7b81f606b6c829b36,phase 2 study,0.364975
uuid-4039c112c77643a7b81f606b6c829b36,not identify any citations relevant to your request,0.559577
uuid-4039c112c77643a7b81f606b6c829b36,present using the following search terms,0.484223
uuid-55ad3a6211d746b7913dba921c862d6a,N Engl J Med,0.689907
uuid-55ad3a6211d746b7913dba921c862d6a,Lancet Oncol,0.584216
uuid-55ad3a6211d746b7913dba921c862d6a,protocol,0.72528
uuid-55ad3a6211d746b7913dba921c862d6a,McDermott DF,0.794444
uuid-55ad3a6211d746b7913dba921c862d6a,Motzer RJ,0.755383
uuid-55ad3a6211d746b7913dba921c862d6a,phase 3 study,0.521307
uuid-55ad3a6211d746b7913dba921c862d6a,Escudier B,0.794743
uuid-55ad3a6211d746b7913dba921c862d6a,NEJM,0.434762
uuid-55ad3a6211d746b7913dba921c862d6a,et al.,0.777092
uuid-55ad3a6211d746b7913dba921c862d6a,J Clin Oncol,0.708338
uuid-55ad3a6211d746b7913dba921c862d6a,Topalian,0.401719
uuid-55ad3a6211d746b7913dba921c862d6a,Rizvi NA,0.731383
uuid-55ad3a6211d746b7913dba921c862d6a,Brahmer J,0.378658
uuid-55ad3a6211d746b7913dba921c862d6a,Weber JS,0.614831
uuid-55ad3a6211d746b7913dba921c862d6a,phase 2 study,0.769458
uuid-27dce4cdc62e4401b4fa8c9275d1ce4d,requested,0.371768
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,search of published literature,0.394524
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,Additionally,0.413583
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,ongoing,0.322117
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,PubMed and EMBASE,0.391671
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,detailed search of www.clinicaltrials.gov,0.375936
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,efficacy and safety of nivolumab,0.370699
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,not identify any planned,0.34283
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,Weber JS,0.319229
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,not identify any citations relevant to your request,0.447813
uuid-4fc88aa5c8b8465ea29b0ea0696aa6f7,present using the following search terms,0.408199
uuid-5431f010aa2e4d4f93a851bf1e9481b6,patients with advanced or metastatic,0.473983
uuid-5431f010aa2e4d4f93a851bf1e9481b6,nivolumab combined with ipilimumab,0.493608
uuid-5431f010aa2e4d4f93a851bf1e9481b6,not approved,0.347942
uuid-5431f010aa2e4d4f93a851bf1e9481b6,clinical trials investigating the safety,0.424758
uuid-5431f010aa2e4d4f93a851bf1e9481b6,bladder cancer,0.649345
uuid-3e325e2af42445bcb8933674f12a44a1,N Engl J Med,0.322506
uuid-3e325e2af42445bcb8933674f12a44a1,requested,0.654492
uuid-aa7ecf41166b49e8a33d4566244e7a89,requested,0.374802
uuid-b8ef650bccb34958ba00096734e8de91,not approved,0.389731
uuid-b8ef650bccb34958ba00096734e8de91,clinical trials investigating the safety,0.464336
uuid-b8ef650bccb34958ba00096734e8de91,fatigue,0.389752
uuid-b48feb64a64249229832374751baa47d,requested,0.374802
uuid-df241e23c1134227bf60376cc01734bf,requested,0.374802
uuid-b3c57f998e1b406bba208a80e588cb2a,provided in the Detailed Information,0.426094
uuid-b3c57f998e1b406bba208a80e588cb2a,clinical,0.519189
uuid-acd4e1515a314f3fab02c50b6bdf5526,trial,0.387221
uuid-b5482c6edd95415ea4fcdc6df803de8d,melanoma,0.410364
uuid-ceeed8a59e744de089b5dc0491fd4356,requested,0.389805
uuid-ceeed8a59e744de089b5dc0491fd4356,BMS,0.302407
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,Additionally,0.311447
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,ongoing,0.344685
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,clinical,0.483912
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,detailed search of www.clinicaltrials.gov,0.31898
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,trial,0.682247
uuid-b64e9ad49b5f4b8cb26b8aac1dbf886e,not identify any planned,0.324296
uuid-d878f84827b543449c5a25613c155250,requested,0.374802
uuid-f3f2db45a0274fd5b80c9d4054faa483,Bristol-Myers Squibb,0.34249
uuid-f3f2db45a0274fd5b80c9d4054faa483,ASCO,0.374707
uuid-21e75c5a34454fd192df79aff49d69d7,ASCO,0.807066
uuid-1ba8d07007a242acbfcec2cf86478f69,OS,0.470033
uuid-1ba8d07007a242acbfcec2cf86478f69,95% CI,0.797074
uuid-1ba8d07007a242acbfcec2cf86478f69,respectively,0.660997
uuid-1ba8d07007a242acbfcec2cf86478f69,Objective response rate,0.578856
uuid-1ba8d07007a242acbfcec2cf86478f69,ORR,0.752854
uuid-1ba8d07007a242acbfcec2cf86478f69,PFS,0.333602
uuid-1ba8d07007a242acbfcec2cf86478f69,Median overall survival,0.740104
uuid-1ba8d07007a242acbfcec2cf86478f69,monotherapy,0.434052
uuid-1ba8d07007a242acbfcec2cf86478f69,Median OS,0.75903
uuid-1ba8d07007a242acbfcec2cf86478f69,docetaxel,0.464916
uuid-1ba8d07007a242acbfcec2cf86478f69,hazard ratio,0.7568
uuid-49f4dbd9569a4575b35759d247d8ea19,ASCO,0.807066
uuid-7bb216adfaa947c9800b47100a34a570,provided in the Detailed Information,0.349112
uuid-7bb216adfaa947c9800b47100a34a570,Weber JS,0.321343
uuid-a5140eff4fd24859951e2e0f04b4a9f9,nivolumab,0.348173
uuid-78d4fc3f906c40da946ea10d2b53c1c2,OS,0.571913
uuid-78d4fc3f906c40da946ea10d2b53c1c2,N Engl J Med,0.369953
uuid-78d4fc3f906c40da946ea10d2b53c1c2,95% CI,0.775208
uuid-78d4fc3f906c40da946ea10d2b53c1c2,respectively,0.413035
uuid-78d4fc3f906c40da946ea10d2b53c1c2,Objective response rate,0.439804
uuid-78d4fc3f906c40da946ea10d2b53c1c2,ORR,0.614911
uuid-78d4fc3f906c40da946ea10d2b53c1c2,PFS,0.460926
uuid-78d4fc3f906c40da946ea10d2b53c1c2,Median overall survival,0.77346
uuid-78d4fc3f906c40da946ea10d2b53c1c2,Median OS,0.729549
uuid-78d4fc3f906c40da946ea10d2b53c1c2,Brahmer J,0.393929
uuid-78d4fc3f906c40da946ea10d2b53c1c2,hazard ratio,0.739375
uuid-78d4fc3f906c40da946ea10d2b53c1c2,Median duration of response,0.331927
uuid-7ac0cd9fcbb54d22b362d0e73c73ba88,fatigue,0.411608
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,N Engl J Med,0.521129
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,95% CI,0.307831
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,respectively,0.33484
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,Objective response rate,0.306455
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,ORR,0.370983
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,Median overall survival,0.324968
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,protocol,0.648147
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,McDermott DF,0.71915
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,Motzer RJ,0.699351
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,phase 3 study,0.3184
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,Escudier B,0.717614
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,NEJM,0.369933
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,et al.,0.676344
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,J Clin Oncol,0.671104
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,Rizvi NA,0.306129
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,phase 2 study,0.56912
uuid-fbb9f59463864f1d8b1f28eac75ee7b8,hazard ratio,0.331774
uuid-0932c7051902407dbbbee5eb51b9df04,OS,0.454113
uuid-0932c7051902407dbbbee5eb51b9df04,AEs,0.320393
uuid-0932c7051902407dbbbee5eb51b9df04,95% CI,0.782912
uuid-0932c7051902407dbbbee5eb51b9df04,respectively,0.42055
uuid-0932c7051902407dbbbee5eb51b9df04,Objective response rate,0.437974
uuid-0932c7051902407dbbbee5eb51b9df04,ORR,0.574623
uuid-0932c7051902407dbbbee5eb51b9df04,PFS,0.335845
uuid-0932c7051902407dbbbee5eb51b9df04,Median overall survival,0.74535
uuid-0932c7051902407dbbbee5eb51b9df04,Median OS,0.743557
uuid-0932c7051902407dbbbee5eb51b9df04,grade,0.330929
uuid-0932c7051902407dbbbee5eb51b9df04,hazard ratio,0.754916
uuid-0932c7051902407dbbbee5eb51b9df04,Median duration of response,0.403617
uuid-da00568a784d440593b75a2c4460e634,Bristol-Myers Squibb,0.34249
uuid-da00568a784d440593b75a2c4460e634,ASCO,0.374707
uuid-316c1f2e161f4cf0a255e668ed57cc41,OS,0.504018
uuid-316c1f2e161f4cf0a255e668ed57cc41,95% CI,0.91849
uuid-316c1f2e161f4cf0a255e668ed57cc41,respectively,0.337474
uuid-316c1f2e161f4cf0a255e668ed57cc41,Objective response rate,0.470012
uuid-316c1f2e161f4cf0a255e668ed57cc41,ORR,0.617999
uuid-316c1f2e161f4cf0a255e668ed57cc41,PFS,0.376169
uuid-316c1f2e161f4cf0a255e668ed57cc41,Median overall survival,0.86272
uuid-316c1f2e161f4cf0a255e668ed57cc41,Median OS,0.876273
uuid-316c1f2e161f4cf0a255e668ed57cc41,hazard ratio,0.90025
uuid-316c1f2e161f4cf0a255e668ed57cc41,Median duration of response,0.475928
uuid-f46502f4ae044e779ec149a7eb88f0da,nivolumab,0.510392
uuid-f46502f4ae044e779ec149a7eb88f0da,Bristol-Myers Squibb,0.464176
uuid-f46502f4ae044e779ec149a7eb88f0da,evaluating,0.683286
uuid-f46502f4ae044e779ec149a7eb88f0da,not conducted any controlled clinical trials/studies,0.682483
uuid-f46502f4ae044e779ec149a7eb88f0da,RCC,0.308694
uuid-f46502f4ae044e779ec149a7eb88f0da,search of published literature,0.839602
uuid-f46502f4ae044e779ec149a7eb88f0da,Additionally,0.446384
uuid-f46502f4ae044e779ec149a7eb88f0da,PubMed and EMBASE,0.823429
uuid-f46502f4ae044e779ec149a7eb88f0da,detailed search of www.clinicaltrials.gov,0.366719
uuid-f46502f4ae044e779ec149a7eb88f0da,efficacy and safety of nivolumab,0.841
uuid-f46502f4ae044e779ec149a7eb88f0da,not identify any citations relevant to your request,0.605656
uuid-f46502f4ae044e779ec149a7eb88f0da,present using the following search terms,0.832619
uuid-b98aa0ab8fb8424d9e7732fa6877a4e5,requested,0.316524
uuid-b98aa0ab8fb8424d9e7732fa6877a4e5,trial,0.339072
uuid-78cac509c1ad4a3d9da1b11a36c9d240,mg,0.463664
uuid-78cac509c1ad4a3d9da1b11a36c9d240,kg,0.366061
uuid-15785d1c55384b97982dbcdb807e6e0a,requested,0.469145
uuid-0b0834a9aa534f23b4457c0e1a4df119,respectively,0.320114
uuid-dcdb18633b9742678ea56568be33f783,N Engl J Med,0.448483
uuid-dcdb18633b9742678ea56568be33f783,protocol,0.770446
uuid-dcdb18633b9742678ea56568be33f783,McDermott DF,0.741196
uuid-dcdb18633b9742678ea56568be33f783,Motzer RJ,0.818144
uuid-dcdb18633b9742678ea56568be33f783,phase 3 study,0.417055
uuid-dcdb18633b9742678ea56568be33f783,Escudier B,0.749917
uuid-dcdb18633b9742678ea56568be33f783,NEJM,0.400698
uuid-dcdb18633b9742678ea56568be33f783,et al.,0.668641
uuid-dcdb18633b9742678ea56568be33f783,J Clin Oncol,0.792018
uuid-dcdb18633b9742678ea56568be33f783,Topalian,0.388894
uuid-dcdb18633b9742678ea56568be33f783,phase 1 study,0.500686
uuid-dcdb18633b9742678ea56568be33f783,CA209-003,0.567381
uuid-dcdb18633b9742678ea56568be33f783,phase 2 study,0.677985
uuid-dcdb18633b9742678ea56568be33f783,present using the following search terms,0.310558
uuid-dcdb18633b9742678ea56568be33f783,investigating,0.615835
uuid-e67331165f55458d8a2ab01944bb5a3d,Bristol-Myers Squibb,0.351139
uuid-e67331165f55458d8a2ab01944bb5a3d,evaluating,0.393781
uuid-e67331165f55458d8a2ab01944bb5a3d,not conducted any controlled clinical trials/studies,0.401959
uuid-e67331165f55458d8a2ab01944bb5a3d,NSCLC,0.316818
uuid-e67331165f55458d8a2ab01944bb5a3d,efficacy and safety of nivolumab,0.448974
uuid-1d8443de3aba493caa1569f37181c3b6,respectively,0.339291
uuid-1d8443de3aba493caa1569f37181c3b6,Objective response rate,0.486358
uuid-1d8443de3aba493caa1569f37181c3b6,ORR,0.449232
uuid-1d8443de3aba493caa1569f37181c3b6,monotherapy,0.606914
uuid-1d8443de3aba493caa1569f37181c3b6,ipilimumab,0.398867
uuid-1d8443de3aba493caa1569f37181c3b6,ASCO 2015,0.519516
uuid-1d8443de3aba493caa1569f37181c3b6,mg,0.359357
uuid-1d8443de3aba493caa1569f37181c3b6,kg,0.308747
uuid-1d8443de3aba493caa1569f37181c3b6,Antonia SJ,0.371943
uuid-2558e99176fd40e7a97d8b817873a804,search of published literature,0.394524
uuid-2558e99176fd40e7a97d8b817873a804,Additionally,0.413583
uuid-2558e99176fd40e7a97d8b817873a804,ongoing,0.322117
uuid-2558e99176fd40e7a97d8b817873a804,PubMed and EMBASE,0.391671
uuid-2558e99176fd40e7a97d8b817873a804,detailed search of www.clinicaltrials.gov,0.375936
uuid-2558e99176fd40e7a97d8b817873a804,efficacy and safety of nivolumab,0.370699
uuid-2558e99176fd40e7a97d8b817873a804,not identify any planned,0.34283
uuid-2558e99176fd40e7a97d8b817873a804,Weber JS,0.319229
uuid-2558e99176fd40e7a97d8b817873a804,not identify any citations relevant to your request,0.447813
uuid-2558e99176fd40e7a97d8b817873a804,present using the following search terms,0.408199
uuid-2bb6e5c5ba614cd993d083c1f79d4224,OS,0.387982
uuid-2bb6e5c5ba614cd993d083c1f79d4224,95% CI,0.745043
uuid-2bb6e5c5ba614cd993d083c1f79d4224,respectively,0.729294
uuid-2bb6e5c5ba614cd993d083c1f79d4224,Objective response rate,0.590876
uuid-2bb6e5c5ba614cd993d083c1f79d4224,ORR,0.722442
uuid-2bb6e5c5ba614cd993d083c1f79d4224,Median overall survival,0.659043
uuid-2bb6e5c5ba614cd993d083c1f79d4224,monotherapy,0.514468
uuid-2bb6e5c5ba614cd993d083c1f79d4224,Median OS,0.696688
uuid-2bb6e5c5ba614cd993d083c1f79d4224,PD-L1,0.300997
uuid-2bb6e5c5ba614cd993d083c1f79d4224,docetaxel,0.635065
uuid-2bb6e5c5ba614cd993d083c1f79d4224,hazard ratio,0.729977
uuid-6bf2ef6989f94ce6a859ace586612760,not conducted any controlled clinical trials/studies,0.323287
uuid-6bf2ef6989f94ce6a859ace586612760,NSCLC,0.557108
uuid-6bf2ef6989f94ce6a859ace586612760,non-small cell lung cancer,0.534716
uuid-6bf2ef6989f94ce6a859ace586612760,considered investigational,0.378666
uuid-6bf2ef6989f94ce6a859ace586612760,phase 3 study,0.332492
uuid-6bf2ef6989f94ce6a859ace586612760,phase 1 study,0.304388
uuid-6bf2ef6989f94ce6a859ace586612760,small cell lung cancer,0.372641
uuid-6bf2ef6989f94ce6a859ace586612760,efficacy and safety of nivolumab,0.317198
uuid-6bf2ef6989f94ce6a859ace586612760,SCLC,0.417011
uuid-6bf2ef6989f94ce6a859ace586612760,therapy,0.620924
uuid-6028970721c9437d9e8f2f37e4507daf,95% CI,0.419478
uuid-6028970721c9437d9e8f2f37e4507daf,respectively,0.497608
uuid-6028970721c9437d9e8f2f37e4507daf,Objective response rate,0.403649
uuid-6028970721c9437d9e8f2f37e4507daf,ORR,0.578109
uuid-6028970721c9437d9e8f2f37e4507daf,patients with advanced or metastatic,0.306625
uuid-6028970721c9437d9e8f2f37e4507daf,Median overall survival,0.498783
uuid-6028970721c9437d9e8f2f37e4507daf,nivolumab combined with ipilimumab,0.300486
uuid-6028970721c9437d9e8f2f37e4507daf,tumors,0.323334
uuid-6028970721c9437d9e8f2f37e4507daf,ESMO,0.534361
uuid-6028970721c9437d9e8f2f37e4507daf,Median OS,0.394058
uuid-6028970721c9437d9e8f2f37e4507daf,small cell lung cancer,0.380999
uuid-6028970721c9437d9e8f2f37e4507daf,SCLC,0.365686
uuid-6028970721c9437d9e8f2f37e4507daf,hazard ratio,0.419392
uuid-6028970721c9437d9e8f2f37e4507daf,grade 3 to 4 AEs,0.414535
uuid-6028970721c9437d9e8f2f37e4507daf,phase 1/2 study CA209-032,0.398283
uuid-6028970721c9437d9e8f2f37e4507daf,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-d2504d9beedf48938b3176f0d8c84e34,N Engl J Med,0.448483
uuid-d2504d9beedf48938b3176f0d8c84e34,protocol,0.770446
uuid-d2504d9beedf48938b3176f0d8c84e34,McDermott DF,0.741196
uuid-d2504d9beedf48938b3176f0d8c84e34,Motzer RJ,0.818144
uuid-d2504d9beedf48938b3176f0d8c84e34,phase 3 study,0.417055
uuid-d2504d9beedf48938b3176f0d8c84e34,Escudier B,0.749917
uuid-d2504d9beedf48938b3176f0d8c84e34,NEJM,0.400698
uuid-d2504d9beedf48938b3176f0d8c84e34,et al.,0.668641
uuid-d2504d9beedf48938b3176f0d8c84e34,J Clin Oncol,0.792018
uuid-d2504d9beedf48938b3176f0d8c84e34,Topalian,0.388894
uuid-d2504d9beedf48938b3176f0d8c84e34,phase 1 study,0.500686
uuid-d2504d9beedf48938b3176f0d8c84e34,CA209-003,0.567381
uuid-d2504d9beedf48938b3176f0d8c84e34,phase 2 study,0.677985
uuid-d2504d9beedf48938b3176f0d8c84e34,present using the following search terms,0.310558
uuid-d2504d9beedf48938b3176f0d8c84e34,investigating,0.615835
uuid-251c3c1584ad4ac9b265392de182e32b,OS,0.387982
uuid-251c3c1584ad4ac9b265392de182e32b,95% CI,0.745043
uuid-251c3c1584ad4ac9b265392de182e32b,respectively,0.729294
uuid-251c3c1584ad4ac9b265392de182e32b,Objective response rate,0.590876
uuid-251c3c1584ad4ac9b265392de182e32b,ORR,0.722442
uuid-251c3c1584ad4ac9b265392de182e32b,Median overall survival,0.659043
uuid-251c3c1584ad4ac9b265392de182e32b,monotherapy,0.514468
uuid-251c3c1584ad4ac9b265392de182e32b,Median OS,0.696688
uuid-251c3c1584ad4ac9b265392de182e32b,PD-L1,0.300997
uuid-251c3c1584ad4ac9b265392de182e32b,docetaxel,0.635065
uuid-251c3c1584ad4ac9b265392de182e32b,hazard ratio,0.729977
uuid-146526d05f1147228fd46ce2c536a65c,Bristol-Myers Squibb,0.351139
uuid-146526d05f1147228fd46ce2c536a65c,evaluating,0.393781
uuid-146526d05f1147228fd46ce2c536a65c,not conducted any controlled clinical trials/studies,0.401959
uuid-146526d05f1147228fd46ce2c536a65c,NSCLC,0.316818
uuid-146526d05f1147228fd46ce2c536a65c,efficacy and safety of nivolumab,0.448974
uuid-763f2d87a4004ce6b70b01f2759e2e7d,Objective response rate,0.451139
uuid-763f2d87a4004ce6b70b01f2759e2e7d,clinicaltrials.gov,0.503706
uuid-8851f36af39246dcab5bfaf243212a59,patients with advanced or metastatic,0.468858
uuid-8851f36af39246dcab5bfaf243212a59,nivolumab combined with ipilimumab,0.446918
uuid-8851f36af39246dcab5bfaf243212a59,not approved,0.352562
uuid-8851f36af39246dcab5bfaf243212a59,clinical trials investigating the safety,0.429501
uuid-8851f36af39246dcab5bfaf243212a59,bladder cancer,0.950698
uuid-05a9e0b9006d4367985bbf050cd5b69a,nivolumab,0.571663
uuid-05a9e0b9006d4367985bbf050cd5b69a,Bristol-Myers Squibb,0.45908
uuid-05a9e0b9006d4367985bbf050cd5b69a,evaluating,0.661558
uuid-05a9e0b9006d4367985bbf050cd5b69a,not conducted any controlled clinical trials/studies,0.693495
uuid-05a9e0b9006d4367985bbf050cd5b69a,Pubmed literature search,0.823455
uuid-05a9e0b9006d4367985bbf050cd5b69a,purposes other than its labeled indication must be considered investigational,0.899762
uuid-05a9e0b9006d4367985bbf050cd5b69a,not identify any citations relevant to your inquiry,0.780264
uuid-05a9e0b9006d4367985bbf050cd5b69a,using the following search terms,0.765167
uuid-05a9e0b9006d4367985bbf050cd5b69a,efficacy and safety of nivolumab,0.48663
uuid-afd8839db0684940bfafd27d1efa15a0,requested,0.380999
uuid-afd8839db0684940bfafd27d1efa15a0,PD-L1,0.467329
uuid-c57d5adc907f4b199a75624c568c2e0e,N Engl J Med,0.710762
uuid-c57d5adc907f4b199a75624c568c2e0e,protocol,0.907069
uuid-c57d5adc907f4b199a75624c568c2e0e,McDermott DF,0.967879
uuid-c57d5adc907f4b199a75624c568c2e0e,Motzer RJ,0.962074
uuid-c57d5adc907f4b199a75624c568c2e0e,phase 3 study,0.539881
uuid-c57d5adc907f4b199a75624c568c2e0e,Escudier B,0.97012
uuid-c57d5adc907f4b199a75624c568c2e0e,NEJM,0.473614
uuid-c57d5adc907f4b199a75624c568c2e0e,et al.,0.93121
uuid-c57d5adc907f4b199a75624c568c2e0e,J Clin Oncol,0.914355
uuid-c57d5adc907f4b199a75624c568c2e0e,Topalian,0.426457
uuid-c57d5adc907f4b199a75624c568c2e0e,Rizvi NA,0.461644
uuid-c57d5adc907f4b199a75624c568c2e0e,Brahmer J,0.350006
uuid-c57d5adc907f4b199a75624c568c2e0e,Weber JS,0.306879
uuid-c57d5adc907f4b199a75624c568c2e0e,phase 2 study,0.862928
uuid-6c75aef94f46457584e49594537340e8,Objective response rate,0.451139
uuid-6c75aef94f46457584e49594537340e8,clinicaltrials.gov,0.503706
uuid-757e734aba3e41059c5d96d9edf0073c,N Engl J Med,0.660586
uuid-757e734aba3e41059c5d96d9edf0073c,Lancet Oncol,0.321742
uuid-757e734aba3e41059c5d96d9edf0073c,protocol,0.80297
uuid-757e734aba3e41059c5d96d9edf0073c,McDermott DF,0.821716
uuid-757e734aba3e41059c5d96d9edf0073c,search of published literature,0.331661
uuid-757e734aba3e41059c5d96d9edf0073c,Motzer RJ,0.83655
uuid-757e734aba3e41059c5d96d9edf0073c,phase 3 study,0.565468
uuid-757e734aba3e41059c5d96d9edf0073c,PubMed and EMBASE,0.330362
uuid-757e734aba3e41059c5d96d9edf0073c,Escudier B,0.829229
uuid-757e734aba3e41059c5d96d9edf0073c,NEJM,0.404738
uuid-757e734aba3e41059c5d96d9edf0073c,et al.,0.775722
uuid-757e734aba3e41059c5d96d9edf0073c,J Clin Oncol,0.779801
uuid-757e734aba3e41059c5d96d9edf0073c,Topalian,0.377428
uuid-757e734aba3e41059c5d96d9edf0073c,phase 1 study,0.401999
uuid-757e734aba3e41059c5d96d9edf0073c,Rizvi NA,0.49708
uuid-757e734aba3e41059c5d96d9edf0073c,Brahmer J,0.363982
uuid-757e734aba3e41059c5d96d9edf0073c,efficacy and safety of nivolumab,0.326147
uuid-757e734aba3e41059c5d96d9edf0073c,CA209-003,0.379463
uuid-757e734aba3e41059c5d96d9edf0073c,Weber JS,0.368111
uuid-757e734aba3e41059c5d96d9edf0073c,phase 2 study,0.810762
uuid-757e734aba3e41059c5d96d9edf0073c,present using the following search terms,0.330526
uuid-757e734aba3e41059c5d96d9edf0073c,investigating,0.312727
uuid-729551446b0347a6adfe4902d3e22370,NSCLC,0.34744
uuid-729551446b0347a6adfe4902d3e22370,respectively,0.479591
uuid-729551446b0347a6adfe4902d3e22370,Objective response rate,0.485623
uuid-729551446b0347a6adfe4902d3e22370,ORR,0.528588
uuid-729551446b0347a6adfe4902d3e22370,monotherapy,0.409083
uuid-729551446b0347a6adfe4902d3e22370,docetaxel,0.39777
uuid-73182a35df1e4866afbc194e83060ba5,N Engl J Med,0.513105
uuid-73182a35df1e4866afbc194e83060ba5,Lancet Oncol,0.352992
uuid-73182a35df1e4866afbc194e83060ba5,protocol,0.477351
uuid-73182a35df1e4866afbc194e83060ba5,McDermott DF,0.517106
uuid-73182a35df1e4866afbc194e83060ba5,Motzer RJ,0.503457
uuid-73182a35df1e4866afbc194e83060ba5,phase 3 study,0.481178
uuid-73182a35df1e4866afbc194e83060ba5,Escudier B,0.516513
uuid-73182a35df1e4866afbc194e83060ba5,et al.,0.487412
uuid-73182a35df1e4866afbc194e83060ba5,J Clin Oncol,0.481245
uuid-73182a35df1e4866afbc194e83060ba5,Rizvi NA,0.461762
uuid-73182a35df1e4866afbc194e83060ba5,Brahmer J,0.327099
uuid-73182a35df1e4866afbc194e83060ba5,Weber JS,0.358686
uuid-73182a35df1e4866afbc194e83060ba5,phase 2 study,0.562921
uuid-51b781cc1458480285cdcf3639a9383a,OS,0.62262
uuid-51b781cc1458480285cdcf3639a9383a,PFS,0.65903
uuid-51b781cc1458480285cdcf3639a9383a,Overall survival,0.644151
uuid-063e5b12578448cbb15ba68887d3210a,protocol,0.367274
uuid-063e5b12578448cbb15ba68887d3210a,McDermott DF,0.315287
uuid-063e5b12578448cbb15ba68887d3210a,Motzer RJ,0.328125
uuid-063e5b12578448cbb15ba68887d3210a,clinical,0.518419
uuid-063e5b12578448cbb15ba68887d3210a,phase 3 study,0.390753
uuid-063e5b12578448cbb15ba68887d3210a,Escudier B,0.317032
uuid-063e5b12578448cbb15ba68887d3210a,J Clin Oncol,0.304138
uuid-063e5b12578448cbb15ba68887d3210a,Rizvi NA,0.375165
uuid-063e5b12578448cbb15ba68887d3210a,trial,0.509426
uuid-063e5b12578448cbb15ba68887d3210a,phase 2 study,0.412062
uuid-e024896fde184fedb36240c241bfa4e9,nivolumab,0.340512
uuid-e024896fde184fedb36240c241bfa4e9,evaluating,0.347093
uuid-e024896fde184fedb36240c241bfa4e9,not conducted any controlled clinical trials/studies,0.34941
uuid-e024896fde184fedb36240c241bfa4e9,purposes other than its labeled indication must be considered investigational,0.345888
uuid-e024896fde184fedb36240c241bfa4e9,search of published literature,0.311089
uuid-e024896fde184fedb36240c241bfa4e9,phase 3 study,0.541205
uuid-e024896fde184fedb36240c241bfa4e9,efficacy and safety of nivolumab,0.384073
uuid-e024896fde184fedb36240c241bfa4e9,Weber JS,0.422927
uuid-156235de1f554b6ca8fe5e1341f240cb,N Engl J Med,0.714946
uuid-156235de1f554b6ca8fe5e1341f240cb,Lancet Oncol,0.448679
uuid-156235de1f554b6ca8fe5e1341f240cb,patients,0.309769
uuid-156235de1f554b6ca8fe5e1341f240cb,protocol,0.700662
uuid-156235de1f554b6ca8fe5e1341f240cb,McDermott DF,0.68799
uuid-156235de1f554b6ca8fe5e1341f240cb,Motzer RJ,0.689932
uuid-156235de1f554b6ca8fe5e1341f240cb,phase 3 study,0.545628
uuid-156235de1f554b6ca8fe5e1341f240cb,Escudier B,0.698812
uuid-156235de1f554b6ca8fe5e1341f240cb,NEJM,0.402095
uuid-156235de1f554b6ca8fe5e1341f240cb,et al.,0.640511
uuid-156235de1f554b6ca8fe5e1341f240cb,J Clin Oncol,0.626106
uuid-156235de1f554b6ca8fe5e1341f240cb,Topalian,0.37979
uuid-156235de1f554b6ca8fe5e1341f240cb,phase 1 study,0.381282
uuid-156235de1f554b6ca8fe5e1341f240cb,Rizvi NA,0.636006
uuid-156235de1f554b6ca8fe5e1341f240cb,Brahmer J,0.517174
uuid-156235de1f554b6ca8fe5e1341f240cb,efficacy and safety of nivolumab,0.368444
uuid-156235de1f554b6ca8fe5e1341f240cb,Weber JS,0.406071
uuid-156235de1f554b6ca8fe5e1341f240cb,phase 2 study,0.692115
uuid-c992e95e144c44518ccf468247c517ce,evaluating,0.312114
uuid-c992e95e144c44518ccf468247c517ce,not conducted any controlled clinical trials/studies,0.307993
uuid-c992e95e144c44518ccf468247c517ce,search of published literature,0.305204
uuid-c992e95e144c44518ccf468247c517ce,Brahmer J,0.340479
uuid-c992e95e144c44518ccf468247c517ce,efficacy and safety of nivolumab,0.403095
uuid-c992e95e144c44518ccf468247c517ce,combination,0.323537
uuid-c992e95e144c44518ccf468247c517ce,BMS,0.356435
uuid-7d4229367e5345f98e56cc7147f76447,Bristol-Myers Squibb,0.351139
uuid-7d4229367e5345f98e56cc7147f76447,evaluating,0.393781
uuid-7d4229367e5345f98e56cc7147f76447,not conducted any controlled clinical trials/studies,0.401959
uuid-7d4229367e5345f98e56cc7147f76447,NSCLC,0.316818
uuid-7d4229367e5345f98e56cc7147f76447,efficacy and safety of nivolumab,0.448974
uuid-16247363253c47398247c90176d07cfe,N Engl J Med,0.585592
uuid-16247363253c47398247c90176d07cfe,protocol,0.703048
uuid-16247363253c47398247c90176d07cfe,McDermott DF,0.808613
uuid-16247363253c47398247c90176d07cfe,Motzer RJ,0.783017
uuid-16247363253c47398247c90176d07cfe,phase 3 study,0.465459
uuid-16247363253c47398247c90176d07cfe,Escudier B,0.804268
uuid-16247363253c47398247c90176d07cfe,NEJM,0.338631
uuid-16247363253c47398247c90176d07cfe,et al.,0.770371
uuid-16247363253c47398247c90176d07cfe,J Clin Oncol,0.754974
uuid-16247363253c47398247c90176d07cfe,Rizvi NA,0.374947
uuid-16247363253c47398247c90176d07cfe,phase 2 study,0.717397
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,use of nivolumab for the treatment,0.316562
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,evaluating,0.549754
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,not conducted any controlled clinical trials/studies,0.475882
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,efficacy,0.475843
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,NSCLC,0.466401
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,non-small cell lung cancer,0.47715
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,patients,0.30827
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,Pubmed literature search,0.308688
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,purposes other than its labeled indication must be considered investigational,0.378542
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,not approved,0.352732
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,efficacy and safety of nivolumab,0.356727
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,docetaxel,0.352618
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,safety of nivolumab monotherapy,0.555475
uuid-e0bdd8c11ea64d4b9b5aa9bf7db47ec9,platinum-based doublet chemotherapy,0.363332
uuid-e98ae47a56b44e3b9a3b84c7f618440f,requested,0.594234
uuid-aa18bb78fe344ba88ea160ede333417d,requested,0.594234
uuid-cab39cc3b3254c0b919ab28fa52d736a,requested,0.59549
uuid-a86e486c735649b7b51d2ebc3c71ab89,fatigue,0.323475
uuid-e48ed7e23f9b479b9625fed1511e80ca,fatigue,0.411608
uuid-dfab8385ff4245afb0eb19fad3517dc0,requested,0.594234
uuid-f5c531fd39044ac68bce53052b88ec22,N Engl J Med,0.781802
uuid-f5c531fd39044ac68bce53052b88ec22,Lancet Oncol,0.368596
uuid-f5c531fd39044ac68bce53052b88ec22,protocol,0.86004
uuid-f5c531fd39044ac68bce53052b88ec22,McDermott DF,0.884253
uuid-f5c531fd39044ac68bce53052b88ec22,Motzer RJ,0.885015
uuid-f5c531fd39044ac68bce53052b88ec22,phase 3 study,0.532331
uuid-f5c531fd39044ac68bce53052b88ec22,Escudier B,0.894127
uuid-f5c531fd39044ac68bce53052b88ec22,NEJM,0.47555
uuid-f5c531fd39044ac68bce53052b88ec22,et al.,0.844349
uuid-f5c531fd39044ac68bce53052b88ec22,J Clin Oncol,0.822173
uuid-f5c531fd39044ac68bce53052b88ec22,Topalian,0.438913
uuid-f5c531fd39044ac68bce53052b88ec22,phase 1 study,0.302662
uuid-f5c531fd39044ac68bce53052b88ec22,Rizvi NA,0.55299
uuid-f5c531fd39044ac68bce53052b88ec22,Brahmer J,0.465592
uuid-f5c531fd39044ac68bce53052b88ec22,Weber JS,0.370181
uuid-f5c531fd39044ac68bce53052b88ec22,phase 2 study,0.794402
uuid-13058b5f9ac049fda40e7dd6a11d346a,evaluating,0.350845
uuid-13058b5f9ac049fda40e7dd6a11d346a,not conducted any controlled clinical trials/studies,0.345107
uuid-13058b5f9ac049fda40e7dd6a11d346a,search of published literature,0.385331
uuid-13058b5f9ac049fda40e7dd6a11d346a,Additionally,0.40981
uuid-13058b5f9ac049fda40e7dd6a11d346a,ongoing,0.457998
uuid-13058b5f9ac049fda40e7dd6a11d346a,PubMed and EMBASE,0.378285
uuid-13058b5f9ac049fda40e7dd6a11d346a,detailed search of www.clinicaltrials.gov,0.428522
uuid-13058b5f9ac049fda40e7dd6a11d346a,efficacy and safety of nivolumab,0.407868
uuid-13058b5f9ac049fda40e7dd6a11d346a,not identify any planned,0.444729
uuid-13058b5f9ac049fda40e7dd6a11d346a,combination,0.388252
uuid-13058b5f9ac049fda40e7dd6a11d346a,BMS,0.316104
uuid-13058b5f9ac049fda40e7dd6a11d346a,not identify any citations relevant to your request,0.438151
uuid-13058b5f9ac049fda40e7dd6a11d346a,present using the following search terms,0.377101
uuid-8d7fa9f5846446bfa55bcaf38e863d35,search of published literature,0.618612
uuid-8d7fa9f5846446bfa55bcaf38e863d35,clinical,0.321414
uuid-8d7fa9f5846446bfa55bcaf38e863d35,phase 3 study,0.411281
uuid-8d7fa9f5846446bfa55bcaf38e863d35,PubMed and EMBASE,0.612715
uuid-8d7fa9f5846446bfa55bcaf38e863d35,trial,0.451362
uuid-8d7fa9f5846446bfa55bcaf38e863d35,efficacy and safety of nivolumab,0.466873
uuid-8d7fa9f5846446bfa55bcaf38e863d35,present using the following search terms,0.586407
uuid-6a730f7b2ea94b84bdb09e5162f254f5,95% CI,0.419478
uuid-6a730f7b2ea94b84bdb09e5162f254f5,respectively,0.497608
uuid-6a730f7b2ea94b84bdb09e5162f254f5,Objective response rate,0.403649
uuid-6a730f7b2ea94b84bdb09e5162f254f5,ORR,0.578109
uuid-6a730f7b2ea94b84bdb09e5162f254f5,patients with advanced or metastatic,0.306625
uuid-6a730f7b2ea94b84bdb09e5162f254f5,Median overall survival,0.498783
uuid-6a730f7b2ea94b84bdb09e5162f254f5,nivolumab combined with ipilimumab,0.300486
uuid-6a730f7b2ea94b84bdb09e5162f254f5,tumors,0.323334
uuid-6a730f7b2ea94b84bdb09e5162f254f5,ESMO,0.534361
uuid-6a730f7b2ea94b84bdb09e5162f254f5,Median OS,0.394058
uuid-6a730f7b2ea94b84bdb09e5162f254f5,small cell lung cancer,0.380999
uuid-6a730f7b2ea94b84bdb09e5162f254f5,SCLC,0.365686
uuid-6a730f7b2ea94b84bdb09e5162f254f5,hazard ratio,0.419392
uuid-6a730f7b2ea94b84bdb09e5162f254f5,grade 3 to 4 AEs,0.414535
uuid-6a730f7b2ea94b84bdb09e5162f254f5,phase 1/2 study CA209-032,0.398283
uuid-6a730f7b2ea94b84bdb09e5162f254f5,evaluates the efficacy of nivolumab monotherapy,0.391682
uuid-e9da4ca1e83b4724a142e069bcfea998,OS,0.517683
uuid-e9da4ca1e83b4724a142e069bcfea998,95% CI,0.887029
uuid-e9da4ca1e83b4724a142e069bcfea998,respectively,0.541932
uuid-e9da4ca1e83b4724a142e069bcfea998,Objective response rate,0.732884
uuid-e9da4ca1e83b4724a142e069bcfea998,ORR,0.826341
uuid-e9da4ca1e83b4724a142e069bcfea998,PFS,0.416378
uuid-e9da4ca1e83b4724a142e069bcfea998,Median overall survival,0.810566
uuid-e9da4ca1e83b4724a142e069bcfea998,monotherapy,0.504664
uuid-e9da4ca1e83b4724a142e069bcfea998,Median OS,0.783041
uuid-e9da4ca1e83b4724a142e069bcfea998,hazard ratio,0.851803
uuid-e9da4ca1e83b4724a142e069bcfea998,Median duration of response,0.350254
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,Bristol-Myers Squibb,0.305703
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,use of nivolumab for the treatment,0.394627
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,evaluating,0.523351
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,not conducted any controlled clinical trials/studies,0.456571
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,efficacy,0.33179
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,NSCLC,0.511983
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,non-small cell lung cancer,0.501
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,patients,0.70531
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,considered investigational,0.515004
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,small cell lung cancer,0.415649
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,efficacy and safety of nivolumab,0.468404
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,SCLC,0.398198
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,safety of nivolumab monotherapy,0.479856
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,phase 1/2 study CA209-032,0.32661
uuid-b1a01b0ecce54e4ba0efd9ac9039ca7c,platinum-based doublet chemotherapy,0.319473
uuid-cd3a232ef76344f6b1629c8d7a964ce7,use of nivolumab for the treatment,0.31241
uuid-cd3a232ef76344f6b1629c8d7a964ce7,efficacy,0.341537
uuid-cd3a232ef76344f6b1629c8d7a964ce7,patients,0.360048
uuid-cd3a232ef76344f6b1629c8d7a964ce7,not approved,0.333942
uuid-cd3a232ef76344f6b1629c8d7a964ce7,clinical trials investigating the safety,0.301073
uuid-cd3a232ef76344f6b1629c8d7a964ce7,safety of nivolumab monotherapy,0.307363
uuid-e8ef35f137454b2c8afcc3bb2874e1da,nivolumab,0.358874
uuid-e8ef35f137454b2c8afcc3bb2874e1da,clinicaltrials.gov,0.62972
uuid-19d26f96dc7a46bbb692bd1b0e78238d,protocol,0.40832
uuid-19d26f96dc7a46bbb692bd1b0e78238d,McDermott DF,0.475644
uuid-19d26f96dc7a46bbb692bd1b0e78238d,Motzer RJ,0.445523
uuid-19d26f96dc7a46bbb692bd1b0e78238d,Escudier B,0.473315
uuid-19d26f96dc7a46bbb692bd1b0e78238d,et al.,0.49715
uuid-19d26f96dc7a46bbb692bd1b0e78238d,J Clin Oncol,0.473878
uuid-19d26f96dc7a46bbb692bd1b0e78238d,clinicaltrials.gov,0.515342
uuid-19d26f96dc7a46bbb692bd1b0e78238d,phase 2 study,0.384813
uuid-965d21a7bb464c22ad1c00d758b91416,95% CI,0.524855
uuid-965d21a7bb464c22ad1c00d758b91416,respectively,0.383655
uuid-965d21a7bb464c22ad1c00d758b91416,ASCO,0.303153
uuid-965d21a7bb464c22ad1c00d758b91416,Lancet Oncol,0.368041
uuid-965d21a7bb464c22ad1c00d758b91416,Objective response rate,0.504846
uuid-965d21a7bb464c22ad1c00d758b91416,ORR,0.465366
uuid-965d21a7bb464c22ad1c00d758b91416,Median overall survival,0.346516
uuid-965d21a7bb464c22ad1c00d758b91416,Median OS,0.33538
uuid-965d21a7bb464c22ad1c00d758b91416,ASCO 2015,0.336983
uuid-965d21a7bb464c22ad1c00d758b91416,small cell lung cancer,0.336892
uuid-965d21a7bb464c22ad1c00d758b91416,SCLC,0.344367
uuid-965d21a7bb464c22ad1c00d758b91416,Antonia SJ,0.55269
uuid-965d21a7bb464c22ad1c00d758b91416,Median duration of response,0.649605
uuid-4b336e3ef2824e5281c4268d76301342,Bristol-Myers Squibb,0.341822
uuid-4b336e3ef2824e5281c4268d76301342,not conducted any controlled clinical trials/studies,0.304507
uuid-4b336e3ef2824e5281c4268d76301342,Opdivo,0.461382
uuid-4b336e3ef2824e5281c4268d76301342,Pubmed literature search,0.614325
uuid-4b336e3ef2824e5281c4268d76301342,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4b336e3ef2824e5281c4268d76301342,not identify any citations relevant to your inquiry,0.606087
uuid-4b336e3ef2824e5281c4268d76301342,adverse,0.304183
uuid-4b336e3ef2824e5281c4268d76301342,using the following search terms,0.642331
uuid-4b336e3ef2824e5281c4268d76301342,databases,0.315039
uuid-4b336e3ef2824e5281c4268d76301342,reported,0.556704
uuid-2fb87122a38b4036a39a9806292bf068,OS,0.387983
uuid-2fb87122a38b4036a39a9806292bf068,95% CI,0.745045
uuid-2fb87122a38b4036a39a9806292bf068,respectively,0.729296
uuid-2fb87122a38b4036a39a9806292bf068,Objective response rate,0.590878
uuid-2fb87122a38b4036a39a9806292bf068,ORR,0.722444
uuid-2fb87122a38b4036a39a9806292bf068,Median overall survival,0.659045
uuid-2fb87122a38b4036a39a9806292bf068,monotherapy,0.514469
uuid-2fb87122a38b4036a39a9806292bf068,Median OS,0.69669
uuid-2fb87122a38b4036a39a9806292bf068,PD-L1,0.300997
uuid-2fb87122a38b4036a39a9806292bf068,docetaxel,0.635065
uuid-2fb87122a38b4036a39a9806292bf068,hazard ratio,0.729978
uuid-64a90f37e36b4af285ee5765726fee79,Bristol-Myers Squibb,0.452181
uuid-64a90f37e36b4af285ee5765726fee79,evaluating,0.333259
uuid-64a90f37e36b4af285ee5765726fee79,not conducted any controlled clinical trials/studies,0.382676
uuid-64a90f37e36b4af285ee5765726fee79,efficacy and safety of nivolumab,0.328689
uuid-9d92d0b97301472dac45476ec1a547f5,patients with advanced or metastatic,0.416496
uuid-9d92d0b97301472dac45476ec1a547f5,nivolumab combined with ipilimumab,0.42507
uuid-9d92d0b97301472dac45476ec1a547f5,not approved,0.346755
uuid-9d92d0b97301472dac45476ec1a547f5,clinical trials investigating the safety,0.400659
uuid-9d92d0b97301472dac45476ec1a547f5,bladder cancer,0.562446
uuid-0a7aaf8bbef242cabf0ebb6140a2a4de,open-label,0.386823
uuid-0a7aaf8bbef242cabf0ebb6140a2a4de,trial,0.414753
uuid-2f36c29ee8ec426db232b02724a20f59,95% CI,0.524855
uuid-2f36c29ee8ec426db232b02724a20f59,respectively,0.383655
uuid-2f36c29ee8ec426db232b02724a20f59,ASCO,0.303153
uuid-2f36c29ee8ec426db232b02724a20f59,Lancet Oncol,0.368041
uuid-2f36c29ee8ec426db232b02724a20f59,Objective response rate,0.504846
uuid-2f36c29ee8ec426db232b02724a20f59,ORR,0.465366
uuid-2f36c29ee8ec426db232b02724a20f59,Median overall survival,0.346516
uuid-2f36c29ee8ec426db232b02724a20f59,Median OS,0.33538
uuid-2f36c29ee8ec426db232b02724a20f59,ASCO 2015,0.336983
uuid-2f36c29ee8ec426db232b02724a20f59,small cell lung cancer,0.336892
uuid-2f36c29ee8ec426db232b02724a20f59,SCLC,0.344367
uuid-2f36c29ee8ec426db232b02724a20f59,Antonia SJ,0.55269
uuid-2f36c29ee8ec426db232b02724a20f59,Median duration of response,0.649605
uuid-cb351777fc9d4a37b83ae582aac8967d,N Engl J Med,0.302601
uuid-cb351777fc9d4a37b83ae582aac8967d,AEs,0.348167
uuid-cb351777fc9d4a37b83ae582aac8967d,patients,0.536884
uuid-cb351777fc9d4a37b83ae582aac8967d,provided in the Detailed Information,0.387544
uuid-cb351777fc9d4a37b83ae582aac8967d,ESMO,0.462801
uuid-cb351777fc9d4a37b83ae582aac8967d,NEJM,0.66427
uuid-cb351777fc9d4a37b83ae582aac8967d,Topalian,0.692873
uuid-cb351777fc9d4a37b83ae582aac8967d,grade 3 to 4 AEs,0.626596
uuid-ce36237948ac4d1bbe23dd7ce51f3471,95% CI,0.524855
uuid-ce36237948ac4d1bbe23dd7ce51f3471,respectively,0.383655
uuid-ce36237948ac4d1bbe23dd7ce51f3471,ASCO,0.303153
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Lancet Oncol,0.368041
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Objective response rate,0.504846
uuid-ce36237948ac4d1bbe23dd7ce51f3471,ORR,0.465366
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Median overall survival,0.346516
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Median OS,0.33538
uuid-ce36237948ac4d1bbe23dd7ce51f3471,ASCO 2015,0.336983
uuid-ce36237948ac4d1bbe23dd7ce51f3471,small cell lung cancer,0.336892
uuid-ce36237948ac4d1bbe23dd7ce51f3471,SCLC,0.344367
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Antonia SJ,0.55269
uuid-ce36237948ac4d1bbe23dd7ce51f3471,Median duration of response,0.649605
uuid-98d80c8388694cbb9f0baa64cb2e8bde,NSCLC,0.340221
uuid-98d80c8388694cbb9f0baa64cb2e8bde,respectively,0.49936
uuid-98d80c8388694cbb9f0baa64cb2e8bde,Objective response rate,0.519659
uuid-98d80c8388694cbb9f0baa64cb2e8bde,ORR,0.550917
uuid-98d80c8388694cbb9f0baa64cb2e8bde,monotherapy,0.433558
uuid-98d80c8388694cbb9f0baa64cb2e8bde,docetaxel,0.409072
uuid-98d80c8388694cbb9f0baa64cb2e8bde,Antonia SJ,0.321941
uuid-f0778f0001834295934d205161bc5373,NSCLC,0.480337
uuid-f0778f0001834295934d205161bc5373,respectively,0.400584
uuid-f0778f0001834295934d205161bc5373,non-small cell lung cancer,0.395662
uuid-f0778f0001834295934d205161bc5373,patients,0.382838
uuid-f0778f0001834295934d205161bc5373,considered investigational,0.378457
uuid-f0778f0001834295934d205161bc5373,Objective response rate,0.446233
uuid-f0778f0001834295934d205161bc5373,ORR,0.488323
uuid-f0778f0001834295934d205161bc5373,monotherapy,0.419452
uuid-f0778f0001834295934d205161bc5373,small cell lung cancer,0.328277
uuid-f0778f0001834295934d205161bc5373,docetaxel,0.370754
uuid-f0778f0001834295934d205161bc5373,SCLC,0.328412
uuid-f0778f0001834295934d205161bc5373,grade 3 to 4 AEs,0.337672
uuid-f0778f0001834295934d205161bc5373,platinum-based doublet chemotherapy,0.355492
uuid-c8beaea1d5764212810c6a61b53f5cf2,Bristol-Myers Squibb,0.605651
uuid-c8beaea1d5764212810c6a61b53f5cf2,evaluating,0.308032
uuid-c8beaea1d5764212810c6a61b53f5cf2,not conducted any controlled clinical trials/studies,0.400427
uuid-cfd4a30d0f1f4a00a070fcc637ba68e8,NEJM,0.426934
uuid-cfd4a30d0f1f4a00a070fcc637ba68e8,Topalian,0.423821
uuid-cfd4a30d0f1f4a00a070fcc637ba68e8,mg,0.525266
uuid-cfd4a30d0f1f4a00a070fcc637ba68e8,kg,0.432984
uuid-d86dc48c8ddb481395956a4d4e910f96,Opdivo,0.476741
uuid-d86dc48c8ddb481395956a4d4e910f96,trial,0.393134
uuid-d86dc48c8ddb481395956a4d4e910f96,docetaxel,0.437864
uuid-d86dc48c8ddb481395956a4d4e910f96,safety of nivolumab monotherapy,0.350737
uuid-d86dc48c8ddb481395956a4d4e910f96,phase,0.406186
uuid-9bda399f761b475f851717547cacf79d,melanoma,0.408733
uuid-79bc82f7b12f4c9ba8ade71b57f1c081,ipilimumab,0.385692
uuid-79bc82f7b12f4c9ba8ade71b57f1c081,ASCO 2015,0.417944
uuid-79bc82f7b12f4c9ba8ade71b57f1c081,partial response,0.382425
uuid-79bc82f7b12f4c9ba8ade71b57f1c081,Stable disease,0.586335
uuid-79bc82f7b12f4c9ba8ade71b57f1c081,cohort,0.307748
uuid-d218cae5160a45768dcd2d5eb988f4f3,N Engl J Med,0.535286
uuid-d218cae5160a45768dcd2d5eb988f4f3,Lancet Oncol,0.364361
uuid-d218cae5160a45768dcd2d5eb988f4f3,protocol,0.50442
uuid-d218cae5160a45768dcd2d5eb988f4f3,McDermott DF,0.548182
uuid-d218cae5160a45768dcd2d5eb988f4f3,Motzer RJ,0.532741
uuid-d218cae5160a45768dcd2d5eb988f4f3,phase 3 study,0.493197
uuid-d218cae5160a45768dcd2d5eb988f4f3,Escudier B,0.547344
uuid-d218cae5160a45768dcd2d5eb988f4f3,et al.,0.519366
uuid-d218cae5160a45768dcd2d5eb988f4f3,J Clin Oncol,0.509597
uuid-d218cae5160a45768dcd2d5eb988f4f3,Rizvi NA,0.478602
uuid-d218cae5160a45768dcd2d5eb988f4f3,Brahmer J,0.338223
uuid-d218cae5160a45768dcd2d5eb988f4f3,Weber JS,0.370952
uuid-d218cae5160a45768dcd2d5eb988f4f3,phase 2 study,0.591434
uuid-0d94ea1a219b478e849ebf355a39aaa3,OS,0.62262
uuid-0d94ea1a219b478e849ebf355a39aaa3,PFS,0.65903
uuid-0d94ea1a219b478e849ebf355a39aaa3,Overall survival,0.644151
uuid-6060c52d4915476793e2da5bf6523804,95% CI,0.524855
uuid-6060c52d4915476793e2da5bf6523804,respectively,0.383655
uuid-6060c52d4915476793e2da5bf6523804,ASCO,0.303153
uuid-6060c52d4915476793e2da5bf6523804,Lancet Oncol,0.368041
uuid-6060c52d4915476793e2da5bf6523804,Objective response rate,0.504846
uuid-6060c52d4915476793e2da5bf6523804,ORR,0.465366
uuid-6060c52d4915476793e2da5bf6523804,Median overall survival,0.346516
uuid-6060c52d4915476793e2da5bf6523804,Median OS,0.33538
uuid-6060c52d4915476793e2da5bf6523804,ASCO 2015,0.336983
uuid-6060c52d4915476793e2da5bf6523804,small cell lung cancer,0.336892
uuid-6060c52d4915476793e2da5bf6523804,SCLC,0.344367
uuid-6060c52d4915476793e2da5bf6523804,Antonia SJ,0.55269
uuid-6060c52d4915476793e2da5bf6523804,Median duration of response,0.649605
uuid-6f44c522c7274522a7e4cd71bf2c6547,nivolumab,0.575864
uuid-6f44c522c7274522a7e4cd71bf2c6547,Bristol-Myers Squibb,0.428106
uuid-6f44c522c7274522a7e4cd71bf2c6547,evaluating,0.622895
uuid-6f44c522c7274522a7e4cd71bf2c6547,not conducted any controlled clinical trials/studies,0.673131
uuid-6f44c522c7274522a7e4cd71bf2c6547,Pubmed literature search,0.827396
uuid-6f44c522c7274522a7e4cd71bf2c6547,purposes other than its labeled indication must be considered investigational,0.893659
uuid-6f44c522c7274522a7e4cd71bf2c6547,not identify any citations relevant to your inquiry,0.789923
uuid-6f44c522c7274522a7e4cd71bf2c6547,search of published literature,0.321906
uuid-6f44c522c7274522a7e4cd71bf2c6547,using the following search terms,0.776671
uuid-6f44c522c7274522a7e4cd71bf2c6547,efficacy and safety of nivolumab,0.515466
uuid-6f44c522c7274522a7e4cd71bf2c6547,present using the following search terms,0.310279
uuid-df8bfab7c27c4749a8408d573965abf9,OS,0.62262
uuid-df8bfab7c27c4749a8408d573965abf9,PFS,0.65903
uuid-df8bfab7c27c4749a8408d573965abf9,Overall survival,0.644151
uuid-b904d4b91b024d40af6f9e3dad9a695f,open-label,0.539462
uuid-b904d4b91b024d40af6f9e3dad9a695f,phase,0.350616
uuid-41507a44501049148fc1ca057ea6addc,nivolumab,0.380188
uuid-41507a44501049148fc1ca057ea6addc,clinicaltrials.gov,0.607529
uuid-2dffbb113e424819bafe7f613a9df46e,Bristol-Myers Squibb,0.341822
uuid-2dffbb113e424819bafe7f613a9df46e,not conducted any controlled clinical trials/studies,0.304507
uuid-2dffbb113e424819bafe7f613a9df46e,Opdivo,0.461382
uuid-2dffbb113e424819bafe7f613a9df46e,Pubmed literature search,0.614325
uuid-2dffbb113e424819bafe7f613a9df46e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-2dffbb113e424819bafe7f613a9df46e,not identify any citations relevant to your inquiry,0.606087
uuid-2dffbb113e424819bafe7f613a9df46e,adverse,0.304183
uuid-2dffbb113e424819bafe7f613a9df46e,using the following search terms,0.642331
uuid-2dffbb113e424819bafe7f613a9df46e,databases,0.315039
uuid-2dffbb113e424819bafe7f613a9df46e,reported,0.556704
uuid-3998a8e12cff461ca53927a1538bca86,Bristol-Myers Squibb,0.341822
uuid-3998a8e12cff461ca53927a1538bca86,not conducted any controlled clinical trials/studies,0.304507
uuid-3998a8e12cff461ca53927a1538bca86,Opdivo,0.461382
uuid-3998a8e12cff461ca53927a1538bca86,Pubmed literature search,0.614325
uuid-3998a8e12cff461ca53927a1538bca86,purposes other than its labeled indication must be considered investigational,0.586645
uuid-3998a8e12cff461ca53927a1538bca86,not identify any citations relevant to your inquiry,0.606087
uuid-3998a8e12cff461ca53927a1538bca86,adverse,0.304183
uuid-3998a8e12cff461ca53927a1538bca86,using the following search terms,0.642331
uuid-3998a8e12cff461ca53927a1538bca86,databases,0.315039
uuid-3998a8e12cff461ca53927a1538bca86,reported,0.556704
uuid-a3564282854f4530b0bc481c419145e0,Opdivo,0.476741
uuid-a3564282854f4530b0bc481c419145e0,trial,0.393134
uuid-a3564282854f4530b0bc481c419145e0,docetaxel,0.437864
uuid-a3564282854f4530b0bc481c419145e0,safety of nivolumab monotherapy,0.350737
uuid-a3564282854f4530b0bc481c419145e0,phase,0.406186
uuid-9e9524c58ba04736aa4c0bb547280088,patients with advanced or metastatic,0.468858
uuid-9e9524c58ba04736aa4c0bb547280088,nivolumab combined with ipilimumab,0.446918
uuid-9e9524c58ba04736aa4c0bb547280088,not approved,0.352562
uuid-9e9524c58ba04736aa4c0bb547280088,clinical trials investigating the safety,0.429501
uuid-9e9524c58ba04736aa4c0bb547280088,bladder cancer,0.950698
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,use of nivolumab for the treatment,0.440423
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,search of published literature,0.311531
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,PubMed and EMBASE,0.312811
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,not approved,0.404782
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,open-label,0.578291
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,clinical trials investigating the safety,0.440014
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,present using the following search terms,0.328669
uuid-f3bef6d86a8d4d0081d15d038b79c5e3,phase,0.41185
uuid-052078ab4a2f4f90942fc08cc3e5b43f,ASCO,0.581281
uuid-052078ab4a2f4f90942fc08cc3e5b43f,requested,0.306406
uuid-53fad0025d42456f90857900234199a5,evaluating,0.33595
uuid-53fad0025d42456f90857900234199a5,not conducted any controlled clinical trials/studies,0.333389
uuid-53fad0025d42456f90857900234199a5,protocol,0.519575
uuid-53fad0025d42456f90857900234199a5,RCC,0.396552
uuid-53fad0025d42456f90857900234199a5,McDermott DF,0.425884
uuid-53fad0025d42456f90857900234199a5,search of published literature,0.498677
uuid-53fad0025d42456f90857900234199a5,Additionally,0.549804
uuid-53fad0025d42456f90857900234199a5,ongoing,0.474606
uuid-53fad0025d42456f90857900234199a5,Motzer RJ,0.459308
uuid-53fad0025d42456f90857900234199a5,PubMed and EMBASE,0.495663
uuid-53fad0025d42456f90857900234199a5,Escudier B,0.441262
uuid-53fad0025d42456f90857900234199a5,et al.,0.378311
uuid-53fad0025d42456f90857900234199a5,J Clin Oncol,0.413083
uuid-53fad0025d42456f90857900234199a5,detailed search of www.clinicaltrials.gov,0.509888
uuid-53fad0025d42456f90857900234199a5,efficacy and safety of nivolumab,0.474675
uuid-53fad0025d42456f90857900234199a5,not identify any planned,0.488523
uuid-53fad0025d42456f90857900234199a5,phase 2 study,0.364975
uuid-53fad0025d42456f90857900234199a5,not identify any citations relevant to your request,0.559577
uuid-53fad0025d42456f90857900234199a5,present using the following search terms,0.484223
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,95% CI,0.524855
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,respectively,0.383655
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,ASCO,0.303153
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Lancet Oncol,0.368041
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Objective response rate,0.504846
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,ORR,0.465366
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Median overall survival,0.346516
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Median OS,0.33538
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,ASCO 2015,0.336983
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,small cell lung cancer,0.336892
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,SCLC,0.344367
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Antonia SJ,0.55269
uuid-bdbda2439f30471a8bc88f8e5c8b8d82,Median duration of response,0.649605
uuid-234339d63ee6484384f232a9c1a7e4da,nivolumab,0.344939
uuid-234339d63ee6484384f232a9c1a7e4da,Bristol-Myers Squibb,0.363004
uuid-234339d63ee6484384f232a9c1a7e4da,evaluating,0.564404
uuid-234339d63ee6484384f232a9c1a7e4da,not conducted any controlled clinical trials/studies,0.538169
uuid-234339d63ee6484384f232a9c1a7e4da,RCC,0.336118
uuid-234339d63ee6484384f232a9c1a7e4da,search of published literature,0.750115
uuid-234339d63ee6484384f232a9c1a7e4da,Additionally,0.766378
uuid-234339d63ee6484384f232a9c1a7e4da,ongoing,0.629393
uuid-234339d63ee6484384f232a9c1a7e4da,PubMed and EMBASE,0.745288
uuid-234339d63ee6484384f232a9c1a7e4da,detailed search of www.clinicaltrials.gov,0.729251
uuid-234339d63ee6484384f232a9c1a7e4da,efficacy and safety of nivolumab,0.716075
uuid-234339d63ee6484384f232a9c1a7e4da,not identify any planned,0.665705
uuid-234339d63ee6484384f232a9c1a7e4da,not identify any citations relevant to your request,0.849476
uuid-234339d63ee6484384f232a9c1a7e4da,present using the following search terms,0.773092
uuid-2dac48b072b44cc19e037fa1277a8e0f,evaluating,0.386776
uuid-2dac48b072b44cc19e037fa1277a8e0f,N Engl J Med,0.512866
uuid-2dac48b072b44cc19e037fa1277a8e0f,not conducted any controlled clinical trials/studies,0.394776
uuid-2dac48b072b44cc19e037fa1277a8e0f,Lancet Oncol,0.345419
uuid-2dac48b072b44cc19e037fa1277a8e0f,protocol,0.473838
uuid-2dac48b072b44cc19e037fa1277a8e0f,McDermott DF,0.480911
uuid-2dac48b072b44cc19e037fa1277a8e0f,search of published literature,0.512526
uuid-2dac48b072b44cc19e037fa1277a8e0f,Additionally,0.430048
uuid-2dac48b072b44cc19e037fa1277a8e0f,ongoing,0.323467
uuid-2dac48b072b44cc19e037fa1277a8e0f,Motzer RJ,0.467766
uuid-2dac48b072b44cc19e037fa1277a8e0f,phase 3 study,0.515921
uuid-2dac48b072b44cc19e037fa1277a8e0f,PubMed and EMBASE,0.49967
uuid-2dac48b072b44cc19e037fa1277a8e0f,Escudier B,0.484102
uuid-2dac48b072b44cc19e037fa1277a8e0f,NEJM,0.301947
uuid-2dac48b072b44cc19e037fa1277a8e0f,et al.,0.445979
uuid-2dac48b072b44cc19e037fa1277a8e0f,J Clin Oncol,0.41572
uuid-2dac48b072b44cc19e037fa1277a8e0f,Topalian,0.300444
uuid-2dac48b072b44cc19e037fa1277a8e0f,detailed search of www.clinicaltrials.gov,0.37789
uuid-2dac48b072b44cc19e037fa1277a8e0f,phase 1 study,0.383416
uuid-2dac48b072b44cc19e037fa1277a8e0f,Rizvi NA,0.490384
uuid-2dac48b072b44cc19e037fa1277a8e0f,Brahmer J,0.341763
uuid-2dac48b072b44cc19e037fa1277a8e0f,efficacy and safety of nivolumab,0.576567
uuid-2dac48b072b44cc19e037fa1277a8e0f,not identify any planned,0.340892
uuid-2dac48b072b44cc19e037fa1277a8e0f,CA209-003,0.300137
uuid-2dac48b072b44cc19e037fa1277a8e0f,Weber JS,0.372229
uuid-2dac48b072b44cc19e037fa1277a8e0f,phase 2 study,0.592048
uuid-2dac48b072b44cc19e037fa1277a8e0f,not identify any citations relevant to your request,0.46767
uuid-2dac48b072b44cc19e037fa1277a8e0f,present using the following search terms,0.494659
uuid-a08a5170659e4e0b8e034740a0abf7ca,95% CI,0.524855
uuid-a08a5170659e4e0b8e034740a0abf7ca,respectively,0.383655
uuid-a08a5170659e4e0b8e034740a0abf7ca,ASCO,0.303153
uuid-a08a5170659e4e0b8e034740a0abf7ca,Lancet Oncol,0.368041
uuid-a08a5170659e4e0b8e034740a0abf7ca,Objective response rate,0.504846
uuid-a08a5170659e4e0b8e034740a0abf7ca,ORR,0.465366
uuid-a08a5170659e4e0b8e034740a0abf7ca,Median overall survival,0.346516
uuid-a08a5170659e4e0b8e034740a0abf7ca,Median OS,0.33538
uuid-a08a5170659e4e0b8e034740a0abf7ca,ASCO 2015,0.336983
uuid-a08a5170659e4e0b8e034740a0abf7ca,small cell lung cancer,0.336892
uuid-a08a5170659e4e0b8e034740a0abf7ca,SCLC,0.344367
uuid-a08a5170659e4e0b8e034740a0abf7ca,Antonia SJ,0.55269
uuid-a08a5170659e4e0b8e034740a0abf7ca,Median duration of response,0.649605
uuid-392fc08e1c954dc2aab95e08cc2fe8e2,ASCO,0.64795
uuid-392fc08e1c954dc2aab95e08cc2fe8e2,Antonia SJ,0.334859
uuid-d9f9f9740012492abce98016b75b9e44,nivolumab,0.635603
uuid-d9f9f9740012492abce98016b75b9e44,Bristol-Myers Squibb,0.456036
uuid-d9f9f9740012492abce98016b75b9e44,evaluating,0.673772
uuid-d9f9f9740012492abce98016b75b9e44,not conducted any controlled clinical trials/studies,0.712484
uuid-d9f9f9740012492abce98016b75b9e44,Pubmed literature search,0.793499
uuid-d9f9f9740012492abce98016b75b9e44,purposes other than its labeled indication must be considered investigational,0.872788
uuid-d9f9f9740012492abce98016b75b9e44,not identify any citations relevant to your inquiry,0.751168
uuid-d9f9f9740012492abce98016b75b9e44,search of published literature,0.356049
uuid-d9f9f9740012492abce98016b75b9e44,PubMed and EMBASE,0.329142
uuid-d9f9f9740012492abce98016b75b9e44,using the following search terms,0.736925
uuid-d9f9f9740012492abce98016b75b9e44,efficacy and safety of nivolumab,0.561735
uuid-d9f9f9740012492abce98016b75b9e44,present using the following search terms,0.342438
uuid-d7be2cbb8975432683446238105c819d,mg,0.489037
uuid-d7be2cbb8975432683446238105c819d,grade,0.337805
uuid-d7be2cbb8975432683446238105c819d,kg,0.463873
uuid-8beda9dc72d546be993bd27091b69e3c,Opdivo,0.49063
uuid-8beda9dc72d546be993bd27091b69e3c,clinical,0.333947
uuid-8beda9dc72d546be993bd27091b69e3c,trial,0.458009
uuid-8beda9dc72d546be993bd27091b69e3c,BMS,0.330144
uuid-8beda9dc72d546be993bd27091b69e3c,reported,0.368591
uuid-50af756c0298495cb2fed666e501bab2,Bristol-Myers Squibb,0.341822
uuid-50af756c0298495cb2fed666e501bab2,not conducted any controlled clinical trials/studies,0.304507
uuid-50af756c0298495cb2fed666e501bab2,Opdivo,0.461382
uuid-50af756c0298495cb2fed666e501bab2,Pubmed literature search,0.614325
uuid-50af756c0298495cb2fed666e501bab2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-50af756c0298495cb2fed666e501bab2,not identify any citations relevant to your inquiry,0.606087
uuid-50af756c0298495cb2fed666e501bab2,adverse,0.304183
uuid-50af756c0298495cb2fed666e501bab2,using the following search terms,0.642331
uuid-50af756c0298495cb2fed666e501bab2,databases,0.315039
uuid-50af756c0298495cb2fed666e501bab2,reported,0.556704
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,Bristol-Myers Squibb,0.357836
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,not conducted any controlled clinical trials/studies,0.320785
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,Opdivo,0.465659
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,Pubmed literature search,0.605801
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,purposes other than its labeled indication must be considered investigational,0.583599
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,not identify any citations relevant to your inquiry,0.597005
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,adverse,0.308387
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,using the following search terms,0.632487
uuid-dbdba4837a794eebaa1f5dd3a4a343e1,reported,0.564722
uuid-b50985179ed444b4a71aaad8aab8f9fe,N Engl J Med,0.304989
uuid-b50985179ed444b4a71aaad8aab8f9fe,AEs,0.337832
uuid-b50985179ed444b4a71aaad8aab8f9fe,patients,0.387033
uuid-b50985179ed444b4a71aaad8aab8f9fe,provided in the Detailed Information,0.370845
uuid-b50985179ed444b4a71aaad8aab8f9fe,ESMO,0.421367
uuid-b50985179ed444b4a71aaad8aab8f9fe,NEJM,0.709799
uuid-b50985179ed444b4a71aaad8aab8f9fe,Topalian,0.735417
uuid-b50985179ed444b4a71aaad8aab8f9fe,grade 3 to 4 AEs,0.538198
uuid-611dcbdea6ed46f0a97ce312ac9b866b,OS,0.387982
uuid-611dcbdea6ed46f0a97ce312ac9b866b,95% CI,0.745043
uuid-611dcbdea6ed46f0a97ce312ac9b866b,respectively,0.729294
uuid-611dcbdea6ed46f0a97ce312ac9b866b,Objective response rate,0.590876
uuid-611dcbdea6ed46f0a97ce312ac9b866b,ORR,0.722442
uuid-611dcbdea6ed46f0a97ce312ac9b866b,Median overall survival,0.659043
uuid-611dcbdea6ed46f0a97ce312ac9b866b,monotherapy,0.514468
uuid-611dcbdea6ed46f0a97ce312ac9b866b,Median OS,0.696688
uuid-611dcbdea6ed46f0a97ce312ac9b866b,PD-L1,0.300997
uuid-611dcbdea6ed46f0a97ce312ac9b866b,docetaxel,0.635065
uuid-611dcbdea6ed46f0a97ce312ac9b866b,hazard ratio,0.729977
uuid-7dadb359470b4e8c9d1ac230b45b0117,N Engl J Med,0.714946
uuid-7dadb359470b4e8c9d1ac230b45b0117,Lancet Oncol,0.448679
uuid-7dadb359470b4e8c9d1ac230b45b0117,patients,0.309769
uuid-7dadb359470b4e8c9d1ac230b45b0117,protocol,0.700662
uuid-7dadb359470b4e8c9d1ac230b45b0117,McDermott DF,0.68799
uuid-7dadb359470b4e8c9d1ac230b45b0117,Motzer RJ,0.689932
uuid-7dadb359470b4e8c9d1ac230b45b0117,phase 3 study,0.545628
uuid-7dadb359470b4e8c9d1ac230b45b0117,Escudier B,0.698812
uuid-7dadb359470b4e8c9d1ac230b45b0117,NEJM,0.402095
uuid-7dadb359470b4e8c9d1ac230b45b0117,et al.,0.640511
uuid-7dadb359470b4e8c9d1ac230b45b0117,J Clin Oncol,0.626106
uuid-7dadb359470b4e8c9d1ac230b45b0117,Topalian,0.37979
uuid-7dadb359470b4e8c9d1ac230b45b0117,phase 1 study,0.381282
uuid-7dadb359470b4e8c9d1ac230b45b0117,Rizvi NA,0.636006
uuid-7dadb359470b4e8c9d1ac230b45b0117,Brahmer J,0.517174
uuid-7dadb359470b4e8c9d1ac230b45b0117,efficacy and safety of nivolumab,0.368444
uuid-7dadb359470b4e8c9d1ac230b45b0117,Weber JS,0.406071
uuid-7dadb359470b4e8c9d1ac230b45b0117,phase 2 study,0.692115
uuid-fcd4c5ed07cc4b098be5171c3f083cac,requested,0.594234
uuid-db86a25851704750a5793bfeff9d68af,nivolumab,0.999168
uuid-db86a25851704750a5793bfeff9d68af,Pubmed literature search,0.395314
uuid-db86a25851704750a5793bfeff9d68af,purposes other than its labeled indication must be considered investigational,0.464236
uuid-db86a25851704750a5793bfeff9d68af,not identify any citations relevant to your inquiry,0.368569
uuid-db86a25851704750a5793bfeff9d68af,using the following search terms,0.364279
uuid-db86a25851704750a5793bfeff9d68af,present using the following search terms,0.329876
uuid-56a2c51c540443be9bbbd479c007a675,AEs,0.35448
uuid-56a2c51c540443be9bbbd479c007a675,respectively,0.546182
uuid-56a2c51c540443be9bbbd479c007a675,Objective response rate,0.322889
uuid-56a2c51c540443be9bbbd479c007a675,ORR,0.462403
uuid-56a2c51c540443be9bbbd479c007a675,NEJM,0.343466
uuid-56a2c51c540443be9bbbd479c007a675,Topalian,0.302778
uuid-56a2c51c540443be9bbbd479c007a675,grade 3 to 4 AEs,0.387539
uuid-b52ab4dc5ef64a54ac19cc1fab8a0095,OS,0.62262
uuid-b52ab4dc5ef64a54ac19cc1fab8a0095,PFS,0.65903
uuid-b52ab4dc5ef64a54ac19cc1fab8a0095,Overall survival,0.644151
uuid-75d2d139ddad40908a29fce9cf3cd448,Bristol-Myers Squibb,0.341822
uuid-75d2d139ddad40908a29fce9cf3cd448,not conducted any controlled clinical trials/studies,0.304507
uuid-75d2d139ddad40908a29fce9cf3cd448,Opdivo,0.461382
uuid-75d2d139ddad40908a29fce9cf3cd448,Pubmed literature search,0.614325
uuid-75d2d139ddad40908a29fce9cf3cd448,purposes other than its labeled indication must be considered investigational,0.586645
uuid-75d2d139ddad40908a29fce9cf3cd448,not identify any citations relevant to your inquiry,0.606087
uuid-75d2d139ddad40908a29fce9cf3cd448,adverse,0.304183
uuid-75d2d139ddad40908a29fce9cf3cd448,using the following search terms,0.642331
uuid-75d2d139ddad40908a29fce9cf3cd448,databases,0.315039
uuid-75d2d139ddad40908a29fce9cf3cd448,reported,0.556704
uuid-e9c05c1a6db2473790035889f9cdb29c,Opdivo,0.665428
uuid-e9c05c1a6db2473790035889f9cdb29c,RCC,0.413058
uuid-9395173e59ef45c0aca46e0621e56b22,clinicaltrials.gov,0.355943
uuid-2f4a07d4ab194c79a6b426bc3097b7ad,trial,0.405524
uuid-2dbe039238f6474eaa25327cb447caf6,Bristol-Myers Squibb,0.546983
uuid-2dbe039238f6474eaa25327cb447caf6,evaluating,0.572068
uuid-2dbe039238f6474eaa25327cb447caf6,not conducted any controlled clinical trials/studies,0.607773
uuid-2dbe039238f6474eaa25327cb447caf6,NSCLC,0.307782
uuid-2dbe039238f6474eaa25327cb447caf6,efficacy and safety of nivolumab,0.579314
uuid-a1e1d4eccb0c4b04b6a357700093059e,nivolumab,0.578557
uuid-a1e1d4eccb0c4b04b6a357700093059e,Bristol-Myers Squibb,0.420352
uuid-a1e1d4eccb0c4b04b6a357700093059e,evaluating,0.557719
uuid-a1e1d4eccb0c4b04b6a357700093059e,not conducted any controlled clinical trials/studies,0.596806
uuid-a1e1d4eccb0c4b04b6a357700093059e,Pubmed literature search,0.710165
uuid-a1e1d4eccb0c4b04b6a357700093059e,purposes other than its labeled indication must be considered investigational,0.775116
uuid-a1e1d4eccb0c4b04b6a357700093059e,not identify any citations relevant to your inquiry,0.683889
uuid-a1e1d4eccb0c4b04b6a357700093059e,using the following search terms,0.661681
uuid-a1e1d4eccb0c4b04b6a357700093059e,efficacy and safety of nivolumab,0.438787
uuid-b9209bade42c4907bf34edee2c9fbf95,nivolumab,0.535047
uuid-ca039169cca442d493b395f845f7aefd,OS,0.304645
uuid-ca039169cca442d493b395f845f7aefd,95% CI,0.408622
uuid-ca039169cca442d493b395f845f7aefd,NSCLC,0.33588
uuid-ca039169cca442d493b395f845f7aefd,respectively,0.499027
uuid-ca039169cca442d493b395f845f7aefd,Objective response rate,0.688609
uuid-ca039169cca442d493b395f845f7aefd,ORR,0.678791
uuid-ca039169cca442d493b395f845f7aefd,Median overall survival,0.445394
uuid-ca039169cca442d493b395f845f7aefd,monotherapy,0.519987
uuid-ca039169cca442d493b395f845f7aefd,Median OS,0.375881
uuid-ca039169cca442d493b395f845f7aefd,docetaxel,0.378462
uuid-ca039169cca442d493b395f845f7aefd,Antonia SJ,0.333337
uuid-ca039169cca442d493b395f845f7aefd,hazard ratio,0.41425
uuid-01a0e77597474a5dbfc879bfeec54917,NSCLC,0.471144
uuid-01a0e77597474a5dbfc879bfeec54917,non-small cell lung cancer,0.477095
uuid-01a0e77597474a5dbfc879bfeec54917,clinical,0.354788
uuid-01a0e77597474a5dbfc879bfeec54917,trial,0.404053
uuid-01a0e77597474a5dbfc879bfeec54917,therapy,0.326239
uuid-4a75bf09a146413eadb8e8491d015b5b,95% CI,0.524855
uuid-4a75bf09a146413eadb8e8491d015b5b,respectively,0.383655
uuid-4a75bf09a146413eadb8e8491d015b5b,ASCO,0.303153
uuid-4a75bf09a146413eadb8e8491d015b5b,Lancet Oncol,0.368041
uuid-4a75bf09a146413eadb8e8491d015b5b,Objective response rate,0.504846
uuid-4a75bf09a146413eadb8e8491d015b5b,ORR,0.465366
uuid-4a75bf09a146413eadb8e8491d015b5b,Median overall survival,0.346516
uuid-4a75bf09a146413eadb8e8491d015b5b,Median OS,0.33538
uuid-4a75bf09a146413eadb8e8491d015b5b,ASCO 2015,0.336983
uuid-4a75bf09a146413eadb8e8491d015b5b,small cell lung cancer,0.336892
uuid-4a75bf09a146413eadb8e8491d015b5b,SCLC,0.344367
uuid-4a75bf09a146413eadb8e8491d015b5b,Antonia SJ,0.55269
uuid-4a75bf09a146413eadb8e8491d015b5b,Median duration of response,0.649605
uuid-5ae6e647ee204e1fb974fc58e7b5d968,Bristol-Myers Squibb,0.341822
uuid-5ae6e647ee204e1fb974fc58e7b5d968,not conducted any controlled clinical trials/studies,0.304507
uuid-5ae6e647ee204e1fb974fc58e7b5d968,Opdivo,0.461382
uuid-5ae6e647ee204e1fb974fc58e7b5d968,Pubmed literature search,0.614325
uuid-5ae6e647ee204e1fb974fc58e7b5d968,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5ae6e647ee204e1fb974fc58e7b5d968,not identify any citations relevant to your inquiry,0.606087
uuid-5ae6e647ee204e1fb974fc58e7b5d968,adverse,0.304183
uuid-5ae6e647ee204e1fb974fc58e7b5d968,using the following search terms,0.642331
uuid-5ae6e647ee204e1fb974fc58e7b5d968,databases,0.315039
uuid-5ae6e647ee204e1fb974fc58e7b5d968,reported,0.556704
uuid-4addddb090604bcbac02738a06c93979,N Engl J Med,0.672096
uuid-4addddb090604bcbac02738a06c93979,ESMO,0.436384
uuid-4addddb090604bcbac02738a06c93979,Rizvi NA,0.472296
uuid-4addddb090604bcbac02738a06c93979,Brahmer J,0.720441
uuid-4addddb090604bcbac02738a06c93979,Horn L,0.608589
uuid-5cc64e76eef34d0595007206edcbc0ed,OS,0.387982
uuid-5cc64e76eef34d0595007206edcbc0ed,95% CI,0.745043
uuid-5cc64e76eef34d0595007206edcbc0ed,respectively,0.729294
uuid-5cc64e76eef34d0595007206edcbc0ed,Objective response rate,0.590876
uuid-5cc64e76eef34d0595007206edcbc0ed,ORR,0.722442
uuid-5cc64e76eef34d0595007206edcbc0ed,Median overall survival,0.659043
uuid-5cc64e76eef34d0595007206edcbc0ed,monotherapy,0.514468
uuid-5cc64e76eef34d0595007206edcbc0ed,Median OS,0.696688
uuid-5cc64e76eef34d0595007206edcbc0ed,PD-L1,0.300997
uuid-5cc64e76eef34d0595007206edcbc0ed,docetaxel,0.635065
uuid-5cc64e76eef34d0595007206edcbc0ed,hazard ratio,0.729977
uuid-468b7e7645004b9cb538346e2b55c22e,nivolumab,0.580625
uuid-468b7e7645004b9cb538346e2b55c22e,patients,0.464608
uuid-468b7e7645004b9cb538346e2b55c22e,therapy,0.346886
uuid-00cb5bff731a40d2aee4c9adba6790e0,reported,0.340463
uuid-7122cf9d84af4c909d8e23ea42630888,N Engl J Med,0.302601
uuid-7122cf9d84af4c909d8e23ea42630888,AEs,0.348167
uuid-7122cf9d84af4c909d8e23ea42630888,patients,0.536884
uuid-7122cf9d84af4c909d8e23ea42630888,provided in the Detailed Information,0.387544
uuid-7122cf9d84af4c909d8e23ea42630888,ESMO,0.462801
uuid-7122cf9d84af4c909d8e23ea42630888,NEJM,0.66427
uuid-7122cf9d84af4c909d8e23ea42630888,Topalian,0.692873
uuid-7122cf9d84af4c909d8e23ea42630888,grade 3 to 4 AEs,0.626596
uuid-0a9c28573b90455286c073583f685b1f,evaluating,0.434159
uuid-0a9c28573b90455286c073583f685b1f,not conducted any controlled clinical trials/studies,0.429128
uuid-0a9c28573b90455286c073583f685b1f,search of published literature,0.527837
uuid-0a9c28573b90455286c073583f685b1f,PubMed and EMBASE,0.514324
uuid-0a9c28573b90455286c073583f685b1f,Rizvi NA,0.339686
uuid-0a9c28573b90455286c073583f685b1f,efficacy and safety of nivolumab,0.561063
uuid-0a9c28573b90455286c073583f685b1f,Weber JS,0.301304
uuid-0a9c28573b90455286c073583f685b1f,not identify any citations relevant to your request,0.360911
uuid-0a9c28573b90455286c073583f685b1f,present using the following search terms,0.52381
uuid-c3eb0527911c484aa0bd603596389982,requested,0.596669
uuid-59c1540e0b064708bde0701d0999b241,RCC,0.577007
uuid-59c1540e0b064708bde0701d0999b241,clinicaltrials.gov,0.560648
uuid-de281eacc69f40979031b5ad60057bb8,nivolumab,0.344939
uuid-de281eacc69f40979031b5ad60057bb8,Bristol-Myers Squibb,0.363004
uuid-de281eacc69f40979031b5ad60057bb8,evaluating,0.564404
uuid-de281eacc69f40979031b5ad60057bb8,not conducted any controlled clinical trials/studies,0.538169
uuid-de281eacc69f40979031b5ad60057bb8,RCC,0.336118
uuid-de281eacc69f40979031b5ad60057bb8,search of published literature,0.750115
uuid-de281eacc69f40979031b5ad60057bb8,Additionally,0.766378
uuid-de281eacc69f40979031b5ad60057bb8,ongoing,0.629393
uuid-de281eacc69f40979031b5ad60057bb8,PubMed and EMBASE,0.745288
uuid-de281eacc69f40979031b5ad60057bb8,detailed search of www.clinicaltrials.gov,0.729251
uuid-de281eacc69f40979031b5ad60057bb8,efficacy and safety of nivolumab,0.716075
uuid-de281eacc69f40979031b5ad60057bb8,not identify any planned,0.665705
uuid-de281eacc69f40979031b5ad60057bb8,not identify any citations relevant to your request,0.849476
uuid-de281eacc69f40979031b5ad60057bb8,present using the following search terms,0.773092
uuid-1058fccc8eca4af3964f54010859fd35,CA209-003,0.412388
uuid-1058fccc8eca4af3964f54010859fd35,grade,0.315781
uuid-1058fccc8eca4af3964f54010859fd35,investigating,0.495901
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,N Engl J Med,0.427636
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,protocol,0.429136
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,McDermott DF,0.44782
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,Motzer RJ,0.430476
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,Escudier B,0.450887
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,et al.,0.456026
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,J Clin Oncol,0.384624
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,Rizvi NA,0.305616
uuid-2fdd4ee4d2504a7f904303e0e046c5b6,phase 2 study,0.351446
uuid-8bfeed502ecc4f24a0766a582ed64fc4,AEs,0.425265
uuid-8bfeed502ecc4f24a0766a582ed64fc4,adverse,0.894052
uuid-8bfeed502ecc4f24a0766a582ed64fc4,grade,0.420007
uuid-8bfeed502ecc4f24a0766a582ed64fc4,reported,0.545088
uuid-0b91edb2cf7c4b01ab0d4bff69747112,respectively,0.559899
uuid-0b91edb2cf7c4b01ab0d4bff69747112,Objective response rate,0.344669
uuid-0b91edb2cf7c4b01ab0d4bff69747112,ORR,0.392723
uuid-0b91edb2cf7c4b01ab0d4bff69747112,monotherapy,0.374644
uuid-0b91edb2cf7c4b01ab0d4bff69747112,adverse,0.355646
uuid-0b91edb2cf7c4b01ab0d4bff69747112,docetaxel,0.321279
uuid-0d6fb7a80bd047938eab1a0f741f5ff2,nivolumab,0.502183
uuid-0d6fb7a80bd047938eab1a0f741f5ff2,RCC,0.756598
uuid-275214cf53654fe5ab707225f32ecb3b,grade,0.464459
uuid-4cc7b8c795f447e2904a736e815c2ce8,requested,0.662269
uuid-576b7dbc8b754cf2b863230c003e77b0,requested,0.540431
uuid-cefe23a8db7d46eb8a2040bbf2be2cf8,Opdivo,0.415016
uuid-260148bcb515482792e9c62111218243,ASCO,0.64795
uuid-260148bcb515482792e9c62111218243,Antonia SJ,0.334859
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,N Engl J Med,0.670787
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Lancet Oncol,0.428734
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,patients,0.30097
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,protocol,0.66884
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,McDermott DF,0.647848
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Motzer RJ,0.648757
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,phase 3 study,0.521947
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Escudier B,0.658725
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,NEJM,0.373992
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,et al.,0.60408
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,J Clin Oncol,0.585945
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Topalian,0.356955
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,phase 1 study,0.36061
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Rizvi NA,0.616604
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Brahmer J,0.486666
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,efficacy and safety of nivolumab,0.348796
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,Weber JS,0.413184
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,BMS,0.32129
uuid-d3f1a712ac2d4e05ae0ddd4011b62790,phase 2 study,0.64821
uuid-2598ac7c396349bab1eef17060f4ddcc,N Engl J Med,0.448483
uuid-2598ac7c396349bab1eef17060f4ddcc,protocol,0.770446
uuid-2598ac7c396349bab1eef17060f4ddcc,McDermott DF,0.741196
uuid-2598ac7c396349bab1eef17060f4ddcc,Motzer RJ,0.818144
uuid-2598ac7c396349bab1eef17060f4ddcc,phase 3 study,0.417055
uuid-2598ac7c396349bab1eef17060f4ddcc,Escudier B,0.749917
uuid-2598ac7c396349bab1eef17060f4ddcc,NEJM,0.400698
uuid-2598ac7c396349bab1eef17060f4ddcc,et al.,0.668641
uuid-2598ac7c396349bab1eef17060f4ddcc,J Clin Oncol,0.792018
uuid-2598ac7c396349bab1eef17060f4ddcc,Topalian,0.388894
uuid-2598ac7c396349bab1eef17060f4ddcc,phase 1 study,0.500686
uuid-2598ac7c396349bab1eef17060f4ddcc,CA209-003,0.567381
uuid-2598ac7c396349bab1eef17060f4ddcc,phase 2 study,0.677985
uuid-2598ac7c396349bab1eef17060f4ddcc,present using the following search terms,0.310558
uuid-2598ac7c396349bab1eef17060f4ddcc,investigating,0.615835
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,OS,0.387982
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,95% CI,0.745043
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,respectively,0.729294
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,Objective response rate,0.590876
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,ORR,0.722442
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,Median overall survival,0.659043
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,monotherapy,0.514468
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,Median OS,0.696688
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,PD-L1,0.300997
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,docetaxel,0.635065
uuid-080bd4a8ac4d424ab4bb4c03abee87d6,hazard ratio,0.729977
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,95% CI,0.524855
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,respectively,0.383655
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,ASCO,0.303153
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Lancet Oncol,0.368041
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Objective response rate,0.504846
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,ORR,0.465366
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Median overall survival,0.346516
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Median OS,0.33538
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,ASCO 2015,0.336983
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,small cell lung cancer,0.336892
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,SCLC,0.344367
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Antonia SJ,0.55269
uuid-e0a3d1c513b84117b6b88ad3fe0e8536,Median duration of response,0.649605
uuid-8d208b0e2ada47ee832eaeb9ac77b783,requested,0.44769
uuid-8d208b0e2ada47ee832eaeb9ac77b783,trial,0.309472
uuid-bb029bbca7f54e90bb9603d046dda378,PD-L1,0.708176
uuid-faf9924f56c344a5ae03d7f01a3bf827,N Engl J Med,0.636726
uuid-faf9924f56c344a5ae03d7f01a3bf827,non-small cell lung cancer,0.351489
uuid-faf9924f56c344a5ae03d7f01a3bf827,ESMO,0.419331
uuid-faf9924f56c344a5ae03d7f01a3bf827,Rizvi NA,0.470388
uuid-faf9924f56c344a5ae03d7f01a3bf827,Brahmer J,0.676477
uuid-faf9924f56c344a5ae03d7f01a3bf827,PD-L1,0.354847
uuid-faf9924f56c344a5ae03d7f01a3bf827,Horn L,0.512976
uuid-faf9924f56c344a5ae03d7f01a3bf827,platinum-based doublet chemotherapy,0.312066
uuid-1bcc60f4dcd1477cb08dcb63379816ce,95% CI,0.524855
uuid-1bcc60f4dcd1477cb08dcb63379816ce,respectively,0.383655
uuid-1bcc60f4dcd1477cb08dcb63379816ce,ASCO,0.303153
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Lancet Oncol,0.368041
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Objective response rate,0.504846
uuid-1bcc60f4dcd1477cb08dcb63379816ce,ORR,0.465366
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Median overall survival,0.346516
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Median OS,0.33538
uuid-1bcc60f4dcd1477cb08dcb63379816ce,ASCO 2015,0.336983
uuid-1bcc60f4dcd1477cb08dcb63379816ce,small cell lung cancer,0.336892
uuid-1bcc60f4dcd1477cb08dcb63379816ce,SCLC,0.344367
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Antonia SJ,0.55269
uuid-1bcc60f4dcd1477cb08dcb63379816ce,Median duration of response,0.649605
uuid-5993a176442346448ac15289e45ea5f6,respectively,0.589071
uuid-5993a176442346448ac15289e45ea5f6,Objective response rate,0.407286
uuid-5993a176442346448ac15289e45ea5f6,ORR,0.526086
uuid-5993a176442346448ac15289e45ea5f6,monotherapy,0.319413
uuid-5993a176442346448ac15289e45ea5f6,docetaxel,0.334344
uuid-9a18afdb596a417e85ca1c80e93b7caf,OS,0.387982
uuid-9a18afdb596a417e85ca1c80e93b7caf,95% CI,0.745043
uuid-9a18afdb596a417e85ca1c80e93b7caf,respectively,0.729294
uuid-9a18afdb596a417e85ca1c80e93b7caf,Objective response rate,0.590876
uuid-9a18afdb596a417e85ca1c80e93b7caf,ORR,0.722442
uuid-9a18afdb596a417e85ca1c80e93b7caf,Median overall survival,0.659043
uuid-9a18afdb596a417e85ca1c80e93b7caf,monotherapy,0.514468
uuid-9a18afdb596a417e85ca1c80e93b7caf,Median OS,0.696688
uuid-9a18afdb596a417e85ca1c80e93b7caf,PD-L1,0.300997
uuid-9a18afdb596a417e85ca1c80e93b7caf,docetaxel,0.635065
uuid-9a18afdb596a417e85ca1c80e93b7caf,hazard ratio,0.729977
uuid-37168275313c416daf2b849ba28fe49d,OS,0.387982
uuid-37168275313c416daf2b849ba28fe49d,95% CI,0.745043
uuid-37168275313c416daf2b849ba28fe49d,respectively,0.729294
uuid-37168275313c416daf2b849ba28fe49d,Objective response rate,0.590876
uuid-37168275313c416daf2b849ba28fe49d,ORR,0.722442
uuid-37168275313c416daf2b849ba28fe49d,Median overall survival,0.659043
uuid-37168275313c416daf2b849ba28fe49d,monotherapy,0.514468
uuid-37168275313c416daf2b849ba28fe49d,Median OS,0.696688
uuid-37168275313c416daf2b849ba28fe49d,PD-L1,0.300997
uuid-37168275313c416daf2b849ba28fe49d,docetaxel,0.635065
uuid-37168275313c416daf2b849ba28fe49d,hazard ratio,0.729977
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,use of nivolumab for the treatment,0.440423
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,search of published literature,0.311531
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,PubMed and EMBASE,0.312811
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,not approved,0.404782
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,open-label,0.578291
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,clinical trials investigating the safety,0.440014
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,present using the following search terms,0.328669
uuid-c1ac7bdde87d4e5e804904fe860c8d0d,phase,0.41185
uuid-a750a7c8ac994678805050ecf94c6a01,95% CI,0.524855
uuid-a750a7c8ac994678805050ecf94c6a01,respectively,0.383655
uuid-a750a7c8ac994678805050ecf94c6a01,ASCO,0.303153
uuid-a750a7c8ac994678805050ecf94c6a01,Lancet Oncol,0.368041
uuid-a750a7c8ac994678805050ecf94c6a01,Objective response rate,0.504846
uuid-a750a7c8ac994678805050ecf94c6a01,ORR,0.465366
uuid-a750a7c8ac994678805050ecf94c6a01,Median overall survival,0.346516
uuid-a750a7c8ac994678805050ecf94c6a01,Median OS,0.33538
uuid-a750a7c8ac994678805050ecf94c6a01,ASCO 2015,0.336983
uuid-a750a7c8ac994678805050ecf94c6a01,small cell lung cancer,0.336892
uuid-a750a7c8ac994678805050ecf94c6a01,SCLC,0.344367
uuid-a750a7c8ac994678805050ecf94c6a01,Antonia SJ,0.55269
uuid-a750a7c8ac994678805050ecf94c6a01,Median duration of response,0.649605
uuid-26329623b653422ab11d1edbc0838f89,95% CI,0.371093
uuid-26329623b653422ab11d1edbc0838f89,respectively,0.350747
uuid-26329623b653422ab11d1edbc0838f89,Objective response rate,0.320462
uuid-26329623b653422ab11d1edbc0838f89,ORR,0.377159
uuid-26329623b653422ab11d1edbc0838f89,Median overall survival,0.310487
uuid-26329623b653422ab11d1edbc0838f89,Median OS,0.360727
uuid-26329623b653422ab11d1edbc0838f89,hazard ratio,0.336858
uuid-c6e4e64becf84a9db1245ebfe77d9008,NSCLC,0.480337
uuid-c6e4e64becf84a9db1245ebfe77d9008,respectively,0.400584
uuid-c6e4e64becf84a9db1245ebfe77d9008,non-small cell lung cancer,0.395662
uuid-c6e4e64becf84a9db1245ebfe77d9008,patients,0.382838
uuid-c6e4e64becf84a9db1245ebfe77d9008,considered investigational,0.378457
uuid-c6e4e64becf84a9db1245ebfe77d9008,Objective response rate,0.446233
uuid-c6e4e64becf84a9db1245ebfe77d9008,ORR,0.488323
uuid-c6e4e64becf84a9db1245ebfe77d9008,monotherapy,0.419452
uuid-c6e4e64becf84a9db1245ebfe77d9008,small cell lung cancer,0.328277
uuid-c6e4e64becf84a9db1245ebfe77d9008,docetaxel,0.370754
uuid-c6e4e64becf84a9db1245ebfe77d9008,SCLC,0.328412
uuid-c6e4e64becf84a9db1245ebfe77d9008,grade 3 to 4 AEs,0.337672
uuid-c6e4e64becf84a9db1245ebfe77d9008,platinum-based doublet chemotherapy,0.355492
uuid-a099a0623c7f4772b9d19f5f5e7f8442,Bristol-Myers Squibb,0.341822
uuid-a099a0623c7f4772b9d19f5f5e7f8442,not conducted any controlled clinical trials/studies,0.304507
uuid-a099a0623c7f4772b9d19f5f5e7f8442,Opdivo,0.461382
uuid-a099a0623c7f4772b9d19f5f5e7f8442,Pubmed literature search,0.614325
uuid-a099a0623c7f4772b9d19f5f5e7f8442,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a099a0623c7f4772b9d19f5f5e7f8442,not identify any citations relevant to your inquiry,0.606087
uuid-a099a0623c7f4772b9d19f5f5e7f8442,adverse,0.304183
uuid-a099a0623c7f4772b9d19f5f5e7f8442,using the following search terms,0.642331
uuid-a099a0623c7f4772b9d19f5f5e7f8442,databases,0.315039
uuid-a099a0623c7f4772b9d19f5f5e7f8442,reported,0.556704
uuid-a231d9c027a748f49836da966e149003,nivolumab,0.57082
uuid-a231d9c027a748f49836da966e149003,clinicaltrials.gov,0.536886
uuid-1cb4a92f13174a95a65379af3dfab8c2,N Engl J Med,0.892438
uuid-1cb4a92f13174a95a65379af3dfab8c2,Lancet Oncol,0.369114
uuid-1cb4a92f13174a95a65379af3dfab8c2,provided in the Detailed Information,0.302862
uuid-1cb4a92f13174a95a65379af3dfab8c2,protocol,0.755063
uuid-1cb4a92f13174a95a65379af3dfab8c2,McDermott DF,0.82995
uuid-1cb4a92f13174a95a65379af3dfab8c2,Motzer RJ,0.803103
uuid-1cb4a92f13174a95a65379af3dfab8c2,ESMO,0.341635
uuid-1cb4a92f13174a95a65379af3dfab8c2,phase 3 study,0.507488
uuid-1cb4a92f13174a95a65379af3dfab8c2,Escudier B,0.832421
uuid-1cb4a92f13174a95a65379af3dfab8c2,NEJM,0.452995
uuid-1cb4a92f13174a95a65379af3dfab8c2,et al.,0.8085
uuid-1cb4a92f13174a95a65379af3dfab8c2,J Clin Oncol,0.737251
uuid-1cb4a92f13174a95a65379af3dfab8c2,Topalian,0.42081
uuid-1cb4a92f13174a95a65379af3dfab8c2,Rizvi NA,0.588152
uuid-1cb4a92f13174a95a65379af3dfab8c2,Brahmer J,0.577339
uuid-1cb4a92f13174a95a65379af3dfab8c2,Weber JS,0.403598
uuid-1cb4a92f13174a95a65379af3dfab8c2,phase 2 study,0.770524
uuid-9e11a08063c648cb9c1eb5b1c00e506c,respectively,0.602014
uuid-9e11a08063c648cb9c1eb5b1c00e506c,Objective response rate,0.389349
uuid-9e11a08063c648cb9c1eb5b1c00e506c,ORR,0.433322
uuid-9e11a08063c648cb9c1eb5b1c00e506c,monotherapy,0.549576
uuid-9e11a08063c648cb9c1eb5b1c00e506c,mg,0.569957
uuid-9e11a08063c648cb9c1eb5b1c00e506c,docetaxel,0.338595
uuid-9e11a08063c648cb9c1eb5b1c00e506c,kg,0.563617
uuid-9e11a08063c648cb9c1eb5b1c00e506c,cohort,0.446503
uuid-7be30e86be074bcd96685ba3cc52ae1e,requested,0.44769
uuid-7be30e86be074bcd96685ba3cc52ae1e,trial,0.309472
uuid-b7787bdb111a4e439594534e72959870,patients,0.324499
uuid-d4e504f8b7eb4ad89fefc2e23353900e,OS,0.387982
uuid-d4e504f8b7eb4ad89fefc2e23353900e,95% CI,0.745043
uuid-d4e504f8b7eb4ad89fefc2e23353900e,respectively,0.729294
uuid-d4e504f8b7eb4ad89fefc2e23353900e,Objective response rate,0.590876
uuid-d4e504f8b7eb4ad89fefc2e23353900e,ORR,0.722442
uuid-d4e504f8b7eb4ad89fefc2e23353900e,Median overall survival,0.659043
uuid-d4e504f8b7eb4ad89fefc2e23353900e,monotherapy,0.514468
uuid-d4e504f8b7eb4ad89fefc2e23353900e,Median OS,0.696688
uuid-d4e504f8b7eb4ad89fefc2e23353900e,PD-L1,0.300997
uuid-d4e504f8b7eb4ad89fefc2e23353900e,docetaxel,0.635065
uuid-d4e504f8b7eb4ad89fefc2e23353900e,hazard ratio,0.729977
uuid-7288d6e9f6524cf98e35038151a28482,patients,0.301923
uuid-7288d6e9f6524cf98e35038151a28482,considered investigational,0.30331
uuid-7288d6e9f6524cf98e35038151a28482,Opdivo,0.380623
uuid-7288d6e9f6524cf98e35038151a28482,melanoma,0.493256
uuid-7288d6e9f6524cf98e35038151a28482,small cell lung cancer,0.362487
uuid-7288d6e9f6524cf98e35038151a28482,clinicaltrials.gov,0.308597
uuid-7288d6e9f6524cf98e35038151a28482,SCLC,0.348698
uuid-7288d6e9f6524cf98e35038151a28482,therapy,0.389675
uuid-7288d6e9f6524cf98e35038151a28482,phase,0.35293
uuid-e050a124777e4cecb0c7d2db40f89da5,requested,0.322675
uuid-e050a124777e4cecb0c7d2db40f89da5,Brahmer J,0.304196
uuid-e050a124777e4cecb0c7d2db40f89da5,BMS,0.696296
uuid-0ff79633eb0c416983b51013f2e38012,Opdivo,0.540929
uuid-0ff79633eb0c416983b51013f2e38012,not approved,0.315115
uuid-0ff79633eb0c416983b51013f2e38012,clinical trials investigating the safety,0.31295
uuid-0ff79633eb0c416983b51013f2e38012,trial,0.472874
uuid-e9dfc501ae37437f9b2e0a783f4ce7cd,respectively,0.608515
uuid-e9dfc501ae37437f9b2e0a783f4ce7cd,Objective response rate,0.390758
uuid-e9dfc501ae37437f9b2e0a783f4ce7cd,ORR,0.422193
uuid-557ca5711e8543188c33e099d8803492,patients,0.323809
uuid-557ca5711e8543188c33e099d8803492,adverse,0.477778
uuid-c124bfc8a7dd402b97a414387e51470f,patients with advanced or metastatic,0.478326
uuid-c124bfc8a7dd402b97a414387e51470f,nivolumab combined with ipilimumab,0.498766
uuid-c124bfc8a7dd402b97a414387e51470f,not approved,0.34724
uuid-c124bfc8a7dd402b97a414387e51470f,clinical trials investigating the safety,0.426729
uuid-c124bfc8a7dd402b97a414387e51470f,bladder cancer,0.6548
uuid-da330d9cd67d4e1797bfd1bf52802e02,melanoma,0.410364
uuid-175d2643e26946969787d4730570330e,use of nivolumab for the treatment,0.409821
uuid-175d2643e26946969787d4730570330e,patients with advanced or metastatic,0.645244
uuid-175d2643e26946969787d4730570330e,nivolumab combined with ipilimumab,0.676339
uuid-175d2643e26946969787d4730570330e,not approved,0.453534
uuid-175d2643e26946969787d4730570330e,clinical trials investigating the safety,0.548799
uuid-175d2643e26946969787d4730570330e,phase 1/2 study CA209-032,0.34114
uuid-175d2643e26946969787d4730570330e,bladder cancer,0.749142
uuid-175d2643e26946969787d4730570330e,evaluates the efficacy of nivolumab monotherapy,0.381221
uuid-32f6c55ab8884f49bb6e289e3b10f148,requested,0.662269
uuid-777f986f31bf420d91a8ac826deebd12,N Engl J Med,0.729204
uuid-777f986f31bf420d91a8ac826deebd12,McDermott DF,0.337542
uuid-777f986f31bf420d91a8ac826deebd12,Motzer RJ,0.31484
uuid-777f986f31bf420d91a8ac826deebd12,phase 3 study,0.322899
uuid-777f986f31bf420d91a8ac826deebd12,Escudier B,0.327813
uuid-777f986f31bf420d91a8ac826deebd12,et al.,0.328508
uuid-777f986f31bf420d91a8ac826deebd12,Rizvi NA,0.449704
uuid-777f986f31bf420d91a8ac826deebd12,Brahmer J,0.700475
uuid-777f986f31bf420d91a8ac826deebd12,phase 2 study,0.468034
uuid-777f986f31bf420d91a8ac826deebd12,Horn L,0.416314
uuid-c8a6384acced4a1f923965ef4e5cc57e,nivolumab,0.439723
uuid-c8a6384acced4a1f923965ef4e5cc57e,patients,0.38616
uuid-c8a6384acced4a1f923965ef4e5cc57e,adverse,0.341293
uuid-1acd1bb8d4bd4509945735b580fa80d3,OS,0.387982
uuid-1acd1bb8d4bd4509945735b580fa80d3,95% CI,0.745043
uuid-1acd1bb8d4bd4509945735b580fa80d3,respectively,0.729294
uuid-1acd1bb8d4bd4509945735b580fa80d3,Objective response rate,0.590876
uuid-1acd1bb8d4bd4509945735b580fa80d3,ORR,0.722442
uuid-1acd1bb8d4bd4509945735b580fa80d3,Median overall survival,0.659043
uuid-1acd1bb8d4bd4509945735b580fa80d3,monotherapy,0.514468
uuid-1acd1bb8d4bd4509945735b580fa80d3,Median OS,0.696688
uuid-1acd1bb8d4bd4509945735b580fa80d3,PD-L1,0.300997
uuid-1acd1bb8d4bd4509945735b580fa80d3,docetaxel,0.635065
uuid-1acd1bb8d4bd4509945735b580fa80d3,hazard ratio,0.729977
uuid-3304a049136c40998d1a0365f423c7f3,respectively,0.589071
uuid-3304a049136c40998d1a0365f423c7f3,Objective response rate,0.407286
uuid-3304a049136c40998d1a0365f423c7f3,ORR,0.526086
uuid-3304a049136c40998d1a0365f423c7f3,monotherapy,0.319413
uuid-3304a049136c40998d1a0365f423c7f3,docetaxel,0.334344
uuid-f6bc4310dbfa420c9832edf1507d4197,nivolumab,0.572865
uuid-f6bc4310dbfa420c9832edf1507d4197,Bristol-Myers Squibb,0.440552
uuid-f6bc4310dbfa420c9832edf1507d4197,evaluating,0.59768
uuid-f6bc4310dbfa420c9832edf1507d4197,not conducted any controlled clinical trials/studies,0.658758
uuid-f6bc4310dbfa420c9832edf1507d4197,Pubmed literature search,0.87332
uuid-f6bc4310dbfa420c9832edf1507d4197,purposes other than its labeled indication must be considered investigational,0.938044
uuid-f6bc4310dbfa420c9832edf1507d4197,not identify any citations relevant to your inquiry,0.832256
uuid-f6bc4310dbfa420c9832edf1507d4197,using the following search terms,0.819071
uuid-f6bc4310dbfa420c9832edf1507d4197,efficacy and safety of nivolumab,0.437337
uuid-e08cd60b83c64293a476bda457c17195,Median OS,0.308346
uuid-91bc3fea2cea44138f7af2db481baa5a,evaluating,0.330685
uuid-91bc3fea2cea44138f7af2db481baa5a,not conducted any controlled clinical trials/studies,0.327345
uuid-91bc3fea2cea44138f7af2db481baa5a,protocol,0.519543
uuid-91bc3fea2cea44138f7af2db481baa5a,RCC,0.386373
uuid-91bc3fea2cea44138f7af2db481baa5a,McDermott DF,0.428134
uuid-91bc3fea2cea44138f7af2db481baa5a,search of published literature,0.502766
uuid-91bc3fea2cea44138f7af2db481baa5a,Additionally,0.557479
uuid-91bc3fea2cea44138f7af2db481baa5a,ongoing,0.481784
uuid-91bc3fea2cea44138f7af2db481baa5a,Motzer RJ,0.460611
uuid-91bc3fea2cea44138f7af2db481baa5a,PubMed and EMBASE,0.500245
uuid-91bc3fea2cea44138f7af2db481baa5a,Escudier B,0.443099
uuid-91bc3fea2cea44138f7af2db481baa5a,et al.,0.381064
uuid-91bc3fea2cea44138f7af2db481baa5a,J Clin Oncol,0.414948
uuid-91bc3fea2cea44138f7af2db481baa5a,detailed search of www.clinicaltrials.gov,0.51767
uuid-91bc3fea2cea44138f7af2db481baa5a,efficacy and safety of nivolumab,0.47306
uuid-91bc3fea2cea44138f7af2db481baa5a,not identify any planned,0.496065
uuid-91bc3fea2cea44138f7af2db481baa5a,phase 2 study,0.368211
uuid-91bc3fea2cea44138f7af2db481baa5a,not identify any citations relevant to your request,0.567555
uuid-91bc3fea2cea44138f7af2db481baa5a,present using the following search terms,0.489389
uuid-f5da448a3ed74909861f66da84ca1e39,nivolumab,0.359772
uuid-deffa8c779cc41cab6cf10b6c416a3ca,N Engl J Med,0.362637
uuid-deffa8c779cc41cab6cf10b6c416a3ca,requested,0.323174
uuid-deffa8c779cc41cab6cf10b6c416a3ca,protocol,0.432257
uuid-deffa8c779cc41cab6cf10b6c416a3ca,McDermott DF,0.522967
uuid-deffa8c779cc41cab6cf10b6c416a3ca,Motzer RJ,0.479534
uuid-deffa8c779cc41cab6cf10b6c416a3ca,phase 3 study,0.365514
uuid-deffa8c779cc41cab6cf10b6c416a3ca,Escudier B,0.509657
uuid-deffa8c779cc41cab6cf10b6c416a3ca,et al.,0.519507
uuid-deffa8c779cc41cab6cf10b6c416a3ca,J Clin Oncol,0.459274
uuid-deffa8c779cc41cab6cf10b6c416a3ca,Rizvi NA,0.363138
uuid-deffa8c779cc41cab6cf10b6c416a3ca,Weber JS,0.328365
uuid-deffa8c779cc41cab6cf10b6c416a3ca,phase 2 study,0.488848
uuid-ea250bac37d2431ea2cac4d087989a2a,use of nivolumab for the treatment,0.440423
uuid-ea250bac37d2431ea2cac4d087989a2a,search of published literature,0.311531
uuid-ea250bac37d2431ea2cac4d087989a2a,PubMed and EMBASE,0.312811
uuid-ea250bac37d2431ea2cac4d087989a2a,not approved,0.404782
uuid-ea250bac37d2431ea2cac4d087989a2a,open-label,0.578291
uuid-ea250bac37d2431ea2cac4d087989a2a,clinical trials investigating the safety,0.440014
uuid-ea250bac37d2431ea2cac4d087989a2a,present using the following search terms,0.328669
uuid-ea250bac37d2431ea2cac4d087989a2a,phase,0.41185
uuid-246d9ac8c2f040b39cafa562c9979c4f,respectively,0.589071
uuid-246d9ac8c2f040b39cafa562c9979c4f,Objective response rate,0.407286
uuid-246d9ac8c2f040b39cafa562c9979c4f,ORR,0.526086
uuid-246d9ac8c2f040b39cafa562c9979c4f,monotherapy,0.319413
uuid-246d9ac8c2f040b39cafa562c9979c4f,docetaxel,0.334344
uuid-768ecbf5bd7b4446bb9cd898bd851471,patients with advanced or metastatic,0.468858
uuid-768ecbf5bd7b4446bb9cd898bd851471,nivolumab combined with ipilimumab,0.446918
uuid-768ecbf5bd7b4446bb9cd898bd851471,not approved,0.352562
uuid-768ecbf5bd7b4446bb9cd898bd851471,clinical trials investigating the safety,0.429501
uuid-768ecbf5bd7b4446bb9cd898bd851471,bladder cancer,0.950698
uuid-531018b8e1fa48e0ade2e78bba6a5395,95% CI,0.524855
uuid-531018b8e1fa48e0ade2e78bba6a5395,respectively,0.383655
uuid-531018b8e1fa48e0ade2e78bba6a5395,ASCO,0.303153
uuid-531018b8e1fa48e0ade2e78bba6a5395,Lancet Oncol,0.368041
uuid-531018b8e1fa48e0ade2e78bba6a5395,Objective response rate,0.504846
uuid-531018b8e1fa48e0ade2e78bba6a5395,ORR,0.465366
uuid-531018b8e1fa48e0ade2e78bba6a5395,Median overall survival,0.346516
uuid-531018b8e1fa48e0ade2e78bba6a5395,Median OS,0.33538
uuid-531018b8e1fa48e0ade2e78bba6a5395,ASCO 2015,0.336983
uuid-531018b8e1fa48e0ade2e78bba6a5395,small cell lung cancer,0.336892
uuid-531018b8e1fa48e0ade2e78bba6a5395,SCLC,0.344367
uuid-531018b8e1fa48e0ade2e78bba6a5395,Antonia SJ,0.55269
uuid-531018b8e1fa48e0ade2e78bba6a5395,Median duration of response,0.649605
uuid-868d4331d4184235b9895508a0492364,respectively,0.589071
uuid-868d4331d4184235b9895508a0492364,Objective response rate,0.407286
uuid-868d4331d4184235b9895508a0492364,ORR,0.526086
uuid-868d4331d4184235b9895508a0492364,monotherapy,0.319413
uuid-868d4331d4184235b9895508a0492364,docetaxel,0.334344
uuid-88f26505d06048178427ec2c8676a2a6,fatigue,0.704358
uuid-079db64e978d439895f4ee96643309a0,monotherapy,0.444089
uuid-079db64e978d439895f4ee96643309a0,mg,0.853025
uuid-079db64e978d439895f4ee96643309a0,kg,0.853742
uuid-079db64e978d439895f4ee96643309a0,phase,0.318256
uuid-079db64e978d439895f4ee96643309a0,cohort,0.461371
uuid-f6cfb60a56bf47c2ad9dbe84b1843a2d,respectively,0.397695
uuid-11913a6c692d473099e2c4eeb085bc5a,Objective response rate,0.427051
uuid-11913a6c692d473099e2c4eeb085bc5a,clinicaltrials.gov,0.524603
uuid-11913a6c692d473099e2c4eeb085bc5a,relapsed,0.306689
uuid-c9112c8f3d56429f85cf7fe2744e996c,requested,0.540431
uuid-90b2e531e8364e7d9242cae505115fa5,respectively,0.604911
uuid-90b2e531e8364e7d9242cae505115fa5,ASCO,0.370609
uuid-90b2e531e8364e7d9242cae505115fa5,Objective response rate,0.472418
uuid-90b2e531e8364e7d9242cae505115fa5,ORR,0.487844
uuid-90b2e531e8364e7d9242cae505115fa5,monotherapy,0.476726
uuid-90b2e531e8364e7d9242cae505115fa5,docetaxel,0.478668
uuid-90b2e531e8364e7d9242cae505115fa5,Antonia SJ,0.346494
uuid-4570bee52d1946229af029fa9c221c24,Bristol-Myers Squibb,0.341822
uuid-4570bee52d1946229af029fa9c221c24,not conducted any controlled clinical trials/studies,0.304507
uuid-4570bee52d1946229af029fa9c221c24,Opdivo,0.461382
uuid-4570bee52d1946229af029fa9c221c24,Pubmed literature search,0.614325
uuid-4570bee52d1946229af029fa9c221c24,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4570bee52d1946229af029fa9c221c24,not identify any citations relevant to your inquiry,0.606087
uuid-4570bee52d1946229af029fa9c221c24,adverse,0.304183
uuid-4570bee52d1946229af029fa9c221c24,using the following search terms,0.642331
uuid-4570bee52d1946229af029fa9c221c24,databases,0.315039
uuid-4570bee52d1946229af029fa9c221c24,reported,0.556704
uuid-cc1fdeccc83b43d4a9c983861ec67236,N Engl J Med,0.520402
uuid-cc1fdeccc83b43d4a9c983861ec67236,provided in the Detailed Information,0.434998
uuid-cc1fdeccc83b43d4a9c983861ec67236,protocol,0.658119
uuid-cc1fdeccc83b43d4a9c983861ec67236,McDermott DF,0.726713
uuid-cc1fdeccc83b43d4a9c983861ec67236,Motzer RJ,0.711974
uuid-cc1fdeccc83b43d4a9c983861ec67236,clinical,0.502249
uuid-cc1fdeccc83b43d4a9c983861ec67236,phase 3 study,0.415967
uuid-cc1fdeccc83b43d4a9c983861ec67236,Escudier B,0.724005
uuid-cc1fdeccc83b43d4a9c983861ec67236,NEJM,0.358371
uuid-cc1fdeccc83b43d4a9c983861ec67236,et al.,0.689006
uuid-cc1fdeccc83b43d4a9c983861ec67236,J Clin Oncol,0.683657
uuid-cc1fdeccc83b43d4a9c983861ec67236,Topalian,0.331782
uuid-cc1fdeccc83b43d4a9c983861ec67236,Rizvi NA,0.344561
uuid-cc1fdeccc83b43d4a9c983861ec67236,phase 2 study,0.635209
uuid-ea5851a80b8d4127a8310411e7742cfb,AEs,0.317894
uuid-ea5851a80b8d4127a8310411e7742cfb,NSCLC,0.328183
uuid-ea5851a80b8d4127a8310411e7742cfb,phase 3 study,0.337839
uuid-ea5851a80b8d4127a8310411e7742cfb,phase 1 study,0.336346
uuid-ea5851a80b8d4127a8310411e7742cfb,phase 2 study,0.332897
uuid-ea5851a80b8d4127a8310411e7742cfb,grade,0.420458
uuid-ea5851a80b8d4127a8310411e7742cfb,grade 3 to 4 AEs,0.318502
uuid-66c8d5541916434bb0bc8ba76f6be3fb,requested,0.540431
uuid-49ed913c77f9407195a1e47f674ce4a0,provided in the Detailed Information,0.332108
uuid-49ed913c77f9407195a1e47f674ce4a0,clinical,0.702252
uuid-49ed913c77f9407195a1e47f674ce4a0,trial,0.320816
uuid-95d4b2ebd61f414da56a4c4e471ffa6b,clinicaltrials.gov,0.434964
uuid-95d4b2ebd61f414da56a4c4e471ffa6b,relapsed,0.549828
uuid-8410f1eef7be48939e61046cc728e49e,respectively,0.589071
uuid-8410f1eef7be48939e61046cc728e49e,Objective response rate,0.407286
uuid-8410f1eef7be48939e61046cc728e49e,ORR,0.526086
uuid-8410f1eef7be48939e61046cc728e49e,monotherapy,0.319413
uuid-8410f1eef7be48939e61046cc728e49e,docetaxel,0.334344
uuid-e5e3dcbcfcc342bd95921411adbb4b81,Bristol-Myers Squibb,0.341822
uuid-e5e3dcbcfcc342bd95921411adbb4b81,not conducted any controlled clinical trials/studies,0.304507
uuid-e5e3dcbcfcc342bd95921411adbb4b81,Opdivo,0.461382
uuid-e5e3dcbcfcc342bd95921411adbb4b81,Pubmed literature search,0.614325
uuid-e5e3dcbcfcc342bd95921411adbb4b81,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e5e3dcbcfcc342bd95921411adbb4b81,not identify any citations relevant to your inquiry,0.606087
uuid-e5e3dcbcfcc342bd95921411adbb4b81,adverse,0.304183
uuid-e5e3dcbcfcc342bd95921411adbb4b81,using the following search terms,0.642331
uuid-e5e3dcbcfcc342bd95921411adbb4b81,databases,0.315039
uuid-e5e3dcbcfcc342bd95921411adbb4b81,reported,0.556704
uuid-cf1279e9f5c34bf7908fcab736464850,Bristol-Myers Squibb,0.351139
uuid-cf1279e9f5c34bf7908fcab736464850,evaluating,0.393781
uuid-cf1279e9f5c34bf7908fcab736464850,not conducted any controlled clinical trials/studies,0.401959
uuid-cf1279e9f5c34bf7908fcab736464850,NSCLC,0.316818
uuid-cf1279e9f5c34bf7908fcab736464850,efficacy and safety of nivolumab,0.448974
uuid-737d7d945e874cd1adb7124335348634,Bristol-Myers Squibb,0.341822
uuid-737d7d945e874cd1adb7124335348634,not conducted any controlled clinical trials/studies,0.304507
uuid-737d7d945e874cd1adb7124335348634,Opdivo,0.461382
uuid-737d7d945e874cd1adb7124335348634,Pubmed literature search,0.614325
uuid-737d7d945e874cd1adb7124335348634,purposes other than its labeled indication must be considered investigational,0.586645
uuid-737d7d945e874cd1adb7124335348634,not identify any citations relevant to your inquiry,0.606087
uuid-737d7d945e874cd1adb7124335348634,adverse,0.304183
uuid-737d7d945e874cd1adb7124335348634,using the following search terms,0.642331
uuid-737d7d945e874cd1adb7124335348634,databases,0.315039
uuid-737d7d945e874cd1adb7124335348634,reported,0.556704
uuid-1091e5e582484820a7ca51b2fca691c6,N Engl J Med,0.383289
uuid-1091e5e582484820a7ca51b2fca691c6,protocol,0.722694
uuid-1091e5e582484820a7ca51b2fca691c6,McDermott DF,0.68886
uuid-1091e5e582484820a7ca51b2fca691c6,Motzer RJ,0.768278
uuid-1091e5e582484820a7ca51b2fca691c6,phase 3 study,0.413674
uuid-1091e5e582484820a7ca51b2fca691c6,Escudier B,0.695048
uuid-1091e5e582484820a7ca51b2fca691c6,NEJM,0.393316
uuid-1091e5e582484820a7ca51b2fca691c6,et al.,0.607771
uuid-1091e5e582484820a7ca51b2fca691c6,J Clin Oncol,0.750602
uuid-1091e5e582484820a7ca51b2fca691c6,Topalian,0.365237
uuid-1091e5e582484820a7ca51b2fca691c6,phase 1 study,0.594118
uuid-1091e5e582484820a7ca51b2fca691c6,efficacy and safety of nivolumab,0.303544
uuid-1091e5e582484820a7ca51b2fca691c6,CA209-003,0.618694
uuid-1091e5e582484820a7ca51b2fca691c6,phase 2 study,0.657809
uuid-1091e5e582484820a7ca51b2fca691c6,investigating,0.619609
uuid-41bc14b9b24c4888af384b6567d04d42,OS,0.44149
uuid-41bc14b9b24c4888af384b6567d04d42,95% CI,0.833403
uuid-41bc14b9b24c4888af384b6567d04d42,ASCO,0.32927
uuid-41bc14b9b24c4888af384b6567d04d42,Objective response rate,0.545269
uuid-41bc14b9b24c4888af384b6567d04d42,ORR,0.618524
uuid-41bc14b9b24c4888af384b6567d04d42,PFS,0.396858
uuid-41bc14b9b24c4888af384b6567d04d42,Median overall survival,0.72593
uuid-41bc14b9b24c4888af384b6567d04d42,monotherapy,0.33356
uuid-41bc14b9b24c4888af384b6567d04d42,Median OS,0.763854
uuid-41bc14b9b24c4888af384b6567d04d42,hazard ratio,0.766648
uuid-41bc14b9b24c4888af384b6567d04d42,Median duration of response,0.442682
uuid-1221e212754743ef806edd126efe11a9,patients with advanced or metastatic,0.468858
uuid-1221e212754743ef806edd126efe11a9,nivolumab combined with ipilimumab,0.446918
uuid-1221e212754743ef806edd126efe11a9,not approved,0.352562
uuid-1221e212754743ef806edd126efe11a9,clinical trials investigating the safety,0.429501
uuid-1221e212754743ef806edd126efe11a9,bladder cancer,0.950698
uuid-936221879fb94f5bb1247d7df3f55f19,requested,0.540431
uuid-9e558af98e494934994cedb8008f412b,requested,0.540431
uuid-9ddb47f106ae45bbb8f973372981a04b,N Engl J Med,0.410302
uuid-9ddb47f106ae45bbb8f973372981a04b,Lancet Oncol,0.340022
uuid-9ddb47f106ae45bbb8f973372981a04b,protocol,0.426669
uuid-9ddb47f106ae45bbb8f973372981a04b,McDermott DF,0.455512
uuid-9ddb47f106ae45bbb8f973372981a04b,search of published literature,0.347327
uuid-9ddb47f106ae45bbb8f973372981a04b,Motzer RJ,0.454256
uuid-9ddb47f106ae45bbb8f973372981a04b,phase 3 study,0.731917
uuid-9ddb47f106ae45bbb8f973372981a04b,PubMed and EMBASE,0.344961
uuid-9ddb47f106ae45bbb8f973372981a04b,Escudier B,0.471443
uuid-9ddb47f106ae45bbb8f973372981a04b,et al.,0.438257
uuid-9ddb47f106ae45bbb8f973372981a04b,J Clin Oncol,0.367066
uuid-9ddb47f106ae45bbb8f973372981a04b,Rizvi NA,0.452482
uuid-9ddb47f106ae45bbb8f973372981a04b,Weber JS,0.580204
uuid-9ddb47f106ae45bbb8f973372981a04b,phase 2 study,0.555004
uuid-9ddb47f106ae45bbb8f973372981a04b,present using the following search terms,0.301715
uuid-0ab6d1b81dae4c26b92fddd38e46fd6c,Bristol-Myers Squibb,0.396485
uuid-9984d22819174f88bf10c634a9c794ad,OS,0.387982
uuid-9984d22819174f88bf10c634a9c794ad,95% CI,0.745043
uuid-9984d22819174f88bf10c634a9c794ad,respectively,0.729294
uuid-9984d22819174f88bf10c634a9c794ad,Objective response rate,0.590876
uuid-9984d22819174f88bf10c634a9c794ad,ORR,0.722442
uuid-9984d22819174f88bf10c634a9c794ad,Median overall survival,0.659043
uuid-9984d22819174f88bf10c634a9c794ad,monotherapy,0.514468
uuid-9984d22819174f88bf10c634a9c794ad,Median OS,0.696688
uuid-9984d22819174f88bf10c634a9c794ad,PD-L1,0.300997
uuid-9984d22819174f88bf10c634a9c794ad,docetaxel,0.635065
uuid-9984d22819174f88bf10c634a9c794ad,hazard ratio,0.729977
uuid-f15bb4672d724156a6fcdb32731a6bf0,evaluating,0.300343
uuid-f15bb4672d724156a6fcdb32731a6bf0,search of published literature,0.392455
uuid-f15bb4672d724156a6fcdb32731a6bf0,Additionally,0.396527
uuid-f15bb4672d724156a6fcdb32731a6bf0,ongoing,0.311936
uuid-f15bb4672d724156a6fcdb32731a6bf0,PubMed and EMBASE,0.387964
uuid-f15bb4672d724156a6fcdb32731a6bf0,detailed search of www.clinicaltrials.gov,0.377365
uuid-f15bb4672d724156a6fcdb32731a6bf0,phase 1 study,0.5676
uuid-f15bb4672d724156a6fcdb32731a6bf0,efficacy and safety of nivolumab,0.421389
uuid-f15bb4672d724156a6fcdb32731a6bf0,not identify any planned,0.335864
uuid-f15bb4672d724156a6fcdb32731a6bf0,CA209-003,0.67129
uuid-f15bb4672d724156a6fcdb32731a6bf0,not identify any citations relevant to your request,0.458264
uuid-f15bb4672d724156a6fcdb32731a6bf0,present using the following search terms,0.429697
uuid-f15bb4672d724156a6fcdb32731a6bf0,investigating,0.81832
uuid-01946351b9ca414cb4eb3893b5b08b08,patients,0.464993
uuid-01946351b9ca414cb4eb3893b5b08b08,grade,0.376008
uuid-01946351b9ca414cb4eb3893b5b08b08,grade 3 to 4 AEs,0.334799
uuid-53ae436d05734eebbc31fd7786287633,95% CI,0.524855
uuid-53ae436d05734eebbc31fd7786287633,respectively,0.383655
uuid-53ae436d05734eebbc31fd7786287633,ASCO,0.303153
uuid-53ae436d05734eebbc31fd7786287633,Lancet Oncol,0.368041
uuid-53ae436d05734eebbc31fd7786287633,Objective response rate,0.504846
uuid-53ae436d05734eebbc31fd7786287633,ORR,0.465366
uuid-53ae436d05734eebbc31fd7786287633,Median overall survival,0.346516
uuid-53ae436d05734eebbc31fd7786287633,Median OS,0.33538
uuid-53ae436d05734eebbc31fd7786287633,ASCO 2015,0.336983
uuid-53ae436d05734eebbc31fd7786287633,small cell lung cancer,0.336892
uuid-53ae436d05734eebbc31fd7786287633,SCLC,0.344367
uuid-53ae436d05734eebbc31fd7786287633,Antonia SJ,0.55269
uuid-53ae436d05734eebbc31fd7786287633,Median duration of response,0.649605
uuid-a425afe0013c4eedb94d5f248273204a,nivolumab,0.502183
uuid-a425afe0013c4eedb94d5f248273204a,RCC,0.756598
uuid-5d11e0dc16e34a52b841be93612bc805,clinical,0.376855
uuid-5d11e0dc16e34a52b841be93612bc805,trial,0.371406
uuid-5d11e0dc16e34a52b841be93612bc805,mg,0.305109
uuid-0856dfe95c5d4bb08c8501d85a47254a,trial,0.405524
uuid-36ac70860b094c64980dc1ab19913350,AEs,0.405203
uuid-36ac70860b094c64980dc1ab19913350,95% CI,0.412773
uuid-36ac70860b094c64980dc1ab19913350,respectively,0.412871
uuid-36ac70860b094c64980dc1ab19913350,ORR,0.38101
uuid-36ac70860b094c64980dc1ab19913350,Median overall survival,0.421531
uuid-36ac70860b094c64980dc1ab19913350,Median OS,0.403449
uuid-36ac70860b094c64980dc1ab19913350,grade,0.571429
uuid-36ac70860b094c64980dc1ab19913350,hazard ratio,0.376628
uuid-36ac70860b094c64980dc1ab19913350,grade 3 to 4 AEs,0.335448
uuid-ee79c3de039e48c5b1179d1b0683c3f0,nivolumab,0.449893
uuid-ee79c3de039e48c5b1179d1b0683c3f0,Bristol-Myers Squibb,0.502737
uuid-ee79c3de039e48c5b1179d1b0683c3f0,evaluating,0.585918
uuid-ee79c3de039e48c5b1179d1b0683c3f0,not conducted any controlled clinical trials/studies,0.643535
uuid-ee79c3de039e48c5b1179d1b0683c3f0,Pubmed literature search,0.740647
uuid-ee79c3de039e48c5b1179d1b0683c3f0,purposes other than its labeled indication must be considered investigational,0.807676
uuid-ee79c3de039e48c5b1179d1b0683c3f0,not identify any citations relevant to your inquiry,0.703546
uuid-ee79c3de039e48c5b1179d1b0683c3f0,adverse,0.43006
uuid-ee79c3de039e48c5b1179d1b0683c3f0,using the following search terms,0.686729
uuid-ee79c3de039e48c5b1179d1b0683c3f0,efficacy and safety of nivolumab,0.410868
uuid-ba88a2db69b94d418a0a83061dd6086c,Bristol-Myers Squibb,0.510215
uuid-ba88a2db69b94d418a0a83061dd6086c,evaluating,0.520713
uuid-ba88a2db69b94d418a0a83061dd6086c,not conducted any controlled clinical trials/studies,0.544991
uuid-ba88a2db69b94d418a0a83061dd6086c,NSCLC,0.331562
uuid-ba88a2db69b94d418a0a83061dd6086c,efficacy and safety of nivolumab,0.549553
uuid-fbf094f70b1942d299c4a9039ef746a8,requested,0.540431
uuid-2bbbde016644494b8665a6a37221cbbd,requested,0.540431
uuid-f107b96463c34790bcb937e967d41528,respectively,0.589071
uuid-f107b96463c34790bcb937e967d41528,Objective response rate,0.407286
uuid-f107b96463c34790bcb937e967d41528,ORR,0.526086
uuid-f107b96463c34790bcb937e967d41528,monotherapy,0.319413
uuid-f107b96463c34790bcb937e967d41528,docetaxel,0.334344
uuid-21399ef6db044a948472a4d0c02fe6e7,evaluating,0.381669
uuid-21399ef6db044a948472a4d0c02fe6e7,not conducted any controlled clinical trials/studies,0.394518
uuid-21399ef6db044a948472a4d0c02fe6e7,AEs,0.454762
uuid-21399ef6db044a948472a4d0c02fe6e7,patients,0.439038
uuid-21399ef6db044a948472a4d0c02fe6e7,Pubmed literature search,0.323488
uuid-21399ef6db044a948472a4d0c02fe6e7,purposes other than its labeled indication must be considered investigational,0.385077
uuid-21399ef6db044a948472a4d0c02fe6e7,grade,0.483031
uuid-21399ef6db044a948472a4d0c02fe6e7,grade 3 to 4 AEs,0.52039
uuid-99a8e03ad041439089bc4929623b8496,nivolumab,0.359772
uuid-c8d1afadf1624d74b3773ee78f2a9144,melanoma,0.410364
uuid-0848e984325f4ee3b53235eb25cbdb57,use of nivolumab for the treatment,0.439738
uuid-0848e984325f4ee3b53235eb25cbdb57,search of published literature,0.309975
uuid-0848e984325f4ee3b53235eb25cbdb57,PubMed and EMBASE,0.311255
uuid-0848e984325f4ee3b53235eb25cbdb57,not approved,0.404554
uuid-0848e984325f4ee3b53235eb25cbdb57,open-label,0.577386
uuid-0848e984325f4ee3b53235eb25cbdb57,clinical trials investigating the safety,0.439892
uuid-0848e984325f4ee3b53235eb25cbdb57,present using the following search terms,0.327146
uuid-0848e984325f4ee3b53235eb25cbdb57,phase,0.411879
uuid-0fdf5830fe7b4af8818e4a7f39441157,nivolumab,0.508357
uuid-479859d890bd404c9ea7b9265fe86467,Bristol-Myers Squibb,0.516532
uuid-479859d890bd404c9ea7b9265fe86467,evaluating,0.540062
uuid-479859d890bd404c9ea7b9265fe86467,not conducted any controlled clinical trials/studies,0.563417
uuid-479859d890bd404c9ea7b9265fe86467,NSCLC,0.326756
uuid-479859d890bd404c9ea7b9265fe86467,efficacy and safety of nivolumab,0.565239
uuid-0740428b226f4ffebb0c62b11981075d,nivolumab,0.54273
uuid-0740428b226f4ffebb0c62b11981075d,Bristol-Myers Squibb,0.628316
uuid-0740428b226f4ffebb0c62b11981075d,evaluating,0.779279
uuid-0740428b226f4ffebb0c62b11981075d,not conducted any controlled clinical trials/studies,0.83421
uuid-0740428b226f4ffebb0c62b11981075d,Pubmed literature search,0.686698
uuid-0740428b226f4ffebb0c62b11981075d,purposes other than its labeled indication must be considered investigational,0.786967
uuid-0740428b226f4ffebb0c62b11981075d,not identify any citations relevant to your inquiry,0.639332
uuid-0740428b226f4ffebb0c62b11981075d,search of published literature,0.376828
uuid-0740428b226f4ffebb0c62b11981075d,PubMed and EMBASE,0.341672
uuid-0740428b226f4ffebb0c62b11981075d,using the following search terms,0.617659
uuid-0740428b226f4ffebb0c62b11981075d,efficacy and safety of nivolumab,0.674666
uuid-0740428b226f4ffebb0c62b11981075d,present using the following search terms,0.360876
uuid-73ebbc8b08634cee90ab34d42c225437,nivolumab,0.401905
uuid-73ebbc8b08634cee90ab34d42c225437,Bristol-Myers Squibb,0.619125
uuid-73ebbc8b08634cee90ab34d42c225437,evaluating,0.66047
uuid-73ebbc8b08634cee90ab34d42c225437,not conducted any controlled clinical trials/studies,0.730369
uuid-73ebbc8b08634cee90ab34d42c225437,Pubmed literature search,0.60232
uuid-73ebbc8b08634cee90ab34d42c225437,purposes other than its labeled indication must be considered investigational,0.686893
uuid-73ebbc8b08634cee90ab34d42c225437,not identify any citations relevant to your inquiry,0.560321
uuid-73ebbc8b08634cee90ab34d42c225437,using the following search terms,0.540057
uuid-73ebbc8b08634cee90ab34d42c225437,efficacy and safety of nivolumab,0.504025
uuid-1440b58b56ad429fad63243d827b3963,Bristol-Myers Squibb,0.511292
uuid-1440b58b56ad429fad63243d827b3963,evaluating,0.362914
uuid-1440b58b56ad429fad63243d827b3963,not conducted any controlled clinical trials/studies,0.409685
uuid-1440b58b56ad429fad63243d827b3963,adverse,0.770311
uuid-1440b58b56ad429fad63243d827b3963,phase 3 study,0.363194
uuid-1440b58b56ad429fad63243d827b3963,melanoma,0.422831
uuid-1440b58b56ad429fad63243d827b3963,efficacy and safety of nivolumab,0.341767
uuid-1440b58b56ad429fad63243d827b3963,reported,0.434293
uuid-7bf943b5a0054121b0c3d257e7f41eeb,nivolumab,0.458322
uuid-7bf943b5a0054121b0c3d257e7f41eeb,Bristol-Myers Squibb,0.585907
uuid-7bf943b5a0054121b0c3d257e7f41eeb,evaluating,0.66974
uuid-7bf943b5a0054121b0c3d257e7f41eeb,not conducted any controlled clinical trials/studies,0.733008
uuid-7bf943b5a0054121b0c3d257e7f41eeb,Pubmed literature search,0.68127
uuid-7bf943b5a0054121b0c3d257e7f41eeb,purposes other than its labeled indication must be considered investigational,0.764804
uuid-7bf943b5a0054121b0c3d257e7f41eeb,not identify any citations relevant to your inquiry,0.644213
uuid-7bf943b5a0054121b0c3d257e7f41eeb,using the following search terms,0.618367
uuid-7bf943b5a0054121b0c3d257e7f41eeb,efficacy and safety of nivolumab,0.51408
uuid-5cb384ca362c4f9a946ce91f8f284fc8,grade,0.394673
uuid-329cab9531ba4077b074941994d3cd99,nivolumab,0.570532
uuid-329cab9531ba4077b074941994d3cd99,Bristol-Myers Squibb,0.335734
uuid-329cab9531ba4077b074941994d3cd99,evaluating,0.495742
uuid-329cab9531ba4077b074941994d3cd99,not conducted any controlled clinical trials/studies,0.54135
uuid-329cab9531ba4077b074941994d3cd99,Pubmed literature search,0.848669
uuid-329cab9531ba4077b074941994d3cd99,purposes other than its labeled indication must be considered investigational,0.898668
uuid-329cab9531ba4077b074941994d3cd99,not identify any citations relevant to your inquiry,0.815304
uuid-329cab9531ba4077b074941994d3cd99,using the following search terms,0.805347
uuid-329cab9531ba4077b074941994d3cd99,efficacy and safety of nivolumab,0.325405
uuid-493e9e936e6046558038592aa90417db,trial,0.317581
uuid-7dbb294168564a13912b3f22ef30cca0,requested,0.540431
uuid-052cc669c86548de81b09cc864839314,requested,0.540431
uuid-578f09166cfa43a1829b84ed37bf57c5,requested,0.540431
uuid-5918497f98b64ffd82a1273d9fc4249e,Bristol-Myers Squibb,0.341822
uuid-5918497f98b64ffd82a1273d9fc4249e,not conducted any controlled clinical trials/studies,0.304507
uuid-5918497f98b64ffd82a1273d9fc4249e,Opdivo,0.461382
uuid-5918497f98b64ffd82a1273d9fc4249e,Pubmed literature search,0.614325
uuid-5918497f98b64ffd82a1273d9fc4249e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5918497f98b64ffd82a1273d9fc4249e,not identify any citations relevant to your inquiry,0.606087
uuid-5918497f98b64ffd82a1273d9fc4249e,adverse,0.304183
uuid-5918497f98b64ffd82a1273d9fc4249e,using the following search terms,0.642331
uuid-5918497f98b64ffd82a1273d9fc4249e,databases,0.315039
uuid-5918497f98b64ffd82a1273d9fc4249e,reported,0.556704
uuid-6637a4a5484d4bd2b93796110f7b3ed2,Bristol-Myers Squibb,0.34001
uuid-20874bc2c1d44b069bdbdbe13f93dadb,melanoma,0.410364
uuid-d1bf429d42af481aa2fea5c7344c5c42,RCC,0.73573
uuid-d1bf429d42af481aa2fea5c7344c5c42,phase 3 study,0.373313
uuid-d1bf429d42af481aa2fea5c7344c5c42,BMS,0.457394
uuid-274e62f6f1fd4bbaaa600b4f8c465efd,ASCO,0.807066
uuid-c6d483eb76964712bd5697481a279ab3,N Engl J Med,0.456474
uuid-c6d483eb76964712bd5697481a279ab3,Lancet Oncol,0.357873
uuid-c6d483eb76964712bd5697481a279ab3,protocol,0.480893
uuid-c6d483eb76964712bd5697481a279ab3,McDermott DF,0.51746
uuid-c6d483eb76964712bd5697481a279ab3,search of published literature,0.343051
uuid-c6d483eb76964712bd5697481a279ab3,Motzer RJ,0.516788
uuid-c6d483eb76964712bd5697481a279ab3,phase 3 study,0.754973
uuid-c6d483eb76964712bd5697481a279ab3,PubMed and EMBASE,0.340792
uuid-c6d483eb76964712bd5697481a279ab3,Escudier B,0.532534
uuid-c6d483eb76964712bd5697481a279ab3,et al.,0.496867
uuid-c6d483eb76964712bd5697481a279ab3,J Clin Oncol,0.430616
uuid-c6d483eb76964712bd5697481a279ab3,Rizvi NA,0.473891
uuid-c6d483eb76964712bd5697481a279ab3,Weber JS,0.580854
uuid-c6d483eb76964712bd5697481a279ab3,phase 2 study,0.6143
uuid-8cb9a6404b3c405fa0184aa9323da6b3,requested,0.540431
uuid-343a390da2e343dea1c62786acacbe3e,N Engl J Med,0.456474
uuid-343a390da2e343dea1c62786acacbe3e,Lancet Oncol,0.357873
uuid-343a390da2e343dea1c62786acacbe3e,protocol,0.480893
uuid-343a390da2e343dea1c62786acacbe3e,McDermott DF,0.51746
uuid-343a390da2e343dea1c62786acacbe3e,search of published literature,0.343051
uuid-343a390da2e343dea1c62786acacbe3e,Motzer RJ,0.516788
uuid-343a390da2e343dea1c62786acacbe3e,phase 3 study,0.754973
uuid-343a390da2e343dea1c62786acacbe3e,PubMed and EMBASE,0.340792
uuid-343a390da2e343dea1c62786acacbe3e,Escudier B,0.532534
uuid-343a390da2e343dea1c62786acacbe3e,et al.,0.496867
uuid-343a390da2e343dea1c62786acacbe3e,J Clin Oncol,0.430616
uuid-343a390da2e343dea1c62786acacbe3e,Rizvi NA,0.473891
uuid-343a390da2e343dea1c62786acacbe3e,Weber JS,0.580854
uuid-343a390da2e343dea1c62786acacbe3e,phase 2 study,0.6143
uuid-99b4ea5ab5284d7989983928e3ef460a,not conducted any controlled clinical trials/studies,0.323378
uuid-99b4ea5ab5284d7989983928e3ef460a,NSCLC,0.557022
uuid-99b4ea5ab5284d7989983928e3ef460a,non-small cell lung cancer,0.534527
uuid-99b4ea5ab5284d7989983928e3ef460a,considered investigational,0.378249
uuid-99b4ea5ab5284d7989983928e3ef460a,phase 3 study,0.333109
uuid-99b4ea5ab5284d7989983928e3ef460a,phase 1 study,0.304417
uuid-99b4ea5ab5284d7989983928e3ef460a,small cell lung cancer,0.371969
uuid-99b4ea5ab5284d7989983928e3ef460a,efficacy and safety of nivolumab,0.317247
uuid-99b4ea5ab5284d7989983928e3ef460a,SCLC,0.416288
uuid-99b4ea5ab5284d7989983928e3ef460a,therapy,0.620258
uuid-e6ca7957bf074d01a6b2630baedb6daf,respectively,0.589071
uuid-e6ca7957bf074d01a6b2630baedb6daf,Objective response rate,0.407286
uuid-e6ca7957bf074d01a6b2630baedb6daf,ORR,0.526086
uuid-e6ca7957bf074d01a6b2630baedb6daf,monotherapy,0.319413
uuid-e6ca7957bf074d01a6b2630baedb6daf,docetaxel,0.334344
uuid-b3c119defaa04da4b07b76153699b1e1,open-label,0.539462
uuid-b3c119defaa04da4b07b76153699b1e1,phase,0.350616
uuid-38ca7e3e97c4426daed418ae22592c4e,requested,0.540431
uuid-0fabd8a4e98845819f4299c4f52f4cd4,requested,0.552985
uuid-b98b1a6297df45a9b080929bb6626489,use of nivolumab for the treatment,0.444892
uuid-b98b1a6297df45a9b080929bb6626489,evaluating,0.30558
uuid-b98b1a6297df45a9b080929bb6626489,patients,0.440855
uuid-b98b1a6297df45a9b080929bb6626489,not approved,0.378002
uuid-b98b1a6297df45a9b080929bb6626489,clinical trials investigating the safety,0.352423
uuid-021021f516de49eb920f043acf1fee22,patients with advanced or metastatic,0.468858
uuid-021021f516de49eb920f043acf1fee22,nivolumab combined with ipilimumab,0.446918
uuid-021021f516de49eb920f043acf1fee22,not approved,0.352562
uuid-021021f516de49eb920f043acf1fee22,clinical trials investigating the safety,0.429501
uuid-021021f516de49eb920f043acf1fee22,bladder cancer,0.950698
uuid-26851b1d6d7140228bdebf659f523b20,Opdivo,0.31116
uuid-26851b1d6d7140228bdebf659f523b20,Pubmed literature search,0.410136
uuid-26851b1d6d7140228bdebf659f523b20,purposes other than its labeled indication must be considered investigational,0.385005
uuid-26851b1d6d7140228bdebf659f523b20,not identify any citations relevant to your inquiry,0.408714
uuid-26851b1d6d7140228bdebf659f523b20,using the following search terms,0.432123
uuid-26851b1d6d7140228bdebf659f523b20,reported,0.371684
uuid-fcdd384976f3426bb13d5fb745ca31be,adverse,0.383165
uuid-f8f674ae393a4ba8a176df8d12c0fdbb,requested,0.633988
uuid-126d150ed9d64bc7892d55e964c73617,relapsed,0.313685
uuid-2b2fbaaf9aa84d7a855f77b82bc2da42,ASCO,0.382205
uuid-8f46e82755b44bfaaa0e1caf0297dba3,ASCO,0.382205
uuid-7d1d54bca1d14675bfd3aac4847f5a75,ASCO,0.762955
uuid-7d1d54bca1d14675bfd3aac4847f5a75,Antonia SJ,0.301443
uuid-e39686b2caba462fbeae252118d527bc,95% CI,0.524855
uuid-e39686b2caba462fbeae252118d527bc,respectively,0.383655
uuid-e39686b2caba462fbeae252118d527bc,ASCO,0.303153
uuid-e39686b2caba462fbeae252118d527bc,Lancet Oncol,0.368041
uuid-e39686b2caba462fbeae252118d527bc,Objective response rate,0.504846
uuid-e39686b2caba462fbeae252118d527bc,ORR,0.465366
uuid-e39686b2caba462fbeae252118d527bc,Median overall survival,0.346516
uuid-e39686b2caba462fbeae252118d527bc,Median OS,0.33538
uuid-e39686b2caba462fbeae252118d527bc,ASCO 2015,0.336983
uuid-e39686b2caba462fbeae252118d527bc,small cell lung cancer,0.336892
uuid-e39686b2caba462fbeae252118d527bc,SCLC,0.344367
uuid-e39686b2caba462fbeae252118d527bc,Antonia SJ,0.55269
uuid-e39686b2caba462fbeae252118d527bc,Median duration of response,0.649605
uuid-2a81227d05484ac79a2b14e99c4bbfcf,patients with advanced or metastatic,0.468858
uuid-2a81227d05484ac79a2b14e99c4bbfcf,nivolumab combined with ipilimumab,0.446918
uuid-2a81227d05484ac79a2b14e99c4bbfcf,not approved,0.352562
uuid-2a81227d05484ac79a2b14e99c4bbfcf,clinical trials investigating the safety,0.429501
uuid-2a81227d05484ac79a2b14e99c4bbfcf,bladder cancer,0.950698
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,nivolumab,0.629258
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,Bristol-Myers Squibb,0.431819
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,evaluating,0.676842
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,not conducted any controlled clinical trials/studies,0.674499
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,efficacy,0.343573
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,Pubmed literature search,0.753939
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,purposes other than its labeled indication must be considered investigational,0.839732
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,not identify any citations relevant to your inquiry,0.709934
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,using the following search terms,0.693724
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,efficacy and safety of nivolumab,0.483236
uuid-6e1ab1ccfa1048f2a432cbd1a4b6dbcd,safety of nivolumab monotherapy,0.335075
uuid-4b4cf30b29e944a484646d6db67e8f70,Bristol-Myers Squibb,0.351139
uuid-4b4cf30b29e944a484646d6db67e8f70,evaluating,0.393781
uuid-4b4cf30b29e944a484646d6db67e8f70,not conducted any controlled clinical trials/studies,0.401959
uuid-4b4cf30b29e944a484646d6db67e8f70,NSCLC,0.316818
uuid-4b4cf30b29e944a484646d6db67e8f70,efficacy and safety of nivolumab,0.448974
uuid-45fb98e59ae34d9db160e2b30454d0df,adverse,0.644514
uuid-45fb98e59ae34d9db160e2b30454d0df,phase 3 study,0.39676
uuid-45fb98e59ae34d9db160e2b30454d0df,melanoma,0.346986
uuid-1e2fb8a1782e436f91f1a27f83048c02,requested,0.541059
uuid-81618fb51b454a61b2f45ec26bc50b9e,provided in the Detailed Information,0.398649
uuid-58107af6aabd49798e616c9828c13bb0,Opdivo,0.389476
uuid-58107af6aabd49798e616c9828c13bb0,Pubmed literature search,0.370437
uuid-58107af6aabd49798e616c9828c13bb0,purposes other than its labeled indication must be considered investigational,0.322764
uuid-58107af6aabd49798e616c9828c13bb0,not identify any citations relevant to your inquiry,0.387589
uuid-58107af6aabd49798e616c9828c13bb0,using the following search terms,0.410003
uuid-58107af6aabd49798e616c9828c13bb0,safety,0.551166
uuid-58107af6aabd49798e616c9828c13bb0,databases,0.497525
uuid-6b31394491b549949189a2a8204e0503,N Engl J Med,0.380755
uuid-6b31394491b549949189a2a8204e0503,phase 3 study,0.338971
uuid-6b31394491b549949189a2a8204e0503,phase 1 study,0.378657
uuid-6b31394491b549949189a2a8204e0503,Rizvi NA,0.380296
uuid-6b31394491b549949189a2a8204e0503,CA209-003,0.373666
uuid-6b31394491b549949189a2a8204e0503,phase 2 study,0.412291
uuid-600916e765b144f6994b90b3f52bf858,requested,0.540431
uuid-86afe1140feb4502bbbcc544457ed214,patients,0.319152
uuid-86afe1140feb4502bbbcc544457ed214,McDermott DF,0.374418
uuid-86afe1140feb4502bbbcc544457ed214,Motzer RJ,0.336603
uuid-86afe1140feb4502bbbcc544457ed214,Escudier B,0.335535
uuid-86afe1140feb4502bbbcc544457ed214,ASCO 2015,0.330848
uuid-86afe1140feb4502bbbcc544457ed214,NEJM,0.438584
uuid-86afe1140feb4502bbbcc544457ed214,et al.,0.333675
uuid-86afe1140feb4502bbbcc544457ed214,J Clin Oncol,0.406649
uuid-86afe1140feb4502bbbcc544457ed214,Topalian,0.437561
uuid-86afe1140feb4502bbbcc544457ed214,phase 1 study,0.436731
uuid-86afe1140feb4502bbbcc544457ed214,CA209-003,0.371186
uuid-86afe1140feb4502bbbcc544457ed214,phase 2 study,0.375862
uuid-86afe1140feb4502bbbcc544457ed214,investigating,0.305192
uuid-5022260337db43c584f4db1f48238ce4,respectively,0.397695
uuid-e028fba2a11a4a0b8d0a16701c80f86d,Opdivo,0.314003
uuid-e028fba2a11a4a0b8d0a16701c80f86d,adverse,0.391413
uuid-e028fba2a11a4a0b8d0a16701c80f86d,safety,0.578983
uuid-e028fba2a11a4a0b8d0a16701c80f86d,databases,0.515255
uuid-e028fba2a11a4a0b8d0a16701c80f86d,reported,0.626038
uuid-bc273c6356514c4b868bdfe4ab4d0365,OS,0.387982
uuid-bc273c6356514c4b868bdfe4ab4d0365,95% CI,0.745043
uuid-bc273c6356514c4b868bdfe4ab4d0365,respectively,0.729294
uuid-bc273c6356514c4b868bdfe4ab4d0365,Objective response rate,0.590876
uuid-bc273c6356514c4b868bdfe4ab4d0365,ORR,0.722442
uuid-bc273c6356514c4b868bdfe4ab4d0365,Median overall survival,0.659043
uuid-bc273c6356514c4b868bdfe4ab4d0365,monotherapy,0.514468
uuid-bc273c6356514c4b868bdfe4ab4d0365,Median OS,0.696688
uuid-bc273c6356514c4b868bdfe4ab4d0365,PD-L1,0.300997
uuid-bc273c6356514c4b868bdfe4ab4d0365,docetaxel,0.635065
uuid-bc273c6356514c4b868bdfe4ab4d0365,hazard ratio,0.729977
uuid-309278166cb04714847766bd1cfe32ac,patients,0.324499
uuid-600e0515571545b4a4103d475b4d1d5a,OS,0.387982
uuid-600e0515571545b4a4103d475b4d1d5a,95% CI,0.745043
uuid-600e0515571545b4a4103d475b4d1d5a,respectively,0.729294
uuid-600e0515571545b4a4103d475b4d1d5a,Objective response rate,0.590876
uuid-600e0515571545b4a4103d475b4d1d5a,ORR,0.722442
uuid-600e0515571545b4a4103d475b4d1d5a,Median overall survival,0.659043
uuid-600e0515571545b4a4103d475b4d1d5a,monotherapy,0.514468
uuid-600e0515571545b4a4103d475b4d1d5a,Median OS,0.696688
uuid-600e0515571545b4a4103d475b4d1d5a,PD-L1,0.300997
uuid-600e0515571545b4a4103d475b4d1d5a,docetaxel,0.635065
uuid-600e0515571545b4a4103d475b4d1d5a,hazard ratio,0.729977
uuid-91fa89675cdd47b5af78a3618e9f90c0,ipilimumab,0.385692
uuid-91fa89675cdd47b5af78a3618e9f90c0,ASCO 2015,0.417944
uuid-91fa89675cdd47b5af78a3618e9f90c0,partial response,0.382425
uuid-91fa89675cdd47b5af78a3618e9f90c0,Stable disease,0.586335
uuid-91fa89675cdd47b5af78a3618e9f90c0,cohort,0.307748
uuid-7b283e66c9014f72a9d8c97a80e525b2,N Engl J Med,0.636726
uuid-7b283e66c9014f72a9d8c97a80e525b2,non-small cell lung cancer,0.351489
uuid-7b283e66c9014f72a9d8c97a80e525b2,ESMO,0.419331
uuid-7b283e66c9014f72a9d8c97a80e525b2,Rizvi NA,0.470388
uuid-7b283e66c9014f72a9d8c97a80e525b2,Brahmer J,0.676477
uuid-7b283e66c9014f72a9d8c97a80e525b2,PD-L1,0.354847
uuid-7b283e66c9014f72a9d8c97a80e525b2,Horn L,0.512976
uuid-7b283e66c9014f72a9d8c97a80e525b2,platinum-based doublet chemotherapy,0.312066
uuid-9a33610cccab4d998eb1676868391076,ipilimumab,0.385692
uuid-9a33610cccab4d998eb1676868391076,ASCO 2015,0.417944
uuid-9a33610cccab4d998eb1676868391076,partial response,0.382425
uuid-9a33610cccab4d998eb1676868391076,Stable disease,0.586335
uuid-9a33610cccab4d998eb1676868391076,cohort,0.307748
uuid-92592ffab5cf457cb30e37c85bc6968a,N Engl J Med,0.699334
uuid-92592ffab5cf457cb30e37c85bc6968a,protocol,0.906238
uuid-92592ffab5cf457cb30e37c85bc6968a,McDermott DF,0.967609
uuid-92592ffab5cf457cb30e37c85bc6968a,Motzer RJ,0.962207
uuid-92592ffab5cf457cb30e37c85bc6968a,phase 3 study,0.540755
uuid-92592ffab5cf457cb30e37c85bc6968a,Escudier B,0.968428
uuid-92592ffab5cf457cb30e37c85bc6968a,NEJM,0.485285
uuid-92592ffab5cf457cb30e37c85bc6968a,et al.,0.928667
uuid-92592ffab5cf457cb30e37c85bc6968a,J Clin Oncol,0.919772
uuid-92592ffab5cf457cb30e37c85bc6968a,Topalian,0.439233
uuid-92592ffab5cf457cb30e37c85bc6968a,Rizvi NA,0.451815
uuid-92592ffab5cf457cb30e37c85bc6968a,Brahmer J,0.336511
uuid-92592ffab5cf457cb30e37c85bc6968a,phase 2 study,0.866719
uuid-d0af16d186244bc8ae6678e2f70f59b2,requested,0.336612
uuid-97e63907a3614ec1b71e1d9aba7717bd,Rizvi NA,0.348211
uuid-97e63907a3614ec1b71e1d9aba7717bd,Brahmer J,0.429694
uuid-97e63907a3614ec1b71e1d9aba7717bd,BMS,0.824971
uuid-116879901ce14887b4f8ed41f4a88b01,OS,0.593573
uuid-116879901ce14887b4f8ed41f4a88b01,95% CI,0.850824
uuid-116879901ce14887b4f8ed41f4a88b01,respectively,0.669108
uuid-116879901ce14887b4f8ed41f4a88b01,Objective response rate,0.651193
uuid-116879901ce14887b4f8ed41f4a88b01,ORR,0.783121
uuid-116879901ce14887b4f8ed41f4a88b01,PFS,0.434607
uuid-116879901ce14887b4f8ed41f4a88b01,Median overall survival,0.814366
uuid-116879901ce14887b4f8ed41f4a88b01,monotherapy,0.446281
uuid-116879901ce14887b4f8ed41f4a88b01,Median OS,0.788703
uuid-116879901ce14887b4f8ed41f4a88b01,docetaxel,0.479063
uuid-116879901ce14887b4f8ed41f4a88b01,hazard ratio,0.801908
uuid-116879901ce14887b4f8ed41f4a88b01,Median duration of response,0.306622
uuid-e301a4de33a341849ffbbaf2da229bbc,requested,0.540431
uuid-b848b737fdda4ba2aa89b21964095f28,requested,0.540431
uuid-652381be78354d82bfb21174ded49799,ASCO,0.807066
uuid-2a6e649ca1484e6ea370a0f544e8ef76,Bristol-Myers Squibb,0.309977
uuid-2a6e649ca1484e6ea370a0f544e8ef76,ASCO,0.421881
uuid-2a6e649ca1484e6ea370a0f544e8ef76,requested,0.312333
uuid-c6d63954592e41b989549bf2c92f8632,OS,0.387982
uuid-c6d63954592e41b989549bf2c92f8632,95% CI,0.745043
uuid-c6d63954592e41b989549bf2c92f8632,respectively,0.729294
uuid-c6d63954592e41b989549bf2c92f8632,Objective response rate,0.590876
uuid-c6d63954592e41b989549bf2c92f8632,ORR,0.722442
uuid-c6d63954592e41b989549bf2c92f8632,Median overall survival,0.659043
uuid-c6d63954592e41b989549bf2c92f8632,monotherapy,0.514468
uuid-c6d63954592e41b989549bf2c92f8632,Median OS,0.696688
uuid-c6d63954592e41b989549bf2c92f8632,PD-L1,0.300997
uuid-c6d63954592e41b989549bf2c92f8632,docetaxel,0.635065
uuid-c6d63954592e41b989549bf2c92f8632,hazard ratio,0.729977
uuid-b5d560cee49d4a0f9c313f567c89b7a6,not conducted any controlled clinical trials/studies,0.305296
uuid-b5d560cee49d4a0f9c313f567c89b7a6,purposes other than its labeled indication must be considered investigational,0.327623
uuid-7e82b2cc3aa24821a2b8bc34f907707b,provided in the Detailed Information,0.38979
uuid-7e82b2cc3aa24821a2b8bc34f907707b,Weber JS,0.30744
uuid-799bc232c0c545668d1f5d8518cbd537,respectively,0.589071
uuid-799bc232c0c545668d1f5d8518cbd537,Objective response rate,0.407286
uuid-799bc232c0c545668d1f5d8518cbd537,ORR,0.526086
uuid-799bc232c0c545668d1f5d8518cbd537,monotherapy,0.319413
uuid-799bc232c0c545668d1f5d8518cbd537,docetaxel,0.334344
uuid-f0bc47475152420c9c581e8550c4b8ea,respectively,0.589071
uuid-f0bc47475152420c9c581e8550c4b8ea,Objective response rate,0.407286
uuid-f0bc47475152420c9c581e8550c4b8ea,ORR,0.526086
uuid-f0bc47475152420c9c581e8550c4b8ea,monotherapy,0.319413
uuid-f0bc47475152420c9c581e8550c4b8ea,docetaxel,0.334344
uuid-b55e8f1a5776437880865b049626bac4,OS,0.387982
uuid-b55e8f1a5776437880865b049626bac4,95% CI,0.745043
uuid-b55e8f1a5776437880865b049626bac4,respectively,0.729294
uuid-b55e8f1a5776437880865b049626bac4,Objective response rate,0.590876
uuid-b55e8f1a5776437880865b049626bac4,ORR,0.722442
uuid-b55e8f1a5776437880865b049626bac4,Median overall survival,0.659043
uuid-b55e8f1a5776437880865b049626bac4,monotherapy,0.514468
uuid-b55e8f1a5776437880865b049626bac4,Median OS,0.696688
uuid-b55e8f1a5776437880865b049626bac4,PD-L1,0.300997
uuid-b55e8f1a5776437880865b049626bac4,docetaxel,0.635065
uuid-b55e8f1a5776437880865b049626bac4,hazard ratio,0.729977
uuid-d7fc235abc5348f5b91de954f34609e4,Bristol-Myers Squibb,0.341822
uuid-d7fc235abc5348f5b91de954f34609e4,not conducted any controlled clinical trials/studies,0.304507
uuid-d7fc235abc5348f5b91de954f34609e4,Opdivo,0.461382
uuid-d7fc235abc5348f5b91de954f34609e4,Pubmed literature search,0.614325
uuid-d7fc235abc5348f5b91de954f34609e4,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d7fc235abc5348f5b91de954f34609e4,not identify any citations relevant to your inquiry,0.606087
uuid-d7fc235abc5348f5b91de954f34609e4,adverse,0.304183
uuid-d7fc235abc5348f5b91de954f34609e4,using the following search terms,0.642331
uuid-d7fc235abc5348f5b91de954f34609e4,databases,0.315039
uuid-d7fc235abc5348f5b91de954f34609e4,reported,0.556704
uuid-7c4ed437cffb48109eb51e6c54d61973,N Engl J Med,0.448483
uuid-7c4ed437cffb48109eb51e6c54d61973,protocol,0.770446
uuid-7c4ed437cffb48109eb51e6c54d61973,McDermott DF,0.741196
uuid-7c4ed437cffb48109eb51e6c54d61973,Motzer RJ,0.818144
uuid-7c4ed437cffb48109eb51e6c54d61973,phase 3 study,0.417055
uuid-7c4ed437cffb48109eb51e6c54d61973,Escudier B,0.749917
uuid-7c4ed437cffb48109eb51e6c54d61973,NEJM,0.400698
uuid-7c4ed437cffb48109eb51e6c54d61973,et al.,0.668641
uuid-7c4ed437cffb48109eb51e6c54d61973,J Clin Oncol,0.792018
uuid-7c4ed437cffb48109eb51e6c54d61973,Topalian,0.388894
uuid-7c4ed437cffb48109eb51e6c54d61973,phase 1 study,0.500686
uuid-7c4ed437cffb48109eb51e6c54d61973,CA209-003,0.567381
uuid-7c4ed437cffb48109eb51e6c54d61973,phase 2 study,0.677985
uuid-7c4ed437cffb48109eb51e6c54d61973,present using the following search terms,0.310558
uuid-7c4ed437cffb48109eb51e6c54d61973,investigating,0.615835
uuid-dc9ca44bbd834fc69b13645f6b033336,requested,0.633988
uuid-d95faf3e93654b96aa782fadf25f2e92,Opdivo,0.306767
uuid-d95faf3e93654b96aa782fadf25f2e92,adverse,0.373913
uuid-d95faf3e93654b96aa782fadf25f2e92,safety,0.56423
uuid-d95faf3e93654b96aa782fadf25f2e92,databases,0.505682
uuid-d95faf3e93654b96aa782fadf25f2e92,reported,0.60455
uuid-3505e5a9f106442a9b562bd3fdeac394,nivolumab,0.457518
uuid-3505e5a9f106442a9b562bd3fdeac394,Bristol-Myers Squibb,0.645113
uuid-3505e5a9f106442a9b562bd3fdeac394,evaluating,0.766448
uuid-3505e5a9f106442a9b562bd3fdeac394,not conducted any controlled clinical trials/studies,0.829421
uuid-3505e5a9f106442a9b562bd3fdeac394,Pubmed literature search,0.705336
uuid-3505e5a9f106442a9b562bd3fdeac394,purposes other than its labeled indication must be considered investigational,0.802625
uuid-3505e5a9f106442a9b562bd3fdeac394,not identify any citations relevant to your inquiry,0.654544
uuid-3505e5a9f106442a9b562bd3fdeac394,using the following search terms,0.633826
uuid-3505e5a9f106442a9b562bd3fdeac394,efficacy and safety of nivolumab,0.611096
uuid-4602c2fc8b5c46198083dfdb5d2668bc,requested,0.572359
uuid-3756a4f1bb9d4412917835a62b2e55c8,OS,0.351965
uuid-3756a4f1bb9d4412917835a62b2e55c8,95% CI,0.718857
uuid-3756a4f1bb9d4412917835a62b2e55c8,Objective response rate,0.522105
uuid-3756a4f1bb9d4412917835a62b2e55c8,ORR,0.498309
uuid-3756a4f1bb9d4412917835a62b2e55c8,Median overall survival,0.70402
uuid-3756a4f1bb9d4412917835a62b2e55c8,Median OS,0.640531
uuid-3756a4f1bb9d4412917835a62b2e55c8,hazard ratio,0.662968
uuid-3756a4f1bb9d4412917835a62b2e55c8,Median duration of response,0.543974
uuid-6f7b26ed8530430dbd2d5fd24b7b0d9a,Opdivo,0.670343
uuid-6f7b26ed8530430dbd2d5fd24b7b0d9a,trial,0.342741
uuid-3101f9826cf448cf90d54f0632323127,respectively,0.397695
uuid-99b525c734be4b13948baac22142232e,95% CI,0.524855
uuid-99b525c734be4b13948baac22142232e,respectively,0.383655
uuid-99b525c734be4b13948baac22142232e,ASCO,0.303153
uuid-99b525c734be4b13948baac22142232e,Lancet Oncol,0.368041
uuid-99b525c734be4b13948baac22142232e,Objective response rate,0.504846
uuid-99b525c734be4b13948baac22142232e,ORR,0.465366
uuid-99b525c734be4b13948baac22142232e,Median overall survival,0.346516
uuid-99b525c734be4b13948baac22142232e,Median OS,0.33538
uuid-99b525c734be4b13948baac22142232e,ASCO 2015,0.336983
uuid-99b525c734be4b13948baac22142232e,small cell lung cancer,0.336892
uuid-99b525c734be4b13948baac22142232e,SCLC,0.344367
uuid-99b525c734be4b13948baac22142232e,Antonia SJ,0.55269
uuid-99b525c734be4b13948baac22142232e,Median duration of response,0.649605
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,OS,0.414567
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,95% CI,0.665879
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,Objective response rate,0.422701
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,ORR,0.463357
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,Median overall survival,0.657258
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,Median OS,0.589662
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,hazard ratio,0.664295
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,Overall survival,0.325083
uuid-9eeb028f1b57453aaa79e0c5357f8f7f,Median duration of response,0.307586
uuid-ac1b2a3be3264cb4a5a36c359da796c6,ASCO,0.825003
uuid-ac1b2a3be3264cb4a5a36c359da796c6,Antonia SJ,0.357827
uuid-98cb7b5bbe5c47569bdf7079c4e0f77c,ASCO,0.815106
uuid-98cb7b5bbe5c47569bdf7079c4e0f77c,Antonia SJ,0.325741
uuid-004ff1ecb0524bcda1395226940985f2,ASCO,0.807066
uuid-645d6afb76d94d918fc6fa8aa98d06ec,ASCO,0.811557
uuid-c3b8a6ec830d425e816456284ed7a5dd,ASCO,0.807066
uuid-bee235a1915e46dea634d6edd51bdd80,ASCO,0.382205
uuid-0d3a62a1ec064aa481f775991526fd70,NSCLC,0.480336
uuid-0d3a62a1ec064aa481f775991526fd70,respectively,0.400584
uuid-0d3a62a1ec064aa481f775991526fd70,non-small cell lung cancer,0.395661
uuid-0d3a62a1ec064aa481f775991526fd70,patients,0.382838
uuid-0d3a62a1ec064aa481f775991526fd70,considered investigational,0.378457
uuid-0d3a62a1ec064aa481f775991526fd70,Objective response rate,0.446233
uuid-0d3a62a1ec064aa481f775991526fd70,ORR,0.488323
uuid-0d3a62a1ec064aa481f775991526fd70,monotherapy,0.419452
uuid-0d3a62a1ec064aa481f775991526fd70,small cell lung cancer,0.328276
uuid-0d3a62a1ec064aa481f775991526fd70,docetaxel,0.370754
uuid-0d3a62a1ec064aa481f775991526fd70,SCLC,0.328411
uuid-0d3a62a1ec064aa481f775991526fd70,grade 3 to 4 AEs,0.337672
uuid-0d3a62a1ec064aa481f775991526fd70,platinum-based doublet chemotherapy,0.355492
uuid-7b23e29592f7495fad7ef5d30f9ff136,Bristol-Myers Squibb,0.338752
uuid-7b23e29592f7495fad7ef5d30f9ff136,requested,0.336854
uuid-8332bb0f4a1c455b9f146b06564e46dc,N Engl J Med,0.373796
uuid-8332bb0f4a1c455b9f146b06564e46dc,protocol,0.420361
uuid-8332bb0f4a1c455b9f146b06564e46dc,McDermott DF,0.513284
uuid-8332bb0f4a1c455b9f146b06564e46dc,Motzer RJ,0.482105
uuid-8332bb0f4a1c455b9f146b06564e46dc,phase 3 study,0.448204
uuid-8332bb0f4a1c455b9f146b06564e46dc,Escudier B,0.482741
uuid-8332bb0f4a1c455b9f146b06564e46dc,NEJM,0.342527
uuid-8332bb0f4a1c455b9f146b06564e46dc,et al.,0.466863
uuid-8332bb0f4a1c455b9f146b06564e46dc,J Clin Oncol,0.523543
uuid-8332bb0f4a1c455b9f146b06564e46dc,Topalian,0.340171
uuid-8332bb0f4a1c455b9f146b06564e46dc,phase 1 study,0.421699
uuid-8332bb0f4a1c455b9f146b06564e46dc,mg,0.324901
uuid-8332bb0f4a1c455b9f146b06564e46dc,CA209-003,0.451562
uuid-8332bb0f4a1c455b9f146b06564e46dc,phase 2 study,0.595096
uuid-8332bb0f4a1c455b9f146b06564e46dc,grade,0.324161
uuid-8332bb0f4a1c455b9f146b06564e46dc,kg,0.310462
uuid-8103486cfb954542a85ad26c8d51ba0a,ASCO,0.807066
uuid-f3d93114f983420b847b582b60bf0a41,ASCO,0.825002
uuid-f3d93114f983420b847b582b60bf0a41,Antonia SJ,0.357826
uuid-7dac144409664ef0a36114ced00853b3,clinical,0.614599
uuid-7dac144409664ef0a36114ced00853b3,trial,0.559827
uuid-cb0dcb562eab40ec9ffc7bff427ea5fc,respectively,0.589071
uuid-cb0dcb562eab40ec9ffc7bff427ea5fc,Objective response rate,0.407286
uuid-cb0dcb562eab40ec9ffc7bff427ea5fc,ORR,0.526086
uuid-cb0dcb562eab40ec9ffc7bff427ea5fc,monotherapy,0.319413
uuid-cb0dcb562eab40ec9ffc7bff427ea5fc,docetaxel,0.334344
uuid-78948048793344178c3cda63c6188980,relapsed,0.313685
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,evaluating,0.333568
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,not conducted any controlled clinical trials/studies,0.330955
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,protocol,0.52114
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,RCC,0.397701
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,McDermott DF,0.428183
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,search of published literature,0.501703
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,Additionally,0.551836
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,ongoing,0.476703
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,Motzer RJ,0.46129
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,PubMed and EMBASE,0.498942
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,Escudier B,0.443727
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,et al.,0.381248
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,J Clin Oncol,0.414316
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,detailed search of www.clinicaltrials.gov,0.512326
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,efficacy and safety of nivolumab,0.474409
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,not identify any planned,0.490772
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,phase 2 study,0.367102
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,not identify any citations relevant to your request,0.562518
uuid-2a4c8e48c8d5483bb2c2f61114b7a332,present using the following search terms,0.487292
uuid-ef176587389f4bc6a98ed71ffdb68001,requested,0.540431
uuid-a20e1936f0ca4287a479fe99d849a495,requested,0.540431
uuid-bedcf0bdd09d4b2ca6d73d9bc7942d0a,ipilimumab,0.385692
uuid-bedcf0bdd09d4b2ca6d73d9bc7942d0a,ASCO 2015,0.417944
uuid-bedcf0bdd09d4b2ca6d73d9bc7942d0a,partial response,0.382425
uuid-bedcf0bdd09d4b2ca6d73d9bc7942d0a,Stable disease,0.586335
uuid-bedcf0bdd09d4b2ca6d73d9bc7942d0a,cohort,0.307748
uuid-f0749121f0d249bdb70f7b607e6dbc51,nivolumab,0.566887
uuid-f0749121f0d249bdb70f7b607e6dbc51,Bristol-Myers Squibb,0.426482
uuid-f0749121f0d249bdb70f7b607e6dbc51,evaluating,0.622259
uuid-f0749121f0d249bdb70f7b607e6dbc51,not conducted any controlled clinical trials/studies,0.640779
uuid-f0749121f0d249bdb70f7b607e6dbc51,Pubmed literature search,0.71228
uuid-f0749121f0d249bdb70f7b607e6dbc51,purposes other than its labeled indication must be considered investigational,0.794129
uuid-f0749121f0d249bdb70f7b607e6dbc51,not identify any citations relevant to your inquiry,0.676646
uuid-f0749121f0d249bdb70f7b607e6dbc51,using the following search terms,0.653146
uuid-f0749121f0d249bdb70f7b607e6dbc51,efficacy and safety of nivolumab,0.453835
uuid-c20b8922ead340d5a32eb88e06eff2a9,nivolumab,0.598079
uuid-c20b8922ead340d5a32eb88e06eff2a9,Bristol-Myers Squibb,0.405876
uuid-c20b8922ead340d5a32eb88e06eff2a9,evaluating,0.550388
uuid-c20b8922ead340d5a32eb88e06eff2a9,not conducted any controlled clinical trials/studies,0.611615
uuid-c20b8922ead340d5a32eb88e06eff2a9,Pubmed literature search,0.824615
uuid-c20b8922ead340d5a32eb88e06eff2a9,purposes other than its labeled indication must be considered investigational,0.891977
uuid-c20b8922ead340d5a32eb88e06eff2a9,not identify any citations relevant to your inquiry,0.786947
uuid-c20b8922ead340d5a32eb88e06eff2a9,using the following search terms,0.772453
uuid-c20b8922ead340d5a32eb88e06eff2a9,efficacy and safety of nivolumab,0.395375
uuid-72a109a8b5f048c9a9d60d3248988d9f,N Engl J Med,0.802402
uuid-72a109a8b5f048c9a9d60d3248988d9f,Lancet Oncol,0.56115
uuid-72a109a8b5f048c9a9d60d3248988d9f,protocol,0.825455
uuid-72a109a8b5f048c9a9d60d3248988d9f,McDermott DF,0.885167
uuid-72a109a8b5f048c9a9d60d3248988d9f,Motzer RJ,0.855335
uuid-72a109a8b5f048c9a9d60d3248988d9f,phase 3 study,0.542754
uuid-72a109a8b5f048c9a9d60d3248988d9f,Escudier B,0.889228
uuid-72a109a8b5f048c9a9d60d3248988d9f,NEJM,0.49481
uuid-72a109a8b5f048c9a9d60d3248988d9f,et al.,0.863613
uuid-72a109a8b5f048c9a9d60d3248988d9f,J Clin Oncol,0.80113
uuid-72a109a8b5f048c9a9d60d3248988d9f,Topalian,0.450909
uuid-72a109a8b5f048c9a9d60d3248988d9f,Rizvi NA,0.701925
uuid-72a109a8b5f048c9a9d60d3248988d9f,Brahmer J,0.469271
uuid-72a109a8b5f048c9a9d60d3248988d9f,Weber JS,0.595586
uuid-72a109a8b5f048c9a9d60d3248988d9f,phase 2 study,0.814538
uuid-1af4c50983bd4589981576506912fb8c,ASCO,0.807066
uuid-e2abda0fb74348f2b9c547c149be22a6,95% CI,0.482283
uuid-e2abda0fb74348f2b9c547c149be22a6,respectively,0.319895
uuid-e2abda0fb74348f2b9c547c149be22a6,ASCO,0.389676
uuid-e2abda0fb74348f2b9c547c149be22a6,Objective response rate,0.357341
uuid-e2abda0fb74348f2b9c547c149be22a6,ORR,0.358789
uuid-e2abda0fb74348f2b9c547c149be22a6,Median overall survival,0.421434
uuid-e2abda0fb74348f2b9c547c149be22a6,Median OS,0.603017
uuid-e2abda0fb74348f2b9c547c149be22a6,docetaxel,0.351836
uuid-e2abda0fb74348f2b9c547c149be22a6,hazard ratio,0.51871
uuid-75bf3197b5d145299384796a6bc2cc46,95% CI,0.322199
uuid-75bf3197b5d145299384796a6bc2cc46,respectively,0.518338
uuid-75bf3197b5d145299384796a6bc2cc46,Objective response rate,0.506459
uuid-75bf3197b5d145299384796a6bc2cc46,ORR,0.56424
uuid-75bf3197b5d145299384796a6bc2cc46,Median overall survival,0.343353
uuid-75bf3197b5d145299384796a6bc2cc46,monotherapy,0.39102
uuid-75bf3197b5d145299384796a6bc2cc46,docetaxel,0.332705
uuid-75bf3197b5d145299384796a6bc2cc46,hazard ratio,0.321066
uuid-46d0deac5c6844328f2a931ce9b17536,OS,0.387982
uuid-46d0deac5c6844328f2a931ce9b17536,95% CI,0.745043
uuid-46d0deac5c6844328f2a931ce9b17536,respectively,0.729294
uuid-46d0deac5c6844328f2a931ce9b17536,Objective response rate,0.590876
uuid-46d0deac5c6844328f2a931ce9b17536,ORR,0.722442
uuid-46d0deac5c6844328f2a931ce9b17536,Median overall survival,0.659043
uuid-46d0deac5c6844328f2a931ce9b17536,monotherapy,0.514468
uuid-46d0deac5c6844328f2a931ce9b17536,Median OS,0.696688
uuid-46d0deac5c6844328f2a931ce9b17536,PD-L1,0.300997
uuid-46d0deac5c6844328f2a931ce9b17536,docetaxel,0.635065
uuid-46d0deac5c6844328f2a931ce9b17536,hazard ratio,0.729977
uuid-16dea325043f440f98bfae4badc151c6,95% CI,0.524855
uuid-16dea325043f440f98bfae4badc151c6,respectively,0.383655
uuid-16dea325043f440f98bfae4badc151c6,ASCO,0.303153
uuid-16dea325043f440f98bfae4badc151c6,Lancet Oncol,0.368041
uuid-16dea325043f440f98bfae4badc151c6,Objective response rate,0.504846
uuid-16dea325043f440f98bfae4badc151c6,ORR,0.465366
uuid-16dea325043f440f98bfae4badc151c6,Median overall survival,0.346516
uuid-16dea325043f440f98bfae4badc151c6,Median OS,0.33538
uuid-16dea325043f440f98bfae4badc151c6,ASCO 2015,0.336983
uuid-16dea325043f440f98bfae4badc151c6,small cell lung cancer,0.336892
uuid-16dea325043f440f98bfae4badc151c6,SCLC,0.344367
uuid-16dea325043f440f98bfae4badc151c6,Antonia SJ,0.55269
uuid-16dea325043f440f98bfae4badc151c6,Median duration of response,0.649605
uuid-128155bc69714153a850b6c24a381638,nivolumab,0.361066
uuid-f60045579fa64745b25efb17483ee160,patients with advanced or metastatic,0.468858
uuid-f60045579fa64745b25efb17483ee160,nivolumab combined with ipilimumab,0.446918
uuid-f60045579fa64745b25efb17483ee160,not approved,0.352562
uuid-f60045579fa64745b25efb17483ee160,clinical trials investigating the safety,0.429501
uuid-f60045579fa64745b25efb17483ee160,bladder cancer,0.950698
uuid-710dbafe45924afda3c322d5bb041ec8,nivolumab,0.359772
uuid-b4f7581573564d09821ac78c30a92302,OS,0.44149
uuid-b4f7581573564d09821ac78c30a92302,95% CI,0.833403
uuid-b4f7581573564d09821ac78c30a92302,ASCO,0.32927
uuid-b4f7581573564d09821ac78c30a92302,Objective response rate,0.545269
uuid-b4f7581573564d09821ac78c30a92302,ORR,0.618524
uuid-b4f7581573564d09821ac78c30a92302,PFS,0.396858
uuid-b4f7581573564d09821ac78c30a92302,Median overall survival,0.72593
uuid-b4f7581573564d09821ac78c30a92302,monotherapy,0.33356
uuid-b4f7581573564d09821ac78c30a92302,Median OS,0.763854
uuid-b4f7581573564d09821ac78c30a92302,hazard ratio,0.766648
uuid-b4f7581573564d09821ac78c30a92302,Median duration of response,0.442682
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,nivolumab,0.344939
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,Bristol-Myers Squibb,0.363004
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,evaluating,0.564404
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,not conducted any controlled clinical trials/studies,0.538169
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,RCC,0.336118
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,search of published literature,0.750115
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,Additionally,0.766378
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,ongoing,0.629393
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,PubMed and EMBASE,0.745288
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,detailed search of www.clinicaltrials.gov,0.729251
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,efficacy and safety of nivolumab,0.716075
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,not identify any planned,0.665705
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,not identify any citations relevant to your request,0.849476
uuid-6ffe3699aad146e7a49682bf9ddbc9c4,present using the following search terms,0.773092
uuid-7e732606513a4dcf85067769342970eb,respectively,0.573559
uuid-7e732606513a4dcf85067769342970eb,Objective response rate,0.415121
uuid-7e732606513a4dcf85067769342970eb,ORR,0.42099
uuid-7e732606513a4dcf85067769342970eb,monotherapy,0.348931
uuid-7e732606513a4dcf85067769342970eb,docetaxel,0.374592
uuid-b9304297a4f945258e62ba41f0bdd224,patients,0.416637
uuid-054899bacd8048d1bd8f0061e81ecfea,Bristol-Myers Squibb,0.501453
uuid-054899bacd8048d1bd8f0061e81ecfea,evaluating,0.686852
uuid-054899bacd8048d1bd8f0061e81ecfea,not conducted any controlled clinical trials/studies,0.674519
uuid-054899bacd8048d1bd8f0061e81ecfea,NSCLC,0.326947
uuid-054899bacd8048d1bd8f0061e81ecfea,non-small cell lung cancer,0.319447
uuid-054899bacd8048d1bd8f0061e81ecfea,considered investigational,0.334026
uuid-054899bacd8048d1bd8f0061e81ecfea,search of published literature,0.657988
uuid-054899bacd8048d1bd8f0061e81ecfea,phase 3 study,0.328307
uuid-054899bacd8048d1bd8f0061e81ecfea,PubMed and EMBASE,0.631737
uuid-054899bacd8048d1bd8f0061e81ecfea,phase 1 study,0.431136
uuid-054899bacd8048d1bd8f0061e81ecfea,efficacy and safety of nivolumab,0.819005
uuid-054899bacd8048d1bd8f0061e81ecfea,CA209-003,0.36284
uuid-054899bacd8048d1bd8f0061e81ecfea,not identify any citations relevant to your request,0.364535
uuid-054899bacd8048d1bd8f0061e81ecfea,present using the following search terms,0.651702
uuid-054899bacd8048d1bd8f0061e81ecfea,investigating,0.351918
uuid-8b176d0e05a6475d917ed45631fb9fb5,nivolumab,0.328354
uuid-af4829afdff043fe81774706bf2e5533,patients with advanced or metastatic,0.478326
uuid-af4829afdff043fe81774706bf2e5533,nivolumab combined with ipilimumab,0.498766
uuid-af4829afdff043fe81774706bf2e5533,not approved,0.34724
uuid-af4829afdff043fe81774706bf2e5533,clinical trials investigating the safety,0.426729
uuid-af4829afdff043fe81774706bf2e5533,bladder cancer,0.6548
uuid-d27c9ebbd82c4997a0b05c079d0776c8,OS,0.387982
uuid-d27c9ebbd82c4997a0b05c079d0776c8,95% CI,0.745043
uuid-d27c9ebbd82c4997a0b05c079d0776c8,respectively,0.729294
uuid-d27c9ebbd82c4997a0b05c079d0776c8,Objective response rate,0.590876
uuid-d27c9ebbd82c4997a0b05c079d0776c8,ORR,0.722442
uuid-d27c9ebbd82c4997a0b05c079d0776c8,Median overall survival,0.659043
uuid-d27c9ebbd82c4997a0b05c079d0776c8,monotherapy,0.514468
uuid-d27c9ebbd82c4997a0b05c079d0776c8,Median OS,0.696688
uuid-d27c9ebbd82c4997a0b05c079d0776c8,PD-L1,0.300997
uuid-d27c9ebbd82c4997a0b05c079d0776c8,docetaxel,0.635065
uuid-d27c9ebbd82c4997a0b05c079d0776c8,hazard ratio,0.729977
uuid-1994a8e4419b456e82fad357bf4a07d8,nivolumab,0.44703
uuid-1994a8e4419b456e82fad357bf4a07d8,Bristol-Myers Squibb,0.608199
uuid-1994a8e4419b456e82fad357bf4a07d8,evaluating,0.720228
uuid-1994a8e4419b456e82fad357bf4a07d8,not conducted any controlled clinical trials/studies,0.77725
uuid-1994a8e4419b456e82fad357bf4a07d8,Pubmed literature search,0.653127
uuid-1994a8e4419b456e82fad357bf4a07d8,purposes other than its labeled indication must be considered investigational,0.747266
uuid-1994a8e4419b456e82fad357bf4a07d8,not identify any citations relevant to your inquiry,0.605506
uuid-1994a8e4419b456e82fad357bf4a07d8,using the following search terms,0.584314
uuid-1994a8e4419b456e82fad357bf4a07d8,efficacy and safety of nivolumab,0.567043
uuid-01ff4b91c49e443cb94a8f6a2227ac23,patients with advanced or metastatic,0.468858
uuid-01ff4b91c49e443cb94a8f6a2227ac23,nivolumab combined with ipilimumab,0.446918
uuid-01ff4b91c49e443cb94a8f6a2227ac23,not approved,0.352562
uuid-01ff4b91c49e443cb94a8f6a2227ac23,clinical trials investigating the safety,0.429501
uuid-01ff4b91c49e443cb94a8f6a2227ac23,bladder cancer,0.950698
uuid-e9a63b3f1fa34009b228f023a0c9cd3b,Bristol-Myers Squibb,0.494637
uuid-df6f3fb392674cf3b39aa36efbd6a864,OS,0.387982
uuid-df6f3fb392674cf3b39aa36efbd6a864,95% CI,0.745043
uuid-df6f3fb392674cf3b39aa36efbd6a864,respectively,0.729294
uuid-df6f3fb392674cf3b39aa36efbd6a864,Objective response rate,0.590876
uuid-df6f3fb392674cf3b39aa36efbd6a864,ORR,0.722442
uuid-df6f3fb392674cf3b39aa36efbd6a864,Median overall survival,0.659043
uuid-df6f3fb392674cf3b39aa36efbd6a864,monotherapy,0.514468
uuid-df6f3fb392674cf3b39aa36efbd6a864,Median OS,0.696688
uuid-df6f3fb392674cf3b39aa36efbd6a864,PD-L1,0.300997
uuid-df6f3fb392674cf3b39aa36efbd6a864,docetaxel,0.635065
uuid-df6f3fb392674cf3b39aa36efbd6a864,hazard ratio,0.729977
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,N Engl J Med,0.714946
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Lancet Oncol,0.448679
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,patients,0.309769
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,protocol,0.700662
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,McDermott DF,0.68799
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Motzer RJ,0.689932
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,phase 3 study,0.545628
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Escudier B,0.698812
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,NEJM,0.402095
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,et al.,0.640511
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,J Clin Oncol,0.626106
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Topalian,0.37979
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,phase 1 study,0.381282
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Rizvi NA,0.636006
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Brahmer J,0.517174
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,efficacy and safety of nivolumab,0.368444
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,Weber JS,0.406071
uuid-0fc28fd8f93340d5b9beb2a83eb1c67d,phase 2 study,0.692115
uuid-e594a31e3e6d447dbc6527dce729da92,OS,0.387982
uuid-e594a31e3e6d447dbc6527dce729da92,95% CI,0.745043
uuid-e594a31e3e6d447dbc6527dce729da92,respectively,0.729294
uuid-e594a31e3e6d447dbc6527dce729da92,Objective response rate,0.590876
uuid-e594a31e3e6d447dbc6527dce729da92,ORR,0.722442
uuid-e594a31e3e6d447dbc6527dce729da92,Median overall survival,0.659043
uuid-e594a31e3e6d447dbc6527dce729da92,monotherapy,0.514468
uuid-e594a31e3e6d447dbc6527dce729da92,Median OS,0.696688
uuid-e594a31e3e6d447dbc6527dce729da92,PD-L1,0.300997
uuid-e594a31e3e6d447dbc6527dce729da92,docetaxel,0.635065
uuid-e594a31e3e6d447dbc6527dce729da92,hazard ratio,0.729977
uuid-4d59d22b150647069e956a0e9fe1d56f,nivolumab,0.549759
uuid-4d59d22b150647069e956a0e9fe1d56f,Bristol-Myers Squibb,0.451554
uuid-4d59d22b150647069e956a0e9fe1d56f,evaluating,0.633202
uuid-4d59d22b150647069e956a0e9fe1d56f,not conducted any controlled clinical trials/studies,0.679876
uuid-4d59d22b150647069e956a0e9fe1d56f,Pubmed literature search,0.81055
uuid-4d59d22b150647069e956a0e9fe1d56f,purposes other than its labeled indication must be considered investigational,0.883285
uuid-4d59d22b150647069e956a0e9fe1d56f,not identify any citations relevant to your inquiry,0.770219
uuid-4d59d22b150647069e956a0e9fe1d56f,using the following search terms,0.752068
uuid-4d59d22b150647069e956a0e9fe1d56f,efficacy and safety of nivolumab,0.470559
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,N Engl J Med,0.441724
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,protocol,0.58369
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,McDermott DF,0.657332
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,Motzer RJ,0.636357
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,phase 3 study,0.333766
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,Escudier B,0.642548
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,NEJM,0.33468
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,et al.,0.615033
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,J Clin Oncol,0.645777
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,Topalian,0.317993
uuid-7bd3fba87f244035ae54dc9b0a5a34c1,phase 2 study,0.552415
uuid-f89b7c81ac3340618ead324c199cffac,nivolumab,0.379893
uuid-f89b7c81ac3340618ead324c199cffac,Bristol-Myers Squibb,0.456909
uuid-f89b7c81ac3340618ead324c199cffac,evaluating,0.556633
uuid-f89b7c81ac3340618ead324c199cffac,not conducted any controlled clinical trials/studies,0.601294
uuid-f89b7c81ac3340618ead324c199cffac,NSCLC,0.485906
uuid-f89b7c81ac3340618ead324c199cffac,non-small cell lung cancer,0.489411
uuid-f89b7c81ac3340618ead324c199cffac,considered investigational,0.388739
uuid-f89b7c81ac3340618ead324c199cffac,Pubmed literature search,0.464205
uuid-f89b7c81ac3340618ead324c199cffac,purposes other than its labeled indication must be considered investigational,0.550814
uuid-f89b7c81ac3340618ead324c199cffac,not identify any citations relevant to your inquiry,0.428313
uuid-f89b7c81ac3340618ead324c199cffac,using the following search terms,0.403038
uuid-f89b7c81ac3340618ead324c199cffac,efficacy and safety of nivolumab,0.447605
uuid-f89b7c81ac3340618ead324c199cffac,SCLC,0.315121
uuid-f89b7c81ac3340618ead324c199cffac,therapy,0.492824
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,evaluating,0.33595
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,not conducted any controlled clinical trials/studies,0.333389
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,protocol,0.519575
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,RCC,0.396552
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,McDermott DF,0.425884
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,search of published literature,0.498677
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,Additionally,0.549804
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,ongoing,0.474606
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,Motzer RJ,0.459308
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,PubMed and EMBASE,0.495663
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,Escudier B,0.441262
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,et al.,0.378311
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,J Clin Oncol,0.413083
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,detailed search of www.clinicaltrials.gov,0.509888
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,efficacy and safety of nivolumab,0.474675
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,not identify any planned,0.488523
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,phase 2 study,0.364975
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,not identify any citations relevant to your request,0.559577
uuid-668fb0afc2cf4f7dbfa4797b7d8a435b,present using the following search terms,0.484223
uuid-9239204bbaac46049f2458d24b2597a4,nivolumab,0.555179
uuid-9239204bbaac46049f2458d24b2597a4,Bristol-Myers Squibb,0.465409
uuid-9239204bbaac46049f2458d24b2597a4,evaluating,0.641466
uuid-9239204bbaac46049f2458d24b2597a4,not conducted any controlled clinical trials/studies,0.692626
uuid-9239204bbaac46049f2458d24b2597a4,Pubmed literature search,0.836984
uuid-9239204bbaac46049f2458d24b2597a4,purposes other than its labeled indication must be considered investigational,0.907887
uuid-9239204bbaac46049f2458d24b2597a4,not identify any citations relevant to your inquiry,0.795222
uuid-9239204bbaac46049f2458d24b2597a4,using the following search terms,0.779697
uuid-9239204bbaac46049f2458d24b2597a4,efficacy and safety of nivolumab,0.476918
uuid-c812831635be47d68220264872e41db8,OS,0.387982
uuid-c812831635be47d68220264872e41db8,95% CI,0.745043
uuid-c812831635be47d68220264872e41db8,respectively,0.729294
uuid-c812831635be47d68220264872e41db8,Objective response rate,0.590876
uuid-c812831635be47d68220264872e41db8,ORR,0.722442
uuid-c812831635be47d68220264872e41db8,Median overall survival,0.659043
uuid-c812831635be47d68220264872e41db8,monotherapy,0.514468
uuid-c812831635be47d68220264872e41db8,Median OS,0.696688
uuid-c812831635be47d68220264872e41db8,PD-L1,0.300997
uuid-c812831635be47d68220264872e41db8,docetaxel,0.635065
uuid-c812831635be47d68220264872e41db8,hazard ratio,0.729977
uuid-4581417c647549d98f624df147550e66,nivolumab,0.596674
uuid-4581417c647549d98f624df147550e66,Bristol-Myers Squibb,0.435794
uuid-4581417c647549d98f624df147550e66,evaluating,0.594779
uuid-4581417c647549d98f624df147550e66,not conducted any controlled clinical trials/studies,0.653423
uuid-4581417c647549d98f624df147550e66,Pubmed literature search,0.861431
uuid-4581417c647549d98f624df147550e66,purposes other than its labeled indication must be considered investigational,0.92756
uuid-4581417c647549d98f624df147550e66,not identify any citations relevant to your inquiry,0.819514
uuid-4581417c647549d98f624df147550e66,using the following search terms,0.807235
uuid-4581417c647549d98f624df147550e66,efficacy and safety of nivolumab,0.431524
uuid-03381d39070f420083268787f79b5377,N Engl J Med,0.636726
uuid-03381d39070f420083268787f79b5377,non-small cell lung cancer,0.351489
uuid-03381d39070f420083268787f79b5377,ESMO,0.419331
uuid-03381d39070f420083268787f79b5377,Rizvi NA,0.470388
uuid-03381d39070f420083268787f79b5377,Brahmer J,0.676477
uuid-03381d39070f420083268787f79b5377,PD-L1,0.354847
uuid-03381d39070f420083268787f79b5377,Horn L,0.512976
uuid-03381d39070f420083268787f79b5377,platinum-based doublet chemotherapy,0.312066
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,patients,0.556054
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,provided in the Detailed Information,0.329929
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,adverse,0.32982
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,phase 3 study,0.523726
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,melanoma,0.382071
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,Weber JS,0.428777
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,phase 2 study,0.307314
uuid-f296251f3c8d43f18daa9bbc81ddf5f7,grade 3 to 4 AEs,0.466022
uuid-26f4e988408d4b47bc99aebca4c2617c,Bristol-Myers Squibb,0.341822
uuid-26f4e988408d4b47bc99aebca4c2617c,not conducted any controlled clinical trials/studies,0.304507
uuid-26f4e988408d4b47bc99aebca4c2617c,Opdivo,0.461382
uuid-26f4e988408d4b47bc99aebca4c2617c,Pubmed literature search,0.614325
uuid-26f4e988408d4b47bc99aebca4c2617c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-26f4e988408d4b47bc99aebca4c2617c,not identify any citations relevant to your inquiry,0.606087
uuid-26f4e988408d4b47bc99aebca4c2617c,adverse,0.304183
uuid-26f4e988408d4b47bc99aebca4c2617c,using the following search terms,0.642331
uuid-26f4e988408d4b47bc99aebca4c2617c,databases,0.315039
uuid-26f4e988408d4b47bc99aebca4c2617c,reported,0.556704
uuid-38c65cca48e24d48be85da77d7525951,use of nivolumab for the treatment,0.440423
uuid-38c65cca48e24d48be85da77d7525951,search of published literature,0.311531
uuid-38c65cca48e24d48be85da77d7525951,PubMed and EMBASE,0.312811
uuid-38c65cca48e24d48be85da77d7525951,not approved,0.404782
uuid-38c65cca48e24d48be85da77d7525951,open-label,0.578291
uuid-38c65cca48e24d48be85da77d7525951,clinical trials investigating the safety,0.440014
uuid-38c65cca48e24d48be85da77d7525951,present using the following search terms,0.328669
uuid-38c65cca48e24d48be85da77d7525951,phase,0.41185
uuid-0a2c2b700c004ff7a4a388d380680b03,Bristol-Myers Squibb,0.341822
uuid-0a2c2b700c004ff7a4a388d380680b03,not conducted any controlled clinical trials/studies,0.304507
uuid-0a2c2b700c004ff7a4a388d380680b03,Opdivo,0.461382
uuid-0a2c2b700c004ff7a4a388d380680b03,Pubmed literature search,0.614325
uuid-0a2c2b700c004ff7a4a388d380680b03,purposes other than its labeled indication must be considered investigational,0.586645
uuid-0a2c2b700c004ff7a4a388d380680b03,not identify any citations relevant to your inquiry,0.606087
uuid-0a2c2b700c004ff7a4a388d380680b03,adverse,0.304183
uuid-0a2c2b700c004ff7a4a388d380680b03,using the following search terms,0.642331
uuid-0a2c2b700c004ff7a4a388d380680b03,databases,0.315039
uuid-0a2c2b700c004ff7a4a388d380680b03,reported,0.556704
uuid-dab28cdaa1bd43489db6d429e896b5b5,NSCLC,0.340221
uuid-dab28cdaa1bd43489db6d429e896b5b5,respectively,0.49936
uuid-dab28cdaa1bd43489db6d429e896b5b5,Objective response rate,0.519659
uuid-dab28cdaa1bd43489db6d429e896b5b5,ORR,0.550917
uuid-dab28cdaa1bd43489db6d429e896b5b5,monotherapy,0.433558
uuid-dab28cdaa1bd43489db6d429e896b5b5,docetaxel,0.409072
uuid-dab28cdaa1bd43489db6d429e896b5b5,Antonia SJ,0.321941
uuid-a9c05494129c497a8bad8a8f37678f93,fatigue,0.76689
uuid-0de489bf8c0a47e2a068dcc9528898c9,patients with advanced or metastatic,0.478326
uuid-0de489bf8c0a47e2a068dcc9528898c9,nivolumab combined with ipilimumab,0.498766
uuid-0de489bf8c0a47e2a068dcc9528898c9,not approved,0.34724
uuid-0de489bf8c0a47e2a068dcc9528898c9,clinical trials investigating the safety,0.426729
uuid-0de489bf8c0a47e2a068dcc9528898c9,bladder cancer,0.6548
uuid-d15043b50d6041bdb67688904e15e18f,patients with advanced or metastatic,0.468858
uuid-d15043b50d6041bdb67688904e15e18f,nivolumab combined with ipilimumab,0.446918
uuid-d15043b50d6041bdb67688904e15e18f,not approved,0.352562
uuid-d15043b50d6041bdb67688904e15e18f,clinical trials investigating the safety,0.429501
uuid-d15043b50d6041bdb67688904e15e18f,bladder cancer,0.950698
uuid-2f363eedecb94dbf9d13381225ae3cf3,OS,0.469578
uuid-2f363eedecb94dbf9d13381225ae3cf3,95% CI,0.681027
uuid-2f363eedecb94dbf9d13381225ae3cf3,ORR,0.335807
uuid-2f363eedecb94dbf9d13381225ae3cf3,PFS,0.353669
uuid-2f363eedecb94dbf9d13381225ae3cf3,Opdivo,0.330599
uuid-2f363eedecb94dbf9d13381225ae3cf3,Median overall survival,0.614031
uuid-2f363eedecb94dbf9d13381225ae3cf3,Median OS,0.637372
uuid-2f363eedecb94dbf9d13381225ae3cf3,docetaxel,0.442764
uuid-2f363eedecb94dbf9d13381225ae3cf3,hazard ratio,0.613072
uuid-2f363eedecb94dbf9d13381225ae3cf3,Median duration of response,0.471207
uuid-34337438fc7d48c7a728c38443f1d091,Opdivo,0.602486
uuid-34337438fc7d48c7a728c38443f1d091,trial,0.383851
uuid-a0c0ccedc65c4d14bb0e8542a41a2605,Opdivo,0.362053
uuid-747e00912ff34fb78fc94eb6225ae510,Bristol-Myers Squibb,0.341822
uuid-747e00912ff34fb78fc94eb6225ae510,not conducted any controlled clinical trials/studies,0.304507
uuid-747e00912ff34fb78fc94eb6225ae510,Opdivo,0.461382
uuid-747e00912ff34fb78fc94eb6225ae510,Pubmed literature search,0.614325
uuid-747e00912ff34fb78fc94eb6225ae510,purposes other than its labeled indication must be considered investigational,0.586645
uuid-747e00912ff34fb78fc94eb6225ae510,not identify any citations relevant to your inquiry,0.606087
uuid-747e00912ff34fb78fc94eb6225ae510,adverse,0.304183
uuid-747e00912ff34fb78fc94eb6225ae510,using the following search terms,0.642331
uuid-747e00912ff34fb78fc94eb6225ae510,databases,0.315039
uuid-747e00912ff34fb78fc94eb6225ae510,reported,0.556704
uuid-f1ff95dffbe74adfaac36a04d43ed875,Bristol-Myers Squibb,0.341822
uuid-f1ff95dffbe74adfaac36a04d43ed875,not conducted any controlled clinical trials/studies,0.304507
uuid-f1ff95dffbe74adfaac36a04d43ed875,Opdivo,0.461382
uuid-f1ff95dffbe74adfaac36a04d43ed875,Pubmed literature search,0.614325
uuid-f1ff95dffbe74adfaac36a04d43ed875,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f1ff95dffbe74adfaac36a04d43ed875,not identify any citations relevant to your inquiry,0.606087
uuid-f1ff95dffbe74adfaac36a04d43ed875,adverse,0.304183
uuid-f1ff95dffbe74adfaac36a04d43ed875,using the following search terms,0.642331
uuid-f1ff95dffbe74adfaac36a04d43ed875,databases,0.315039
uuid-f1ff95dffbe74adfaac36a04d43ed875,reported,0.556704
uuid-c3a1ef34c5be4415af9de4ff034a5523,provided in the Detailed Information,0.308113
uuid-c3a1ef34c5be4415af9de4ff034a5523,adverse,0.457662
uuid-c3a1ef34c5be4415af9de4ff034a5523,clinical,0.313643
uuid-c3a1ef34c5be4415af9de4ff034a5523,safety,0.393098
uuid-c3a1ef34c5be4415af9de4ff034a5523,databases,0.370813
uuid-c3a1ef34c5be4415af9de4ff034a5523,reported,0.632498
uuid-7680842736294e39a4bf0874b330f58c,ASCO,0.382205
uuid-074bddc3489c4c14a82f599655824a76,ASCO,0.839149
uuid-074bddc3489c4c14a82f599655824a76,Lancet Oncol,0.330863
uuid-074bddc3489c4c14a82f599655824a76,requested,0.384292
uuid-074bddc3489c4c14a82f599655824a76,Antonia SJ,0.484747
uuid-7a183e8af1d04eb3970a712e68b302a2,nivolumab,0.999168
uuid-7a183e8af1d04eb3970a712e68b302a2,Pubmed literature search,0.395314
uuid-7a183e8af1d04eb3970a712e68b302a2,purposes other than its labeled indication must be considered investigational,0.464236
uuid-7a183e8af1d04eb3970a712e68b302a2,not identify any citations relevant to your inquiry,0.368569
uuid-7a183e8af1d04eb3970a712e68b302a2,using the following search terms,0.364279
uuid-7a183e8af1d04eb3970a712e68b302a2,present using the following search terms,0.329876
uuid-3f26e8b04b0c453d958c04bbc1353924,Bristol-Myers Squibb,0.322674
uuid-3f26e8b04b0c453d958c04bbc1353924,ASCO,0.393536
uuid-6c118f274d9044a281d95fee1b3b7cf8,NSCLC,0.388226
uuid-6c118f274d9044a281d95fee1b3b7cf8,respectively,0.497803
uuid-6c118f274d9044a281d95fee1b3b7cf8,non-small cell lung cancer,0.319807
uuid-6c118f274d9044a281d95fee1b3b7cf8,Objective response rate,0.524986
uuid-6c118f274d9044a281d95fee1b3b7cf8,ORR,0.560171
uuid-6c118f274d9044a281d95fee1b3b7cf8,monotherapy,0.449158
uuid-6c118f274d9044a281d95fee1b3b7cf8,docetaxel,0.417873
uuid-6c118f274d9044a281d95fee1b3b7cf8,Antonia SJ,0.315371
uuid-6c118f274d9044a281d95fee1b3b7cf8,platinum-based doublet chemotherapy,0.300831
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,95% CI,0.524855
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,respectively,0.383655
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,ASCO,0.303153
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Lancet Oncol,0.368041
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Objective response rate,0.504846
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,ORR,0.465366
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Median overall survival,0.346516
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Median OS,0.33538
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,ASCO 2015,0.336983
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,small cell lung cancer,0.336892
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,SCLC,0.344367
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Antonia SJ,0.55269
uuid-87d215c0a6a2416cb38cc6a1b3b7ae4b,Median duration of response,0.649605
uuid-4543179204f640d98a928cc193309418,Bristol-Myers Squibb,0.341822
uuid-4543179204f640d98a928cc193309418,not conducted any controlled clinical trials/studies,0.304507
uuid-4543179204f640d98a928cc193309418,Opdivo,0.461382
uuid-4543179204f640d98a928cc193309418,Pubmed literature search,0.614325
uuid-4543179204f640d98a928cc193309418,purposes other than its labeled indication must be considered investigational,0.586645
uuid-4543179204f640d98a928cc193309418,not identify any citations relevant to your inquiry,0.606087
uuid-4543179204f640d98a928cc193309418,adverse,0.304183
uuid-4543179204f640d98a928cc193309418,using the following search terms,0.642331
uuid-4543179204f640d98a928cc193309418,databases,0.315039
uuid-4543179204f640d98a928cc193309418,reported,0.556704
uuid-21271f6f47c84ce8869e6de59263e71d,AEs,0.486453
uuid-21271f6f47c84ce8869e6de59263e71d,adverse,0.675839
uuid-21271f6f47c84ce8869e6de59263e71d,grade,0.50572
uuid-21271f6f47c84ce8869e6de59263e71d,grade 3 to 4 AEs,0.348608
uuid-21271f6f47c84ce8869e6de59263e71d,reported,0.481721
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,OS,0.387982
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,95% CI,0.745043
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,respectively,0.729294
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,Objective response rate,0.590876
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,ORR,0.722442
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,Median overall survival,0.659043
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,monotherapy,0.514468
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,Median OS,0.696688
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,PD-L1,0.300997
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,docetaxel,0.635065
uuid-82aebc0fd55e4dd5b0eabdb43b887f02,hazard ratio,0.729977
uuid-bc80b312ac81404fa8d4417643333fc9,relapsed,0.313685
uuid-6c14b6ad57bd4e2da504055d2de8d4f4,ipilimumab,0.385692
uuid-6c14b6ad57bd4e2da504055d2de8d4f4,ASCO 2015,0.417944
uuid-6c14b6ad57bd4e2da504055d2de8d4f4,partial response,0.382425
uuid-6c14b6ad57bd4e2da504055d2de8d4f4,Stable disease,0.586335
uuid-6c14b6ad57bd4e2da504055d2de8d4f4,cohort,0.307748
uuid-d3ff9f5c2f1a477bb98653471658e5c1,OS,0.387982
uuid-d3ff9f5c2f1a477bb98653471658e5c1,95% CI,0.745043
uuid-d3ff9f5c2f1a477bb98653471658e5c1,respectively,0.729294
uuid-d3ff9f5c2f1a477bb98653471658e5c1,Objective response rate,0.590876
uuid-d3ff9f5c2f1a477bb98653471658e5c1,ORR,0.722442
uuid-d3ff9f5c2f1a477bb98653471658e5c1,Median overall survival,0.659043
uuid-d3ff9f5c2f1a477bb98653471658e5c1,monotherapy,0.514468
uuid-d3ff9f5c2f1a477bb98653471658e5c1,Median OS,0.696688
uuid-d3ff9f5c2f1a477bb98653471658e5c1,PD-L1,0.300997
uuid-d3ff9f5c2f1a477bb98653471658e5c1,docetaxel,0.635065
uuid-d3ff9f5c2f1a477bb98653471658e5c1,hazard ratio,0.729977
uuid-495fb10a3b3e4fc89fab122f8c1b8009,patients,0.445346
uuid-495fb10a3b3e4fc89fab122f8c1b8009,adverse,0.306495
uuid-495fb10a3b3e4fc89fab122f8c1b8009,grade,0.323313
uuid-495fb10a3b3e4fc89fab122f8c1b8009,grade 3 to 4 AEs,0.305669
uuid-6f3947cc07cc4490b5622137b0c2fb30,relapsed,0.313685
uuid-a0f2bf4c084841bb9e02bcd513ad26ed,requested,0.622618
uuid-84631bb232b446ef8dc480713ff1df7f,OS,0.439366
uuid-84631bb232b446ef8dc480713ff1df7f,95% CI,0.724878
uuid-84631bb232b446ef8dc480713ff1df7f,respectively,0.420254
uuid-84631bb232b446ef8dc480713ff1df7f,Objective response rate,0.629031
uuid-84631bb232b446ef8dc480713ff1df7f,ORR,0.706483
uuid-84631bb232b446ef8dc480713ff1df7f,PFS,0.31891
uuid-84631bb232b446ef8dc480713ff1df7f,Median overall survival,0.660304
uuid-84631bb232b446ef8dc480713ff1df7f,monotherapy,0.45248
uuid-84631bb232b446ef8dc480713ff1df7f,Median OS,0.638607
uuid-84631bb232b446ef8dc480713ff1df7f,docetaxel,0.337072
uuid-84631bb232b446ef8dc480713ff1df7f,hazard ratio,0.727691
uuid-2151ee2bb55a4c82a5b487e976efb978,OS,0.442258
uuid-2151ee2bb55a4c82a5b487e976efb978,95% CI,0.857623
uuid-2151ee2bb55a4c82a5b487e976efb978,respectively,0.614394
uuid-2151ee2bb55a4c82a5b487e976efb978,Objective response rate,0.687157
uuid-2151ee2bb55a4c82a5b487e976efb978,ORR,0.80571
uuid-2151ee2bb55a4c82a5b487e976efb978,PFS,0.329567
uuid-2151ee2bb55a4c82a5b487e976efb978,Median overall survival,0.76721
uuid-2151ee2bb55a4c82a5b487e976efb978,monotherapy,0.477688
uuid-2151ee2bb55a4c82a5b487e976efb978,Median OS,0.753718
uuid-2151ee2bb55a4c82a5b487e976efb978,docetaxel,0.344498
uuid-2151ee2bb55a4c82a5b487e976efb978,hazard ratio,0.829835
uuid-2151ee2bb55a4c82a5b487e976efb978,Median duration of response,0.336592
uuid-667f8881a1934dea9281e04b0af4b725,requested,0.34444
uuid-e20090b1488b47b9862e05013306e9c9,OS,0.387982
uuid-e20090b1488b47b9862e05013306e9c9,95% CI,0.745043
uuid-e20090b1488b47b9862e05013306e9c9,respectively,0.729294
uuid-e20090b1488b47b9862e05013306e9c9,Objective response rate,0.590876
uuid-e20090b1488b47b9862e05013306e9c9,ORR,0.722442
uuid-e20090b1488b47b9862e05013306e9c9,Median overall survival,0.659043
uuid-e20090b1488b47b9862e05013306e9c9,monotherapy,0.514468
uuid-e20090b1488b47b9862e05013306e9c9,Median OS,0.696688
uuid-e20090b1488b47b9862e05013306e9c9,PD-L1,0.300997
uuid-e20090b1488b47b9862e05013306e9c9,docetaxel,0.635065
uuid-e20090b1488b47b9862e05013306e9c9,hazard ratio,0.729977
uuid-895e3ec6f5884878ae12576f07dab845,not approved,0.389731
uuid-895e3ec6f5884878ae12576f07dab845,clinical trials investigating the safety,0.464336
uuid-895e3ec6f5884878ae12576f07dab845,fatigue,0.389752
uuid-064cbb9e9e6b4df7b9144378d380c945,nivolumab,0.583313
uuid-064cbb9e9e6b4df7b9144378d380c945,Bristol-Myers Squibb,0.426167
uuid-064cbb9e9e6b4df7b9144378d380c945,evaluating,0.602899
uuid-064cbb9e9e6b4df7b9144378d380c945,not conducted any controlled clinical trials/studies,0.648446
uuid-064cbb9e9e6b4df7b9144378d380c945,Pubmed literature search,0.810821
uuid-064cbb9e9e6b4df7b9144378d380c945,purposes other than its labeled indication must be considered investigational,0.87969
uuid-064cbb9e9e6b4df7b9144378d380c945,not identify any citations relevant to your inquiry,0.770534
uuid-064cbb9e9e6b4df7b9144378d380c945,using the following search terms,0.756434
uuid-064cbb9e9e6b4df7b9144378d380c945,efficacy and safety of nivolumab,0.449113
uuid-45415899d840403bba4fb689fae3bd8b,requested,0.540431
uuid-ca8524507fd548218f95f6b1024c4ba1,requested,0.540431
uuid-56cbac5c1ee542a08b51f3c5c86f750c,requested,0.540431
uuid-cd2507d5223e4bc8938cffe6ac551238,ASCO,0.790208
uuid-a28e7f349eeb4ab0b768eb4574c27f31,Opdivo,0.522306
uuid-a28e7f349eeb4ab0b768eb4574c27f31,trial,0.360056
uuid-5e0d6a088ec84c2b81372b9abb42156c,ASCO,0.803712
uuid-2b1f937756fc49b9a5cf9763352127c4,mg,0.411839
uuid-2b1f937756fc49b9a5cf9763352127c4,kg,0.342442
uuid-8271a6b595f84a7b88cd08979fb32647,95% CI,0.524855
uuid-8271a6b595f84a7b88cd08979fb32647,respectively,0.383655
uuid-8271a6b595f84a7b88cd08979fb32647,ASCO,0.303153
uuid-8271a6b595f84a7b88cd08979fb32647,Lancet Oncol,0.368041
uuid-8271a6b595f84a7b88cd08979fb32647,Objective response rate,0.504846
uuid-8271a6b595f84a7b88cd08979fb32647,ORR,0.465366
uuid-8271a6b595f84a7b88cd08979fb32647,Median overall survival,0.346516
uuid-8271a6b595f84a7b88cd08979fb32647,Median OS,0.33538
uuid-8271a6b595f84a7b88cd08979fb32647,ASCO 2015,0.336983
uuid-8271a6b595f84a7b88cd08979fb32647,small cell lung cancer,0.336892
uuid-8271a6b595f84a7b88cd08979fb32647,SCLC,0.344367
uuid-8271a6b595f84a7b88cd08979fb32647,Antonia SJ,0.55269
uuid-8271a6b595f84a7b88cd08979fb32647,Median duration of response,0.649605
uuid-6a5bd662aef0460fa5733c5713f1987d,fatigue,0.704358
uuid-7ca655d90675430783c4a4a65c2109b7,Opdivo,0.350032
uuid-7ca655d90675430783c4a4a65c2109b7,adverse,0.401514
uuid-7ca655d90675430783c4a4a65c2109b7,safety,0.544203
uuid-7ca655d90675430783c4a4a65c2109b7,databases,0.486647
uuid-7ca655d90675430783c4a4a65c2109b7,reported,0.657519
uuid-7d340b2b32d34279831285bcde320bc8,AEs,0.303608
uuid-7d340b2b32d34279831285bcde320bc8,adverse,0.913056
uuid-7d340b2b32d34279831285bcde320bc8,reported,0.579353
uuid-c55ec1652bdd4cf9807cf8163cd6dfbc,use of nivolumab for the treatment,0.441253
uuid-c55ec1652bdd4cf9807cf8163cd6dfbc,evaluating,0.311973
uuid-c55ec1652bdd4cf9807cf8163cd6dfbc,patients,0.437312
uuid-c55ec1652bdd4cf9807cf8163cd6dfbc,not approved,0.375686
uuid-c55ec1652bdd4cf9807cf8163cd6dfbc,clinical trials investigating the safety,0.35096
uuid-efa974c738c74554a3f134b7336605a3,search of published literature,0.394524
uuid-efa974c738c74554a3f134b7336605a3,Additionally,0.413583
uuid-efa974c738c74554a3f134b7336605a3,ongoing,0.322117
uuid-efa974c738c74554a3f134b7336605a3,PubMed and EMBASE,0.391671
uuid-efa974c738c74554a3f134b7336605a3,detailed search of www.clinicaltrials.gov,0.375936
uuid-efa974c738c74554a3f134b7336605a3,efficacy and safety of nivolumab,0.370699
uuid-efa974c738c74554a3f134b7336605a3,not identify any planned,0.34283
uuid-efa974c738c74554a3f134b7336605a3,Weber JS,0.319229
uuid-efa974c738c74554a3f134b7336605a3,not identify any citations relevant to your request,0.447813
uuid-efa974c738c74554a3f134b7336605a3,present using the following search terms,0.408199
uuid-862593c111d6432ab830cbdad72f95ec,nivolumab,0.572048
uuid-862593c111d6432ab830cbdad72f95ec,Bristol-Myers Squibb,0.438697
uuid-862593c111d6432ab830cbdad72f95ec,evaluating,0.59721
uuid-862593c111d6432ab830cbdad72f95ec,not conducted any controlled clinical trials/studies,0.656767
uuid-862593c111d6432ab830cbdad72f95ec,Pubmed literature search,0.875413
uuid-862593c111d6432ab830cbdad72f95ec,purposes other than its labeled indication must be considered investigational,0.938534
uuid-862593c111d6432ab830cbdad72f95ec,not identify any citations relevant to your inquiry,0.835188
uuid-862593c111d6432ab830cbdad72f95ec,using the following search terms,0.822371
uuid-862593c111d6432ab830cbdad72f95ec,efficacy and safety of nivolumab,0.437688
uuid-3ced0445a1fc4aa09d499790601d9f9e,OS,0.62262
uuid-3ced0445a1fc4aa09d499790601d9f9e,PFS,0.65903
uuid-3ced0445a1fc4aa09d499790601d9f9e,Overall survival,0.644151
uuid-3bb473ee9694492e8eba067c5efbd2d8,patients,0.429499
uuid-3bb473ee9694492e8eba067c5efbd2d8,considered investigational,0.311057
uuid-3bb473ee9694492e8eba067c5efbd2d8,investigating,0.300286
uuid-64100d8cc4744c9a9e9fe8910303e2a9,patients with advanced or metastatic,0.468858
uuid-64100d8cc4744c9a9e9fe8910303e2a9,nivolumab combined with ipilimumab,0.446918
uuid-64100d8cc4744c9a9e9fe8910303e2a9,not approved,0.352562
uuid-64100d8cc4744c9a9e9fe8910303e2a9,clinical trials investigating the safety,0.429501
uuid-64100d8cc4744c9a9e9fe8910303e2a9,bladder cancer,0.950698
uuid-c34635f66f8d4346b4dee5d225233009,N Engl J Med,0.302601
uuid-c34635f66f8d4346b4dee5d225233009,AEs,0.348167
uuid-c34635f66f8d4346b4dee5d225233009,patients,0.536884
uuid-c34635f66f8d4346b4dee5d225233009,provided in the Detailed Information,0.387544
uuid-c34635f66f8d4346b4dee5d225233009,ESMO,0.462801
uuid-c34635f66f8d4346b4dee5d225233009,NEJM,0.66427
uuid-c34635f66f8d4346b4dee5d225233009,Topalian,0.692873
uuid-c34635f66f8d4346b4dee5d225233009,grade 3 to 4 AEs,0.626596
uuid-c8fb720284534afb813a5990b1fb8735,use of nivolumab for the treatment,0.444892
uuid-c8fb720284534afb813a5990b1fb8735,evaluating,0.30558
uuid-c8fb720284534afb813a5990b1fb8735,patients,0.440855
uuid-c8fb720284534afb813a5990b1fb8735,not approved,0.378002
uuid-c8fb720284534afb813a5990b1fb8735,clinical trials investigating the safety,0.352423
uuid-77d8af8e5de946ffbeb38f171c9febc4,nivolumab,0.639358
uuid-77d8af8e5de946ffbeb38f171c9febc4,Bristol-Myers Squibb,0.466107
uuid-77d8af8e5de946ffbeb38f171c9febc4,evaluating,0.669471
uuid-77d8af8e5de946ffbeb38f171c9febc4,not conducted any controlled clinical trials/studies,0.705421
uuid-77d8af8e5de946ffbeb38f171c9febc4,Pubmed literature search,0.716678
uuid-77d8af8e5de946ffbeb38f171c9febc4,purposes other than its labeled indication must be considered investigational,0.803176
uuid-77d8af8e5de946ffbeb38f171c9febc4,not identify any citations relevant to your inquiry,0.679044
uuid-77d8af8e5de946ffbeb38f171c9febc4,search of published literature,0.371718
uuid-77d8af8e5de946ffbeb38f171c9febc4,PubMed and EMBASE,0.346088
uuid-77d8af8e5de946ffbeb38f171c9febc4,using the following search terms,0.657065
uuid-77d8af8e5de946ffbeb38f171c9febc4,efficacy and safety of nivolumab,0.583286
uuid-77d8af8e5de946ffbeb38f171c9febc4,present using the following search terms,0.373723
uuid-59c89b256e5d46bd8482c792f9da6fb4,nivolumab,0.351869
uuid-59c89b256e5d46bd8482c792f9da6fb4,Bristol-Myers Squibb,0.457453
uuid-59c89b256e5d46bd8482c792f9da6fb4,evaluating,0.64695
uuid-59c89b256e5d46bd8482c792f9da6fb4,not conducted any controlled clinical trials/studies,0.62998
uuid-59c89b256e5d46bd8482c792f9da6fb4,RCC,0.356137
uuid-59c89b256e5d46bd8482c792f9da6fb4,search of published literature,0.722085
uuid-59c89b256e5d46bd8482c792f9da6fb4,Additionally,0.68432
uuid-59c89b256e5d46bd8482c792f9da6fb4,ongoing,0.555203
uuid-59c89b256e5d46bd8482c792f9da6fb4,PubMed and EMBASE,0.710232
uuid-59c89b256e5d46bd8482c792f9da6fb4,detailed search of www.clinicaltrials.gov,0.647817
uuid-59c89b256e5d46bd8482c792f9da6fb4,efficacy and safety of nivolumab,0.757459
uuid-59c89b256e5d46bd8482c792f9da6fb4,not identify any planned,0.58682
uuid-59c89b256e5d46bd8482c792f9da6fb4,not identify any citations relevant to your request,0.767844
uuid-59c89b256e5d46bd8482c792f9da6fb4,present using the following search terms,0.731237
uuid-185c8e01f0a24211abdae355eca8a2bf,use of nivolumab for the treatment,0.326278
uuid-185c8e01f0a24211abdae355eca8a2bf,efficacy,0.376348
uuid-185c8e01f0a24211abdae355eca8a2bf,not approved,0.408681
uuid-185c8e01f0a24211abdae355eca8a2bf,clinical trials investigating the safety,0.410983
uuid-c362e7d681e644be8f15d891df0dd3a1,nivolumab,0.445312
uuid-c362e7d681e644be8f15d891df0dd3a1,patients,0.52205
uuid-952f4c5fe03940df9f568d1b7a77b432,OS,0.62262
uuid-952f4c5fe03940df9f568d1b7a77b432,PFS,0.65903
uuid-952f4c5fe03940df9f568d1b7a77b432,Overall survival,0.644151
uuid-cd54346878ed40658112f3331ab45870,trial,0.34536
uuid-931604191a784017ae34bb33b1688bad,Bristol-Myers Squibb,0.341822
uuid-931604191a784017ae34bb33b1688bad,not conducted any controlled clinical trials/studies,0.304507
uuid-931604191a784017ae34bb33b1688bad,Opdivo,0.461382
uuid-931604191a784017ae34bb33b1688bad,Pubmed literature search,0.614325
uuid-931604191a784017ae34bb33b1688bad,purposes other than its labeled indication must be considered investigational,0.586645
uuid-931604191a784017ae34bb33b1688bad,not identify any citations relevant to your inquiry,0.606087
uuid-931604191a784017ae34bb33b1688bad,adverse,0.304183
uuid-931604191a784017ae34bb33b1688bad,using the following search terms,0.642331
uuid-931604191a784017ae34bb33b1688bad,databases,0.315039
uuid-931604191a784017ae34bb33b1688bad,reported,0.556704
uuid-8cc17126ac92416ba034ea9ac711f21a,Bristol-Myers Squibb,0.341822
uuid-8cc17126ac92416ba034ea9ac711f21a,not conducted any controlled clinical trials/studies,0.304507
uuid-8cc17126ac92416ba034ea9ac711f21a,Opdivo,0.461382
uuid-8cc17126ac92416ba034ea9ac711f21a,Pubmed literature search,0.614325
uuid-8cc17126ac92416ba034ea9ac711f21a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8cc17126ac92416ba034ea9ac711f21a,not identify any citations relevant to your inquiry,0.606087
uuid-8cc17126ac92416ba034ea9ac711f21a,adverse,0.304183
uuid-8cc17126ac92416ba034ea9ac711f21a,using the following search terms,0.642331
uuid-8cc17126ac92416ba034ea9ac711f21a,databases,0.315039
uuid-8cc17126ac92416ba034ea9ac711f21a,reported,0.556704
uuid-9f058e3284ce43cebdd4538906b3f29f,patients,0.369056
uuid-9f058e3284ce43cebdd4538906b3f29f,adverse,0.504452
uuid-9f058e3284ce43cebdd4538906b3f29f,reported,0.411008
uuid-1a4be225d903407281728ad678a4a0a5,95% CI,0.524855
uuid-1a4be225d903407281728ad678a4a0a5,respectively,0.383655
uuid-1a4be225d903407281728ad678a4a0a5,ASCO,0.303153
uuid-1a4be225d903407281728ad678a4a0a5,Lancet Oncol,0.368041
uuid-1a4be225d903407281728ad678a4a0a5,Objective response rate,0.504846
uuid-1a4be225d903407281728ad678a4a0a5,ORR,0.465366
uuid-1a4be225d903407281728ad678a4a0a5,Median overall survival,0.346516
uuid-1a4be225d903407281728ad678a4a0a5,Median OS,0.33538
uuid-1a4be225d903407281728ad678a4a0a5,ASCO 2015,0.336983
uuid-1a4be225d903407281728ad678a4a0a5,small cell lung cancer,0.336892
uuid-1a4be225d903407281728ad678a4a0a5,SCLC,0.344367
uuid-1a4be225d903407281728ad678a4a0a5,Antonia SJ,0.55269
uuid-1a4be225d903407281728ad678a4a0a5,Median duration of response,0.649605
uuid-9430201d0a8d484aa9b6b301f2675b7d,open-label,0.306714
uuid-9430201d0a8d484aa9b6b301f2675b7d,phase,0.336471
uuid-a3fc794777e84c9082a9af2a9405f839,trial,0.346953
uuid-931a4f5abdef4b5db9de83fe11f6f52c,Opdivo,0.99227
uuid-931a4f5abdef4b5db9de83fe11f6f52c,using the following search terms,0.344462
uuid-931a4f5abdef4b5db9de83fe11f6f52c,trial,0.459366
uuid-931a4f5abdef4b5db9de83fe11f6f52c,reported,0.3684
uuid-f209e4a80e2947e98f6204b779f07a25,open-label,0.30716
uuid-f209e4a80e2947e98f6204b779f07a25,trial,0.708671
uuid-f209e4a80e2947e98f6204b779f07a25,phase,0.368545
uuid-100a935ac55244d2944a9329978bbb6f,use of nivolumab for the treatment,0.414666
uuid-100a935ac55244d2944a9329978bbb6f,efficacy,0.480746
uuid-100a935ac55244d2944a9329978bbb6f,not approved,0.593553
uuid-100a935ac55244d2944a9329978bbb6f,clinical trials investigating the safety,0.700325
uuid-100a935ac55244d2944a9329978bbb6f,safety,0.303666
uuid-b92b3f5271824f0ab4e032c7e77a239f,mg,0.515126
uuid-b92b3f5271824f0ab4e032c7e77a239f,safety,0.52355
uuid-b92b3f5271824f0ab4e032c7e77a239f,kg,0.492123
uuid-b92b3f5271824f0ab4e032c7e77a239f,databases,0.442195
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,AEs,0.348328
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,respectively,0.676783
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,ASCO,0.356916
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,Objective response rate,0.548091
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,ORR,0.574881
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,monotherapy,0.366665
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,docetaxel,0.374461
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,grade,0.325212
uuid-6576705cc4164097bdb3ce5f5b0b1fcc,Antonia SJ,0.407708
uuid-cffeab35d2c540f799036180cf510246,95% CI,0.520262
uuid-cffeab35d2c540f799036180cf510246,respectively,0.504068
uuid-cffeab35d2c540f799036180cf510246,Objective response rate,0.458568
uuid-cffeab35d2c540f799036180cf510246,ORR,0.525868
uuid-cffeab35d2c540f799036180cf510246,Median overall survival,0.455633
uuid-cffeab35d2c540f799036180cf510246,Median OS,0.507448
uuid-cffeab35d2c540f799036180cf510246,docetaxel,0.383115
uuid-cffeab35d2c540f799036180cf510246,hazard ratio,0.462119
uuid-11a8e1a136744042ae1582ce3f2f836e,N Engl J Med,0.636726
uuid-11a8e1a136744042ae1582ce3f2f836e,non-small cell lung cancer,0.351489
uuid-11a8e1a136744042ae1582ce3f2f836e,ESMO,0.419331
uuid-11a8e1a136744042ae1582ce3f2f836e,Rizvi NA,0.470388
uuid-11a8e1a136744042ae1582ce3f2f836e,Brahmer J,0.676477
uuid-11a8e1a136744042ae1582ce3f2f836e,PD-L1,0.354847
uuid-11a8e1a136744042ae1582ce3f2f836e,Horn L,0.512976
uuid-11a8e1a136744042ae1582ce3f2f836e,platinum-based doublet chemotherapy,0.312066
uuid-57edccfde855450d88e3c39470fd6507,patients,0.532757
uuid-d4c0aeb46e794b20a8079ad768a0d808,BMS,0.512521
uuid-70e3b2c7937048e1bcc970f7caf078a6,patients with advanced or metastatic,0.468858
uuid-70e3b2c7937048e1bcc970f7caf078a6,nivolumab combined with ipilimumab,0.446918
uuid-70e3b2c7937048e1bcc970f7caf078a6,not approved,0.352562
uuid-70e3b2c7937048e1bcc970f7caf078a6,clinical trials investigating the safety,0.429501
uuid-70e3b2c7937048e1bcc970f7caf078a6,bladder cancer,0.950698
uuid-07056358e899450eb790785e54cdaf6c,patients with advanced or metastatic,0.478326
uuid-07056358e899450eb790785e54cdaf6c,nivolumab combined with ipilimumab,0.498766
uuid-07056358e899450eb790785e54cdaf6c,not approved,0.34724
uuid-07056358e899450eb790785e54cdaf6c,clinical trials investigating the safety,0.426729
uuid-07056358e899450eb790785e54cdaf6c,bladder cancer,0.6548
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,OS,0.413056
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,AEs,0.33704
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,95% CI,0.514272
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,respectively,0.628627
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,Objective response rate,0.58922
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,ORR,0.695972
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,Median overall survival,0.57829
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,monotherapy,0.365337
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,Median OS,0.535408
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,grade,0.329816
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,hazard ratio,0.509882
uuid-c2b69c7a5f5d4032b3ee7e056a7d4e70,grade 3 to 4 AEs,0.32235
uuid-6982162d084140a98c3d1fb0351eb6ba,respectively,0.629961
uuid-6982162d084140a98c3d1fb0351eb6ba,Objective response rate,0.439951
uuid-6982162d084140a98c3d1fb0351eb6ba,ORR,0.462322
uuid-6982162d084140a98c3d1fb0351eb6ba,monotherapy,0.352421
uuid-6982162d084140a98c3d1fb0351eb6ba,docetaxel,0.410479
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,Bristol-Myers Squibb,0.341822
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,not conducted any controlled clinical trials/studies,0.304507
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,Opdivo,0.461382
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,Pubmed literature search,0.614325
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,not identify any citations relevant to your inquiry,0.606087
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,adverse,0.304183
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,using the following search terms,0.642331
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,databases,0.315039
uuid-3b62aa6f352f48c38f6937c3aa5a14c6,reported,0.556704
uuid-69a5a1322d644cbc9116a53f45919ed2,N Engl J Med,0.456474
uuid-69a5a1322d644cbc9116a53f45919ed2,Lancet Oncol,0.357873
uuid-69a5a1322d644cbc9116a53f45919ed2,protocol,0.480893
uuid-69a5a1322d644cbc9116a53f45919ed2,McDermott DF,0.51746
uuid-69a5a1322d644cbc9116a53f45919ed2,search of published literature,0.343051
uuid-69a5a1322d644cbc9116a53f45919ed2,Motzer RJ,0.516788
uuid-69a5a1322d644cbc9116a53f45919ed2,phase 3 study,0.754973
uuid-69a5a1322d644cbc9116a53f45919ed2,PubMed and EMBASE,0.340792
uuid-69a5a1322d644cbc9116a53f45919ed2,Escudier B,0.532534
uuid-69a5a1322d644cbc9116a53f45919ed2,et al.,0.496867
uuid-69a5a1322d644cbc9116a53f45919ed2,J Clin Oncol,0.430616
uuid-69a5a1322d644cbc9116a53f45919ed2,Rizvi NA,0.473891
uuid-69a5a1322d644cbc9116a53f45919ed2,Weber JS,0.580854
uuid-69a5a1322d644cbc9116a53f45919ed2,phase 2 study,0.6143
uuid-4569d07503674634b30aec15f45f7eea,N Engl J Med,0.351352
uuid-4569d07503674634b30aec15f45f7eea,protocol,0.442543
uuid-4569d07503674634b30aec15f45f7eea,McDermott DF,0.464243
uuid-4569d07503674634b30aec15f45f7eea,Motzer RJ,0.440444
uuid-4569d07503674634b30aec15f45f7eea,phase 3 study,0.445054
uuid-4569d07503674634b30aec15f45f7eea,Escudier B,0.45704
uuid-4569d07503674634b30aec15f45f7eea,NEJM,0.30008
uuid-4569d07503674634b30aec15f45f7eea,et al.,0.431407
uuid-4569d07503674634b30aec15f45f7eea,J Clin Oncol,0.419805
uuid-4569d07503674634b30aec15f45f7eea,Rizvi NA,0.372481
uuid-4569d07503674634b30aec15f45f7eea,Weber JS,0.310738
uuid-4569d07503674634b30aec15f45f7eea,phase 2 study,0.478771
uuid-b249adad1c624d0fadb23bd4bedfc718,requested,0.706913
uuid-21be0651ebad483ea9b4fc4b6edc2d23,Objective response rate,0.451139
uuid-21be0651ebad483ea9b4fc4b6edc2d23,clinicaltrials.gov,0.503706
uuid-c8903416c8264f0eb27a87cb5128eec1,respectively,0.629961
uuid-c8903416c8264f0eb27a87cb5128eec1,Objective response rate,0.439951
uuid-c8903416c8264f0eb27a87cb5128eec1,ORR,0.462322
uuid-c8903416c8264f0eb27a87cb5128eec1,monotherapy,0.352421
uuid-c8903416c8264f0eb27a87cb5128eec1,docetaxel,0.410479
uuid-a23864abc101491abe746c1529c63c55,OS,0.62262
uuid-a23864abc101491abe746c1529c63c55,PFS,0.65903
uuid-a23864abc101491abe746c1529c63c55,Overall survival,0.644151
uuid-d6d4d20cec8048679e2127d6a18d42db,ipilimumab,0.385692
uuid-d6d4d20cec8048679e2127d6a18d42db,ASCO 2015,0.417944
uuid-d6d4d20cec8048679e2127d6a18d42db,partial response,0.382425
uuid-d6d4d20cec8048679e2127d6a18d42db,Stable disease,0.586335
uuid-d6d4d20cec8048679e2127d6a18d42db,cohort,0.307748
uuid-77c12ade5cbc4bd7a30d1bc28f8f01da,patients,0.515686
uuid-77c12ade5cbc4bd7a30d1bc28f8f01da,clinical,0.47163
uuid-77c12ade5cbc4bd7a30d1bc28f8f01da,trial,0.635448
uuid-93d45d0680af4d339f2fd8d240759dea,use of nivolumab for the treatment,0.444892
uuid-93d45d0680af4d339f2fd8d240759dea,evaluating,0.30558
uuid-93d45d0680af4d339f2fd8d240759dea,patients,0.440855
uuid-93d45d0680af4d339f2fd8d240759dea,not approved,0.378002
uuid-93d45d0680af4d339f2fd8d240759dea,clinical trials investigating the safety,0.352423
uuid-aa563d71adee4061885a17eaa020dca8,trial,0.405524
uuid-7dc3c8e03c7e48029c1eb69b98651884,ipilimumab,0.385692
uuid-7dc3c8e03c7e48029c1eb69b98651884,ASCO 2015,0.417944
uuid-7dc3c8e03c7e48029c1eb69b98651884,partial response,0.382425
uuid-7dc3c8e03c7e48029c1eb69b98651884,Stable disease,0.586335
uuid-7dc3c8e03c7e48029c1eb69b98651884,cohort,0.307748
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,ASCO,0.561054
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,Objective response rate,0.448379
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,ORR,0.336123
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,ASCO 2015,0.432217
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,phase 1 study,0.353293
uuid-a41ce12a6a8a4f289d35ffaf81cebef1,Antonia SJ,0.340846
uuid-d4acbfe5a5fb489a8471ef535a6119a0,OS,0.62262
uuid-d4acbfe5a5fb489a8471ef535a6119a0,PFS,0.65903
uuid-d4acbfe5a5fb489a8471ef535a6119a0,Overall survival,0.644151
uuid-318a6ebe18da429fb97cb5c1182a9c0c,OS,0.387982
uuid-318a6ebe18da429fb97cb5c1182a9c0c,95% CI,0.745043
uuid-318a6ebe18da429fb97cb5c1182a9c0c,respectively,0.729294
uuid-318a6ebe18da429fb97cb5c1182a9c0c,Objective response rate,0.590876
uuid-318a6ebe18da429fb97cb5c1182a9c0c,ORR,0.722442
uuid-318a6ebe18da429fb97cb5c1182a9c0c,Median overall survival,0.659043
uuid-318a6ebe18da429fb97cb5c1182a9c0c,monotherapy,0.514468
uuid-318a6ebe18da429fb97cb5c1182a9c0c,Median OS,0.696688
uuid-318a6ebe18da429fb97cb5c1182a9c0c,PD-L1,0.300997
uuid-318a6ebe18da429fb97cb5c1182a9c0c,docetaxel,0.635065
uuid-318a6ebe18da429fb97cb5c1182a9c0c,hazard ratio,0.729977
uuid-03e7b5f6a2c24f9a91325da1b3181cdf,AEs,0.687473
uuid-03e7b5f6a2c24f9a91325da1b3181cdf,patients,0.307118
uuid-03e7b5f6a2c24f9a91325da1b3181cdf,grade,0.735469
uuid-03e7b5f6a2c24f9a91325da1b3181cdf,grade 3 to 4 AEs,0.66921
uuid-202d573b473842958013cc0946f3663e,use of nivolumab for the treatment,0.440423
uuid-202d573b473842958013cc0946f3663e,search of published literature,0.311531
uuid-202d573b473842958013cc0946f3663e,PubMed and EMBASE,0.312811
uuid-202d573b473842958013cc0946f3663e,not approved,0.404782
uuid-202d573b473842958013cc0946f3663e,open-label,0.578291
uuid-202d573b473842958013cc0946f3663e,clinical trials investigating the safety,0.440014
uuid-202d573b473842958013cc0946f3663e,present using the following search terms,0.328669
uuid-202d573b473842958013cc0946f3663e,phase,0.41185
uuid-ca9aec1b91514955b1d9e72d12c5d159,Bristol-Myers Squibb,0.341822
uuid-ca9aec1b91514955b1d9e72d12c5d159,not conducted any controlled clinical trials/studies,0.304507
uuid-ca9aec1b91514955b1d9e72d12c5d159,Opdivo,0.461382
uuid-ca9aec1b91514955b1d9e72d12c5d159,Pubmed literature search,0.614325
uuid-ca9aec1b91514955b1d9e72d12c5d159,purposes other than its labeled indication must be considered investigational,0.586645
uuid-ca9aec1b91514955b1d9e72d12c5d159,not identify any citations relevant to your inquiry,0.606087
uuid-ca9aec1b91514955b1d9e72d12c5d159,adverse,0.304183
uuid-ca9aec1b91514955b1d9e72d12c5d159,using the following search terms,0.642331
uuid-ca9aec1b91514955b1d9e72d12c5d159,databases,0.315039
uuid-ca9aec1b91514955b1d9e72d12c5d159,reported,0.556704
uuid-68a5da7275d049018c4f26b2e4f8a829,nivolumab,0.324658
uuid-68a5da7275d049018c4f26b2e4f8a829,use of nivolumab for the treatment,0.543355
uuid-68a5da7275d049018c4f26b2e4f8a829,evaluating,0.348676
uuid-68a5da7275d049018c4f26b2e4f8a829,efficacy,0.388907
uuid-68a5da7275d049018c4f26b2e4f8a829,patients,0.419915
uuid-68a5da7275d049018c4f26b2e4f8a829,search of published literature,0.449959
uuid-68a5da7275d049018c4f26b2e4f8a829,PubMed and EMBASE,0.444573
uuid-68a5da7275d049018c4f26b2e4f8a829,not approved,0.582429
uuid-68a5da7275d049018c4f26b2e4f8a829,clinical trials investigating the safety,0.64854
uuid-68a5da7275d049018c4f26b2e4f8a829,efficacy and safety of nivolumab,0.399101
uuid-68a5da7275d049018c4f26b2e4f8a829,present using the following search terms,0.465296
uuid-bc179d09ef874bff90aa7b08de3aba6c,N Engl J Med,0.423951
uuid-bc179d09ef874bff90aa7b08de3aba6c,protocol,0.749572
uuid-bc179d09ef874bff90aa7b08de3aba6c,McDermott DF,0.716225
uuid-bc179d09ef874bff90aa7b08de3aba6c,search of published literature,0.321041
uuid-bc179d09ef874bff90aa7b08de3aba6c,Motzer RJ,0.794997
uuid-bc179d09ef874bff90aa7b08de3aba6c,phase 3 study,0.415285
uuid-bc179d09ef874bff90aa7b08de3aba6c,PubMed and EMBASE,0.316564
uuid-bc179d09ef874bff90aa7b08de3aba6c,Escudier B,0.72567
uuid-bc179d09ef874bff90aa7b08de3aba6c,NEJM,0.383413
uuid-bc179d09ef874bff90aa7b08de3aba6c,et al.,0.64236
uuid-bc179d09ef874bff90aa7b08de3aba6c,J Clin Oncol,0.766474
uuid-bc179d09ef874bff90aa7b08de3aba6c,Topalian,0.375453
uuid-bc179d09ef874bff90aa7b08de3aba6c,phase 1 study,0.506307
uuid-bc179d09ef874bff90aa7b08de3aba6c,efficacy and safety of nivolumab,0.347608
uuid-bc179d09ef874bff90aa7b08de3aba6c,CA209-003,0.564805
uuid-bc179d09ef874bff90aa7b08de3aba6c,phase 2 study,0.656124
uuid-bc179d09ef874bff90aa7b08de3aba6c,present using the following search terms,0.331505
uuid-bc179d09ef874bff90aa7b08de3aba6c,investigating,0.616131
uuid-58edcae33ae84ecf8929cd3c0091179d,provided in the Detailed Information,0.37195
uuid-8b34bfb023c34e788076339c5ef940f6,N Engl J Med,0.636726
uuid-8b34bfb023c34e788076339c5ef940f6,non-small cell lung cancer,0.351489
uuid-8b34bfb023c34e788076339c5ef940f6,ESMO,0.419331
uuid-8b34bfb023c34e788076339c5ef940f6,Rizvi NA,0.470388
uuid-8b34bfb023c34e788076339c5ef940f6,Brahmer J,0.676477
uuid-8b34bfb023c34e788076339c5ef940f6,PD-L1,0.354847
uuid-8b34bfb023c34e788076339c5ef940f6,Horn L,0.512976
uuid-8b34bfb023c34e788076339c5ef940f6,platinum-based doublet chemotherapy,0.312066
uuid-a3b8b411790347ae8c3b1c1c89180ab4,NSCLC,0.480337
uuid-a3b8b411790347ae8c3b1c1c89180ab4,respectively,0.400584
uuid-a3b8b411790347ae8c3b1c1c89180ab4,non-small cell lung cancer,0.395662
uuid-a3b8b411790347ae8c3b1c1c89180ab4,patients,0.382838
uuid-a3b8b411790347ae8c3b1c1c89180ab4,considered investigational,0.378457
uuid-a3b8b411790347ae8c3b1c1c89180ab4,Objective response rate,0.446233
uuid-a3b8b411790347ae8c3b1c1c89180ab4,ORR,0.488323
uuid-a3b8b411790347ae8c3b1c1c89180ab4,monotherapy,0.419452
uuid-a3b8b411790347ae8c3b1c1c89180ab4,small cell lung cancer,0.328277
uuid-a3b8b411790347ae8c3b1c1c89180ab4,docetaxel,0.370754
uuid-a3b8b411790347ae8c3b1c1c89180ab4,SCLC,0.328412
uuid-a3b8b411790347ae8c3b1c1c89180ab4,grade 3 to 4 AEs,0.337672
uuid-a3b8b411790347ae8c3b1c1c89180ab4,platinum-based doublet chemotherapy,0.355492
uuid-6c8f296035b74458824f68076b529013,patients with advanced or metastatic,0.468858
uuid-6c8f296035b74458824f68076b529013,nivolumab combined with ipilimumab,0.446918
uuid-6c8f296035b74458824f68076b529013,not approved,0.352562
uuid-6c8f296035b74458824f68076b529013,clinical trials investigating the safety,0.429501
uuid-6c8f296035b74458824f68076b529013,bladder cancer,0.950698
uuid-b7a30cb492eb4f46a0ab699578d5b368,ASCO,0.64795
uuid-b7a30cb492eb4f46a0ab699578d5b368,Antonia SJ,0.334859
uuid-5c39eabab01c417e8e30baa43205031a,N Engl J Med,0.689907
uuid-5c39eabab01c417e8e30baa43205031a,Lancet Oncol,0.584216
uuid-5c39eabab01c417e8e30baa43205031a,protocol,0.72528
uuid-5c39eabab01c417e8e30baa43205031a,McDermott DF,0.794444
uuid-5c39eabab01c417e8e30baa43205031a,Motzer RJ,0.755383
uuid-5c39eabab01c417e8e30baa43205031a,phase 3 study,0.521307
uuid-5c39eabab01c417e8e30baa43205031a,Escudier B,0.794743
uuid-5c39eabab01c417e8e30baa43205031a,NEJM,0.434762
uuid-5c39eabab01c417e8e30baa43205031a,et al.,0.777092
uuid-5c39eabab01c417e8e30baa43205031a,J Clin Oncol,0.708338
uuid-5c39eabab01c417e8e30baa43205031a,Topalian,0.401719
uuid-5c39eabab01c417e8e30baa43205031a,Rizvi NA,0.731383
uuid-5c39eabab01c417e8e30baa43205031a,Brahmer J,0.378658
uuid-5c39eabab01c417e8e30baa43205031a,Weber JS,0.614831
uuid-5c39eabab01c417e8e30baa43205031a,phase 2 study,0.769458
uuid-b1c672eb0290439b80f2eb2ceb25865c,OS,0.387982
uuid-b1c672eb0290439b80f2eb2ceb25865c,95% CI,0.745043
uuid-b1c672eb0290439b80f2eb2ceb25865c,respectively,0.729294
uuid-b1c672eb0290439b80f2eb2ceb25865c,Objective response rate,0.590876
uuid-b1c672eb0290439b80f2eb2ceb25865c,ORR,0.722442
uuid-b1c672eb0290439b80f2eb2ceb25865c,Median overall survival,0.659043
uuid-b1c672eb0290439b80f2eb2ceb25865c,monotherapy,0.514468
uuid-b1c672eb0290439b80f2eb2ceb25865c,Median OS,0.696688
uuid-b1c672eb0290439b80f2eb2ceb25865c,PD-L1,0.300997
uuid-b1c672eb0290439b80f2eb2ceb25865c,docetaxel,0.635065
uuid-b1c672eb0290439b80f2eb2ceb25865c,hazard ratio,0.729977
uuid-3493bc2f0e4b4141b4bddc55f811f19c,requested,0.44769
uuid-3493bc2f0e4b4141b4bddc55f811f19c,trial,0.309472
uuid-ee28149b3e3643a5943153f3330bcb93,nivolumab,0.562637
uuid-ee28149b3e3643a5943153f3330bcb93,Bristol-Myers Squibb,0.432796
uuid-ee28149b3e3643a5943153f3330bcb93,evaluating,0.582438
uuid-ee28149b3e3643a5943153f3330bcb93,not conducted any controlled clinical trials/studies,0.645175
uuid-ee28149b3e3643a5943153f3330bcb93,Pubmed literature search,0.882004
uuid-ee28149b3e3643a5943153f3330bcb93,purposes other than its labeled indication must be considered investigational,0.942401
uuid-ee28149b3e3643a5943153f3330bcb93,not identify any citations relevant to your inquiry,0.842073
uuid-ee28149b3e3643a5943153f3330bcb93,using the following search terms,0.829823
uuid-ee28149b3e3643a5943153f3330bcb93,efficacy and safety of nivolumab,0.419952
uuid-73c6014926a74a999f2c8053f1849949,patients with advanced or metastatic,0.468858
uuid-73c6014926a74a999f2c8053f1849949,nivolumab combined with ipilimumab,0.446918
uuid-73c6014926a74a999f2c8053f1849949,not approved,0.352562
uuid-73c6014926a74a999f2c8053f1849949,clinical trials investigating the safety,0.429501
uuid-73c6014926a74a999f2c8053f1849949,bladder cancer,0.950698
uuid-818d8509224a4b84a7a3ad6c63136a90,requested,0.594234
uuid-5ccfd604d225413d8357894fb88dad44,Bristol-Myers Squibb,0.341822
uuid-5ccfd604d225413d8357894fb88dad44,not conducted any controlled clinical trials/studies,0.304507
uuid-5ccfd604d225413d8357894fb88dad44,Opdivo,0.461382
uuid-5ccfd604d225413d8357894fb88dad44,Pubmed literature search,0.614325
uuid-5ccfd604d225413d8357894fb88dad44,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5ccfd604d225413d8357894fb88dad44,not identify any citations relevant to your inquiry,0.606087
uuid-5ccfd604d225413d8357894fb88dad44,adverse,0.304183
uuid-5ccfd604d225413d8357894fb88dad44,using the following search terms,0.642331
uuid-5ccfd604d225413d8357894fb88dad44,databases,0.315039
uuid-5ccfd604d225413d8357894fb88dad44,reported,0.556704
uuid-62571f18cdc64b02896e0d90ee84201c,nivolumab,0.565095
uuid-62571f18cdc64b02896e0d90ee84201c,Bristol-Myers Squibb,0.457248
uuid-62571f18cdc64b02896e0d90ee84201c,evaluating,0.670258
uuid-62571f18cdc64b02896e0d90ee84201c,not conducted any controlled clinical trials/studies,0.698186
uuid-62571f18cdc64b02896e0d90ee84201c,Pubmed literature search,0.736158
uuid-62571f18cdc64b02896e0d90ee84201c,purposes other than its labeled indication must be considered investigational,0.810161
uuid-62571f18cdc64b02896e0d90ee84201c,not identify any citations relevant to your inquiry,0.712096
uuid-62571f18cdc64b02896e0d90ee84201c,search of published literature,0.342442
uuid-62571f18cdc64b02896e0d90ee84201c,Additionally,0.321852
uuid-62571f18cdc64b02896e0d90ee84201c,PubMed and EMBASE,0.319052
uuid-62571f18cdc64b02896e0d90ee84201c,using the following search terms,0.681978
uuid-62571f18cdc64b02896e0d90ee84201c,detailed search of www.clinicaltrials.gov,0.327991
uuid-62571f18cdc64b02896e0d90ee84201c,efficacy and safety of nivolumab,0.563965
uuid-62571f18cdc64b02896e0d90ee84201c,not identify any planned,0.305857
uuid-62571f18cdc64b02896e0d90ee84201c,not identify any citations relevant to your request,0.362042
uuid-62571f18cdc64b02896e0d90ee84201c,present using the following search terms,0.348374
uuid-fd370d7e34404d7db70b66148130cb79,adverse,0.828227
uuid-fd370d7e34404d7db70b66148130cb79,grade,0.320896
uuid-fd370d7e34404d7db70b66148130cb79,reported,0.496565
uuid-8c158b01e01e48b98f6c2d70443e93c2,provided in the Detailed Information,0.467189
uuid-8c158b01e01e48b98f6c2d70443e93c2,Overall survival,0.383808
uuid-3eee37e6b5824545be1b9bbab0107cd1,trial,0.308003
uuid-0f261903c5c8404c88737be19ab28686,OS,0.387982
uuid-0f261903c5c8404c88737be19ab28686,95% CI,0.745043
uuid-0f261903c5c8404c88737be19ab28686,respectively,0.729294
uuid-0f261903c5c8404c88737be19ab28686,Objective response rate,0.590876
uuid-0f261903c5c8404c88737be19ab28686,ORR,0.722442
uuid-0f261903c5c8404c88737be19ab28686,Median overall survival,0.659043
uuid-0f261903c5c8404c88737be19ab28686,monotherapy,0.514468
uuid-0f261903c5c8404c88737be19ab28686,Median OS,0.696688
uuid-0f261903c5c8404c88737be19ab28686,PD-L1,0.300997
uuid-0f261903c5c8404c88737be19ab28686,docetaxel,0.635065
uuid-0f261903c5c8404c88737be19ab28686,hazard ratio,0.729977
uuid-94a36e091ade4ff59bf05ff927cb1803,search of published literature,0.335599
uuid-94a36e091ade4ff59bf05ff927cb1803,Additionally,0.357566
uuid-94a36e091ade4ff59bf05ff927cb1803,PubMed and EMBASE,0.34306
uuid-94a36e091ade4ff59bf05ff927cb1803,detailed search of www.clinicaltrials.gov,0.313212
uuid-94a36e091ade4ff59bf05ff927cb1803,not identify any citations relevant to your request,0.407277
uuid-94a36e091ade4ff59bf05ff927cb1803,present using the following search terms,0.368991
uuid-d54fb24dbaa04ff0912959ce20ab7b70,nivolumab,0.338245
uuid-d54fb24dbaa04ff0912959ce20ab7b70,Bristol-Myers Squibb,0.360358
uuid-d54fb24dbaa04ff0912959ce20ab7b70,evaluating,0.355364
uuid-d54fb24dbaa04ff0912959ce20ab7b70,N Engl J Med,0.313217
uuid-d54fb24dbaa04ff0912959ce20ab7b70,not conducted any controlled clinical trials/studies,0.420822
uuid-d54fb24dbaa04ff0912959ce20ab7b70,Pubmed literature search,0.431184
uuid-d54fb24dbaa04ff0912959ce20ab7b70,purposes other than its labeled indication must be considered investigational,0.475907
uuid-d54fb24dbaa04ff0912959ce20ab7b70,protocol,0.498316
uuid-d54fb24dbaa04ff0912959ce20ab7b70,not identify any citations relevant to your inquiry,0.399632
uuid-d54fb24dbaa04ff0912959ce20ab7b70,McDermott DF,0.548425
uuid-d54fb24dbaa04ff0912959ce20ab7b70,Motzer RJ,0.543554
uuid-d54fb24dbaa04ff0912959ce20ab7b70,clinical,0.325774
uuid-d54fb24dbaa04ff0912959ce20ab7b70,phase 3 study,0.344725
uuid-d54fb24dbaa04ff0912959ce20ab7b70,Escudier B,0.544714
uuid-d54fb24dbaa04ff0912959ce20ab7b70,et al.,0.503865
uuid-d54fb24dbaa04ff0912959ce20ab7b70,J Clin Oncol,0.529436
uuid-d54fb24dbaa04ff0912959ce20ab7b70,using the following search terms,0.394859
uuid-d54fb24dbaa04ff0912959ce20ab7b70,efficacy and safety of nivolumab,0.34123
uuid-d54fb24dbaa04ff0912959ce20ab7b70,phase 2 study,0.49181
uuid-2e4226ca103546dbb7e65966bbdd965c,nivolumab,0.344939
uuid-2e4226ca103546dbb7e65966bbdd965c,Bristol-Myers Squibb,0.363004
uuid-2e4226ca103546dbb7e65966bbdd965c,evaluating,0.564404
uuid-2e4226ca103546dbb7e65966bbdd965c,not conducted any controlled clinical trials/studies,0.538169
uuid-2e4226ca103546dbb7e65966bbdd965c,RCC,0.336118
uuid-2e4226ca103546dbb7e65966bbdd965c,search of published literature,0.750115
uuid-2e4226ca103546dbb7e65966bbdd965c,Additionally,0.766378
uuid-2e4226ca103546dbb7e65966bbdd965c,ongoing,0.629393
uuid-2e4226ca103546dbb7e65966bbdd965c,PubMed and EMBASE,0.745288
uuid-2e4226ca103546dbb7e65966bbdd965c,detailed search of www.clinicaltrials.gov,0.729251
uuid-2e4226ca103546dbb7e65966bbdd965c,efficacy and safety of nivolumab,0.716075
uuid-2e4226ca103546dbb7e65966bbdd965c,not identify any planned,0.665705
uuid-2e4226ca103546dbb7e65966bbdd965c,not identify any citations relevant to your request,0.849476
uuid-2e4226ca103546dbb7e65966bbdd965c,present using the following search terms,0.773092
uuid-7f8bea5fbc9140deb097d351605afbaf,provided in the Detailed Information,0.398621
uuid-7f8bea5fbc9140deb097d351605afbaf,Weber JS,0.399971
uuid-2cd008bd15fd4fc79d20f3ed3bb8b415,clinical,0.415708
uuid-2cd008bd15fd4fc79d20f3ed3bb8b415,trial,0.402448
uuid-f336ef2364bd48489f7b39aa207a8f16,95% CI,0.321852
uuid-f336ef2364bd48489f7b39aa207a8f16,NSCLC,0.328803
uuid-f336ef2364bd48489f7b39aa207a8f16,Objective response rate,0.474943
uuid-f336ef2364bd48489f7b39aa207a8f16,ORR,0.483999
uuid-f336ef2364bd48489f7b39aa207a8f16,Median overall survival,0.3799
uuid-f336ef2364bd48489f7b39aa207a8f16,hazard ratio,0.325692
uuid-bef53f4965e4448f9f8cac9d00540d25,patients with advanced or metastatic,0.478326
uuid-bef53f4965e4448f9f8cac9d00540d25,nivolumab combined with ipilimumab,0.498766
uuid-bef53f4965e4448f9f8cac9d00540d25,not approved,0.34724
uuid-bef53f4965e4448f9f8cac9d00540d25,clinical trials investigating the safety,0.426729
uuid-bef53f4965e4448f9f8cac9d00540d25,bladder cancer,0.6548
uuid-c13ca03004af412e953cfa801a48a8d5,Opdivo,0.659473
uuid-c13ca03004af412e953cfa801a48a8d5,trial,0.505829
uuid-b977a157dd5f4076979518f10639b132,Objective response rate,0.427051
uuid-b977a157dd5f4076979518f10639b132,clinicaltrials.gov,0.524603
uuid-b977a157dd5f4076979518f10639b132,relapsed,0.306689
uuid-38832352ab364ab48553411cf0116801,OS,0.387982
uuid-38832352ab364ab48553411cf0116801,95% CI,0.745043
uuid-38832352ab364ab48553411cf0116801,respectively,0.729294
uuid-38832352ab364ab48553411cf0116801,Objective response rate,0.590876
uuid-38832352ab364ab48553411cf0116801,ORR,0.722442
uuid-38832352ab364ab48553411cf0116801,Median overall survival,0.659043
uuid-38832352ab364ab48553411cf0116801,monotherapy,0.514468
uuid-38832352ab364ab48553411cf0116801,Median OS,0.696688
uuid-38832352ab364ab48553411cf0116801,PD-L1,0.300997
uuid-38832352ab364ab48553411cf0116801,docetaxel,0.635065
uuid-38832352ab364ab48553411cf0116801,hazard ratio,0.729977
uuid-d4bc51d97b624fb4867a7734308b00db,95% CI,0.524855
uuid-d4bc51d97b624fb4867a7734308b00db,respectively,0.383655
uuid-d4bc51d97b624fb4867a7734308b00db,ASCO,0.303153
uuid-d4bc51d97b624fb4867a7734308b00db,Lancet Oncol,0.368041
uuid-d4bc51d97b624fb4867a7734308b00db,Objective response rate,0.504846
uuid-d4bc51d97b624fb4867a7734308b00db,ORR,0.465366
uuid-d4bc51d97b624fb4867a7734308b00db,Median overall survival,0.346516
uuid-d4bc51d97b624fb4867a7734308b00db,Median OS,0.33538
uuid-d4bc51d97b624fb4867a7734308b00db,ASCO 2015,0.336983
uuid-d4bc51d97b624fb4867a7734308b00db,small cell lung cancer,0.336892
uuid-d4bc51d97b624fb4867a7734308b00db,SCLC,0.344367
uuid-d4bc51d97b624fb4867a7734308b00db,Antonia SJ,0.55269
uuid-d4bc51d97b624fb4867a7734308b00db,Median duration of response,0.649605
uuid-a3e6b3e6f2fd49928aaf1fd7ec3ab4db,ASCO,0.701894
uuid-a3e6b3e6f2fd49928aaf1fd7ec3ab4db,Antonia SJ,0.317017
uuid-48a36c2d63f24c6e859b2d1e2cd73426,95% CI,0.524855
uuid-48a36c2d63f24c6e859b2d1e2cd73426,respectively,0.383655
uuid-48a36c2d63f24c6e859b2d1e2cd73426,ASCO,0.303153
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Lancet Oncol,0.368041
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Objective response rate,0.504846
uuid-48a36c2d63f24c6e859b2d1e2cd73426,ORR,0.465366
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Median overall survival,0.346516
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Median OS,0.33538
uuid-48a36c2d63f24c6e859b2d1e2cd73426,ASCO 2015,0.336983
uuid-48a36c2d63f24c6e859b2d1e2cd73426,small cell lung cancer,0.336892
uuid-48a36c2d63f24c6e859b2d1e2cd73426,SCLC,0.344367
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Antonia SJ,0.55269
uuid-48a36c2d63f24c6e859b2d1e2cd73426,Median duration of response,0.649605
uuid-fec418c9b0034b60b0660e8f5eae2691,ASCO,0.807066
uuid-a2e3a67d0c5541d4b57d15b38e0af5cd,Opdivo,0.577591
uuid-a2e3a67d0c5541d4b57d15b38e0af5cd,trial,0.460851
uuid-c8877eee321e441ca87ca5094a74ef27,patients,0.306439
uuid-c8877eee321e441ca87ca5094a74ef27,trial,0.472373
uuid-da67732abee648e2803444c7d14eb42f,McDermott DF,0.308113
uuid-da67732abee648e2803444c7d14eb42f,phase 3 study,0.337558
uuid-da67732abee648e2803444c7d14eb42f,et al.,0.322351
uuid-da67732abee648e2803444c7d14eb42f,phase 2 study,0.377413
uuid-a7126933f6934951864ec9515a98b581,95% CI,0.520262
uuid-a7126933f6934951864ec9515a98b581,respectively,0.504068
uuid-a7126933f6934951864ec9515a98b581,Objective response rate,0.458568
uuid-a7126933f6934951864ec9515a98b581,ORR,0.525868
uuid-a7126933f6934951864ec9515a98b581,Median overall survival,0.455633
uuid-a7126933f6934951864ec9515a98b581,Median OS,0.507448
uuid-a7126933f6934951864ec9515a98b581,docetaxel,0.383115
uuid-a7126933f6934951864ec9515a98b581,hazard ratio,0.462119
uuid-68dcc83f3826457991fd28491ac00e97,requested,0.594234
uuid-9910bfc7630f4a14a94b468cfa361659,Bristol-Myers Squibb,0.840451
uuid-9910bfc7630f4a14a94b468cfa361659,evaluating,0.718784
uuid-9910bfc7630f4a14a94b468cfa361659,not conducted any controlled clinical trials/studies,0.798502
uuid-9910bfc7630f4a14a94b468cfa361659,adverse,0.316881
uuid-9910bfc7630f4a14a94b468cfa361659,efficacy and safety of nivolumab,0.640661
uuid-9910bfc7630f4a14a94b468cfa361659,reported,0.342563
uuid-21947624b581481587800d39b9247631,nivolumab,0.359772
uuid-12b8d8f937cc49a2a56c674e88094095,OS,0.49041
uuid-12b8d8f937cc49a2a56c674e88094095,95% CI,0.825429
uuid-12b8d8f937cc49a2a56c674e88094095,respectively,0.492272
uuid-12b8d8f937cc49a2a56c674e88094095,Objective response rate,0.698008
uuid-12b8d8f937cc49a2a56c674e88094095,ORR,0.785548
uuid-12b8d8f937cc49a2a56c674e88094095,PFS,0.376104
uuid-12b8d8f937cc49a2a56c674e88094095,Median overall survival,0.753164
uuid-12b8d8f937cc49a2a56c674e88094095,monotherapy,0.490929
uuid-12b8d8f937cc49a2a56c674e88094095,Median OS,0.727975
uuid-12b8d8f937cc49a2a56c674e88094095,docetaxel,0.325576
uuid-12b8d8f937cc49a2a56c674e88094095,hazard ratio,0.809456
uuid-6da930b0b7634fe2a704a7802bf68b54,respectively,0.636563
uuid-6da930b0b7634fe2a704a7802bf68b54,ASCO,0.333124
uuid-6da930b0b7634fe2a704a7802bf68b54,Objective response rate,0.555798
uuid-6da930b0b7634fe2a704a7802bf68b54,ORR,0.594251
uuid-6da930b0b7634fe2a704a7802bf68b54,monotherapy,0.526508
uuid-6da930b0b7634fe2a704a7802bf68b54,docetaxel,0.505938
uuid-6da930b0b7634fe2a704a7802bf68b54,Antonia SJ,0.332377
uuid-a96dc7bc157648d4a4f4394eba9939cc,melanoma,0.410364
uuid-9e0cfa26171842918e3764e7758f82f0,ASCO,0.807067
uuid-20b5b04e73aa484295e21c0cfac7324e,requested,0.999444
uuid-20b5b04e73aa484295e21c0cfac7324e,Horn L,0.43038
uuid-20b5b04e73aa484295e21c0cfac7324e,platinum-based doublet chemotherapy,0.393038
uuid-b7e2c6b91c2d4ac3b6afc05d796cdd83,OS,0.62262
uuid-b7e2c6b91c2d4ac3b6afc05d796cdd83,PFS,0.65903
uuid-b7e2c6b91c2d4ac3b6afc05d796cdd83,Overall survival,0.644151
uuid-8e96eb6bb3524ef1b81770519d01eac6,OS,0.393056
uuid-8e96eb6bb3524ef1b81770519d01eac6,95% CI,0.603431
uuid-8e96eb6bb3524ef1b81770519d01eac6,ORR,0.332822
uuid-8e96eb6bb3524ef1b81770519d01eac6,PFS,0.358738
uuid-8e96eb6bb3524ef1b81770519d01eac6,Median overall survival,0.583106
uuid-8e96eb6bb3524ef1b81770519d01eac6,Median OS,0.55622
uuid-8e96eb6bb3524ef1b81770519d01eac6,hazard ratio,0.556985
uuid-8e96eb6bb3524ef1b81770519d01eac6,Median duration of response,0.423056
uuid-5b782b87fe484ac3beb06517f47b65d7,N Engl J Med,0.436802
uuid-5b782b87fe484ac3beb06517f47b65d7,protocol,0.512976
uuid-5b782b87fe484ac3beb06517f47b65d7,McDermott DF,0.538707
uuid-5b782b87fe484ac3beb06517f47b65d7,Motzer RJ,0.514371
uuid-5b782b87fe484ac3beb06517f47b65d7,phase 3 study,0.483284
uuid-5b782b87fe484ac3beb06517f47b65d7,Escudier B,0.531972
uuid-5b782b87fe484ac3beb06517f47b65d7,NEJM,0.351587
uuid-5b782b87fe484ac3beb06517f47b65d7,et al.,0.506988
uuid-5b782b87fe484ac3beb06517f47b65d7,J Clin Oncol,0.491242
uuid-5b782b87fe484ac3beb06517f47b65d7,Topalian,0.334358
uuid-5b782b87fe484ac3beb06517f47b65d7,Rizvi NA,0.443279
uuid-5b782b87fe484ac3beb06517f47b65d7,Weber JS,0.361925
uuid-5b782b87fe484ac3beb06517f47b65d7,phase 2 study,0.556414
uuid-9043df3dee254753825c7ed02103b55e,Bristol-Myers Squibb,0.341822
uuid-9043df3dee254753825c7ed02103b55e,not conducted any controlled clinical trials/studies,0.304507
uuid-9043df3dee254753825c7ed02103b55e,Opdivo,0.461382
uuid-9043df3dee254753825c7ed02103b55e,Pubmed literature search,0.614325
uuid-9043df3dee254753825c7ed02103b55e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9043df3dee254753825c7ed02103b55e,not identify any citations relevant to your inquiry,0.606087
uuid-9043df3dee254753825c7ed02103b55e,adverse,0.304183
uuid-9043df3dee254753825c7ed02103b55e,using the following search terms,0.642331
uuid-9043df3dee254753825c7ed02103b55e,databases,0.315039
uuid-9043df3dee254753825c7ed02103b55e,reported,0.556704
uuid-d41a4bc2ba624495a6015a8d8007e383,use of nivolumab for the treatment,0.378738
uuid-d41a4bc2ba624495a6015a8d8007e383,efficacy,0.316551
uuid-d41a4bc2ba624495a6015a8d8007e383,patients with advanced or metastatic,0.475531
uuid-d41a4bc2ba624495a6015a8d8007e383,nivolumab combined with ipilimumab,0.506671
uuid-d41a4bc2ba624495a6015a8d8007e383,not approved,0.435833
uuid-d41a4bc2ba624495a6015a8d8007e383,clinical trials investigating the safety,0.501984
uuid-d41a4bc2ba624495a6015a8d8007e383,bladder cancer,0.566357
uuid-badcf394a6954a99903661eb6bfa8676,OS,0.62262
uuid-badcf394a6954a99903661eb6bfa8676,PFS,0.65903
uuid-badcf394a6954a99903661eb6bfa8676,Overall survival,0.644151
uuid-7d16e6e8e2094c32baf8e9cd02892c31,nivolumab,0.324658
uuid-7d16e6e8e2094c32baf8e9cd02892c31,use of nivolumab for the treatment,0.543355
uuid-7d16e6e8e2094c32baf8e9cd02892c31,evaluating,0.348676
uuid-7d16e6e8e2094c32baf8e9cd02892c31,efficacy,0.388907
uuid-7d16e6e8e2094c32baf8e9cd02892c31,patients,0.419915
uuid-7d16e6e8e2094c32baf8e9cd02892c31,search of published literature,0.449959
uuid-7d16e6e8e2094c32baf8e9cd02892c31,PubMed and EMBASE,0.444573
uuid-7d16e6e8e2094c32baf8e9cd02892c31,not approved,0.582429
uuid-7d16e6e8e2094c32baf8e9cd02892c31,clinical trials investigating the safety,0.64854
uuid-7d16e6e8e2094c32baf8e9cd02892c31,efficacy and safety of nivolumab,0.399101
uuid-7d16e6e8e2094c32baf8e9cd02892c31,present using the following search terms,0.465296
uuid-5a0bed355a1f4ea58813153a1202c985,respectively,0.397695
uuid-a347dc49344149a0bc54b06d42000895,requested,0.38976
uuid-fbd8343654f94ec5925276562650764f,search of published literature,0.394524
uuid-fbd8343654f94ec5925276562650764f,Additionally,0.413583
uuid-fbd8343654f94ec5925276562650764f,ongoing,0.322117
uuid-fbd8343654f94ec5925276562650764f,PubMed and EMBASE,0.391671
uuid-fbd8343654f94ec5925276562650764f,detailed search of www.clinicaltrials.gov,0.375936
uuid-fbd8343654f94ec5925276562650764f,efficacy and safety of nivolumab,0.370699
uuid-fbd8343654f94ec5925276562650764f,not identify any planned,0.34283
uuid-fbd8343654f94ec5925276562650764f,Weber JS,0.319229
uuid-fbd8343654f94ec5925276562650764f,not identify any citations relevant to your request,0.447813
uuid-fbd8343654f94ec5925276562650764f,present using the following search terms,0.408199
uuid-1f80443f95514b15a9f2ca8ff311ba87,ASCO,0.807066
uuid-8b40346e835545c6b85aed12d868caae,requested,0.594234
uuid-0789859a85014cc2b1ba0a83fa828e40,requested,0.594234
uuid-f05fd4e6bc3040a1bdacc9c4ab44fed0,ASCO,0.806847
uuid-cccca8002ac54c90a1e2d980424eda28,respectively,0.573559
uuid-cccca8002ac54c90a1e2d980424eda28,Objective response rate,0.415121
uuid-cccca8002ac54c90a1e2d980424eda28,ORR,0.42099
uuid-cccca8002ac54c90a1e2d980424eda28,monotherapy,0.348931
uuid-cccca8002ac54c90a1e2d980424eda28,docetaxel,0.374592
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,95% CI,0.520262
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,respectively,0.504068
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,Objective response rate,0.458568
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,ORR,0.525868
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,Median overall survival,0.455633
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,Median OS,0.507448
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,docetaxel,0.383115
uuid-8a2dfc7b050a49828c2a22844cb1c3bc,hazard ratio,0.462119
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,nivolumab,0.567445
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,Bristol-Myers Squibb,0.439784
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,evaluating,0.594796
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,not conducted any controlled clinical trials/studies,0.656647
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,Pubmed literature search,0.878652
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,purposes other than its labeled indication must be considered investigational,0.941484
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,not identify any citations relevant to your inquiry,0.837621
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,using the following search terms,0.825277
uuid-660c32c4dcdd4441bdebdaec7cba4ac8,efficacy and safety of nivolumab,0.433238
uuid-9fd4b9e750044c8fa207466d0affab98,N Engl J Med,0.424221
uuid-9fd4b9e750044c8fa207466d0affab98,protocol,0.427549
uuid-9fd4b9e750044c8fa207466d0affab98,McDermott DF,0.44522
uuid-9fd4b9e750044c8fa207466d0affab98,Motzer RJ,0.428087
uuid-9fd4b9e750044c8fa207466d0affab98,Escudier B,0.448342
uuid-9fd4b9e750044c8fa207466d0affab98,et al.,0.453483
uuid-9fd4b9e750044c8fa207466d0affab98,J Clin Oncol,0.381958
uuid-9fd4b9e750044c8fa207466d0affab98,Rizvi NA,0.304882
uuid-9fd4b9e750044c8fa207466d0affab98,phase 2 study,0.349386
uuid-a4aec1c5418a4878b6b0cf1673352e10,nivolumab,0.472513
uuid-a4aec1c5418a4878b6b0cf1673352e10,evaluating,0.402666
uuid-a4aec1c5418a4878b6b0cf1673352e10,not conducted any controlled clinical trials/studies,0.447617
uuid-a4aec1c5418a4878b6b0cf1673352e10,Pubmed literature search,0.675506
uuid-a4aec1c5418a4878b6b0cf1673352e10,purposes other than its labeled indication must be considered investigational,0.716186
uuid-a4aec1c5418a4878b6b0cf1673352e10,not identify any citations relevant to your inquiry,0.663947
uuid-a4aec1c5418a4878b6b0cf1673352e10,using the following search terms,0.641186
uuid-a4aec1c5418a4878b6b0cf1673352e10,efficacy and safety of nivolumab,0.300997
uuid-cf3c4958fa2649858c21d2b716a180d0,requested,0.568943
uuid-cf3c4958fa2649858c21d2b716a180d0,Horn L,0.49818
uuid-cf3c4958fa2649858c21d2b716a180d0,platinum-based doublet chemotherapy,0.525283
uuid-948a6edda4b041998ccb49e8d45ce133,clinical,0.340798
uuid-948a6edda4b041998ccb49e8d45ce133,trial,0.37265
uuid-948a6edda4b041998ccb49e8d45ce133,therapy,0.300081
uuid-90105a0f70d04e2698990e634b8fd0d8,nivolumab,0.999168
uuid-90105a0f70d04e2698990e634b8fd0d8,Pubmed literature search,0.395314
uuid-90105a0f70d04e2698990e634b8fd0d8,purposes other than its labeled indication must be considered investigational,0.464236
uuid-90105a0f70d04e2698990e634b8fd0d8,not identify any citations relevant to your inquiry,0.368569
uuid-90105a0f70d04e2698990e634b8fd0d8,using the following search terms,0.364279
uuid-90105a0f70d04e2698990e634b8fd0d8,present using the following search terms,0.329876
uuid-c98fb87a83664cdfa0f3696953a5f11f,safety,0.348881
uuid-c98fb87a83664cdfa0f3696953a5f11f,databases,0.314131
uuid-c98fb87a83664cdfa0f3696953a5f11f,reported,0.44576
uuid-88661de1c0de4df3b251b92ed4139da8,PD-L1,0.729546
uuid-2665425f4fc14987b42584e6889a4482,evaluating,0.375352
uuid-2665425f4fc14987b42584e6889a4482,not conducted any controlled clinical trials/studies,0.379245
uuid-2665425f4fc14987b42584e6889a4482,search of published literature,0.307307
uuid-2665425f4fc14987b42584e6889a4482,efficacy and safety of nivolumab,0.393441
uuid-2665425f4fc14987b42584e6889a4482,BMS,0.301744
uuid-689a9f6cafb942ed84dc5e65af587418,adverse,0.419275
uuid-d302575ec5b94c31b631946031e5142c,OS,0.44149
uuid-d302575ec5b94c31b631946031e5142c,95% CI,0.833403
uuid-d302575ec5b94c31b631946031e5142c,ASCO,0.32927
uuid-d302575ec5b94c31b631946031e5142c,Objective response rate,0.545269
uuid-d302575ec5b94c31b631946031e5142c,ORR,0.618524
uuid-d302575ec5b94c31b631946031e5142c,PFS,0.396858
uuid-d302575ec5b94c31b631946031e5142c,Median overall survival,0.72593
uuid-d302575ec5b94c31b631946031e5142c,monotherapy,0.33356
uuid-d302575ec5b94c31b631946031e5142c,Median OS,0.763854
uuid-d302575ec5b94c31b631946031e5142c,hazard ratio,0.766648
uuid-d302575ec5b94c31b631946031e5142c,Median duration of response,0.442682
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,N Engl J Med,0.604857
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,non-small cell lung cancer,0.34354
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,ESMO,0.393944
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,Rizvi NA,0.452745
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,Brahmer J,0.679154
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,PD-L1,0.347566
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,Horn L,0.50259
uuid-6ba2f0f33e82478ab5ae9dbeee7498ed,platinum-based doublet chemotherapy,0.304136
uuid-98a038efafaf4dd2b91ae40d8990b94a,nivolumab,0.309338
uuid-ec17bd71dea14c069953b340df65429a,95% CI,0.524855
uuid-ec17bd71dea14c069953b340df65429a,respectively,0.383655
uuid-ec17bd71dea14c069953b340df65429a,ASCO,0.303153
uuid-ec17bd71dea14c069953b340df65429a,Lancet Oncol,0.368041
uuid-ec17bd71dea14c069953b340df65429a,Objective response rate,0.504846
uuid-ec17bd71dea14c069953b340df65429a,ORR,0.465366
uuid-ec17bd71dea14c069953b340df65429a,Median overall survival,0.346516
uuid-ec17bd71dea14c069953b340df65429a,Median OS,0.33538
uuid-ec17bd71dea14c069953b340df65429a,ASCO 2015,0.336983
uuid-ec17bd71dea14c069953b340df65429a,small cell lung cancer,0.336892
uuid-ec17bd71dea14c069953b340df65429a,SCLC,0.344367
uuid-ec17bd71dea14c069953b340df65429a,Antonia SJ,0.55269
uuid-ec17bd71dea14c069953b340df65429a,Median duration of response,0.649605
uuid-65211690ec854002a71f451da6edfd15,Opdivo,0.39239
uuid-65211690ec854002a71f451da6edfd15,Pubmed literature search,0.512384
uuid-65211690ec854002a71f451da6edfd15,purposes other than its labeled indication must be considered investigational,0.484466
uuid-65211690ec854002a71f451da6edfd15,not identify any citations relevant to your inquiry,0.507512
uuid-65211690ec854002a71f451da6edfd15,adverse,0.388743
uuid-65211690ec854002a71f451da6edfd15,using the following search terms,0.541089
uuid-65211690ec854002a71f451da6edfd15,reported,0.567061
uuid-6f51225bc28b4b189b6f819996fdddcc,ASCO,0.807066
uuid-d2d913e97ce046e6b374699793aae0dc,OS,0.387982
uuid-d2d913e97ce046e6b374699793aae0dc,95% CI,0.745043
uuid-d2d913e97ce046e6b374699793aae0dc,respectively,0.729294
uuid-d2d913e97ce046e6b374699793aae0dc,Objective response rate,0.590876
uuid-d2d913e97ce046e6b374699793aae0dc,ORR,0.722442
uuid-d2d913e97ce046e6b374699793aae0dc,Median overall survival,0.659043
uuid-d2d913e97ce046e6b374699793aae0dc,monotherapy,0.514468
uuid-d2d913e97ce046e6b374699793aae0dc,Median OS,0.696688
uuid-d2d913e97ce046e6b374699793aae0dc,PD-L1,0.300997
uuid-d2d913e97ce046e6b374699793aae0dc,docetaxel,0.635065
uuid-d2d913e97ce046e6b374699793aae0dc,hazard ratio,0.729977
uuid-2640a607867b4723a74913238ff8b3b5,95% CI,0.313765
uuid-2640a607867b4723a74913238ff8b3b5,NSCLC,0.359311
uuid-2640a607867b4723a74913238ff8b3b5,respectively,0.471212
uuid-2640a607867b4723a74913238ff8b3b5,non-small cell lung cancer,0.300752
uuid-2640a607867b4723a74913238ff8b3b5,Objective response rate,0.597391
uuid-2640a607867b4723a74913238ff8b3b5,ORR,0.609438
uuid-2640a607867b4723a74913238ff8b3b5,Median overall survival,0.344389
uuid-2640a607867b4723a74913238ff8b3b5,monotherapy,0.463323
uuid-2640a607867b4723a74913238ff8b3b5,docetaxel,0.380207
uuid-2640a607867b4723a74913238ff8b3b5,Antonia SJ,0.318404
uuid-2640a607867b4723a74913238ff8b3b5,hazard ratio,0.301138
uuid-061906448d5242dcb9b8cc75af1e8de0,95% CI,0.524855
uuid-061906448d5242dcb9b8cc75af1e8de0,respectively,0.383655
uuid-061906448d5242dcb9b8cc75af1e8de0,ASCO,0.303153
uuid-061906448d5242dcb9b8cc75af1e8de0,Lancet Oncol,0.368041
uuid-061906448d5242dcb9b8cc75af1e8de0,Objective response rate,0.504846
uuid-061906448d5242dcb9b8cc75af1e8de0,ORR,0.465366
uuid-061906448d5242dcb9b8cc75af1e8de0,Median overall survival,0.346516
uuid-061906448d5242dcb9b8cc75af1e8de0,Median OS,0.33538
uuid-061906448d5242dcb9b8cc75af1e8de0,ASCO 2015,0.336983
uuid-061906448d5242dcb9b8cc75af1e8de0,small cell lung cancer,0.336892
uuid-061906448d5242dcb9b8cc75af1e8de0,SCLC,0.344367
uuid-061906448d5242dcb9b8cc75af1e8de0,Antonia SJ,0.55269
uuid-061906448d5242dcb9b8cc75af1e8de0,Median duration of response,0.649605
uuid-d5cd8f3136ee403996a122dde2c089ec,use of nivolumab for the treatment,0.440423
uuid-d5cd8f3136ee403996a122dde2c089ec,search of published literature,0.311531
uuid-d5cd8f3136ee403996a122dde2c089ec,PubMed and EMBASE,0.312811
uuid-d5cd8f3136ee403996a122dde2c089ec,not approved,0.404782
uuid-d5cd8f3136ee403996a122dde2c089ec,open-label,0.578291
uuid-d5cd8f3136ee403996a122dde2c089ec,clinical trials investigating the safety,0.440014
uuid-d5cd8f3136ee403996a122dde2c089ec,present using the following search terms,0.328669
uuid-d5cd8f3136ee403996a122dde2c089ec,phase,0.41185
uuid-30ce976a3e76462fbdbefafbfcb26e24,95% CI,0.504025
uuid-30ce976a3e76462fbdbefafbfcb26e24,respectively,0.530207
uuid-30ce976a3e76462fbdbefafbfcb26e24,Objective response rate,0.458259
uuid-30ce976a3e76462fbdbefafbfcb26e24,ORR,0.467546
uuid-30ce976a3e76462fbdbefafbfcb26e24,Median overall survival,0.324278
uuid-30ce976a3e76462fbdbefafbfcb26e24,Median OS,0.319466
uuid-30ce976a3e76462fbdbefafbfcb26e24,Antonia SJ,0.417489
uuid-30ce976a3e76462fbdbefafbfcb26e24,Median duration of response,0.591482
uuid-b8075896733c4e3c9cfd88d86bcb9706,Objective response rate,0.427051
uuid-b8075896733c4e3c9cfd88d86bcb9706,clinicaltrials.gov,0.524603
uuid-b8075896733c4e3c9cfd88d86bcb9706,relapsed,0.306689
uuid-1a53dab4ce26459589d20f43e64c1c6b,nivolumab,0.324658
uuid-1a53dab4ce26459589d20f43e64c1c6b,use of nivolumab for the treatment,0.543355
uuid-1a53dab4ce26459589d20f43e64c1c6b,evaluating,0.348676
uuid-1a53dab4ce26459589d20f43e64c1c6b,efficacy,0.388907
uuid-1a53dab4ce26459589d20f43e64c1c6b,patients,0.419915
uuid-1a53dab4ce26459589d20f43e64c1c6b,search of published literature,0.449959
uuid-1a53dab4ce26459589d20f43e64c1c6b,PubMed and EMBASE,0.444573
uuid-1a53dab4ce26459589d20f43e64c1c6b,not approved,0.582429
uuid-1a53dab4ce26459589d20f43e64c1c6b,clinical trials investigating the safety,0.64854
uuid-1a53dab4ce26459589d20f43e64c1c6b,efficacy and safety of nivolumab,0.399101
uuid-1a53dab4ce26459589d20f43e64c1c6b,present using the following search terms,0.465296
uuid-8fe6e6a1c1ab407cae98de2646e1828a,OS,0.62262
uuid-8fe6e6a1c1ab407cae98de2646e1828a,PFS,0.65903
uuid-8fe6e6a1c1ab407cae98de2646e1828a,Overall survival,0.644151
uuid-7d24c571be2e4c0b91e4e3d7421e99d6,melanoma,0.410364
uuid-ad7010122ad940b08b622f6bf554d410,nivolumab,0.403279
uuid-ad7010122ad940b08b622f6bf554d410,Bristol-Myers Squibb,0.517272
uuid-ad7010122ad940b08b622f6bf554d410,evaluating,0.705761
uuid-ad7010122ad940b08b622f6bf554d410,not conducted any controlled clinical trials/studies,0.68678
uuid-ad7010122ad940b08b622f6bf554d410,search of published literature,0.666995
uuid-ad7010122ad940b08b622f6bf554d410,Additionally,0.599528
uuid-ad7010122ad940b08b622f6bf554d410,ongoing,0.502407
uuid-ad7010122ad940b08b622f6bf554d410,PubMed and EMBASE,0.648507
uuid-ad7010122ad940b08b622f6bf554d410,detailed search of www.clinicaltrials.gov,0.57215
uuid-ad7010122ad940b08b622f6bf554d410,efficacy and safety of nivolumab,0.785704
uuid-ad7010122ad940b08b622f6bf554d410,not identify any planned,0.522329
uuid-ad7010122ad940b08b622f6bf554d410,safety,0.310551
uuid-ad7010122ad940b08b622f6bf554d410,not identify any citations relevant to your request,0.68709
uuid-ad7010122ad940b08b622f6bf554d410,present using the following search terms,0.685697
uuid-f0f55b7ac5cc4a35b01ecf0f39149335,nivolumab,0.843012
uuid-f0f55b7ac5cc4a35b01ecf0f39149335,Pubmed literature search,0.306388
uuid-f0f55b7ac5cc4a35b01ecf0f39149335,purposes other than its labeled indication must be considered investigational,0.356724
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,nivolumab,0.538071
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,evaluating,0.533121
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,not conducted any controlled clinical trials/studies,0.463217
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,patients,0.363759
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,search of published literature,0.638834
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,Additionally,0.394987
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,PubMed and EMBASE,0.628231
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,detailed search of www.clinicaltrials.gov,0.335474
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,phase 1 study,0.359141
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,efficacy and safety of nivolumab,0.636765
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,not identify any citations relevant to your request,0.517853
uuid-3c9a8f48ffb34dabb20cb32df5d41eb3,present using the following search terms,0.671468
uuid-b3e791c2d8764711bd8b5afa0e172e71,Opdivo,0.585737
uuid-b3e791c2d8764711bd8b5afa0e172e71,adverse,0.320598
uuid-b3e791c2d8764711bd8b5afa0e172e71,trial,0.366097
uuid-b3e791c2d8764711bd8b5afa0e172e71,reported,0.600959
uuid-03e772f40ede4d06b3877ce673057f9e,OS,0.387982
uuid-03e772f40ede4d06b3877ce673057f9e,95% CI,0.745043
uuid-03e772f40ede4d06b3877ce673057f9e,respectively,0.729294
uuid-03e772f40ede4d06b3877ce673057f9e,Objective response rate,0.590876
uuid-03e772f40ede4d06b3877ce673057f9e,ORR,0.722442
uuid-03e772f40ede4d06b3877ce673057f9e,Median overall survival,0.659043
uuid-03e772f40ede4d06b3877ce673057f9e,monotherapy,0.514468
uuid-03e772f40ede4d06b3877ce673057f9e,Median OS,0.696688
uuid-03e772f40ede4d06b3877ce673057f9e,PD-L1,0.300997
uuid-03e772f40ede4d06b3877ce673057f9e,docetaxel,0.635065
uuid-03e772f40ede4d06b3877ce673057f9e,hazard ratio,0.729977
uuid-e120f50a2814442c840088b8431243f7,95% CI,0.524855
uuid-e120f50a2814442c840088b8431243f7,respectively,0.383655
uuid-e120f50a2814442c840088b8431243f7,ASCO,0.303153
uuid-e120f50a2814442c840088b8431243f7,Lancet Oncol,0.368041
uuid-e120f50a2814442c840088b8431243f7,Objective response rate,0.504846
uuid-e120f50a2814442c840088b8431243f7,ORR,0.465366
uuid-e120f50a2814442c840088b8431243f7,Median overall survival,0.346516
uuid-e120f50a2814442c840088b8431243f7,Median OS,0.33538
uuid-e120f50a2814442c840088b8431243f7,ASCO 2015,0.336983
uuid-e120f50a2814442c840088b8431243f7,small cell lung cancer,0.336892
uuid-e120f50a2814442c840088b8431243f7,SCLC,0.344367
uuid-e120f50a2814442c840088b8431243f7,Antonia SJ,0.55269
uuid-e120f50a2814442c840088b8431243f7,Median duration of response,0.649605
uuid-538e81fd37194f6cb0bc5bd00165c703,Bristol-Myers Squibb,0.346284
uuid-538e81fd37194f6cb0bc5bd00165c703,requested,0.318394
uuid-7a6efd4b7b3e4438bbc49cbe5e45855d,requested,0.594438
uuid-de1cee47b3bc4145b773e654de71fe7a,ASCO,0.382205
uuid-54102f378ba84441a7b96f7284305aeb,nivolumab,0.354126
uuid-54102f378ba84441a7b96f7284305aeb,use of nivolumab for the treatment,0.53766
uuid-54102f378ba84441a7b96f7284305aeb,evaluating,0.357126
uuid-54102f378ba84441a7b96f7284305aeb,efficacy,0.39157
uuid-54102f378ba84441a7b96f7284305aeb,patients,0.436611
uuid-54102f378ba84441a7b96f7284305aeb,search of published literature,0.44389
uuid-54102f378ba84441a7b96f7284305aeb,PubMed and EMBASE,0.438482
uuid-54102f378ba84441a7b96f7284305aeb,not approved,0.573456
uuid-54102f378ba84441a7b96f7284305aeb,clinical trials investigating the safety,0.635698
uuid-54102f378ba84441a7b96f7284305aeb,efficacy and safety of nivolumab,0.396355
uuid-54102f378ba84441a7b96f7284305aeb,present using the following search terms,0.460064
uuid-35b05bb80a754f5bad78966bf03b091d,provided in the Detailed Information,0.349112
uuid-35b05bb80a754f5bad78966bf03b091d,Weber JS,0.321343
uuid-7b5b01e6f1044da78649091c4652de54,nivolumab,0.653413
uuid-7b5b01e6f1044da78649091c4652de54,Bristol-Myers Squibb,0.411836
uuid-7b5b01e6f1044da78649091c4652de54,evaluating,0.599153
uuid-7b5b01e6f1044da78649091c4652de54,not conducted any controlled clinical trials/studies,0.633052
uuid-7b5b01e6f1044da78649091c4652de54,Pubmed literature search,0.808217
uuid-7b5b01e6f1044da78649091c4652de54,purposes other than its labeled indication must be considered investigational,0.878697
uuid-7b5b01e6f1044da78649091c4652de54,not identify any citations relevant to your inquiry,0.769955
uuid-7b5b01e6f1044da78649091c4652de54,using the following search terms,0.755358
uuid-7b5b01e6f1044da78649091c4652de54,efficacy and safety of nivolumab,0.446166
uuid-f0d05716400742caa964c087b6b84890,patients,0.30092
uuid-f0d05716400742caa964c087b6b84890,phase 3 study,0.31992
uuid-f0d05716400742caa964c087b6b84890,mg,0.546615
uuid-f0d05716400742caa964c087b6b84890,kg,0.485938
uuid-07fc60b37d5d4870b4ace8243e5c65b9,fatigue,0.704358
uuid-f2c71885e7b142a5a0f81d442486651c,Bristol-Myers Squibb,0.398191
uuid-f2c71885e7b142a5a0f81d442486651c,requested,0.827269
uuid-95e365d5e42a40359618ba3749ab05ae,requested,0.594234
uuid-fd1953e0470f40bd979d008695f89d99,95% CI,0.38691
uuid-fd1953e0470f40bd979d008695f89d99,NSCLC,0.309907
uuid-fd1953e0470f40bd979d008695f89d99,respectively,0.520194
uuid-fd1953e0470f40bd979d008695f89d99,Objective response rate,0.573555
uuid-fd1953e0470f40bd979d008695f89d99,ORR,0.626348
uuid-fd1953e0470f40bd979d008695f89d99,Median overall survival,0.400007
uuid-fd1953e0470f40bd979d008695f89d99,monotherapy,0.453522
uuid-fd1953e0470f40bd979d008695f89d99,Median OS,0.354493
uuid-fd1953e0470f40bd979d008695f89d99,docetaxel,0.412975
uuid-fd1953e0470f40bd979d008695f89d99,hazard ratio,0.358112
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,N Engl J Med,0.689907
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Lancet Oncol,0.584216
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,protocol,0.72528
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,McDermott DF,0.794444
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Motzer RJ,0.755383
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,phase 3 study,0.521307
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Escudier B,0.794743
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,NEJM,0.434762
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,et al.,0.777092
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,J Clin Oncol,0.708338
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Topalian,0.401719
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Rizvi NA,0.731383
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Brahmer J,0.378658
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,Weber JS,0.614831
uuid-5a572e29b7bf47f4ab3a6071bfd0ac81,phase 2 study,0.769458
uuid-f9475f44a6ee4c2fa95399924132c877,search of published literature,0.394524
uuid-f9475f44a6ee4c2fa95399924132c877,Additionally,0.413583
uuid-f9475f44a6ee4c2fa95399924132c877,ongoing,0.322117
uuid-f9475f44a6ee4c2fa95399924132c877,PubMed and EMBASE,0.391671
uuid-f9475f44a6ee4c2fa95399924132c877,detailed search of www.clinicaltrials.gov,0.375936
uuid-f9475f44a6ee4c2fa95399924132c877,efficacy and safety of nivolumab,0.370699
uuid-f9475f44a6ee4c2fa95399924132c877,not identify any planned,0.34283
uuid-f9475f44a6ee4c2fa95399924132c877,Weber JS,0.319229
uuid-f9475f44a6ee4c2fa95399924132c877,not identify any citations relevant to your request,0.447813
uuid-f9475f44a6ee4c2fa95399924132c877,present using the following search terms,0.408199
uuid-b2949dc5512d4c40b0ad2f5e4d275dd7,patients,0.324499
uuid-6303db36c555459c913bbf40cb869245,95% CI,0.524855
uuid-6303db36c555459c913bbf40cb869245,respectively,0.383655
uuid-6303db36c555459c913bbf40cb869245,ASCO,0.303153
uuid-6303db36c555459c913bbf40cb869245,Lancet Oncol,0.368041
uuid-6303db36c555459c913bbf40cb869245,Objective response rate,0.504846
uuid-6303db36c555459c913bbf40cb869245,ORR,0.465366
uuid-6303db36c555459c913bbf40cb869245,Median overall survival,0.346516
uuid-6303db36c555459c913bbf40cb869245,Median OS,0.33538
uuid-6303db36c555459c913bbf40cb869245,ASCO 2015,0.336983
uuid-6303db36c555459c913bbf40cb869245,small cell lung cancer,0.336892
uuid-6303db36c555459c913bbf40cb869245,SCLC,0.344367
uuid-6303db36c555459c913bbf40cb869245,Antonia SJ,0.55269
uuid-6303db36c555459c913bbf40cb869245,Median duration of response,0.649605
uuid-029e27c2a8974e6cb84c1599348c6ae6,clinical,0.372032
uuid-029e27c2a8974e6cb84c1599348c6ae6,phase 3 study,0.591711
uuid-029e27c2a8974e6cb84c1599348c6ae6,open-label,0.529042
uuid-029e27c2a8974e6cb84c1599348c6ae6,melanoma,0.319355
uuid-029e27c2a8974e6cb84c1599348c6ae6,Rizvi NA,0.369539
uuid-029e27c2a8974e6cb84c1599348c6ae6,trial,0.643113
uuid-029e27c2a8974e6cb84c1599348c6ae6,Weber JS,0.308173
uuid-029e27c2a8974e6cb84c1599348c6ae6,phase 2 study,0.363697
uuid-029e27c2a8974e6cb84c1599348c6ae6,phase,0.632178
uuid-2c154c0905bc4e9aa38b7e534c50c421,requested,0.307399
uuid-88bf837c668046ce89061e349ee4b2b1,RCC,0.33833
uuid-6fcc97b0411e4c44850690c556b557c8,NEJM,0.318074
uuid-d06fc4abc2a5411a9d7abdaca427db01,nivolumab,0.569495
uuid-d06fc4abc2a5411a9d7abdaca427db01,Bristol-Myers Squibb,0.43553
uuid-d06fc4abc2a5411a9d7abdaca427db01,evaluating,0.591535
uuid-d06fc4abc2a5411a9d7abdaca427db01,not conducted any controlled clinical trials/studies,0.652028
uuid-d06fc4abc2a5411a9d7abdaca427db01,Pubmed literature search,0.877387
uuid-d06fc4abc2a5411a9d7abdaca427db01,purposes other than its labeled indication must be considered investigational,0.939428
uuid-d06fc4abc2a5411a9d7abdaca427db01,not identify any citations relevant to your inquiry,0.83758
uuid-d06fc4abc2a5411a9d7abdaca427db01,using the following search terms,0.825215
uuid-d06fc4abc2a5411a9d7abdaca427db01,efficacy and safety of nivolumab,0.432123
uuid-c3110d398ef142baa88432cabde4a743,95% CI,0.520262
uuid-c3110d398ef142baa88432cabde4a743,respectively,0.504068
uuid-c3110d398ef142baa88432cabde4a743,Objective response rate,0.458568
uuid-c3110d398ef142baa88432cabde4a743,ORR,0.525868
uuid-c3110d398ef142baa88432cabde4a743,Median overall survival,0.455633
uuid-c3110d398ef142baa88432cabde4a743,Median OS,0.507448
uuid-c3110d398ef142baa88432cabde4a743,docetaxel,0.383115
uuid-c3110d398ef142baa88432cabde4a743,hazard ratio,0.462119
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,Bristol-Myers Squibb,0.341822
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,not conducted any controlled clinical trials/studies,0.304507
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,Opdivo,0.461382
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,Pubmed literature search,0.614325
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,purposes other than its labeled indication must be considered investigational,0.586645
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,not identify any citations relevant to your inquiry,0.606087
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,adverse,0.304183
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,using the following search terms,0.642331
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,databases,0.315039
uuid-6d9ee34a6b0542de98fcc4ec0f2fde82,reported,0.556704
uuid-2b1209d7907147a596d01e4b775042cd,patients,0.316603
uuid-3a80543639a94e48a311d095dda9708b,N Engl J Med,0.319272
uuid-3a80543639a94e48a311d095dda9708b,patients,0.325616
uuid-3a80543639a94e48a311d095dda9708b,protocol,0.382531
uuid-3a80543639a94e48a311d095dda9708b,McDermott DF,0.441084
uuid-3a80543639a94e48a311d095dda9708b,Motzer RJ,0.41441
uuid-3a80543639a94e48a311d095dda9708b,phase 3 study,0.437334
uuid-3a80543639a94e48a311d095dda9708b,Escudier B,0.421257
uuid-3a80543639a94e48a311d095dda9708b,NEJM,0.321137
uuid-3a80543639a94e48a311d095dda9708b,et al.,0.408832
uuid-3a80543639a94e48a311d095dda9708b,J Clin Oncol,0.414371
uuid-3a80543639a94e48a311d095dda9708b,phase 1 study,0.335004
uuid-3a80543639a94e48a311d095dda9708b,Weber JS,0.329799
uuid-3a80543639a94e48a311d095dda9708b,phase 2 study,0.47241
uuid-3a80543639a94e48a311d095dda9708b,grade 3 to 4 AEs,0.354735
uuid-a5d99ada636a4a59b7c9fc839e470a88,OS,0.44149
uuid-a5d99ada636a4a59b7c9fc839e470a88,95% CI,0.833403
uuid-a5d99ada636a4a59b7c9fc839e470a88,ASCO,0.32927
uuid-a5d99ada636a4a59b7c9fc839e470a88,Objective response rate,0.545269
uuid-a5d99ada636a4a59b7c9fc839e470a88,ORR,0.618524
uuid-a5d99ada636a4a59b7c9fc839e470a88,PFS,0.396858
uuid-a5d99ada636a4a59b7c9fc839e470a88,Median overall survival,0.72593
uuid-a5d99ada636a4a59b7c9fc839e470a88,monotherapy,0.33356
uuid-a5d99ada636a4a59b7c9fc839e470a88,Median OS,0.763854
uuid-a5d99ada636a4a59b7c9fc839e470a88,hazard ratio,0.766648
uuid-a5d99ada636a4a59b7c9fc839e470a88,Median duration of response,0.442682
uuid-38889c9d7b914fa4ba2f65c4da8dc986,requested,0.622618
uuid-4ba9d54c2557402f82ba7d8d8d101673,nivolumab,0.502183
uuid-4ba9d54c2557402f82ba7d8d8d101673,RCC,0.756598
uuid-0e14258bd45c43b88ebe15af60bd1368,Bristol-Myers Squibb,0.341822
uuid-0e14258bd45c43b88ebe15af60bd1368,not conducted any controlled clinical trials/studies,0.304507
uuid-0e14258bd45c43b88ebe15af60bd1368,Opdivo,0.461382
uuid-0e14258bd45c43b88ebe15af60bd1368,Pubmed literature search,0.614325
uuid-0e14258bd45c43b88ebe15af60bd1368,purposes other than its labeled indication must be considered investigational,0.586645
uuid-0e14258bd45c43b88ebe15af60bd1368,not identify any citations relevant to your inquiry,0.606087
uuid-0e14258bd45c43b88ebe15af60bd1368,adverse,0.304183
uuid-0e14258bd45c43b88ebe15af60bd1368,using the following search terms,0.642331
uuid-0e14258bd45c43b88ebe15af60bd1368,databases,0.315039
uuid-0e14258bd45c43b88ebe15af60bd1368,reported,0.556704
uuid-275379d221234b2d834e543aa153430b,N Engl J Med,0.580351
uuid-275379d221234b2d834e543aa153430b,ASCO,0.383128
uuid-275379d221234b2d834e543aa153430b,Lancet Oncol,0.318957
uuid-275379d221234b2d834e543aa153430b,protocol,0.374551
uuid-275379d221234b2d834e543aa153430b,McDermott DF,0.427286
uuid-275379d221234b2d834e543aa153430b,Motzer RJ,0.39691
uuid-275379d221234b2d834e543aa153430b,phase 3 study,0.392158
uuid-275379d221234b2d834e543aa153430b,Escudier B,0.416218
uuid-275379d221234b2d834e543aa153430b,et al.,0.441208
uuid-275379d221234b2d834e543aa153430b,J Clin Oncol,0.37546
uuid-275379d221234b2d834e543aa153430b,Rizvi NA,0.482308
uuid-275379d221234b2d834e543aa153430b,Brahmer J,0.482921
uuid-275379d221234b2d834e543aa153430b,phase 2 study,0.507144
uuid-97edf7b6a98a4804a06cf3ecf9917a4d,patients,0.324499
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,95% CI,0.384282
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,ASCO,0.40687
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,Objective response rate,0.409634
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,Median overall survival,0.319094
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,Median OS,0.403026
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,ASCO 2015,0.386899
uuid-a73c4fc0a1c64d958c9bb2b774e644f9,hazard ratio,0.403406
uuid-6ed7c71fba4040e09763a70491f1ebf1,respectively,0.629961
uuid-6ed7c71fba4040e09763a70491f1ebf1,Objective response rate,0.439951
uuid-6ed7c71fba4040e09763a70491f1ebf1,ORR,0.462322
uuid-6ed7c71fba4040e09763a70491f1ebf1,monotherapy,0.352421
uuid-6ed7c71fba4040e09763a70491f1ebf1,docetaxel,0.410479
uuid-bfb3c4c9c3f74395b66149cddf8d1543,relapsed,0.313685
uuid-087883f4b0334a1ea3356a727e6ff005,patients,0.324499
uuid-25274c88215847e2b1a7dc8c5f4028bb,Bristol-Myers Squibb,0.817404
uuid-25274c88215847e2b1a7dc8c5f4028bb,evaluating,0.719785
uuid-25274c88215847e2b1a7dc8c5f4028bb,not conducted any controlled clinical trials/studies,0.780935
uuid-25274c88215847e2b1a7dc8c5f4028bb,patients,0.461151
uuid-25274c88215847e2b1a7dc8c5f4028bb,considered investigational,0.325339
uuid-25274c88215847e2b1a7dc8c5f4028bb,efficacy and safety of nivolumab,0.625504
uuid-1fc3ddd4eab5469385349ed93d6e4f76,95% CI,0.524855
uuid-1fc3ddd4eab5469385349ed93d6e4f76,respectively,0.383655
uuid-1fc3ddd4eab5469385349ed93d6e4f76,ASCO,0.303153
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Lancet Oncol,0.368041
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Objective response rate,0.504846
uuid-1fc3ddd4eab5469385349ed93d6e4f76,ORR,0.465366
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Median overall survival,0.346516
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Median OS,0.33538
uuid-1fc3ddd4eab5469385349ed93d6e4f76,ASCO 2015,0.336983
uuid-1fc3ddd4eab5469385349ed93d6e4f76,small cell lung cancer,0.336892
uuid-1fc3ddd4eab5469385349ed93d6e4f76,SCLC,0.344367
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Antonia SJ,0.55269
uuid-1fc3ddd4eab5469385349ed93d6e4f76,Median duration of response,0.649605
uuid-7a4657a0e5fb44f086f77aea5ca717b6,N Engl J Med,0.463565
uuid-7a4657a0e5fb44f086f77aea5ca717b6,protocol,0.790566
uuid-7a4657a0e5fb44f086f77aea5ca717b6,McDermott DF,0.758683
uuid-7a4657a0e5fb44f086f77aea5ca717b6,Motzer RJ,0.836591
uuid-7a4657a0e5fb44f086f77aea5ca717b6,phase 3 study,0.420445
uuid-7a4657a0e5fb44f086f77aea5ca717b6,Escudier B,0.767948
uuid-7a4657a0e5fb44f086f77aea5ca717b6,NEJM,0.41238
uuid-7a4657a0e5fb44f086f77aea5ca717b6,et al.,0.685954
uuid-7a4657a0e5fb44f086f77aea5ca717b6,J Clin Oncol,0.809332
uuid-7a4657a0e5fb44f086f77aea5ca717b6,Topalian,0.398734
uuid-7a4657a0e5fb44f086f77aea5ca717b6,phase 1 study,0.490434
uuid-7a4657a0e5fb44f086f77aea5ca717b6,CA209-003,0.559752
uuid-7a4657a0e5fb44f086f77aea5ca717b6,phase 2 study,0.687519
uuid-7a4657a0e5fb44f086f77aea5ca717b6,investigating,0.614892
uuid-e1353ab126324b0dae0f3821383448c4,respectively,0.629961
uuid-e1353ab126324b0dae0f3821383448c4,Objective response rate,0.439951
uuid-e1353ab126324b0dae0f3821383448c4,ORR,0.462322
uuid-e1353ab126324b0dae0f3821383448c4,monotherapy,0.352421
uuid-e1353ab126324b0dae0f3821383448c4,docetaxel,0.410479
uuid-a3cff3362659407abfef156149d88498,N Engl J Med,0.684265
uuid-a3cff3362659407abfef156149d88498,Lancet Oncol,0.312863
uuid-a3cff3362659407abfef156149d88498,provided in the Detailed Information,0.543018
uuid-a3cff3362659407abfef156149d88498,protocol,0.415533
uuid-a3cff3362659407abfef156149d88498,McDermott DF,0.49302
uuid-a3cff3362659407abfef156149d88498,Motzer RJ,0.435966
uuid-a3cff3362659407abfef156149d88498,ESMO,0.309441
uuid-a3cff3362659407abfef156149d88498,phase 3 study,0.32485
uuid-a3cff3362659407abfef156149d88498,Escudier B,0.486651
uuid-a3cff3362659407abfef156149d88498,NEJM,0.328856
uuid-a3cff3362659407abfef156149d88498,et al.,0.483913
uuid-a3cff3362659407abfef156149d88498,J Clin Oncol,0.391169
uuid-a3cff3362659407abfef156149d88498,Topalian,0.318568
uuid-a3cff3362659407abfef156149d88498,Rizvi NA,0.441235
uuid-a3cff3362659407abfef156149d88498,Brahmer J,0.500908
uuid-a3cff3362659407abfef156149d88498,Weber JS,0.406817
uuid-a3cff3362659407abfef156149d88498,BMS,0.358695
uuid-a3cff3362659407abfef156149d88498,phase 2 study,0.448501
uuid-a3cff3362659407abfef156149d88498,grade 3 to 4 AEs,0.363212
uuid-a1f761b9f77d4b0688c927b8fdee5e3e,ASCO,0.807066
uuid-4105b5246d20448689e1614670b01d77,requested,0.594234
uuid-4a49319b0f5a4584bf96afdca41c4720,N Engl J Med,0.775913
uuid-4a49319b0f5a4584bf96afdca41c4720,Lancet Oncol,0.394515
uuid-4a49319b0f5a4584bf96afdca41c4720,protocol,0.831494
uuid-4a49319b0f5a4584bf96afdca41c4720,McDermott DF,0.846573
uuid-4a49319b0f5a4584bf96afdca41c4720,Motzer RJ,0.84765
uuid-4a49319b0f5a4584bf96afdca41c4720,phase 3 study,0.543442
uuid-4a49319b0f5a4584bf96afdca41c4720,Escudier B,0.856834
uuid-4a49319b0f5a4584bf96afdca41c4720,NEJM,0.463538
uuid-4a49319b0f5a4584bf96afdca41c4720,et al.,0.804146
uuid-4a49319b0f5a4584bf96afdca41c4720,J Clin Oncol,0.783647
uuid-4a49319b0f5a4584bf96afdca41c4720,Topalian,0.430057
uuid-4a49319b0f5a4584bf96afdca41c4720,phase 1 study,0.32725
uuid-4a49319b0f5a4584bf96afdca41c4720,Rizvi NA,0.582327
uuid-4a49319b0f5a4584bf96afdca41c4720,Brahmer J,0.485583
uuid-4a49319b0f5a4584bf96afdca41c4720,Weber JS,0.384759
uuid-4a49319b0f5a4584bf96afdca41c4720,phase 2 study,0.779584
uuid-666185c0b6c74ba18f46f2e23668e3aa,trial,0.446753
uuid-80959cb49a4f4e529f39221d42c2705d,provided in the Detailed Information,0.309309
uuid-1f9464a0b4054469ad96735ecfce74bd,OS,0.532893
uuid-1f9464a0b4054469ad96735ecfce74bd,AEs,0.3179
uuid-1f9464a0b4054469ad96735ecfce74bd,95% CI,0.541226
uuid-1f9464a0b4054469ad96735ecfce74bd,patients,0.30081
uuid-1f9464a0b4054469ad96735ecfce74bd,ORR,0.348307
uuid-1f9464a0b4054469ad96735ecfce74bd,PFS,0.429451
uuid-1f9464a0b4054469ad96735ecfce74bd,Median overall survival,0.611393
uuid-1f9464a0b4054469ad96735ecfce74bd,Median OS,0.50466
uuid-1f9464a0b4054469ad96735ecfce74bd,hazard ratio,0.51967
uuid-1f9464a0b4054469ad96735ecfce74bd,Overall survival,0.414713
uuid-1f9464a0b4054469ad96735ecfce74bd,grade 3 to 4 AEs,0.305726
uuid-e5b2eae24587446ca63580fd22103e92,patients with advanced or metastatic,0.468858
uuid-e5b2eae24587446ca63580fd22103e92,nivolumab combined with ipilimumab,0.446918
uuid-e5b2eae24587446ca63580fd22103e92,not approved,0.352562
uuid-e5b2eae24587446ca63580fd22103e92,clinical trials investigating the safety,0.429501
uuid-e5b2eae24587446ca63580fd22103e92,bladder cancer,0.950698
uuid-2ad2d292d2964d40ac66f9575af52cdd,patients,0.556054
uuid-2ad2d292d2964d40ac66f9575af52cdd,provided in the Detailed Information,0.329929
uuid-2ad2d292d2964d40ac66f9575af52cdd,adverse,0.32982
uuid-2ad2d292d2964d40ac66f9575af52cdd,phase 3 study,0.523726
uuid-2ad2d292d2964d40ac66f9575af52cdd,melanoma,0.382071
uuid-2ad2d292d2964d40ac66f9575af52cdd,Weber JS,0.428777
uuid-2ad2d292d2964d40ac66f9575af52cdd,phase 2 study,0.307314
uuid-2ad2d292d2964d40ac66f9575af52cdd,grade 3 to 4 AEs,0.466022
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,N Engl J Med,0.495649
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,protocol,0.736971
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,McDermott DF,0.762108
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,Motzer RJ,0.773565
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,phase 3 study,0.454434
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,Escudier B,0.763658
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,NEJM,0.4325
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,et al.,0.712875
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,J Clin Oncol,0.738632
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,Topalian,0.412144
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,Rizvi NA,0.375979
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,Weber JS,0.324917
uuid-b1b686525e1f4d8aa7d0a378fc7eb9b0,phase 2 study,0.660323
uuid-27be9d1d730b44f28bbe1c489ac4f111,Bristol-Myers Squibb,0.341822
uuid-27be9d1d730b44f28bbe1c489ac4f111,not conducted any controlled clinical trials/studies,0.304507
uuid-27be9d1d730b44f28bbe1c489ac4f111,Opdivo,0.461382
uuid-27be9d1d730b44f28bbe1c489ac4f111,Pubmed literature search,0.614325
uuid-27be9d1d730b44f28bbe1c489ac4f111,purposes other than its labeled indication must be considered investigational,0.586645
uuid-27be9d1d730b44f28bbe1c489ac4f111,not identify any citations relevant to your inquiry,0.606087
uuid-27be9d1d730b44f28bbe1c489ac4f111,adverse,0.304183
uuid-27be9d1d730b44f28bbe1c489ac4f111,using the following search terms,0.642331
uuid-27be9d1d730b44f28bbe1c489ac4f111,databases,0.315039
uuid-27be9d1d730b44f28bbe1c489ac4f111,reported,0.556704
uuid-5d116ea2072a4c938fcccaf88c05908b,nivolumab,0.314994
uuid-f68a8c502f914eb782899b169338f4d2,respectively,0.378796
uuid-4424c22507df4871b1ea4d2954ec320f,requested,0.44769
uuid-4424c22507df4871b1ea4d2954ec320f,trial,0.309472
uuid-259970f5a00545adbeac53057374b4ed,nivolumab,0.593251
uuid-259970f5a00545adbeac53057374b4ed,Bristol-Myers Squibb,0.456199
uuid-259970f5a00545adbeac53057374b4ed,evaluating,0.658528
uuid-259970f5a00545adbeac53057374b4ed,not conducted any controlled clinical trials/studies,0.70313
uuid-259970f5a00545adbeac53057374b4ed,Pubmed literature search,0.793066
uuid-259970f5a00545adbeac53057374b4ed,purposes other than its labeled indication must be considered investigational,0.870439
uuid-259970f5a00545adbeac53057374b4ed,not identify any citations relevant to your inquiry,0.755328
uuid-259970f5a00545adbeac53057374b4ed,search of published literature,0.339611
uuid-259970f5a00545adbeac53057374b4ed,PubMed and EMBASE,0.313239
uuid-259970f5a00545adbeac53057374b4ed,using the following search terms,0.737309
uuid-259970f5a00545adbeac53057374b4ed,efficacy and safety of nivolumab,0.545875
uuid-259970f5a00545adbeac53057374b4ed,present using the following search terms,0.326384
uuid-abfddae85cdb427d89fc09c33cf22640,requested,0.44769
uuid-abfddae85cdb427d89fc09c33cf22640,trial,0.309472
uuid-9f9e9b363afb4d9ab185470bbcf99d15,grade,0.400542
uuid-8f3068ef381c4d0b9079a51d2465290a,NSCLC,0.351198
uuid-8f3068ef381c4d0b9079a51d2465290a,efficacy and safety of nivolumab,0.343313
uuid-67d0effd253f42f298b87ad462afdc60,N Engl J Med,0.456474
uuid-67d0effd253f42f298b87ad462afdc60,Lancet Oncol,0.357873
uuid-67d0effd253f42f298b87ad462afdc60,protocol,0.480893
uuid-67d0effd253f42f298b87ad462afdc60,McDermott DF,0.51746
uuid-67d0effd253f42f298b87ad462afdc60,search of published literature,0.343051
uuid-67d0effd253f42f298b87ad462afdc60,Motzer RJ,0.516788
uuid-67d0effd253f42f298b87ad462afdc60,phase 3 study,0.754973
uuid-67d0effd253f42f298b87ad462afdc60,PubMed and EMBASE,0.340792
uuid-67d0effd253f42f298b87ad462afdc60,Escudier B,0.532534
uuid-67d0effd253f42f298b87ad462afdc60,et al.,0.496867
uuid-67d0effd253f42f298b87ad462afdc60,J Clin Oncol,0.430616
uuid-67d0effd253f42f298b87ad462afdc60,Rizvi NA,0.473891
uuid-67d0effd253f42f298b87ad462afdc60,Weber JS,0.580854
uuid-67d0effd253f42f298b87ad462afdc60,phase 2 study,0.6143
uuid-6e14e14f026a4bac85583177cad0e56e,OS,0.387982
uuid-6e14e14f026a4bac85583177cad0e56e,95% CI,0.745043
uuid-6e14e14f026a4bac85583177cad0e56e,respectively,0.729294
uuid-6e14e14f026a4bac85583177cad0e56e,Objective response rate,0.590876
uuid-6e14e14f026a4bac85583177cad0e56e,ORR,0.722442
uuid-6e14e14f026a4bac85583177cad0e56e,Median overall survival,0.659043
uuid-6e14e14f026a4bac85583177cad0e56e,monotherapy,0.514468
uuid-6e14e14f026a4bac85583177cad0e56e,Median OS,0.696688
uuid-6e14e14f026a4bac85583177cad0e56e,PD-L1,0.300997
uuid-6e14e14f026a4bac85583177cad0e56e,docetaxel,0.635065
uuid-6e14e14f026a4bac85583177cad0e56e,hazard ratio,0.729977
uuid-766c6cb8384b404d9224541d19cb4c3d,trial,0.337796
uuid-b6abb0b2ec8e4ecdafbb1c286a1e8894,patients,0.324499
uuid-6b4de80802504c9dae00240580a3d597,evaluating,0.368864
uuid-6b4de80802504c9dae00240580a3d597,not conducted any controlled clinical trials/studies,0.367267
uuid-6b4de80802504c9dae00240580a3d597,search of published literature,0.388405
uuid-6b4de80802504c9dae00240580a3d597,Additionally,0.395689
uuid-6b4de80802504c9dae00240580a3d597,ongoing,0.435792
uuid-6b4de80802504c9dae00240580a3d597,PubMed and EMBASE,0.381076
uuid-6b4de80802504c9dae00240580a3d597,detailed search of www.clinicaltrials.gov,0.410839
uuid-6b4de80802504c9dae00240580a3d597,efficacy and safety of nivolumab,0.420969
uuid-6b4de80802504c9dae00240580a3d597,not identify any planned,0.421855
uuid-6b4de80802504c9dae00240580a3d597,combination,0.366296
uuid-6b4de80802504c9dae00240580a3d597,BMS,0.321327
uuid-6b4de80802504c9dae00240580a3d597,not identify any citations relevant to your request,0.430346
uuid-6b4de80802504c9dae00240580a3d597,present using the following search terms,0.383321
uuid-9bdc77177acd49fe9aac88c961e17ae7,NSCLC,0.359364
uuid-9bdc77177acd49fe9aac88c961e17ae7,non-small cell lung cancer,0.350403
uuid-e9703554a69a4df7a8315758d2224db0,SCLC,0.319326
uuid-e9703554a69a4df7a8315758d2224db0,therapy,0.448079
uuid-7eb595c02337470184b81e0a380091e7,Bristol-Myers Squibb,0.341822
uuid-7eb595c02337470184b81e0a380091e7,not conducted any controlled clinical trials/studies,0.304507
uuid-7eb595c02337470184b81e0a380091e7,Opdivo,0.461382
uuid-7eb595c02337470184b81e0a380091e7,Pubmed literature search,0.614325
uuid-7eb595c02337470184b81e0a380091e7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-7eb595c02337470184b81e0a380091e7,not identify any citations relevant to your inquiry,0.606087
uuid-7eb595c02337470184b81e0a380091e7,adverse,0.304183
uuid-7eb595c02337470184b81e0a380091e7,using the following search terms,0.642331
uuid-7eb595c02337470184b81e0a380091e7,databases,0.315039
uuid-7eb595c02337470184b81e0a380091e7,reported,0.556704
uuid-ceee37fdd0704d2fa049f8c646c849cd,search of published literature,0.404068
uuid-ceee37fdd0704d2fa049f8c646c849cd,phase 3 study,0.655867
uuid-ceee37fdd0704d2fa049f8c646c849cd,PubMed and EMBASE,0.401878
uuid-ceee37fdd0704d2fa049f8c646c849cd,Rizvi NA,0.345724
uuid-ceee37fdd0704d2fa049f8c646c849cd,Weber JS,0.549683
uuid-ceee37fdd0704d2fa049f8c646c849cd,phase 2 study,0.345605
uuid-ceee37fdd0704d2fa049f8c646c849cd,present using the following search terms,0.364403
uuid-bcb4268e28794f82b5dfc1f22e97318c,nivolumab,0.415684
uuid-bcb4268e28794f82b5dfc1f22e97318c,Bristol-Myers Squibb,0.567662
uuid-bcb4268e28794f82b5dfc1f22e97318c,evaluating,0.683003
uuid-bcb4268e28794f82b5dfc1f22e97318c,not conducted any controlled clinical trials/studies,0.728702
uuid-bcb4268e28794f82b5dfc1f22e97318c,Pubmed literature search,0.589718
uuid-bcb4268e28794f82b5dfc1f22e97318c,purposes other than its labeled indication must be considered investigational,0.675293
uuid-bcb4268e28794f82b5dfc1f22e97318c,not identify any citations relevant to your inquiry,0.562894
uuid-bcb4268e28794f82b5dfc1f22e97318c,using the following search terms,0.528526
uuid-bcb4268e28794f82b5dfc1f22e97318c,efficacy and safety of nivolumab,0.56859
uuid-1a304b762a164ccf95b38fc3b87a88e5,95% CI,0.38691
uuid-1a304b762a164ccf95b38fc3b87a88e5,NSCLC,0.309907
uuid-1a304b762a164ccf95b38fc3b87a88e5,respectively,0.520194
uuid-1a304b762a164ccf95b38fc3b87a88e5,Objective response rate,0.573555
uuid-1a304b762a164ccf95b38fc3b87a88e5,ORR,0.626348
uuid-1a304b762a164ccf95b38fc3b87a88e5,Median overall survival,0.400007
uuid-1a304b762a164ccf95b38fc3b87a88e5,monotherapy,0.453522
uuid-1a304b762a164ccf95b38fc3b87a88e5,Median OS,0.354493
uuid-1a304b762a164ccf95b38fc3b87a88e5,docetaxel,0.412975
uuid-1a304b762a164ccf95b38fc3b87a88e5,hazard ratio,0.358112
uuid-1f9dcb37a5ac4007921d3c9646625624,N Engl J Med,0.427636
uuid-1f9dcb37a5ac4007921d3c9646625624,protocol,0.429136
uuid-1f9dcb37a5ac4007921d3c9646625624,McDermott DF,0.44782
uuid-1f9dcb37a5ac4007921d3c9646625624,Motzer RJ,0.430476
uuid-1f9dcb37a5ac4007921d3c9646625624,Escudier B,0.450887
uuid-1f9dcb37a5ac4007921d3c9646625624,et al.,0.456026
uuid-1f9dcb37a5ac4007921d3c9646625624,J Clin Oncol,0.384624
uuid-1f9dcb37a5ac4007921d3c9646625624,Rizvi NA,0.305616
uuid-1f9dcb37a5ac4007921d3c9646625624,phase 2 study,0.351446
uuid-56872caaf4244914a92cc5fd4cfff84e,requested,0.662269
uuid-e49765934aa94fd2a65d49f73d6b60d2,Opdivo,0.339423
uuid-e49765934aa94fd2a65d49f73d6b60d2,partial response,0.397464
uuid-e49765934aa94fd2a65d49f73d6b60d2,reported,0.353136
uuid-750699f1f26546a3a2a651e1fe9dd752,N Engl J Med,0.748881
uuid-750699f1f26546a3a2a651e1fe9dd752,protocol,0.760798
uuid-750699f1f26546a3a2a651e1fe9dd752,McDermott DF,0.820165
uuid-750699f1f26546a3a2a651e1fe9dd752,Motzer RJ,0.805264
uuid-750699f1f26546a3a2a651e1fe9dd752,phase 3 study,0.582383
uuid-750699f1f26546a3a2a651e1fe9dd752,Escudier B,0.819992
uuid-750699f1f26546a3a2a651e1fe9dd752,NEJM,0.396015
uuid-750699f1f26546a3a2a651e1fe9dd752,et al.,0.795985
uuid-750699f1f26546a3a2a651e1fe9dd752,J Clin Oncol,0.759213
uuid-750699f1f26546a3a2a651e1fe9dd752,Topalian,0.370773
uuid-750699f1f26546a3a2a651e1fe9dd752,phase 1 study,0.303685
uuid-750699f1f26546a3a2a651e1fe9dd752,Rizvi NA,0.527565
uuid-750699f1f26546a3a2a651e1fe9dd752,Brahmer J,0.479102
uuid-750699f1f26546a3a2a651e1fe9dd752,Weber JS,0.322817
uuid-750699f1f26546a3a2a651e1fe9dd752,phase 2 study,0.81581
uuid-79b04f4bb50b446782b74c0936cfcd8f,Opdivo,0.377676
uuid-fe8d14a52d3b4787b80420d7a52011a0,nivolumab,0.369777
uuid-b965fac64f804882be099bfa93067a4d,evaluating,0.350845
uuid-b965fac64f804882be099bfa93067a4d,not conducted any controlled clinical trials/studies,0.345107
uuid-b965fac64f804882be099bfa93067a4d,search of published literature,0.385331
uuid-b965fac64f804882be099bfa93067a4d,Additionally,0.40981
uuid-b965fac64f804882be099bfa93067a4d,ongoing,0.457998
uuid-b965fac64f804882be099bfa93067a4d,PubMed and EMBASE,0.378285
uuid-b965fac64f804882be099bfa93067a4d,detailed search of www.clinicaltrials.gov,0.428522
uuid-b965fac64f804882be099bfa93067a4d,efficacy and safety of nivolumab,0.407868
uuid-b965fac64f804882be099bfa93067a4d,not identify any planned,0.444729
uuid-b965fac64f804882be099bfa93067a4d,combination,0.388252
uuid-b965fac64f804882be099bfa93067a4d,BMS,0.316104
uuid-b965fac64f804882be099bfa93067a4d,not identify any citations relevant to your request,0.438151
uuid-b965fac64f804882be099bfa93067a4d,present using the following search terms,0.377101
uuid-aceb11e220794074a6c223f2f6ca31b3,Bristol-Myers Squibb,0.472032
uuid-3e18f31358a743b6b1e0f25434decd37,nivolumab,0.403825
uuid-076412a80a654f87b16eb40acff47cf2,requested,0.687331
uuid-13451f9287314a13b27580e19fb6f0ac,Bristol-Myers Squibb,0.324718
uuid-13451f9287314a13b27580e19fb6f0ac,evaluating,0.510191
uuid-13451f9287314a13b27580e19fb6f0ac,not conducted any controlled clinical trials/studies,0.475016
uuid-13451f9287314a13b27580e19fb6f0ac,NSCLC,0.894749
uuid-13451f9287314a13b27580e19fb6f0ac,non-small cell lung cancer,0.895525
uuid-13451f9287314a13b27580e19fb6f0ac,patients,0.517851
uuid-13451f9287314a13b27580e19fb6f0ac,considered investigational,0.543721
uuid-13451f9287314a13b27580e19fb6f0ac,phase 1 study,0.351869
uuid-13451f9287314a13b27580e19fb6f0ac,efficacy and safety of nivolumab,0.434173
uuid-13451f9287314a13b27580e19fb6f0ac,safety of nivolumab monotherapy,0.452151
uuid-13451f9287314a13b27580e19fb6f0ac,platinum-based doublet chemotherapy,0.413425
uuid-f47d2f839bfc4033907f89a8165089fd,phase 1 study,0.342744
uuid-f47d2f839bfc4033907f89a8165089fd,CA209-003,0.465129
uuid-f47d2f839bfc4033907f89a8165089fd,investigating,0.659334
uuid-6bd040a95dd748d8b70a7c1ba9d12992,nivolumab,0.595987
uuid-6bd040a95dd748d8b70a7c1ba9d12992,Bristol-Myers Squibb,0.406528
uuid-6bd040a95dd748d8b70a7c1ba9d12992,evaluating,0.550731
uuid-6bd040a95dd748d8b70a7c1ba9d12992,not conducted any controlled clinical trials/studies,0.612892
uuid-6bd040a95dd748d8b70a7c1ba9d12992,Pubmed literature search,0.829073
uuid-6bd040a95dd748d8b70a7c1ba9d12992,purposes other than its labeled indication must be considered investigational,0.895912
uuid-6bd040a95dd748d8b70a7c1ba9d12992,not identify any citations relevant to your inquiry,0.791159
uuid-6bd040a95dd748d8b70a7c1ba9d12992,using the following search terms,0.776941
uuid-6bd040a95dd748d8b70a7c1ba9d12992,efficacy and safety of nivolumab,0.395961
uuid-79de96f45cf2429ba11d723e1f3a8ef6,use of nivolumab for the treatment,0.444892
uuid-79de96f45cf2429ba11d723e1f3a8ef6,evaluating,0.30558
uuid-79de96f45cf2429ba11d723e1f3a8ef6,patients,0.440855
uuid-79de96f45cf2429ba11d723e1f3a8ef6,not approved,0.378002
uuid-79de96f45cf2429ba11d723e1f3a8ef6,clinical trials investigating the safety,0.352423
uuid-f64753b322074bb7901ac49a16ccc0c0,95% CI,0.524855
uuid-f64753b322074bb7901ac49a16ccc0c0,respectively,0.383655
uuid-f64753b322074bb7901ac49a16ccc0c0,ASCO,0.303153
uuid-f64753b322074bb7901ac49a16ccc0c0,Lancet Oncol,0.368041
uuid-f64753b322074bb7901ac49a16ccc0c0,Objective response rate,0.504846
uuid-f64753b322074bb7901ac49a16ccc0c0,ORR,0.465366
uuid-f64753b322074bb7901ac49a16ccc0c0,Median overall survival,0.346516
uuid-f64753b322074bb7901ac49a16ccc0c0,Median OS,0.33538
uuid-f64753b322074bb7901ac49a16ccc0c0,ASCO 2015,0.336983
uuid-f64753b322074bb7901ac49a16ccc0c0,small cell lung cancer,0.336892
uuid-f64753b322074bb7901ac49a16ccc0c0,SCLC,0.344367
uuid-f64753b322074bb7901ac49a16ccc0c0,Antonia SJ,0.55269
uuid-f64753b322074bb7901ac49a16ccc0c0,Median duration of response,0.649605
uuid-7d951caf66cf42c8b8eb0b650724d0d2,AEs,0.317894
uuid-7d951caf66cf42c8b8eb0b650724d0d2,NSCLC,0.328183
uuid-7d951caf66cf42c8b8eb0b650724d0d2,phase 3 study,0.337839
uuid-7d951caf66cf42c8b8eb0b650724d0d2,phase 1 study,0.336346
uuid-7d951caf66cf42c8b8eb0b650724d0d2,phase 2 study,0.332897
uuid-7d951caf66cf42c8b8eb0b650724d0d2,grade,0.420458
uuid-7d951caf66cf42c8b8eb0b650724d0d2,grade 3 to 4 AEs,0.318502
uuid-1cc7e88773904d37b961e729c0f52628,evaluating,0.374249
uuid-1cc7e88773904d37b961e729c0f52628,not conducted any controlled clinical trials/studies,0.375643
uuid-1cc7e88773904d37b961e729c0f52628,protocol,0.505396
uuid-1cc7e88773904d37b961e729c0f52628,RCC,0.394232
uuid-1cc7e88773904d37b961e729c0f52628,McDermott DF,0.408791
uuid-1cc7e88773904d37b961e729c0f52628,search of published literature,0.500542
uuid-1cc7e88773904d37b961e729c0f52628,Additionally,0.535364
uuid-1cc7e88773904d37b961e729c0f52628,ongoing,0.460126
uuid-1cc7e88773904d37b961e729c0f52628,Motzer RJ,0.4437
uuid-1cc7e88773904d37b961e729c0f52628,PubMed and EMBASE,0.494799
uuid-1cc7e88773904d37b961e729c0f52628,Escudier B,0.424656
uuid-1cc7e88773904d37b961e729c0f52628,et al.,0.360783
uuid-1cc7e88773904d37b961e729c0f52628,J Clin Oncol,0.39605
uuid-1cc7e88773904d37b961e729c0f52628,detailed search of www.clinicaltrials.gov,0.494316
uuid-1cc7e88773904d37b961e729c0f52628,efficacy and safety of nivolumab,0.505327
uuid-1cc7e88773904d37b961e729c0f52628,not identify any planned,0.472878
uuid-1cc7e88773904d37b961e729c0f52628,phase 2 study,0.350087
uuid-1cc7e88773904d37b961e729c0f52628,not identify any citations relevant to your request,0.546331
uuid-1cc7e88773904d37b961e729c0f52628,present using the following search terms,0.484044
uuid-de00e44ed3cc4fe28fc7ca5b5e5b35d0,patients,0.324499
uuid-74a0a1e7a3724876804e5d953c678b96,nivolumab,0.509998
uuid-74a0a1e7a3724876804e5d953c678b96,Bristol-Myers Squibb,0.440541
uuid-74a0a1e7a3724876804e5d953c678b96,evaluating,0.596011
uuid-74a0a1e7a3724876804e5d953c678b96,not conducted any controlled clinical trials/studies,0.652468
uuid-74a0a1e7a3724876804e5d953c678b96,Pubmed literature search,0.88643
uuid-74a0a1e7a3724876804e5d953c678b96,purposes other than its labeled indication must be considered investigational,0.943834
uuid-74a0a1e7a3724876804e5d953c678b96,not identify any citations relevant to your inquiry,0.847356
uuid-74a0a1e7a3724876804e5d953c678b96,using the following search terms,0.836212
uuid-74a0a1e7a3724876804e5d953c678b96,efficacy and safety of nivolumab,0.418248
uuid-fb0bf3fb4adb454d91e886162103140b,N Engl J Med,0.580351
uuid-fb0bf3fb4adb454d91e886162103140b,ASCO,0.383128
uuid-fb0bf3fb4adb454d91e886162103140b,Lancet Oncol,0.318957
uuid-fb0bf3fb4adb454d91e886162103140b,protocol,0.374551
uuid-fb0bf3fb4adb454d91e886162103140b,McDermott DF,0.427286
uuid-fb0bf3fb4adb454d91e886162103140b,Motzer RJ,0.39691
uuid-fb0bf3fb4adb454d91e886162103140b,phase 3 study,0.392158
uuid-fb0bf3fb4adb454d91e886162103140b,Escudier B,0.416218
uuid-fb0bf3fb4adb454d91e886162103140b,et al.,0.441208
uuid-fb0bf3fb4adb454d91e886162103140b,J Clin Oncol,0.37546
uuid-fb0bf3fb4adb454d91e886162103140b,Rizvi NA,0.482308
uuid-fb0bf3fb4adb454d91e886162103140b,Brahmer J,0.482921
uuid-fb0bf3fb4adb454d91e886162103140b,phase 2 study,0.507144
uuid-b7ef27cd34e14089b1fd33a7982a2b54,Bristol-Myers Squibb,0.341822
uuid-b7ef27cd34e14089b1fd33a7982a2b54,not conducted any controlled clinical trials/studies,0.304507
uuid-b7ef27cd34e14089b1fd33a7982a2b54,Opdivo,0.461382
uuid-b7ef27cd34e14089b1fd33a7982a2b54,Pubmed literature search,0.614325
uuid-b7ef27cd34e14089b1fd33a7982a2b54,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b7ef27cd34e14089b1fd33a7982a2b54,not identify any citations relevant to your inquiry,0.606087
uuid-b7ef27cd34e14089b1fd33a7982a2b54,adverse,0.304183
uuid-b7ef27cd34e14089b1fd33a7982a2b54,using the following search terms,0.642331
uuid-b7ef27cd34e14089b1fd33a7982a2b54,databases,0.315039
uuid-b7ef27cd34e14089b1fd33a7982a2b54,reported,0.556704
uuid-d5cd2544f6e14641944a7cd9bb810c13,evaluating,0.364215
uuid-d5cd2544f6e14641944a7cd9bb810c13,not conducted any controlled clinical trials/studies,0.349185
uuid-d5cd2544f6e14641944a7cd9bb810c13,search of published literature,0.382954
uuid-d5cd2544f6e14641944a7cd9bb810c13,Additionally,0.379057
uuid-d5cd2544f6e14641944a7cd9bb810c13,ongoing,0.315649
uuid-d5cd2544f6e14641944a7cd9bb810c13,PubMed and EMBASE,0.372143
uuid-d5cd2544f6e14641944a7cd9bb810c13,detailed search of www.clinicaltrials.gov,0.356789
uuid-d5cd2544f6e14641944a7cd9bb810c13,efficacy and safety of nivolumab,0.446546
uuid-d5cd2544f6e14641944a7cd9bb810c13,not identify any planned,0.3282
uuid-d5cd2544f6e14641944a7cd9bb810c13,not identify any citations relevant to your request,0.419324
uuid-d5cd2544f6e14641944a7cd9bb810c13,present using the following search terms,0.394242
uuid-bed7d875da5c4cee8939bfc02f83f956,nivolumab,0.455495
uuid-bed7d875da5c4cee8939bfc02f83f956,Bristol-Myers Squibb,0.422787
uuid-bed7d875da5c4cee8939bfc02f83f956,evaluating,0.562234
uuid-bed7d875da5c4cee8939bfc02f83f956,not conducted any controlled clinical trials/studies,0.594531
uuid-bed7d875da5c4cee8939bfc02f83f956,Opdivo,0.362645
uuid-bed7d875da5c4cee8939bfc02f83f956,Pubmed literature search,0.859695
uuid-bed7d875da5c4cee8939bfc02f83f956,purposes other than its labeled indication must be considered investigational,0.891011
uuid-bed7d875da5c4cee8939bfc02f83f956,not identify any citations relevant to your inquiry,0.830298
uuid-bed7d875da5c4cee8939bfc02f83f956,using the following search terms,0.839929
uuid-bed7d875da5c4cee8939bfc02f83f956,efficacy and safety of nivolumab,0.391878
uuid-4382a0debe0645b0bd27233a167ec4de,N Engl J Med,0.54825
uuid-4382a0debe0645b0bd27233a167ec4de,NSCLC,0.358785
uuid-4382a0debe0645b0bd27233a167ec4de,non-small cell lung cancer,0.308706
uuid-4382a0debe0645b0bd27233a167ec4de,ESMO,0.396697
uuid-4382a0debe0645b0bd27233a167ec4de,phase 3 study,0.368632
uuid-4382a0debe0645b0bd27233a167ec4de,phase 1 study,0.306384
uuid-4382a0debe0645b0bd27233a167ec4de,Rizvi NA,0.47921
uuid-4382a0debe0645b0bd27233a167ec4de,Brahmer J,0.605319
uuid-4382a0debe0645b0bd27233a167ec4de,phase 2 study,0.362302
uuid-4382a0debe0645b0bd27233a167ec4de,Horn L,0.443225
uuid-4446202286b74ad3a20b73e99653875a,95% CI,0.524855
uuid-4446202286b74ad3a20b73e99653875a,respectively,0.383655
uuid-4446202286b74ad3a20b73e99653875a,ASCO,0.303153
uuid-4446202286b74ad3a20b73e99653875a,Lancet Oncol,0.368041
uuid-4446202286b74ad3a20b73e99653875a,Objective response rate,0.504846
uuid-4446202286b74ad3a20b73e99653875a,ORR,0.465366
uuid-4446202286b74ad3a20b73e99653875a,Median overall survival,0.346516
uuid-4446202286b74ad3a20b73e99653875a,Median OS,0.33538
uuid-4446202286b74ad3a20b73e99653875a,ASCO 2015,0.336983
uuid-4446202286b74ad3a20b73e99653875a,small cell lung cancer,0.336892
uuid-4446202286b74ad3a20b73e99653875a,SCLC,0.344367
uuid-4446202286b74ad3a20b73e99653875a,Antonia SJ,0.55269
uuid-4446202286b74ad3a20b73e99653875a,Median duration of response,0.649605
uuid-4204819532f7489593261e490c54ea38,N Engl J Med,0.306444
uuid-4204819532f7489593261e490c54ea38,protocol,0.31755
uuid-4204819532f7489593261e490c54ea38,McDermott DF,0.426545
uuid-4204819532f7489593261e490c54ea38,Motzer RJ,0.389884
uuid-4204819532f7489593261e490c54ea38,phase 3 study,0.427042
uuid-4204819532f7489593261e490c54ea38,Escudier B,0.410046
uuid-4204819532f7489593261e490c54ea38,et al.,0.390988
uuid-4204819532f7489593261e490c54ea38,J Clin Oncol,0.382309
uuid-4204819532f7489593261e490c54ea38,phase 2 study,0.47848
uuid-6e188349a19f47a087038267f3d8d7a5,requested,0.662269
uuid-ddf919661dbb4cc3acdba2e16e057060,PD-L1,0.753859
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,search of published literature,0.394524
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,Additionally,0.413583
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,ongoing,0.322117
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,PubMed and EMBASE,0.391671
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,detailed search of www.clinicaltrials.gov,0.375936
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,efficacy and safety of nivolumab,0.370699
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,not identify any planned,0.34283
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,Weber JS,0.319229
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,not identify any citations relevant to your request,0.447813
uuid-9694fba1916d48a3ac0c0f09ad5d8d69,present using the following search terms,0.408199
uuid-a18e1c19c0e14b78a9418738e5633281,clinical,0.340788
uuid-a18e1c19c0e14b78a9418738e5633281,PD-L1,0.508455
uuid-a796a0f811a54098ac9b93f9aae5d44c,PD-L1,0.760788
uuid-3a66c78d1aba4316a583ab38a6e33aae,evaluating,0.393485
uuid-3a66c78d1aba4316a583ab38a6e33aae,not conducted any controlled clinical trials/studies,0.366451
uuid-3a66c78d1aba4316a583ab38a6e33aae,search of published literature,0.439991
uuid-3a66c78d1aba4316a583ab38a6e33aae,Additionally,0.388494
uuid-3a66c78d1aba4316a583ab38a6e33aae,PubMed and EMBASE,0.431263
uuid-3a66c78d1aba4316a583ab38a6e33aae,detailed search of www.clinicaltrials.gov,0.362006
uuid-3a66c78d1aba4316a583ab38a6e33aae,phase 1 study,0.562827
uuid-3a66c78d1aba4316a583ab38a6e33aae,efficacy and safety of nivolumab,0.50802
uuid-3a66c78d1aba4316a583ab38a6e33aae,not identify any planned,0.315176
uuid-3a66c78d1aba4316a583ab38a6e33aae,CA209-003,0.643871
uuid-3a66c78d1aba4316a583ab38a6e33aae,not identify any citations relevant to your request,0.464845
uuid-3a66c78d1aba4316a583ab38a6e33aae,present using the following search terms,0.476675
uuid-3a66c78d1aba4316a583ab38a6e33aae,investigating,0.768675
uuid-d95bdf7acba54fc4861e044f14823f13,adverse,0.421902
uuid-d95bdf7acba54fc4861e044f14823f13,reported,0.630857
uuid-db608bbf1755430db0e3b039532b6277,nivolumab,0.359772
uuid-4e83661dc22d4f65bff57cc582d982a6,respectively,0.589071
uuid-4e83661dc22d4f65bff57cc582d982a6,Objective response rate,0.407286
uuid-4e83661dc22d4f65bff57cc582d982a6,ORR,0.526086
uuid-4e83661dc22d4f65bff57cc582d982a6,monotherapy,0.319413
uuid-4e83661dc22d4f65bff57cc582d982a6,docetaxel,0.334344
uuid-9b81cf24c7d945a8a7ed93d0d5d4ea4d,phase 1 study,0.317998
uuid-9b81cf24c7d945a8a7ed93d0d5d4ea4d,grade,0.336353
uuid-b5e5755e5cfb44d499670842a6d7f9c6,mg,0.379493
uuid-b5e5755e5cfb44d499670842a6d7f9c6,kg,0.367219
uuid-4a1a569bef1247e0b843978a85328e46,requested,0.594234
uuid-08f9e940eb8c4dc79c5ac71e4a7e2bd6,requested,0.307819
uuid-08f9e940eb8c4dc79c5ac71e4a7e2bd6,search of published literature,0.351059
uuid-08f9e940eb8c4dc79c5ac71e4a7e2bd6,PubMed and EMBASE,0.350931
uuid-08f9e940eb8c4dc79c5ac71e4a7e2bd6,present using the following search terms,0.355354
uuid-d95b5ad4e5f54bf09cc58466192eaf61,N Engl J Med,0.320726
uuid-d95b5ad4e5f54bf09cc58466192eaf61,provided in the Detailed Information,0.366677
uuid-d95b5ad4e5f54bf09cc58466192eaf61,clinical,0.40856
uuid-53a12882b67049b9a99d74c6bd312377,nivolumab,0.513924
uuid-10b0d9da59314b98b398db603f88eb17,Bristol-Myers Squibb,0.341822
uuid-10b0d9da59314b98b398db603f88eb17,not conducted any controlled clinical trials/studies,0.304507
uuid-10b0d9da59314b98b398db603f88eb17,Opdivo,0.461382
uuid-10b0d9da59314b98b398db603f88eb17,Pubmed literature search,0.614325
uuid-10b0d9da59314b98b398db603f88eb17,purposes other than its labeled indication must be considered investigational,0.586645
uuid-10b0d9da59314b98b398db603f88eb17,not identify any citations relevant to your inquiry,0.606087
uuid-10b0d9da59314b98b398db603f88eb17,adverse,0.304183
uuid-10b0d9da59314b98b398db603f88eb17,using the following search terms,0.642331
uuid-10b0d9da59314b98b398db603f88eb17,databases,0.315039
uuid-10b0d9da59314b98b398db603f88eb17,reported,0.556704
uuid-9aa7017027b64b6cb2a730d5d41da84f,clinical,0.358154
uuid-9aa7017027b64b6cb2a730d5d41da84f,trial,0.740972
uuid-b0dff200852a4338933e78b4f6b6e1ca,N Engl J Med,0.317071
uuid-b0dff200852a4338933e78b4f6b6e1ca,protocol,0.352142
uuid-b0dff200852a4338933e78b4f6b6e1ca,McDermott DF,0.356845
uuid-b0dff200852a4338933e78b4f6b6e1ca,Motzer RJ,0.344076
uuid-b0dff200852a4338933e78b4f6b6e1ca,Escudier B,0.36009
uuid-b0dff200852a4338933e78b4f6b6e1ca,et al.,0.363169
uuid-b0dff200852a4338933e78b4f6b6e1ca,J Clin Oncol,0.304749
uuid-cd4c230e4a364f1a8a42db5d19688226,NSCLC,0.458795
uuid-cd4c230e4a364f1a8a42db5d19688226,respectively,0.328929
uuid-cd4c230e4a364f1a8a42db5d19688226,non-small cell lung cancer,0.356077
uuid-cd4c230e4a364f1a8a42db5d19688226,considered investigational,0.349545
uuid-cd4c230e4a364f1a8a42db5d19688226,patients with advanced or metastatic,0.508154
uuid-cd4c230e4a364f1a8a42db5d19688226,nivolumab combined with ipilimumab,0.435419
uuid-cd4c230e4a364f1a8a42db5d19688226,docetaxel,0.573524
uuid-cd4c230e4a364f1a8a42db5d19688226,phase 1/2 study CA209-032,0.401449
uuid-cd4c230e4a364f1a8a42db5d19688226,evaluates the efficacy of nivolumab monotherapy,0.426477
uuid-4b8de7abc9a14e69b19a51fda517d0dc,OS,0.458052
uuid-4b8de7abc9a14e69b19a51fda517d0dc,95% CI,0.853244
uuid-4b8de7abc9a14e69b19a51fda517d0dc,respectively,0.523247
uuid-4b8de7abc9a14e69b19a51fda517d0dc,Objective response rate,0.620389
uuid-4b8de7abc9a14e69b19a51fda517d0dc,ORR,0.73365
uuid-4b8de7abc9a14e69b19a51fda517d0dc,PFS,0.348462
uuid-4b8de7abc9a14e69b19a51fda517d0dc,Median overall survival,0.771789
uuid-4b8de7abc9a14e69b19a51fda517d0dc,monotherapy,0.392496
uuid-4b8de7abc9a14e69b19a51fda517d0dc,Median OS,0.754645
uuid-4b8de7abc9a14e69b19a51fda517d0dc,docetaxel,0.302866
uuid-4b8de7abc9a14e69b19a51fda517d0dc,hazard ratio,0.828188
uuid-4b8de7abc9a14e69b19a51fda517d0dc,Median duration of response,0.375297
uuid-7e112aa9de5e465dac6669674da39219,clinical,0.327537
uuid-7e112aa9de5e465dac6669674da39219,safety,0.437639
uuid-7e112aa9de5e465dac6669674da39219,databases,0.47294
uuid-f8e4ee35a723490a9269d2712d279e90,clinical,0.369049
uuid-f8e4ee35a723490a9269d2712d279e90,trial,0.4933
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,Bristol-Myers Squibb,0.322856
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,evaluating,0.450622
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,not conducted any controlled clinical trials/studies,0.451107
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,search of published literature,0.378318
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,Additionally,0.348385
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,ongoing,0.395402
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,PubMed and EMBASE,0.363197
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,detailed search of www.clinicaltrials.gov,0.363057
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,efficacy and safety of nivolumab,0.484483
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,not identify any planned,0.378613
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,combination,0.372337
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,not identify any citations relevant to your request,0.378834
uuid-00ed8bfde53f4eacbe4de8dac3903e9a,present using the following search terms,0.360797
uuid-c8e90cee03184e80857f27a3139b31dd,OS,0.44149
uuid-c8e90cee03184e80857f27a3139b31dd,95% CI,0.833403
uuid-c8e90cee03184e80857f27a3139b31dd,ASCO,0.32927
uuid-c8e90cee03184e80857f27a3139b31dd,Objective response rate,0.545269
uuid-c8e90cee03184e80857f27a3139b31dd,ORR,0.618524
uuid-c8e90cee03184e80857f27a3139b31dd,PFS,0.396858
uuid-c8e90cee03184e80857f27a3139b31dd,Median overall survival,0.72593
uuid-c8e90cee03184e80857f27a3139b31dd,monotherapy,0.33356
uuid-c8e90cee03184e80857f27a3139b31dd,Median OS,0.763854
uuid-c8e90cee03184e80857f27a3139b31dd,hazard ratio,0.766648
uuid-c8e90cee03184e80857f27a3139b31dd,Median duration of response,0.442682
uuid-3f55173e315741519906fd3e3b7736a4,clinical,0.361852
uuid-3f55173e315741519906fd3e3b7736a4,trial,0.70755
uuid-90a13508d4fc4aac8e9b5acb15163947,nivolumab,0.495014
uuid-90a13508d4fc4aac8e9b5acb15163947,evaluating,0.420671
uuid-90a13508d4fc4aac8e9b5acb15163947,not conducted any controlled clinical trials/studies,0.466896
uuid-90a13508d4fc4aac8e9b5acb15163947,Pubmed literature search,0.694693
uuid-90a13508d4fc4aac8e9b5acb15163947,purposes other than its labeled indication must be considered investigational,0.737346
uuid-90a13508d4fc4aac8e9b5acb15163947,not identify any citations relevant to your inquiry,0.682644
uuid-90a13508d4fc4aac8e9b5acb15163947,using the following search terms,0.65909
uuid-90a13508d4fc4aac8e9b5acb15163947,efficacy and safety of nivolumab,0.316733
uuid-157a83f5ddaf412f9ec1bfd3f7b8de5a,open-label,0.375792
uuid-157a83f5ddaf412f9ec1bfd3f7b8de5a,trial,0.480107
uuid-157a83f5ddaf412f9ec1bfd3f7b8de5a,phase,0.319941
uuid-dcb61f6330cd4614bf40802544bd7026,nivolumab,0.639032
uuid-dcb61f6330cd4614bf40802544bd7026,clinical,0.507135
uuid-5a994d5772df4703b22c42f8abba9781,patients with advanced or metastatic,0.468858
uuid-5a994d5772df4703b22c42f8abba9781,nivolumab combined with ipilimumab,0.446918
uuid-5a994d5772df4703b22c42f8abba9781,not approved,0.352562
uuid-5a994d5772df4703b22c42f8abba9781,clinical trials investigating the safety,0.429501
uuid-5a994d5772df4703b22c42f8abba9781,bladder cancer,0.950698
uuid-b63b2e3342624e948d911c9cbeeac832,nivolumab,0.486328
uuid-b63b2e3342624e948d911c9cbeeac832,clinical,0.316386
uuid-b63b2e3342624e948d911c9cbeeac832,trial,0.471201
uuid-b63b2e3342624e948d911c9cbeeac832,phase,0.377416
uuid-426f916da3ee460e82e1b1bd44951913,trial,0.434006
uuid-426f916da3ee460e82e1b1bd44951913,safety of nivolumab monotherapy,0.302159
uuid-426f916da3ee460e82e1b1bd44951913,phase,0.319595
uuid-de6383c7c93a45e9be9522ddcb0a98e5,nivolumab,0.315199
uuid-de6383c7c93a45e9be9522ddcb0a98e5,melanoma,0.445165
uuid-03aec12f5a224e5fb79fece102f31a77,Opdivo,0.310808
uuid-03aec12f5a224e5fb79fece102f31a77,trial,0.677803
uuid-06788d99d9ea4da8bdf3b9c546afd22d,phase 3 study,0.335117
uuid-06788d99d9ea4da8bdf3b9c546afd22d,Weber JS,0.36948
uuid-b46dae9fb79d43c782aad974ae8b241c,nivolumab,0.301484
uuid-b46dae9fb79d43c782aad974ae8b241c,evaluating,0.439462
uuid-b46dae9fb79d43c782aad974ae8b241c,not conducted any controlled clinical trials/studies,0.408446
uuid-b46dae9fb79d43c782aad974ae8b241c,search of published literature,0.60536
uuid-b46dae9fb79d43c782aad974ae8b241c,Additionally,0.55475
uuid-b46dae9fb79d43c782aad974ae8b241c,ongoing,0.4296
uuid-b46dae9fb79d43c782aad974ae8b241c,PubMed and EMBASE,0.601144
uuid-b46dae9fb79d43c782aad974ae8b241c,detailed search of www.clinicaltrials.gov,0.521985
uuid-b46dae9fb79d43c782aad974ae8b241c,phase 1 study,0.46106
uuid-b46dae9fb79d43c782aad974ae8b241c,efficacy and safety of nivolumab,0.597041
uuid-b46dae9fb79d43c782aad974ae8b241c,not identify any planned,0.462982
uuid-b46dae9fb79d43c782aad974ae8b241c,CA209-003,0.512448
uuid-b46dae9fb79d43c782aad974ae8b241c,not identify any citations relevant to your request,0.648228
uuid-b46dae9fb79d43c782aad974ae8b241c,present using the following search terms,0.641401
uuid-b46dae9fb79d43c782aad974ae8b241c,investigating,0.591243
uuid-0e0cf333f72145ed86b64608fa8802b7,N Engl J Med,0.448483
uuid-0e0cf333f72145ed86b64608fa8802b7,protocol,0.770446
uuid-0e0cf333f72145ed86b64608fa8802b7,McDermott DF,0.741196
uuid-0e0cf333f72145ed86b64608fa8802b7,Motzer RJ,0.818144
uuid-0e0cf333f72145ed86b64608fa8802b7,phase 3 study,0.417055
uuid-0e0cf333f72145ed86b64608fa8802b7,Escudier B,0.749917
uuid-0e0cf333f72145ed86b64608fa8802b7,NEJM,0.400698
uuid-0e0cf333f72145ed86b64608fa8802b7,et al.,0.668641
uuid-0e0cf333f72145ed86b64608fa8802b7,J Clin Oncol,0.792018
uuid-0e0cf333f72145ed86b64608fa8802b7,Topalian,0.388894
uuid-0e0cf333f72145ed86b64608fa8802b7,phase 1 study,0.500686
uuid-0e0cf333f72145ed86b64608fa8802b7,CA209-003,0.567381
uuid-0e0cf333f72145ed86b64608fa8802b7,phase 2 study,0.677985
uuid-0e0cf333f72145ed86b64608fa8802b7,present using the following search terms,0.310558
uuid-0e0cf333f72145ed86b64608fa8802b7,investigating,0.615835
uuid-3b7a5ffcdcc043778a5525a7a1edecb2,adverse,0.390761
uuid-3b7a5ffcdcc043778a5525a7a1edecb2,melanoma,0.479196
uuid-3b7a5ffcdcc043778a5525a7a1edecb2,mg,0.385976
uuid-3b7a5ffcdcc043778a5525a7a1edecb2,kg,0.351546
uuid-259d462e0f384af8b374baf613d8e591,patients with advanced or metastatic,0.478326
uuid-259d462e0f384af8b374baf613d8e591,nivolumab combined with ipilimumab,0.498766
uuid-259d462e0f384af8b374baf613d8e591,not approved,0.34724
uuid-259d462e0f384af8b374baf613d8e591,clinical trials investigating the safety,0.426729
uuid-259d462e0f384af8b374baf613d8e591,bladder cancer,0.6548
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,N Engl J Med,0.302601
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,AEs,0.348167
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,patients,0.536884
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,provided in the Detailed Information,0.387544
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,ESMO,0.462801
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,NEJM,0.66427
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,Topalian,0.692873
uuid-fe0aec4abeeb46e0ab6c4f6d84e16891,grade 3 to 4 AEs,0.626596
uuid-b3ac0791039f4d6e9fa4fd991361a482,search of published literature,0.33219
uuid-b3ac0791039f4d6e9fa4fd991361a482,phase 3 study,0.644743
uuid-b3ac0791039f4d6e9fa4fd991361a482,PubMed and EMBASE,0.325306
uuid-b3ac0791039f4d6e9fa4fd991361a482,Rizvi NA,0.303792
uuid-b3ac0791039f4d6e9fa4fd991361a482,Weber JS,0.510786
uuid-d0d57455797b4193a7a8c983255d568a,evaluating,0.303308
uuid-d0d57455797b4193a7a8c983255d568a,efficacy,0.445308
uuid-d0d57455797b4193a7a8c983255d568a,patients,0.358174
uuid-d0d57455797b4193a7a8c983255d568a,not approved,0.343676
uuid-d0d57455797b4193a7a8c983255d568a,docetaxel,0.710312
uuid-d0d57455797b4193a7a8c983255d568a,safety of nivolumab monotherapy,0.659782
uuid-df2818c728344299bdfbc6b9d3826c32,requested,0.594234
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,N Engl J Med,0.456474
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,Lancet Oncol,0.357873
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,protocol,0.480893
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,McDermott DF,0.51746
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,search of published literature,0.343051
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,Motzer RJ,0.516788
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,phase 3 study,0.754973
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,PubMed and EMBASE,0.340792
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,Escudier B,0.532534
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,et al.,0.496867
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,J Clin Oncol,0.430616
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,Rizvi NA,0.473891
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,Weber JS,0.580854
uuid-96b94dcd7fca49fbbb74d8ff28fd69d0,phase 2 study,0.6143
uuid-c3f9f7cc795c4e6a963ccdbdce653596,95% CI,0.524855
uuid-c3f9f7cc795c4e6a963ccdbdce653596,respectively,0.383655
uuid-c3f9f7cc795c4e6a963ccdbdce653596,ASCO,0.303153
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Lancet Oncol,0.368041
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Objective response rate,0.504846
uuid-c3f9f7cc795c4e6a963ccdbdce653596,ORR,0.465366
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Median overall survival,0.346516
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Median OS,0.33538
uuid-c3f9f7cc795c4e6a963ccdbdce653596,ASCO 2015,0.336983
uuid-c3f9f7cc795c4e6a963ccdbdce653596,small cell lung cancer,0.336892
uuid-c3f9f7cc795c4e6a963ccdbdce653596,SCLC,0.344367
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Antonia SJ,0.55269
uuid-c3f9f7cc795c4e6a963ccdbdce653596,Median duration of response,0.649605
uuid-b906099df3b2467a8e17b429b0459cf7,N Engl J Med,0.360217
uuid-b906099df3b2467a8e17b429b0459cf7,protocol,0.387467
uuid-b906099df3b2467a8e17b429b0459cf7,McDermott DF,0.394954
uuid-b906099df3b2467a8e17b429b0459cf7,Motzer RJ,0.381775
uuid-b906099df3b2467a8e17b429b0459cf7,Escudier B,0.400732
uuid-b906099df3b2467a8e17b429b0459cf7,et al.,0.397925
uuid-b906099df3b2467a8e17b429b0459cf7,J Clin Oncol,0.333388
uuid-90d60db33291445db2d02b913d30d4ac,trial,0.507309
uuid-e33189652bbf4322830bb6e3f21fcec4,respectively,0.645386
uuid-e33189652bbf4322830bb6e3f21fcec4,Objective response rate,0.435359
uuid-e33189652bbf4322830bb6e3f21fcec4,ORR,0.487028
uuid-e33189652bbf4322830bb6e3f21fcec4,monotherapy,0.329851
uuid-e33189652bbf4322830bb6e3f21fcec4,docetaxel,0.385794
uuid-29bcc12cbea443349866ef22f546c98e,requested,0.594234
uuid-d20e027987df4469a070f505b49dc08e,Bristol-Myers Squibb,0.341822
uuid-d20e027987df4469a070f505b49dc08e,not conducted any controlled clinical trials/studies,0.304507
uuid-d20e027987df4469a070f505b49dc08e,Opdivo,0.461382
uuid-d20e027987df4469a070f505b49dc08e,Pubmed literature search,0.614325
uuid-d20e027987df4469a070f505b49dc08e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d20e027987df4469a070f505b49dc08e,not identify any citations relevant to your inquiry,0.606087
uuid-d20e027987df4469a070f505b49dc08e,adverse,0.304183
uuid-d20e027987df4469a070f505b49dc08e,using the following search terms,0.642331
uuid-d20e027987df4469a070f505b49dc08e,databases,0.315039
uuid-d20e027987df4469a070f505b49dc08e,reported,0.556704
uuid-e0002e3703cc4b45a2f057c6f1e989d3,95% CI,0.371093
uuid-e0002e3703cc4b45a2f057c6f1e989d3,respectively,0.350747
uuid-e0002e3703cc4b45a2f057c6f1e989d3,Objective response rate,0.320462
uuid-e0002e3703cc4b45a2f057c6f1e989d3,ORR,0.377159
uuid-e0002e3703cc4b45a2f057c6f1e989d3,Median overall survival,0.310487
uuid-e0002e3703cc4b45a2f057c6f1e989d3,Median OS,0.360727
uuid-e0002e3703cc4b45a2f057c6f1e989d3,hazard ratio,0.336858
uuid-4052f52137d7460cb1a60bc45b159b6b,requested,0.594234
uuid-b2588ac3cea84ae39b0cc25fee7f97dc,requested,0.594234
uuid-d1308e54c21544ae9c1f1e86c5ee276a,provided in the Detailed Information,0.349112
uuid-d1308e54c21544ae9c1f1e86c5ee276a,Weber JS,0.321343
uuid-378c635fb9324fc1b5432c418ae6c8d2,95% CI,0.409745
uuid-378c635fb9324fc1b5432c418ae6c8d2,NSCLC,0.434543
uuid-378c635fb9324fc1b5432c418ae6c8d2,respectively,0.35512
uuid-378c635fb9324fc1b5432c418ae6c8d2,non-small cell lung cancer,0.368415
uuid-378c635fb9324fc1b5432c418ae6c8d2,Objective response rate,0.620281
uuid-378c635fb9324fc1b5432c418ae6c8d2,ORR,0.613032
uuid-378c635fb9324fc1b5432c418ae6c8d2,Median overall survival,0.429229
uuid-378c635fb9324fc1b5432c418ae6c8d2,monotherapy,0.46499
uuid-378c635fb9324fc1b5432c418ae6c8d2,Median OS,0.381578
uuid-378c635fb9324fc1b5432c418ae6c8d2,phase 1 study,0.304557
uuid-378c635fb9324fc1b5432c418ae6c8d2,docetaxel,0.300415
uuid-378c635fb9324fc1b5432c418ae6c8d2,hazard ratio,0.413778
uuid-69ebe057235f4d86b461107db37841d9,nivolumab,0.335604
uuid-69ebe057235f4d86b461107db37841d9,evaluating,0.332179
uuid-69ebe057235f4d86b461107db37841d9,NSCLC,0.728268
uuid-69ebe057235f4d86b461107db37841d9,non-small cell lung cancer,0.735641
uuid-69ebe057235f4d86b461107db37841d9,phase 1 study,0.349863
uuid-69ebe057235f4d86b461107db37841d9,safety,0.30889
uuid-69ebe057235f4d86b461107db37841d9,safety of nivolumab monotherapy,0.384421
uuid-69ebe057235f4d86b461107db37841d9,platinum-based doublet chemotherapy,0.354224
uuid-9bf5485182264ef6967dab834025fcc3,evaluating,0.434159
uuid-9bf5485182264ef6967dab834025fcc3,not conducted any controlled clinical trials/studies,0.429128
uuid-9bf5485182264ef6967dab834025fcc3,search of published literature,0.527837
uuid-9bf5485182264ef6967dab834025fcc3,PubMed and EMBASE,0.514324
uuid-9bf5485182264ef6967dab834025fcc3,Rizvi NA,0.339686
uuid-9bf5485182264ef6967dab834025fcc3,efficacy and safety of nivolumab,0.561063
uuid-9bf5485182264ef6967dab834025fcc3,Weber JS,0.301304
uuid-9bf5485182264ef6967dab834025fcc3,not identify any citations relevant to your request,0.360911
uuid-9bf5485182264ef6967dab834025fcc3,present using the following search terms,0.52381
uuid-ab08ffc2b36647e69d5f0771403a7e1f,ongoing,0.338094
uuid-ab08ffc2b36647e69d5f0771403a7e1f,detailed search of www.clinicaltrials.gov,0.308058
uuid-ab08ffc2b36647e69d5f0771403a7e1f,not identify any planned,0.329262
uuid-fc70cc7e02934e499f9a7b6c21f72229,95% CI,0.524855
uuid-fc70cc7e02934e499f9a7b6c21f72229,respectively,0.383655
uuid-fc70cc7e02934e499f9a7b6c21f72229,ASCO,0.303153
uuid-fc70cc7e02934e499f9a7b6c21f72229,Lancet Oncol,0.368041
uuid-fc70cc7e02934e499f9a7b6c21f72229,Objective response rate,0.504846
uuid-fc70cc7e02934e499f9a7b6c21f72229,ORR,0.465366
uuid-fc70cc7e02934e499f9a7b6c21f72229,Median overall survival,0.346516
uuid-fc70cc7e02934e499f9a7b6c21f72229,Median OS,0.33538
uuid-fc70cc7e02934e499f9a7b6c21f72229,ASCO 2015,0.336983
uuid-fc70cc7e02934e499f9a7b6c21f72229,small cell lung cancer,0.336892
uuid-fc70cc7e02934e499f9a7b6c21f72229,SCLC,0.344367
uuid-fc70cc7e02934e499f9a7b6c21f72229,Antonia SJ,0.55269
uuid-fc70cc7e02934e499f9a7b6c21f72229,Median duration of response,0.649605
uuid-4a63ef2abe9749c298a4e35d95f7f090,nivolumab,0.359772
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,Bristol-Myers Squibb,0.341822
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,not conducted any controlled clinical trials/studies,0.304507
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,Opdivo,0.461382
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,Pubmed literature search,0.614325
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,not identify any citations relevant to your inquiry,0.606087
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,adverse,0.304183
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,using the following search terms,0.642331
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,databases,0.315039
uuid-b02a0e59ed074d2e901e177f8e2ebb4a,reported,0.556704
uuid-12eaba8878dc433ebf7be9dd591a30c5,95% CI,0.55698
uuid-12eaba8878dc433ebf7be9dd591a30c5,respectively,0.49597
uuid-12eaba8878dc433ebf7be9dd591a30c5,Objective response rate,0.454852
uuid-12eaba8878dc433ebf7be9dd591a30c5,ORR,0.528895
uuid-12eaba8878dc433ebf7be9dd591a30c5,Median overall survival,0.483762
uuid-12eaba8878dc433ebf7be9dd591a30c5,Median OS,0.539395
uuid-12eaba8878dc433ebf7be9dd591a30c5,docetaxel,0.390557
uuid-12eaba8878dc433ebf7be9dd591a30c5,hazard ratio,0.49662
uuid-e16fa6241d914f97941b70f552169922,evaluating,0.350845
uuid-e16fa6241d914f97941b70f552169922,not conducted any controlled clinical trials/studies,0.345107
uuid-e16fa6241d914f97941b70f552169922,search of published literature,0.385331
uuid-e16fa6241d914f97941b70f552169922,Additionally,0.40981
uuid-e16fa6241d914f97941b70f552169922,ongoing,0.457998
uuid-e16fa6241d914f97941b70f552169922,PubMed and EMBASE,0.378285
uuid-e16fa6241d914f97941b70f552169922,detailed search of www.clinicaltrials.gov,0.428522
uuid-e16fa6241d914f97941b70f552169922,efficacy and safety of nivolumab,0.407868
uuid-e16fa6241d914f97941b70f552169922,not identify any planned,0.444729
uuid-e16fa6241d914f97941b70f552169922,combination,0.388252
uuid-e16fa6241d914f97941b70f552169922,BMS,0.316104
uuid-e16fa6241d914f97941b70f552169922,not identify any citations relevant to your request,0.438151
uuid-e16fa6241d914f97941b70f552169922,present using the following search terms,0.377101
uuid-bd87d14f1bcc485cab426ed14adb7124,Opdivo,0.440604
uuid-bd87d14f1bcc485cab426ed14adb7124,BMS,0.340476
uuid-bd87d14f1bcc485cab426ed14adb7124,reported,0.407643
uuid-b72c0d5abedb4da3ae925df9ca6c6260,AEs,0.543722
uuid-b72c0d5abedb4da3ae925df9ca6c6260,Opdivo,0.340136
uuid-b72c0d5abedb4da3ae925df9ca6c6260,grade,0.472851
uuid-b72c0d5abedb4da3ae925df9ca6c6260,grade 3 to 4 AEs,0.45246
uuid-1914225c83304ac18b319f447808456d,N Engl J Med,0.448483
uuid-1914225c83304ac18b319f447808456d,protocol,0.770446
uuid-1914225c83304ac18b319f447808456d,McDermott DF,0.741196
uuid-1914225c83304ac18b319f447808456d,Motzer RJ,0.818144
uuid-1914225c83304ac18b319f447808456d,phase 3 study,0.417055
uuid-1914225c83304ac18b319f447808456d,Escudier B,0.749917
uuid-1914225c83304ac18b319f447808456d,NEJM,0.400698
uuid-1914225c83304ac18b319f447808456d,et al.,0.668641
uuid-1914225c83304ac18b319f447808456d,J Clin Oncol,0.792018
uuid-1914225c83304ac18b319f447808456d,Topalian,0.388894
uuid-1914225c83304ac18b319f447808456d,phase 1 study,0.500686
uuid-1914225c83304ac18b319f447808456d,CA209-003,0.567381
uuid-1914225c83304ac18b319f447808456d,phase 2 study,0.677985
uuid-1914225c83304ac18b319f447808456d,present using the following search terms,0.310558
uuid-1914225c83304ac18b319f447808456d,investigating,0.615835
uuid-aedac80b696243789abec8e5c246874f,Bristol-Myers Squibb,0.341822
uuid-aedac80b696243789abec8e5c246874f,not conducted any controlled clinical trials/studies,0.304507
uuid-aedac80b696243789abec8e5c246874f,Opdivo,0.461382
uuid-aedac80b696243789abec8e5c246874f,Pubmed literature search,0.614325
uuid-aedac80b696243789abec8e5c246874f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-aedac80b696243789abec8e5c246874f,not identify any citations relevant to your inquiry,0.606087
uuid-aedac80b696243789abec8e5c246874f,adverse,0.304183
uuid-aedac80b696243789abec8e5c246874f,using the following search terms,0.642331
uuid-aedac80b696243789abec8e5c246874f,databases,0.315039
uuid-aedac80b696243789abec8e5c246874f,reported,0.556704
uuid-c2acb55e143d4ed6adfa8968e99d6258,small cell lung cancer,0.393135
uuid-c2acb55e143d4ed6adfa8968e99d6258,SCLC,0.441325
uuid-c2acb55e143d4ed6adfa8968e99d6258,therapy,0.512398
uuid-a987fb14dbe04174b6e163ed045119a8,respectively,0.629961
uuid-a987fb14dbe04174b6e163ed045119a8,Objective response rate,0.439951
uuid-a987fb14dbe04174b6e163ed045119a8,ORR,0.462322
uuid-a987fb14dbe04174b6e163ed045119a8,monotherapy,0.352421
uuid-a987fb14dbe04174b6e163ed045119a8,docetaxel,0.410479
uuid-9166dd57e977455e901d852718d17681,OS,0.521365
uuid-9166dd57e977455e901d852718d17681,95% CI,0.919678
uuid-9166dd57e977455e901d852718d17681,respectively,0.467176
uuid-9166dd57e977455e901d852718d17681,Objective response rate,0.59328
uuid-9166dd57e977455e901d852718d17681,ORR,0.741808
uuid-9166dd57e977455e901d852718d17681,PFS,0.393216
uuid-9166dd57e977455e901d852718d17681,Median overall survival,0.883951
uuid-9166dd57e977455e901d852718d17681,monotherapy,0.348005
uuid-9166dd57e977455e901d852718d17681,Median OS,0.858361
uuid-9166dd57e977455e901d852718d17681,hazard ratio,0.902487
uuid-9166dd57e977455e901d852718d17681,Median duration of response,0.411448
uuid-56471fb16af94a4190bd33de93178cb1,ASCO,0.807066
uuid-b7c70247d4ec45b39b42e98806638772,N Engl J Med,0.320408
uuid-b7c70247d4ec45b39b42e98806638772,protocol,0.436415
uuid-b7c70247d4ec45b39b42e98806638772,McDermott DF,0.471417
uuid-b7c70247d4ec45b39b42e98806638772,Motzer RJ,0.444215
uuid-b7c70247d4ec45b39b42e98806638772,phase 3 study,0.361887
uuid-b7c70247d4ec45b39b42e98806638772,Escudier B,0.444145
uuid-b7c70247d4ec45b39b42e98806638772,NEJM,0.622061
uuid-b7c70247d4ec45b39b42e98806638772,et al.,0.4155
uuid-b7c70247d4ec45b39b42e98806638772,J Clin Oncol,0.510911
uuid-b7c70247d4ec45b39b42e98806638772,Topalian,0.632939
uuid-b7c70247d4ec45b39b42e98806638772,phase 1 study,0.426771
uuid-b7c70247d4ec45b39b42e98806638772,Rizvi NA,0.315936
uuid-b7c70247d4ec45b39b42e98806638772,mg,0.35548
uuid-b7c70247d4ec45b39b42e98806638772,CA209-003,0.439179
uuid-b7c70247d4ec45b39b42e98806638772,Weber JS,0.336225
uuid-b7c70247d4ec45b39b42e98806638772,phase 2 study,0.495601
uuid-b7c70247d4ec45b39b42e98806638772,kg,0.30521
uuid-8c1025985d984adfaa67f577bc0a80c4,patients with advanced or metastatic,0.478326
uuid-8c1025985d984adfaa67f577bc0a80c4,nivolumab combined with ipilimumab,0.498766
uuid-8c1025985d984adfaa67f577bc0a80c4,not approved,0.34724
uuid-8c1025985d984adfaa67f577bc0a80c4,clinical trials investigating the safety,0.426729
uuid-8c1025985d984adfaa67f577bc0a80c4,bladder cancer,0.6548
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,N Engl J Med,0.398937
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,McDermott DF,0.305112
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,Motzer RJ,0.312039
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,phase 3 study,0.341299
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,J Clin Oncol,0.304987
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,phase 1 study,0.339753
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,Brahmer J,0.303426
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,CA209-003,0.383034
uuid-b8dd8d92e6a54cc4aa1fecde0241f04d,phase 2 study,0.391349
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,95% CI,0.539167
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,Median overall survival,0.479815
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,protocol,0.426554
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,McDermott DF,0.500131
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,Motzer RJ,0.477178
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,Median OS,0.603398
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,Escudier B,0.469696
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,NEJM,0.387615
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,et al.,0.46851
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,J Clin Oncol,0.51661
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,Topalian,0.337057
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,phase 2 study,0.399402
uuid-8eb5359059ad4fc1a04d7f0a43f7330a,hazard ratio,0.538097
uuid-f94601cda6224435a249b96a1ac918ab,search of published literature,0.827728
uuid-f94601cda6224435a249b96a1ac918ab,phase 3 study,0.363266
uuid-f94601cda6224435a249b96a1ac918ab,PubMed and EMBASE,0.82543
uuid-f94601cda6224435a249b96a1ac918ab,trial,0.3086
uuid-f94601cda6224435a249b96a1ac918ab,efficacy and safety of nivolumab,0.562181
uuid-f94601cda6224435a249b96a1ac918ab,not identify any citations relevant to your request,0.306693
uuid-f94601cda6224435a249b96a1ac918ab,present using the following search terms,0.773341
uuid-824205f27504420fa9da5725f8ef8afa,95% CI,0.524855
uuid-824205f27504420fa9da5725f8ef8afa,respectively,0.383655
uuid-824205f27504420fa9da5725f8ef8afa,ASCO,0.303153
uuid-824205f27504420fa9da5725f8ef8afa,Lancet Oncol,0.368041
uuid-824205f27504420fa9da5725f8ef8afa,Objective response rate,0.504846
uuid-824205f27504420fa9da5725f8ef8afa,ORR,0.465366
uuid-824205f27504420fa9da5725f8ef8afa,Median overall survival,0.346516
uuid-824205f27504420fa9da5725f8ef8afa,Median OS,0.33538
uuid-824205f27504420fa9da5725f8ef8afa,ASCO 2015,0.336983
uuid-824205f27504420fa9da5725f8ef8afa,small cell lung cancer,0.336892
uuid-824205f27504420fa9da5725f8ef8afa,SCLC,0.344367
uuid-824205f27504420fa9da5725f8ef8afa,Antonia SJ,0.55269
uuid-824205f27504420fa9da5725f8ef8afa,Median duration of response,0.649605
uuid-d6da78de6f194a73a337238a86edb987,requested,0.704633
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,OS,0.378195
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,95% CI,0.644242
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,respectively,0.623787
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,Objective response rate,0.468031
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,ORR,0.573903
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,Median overall survival,0.575132
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,monotherapy,0.390892
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,Median OS,0.635904
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,docetaxel,0.696215
uuid-f8cb8a3ffca84a8b85ea9e1eb14535df,hazard ratio,0.630759
uuid-d79222521193428f8908a2f2aad04cc9,nivolumab,0.359772
uuid-cfaa6a70bb70470cb7dfc9cf777fc418,adverse,0.363655
uuid-cfaa6a70bb70470cb7dfc9cf777fc418,clinical,0.384484
uuid-cfaa6a70bb70470cb7dfc9cf777fc418,trial,0.485861
uuid-6d2e97f8109346b485832eab3fa031bb,Topalian,0.327854
uuid-5d1f5ffccc9f498b941c6e6ef1dee5ad,Opdivo,0.373215
uuid-5d1f5ffccc9f498b941c6e6ef1dee5ad,not approved,0.335923
uuid-5d1f5ffccc9f498b941c6e6ef1dee5ad,clinical trials investigating the safety,0.463791
uuid-7b215a87861a4c92b1e53df25bbf45ff,nivolumab,0.586865
uuid-7b215a87861a4c92b1e53df25bbf45ff,Bristol-Myers Squibb,0.486383
uuid-7b215a87861a4c92b1e53df25bbf45ff,evaluating,0.717361
uuid-7b215a87861a4c92b1e53df25bbf45ff,not conducted any controlled clinical trials/studies,0.737379
uuid-7b215a87861a4c92b1e53df25bbf45ff,Pubmed literature search,0.783572
uuid-7b215a87861a4c92b1e53df25bbf45ff,purposes other than its labeled indication must be considered investigational,0.868008
uuid-7b215a87861a4c92b1e53df25bbf45ff,not identify any citations relevant to your inquiry,0.739232
uuid-7b215a87861a4c92b1e53df25bbf45ff,search of published literature,0.315797
uuid-7b215a87861a4c92b1e53df25bbf45ff,using the following search terms,0.722654
uuid-7b215a87861a4c92b1e53df25bbf45ff,efficacy and safety of nivolumab,0.569864
uuid-7b215a87861a4c92b1e53df25bbf45ff,present using the following search terms,0.316968
uuid-411b5436a5234ae1819a989fdd4d2c8b,nivolumab,0.510392
uuid-411b5436a5234ae1819a989fdd4d2c8b,Bristol-Myers Squibb,0.464176
uuid-411b5436a5234ae1819a989fdd4d2c8b,evaluating,0.683286
uuid-411b5436a5234ae1819a989fdd4d2c8b,not conducted any controlled clinical trials/studies,0.682483
uuid-411b5436a5234ae1819a989fdd4d2c8b,RCC,0.308694
uuid-411b5436a5234ae1819a989fdd4d2c8b,search of published literature,0.839602
uuid-411b5436a5234ae1819a989fdd4d2c8b,Additionally,0.446384
uuid-411b5436a5234ae1819a989fdd4d2c8b,PubMed and EMBASE,0.823429
uuid-411b5436a5234ae1819a989fdd4d2c8b,detailed search of www.clinicaltrials.gov,0.366719
uuid-411b5436a5234ae1819a989fdd4d2c8b,efficacy and safety of nivolumab,0.841
uuid-411b5436a5234ae1819a989fdd4d2c8b,not identify any citations relevant to your request,0.605656
uuid-411b5436a5234ae1819a989fdd4d2c8b,present using the following search terms,0.832619
uuid-6a42390c3e504f96b6875ea29ded5b3a,ongoing,0.338094
uuid-6a42390c3e504f96b6875ea29ded5b3a,detailed search of www.clinicaltrials.gov,0.308058
uuid-6a42390c3e504f96b6875ea29ded5b3a,not identify any planned,0.329262
uuid-dea5903bb1044eaa8244bd53f28b62ee,AEs,0.460889
uuid-dea5903bb1044eaa8244bd53f28b62ee,adverse,0.611189
uuid-dea5903bb1044eaa8244bd53f28b62ee,grade,0.593874
uuid-dea5903bb1044eaa8244bd53f28b62ee,reported,0.426445
uuid-e80d73ee4cfe440c932991c2010820ed,open-label,0.539462
uuid-e80d73ee4cfe440c932991c2010820ed,phase,0.350616
uuid-425c4398d1024a3389c3c17d0ef4f189,OS,0.62262
uuid-425c4398d1024a3389c3c17d0ef4f189,PFS,0.65903
uuid-425c4398d1024a3389c3c17d0ef4f189,Overall survival,0.644151
uuid-9a9d060eaa8140589b7dd115e88e5ad5,N Engl J Med,0.560325
uuid-9a9d060eaa8140589b7dd115e88e5ad5,protocol,0.530553
uuid-9a9d060eaa8140589b7dd115e88e5ad5,McDermott DF,0.644466
uuid-9a9d060eaa8140589b7dd115e88e5ad5,Motzer RJ,0.598229
uuid-9a9d060eaa8140589b7dd115e88e5ad5,phase 3 study,0.516843
uuid-9a9d060eaa8140589b7dd115e88e5ad5,Escudier B,0.627784
uuid-9a9d060eaa8140589b7dd115e88e5ad5,NEJM,0.345118
uuid-9a9d060eaa8140589b7dd115e88e5ad5,et al.,0.603041
uuid-9a9d060eaa8140589b7dd115e88e5ad5,J Clin Oncol,0.582246
uuid-9a9d060eaa8140589b7dd115e88e5ad5,Rizvi NA,0.453829
uuid-9a9d060eaa8140589b7dd115e88e5ad5,Brahmer J,0.343379
uuid-9a9d060eaa8140589b7dd115e88e5ad5,phase 2 study,0.68826
uuid-2eef43603d9c41d691f5ed2b631dc189,ipilimumab,0.385692
uuid-2eef43603d9c41d691f5ed2b631dc189,ASCO 2015,0.417944
uuid-2eef43603d9c41d691f5ed2b631dc189,partial response,0.382425
uuid-2eef43603d9c41d691f5ed2b631dc189,Stable disease,0.586335
uuid-2eef43603d9c41d691f5ed2b631dc189,cohort,0.307748
uuid-074c8437101f481192d336990f82b20e,melanoma,0.353822
uuid-981613caa7fe44f0a3b93593ef7eacd7,adverse,0.416199
uuid-7c29e8f2f64a4878a9c7e3e99d6f1601,Bristol-Myers Squibb,0.332778
uuid-7c29e8f2f64a4878a9c7e3e99d6f1601,provided in the Detailed Information,0.389401
uuid-31c61d07b0914524b7a612c030d2f8a4,95% CI,0.38691
uuid-31c61d07b0914524b7a612c030d2f8a4,NSCLC,0.309907
uuid-31c61d07b0914524b7a612c030d2f8a4,respectively,0.520194
uuid-31c61d07b0914524b7a612c030d2f8a4,Objective response rate,0.573555
uuid-31c61d07b0914524b7a612c030d2f8a4,ORR,0.626348
uuid-31c61d07b0914524b7a612c030d2f8a4,Median overall survival,0.400007
uuid-31c61d07b0914524b7a612c030d2f8a4,monotherapy,0.453522
uuid-31c61d07b0914524b7a612c030d2f8a4,Median OS,0.354493
uuid-31c61d07b0914524b7a612c030d2f8a4,docetaxel,0.412975
uuid-31c61d07b0914524b7a612c030d2f8a4,hazard ratio,0.358112
uuid-541a7a729be54283b92623c1508a13dc,95% CI,0.520262
uuid-541a7a729be54283b92623c1508a13dc,respectively,0.504068
uuid-541a7a729be54283b92623c1508a13dc,Objective response rate,0.458568
uuid-541a7a729be54283b92623c1508a13dc,ORR,0.525868
uuid-541a7a729be54283b92623c1508a13dc,Median overall survival,0.455633
uuid-541a7a729be54283b92623c1508a13dc,Median OS,0.507448
uuid-541a7a729be54283b92623c1508a13dc,docetaxel,0.383115
uuid-541a7a729be54283b92623c1508a13dc,hazard ratio,0.462119
uuid-c8b7fbfabfdb4b5d92151a8950789f99,Bristol-Myers Squibb,0.341822
uuid-c8b7fbfabfdb4b5d92151a8950789f99,not conducted any controlled clinical trials/studies,0.304507
uuid-c8b7fbfabfdb4b5d92151a8950789f99,Opdivo,0.461382
uuid-c8b7fbfabfdb4b5d92151a8950789f99,Pubmed literature search,0.614325
uuid-c8b7fbfabfdb4b5d92151a8950789f99,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c8b7fbfabfdb4b5d92151a8950789f99,not identify any citations relevant to your inquiry,0.606087
uuid-c8b7fbfabfdb4b5d92151a8950789f99,adverse,0.304183
uuid-c8b7fbfabfdb4b5d92151a8950789f99,using the following search terms,0.642331
uuid-c8b7fbfabfdb4b5d92151a8950789f99,databases,0.315039
uuid-c8b7fbfabfdb4b5d92151a8950789f99,reported,0.556704
uuid-820bd9ad2b6c40608db0f7a7e77240cc,95% CI,0.38691
uuid-820bd9ad2b6c40608db0f7a7e77240cc,NSCLC,0.309907
uuid-820bd9ad2b6c40608db0f7a7e77240cc,respectively,0.520194
uuid-820bd9ad2b6c40608db0f7a7e77240cc,Objective response rate,0.573555
uuid-820bd9ad2b6c40608db0f7a7e77240cc,ORR,0.626348
uuid-820bd9ad2b6c40608db0f7a7e77240cc,Median overall survival,0.400007
uuid-820bd9ad2b6c40608db0f7a7e77240cc,monotherapy,0.453522
uuid-820bd9ad2b6c40608db0f7a7e77240cc,Median OS,0.354493
uuid-820bd9ad2b6c40608db0f7a7e77240cc,docetaxel,0.412975
uuid-820bd9ad2b6c40608db0f7a7e77240cc,hazard ratio,0.358112
uuid-0e6c2660387240b692b85a61a387bf83,AEs,0.457815
uuid-0e6c2660387240b692b85a61a387bf83,respectively,0.302526
uuid-0e6c2660387240b692b85a61a387bf83,patients,0.496729
uuid-0e6c2660387240b692b85a61a387bf83,adverse,0.410514
uuid-0e6c2660387240b692b85a61a387bf83,docetaxel,0.466709
uuid-0e6c2660387240b692b85a61a387bf83,grade,0.443259
uuid-0e6c2660387240b692b85a61a387bf83,grade 3 to 4 AEs,0.52941
uuid-8cd41e854aba41fc900a791a46983157,efficacy,0.301539
uuid-8cd41e854aba41fc900a791a46983157,Opdivo,0.460529
uuid-8cd41e854aba41fc900a791a46983157,not approved,0.304528
uuid-8cd41e854aba41fc900a791a46983157,trial,0.366018
uuid-8cd41e854aba41fc900a791a46983157,clinicaltrials.gov,0.338658
uuid-8cd41e854aba41fc900a791a46983157,docetaxel,0.35456
uuid-8cd41e854aba41fc900a791a46983157,safety of nivolumab monotherapy,0.304249
uuid-0ad932a03d034d0e997901c36cc8973b,N Engl J Med,0.643107
uuid-0ad932a03d034d0e997901c36cc8973b,respectively,0.398989
uuid-0ad932a03d034d0e997901c36cc8973b,Median overall survival,0.30615
uuid-0ad932a03d034d0e997901c36cc8973b,ESMO,0.534703
uuid-0ad932a03d034d0e997901c36cc8973b,Median OS,0.319939
uuid-0ad932a03d034d0e997901c36cc8973b,Brahmer J,0.658171
uuid-0ad932a03d034d0e997901c36cc8973b,Horn L,0.594193
uuid-e30a10f1b46d457db10c057c33214ca2,nivolumab,0.526729
uuid-e30a10f1b46d457db10c057c33214ca2,use of nivolumab for the treatment,0.327774
uuid-e30a10f1b46d457db10c057c33214ca2,evaluating,0.408019
uuid-e30a10f1b46d457db10c057c33214ca2,not conducted any controlled clinical trials/studies,0.33132
uuid-e30a10f1b46d457db10c057c33214ca2,efficacy,0.3436
uuid-e30a10f1b46d457db10c057c33214ca2,not approved,0.360536
uuid-e30a10f1b46d457db10c057c33214ca2,clinical trials investigating the safety,0.354194
uuid-05f180ed857544a9ae0ae71945a2b11d,ipilimumab,0.385692
uuid-05f180ed857544a9ae0ae71945a2b11d,ASCO 2015,0.417944
uuid-05f180ed857544a9ae0ae71945a2b11d,partial response,0.382425
uuid-05f180ed857544a9ae0ae71945a2b11d,Stable disease,0.586335
uuid-05f180ed857544a9ae0ae71945a2b11d,cohort,0.307748
uuid-831b91dd322d4689a04432a729f5158b,nivolumab,0.414315
uuid-831b91dd322d4689a04432a729f5158b,Bristol-Myers Squibb,0.500934
uuid-831b91dd322d4689a04432a729f5158b,evaluating,0.682849
uuid-831b91dd322d4689a04432a729f5158b,not conducted any controlled clinical trials/studies,0.67099
uuid-831b91dd322d4689a04432a729f5158b,search of published literature,0.699959
uuid-831b91dd322d4689a04432a729f5158b,Additionally,0.649786
uuid-831b91dd322d4689a04432a729f5158b,ongoing,0.551495
uuid-831b91dd322d4689a04432a729f5158b,PubMed and EMBASE,0.684956
uuid-831b91dd322d4689a04432a729f5158b,detailed search of www.clinicaltrials.gov,0.625577
uuid-831b91dd322d4689a04432a729f5158b,efficacy and safety of nivolumab,0.769377
uuid-831b91dd322d4689a04432a729f5158b,not identify any planned,0.574235
uuid-831b91dd322d4689a04432a729f5158b,not identify any citations relevant to your request,0.735624
uuid-831b91dd322d4689a04432a729f5158b,present using the following search terms,0.712619
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,95% CI,0.384282
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,ASCO,0.40687
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,Objective response rate,0.409634
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,Median overall survival,0.319094
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,Median OS,0.403026
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,ASCO 2015,0.386899
uuid-d7cfd6b68d1e4471a376b56d39a5f23d,hazard ratio,0.403406
uuid-2630c0c10c184a79a8684ea2ce48d934,N Engl J Med,0.347615
uuid-2630c0c10c184a79a8684ea2ce48d934,protocol,0.378688
uuid-2630c0c10c184a79a8684ea2ce48d934,McDermott DF,0.38982
uuid-2630c0c10c184a79a8684ea2ce48d934,Motzer RJ,0.376727
uuid-2630c0c10c184a79a8684ea2ce48d934,Escudier B,0.3954
uuid-2630c0c10c184a79a8684ea2ce48d934,et al.,0.394533
uuid-2630c0c10c184a79a8684ea2ce48d934,J Clin Oncol,0.328265
uuid-2630c0c10c184a79a8684ea2ce48d934,phase 2 study,0.300772
uuid-959be31721d5432997ff1185a1fa586e,respectively,0.629961
uuid-959be31721d5432997ff1185a1fa586e,Objective response rate,0.439951
uuid-959be31721d5432997ff1185a1fa586e,ORR,0.462322
uuid-959be31721d5432997ff1185a1fa586e,monotherapy,0.352421
uuid-959be31721d5432997ff1185a1fa586e,docetaxel,0.410479
uuid-d762717386624ee28a8393ed31f7893f,N Engl J Med,0.604857
uuid-d762717386624ee28a8393ed31f7893f,non-small cell lung cancer,0.34354
uuid-d762717386624ee28a8393ed31f7893f,ESMO,0.393944
uuid-d762717386624ee28a8393ed31f7893f,Rizvi NA,0.452745
uuid-d762717386624ee28a8393ed31f7893f,Brahmer J,0.679154
uuid-d762717386624ee28a8393ed31f7893f,PD-L1,0.347566
uuid-d762717386624ee28a8393ed31f7893f,Horn L,0.50259
uuid-d762717386624ee28a8393ed31f7893f,platinum-based doublet chemotherapy,0.304136
uuid-2c293c5dffa14c00bfc815badb43b057,requested,0.594234
uuid-4f334a38b960458faacc95225eae6ce9,nivolumab,0.359772
uuid-e67f55aab83843f9bb8d7e22e77c7acd,N Engl J Med,0.390245
uuid-e67f55aab83843f9bb8d7e22e77c7acd,protocol,0.404658
uuid-e67f55aab83843f9bb8d7e22e77c7acd,McDermott DF,0.41537
uuid-e67f55aab83843f9bb8d7e22e77c7acd,Motzer RJ,0.402119
uuid-e67f55aab83843f9bb8d7e22e77c7acd,Escudier B,0.419755
uuid-e67f55aab83843f9bb8d7e22e77c7acd,et al.,0.421068
uuid-e67f55aab83843f9bb8d7e22e77c7acd,J Clin Oncol,0.354434
uuid-e67f55aab83843f9bb8d7e22e77c7acd,phase 2 study,0.323833
uuid-daf3b506cea24c6c9fa4c1947c739fb5,N Engl J Med,0.456474
uuid-daf3b506cea24c6c9fa4c1947c739fb5,Lancet Oncol,0.357873
uuid-daf3b506cea24c6c9fa4c1947c739fb5,protocol,0.480893
uuid-daf3b506cea24c6c9fa4c1947c739fb5,McDermott DF,0.51746
uuid-daf3b506cea24c6c9fa4c1947c739fb5,search of published literature,0.343051
uuid-daf3b506cea24c6c9fa4c1947c739fb5,Motzer RJ,0.516788
uuid-daf3b506cea24c6c9fa4c1947c739fb5,phase 3 study,0.754973
uuid-daf3b506cea24c6c9fa4c1947c739fb5,PubMed and EMBASE,0.340792
uuid-daf3b506cea24c6c9fa4c1947c739fb5,Escudier B,0.532534
uuid-daf3b506cea24c6c9fa4c1947c739fb5,et al.,0.496867
uuid-daf3b506cea24c6c9fa4c1947c739fb5,J Clin Oncol,0.430616
uuid-daf3b506cea24c6c9fa4c1947c739fb5,Rizvi NA,0.473891
uuid-daf3b506cea24c6c9fa4c1947c739fb5,Weber JS,0.580854
uuid-daf3b506cea24c6c9fa4c1947c739fb5,phase 2 study,0.6143
uuid-912beb9a085d4614b58061de3a46fc68,N Engl J Med,0.427636
uuid-912beb9a085d4614b58061de3a46fc68,protocol,0.429136
uuid-912beb9a085d4614b58061de3a46fc68,McDermott DF,0.44782
uuid-912beb9a085d4614b58061de3a46fc68,Motzer RJ,0.430476
uuid-912beb9a085d4614b58061de3a46fc68,Escudier B,0.450887
uuid-912beb9a085d4614b58061de3a46fc68,et al.,0.456026
uuid-912beb9a085d4614b58061de3a46fc68,J Clin Oncol,0.384624
uuid-912beb9a085d4614b58061de3a46fc68,Rizvi NA,0.305616
uuid-912beb9a085d4614b58061de3a46fc68,phase 2 study,0.351446
uuid-38a40f7031f84e7b82c222ad853ec4e1,nivolumab,0.376852
uuid-38a40f7031f84e7b82c222ad853ec4e1,requested,0.300704
uuid-ac5ed33f3d964d0ca29579be6b45d381,N Engl J Med,0.549738
uuid-ac5ed33f3d964d0ca29579be6b45d381,respectively,0.391562
uuid-ac5ed33f3d964d0ca29579be6b45d381,ASCO,0.436507
uuid-ac5ed33f3d964d0ca29579be6b45d381,Brahmer J,0.716533
uuid-ac5ed33f3d964d0ca29579be6b45d381,docetaxel,0.356983
uuid-ac5ed33f3d964d0ca29579be6b45d381,Horn L,0.382378
uuid-62ce33d4cd04415fb3b82f85b3e5c101,N Engl J Med,0.772728
uuid-62ce33d4cd04415fb3b82f85b3e5c101,protocol,0.330852
uuid-62ce33d4cd04415fb3b82f85b3e5c101,McDermott DF,0.347313
uuid-62ce33d4cd04415fb3b82f85b3e5c101,Motzer RJ,0.326548
uuid-62ce33d4cd04415fb3b82f85b3e5c101,phase 3 study,0.373224
uuid-62ce33d4cd04415fb3b82f85b3e5c101,Escudier B,0.353262
uuid-62ce33d4cd04415fb3b82f85b3e5c101,et al.,0.350852
uuid-62ce33d4cd04415fb3b82f85b3e5c101,Rizvi NA,0.495124
uuid-62ce33d4cd04415fb3b82f85b3e5c101,Brahmer J,0.772439
uuid-62ce33d4cd04415fb3b82f85b3e5c101,phase 2 study,0.464349
uuid-62ce33d4cd04415fb3b82f85b3e5c101,Horn L,0.38216
uuid-c3eaaa8ae4eb4129bdbda6bdcb08b9d9,patients with advanced or metastatic,0.478326
uuid-c3eaaa8ae4eb4129bdbda6bdcb08b9d9,nivolumab combined with ipilimumab,0.498766
uuid-c3eaaa8ae4eb4129bdbda6bdcb08b9d9,not approved,0.34724
uuid-c3eaaa8ae4eb4129bdbda6bdcb08b9d9,clinical trials investigating the safety,0.426729
uuid-c3eaaa8ae4eb4129bdbda6bdcb08b9d9,bladder cancer,0.6548
uuid-a7ebe848ba784532aa0345eb8ea5c812,Bristol-Myers Squibb,0.311361
uuid-a7ebe848ba784532aa0345eb8ea5c812,AEs,0.302863
uuid-a7ebe848ba784532aa0345eb8ea5c812,adverse,0.85465
uuid-a7ebe848ba784532aa0345eb8ea5c812,melanoma,0.440517
uuid-a7ebe848ba784532aa0345eb8ea5c812,reported,0.458488
uuid-1c6dc9d4a1994c41a5c19d0201990ac9,docetaxel,0.418351
uuid-116fe91b1c15450d9027766747b11fd9,nivolumab,0.502183
uuid-116fe91b1c15450d9027766747b11fd9,RCC,0.756598
uuid-32c337db8eef42c5b791180005d7e0a7,respectively,0.589071
uuid-32c337db8eef42c5b791180005d7e0a7,Objective response rate,0.407286
uuid-32c337db8eef42c5b791180005d7e0a7,ORR,0.526086
uuid-32c337db8eef42c5b791180005d7e0a7,monotherapy,0.319413
uuid-32c337db8eef42c5b791180005d7e0a7,docetaxel,0.334344
uuid-0322130e049a45ecaae9a2c096a03118,phase 3 study,0.305139
uuid-0322130e049a45ecaae9a2c096a03118,phase 1 study,0.316589
uuid-2613a083024740c1853918e881f0c79e,ipilimumab,0.385692
uuid-2613a083024740c1853918e881f0c79e,ASCO 2015,0.417944
uuid-2613a083024740c1853918e881f0c79e,partial response,0.382425
uuid-2613a083024740c1853918e881f0c79e,Stable disease,0.586335
uuid-2613a083024740c1853918e881f0c79e,cohort,0.307748
uuid-fa7b49123db54ae9890762199edd6a8a,OS,0.62262
uuid-fa7b49123db54ae9890762199edd6a8a,PFS,0.65903
uuid-fa7b49123db54ae9890762199edd6a8a,Overall survival,0.644151
uuid-fe2977817d4d4282b01c1060caac2c12,NSCLC,0.570413
uuid-fe2977817d4d4282b01c1060caac2c12,non-small cell lung cancer,0.664008
uuid-fe2977817d4d4282b01c1060caac2c12,phase 3 study,0.331058
uuid-fe2977817d4d4282b01c1060caac2c12,PD-L1,0.60615
uuid-fe2977817d4d4282b01c1060caac2c12,platinum-based doublet chemotherapy,0.308453
uuid-0a1ca226f8014b269cae64a4b10083a2,N Engl J Med,0.764423
uuid-0a1ca226f8014b269cae64a4b10083a2,ASCO,0.329482
uuid-0a1ca226f8014b269cae64a4b10083a2,ESMO,0.637422
uuid-0a1ca226f8014b269cae64a4b10083a2,et al.,0.313255
uuid-0a1ca226f8014b269cae64a4b10083a2,Rizvi NA,0.412572
uuid-0a1ca226f8014b269cae64a4b10083a2,Brahmer J,0.668132
uuid-0a1ca226f8014b269cae64a4b10083a2,phase 2 study,0.340523
uuid-0a1ca226f8014b269cae64a4b10083a2,Horn L,0.586117
uuid-e5e76d57e9684f629705cd9fb69f9fec,OS,0.387982
uuid-e5e76d57e9684f629705cd9fb69f9fec,95% CI,0.745043
uuid-e5e76d57e9684f629705cd9fb69f9fec,respectively,0.729294
uuid-e5e76d57e9684f629705cd9fb69f9fec,Objective response rate,0.590876
uuid-e5e76d57e9684f629705cd9fb69f9fec,ORR,0.722442
uuid-e5e76d57e9684f629705cd9fb69f9fec,Median overall survival,0.659043
uuid-e5e76d57e9684f629705cd9fb69f9fec,monotherapy,0.514468
uuid-e5e76d57e9684f629705cd9fb69f9fec,Median OS,0.696688
uuid-e5e76d57e9684f629705cd9fb69f9fec,PD-L1,0.300997
uuid-e5e76d57e9684f629705cd9fb69f9fec,docetaxel,0.635065
uuid-e5e76d57e9684f629705cd9fb69f9fec,hazard ratio,0.729977
uuid-61bf99417416482a8f0a309fd483526f,use of nivolumab for the treatment,0.308357
uuid-61bf99417416482a8f0a309fd483526f,patients,0.781529
uuid-61bf99417416482a8f0a309fd483526f,small cell lung cancer,0.382038
uuid-61bf99417416482a8f0a309fd483526f,partial response,0.340063
uuid-61bf99417416482a8f0a309fd483526f,SCLC,0.362388
uuid-61bf99417416482a8f0a309fd483526f,Stable disease,0.305255
uuid-61bf99417416482a8f0a309fd483526f,grade 3 to 4 AEs,0.456804
uuid-c522e552a71043cb81df999495405528,patients with advanced or metastatic,0.468858
uuid-c522e552a71043cb81df999495405528,nivolumab combined with ipilimumab,0.446918
uuid-c522e552a71043cb81df999495405528,not approved,0.352562
uuid-c522e552a71043cb81df999495405528,clinical trials investigating the safety,0.429501
uuid-c522e552a71043cb81df999495405528,bladder cancer,0.950698
uuid-4553a62e276d498eb752529b333087ac,N Engl J Med,0.456474
uuid-4553a62e276d498eb752529b333087ac,Lancet Oncol,0.357873
uuid-4553a62e276d498eb752529b333087ac,protocol,0.480893
uuid-4553a62e276d498eb752529b333087ac,McDermott DF,0.51746
uuid-4553a62e276d498eb752529b333087ac,search of published literature,0.343051
uuid-4553a62e276d498eb752529b333087ac,Motzer RJ,0.516788
uuid-4553a62e276d498eb752529b333087ac,phase 3 study,0.754973
uuid-4553a62e276d498eb752529b333087ac,PubMed and EMBASE,0.340792
uuid-4553a62e276d498eb752529b333087ac,Escudier B,0.532534
uuid-4553a62e276d498eb752529b333087ac,et al.,0.496867
uuid-4553a62e276d498eb752529b333087ac,J Clin Oncol,0.430616
uuid-4553a62e276d498eb752529b333087ac,Rizvi NA,0.473891
uuid-4553a62e276d498eb752529b333087ac,Weber JS,0.580854
uuid-4553a62e276d498eb752529b333087ac,phase 2 study,0.6143
uuid-0580de7e06e0412da876bcd079db1490,Bristol-Myers Squibb,0.341822
uuid-0580de7e06e0412da876bcd079db1490,not conducted any controlled clinical trials/studies,0.304507
uuid-0580de7e06e0412da876bcd079db1490,Opdivo,0.461382
uuid-0580de7e06e0412da876bcd079db1490,Pubmed literature search,0.614325
uuid-0580de7e06e0412da876bcd079db1490,purposes other than its labeled indication must be considered investigational,0.586645
uuid-0580de7e06e0412da876bcd079db1490,not identify any citations relevant to your inquiry,0.606087
uuid-0580de7e06e0412da876bcd079db1490,adverse,0.304183
uuid-0580de7e06e0412da876bcd079db1490,using the following search terms,0.642331
uuid-0580de7e06e0412da876bcd079db1490,databases,0.315039
uuid-0580de7e06e0412da876bcd079db1490,reported,0.556704
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,N Engl J Med,0.427636
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,protocol,0.429136
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,McDermott DF,0.44782
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,Motzer RJ,0.430476
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,Escudier B,0.450887
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,et al.,0.456026
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,J Clin Oncol,0.384624
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,Rizvi NA,0.305616
uuid-4d0f9ac7fb2e41db8485af15e81ba6d1,phase 2 study,0.351446
uuid-aa721ead6abe4bfb87499906f12f1065,N Engl J Med,0.687116
uuid-aa721ead6abe4bfb87499906f12f1065,Lancet Oncol,0.366515
uuid-aa721ead6abe4bfb87499906f12f1065,provided in the Detailed Information,0.347151
uuid-aa721ead6abe4bfb87499906f12f1065,protocol,0.58561
uuid-aa721ead6abe4bfb87499906f12f1065,McDermott DF,0.654927
uuid-aa721ead6abe4bfb87499906f12f1065,Motzer RJ,0.622045
uuid-aa721ead6abe4bfb87499906f12f1065,phase 3 study,0.621245
uuid-aa721ead6abe4bfb87499906f12f1065,Escudier B,0.645457
uuid-aa721ead6abe4bfb87499906f12f1065,NEJM,0.348548
uuid-aa721ead6abe4bfb87499906f12f1065,et al.,0.624593
uuid-aa721ead6abe4bfb87499906f12f1065,J Clin Oncol,0.585323
uuid-aa721ead6abe4bfb87499906f12f1065,Topalian,0.329182
uuid-aa721ead6abe4bfb87499906f12f1065,phase 1 study,0.316753
uuid-aa721ead6abe4bfb87499906f12f1065,Rizvi NA,0.575411
uuid-aa721ead6abe4bfb87499906f12f1065,Brahmer J,0.480504
uuid-aa721ead6abe4bfb87499906f12f1065,Weber JS,0.469173
uuid-aa721ead6abe4bfb87499906f12f1065,BMS,0.347202
uuid-aa721ead6abe4bfb87499906f12f1065,phase 2 study,0.730999
uuid-bc19c9a7b1a04fa38ed5eac8688153e5,ipilimumab,0.385692
uuid-bc19c9a7b1a04fa38ed5eac8688153e5,ASCO 2015,0.417944
uuid-bc19c9a7b1a04fa38ed5eac8688153e5,partial response,0.382425
uuid-bc19c9a7b1a04fa38ed5eac8688153e5,Stable disease,0.586335
uuid-bc19c9a7b1a04fa38ed5eac8688153e5,cohort,0.307748
uuid-8a37d6f471834d7cae316e35e12b38d5,provided in the Detailed Information,0.349112
uuid-8a37d6f471834d7cae316e35e12b38d5,Weber JS,0.321343
uuid-81def3fd30f24f42b62e0abd0a5f7e08,evaluating,0.350845
uuid-81def3fd30f24f42b62e0abd0a5f7e08,not conducted any controlled clinical trials/studies,0.345107
uuid-81def3fd30f24f42b62e0abd0a5f7e08,search of published literature,0.385331
uuid-81def3fd30f24f42b62e0abd0a5f7e08,Additionally,0.40981
uuid-81def3fd30f24f42b62e0abd0a5f7e08,ongoing,0.457998
uuid-81def3fd30f24f42b62e0abd0a5f7e08,PubMed and EMBASE,0.378285
uuid-81def3fd30f24f42b62e0abd0a5f7e08,detailed search of www.clinicaltrials.gov,0.428522
uuid-81def3fd30f24f42b62e0abd0a5f7e08,efficacy and safety of nivolumab,0.407868
uuid-81def3fd30f24f42b62e0abd0a5f7e08,not identify any planned,0.444729
uuid-81def3fd30f24f42b62e0abd0a5f7e08,combination,0.388252
uuid-81def3fd30f24f42b62e0abd0a5f7e08,BMS,0.316104
uuid-81def3fd30f24f42b62e0abd0a5f7e08,not identify any citations relevant to your request,0.438151
uuid-81def3fd30f24f42b62e0abd0a5f7e08,present using the following search terms,0.377101
uuid-c766eec57b8d4eb3b762f68f1b43e24c,respectively,0.510423
uuid-c766eec57b8d4eb3b762f68f1b43e24c,ORR,0.332225
uuid-c766eec57b8d4eb3b762f68f1b43e24c,docetaxel,0.338634
uuid-c766eec57b8d4eb3b762f68f1b43e24c,relapsed,0.321595
uuid-e289402c64134789baa589b782b9c721,provided in the Detailed Information,0.426094
uuid-e289402c64134789baa589b782b9c721,clinical,0.519189
uuid-d31800c0909144038adc0af4568e9de4,clinical,0.340788
uuid-d31800c0909144038adc0af4568e9de4,PD-L1,0.508455
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,Bristol-Myers Squibb,0.341822
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,not conducted any controlled clinical trials/studies,0.304507
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,Opdivo,0.461382
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,Pubmed literature search,0.614325
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,not identify any citations relevant to your inquiry,0.606087
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,adverse,0.304183
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,using the following search terms,0.642331
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,databases,0.315039
uuid-96e897f9cf9d42bfa3ece0f9a54bf00f,reported,0.556704
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,N Engl J Med,0.892438
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Lancet Oncol,0.369114
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,provided in the Detailed Information,0.302862
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,protocol,0.755063
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,McDermott DF,0.82995
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Motzer RJ,0.803103
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,ESMO,0.341635
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,phase 3 study,0.507488
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Escudier B,0.832421
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,NEJM,0.452995
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,et al.,0.8085
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,J Clin Oncol,0.737251
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Topalian,0.42081
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Rizvi NA,0.588152
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Brahmer J,0.577339
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,Weber JS,0.403598
uuid-7f2df7b7ac5543ab9e79ef6f67460fd8,phase 2 study,0.770524
uuid-32dec914f94247cebeb62600b9e46687,respectively,0.397695
uuid-1140abd0dd25493bb8308694a6f2ec28,N Engl J Med,0.604857
uuid-1140abd0dd25493bb8308694a6f2ec28,non-small cell lung cancer,0.34354
uuid-1140abd0dd25493bb8308694a6f2ec28,ESMO,0.393944
uuid-1140abd0dd25493bb8308694a6f2ec28,Rizvi NA,0.452745
uuid-1140abd0dd25493bb8308694a6f2ec28,Brahmer J,0.679154
uuid-1140abd0dd25493bb8308694a6f2ec28,PD-L1,0.347566
uuid-1140abd0dd25493bb8308694a6f2ec28,Horn L,0.50259
uuid-1140abd0dd25493bb8308694a6f2ec28,platinum-based doublet chemotherapy,0.304136
uuid-cca9ac1e45244d7cbd97a238060d75dd,Opdivo,0.301598
uuid-cca9ac1e45244d7cbd97a238060d75dd,open-label,0.365374
uuid-cca9ac1e45244d7cbd97a238060d75dd,trial,0.329446
uuid-cca9ac1e45244d7cbd97a238060d75dd,safety of nivolumab monotherapy,0.462538
uuid-cca9ac1e45244d7cbd97a238060d75dd,phase,0.541907
uuid-8ad54fb387fc4bea840a28b0bb83ce46,patients,0.66884
uuid-8ad54fb387fc4bea840a28b0bb83ce46,therapy,0.31258
uuid-c73d19f2c6d745cf8787a582c438ca37,patients,0.701391
uuid-c73d19f2c6d745cf8787a582c438ca37,small cell lung cancer,0.325991
uuid-c73d19f2c6d745cf8787a582c438ca37,therapy,0.330234
uuid-c73d19f2c6d745cf8787a582c438ca37,grade 3 to 4 AEs,0.300214
uuid-741783d70bb648dbb377a2bf50224b5c,Bristol-Myers Squibb,0.341822
uuid-741783d70bb648dbb377a2bf50224b5c,not conducted any controlled clinical trials/studies,0.304507
uuid-741783d70bb648dbb377a2bf50224b5c,Opdivo,0.461382
uuid-741783d70bb648dbb377a2bf50224b5c,Pubmed literature search,0.614325
uuid-741783d70bb648dbb377a2bf50224b5c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-741783d70bb648dbb377a2bf50224b5c,not identify any citations relevant to your inquiry,0.606087
uuid-741783d70bb648dbb377a2bf50224b5c,adverse,0.304183
uuid-741783d70bb648dbb377a2bf50224b5c,using the following search terms,0.642331
uuid-741783d70bb648dbb377a2bf50224b5c,databases,0.315039
uuid-741783d70bb648dbb377a2bf50224b5c,reported,0.556704
uuid-02b6da47faae4db490bbb8de02ab97b7,Opdivo,0.413745
uuid-02b6da47faae4db490bbb8de02ab97b7,Pubmed literature search,0.570065
uuid-02b6da47faae4db490bbb8de02ab97b7,purposes other than its labeled indication must be considered investigational,0.540991
uuid-02b6da47faae4db490bbb8de02ab97b7,not identify any citations relevant to your inquiry,0.557631
uuid-02b6da47faae4db490bbb8de02ab97b7,using the following search terms,0.595841
uuid-02b6da47faae4db490bbb8de02ab97b7,reported,0.476611
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,OS,0.517683
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,95% CI,0.887029
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,respectively,0.541932
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,Objective response rate,0.732884
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,ORR,0.826341
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,PFS,0.416378
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,Median overall survival,0.810566
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,monotherapy,0.504664
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,Median OS,0.783041
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,hazard ratio,0.851803
uuid-ee694b7853df4b3e8b0e6385d3aadfe0,Median duration of response,0.350254
uuid-5fa3dc2cfb6244c28c3a9a241dcc3de0,Opdivo,0.705675
uuid-5fa3dc2cfb6244c28c3a9a241dcc3de0,trial,0.491115
uuid-bb51525a4ec640359fa49a6d8303f7d7,OS,0.62262
uuid-bb51525a4ec640359fa49a6d8303f7d7,PFS,0.65903
uuid-bb51525a4ec640359fa49a6d8303f7d7,Overall survival,0.644151
uuid-29b531b79b9b4af48c3751836f5b0114,nivolumab,0.359772
uuid-6e07154e67174470a86bd970bbada970,OS,0.387982
uuid-6e07154e67174470a86bd970bbada970,95% CI,0.745043
uuid-6e07154e67174470a86bd970bbada970,respectively,0.729294
uuid-6e07154e67174470a86bd970bbada970,Objective response rate,0.590876
uuid-6e07154e67174470a86bd970bbada970,ORR,0.722442
uuid-6e07154e67174470a86bd970bbada970,Median overall survival,0.659043
uuid-6e07154e67174470a86bd970bbada970,monotherapy,0.514468
uuid-6e07154e67174470a86bd970bbada970,Median OS,0.696688
uuid-6e07154e67174470a86bd970bbada970,PD-L1,0.300997
uuid-6e07154e67174470a86bd970bbada970,docetaxel,0.635065
uuid-6e07154e67174470a86bd970bbada970,hazard ratio,0.729977
uuid-5839f18085944688b91fe2c227eecb0c,Opdivo,0.304291
uuid-5839f18085944688b91fe2c227eecb0c,open-label,0.363658
uuid-5839f18085944688b91fe2c227eecb0c,trial,0.328465
uuid-5839f18085944688b91fe2c227eecb0c,safety of nivolumab monotherapy,0.457426
uuid-5839f18085944688b91fe2c227eecb0c,phase,0.535062
uuid-312711cd46404cd0b4cf1f7975091cf5,adverse,0.476734
uuid-312711cd46404cd0b4cf1f7975091cf5,grade,0.383532
uuid-8150c3604d3743fe8a381f80c103256a,95% CI,0.524855
uuid-8150c3604d3743fe8a381f80c103256a,respectively,0.383655
uuid-8150c3604d3743fe8a381f80c103256a,ASCO,0.303153
uuid-8150c3604d3743fe8a381f80c103256a,Lancet Oncol,0.368041
uuid-8150c3604d3743fe8a381f80c103256a,Objective response rate,0.504846
uuid-8150c3604d3743fe8a381f80c103256a,ORR,0.465366
uuid-8150c3604d3743fe8a381f80c103256a,Median overall survival,0.346516
uuid-8150c3604d3743fe8a381f80c103256a,Median OS,0.33538
uuid-8150c3604d3743fe8a381f80c103256a,ASCO 2015,0.336983
uuid-8150c3604d3743fe8a381f80c103256a,small cell lung cancer,0.336892
uuid-8150c3604d3743fe8a381f80c103256a,SCLC,0.344367
uuid-8150c3604d3743fe8a381f80c103256a,Antonia SJ,0.55269
uuid-8150c3604d3743fe8a381f80c103256a,Median duration of response,0.649605
uuid-c58c3c9f7cfd4e9a86409198cb9eb9fa,therapy,0.323989
uuid-c58c3c9f7cfd4e9a86409198cb9eb9fa,hazard ratio,0.326877
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,95% CI,0.524855
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,respectively,0.383655
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,ASCO,0.303153
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Lancet Oncol,0.368041
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Objective response rate,0.504846
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,ORR,0.465366
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Median overall survival,0.346516
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Median OS,0.33538
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,ASCO 2015,0.336983
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,small cell lung cancer,0.336892
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,SCLC,0.344367
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Antonia SJ,0.55269
uuid-8dc79c74bbed48c28a5bdcd1272d9c38,Median duration of response,0.649605
uuid-ad744d845e7e46c7af07862c2440bfba,requested,0.589334
uuid-9188820d645a4f7eb7a3f5767ae74d8e,OS,0.451716
uuid-9188820d645a4f7eb7a3f5767ae74d8e,N Engl J Med,0.423283
uuid-9188820d645a4f7eb7a3f5767ae74d8e,95% CI,0.60587
uuid-9188820d645a4f7eb7a3f5767ae74d8e,respectively,0.563707
uuid-9188820d645a4f7eb7a3f5767ae74d8e,Objective response rate,0.422194
uuid-9188820d645a4f7eb7a3f5767ae74d8e,ORR,0.597187
uuid-9188820d645a4f7eb7a3f5767ae74d8e,PFS,0.323877
uuid-9188820d645a4f7eb7a3f5767ae74d8e,Median overall survival,0.605177
uuid-9188820d645a4f7eb7a3f5767ae74d8e,Median OS,0.6344
uuid-9188820d645a4f7eb7a3f5767ae74d8e,Brahmer J,0.486588
uuid-9188820d645a4f7eb7a3f5767ae74d8e,docetaxel,0.384586
uuid-9188820d645a4f7eb7a3f5767ae74d8e,hazard ratio,0.568473
uuid-7289b94e1aef4398a7c539b90f407be8,safety,0.968498
uuid-7289b94e1aef4398a7c539b90f407be8,databases,0.876943
uuid-f112089bc7d042e38e164e7072f742a5,respectively,0.397695
uuid-66949613763d40878d8c802d76beeb08,95% CI,0.524855
uuid-66949613763d40878d8c802d76beeb08,respectively,0.383655
uuid-66949613763d40878d8c802d76beeb08,ASCO,0.303153
uuid-66949613763d40878d8c802d76beeb08,Lancet Oncol,0.368041
uuid-66949613763d40878d8c802d76beeb08,Objective response rate,0.504846
uuid-66949613763d40878d8c802d76beeb08,ORR,0.465366
uuid-66949613763d40878d8c802d76beeb08,Median overall survival,0.346516
uuid-66949613763d40878d8c802d76beeb08,Median OS,0.33538
uuid-66949613763d40878d8c802d76beeb08,ASCO 2015,0.336983
uuid-66949613763d40878d8c802d76beeb08,small cell lung cancer,0.336892
uuid-66949613763d40878d8c802d76beeb08,SCLC,0.344367
uuid-66949613763d40878d8c802d76beeb08,Antonia SJ,0.55269
uuid-66949613763d40878d8c802d76beeb08,Median duration of response,0.649605
uuid-946405a264dd45d8933ad6ab3a76f1cb,Bristol-Myers Squibb,0.347958
uuid-946405a264dd45d8933ad6ab3a76f1cb,Opdivo,0.469446
uuid-946405a264dd45d8933ad6ab3a76f1cb,Pubmed literature search,0.594459
uuid-946405a264dd45d8933ad6ab3a76f1cb,purposes other than its labeled indication must be considered investigational,0.567011
uuid-946405a264dd45d8933ad6ab3a76f1cb,not identify any citations relevant to your inquiry,0.586659
uuid-946405a264dd45d8933ad6ab3a76f1cb,adverse,0.323934
uuid-946405a264dd45d8933ad6ab3a76f1cb,using the following search terms,0.623894
uuid-946405a264dd45d8933ad6ab3a76f1cb,databases,0.303591
uuid-946405a264dd45d8933ad6ab3a76f1cb,reported,0.582414
uuid-72a70c658338489cbe9d73ad80b9cab0,Bristol-Myers Squibb,0.341822
uuid-72a70c658338489cbe9d73ad80b9cab0,not conducted any controlled clinical trials/studies,0.304507
uuid-72a70c658338489cbe9d73ad80b9cab0,Opdivo,0.461382
uuid-72a70c658338489cbe9d73ad80b9cab0,Pubmed literature search,0.614325
uuid-72a70c658338489cbe9d73ad80b9cab0,purposes other than its labeled indication must be considered investigational,0.586645
uuid-72a70c658338489cbe9d73ad80b9cab0,not identify any citations relevant to your inquiry,0.606087
uuid-72a70c658338489cbe9d73ad80b9cab0,adverse,0.304183
uuid-72a70c658338489cbe9d73ad80b9cab0,using the following search terms,0.642331
uuid-72a70c658338489cbe9d73ad80b9cab0,databases,0.315039
uuid-72a70c658338489cbe9d73ad80b9cab0,reported,0.556704
uuid-efd37260fedd45508bee2f99762e94e0,Opdivo,0.304291
uuid-efd37260fedd45508bee2f99762e94e0,open-label,0.363658
uuid-efd37260fedd45508bee2f99762e94e0,trial,0.328465
uuid-efd37260fedd45508bee2f99762e94e0,safety of nivolumab monotherapy,0.457426
uuid-efd37260fedd45508bee2f99762e94e0,phase,0.535062
uuid-0a2bd43afd684584ab1020c8cd4c64b5,OS,0.391779
uuid-0a2bd43afd684584ab1020c8cd4c64b5,95% CI,0.686315
uuid-0a2bd43afd684584ab1020c8cd4c64b5,respectively,0.564679
uuid-0a2bd43afd684584ab1020c8cd4c64b5,Objective response rate,0.598198
uuid-0a2bd43afd684584ab1020c8cd4c64b5,ORR,0.688372
uuid-0a2bd43afd684584ab1020c8cd4c64b5,Median overall survival,0.672689
uuid-0a2bd43afd684584ab1020c8cd4c64b5,monotherapy,0.619554
uuid-0a2bd43afd684584ab1020c8cd4c64b5,Median OS,0.637398
uuid-0a2bd43afd684584ab1020c8cd4c64b5,hazard ratio,0.682404
uuid-b36d5953bc744fc5b0cd3911d84a63dd,patients with advanced or metastatic,0.468858
uuid-b36d5953bc744fc5b0cd3911d84a63dd,nivolumab combined with ipilimumab,0.446918
uuid-b36d5953bc744fc5b0cd3911d84a63dd,not approved,0.352562
uuid-b36d5953bc744fc5b0cd3911d84a63dd,clinical trials investigating the safety,0.429501
uuid-b36d5953bc744fc5b0cd3911d84a63dd,bladder cancer,0.950698
uuid-f192e378ca0645d398d953b972de24a7,OS,0.387982
uuid-f192e378ca0645d398d953b972de24a7,95% CI,0.745043
uuid-f192e378ca0645d398d953b972de24a7,respectively,0.729294
uuid-f192e378ca0645d398d953b972de24a7,Objective response rate,0.590876
uuid-f192e378ca0645d398d953b972de24a7,ORR,0.722442
uuid-f192e378ca0645d398d953b972de24a7,Median overall survival,0.659043
uuid-f192e378ca0645d398d953b972de24a7,monotherapy,0.514468
uuid-f192e378ca0645d398d953b972de24a7,Median OS,0.696688
uuid-f192e378ca0645d398d953b972de24a7,PD-L1,0.300997
uuid-f192e378ca0645d398d953b972de24a7,docetaxel,0.635065
uuid-f192e378ca0645d398d953b972de24a7,hazard ratio,0.729977
uuid-ef8fb23bc343496789bae2652cfef8a5,NEJM,0.426934
uuid-ef8fb23bc343496789bae2652cfef8a5,Topalian,0.423821
uuid-ef8fb23bc343496789bae2652cfef8a5,mg,0.525266
uuid-ef8fb23bc343496789bae2652cfef8a5,kg,0.432984
uuid-3438d760419c4a0c99a57e6952d6121f,AEs,0.349137
uuid-3438d760419c4a0c99a57e6952d6121f,respectively,0.682073
uuid-3438d760419c4a0c99a57e6952d6121f,ASCO,0.363164
uuid-3438d760419c4a0c99a57e6952d6121f,Objective response rate,0.555115
uuid-3438d760419c4a0c99a57e6952d6121f,ORR,0.580944
uuid-3438d760419c4a0c99a57e6952d6121f,monotherapy,0.373693
uuid-3438d760419c4a0c99a57e6952d6121f,docetaxel,0.383382
uuid-3438d760419c4a0c99a57e6952d6121f,grade,0.321955
uuid-3438d760419c4a0c99a57e6952d6121f,Antonia SJ,0.413063
uuid-eeed2fe1ee154208b5a8bf4826b01bb7,melanoma,0.422785
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,OS,0.615067
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,95% CI,0.762805
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,NSCLC,0.301867
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,respectively,0.409113
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,Objective response rate,0.535047
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,ORR,0.654715
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,PFS,0.4748
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,Median overall survival,0.733561
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,monotherapy,0.413133
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,Median OS,0.673144
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,docetaxel,0.322223
uuid-840f5ef2906e4c75bc026fd9d3b9e01d,hazard ratio,0.746378
uuid-4262ad617bd6469d871777346e9a7d6a,nivolumab,0.480126
uuid-af7f732b146d4aff9794024da40da206,NEJM,0.426934
uuid-af7f732b146d4aff9794024da40da206,Topalian,0.423821
uuid-af7f732b146d4aff9794024da40da206,mg,0.525266
uuid-af7f732b146d4aff9794024da40da206,kg,0.432984
uuid-91062727a281467b98b88ebbcec33755,N Engl J Med,0.427636
uuid-91062727a281467b98b88ebbcec33755,protocol,0.429136
uuid-91062727a281467b98b88ebbcec33755,McDermott DF,0.44782
uuid-91062727a281467b98b88ebbcec33755,Motzer RJ,0.430476
uuid-91062727a281467b98b88ebbcec33755,Escudier B,0.450887
uuid-91062727a281467b98b88ebbcec33755,et al.,0.456026
uuid-91062727a281467b98b88ebbcec33755,J Clin Oncol,0.384624
uuid-91062727a281467b98b88ebbcec33755,Rizvi NA,0.305616
uuid-91062727a281467b98b88ebbcec33755,phase 2 study,0.351446
uuid-8111593b1dd74126bf4eb059ecac040f,NSCLC,0.374836
uuid-8111593b1dd74126bf4eb059ecac040f,non-small cell lung cancer,0.365621
uuid-8111593b1dd74126bf4eb059ecac040f,provided in the Detailed Information,0.52526
uuid-8111593b1dd74126bf4eb059ecac040f,clinical,0.700278
uuid-8111593b1dd74126bf4eb059ecac040f,phase 1 study,0.324172
uuid-8111593b1dd74126bf4eb059ecac040f,reported,0.358016
uuid-9e9a38b043be4210b6f7a7e700a3f146,Bristol-Myers Squibb,0.341822
uuid-9e9a38b043be4210b6f7a7e700a3f146,not conducted any controlled clinical trials/studies,0.304507
uuid-9e9a38b043be4210b6f7a7e700a3f146,Opdivo,0.461382
uuid-9e9a38b043be4210b6f7a7e700a3f146,Pubmed literature search,0.614325
uuid-9e9a38b043be4210b6f7a7e700a3f146,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9e9a38b043be4210b6f7a7e700a3f146,not identify any citations relevant to your inquiry,0.606087
uuid-9e9a38b043be4210b6f7a7e700a3f146,adverse,0.304183
uuid-9e9a38b043be4210b6f7a7e700a3f146,using the following search terms,0.642331
uuid-9e9a38b043be4210b6f7a7e700a3f146,databases,0.315039
uuid-9e9a38b043be4210b6f7a7e700a3f146,reported,0.556704
uuid-e6e1d932ab134f4f869737bfd3acf1e6,N Engl J Med,0.535286
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Lancet Oncol,0.364361
uuid-e6e1d932ab134f4f869737bfd3acf1e6,protocol,0.50442
uuid-e6e1d932ab134f4f869737bfd3acf1e6,McDermott DF,0.548182
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Motzer RJ,0.532741
uuid-e6e1d932ab134f4f869737bfd3acf1e6,phase 3 study,0.493197
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Escudier B,0.547344
uuid-e6e1d932ab134f4f869737bfd3acf1e6,et al.,0.519366
uuid-e6e1d932ab134f4f869737bfd3acf1e6,J Clin Oncol,0.509597
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Rizvi NA,0.478602
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Brahmer J,0.338223
uuid-e6e1d932ab134f4f869737bfd3acf1e6,Weber JS,0.370952
uuid-e6e1d932ab134f4f869737bfd3acf1e6,phase 2 study,0.591434
uuid-b802e31d6e854d98be5615837a8cb216,Bristol-Myers Squibb,0.341822
uuid-b802e31d6e854d98be5615837a8cb216,not conducted any controlled clinical trials/studies,0.304507
uuid-b802e31d6e854d98be5615837a8cb216,Opdivo,0.461382
uuid-b802e31d6e854d98be5615837a8cb216,Pubmed literature search,0.614325
uuid-b802e31d6e854d98be5615837a8cb216,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b802e31d6e854d98be5615837a8cb216,not identify any citations relevant to your inquiry,0.606087
uuid-b802e31d6e854d98be5615837a8cb216,adverse,0.304183
uuid-b802e31d6e854d98be5615837a8cb216,using the following search terms,0.642331
uuid-b802e31d6e854d98be5615837a8cb216,databases,0.315039
uuid-b802e31d6e854d98be5615837a8cb216,reported,0.556704
uuid-0205f7b0873441db8f830dd4ca149d9a,95% CI,0.524855
uuid-0205f7b0873441db8f830dd4ca149d9a,respectively,0.383655
uuid-0205f7b0873441db8f830dd4ca149d9a,ASCO,0.303153
uuid-0205f7b0873441db8f830dd4ca149d9a,Lancet Oncol,0.368041
uuid-0205f7b0873441db8f830dd4ca149d9a,Objective response rate,0.504846
uuid-0205f7b0873441db8f830dd4ca149d9a,ORR,0.465366
uuid-0205f7b0873441db8f830dd4ca149d9a,Median overall survival,0.346516
uuid-0205f7b0873441db8f830dd4ca149d9a,Median OS,0.33538
uuid-0205f7b0873441db8f830dd4ca149d9a,ASCO 2015,0.336983
uuid-0205f7b0873441db8f830dd4ca149d9a,small cell lung cancer,0.336892
uuid-0205f7b0873441db8f830dd4ca149d9a,SCLC,0.344367
uuid-0205f7b0873441db8f830dd4ca149d9a,Antonia SJ,0.55269
uuid-0205f7b0873441db8f830dd4ca149d9a,Median duration of response,0.649605
uuid-1f46120f2911463da4a12af53547fb4d,considered investigational,0.451831
uuid-1f46120f2911463da4a12af53547fb4d,small cell lung cancer,0.703291
uuid-1f46120f2911463da4a12af53547fb4d,partial response,0.47335
uuid-1f46120f2911463da4a12af53547fb4d,SCLC,0.782078
uuid-1f46120f2911463da4a12af53547fb4d,therapy,0.847008
uuid-1f46120f2911463da4a12af53547fb4d,relapsed,0.577041
uuid-1f46120f2911463da4a12af53547fb4d,phase 1/2 study CA209-032,0.457462
uuid-1f46120f2911463da4a12af53547fb4d,evaluates the efficacy of nivolumab monotherapy,0.382655
uuid-a54f7945d4e147ad82ecd771ea4fa51b,Opdivo,0.304291
uuid-a54f7945d4e147ad82ecd771ea4fa51b,open-label,0.363658
uuid-a54f7945d4e147ad82ecd771ea4fa51b,trial,0.328465
uuid-a54f7945d4e147ad82ecd771ea4fa51b,safety of nivolumab monotherapy,0.457426
uuid-a54f7945d4e147ad82ecd771ea4fa51b,phase,0.535062
uuid-f6e2f6e03cc24a7b94166ded9e4d3546,Opdivo,0.304291
uuid-f6e2f6e03cc24a7b94166ded9e4d3546,open-label,0.363658
uuid-f6e2f6e03cc24a7b94166ded9e4d3546,trial,0.328465
uuid-f6e2f6e03cc24a7b94166ded9e4d3546,safety of nivolumab monotherapy,0.457426
uuid-f6e2f6e03cc24a7b94166ded9e4d3546,phase,0.535062
uuid-af5fe37441084f988541fe6ce2dede21,Bristol-Myers Squibb,0.452181
uuid-af5fe37441084f988541fe6ce2dede21,evaluating,0.333259
uuid-af5fe37441084f988541fe6ce2dede21,not conducted any controlled clinical trials/studies,0.382676
uuid-af5fe37441084f988541fe6ce2dede21,efficacy and safety of nivolumab,0.328689
uuid-20208e6e32e6474b989df7098a807e41,AEs,0.458859
uuid-20208e6e32e6474b989df7098a807e41,adverse,0.36572
uuid-20208e6e32e6474b989df7098a807e41,grade,0.482309
uuid-20208e6e32e6474b989df7098a807e41,grade 3 to 4 AEs,0.409644
uuid-68841c13401f4adaa4344c544c7ea3b9,95% CI,0.524855
uuid-68841c13401f4adaa4344c544c7ea3b9,respectively,0.383655
uuid-68841c13401f4adaa4344c544c7ea3b9,ASCO,0.303153
uuid-68841c13401f4adaa4344c544c7ea3b9,Lancet Oncol,0.368041
uuid-68841c13401f4adaa4344c544c7ea3b9,Objective response rate,0.504846
uuid-68841c13401f4adaa4344c544c7ea3b9,ORR,0.465366
uuid-68841c13401f4adaa4344c544c7ea3b9,Median overall survival,0.346516
uuid-68841c13401f4adaa4344c544c7ea3b9,Median OS,0.33538
uuid-68841c13401f4adaa4344c544c7ea3b9,ASCO 2015,0.336983
uuid-68841c13401f4adaa4344c544c7ea3b9,small cell lung cancer,0.336892
uuid-68841c13401f4adaa4344c544c7ea3b9,SCLC,0.344367
uuid-68841c13401f4adaa4344c544c7ea3b9,Antonia SJ,0.55269
uuid-68841c13401f4adaa4344c544c7ea3b9,Median duration of response,0.649605
uuid-c9171097a33146189dcdd984a46ee8a0,OS,0.44149
uuid-c9171097a33146189dcdd984a46ee8a0,95% CI,0.833403
uuid-c9171097a33146189dcdd984a46ee8a0,ASCO,0.32927
uuid-c9171097a33146189dcdd984a46ee8a0,Objective response rate,0.545269
uuid-c9171097a33146189dcdd984a46ee8a0,ORR,0.618524
uuid-c9171097a33146189dcdd984a46ee8a0,PFS,0.396858
uuid-c9171097a33146189dcdd984a46ee8a0,Median overall survival,0.72593
uuid-c9171097a33146189dcdd984a46ee8a0,monotherapy,0.33356
uuid-c9171097a33146189dcdd984a46ee8a0,Median OS,0.763854
uuid-c9171097a33146189dcdd984a46ee8a0,hazard ratio,0.766648
uuid-c9171097a33146189dcdd984a46ee8a0,Median duration of response,0.442682
uuid-acfc816b1679464aba51132e6cb832d8,search of published literature,0.394524
uuid-acfc816b1679464aba51132e6cb832d8,Additionally,0.413583
uuid-acfc816b1679464aba51132e6cb832d8,ongoing,0.322117
uuid-acfc816b1679464aba51132e6cb832d8,PubMed and EMBASE,0.391671
uuid-acfc816b1679464aba51132e6cb832d8,detailed search of www.clinicaltrials.gov,0.375936
uuid-acfc816b1679464aba51132e6cb832d8,efficacy and safety of nivolumab,0.370699
uuid-acfc816b1679464aba51132e6cb832d8,not identify any planned,0.34283
uuid-acfc816b1679464aba51132e6cb832d8,Weber JS,0.319229
uuid-acfc816b1679464aba51132e6cb832d8,not identify any citations relevant to your request,0.447813
uuid-acfc816b1679464aba51132e6cb832d8,present using the following search terms,0.408199
uuid-033faf819aeb400db197980c4e412229,OS,0.44149
uuid-033faf819aeb400db197980c4e412229,95% CI,0.833403
uuid-033faf819aeb400db197980c4e412229,ASCO,0.32927
uuid-033faf819aeb400db197980c4e412229,Objective response rate,0.545269
uuid-033faf819aeb400db197980c4e412229,ORR,0.618524
uuid-033faf819aeb400db197980c4e412229,PFS,0.396858
uuid-033faf819aeb400db197980c4e412229,Median overall survival,0.72593
uuid-033faf819aeb400db197980c4e412229,monotherapy,0.33356
uuid-033faf819aeb400db197980c4e412229,Median OS,0.763854
uuid-033faf819aeb400db197980c4e412229,hazard ratio,0.766648
uuid-033faf819aeb400db197980c4e412229,Median duration of response,0.442682
uuid-529bb776788c4f77a375441846dd4748,OS,0.387982
uuid-529bb776788c4f77a375441846dd4748,95% CI,0.745043
uuid-529bb776788c4f77a375441846dd4748,respectively,0.729294
uuid-529bb776788c4f77a375441846dd4748,Objective response rate,0.590876
uuid-529bb776788c4f77a375441846dd4748,ORR,0.722442
uuid-529bb776788c4f77a375441846dd4748,Median overall survival,0.659043
uuid-529bb776788c4f77a375441846dd4748,monotherapy,0.514468
uuid-529bb776788c4f77a375441846dd4748,Median OS,0.696688
uuid-529bb776788c4f77a375441846dd4748,PD-L1,0.300997
uuid-529bb776788c4f77a375441846dd4748,docetaxel,0.635065
uuid-529bb776788c4f77a375441846dd4748,hazard ratio,0.729977
uuid-93b865bbc2c24120b7fd1a59995e4c7a,Opdivo,0.304291
uuid-93b865bbc2c24120b7fd1a59995e4c7a,open-label,0.363658
uuid-93b865bbc2c24120b7fd1a59995e4c7a,trial,0.328465
uuid-93b865bbc2c24120b7fd1a59995e4c7a,safety of nivolumab monotherapy,0.457426
uuid-93b865bbc2c24120b7fd1a59995e4c7a,phase,0.535062
uuid-f08a24ed44224955b6743f0d0ec8933c,Opdivo,0.910967
uuid-f08a24ed44224955b6743f0d0ec8933c,Pubmed literature search,0.327737
uuid-f08a24ed44224955b6743f0d0ec8933c,not identify any citations relevant to your inquiry,0.356381
uuid-f08a24ed44224955b6743f0d0ec8933c,using the following search terms,0.413921
uuid-f08a24ed44224955b6743f0d0ec8933c,trial,0.486452
uuid-f08a24ed44224955b6743f0d0ec8933c,reported,0.357325
uuid-34447ada683a41579b03bcbbcf109c2f,Bristol-Myers Squibb,0.341822
uuid-34447ada683a41579b03bcbbcf109c2f,not conducted any controlled clinical trials/studies,0.304507
uuid-34447ada683a41579b03bcbbcf109c2f,Opdivo,0.461382
uuid-34447ada683a41579b03bcbbcf109c2f,Pubmed literature search,0.614325
uuid-34447ada683a41579b03bcbbcf109c2f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-34447ada683a41579b03bcbbcf109c2f,not identify any citations relevant to your inquiry,0.606087
uuid-34447ada683a41579b03bcbbcf109c2f,adverse,0.304183
uuid-34447ada683a41579b03bcbbcf109c2f,using the following search terms,0.642331
uuid-34447ada683a41579b03bcbbcf109c2f,databases,0.315039
uuid-34447ada683a41579b03bcbbcf109c2f,reported,0.556704
uuid-51d8a104b76b4fe68178825d3347837f,patients,0.523362
uuid-51d8a104b76b4fe68178825d3347837f,considered investigational,0.868282
uuid-51d8a104b76b4fe68178825d3347837f,patients with advanced or metastatic,0.819374
uuid-51d8a104b76b4fe68178825d3347837f,nivolumab combined with ipilimumab,0.79905
uuid-51d8a104b76b4fe68178825d3347837f,tumors,0.788134
uuid-51d8a104b76b4fe68178825d3347837f,small cell lung cancer,0.929038
uuid-51d8a104b76b4fe68178825d3347837f,SCLC,0.886467
uuid-51d8a104b76b4fe68178825d3347837f,therapy,0.348941
uuid-51d8a104b76b4fe68178825d3347837f,grade 3 to 4 AEs,0.308254
uuid-51d8a104b76b4fe68178825d3347837f,phase 1/2 study CA209-032,0.968785
uuid-51d8a104b76b4fe68178825d3347837f,bladder cancer,0.372914
uuid-51d8a104b76b4fe68178825d3347837f,evaluates the efficacy of nivolumab monotherapy,0.950025
uuid-2b489ad3a80146a583eb15b75fddfdf0,fatigue,0.704358
uuid-7dc24ca981a94657b67b1d443c721fa7,AEs,0.324627
uuid-7dc24ca981a94657b67b1d443c721fa7,95% CI,0.338861
uuid-7dc24ca981a94657b67b1d443c721fa7,respectively,0.453901
uuid-7dc24ca981a94657b67b1d443c721fa7,ORR,0.475981
uuid-7dc24ca981a94657b67b1d443c721fa7,Median overall survival,0.39964
uuid-7dc24ca981a94657b67b1d443c721fa7,monotherapy,0.429309
uuid-7dc24ca981a94657b67b1d443c721fa7,ESMO,0.519283
uuid-7dc24ca981a94657b67b1d443c721fa7,Median OS,0.3335
uuid-7dc24ca981a94657b67b1d443c721fa7,mg,0.327485
uuid-7dc24ca981a94657b67b1d443c721fa7,kg,0.315577
uuid-7dc24ca981a94657b67b1d443c721fa7,Horn L,0.461305
uuid-7dc24ca981a94657b67b1d443c721fa7,hazard ratio,0.344281
uuid-7dc24ca981a94657b67b1d443c721fa7,grade 3 to 4 AEs,0.409181
uuid-7dc24ca981a94657b67b1d443c721fa7,platinum-based doublet chemotherapy,0.329446
uuid-6faad92c67284a2784757753c9cd133a,95% CI,0.524855
uuid-6faad92c67284a2784757753c9cd133a,respectively,0.383655
uuid-6faad92c67284a2784757753c9cd133a,ASCO,0.303153
uuid-6faad92c67284a2784757753c9cd133a,Lancet Oncol,0.368041
uuid-6faad92c67284a2784757753c9cd133a,Objective response rate,0.504846
uuid-6faad92c67284a2784757753c9cd133a,ORR,0.465366
uuid-6faad92c67284a2784757753c9cd133a,Median overall survival,0.346516
uuid-6faad92c67284a2784757753c9cd133a,Median OS,0.33538
uuid-6faad92c67284a2784757753c9cd133a,ASCO 2015,0.336983
uuid-6faad92c67284a2784757753c9cd133a,small cell lung cancer,0.336892
uuid-6faad92c67284a2784757753c9cd133a,SCLC,0.344367
uuid-6faad92c67284a2784757753c9cd133a,Antonia SJ,0.55269
uuid-6faad92c67284a2784757753c9cd133a,Median duration of response,0.649605
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,nivolumab,0.583444
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,Bristol-Myers Squibb,0.44216
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,evaluating,0.650502
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,not conducted any controlled clinical trials/studies,0.675952
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,Pubmed literature search,0.775688
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,purposes other than its labeled indication must be considered investigational,0.85082
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,not identify any citations relevant to your inquiry,0.730108
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,ipilimumab,0.309262
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,using the following search terms,0.718232
uuid-1c37215d381d47a3a2b9d45ae2b0b8a0,efficacy and safety of nivolumab,0.485622
uuid-536cc98e36ff4bf4a0d5a2ec44d1bd66,fatigue,0.704358
uuid-e1606a69cbc8483fa32ad53ae9331b44,use of nivolumab for the treatment,0.440423
uuid-e1606a69cbc8483fa32ad53ae9331b44,search of published literature,0.311531
uuid-e1606a69cbc8483fa32ad53ae9331b44,PubMed and EMBASE,0.312811
uuid-e1606a69cbc8483fa32ad53ae9331b44,not approved,0.404782
uuid-e1606a69cbc8483fa32ad53ae9331b44,open-label,0.578291
uuid-e1606a69cbc8483fa32ad53ae9331b44,clinical trials investigating the safety,0.440014
uuid-e1606a69cbc8483fa32ad53ae9331b44,present using the following search terms,0.328669
uuid-e1606a69cbc8483fa32ad53ae9331b44,phase,0.41185
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,nivolumab,0.567409
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,Bristol-Myers Squibb,0.438565
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,evaluating,0.594286
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,not conducted any controlled clinical trials/studies,0.655858
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,Pubmed literature search,0.879255
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,purposes other than its labeled indication must be considered investigational,0.941881
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,not identify any citations relevant to your inquiry,0.838346
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,using the following search terms,0.825992
uuid-b174ff06eb374aa5ab8dd6703dd1ecc4,efficacy and safety of nivolumab,0.432448
uuid-787594e71eb94135a4e19334882ad9e7,nivolumab,0.510392
uuid-787594e71eb94135a4e19334882ad9e7,Bristol-Myers Squibb,0.464176
uuid-787594e71eb94135a4e19334882ad9e7,evaluating,0.683286
uuid-787594e71eb94135a4e19334882ad9e7,not conducted any controlled clinical trials/studies,0.682483
uuid-787594e71eb94135a4e19334882ad9e7,RCC,0.308694
uuid-787594e71eb94135a4e19334882ad9e7,search of published literature,0.839602
uuid-787594e71eb94135a4e19334882ad9e7,Additionally,0.446384
uuid-787594e71eb94135a4e19334882ad9e7,PubMed and EMBASE,0.823429
uuid-787594e71eb94135a4e19334882ad9e7,detailed search of www.clinicaltrials.gov,0.366719
uuid-787594e71eb94135a4e19334882ad9e7,efficacy and safety of nivolumab,0.841
uuid-787594e71eb94135a4e19334882ad9e7,not identify any citations relevant to your request,0.605656
uuid-787594e71eb94135a4e19334882ad9e7,present using the following search terms,0.832619
uuid-0edfee8957384c58bbd5d80e384d9754,melanoma,0.410364
uuid-df41d7ca89964de5b82747760a5b7a79,open-label,0.539462
uuid-df41d7ca89964de5b82747760a5b7a79,phase,0.350616
uuid-c8f4a22095e547b6be01ed029a8c0aa9,OS,0.337471
uuid-c8f4a22095e547b6be01ed029a8c0aa9,95% CI,0.64079
uuid-c8f4a22095e547b6be01ed029a8c0aa9,respectively,0.642949
uuid-c8f4a22095e547b6be01ed029a8c0aa9,Objective response rate,0.489907
uuid-c8f4a22095e547b6be01ed029a8c0aa9,ORR,0.608003
uuid-c8f4a22095e547b6be01ed029a8c0aa9,Median overall survival,0.56784
uuid-c8f4a22095e547b6be01ed029a8c0aa9,monotherapy,0.45385
uuid-c8f4a22095e547b6be01ed029a8c0aa9,Median OS,0.607372
uuid-c8f4a22095e547b6be01ed029a8c0aa9,docetaxel,0.663698
uuid-c8f4a22095e547b6be01ed029a8c0aa9,hazard ratio,0.637606
uuid-0f49659238b8442fbd2a4657e9ed40d8,patients with advanced or metastatic,0.468858
uuid-0f49659238b8442fbd2a4657e9ed40d8,nivolumab combined with ipilimumab,0.446918
uuid-0f49659238b8442fbd2a4657e9ed40d8,not approved,0.352562
uuid-0f49659238b8442fbd2a4657e9ed40d8,clinical trials investigating the safety,0.429501
uuid-0f49659238b8442fbd2a4657e9ed40d8,bladder cancer,0.950698
uuid-24589da481d44105afb6e0f9de896021,OS,0.387982
uuid-24589da481d44105afb6e0f9de896021,95% CI,0.745043
uuid-24589da481d44105afb6e0f9de896021,respectively,0.729294
uuid-24589da481d44105afb6e0f9de896021,Objective response rate,0.590876
uuid-24589da481d44105afb6e0f9de896021,ORR,0.722442
uuid-24589da481d44105afb6e0f9de896021,Median overall survival,0.659043
uuid-24589da481d44105afb6e0f9de896021,monotherapy,0.514468
uuid-24589da481d44105afb6e0f9de896021,Median OS,0.696688
uuid-24589da481d44105afb6e0f9de896021,PD-L1,0.300997
uuid-24589da481d44105afb6e0f9de896021,docetaxel,0.635065
uuid-24589da481d44105afb6e0f9de896021,hazard ratio,0.729977
uuid-cac4db0d47674d5997af683dd566c28f,N Engl J Med,0.604857
uuid-cac4db0d47674d5997af683dd566c28f,non-small cell lung cancer,0.34354
uuid-cac4db0d47674d5997af683dd566c28f,ESMO,0.393944
uuid-cac4db0d47674d5997af683dd566c28f,Rizvi NA,0.452745
uuid-cac4db0d47674d5997af683dd566c28f,Brahmer J,0.679154
uuid-cac4db0d47674d5997af683dd566c28f,PD-L1,0.347566
uuid-cac4db0d47674d5997af683dd566c28f,Horn L,0.50259
uuid-cac4db0d47674d5997af683dd566c28f,platinum-based doublet chemotherapy,0.304136
uuid-6965340f119142a0a7e1909e48e140b2,OS,0.387982
uuid-6965340f119142a0a7e1909e48e140b2,95% CI,0.745043
uuid-6965340f119142a0a7e1909e48e140b2,respectively,0.729294
uuid-6965340f119142a0a7e1909e48e140b2,Objective response rate,0.590876
uuid-6965340f119142a0a7e1909e48e140b2,ORR,0.722442
uuid-6965340f119142a0a7e1909e48e140b2,Median overall survival,0.659043
uuid-6965340f119142a0a7e1909e48e140b2,monotherapy,0.514468
uuid-6965340f119142a0a7e1909e48e140b2,Median OS,0.696688
uuid-6965340f119142a0a7e1909e48e140b2,PD-L1,0.300997
uuid-6965340f119142a0a7e1909e48e140b2,docetaxel,0.635065
uuid-6965340f119142a0a7e1909e48e140b2,hazard ratio,0.729977
uuid-c7fa8c7a58424e15aa4e0c0a6baa6e79,requested,0.594234
uuid-808455d59d3646ac9b8a7119722c88eb,provided in the Detailed Information,0.309154
uuid-808455d59d3646ac9b8a7119722c88eb,McDermott DF,0.326735
uuid-808455d59d3646ac9b8a7119722c88eb,phase 3 study,0.472421
uuid-808455d59d3646ac9b8a7119722c88eb,Escudier B,0.312914
uuid-808455d59d3646ac9b8a7119722c88eb,phase 2 study,0.43281
uuid-64948fb4d90f40e982085a7bdfbb06b9,use of nivolumab for the treatment,0.444892
uuid-64948fb4d90f40e982085a7bdfbb06b9,evaluating,0.30558
uuid-64948fb4d90f40e982085a7bdfbb06b9,patients,0.440855
uuid-64948fb4d90f40e982085a7bdfbb06b9,not approved,0.378002
uuid-64948fb4d90f40e982085a7bdfbb06b9,clinical trials investigating the safety,0.352423
uuid-b09862a1774e42619ec10426d77f72df,Lancet Oncol,0.693877
uuid-b09862a1774e42619ec10426d77f72df,patients,0.405972
uuid-b09862a1774e42619ec10426d77f72df,ipilimumab,0.370825
uuid-b09862a1774e42619ec10426d77f72df,phase 3 study,0.623784
uuid-b09862a1774e42619ec10426d77f72df,ASCO 2015,0.343144
uuid-b09862a1774e42619ec10426d77f72df,melanoma,0.311721
uuid-b09862a1774e42619ec10426d77f72df,phase 1 study,0.381973
uuid-b09862a1774e42619ec10426d77f72df,Rizvi NA,0.651494
uuid-b09862a1774e42619ec10426d77f72df,CA209-003,0.307938
uuid-b09862a1774e42619ec10426d77f72df,Weber JS,0.728839
uuid-b09862a1774e42619ec10426d77f72df,phase 2 study,0.401293
uuid-b09862a1774e42619ec10426d77f72df,Antonia SJ,0.482552
uuid-2073120a29004e10adccd67113b2bd55,95% CI,0.524855
uuid-2073120a29004e10adccd67113b2bd55,respectively,0.383655
uuid-2073120a29004e10adccd67113b2bd55,ASCO,0.303153
uuid-2073120a29004e10adccd67113b2bd55,Lancet Oncol,0.368041
uuid-2073120a29004e10adccd67113b2bd55,Objective response rate,0.504846
uuid-2073120a29004e10adccd67113b2bd55,ORR,0.465366
uuid-2073120a29004e10adccd67113b2bd55,Median overall survival,0.346516
uuid-2073120a29004e10adccd67113b2bd55,Median OS,0.33538
uuid-2073120a29004e10adccd67113b2bd55,ASCO 2015,0.336983
uuid-2073120a29004e10adccd67113b2bd55,small cell lung cancer,0.336892
uuid-2073120a29004e10adccd67113b2bd55,SCLC,0.344367
uuid-2073120a29004e10adccd67113b2bd55,Antonia SJ,0.55269
uuid-2073120a29004e10adccd67113b2bd55,Median duration of response,0.649605
uuid-c7db4b7ddfd94b81acae3606326f976a,Bristol-Myers Squibb,0.341822
uuid-c7db4b7ddfd94b81acae3606326f976a,not conducted any controlled clinical trials/studies,0.304507
uuid-c7db4b7ddfd94b81acae3606326f976a,Opdivo,0.461382
uuid-c7db4b7ddfd94b81acae3606326f976a,Pubmed literature search,0.614325
uuid-c7db4b7ddfd94b81acae3606326f976a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c7db4b7ddfd94b81acae3606326f976a,not identify any citations relevant to your inquiry,0.606087
uuid-c7db4b7ddfd94b81acae3606326f976a,adverse,0.304183
uuid-c7db4b7ddfd94b81acae3606326f976a,using the following search terms,0.642331
uuid-c7db4b7ddfd94b81acae3606326f976a,databases,0.315039
uuid-c7db4b7ddfd94b81acae3606326f976a,reported,0.556704
uuid-a94535c2b9de4a62ab595d68337d5971,N Engl J Med,0.714946
uuid-a94535c2b9de4a62ab595d68337d5971,Lancet Oncol,0.448679
uuid-a94535c2b9de4a62ab595d68337d5971,patients,0.309769
uuid-a94535c2b9de4a62ab595d68337d5971,protocol,0.700662
uuid-a94535c2b9de4a62ab595d68337d5971,McDermott DF,0.68799
uuid-a94535c2b9de4a62ab595d68337d5971,Motzer RJ,0.689932
uuid-a94535c2b9de4a62ab595d68337d5971,phase 3 study,0.545628
uuid-a94535c2b9de4a62ab595d68337d5971,Escudier B,0.698812
uuid-a94535c2b9de4a62ab595d68337d5971,NEJM,0.402095
uuid-a94535c2b9de4a62ab595d68337d5971,et al.,0.640511
uuid-a94535c2b9de4a62ab595d68337d5971,J Clin Oncol,0.626106
uuid-a94535c2b9de4a62ab595d68337d5971,Topalian,0.37979
uuid-a94535c2b9de4a62ab595d68337d5971,phase 1 study,0.381282
uuid-a94535c2b9de4a62ab595d68337d5971,Rizvi NA,0.636006
uuid-a94535c2b9de4a62ab595d68337d5971,Brahmer J,0.517174
uuid-a94535c2b9de4a62ab595d68337d5971,efficacy and safety of nivolumab,0.368444
uuid-a94535c2b9de4a62ab595d68337d5971,Weber JS,0.406071
uuid-a94535c2b9de4a62ab595d68337d5971,phase 2 study,0.692115
uuid-c9d5a60e544f4a86873dafd2fe05f38b,respectively,0.604911
uuid-c9d5a60e544f4a86873dafd2fe05f38b,ASCO,0.370609
uuid-c9d5a60e544f4a86873dafd2fe05f38b,Objective response rate,0.472418
uuid-c9d5a60e544f4a86873dafd2fe05f38b,ORR,0.487844
uuid-c9d5a60e544f4a86873dafd2fe05f38b,monotherapy,0.476726
uuid-c9d5a60e544f4a86873dafd2fe05f38b,docetaxel,0.478668
uuid-c9d5a60e544f4a86873dafd2fe05f38b,Antonia SJ,0.346494
uuid-3573334288eb48e990a436aea5255913,respectively,0.63545
uuid-3573334288eb48e990a436aea5255913,ASCO,0.390227
uuid-3573334288eb48e990a436aea5255913,Lancet Oncol,0.474369
uuid-3573334288eb48e990a436aea5255913,Objective response rate,0.517371
uuid-3573334288eb48e990a436aea5255913,ORR,0.505132
uuid-3573334288eb48e990a436aea5255913,monotherapy,0.365256
uuid-3573334288eb48e990a436aea5255913,Rizvi NA,0.374498
uuid-3573334288eb48e990a436aea5255913,Weber JS,0.360633
uuid-3573334288eb48e990a436aea5255913,docetaxel,0.33687
uuid-3573334288eb48e990a436aea5255913,Antonia SJ,0.483446
uuid-abcfdac21af4494c81fb47e7892367ab,use of nivolumab for the treatment,0.440423
uuid-abcfdac21af4494c81fb47e7892367ab,search of published literature,0.311531
uuid-abcfdac21af4494c81fb47e7892367ab,PubMed and EMBASE,0.312811
uuid-abcfdac21af4494c81fb47e7892367ab,not approved,0.404782
uuid-abcfdac21af4494c81fb47e7892367ab,open-label,0.578291
uuid-abcfdac21af4494c81fb47e7892367ab,clinical trials investigating the safety,0.440014
uuid-abcfdac21af4494c81fb47e7892367ab,present using the following search terms,0.328669
uuid-abcfdac21af4494c81fb47e7892367ab,phase,0.41185
uuid-3b44e7f476244f5db278b74dfe622820,trial,0.306565
uuid-d1575ebfd74247c8a75b75b990d78a5c,provided in the Detailed Information,0.317297
uuid-d1575ebfd74247c8a75b75b990d78a5c,Opdivo,0.30313
uuid-d1575ebfd74247c8a75b75b990d78a5c,clinical,0.440432
uuid-d1575ebfd74247c8a75b75b990d78a5c,BMS,0.330571
uuid-d1575ebfd74247c8a75b75b990d78a5c,safety,0.420301
uuid-d1575ebfd74247c8a75b75b990d78a5c,databases,0.373639
uuid-4a00a9431dd042abaf3385cbd863f4c4,N Engl J Med,0.689907
uuid-4a00a9431dd042abaf3385cbd863f4c4,Lancet Oncol,0.584216
uuid-4a00a9431dd042abaf3385cbd863f4c4,protocol,0.72528
uuid-4a00a9431dd042abaf3385cbd863f4c4,McDermott DF,0.794444
uuid-4a00a9431dd042abaf3385cbd863f4c4,Motzer RJ,0.755383
uuid-4a00a9431dd042abaf3385cbd863f4c4,phase 3 study,0.521307
uuid-4a00a9431dd042abaf3385cbd863f4c4,Escudier B,0.794743
uuid-4a00a9431dd042abaf3385cbd863f4c4,NEJM,0.434762
uuid-4a00a9431dd042abaf3385cbd863f4c4,et al.,0.777092
uuid-4a00a9431dd042abaf3385cbd863f4c4,J Clin Oncol,0.708338
uuid-4a00a9431dd042abaf3385cbd863f4c4,Topalian,0.401719
uuid-4a00a9431dd042abaf3385cbd863f4c4,Rizvi NA,0.731383
uuid-4a00a9431dd042abaf3385cbd863f4c4,Brahmer J,0.378658
uuid-4a00a9431dd042abaf3385cbd863f4c4,Weber JS,0.614831
uuid-4a00a9431dd042abaf3385cbd863f4c4,phase 2 study,0.769458
uuid-016b5f529e744be08eddd25fe060e2f3,nivolumab,0.567186
uuid-016b5f529e744be08eddd25fe060e2f3,Bristol-Myers Squibb,0.471853
uuid-016b5f529e744be08eddd25fe060e2f3,evaluating,0.646756
uuid-016b5f529e744be08eddd25fe060e2f3,not conducted any controlled clinical trials/studies,0.696982
uuid-016b5f529e744be08eddd25fe060e2f3,Pubmed literature search,0.845093
uuid-016b5f529e744be08eddd25fe060e2f3,purposes other than its labeled indication must be considered investigational,0.916809
uuid-016b5f529e744be08eddd25fe060e2f3,not identify any citations relevant to your inquiry,0.802441
uuid-016b5f529e744be08eddd25fe060e2f3,using the following search terms,0.787232
uuid-016b5f529e744be08eddd25fe060e2f3,efficacy and safety of nivolumab,0.484634
uuid-27af83653d9d43358d42fc0460827d48,nivolumab,0.515895
uuid-27af83653d9d43358d42fc0460827d48,Bristol-Myers Squibb,0.479277
uuid-27af83653d9d43358d42fc0460827d48,evaluating,0.688379
uuid-27af83653d9d43358d42fc0460827d48,not conducted any controlled clinical trials/studies,0.716895
uuid-27af83653d9d43358d42fc0460827d48,NSCLC,0.448711
uuid-27af83653d9d43358d42fc0460827d48,non-small cell lung cancer,0.494408
uuid-27af83653d9d43358d42fc0460827d48,Pubmed literature search,0.746691
uuid-27af83653d9d43358d42fc0460827d48,purposes other than its labeled indication must be considered investigational,0.832512
uuid-27af83653d9d43358d42fc0460827d48,not identify any citations relevant to your inquiry,0.696454
uuid-27af83653d9d43358d42fc0460827d48,using the following search terms,0.682271
uuid-27af83653d9d43358d42fc0460827d48,efficacy and safety of nivolumab,0.522345
uuid-27af83653d9d43358d42fc0460827d48,safety of nivolumab monotherapy,0.307075
uuid-2fc3f813ad914ac38152f6bb605ac336,evaluating,0.335951
uuid-2fc3f813ad914ac38152f6bb605ac336,not conducted any controlled clinical trials/studies,0.333389
uuid-2fc3f813ad914ac38152f6bb605ac336,protocol,0.519575
uuid-2fc3f813ad914ac38152f6bb605ac336,RCC,0.396553
uuid-2fc3f813ad914ac38152f6bb605ac336,McDermott DF,0.425884
uuid-2fc3f813ad914ac38152f6bb605ac336,search of published literature,0.498677
uuid-2fc3f813ad914ac38152f6bb605ac336,Additionally,0.549805
uuid-2fc3f813ad914ac38152f6bb605ac336,ongoing,0.474607
uuid-2fc3f813ad914ac38152f6bb605ac336,Motzer RJ,0.459307
uuid-2fc3f813ad914ac38152f6bb605ac336,PubMed and EMBASE,0.495664
uuid-2fc3f813ad914ac38152f6bb605ac336,Escudier B,0.441261
uuid-2fc3f813ad914ac38152f6bb605ac336,et al.,0.378311
uuid-2fc3f813ad914ac38152f6bb605ac336,J Clin Oncol,0.413082
uuid-2fc3f813ad914ac38152f6bb605ac336,detailed search of www.clinicaltrials.gov,0.509889
uuid-2fc3f813ad914ac38152f6bb605ac336,efficacy and safety of nivolumab,0.474675
uuid-2fc3f813ad914ac38152f6bb605ac336,not identify any planned,0.488524
uuid-2fc3f813ad914ac38152f6bb605ac336,phase 2 study,0.364975
uuid-2fc3f813ad914ac38152f6bb605ac336,not identify any citations relevant to your request,0.559578
uuid-2fc3f813ad914ac38152f6bb605ac336,present using the following search terms,0.484223
uuid-8983b975db65472595bbe9b9a99e8137,nivolumab,0.570883
uuid-8983b975db65472595bbe9b9a99e8137,Bristol-Myers Squibb,0.436384
uuid-8983b975db65472595bbe9b9a99e8137,evaluating,0.597068
uuid-8983b975db65472595bbe9b9a99e8137,not conducted any controlled clinical trials/studies,0.653782
uuid-8983b975db65472595bbe9b9a99e8137,Pubmed literature search,0.877534
uuid-8983b975db65472595bbe9b9a99e8137,purposes other than its labeled indication must be considered investigational,0.940051
uuid-8983b975db65472595bbe9b9a99e8137,not identify any citations relevant to your inquiry,0.836947
uuid-8983b975db65472595bbe9b9a99e8137,using the following search terms,0.824792
uuid-8983b975db65472595bbe9b9a99e8137,efficacy and safety of nivolumab,0.430795
uuid-8c97225623d24798bcc676703319f2c5,patients,0.468224
uuid-ca33657ff0ce4ebbb4b85fd6385c0503,clinical,0.326217
uuid-ca33657ff0ce4ebbb4b85fd6385c0503,trial,0.412599
uuid-c22044441dac4ad98477ec0a3b9a9003,ipilimumab,0.385692
uuid-c22044441dac4ad98477ec0a3b9a9003,ASCO 2015,0.417944
uuid-c22044441dac4ad98477ec0a3b9a9003,partial response,0.382425
uuid-c22044441dac4ad98477ec0a3b9a9003,Stable disease,0.586335
uuid-c22044441dac4ad98477ec0a3b9a9003,cohort,0.307748
uuid-4ec57971a51b40498c17c636b34d854c,evaluating,0.350845
uuid-4ec57971a51b40498c17c636b34d854c,not conducted any controlled clinical trials/studies,0.345107
uuid-4ec57971a51b40498c17c636b34d854c,search of published literature,0.385331
uuid-4ec57971a51b40498c17c636b34d854c,Additionally,0.40981
uuid-4ec57971a51b40498c17c636b34d854c,ongoing,0.457998
uuid-4ec57971a51b40498c17c636b34d854c,PubMed and EMBASE,0.378285
uuid-4ec57971a51b40498c17c636b34d854c,detailed search of www.clinicaltrials.gov,0.428522
uuid-4ec57971a51b40498c17c636b34d854c,efficacy and safety of nivolumab,0.407868
uuid-4ec57971a51b40498c17c636b34d854c,not identify any planned,0.444729
uuid-4ec57971a51b40498c17c636b34d854c,combination,0.388252
uuid-4ec57971a51b40498c17c636b34d854c,BMS,0.316104
uuid-4ec57971a51b40498c17c636b34d854c,not identify any citations relevant to your request,0.438151
uuid-4ec57971a51b40498c17c636b34d854c,present using the following search terms,0.377101
uuid-1b77d88512804f09b526af15f565f411,considered investigational,0.451831
uuid-1b77d88512804f09b526af15f565f411,small cell lung cancer,0.703291
uuid-1b77d88512804f09b526af15f565f411,partial response,0.47335
uuid-1b77d88512804f09b526af15f565f411,SCLC,0.782078
uuid-1b77d88512804f09b526af15f565f411,therapy,0.847008
uuid-1b77d88512804f09b526af15f565f411,relapsed,0.577041
uuid-1b77d88512804f09b526af15f565f411,phase 1/2 study CA209-032,0.457462
uuid-1b77d88512804f09b526af15f565f411,evaluates the efficacy of nivolumab monotherapy,0.382655
uuid-9c231ce33d7749cfa8245ee201c17488,NSCLC,0.35614
uuid-9c231ce33d7749cfa8245ee201c17488,non-small cell lung cancer,0.303269
uuid-9c231ce33d7749cfa8245ee201c17488,phase 3 study,0.45311
uuid-d49e3d6463dd40fdba2244c51f43b024,nivolumab,0.496597
uuid-d49e3d6463dd40fdba2244c51f43b024,Bristol-Myers Squibb,0.470341
uuid-d49e3d6463dd40fdba2244c51f43b024,evaluating,0.616783
uuid-d49e3d6463dd40fdba2244c51f43b024,not conducted any controlled clinical trials/studies,0.67982
uuid-d49e3d6463dd40fdba2244c51f43b024,Pubmed literature search,0.869363
uuid-d49e3d6463dd40fdba2244c51f43b024,purposes other than its labeled indication must be considered investigational,0.932012
uuid-d49e3d6463dd40fdba2244c51f43b024,not identify any citations relevant to your inquiry,0.82679
uuid-d49e3d6463dd40fdba2244c51f43b024,using the following search terms,0.814989
uuid-d49e3d6463dd40fdba2244c51f43b024,efficacy and safety of nivolumab,0.445583
uuid-1892fb4c1dbd42a79ee7e88aad8a3237,provided in the Detailed Information,0.408633
uuid-e3db6c7ba80044449b905317db9c42ad,95% CI,0.524855
uuid-e3db6c7ba80044449b905317db9c42ad,respectively,0.383655
uuid-e3db6c7ba80044449b905317db9c42ad,ASCO,0.303153
uuid-e3db6c7ba80044449b905317db9c42ad,Lancet Oncol,0.368041
uuid-e3db6c7ba80044449b905317db9c42ad,Objective response rate,0.504846
uuid-e3db6c7ba80044449b905317db9c42ad,ORR,0.465366
uuid-e3db6c7ba80044449b905317db9c42ad,Median overall survival,0.346516
uuid-e3db6c7ba80044449b905317db9c42ad,Median OS,0.33538
uuid-e3db6c7ba80044449b905317db9c42ad,ASCO 2015,0.336983
uuid-e3db6c7ba80044449b905317db9c42ad,small cell lung cancer,0.336892
uuid-e3db6c7ba80044449b905317db9c42ad,SCLC,0.344367
uuid-e3db6c7ba80044449b905317db9c42ad,Antonia SJ,0.55269
uuid-e3db6c7ba80044449b905317db9c42ad,Median duration of response,0.649605
uuid-73635dead22440e3a15d56b9954bc071,Bristol-Myers Squibb,0.341822
uuid-73635dead22440e3a15d56b9954bc071,not conducted any controlled clinical trials/studies,0.304507
uuid-73635dead22440e3a15d56b9954bc071,Opdivo,0.461382
uuid-73635dead22440e3a15d56b9954bc071,Pubmed literature search,0.614325
uuid-73635dead22440e3a15d56b9954bc071,purposes other than its labeled indication must be considered investigational,0.586645
uuid-73635dead22440e3a15d56b9954bc071,not identify any citations relevant to your inquiry,0.606087
uuid-73635dead22440e3a15d56b9954bc071,adverse,0.304183
uuid-73635dead22440e3a15d56b9954bc071,using the following search terms,0.642331
uuid-73635dead22440e3a15d56b9954bc071,databases,0.315039
uuid-73635dead22440e3a15d56b9954bc071,reported,0.556704
uuid-59e1753b14dd466fa625ef249a3bd426,Bristol-Myers Squibb,0.341822
uuid-59e1753b14dd466fa625ef249a3bd426,not conducted any controlled clinical trials/studies,0.304507
uuid-59e1753b14dd466fa625ef249a3bd426,Opdivo,0.461382
uuid-59e1753b14dd466fa625ef249a3bd426,Pubmed literature search,0.614325
uuid-59e1753b14dd466fa625ef249a3bd426,purposes other than its labeled indication must be considered investigational,0.586645
uuid-59e1753b14dd466fa625ef249a3bd426,not identify any citations relevant to your inquiry,0.606087
uuid-59e1753b14dd466fa625ef249a3bd426,adverse,0.304183
uuid-59e1753b14dd466fa625ef249a3bd426,using the following search terms,0.642331
uuid-59e1753b14dd466fa625ef249a3bd426,databases,0.315039
uuid-59e1753b14dd466fa625ef249a3bd426,reported,0.556704
uuid-f5f4c789ac194cf4a711d5b888c7ff03,OS,0.387982
uuid-f5f4c789ac194cf4a711d5b888c7ff03,95% CI,0.745043
uuid-f5f4c789ac194cf4a711d5b888c7ff03,respectively,0.729294
uuid-f5f4c789ac194cf4a711d5b888c7ff03,Objective response rate,0.590876
uuid-f5f4c789ac194cf4a711d5b888c7ff03,ORR,0.722442
uuid-f5f4c789ac194cf4a711d5b888c7ff03,Median overall survival,0.659043
uuid-f5f4c789ac194cf4a711d5b888c7ff03,monotherapy,0.514468
uuid-f5f4c789ac194cf4a711d5b888c7ff03,Median OS,0.696688
uuid-f5f4c789ac194cf4a711d5b888c7ff03,PD-L1,0.300997
uuid-f5f4c789ac194cf4a711d5b888c7ff03,docetaxel,0.635065
uuid-f5f4c789ac194cf4a711d5b888c7ff03,hazard ratio,0.729977
uuid-13b42fed8c5c4305b5f7dfd3affe404d,OS,0.62262
uuid-13b42fed8c5c4305b5f7dfd3affe404d,PFS,0.65903
uuid-13b42fed8c5c4305b5f7dfd3affe404d,Overall survival,0.644151
uuid-843d07368f4f4a84b56ce3f299dd7a6f,nivolumab,0.359772
uuid-4721a668ba9a4b968536928e3fb7c16c,OS,0.410007
uuid-4721a668ba9a4b968536928e3fb7c16c,N Engl J Med,0.349428
uuid-4721a668ba9a4b968536928e3fb7c16c,95% CI,0.590957
uuid-4721a668ba9a4b968536928e3fb7c16c,respectively,0.580507
uuid-4721a668ba9a4b968536928e3fb7c16c,Objective response rate,0.544022
uuid-4721a668ba9a4b968536928e3fb7c16c,ORR,0.628182
uuid-4721a668ba9a4b968536928e3fb7c16c,Median overall survival,0.623076
uuid-4721a668ba9a4b968536928e3fb7c16c,Median OS,0.596352
uuid-4721a668ba9a4b968536928e3fb7c16c,Brahmer J,0.416024
uuid-4721a668ba9a4b968536928e3fb7c16c,docetaxel,0.392529
uuid-4721a668ba9a4b968536928e3fb7c16c,hazard ratio,0.55336
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,nivolumab,0.367706
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,Bristol-Myers Squibb,0.306467
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,evaluating,0.530532
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,not conducted any controlled clinical trials/studies,0.479216
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,RCC,0.305062
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,search of published literature,0.678238
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,Additionally,0.595912
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,ongoing,0.441687
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,PubMed and EMBASE,0.674815
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,detailed search of www.clinicaltrials.gov,0.548327
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,phase 1 study,0.395894
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,efficacy and safety of nivolumab,0.669482
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,not identify any planned,0.477355
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,CA209-003,0.39471
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,not identify any citations relevant to your request,0.710902
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,present using the following search terms,0.731245
uuid-c320effd46e247aa9ab7bbf10ce7c4d6,investigating,0.414816
uuid-b75712949f4e4f6d83ab9e48eb26f54d,Bristol-Myers Squibb,0.352546
uuid-b75712949f4e4f6d83ab9e48eb26f54d,requested,0.353049
uuid-79c447846f95408e9d75d985e760517b,patients with advanced or metastatic,0.478326
uuid-79c447846f95408e9d75d985e760517b,nivolumab combined with ipilimumab,0.498766
uuid-79c447846f95408e9d75d985e760517b,not approved,0.34724
uuid-79c447846f95408e9d75d985e760517b,clinical trials investigating the safety,0.426729
uuid-79c447846f95408e9d75d985e760517b,bladder cancer,0.6548
uuid-aa4afe8633474945809f246f1fd08bed,Bristol-Myers Squibb,0.341822
uuid-aa4afe8633474945809f246f1fd08bed,not conducted any controlled clinical trials/studies,0.304507
uuid-aa4afe8633474945809f246f1fd08bed,Opdivo,0.461382
uuid-aa4afe8633474945809f246f1fd08bed,Pubmed literature search,0.614325
uuid-aa4afe8633474945809f246f1fd08bed,purposes other than its labeled indication must be considered investigational,0.586645
uuid-aa4afe8633474945809f246f1fd08bed,not identify any citations relevant to your inquiry,0.606087
uuid-aa4afe8633474945809f246f1fd08bed,adverse,0.304183
uuid-aa4afe8633474945809f246f1fd08bed,using the following search terms,0.642331
uuid-aa4afe8633474945809f246f1fd08bed,databases,0.315039
uuid-aa4afe8633474945809f246f1fd08bed,reported,0.556704
uuid-9aacffd1070944b7b17928959eefcc86,evaluating,0.33595
uuid-9aacffd1070944b7b17928959eefcc86,not conducted any controlled clinical trials/studies,0.333389
uuid-9aacffd1070944b7b17928959eefcc86,protocol,0.519575
uuid-9aacffd1070944b7b17928959eefcc86,RCC,0.396552
uuid-9aacffd1070944b7b17928959eefcc86,McDermott DF,0.425884
uuid-9aacffd1070944b7b17928959eefcc86,search of published literature,0.498677
uuid-9aacffd1070944b7b17928959eefcc86,Additionally,0.549804
uuid-9aacffd1070944b7b17928959eefcc86,ongoing,0.474606
uuid-9aacffd1070944b7b17928959eefcc86,Motzer RJ,0.459308
uuid-9aacffd1070944b7b17928959eefcc86,PubMed and EMBASE,0.495663
uuid-9aacffd1070944b7b17928959eefcc86,Escudier B,0.441262
uuid-9aacffd1070944b7b17928959eefcc86,et al.,0.378311
uuid-9aacffd1070944b7b17928959eefcc86,J Clin Oncol,0.413083
uuid-9aacffd1070944b7b17928959eefcc86,detailed search of www.clinicaltrials.gov,0.509888
uuid-9aacffd1070944b7b17928959eefcc86,efficacy and safety of nivolumab,0.474675
uuid-9aacffd1070944b7b17928959eefcc86,not identify any planned,0.488523
uuid-9aacffd1070944b7b17928959eefcc86,phase 2 study,0.364975
uuid-9aacffd1070944b7b17928959eefcc86,not identify any citations relevant to your request,0.559577
uuid-9aacffd1070944b7b17928959eefcc86,present using the following search terms,0.484223
uuid-034981d9665c4397bb00f52fb2745646,95% CI,0.524855
uuid-034981d9665c4397bb00f52fb2745646,respectively,0.383655
uuid-034981d9665c4397bb00f52fb2745646,ASCO,0.303153
uuid-034981d9665c4397bb00f52fb2745646,Lancet Oncol,0.368041
uuid-034981d9665c4397bb00f52fb2745646,Objective response rate,0.504846
uuid-034981d9665c4397bb00f52fb2745646,ORR,0.465366
uuid-034981d9665c4397bb00f52fb2745646,Median overall survival,0.346516
uuid-034981d9665c4397bb00f52fb2745646,Median OS,0.33538
uuid-034981d9665c4397bb00f52fb2745646,ASCO 2015,0.336983
uuid-034981d9665c4397bb00f52fb2745646,small cell lung cancer,0.336892
uuid-034981d9665c4397bb00f52fb2745646,SCLC,0.344367
uuid-034981d9665c4397bb00f52fb2745646,Antonia SJ,0.55269
uuid-034981d9665c4397bb00f52fb2745646,Median duration of response,0.649605
uuid-590c502177144b909bb93a027089f84e,nivolumab,0.506657
uuid-590c502177144b909bb93a027089f84e,Bristol-Myers Squibb,0.634643
uuid-590c502177144b909bb93a027089f84e,evaluating,0.758297
uuid-590c502177144b909bb93a027089f84e,not conducted any controlled clinical trials/studies,0.81944
uuid-590c502177144b909bb93a027089f84e,Pubmed literature search,0.706202
uuid-590c502177144b909bb93a027089f84e,purposes other than its labeled indication must be considered investigational,0.804727
uuid-590c502177144b909bb93a027089f84e,not identify any citations relevant to your inquiry,0.655924
uuid-590c502177144b909bb93a027089f84e,using the following search terms,0.635088
uuid-590c502177144b909bb93a027089f84e,efficacy and safety of nivolumab,0.604731
uuid-c37b3036a79048b89dbddde49d897d6e,Bristol-Myers Squibb,0.398191
uuid-c37b3036a79048b89dbddde49d897d6e,requested,0.827269
uuid-599ca33d71474f8aadecd0b31b257452,patients with advanced or metastatic,0.468858
uuid-599ca33d71474f8aadecd0b31b257452,nivolumab combined with ipilimumab,0.446918
uuid-599ca33d71474f8aadecd0b31b257452,not approved,0.352562
uuid-599ca33d71474f8aadecd0b31b257452,clinical trials investigating the safety,0.429501
uuid-599ca33d71474f8aadecd0b31b257452,bladder cancer,0.950698
uuid-aff2a1c612604bdfa276dd4dadb98cc4,respectively,0.629961
uuid-aff2a1c612604bdfa276dd4dadb98cc4,Objective response rate,0.439951
uuid-aff2a1c612604bdfa276dd4dadb98cc4,ORR,0.462322
uuid-aff2a1c612604bdfa276dd4dadb98cc4,monotherapy,0.352421
uuid-aff2a1c612604bdfa276dd4dadb98cc4,docetaxel,0.410479
uuid-59a2d6d0e5744d11b3f2bc22eb2f258d,AEs,0.316681
uuid-59a2d6d0e5744d11b3f2bc22eb2f258d,requested,0.309845
uuid-59a2d6d0e5744d11b3f2bc22eb2f258d,grade,0.343881
uuid-749e4df3d24344ba8adb6f56f8f48e29,nivolumab,0.405983
uuid-749e4df3d24344ba8adb6f56f8f48e29,Bristol-Myers Squibb,0.416169
uuid-749e4df3d24344ba8adb6f56f8f48e29,evaluating,0.568723
uuid-749e4df3d24344ba8adb6f56f8f48e29,not conducted any controlled clinical trials/studies,0.627182
uuid-749e4df3d24344ba8adb6f56f8f48e29,Pubmed literature search,0.914252
uuid-749e4df3d24344ba8adb6f56f8f48e29,purposes other than its labeled indication must be considered investigational,0.957031
uuid-749e4df3d24344ba8adb6f56f8f48e29,not identify any citations relevant to your inquiry,0.878631
uuid-749e4df3d24344ba8adb6f56f8f48e29,using the following search terms,0.87028
uuid-749e4df3d24344ba8adb6f56f8f48e29,efficacy and safety of nivolumab,0.387076
uuid-05c36641f2c342afb9a421b5de863b7f,respectively,0.589071
uuid-05c36641f2c342afb9a421b5de863b7f,Objective response rate,0.407286
uuid-05c36641f2c342afb9a421b5de863b7f,ORR,0.526086
uuid-05c36641f2c342afb9a421b5de863b7f,monotherapy,0.319413
uuid-05c36641f2c342afb9a421b5de863b7f,docetaxel,0.334344
uuid-b049d7898fa74862a9ebda1c0ff47187,AEs,0.464855
uuid-b049d7898fa74862a9ebda1c0ff47187,respectively,0.550563
uuid-b049d7898fa74862a9ebda1c0ff47187,ORR,0.331959
uuid-b049d7898fa74862a9ebda1c0ff47187,mg,0.474495
uuid-b049d7898fa74862a9ebda1c0ff47187,grade,0.440026
uuid-b049d7898fa74862a9ebda1c0ff47187,kg,0.438473
uuid-b049d7898fa74862a9ebda1c0ff47187,grade 3 to 4 AEs,0.453426
uuid-63b456a090f444248c4d777751d0e111,nivolumab,0.359772
uuid-b21b6bc633654581bd3c25208fbadc2d,N Engl J Med,0.409425
uuid-b21b6bc633654581bd3c25208fbadc2d,phase 3 study,0.344105
uuid-b21b6bc633654581bd3c25208fbadc2d,phase 1 study,0.42025
uuid-b21b6bc633654581bd3c25208fbadc2d,Rizvi NA,0.372987
uuid-b21b6bc633654581bd3c25208fbadc2d,Brahmer J,0.32571
uuid-b21b6bc633654581bd3c25208fbadc2d,mg,0.34664
uuid-b21b6bc633654581bd3c25208fbadc2d,CA209-003,0.428482
uuid-b21b6bc633654581bd3c25208fbadc2d,phase 2 study,0.427642
uuid-b21b6bc633654581bd3c25208fbadc2d,kg,0.335258
uuid-62f262a086a84e7fb3bf1f744a886cbb,patients with advanced or metastatic,0.468858
uuid-62f262a086a84e7fb3bf1f744a886cbb,nivolumab combined with ipilimumab,0.446918
uuid-62f262a086a84e7fb3bf1f744a886cbb,not approved,0.352562
uuid-62f262a086a84e7fb3bf1f744a886cbb,clinical trials investigating the safety,0.429501
uuid-62f262a086a84e7fb3bf1f744a886cbb,bladder cancer,0.950698
uuid-ae9f7784fab443afbcf480db69560b8b,nivolumab,0.401764
uuid-ae9f7784fab443afbcf480db69560b8b,adverse,0.414102
uuid-45329a94008042d68821de3cdeba1c8b,nivolumab,0.447125
uuid-45329a94008042d68821de3cdeba1c8b,Additionally,0.497897
uuid-45329a94008042d68821de3cdeba1c8b,ongoing,0.505601
uuid-45329a94008042d68821de3cdeba1c8b,clinical,0.496348
uuid-45329a94008042d68821de3cdeba1c8b,detailed search of www.clinicaltrials.gov,0.494982
uuid-45329a94008042d68821de3cdeba1c8b,trial,0.481676
uuid-45329a94008042d68821de3cdeba1c8b,not identify any planned,0.493427
uuid-45329a94008042d68821de3cdeba1c8b,clinicaltrials.gov,0.444492
uuid-45329a94008042d68821de3cdeba1c8b,not identify any citations relevant to your request,0.490037
uuid-a5962502070b4da9aab17796ed893fbe,requested,0.44769
uuid-a5962502070b4da9aab17796ed893fbe,trial,0.309472
uuid-54918b944a24469d822f32252113492d,N Engl J Med,0.409425
uuid-54918b944a24469d822f32252113492d,phase 3 study,0.344105
uuid-54918b944a24469d822f32252113492d,phase 1 study,0.42025
uuid-54918b944a24469d822f32252113492d,Rizvi NA,0.372987
uuid-54918b944a24469d822f32252113492d,Brahmer J,0.32571
uuid-54918b944a24469d822f32252113492d,mg,0.34664
uuid-54918b944a24469d822f32252113492d,CA209-003,0.428482
uuid-54918b944a24469d822f32252113492d,phase 2 study,0.427642
uuid-54918b944a24469d822f32252113492d,kg,0.335258
uuid-a8bdbf858d9b41279ec6fa28a5d14716,N Engl J Med,0.351111
uuid-a8bdbf858d9b41279ec6fa28a5d14716,protocol,0.35804
uuid-a8bdbf858d9b41279ec6fa28a5d14716,McDermott DF,0.384209
uuid-a8bdbf858d9b41279ec6fa28a5d14716,Motzer RJ,0.363703
uuid-a8bdbf858d9b41279ec6fa28a5d14716,Escudier B,0.384663
uuid-a8bdbf858d9b41279ec6fa28a5d14716,et al.,0.391576
uuid-a8bdbf858d9b41279ec6fa28a5d14716,J Clin Oncol,0.325264
uuid-525ff32089c74520a7b8c0f90a38e7a3,N Engl J Med,0.427636
uuid-525ff32089c74520a7b8c0f90a38e7a3,protocol,0.429136
uuid-525ff32089c74520a7b8c0f90a38e7a3,McDermott DF,0.44782
uuid-525ff32089c74520a7b8c0f90a38e7a3,Motzer RJ,0.430476
uuid-525ff32089c74520a7b8c0f90a38e7a3,Escudier B,0.450887
uuid-525ff32089c74520a7b8c0f90a38e7a3,et al.,0.456026
uuid-525ff32089c74520a7b8c0f90a38e7a3,J Clin Oncol,0.384624
uuid-525ff32089c74520a7b8c0f90a38e7a3,Rizvi NA,0.305616
uuid-525ff32089c74520a7b8c0f90a38e7a3,phase 2 study,0.351446
uuid-af62a954d5f74af1bbad49219c105ce3,95% CI,0.472879
uuid-af62a954d5f74af1bbad49219c105ce3,respectively,0.542827
uuid-af62a954d5f74af1bbad49219c105ce3,ASCO,0.362761
uuid-af62a954d5f74af1bbad49219c105ce3,Lancet Oncol,0.443084
uuid-af62a954d5f74af1bbad49219c105ce3,Objective response rate,0.592942
uuid-af62a954d5f74af1bbad49219c105ce3,ORR,0.550157
uuid-af62a954d5f74af1bbad49219c105ce3,Median overall survival,0.326084
uuid-af62a954d5f74af1bbad49219c105ce3,Median OS,0.329485
uuid-af62a954d5f74af1bbad49219c105ce3,ASCO 2015,0.342116
uuid-af62a954d5f74af1bbad49219c105ce3,small cell lung cancer,0.332143
uuid-af62a954d5f74af1bbad49219c105ce3,SCLC,0.341666
uuid-af62a954d5f74af1bbad49219c105ce3,Antonia SJ,0.646188
uuid-af62a954d5f74af1bbad49219c105ce3,Median duration of response,0.47703
uuid-eb2431056ac54be29cc8bb3da46c06e4,95% CI,0.524855
uuid-eb2431056ac54be29cc8bb3da46c06e4,respectively,0.383655
uuid-eb2431056ac54be29cc8bb3da46c06e4,ASCO,0.303153
uuid-eb2431056ac54be29cc8bb3da46c06e4,Lancet Oncol,0.368041
uuid-eb2431056ac54be29cc8bb3da46c06e4,Objective response rate,0.504846
uuid-eb2431056ac54be29cc8bb3da46c06e4,ORR,0.465366
uuid-eb2431056ac54be29cc8bb3da46c06e4,Median overall survival,0.346516
uuid-eb2431056ac54be29cc8bb3da46c06e4,Median OS,0.33538
uuid-eb2431056ac54be29cc8bb3da46c06e4,ASCO 2015,0.336983
uuid-eb2431056ac54be29cc8bb3da46c06e4,small cell lung cancer,0.336892
uuid-eb2431056ac54be29cc8bb3da46c06e4,SCLC,0.344367
uuid-eb2431056ac54be29cc8bb3da46c06e4,Antonia SJ,0.55269
uuid-eb2431056ac54be29cc8bb3da46c06e4,Median duration of response,0.649605
uuid-3dc5614e1a6a49ec9b09416b3277f96d,use of nivolumab for the treatment,0.440423
uuid-3dc5614e1a6a49ec9b09416b3277f96d,search of published literature,0.311531
uuid-3dc5614e1a6a49ec9b09416b3277f96d,PubMed and EMBASE,0.312811
uuid-3dc5614e1a6a49ec9b09416b3277f96d,not approved,0.404782
uuid-3dc5614e1a6a49ec9b09416b3277f96d,open-label,0.578291
uuid-3dc5614e1a6a49ec9b09416b3277f96d,clinical trials investigating the safety,0.440014
uuid-3dc5614e1a6a49ec9b09416b3277f96d,present using the following search terms,0.328669
uuid-3dc5614e1a6a49ec9b09416b3277f96d,phase,0.41185
uuid-33f0ad49ea6f46ec9e1190df38b29df9,95% CI,0.524855
uuid-33f0ad49ea6f46ec9e1190df38b29df9,respectively,0.383655
uuid-33f0ad49ea6f46ec9e1190df38b29df9,ASCO,0.303153
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Lancet Oncol,0.368041
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Objective response rate,0.504846
uuid-33f0ad49ea6f46ec9e1190df38b29df9,ORR,0.465366
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Median overall survival,0.346516
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Median OS,0.33538
uuid-33f0ad49ea6f46ec9e1190df38b29df9,ASCO 2015,0.336983
uuid-33f0ad49ea6f46ec9e1190df38b29df9,small cell lung cancer,0.336892
uuid-33f0ad49ea6f46ec9e1190df38b29df9,SCLC,0.344367
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Antonia SJ,0.55269
uuid-33f0ad49ea6f46ec9e1190df38b29df9,Median duration of response,0.649605
uuid-005c4caeab954aa7a26035edefb855a1,considered investigational,0.451831
uuid-005c4caeab954aa7a26035edefb855a1,small cell lung cancer,0.703291
uuid-005c4caeab954aa7a26035edefb855a1,partial response,0.47335
uuid-005c4caeab954aa7a26035edefb855a1,SCLC,0.782078
uuid-005c4caeab954aa7a26035edefb855a1,therapy,0.847008
uuid-005c4caeab954aa7a26035edefb855a1,relapsed,0.577041
uuid-005c4caeab954aa7a26035edefb855a1,phase 1/2 study CA209-032,0.457462
uuid-005c4caeab954aa7a26035edefb855a1,evaluates the efficacy of nivolumab monotherapy,0.382655
uuid-b4633c1ed2b14afeb49a138ff5ac8343,trial,0.306003
uuid-d49c75b6c23e4ac8a175b297f237254e,95% CI,0.524855
uuid-d49c75b6c23e4ac8a175b297f237254e,respectively,0.383655
uuid-d49c75b6c23e4ac8a175b297f237254e,ASCO,0.303153
uuid-d49c75b6c23e4ac8a175b297f237254e,Lancet Oncol,0.368041
uuid-d49c75b6c23e4ac8a175b297f237254e,Objective response rate,0.504846
uuid-d49c75b6c23e4ac8a175b297f237254e,ORR,0.465366
uuid-d49c75b6c23e4ac8a175b297f237254e,Median overall survival,0.346516
uuid-d49c75b6c23e4ac8a175b297f237254e,Median OS,0.33538
uuid-d49c75b6c23e4ac8a175b297f237254e,ASCO 2015,0.336983
uuid-d49c75b6c23e4ac8a175b297f237254e,small cell lung cancer,0.336892
uuid-d49c75b6c23e4ac8a175b297f237254e,SCLC,0.344367
uuid-d49c75b6c23e4ac8a175b297f237254e,Antonia SJ,0.55269
uuid-d49c75b6c23e4ac8a175b297f237254e,Median duration of response,0.649605
uuid-5eef88749e0d46be9d5057429decb639,OS,0.344846
uuid-5eef88749e0d46be9d5057429decb639,95% CI,0.629468
uuid-5eef88749e0d46be9d5057429decb639,NSCLC,0.336139
uuid-5eef88749e0d46be9d5057429decb639,respectively,0.407674
uuid-5eef88749e0d46be9d5057429decb639,Objective response rate,0.54429
uuid-5eef88749e0d46be9d5057429decb639,ORR,0.630459
uuid-5eef88749e0d46be9d5057429decb639,Median overall survival,0.590912
uuid-5eef88749e0d46be9d5057429decb639,monotherapy,0.467134
uuid-5eef88749e0d46be9d5057429decb639,Median OS,0.552454
uuid-5eef88749e0d46be9d5057429decb639,docetaxel,0.349054
uuid-5eef88749e0d46be9d5057429decb639,hazard ratio,0.607507
uuid-9b8ed8196b6d456192522e64fe80ff14,respectively,0.589071
uuid-9b8ed8196b6d456192522e64fe80ff14,Objective response rate,0.407286
uuid-9b8ed8196b6d456192522e64fe80ff14,ORR,0.526086
uuid-9b8ed8196b6d456192522e64fe80ff14,monotherapy,0.319413
uuid-9b8ed8196b6d456192522e64fe80ff14,docetaxel,0.334344
uuid-6874af49a420410286f5ffceedf8cc85,Bristol-Myers Squibb,0.307109
uuid-6874af49a420410286f5ffceedf8cc85,evaluating,0.451598
uuid-6874af49a420410286f5ffceedf8cc85,not conducted any controlled clinical trials/studies,0.448899
uuid-6874af49a420410286f5ffceedf8cc85,search of published literature,0.528439
uuid-6874af49a420410286f5ffceedf8cc85,PubMed and EMBASE,0.513725
uuid-6874af49a420410286f5ffceedf8cc85,Rizvi NA,0.334857
uuid-6874af49a420410286f5ffceedf8cc85,efficacy and safety of nivolumab,0.573306
uuid-6874af49a420410286f5ffceedf8cc85,not identify any citations relevant to your request,0.35497
uuid-6874af49a420410286f5ffceedf8cc85,present using the following search terms,0.522903
uuid-8504e9881fb847a588af9ad72f8a4a66,Opdivo,0.476741
uuid-8504e9881fb847a588af9ad72f8a4a66,trial,0.393134
uuid-8504e9881fb847a588af9ad72f8a4a66,docetaxel,0.437864
uuid-8504e9881fb847a588af9ad72f8a4a66,safety of nivolumab monotherapy,0.350737
uuid-8504e9881fb847a588af9ad72f8a4a66,phase,0.406186
uuid-0575bb12d0e94542b4455f0956b8c688,ipilimumab,0.385692
uuid-0575bb12d0e94542b4455f0956b8c688,ASCO 2015,0.417944
uuid-0575bb12d0e94542b4455f0956b8c688,partial response,0.382425
uuid-0575bb12d0e94542b4455f0956b8c688,Stable disease,0.586335
uuid-0575bb12d0e94542b4455f0956b8c688,cohort,0.307748
uuid-71a29e2d201245799b2f1e925df43c6e,ipilimumab,0.385692
uuid-71a29e2d201245799b2f1e925df43c6e,ASCO 2015,0.417944
uuid-71a29e2d201245799b2f1e925df43c6e,partial response,0.382425
uuid-71a29e2d201245799b2f1e925df43c6e,Stable disease,0.586335
uuid-71a29e2d201245799b2f1e925df43c6e,cohort,0.307748
uuid-461a0ffba19a4b29ade26702a668c7df,AEs,0.349137
uuid-461a0ffba19a4b29ade26702a668c7df,respectively,0.682073
uuid-461a0ffba19a4b29ade26702a668c7df,ASCO,0.363164
uuid-461a0ffba19a4b29ade26702a668c7df,Objective response rate,0.555115
uuid-461a0ffba19a4b29ade26702a668c7df,ORR,0.580944
uuid-461a0ffba19a4b29ade26702a668c7df,monotherapy,0.373693
uuid-461a0ffba19a4b29ade26702a668c7df,docetaxel,0.383382
uuid-461a0ffba19a4b29ade26702a668c7df,grade,0.321955
uuid-461a0ffba19a4b29ade26702a668c7df,Antonia SJ,0.413063
uuid-7e255ba842cf4082ad41be064ad0e678,BMS,0.497267
uuid-8d3c774e626846fd9dc2881a54b7f85c,Bristol-Myers Squibb,0.341822
uuid-8d3c774e626846fd9dc2881a54b7f85c,not conducted any controlled clinical trials/studies,0.304507
uuid-8d3c774e626846fd9dc2881a54b7f85c,Opdivo,0.461382
uuid-8d3c774e626846fd9dc2881a54b7f85c,Pubmed literature search,0.614325
uuid-8d3c774e626846fd9dc2881a54b7f85c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8d3c774e626846fd9dc2881a54b7f85c,not identify any citations relevant to your inquiry,0.606087
uuid-8d3c774e626846fd9dc2881a54b7f85c,adverse,0.304183
uuid-8d3c774e626846fd9dc2881a54b7f85c,using the following search terms,0.642331
uuid-8d3c774e626846fd9dc2881a54b7f85c,databases,0.315039
uuid-8d3c774e626846fd9dc2881a54b7f85c,reported,0.556704
uuid-f955588d84ff4d0b8f923ed4f35890c2,95% CI,0.524855
uuid-f955588d84ff4d0b8f923ed4f35890c2,respectively,0.383655
uuid-f955588d84ff4d0b8f923ed4f35890c2,ASCO,0.303153
uuid-f955588d84ff4d0b8f923ed4f35890c2,Lancet Oncol,0.368041
uuid-f955588d84ff4d0b8f923ed4f35890c2,Objective response rate,0.504846
uuid-f955588d84ff4d0b8f923ed4f35890c2,ORR,0.465366
uuid-f955588d84ff4d0b8f923ed4f35890c2,Median overall survival,0.346516
uuid-f955588d84ff4d0b8f923ed4f35890c2,Median OS,0.33538
uuid-f955588d84ff4d0b8f923ed4f35890c2,ASCO 2015,0.336983
uuid-f955588d84ff4d0b8f923ed4f35890c2,small cell lung cancer,0.336892
uuid-f955588d84ff4d0b8f923ed4f35890c2,SCLC,0.344367
uuid-f955588d84ff4d0b8f923ed4f35890c2,Antonia SJ,0.55269
uuid-f955588d84ff4d0b8f923ed4f35890c2,Median duration of response,0.649605
uuid-6099c6afb07b4205bf46ab9884633bf9,95% CI,0.524855
uuid-6099c6afb07b4205bf46ab9884633bf9,respectively,0.383655
uuid-6099c6afb07b4205bf46ab9884633bf9,ASCO,0.303153
uuid-6099c6afb07b4205bf46ab9884633bf9,Lancet Oncol,0.368041
uuid-6099c6afb07b4205bf46ab9884633bf9,Objective response rate,0.504846
uuid-6099c6afb07b4205bf46ab9884633bf9,ORR,0.465366
uuid-6099c6afb07b4205bf46ab9884633bf9,Median overall survival,0.346516
uuid-6099c6afb07b4205bf46ab9884633bf9,Median OS,0.33538
uuid-6099c6afb07b4205bf46ab9884633bf9,ASCO 2015,0.336983
uuid-6099c6afb07b4205bf46ab9884633bf9,small cell lung cancer,0.336892
uuid-6099c6afb07b4205bf46ab9884633bf9,SCLC,0.344367
uuid-6099c6afb07b4205bf46ab9884633bf9,Antonia SJ,0.55269
uuid-6099c6afb07b4205bf46ab9884633bf9,Median duration of response,0.649605
uuid-220f6ec0912a4d2fbfae7589260ee34d,nivolumab,0.631861
uuid-220f6ec0912a4d2fbfae7589260ee34d,clinicaltrials.gov,0.46529
uuid-d432d4068cab417b842407be2835de6d,evaluating,0.33595
uuid-d432d4068cab417b842407be2835de6d,not conducted any controlled clinical trials/studies,0.333389
uuid-d432d4068cab417b842407be2835de6d,protocol,0.519575
uuid-d432d4068cab417b842407be2835de6d,RCC,0.396552
uuid-d432d4068cab417b842407be2835de6d,McDermott DF,0.425884
uuid-d432d4068cab417b842407be2835de6d,search of published literature,0.498677
uuid-d432d4068cab417b842407be2835de6d,Additionally,0.549804
uuid-d432d4068cab417b842407be2835de6d,ongoing,0.474606
uuid-d432d4068cab417b842407be2835de6d,Motzer RJ,0.459308
uuid-d432d4068cab417b842407be2835de6d,PubMed and EMBASE,0.495663
uuid-d432d4068cab417b842407be2835de6d,Escudier B,0.441262
uuid-d432d4068cab417b842407be2835de6d,et al.,0.378311
uuid-d432d4068cab417b842407be2835de6d,J Clin Oncol,0.413083
uuid-d432d4068cab417b842407be2835de6d,detailed search of www.clinicaltrials.gov,0.509888
uuid-d432d4068cab417b842407be2835de6d,efficacy and safety of nivolumab,0.474675
uuid-d432d4068cab417b842407be2835de6d,not identify any planned,0.488523
uuid-d432d4068cab417b842407be2835de6d,phase 2 study,0.364975
uuid-d432d4068cab417b842407be2835de6d,not identify any citations relevant to your request,0.559577
uuid-d432d4068cab417b842407be2835de6d,present using the following search terms,0.484223
uuid-d5e691cf00cd4a5eae27f7b8fca42732,therapy,0.321161
uuid-246014e4e232489db4af7ab92298bb1d,nivolumab,0.40655
uuid-246014e4e232489db4af7ab92298bb1d,evaluating,0.48844
uuid-246014e4e232489db4af7ab92298bb1d,not conducted any controlled clinical trials/studies,0.485696
uuid-246014e4e232489db4af7ab92298bb1d,NSCLC,0.549854
uuid-246014e4e232489db4af7ab92298bb1d,non-small cell lung cancer,0.567066
uuid-246014e4e232489db4af7ab92298bb1d,Pubmed literature search,0.494374
uuid-246014e4e232489db4af7ab92298bb1d,purposes other than its labeled indication must be considered investigational,0.557212
uuid-246014e4e232489db4af7ab92298bb1d,not identify any citations relevant to your inquiry,0.470775
uuid-246014e4e232489db4af7ab92298bb1d,using the following search terms,0.450179
uuid-246014e4e232489db4af7ab92298bb1d,efficacy and safety of nivolumab,0.401114
uuid-b95eaa298cd9497386f0fab193020e63,PD-L1,0.367429
uuid-86b6d5dce404477ca5c4b523af8dfaa8,N Engl J Med,0.427636
uuid-86b6d5dce404477ca5c4b523af8dfaa8,protocol,0.429136
uuid-86b6d5dce404477ca5c4b523af8dfaa8,McDermott DF,0.44782
uuid-86b6d5dce404477ca5c4b523af8dfaa8,Motzer RJ,0.430476
uuid-86b6d5dce404477ca5c4b523af8dfaa8,Escudier B,0.450887
uuid-86b6d5dce404477ca5c4b523af8dfaa8,et al.,0.456026
uuid-86b6d5dce404477ca5c4b523af8dfaa8,J Clin Oncol,0.384624
uuid-86b6d5dce404477ca5c4b523af8dfaa8,Rizvi NA,0.305616
uuid-86b6d5dce404477ca5c4b523af8dfaa8,phase 2 study,0.351446
uuid-d7c569073e434bc3996dbc621ad52f41,95% CI,0.524855
uuid-d7c569073e434bc3996dbc621ad52f41,respectively,0.383655
uuid-d7c569073e434bc3996dbc621ad52f41,ASCO,0.303153
uuid-d7c569073e434bc3996dbc621ad52f41,Lancet Oncol,0.368041
uuid-d7c569073e434bc3996dbc621ad52f41,Objective response rate,0.504846
uuid-d7c569073e434bc3996dbc621ad52f41,ORR,0.465366
uuid-d7c569073e434bc3996dbc621ad52f41,Median overall survival,0.346516
uuid-d7c569073e434bc3996dbc621ad52f41,Median OS,0.33538
uuid-d7c569073e434bc3996dbc621ad52f41,ASCO 2015,0.336983
uuid-d7c569073e434bc3996dbc621ad52f41,small cell lung cancer,0.336892
uuid-d7c569073e434bc3996dbc621ad52f41,SCLC,0.344367
uuid-d7c569073e434bc3996dbc621ad52f41,Antonia SJ,0.55269
uuid-d7c569073e434bc3996dbc621ad52f41,Median duration of response,0.649605
uuid-72039baebf4d43acb380c84ad12a5da5,patients with advanced or metastatic,0.478326
uuid-72039baebf4d43acb380c84ad12a5da5,nivolumab combined with ipilimumab,0.498766
uuid-72039baebf4d43acb380c84ad12a5da5,not approved,0.34724
uuid-72039baebf4d43acb380c84ad12a5da5,clinical trials investigating the safety,0.426729
uuid-72039baebf4d43acb380c84ad12a5da5,bladder cancer,0.6548
uuid-1e4bc7fd39444acc9330c807fe3ad00a,95% CI,0.524855
uuid-1e4bc7fd39444acc9330c807fe3ad00a,respectively,0.383655
uuid-1e4bc7fd39444acc9330c807fe3ad00a,ASCO,0.303153
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Lancet Oncol,0.368041
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Objective response rate,0.504846
uuid-1e4bc7fd39444acc9330c807fe3ad00a,ORR,0.465366
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Median overall survival,0.346516
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Median OS,0.33538
uuid-1e4bc7fd39444acc9330c807fe3ad00a,ASCO 2015,0.336983
uuid-1e4bc7fd39444acc9330c807fe3ad00a,small cell lung cancer,0.336892
uuid-1e4bc7fd39444acc9330c807fe3ad00a,SCLC,0.344367
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Antonia SJ,0.55269
uuid-1e4bc7fd39444acc9330c807fe3ad00a,Median duration of response,0.649605
uuid-aa6c752336b844cbbdd604cda0eeee76,N Engl J Med,0.427636
uuid-aa6c752336b844cbbdd604cda0eeee76,protocol,0.429136
uuid-aa6c752336b844cbbdd604cda0eeee76,McDermott DF,0.44782
uuid-aa6c752336b844cbbdd604cda0eeee76,Motzer RJ,0.430476
uuid-aa6c752336b844cbbdd604cda0eeee76,Escudier B,0.450887
uuid-aa6c752336b844cbbdd604cda0eeee76,et al.,0.456026
uuid-aa6c752336b844cbbdd604cda0eeee76,J Clin Oncol,0.384624
uuid-aa6c752336b844cbbdd604cda0eeee76,Rizvi NA,0.305616
uuid-aa6c752336b844cbbdd604cda0eeee76,phase 2 study,0.351446
uuid-229104ea29214467aa561aafb329d774,patients with advanced or metastatic,0.478326
uuid-229104ea29214467aa561aafb329d774,nivolumab combined with ipilimumab,0.498766
uuid-229104ea29214467aa561aafb329d774,not approved,0.34724
uuid-229104ea29214467aa561aafb329d774,clinical trials investigating the safety,0.426729
uuid-229104ea29214467aa561aafb329d774,bladder cancer,0.6548
uuid-c15fb9f12aaa4e4381cdb723ed291183,nivolumab,0.359772
uuid-9705af80ef1f4da09f84abfe1bba52e0,considered investigational,0.451831
uuid-9705af80ef1f4da09f84abfe1bba52e0,small cell lung cancer,0.703291
uuid-9705af80ef1f4da09f84abfe1bba52e0,partial response,0.47335
uuid-9705af80ef1f4da09f84abfe1bba52e0,SCLC,0.782078
uuid-9705af80ef1f4da09f84abfe1bba52e0,therapy,0.847008
uuid-9705af80ef1f4da09f84abfe1bba52e0,relapsed,0.577041
uuid-9705af80ef1f4da09f84abfe1bba52e0,phase 1/2 study CA209-032,0.457462
uuid-9705af80ef1f4da09f84abfe1bba52e0,evaluates the efficacy of nivolumab monotherapy,0.382655
uuid-96b14b04e80144dc94b09e5665409695,OS,0.331916
uuid-96b14b04e80144dc94b09e5665409695,95% CI,0.500899
uuid-96b14b04e80144dc94b09e5665409695,NSCLC,0.456997
uuid-96b14b04e80144dc94b09e5665409695,non-small cell lung cancer,0.462045
uuid-96b14b04e80144dc94b09e5665409695,considered investigational,0.301329
uuid-96b14b04e80144dc94b09e5665409695,ORR,0.385403
uuid-96b14b04e80144dc94b09e5665409695,Median overall survival,0.506447
uuid-96b14b04e80144dc94b09e5665409695,Median OS,0.428635
uuid-96b14b04e80144dc94b09e5665409695,therapy,0.407998
uuid-96b14b04e80144dc94b09e5665409695,hazard ratio,0.496205
uuid-334039c978294661beaba5c0fad66c6c,OS,0.387982
uuid-334039c978294661beaba5c0fad66c6c,95% CI,0.745043
uuid-334039c978294661beaba5c0fad66c6c,respectively,0.729294
uuid-334039c978294661beaba5c0fad66c6c,Objective response rate,0.590876
uuid-334039c978294661beaba5c0fad66c6c,ORR,0.722442
uuid-334039c978294661beaba5c0fad66c6c,Median overall survival,0.659043
uuid-334039c978294661beaba5c0fad66c6c,monotherapy,0.514468
uuid-334039c978294661beaba5c0fad66c6c,Median OS,0.696688
uuid-334039c978294661beaba5c0fad66c6c,PD-L1,0.300997
uuid-334039c978294661beaba5c0fad66c6c,docetaxel,0.635065
uuid-334039c978294661beaba5c0fad66c6c,hazard ratio,0.729977
uuid-d94626a6881f42979041c85c971d6dea,patients with advanced or metastatic,0.478326
uuid-d94626a6881f42979041c85c971d6dea,nivolumab combined with ipilimumab,0.498766
uuid-d94626a6881f42979041c85c971d6dea,not approved,0.34724
uuid-d94626a6881f42979041c85c971d6dea,clinical trials investigating the safety,0.426729
uuid-d94626a6881f42979041c85c971d6dea,bladder cancer,0.6548
uuid-e58cb0de4f2d4a58bb259fb112127c4d,N Engl J Med,0.585592
uuid-e58cb0de4f2d4a58bb259fb112127c4d,protocol,0.703048
uuid-e58cb0de4f2d4a58bb259fb112127c4d,McDermott DF,0.808613
uuid-e58cb0de4f2d4a58bb259fb112127c4d,Motzer RJ,0.783017
uuid-e58cb0de4f2d4a58bb259fb112127c4d,phase 3 study,0.465459
uuid-e58cb0de4f2d4a58bb259fb112127c4d,Escudier B,0.804268
uuid-e58cb0de4f2d4a58bb259fb112127c4d,NEJM,0.338631
uuid-e58cb0de4f2d4a58bb259fb112127c4d,et al.,0.770371
uuid-e58cb0de4f2d4a58bb259fb112127c4d,J Clin Oncol,0.754974
uuid-e58cb0de4f2d4a58bb259fb112127c4d,Rizvi NA,0.374947
uuid-e58cb0de4f2d4a58bb259fb112127c4d,phase 2 study,0.717397
uuid-1f6000aa23a64a489a35fee0dbd71990,95% CI,0.524855
uuid-1f6000aa23a64a489a35fee0dbd71990,respectively,0.383655
uuid-1f6000aa23a64a489a35fee0dbd71990,ASCO,0.303153
uuid-1f6000aa23a64a489a35fee0dbd71990,Lancet Oncol,0.368041
uuid-1f6000aa23a64a489a35fee0dbd71990,Objective response rate,0.504846
uuid-1f6000aa23a64a489a35fee0dbd71990,ORR,0.465366
uuid-1f6000aa23a64a489a35fee0dbd71990,Median overall survival,0.346516
uuid-1f6000aa23a64a489a35fee0dbd71990,Median OS,0.33538
uuid-1f6000aa23a64a489a35fee0dbd71990,ASCO 2015,0.336983
uuid-1f6000aa23a64a489a35fee0dbd71990,small cell lung cancer,0.336892
uuid-1f6000aa23a64a489a35fee0dbd71990,SCLC,0.344367
uuid-1f6000aa23a64a489a35fee0dbd71990,Antonia SJ,0.55269
uuid-1f6000aa23a64a489a35fee0dbd71990,Median duration of response,0.649605
uuid-8e52ff356ccf42c493d2739c1554f83c,Bristol-Myers Squibb,0.34714
uuid-4da90e62c74c466b94393faa729e848b,nivolumab,0.543785
uuid-4da90e62c74c466b94393faa729e848b,Bristol-Myers Squibb,0.379533
uuid-4da90e62c74c466b94393faa729e848b,evaluating,0.535148
uuid-4da90e62c74c466b94393faa729e848b,not conducted any controlled clinical trials/studies,0.581983
uuid-4da90e62c74c466b94393faa729e848b,Pubmed literature search,0.814591
uuid-4da90e62c74c466b94393faa729e848b,purposes other than its labeled indication must be considered investigational,0.871936
uuid-4da90e62c74c466b94393faa729e848b,not identify any citations relevant to your inquiry,0.784618
uuid-4da90e62c74c466b94393faa729e848b,using the following search terms,0.765672
uuid-4da90e62c74c466b94393faa729e848b,efficacy and safety of nivolumab,0.369335
uuid-1b47a6efd42640bd813e064a0c95a109,95% CI,0.458541
uuid-1b47a6efd42640bd813e064a0c95a109,NSCLC,0.324921
uuid-1b47a6efd42640bd813e064a0c95a109,respectively,0.521446
uuid-1b47a6efd42640bd813e064a0c95a109,Objective response rate,0.591537
uuid-1b47a6efd42640bd813e064a0c95a109,ORR,0.644067
uuid-1b47a6efd42640bd813e064a0c95a109,Median overall survival,0.46301
uuid-1b47a6efd42640bd813e064a0c95a109,monotherapy,0.49022
uuid-1b47a6efd42640bd813e064a0c95a109,Median OS,0.422509
uuid-1b47a6efd42640bd813e064a0c95a109,docetaxel,0.420006
uuid-1b47a6efd42640bd813e064a0c95a109,hazard ratio,0.424683
uuid-6ff6e99b21794e77984b704f95a54052,requested,0.594234
uuid-e7182eb23f574e0b9f644cec7f4cd738,N Engl J Med,0.585592
uuid-e7182eb23f574e0b9f644cec7f4cd738,protocol,0.703048
uuid-e7182eb23f574e0b9f644cec7f4cd738,McDermott DF,0.808613
uuid-e7182eb23f574e0b9f644cec7f4cd738,Motzer RJ,0.783017
uuid-e7182eb23f574e0b9f644cec7f4cd738,phase 3 study,0.465459
uuid-e7182eb23f574e0b9f644cec7f4cd738,Escudier B,0.804268
uuid-e7182eb23f574e0b9f644cec7f4cd738,NEJM,0.338631
uuid-e7182eb23f574e0b9f644cec7f4cd738,et al.,0.770371
uuid-e7182eb23f574e0b9f644cec7f4cd738,J Clin Oncol,0.754974
uuid-e7182eb23f574e0b9f644cec7f4cd738,Rizvi NA,0.374947
uuid-e7182eb23f574e0b9f644cec7f4cd738,phase 2 study,0.717397
uuid-0fb5d3f795a241ea8f3418570bd582d6,use of nivolumab for the treatment,0.440423
uuid-0fb5d3f795a241ea8f3418570bd582d6,search of published literature,0.311531
uuid-0fb5d3f795a241ea8f3418570bd582d6,PubMed and EMBASE,0.312811
uuid-0fb5d3f795a241ea8f3418570bd582d6,not approved,0.404782
uuid-0fb5d3f795a241ea8f3418570bd582d6,open-label,0.578291
uuid-0fb5d3f795a241ea8f3418570bd582d6,clinical trials investigating the safety,0.440014
uuid-0fb5d3f795a241ea8f3418570bd582d6,present using the following search terms,0.328669
uuid-0fb5d3f795a241ea8f3418570bd582d6,phase,0.41185
uuid-0f299e5fe15942b5a554def4592d6599,ASCO,0.382205
uuid-09442e82d79144e7b480cc6a00d68b74,evaluating,0.350845
uuid-09442e82d79144e7b480cc6a00d68b74,not conducted any controlled clinical trials/studies,0.345107
uuid-09442e82d79144e7b480cc6a00d68b74,search of published literature,0.385331
uuid-09442e82d79144e7b480cc6a00d68b74,Additionally,0.40981
uuid-09442e82d79144e7b480cc6a00d68b74,ongoing,0.457998
uuid-09442e82d79144e7b480cc6a00d68b74,PubMed and EMBASE,0.378285
uuid-09442e82d79144e7b480cc6a00d68b74,detailed search of www.clinicaltrials.gov,0.428522
uuid-09442e82d79144e7b480cc6a00d68b74,efficacy and safety of nivolumab,0.407868
uuid-09442e82d79144e7b480cc6a00d68b74,not identify any planned,0.444729
uuid-09442e82d79144e7b480cc6a00d68b74,combination,0.388252
uuid-09442e82d79144e7b480cc6a00d68b74,BMS,0.316104
uuid-09442e82d79144e7b480cc6a00d68b74,not identify any citations relevant to your request,0.438151
uuid-09442e82d79144e7b480cc6a00d68b74,present using the following search terms,0.377101
uuid-3e7467f6a7c945978b2c31b00c424e92,N Engl J Med,0.406474
uuid-3e7467f6a7c945978b2c31b00c424e92,protocol,0.734876
uuid-3e7467f6a7c945978b2c31b00c424e92,McDermott DF,0.700052
uuid-3e7467f6a7c945978b2c31b00c424e92,search of published literature,0.348341
uuid-3e7467f6a7c945978b2c31b00c424e92,Motzer RJ,0.778891
uuid-3e7467f6a7c945978b2c31b00c424e92,phase 3 study,0.411505
uuid-3e7467f6a7c945978b2c31b00c424e92,PubMed and EMBASE,0.343638
uuid-3e7467f6a7c945978b2c31b00c424e92,Escudier B,0.709778
uuid-3e7467f6a7c945978b2c31b00c424e92,NEJM,0.375092
uuid-3e7467f6a7c945978b2c31b00c424e92,et al.,0.62631
uuid-3e7467f6a7c945978b2c31b00c424e92,J Clin Oncol,0.750233
uuid-3e7467f6a7c945978b2c31b00c424e92,Topalian,0.367751
uuid-3e7467f6a7c945978b2c31b00c424e92,phase 1 study,0.511455
uuid-3e7467f6a7c945978b2c31b00c424e92,efficacy and safety of nivolumab,0.372817
uuid-3e7467f6a7c945978b2c31b00c424e92,CA209-003,0.564944
uuid-3e7467f6a7c945978b2c31b00c424e92,phase 2 study,0.646701
uuid-3e7467f6a7c945978b2c31b00c424e92,not identify any citations relevant to your request,0.303842
uuid-3e7467f6a7c945978b2c31b00c424e92,present using the following search terms,0.360145
uuid-3e7467f6a7c945978b2c31b00c424e92,investigating,0.613515
uuid-694c83da3fcc4f44872f72c9f472eb3f,N Engl J Med,0.527761
uuid-694c83da3fcc4f44872f72c9f472eb3f,protocol,0.819783
uuid-694c83da3fcc4f44872f72c9f472eb3f,McDermott DF,0.805399
uuid-694c83da3fcc4f44872f72c9f472eb3f,Motzer RJ,0.866945
uuid-694c83da3fcc4f44872f72c9f472eb3f,phase 3 study,0.472407
uuid-694c83da3fcc4f44872f72c9f472eb3f,Escudier B,0.813162
uuid-694c83da3fcc4f44872f72c9f472eb3f,NEJM,0.438713
uuid-694c83da3fcc4f44872f72c9f472eb3f,et al.,0.738346
uuid-694c83da3fcc4f44872f72c9f472eb3f,J Clin Oncol,0.835648
uuid-694c83da3fcc4f44872f72c9f472eb3f,Topalian,0.420949
uuid-694c83da3fcc4f44872f72c9f472eb3f,phase 1 study,0.491346
uuid-694c83da3fcc4f44872f72c9f472eb3f,Rizvi NA,0.34323
uuid-694c83da3fcc4f44872f72c9f472eb3f,CA209-003,0.543692
uuid-694c83da3fcc4f44872f72c9f472eb3f,phase 2 study,0.748558
uuid-694c83da3fcc4f44872f72c9f472eb3f,investigating,0.56088
uuid-b95072907e9d42e9becf7bef2bbde5e9,Bristol-Myers Squibb,0.324417
uuid-b95072907e9d42e9becf7bef2bbde5e9,Opdivo,0.373566
uuid-b95072907e9d42e9becf7bef2bbde5e9,Pubmed literature search,0.525905
uuid-b95072907e9d42e9becf7bef2bbde5e9,purposes other than its labeled indication must be considered investigational,0.50449
uuid-b95072907e9d42e9becf7bef2bbde5e9,not identify any citations relevant to your inquiry,0.520346
uuid-b95072907e9d42e9becf7bef2bbde5e9,adverse,0.451996
uuid-b95072907e9d42e9becf7bef2bbde5e9,using the following search terms,0.547063
uuid-b95072907e9d42e9becf7bef2bbde5e9,reported,0.554689
uuid-dfff2f633f4045b185b411ed3d4815d8,mg,0.482795
uuid-dfff2f633f4045b185b411ed3d4815d8,kg,0.418546
uuid-412fb5fbba7d41a397456c080879e64f,N Engl J Med,0.302601
uuid-412fb5fbba7d41a397456c080879e64f,AEs,0.348167
uuid-412fb5fbba7d41a397456c080879e64f,patients,0.536884
uuid-412fb5fbba7d41a397456c080879e64f,provided in the Detailed Information,0.387544
uuid-412fb5fbba7d41a397456c080879e64f,ESMO,0.462801
uuid-412fb5fbba7d41a397456c080879e64f,NEJM,0.66427
uuid-412fb5fbba7d41a397456c080879e64f,Topalian,0.692873
uuid-412fb5fbba7d41a397456c080879e64f,grade 3 to 4 AEs,0.626596
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,N Engl J Med,0.302601
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,AEs,0.348167
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,patients,0.536884
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,provided in the Detailed Information,0.387544
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,ESMO,0.462801
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,NEJM,0.66427
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,Topalian,0.692873
uuid-cfc9eed4e99f4203a7d3eb6d1dc18925,grade 3 to 4 AEs,0.626596
uuid-98f4df101dee4e97bc71605174a1ed38,nivolumab,0.999168
uuid-98f4df101dee4e97bc71605174a1ed38,Pubmed literature search,0.395314
uuid-98f4df101dee4e97bc71605174a1ed38,purposes other than its labeled indication must be considered investigational,0.464236
uuid-98f4df101dee4e97bc71605174a1ed38,not identify any citations relevant to your inquiry,0.368569
uuid-98f4df101dee4e97bc71605174a1ed38,using the following search terms,0.364279
uuid-98f4df101dee4e97bc71605174a1ed38,present using the following search terms,0.329876
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,nivolumab,0.483553
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,Bristol-Myers Squibb,0.523673
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,evaluating,0.578789
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,not conducted any controlled clinical trials/studies,0.600989
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,search of published literature,0.514478
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,Additionally,0.518123
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,ongoing,0.447069
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,PubMed and EMBASE,0.497079
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,detailed search of www.clinicaltrials.gov,0.491159
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,efficacy and safety of nivolumab,0.652414
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,not identify any planned,0.458584
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,not identify any citations relevant to your request,0.567422
uuid-12ad6d86831743f5ab3fa6a39bcdf4b2,present using the following search terms,0.519995
uuid-d9f6e955366b4eb39f6127012e9f6ecf,patients,0.556054
uuid-d9f6e955366b4eb39f6127012e9f6ecf,provided in the Detailed Information,0.329929
uuid-d9f6e955366b4eb39f6127012e9f6ecf,adverse,0.32982
uuid-d9f6e955366b4eb39f6127012e9f6ecf,phase 3 study,0.523726
uuid-d9f6e955366b4eb39f6127012e9f6ecf,melanoma,0.382071
uuid-d9f6e955366b4eb39f6127012e9f6ecf,Weber JS,0.428777
uuid-d9f6e955366b4eb39f6127012e9f6ecf,phase 2 study,0.307314
uuid-d9f6e955366b4eb39f6127012e9f6ecf,grade 3 to 4 AEs,0.466022
uuid-f2ecc63851134e5e9c18289d3c19ac0e,N Engl J Med,0.427636
uuid-f2ecc63851134e5e9c18289d3c19ac0e,protocol,0.429136
uuid-f2ecc63851134e5e9c18289d3c19ac0e,McDermott DF,0.44782
uuid-f2ecc63851134e5e9c18289d3c19ac0e,Motzer RJ,0.430476
uuid-f2ecc63851134e5e9c18289d3c19ac0e,Escudier B,0.450887
uuid-f2ecc63851134e5e9c18289d3c19ac0e,et al.,0.456026
uuid-f2ecc63851134e5e9c18289d3c19ac0e,J Clin Oncol,0.384624
uuid-f2ecc63851134e5e9c18289d3c19ac0e,Rizvi NA,0.305616
uuid-f2ecc63851134e5e9c18289d3c19ac0e,phase 2 study,0.351446
uuid-81cf85e550084ba9a2eebb9a3785b137,Objective response rate,0.451139
uuid-81cf85e550084ba9a2eebb9a3785b137,clinicaltrials.gov,0.503706
uuid-b0d06b0096ac4566ba7e79e63ac01c07,requested,0.594234
uuid-3c330612c4fe4762b9364ef2debfdefb,95% CI,0.524855
uuid-3c330612c4fe4762b9364ef2debfdefb,respectively,0.383655
uuid-3c330612c4fe4762b9364ef2debfdefb,ASCO,0.303153
uuid-3c330612c4fe4762b9364ef2debfdefb,Lancet Oncol,0.368041
uuid-3c330612c4fe4762b9364ef2debfdefb,Objective response rate,0.504846
uuid-3c330612c4fe4762b9364ef2debfdefb,ORR,0.465366
uuid-3c330612c4fe4762b9364ef2debfdefb,Median overall survival,0.346516
uuid-3c330612c4fe4762b9364ef2debfdefb,Median OS,0.33538
uuid-3c330612c4fe4762b9364ef2debfdefb,ASCO 2015,0.336983
uuid-3c330612c4fe4762b9364ef2debfdefb,small cell lung cancer,0.336892
uuid-3c330612c4fe4762b9364ef2debfdefb,SCLC,0.344367
uuid-3c330612c4fe4762b9364ef2debfdefb,Antonia SJ,0.55269
uuid-3c330612c4fe4762b9364ef2debfdefb,Median duration of response,0.649605
uuid-757440e0ae7c48da8174486172b77afc,95% CI,0.524855
uuid-757440e0ae7c48da8174486172b77afc,respectively,0.383655
uuid-757440e0ae7c48da8174486172b77afc,ASCO,0.303153
uuid-757440e0ae7c48da8174486172b77afc,Lancet Oncol,0.368041
uuid-757440e0ae7c48da8174486172b77afc,Objective response rate,0.504846
uuid-757440e0ae7c48da8174486172b77afc,ORR,0.465366
uuid-757440e0ae7c48da8174486172b77afc,Median overall survival,0.346516
uuid-757440e0ae7c48da8174486172b77afc,Median OS,0.33538
uuid-757440e0ae7c48da8174486172b77afc,ASCO 2015,0.336983
uuid-757440e0ae7c48da8174486172b77afc,small cell lung cancer,0.336892
uuid-757440e0ae7c48da8174486172b77afc,SCLC,0.344367
uuid-757440e0ae7c48da8174486172b77afc,Antonia SJ,0.55269
uuid-757440e0ae7c48da8174486172b77afc,Median duration of response,0.649605
uuid-e49cba0677564be79e902e738c2f61a7,Bristol-Myers Squibb,0.341822
uuid-e49cba0677564be79e902e738c2f61a7,not conducted any controlled clinical trials/studies,0.304507
uuid-e49cba0677564be79e902e738c2f61a7,Opdivo,0.461382
uuid-e49cba0677564be79e902e738c2f61a7,Pubmed literature search,0.614325
uuid-e49cba0677564be79e902e738c2f61a7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e49cba0677564be79e902e738c2f61a7,not identify any citations relevant to your inquiry,0.606087
uuid-e49cba0677564be79e902e738c2f61a7,adverse,0.304183
uuid-e49cba0677564be79e902e738c2f61a7,using the following search terms,0.642331
uuid-e49cba0677564be79e902e738c2f61a7,databases,0.315039
uuid-e49cba0677564be79e902e738c2f61a7,reported,0.556704
uuid-f1b422b9404944148763585e29bb5220,nivolumab,0.999168
uuid-f1b422b9404944148763585e29bb5220,Pubmed literature search,0.395314
uuid-f1b422b9404944148763585e29bb5220,purposes other than its labeled indication must be considered investigational,0.464236
uuid-f1b422b9404944148763585e29bb5220,not identify any citations relevant to your inquiry,0.368569
uuid-f1b422b9404944148763585e29bb5220,using the following search terms,0.364279
uuid-f1b422b9404944148763585e29bb5220,present using the following search terms,0.329876
uuid-888891478aa54bfcaa6e4405d121dec4,Bristol-Myers Squibb,0.302814
uuid-888891478aa54bfcaa6e4405d121dec4,adverse,0.863709
uuid-888891478aa54bfcaa6e4405d121dec4,reported,0.811759
uuid-528858fcc5ab4c8eb34adbb2df15150b,N Engl J Med,0.802402
uuid-528858fcc5ab4c8eb34adbb2df15150b,Lancet Oncol,0.56115
uuid-528858fcc5ab4c8eb34adbb2df15150b,protocol,0.825455
uuid-528858fcc5ab4c8eb34adbb2df15150b,McDermott DF,0.885167
uuid-528858fcc5ab4c8eb34adbb2df15150b,Motzer RJ,0.855335
uuid-528858fcc5ab4c8eb34adbb2df15150b,phase 3 study,0.542754
uuid-528858fcc5ab4c8eb34adbb2df15150b,Escudier B,0.889228
uuid-528858fcc5ab4c8eb34adbb2df15150b,NEJM,0.49481
uuid-528858fcc5ab4c8eb34adbb2df15150b,et al.,0.863613
uuid-528858fcc5ab4c8eb34adbb2df15150b,J Clin Oncol,0.80113
uuid-528858fcc5ab4c8eb34adbb2df15150b,Topalian,0.450909
uuid-528858fcc5ab4c8eb34adbb2df15150b,Rizvi NA,0.701925
uuid-528858fcc5ab4c8eb34adbb2df15150b,Brahmer J,0.469271
uuid-528858fcc5ab4c8eb34adbb2df15150b,Weber JS,0.595586
uuid-528858fcc5ab4c8eb34adbb2df15150b,phase 2 study,0.814538
uuid-e53d1cbafa834066be03c09d756f64d9,respectively,0.589071
uuid-e53d1cbafa834066be03c09d756f64d9,Objective response rate,0.407286
uuid-e53d1cbafa834066be03c09d756f64d9,ORR,0.526086
uuid-e53d1cbafa834066be03c09d756f64d9,monotherapy,0.319413
uuid-e53d1cbafa834066be03c09d756f64d9,docetaxel,0.334344
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,95% CI,0.458541
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,NSCLC,0.324921
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,respectively,0.521446
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,Objective response rate,0.591537
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,ORR,0.644067
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,Median overall survival,0.46301
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,monotherapy,0.49022
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,Median OS,0.422509
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,docetaxel,0.420006
uuid-f64f37bc1cad4b6394003aaf3eec9f1e,hazard ratio,0.424683
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,Bristol-Myers Squibb,0.341822
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,not conducted any controlled clinical trials/studies,0.304507
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,Opdivo,0.461382
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,Pubmed literature search,0.614325
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,purposes other than its labeled indication must be considered investigational,0.586645
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,not identify any citations relevant to your inquiry,0.606087
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,adverse,0.304183
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,using the following search terms,0.642331
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,databases,0.315039
uuid-2c5e511bd8514e188fd9aa7024e0a4ac,reported,0.556704
uuid-e03246dfcb59447f9f7b885aed4e0321,Bristol-Myers Squibb,0.36472
uuid-8e22a82487a749f1ace8b9a386772993,provided in the Detailed Information,0.35131
uuid-8e22a82487a749f1ace8b9a386772993,Weber JS,0.300971
uuid-0963d818359d4bb0a601412e86a6f237,95% CI,0.524855
uuid-0963d818359d4bb0a601412e86a6f237,respectively,0.383655
uuid-0963d818359d4bb0a601412e86a6f237,ASCO,0.303153
uuid-0963d818359d4bb0a601412e86a6f237,Lancet Oncol,0.368041
uuid-0963d818359d4bb0a601412e86a6f237,Objective response rate,0.504846
uuid-0963d818359d4bb0a601412e86a6f237,ORR,0.465366
uuid-0963d818359d4bb0a601412e86a6f237,Median overall survival,0.346516
uuid-0963d818359d4bb0a601412e86a6f237,Median OS,0.33538
uuid-0963d818359d4bb0a601412e86a6f237,ASCO 2015,0.336983
uuid-0963d818359d4bb0a601412e86a6f237,small cell lung cancer,0.336892
uuid-0963d818359d4bb0a601412e86a6f237,SCLC,0.344367
uuid-0963d818359d4bb0a601412e86a6f237,Antonia SJ,0.55269
uuid-0963d818359d4bb0a601412e86a6f237,Median duration of response,0.649605
uuid-83db60571a67438ca0675024a7c7d6e1,Objective response rate,0.424629
uuid-83db60571a67438ca0675024a7c7d6e1,clinicaltrials.gov,0.507262
uuid-44c4f8d2a9c34fe0bcae0eee05d69e86,requested,0.644628
uuid-44c4f8d2a9c34fe0bcae0eee05d69e86,relapsed,0.303964
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,95% CI,0.524855
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,respectively,0.383655
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,ASCO,0.303153
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Lancet Oncol,0.368041
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Objective response rate,0.504846
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,ORR,0.465366
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Median overall survival,0.346516
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Median OS,0.33538
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,ASCO 2015,0.336983
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,small cell lung cancer,0.336892
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,SCLC,0.344367
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Antonia SJ,0.55269
uuid-4c3ca3a64afd4b65a97b525dfd3c79ca,Median duration of response,0.649605
uuid-115ff6f539bf43e19ed86044947e9a23,nivolumab,0.359772
uuid-cfb602fad4564208be3c3a62b3fc88da,ASCO,0.64795
uuid-cfb602fad4564208be3c3a62b3fc88da,Antonia SJ,0.334859
uuid-2ad4aa7a529c405d8fc7dabade42c949,nivolumab,0.446117
uuid-2ad4aa7a529c405d8fc7dabade42c949,clinical trials investigating the safety,0.341011
uuid-2ad4aa7a529c405d8fc7dabade42c949,melanoma,0.399487
uuid-a9f1fd881d194f73aa70ac4536447549,95% CI,0.524855
uuid-a9f1fd881d194f73aa70ac4536447549,respectively,0.383655
uuid-a9f1fd881d194f73aa70ac4536447549,ASCO,0.303153
uuid-a9f1fd881d194f73aa70ac4536447549,Lancet Oncol,0.368041
uuid-a9f1fd881d194f73aa70ac4536447549,Objective response rate,0.504846
uuid-a9f1fd881d194f73aa70ac4536447549,ORR,0.465366
uuid-a9f1fd881d194f73aa70ac4536447549,Median overall survival,0.346516
uuid-a9f1fd881d194f73aa70ac4536447549,Median OS,0.33538
uuid-a9f1fd881d194f73aa70ac4536447549,ASCO 2015,0.336983
uuid-a9f1fd881d194f73aa70ac4536447549,small cell lung cancer,0.336892
uuid-a9f1fd881d194f73aa70ac4536447549,SCLC,0.344367
uuid-a9f1fd881d194f73aa70ac4536447549,Antonia SJ,0.55269
uuid-a9f1fd881d194f73aa70ac4536447549,Median duration of response,0.649605
uuid-0dbee747ef56406abcf78b68a91aa820,95% CI,0.524855
uuid-0dbee747ef56406abcf78b68a91aa820,respectively,0.383655
uuid-0dbee747ef56406abcf78b68a91aa820,ASCO,0.303153
uuid-0dbee747ef56406abcf78b68a91aa820,Lancet Oncol,0.368041
uuid-0dbee747ef56406abcf78b68a91aa820,Objective response rate,0.504846
uuid-0dbee747ef56406abcf78b68a91aa820,ORR,0.465366
uuid-0dbee747ef56406abcf78b68a91aa820,Median overall survival,0.346516
uuid-0dbee747ef56406abcf78b68a91aa820,Median OS,0.33538
uuid-0dbee747ef56406abcf78b68a91aa820,ASCO 2015,0.336983
uuid-0dbee747ef56406abcf78b68a91aa820,small cell lung cancer,0.336892
uuid-0dbee747ef56406abcf78b68a91aa820,SCLC,0.344367
uuid-0dbee747ef56406abcf78b68a91aa820,Antonia SJ,0.55269
uuid-0dbee747ef56406abcf78b68a91aa820,Median duration of response,0.649605
uuid-2629dd3e39944c62a0fa4d18a9fe5241,considered investigational,0.402849
uuid-2629dd3e39944c62a0fa4d18a9fe5241,small cell lung cancer,0.651985
uuid-2629dd3e39944c62a0fa4d18a9fe5241,partial response,0.50367
uuid-2629dd3e39944c62a0fa4d18a9fe5241,SCLC,0.736863
uuid-2629dd3e39944c62a0fa4d18a9fe5241,therapy,0.843488
uuid-2629dd3e39944c62a0fa4d18a9fe5241,relapsed,0.613852
uuid-2629dd3e39944c62a0fa4d18a9fe5241,phase 1/2 study CA209-032,0.40439
uuid-2629dd3e39944c62a0fa4d18a9fe5241,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-18330caad33943d2b429ffa21320280f,considered investigational,0.402849
uuid-18330caad33943d2b429ffa21320280f,small cell lung cancer,0.651985
uuid-18330caad33943d2b429ffa21320280f,partial response,0.50367
uuid-18330caad33943d2b429ffa21320280f,SCLC,0.736863
uuid-18330caad33943d2b429ffa21320280f,therapy,0.843488
uuid-18330caad33943d2b429ffa21320280f,relapsed,0.613852
uuid-18330caad33943d2b429ffa21320280f,phase 1/2 study CA209-032,0.40439
uuid-18330caad33943d2b429ffa21320280f,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-4efedc20343643cd91b40daca47cb474,OS,0.387982
uuid-4efedc20343643cd91b40daca47cb474,95% CI,0.745043
uuid-4efedc20343643cd91b40daca47cb474,respectively,0.729294
uuid-4efedc20343643cd91b40daca47cb474,Objective response rate,0.590876
uuid-4efedc20343643cd91b40daca47cb474,ORR,0.722442
uuid-4efedc20343643cd91b40daca47cb474,Median overall survival,0.659043
uuid-4efedc20343643cd91b40daca47cb474,monotherapy,0.514468
uuid-4efedc20343643cd91b40daca47cb474,Median OS,0.696688
uuid-4efedc20343643cd91b40daca47cb474,PD-L1,0.300997
uuid-4efedc20343643cd91b40daca47cb474,docetaxel,0.635065
uuid-4efedc20343643cd91b40daca47cb474,hazard ratio,0.729977
uuid-9a33d4b1bd6e48b684b6fe269e34d824,nivolumab,0.502838
uuid-9a33d4b1bd6e48b684b6fe269e34d824,Bristol-Myers Squibb,0.603808
uuid-9a33d4b1bd6e48b684b6fe269e34d824,use of nivolumab for the treatment,0.305765
uuid-9a33d4b1bd6e48b684b6fe269e34d824,evaluating,0.803211
uuid-9a33d4b1bd6e48b684b6fe269e34d824,not conducted any controlled clinical trials/studies,0.786603
uuid-9a33d4b1bd6e48b684b6fe269e34d824,search of published literature,0.63418
uuid-9a33d4b1bd6e48b684b6fe269e34d824,PubMed and EMBASE,0.602278
uuid-9a33d4b1bd6e48b684b6fe269e34d824,efficacy and safety of nivolumab,0.836625
uuid-9a33d4b1bd6e48b684b6fe269e34d824,not identify any citations relevant to your request,0.352718
uuid-9a33d4b1bd6e48b684b6fe269e34d824,present using the following search terms,0.626356
uuid-9a33d4b1bd6e48b684b6fe269e34d824,safety of nivolumab monotherapy,0.305368
uuid-4d51b542be234221b09457caf90f6cec,Opdivo,0.345109
uuid-4d51b542be234221b09457caf90f6cec,clinical,0.324695
uuid-4d51b542be234221b09457caf90f6cec,trial,0.799344
uuid-785556d263534f288b85eb4101aa4bc7,95% CI,0.524855
uuid-785556d263534f288b85eb4101aa4bc7,respectively,0.383655
uuid-785556d263534f288b85eb4101aa4bc7,ASCO,0.303153
uuid-785556d263534f288b85eb4101aa4bc7,Lancet Oncol,0.368041
uuid-785556d263534f288b85eb4101aa4bc7,Objective response rate,0.504846
uuid-785556d263534f288b85eb4101aa4bc7,ORR,0.465366
uuid-785556d263534f288b85eb4101aa4bc7,Median overall survival,0.346516
uuid-785556d263534f288b85eb4101aa4bc7,Median OS,0.33538
uuid-785556d263534f288b85eb4101aa4bc7,ASCO 2015,0.336983
uuid-785556d263534f288b85eb4101aa4bc7,small cell lung cancer,0.336892
uuid-785556d263534f288b85eb4101aa4bc7,SCLC,0.344367
uuid-785556d263534f288b85eb4101aa4bc7,Antonia SJ,0.55269
uuid-785556d263534f288b85eb4101aa4bc7,Median duration of response,0.649605
uuid-2dd76d68a09d4662b2f0259c4d5f5ec4,requested,0.594234
uuid-f3bd60176e394cacae156b61112cf065,requested,0.594234
uuid-6bc37620017d4c34a52b20d0945f8055,95% CI,0.524855
uuid-6bc37620017d4c34a52b20d0945f8055,respectively,0.383655
uuid-6bc37620017d4c34a52b20d0945f8055,ASCO,0.303153
uuid-6bc37620017d4c34a52b20d0945f8055,Lancet Oncol,0.368041
uuid-6bc37620017d4c34a52b20d0945f8055,Objective response rate,0.504846
uuid-6bc37620017d4c34a52b20d0945f8055,ORR,0.465366
uuid-6bc37620017d4c34a52b20d0945f8055,Median overall survival,0.346516
uuid-6bc37620017d4c34a52b20d0945f8055,Median OS,0.33538
uuid-6bc37620017d4c34a52b20d0945f8055,ASCO 2015,0.336983
uuid-6bc37620017d4c34a52b20d0945f8055,small cell lung cancer,0.336892
uuid-6bc37620017d4c34a52b20d0945f8055,SCLC,0.344367
uuid-6bc37620017d4c34a52b20d0945f8055,Antonia SJ,0.55269
uuid-6bc37620017d4c34a52b20d0945f8055,Median duration of response,0.649605
uuid-c57a4201382b42eaa94a8fb0fb677ce8,Bristol-Myers Squibb,0.341822
uuid-c57a4201382b42eaa94a8fb0fb677ce8,not conducted any controlled clinical trials/studies,0.304507
uuid-c57a4201382b42eaa94a8fb0fb677ce8,Opdivo,0.461382
uuid-c57a4201382b42eaa94a8fb0fb677ce8,Pubmed literature search,0.614325
uuid-c57a4201382b42eaa94a8fb0fb677ce8,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c57a4201382b42eaa94a8fb0fb677ce8,not identify any citations relevant to your inquiry,0.606087
uuid-c57a4201382b42eaa94a8fb0fb677ce8,adverse,0.304183
uuid-c57a4201382b42eaa94a8fb0fb677ce8,using the following search terms,0.642331
uuid-c57a4201382b42eaa94a8fb0fb677ce8,databases,0.315039
uuid-c57a4201382b42eaa94a8fb0fb677ce8,reported,0.556704
uuid-8f11b5d2c53545a6b5509b762214e3dc,95% CI,0.524855
uuid-8f11b5d2c53545a6b5509b762214e3dc,respectively,0.383655
uuid-8f11b5d2c53545a6b5509b762214e3dc,ASCO,0.303153
uuid-8f11b5d2c53545a6b5509b762214e3dc,Lancet Oncol,0.368041
uuid-8f11b5d2c53545a6b5509b762214e3dc,Objective response rate,0.504846
uuid-8f11b5d2c53545a6b5509b762214e3dc,ORR,0.465366
uuid-8f11b5d2c53545a6b5509b762214e3dc,Median overall survival,0.346516
uuid-8f11b5d2c53545a6b5509b762214e3dc,Median OS,0.33538
uuid-8f11b5d2c53545a6b5509b762214e3dc,ASCO 2015,0.336983
uuid-8f11b5d2c53545a6b5509b762214e3dc,small cell lung cancer,0.336892
uuid-8f11b5d2c53545a6b5509b762214e3dc,SCLC,0.344367
uuid-8f11b5d2c53545a6b5509b762214e3dc,Antonia SJ,0.55269
uuid-8f11b5d2c53545a6b5509b762214e3dc,Median duration of response,0.649605
uuid-4605d31fb3934140bcdece14b38ceed4,nivolumab,0.444791
uuid-4605d31fb3934140bcdece14b38ceed4,Bristol-Myers Squibb,0.578409
uuid-4605d31fb3934140bcdece14b38ceed4,use of nivolumab for the treatment,0.501003
uuid-4605d31fb3934140bcdece14b38ceed4,evaluating,0.833182
uuid-4605d31fb3934140bcdece14b38ceed4,not conducted any controlled clinical trials/studies,0.800235
uuid-4605d31fb3934140bcdece14b38ceed4,efficacy,0.356517
uuid-4605d31fb3934140bcdece14b38ceed4,considered investigational,0.300385
uuid-4605d31fb3934140bcdece14b38ceed4,search of published literature,0.791799
uuid-4605d31fb3934140bcdece14b38ceed4,PubMed and EMBASE,0.761018
uuid-4605d31fb3934140bcdece14b38ceed4,not approved,0.424662
uuid-4605d31fb3934140bcdece14b38ceed4,clinical trials investigating the safety,0.405541
uuid-4605d31fb3934140bcdece14b38ceed4,efficacy and safety of nivolumab,0.900462
uuid-4605d31fb3934140bcdece14b38ceed4,not identify any citations relevant to your request,0.344295
uuid-4605d31fb3934140bcdece14b38ceed4,present using the following search terms,0.765148
uuid-4605d31fb3934140bcdece14b38ceed4,safety of nivolumab monotherapy,0.364085
uuid-36d32981c2cc4894a5a80a91c3d9b778,patients with advanced or metastatic,0.478326
uuid-36d32981c2cc4894a5a80a91c3d9b778,nivolumab combined with ipilimumab,0.498766
uuid-36d32981c2cc4894a5a80a91c3d9b778,not approved,0.34724
uuid-36d32981c2cc4894a5a80a91c3d9b778,clinical trials investigating the safety,0.426729
uuid-36d32981c2cc4894a5a80a91c3d9b778,bladder cancer,0.6548
uuid-4454ff58ee2040cc8b3abf16a149ee90,nivolumab,0.361138
uuid-6dd29803e9374f9ea98512d5548cb61e,adverse,0.31962
uuid-ce222f6f37a945c4a56611c56db1ab70,search of published literature,0.394524
uuid-ce222f6f37a945c4a56611c56db1ab70,Additionally,0.413583
uuid-ce222f6f37a945c4a56611c56db1ab70,ongoing,0.322117
uuid-ce222f6f37a945c4a56611c56db1ab70,PubMed and EMBASE,0.391671
uuid-ce222f6f37a945c4a56611c56db1ab70,detailed search of www.clinicaltrials.gov,0.375936
uuid-ce222f6f37a945c4a56611c56db1ab70,efficacy and safety of nivolumab,0.370699
uuid-ce222f6f37a945c4a56611c56db1ab70,not identify any planned,0.34283
uuid-ce222f6f37a945c4a56611c56db1ab70,Weber JS,0.319229
uuid-ce222f6f37a945c4a56611c56db1ab70,not identify any citations relevant to your request,0.447813
uuid-ce222f6f37a945c4a56611c56db1ab70,present using the following search terms,0.408199
uuid-5f14cec7f8104029bf4f55c451ed2c11,search of published literature,0.32483
uuid-5f14cec7f8104029bf4f55c451ed2c11,Additionally,0.357412
uuid-5f14cec7f8104029bf4f55c451ed2c11,ongoing,0.418729
uuid-5f14cec7f8104029bf4f55c451ed2c11,PubMed and EMBASE,0.320362
uuid-5f14cec7f8104029bf4f55c451ed2c11,detailed search of www.clinicaltrials.gov,0.386944
uuid-5f14cec7f8104029bf4f55c451ed2c11,efficacy and safety of nivolumab,0.335256
uuid-5f14cec7f8104029bf4f55c451ed2c11,not identify any planned,0.407161
uuid-5f14cec7f8104029bf4f55c451ed2c11,combination,0.341626
uuid-5f14cec7f8104029bf4f55c451ed2c11,not identify any citations relevant to your request,0.384952
uuid-5f14cec7f8104029bf4f55c451ed2c11,present using the following search terms,0.319355
uuid-33ab69d144c940da92538d9268232364,Bristol-Myers Squibb,0.35251
uuid-33ab69d144c940da92538d9268232364,not conducted any controlled clinical trials/studies,0.305676
uuid-33ab69d144c940da92538d9268232364,protocol,0.362063
uuid-33ab69d144c940da92538d9268232364,McDermott DF,0.367467
uuid-33ab69d144c940da92538d9268232364,Motzer RJ,0.364709
uuid-33ab69d144c940da92538d9268232364,phase 3 study,0.336878
uuid-33ab69d144c940da92538d9268232364,Escudier B,0.348177
uuid-33ab69d144c940da92538d9268232364,NEJM,0.498831
uuid-33ab69d144c940da92538d9268232364,et al.,0.309171
uuid-33ab69d144c940da92538d9268232364,J Clin Oncol,0.411184
uuid-33ab69d144c940da92538d9268232364,Topalian,0.52152
uuid-33ab69d144c940da92538d9268232364,phase 1 study,0.432845
uuid-33ab69d144c940da92538d9268232364,mg,0.346553
uuid-33ab69d144c940da92538d9268232364,CA209-003,0.441789
uuid-33ab69d144c940da92538d9268232364,phase 2 study,0.401071
uuid-33ab69d144c940da92538d9268232364,investigating,0.300191
uuid-746b167b37564a8fa4e9c297490fd05e,nivolumab,0.568189
uuid-746b167b37564a8fa4e9c297490fd05e,Bristol-Myers Squibb,0.441443
uuid-746b167b37564a8fa4e9c297490fd05e,evaluating,0.596025
uuid-746b167b37564a8fa4e9c297490fd05e,not conducted any controlled clinical trials/studies,0.657768
uuid-746b167b37564a8fa4e9c297490fd05e,Pubmed literature search,0.877734
uuid-746b167b37564a8fa4e9c297490fd05e,purposes other than its labeled indication must be considered investigational,0.940677
uuid-746b167b37564a8fa4e9c297490fd05e,not identify any citations relevant to your inquiry,0.836586
uuid-746b167b37564a8fa4e9c297490fd05e,using the following search terms,0.824404
uuid-746b167b37564a8fa4e9c297490fd05e,efficacy and safety of nivolumab,0.434585
uuid-3029ff730935439bb14466780d4c7aa9,nivolumab,0.379584
uuid-3029ff730935439bb14466780d4c7aa9,evaluating,0.396762
uuid-3029ff730935439bb14466780d4c7aa9,not conducted any controlled clinical trials/studies,0.434234
uuid-3029ff730935439bb14466780d4c7aa9,Pubmed literature search,0.590755
uuid-3029ff730935439bb14466780d4c7aa9,purposes other than its labeled indication must be considered investigational,0.628312
uuid-3029ff730935439bb14466780d4c7aa9,not identify any citations relevant to your inquiry,0.565847
uuid-3029ff730935439bb14466780d4c7aa9,using the following search terms,0.554787
uuid-ca53d74bfb28403d852b987b88f4157d,patients,0.324499
uuid-a6449840cc5f4e98bb2363a4b3af667a,95% CI,0.524855
uuid-a6449840cc5f4e98bb2363a4b3af667a,respectively,0.383655
uuid-a6449840cc5f4e98bb2363a4b3af667a,ASCO,0.303153
uuid-a6449840cc5f4e98bb2363a4b3af667a,Lancet Oncol,0.368041
uuid-a6449840cc5f4e98bb2363a4b3af667a,Objective response rate,0.504846
uuid-a6449840cc5f4e98bb2363a4b3af667a,ORR,0.465366
uuid-a6449840cc5f4e98bb2363a4b3af667a,Median overall survival,0.346516
uuid-a6449840cc5f4e98bb2363a4b3af667a,Median OS,0.33538
uuid-a6449840cc5f4e98bb2363a4b3af667a,ASCO 2015,0.336983
uuid-a6449840cc5f4e98bb2363a4b3af667a,small cell lung cancer,0.336892
uuid-a6449840cc5f4e98bb2363a4b3af667a,SCLC,0.344367
uuid-a6449840cc5f4e98bb2363a4b3af667a,Antonia SJ,0.55269
uuid-a6449840cc5f4e98bb2363a4b3af667a,Median duration of response,0.649605
uuid-71f5856d071946baa8dde680f8685717,N Engl J Med,0.427636
uuid-71f5856d071946baa8dde680f8685717,protocol,0.429136
uuid-71f5856d071946baa8dde680f8685717,McDermott DF,0.44782
uuid-71f5856d071946baa8dde680f8685717,Motzer RJ,0.430476
uuid-71f5856d071946baa8dde680f8685717,Escudier B,0.450887
uuid-71f5856d071946baa8dde680f8685717,et al.,0.456026
uuid-71f5856d071946baa8dde680f8685717,J Clin Oncol,0.384624
uuid-71f5856d071946baa8dde680f8685717,Rizvi NA,0.305616
uuid-71f5856d071946baa8dde680f8685717,phase 2 study,0.351446
uuid-a9342f5e5c964102a4306017a64aa26e,evaluating,0.350845
uuid-a9342f5e5c964102a4306017a64aa26e,not conducted any controlled clinical trials/studies,0.345107
uuid-a9342f5e5c964102a4306017a64aa26e,search of published literature,0.385331
uuid-a9342f5e5c964102a4306017a64aa26e,Additionally,0.40981
uuid-a9342f5e5c964102a4306017a64aa26e,ongoing,0.457998
uuid-a9342f5e5c964102a4306017a64aa26e,PubMed and EMBASE,0.378285
uuid-a9342f5e5c964102a4306017a64aa26e,detailed search of www.clinicaltrials.gov,0.428522
uuid-a9342f5e5c964102a4306017a64aa26e,efficacy and safety of nivolumab,0.407868
uuid-a9342f5e5c964102a4306017a64aa26e,not identify any planned,0.444729
uuid-a9342f5e5c964102a4306017a64aa26e,combination,0.388252
uuid-a9342f5e5c964102a4306017a64aa26e,BMS,0.316104
uuid-a9342f5e5c964102a4306017a64aa26e,not identify any citations relevant to your request,0.438151
uuid-a9342f5e5c964102a4306017a64aa26e,present using the following search terms,0.377101
uuid-ee1087c9027c400a8a02609f5728baba,95% CI,0.439861
uuid-ee1087c9027c400a8a02609f5728baba,Objective response rate,0.389061
uuid-ee1087c9027c400a8a02609f5728baba,ORR,0.356308
uuid-ee1087c9027c400a8a02609f5728baba,patients with advanced or metastatic,0.37124
uuid-ee1087c9027c400a8a02609f5728baba,nivolumab combined with ipilimumab,0.361166
uuid-ee1087c9027c400a8a02609f5728baba,small cell lung cancer,0.340963
uuid-ee1087c9027c400a8a02609f5728baba,SCLC,0.30976
uuid-ee1087c9027c400a8a02609f5728baba,Antonia SJ,0.459276
uuid-ee1087c9027c400a8a02609f5728baba,Median duration of response,0.560833
uuid-ee1087c9027c400a8a02609f5728baba,bladder cancer,0.468916
uuid-e1499faf9d314c5fb33b14a906e6e7b5,Bristol-Myers Squibb,0.341822
uuid-e1499faf9d314c5fb33b14a906e6e7b5,not conducted any controlled clinical trials/studies,0.304507
uuid-e1499faf9d314c5fb33b14a906e6e7b5,Opdivo,0.461382
uuid-e1499faf9d314c5fb33b14a906e6e7b5,Pubmed literature search,0.614325
uuid-e1499faf9d314c5fb33b14a906e6e7b5,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e1499faf9d314c5fb33b14a906e6e7b5,not identify any citations relevant to your inquiry,0.606087
uuid-e1499faf9d314c5fb33b14a906e6e7b5,adverse,0.304183
uuid-e1499faf9d314c5fb33b14a906e6e7b5,using the following search terms,0.642331
uuid-e1499faf9d314c5fb33b14a906e6e7b5,databases,0.315039
uuid-e1499faf9d314c5fb33b14a906e6e7b5,reported,0.556704
uuid-7b07baa5a1324d8b847a0e31921d2b76,monotherapy,0.527319
uuid-7b07baa5a1324d8b847a0e31921d2b76,ipilimumab,0.341041
uuid-7b07baa5a1324d8b847a0e31921d2b76,mg,0.595068
uuid-7b07baa5a1324d8b847a0e31921d2b76,kg,0.644622
uuid-7b07baa5a1324d8b847a0e31921d2b76,cohort,0.794725
uuid-a56362854e944da292b7761f51368f10,Opdivo,0.304291
uuid-a56362854e944da292b7761f51368f10,open-label,0.363658
uuid-a56362854e944da292b7761f51368f10,trial,0.328465
uuid-a56362854e944da292b7761f51368f10,safety of nivolumab monotherapy,0.457426
uuid-a56362854e944da292b7761f51368f10,phase,0.535062
uuid-92a2acc46a894781b4e0b3ddd94e9e02,Lancet Oncol,0.405203
uuid-92a2acc46a894781b4e0b3ddd94e9e02,requested,0.689771
uuid-92a2acc46a894781b4e0b3ddd94e9e02,Rizvi NA,0.30306
uuid-92a2acc46a894781b4e0b3ddd94e9e02,Weber JS,0.313145
uuid-92a2acc46a894781b4e0b3ddd94e9e02,Antonia SJ,0.412316
uuid-f18824051e614778bd2320b624af067a,OS,0.62262
uuid-f18824051e614778bd2320b624af067a,PFS,0.65903
uuid-f18824051e614778bd2320b624af067a,Overall survival,0.644151
uuid-d7e46309438d4c9bb60b9496b5b68366,nivolumab,0.317027
uuid-d7e46309438d4c9bb60b9496b5b68366,clinicaltrials.gov,0.619562
uuid-5a9d68add0ce4930bd5e95ddba415bf9,requested,0.650717
uuid-ec1faf9c16cb405ab89b1f30dc8da182,95% CI,0.449664
uuid-ec1faf9c16cb405ab89b1f30dc8da182,Objective response rate,0.401881
uuid-ec1faf9c16cb405ab89b1f30dc8da182,ORR,0.37001
uuid-ec1faf9c16cb405ab89b1f30dc8da182,patients with advanced or metastatic,0.359684
uuid-ec1faf9c16cb405ab89b1f30dc8da182,nivolumab combined with ipilimumab,0.368974
uuid-ec1faf9c16cb405ab89b1f30dc8da182,small cell lung cancer,0.351902
uuid-ec1faf9c16cb405ab89b1f30dc8da182,SCLC,0.33483
uuid-ec1faf9c16cb405ab89b1f30dc8da182,Antonia SJ,0.467278
uuid-ec1faf9c16cb405ab89b1f30dc8da182,Median duration of response,0.570678
uuid-ec1faf9c16cb405ab89b1f30dc8da182,phase 1/2 study CA209-032,0.332335
uuid-ec1faf9c16cb405ab89b1f30dc8da182,bladder cancer,0.303581
uuid-ec1faf9c16cb405ab89b1f30dc8da182,evaluates the efficacy of nivolumab monotherapy,0.330013
uuid-20fd23533a444a3681d6614db1f35c62,patients with advanced or metastatic,0.478326
uuid-20fd23533a444a3681d6614db1f35c62,nivolumab combined with ipilimumab,0.498766
uuid-20fd23533a444a3681d6614db1f35c62,not approved,0.34724
uuid-20fd23533a444a3681d6614db1f35c62,clinical trials investigating the safety,0.426729
uuid-20fd23533a444a3681d6614db1f35c62,bladder cancer,0.6548
uuid-05b524a60acd43c4b5e22f7207564c08,95% CI,0.524855
uuid-05b524a60acd43c4b5e22f7207564c08,respectively,0.383655
uuid-05b524a60acd43c4b5e22f7207564c08,ASCO,0.303153
uuid-05b524a60acd43c4b5e22f7207564c08,Lancet Oncol,0.368041
uuid-05b524a60acd43c4b5e22f7207564c08,Objective response rate,0.504846
uuid-05b524a60acd43c4b5e22f7207564c08,ORR,0.465366
uuid-05b524a60acd43c4b5e22f7207564c08,Median overall survival,0.346516
uuid-05b524a60acd43c4b5e22f7207564c08,Median OS,0.33538
uuid-05b524a60acd43c4b5e22f7207564c08,ASCO 2015,0.336983
uuid-05b524a60acd43c4b5e22f7207564c08,small cell lung cancer,0.336892
uuid-05b524a60acd43c4b5e22f7207564c08,SCLC,0.344367
uuid-05b524a60acd43c4b5e22f7207564c08,Antonia SJ,0.55269
uuid-05b524a60acd43c4b5e22f7207564c08,Median duration of response,0.649605
uuid-f75989a4e43f44bbaa80de898d062aae,Opdivo,0.402673
uuid-f75989a4e43f44bbaa80de898d062aae,trial,0.406937
uuid-f75989a4e43f44bbaa80de898d062aae,mg,0.453256
uuid-f75989a4e43f44bbaa80de898d062aae,kg,0.410308
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,N Engl J Med,0.456474
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,Lancet Oncol,0.357873
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,protocol,0.480893
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,McDermott DF,0.51746
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,search of published literature,0.343051
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,Motzer RJ,0.516788
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,phase 3 study,0.754973
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,PubMed and EMBASE,0.340792
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,Escudier B,0.532534
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,et al.,0.496867
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,J Clin Oncol,0.430616
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,Rizvi NA,0.473891
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,Weber JS,0.580854
uuid-75d9c1a0cfd446d99fd98bdc4d6d1dbb,phase 2 study,0.6143
uuid-afe768bf0ed24e35827d704fbbac971c,nivolumab,0.324658
uuid-afe768bf0ed24e35827d704fbbac971c,use of nivolumab for the treatment,0.543355
uuid-afe768bf0ed24e35827d704fbbac971c,evaluating,0.348676
uuid-afe768bf0ed24e35827d704fbbac971c,efficacy,0.388907
uuid-afe768bf0ed24e35827d704fbbac971c,patients,0.419915
uuid-afe768bf0ed24e35827d704fbbac971c,search of published literature,0.449959
uuid-afe768bf0ed24e35827d704fbbac971c,PubMed and EMBASE,0.444573
uuid-afe768bf0ed24e35827d704fbbac971c,not approved,0.582429
uuid-afe768bf0ed24e35827d704fbbac971c,clinical trials investigating the safety,0.64854
uuid-afe768bf0ed24e35827d704fbbac971c,efficacy and safety of nivolumab,0.399101
uuid-afe768bf0ed24e35827d704fbbac971c,present using the following search terms,0.465296
uuid-1e63c149bc8a40e4828c291daab25e79,N Engl J Med,0.751584
uuid-1e63c149bc8a40e4828c291daab25e79,Lancet Oncol,0.473486
uuid-1e63c149bc8a40e4828c291daab25e79,protocol,0.389524
uuid-1e63c149bc8a40e4828c291daab25e79,McDermott DF,0.464499
uuid-1e63c149bc8a40e4828c291daab25e79,Motzer RJ,0.429791
uuid-1e63c149bc8a40e4828c291daab25e79,ESMO,0.394362
uuid-1e63c149bc8a40e4828c291daab25e79,phase 3 study,0.498455
uuid-1e63c149bc8a40e4828c291daab25e79,Escudier B,0.464846
uuid-1e63c149bc8a40e4828c291daab25e79,NEJM,0.362533
uuid-1e63c149bc8a40e4828c291daab25e79,et al.,0.481176
uuid-1e63c149bc8a40e4828c291daab25e79,J Clin Oncol,0.356969
uuid-1e63c149bc8a40e4828c291daab25e79,Topalian,0.318431
uuid-1e63c149bc8a40e4828c291daab25e79,Rizvi NA,0.637367
uuid-1e63c149bc8a40e4828c291daab25e79,Brahmer J,0.584521
uuid-1e63c149bc8a40e4828c291daab25e79,PD-L1,0.34848
uuid-1e63c149bc8a40e4828c291daab25e79,Weber JS,0.453116
uuid-1e63c149bc8a40e4828c291daab25e79,phase 2 study,0.570384
uuid-1e63c149bc8a40e4828c291daab25e79,Horn L,0.354795
uuid-1963c9208d9b4644a23c0ad941c3b72e,95% CI,0.524855
uuid-1963c9208d9b4644a23c0ad941c3b72e,respectively,0.383655
uuid-1963c9208d9b4644a23c0ad941c3b72e,ASCO,0.303153
uuid-1963c9208d9b4644a23c0ad941c3b72e,Lancet Oncol,0.368041
uuid-1963c9208d9b4644a23c0ad941c3b72e,Objective response rate,0.504846
uuid-1963c9208d9b4644a23c0ad941c3b72e,ORR,0.465366
uuid-1963c9208d9b4644a23c0ad941c3b72e,Median overall survival,0.346516
uuid-1963c9208d9b4644a23c0ad941c3b72e,Median OS,0.33538
uuid-1963c9208d9b4644a23c0ad941c3b72e,ASCO 2015,0.336983
uuid-1963c9208d9b4644a23c0ad941c3b72e,small cell lung cancer,0.336892
uuid-1963c9208d9b4644a23c0ad941c3b72e,SCLC,0.344367
uuid-1963c9208d9b4644a23c0ad941c3b72e,Antonia SJ,0.55269
uuid-1963c9208d9b4644a23c0ad941c3b72e,Median duration of response,0.649605
uuid-2f90b68a05f54a3a9d3150a72b38220f,open-label,0.331973
uuid-2f90b68a05f54a3a9d3150a72b38220f,safety of nivolumab monotherapy,0.473796
uuid-2f90b68a05f54a3a9d3150a72b38220f,phase,0.499584
uuid-b676c919580b42e1ba6f7d3b21400d2b,N Engl J Med,0.448483
uuid-b676c919580b42e1ba6f7d3b21400d2b,protocol,0.770446
uuid-b676c919580b42e1ba6f7d3b21400d2b,McDermott DF,0.741196
uuid-b676c919580b42e1ba6f7d3b21400d2b,Motzer RJ,0.818144
uuid-b676c919580b42e1ba6f7d3b21400d2b,phase 3 study,0.417055
uuid-b676c919580b42e1ba6f7d3b21400d2b,Escudier B,0.749917
uuid-b676c919580b42e1ba6f7d3b21400d2b,NEJM,0.400698
uuid-b676c919580b42e1ba6f7d3b21400d2b,et al.,0.668641
uuid-b676c919580b42e1ba6f7d3b21400d2b,J Clin Oncol,0.792018
uuid-b676c919580b42e1ba6f7d3b21400d2b,Topalian,0.388894
uuid-b676c919580b42e1ba6f7d3b21400d2b,phase 1 study,0.500686
uuid-b676c919580b42e1ba6f7d3b21400d2b,CA209-003,0.567381
uuid-b676c919580b42e1ba6f7d3b21400d2b,phase 2 study,0.677985
uuid-b676c919580b42e1ba6f7d3b21400d2b,present using the following search terms,0.310558
uuid-b676c919580b42e1ba6f7d3b21400d2b,investigating,0.615835
uuid-f86846b00329493b810f72c2ea065721,considered investigational,0.402849
uuid-f86846b00329493b810f72c2ea065721,small cell lung cancer,0.651985
uuid-f86846b00329493b810f72c2ea065721,partial response,0.50367
uuid-f86846b00329493b810f72c2ea065721,SCLC,0.736863
uuid-f86846b00329493b810f72c2ea065721,therapy,0.843488
uuid-f86846b00329493b810f72c2ea065721,relapsed,0.613852
uuid-f86846b00329493b810f72c2ea065721,phase 1/2 study CA209-032,0.40439
uuid-f86846b00329493b810f72c2ea065721,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-cc568abc615744a7b5f3b56d3856c804,Bristol-Myers Squibb,0.341822
uuid-cc568abc615744a7b5f3b56d3856c804,not conducted any controlled clinical trials/studies,0.304507
uuid-cc568abc615744a7b5f3b56d3856c804,Opdivo,0.461382
uuid-cc568abc615744a7b5f3b56d3856c804,Pubmed literature search,0.614325
uuid-cc568abc615744a7b5f3b56d3856c804,purposes other than its labeled indication must be considered investigational,0.586645
uuid-cc568abc615744a7b5f3b56d3856c804,not identify any citations relevant to your inquiry,0.606087
uuid-cc568abc615744a7b5f3b56d3856c804,adverse,0.304183
uuid-cc568abc615744a7b5f3b56d3856c804,using the following search terms,0.642331
uuid-cc568abc615744a7b5f3b56d3856c804,databases,0.315039
uuid-cc568abc615744a7b5f3b56d3856c804,reported,0.556704
uuid-83cc5887ff524323837be5d5f5c3d568,melanoma,0.410364
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,OS,0.306979
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,95% CI,0.378929
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,ORR,0.325152
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,Median overall survival,0.416865
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,Median OS,0.343981
uuid-c9fd2c6078de4dd2ad9983c1088e8d1b,hazard ratio,0.35636
uuid-f73a14187f5c47d7af9c75b6cbe856c7,N Engl J Med,0.585592
uuid-f73a14187f5c47d7af9c75b6cbe856c7,protocol,0.703048
uuid-f73a14187f5c47d7af9c75b6cbe856c7,McDermott DF,0.808613
uuid-f73a14187f5c47d7af9c75b6cbe856c7,Motzer RJ,0.783017
uuid-f73a14187f5c47d7af9c75b6cbe856c7,phase 3 study,0.465459
uuid-f73a14187f5c47d7af9c75b6cbe856c7,Escudier B,0.804268
uuid-f73a14187f5c47d7af9c75b6cbe856c7,NEJM,0.338631
uuid-f73a14187f5c47d7af9c75b6cbe856c7,et al.,0.770371
uuid-f73a14187f5c47d7af9c75b6cbe856c7,J Clin Oncol,0.754974
uuid-f73a14187f5c47d7af9c75b6cbe856c7,Rizvi NA,0.374947
uuid-f73a14187f5c47d7af9c75b6cbe856c7,phase 2 study,0.717397
uuid-84852e40eabd4f649d3ddc00d44bdc0d,Bristol-Myers Squibb,0.346284
uuid-84852e40eabd4f649d3ddc00d44bdc0d,requested,0.318394
uuid-368763c29c664ab09c87a4a41fb55b06,95% CI,0.524855
uuid-368763c29c664ab09c87a4a41fb55b06,respectively,0.383655
uuid-368763c29c664ab09c87a4a41fb55b06,ASCO,0.303153
uuid-368763c29c664ab09c87a4a41fb55b06,Lancet Oncol,0.368041
uuid-368763c29c664ab09c87a4a41fb55b06,Objective response rate,0.504846
uuid-368763c29c664ab09c87a4a41fb55b06,ORR,0.465366
uuid-368763c29c664ab09c87a4a41fb55b06,Median overall survival,0.346516
uuid-368763c29c664ab09c87a4a41fb55b06,Median OS,0.33538
uuid-368763c29c664ab09c87a4a41fb55b06,ASCO 2015,0.336983
uuid-368763c29c664ab09c87a4a41fb55b06,small cell lung cancer,0.336892
uuid-368763c29c664ab09c87a4a41fb55b06,SCLC,0.344367
uuid-368763c29c664ab09c87a4a41fb55b06,Antonia SJ,0.55269
uuid-368763c29c664ab09c87a4a41fb55b06,Median duration of response,0.649605
uuid-1672556fc4984283872651b425460d84,OS,0.62262
uuid-1672556fc4984283872651b425460d84,PFS,0.65903
uuid-1672556fc4984283872651b425460d84,Overall survival,0.644151
uuid-1ef70c243ed84b3ab6e619c625fddd11,OS,0.62262
uuid-1ef70c243ed84b3ab6e619c625fddd11,PFS,0.65903
uuid-1ef70c243ed84b3ab6e619c625fddd11,Overall survival,0.644151
uuid-001c1a636f2d46e8850231ce77d40c6d,Bristol-Myers Squibb,0.341822
uuid-001c1a636f2d46e8850231ce77d40c6d,not conducted any controlled clinical trials/studies,0.304507
uuid-001c1a636f2d46e8850231ce77d40c6d,Opdivo,0.461382
uuid-001c1a636f2d46e8850231ce77d40c6d,Pubmed literature search,0.614325
uuid-001c1a636f2d46e8850231ce77d40c6d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-001c1a636f2d46e8850231ce77d40c6d,not identify any citations relevant to your inquiry,0.606087
uuid-001c1a636f2d46e8850231ce77d40c6d,adverse,0.304183
uuid-001c1a636f2d46e8850231ce77d40c6d,using the following search terms,0.642331
uuid-001c1a636f2d46e8850231ce77d40c6d,databases,0.315039
uuid-001c1a636f2d46e8850231ce77d40c6d,reported,0.556704
uuid-01ffd432de614fdc8f890239a4847759,95% CI,0.524855
uuid-01ffd432de614fdc8f890239a4847759,respectively,0.383655
uuid-01ffd432de614fdc8f890239a4847759,ASCO,0.303153
uuid-01ffd432de614fdc8f890239a4847759,Lancet Oncol,0.368041
uuid-01ffd432de614fdc8f890239a4847759,Objective response rate,0.504846
uuid-01ffd432de614fdc8f890239a4847759,ORR,0.465366
uuid-01ffd432de614fdc8f890239a4847759,Median overall survival,0.346516
uuid-01ffd432de614fdc8f890239a4847759,Median OS,0.33538
uuid-01ffd432de614fdc8f890239a4847759,ASCO 2015,0.336983
uuid-01ffd432de614fdc8f890239a4847759,small cell lung cancer,0.336892
uuid-01ffd432de614fdc8f890239a4847759,SCLC,0.344367
uuid-01ffd432de614fdc8f890239a4847759,Antonia SJ,0.55269
uuid-01ffd432de614fdc8f890239a4847759,Median duration of response,0.649605
uuid-0aa1282cb0c342f1927bda2430368013,95% CI,0.368332
uuid-0aa1282cb0c342f1927bda2430368013,NSCLC,0.498467
uuid-0aa1282cb0c342f1927bda2430368013,non-small cell lung cancer,0.430459
uuid-0aa1282cb0c342f1927bda2430368013,Objective response rate,0.480097
uuid-0aa1282cb0c342f1927bda2430368013,ORR,0.476446
uuid-0aa1282cb0c342f1927bda2430368013,Median overall survival,0.366656
uuid-0aa1282cb0c342f1927bda2430368013,monotherapy,0.355726
uuid-0aa1282cb0c342f1927bda2430368013,Median OS,0.348153
uuid-0aa1282cb0c342f1927bda2430368013,phase 1 study,0.35881
uuid-0aa1282cb0c342f1927bda2430368013,hazard ratio,0.370178
uuid-81574adc691443679630cd166f0f6c7c,ipilimumab,0.385692
uuid-81574adc691443679630cd166f0f6c7c,ASCO 2015,0.417944
uuid-81574adc691443679630cd166f0f6c7c,partial response,0.382425
uuid-81574adc691443679630cd166f0f6c7c,Stable disease,0.586335
uuid-81574adc691443679630cd166f0f6c7c,cohort,0.307748
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,Bristol-Myers Squibb,0.341822
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,not conducted any controlled clinical trials/studies,0.304507
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,Opdivo,0.461382
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,Pubmed literature search,0.614325
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,not identify any citations relevant to your inquiry,0.606087
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,adverse,0.304183
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,using the following search terms,0.642331
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,databases,0.315039
uuid-7dbc375b1e1a498d84b1dd92e1d5304c,reported,0.556704
uuid-51b40946dea1455685c509699dc64a7f,OS,0.3276
uuid-51b40946dea1455685c509699dc64a7f,95% CI,0.73865
uuid-51b40946dea1455685c509699dc64a7f,respectively,0.64965
uuid-51b40946dea1455685c509699dc64a7f,Objective response rate,0.635781
uuid-51b40946dea1455685c509699dc64a7f,ORR,0.69167
uuid-51b40946dea1455685c509699dc64a7f,Median overall survival,0.586969
uuid-51b40946dea1455685c509699dc64a7f,monotherapy,0.412388
uuid-51b40946dea1455685c509699dc64a7f,Median OS,0.603051
uuid-51b40946dea1455685c509699dc64a7f,docetaxel,0.472318
uuid-51b40946dea1455685c509699dc64a7f,Antonia SJ,0.392836
uuid-51b40946dea1455685c509699dc64a7f,hazard ratio,0.599128
uuid-51b40946dea1455685c509699dc64a7f,Median duration of response,0.483887
uuid-88e0df31257845059912ccca5deccbfe,Bristol-Myers Squibb,0.341822
uuid-88e0df31257845059912ccca5deccbfe,not conducted any controlled clinical trials/studies,0.304507
uuid-88e0df31257845059912ccca5deccbfe,Opdivo,0.461382
uuid-88e0df31257845059912ccca5deccbfe,Pubmed literature search,0.614325
uuid-88e0df31257845059912ccca5deccbfe,purposes other than its labeled indication must be considered investigational,0.586645
uuid-88e0df31257845059912ccca5deccbfe,not identify any citations relevant to your inquiry,0.606087
uuid-88e0df31257845059912ccca5deccbfe,adverse,0.304183
uuid-88e0df31257845059912ccca5deccbfe,using the following search terms,0.642331
uuid-88e0df31257845059912ccca5deccbfe,databases,0.315039
uuid-88e0df31257845059912ccca5deccbfe,reported,0.556704
uuid-3f800ec2849a4a65a5939abd2a399931,nivolumab,0.33639
uuid-3f800ec2849a4a65a5939abd2a399931,Objective response rate,0.459398
uuid-3f800ec2849a4a65a5939abd2a399931,clinicaltrials.gov,0.632338
uuid-df27ffc401334a19b41d4394a4d292ae,OS,0.387982
uuid-df27ffc401334a19b41d4394a4d292ae,95% CI,0.745043
uuid-df27ffc401334a19b41d4394a4d292ae,respectively,0.729294
uuid-df27ffc401334a19b41d4394a4d292ae,Objective response rate,0.590876
uuid-df27ffc401334a19b41d4394a4d292ae,ORR,0.722442
uuid-df27ffc401334a19b41d4394a4d292ae,Median overall survival,0.659043
uuid-df27ffc401334a19b41d4394a4d292ae,monotherapy,0.514468
uuid-df27ffc401334a19b41d4394a4d292ae,Median OS,0.696688
uuid-df27ffc401334a19b41d4394a4d292ae,PD-L1,0.300997
uuid-df27ffc401334a19b41d4394a4d292ae,docetaxel,0.635065
uuid-df27ffc401334a19b41d4394a4d292ae,hazard ratio,0.729977
uuid-16ca79b85b1a4c8db83b226ada6742c0,ipilimumab,0.385692
uuid-16ca79b85b1a4c8db83b226ada6742c0,ASCO 2015,0.417944
uuid-16ca79b85b1a4c8db83b226ada6742c0,partial response,0.382425
uuid-16ca79b85b1a4c8db83b226ada6742c0,Stable disease,0.586335
uuid-16ca79b85b1a4c8db83b226ada6742c0,cohort,0.307748
uuid-05851a20b4e04c70b65acf22219f8bea,provided in the Detailed Information,0.349112
uuid-05851a20b4e04c70b65acf22219f8bea,Weber JS,0.321343
uuid-705dc4ce3e4643b5a3a0ed51bd11c152,adverse,0.416199
uuid-7e9ec3108fc34d399836dc8faef13e24,respectively,0.589071
uuid-7e9ec3108fc34d399836dc8faef13e24,Objective response rate,0.407286
uuid-7e9ec3108fc34d399836dc8faef13e24,ORR,0.526086
uuid-7e9ec3108fc34d399836dc8faef13e24,monotherapy,0.319413
uuid-7e9ec3108fc34d399836dc8faef13e24,docetaxel,0.334344
uuid-dd3929df0d9f4959938343a2f04564a1,nivolumab,0.383487
uuid-dd3929df0d9f4959938343a2f04564a1,monotherapy,0.522208
uuid-dd3929df0d9f4959938343a2f04564a1,ipilimumab,0.574535
uuid-dd3929df0d9f4959938343a2f04564a1,ASCO 2015,0.398452
uuid-dd3929df0d9f4959938343a2f04564a1,mg,0.57662
uuid-dd3929df0d9f4959938343a2f04564a1,combination,0.340802
uuid-dd3929df0d9f4959938343a2f04564a1,kg,0.542437
uuid-dd3929df0d9f4959938343a2f04564a1,Antonia SJ,0.305229
uuid-9ce53f81e4ab4d9f8304b65b0eca8863,PD-L1,0.550598
uuid-9ce53f81e4ab4d9f8304b65b0eca8863,bladder cancer,0.358757
uuid-be584e6a32df4930b5d525e957491752,melanoma,0.410364
uuid-9500726f5be54ef1b5ae558f37603d62,respectively,0.397695
uuid-3bab07e3144b4f0d93ad2a444991e7ec,nivolumab,0.439692
uuid-3bab07e3144b4f0d93ad2a444991e7ec,Bristol-Myers Squibb,0.591751
uuid-3bab07e3144b4f0d93ad2a444991e7ec,evaluating,0.657908
uuid-3bab07e3144b4f0d93ad2a444991e7ec,not conducted any controlled clinical trials/studies,0.724183
uuid-3bab07e3144b4f0d93ad2a444991e7ec,Pubmed literature search,0.658414
uuid-3bab07e3144b4f0d93ad2a444991e7ec,purposes other than its labeled indication must be considered investigational,0.739997
uuid-3bab07e3144b4f0d93ad2a444991e7ec,not identify any citations relevant to your inquiry,0.61916
uuid-3bab07e3144b4f0d93ad2a444991e7ec,using the following search terms,0.597742
uuid-3bab07e3144b4f0d93ad2a444991e7ec,efficacy and safety of nivolumab,0.504082
uuid-ba11836f5e1945fd81fed8a2f1015d8e,NSCLC,0.323559
uuid-ba11836f5e1945fd81fed8a2f1015d8e,non-small cell lung cancer,0.349718
uuid-ba11836f5e1945fd81fed8a2f1015d8e,patients,0.349857
uuid-ba11836f5e1945fd81fed8a2f1015d8e,safety of nivolumab monotherapy,0.473245
uuid-ba11836f5e1945fd81fed8a2f1015d8e,phase,0.44395
uuid-ec5e02104b27429aab254445e6253b89,nivolumab,0.538061
uuid-ec5e02104b27429aab254445e6253b89,Bristol-Myers Squibb,0.612132
uuid-ec5e02104b27429aab254445e6253b89,evaluating,0.749955
uuid-ec5e02104b27429aab254445e6253b89,not conducted any controlled clinical trials/studies,0.785812
uuid-ec5e02104b27429aab254445e6253b89,Pubmed literature search,0.678828
uuid-ec5e02104b27429aab254445e6253b89,purposes other than its labeled indication must be considered investigational,0.776504
uuid-ec5e02104b27429aab254445e6253b89,not identify any citations relevant to your inquiry,0.627015
uuid-ec5e02104b27429aab254445e6253b89,using the following search terms,0.610266
uuid-ec5e02104b27429aab254445e6253b89,efficacy and safety of nivolumab,0.55956
uuid-ec5e02104b27429aab254445e6253b89,safety of nivolumab monotherapy,0.321287
uuid-a0f125c1059f430faf1016b96bc4f284,AEs,0.302537
uuid-a0f125c1059f430faf1016b96bc4f284,respectively,0.59994
uuid-a0f125c1059f430faf1016b96bc4f284,Objective response rate,0.497458
uuid-a0f125c1059f430faf1016b96bc4f284,ORR,0.568503
uuid-a0f125c1059f430faf1016b96bc4f284,monotherapy,0.393188
uuid-a0f125c1059f430faf1016b96bc4f284,docetaxel,0.364808
uuid-a0f125c1059f430faf1016b96bc4f284,fatigue,0.408713
uuid-0a7dd2e534c742f5b7076466639b34b4,provided in the Detailed Information,0.349112
uuid-0a7dd2e534c742f5b7076466639b34b4,Weber JS,0.321343
uuid-ae32e34fab7547ceb74436c95370c0e2,ASCO,0.647697
uuid-ae32e34fab7547ceb74436c95370c0e2,Objective response rate,0.35036
uuid-ae32e34fab7547ceb74436c95370c0e2,phase 1 study,0.319836
uuid-67c45c97f269476bb3183ecc429ff144,N Engl J Med,0.448483
uuid-67c45c97f269476bb3183ecc429ff144,protocol,0.770446
uuid-67c45c97f269476bb3183ecc429ff144,McDermott DF,0.741196
uuid-67c45c97f269476bb3183ecc429ff144,Motzer RJ,0.818144
uuid-67c45c97f269476bb3183ecc429ff144,phase 3 study,0.417055
uuid-67c45c97f269476bb3183ecc429ff144,Escudier B,0.749917
uuid-67c45c97f269476bb3183ecc429ff144,NEJM,0.400698
uuid-67c45c97f269476bb3183ecc429ff144,et al.,0.668641
uuid-67c45c97f269476bb3183ecc429ff144,J Clin Oncol,0.792018
uuid-67c45c97f269476bb3183ecc429ff144,Topalian,0.388894
uuid-67c45c97f269476bb3183ecc429ff144,phase 1 study,0.500686
uuid-67c45c97f269476bb3183ecc429ff144,CA209-003,0.567381
uuid-67c45c97f269476bb3183ecc429ff144,phase 2 study,0.677985
uuid-67c45c97f269476bb3183ecc429ff144,present using the following search terms,0.310558
uuid-67c45c97f269476bb3183ecc429ff144,investigating,0.615835
uuid-af577689f20a47108d5ac312b3c2c61b,95% CI,0.524855
uuid-af577689f20a47108d5ac312b3c2c61b,respectively,0.383655
uuid-af577689f20a47108d5ac312b3c2c61b,ASCO,0.303153
uuid-af577689f20a47108d5ac312b3c2c61b,Lancet Oncol,0.368041
uuid-af577689f20a47108d5ac312b3c2c61b,Objective response rate,0.504846
uuid-af577689f20a47108d5ac312b3c2c61b,ORR,0.465366
uuid-af577689f20a47108d5ac312b3c2c61b,Median overall survival,0.346516
uuid-af577689f20a47108d5ac312b3c2c61b,Median OS,0.33538
uuid-af577689f20a47108d5ac312b3c2c61b,ASCO 2015,0.336983
uuid-af577689f20a47108d5ac312b3c2c61b,small cell lung cancer,0.336892
uuid-af577689f20a47108d5ac312b3c2c61b,SCLC,0.344367
uuid-af577689f20a47108d5ac312b3c2c61b,Antonia SJ,0.55269
uuid-af577689f20a47108d5ac312b3c2c61b,Median duration of response,0.649605
uuid-d5cefe2eaf9749fc9ff1d016601d781c,nivolumab,0.418874
uuid-d5cefe2eaf9749fc9ff1d016601d781c,evaluating,0.421117
uuid-d5cefe2eaf9749fc9ff1d016601d781c,not conducted any controlled clinical trials/studies,0.434763
uuid-d5cefe2eaf9749fc9ff1d016601d781c,Pubmed literature search,0.475608
uuid-d5cefe2eaf9749fc9ff1d016601d781c,purposes other than its labeled indication must be considered investigational,0.520393
uuid-d5cefe2eaf9749fc9ff1d016601d781c,not identify any citations relevant to your inquiry,0.479395
uuid-d5cefe2eaf9749fc9ff1d016601d781c,Additionally,0.47573
uuid-d5cefe2eaf9749fc9ff1d016601d781c,ongoing,0.44309
uuid-d5cefe2eaf9749fc9ff1d016601d781c,using the following search terms,0.448939
uuid-d5cefe2eaf9749fc9ff1d016601d781c,detailed search of www.clinicaltrials.gov,0.456583
uuid-d5cefe2eaf9749fc9ff1d016601d781c,efficacy and safety of nivolumab,0.386115
uuid-d5cefe2eaf9749fc9ff1d016601d781c,not identify any planned,0.445299
uuid-d5cefe2eaf9749fc9ff1d016601d781c,not identify any citations relevant to your request,0.442534
uuid-a697281bff0c49c4ae2499ae5ee45d0a,OS,0.387982
uuid-a697281bff0c49c4ae2499ae5ee45d0a,95% CI,0.745043
uuid-a697281bff0c49c4ae2499ae5ee45d0a,respectively,0.729294
uuid-a697281bff0c49c4ae2499ae5ee45d0a,Objective response rate,0.590876
uuid-a697281bff0c49c4ae2499ae5ee45d0a,ORR,0.722442
uuid-a697281bff0c49c4ae2499ae5ee45d0a,Median overall survival,0.659043
uuid-a697281bff0c49c4ae2499ae5ee45d0a,monotherapy,0.514468
uuid-a697281bff0c49c4ae2499ae5ee45d0a,Median OS,0.696688
uuid-a697281bff0c49c4ae2499ae5ee45d0a,PD-L1,0.300997
uuid-a697281bff0c49c4ae2499ae5ee45d0a,docetaxel,0.635065
uuid-a697281bff0c49c4ae2499ae5ee45d0a,hazard ratio,0.729977
uuid-8204670e131347348c74f4d21a1fb397,Opdivo,0.355687
uuid-8204670e131347348c74f4d21a1fb397,Pubmed literature search,0.339298
uuid-8204670e131347348c74f4d21a1fb397,not identify any citations relevant to your inquiry,0.359341
uuid-8204670e131347348c74f4d21a1fb397,using the following search terms,0.3769
uuid-8204670e131347348c74f4d21a1fb397,safety,0.544513
uuid-8204670e131347348c74f4d21a1fb397,databases,0.49199
uuid-4d5d562eb141458d9f490aa57088c896,ASCO,0.732441
uuid-4d5d562eb141458d9f490aa57088c896,requested,0.308827
uuid-4d5d562eb141458d9f490aa57088c896,ASCO 2015,0.319854
uuid-4d5d562eb141458d9f490aa57088c896,Antonia SJ,0.425024
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,nivolumab,0.560085
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,Bristol-Myers Squibb,0.448204
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,evaluating,0.619061
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,not conducted any controlled clinical trials/studies,0.675179
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,Pubmed literature search,0.860443
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,purposes other than its labeled indication must be considered investigational,0.92844
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,not identify any citations relevant to your inquiry,0.818151
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,using the following search terms,0.804243
uuid-6dcf8dfa87f0486f905ef4f08b70ab68,efficacy and safety of nivolumab,0.458836
uuid-85d1942d11dd4f36af0cd5b7bb64939f,ipilimumab,0.385692
uuid-85d1942d11dd4f36af0cd5b7bb64939f,ASCO 2015,0.417944
uuid-85d1942d11dd4f36af0cd5b7bb64939f,partial response,0.382425
uuid-85d1942d11dd4f36af0cd5b7bb64939f,Stable disease,0.586335
uuid-85d1942d11dd4f36af0cd5b7bb64939f,cohort,0.307748
uuid-206599ace12142ad91af9cdaa36a68cd,requested,0.44769
uuid-206599ace12142ad91af9cdaa36a68cd,trial,0.309472
uuid-8835c82a969a4cee92d7496863c15c2c,N Engl J Med,0.689907
uuid-8835c82a969a4cee92d7496863c15c2c,Lancet Oncol,0.584216
uuid-8835c82a969a4cee92d7496863c15c2c,protocol,0.72528
uuid-8835c82a969a4cee92d7496863c15c2c,McDermott DF,0.794444
uuid-8835c82a969a4cee92d7496863c15c2c,Motzer RJ,0.755383
uuid-8835c82a969a4cee92d7496863c15c2c,phase 3 study,0.521307
uuid-8835c82a969a4cee92d7496863c15c2c,Escudier B,0.794743
uuid-8835c82a969a4cee92d7496863c15c2c,NEJM,0.434762
uuid-8835c82a969a4cee92d7496863c15c2c,et al.,0.777092
uuid-8835c82a969a4cee92d7496863c15c2c,J Clin Oncol,0.708338
uuid-8835c82a969a4cee92d7496863c15c2c,Topalian,0.401719
uuid-8835c82a969a4cee92d7496863c15c2c,Rizvi NA,0.731383
uuid-8835c82a969a4cee92d7496863c15c2c,Brahmer J,0.378658
uuid-8835c82a969a4cee92d7496863c15c2c,Weber JS,0.614831
uuid-8835c82a969a4cee92d7496863c15c2c,phase 2 study,0.769458
uuid-c9b50040d612434f940315dd40977dbe,OS,0.62262
uuid-c9b50040d612434f940315dd40977dbe,PFS,0.65903
uuid-c9b50040d612434f940315dd40977dbe,Overall survival,0.644151
uuid-4c61e7046d32447b92e20ee145cdb744,patients with advanced or metastatic,0.478326
uuid-4c61e7046d32447b92e20ee145cdb744,nivolumab combined with ipilimumab,0.498766
uuid-4c61e7046d32447b92e20ee145cdb744,not approved,0.34724
uuid-4c61e7046d32447b92e20ee145cdb744,clinical trials investigating the safety,0.426729
uuid-4c61e7046d32447b92e20ee145cdb744,bladder cancer,0.6548
uuid-4bb4bcf3ee244ec38172a214b2f881ab,not approved,0.389731
uuid-4bb4bcf3ee244ec38172a214b2f881ab,clinical trials investigating the safety,0.464336
uuid-4bb4bcf3ee244ec38172a214b2f881ab,fatigue,0.389752
uuid-3619f32a0b1d4f78a53101faf4a068e5,nivolumab,0.811201
uuid-1803a46241f84e928fa0e43231a9997f,patients with advanced or metastatic,0.468858
uuid-1803a46241f84e928fa0e43231a9997f,nivolumab combined with ipilimumab,0.446918
uuid-1803a46241f84e928fa0e43231a9997f,not approved,0.352562
uuid-1803a46241f84e928fa0e43231a9997f,clinical trials investigating the safety,0.429501
uuid-1803a46241f84e928fa0e43231a9997f,bladder cancer,0.950698
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,95% CI,0.524855
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,respectively,0.383655
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,ASCO,0.303153
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Lancet Oncol,0.368041
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Objective response rate,0.504846
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,ORR,0.465366
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Median overall survival,0.346516
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Median OS,0.33538
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,ASCO 2015,0.336983
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,small cell lung cancer,0.336892
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,SCLC,0.344367
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Antonia SJ,0.55269
uuid-f0ff0bdfbd4743fc9dde1a821f3a1d6e,Median duration of response,0.649605
uuid-1e24f6f0a34d45ce95c95227ac2642ed,Opdivo,0.516971
uuid-1e24f6f0a34d45ce95c95227ac2642ed,trial,0.312142
uuid-6afcd62a32014f2ebb1a143d1cb44631,nivolumab,0.589947
uuid-6afcd62a32014f2ebb1a143d1cb44631,Bristol-Myers Squibb,0.452109
uuid-6afcd62a32014f2ebb1a143d1cb44631,evaluating,0.612097
uuid-6afcd62a32014f2ebb1a143d1cb44631,not conducted any controlled clinical trials/studies,0.668004
uuid-6afcd62a32014f2ebb1a143d1cb44631,Pubmed literature search,0.786024
uuid-6afcd62a32014f2ebb1a143d1cb44631,purposes other than its labeled indication must be considered investigational,0.863143
uuid-6afcd62a32014f2ebb1a143d1cb44631,not identify any citations relevant to your inquiry,0.741347
uuid-6afcd62a32014f2ebb1a143d1cb44631,using the following search terms,0.726034
uuid-6afcd62a32014f2ebb1a143d1cb44631,efficacy and safety of nivolumab,0.451996
uuid-91e934d6ed70494f91b75fa07b9ba4eb,95% CI,0.524855
uuid-91e934d6ed70494f91b75fa07b9ba4eb,respectively,0.383655
uuid-91e934d6ed70494f91b75fa07b9ba4eb,ASCO,0.303153
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Lancet Oncol,0.368041
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Objective response rate,0.504846
uuid-91e934d6ed70494f91b75fa07b9ba4eb,ORR,0.465366
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Median overall survival,0.346516
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Median OS,0.33538
uuid-91e934d6ed70494f91b75fa07b9ba4eb,ASCO 2015,0.336983
uuid-91e934d6ed70494f91b75fa07b9ba4eb,small cell lung cancer,0.336892
uuid-91e934d6ed70494f91b75fa07b9ba4eb,SCLC,0.344367
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Antonia SJ,0.55269
uuid-91e934d6ed70494f91b75fa07b9ba4eb,Median duration of response,0.649605
uuid-640867ca0b394bb9a6318787ffb70456,ASCO,0.771943
uuid-640867ca0b394bb9a6318787ffb70456,Antonia SJ,0.300783
uuid-aee94ed45cd545589be719634b74e6a5,patients,0.324499
uuid-a866f99e5c7642c797e55b0ded237281,nivolumab,0.629259
uuid-a866f99e5c7642c797e55b0ded237281,Opdivo,0.767272
uuid-a866f99e5c7642c797e55b0ded237281,Pubmed literature search,0.444986
uuid-a866f99e5c7642c797e55b0ded237281,purposes other than its labeled indication must be considered investigational,0.398329
uuid-a866f99e5c7642c797e55b0ded237281,not identify any citations relevant to your inquiry,0.457811
uuid-a866f99e5c7642c797e55b0ded237281,using the following search terms,0.514101
uuid-a866f99e5c7642c797e55b0ded237281,trial,0.321018
uuid-707b2a78f72547c5b413f801fbdf71e3,not approved,0.389731
uuid-707b2a78f72547c5b413f801fbdf71e3,clinical trials investigating the safety,0.464336
uuid-707b2a78f72547c5b413f801fbdf71e3,fatigue,0.389752
uuid-a63f33fefab74c6581e0e99684386b7f,fatigue,0.413597
uuid-738b0cbb567a4079b5b436c4172e4de8,N Engl J Med,0.302601
uuid-738b0cbb567a4079b5b436c4172e4de8,AEs,0.348167
uuid-738b0cbb567a4079b5b436c4172e4de8,patients,0.536884
uuid-738b0cbb567a4079b5b436c4172e4de8,provided in the Detailed Information,0.387544
uuid-738b0cbb567a4079b5b436c4172e4de8,ESMO,0.462801
uuid-738b0cbb567a4079b5b436c4172e4de8,NEJM,0.66427
uuid-738b0cbb567a4079b5b436c4172e4de8,Topalian,0.692873
uuid-738b0cbb567a4079b5b436c4172e4de8,grade 3 to 4 AEs,0.626596
uuid-556f6f746a1e4b1c9fd7a4d58e7bee09,Opdivo,0.776648
uuid-556f6f746a1e4b1c9fd7a4d58e7bee09,trial,0.412112
uuid-2890651dd91d42a7a05ca8843fd82967,ipilimumab,0.385692
uuid-2890651dd91d42a7a05ca8843fd82967,ASCO 2015,0.417944
uuid-2890651dd91d42a7a05ca8843fd82967,partial response,0.382425
uuid-2890651dd91d42a7a05ca8843fd82967,Stable disease,0.586335
uuid-2890651dd91d42a7a05ca8843fd82967,cohort,0.307748
uuid-4f37dc783804417b89a8a3f9f34f4f4a,patients with advanced or metastatic,0.390591
uuid-4f37dc783804417b89a8a3f9f34f4f4a,Opdivo,0.44749
uuid-4f37dc783804417b89a8a3f9f34f4f4a,nivolumab combined with ipilimumab,0.424715
uuid-4f37dc783804417b89a8a3f9f34f4f4a,phase 1/2 study CA209-032,0.324023
uuid-4f37dc783804417b89a8a3f9f34f4f4a,evaluates the efficacy of nivolumab monotherapy,0.33824
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,Bristol-Myers Squibb,0.341822
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,not conducted any controlled clinical trials/studies,0.304507
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,Opdivo,0.461382
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,Pubmed literature search,0.614325
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,not identify any citations relevant to your inquiry,0.606087
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,adverse,0.304183
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,using the following search terms,0.642331
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,databases,0.315039
uuid-9d3b24c3ee4845d8ba11a5654ab0010e,reported,0.556704
uuid-5860f0ca901b403b9da900c766e700b2,provided in the Detailed Information,0.397276
uuid-5860f0ca901b403b9da900c766e700b2,adverse,0.418112
uuid-f6286ed587e44ae0ada3c38a5c3152fd,OS,0.44149
uuid-f6286ed587e44ae0ada3c38a5c3152fd,95% CI,0.833403
uuid-f6286ed587e44ae0ada3c38a5c3152fd,ASCO,0.32927
uuid-f6286ed587e44ae0ada3c38a5c3152fd,Objective response rate,0.545269
uuid-f6286ed587e44ae0ada3c38a5c3152fd,ORR,0.618524
uuid-f6286ed587e44ae0ada3c38a5c3152fd,PFS,0.396858
uuid-f6286ed587e44ae0ada3c38a5c3152fd,Median overall survival,0.72593
uuid-f6286ed587e44ae0ada3c38a5c3152fd,monotherapy,0.33356
uuid-f6286ed587e44ae0ada3c38a5c3152fd,Median OS,0.763854
uuid-f6286ed587e44ae0ada3c38a5c3152fd,hazard ratio,0.766648
uuid-f6286ed587e44ae0ada3c38a5c3152fd,Median duration of response,0.442682
uuid-d1458861205e4dd99f3afa79c8975201,N Engl J Med,0.435857
uuid-d1458861205e4dd99f3afa79c8975201,protocol,0.60357
uuid-d1458861205e4dd99f3afa79c8975201,McDermott DF,0.652085
uuid-d1458861205e4dd99f3afa79c8975201,Motzer RJ,0.655663
uuid-d1458861205e4dd99f3afa79c8975201,phase 3 study,0.362919
uuid-d1458861205e4dd99f3afa79c8975201,Escudier B,0.646829
uuid-d1458861205e4dd99f3afa79c8975201,NEJM,0.316465
uuid-d1458861205e4dd99f3afa79c8975201,et al.,0.608019
uuid-d1458861205e4dd99f3afa79c8975201,J Clin Oncol,0.644294
uuid-d1458861205e4dd99f3afa79c8975201,Topalian,0.301021
uuid-d1458861205e4dd99f3afa79c8975201,phase 2 study,0.567954
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,nivolumab,0.572755
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,Bristol-Myers Squibb,0.511891
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,evaluating,0.698601
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,not conducted any controlled clinical trials/studies,0.717794
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,Pubmed literature search,0.76487
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,purposes other than its labeled indication must be considered investigational,0.849464
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,not identify any citations relevant to your inquiry,0.71795
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,using the following search terms,0.703108
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,efficacy and safety of nivolumab,0.500246
uuid-f9599dcc3a2a47ac932d0ba0d6f4235f,safety of nivolumab monotherapy,0.303828
uuid-ffd828f6d5f84c61ba6c050de3f6794b,nivolumab,0.35703
uuid-ffd828f6d5f84c61ba6c050de3f6794b,Bristol-Myers Squibb,0.705841
uuid-ffd828f6d5f84c61ba6c050de3f6794b,evaluating,0.837931
uuid-ffd828f6d5f84c61ba6c050de3f6794b,not conducted any controlled clinical trials/studies,0.900498
uuid-ffd828f6d5f84c61ba6c050de3f6794b,Pubmed literature search,0.648082
uuid-ffd828f6d5f84c61ba6c050de3f6794b,purposes other than its labeled indication must be considered investigational,0.758555
uuid-ffd828f6d5f84c61ba6c050de3f6794b,not identify any citations relevant to your inquiry,0.584813
uuid-ffd828f6d5f84c61ba6c050de3f6794b,using the following search terms,0.564703
uuid-ffd828f6d5f84c61ba6c050de3f6794b,efficacy and safety of nivolumab,0.678064
uuid-ffd828f6d5f84c61ba6c050de3f6794b,safety of nivolumab monotherapy,0.309964
uuid-45aa83f156294c9c88b5df0d31437d9f,Opdivo,0.476741
uuid-45aa83f156294c9c88b5df0d31437d9f,trial,0.393134
uuid-45aa83f156294c9c88b5df0d31437d9f,docetaxel,0.437864
uuid-45aa83f156294c9c88b5df0d31437d9f,safety of nivolumab monotherapy,0.350737
uuid-45aa83f156294c9c88b5df0d31437d9f,phase,0.406186
uuid-e1998559da1741c49039a8f218bb4aac,nivolumab,0.510392
uuid-e1998559da1741c49039a8f218bb4aac,Bristol-Myers Squibb,0.464176
uuid-e1998559da1741c49039a8f218bb4aac,evaluating,0.683286
uuid-e1998559da1741c49039a8f218bb4aac,not conducted any controlled clinical trials/studies,0.682483
uuid-e1998559da1741c49039a8f218bb4aac,RCC,0.308694
uuid-e1998559da1741c49039a8f218bb4aac,search of published literature,0.839602
uuid-e1998559da1741c49039a8f218bb4aac,Additionally,0.446384
uuid-e1998559da1741c49039a8f218bb4aac,PubMed and EMBASE,0.823429
uuid-e1998559da1741c49039a8f218bb4aac,detailed search of www.clinicaltrials.gov,0.366719
uuid-e1998559da1741c49039a8f218bb4aac,efficacy and safety of nivolumab,0.841
uuid-e1998559da1741c49039a8f218bb4aac,not identify any citations relevant to your request,0.605656
uuid-e1998559da1741c49039a8f218bb4aac,present using the following search terms,0.832619
uuid-80a5f9bc6295486997e63656b7de4f87,mg,0.332702
uuid-bff1b792ba4549b5a6b9a92d95399680,N Engl J Med,0.302601
uuid-bff1b792ba4549b5a6b9a92d95399680,AEs,0.348167
uuid-bff1b792ba4549b5a6b9a92d95399680,patients,0.536884
uuid-bff1b792ba4549b5a6b9a92d95399680,provided in the Detailed Information,0.387544
uuid-bff1b792ba4549b5a6b9a92d95399680,ESMO,0.462801
uuid-bff1b792ba4549b5a6b9a92d95399680,NEJM,0.66427
uuid-bff1b792ba4549b5a6b9a92d95399680,Topalian,0.692873
uuid-bff1b792ba4549b5a6b9a92d95399680,grade 3 to 4 AEs,0.626596
uuid-6f478b0ac0024238aaa150adaf23d7ba,Bristol-Myers Squibb,0.309977
uuid-6f478b0ac0024238aaa150adaf23d7ba,ASCO,0.421881
uuid-6f478b0ac0024238aaa150adaf23d7ba,requested,0.312333
uuid-402f96beb2514f2887133abadd6d4078,nivolumab,0.419774
uuid-402f96beb2514f2887133abadd6d4078,Bristol-Myers Squibb,0.55223
uuid-402f96beb2514f2887133abadd6d4078,evaluating,0.75887
uuid-402f96beb2514f2887133abadd6d4078,not conducted any controlled clinical trials/studies,0.761929
uuid-402f96beb2514f2887133abadd6d4078,NSCLC,0.491324
uuid-402f96beb2514f2887133abadd6d4078,non-small cell lung cancer,0.527178
uuid-402f96beb2514f2887133abadd6d4078,patients,0.307923
uuid-402f96beb2514f2887133abadd6d4078,considered investigational,0.357973
uuid-402f96beb2514f2887133abadd6d4078,Pubmed literature search,0.489302
uuid-402f96beb2514f2887133abadd6d4078,purposes other than its labeled indication must be considered investigational,0.591927
uuid-402f96beb2514f2887133abadd6d4078,not identify any citations relevant to your inquiry,0.456993
uuid-402f96beb2514f2887133abadd6d4078,using the following search terms,0.421369
uuid-402f96beb2514f2887133abadd6d4078,efficacy and safety of nivolumab,0.657404
uuid-402f96beb2514f2887133abadd6d4078,safety of nivolumab monotherapy,0.348274
uuid-e44b655c46494e64a33affa18c696358,N Engl J Med,0.410025
uuid-e44b655c46494e64a33affa18c696358,protocol,0.663749
uuid-e44b655c46494e64a33affa18c696358,RCC,0.370429
uuid-e44b655c46494e64a33affa18c696358,McDermott DF,0.577168
uuid-e44b655c46494e64a33affa18c696358,search of published literature,0.443686
uuid-e44b655c46494e64a33affa18c696358,Additionally,0.395847
uuid-e44b655c46494e64a33affa18c696358,ongoing,0.335873
uuid-e44b655c46494e64a33affa18c696358,Motzer RJ,0.609458
uuid-e44b655c46494e64a33affa18c696358,phase 3 study,0.312748
uuid-e44b655c46494e64a33affa18c696358,PubMed and EMBASE,0.438896
uuid-e44b655c46494e64a33affa18c696358,Escudier B,0.595328
uuid-e44b655c46494e64a33affa18c696358,et al.,0.521538
uuid-e44b655c46494e64a33affa18c696358,J Clin Oncol,0.545137
uuid-e44b655c46494e64a33affa18c696358,detailed search of www.clinicaltrials.gov,0.358127
uuid-e44b655c46494e64a33affa18c696358,efficacy and safety of nivolumab,0.429052
uuid-e44b655c46494e64a33affa18c696358,not identify any planned,0.344155
uuid-e44b655c46494e64a33affa18c696358,phase 2 study,0.513121
uuid-e44b655c46494e64a33affa18c696358,not identify any citations relevant to your request,0.414617
uuid-e44b655c46494e64a33affa18c696358,present using the following search terms,0.417875
uuid-a1cbf1bab17d4389b0ba1c903553152c,NSCLC,0.723007
uuid-a1cbf1bab17d4389b0ba1c903553152c,non-small cell lung cancer,0.699887
uuid-a1cbf1bab17d4389b0ba1c903553152c,phase 3 study,0.541189
uuid-a1cbf1bab17d4389b0ba1c903553152c,phase 1 study,0.524481
uuid-a1cbf1bab17d4389b0ba1c903553152c,Rizvi NA,0.301077
uuid-a1cbf1bab17d4389b0ba1c903553152c,efficacy and safety of nivolumab,0.305546
uuid-a1cbf1bab17d4389b0ba1c903553152c,CA209-003,0.348772
uuid-a1cbf1bab17d4389b0ba1c903553152c,phase 2 study,0.341501
uuid-a1cbf1bab17d4389b0ba1c903553152c,safety of nivolumab monotherapy,0.329275
uuid-a1cbf1bab17d4389b0ba1c903553152c,platinum-based doublet chemotherapy,0.442532
uuid-ca36b939327e4827895f072080f61afa,95% CI,0.524855
uuid-ca36b939327e4827895f072080f61afa,respectively,0.383655
uuid-ca36b939327e4827895f072080f61afa,ASCO,0.303153
uuid-ca36b939327e4827895f072080f61afa,Lancet Oncol,0.368041
uuid-ca36b939327e4827895f072080f61afa,Objective response rate,0.504846
uuid-ca36b939327e4827895f072080f61afa,ORR,0.465366
uuid-ca36b939327e4827895f072080f61afa,Median overall survival,0.346516
uuid-ca36b939327e4827895f072080f61afa,Median OS,0.33538
uuid-ca36b939327e4827895f072080f61afa,ASCO 2015,0.336983
uuid-ca36b939327e4827895f072080f61afa,small cell lung cancer,0.336892
uuid-ca36b939327e4827895f072080f61afa,SCLC,0.344367
uuid-ca36b939327e4827895f072080f61afa,Antonia SJ,0.55269
uuid-ca36b939327e4827895f072080f61afa,Median duration of response,0.649605
uuid-b0413b9eae4c4071a9f652dd6ef2d323,N Engl J Med,0.373796
uuid-b0413b9eae4c4071a9f652dd6ef2d323,protocol,0.420361
uuid-b0413b9eae4c4071a9f652dd6ef2d323,McDermott DF,0.513284
uuid-b0413b9eae4c4071a9f652dd6ef2d323,Motzer RJ,0.482105
uuid-b0413b9eae4c4071a9f652dd6ef2d323,phase 3 study,0.448204
uuid-b0413b9eae4c4071a9f652dd6ef2d323,Escudier B,0.482741
uuid-b0413b9eae4c4071a9f652dd6ef2d323,NEJM,0.342527
uuid-b0413b9eae4c4071a9f652dd6ef2d323,et al.,0.466863
uuid-b0413b9eae4c4071a9f652dd6ef2d323,J Clin Oncol,0.523543
uuid-b0413b9eae4c4071a9f652dd6ef2d323,Topalian,0.340171
uuid-b0413b9eae4c4071a9f652dd6ef2d323,phase 1 study,0.421699
uuid-b0413b9eae4c4071a9f652dd6ef2d323,mg,0.324901
uuid-b0413b9eae4c4071a9f652dd6ef2d323,CA209-003,0.451562
uuid-b0413b9eae4c4071a9f652dd6ef2d323,phase 2 study,0.595096
uuid-b0413b9eae4c4071a9f652dd6ef2d323,grade,0.324161
uuid-b0413b9eae4c4071a9f652dd6ef2d323,kg,0.310462
uuid-fa32d7a6f20840f58b73ea1240f36829,N Engl J Med,0.306444
uuid-fa32d7a6f20840f58b73ea1240f36829,protocol,0.31755
uuid-fa32d7a6f20840f58b73ea1240f36829,McDermott DF,0.426545
uuid-fa32d7a6f20840f58b73ea1240f36829,Motzer RJ,0.389884
uuid-fa32d7a6f20840f58b73ea1240f36829,phase 3 study,0.427042
uuid-fa32d7a6f20840f58b73ea1240f36829,Escudier B,0.410046
uuid-fa32d7a6f20840f58b73ea1240f36829,et al.,0.390988
uuid-fa32d7a6f20840f58b73ea1240f36829,J Clin Oncol,0.382308
uuid-fa32d7a6f20840f58b73ea1240f36829,phase 2 study,0.47848
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,N Engl J Med,0.678191
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Lancet Oncol,0.348987
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,protocol,0.605922
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,McDermott DF,0.662997
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Motzer RJ,0.632892
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,phase 3 study,0.5029
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Escudier B,0.65831
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,NEJM,0.422484
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,et al.,0.636464
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,J Clin Oncol,0.594153
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Topalian,0.400934
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Rizvi NA,0.537096
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Brahmer J,0.422973
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,Weber JS,0.423733
uuid-3e7d5d28469e46bdbb1b4d3b20f8f9b9,phase 2 study,0.657052
uuid-68a97a3c087b49e3b8718ca15ae4c66b,95% CI,0.524855
uuid-68a97a3c087b49e3b8718ca15ae4c66b,respectively,0.383655
uuid-68a97a3c087b49e3b8718ca15ae4c66b,ASCO,0.303153
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Lancet Oncol,0.368041
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Objective response rate,0.504846
uuid-68a97a3c087b49e3b8718ca15ae4c66b,ORR,0.465366
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Median overall survival,0.346516
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Median OS,0.33538
uuid-68a97a3c087b49e3b8718ca15ae4c66b,ASCO 2015,0.336983
uuid-68a97a3c087b49e3b8718ca15ae4c66b,small cell lung cancer,0.336892
uuid-68a97a3c087b49e3b8718ca15ae4c66b,SCLC,0.344367
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Antonia SJ,0.55269
uuid-68a97a3c087b49e3b8718ca15ae4c66b,Median duration of response,0.649605
uuid-97aa1350eade419295f3b36737a3668d,Bristol-Myers Squibb,0.341822
uuid-97aa1350eade419295f3b36737a3668d,not conducted any controlled clinical trials/studies,0.304507
uuid-97aa1350eade419295f3b36737a3668d,Opdivo,0.461382
uuid-97aa1350eade419295f3b36737a3668d,Pubmed literature search,0.614325
uuid-97aa1350eade419295f3b36737a3668d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-97aa1350eade419295f3b36737a3668d,not identify any citations relevant to your inquiry,0.606087
uuid-97aa1350eade419295f3b36737a3668d,adverse,0.304183
uuid-97aa1350eade419295f3b36737a3668d,using the following search terms,0.642331
uuid-97aa1350eade419295f3b36737a3668d,databases,0.315039
uuid-97aa1350eade419295f3b36737a3668d,reported,0.556704
uuid-f67b146fc8ba466bb80826fca5850821,requested,0.553831
uuid-f67b146fc8ba466bb80826fca5850821,Horn L,0.582928
uuid-f67b146fc8ba466bb80826fca5850821,platinum-based doublet chemotherapy,0.625968
uuid-cc2f05a268b7497d9224740444a23bcb,not conducted any controlled clinical trials/studies,0.319418
uuid-cc2f05a268b7497d9224740444a23bcb,95% CI,0.424457
uuid-cc2f05a268b7497d9224740444a23bcb,respectively,0.418268
uuid-cc2f05a268b7497d9224740444a23bcb,Objective response rate,0.380299
uuid-cc2f05a268b7497d9224740444a23bcb,ORR,0.43776
uuid-cc2f05a268b7497d9224740444a23bcb,Pubmed literature search,0.378652
uuid-cc2f05a268b7497d9224740444a23bcb,Median overall survival,0.398385
uuid-cc2f05a268b7497d9224740444a23bcb,purposes other than its labeled indication must be considered investigational,0.420671
uuid-cc2f05a268b7497d9224740444a23bcb,not identify any citations relevant to your inquiry,0.345849
uuid-cc2f05a268b7497d9224740444a23bcb,Median OS,0.394817
uuid-cc2f05a268b7497d9224740444a23bcb,using the following search terms,0.336924
uuid-cc2f05a268b7497d9224740444a23bcb,hazard ratio,0.424821
uuid-8b98d122444b4020a8b6f5b08b826ce1,Bristol-Myers Squibb,0.341822
uuid-8b98d122444b4020a8b6f5b08b826ce1,not conducted any controlled clinical trials/studies,0.304507
uuid-8b98d122444b4020a8b6f5b08b826ce1,Opdivo,0.461382
uuid-8b98d122444b4020a8b6f5b08b826ce1,Pubmed literature search,0.614325
uuid-8b98d122444b4020a8b6f5b08b826ce1,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8b98d122444b4020a8b6f5b08b826ce1,not identify any citations relevant to your inquiry,0.606087
uuid-8b98d122444b4020a8b6f5b08b826ce1,adverse,0.304183
uuid-8b98d122444b4020a8b6f5b08b826ce1,using the following search terms,0.642331
uuid-8b98d122444b4020a8b6f5b08b826ce1,databases,0.315039
uuid-8b98d122444b4020a8b6f5b08b826ce1,reported,0.556704
uuid-624b1eef23554570b35972fa81485989,nivolumab,0.557964
uuid-624b1eef23554570b35972fa81485989,RCC,0.714062
uuid-d90d617ff8364d608a712009166cb808,Opdivo,0.480023
uuid-d90d617ff8364d608a712009166cb808,Pubmed literature search,0.54653
uuid-d90d617ff8364d608a712009166cb808,purposes other than its labeled indication must be considered investigational,0.508601
uuid-d90d617ff8364d608a712009166cb808,not identify any citations relevant to your inquiry,0.548999
uuid-d90d617ff8364d608a712009166cb808,adverse,0.383057
uuid-d90d617ff8364d608a712009166cb808,using the following search terms,0.581259
uuid-d90d617ff8364d608a712009166cb808,reported,0.565472
uuid-6a8cdce3dc624ca8a3949530b68e87c1,95% CI,0.524855
uuid-6a8cdce3dc624ca8a3949530b68e87c1,respectively,0.383655
uuid-6a8cdce3dc624ca8a3949530b68e87c1,ASCO,0.303153
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Lancet Oncol,0.368041
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Objective response rate,0.504846
uuid-6a8cdce3dc624ca8a3949530b68e87c1,ORR,0.465366
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Median overall survival,0.346516
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Median OS,0.33538
uuid-6a8cdce3dc624ca8a3949530b68e87c1,ASCO 2015,0.336983
uuid-6a8cdce3dc624ca8a3949530b68e87c1,small cell lung cancer,0.336892
uuid-6a8cdce3dc624ca8a3949530b68e87c1,SCLC,0.344367
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Antonia SJ,0.55269
uuid-6a8cdce3dc624ca8a3949530b68e87c1,Median duration of response,0.649605
uuid-847f2957433e490e83a535543f4e6202,patients,0.360078
uuid-847f2957433e490e83a535543f4e6202,adverse,0.758565
uuid-847f2957433e490e83a535543f4e6202,safety,0.353444
uuid-847f2957433e490e83a535543f4e6202,reported,0.470632
uuid-2a2da67c21d347f98ffab4956f04c342,nivolumab,0.617765
uuid-2a2da67c21d347f98ffab4956f04c342,Bristol-Myers Squibb,0.461424
uuid-2a2da67c21d347f98ffab4956f04c342,use of nivolumab for the treatment,0.373685
uuid-2a2da67c21d347f98ffab4956f04c342,evaluating,0.700407
uuid-2a2da67c21d347f98ffab4956f04c342,not conducted any controlled clinical trials/studies,0.670053
uuid-2a2da67c21d347f98ffab4956f04c342,efficacy,0.434395
uuid-2a2da67c21d347f98ffab4956f04c342,Pubmed literature search,0.556457
uuid-2a2da67c21d347f98ffab4956f04c342,purposes other than its labeled indication must be considered investigational,0.654059
uuid-2a2da67c21d347f98ffab4956f04c342,not identify any citations relevant to your inquiry,0.509303
uuid-2a2da67c21d347f98ffab4956f04c342,not approved,0.404054
uuid-2a2da67c21d347f98ffab4956f04c342,using the following search terms,0.494147
uuid-2a2da67c21d347f98ffab4956f04c342,clinical trials investigating the safety,0.372112
uuid-2a2da67c21d347f98ffab4956f04c342,efficacy and safety of nivolumab,0.528747
uuid-2a2da67c21d347f98ffab4956f04c342,safety of nivolumab monotherapy,0.403452
uuid-66a04f5dc8624a7ca335d427e752c611,N Engl J Med,0.481075
uuid-66a04f5dc8624a7ca335d427e752c611,provided in the Detailed Information,0.336673
uuid-66a04f5dc8624a7ca335d427e752c611,protocol,0.37644
uuid-66a04f5dc8624a7ca335d427e752c611,McDermott DF,0.440196
uuid-66a04f5dc8624a7ca335d427e752c611,Motzer RJ,0.416802
uuid-66a04f5dc8624a7ca335d427e752c611,clinical,0.32283
uuid-66a04f5dc8624a7ca335d427e752c611,phase 3 study,0.470403
uuid-66a04f5dc8624a7ca335d427e752c611,Escudier B,0.434669
uuid-66a04f5dc8624a7ca335d427e752c611,et al.,0.458922
uuid-66a04f5dc8624a7ca335d427e752c611,J Clin Oncol,0.394822
uuid-66a04f5dc8624a7ca335d427e752c611,phase 1 study,0.316763
uuid-66a04f5dc8624a7ca335d427e752c611,Rizvi NA,0.416939
uuid-66a04f5dc8624a7ca335d427e752c611,Brahmer J,0.343384
uuid-66a04f5dc8624a7ca335d427e752c611,phase 2 study,0.548995
uuid-0e0216bc49674b01901683478a544b57,Objective response rate,0.448204
uuid-0e0216bc49674b01901683478a544b57,clinicaltrials.gov,0.511687
uuid-86cf33cb340d4e7d8884a4ec25cf2777,95% CI,0.524855
uuid-86cf33cb340d4e7d8884a4ec25cf2777,respectively,0.383654
uuid-86cf33cb340d4e7d8884a4ec25cf2777,ASCO,0.303154
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Lancet Oncol,0.368042
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Objective response rate,0.504847
uuid-86cf33cb340d4e7d8884a4ec25cf2777,ORR,0.465366
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Median overall survival,0.346517
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Median OS,0.335381
uuid-86cf33cb340d4e7d8884a4ec25cf2777,ASCO 2015,0.336984
uuid-86cf33cb340d4e7d8884a4ec25cf2777,small cell lung cancer,0.336893
uuid-86cf33cb340d4e7d8884a4ec25cf2777,SCLC,0.344368
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Antonia SJ,0.552691
uuid-86cf33cb340d4e7d8884a4ec25cf2777,Median duration of response,0.649604
uuid-5e7b560e5cb74a41a9ab8d74059f7901,patients,0.30941
uuid-5e7b560e5cb74a41a9ab8d74059f7901,trial,0.389215
uuid-9a65da28568b43d482faf5f248d0f048,respectively,0.629961
uuid-9a65da28568b43d482faf5f248d0f048,Objective response rate,0.439951
uuid-9a65da28568b43d482faf5f248d0f048,ORR,0.462322
uuid-9a65da28568b43d482faf5f248d0f048,monotherapy,0.352421
uuid-9a65da28568b43d482faf5f248d0f048,docetaxel,0.410479
uuid-05fe265c92e14d8fb44a52a672694845,Bristol-Myers Squibb,0.341822
uuid-05fe265c92e14d8fb44a52a672694845,not conducted any controlled clinical trials/studies,0.304507
uuid-05fe265c92e14d8fb44a52a672694845,Opdivo,0.461382
uuid-05fe265c92e14d8fb44a52a672694845,Pubmed literature search,0.614325
uuid-05fe265c92e14d8fb44a52a672694845,purposes other than its labeled indication must be considered investigational,0.586645
uuid-05fe265c92e14d8fb44a52a672694845,not identify any citations relevant to your inquiry,0.606087
uuid-05fe265c92e14d8fb44a52a672694845,adverse,0.304183
uuid-05fe265c92e14d8fb44a52a672694845,using the following search terms,0.642331
uuid-05fe265c92e14d8fb44a52a672694845,databases,0.315039
uuid-05fe265c92e14d8fb44a52a672694845,reported,0.556704
uuid-6943dd4e27e442d0923ea665b1ab0937,requested,0.351911
uuid-6943dd4e27e442d0923ea665b1ab0937,adverse,0.592474
uuid-6943dd4e27e442d0923ea665b1ab0937,reported,0.357606
uuid-11a50cd1a40c46afaa24fc780e3a9b70,95% CI,0.524855
uuid-11a50cd1a40c46afaa24fc780e3a9b70,respectively,0.383654
uuid-11a50cd1a40c46afaa24fc780e3a9b70,ASCO,0.303154
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Lancet Oncol,0.368042
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Objective response rate,0.504847
uuid-11a50cd1a40c46afaa24fc780e3a9b70,ORR,0.465366
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Median overall survival,0.346517
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Median OS,0.335381
uuid-11a50cd1a40c46afaa24fc780e3a9b70,ASCO 2015,0.336984
uuid-11a50cd1a40c46afaa24fc780e3a9b70,small cell lung cancer,0.336893
uuid-11a50cd1a40c46afaa24fc780e3a9b70,SCLC,0.344368
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Antonia SJ,0.552691
uuid-11a50cd1a40c46afaa24fc780e3a9b70,Median duration of response,0.649604
uuid-0e44d5863134431095761d40591be016,patients with advanced or metastatic,0.478326
uuid-0e44d5863134431095761d40591be016,nivolumab combined with ipilimumab,0.498766
uuid-0e44d5863134431095761d40591be016,not approved,0.34724
uuid-0e44d5863134431095761d40591be016,clinical trials investigating the safety,0.426729
uuid-0e44d5863134431095761d40591be016,bladder cancer,0.6548
uuid-7ecc496280aa46adb39a3f276d83373a,respectively,0.589071
uuid-7ecc496280aa46adb39a3f276d83373a,Objective response rate,0.407286
uuid-7ecc496280aa46adb39a3f276d83373a,ORR,0.526086
uuid-7ecc496280aa46adb39a3f276d83373a,monotherapy,0.319413
uuid-7ecc496280aa46adb39a3f276d83373a,docetaxel,0.334344
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,Bristol-Myers Squibb,0.42861
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,evaluating,0.420827
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,not conducted any controlled clinical trials/studies,0.490137
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,Pubmed literature search,0.459025
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,purposes other than its labeled indication must be considered investigational,0.517533
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,not identify any citations relevant to your inquiry,0.436442
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,adverse,0.35205
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,using the following search terms,0.412315
uuid-3a6ebb4a3aaa4e5b91273bae31079a60,efficacy and safety of nivolumab,0.303611
uuid-c7bc79d1b4f4454392ee18dcb98f4852,nivolumab,0.317097
uuid-c7bc79d1b4f4454392ee18dcb98f4852,clinicaltrials.gov,0.50526
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,Bristol-Myers Squibb,0.341822
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,not conducted any controlled clinical trials/studies,0.304507
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,Opdivo,0.461382
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,Pubmed literature search,0.614325
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,purposes other than its labeled indication must be considered investigational,0.586645
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,not identify any citations relevant to your inquiry,0.606087
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,adverse,0.304183
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,using the following search terms,0.642331
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,databases,0.315039
uuid-08ebc4922a0241e6a590d3bbe8ba7a75,reported,0.556704
uuid-d3110a8a19024b30910a5e72b4009dfa,95% CI,0.524855
uuid-d3110a8a19024b30910a5e72b4009dfa,respectively,0.383655
uuid-d3110a8a19024b30910a5e72b4009dfa,ASCO,0.303153
uuid-d3110a8a19024b30910a5e72b4009dfa,Lancet Oncol,0.368041
uuid-d3110a8a19024b30910a5e72b4009dfa,Objective response rate,0.504846
uuid-d3110a8a19024b30910a5e72b4009dfa,ORR,0.465366
uuid-d3110a8a19024b30910a5e72b4009dfa,Median overall survival,0.346516
uuid-d3110a8a19024b30910a5e72b4009dfa,Median OS,0.33538
uuid-d3110a8a19024b30910a5e72b4009dfa,ASCO 2015,0.336983
uuid-d3110a8a19024b30910a5e72b4009dfa,small cell lung cancer,0.336892
uuid-d3110a8a19024b30910a5e72b4009dfa,SCLC,0.344367
uuid-d3110a8a19024b30910a5e72b4009dfa,Antonia SJ,0.55269
uuid-d3110a8a19024b30910a5e72b4009dfa,Median duration of response,0.649605
uuid-94c9fe7971b34f70ac035377266ece29,N Engl J Med,0.302601
uuid-94c9fe7971b34f70ac035377266ece29,AEs,0.348167
uuid-94c9fe7971b34f70ac035377266ece29,patients,0.536884
uuid-94c9fe7971b34f70ac035377266ece29,provided in the Detailed Information,0.387544
uuid-94c9fe7971b34f70ac035377266ece29,ESMO,0.462801
uuid-94c9fe7971b34f70ac035377266ece29,NEJM,0.66427
uuid-94c9fe7971b34f70ac035377266ece29,Topalian,0.692873
uuid-94c9fe7971b34f70ac035377266ece29,grade 3 to 4 AEs,0.626596
uuid-3b0b5c07d7f340daad6a35e0f75b8345,clinical,0.393512
uuid-0db7f99285ec49a0b6a838f34f000914,nivolumab,0.502183
uuid-0db7f99285ec49a0b6a838f34f000914,RCC,0.756598
uuid-26559a73eee3486f8db92555fccfaf8f,patients,0.327079
uuid-26559a73eee3486f8db92555fccfaf8f,requested,0.30011
uuid-26559a73eee3486f8db92555fccfaf8f,Opdivo,0.47623
uuid-26559a73eee3486f8db92555fccfaf8f,trial,0.466977
uuid-126d5144ced746a388e58eafbdd27ba2,nivolumab,0.61463
uuid-126d5144ced746a388e58eafbdd27ba2,Opdivo,0.755669
uuid-126d5144ced746a388e58eafbdd27ba2,Pubmed literature search,0.426349
uuid-126d5144ced746a388e58eafbdd27ba2,purposes other than its labeled indication must be considered investigational,0.381442
uuid-126d5144ced746a388e58eafbdd27ba2,not identify any citations relevant to your inquiry,0.440183
uuid-126d5144ced746a388e58eafbdd27ba2,using the following search terms,0.494049
uuid-126d5144ced746a388e58eafbdd27ba2,trial,0.318788
uuid-9b1a74104c4f43b495a8905afb453a9f,95% CI,0.524855
uuid-9b1a74104c4f43b495a8905afb453a9f,respectively,0.383655
uuid-9b1a74104c4f43b495a8905afb453a9f,ASCO,0.303153
uuid-9b1a74104c4f43b495a8905afb453a9f,Lancet Oncol,0.368041
uuid-9b1a74104c4f43b495a8905afb453a9f,Objective response rate,0.504846
uuid-9b1a74104c4f43b495a8905afb453a9f,ORR,0.465366
uuid-9b1a74104c4f43b495a8905afb453a9f,Median overall survival,0.346516
uuid-9b1a74104c4f43b495a8905afb453a9f,Median OS,0.33538
uuid-9b1a74104c4f43b495a8905afb453a9f,ASCO 2015,0.336983
uuid-9b1a74104c4f43b495a8905afb453a9f,small cell lung cancer,0.336892
uuid-9b1a74104c4f43b495a8905afb453a9f,SCLC,0.344367
uuid-9b1a74104c4f43b495a8905afb453a9f,Antonia SJ,0.55269
uuid-9b1a74104c4f43b495a8905afb453a9f,Median duration of response,0.649605
uuid-aee1d357489e40aa9fbfcab5e5169f81,Opdivo,0.560839
uuid-3c82251e43e14ae3bd94e8d6171e8553,patients,0.51915
uuid-3c82251e43e14ae3bd94e8d6171e8553,clinical,0.357285
uuid-3c82251e43e14ae3bd94e8d6171e8553,trial,0.360765
uuid-2b4b351396a24479b9240fef790c507e,considered investigational,0.395723
uuid-2b4b351396a24479b9240fef790c507e,patients with advanced or metastatic,0.462558
uuid-2b4b351396a24479b9240fef790c507e,nivolumab combined with ipilimumab,0.44353
uuid-2b4b351396a24479b9240fef790c507e,clinical,0.526005
uuid-2b4b351396a24479b9240fef790c507e,tumors,0.643126
uuid-2b4b351396a24479b9240fef790c507e,small cell lung cancer,0.461174
uuid-2b4b351396a24479b9240fef790c507e,trial,0.508172
uuid-2b4b351396a24479b9240fef790c507e,SCLC,0.417309
uuid-2b4b351396a24479b9240fef790c507e,phase 1/2 study CA209-032,0.517249
uuid-2b4b351396a24479b9240fef790c507e,evaluates the efficacy of nivolumab monotherapy,0.537932
uuid-8266a96930ab48a9a7f65056f2f5d2e4,patients,0.351212
uuid-8266a96930ab48a9a7f65056f2f5d2e4,clinical,0.471139
uuid-8266a96930ab48a9a7f65056f2f5d2e4,trial,0.430431
uuid-8266a96930ab48a9a7f65056f2f5d2e4,BMS,0.374214
uuid-1cfe888317ff4a9b82df290ee7404fd1,requested,0.342395
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,Bristol-Myers Squibb,0.341822
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,not conducted any controlled clinical trials/studies,0.304507
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,Opdivo,0.461382
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,Pubmed literature search,0.614325
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,not identify any citations relevant to your inquiry,0.606087
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,adverse,0.304183
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,using the following search terms,0.642331
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,databases,0.315039
uuid-e49ea24b5cc34d99ba6432b9b8f62c04,reported,0.556704
uuid-b785f9427bd14de6b86a8eb933ed14c4,N Engl J Med,0.643107
uuid-b785f9427bd14de6b86a8eb933ed14c4,respectively,0.398989
uuid-b785f9427bd14de6b86a8eb933ed14c4,Median overall survival,0.30615
uuid-b785f9427bd14de6b86a8eb933ed14c4,ESMO,0.534703
uuid-b785f9427bd14de6b86a8eb933ed14c4,Median OS,0.319939
uuid-b785f9427bd14de6b86a8eb933ed14c4,Brahmer J,0.658171
uuid-b785f9427bd14de6b86a8eb933ed14c4,Horn L,0.594193
uuid-3d59fefbac00409c8a8564c7835af6e8,patients,0.471556
uuid-1ad60ff3632945649ed58e1d3bd4a8be,N Engl J Med,0.302601
uuid-1ad60ff3632945649ed58e1d3bd4a8be,AEs,0.348167
uuid-1ad60ff3632945649ed58e1d3bd4a8be,patients,0.536884
uuid-1ad60ff3632945649ed58e1d3bd4a8be,provided in the Detailed Information,0.387544
uuid-1ad60ff3632945649ed58e1d3bd4a8be,ESMO,0.462801
uuid-1ad60ff3632945649ed58e1d3bd4a8be,NEJM,0.66427
uuid-1ad60ff3632945649ed58e1d3bd4a8be,Topalian,0.692873
uuid-1ad60ff3632945649ed58e1d3bd4a8be,grade 3 to 4 AEs,0.626596
uuid-567b6a9b84a14026b5349f8a8f8432f1,phase 1 study,0.552717
uuid-567b6a9b84a14026b5349f8a8f8432f1,CA209-003,0.677459
uuid-567b6a9b84a14026b5349f8a8f8432f1,investigating,0.912433
uuid-59a5e0b0e695495da68d04c13f7c8ef1,N Engl J Med,0.302601
uuid-59a5e0b0e695495da68d04c13f7c8ef1,AEs,0.348167
uuid-59a5e0b0e695495da68d04c13f7c8ef1,patients,0.536884
uuid-59a5e0b0e695495da68d04c13f7c8ef1,provided in the Detailed Information,0.387544
uuid-59a5e0b0e695495da68d04c13f7c8ef1,ESMO,0.462801
uuid-59a5e0b0e695495da68d04c13f7c8ef1,NEJM,0.66427
uuid-59a5e0b0e695495da68d04c13f7c8ef1,Topalian,0.692873
uuid-59a5e0b0e695495da68d04c13f7c8ef1,grade 3 to 4 AEs,0.626596
uuid-0c09678492264d65a04c1ce4b1ca0d3f,nivolumab,0.425049
uuid-0c09678492264d65a04c1ce4b1ca0d3f,mg,0.312132
uuid-1a79fe48c650461a8a83bb73f606def4,considered investigational,0.402849
uuid-1a79fe48c650461a8a83bb73f606def4,small cell lung cancer,0.651985
uuid-1a79fe48c650461a8a83bb73f606def4,partial response,0.50367
uuid-1a79fe48c650461a8a83bb73f606def4,SCLC,0.736863
uuid-1a79fe48c650461a8a83bb73f606def4,therapy,0.843488
uuid-1a79fe48c650461a8a83bb73f606def4,relapsed,0.613852
uuid-1a79fe48c650461a8a83bb73f606def4,phase 1/2 study CA209-032,0.40439
uuid-1a79fe48c650461a8a83bb73f606def4,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-ce6819dad8004b3f86ebc2e85f74073c,Rizvi NA,0.328583
uuid-ce6819dad8004b3f86ebc2e85f74073c,Brahmer J,0.482621
uuid-ce6819dad8004b3f86ebc2e85f74073c,BMS,0.884728
uuid-4f25037e54c84a3396077779a3e49460,nivolumab,0.335182
uuid-09318a4d0f1148ebb4659d4111d538a6,provided in the Detailed Information,0.351008
uuid-09318a4d0f1148ebb4659d4111d538a6,clinical,0.700096
uuid-09318a4d0f1148ebb4659d4111d538a6,trial,0.319595
uuid-9334f89a4246456a90635fad1d47b3b5,OS,0.44149
uuid-9334f89a4246456a90635fad1d47b3b5,95% CI,0.833403
uuid-9334f89a4246456a90635fad1d47b3b5,ASCO,0.32927
uuid-9334f89a4246456a90635fad1d47b3b5,Objective response rate,0.545269
uuid-9334f89a4246456a90635fad1d47b3b5,ORR,0.618524
uuid-9334f89a4246456a90635fad1d47b3b5,PFS,0.396858
uuid-9334f89a4246456a90635fad1d47b3b5,Median overall survival,0.72593
uuid-9334f89a4246456a90635fad1d47b3b5,monotherapy,0.33356
uuid-9334f89a4246456a90635fad1d47b3b5,Median OS,0.763854
uuid-9334f89a4246456a90635fad1d47b3b5,hazard ratio,0.766648
uuid-9334f89a4246456a90635fad1d47b3b5,Median duration of response,0.442682
uuid-26b8578112b94c6a898f4f33f2ca8e36,nivolumab,0.542241
uuid-26b8578112b94c6a898f4f33f2ca8e36,Bristol-Myers Squibb,0.324479
uuid-26b8578112b94c6a898f4f33f2ca8e36,evaluating,0.505616
uuid-26b8578112b94c6a898f4f33f2ca8e36,not conducted any controlled clinical trials/studies,0.518733
uuid-26b8578112b94c6a898f4f33f2ca8e36,Pubmed literature search,0.53547
uuid-26b8578112b94c6a898f4f33f2ca8e36,purposes other than its labeled indication must be considered investigational,0.605196
uuid-26b8578112b94c6a898f4f33f2ca8e36,not identify any citations relevant to your inquiry,0.510051
uuid-26b8578112b94c6a898f4f33f2ca8e36,using the following search terms,0.490186
uuid-26b8578112b94c6a898f4f33f2ca8e36,efficacy and safety of nivolumab,0.423577
uuid-8cd358a323d54b479a1c9e4528863c7c,95% CI,0.524855
uuid-8cd358a323d54b479a1c9e4528863c7c,respectively,0.383655
uuid-8cd358a323d54b479a1c9e4528863c7c,ASCO,0.303153
uuid-8cd358a323d54b479a1c9e4528863c7c,Lancet Oncol,0.368041
uuid-8cd358a323d54b479a1c9e4528863c7c,Objective response rate,0.504846
uuid-8cd358a323d54b479a1c9e4528863c7c,ORR,0.465366
uuid-8cd358a323d54b479a1c9e4528863c7c,Median overall survival,0.346516
uuid-8cd358a323d54b479a1c9e4528863c7c,Median OS,0.33538
uuid-8cd358a323d54b479a1c9e4528863c7c,ASCO 2015,0.336983
uuid-8cd358a323d54b479a1c9e4528863c7c,small cell lung cancer,0.336892
uuid-8cd358a323d54b479a1c9e4528863c7c,SCLC,0.344367
uuid-8cd358a323d54b479a1c9e4528863c7c,Antonia SJ,0.55269
uuid-8cd358a323d54b479a1c9e4528863c7c,Median duration of response,0.649605
uuid-aa3e579c64174ff09b0457622dd3986d,OS,0.44149
uuid-aa3e579c64174ff09b0457622dd3986d,95% CI,0.833403
uuid-aa3e579c64174ff09b0457622dd3986d,ASCO,0.32927
uuid-aa3e579c64174ff09b0457622dd3986d,Objective response rate,0.545269
uuid-aa3e579c64174ff09b0457622dd3986d,ORR,0.618524
uuid-aa3e579c64174ff09b0457622dd3986d,PFS,0.396858
uuid-aa3e579c64174ff09b0457622dd3986d,Median overall survival,0.72593
uuid-aa3e579c64174ff09b0457622dd3986d,monotherapy,0.33356
uuid-aa3e579c64174ff09b0457622dd3986d,Median OS,0.763854
uuid-aa3e579c64174ff09b0457622dd3986d,hazard ratio,0.766648
uuid-aa3e579c64174ff09b0457622dd3986d,Median duration of response,0.442682
uuid-f17e07be4e27412cb09211d6ada308b4,provided in the Detailed Information,0.349112
uuid-f17e07be4e27412cb09211d6ada308b4,Weber JS,0.321343
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,nivolumab,0.562297
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,Bristol-Myers Squibb,0.468679
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,evaluating,0.649656
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,not conducted any controlled clinical trials/studies,0.697075
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,Pubmed literature search,0.843759
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,purposes other than its labeled indication must be considered investigational,0.915472
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,not identify any citations relevant to your inquiry,0.80108
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,using the following search terms,0.785928
uuid-e7ce0ccf963a4f2ebea773ee77542a9c,efficacy and safety of nivolumab,0.479606
uuid-6c38f4dea6d54a0e94f6dc7777ffccb5,NSCLC,0.351198
uuid-6c38f4dea6d54a0e94f6dc7777ffccb5,efficacy and safety of nivolumab,0.343313
uuid-05b5b2587145457a8b940726fcc47f5f,Bristol-Myers Squibb,0.330754
uuid-05b5b2587145457a8b940726fcc47f5f,NSCLC,0.330283
uuid-05b5b2587145457a8b940726fcc47f5f,non-small cell lung cancer,0.324946
uuid-05b5b2587145457a8b940726fcc47f5f,patients,0.406858
uuid-05b5b2587145457a8b940726fcc47f5f,provided in the Detailed Information,0.4446
uuid-05b5b2587145457a8b940726fcc47f5f,clinical,0.46747
uuid-05b5b2587145457a8b940726fcc47f5f,grade,0.407878
uuid-05b5b2587145457a8b940726fcc47f5f,grade 3 to 4 AEs,0.335272
uuid-e8210b855cb64007973431d129056b14,evaluating,0.311334
uuid-e8210b855cb64007973431d129056b14,not conducted any controlled clinical trials/studies,0.328007
uuid-e8210b855cb64007973431d129056b14,purposes other than its labeled indication must be considered investigational,0.332027
uuid-f9d15e079906470099388f4173747297,N Engl J Med,0.689907
uuid-f9d15e079906470099388f4173747297,Lancet Oncol,0.584216
uuid-f9d15e079906470099388f4173747297,protocol,0.72528
uuid-f9d15e079906470099388f4173747297,McDermott DF,0.794444
uuid-f9d15e079906470099388f4173747297,Motzer RJ,0.755383
uuid-f9d15e079906470099388f4173747297,phase 3 study,0.521307
uuid-f9d15e079906470099388f4173747297,Escudier B,0.794743
uuid-f9d15e079906470099388f4173747297,NEJM,0.434762
uuid-f9d15e079906470099388f4173747297,et al.,0.777092
uuid-f9d15e079906470099388f4173747297,J Clin Oncol,0.708338
uuid-f9d15e079906470099388f4173747297,Topalian,0.401719
uuid-f9d15e079906470099388f4173747297,Rizvi NA,0.731383
uuid-f9d15e079906470099388f4173747297,Brahmer J,0.378658
uuid-f9d15e079906470099388f4173747297,Weber JS,0.614831
uuid-f9d15e079906470099388f4173747297,phase 2 study,0.769458
uuid-22edbe5e89364676b67f2c0a0d165238,nivolumab,0.999168
uuid-22edbe5e89364676b67f2c0a0d165238,Pubmed literature search,0.395314
uuid-22edbe5e89364676b67f2c0a0d165238,purposes other than its labeled indication must be considered investigational,0.464236
uuid-22edbe5e89364676b67f2c0a0d165238,not identify any citations relevant to your inquiry,0.368569
uuid-22edbe5e89364676b67f2c0a0d165238,using the following search terms,0.364279
uuid-22edbe5e89364676b67f2c0a0d165238,present using the following search terms,0.329876
uuid-f57100838d514889ae0f49f1a94df5b3,95% CI,0.524855
uuid-f57100838d514889ae0f49f1a94df5b3,respectively,0.383655
uuid-f57100838d514889ae0f49f1a94df5b3,ASCO,0.303153
uuid-f57100838d514889ae0f49f1a94df5b3,Lancet Oncol,0.368041
uuid-f57100838d514889ae0f49f1a94df5b3,Objective response rate,0.504846
uuid-f57100838d514889ae0f49f1a94df5b3,ORR,0.465366
uuid-f57100838d514889ae0f49f1a94df5b3,Median overall survival,0.346516
uuid-f57100838d514889ae0f49f1a94df5b3,Median OS,0.33538
uuid-f57100838d514889ae0f49f1a94df5b3,ASCO 2015,0.336983
uuid-f57100838d514889ae0f49f1a94df5b3,small cell lung cancer,0.336892
uuid-f57100838d514889ae0f49f1a94df5b3,SCLC,0.344367
uuid-f57100838d514889ae0f49f1a94df5b3,Antonia SJ,0.55269
uuid-f57100838d514889ae0f49f1a94df5b3,Median duration of response,0.649605
uuid-6757d882e4f543348c104f0645daa04d,95% CI,0.524855
uuid-6757d882e4f543348c104f0645daa04d,respectively,0.383655
uuid-6757d882e4f543348c104f0645daa04d,ASCO,0.303153
uuid-6757d882e4f543348c104f0645daa04d,Lancet Oncol,0.368041
uuid-6757d882e4f543348c104f0645daa04d,Objective response rate,0.504846
uuid-6757d882e4f543348c104f0645daa04d,ORR,0.465366
uuid-6757d882e4f543348c104f0645daa04d,Median overall survival,0.346516
uuid-6757d882e4f543348c104f0645daa04d,Median OS,0.33538
uuid-6757d882e4f543348c104f0645daa04d,ASCO 2015,0.336983
uuid-6757d882e4f543348c104f0645daa04d,small cell lung cancer,0.336892
uuid-6757d882e4f543348c104f0645daa04d,SCLC,0.344367
uuid-6757d882e4f543348c104f0645daa04d,Antonia SJ,0.55269
uuid-6757d882e4f543348c104f0645daa04d,Median duration of response,0.649605
uuid-ca709a73c2ec47e7acac94bdf4738bc5,N Engl J Med,0.673548
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Lancet Oncol,0.350563
uuid-ca709a73c2ec47e7acac94bdf4738bc5,protocol,0.837793
uuid-ca709a73c2ec47e7acac94bdf4738bc5,McDermott DF,0.912384
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Motzer RJ,0.895454
uuid-ca709a73c2ec47e7acac94bdf4738bc5,phase 3 study,0.484739
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Escudier B,0.908217
uuid-ca709a73c2ec47e7acac94bdf4738bc5,NEJM,0.491067
uuid-ca709a73c2ec47e7acac94bdf4738bc5,et al.,0.901246
uuid-ca709a73c2ec47e7acac94bdf4738bc5,J Clin Oncol,0.862956
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Topalian,0.429989
uuid-ca709a73c2ec47e7acac94bdf4738bc5,phase 1 study,0.302978
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Rizvi NA,0.485777
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Brahmer J,0.342618
uuid-ca709a73c2ec47e7acac94bdf4738bc5,Weber JS,0.307765
uuid-ca709a73c2ec47e7acac94bdf4738bc5,phase 2 study,0.81115
uuid-f38e321eaa0b4ef786a5521357ac3303,requested,0.594234
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,NSCLC,0.813378
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,non-small cell lung cancer,0.828363
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,phase 3 study,0.413491
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,phase 1 study,0.472278
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,PD-L1,0.432576
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,CA209-003,0.36282
uuid-eff1a49ebc8a4dd1b55d18cdd1b8c345,platinum-based doublet chemotherapy,0.400318
uuid-9e7a03419cab497d8048d7f1c99335ef,OS,0.62262
uuid-9e7a03419cab497d8048d7f1c99335ef,PFS,0.65903
uuid-9e7a03419cab497d8048d7f1c99335ef,Overall survival,0.644151
uuid-a6e59ecf004f4ce3ae553341fff3073b,ASCO,0.6445
uuid-a6e59ecf004f4ce3ae553341fff3073b,Lancet Oncol,0.32865
uuid-a6e59ecf004f4ce3ae553341fff3073b,Antonia SJ,0.322704
uuid-40755b17555a4792b4f05672ea9f0d9c,N Engl J Med,0.707725
uuid-40755b17555a4792b4f05672ea9f0d9c,Lancet Oncol,0.347956
uuid-40755b17555a4792b4f05672ea9f0d9c,protocol,0.812355
uuid-40755b17555a4792b4f05672ea9f0d9c,McDermott DF,0.836415
uuid-40755b17555a4792b4f05672ea9f0d9c,Motzer RJ,0.847157
uuid-40755b17555a4792b4f05672ea9f0d9c,phase 3 study,0.575473
uuid-40755b17555a4792b4f05672ea9f0d9c,Escudier B,0.841503
uuid-40755b17555a4792b4f05672ea9f0d9c,NEJM,0.443965
uuid-40755b17555a4792b4f05672ea9f0d9c,et al.,0.78974
uuid-40755b17555a4792b4f05672ea9f0d9c,J Clin Oncol,0.797251
uuid-40755b17555a4792b4f05672ea9f0d9c,Topalian,0.418109
uuid-40755b17555a4792b4f05672ea9f0d9c,phase 1 study,0.422752
uuid-40755b17555a4792b4f05672ea9f0d9c,Rizvi NA,0.534567
uuid-40755b17555a4792b4f05672ea9f0d9c,Brahmer J,0.403976
uuid-40755b17555a4792b4f05672ea9f0d9c,CA209-003,0.399546
uuid-40755b17555a4792b4f05672ea9f0d9c,Weber JS,0.374794
uuid-40755b17555a4792b4f05672ea9f0d9c,phase 2 study,0.830089
uuid-40755b17555a4792b4f05672ea9f0d9c,investigating,0.320009
uuid-d4478f7722a243c1b57551470a274c3b,Bristol-Myers Squibb,0.341822
uuid-d4478f7722a243c1b57551470a274c3b,not conducted any controlled clinical trials/studies,0.304507
uuid-d4478f7722a243c1b57551470a274c3b,Opdivo,0.461382
uuid-d4478f7722a243c1b57551470a274c3b,Pubmed literature search,0.614325
uuid-d4478f7722a243c1b57551470a274c3b,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d4478f7722a243c1b57551470a274c3b,not identify any citations relevant to your inquiry,0.606087
uuid-d4478f7722a243c1b57551470a274c3b,adverse,0.304183
uuid-d4478f7722a243c1b57551470a274c3b,using the following search terms,0.642331
uuid-d4478f7722a243c1b57551470a274c3b,databases,0.315039
uuid-d4478f7722a243c1b57551470a274c3b,reported,0.556704
uuid-9596d676fd94487a91d87111ca53cec7,nivolumab,0.394858
uuid-9596d676fd94487a91d87111ca53cec7,Objective response rate,0.398986
uuid-9596d676fd94487a91d87111ca53cec7,clinicaltrials.gov,0.505534
uuid-c56858648db141798e5d09dfeab9d2c5,nivolumab,0.61876
uuid-c56858648db141798e5d09dfeab9d2c5,Bristol-Myers Squibb,0.399492
uuid-c56858648db141798e5d09dfeab9d2c5,evaluating,0.606701
uuid-c56858648db141798e5d09dfeab9d2c5,not conducted any controlled clinical trials/studies,0.625715
uuid-c56858648db141798e5d09dfeab9d2c5,Pubmed literature search,0.682783
uuid-c56858648db141798e5d09dfeab9d2c5,purposes other than its labeled indication must be considered investigational,0.754315
uuid-c56858648db141798e5d09dfeab9d2c5,not identify any citations relevant to your inquiry,0.66113
uuid-c56858648db141798e5d09dfeab9d2c5,Additionally,0.308954
uuid-c56858648db141798e5d09dfeab9d2c5,ongoing,0.321091
uuid-c56858648db141798e5d09dfeab9d2c5,using the following search terms,0.633005
uuid-c56858648db141798e5d09dfeab9d2c5,detailed search of www.clinicaltrials.gov,0.323357
uuid-c56858648db141798e5d09dfeab9d2c5,efficacy and safety of nivolumab,0.494853
uuid-c56858648db141798e5d09dfeab9d2c5,not identify any planned,0.318519
uuid-c56858648db141798e5d09dfeab9d2c5,not identify any citations relevant to your request,0.335287
uuid-3905caa0b66e466e8cadd029a1d1bc9b,ASCO,0.501285
uuid-3905caa0b66e466e8cadd029a1d1bc9b,requested,0.359612
uuid-89a07fed0d0b4598a06cc539518d2d53,Bristol-Myers Squibb,0.353539
uuid-89a07fed0d0b4598a06cc539518d2d53,Opdivo,0.470382
uuid-89a07fed0d0b4598a06cc539518d2d53,Pubmed literature search,0.57887
uuid-89a07fed0d0b4598a06cc539518d2d53,purposes other than its labeled indication must be considered investigational,0.550584
uuid-89a07fed0d0b4598a06cc539518d2d53,not identify any citations relevant to your inquiry,0.571676
uuid-89a07fed0d0b4598a06cc539518d2d53,adverse,0.342534
uuid-89a07fed0d0b4598a06cc539518d2d53,using the following search terms,0.609697
uuid-89a07fed0d0b4598a06cc539518d2d53,reported,0.605973
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,Bristol-Myers Squibb,0.336874
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,Opdivo,0.471051
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,Pubmed literature search,0.605058
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,purposes other than its labeled indication must be considered investigational,0.575084
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,not identify any citations relevant to your inquiry,0.599898
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,adverse,0.341202
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,using the following search terms,0.634615
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,databases,0.310948
uuid-7fd9c8f62cc14c34a40e7b0d2ed1cb3d,reported,0.565362
uuid-67c91d413d20430798bce381c9d0220d,trial,0.422532
uuid-63e4f7320b6245998d4c445a0a4daa15,ASCO,0.732554
uuid-c6525162fa574c1691c415b9d37b7655,melanoma,0.410364
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,N Engl J Med,0.448483
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,protocol,0.770446
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,McDermott DF,0.741196
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,Motzer RJ,0.818144
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,phase 3 study,0.417055
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,Escudier B,0.749917
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,NEJM,0.400698
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,et al.,0.668641
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,J Clin Oncol,0.792018
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,Topalian,0.388894
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,phase 1 study,0.500686
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,CA209-003,0.567381
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,phase 2 study,0.677985
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,present using the following search terms,0.310558
uuid-7fbfd1647ad24855ad7aa66fe71a5bea,investigating,0.615835
uuid-3303125e69944d8393a0514639297542,respectively,0.629961
uuid-3303125e69944d8393a0514639297542,Objective response rate,0.439951
uuid-3303125e69944d8393a0514639297542,ORR,0.462322
uuid-3303125e69944d8393a0514639297542,monotherapy,0.352421
uuid-3303125e69944d8393a0514639297542,docetaxel,0.410479
uuid-a588d143e698417c9364ab0934305e39,OS,0.62262
uuid-a588d143e698417c9364ab0934305e39,PFS,0.65903
uuid-a588d143e698417c9364ab0934305e39,Overall survival,0.644151
uuid-14f38e39661743349868666747dd8126,grade,0.39737
uuid-fdbc18b08533469d923ab0f23faff684,95% CI,0.524855
uuid-fdbc18b08533469d923ab0f23faff684,respectively,0.383655
uuid-fdbc18b08533469d923ab0f23faff684,ASCO,0.303153
uuid-fdbc18b08533469d923ab0f23faff684,Lancet Oncol,0.368041
uuid-fdbc18b08533469d923ab0f23faff684,Objective response rate,0.504846
uuid-fdbc18b08533469d923ab0f23faff684,ORR,0.465366
uuid-fdbc18b08533469d923ab0f23faff684,Median overall survival,0.346516
uuid-fdbc18b08533469d923ab0f23faff684,Median OS,0.33538
uuid-fdbc18b08533469d923ab0f23faff684,ASCO 2015,0.336983
uuid-fdbc18b08533469d923ab0f23faff684,small cell lung cancer,0.336892
uuid-fdbc18b08533469d923ab0f23faff684,SCLC,0.344367
uuid-fdbc18b08533469d923ab0f23faff684,Antonia SJ,0.55269
uuid-fdbc18b08533469d923ab0f23faff684,Median duration of response,0.649605
uuid-dfb9688217794532bca46b4d10cdf18e,95% CI,0.524855
uuid-dfb9688217794532bca46b4d10cdf18e,respectively,0.383655
uuid-dfb9688217794532bca46b4d10cdf18e,ASCO,0.303153
uuid-dfb9688217794532bca46b4d10cdf18e,Lancet Oncol,0.368041
uuid-dfb9688217794532bca46b4d10cdf18e,Objective response rate,0.504846
uuid-dfb9688217794532bca46b4d10cdf18e,ORR,0.465366
uuid-dfb9688217794532bca46b4d10cdf18e,Median overall survival,0.346516
uuid-dfb9688217794532bca46b4d10cdf18e,Median OS,0.33538
uuid-dfb9688217794532bca46b4d10cdf18e,ASCO 2015,0.336983
uuid-dfb9688217794532bca46b4d10cdf18e,small cell lung cancer,0.336892
uuid-dfb9688217794532bca46b4d10cdf18e,SCLC,0.344367
uuid-dfb9688217794532bca46b4d10cdf18e,Antonia SJ,0.55269
uuid-dfb9688217794532bca46b4d10cdf18e,Median duration of response,0.649605
uuid-807b5c118afa436bb2fc43bfa29f739a,nivolumab,0.441761
uuid-807b5c118afa436bb2fc43bfa29f739a,Bristol-Myers Squibb,0.578794
uuid-807b5c118afa436bb2fc43bfa29f739a,evaluating,0.676334
uuid-807b5c118afa436bb2fc43bfa29f739a,not conducted any controlled clinical trials/studies,0.740635
uuid-807b5c118afa436bb2fc43bfa29f739a,Pubmed literature search,0.702441
uuid-807b5c118afa436bb2fc43bfa29f739a,purposes other than its labeled indication must be considered investigational,0.790505
uuid-807b5c118afa436bb2fc43bfa29f739a,not identify any citations relevant to your inquiry,0.662194
uuid-807b5c118afa436bb2fc43bfa29f739a,using the following search terms,0.638212
uuid-807b5c118afa436bb2fc43bfa29f739a,efficacy and safety of nivolumab,0.513865
uuid-5686306a239e4fcb96a3c4db1596169e,evaluating,0.439461
uuid-5686306a239e4fcb96a3c4db1596169e,not conducted any controlled clinical trials/studies,0.431506
uuid-5686306a239e4fcb96a3c4db1596169e,search of published literature,0.657775
uuid-5686306a239e4fcb96a3c4db1596169e,Additionally,0.629271
uuid-5686306a239e4fcb96a3c4db1596169e,ongoing,0.490203
uuid-5686306a239e4fcb96a3c4db1596169e,PubMed and EMBASE,0.654377
uuid-5686306a239e4fcb96a3c4db1596169e,detailed search of www.clinicaltrials.gov,0.581655
uuid-5686306a239e4fcb96a3c4db1596169e,efficacy and safety of nivolumab,0.604991
uuid-5686306a239e4fcb96a3c4db1596169e,not identify any planned,0.523312
uuid-5686306a239e4fcb96a3c4db1596169e,not identify any citations relevant to your request,0.702799
uuid-5686306a239e4fcb96a3c4db1596169e,present using the following search terms,0.670227
uuid-1966f7ea098549099fbb9d5fc38a1daf,nivolumab,0.509903
uuid-1966f7ea098549099fbb9d5fc38a1daf,Bristol-Myers Squibb,0.312873
uuid-1966f7ea098549099fbb9d5fc38a1daf,evaluating,0.486981
uuid-1966f7ea098549099fbb9d5fc38a1daf,not conducted any controlled clinical trials/studies,0.443074
uuid-1966f7ea098549099fbb9d5fc38a1daf,RCC,0.307224
uuid-1966f7ea098549099fbb9d5fc38a1daf,search of published literature,0.735642
uuid-1966f7ea098549099fbb9d5fc38a1daf,Additionally,0.304048
uuid-1966f7ea098549099fbb9d5fc38a1daf,PubMed and EMBASE,0.728066
uuid-1966f7ea098549099fbb9d5fc38a1daf,trial,0.401423
uuid-1966f7ea098549099fbb9d5fc38a1daf,efficacy and safety of nivolumab,0.622125
uuid-1966f7ea098549099fbb9d5fc38a1daf,not identify any citations relevant to your request,0.456042
uuid-1966f7ea098549099fbb9d5fc38a1daf,present using the following search terms,0.724413
uuid-e42cd941c12a438796786be4e15ab0bb,patients,0.324499
uuid-1a6221d8b1584cefa12290479a04b8d0,use of nivolumab for the treatment,0.444892
uuid-1a6221d8b1584cefa12290479a04b8d0,evaluating,0.30558
uuid-1a6221d8b1584cefa12290479a04b8d0,patients,0.440855
uuid-1a6221d8b1584cefa12290479a04b8d0,not approved,0.378002
uuid-1a6221d8b1584cefa12290479a04b8d0,clinical trials investigating the safety,0.352423
uuid-369c39cc7376425691ad5968e25993e8,N Engl J Med,0.604857
uuid-369c39cc7376425691ad5968e25993e8,non-small cell lung cancer,0.34354
uuid-369c39cc7376425691ad5968e25993e8,ESMO,0.393944
uuid-369c39cc7376425691ad5968e25993e8,Rizvi NA,0.452745
uuid-369c39cc7376425691ad5968e25993e8,Brahmer J,0.679154
uuid-369c39cc7376425691ad5968e25993e8,PD-L1,0.347566
uuid-369c39cc7376425691ad5968e25993e8,Horn L,0.50259
uuid-369c39cc7376425691ad5968e25993e8,platinum-based doublet chemotherapy,0.304136
uuid-6b688b78c73249f39d0e9f432bf9fbab,use of nivolumab for the treatment,0.440423
uuid-6b688b78c73249f39d0e9f432bf9fbab,search of published literature,0.311531
uuid-6b688b78c73249f39d0e9f432bf9fbab,PubMed and EMBASE,0.312811
uuid-6b688b78c73249f39d0e9f432bf9fbab,not approved,0.404782
uuid-6b688b78c73249f39d0e9f432bf9fbab,open-label,0.578291
uuid-6b688b78c73249f39d0e9f432bf9fbab,clinical trials investigating the safety,0.440014
uuid-6b688b78c73249f39d0e9f432bf9fbab,present using the following search terms,0.328669
uuid-6b688b78c73249f39d0e9f432bf9fbab,phase,0.41185
uuid-d4ceed365af64fc6b7e0de27874ad78e,nivolumab,0.441653
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,use of nivolumab for the treatment,0.321709
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,efficacy,0.367178
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,Opdivo,0.62311
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,clinical,0.414123
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,not approved,0.416088
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,clinical trials investigating the safety,0.426879
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,trial,0.438483
uuid-bf693fd9ee1549e6a0ef3ea8c5d4cda5,safety of nivolumab monotherapy,0.308564
uuid-f14d23bf4c41497fab260e535bb72d1b,use of nivolumab for the treatment,0.515546
uuid-f14d23bf4c41497fab260e535bb72d1b,evaluating,0.364847
uuid-f14d23bf4c41497fab260e535bb72d1b,efficacy,0.5682
uuid-f14d23bf4c41497fab260e535bb72d1b,patients,0.495366
uuid-f14d23bf4c41497fab260e535bb72d1b,not approved,0.542882
uuid-f14d23bf4c41497fab260e535bb72d1b,clinical trials investigating the safety,0.471685
uuid-f14d23bf4c41497fab260e535bb72d1b,docetaxel,0.5993
uuid-f14d23bf4c41497fab260e535bb72d1b,safety of nivolumab monotherapy,0.666305
uuid-b187f6c491854255abd9f1839021ccde,ipilimumab,0.385692
uuid-b187f6c491854255abd9f1839021ccde,ASCO 2015,0.417944
uuid-b187f6c491854255abd9f1839021ccde,partial response,0.382425
uuid-b187f6c491854255abd9f1839021ccde,Stable disease,0.586335
uuid-b187f6c491854255abd9f1839021ccde,cohort,0.307748
uuid-f4b24511d82d4765ac2e93b9acc61b7d,Bristol-Myers Squibb,0.419113
uuid-f4b24511d82d4765ac2e93b9acc61b7d,use of nivolumab for the treatment,0.424971
uuid-f4b24511d82d4765ac2e93b9acc61b7d,evaluating,0.510955
uuid-f4b24511d82d4765ac2e93b9acc61b7d,not conducted any controlled clinical trials/studies,0.514915
uuid-f4b24511d82d4765ac2e93b9acc61b7d,patients,0.432521
uuid-f4b24511d82d4765ac2e93b9acc61b7d,considered investigational,0.323637
uuid-f4b24511d82d4765ac2e93b9acc61b7d,not approved,0.348986
uuid-f4b24511d82d4765ac2e93b9acc61b7d,clinical trials investigating the safety,0.309716
uuid-f4b24511d82d4765ac2e93b9acc61b7d,efficacy and safety of nivolumab,0.43176
uuid-f83b937141ae4e879e7debea3dac6020,nivolumab,0.574317
uuid-f83b937141ae4e879e7debea3dac6020,Bristol-Myers Squibb,0.425512
uuid-f83b937141ae4e879e7debea3dac6020,evaluating,0.589313
uuid-f83b937141ae4e879e7debea3dac6020,not conducted any controlled clinical trials/studies,0.643149
uuid-f83b937141ae4e879e7debea3dac6020,Pubmed literature search,0.860963
uuid-f83b937141ae4e879e7debea3dac6020,purposes other than its labeled indication must be considered investigational,0.923664
uuid-f83b937141ae4e879e7debea3dac6020,not identify any citations relevant to your inquiry,0.823752
uuid-f83b937141ae4e879e7debea3dac6020,using the following search terms,0.807481
uuid-f83b937141ae4e879e7debea3dac6020,efficacy and safety of nivolumab,0.420341
uuid-f71a374e238646d5b1848983cfa9ff3e,nivolumab,0.999168
uuid-f71a374e238646d5b1848983cfa9ff3e,Pubmed literature search,0.395314
uuid-f71a374e238646d5b1848983cfa9ff3e,purposes other than its labeled indication must be considered investigational,0.464236
uuid-f71a374e238646d5b1848983cfa9ff3e,not identify any citations relevant to your inquiry,0.368569
uuid-f71a374e238646d5b1848983cfa9ff3e,using the following search terms,0.364279
uuid-f71a374e238646d5b1848983cfa9ff3e,present using the following search terms,0.329876
uuid-902cdb63667044e489f06364903c03ad,evaluating,0.314463
uuid-902cdb63667044e489f06364903c03ad,NSCLC,0.964314
uuid-902cdb63667044e489f06364903c03ad,non-small cell lung cancer,0.928342
uuid-902cdb63667044e489f06364903c03ad,considered investigational,0.40954
uuid-902cdb63667044e489f06364903c03ad,phase 1 study,0.380819
uuid-902cdb63667044e489f06364903c03ad,safety of nivolumab monotherapy,0.331636
uuid-902cdb63667044e489f06364903c03ad,platinum-based doublet chemotherapy,0.451834
uuid-a0a636b6100f44b49cf3baa8d1833b8a,adverse,0.486263
uuid-a0a636b6100f44b49cf3baa8d1833b8a,grade,0.359214
uuid-a0a636b6100f44b49cf3baa8d1833b8a,therapy,0.314394
uuid-a7633d1a580d4c1092216fe5581a17b4,provided in the Detailed Information,0.349112
uuid-a7633d1a580d4c1092216fe5581a17b4,Weber JS,0.321343
uuid-086994f19fc74a349d4b64ae78b601ca,patients,0.387216
uuid-086994f19fc74a349d4b64ae78b601ca,considered investigational,0.572483
uuid-086994f19fc74a349d4b64ae78b601ca,patients with advanced or metastatic,0.390918
uuid-086994f19fc74a349d4b64ae78b601ca,nivolumab combined with ipilimumab,0.381545
uuid-086994f19fc74a349d4b64ae78b601ca,ipilimumab,0.418119
uuid-086994f19fc74a349d4b64ae78b601ca,tumors,0.487867
uuid-086994f19fc74a349d4b64ae78b601ca,ASCO 2015,0.485832
uuid-086994f19fc74a349d4b64ae78b601ca,small cell lung cancer,0.673131
uuid-086994f19fc74a349d4b64ae78b601ca,PD-L1,0.317304
uuid-086994f19fc74a349d4b64ae78b601ca,combination,0.374435
uuid-086994f19fc74a349d4b64ae78b601ca,SCLC,0.676534
uuid-086994f19fc74a349d4b64ae78b601ca,Antonia SJ,0.423577
uuid-086994f19fc74a349d4b64ae78b601ca,therapy,0.309098
uuid-086994f19fc74a349d4b64ae78b601ca,phase 1/2 study CA209-032,0.582404
uuid-086994f19fc74a349d4b64ae78b601ca,evaluates the efficacy of nivolumab monotherapy,0.546434
uuid-3b195d27b03b43c6bed598d408e02248,nivolumab,0.502183
uuid-3b195d27b03b43c6bed598d408e02248,RCC,0.756598
uuid-34512e63e3594cb9bdf67debf2c3a1e3,Bristol-Myers Squibb,0.341822
uuid-34512e63e3594cb9bdf67debf2c3a1e3,not conducted any controlled clinical trials/studies,0.304507
uuid-34512e63e3594cb9bdf67debf2c3a1e3,Opdivo,0.461382
uuid-34512e63e3594cb9bdf67debf2c3a1e3,Pubmed literature search,0.614325
uuid-34512e63e3594cb9bdf67debf2c3a1e3,purposes other than its labeled indication must be considered investigational,0.586645
uuid-34512e63e3594cb9bdf67debf2c3a1e3,not identify any citations relevant to your inquiry,0.606087
uuid-34512e63e3594cb9bdf67debf2c3a1e3,adverse,0.304183
uuid-34512e63e3594cb9bdf67debf2c3a1e3,using the following search terms,0.642331
uuid-34512e63e3594cb9bdf67debf2c3a1e3,databases,0.315039
uuid-34512e63e3594cb9bdf67debf2c3a1e3,reported,0.556704
uuid-7c6554c769e64b93bee2654f46b186ea,95% CI,0.539167
uuid-7c6554c769e64b93bee2654f46b186ea,Median overall survival,0.479815
uuid-7c6554c769e64b93bee2654f46b186ea,protocol,0.426554
uuid-7c6554c769e64b93bee2654f46b186ea,McDermott DF,0.500131
uuid-7c6554c769e64b93bee2654f46b186ea,Motzer RJ,0.477178
uuid-7c6554c769e64b93bee2654f46b186ea,Median OS,0.603398
uuid-7c6554c769e64b93bee2654f46b186ea,Escudier B,0.469696
uuid-7c6554c769e64b93bee2654f46b186ea,NEJM,0.387615
uuid-7c6554c769e64b93bee2654f46b186ea,et al.,0.46851
uuid-7c6554c769e64b93bee2654f46b186ea,J Clin Oncol,0.51661
uuid-7c6554c769e64b93bee2654f46b186ea,Topalian,0.337057
uuid-7c6554c769e64b93bee2654f46b186ea,phase 2 study,0.399402
uuid-7c6554c769e64b93bee2654f46b186ea,hazard ratio,0.538097
uuid-6de63aadd4c6428d93c9365e7220e47c,nivolumab,0.381172
uuid-810206cf74894933ab8936b72bf45555,95% CI,0.524855
uuid-810206cf74894933ab8936b72bf45555,respectively,0.383655
uuid-810206cf74894933ab8936b72bf45555,ASCO,0.303153
uuid-810206cf74894933ab8936b72bf45555,Lancet Oncol,0.368041
uuid-810206cf74894933ab8936b72bf45555,Objective response rate,0.504846
uuid-810206cf74894933ab8936b72bf45555,ORR,0.465366
uuid-810206cf74894933ab8936b72bf45555,Median overall survival,0.346516
uuid-810206cf74894933ab8936b72bf45555,Median OS,0.33538
uuid-810206cf74894933ab8936b72bf45555,ASCO 2015,0.336983
uuid-810206cf74894933ab8936b72bf45555,small cell lung cancer,0.336892
uuid-810206cf74894933ab8936b72bf45555,SCLC,0.344367
uuid-810206cf74894933ab8936b72bf45555,Antonia SJ,0.55269
uuid-810206cf74894933ab8936b72bf45555,Median duration of response,0.649605
uuid-ee77ff9240094d489930c8831bcb914d,respectively,0.589071
uuid-ee77ff9240094d489930c8831bcb914d,Objective response rate,0.407286
uuid-ee77ff9240094d489930c8831bcb914d,ORR,0.526086
uuid-ee77ff9240094d489930c8831bcb914d,monotherapy,0.319413
uuid-ee77ff9240094d489930c8831bcb914d,docetaxel,0.334344
uuid-0773a89db4224829b5c837601a1ae7ea,nivolumab,0.42693
uuid-0773a89db4224829b5c837601a1ae7ea,melanoma,0.440957
uuid-3ffcdb3be32643599581b75c68d0b20c,nivolumab,0.349876
uuid-cd52772a8adf4c319fe4549eaeebea56,Bristol-Myers Squibb,0.396485
uuid-168c6f25b717417885ba2c218ea6cf34,OS,0.387982
uuid-168c6f25b717417885ba2c218ea6cf34,95% CI,0.745043
uuid-168c6f25b717417885ba2c218ea6cf34,respectively,0.729294
uuid-168c6f25b717417885ba2c218ea6cf34,Objective response rate,0.590876
uuid-168c6f25b717417885ba2c218ea6cf34,ORR,0.722442
uuid-168c6f25b717417885ba2c218ea6cf34,Median overall survival,0.659043
uuid-168c6f25b717417885ba2c218ea6cf34,monotherapy,0.514468
uuid-168c6f25b717417885ba2c218ea6cf34,Median OS,0.696688
uuid-168c6f25b717417885ba2c218ea6cf34,PD-L1,0.300997
uuid-168c6f25b717417885ba2c218ea6cf34,docetaxel,0.635065
uuid-168c6f25b717417885ba2c218ea6cf34,hazard ratio,0.729977
uuid-1a49e22354ae4e96b27e59ecf8c7b5be,requested,0.662269
uuid-75aad2d34ff64214a05b7e86823f677f,95% CI,0.524855
uuid-75aad2d34ff64214a05b7e86823f677f,respectively,0.383655
uuid-75aad2d34ff64214a05b7e86823f677f,ASCO,0.303153
uuid-75aad2d34ff64214a05b7e86823f677f,Lancet Oncol,0.368041
uuid-75aad2d34ff64214a05b7e86823f677f,Objective response rate,0.504846
uuid-75aad2d34ff64214a05b7e86823f677f,ORR,0.465366
uuid-75aad2d34ff64214a05b7e86823f677f,Median overall survival,0.346516
uuid-75aad2d34ff64214a05b7e86823f677f,Median OS,0.33538
uuid-75aad2d34ff64214a05b7e86823f677f,ASCO 2015,0.336983
uuid-75aad2d34ff64214a05b7e86823f677f,small cell lung cancer,0.336892
uuid-75aad2d34ff64214a05b7e86823f677f,SCLC,0.344367
uuid-75aad2d34ff64214a05b7e86823f677f,Antonia SJ,0.55269
uuid-75aad2d34ff64214a05b7e86823f677f,Median duration of response,0.649605
uuid-5aa653b09629460dbf85cc43a1daaea2,search of published literature,0.394524
uuid-5aa653b09629460dbf85cc43a1daaea2,Additionally,0.413583
uuid-5aa653b09629460dbf85cc43a1daaea2,ongoing,0.322117
uuid-5aa653b09629460dbf85cc43a1daaea2,PubMed and EMBASE,0.391671
uuid-5aa653b09629460dbf85cc43a1daaea2,detailed search of www.clinicaltrials.gov,0.375936
uuid-5aa653b09629460dbf85cc43a1daaea2,efficacy and safety of nivolumab,0.370699
uuid-5aa653b09629460dbf85cc43a1daaea2,not identify any planned,0.34283
uuid-5aa653b09629460dbf85cc43a1daaea2,Weber JS,0.319229
uuid-5aa653b09629460dbf85cc43a1daaea2,not identify any citations relevant to your request,0.447813
uuid-5aa653b09629460dbf85cc43a1daaea2,present using the following search terms,0.408199
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,N Engl J Med,0.410025
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,protocol,0.663749
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,RCC,0.370429
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,McDermott DF,0.577168
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,search of published literature,0.443686
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,Additionally,0.395847
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,ongoing,0.335873
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,Motzer RJ,0.609458
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,phase 3 study,0.312748
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,PubMed and EMBASE,0.438896
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,Escudier B,0.595328
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,et al.,0.521538
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,J Clin Oncol,0.545137
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,detailed search of www.clinicaltrials.gov,0.358127
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,efficacy and safety of nivolumab,0.429052
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,not identify any planned,0.344155
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,phase 2 study,0.513121
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,not identify any citations relevant to your request,0.414617
uuid-aa95d940a55d42e3abb46acf9c4dc5a7,present using the following search terms,0.417875
uuid-c26c5bae15264928990348e26c60fdc2,considered investigational,0.402849
uuid-c26c5bae15264928990348e26c60fdc2,small cell lung cancer,0.651985
uuid-c26c5bae15264928990348e26c60fdc2,partial response,0.50367
uuid-c26c5bae15264928990348e26c60fdc2,SCLC,0.736863
uuid-c26c5bae15264928990348e26c60fdc2,therapy,0.843488
uuid-c26c5bae15264928990348e26c60fdc2,relapsed,0.613852
uuid-c26c5bae15264928990348e26c60fdc2,phase 1/2 study CA209-032,0.40439
uuid-c26c5bae15264928990348e26c60fdc2,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-69d7cf4c8cae458b908aba2d567ee86f,nivolumab,0.580489
uuid-69d7cf4c8cae458b908aba2d567ee86f,Bristol-Myers Squibb,0.466276
uuid-69d7cf4c8cae458b908aba2d567ee86f,evaluating,0.683628
uuid-69d7cf4c8cae458b908aba2d567ee86f,not conducted any controlled clinical trials/studies,0.7184
uuid-69d7cf4c8cae458b908aba2d567ee86f,Pubmed literature search,0.766613
uuid-69d7cf4c8cae458b908aba2d567ee86f,purposes other than its labeled indication must be considered investigational,0.844834
uuid-69d7cf4c8cae458b908aba2d567ee86f,not identify any citations relevant to your inquiry,0.727902
uuid-69d7cf4c8cae458b908aba2d567ee86f,search of published literature,0.360177
uuid-69d7cf4c8cae458b908aba2d567ee86f,PubMed and EMBASE,0.332257
uuid-69d7cf4c8cae458b908aba2d567ee86f,using the following search terms,0.710592
uuid-69d7cf4c8cae458b908aba2d567ee86f,efficacy and safety of nivolumab,0.574928
uuid-69d7cf4c8cae458b908aba2d567ee86f,present using the following search terms,0.344497
uuid-d03a5d41e3214beea488d4b6ad484a90,nivolumab,0.811201
uuid-0f9b39b0278d4085a7daca62e48f1dad,adverse,0.754591
uuid-0f9b39b0278d4085a7daca62e48f1dad,safety,0.406494
uuid-0f9b39b0278d4085a7daca62e48f1dad,reported,0.491832
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,95% CI,0.539167
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,Median overall survival,0.479815
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,protocol,0.426554
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,McDermott DF,0.500131
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,Motzer RJ,0.477178
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,Median OS,0.603398
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,Escudier B,0.469696
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,NEJM,0.387615
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,et al.,0.46851
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,J Clin Oncol,0.51661
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,Topalian,0.337057
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,phase 2 study,0.399402
uuid-aef6a7d6a24a436d8f48e3852ff4c9f5,hazard ratio,0.538097
uuid-73aaa2ca062c4a3eace1bdf53dafe0d7,patients with advanced or metastatic,0.478326
uuid-73aaa2ca062c4a3eace1bdf53dafe0d7,nivolumab combined with ipilimumab,0.498766
uuid-73aaa2ca062c4a3eace1bdf53dafe0d7,not approved,0.34724
uuid-73aaa2ca062c4a3eace1bdf53dafe0d7,clinical trials investigating the safety,0.426729
uuid-73aaa2ca062c4a3eace1bdf53dafe0d7,bladder cancer,0.6548
uuid-60bbd234bccd4ab186affa271db1e266,N Engl J Med,0.448483
uuid-60bbd234bccd4ab186affa271db1e266,protocol,0.770446
uuid-60bbd234bccd4ab186affa271db1e266,McDermott DF,0.741196
uuid-60bbd234bccd4ab186affa271db1e266,Motzer RJ,0.818144
uuid-60bbd234bccd4ab186affa271db1e266,phase 3 study,0.417055
uuid-60bbd234bccd4ab186affa271db1e266,Escudier B,0.749917
uuid-60bbd234bccd4ab186affa271db1e266,NEJM,0.400698
uuid-60bbd234bccd4ab186affa271db1e266,et al.,0.668641
uuid-60bbd234bccd4ab186affa271db1e266,J Clin Oncol,0.792018
uuid-60bbd234bccd4ab186affa271db1e266,Topalian,0.388894
uuid-60bbd234bccd4ab186affa271db1e266,phase 1 study,0.500686
uuid-60bbd234bccd4ab186affa271db1e266,CA209-003,0.567381
uuid-60bbd234bccd4ab186affa271db1e266,phase 2 study,0.677985
uuid-60bbd234bccd4ab186affa271db1e266,present using the following search terms,0.310558
uuid-60bbd234bccd4ab186affa271db1e266,investigating,0.615835
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,N Engl J Med,0.362637
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,requested,0.323174
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,protocol,0.432257
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,McDermott DF,0.522967
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,Motzer RJ,0.479534
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,phase 3 study,0.365514
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,Escudier B,0.509657
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,et al.,0.519507
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,J Clin Oncol,0.459274
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,Rizvi NA,0.363138
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,Weber JS,0.328365
uuid-94b7b5dfeab34e3d8942fdc3fdd64181,phase 2 study,0.488848
uuid-3aff14560ec84557902f651c60fc56e6,provided in the Detailed Information,0.428571
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,nivolumab,0.308696
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,respectively,0.474596
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,Objective response rate,0.398542
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,ORR,0.387529
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,monotherapy,0.618934
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,clinical,0.310702
uuid-ba6a8f566e404df5b0ecb874bfb7b0db,Antonia SJ,0.303123
uuid-3fd41446a09746e58c97108db9d00376,N Engl J Med,0.699334
uuid-3fd41446a09746e58c97108db9d00376,protocol,0.906238
uuid-3fd41446a09746e58c97108db9d00376,McDermott DF,0.967609
uuid-3fd41446a09746e58c97108db9d00376,Motzer RJ,0.962207
uuid-3fd41446a09746e58c97108db9d00376,phase 3 study,0.540755
uuid-3fd41446a09746e58c97108db9d00376,Escudier B,0.968428
uuid-3fd41446a09746e58c97108db9d00376,NEJM,0.485285
uuid-3fd41446a09746e58c97108db9d00376,et al.,0.928667
uuid-3fd41446a09746e58c97108db9d00376,J Clin Oncol,0.919772
uuid-3fd41446a09746e58c97108db9d00376,Topalian,0.439233
uuid-3fd41446a09746e58c97108db9d00376,Rizvi NA,0.451815
uuid-3fd41446a09746e58c97108db9d00376,Brahmer J,0.336511
uuid-3fd41446a09746e58c97108db9d00376,phase 2 study,0.866719
uuid-eecca53763414c7cb881b8223f2786fa,95% CI,0.524855
uuid-eecca53763414c7cb881b8223f2786fa,respectively,0.383655
uuid-eecca53763414c7cb881b8223f2786fa,ASCO,0.303153
uuid-eecca53763414c7cb881b8223f2786fa,Lancet Oncol,0.368041
uuid-eecca53763414c7cb881b8223f2786fa,Objective response rate,0.504846
uuid-eecca53763414c7cb881b8223f2786fa,ORR,0.465366
uuid-eecca53763414c7cb881b8223f2786fa,Median overall survival,0.346516
uuid-eecca53763414c7cb881b8223f2786fa,Median OS,0.33538
uuid-eecca53763414c7cb881b8223f2786fa,ASCO 2015,0.336983
uuid-eecca53763414c7cb881b8223f2786fa,small cell lung cancer,0.336892
uuid-eecca53763414c7cb881b8223f2786fa,SCLC,0.344367
uuid-eecca53763414c7cb881b8223f2786fa,Antonia SJ,0.55269
uuid-eecca53763414c7cb881b8223f2786fa,Median duration of response,0.649605
uuid-6ac243bf595f42079b2084b1538164f4,requested,0.594234
uuid-2fc3c6445ab24e91bf17dbc361ef162e,considered investigational,0.402849
uuid-2fc3c6445ab24e91bf17dbc361ef162e,small cell lung cancer,0.651985
uuid-2fc3c6445ab24e91bf17dbc361ef162e,partial response,0.50367
uuid-2fc3c6445ab24e91bf17dbc361ef162e,SCLC,0.736863
uuid-2fc3c6445ab24e91bf17dbc361ef162e,therapy,0.843488
uuid-2fc3c6445ab24e91bf17dbc361ef162e,relapsed,0.613852
uuid-2fc3c6445ab24e91bf17dbc361ef162e,phase 1/2 study CA209-032,0.40439
uuid-2fc3c6445ab24e91bf17dbc361ef162e,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-16fde16a15004ac4bd58c71ef783d704,nivolumab,0.36554
uuid-16fde16a15004ac4bd58c71ef783d704,Bristol-Myers Squibb,0.428594
uuid-16fde16a15004ac4bd58c71ef783d704,evaluating,0.483003
uuid-16fde16a15004ac4bd58c71ef783d704,not conducted any controlled clinical trials/studies,0.521471
uuid-16fde16a15004ac4bd58c71ef783d704,Pubmed literature search,0.393529
uuid-16fde16a15004ac4bd58c71ef783d704,purposes other than its labeled indication must be considered investigational,0.46715
uuid-16fde16a15004ac4bd58c71ef783d704,not identify any citations relevant to your inquiry,0.366558
uuid-16fde16a15004ac4bd58c71ef783d704,using the following search terms,0.343275
uuid-16fde16a15004ac4bd58c71ef783d704,efficacy and safety of nivolumab,0.388005
uuid-7dda1cc1bcbb4e5394c340bd620c373e,safety,0.73739
uuid-7dda1cc1bcbb4e5394c340bd620c373e,databases,0.610916
uuid-a99a5b4d04794fa89e0e162e1ebd643f,ASCO,0.822835
uuid-a99a5b4d04794fa89e0e162e1ebd643f,Antonia SJ,0.351104
uuid-9b2f83e00c524b24a98af6f2a35fbdff,adverse,0.754591
uuid-9b2f83e00c524b24a98af6f2a35fbdff,safety,0.406494
uuid-9b2f83e00c524b24a98af6f2a35fbdff,reported,0.491832
uuid-d89d20ba2560472291805c56a46148bd,NSCLC,0.334422
uuid-d89d20ba2560472291805c56a46148bd,non-small cell lung cancer,0.364633
uuid-d89d20ba2560472291805c56a46148bd,safety of nivolumab monotherapy,0.474385
uuid-d89d20ba2560472291805c56a46148bd,phase,0.445607
uuid-240ea49bb17f43ac9aaf5660a19626a2,nivolumab,0.548114
uuid-240ea49bb17f43ac9aaf5660a19626a2,Bristol-Myers Squibb,0.429742
uuid-240ea49bb17f43ac9aaf5660a19626a2,evaluating,0.643846
uuid-240ea49bb17f43ac9aaf5660a19626a2,not conducted any controlled clinical trials/studies,0.667353
uuid-240ea49bb17f43ac9aaf5660a19626a2,Pubmed literature search,0.74503
uuid-240ea49bb17f43ac9aaf5660a19626a2,purposes other than its labeled indication must be considered investigational,0.812667
uuid-240ea49bb17f43ac9aaf5660a19626a2,not identify any citations relevant to your inquiry,0.72423
uuid-240ea49bb17f43ac9aaf5660a19626a2,search of published literature,0.304135
uuid-240ea49bb17f43ac9aaf5660a19626a2,Additionally,0.323594
uuid-240ea49bb17f43ac9aaf5660a19626a2,ongoing,0.315871
uuid-240ea49bb17f43ac9aaf5660a19626a2,using the following search terms,0.693727
uuid-240ea49bb17f43ac9aaf5660a19626a2,detailed search of www.clinicaltrials.gov,0.335273
uuid-240ea49bb17f43ac9aaf5660a19626a2,efficacy and safety of nivolumab,0.532125
uuid-240ea49bb17f43ac9aaf5660a19626a2,not identify any planned,0.318645
uuid-240ea49bb17f43ac9aaf5660a19626a2,not identify any citations relevant to your request,0.35325
uuid-240ea49bb17f43ac9aaf5660a19626a2,present using the following search terms,0.313139
uuid-770821e52f8c45baa9fdbc8e86dfc573,Objective response rate,0.451139
uuid-770821e52f8c45baa9fdbc8e86dfc573,clinicaltrials.gov,0.503706
uuid-6f99ead76ee5485aa0e0e2af88f7ed2b,AEs,0.342616
uuid-6f99ead76ee5485aa0e0e2af88f7ed2b,respectively,0.486558
uuid-6f99ead76ee5485aa0e0e2af88f7ed2b,ORR,0.415456
uuid-6f99ead76ee5485aa0e0e2af88f7ed2b,grade 3 to 4 AEs,0.342166
uuid-6456b7827e934b4298cbf2bd4019af66,95% CI,0.524855
uuid-6456b7827e934b4298cbf2bd4019af66,respectively,0.383655
uuid-6456b7827e934b4298cbf2bd4019af66,ASCO,0.303153
uuid-6456b7827e934b4298cbf2bd4019af66,Lancet Oncol,0.368041
uuid-6456b7827e934b4298cbf2bd4019af66,Objective response rate,0.504846
uuid-6456b7827e934b4298cbf2bd4019af66,ORR,0.465366
uuid-6456b7827e934b4298cbf2bd4019af66,Median overall survival,0.346516
uuid-6456b7827e934b4298cbf2bd4019af66,Median OS,0.33538
uuid-6456b7827e934b4298cbf2bd4019af66,ASCO 2015,0.336983
uuid-6456b7827e934b4298cbf2bd4019af66,small cell lung cancer,0.336892
uuid-6456b7827e934b4298cbf2bd4019af66,SCLC,0.344367
uuid-6456b7827e934b4298cbf2bd4019af66,Antonia SJ,0.55269
uuid-6456b7827e934b4298cbf2bd4019af66,Median duration of response,0.649605
uuid-de1338a3f9064f01a20fe916ecff98d0,ASCO,0.477756
uuid-de1338a3f9064f01a20fe916ecff98d0,requested,0.30944
uuid-3c9785b5bed6418e8a675935085069b3,Bristol-Myers Squibb,0.31921
uuid-3c9785b5bed6418e8a675935085069b3,evaluating,0.507726
uuid-3c9785b5bed6418e8a675935085069b3,not conducted any controlled clinical trials/studies,0.454883
uuid-3c9785b5bed6418e8a675935085069b3,efficacy,0.323832
uuid-3c9785b5bed6418e8a675935085069b3,NSCLC,0.658595
uuid-3c9785b5bed6418e8a675935085069b3,non-small cell lung cancer,0.632222
uuid-3c9785b5bed6418e8a675935085069b3,considered investigational,0.336504
uuid-3c9785b5bed6418e8a675935085069b3,monotherapy,0.381284
uuid-3c9785b5bed6418e8a675935085069b3,efficacy and safety of nivolumab,0.404933
uuid-3c9785b5bed6418e8a675935085069b3,docetaxel,0.54884
uuid-3c9785b5bed6418e8a675935085069b3,safety of nivolumab monotherapy,0.552482
uuid-3c9785b5bed6418e8a675935085069b3,platinum-based doublet chemotherapy,0.513607
uuid-d792a39ffbc445fb95c261594f3a8f55,95% CI,0.524855
uuid-d792a39ffbc445fb95c261594f3a8f55,respectively,0.383655
uuid-d792a39ffbc445fb95c261594f3a8f55,ASCO,0.303153
uuid-d792a39ffbc445fb95c261594f3a8f55,Lancet Oncol,0.368041
uuid-d792a39ffbc445fb95c261594f3a8f55,Objective response rate,0.504846
uuid-d792a39ffbc445fb95c261594f3a8f55,ORR,0.465366
uuid-d792a39ffbc445fb95c261594f3a8f55,Median overall survival,0.346516
uuid-d792a39ffbc445fb95c261594f3a8f55,Median OS,0.33538
uuid-d792a39ffbc445fb95c261594f3a8f55,ASCO 2015,0.336983
uuid-d792a39ffbc445fb95c261594f3a8f55,small cell lung cancer,0.336892
uuid-d792a39ffbc445fb95c261594f3a8f55,SCLC,0.344367
uuid-d792a39ffbc445fb95c261594f3a8f55,Antonia SJ,0.55269
uuid-d792a39ffbc445fb95c261594f3a8f55,Median duration of response,0.649605
uuid-f7e1f63d32d3421eb879c4900ca554ee,NSCLC,0.351198
uuid-f7e1f63d32d3421eb879c4900ca554ee,efficacy and safety of nivolumab,0.343313
uuid-c4b01f765e0d4870b92ded5e34306cad,N Engl J Med,0.405735
uuid-c4b01f765e0d4870b92ded5e34306cad,Lancet Oncol,0.311012
uuid-c4b01f765e0d4870b92ded5e34306cad,provided in the Detailed Information,0.356773
uuid-c4b01f765e0d4870b92ded5e34306cad,protocol,0.332823
uuid-c4b01f765e0d4870b92ded5e34306cad,McDermott DF,0.388164
uuid-c4b01f765e0d4870b92ded5e34306cad,Motzer RJ,0.36016
uuid-c4b01f765e0d4870b92ded5e34306cad,phase 3 study,0.602798
uuid-c4b01f765e0d4870b92ded5e34306cad,Escudier B,0.374179
uuid-c4b01f765e0d4870b92ded5e34306cad,et al.,0.361025
uuid-c4b01f765e0d4870b92ded5e34306cad,J Clin Oncol,0.342529
uuid-c4b01f765e0d4870b92ded5e34306cad,phase 1 study,0.35883
uuid-c4b01f765e0d4870b92ded5e34306cad,Rizvi NA,0.461148
uuid-c4b01f765e0d4870b92ded5e34306cad,Brahmer J,0.301287
uuid-c4b01f765e0d4870b92ded5e34306cad,CA209-003,0.342488
uuid-c4b01f765e0d4870b92ded5e34306cad,Weber JS,0.457076
uuid-c4b01f765e0d4870b92ded5e34306cad,BMS,0.326856
uuid-c4b01f765e0d4870b92ded5e34306cad,phase 2 study,0.556921
uuid-c4b01f765e0d4870b92ded5e34306cad,grade,0.388497
uuid-03c6a3b1d2b04625b5d203077903d231,patients with advanced or metastatic,0.478326
uuid-03c6a3b1d2b04625b5d203077903d231,nivolumab combined with ipilimumab,0.498766
uuid-03c6a3b1d2b04625b5d203077903d231,not approved,0.34724
uuid-03c6a3b1d2b04625b5d203077903d231,clinical trials investigating the safety,0.426729
uuid-03c6a3b1d2b04625b5d203077903d231,bladder cancer,0.6548
uuid-e03dfa17a098481991fbbcd42108acd6,respectively,0.397695
uuid-949e3c709325477b8d1b4baf6f51ff27,95% CI,0.524855
uuid-949e3c709325477b8d1b4baf6f51ff27,respectively,0.383655
uuid-949e3c709325477b8d1b4baf6f51ff27,ASCO,0.303153
uuid-949e3c709325477b8d1b4baf6f51ff27,Lancet Oncol,0.368041
uuid-949e3c709325477b8d1b4baf6f51ff27,Objective response rate,0.504846
uuid-949e3c709325477b8d1b4baf6f51ff27,ORR,0.465366
uuid-949e3c709325477b8d1b4baf6f51ff27,Median overall survival,0.346516
uuid-949e3c709325477b8d1b4baf6f51ff27,Median OS,0.33538
uuid-949e3c709325477b8d1b4baf6f51ff27,ASCO 2015,0.336983
uuid-949e3c709325477b8d1b4baf6f51ff27,small cell lung cancer,0.336892
uuid-949e3c709325477b8d1b4baf6f51ff27,SCLC,0.344367
uuid-949e3c709325477b8d1b4baf6f51ff27,Antonia SJ,0.55269
uuid-949e3c709325477b8d1b4baf6f51ff27,Median duration of response,0.649605
uuid-9c0a951c3dee42e5abf3ed292040b347,considered investigational,0.402849
uuid-9c0a951c3dee42e5abf3ed292040b347,small cell lung cancer,0.651985
uuid-9c0a951c3dee42e5abf3ed292040b347,partial response,0.50367
uuid-9c0a951c3dee42e5abf3ed292040b347,SCLC,0.736863
uuid-9c0a951c3dee42e5abf3ed292040b347,therapy,0.843488
uuid-9c0a951c3dee42e5abf3ed292040b347,relapsed,0.613852
uuid-9c0a951c3dee42e5abf3ed292040b347,phase 1/2 study CA209-032,0.40439
uuid-9c0a951c3dee42e5abf3ed292040b347,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-22abce345a5a4e08b330156130295aa6,open-label,0.539462
uuid-22abce345a5a4e08b330156130295aa6,phase,0.350616
uuid-23841d7d8a8c40a381a43e68e86be818,N Engl J Med,0.707725
uuid-23841d7d8a8c40a381a43e68e86be818,Lancet Oncol,0.347956
uuid-23841d7d8a8c40a381a43e68e86be818,protocol,0.812355
uuid-23841d7d8a8c40a381a43e68e86be818,McDermott DF,0.836415
uuid-23841d7d8a8c40a381a43e68e86be818,Motzer RJ,0.847157
uuid-23841d7d8a8c40a381a43e68e86be818,phase 3 study,0.575473
uuid-23841d7d8a8c40a381a43e68e86be818,Escudier B,0.841503
uuid-23841d7d8a8c40a381a43e68e86be818,NEJM,0.443965
uuid-23841d7d8a8c40a381a43e68e86be818,et al.,0.78974
uuid-23841d7d8a8c40a381a43e68e86be818,J Clin Oncol,0.797251
uuid-23841d7d8a8c40a381a43e68e86be818,Topalian,0.418109
uuid-23841d7d8a8c40a381a43e68e86be818,phase 1 study,0.422752
uuid-23841d7d8a8c40a381a43e68e86be818,Rizvi NA,0.534567
uuid-23841d7d8a8c40a381a43e68e86be818,Brahmer J,0.403976
uuid-23841d7d8a8c40a381a43e68e86be818,CA209-003,0.399546
uuid-23841d7d8a8c40a381a43e68e86be818,Weber JS,0.374794
uuid-23841d7d8a8c40a381a43e68e86be818,phase 2 study,0.830089
uuid-23841d7d8a8c40a381a43e68e86be818,investigating,0.320009
uuid-e637957c2beb4fd6bbe55dc8fd4dc429,Bristol-Myers Squibb,0.382596
uuid-e637957c2beb4fd6bbe55dc8fd4dc429,requested,0.358269
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,95% CI,0.524855
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,respectively,0.383655
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,ASCO,0.303153
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Lancet Oncol,0.368041
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Objective response rate,0.504846
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,ORR,0.465366
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Median overall survival,0.346516
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Median OS,0.33538
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,ASCO 2015,0.336983
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,small cell lung cancer,0.336892
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,SCLC,0.344367
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Antonia SJ,0.55269
uuid-ed05aa5562bc4d88bbc89fb32f0b36b8,Median duration of response,0.649605
uuid-18df78ed9df84e0f9f0df89651f415c8,N Engl J Med,0.604857
uuid-18df78ed9df84e0f9f0df89651f415c8,non-small cell lung cancer,0.34354
uuid-18df78ed9df84e0f9f0df89651f415c8,ESMO,0.393944
uuid-18df78ed9df84e0f9f0df89651f415c8,Rizvi NA,0.452745
uuid-18df78ed9df84e0f9f0df89651f415c8,Brahmer J,0.679154
uuid-18df78ed9df84e0f9f0df89651f415c8,PD-L1,0.347566
uuid-18df78ed9df84e0f9f0df89651f415c8,Horn L,0.50259
uuid-18df78ed9df84e0f9f0df89651f415c8,platinum-based doublet chemotherapy,0.304136
uuid-b11a306544404fc0a02be9758bb55557,nivolumab,0.59708
uuid-5dde31b6904a44abb16e634b398c1171,patients with advanced or metastatic,0.478326
uuid-5dde31b6904a44abb16e634b398c1171,nivolumab combined with ipilimumab,0.498766
uuid-5dde31b6904a44abb16e634b398c1171,not approved,0.34724
uuid-5dde31b6904a44abb16e634b398c1171,clinical trials investigating the safety,0.426729
uuid-5dde31b6904a44abb16e634b398c1171,bladder cancer,0.6548
uuid-dbbb78d46b2d44d2b8a107450d3ff102,provided in the Detailed Information,0.349112
uuid-dbbb78d46b2d44d2b8a107450d3ff102,Weber JS,0.321343
uuid-2b918d9a0d804cf28e2176fec9fe6cf1,patients with advanced or metastatic,0.478326
uuid-2b918d9a0d804cf28e2176fec9fe6cf1,nivolumab combined with ipilimumab,0.498766
uuid-2b918d9a0d804cf28e2176fec9fe6cf1,not approved,0.34724
uuid-2b918d9a0d804cf28e2176fec9fe6cf1,clinical trials investigating the safety,0.426729
uuid-2b918d9a0d804cf28e2176fec9fe6cf1,bladder cancer,0.6548
uuid-453fb2b879344fcbaf99097a7869fa33,nivolumab,0.322725
uuid-453fb2b879344fcbaf99097a7869fa33,NSCLC,0.321674
uuid-453fb2b879344fcbaf99097a7869fa33,non-small cell lung cancer,0.400236
uuid-453fb2b879344fcbaf99097a7869fa33,RCC,0.392975
uuid-453fb2b879344fcbaf99097a7869fa33,phase 3 study,0.302848
uuid-453fb2b879344fcbaf99097a7869fa33,phase 1 study,0.330164
uuid-453fb2b879344fcbaf99097a7869fa33,PD-L1,0.631134
uuid-453fb2b879344fcbaf99097a7869fa33,CA209-003,0.363707
uuid-453fb2b879344fcbaf99097a7869fa33,investigating,0.396556
uuid-bc9644c95ef44ef1892f31a30783fa6d,BMS,0.349063
uuid-d1145013543a4316bf64eed76ec97c0a,OS,0.387982
uuid-d1145013543a4316bf64eed76ec97c0a,95% CI,0.745043
uuid-d1145013543a4316bf64eed76ec97c0a,respectively,0.729294
uuid-d1145013543a4316bf64eed76ec97c0a,Objective response rate,0.590876
uuid-d1145013543a4316bf64eed76ec97c0a,ORR,0.722442
uuid-d1145013543a4316bf64eed76ec97c0a,Median overall survival,0.659043
uuid-d1145013543a4316bf64eed76ec97c0a,monotherapy,0.514468
uuid-d1145013543a4316bf64eed76ec97c0a,Median OS,0.696688
uuid-d1145013543a4316bf64eed76ec97c0a,PD-L1,0.300997
uuid-d1145013543a4316bf64eed76ec97c0a,docetaxel,0.635065
uuid-d1145013543a4316bf64eed76ec97c0a,hazard ratio,0.729977
uuid-d22263951fa1452eba071a552101401a,nivolumab,0.513293
uuid-d22263951fa1452eba071a552101401a,Bristol-Myers Squibb,0.378469
uuid-d22263951fa1452eba071a552101401a,evaluating,0.542885
uuid-d22263951fa1452eba071a552101401a,not conducted any controlled clinical trials/studies,0.58613
uuid-d22263951fa1452eba071a552101401a,Pubmed literature search,0.796932
uuid-d22263951fa1452eba071a552101401a,purposes other than its labeled indication must be considered investigational,0.84429
uuid-d22263951fa1452eba071a552101401a,not identify any citations relevant to your inquiry,0.785823
uuid-d22263951fa1452eba071a552101401a,Additionally,0.351796
uuid-d22263951fa1452eba071a552101401a,ongoing,0.357986
uuid-d22263951fa1452eba071a552101401a,using the following search terms,0.755799
uuid-d22263951fa1452eba071a552101401a,detailed search of www.clinicaltrials.gov,0.373406
uuid-d22263951fa1452eba071a552101401a,efficacy and safety of nivolumab,0.422597
uuid-d22263951fa1452eba071a552101401a,not identify any planned,0.362113
uuid-d22263951fa1452eba071a552101401a,not identify any citations relevant to your request,0.360638
uuid-bcdcbd747cf545f08be1fc6a05fdaa6e,nivolumab,0.33639
uuid-bcdcbd747cf545f08be1fc6a05fdaa6e,Objective response rate,0.459398
uuid-bcdcbd747cf545f08be1fc6a05fdaa6e,clinicaltrials.gov,0.632338
uuid-da6ffc1d7ac9414aa1982c7244016dae,respectively,0.499696
uuid-da6ffc1d7ac9414aa1982c7244016dae,ORR,0.325922
uuid-da6ffc1d7ac9414aa1982c7244016dae,docetaxel,0.335341
uuid-da6ffc1d7ac9414aa1982c7244016dae,relapsed,0.328126
uuid-065437e1306e42249575965669c08102,use of nivolumab for the treatment,0.4866
uuid-065437e1306e42249575965669c08102,efficacy,0.349402
uuid-065437e1306e42249575965669c08102,patients,0.708717
uuid-065437e1306e42249575965669c08102,not approved,0.394264
uuid-065437e1306e42249575965669c08102,clinical trials investigating the safety,0.319556
uuid-065437e1306e42249575965669c08102,Weber JS,0.322062
uuid-065437e1306e42249575965669c08102,grade 3 to 4 AEs,0.334761
uuid-3f53cdaddba94a5cbb7475004d7dae2d,95% CI,0.524855
uuid-3f53cdaddba94a5cbb7475004d7dae2d,respectively,0.383655
uuid-3f53cdaddba94a5cbb7475004d7dae2d,ASCO,0.303153
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Lancet Oncol,0.368041
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Objective response rate,0.504846
uuid-3f53cdaddba94a5cbb7475004d7dae2d,ORR,0.465366
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Median overall survival,0.346516
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Median OS,0.33538
uuid-3f53cdaddba94a5cbb7475004d7dae2d,ASCO 2015,0.336983
uuid-3f53cdaddba94a5cbb7475004d7dae2d,small cell lung cancer,0.336892
uuid-3f53cdaddba94a5cbb7475004d7dae2d,SCLC,0.344367
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Antonia SJ,0.55269
uuid-3f53cdaddba94a5cbb7475004d7dae2d,Median duration of response,0.649605
uuid-7708e54acfd644e0b2b4108e85b641f8,nivolumab,0.354033
uuid-7708e54acfd644e0b2b4108e85b641f8,patients,0.301988
uuid-21e071c30f40455e9ae02a8b17803e94,nivolumab,0.493389
uuid-21e071c30f40455e9ae02a8b17803e94,Bristol-Myers Squibb,0.598477
uuid-21e071c30f40455e9ae02a8b17803e94,evaluating,0.837805
uuid-21e071c30f40455e9ae02a8b17803e94,not conducted any controlled clinical trials/studies,0.848713
uuid-21e071c30f40455e9ae02a8b17803e94,Pubmed literature search,0.314091
uuid-21e071c30f40455e9ae02a8b17803e94,purposes other than its labeled indication must be considered investigational,0.4415
uuid-21e071c30f40455e9ae02a8b17803e94,search of published literature,0.772891
uuid-21e071c30f40455e9ae02a8b17803e94,PubMed and EMBASE,0.743175
uuid-21e071c30f40455e9ae02a8b17803e94,efficacy and safety of nivolumab,0.905749
uuid-21e071c30f40455e9ae02a8b17803e94,not identify any citations relevant to your request,0.417576
uuid-21e071c30f40455e9ae02a8b17803e94,present using the following search terms,0.748132
uuid-5ee9aed9d9164fe4815fe831d75d3103,BMS,0.515392
uuid-e4af517a06204998b5580b154cf19a6f,Bristol-Myers Squibb,0.602636
uuid-e4af517a06204998b5580b154cf19a6f,evaluating,0.316036
uuid-e4af517a06204998b5580b154cf19a6f,not conducted any controlled clinical trials/studies,0.406869
uuid-5c88b23d1f924c17b9d6f08b20c88973,nivolumab,0.359772
uuid-a23ad2d79c924125baad855b8ea94542,95% CI,0.524855
uuid-a23ad2d79c924125baad855b8ea94542,respectively,0.383655
uuid-a23ad2d79c924125baad855b8ea94542,ASCO,0.303153
uuid-a23ad2d79c924125baad855b8ea94542,Lancet Oncol,0.368041
uuid-a23ad2d79c924125baad855b8ea94542,Objective response rate,0.504846
uuid-a23ad2d79c924125baad855b8ea94542,ORR,0.465366
uuid-a23ad2d79c924125baad855b8ea94542,Median overall survival,0.346516
uuid-a23ad2d79c924125baad855b8ea94542,Median OS,0.33538
uuid-a23ad2d79c924125baad855b8ea94542,ASCO 2015,0.336983
uuid-a23ad2d79c924125baad855b8ea94542,small cell lung cancer,0.336892
uuid-a23ad2d79c924125baad855b8ea94542,SCLC,0.344367
uuid-a23ad2d79c924125baad855b8ea94542,Antonia SJ,0.55269
uuid-a23ad2d79c924125baad855b8ea94542,Median duration of response,0.649605
uuid-ebd3e6294eaf4381ae93173a8c083a71,ASCO,0.807066
uuid-cf76c69b93dd4174bd5414b61b94aa24,95% CI,0.520262
uuid-cf76c69b93dd4174bd5414b61b94aa24,respectively,0.504068
uuid-cf76c69b93dd4174bd5414b61b94aa24,Objective response rate,0.458568
uuid-cf76c69b93dd4174bd5414b61b94aa24,ORR,0.525868
uuid-cf76c69b93dd4174bd5414b61b94aa24,Median overall survival,0.455633
uuid-cf76c69b93dd4174bd5414b61b94aa24,Median OS,0.507448
uuid-cf76c69b93dd4174bd5414b61b94aa24,docetaxel,0.383115
uuid-cf76c69b93dd4174bd5414b61b94aa24,hazard ratio,0.462119
uuid-dd59625a991b4d78883539ec4beaa579,provided in the Detailed Information,0.349112
uuid-dd59625a991b4d78883539ec4beaa579,Weber JS,0.321343
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,phase 3 study,0.372743
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,phase 1 study,0.308138
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,Rizvi NA,0.428496
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,mg,0.458128
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,Weber JS,0.353923
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,phase 2 study,0.405492
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,kg,0.392491
uuid-2070a7e6278c4bf8b6d3c6efb64cac30,therapy,0.305709
uuid-05f38e34d45e4d6ab44c40553757467e,95% CI,0.524855
uuid-05f38e34d45e4d6ab44c40553757467e,respectively,0.383655
uuid-05f38e34d45e4d6ab44c40553757467e,ASCO,0.303153
uuid-05f38e34d45e4d6ab44c40553757467e,Lancet Oncol,0.368041
uuid-05f38e34d45e4d6ab44c40553757467e,Objective response rate,0.504846
uuid-05f38e34d45e4d6ab44c40553757467e,ORR,0.465366
uuid-05f38e34d45e4d6ab44c40553757467e,Median overall survival,0.346516
uuid-05f38e34d45e4d6ab44c40553757467e,Median OS,0.33538
uuid-05f38e34d45e4d6ab44c40553757467e,ASCO 2015,0.336983
uuid-05f38e34d45e4d6ab44c40553757467e,small cell lung cancer,0.336892
uuid-05f38e34d45e4d6ab44c40553757467e,SCLC,0.344367
uuid-05f38e34d45e4d6ab44c40553757467e,Antonia SJ,0.55269
uuid-05f38e34d45e4d6ab44c40553757467e,Median duration of response,0.649605
uuid-e9015fd6720b4a4e8a0b391203acf543,patients with advanced or metastatic,0.478326
uuid-e9015fd6720b4a4e8a0b391203acf543,nivolumab combined with ipilimumab,0.498766
uuid-e9015fd6720b4a4e8a0b391203acf543,not approved,0.34724
uuid-e9015fd6720b4a4e8a0b391203acf543,clinical trials investigating the safety,0.426729
uuid-e9015fd6720b4a4e8a0b391203acf543,bladder cancer,0.6548
uuid-25957608a8c641b8afe066022d256cb3,Bristol-Myers Squibb,0.307009
uuid-25957608a8c641b8afe066022d256cb3,requested,0.323839
uuid-e9be32e582d74e5a9cd6b2539077b3ee,efficacy,0.339268
uuid-e9be32e582d74e5a9cd6b2539077b3ee,relapsed,0.429836
uuid-a329a836a6554abfb780770269c6d71c,considered investigational,0.402849
uuid-a329a836a6554abfb780770269c6d71c,small cell lung cancer,0.651985
uuid-a329a836a6554abfb780770269c6d71c,partial response,0.50367
uuid-a329a836a6554abfb780770269c6d71c,SCLC,0.736863
uuid-a329a836a6554abfb780770269c6d71c,therapy,0.843488
uuid-a329a836a6554abfb780770269c6d71c,relapsed,0.613852
uuid-a329a836a6554abfb780770269c6d71c,phase 1/2 study CA209-032,0.40439
uuid-a329a836a6554abfb780770269c6d71c,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-0b51763e354f4315bb4173fbf1f823b7,provided in the Detailed Information,0.491033
uuid-0b51763e354f4315bb4173fbf1f823b7,clinical,0.619728
uuid-0b51763e354f4315bb4173fbf1f823b7,grade,0.358357
uuid-9047d589a48c43c4baf30717e45febe6,ASCO,0.382205
uuid-f13e55650f2144bb9678c300a26d15b1,AEs,0.314686
uuid-f13e55650f2144bb9678c300a26d15b1,grade,0.526055
uuid-f13e55650f2144bb9678c300a26d15b1,grade 3 to 4 AEs,0.377909
uuid-f13e55650f2144bb9678c300a26d15b1,reported,0.301009
uuid-1b8b31c2c4f44973a729947d362ce3b0,Bristol-Myers Squibb,0.341822
uuid-1b8b31c2c4f44973a729947d362ce3b0,not conducted any controlled clinical trials/studies,0.304507
uuid-1b8b31c2c4f44973a729947d362ce3b0,Opdivo,0.461382
uuid-1b8b31c2c4f44973a729947d362ce3b0,Pubmed literature search,0.614325
uuid-1b8b31c2c4f44973a729947d362ce3b0,purposes other than its labeled indication must be considered investigational,0.586645
uuid-1b8b31c2c4f44973a729947d362ce3b0,not identify any citations relevant to your inquiry,0.606087
uuid-1b8b31c2c4f44973a729947d362ce3b0,adverse,0.304183
uuid-1b8b31c2c4f44973a729947d362ce3b0,using the following search terms,0.642331
uuid-1b8b31c2c4f44973a729947d362ce3b0,databases,0.315039
uuid-1b8b31c2c4f44973a729947d362ce3b0,reported,0.556704
uuid-06e229005d45436eb0041621c253b30b,N Engl J Med,0.432672
uuid-06e229005d45436eb0041621c253b30b,protocol,0.505106
uuid-06e229005d45436eb0041621c253b30b,McDermott DF,0.531922
uuid-06e229005d45436eb0041621c253b30b,Motzer RJ,0.507084
uuid-06e229005d45436eb0041621c253b30b,phase 3 study,0.479964
uuid-06e229005d45436eb0041621c253b30b,Escudier B,0.524679
uuid-06e229005d45436eb0041621c253b30b,NEJM,0.355472
uuid-06e229005d45436eb0041621c253b30b,et al.,0.500528
uuid-06e229005d45436eb0041621c253b30b,J Clin Oncol,0.485366
uuid-06e229005d45436eb0041621c253b30b,Topalian,0.338371
uuid-06e229005d45436eb0041621c253b30b,Rizvi NA,0.442598
uuid-06e229005d45436eb0041621c253b30b,Weber JS,0.36473
uuid-06e229005d45436eb0041621c253b30b,phase 2 study,0.551339
uuid-2c80863315cb48b096f9328de8cb5c5b,melanoma,0.515009
uuid-43a6d9cd5d4f4725b97c47504a3ca257,provided in the Detailed Information,0.349112
uuid-43a6d9cd5d4f4725b97c47504a3ca257,Weber JS,0.321343
uuid-515397e0da3f481b841e1e2f1b2a5e8b,nivolumab,0.510392
uuid-515397e0da3f481b841e1e2f1b2a5e8b,Bristol-Myers Squibb,0.464176
uuid-515397e0da3f481b841e1e2f1b2a5e8b,evaluating,0.683286
uuid-515397e0da3f481b841e1e2f1b2a5e8b,not conducted any controlled clinical trials/studies,0.682483
uuid-515397e0da3f481b841e1e2f1b2a5e8b,RCC,0.308694
uuid-515397e0da3f481b841e1e2f1b2a5e8b,search of published literature,0.839602
uuid-515397e0da3f481b841e1e2f1b2a5e8b,Additionally,0.446384
uuid-515397e0da3f481b841e1e2f1b2a5e8b,PubMed and EMBASE,0.823429
uuid-515397e0da3f481b841e1e2f1b2a5e8b,detailed search of www.clinicaltrials.gov,0.366719
uuid-515397e0da3f481b841e1e2f1b2a5e8b,efficacy and safety of nivolumab,0.841
uuid-515397e0da3f481b841e1e2f1b2a5e8b,not identify any citations relevant to your request,0.605656
uuid-515397e0da3f481b841e1e2f1b2a5e8b,present using the following search terms,0.832619
uuid-f1ed4e82a405455f98db01d427b12641,95% CI,0.524855
uuid-f1ed4e82a405455f98db01d427b12641,respectively,0.383655
uuid-f1ed4e82a405455f98db01d427b12641,ASCO,0.303153
uuid-f1ed4e82a405455f98db01d427b12641,Lancet Oncol,0.368041
uuid-f1ed4e82a405455f98db01d427b12641,Objective response rate,0.504846
uuid-f1ed4e82a405455f98db01d427b12641,ORR,0.465366
uuid-f1ed4e82a405455f98db01d427b12641,Median overall survival,0.346516
uuid-f1ed4e82a405455f98db01d427b12641,Median OS,0.33538
uuid-f1ed4e82a405455f98db01d427b12641,ASCO 2015,0.336983
uuid-f1ed4e82a405455f98db01d427b12641,small cell lung cancer,0.336892
uuid-f1ed4e82a405455f98db01d427b12641,SCLC,0.344367
uuid-f1ed4e82a405455f98db01d427b12641,Antonia SJ,0.55269
uuid-f1ed4e82a405455f98db01d427b12641,Median duration of response,0.649605
uuid-d4bee1a5f13d45b298cd6206db1246f0,N Engl J Med,0.604857
uuid-d4bee1a5f13d45b298cd6206db1246f0,non-small cell lung cancer,0.34354
uuid-d4bee1a5f13d45b298cd6206db1246f0,ESMO,0.393944
uuid-d4bee1a5f13d45b298cd6206db1246f0,Rizvi NA,0.452745
uuid-d4bee1a5f13d45b298cd6206db1246f0,Brahmer J,0.679154
uuid-d4bee1a5f13d45b298cd6206db1246f0,PD-L1,0.347566
uuid-d4bee1a5f13d45b298cd6206db1246f0,Horn L,0.50259
uuid-d4bee1a5f13d45b298cd6206db1246f0,platinum-based doublet chemotherapy,0.304136
uuid-aff6639a7f9c48aaaab34830ff7f8562,95% CI,0.524855
uuid-aff6639a7f9c48aaaab34830ff7f8562,respectively,0.383655
uuid-aff6639a7f9c48aaaab34830ff7f8562,ASCO,0.303153
uuid-aff6639a7f9c48aaaab34830ff7f8562,Lancet Oncol,0.368041
uuid-aff6639a7f9c48aaaab34830ff7f8562,Objective response rate,0.504846
uuid-aff6639a7f9c48aaaab34830ff7f8562,ORR,0.465366
uuid-aff6639a7f9c48aaaab34830ff7f8562,Median overall survival,0.346516
uuid-aff6639a7f9c48aaaab34830ff7f8562,Median OS,0.33538
uuid-aff6639a7f9c48aaaab34830ff7f8562,ASCO 2015,0.336983
uuid-aff6639a7f9c48aaaab34830ff7f8562,small cell lung cancer,0.336892
uuid-aff6639a7f9c48aaaab34830ff7f8562,SCLC,0.344367
uuid-aff6639a7f9c48aaaab34830ff7f8562,Antonia SJ,0.55269
uuid-aff6639a7f9c48aaaab34830ff7f8562,Median duration of response,0.649605
uuid-022dcfd5a9014947a9d008be285d9eae,OS,0.387982
uuid-022dcfd5a9014947a9d008be285d9eae,95% CI,0.745043
uuid-022dcfd5a9014947a9d008be285d9eae,respectively,0.729294
uuid-022dcfd5a9014947a9d008be285d9eae,Objective response rate,0.590876
uuid-022dcfd5a9014947a9d008be285d9eae,ORR,0.722442
uuid-022dcfd5a9014947a9d008be285d9eae,Median overall survival,0.659043
uuid-022dcfd5a9014947a9d008be285d9eae,monotherapy,0.514468
uuid-022dcfd5a9014947a9d008be285d9eae,Median OS,0.696688
uuid-022dcfd5a9014947a9d008be285d9eae,PD-L1,0.300997
uuid-022dcfd5a9014947a9d008be285d9eae,docetaxel,0.635065
uuid-022dcfd5a9014947a9d008be285d9eae,hazard ratio,0.729977
uuid-12e1787d6fbb48d4a49821adc1369bcd,use of nivolumab for the treatment,0.440423
uuid-12e1787d6fbb48d4a49821adc1369bcd,search of published literature,0.311531
uuid-12e1787d6fbb48d4a49821adc1369bcd,PubMed and EMBASE,0.312811
uuid-12e1787d6fbb48d4a49821adc1369bcd,not approved,0.404782
uuid-12e1787d6fbb48d4a49821adc1369bcd,open-label,0.578291
uuid-12e1787d6fbb48d4a49821adc1369bcd,clinical trials investigating the safety,0.440014
uuid-12e1787d6fbb48d4a49821adc1369bcd,present using the following search terms,0.328669
uuid-12e1787d6fbb48d4a49821adc1369bcd,phase,0.41185
uuid-8b1f947efc0a429396a580b7ff5776b9,nivolumab,0.344939
uuid-8b1f947efc0a429396a580b7ff5776b9,Bristol-Myers Squibb,0.363004
uuid-8b1f947efc0a429396a580b7ff5776b9,evaluating,0.564404
uuid-8b1f947efc0a429396a580b7ff5776b9,not conducted any controlled clinical trials/studies,0.538169
uuid-8b1f947efc0a429396a580b7ff5776b9,RCC,0.336118
uuid-8b1f947efc0a429396a580b7ff5776b9,search of published literature,0.750115
uuid-8b1f947efc0a429396a580b7ff5776b9,Additionally,0.766378
uuid-8b1f947efc0a429396a580b7ff5776b9,ongoing,0.629393
uuid-8b1f947efc0a429396a580b7ff5776b9,PubMed and EMBASE,0.745288
uuid-8b1f947efc0a429396a580b7ff5776b9,detailed search of www.clinicaltrials.gov,0.729251
uuid-8b1f947efc0a429396a580b7ff5776b9,efficacy and safety of nivolumab,0.716075
uuid-8b1f947efc0a429396a580b7ff5776b9,not identify any planned,0.665705
uuid-8b1f947efc0a429396a580b7ff5776b9,not identify any citations relevant to your request,0.849476
uuid-8b1f947efc0a429396a580b7ff5776b9,present using the following search terms,0.773092
uuid-c97d9b5f15df45c380ac21b3b7104e6b,Bristol-Myers Squibb,0.315108
uuid-c97d9b5f15df45c380ac21b3b7104e6b,adverse,0.618148
uuid-c97d9b5f15df45c380ac21b3b7104e6b,grade,0.339773
uuid-c97d9b5f15df45c380ac21b3b7104e6b,reported,0.374857
uuid-453682837d9f439187f05b3961cef895,nivolumab,0.359772
uuid-6452c97e1f1840a4b461c9e21559c095,OS,0.62262
uuid-6452c97e1f1840a4b461c9e21559c095,PFS,0.65903
uuid-6452c97e1f1840a4b461c9e21559c095,Overall survival,0.644151
uuid-3c24c50c816247e9942a01e76ad5a698,respectively,0.589071
uuid-3c24c50c816247e9942a01e76ad5a698,Objective response rate,0.407286
uuid-3c24c50c816247e9942a01e76ad5a698,ORR,0.526086
uuid-3c24c50c816247e9942a01e76ad5a698,monotherapy,0.319413
uuid-3c24c50c816247e9942a01e76ad5a698,docetaxel,0.334344
uuid-00b0fda113b64f42a99570a199fc9a2b,nivolumab,0.512783
uuid-00b0fda113b64f42a99570a199fc9a2b,Bristol-Myers Squibb,0.381431
uuid-00b0fda113b64f42a99570a199fc9a2b,evaluating,0.54502
uuid-00b0fda113b64f42a99570a199fc9a2b,not conducted any controlled clinical trials/studies,0.588212
uuid-00b0fda113b64f42a99570a199fc9a2b,Pubmed literature search,0.792135
uuid-00b0fda113b64f42a99570a199fc9a2b,purposes other than its labeled indication must be considered investigational,0.840065
uuid-00b0fda113b64f42a99570a199fc9a2b,not identify any citations relevant to your inquiry,0.781077
uuid-00b0fda113b64f42a99570a199fc9a2b,Additionally,0.356835
uuid-00b0fda113b64f42a99570a199fc9a2b,ongoing,0.363055
uuid-00b0fda113b64f42a99570a199fc9a2b,using the following search terms,0.750799
uuid-00b0fda113b64f42a99570a199fc9a2b,detailed search of www.clinicaltrials.gov,0.378409
uuid-00b0fda113b64f42a99570a199fc9a2b,efficacy and safety of nivolumab,0.42594
uuid-00b0fda113b64f42a99570a199fc9a2b,not identify any planned,0.367139
uuid-00b0fda113b64f42a99570a199fc9a2b,not identify any citations relevant to your request,0.365447
uuid-2675b730b89542b6b8acdce819ae931b,considered investigational,0.402849
uuid-2675b730b89542b6b8acdce819ae931b,small cell lung cancer,0.651985
uuid-2675b730b89542b6b8acdce819ae931b,partial response,0.50367
uuid-2675b730b89542b6b8acdce819ae931b,SCLC,0.736863
uuid-2675b730b89542b6b8acdce819ae931b,therapy,0.843488
uuid-2675b730b89542b6b8acdce819ae931b,relapsed,0.613852
uuid-2675b730b89542b6b8acdce819ae931b,phase 1/2 study CA209-032,0.40439
uuid-2675b730b89542b6b8acdce819ae931b,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-51df6a442abf4f1ca23295e4ec0f7d05,N Engl J Med,0.320726
uuid-51df6a442abf4f1ca23295e4ec0f7d05,provided in the Detailed Information,0.366677
uuid-51df6a442abf4f1ca23295e4ec0f7d05,clinical,0.40856
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,search of published literature,0.394524
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,Additionally,0.413583
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,ongoing,0.322117
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,PubMed and EMBASE,0.391671
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,detailed search of www.clinicaltrials.gov,0.375936
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,efficacy and safety of nivolumab,0.370699
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,not identify any planned,0.34283
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,Weber JS,0.319229
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,not identify any citations relevant to your request,0.447813
uuid-3dba166d3e7d4ef98b71ac6da7c1e1e5,present using the following search terms,0.408199
uuid-383775e677a84c37a610eebf39cdd6ce,RCC,0.906223
uuid-5b079e798dd541e48af2e58cb3473aa6,nivolumab,0.344939
uuid-5b079e798dd541e48af2e58cb3473aa6,Bristol-Myers Squibb,0.363004
uuid-5b079e798dd541e48af2e58cb3473aa6,evaluating,0.564404
uuid-5b079e798dd541e48af2e58cb3473aa6,not conducted any controlled clinical trials/studies,0.538169
uuid-5b079e798dd541e48af2e58cb3473aa6,RCC,0.336118
uuid-5b079e798dd541e48af2e58cb3473aa6,search of published literature,0.750115
uuid-5b079e798dd541e48af2e58cb3473aa6,Additionally,0.766378
uuid-5b079e798dd541e48af2e58cb3473aa6,ongoing,0.629393
uuid-5b079e798dd541e48af2e58cb3473aa6,PubMed and EMBASE,0.745288
uuid-5b079e798dd541e48af2e58cb3473aa6,detailed search of www.clinicaltrials.gov,0.729251
uuid-5b079e798dd541e48af2e58cb3473aa6,efficacy and safety of nivolumab,0.716075
uuid-5b079e798dd541e48af2e58cb3473aa6,not identify any planned,0.665705
uuid-5b079e798dd541e48af2e58cb3473aa6,not identify any citations relevant to your request,0.849476
uuid-5b079e798dd541e48af2e58cb3473aa6,present using the following search terms,0.773092
uuid-6d6d6304a90b4862bcfabaeec3f84e26,N Engl J Med,0.373796
uuid-6d6d6304a90b4862bcfabaeec3f84e26,protocol,0.420361
uuid-6d6d6304a90b4862bcfabaeec3f84e26,McDermott DF,0.513284
uuid-6d6d6304a90b4862bcfabaeec3f84e26,Motzer RJ,0.482105
uuid-6d6d6304a90b4862bcfabaeec3f84e26,phase 3 study,0.448204
uuid-6d6d6304a90b4862bcfabaeec3f84e26,Escudier B,0.482741
uuid-6d6d6304a90b4862bcfabaeec3f84e26,NEJM,0.342527
uuid-6d6d6304a90b4862bcfabaeec3f84e26,et al.,0.466863
uuid-6d6d6304a90b4862bcfabaeec3f84e26,J Clin Oncol,0.523543
uuid-6d6d6304a90b4862bcfabaeec3f84e26,Topalian,0.340171
uuid-6d6d6304a90b4862bcfabaeec3f84e26,phase 1 study,0.421699
uuid-6d6d6304a90b4862bcfabaeec3f84e26,mg,0.324901
uuid-6d6d6304a90b4862bcfabaeec3f84e26,CA209-003,0.451562
uuid-6d6d6304a90b4862bcfabaeec3f84e26,phase 2 study,0.595096
uuid-6d6d6304a90b4862bcfabaeec3f84e26,grade,0.324161
uuid-6d6d6304a90b4862bcfabaeec3f84e26,kg,0.310462
uuid-8db3063ecd62484db5e0a266d138dcaa,RCC,0.906223
uuid-68768fafbb4a4f9db8648ad49aef67f5,NSCLC,0.361614
uuid-68768fafbb4a4f9db8648ad49aef67f5,non-small cell lung cancer,0.3001
uuid-68768fafbb4a4f9db8648ad49aef67f5,RCC,0.879698
uuid-e03864ca22274321aacca43340be6996,evaluating,0.350845
uuid-e03864ca22274321aacca43340be6996,not conducted any controlled clinical trials/studies,0.345107
uuid-e03864ca22274321aacca43340be6996,search of published literature,0.385331
uuid-e03864ca22274321aacca43340be6996,Additionally,0.40981
uuid-e03864ca22274321aacca43340be6996,ongoing,0.457998
uuid-e03864ca22274321aacca43340be6996,PubMed and EMBASE,0.378285
uuid-e03864ca22274321aacca43340be6996,detailed search of www.clinicaltrials.gov,0.428522
uuid-e03864ca22274321aacca43340be6996,efficacy and safety of nivolumab,0.407868
uuid-e03864ca22274321aacca43340be6996,not identify any planned,0.444729
uuid-e03864ca22274321aacca43340be6996,combination,0.388252
uuid-e03864ca22274321aacca43340be6996,BMS,0.316104
uuid-e03864ca22274321aacca43340be6996,not identify any citations relevant to your request,0.438151
uuid-e03864ca22274321aacca43340be6996,present using the following search terms,0.377101
uuid-bc98b7bee34647b2844782c641d4d21c,RCC,0.906223
uuid-9891cb2f4a50455ebf9aa643f578757f,mg,0.340345
uuid-9891cb2f4a50455ebf9aa643f578757f,fatigue,0.466601
uuid-9891cb2f4a50455ebf9aa643f578757f,kg,0.404404
uuid-9891cb2f4a50455ebf9aa643f578757f,relapsed,0.449896
uuid-9891cb2f4a50455ebf9aa643f578757f,Overall survival,0.583426
uuid-e1e8c9521beb4161b9fc2cc9cf786319,RCC,0.888695
uuid-1dae3b68c6e04f74b545da62085f624d,N Engl J Med,0.448483
uuid-1dae3b68c6e04f74b545da62085f624d,protocol,0.770446
uuid-1dae3b68c6e04f74b545da62085f624d,McDermott DF,0.741196
uuid-1dae3b68c6e04f74b545da62085f624d,Motzer RJ,0.818144
uuid-1dae3b68c6e04f74b545da62085f624d,phase 3 study,0.417055
uuid-1dae3b68c6e04f74b545da62085f624d,Escudier B,0.749917
uuid-1dae3b68c6e04f74b545da62085f624d,NEJM,0.400698
uuid-1dae3b68c6e04f74b545da62085f624d,et al.,0.668641
uuid-1dae3b68c6e04f74b545da62085f624d,J Clin Oncol,0.792018
uuid-1dae3b68c6e04f74b545da62085f624d,Topalian,0.388894
uuid-1dae3b68c6e04f74b545da62085f624d,phase 1 study,0.500686
uuid-1dae3b68c6e04f74b545da62085f624d,CA209-003,0.567381
uuid-1dae3b68c6e04f74b545da62085f624d,phase 2 study,0.677985
uuid-1dae3b68c6e04f74b545da62085f624d,present using the following search terms,0.310558
uuid-1dae3b68c6e04f74b545da62085f624d,investigating,0.615835
uuid-983320f33f274c5e8f3ee6021bce7032,RCC,0.906223
uuid-1e405a79769f4a9594cf88dce3c9f5e8,Bristol-Myers Squibb,0.748381
uuid-1e405a79769f4a9594cf88dce3c9f5e8,evaluating,0.599347
uuid-1e405a79769f4a9594cf88dce3c9f5e8,not conducted any controlled clinical trials/studies,0.676947
uuid-1e405a79769f4a9594cf88dce3c9f5e8,efficacy and safety of nivolumab,0.50551
uuid-529fbbe662ac4c64baa98fa6b8af91df,clinical,0.364471
uuid-529fbbe662ac4c64baa98fa6b8af91df,tumors,0.346796
uuid-529fbbe662ac4c64baa98fa6b8af91df,trial,0.322899
uuid-d0bde4cd12aa46be88b2d7b5260946bd,use of nivolumab for the treatment,0.342309
uuid-d0bde4cd12aa46be88b2d7b5260946bd,evaluating,0.303233
uuid-d0bde4cd12aa46be88b2d7b5260946bd,patients,0.87132
uuid-d0bde4cd12aa46be88b2d7b5260946bd,considered investigational,0.376713
uuid-d0bde4cd12aa46be88b2d7b5260946bd,small cell lung cancer,0.4035
uuid-d0bde4cd12aa46be88b2d7b5260946bd,SCLC,0.365465
uuid-d0bde4cd12aa46be88b2d7b5260946bd,therapy,0.340954
uuid-d0bde4cd12aa46be88b2d7b5260946bd,grade 3 to 4 AEs,0.384841
uuid-e25233cab4144ebea36abae1d648f36c,N Engl J Med,0.466497
uuid-e25233cab4144ebea36abae1d648f36c,ASCO,0.491786
uuid-e25233cab4144ebea36abae1d648f36c,Lancet Oncol,0.34677
uuid-e25233cab4144ebea36abae1d648f36c,protocol,0.608956
uuid-e25233cab4144ebea36abae1d648f36c,McDermott DF,0.714024
uuid-e25233cab4144ebea36abae1d648f36c,Motzer RJ,0.665237
uuid-e25233cab4144ebea36abae1d648f36c,phase 3 study,0.390315
uuid-e25233cab4144ebea36abae1d648f36c,Escudier B,0.683678
uuid-e25233cab4144ebea36abae1d648f36c,NEJM,0.444843
uuid-e25233cab4144ebea36abae1d648f36c,et al.,0.725231
uuid-e25233cab4144ebea36abae1d648f36c,J Clin Oncol,0.701894
uuid-e25233cab4144ebea36abae1d648f36c,Topalian,0.420717
uuid-e25233cab4144ebea36abae1d648f36c,phase 1 study,0.445517
uuid-e25233cab4144ebea36abae1d648f36c,Rizvi NA,0.400269
uuid-e25233cab4144ebea36abae1d648f36c,CA209-003,0.399706
uuid-e25233cab4144ebea36abae1d648f36c,phase 2 study,0.658621
uuid-e25233cab4144ebea36abae1d648f36c,investigating,0.330817
uuid-08daf1fc055b4eebb472f04cddcc6c43,protocol,0.330688
uuid-08daf1fc055b4eebb472f04cddcc6c43,clinical,0.451329
uuid-7cfc5a1b9a85488490bf26e4450abe18,RCC,0.906223
uuid-4e9545dfb1fa4234928a3145dacb74bb,mg,0.777444
uuid-4e9545dfb1fa4234928a3145dacb74bb,kg,0.703518
uuid-77f50122bfa9447ea83cdbe261855d8a,use of nivolumab for the treatment,0.416171
uuid-77f50122bfa9447ea83cdbe261855d8a,considered investigational,0.55653
uuid-77f50122bfa9447ea83cdbe261855d8a,open-label,0.368112
uuid-aa9f2851c4754abf8236766b8f32cd03,evaluating,0.338275
uuid-aa9f2851c4754abf8236766b8f32cd03,not conducted any controlled clinical trials/studies,0.356375
uuid-aa9f2851c4754abf8236766b8f32cd03,NSCLC,0.449527
uuid-aa9f2851c4754abf8236766b8f32cd03,non-small cell lung cancer,0.392351
uuid-aa9f2851c4754abf8236766b8f32cd03,patients,0.406033
uuid-aa9f2851c4754abf8236766b8f32cd03,considered investigational,0.314398
uuid-aa9f2851c4754abf8236766b8f32cd03,RCC,0.342034
uuid-aa9f2851c4754abf8236766b8f32cd03,phase 3 study,0.440093
uuid-aa9f2851c4754abf8236766b8f32cd03,melanoma,0.327963
uuid-aa9f2851c4754abf8236766b8f32cd03,phase 1 study,0.452421
uuid-aa9f2851c4754abf8236766b8f32cd03,efficacy and safety of nivolumab,0.320273
uuid-038d6429d6e544dba61eea1f829b8b1d,NSCLC,0.522939
uuid-038d6429d6e544dba61eea1f829b8b1d,non-small cell lung cancer,0.501626
uuid-9e73b95cfac3462a97249c3b2afe3b30,considered investigational,0.402849
uuid-9e73b95cfac3462a97249c3b2afe3b30,small cell lung cancer,0.651985
uuid-9e73b95cfac3462a97249c3b2afe3b30,partial response,0.50367
uuid-9e73b95cfac3462a97249c3b2afe3b30,SCLC,0.736863
uuid-9e73b95cfac3462a97249c3b2afe3b30,therapy,0.843488
uuid-9e73b95cfac3462a97249c3b2afe3b30,relapsed,0.613852
uuid-9e73b95cfac3462a97249c3b2afe3b30,phase 1/2 study CA209-032,0.40439
uuid-9e73b95cfac3462a97249c3b2afe3b30,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-dc262c2f428748a78b80f15fbba30609,RCC,0.906223
uuid-e8e5f79d0385497dafc7c490e42fc62d,95% CI,0.524855
uuid-e8e5f79d0385497dafc7c490e42fc62d,respectively,0.383655
uuid-e8e5f79d0385497dafc7c490e42fc62d,ASCO,0.303153
uuid-e8e5f79d0385497dafc7c490e42fc62d,Lancet Oncol,0.368041
uuid-e8e5f79d0385497dafc7c490e42fc62d,Objective response rate,0.504846
uuid-e8e5f79d0385497dafc7c490e42fc62d,ORR,0.465366
uuid-e8e5f79d0385497dafc7c490e42fc62d,Median overall survival,0.346516
uuid-e8e5f79d0385497dafc7c490e42fc62d,Median OS,0.33538
uuid-e8e5f79d0385497dafc7c490e42fc62d,ASCO 2015,0.336983
uuid-e8e5f79d0385497dafc7c490e42fc62d,small cell lung cancer,0.336892
uuid-e8e5f79d0385497dafc7c490e42fc62d,SCLC,0.344367
uuid-e8e5f79d0385497dafc7c490e42fc62d,Antonia SJ,0.55269
uuid-e8e5f79d0385497dafc7c490e42fc62d,Median duration of response,0.649605
uuid-4c879c85b01a4a02b468b6393d99d27f,requested,0.594234
uuid-6dcb3fae4a96455185b87fd70f52bd82,RCC,0.906223
uuid-c48719339a974720bb80db28857f21ce,RCC,0.888695
uuid-d3c6c78133ba4273892cf10c536be2f7,95% CI,0.524855
uuid-d3c6c78133ba4273892cf10c536be2f7,respectively,0.383655
uuid-d3c6c78133ba4273892cf10c536be2f7,ASCO,0.303153
uuid-d3c6c78133ba4273892cf10c536be2f7,Lancet Oncol,0.368041
uuid-d3c6c78133ba4273892cf10c536be2f7,Objective response rate,0.504846
uuid-d3c6c78133ba4273892cf10c536be2f7,ORR,0.465366
uuid-d3c6c78133ba4273892cf10c536be2f7,Median overall survival,0.346516
uuid-d3c6c78133ba4273892cf10c536be2f7,Median OS,0.33538
uuid-d3c6c78133ba4273892cf10c536be2f7,ASCO 2015,0.336983
uuid-d3c6c78133ba4273892cf10c536be2f7,small cell lung cancer,0.336892
uuid-d3c6c78133ba4273892cf10c536be2f7,SCLC,0.344367
uuid-d3c6c78133ba4273892cf10c536be2f7,Antonia SJ,0.55269
uuid-d3c6c78133ba4273892cf10c536be2f7,Median duration of response,0.649605
uuid-da601e837fe94869a4f69efe1fa0bade,NSCLC,0.696007
uuid-da601e837fe94869a4f69efe1fa0bade,non-small cell lung cancer,0.658519
uuid-da601e837fe94869a4f69efe1fa0bade,patients,0.467921
uuid-da601e837fe94869a4f69efe1fa0bade,considered investigational,0.795993
uuid-da601e837fe94869a4f69efe1fa0bade,patients with advanced or metastatic,0.453526
uuid-da601e837fe94869a4f69efe1fa0bade,nivolumab combined with ipilimumab,0.401691
uuid-da601e837fe94869a4f69efe1fa0bade,tumors,0.517568
uuid-da601e837fe94869a4f69efe1fa0bade,small cell lung cancer,0.754774
uuid-da601e837fe94869a4f69efe1fa0bade,SCLC,0.756006
uuid-da601e837fe94869a4f69efe1fa0bade,therapy,0.467239
uuid-da601e837fe94869a4f69efe1fa0bade,phase 1/2 study CA209-032,0.676562
uuid-da601e837fe94869a4f69efe1fa0bade,evaluates the efficacy of nivolumab monotherapy,0.620312
uuid-120f644015c54f44b62e403579d320f3,RCC,0.889983
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,patients,0.505883
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,considered investigational,0.699202
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,patients with advanced or metastatic,0.471186
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,nivolumab combined with ipilimumab,0.455879
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,tumors,0.588241
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,small cell lung cancer,0.887145
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,SCLC,0.890228
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,therapy,0.642719
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,phase 1/2 study CA209-032,0.751096
uuid-89a3986f5b7a4c1e9e0c3112caf9f1dd,evaluates the efficacy of nivolumab monotherapy,0.693187
uuid-b9190d72339c41b6a0015669b576790e,RCC,0.811225
uuid-0efb5fbaaa8e4fd9a88e4966af9cd78e,RCC,0.906223
uuid-f4ad07c23e324faa9a865620157bfa23,N Engl J Med,0.347178
uuid-f4ad07c23e324faa9a865620157bfa23,Lancet Oncol,0.359155
uuid-f4ad07c23e324faa9a865620157bfa23,protocol,0.371457
uuid-f4ad07c23e324faa9a865620157bfa23,McDermott DF,0.414017
uuid-f4ad07c23e324faa9a865620157bfa23,Motzer RJ,0.384536
uuid-f4ad07c23e324faa9a865620157bfa23,phase 3 study,0.443559
uuid-f4ad07c23e324faa9a865620157bfa23,Escudier B,0.411866
uuid-f4ad07c23e324faa9a865620157bfa23,et al.,0.39703
uuid-f4ad07c23e324faa9a865620157bfa23,J Clin Oncol,0.378141
uuid-f4ad07c23e324faa9a865620157bfa23,phase 1 study,0.326203
uuid-f4ad07c23e324faa9a865620157bfa23,Rizvi NA,0.563772
uuid-f4ad07c23e324faa9a865620157bfa23,mg,0.40261
uuid-f4ad07c23e324faa9a865620157bfa23,Weber JS,0.418348
uuid-f4ad07c23e324faa9a865620157bfa23,phase 2 study,0.587446
uuid-f4ad07c23e324faa9a865620157bfa23,kg,0.361586
uuid-36284dbb48094a6b9345afb8d5effb20,RCC,0.906223
uuid-7ea7eaa16d234a299f7f4690066c7538,RCC,0.906223
uuid-8067cd6e20cf40b4985ebeeb6bced4fa,RCC,0.906223
uuid-c4a0dec465be4ddf80ea478b46bf1eee,evaluating,0.305205
uuid-c4a0dec465be4ddf80ea478b46bf1eee,not conducted any controlled clinical trials/studies,0.32039
uuid-c4a0dec465be4ddf80ea478b46bf1eee,NSCLC,0.343965
uuid-c4a0dec465be4ddf80ea478b46bf1eee,non-small cell lung cancer,0.302571
uuid-c4a0dec465be4ddf80ea478b46bf1eee,RCC,0.756684
uuid-bc0d30da696f487cb900e21b297030e5,RCC,0.906223
uuid-358b5664729e4e43a871aeab0586de09,RCC,0.906223
uuid-8194bc18d69a46f3864c4ceb057cd94c,RCC,0.906223
uuid-9257154df4b9493b8797b504a1a23981,mg,0.872768
uuid-9257154df4b9493b8797b504a1a23981,kg,0.820977
uuid-c0e782eefce34b9d89a3ee874af01105,requested,0.662269
uuid-4aa8539714784ddfb9f2c20bfc0eb919,requested,0.662269
uuid-cbb8426cd762481f9c27d3047573cfb9,requested,0.662269
uuid-14d7fe0b6e6143fda1083ea61eeb195d,requested,0.662269
uuid-bd01fe9762da4492ae2d5c95c5408da6,N Engl J Med,0.475636
uuid-bd01fe9762da4492ae2d5c95c5408da6,respectively,0.310498
uuid-bd01fe9762da4492ae2d5c95c5408da6,Lancet Oncol,0.354401
uuid-bd01fe9762da4492ae2d5c95c5408da6,protocol,0.560082
uuid-bd01fe9762da4492ae2d5c95c5408da6,McDermott DF,0.63233
uuid-bd01fe9762da4492ae2d5c95c5408da6,Motzer RJ,0.587606
uuid-bd01fe9762da4492ae2d5c95c5408da6,phase 3 study,0.497255
uuid-bd01fe9762da4492ae2d5c95c5408da6,Escudier B,0.61201
uuid-bd01fe9762da4492ae2d5c95c5408da6,NEJM,0.435204
uuid-bd01fe9762da4492ae2d5c95c5408da6,et al.,0.598168
uuid-bd01fe9762da4492ae2d5c95c5408da6,J Clin Oncol,0.595813
uuid-bd01fe9762da4492ae2d5c95c5408da6,Topalian,0.351089
uuid-bd01fe9762da4492ae2d5c95c5408da6,Rizvi NA,0.443715
uuid-bd01fe9762da4492ae2d5c95c5408da6,CA209-003,0.317774
uuid-bd01fe9762da4492ae2d5c95c5408da6,Weber JS,0.358025
uuid-bd01fe9762da4492ae2d5c95c5408da6,phase 2 study,0.644323
uuid-2277a8721e7d43929c4d0883d1728228,RCC,0.832075
uuid-9c51e3f58c474951b36ff8d6cdb611df,nivolumab,0.493389
uuid-9c51e3f58c474951b36ff8d6cdb611df,Bristol-Myers Squibb,0.598477
uuid-9c51e3f58c474951b36ff8d6cdb611df,evaluating,0.837805
uuid-9c51e3f58c474951b36ff8d6cdb611df,not conducted any controlled clinical trials/studies,0.848713
uuid-9c51e3f58c474951b36ff8d6cdb611df,Pubmed literature search,0.314091
uuid-9c51e3f58c474951b36ff8d6cdb611df,purposes other than its labeled indication must be considered investigational,0.4415
uuid-9c51e3f58c474951b36ff8d6cdb611df,search of published literature,0.772891
uuid-9c51e3f58c474951b36ff8d6cdb611df,PubMed and EMBASE,0.743175
uuid-9c51e3f58c474951b36ff8d6cdb611df,efficacy and safety of nivolumab,0.905749
uuid-9c51e3f58c474951b36ff8d6cdb611df,not identify any citations relevant to your request,0.417576
uuid-9c51e3f58c474951b36ff8d6cdb611df,present using the following search terms,0.748132
uuid-22e9feff28634ce9a0fdbc8b478660a7,mg,0.812679
uuid-22e9feff28634ce9a0fdbc8b478660a7,kg,0.742363
uuid-b780074acd8f4200b665025564f1b4d8,requested,0.592788
uuid-2e2049b80ca0474fafb027c843bb1106,Bristol-Myers Squibb,0.307454
uuid-2e2049b80ca0474fafb027c843bb1106,NSCLC,0.360167
uuid-2e2049b80ca0474fafb027c843bb1106,non-small cell lung cancer,0.358938
uuid-2e2049b80ca0474fafb027c843bb1106,adverse,0.448313
uuid-2e2049b80ca0474fafb027c843bb1106,reported,0.719161
uuid-f8e2a23af5d649e889b924065dfe871d,Bristol-Myers Squibb,0.341822
uuid-f8e2a23af5d649e889b924065dfe871d,not conducted any controlled clinical trials/studies,0.304507
uuid-f8e2a23af5d649e889b924065dfe871d,Opdivo,0.461382
uuid-f8e2a23af5d649e889b924065dfe871d,Pubmed literature search,0.614325
uuid-f8e2a23af5d649e889b924065dfe871d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f8e2a23af5d649e889b924065dfe871d,not identify any citations relevant to your inquiry,0.606087
uuid-f8e2a23af5d649e889b924065dfe871d,adverse,0.304183
uuid-f8e2a23af5d649e889b924065dfe871d,using the following search terms,0.642331
uuid-f8e2a23af5d649e889b924065dfe871d,databases,0.315039
uuid-f8e2a23af5d649e889b924065dfe871d,reported,0.556704
uuid-85fa402442db420b8673efe73bdd0491,NSCLC,0.495935
uuid-85fa402442db420b8673efe73bdd0491,non-small cell lung cancer,0.43311
uuid-85fa402442db420b8673efe73bdd0491,phase 1 study,0.4137
uuid-85fa402442db420b8673efe73bdd0491,Rizvi NA,0.304817
uuid-85fa402442db420b8673efe73bdd0491,Brahmer J,0.405499
uuid-85fa402442db420b8673efe73bdd0491,BMS,0.666452
uuid-85fa402442db420b8673efe73bdd0491,platinum-based doublet chemotherapy,0.304823
uuid-0718e1c12c3c41a790081c2437afb808,N Engl J Med,0.442834
uuid-0718e1c12c3c41a790081c2437afb808,protocol,0.763252
uuid-0718e1c12c3c41a790081c2437afb808,McDermott DF,0.733103
uuid-0718e1c12c3c41a790081c2437afb808,Motzer RJ,0.811057
uuid-0718e1c12c3c41a790081c2437afb808,phase 3 study,0.420895
uuid-0718e1c12c3c41a790081c2437afb808,Escudier B,0.741048
uuid-0718e1c12c3c41a790081c2437afb808,NEJM,0.402544
uuid-0718e1c12c3c41a790081c2437afb808,et al.,0.660398
uuid-0718e1c12c3c41a790081c2437afb808,J Clin Oncol,0.786367
uuid-0718e1c12c3c41a790081c2437afb808,Topalian,0.392395
uuid-0718e1c12c3c41a790081c2437afb808,phase 1 study,0.513779
uuid-0718e1c12c3c41a790081c2437afb808,CA209-003,0.583337
uuid-0718e1c12c3c41a790081c2437afb808,phase 2 study,0.675447
uuid-0718e1c12c3c41a790081c2437afb808,present using the following search terms,0.304589
uuid-0718e1c12c3c41a790081c2437afb808,investigating,0.633101
uuid-e74cd8abac5e4de8ad7a2b02022b0153,RCC,0.80811
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,use of nivolumab for the treatment,0.444737
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,evaluating,0.347303
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,efficacy,0.466529
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,NSCLC,0.323348
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,non-small cell lung cancer,0.319709
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,not approved,0.48525
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,clinical trials investigating the safety,0.476018
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,safety of nivolumab monotherapy,0.430357
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,cohort,0.325516
uuid-9fa1a3aa47ce4c8db0b01670db7ea032,platinum-based doublet chemotherapy,0.477291
uuid-78783550545e4bd0963ce726bd864623,clinical,0.676048
uuid-78783550545e4bd0963ce726bd864623,trial,0.59083
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,N Engl J Med,0.410025
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,protocol,0.663749
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,RCC,0.370429
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,McDermott DF,0.577168
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,search of published literature,0.443686
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,Additionally,0.395847
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,ongoing,0.335873
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,Motzer RJ,0.609458
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,phase 3 study,0.312748
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,PubMed and EMBASE,0.438896
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,Escudier B,0.595328
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,et al.,0.521538
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,J Clin Oncol,0.545137
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,detailed search of www.clinicaltrials.gov,0.358127
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,efficacy and safety of nivolumab,0.429052
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,not identify any planned,0.344155
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,phase 2 study,0.513121
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,not identify any citations relevant to your request,0.414617
uuid-16b971f9a6ea4d0881dbb7d66b88a7f0,present using the following search terms,0.417875
uuid-df7c23c82f164f99af86b58723f3cd30,N Engl J Med,0.410025
uuid-df7c23c82f164f99af86b58723f3cd30,protocol,0.663749
uuid-df7c23c82f164f99af86b58723f3cd30,RCC,0.370429
uuid-df7c23c82f164f99af86b58723f3cd30,McDermott DF,0.577168
uuid-df7c23c82f164f99af86b58723f3cd30,search of published literature,0.443686
uuid-df7c23c82f164f99af86b58723f3cd30,Additionally,0.395847
uuid-df7c23c82f164f99af86b58723f3cd30,ongoing,0.335873
uuid-df7c23c82f164f99af86b58723f3cd30,Motzer RJ,0.609458
uuid-df7c23c82f164f99af86b58723f3cd30,phase 3 study,0.312748
uuid-df7c23c82f164f99af86b58723f3cd30,PubMed and EMBASE,0.438896
uuid-df7c23c82f164f99af86b58723f3cd30,Escudier B,0.595328
uuid-df7c23c82f164f99af86b58723f3cd30,et al.,0.521538
uuid-df7c23c82f164f99af86b58723f3cd30,J Clin Oncol,0.545137
uuid-df7c23c82f164f99af86b58723f3cd30,detailed search of www.clinicaltrials.gov,0.358127
uuid-df7c23c82f164f99af86b58723f3cd30,efficacy and safety of nivolumab,0.429052
uuid-df7c23c82f164f99af86b58723f3cd30,not identify any planned,0.344155
uuid-df7c23c82f164f99af86b58723f3cd30,phase 2 study,0.513121
uuid-df7c23c82f164f99af86b58723f3cd30,not identify any citations relevant to your request,0.414617
uuid-df7c23c82f164f99af86b58723f3cd30,present using the following search terms,0.417875
uuid-d3c281e492314d31b874c16999baa9b8,RCC,0.906223
uuid-bce5441c871c4c5b89a7a378f197bbde,protocol,0.374983
uuid-bce5441c871c4c5b89a7a378f197bbde,McDermott DF,0.336145
uuid-bce5441c871c4c5b89a7a378f197bbde,Additionally,0.421598
uuid-bce5441c871c4c5b89a7a378f197bbde,ongoing,0.30475
uuid-bce5441c871c4c5b89a7a378f197bbde,Motzer RJ,0.330515
uuid-bce5441c871c4c5b89a7a378f197bbde,Escudier B,0.324042
uuid-bce5441c871c4c5b89a7a378f197bbde,NEJM,0.518945
uuid-bce5441c871c4c5b89a7a378f197bbde,J Clin Oncol,0.363847
uuid-bce5441c871c4c5b89a7a378f197bbde,Topalian,0.517327
uuid-bce5441c871c4c5b89a7a378f197bbde,detailed search of www.clinicaltrials.gov,0.343468
uuid-bce5441c871c4c5b89a7a378f197bbde,not identify any planned,0.320948
uuid-bce5441c871c4c5b89a7a378f197bbde,not identify any citations relevant to your request,0.348107
uuid-9b1296222bfd453796c3132ead1aa488,RCC,0.909054
uuid-9f39a9218f5e4779bb5178c83d3feee8,ASCO,0.503827
uuid-9f39a9218f5e4779bb5178c83d3feee8,requested,0.447451
uuid-95e0ec91467f426eac6e52f21eba5271,RCC,0.555727
uuid-95e0ec91467f426eac6e52f21eba5271,phase 3 study,0.397731
uuid-95e0ec91467f426eac6e52f21eba5271,open-label,0.4165
uuid-95e0ec91467f426eac6e52f21eba5271,phase 1 study,0.30226
uuid-95e0ec91467f426eac6e52f21eba5271,phase,0.448318
uuid-95e0ec91467f426eac6e52f21eba5271,investigating,0.327654
uuid-f72bb31fcf0a4d8690e22f034647a1fd,N Engl J Med,0.410025
uuid-f72bb31fcf0a4d8690e22f034647a1fd,protocol,0.663749
uuid-f72bb31fcf0a4d8690e22f034647a1fd,RCC,0.370429
uuid-f72bb31fcf0a4d8690e22f034647a1fd,McDermott DF,0.577168
uuid-f72bb31fcf0a4d8690e22f034647a1fd,search of published literature,0.443686
uuid-f72bb31fcf0a4d8690e22f034647a1fd,Additionally,0.395847
uuid-f72bb31fcf0a4d8690e22f034647a1fd,ongoing,0.335873
uuid-f72bb31fcf0a4d8690e22f034647a1fd,Motzer RJ,0.609458
uuid-f72bb31fcf0a4d8690e22f034647a1fd,phase 3 study,0.312748
uuid-f72bb31fcf0a4d8690e22f034647a1fd,PubMed and EMBASE,0.438896
uuid-f72bb31fcf0a4d8690e22f034647a1fd,Escudier B,0.595328
uuid-f72bb31fcf0a4d8690e22f034647a1fd,et al.,0.521538
uuid-f72bb31fcf0a4d8690e22f034647a1fd,J Clin Oncol,0.545137
uuid-f72bb31fcf0a4d8690e22f034647a1fd,detailed search of www.clinicaltrials.gov,0.358127
uuid-f72bb31fcf0a4d8690e22f034647a1fd,efficacy and safety of nivolumab,0.429052
uuid-f72bb31fcf0a4d8690e22f034647a1fd,not identify any planned,0.344155
uuid-f72bb31fcf0a4d8690e22f034647a1fd,phase 2 study,0.513121
uuid-f72bb31fcf0a4d8690e22f034647a1fd,not identify any citations relevant to your request,0.414617
uuid-f72bb31fcf0a4d8690e22f034647a1fd,present using the following search terms,0.417875
uuid-3c316a5004cb49dc89ea31052a2c1e21,trial,0.347424
uuid-506838ba1f4f4e68a6b2cb22081a32d0,phase 3 study,0.319955
uuid-506838ba1f4f4e68a6b2cb22081a32d0,phase 1 study,0.446598
uuid-506838ba1f4f4e68a6b2cb22081a32d0,Rizvi NA,0.340455
uuid-506838ba1f4f4e68a6b2cb22081a32d0,mg,0.54474
uuid-506838ba1f4f4e68a6b2cb22081a32d0,CA209-003,0.386745
uuid-506838ba1f4f4e68a6b2cb22081a32d0,phase 2 study,0.37122
uuid-506838ba1f4f4e68a6b2cb22081a32d0,kg,0.481395
uuid-9f923473563c429f90a3e7336d506558,Bristol-Myers Squibb,0.840451
uuid-9f923473563c429f90a3e7336d506558,evaluating,0.718784
uuid-9f923473563c429f90a3e7336d506558,not conducted any controlled clinical trials/studies,0.798502
uuid-9f923473563c429f90a3e7336d506558,adverse,0.316881
uuid-9f923473563c429f90a3e7336d506558,efficacy and safety of nivolumab,0.640661
uuid-9f923473563c429f90a3e7336d506558,reported,0.342563
uuid-149cb466661b467ca6913119e69b6fbd,search of published literature,0.433668
uuid-149cb466661b467ca6913119e69b6fbd,Additionally,0.36539
uuid-149cb466661b467ca6913119e69b6fbd,PubMed and EMBASE,0.441504
uuid-149cb466661b467ca6913119e69b6fbd,detailed search of www.clinicaltrials.gov,0.339001
uuid-149cb466661b467ca6913119e69b6fbd,PD-L1,0.831435
uuid-149cb466661b467ca6913119e69b6fbd,not identify any citations relevant to your request,0.431418
uuid-149cb466661b467ca6913119e69b6fbd,present using the following search terms,0.438671
uuid-53e9b873a5d840c2b871bd3484e59139,RCC,0.906223
uuid-2e894bbd4ef14149a1711246be6eed28,RCC,0.909054
uuid-cfa713908642437b9342944213176f45,considered investigational,0.402849
uuid-cfa713908642437b9342944213176f45,small cell lung cancer,0.651985
uuid-cfa713908642437b9342944213176f45,partial response,0.50367
uuid-cfa713908642437b9342944213176f45,SCLC,0.736863
uuid-cfa713908642437b9342944213176f45,therapy,0.843488
uuid-cfa713908642437b9342944213176f45,relapsed,0.613852
uuid-cfa713908642437b9342944213176f45,phase 1/2 study CA209-032,0.40439
uuid-cfa713908642437b9342944213176f45,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-2daed50c63cb4e8eae669cef05db4167,patients,0.324499
uuid-852edc0829074edcb6b76f600f9cafbd,RCC,0.906223
uuid-c832513a030843d3a47c5379440b9145,RCC,0.906223
uuid-c827ae96a153471ebb4c6238990aa7dd,95% CI,0.539167
uuid-c827ae96a153471ebb4c6238990aa7dd,Median overall survival,0.479815
uuid-c827ae96a153471ebb4c6238990aa7dd,protocol,0.426554
uuid-c827ae96a153471ebb4c6238990aa7dd,McDermott DF,0.500131
uuid-c827ae96a153471ebb4c6238990aa7dd,Motzer RJ,0.477178
uuid-c827ae96a153471ebb4c6238990aa7dd,Median OS,0.603398
uuid-c827ae96a153471ebb4c6238990aa7dd,Escudier B,0.469696
uuid-c827ae96a153471ebb4c6238990aa7dd,NEJM,0.387615
uuid-c827ae96a153471ebb4c6238990aa7dd,et al.,0.46851
uuid-c827ae96a153471ebb4c6238990aa7dd,J Clin Oncol,0.51661
uuid-c827ae96a153471ebb4c6238990aa7dd,Topalian,0.337057
uuid-c827ae96a153471ebb4c6238990aa7dd,phase 2 study,0.399402
uuid-c827ae96a153471ebb4c6238990aa7dd,hazard ratio,0.538097
uuid-dc853ffaf9e24b798a55841d20615038,95% CI,0.524855
uuid-dc853ffaf9e24b798a55841d20615038,respectively,0.383655
uuid-dc853ffaf9e24b798a55841d20615038,ASCO,0.303153
uuid-dc853ffaf9e24b798a55841d20615038,Lancet Oncol,0.368041
uuid-dc853ffaf9e24b798a55841d20615038,Objective response rate,0.504846
uuid-dc853ffaf9e24b798a55841d20615038,ORR,0.465366
uuid-dc853ffaf9e24b798a55841d20615038,Median overall survival,0.346516
uuid-dc853ffaf9e24b798a55841d20615038,Median OS,0.33538
uuid-dc853ffaf9e24b798a55841d20615038,ASCO 2015,0.336983
uuid-dc853ffaf9e24b798a55841d20615038,small cell lung cancer,0.336892
uuid-dc853ffaf9e24b798a55841d20615038,SCLC,0.344367
uuid-dc853ffaf9e24b798a55841d20615038,Antonia SJ,0.55269
uuid-dc853ffaf9e24b798a55841d20615038,Median duration of response,0.649605
uuid-ca288a58e11f4a95b98b05e6c6002547,nivolumab,0.379584
uuid-ca288a58e11f4a95b98b05e6c6002547,evaluating,0.396762
uuid-ca288a58e11f4a95b98b05e6c6002547,not conducted any controlled clinical trials/studies,0.434234
uuid-ca288a58e11f4a95b98b05e6c6002547,Pubmed literature search,0.590755
uuid-ca288a58e11f4a95b98b05e6c6002547,purposes other than its labeled indication must be considered investigational,0.628312
uuid-ca288a58e11f4a95b98b05e6c6002547,not identify any citations relevant to your inquiry,0.565847
uuid-ca288a58e11f4a95b98b05e6c6002547,using the following search terms,0.554787
uuid-f5653a7168144b6c9ac3ec2679df54e9,N Engl J Med,0.302601
uuid-f5653a7168144b6c9ac3ec2679df54e9,AEs,0.348167
uuid-f5653a7168144b6c9ac3ec2679df54e9,patients,0.536884
uuid-f5653a7168144b6c9ac3ec2679df54e9,provided in the Detailed Information,0.387544
uuid-f5653a7168144b6c9ac3ec2679df54e9,ESMO,0.462801
uuid-f5653a7168144b6c9ac3ec2679df54e9,NEJM,0.66427
uuid-f5653a7168144b6c9ac3ec2679df54e9,Topalian,0.692873
uuid-f5653a7168144b6c9ac3ec2679df54e9,grade 3 to 4 AEs,0.626596
uuid-8e79b509f1e24fb788050879eee0a862,N Engl J Med,0.672096
uuid-8e79b509f1e24fb788050879eee0a862,ESMO,0.436384
uuid-8e79b509f1e24fb788050879eee0a862,Rizvi NA,0.472296
uuid-8e79b509f1e24fb788050879eee0a862,Brahmer J,0.720441
uuid-8e79b509f1e24fb788050879eee0a862,Horn L,0.608589
uuid-6685af6b396a40db92023863df23eab6,RCC,0.906223
uuid-6b6cad1d0005431f9494dea1227f240f,use of nivolumab for the treatment,0.658514
uuid-6b6cad1d0005431f9494dea1227f240f,efficacy,0.5179
uuid-6b6cad1d0005431f9494dea1227f240f,patients,0.713293
uuid-6b6cad1d0005431f9494dea1227f240f,not approved,0.597052
uuid-6b6cad1d0005431f9494dea1227f240f,clinical trials investigating the safety,0.560022
uuid-6b6cad1d0005431f9494dea1227f240f,mg,0.642169
uuid-6b6cad1d0005431f9494dea1227f240f,kg,0.618427
uuid-6b6cad1d0005431f9494dea1227f240f,safety of nivolumab monotherapy,0.364073
uuid-7170111692b14a3a9949df78c568655d,Opdivo,0.81708
uuid-7170111692b14a3a9949df78c568655d,trial,0.365276
uuid-7170111692b14a3a9949df78c568655d,reported,0.311921
uuid-30ba8b6fbe814fbc83859a741cc17943,RCC,0.909054
uuid-338fe9e73bac453c9b1c5dd7cc6ae09d,clinical,0.713036
uuid-338fe9e73bac453c9b1c5dd7cc6ae09d,trial,0.680423
uuid-338fe9e73bac453c9b1c5dd7cc6ae09d,clinicaltrials.gov,0.438308
uuid-ccfb894441dd4fe4af8a158e885618da,considered investigational,0.402849
uuid-ccfb894441dd4fe4af8a158e885618da,small cell lung cancer,0.651985
uuid-ccfb894441dd4fe4af8a158e885618da,partial response,0.50367
uuid-ccfb894441dd4fe4af8a158e885618da,SCLC,0.736863
uuid-ccfb894441dd4fe4af8a158e885618da,therapy,0.843488
uuid-ccfb894441dd4fe4af8a158e885618da,relapsed,0.613852
uuid-ccfb894441dd4fe4af8a158e885618da,phase 1/2 study CA209-032,0.40439
uuid-ccfb894441dd4fe4af8a158e885618da,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-af9d2990a0b04ade966745cec4c03f5c,mg,0.856025
uuid-af9d2990a0b04ade966745cec4c03f5c,kg,0.794027
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,N Engl J Med,0.544875
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Lancet Oncol,0.460432
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,protocol,0.48613
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,McDermott DF,0.495478
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Motzer RJ,0.4795
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,phase 3 study,0.473269
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Escudier B,0.50613
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,et al.,0.484285
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,J Clin Oncol,0.413824
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Rizvi NA,0.631606
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Brahmer J,0.376922
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,Weber JS,0.443031
uuid-5bd8793fdb5a4de59e1ac8cd1fa680fe,phase 2 study,0.613035
uuid-33abe50cac3a4327956039c4644b9b4e,patients,0.327079
uuid-33abe50cac3a4327956039c4644b9b4e,requested,0.30011
uuid-33abe50cac3a4327956039c4644b9b4e,Opdivo,0.47623
uuid-33abe50cac3a4327956039c4644b9b4e,trial,0.466977
uuid-9fe6fd454b6d47ff9d69ecbd06ce77c5,patients,0.455513
uuid-9fe6fd454b6d47ff9d69ecbd06ce77c5,therapy,0.354054
uuid-8c5e3725b6eb4abda893e93c85343eec,trial,0.316564
uuid-380ae88afcfb44bbaa461e442cd9a5da,95% CI,0.524855
uuid-380ae88afcfb44bbaa461e442cd9a5da,respectively,0.383655
uuid-380ae88afcfb44bbaa461e442cd9a5da,ASCO,0.303153
uuid-380ae88afcfb44bbaa461e442cd9a5da,Lancet Oncol,0.368041
uuid-380ae88afcfb44bbaa461e442cd9a5da,Objective response rate,0.504846
uuid-380ae88afcfb44bbaa461e442cd9a5da,ORR,0.465366
uuid-380ae88afcfb44bbaa461e442cd9a5da,Median overall survival,0.346516
uuid-380ae88afcfb44bbaa461e442cd9a5da,Median OS,0.33538
uuid-380ae88afcfb44bbaa461e442cd9a5da,ASCO 2015,0.336983
uuid-380ae88afcfb44bbaa461e442cd9a5da,small cell lung cancer,0.336892
uuid-380ae88afcfb44bbaa461e442cd9a5da,SCLC,0.344367
uuid-380ae88afcfb44bbaa461e442cd9a5da,Antonia SJ,0.55269
uuid-380ae88afcfb44bbaa461e442cd9a5da,Median duration of response,0.649605
uuid-9dde85632c6b4e42bd67440b8a3c6c3a,Brahmer J,0.424224
uuid-9dde85632c6b4e42bd67440b8a3c6c3a,BMS,0.790254
uuid-649a8f8824f14604864a18d5f01d5b6a,95% CI,0.368332
uuid-649a8f8824f14604864a18d5f01d5b6a,NSCLC,0.498467
uuid-649a8f8824f14604864a18d5f01d5b6a,non-small cell lung cancer,0.430459
uuid-649a8f8824f14604864a18d5f01d5b6a,Objective response rate,0.480097
uuid-649a8f8824f14604864a18d5f01d5b6a,ORR,0.476446
uuid-649a8f8824f14604864a18d5f01d5b6a,Median overall survival,0.366656
uuid-649a8f8824f14604864a18d5f01d5b6a,monotherapy,0.355726
uuid-649a8f8824f14604864a18d5f01d5b6a,Median OS,0.348153
uuid-649a8f8824f14604864a18d5f01d5b6a,phase 1 study,0.35881
uuid-649a8f8824f14604864a18d5f01d5b6a,hazard ratio,0.370178
uuid-a7395013f5b74f26ad67c35f23a1dc64,clinical,0.41654
uuid-50da62b6ea0940f398a70ec148cbdc2e,RCC,0.906223
uuid-377f8c742d0b4b679c40b6dc8c310fa3,RCC,0.916859
uuid-483037a00fb54dee91d89a498784aa3d,N Engl J Med,0.347178
uuid-483037a00fb54dee91d89a498784aa3d,Lancet Oncol,0.359155
uuid-483037a00fb54dee91d89a498784aa3d,protocol,0.371457
uuid-483037a00fb54dee91d89a498784aa3d,McDermott DF,0.414017
uuid-483037a00fb54dee91d89a498784aa3d,Motzer RJ,0.384536
uuid-483037a00fb54dee91d89a498784aa3d,phase 3 study,0.443559
uuid-483037a00fb54dee91d89a498784aa3d,Escudier B,0.411866
uuid-483037a00fb54dee91d89a498784aa3d,et al.,0.39703
uuid-483037a00fb54dee91d89a498784aa3d,J Clin Oncol,0.378141
uuid-483037a00fb54dee91d89a498784aa3d,phase 1 study,0.326203
uuid-483037a00fb54dee91d89a498784aa3d,Rizvi NA,0.563772
uuid-483037a00fb54dee91d89a498784aa3d,mg,0.40261
uuid-483037a00fb54dee91d89a498784aa3d,Weber JS,0.418348
uuid-483037a00fb54dee91d89a498784aa3d,phase 2 study,0.587446
uuid-483037a00fb54dee91d89a498784aa3d,kg,0.361586
uuid-23eb255a8d654cae9f7d5abda456fc43,N Engl J Med,0.660586
uuid-23eb255a8d654cae9f7d5abda456fc43,Lancet Oncol,0.321742
uuid-23eb255a8d654cae9f7d5abda456fc43,protocol,0.80297
uuid-23eb255a8d654cae9f7d5abda456fc43,McDermott DF,0.821716
uuid-23eb255a8d654cae9f7d5abda456fc43,search of published literature,0.331661
uuid-23eb255a8d654cae9f7d5abda456fc43,Motzer RJ,0.83655
uuid-23eb255a8d654cae9f7d5abda456fc43,phase 3 study,0.565468
uuid-23eb255a8d654cae9f7d5abda456fc43,PubMed and EMBASE,0.330362
uuid-23eb255a8d654cae9f7d5abda456fc43,Escudier B,0.829229
uuid-23eb255a8d654cae9f7d5abda456fc43,NEJM,0.404738
uuid-23eb255a8d654cae9f7d5abda456fc43,et al.,0.775722
uuid-23eb255a8d654cae9f7d5abda456fc43,J Clin Oncol,0.779801
uuid-23eb255a8d654cae9f7d5abda456fc43,Topalian,0.377428
uuid-23eb255a8d654cae9f7d5abda456fc43,phase 1 study,0.401999
uuid-23eb255a8d654cae9f7d5abda456fc43,Rizvi NA,0.49708
uuid-23eb255a8d654cae9f7d5abda456fc43,Brahmer J,0.363982
uuid-23eb255a8d654cae9f7d5abda456fc43,efficacy and safety of nivolumab,0.326147
uuid-23eb255a8d654cae9f7d5abda456fc43,CA209-003,0.379463
uuid-23eb255a8d654cae9f7d5abda456fc43,Weber JS,0.368111
uuid-23eb255a8d654cae9f7d5abda456fc43,phase 2 study,0.810762
uuid-23eb255a8d654cae9f7d5abda456fc43,present using the following search terms,0.330526
uuid-23eb255a8d654cae9f7d5abda456fc43,investigating,0.312727
uuid-d7fc39072b0540dba1f8f9a0008fefd7,considered investigational,0.402849
uuid-d7fc39072b0540dba1f8f9a0008fefd7,small cell lung cancer,0.651985
uuid-d7fc39072b0540dba1f8f9a0008fefd7,partial response,0.50367
uuid-d7fc39072b0540dba1f8f9a0008fefd7,SCLC,0.736863
uuid-d7fc39072b0540dba1f8f9a0008fefd7,therapy,0.843488
uuid-d7fc39072b0540dba1f8f9a0008fefd7,relapsed,0.613852
uuid-d7fc39072b0540dba1f8f9a0008fefd7,phase 1/2 study CA209-032,0.40439
uuid-d7fc39072b0540dba1f8f9a0008fefd7,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-805c0c1eef7c47439546f2519c4a90c0,RCC,0.906223
uuid-db650ad9dbdf4ce8b8a0567a06f33dc9,RCC,0.888695
uuid-c77a2a9ef8de4b40a4513f8310c56df3,respectively,0.397695
uuid-4596a1c15f8e41c8ba13cda1d69f9d88,RCC,0.909054
uuid-54506da5c75b48be81954ba3d9bd39c4,RCC,0.906223
uuid-8f3e91667a6349eb8a30e8df571be43b,N Engl J Med,0.410025
uuid-8f3e91667a6349eb8a30e8df571be43b,protocol,0.663749
uuid-8f3e91667a6349eb8a30e8df571be43b,RCC,0.370429
uuid-8f3e91667a6349eb8a30e8df571be43b,McDermott DF,0.577168
uuid-8f3e91667a6349eb8a30e8df571be43b,search of published literature,0.443686
uuid-8f3e91667a6349eb8a30e8df571be43b,Additionally,0.395847
uuid-8f3e91667a6349eb8a30e8df571be43b,ongoing,0.335873
uuid-8f3e91667a6349eb8a30e8df571be43b,Motzer RJ,0.609458
uuid-8f3e91667a6349eb8a30e8df571be43b,phase 3 study,0.312748
uuid-8f3e91667a6349eb8a30e8df571be43b,PubMed and EMBASE,0.438896
uuid-8f3e91667a6349eb8a30e8df571be43b,Escudier B,0.595328
uuid-8f3e91667a6349eb8a30e8df571be43b,et al.,0.521538
uuid-8f3e91667a6349eb8a30e8df571be43b,J Clin Oncol,0.545137
uuid-8f3e91667a6349eb8a30e8df571be43b,detailed search of www.clinicaltrials.gov,0.358127
uuid-8f3e91667a6349eb8a30e8df571be43b,efficacy and safety of nivolumab,0.429052
uuid-8f3e91667a6349eb8a30e8df571be43b,not identify any planned,0.344155
uuid-8f3e91667a6349eb8a30e8df571be43b,phase 2 study,0.513121
uuid-8f3e91667a6349eb8a30e8df571be43b,not identify any citations relevant to your request,0.414617
uuid-8f3e91667a6349eb8a30e8df571be43b,present using the following search terms,0.417875
uuid-dc27de9dc7e1433d8366892970c9f7f0,mg,0.819539
uuid-dc27de9dc7e1433d8366892970c9f7f0,kg,0.764977
uuid-a150649e53d54fa8bead75f1998934d4,N Engl J Med,0.442834
uuid-a150649e53d54fa8bead75f1998934d4,protocol,0.763252
uuid-a150649e53d54fa8bead75f1998934d4,McDermott DF,0.733103
uuid-a150649e53d54fa8bead75f1998934d4,Motzer RJ,0.811057
uuid-a150649e53d54fa8bead75f1998934d4,phase 3 study,0.420895
uuid-a150649e53d54fa8bead75f1998934d4,Escudier B,0.741048
uuid-a150649e53d54fa8bead75f1998934d4,NEJM,0.402544
uuid-a150649e53d54fa8bead75f1998934d4,et al.,0.660398
uuid-a150649e53d54fa8bead75f1998934d4,J Clin Oncol,0.786367
uuid-a150649e53d54fa8bead75f1998934d4,Topalian,0.392395
uuid-a150649e53d54fa8bead75f1998934d4,phase 1 study,0.513779
uuid-a150649e53d54fa8bead75f1998934d4,CA209-003,0.583337
uuid-a150649e53d54fa8bead75f1998934d4,phase 2 study,0.675447
uuid-a150649e53d54fa8bead75f1998934d4,present using the following search terms,0.304589
uuid-a150649e53d54fa8bead75f1998934d4,investigating,0.633101
uuid-709a9cac5b5a4981800d66b66e429526,RCC,0.906223
uuid-b1b4dec2af4942e79282e2a4ad15f5e5,RCC,0.909054
uuid-0e9ad37d1a2a4cd596dd0225bfe91062,trial,0.434654
uuid-40d1fee20e51480e9837b6cb70b5fc63,RCC,0.846357
uuid-4a963831ab234f2e93354960c1530eba,RCC,0.906223
uuid-722b81fca2a34d0eaac2c2d76bd670d6,RCC,0.906223
uuid-30672169e36f473d960b0e5139fadb99,ipilimumab,0.385692
uuid-30672169e36f473d960b0e5139fadb99,ASCO 2015,0.417944
uuid-30672169e36f473d960b0e5139fadb99,partial response,0.382425
uuid-30672169e36f473d960b0e5139fadb99,Stable disease,0.586335
uuid-30672169e36f473d960b0e5139fadb99,cohort,0.307748
uuid-f47fc1669b004992aa485bdc92eb22d7,respectively,0.589071
uuid-f47fc1669b004992aa485bdc92eb22d7,Objective response rate,0.407286
uuid-f47fc1669b004992aa485bdc92eb22d7,ORR,0.526086
uuid-f47fc1669b004992aa485bdc92eb22d7,monotherapy,0.319413
uuid-f47fc1669b004992aa485bdc92eb22d7,docetaxel,0.334344
uuid-106a7ae9516e4097bd0403165bd925cf,ASCO,0.776438
uuid-969538c6883d4fc6aea257ea44501bfd,patients,0.324499
uuid-02d325b4d9f643fa96f557339303e20d,RCC,0.906223
uuid-0e06d65705594dc594c42328f9727010,nivolumab,0.607601
uuid-0e06d65705594dc594c42328f9727010,Bristol-Myers Squibb,0.44973
uuid-0e06d65705594dc594c42328f9727010,evaluating,0.619167
uuid-0e06d65705594dc594c42328f9727010,not conducted any controlled clinical trials/studies,0.671644
uuid-0e06d65705594dc594c42328f9727010,Pubmed literature search,0.828798
uuid-0e06d65705594dc594c42328f9727010,purposes other than its labeled indication must be considered investigational,0.900214
uuid-0e06d65705594dc594c42328f9727010,not identify any citations relevant to your inquiry,0.787977
uuid-0e06d65705594dc594c42328f9727010,using the following search terms,0.771667
uuid-0e06d65705594dc594c42328f9727010,efficacy and safety of nivolumab,0.467738
uuid-fc525a5f59e7440ea41d2fc4396c0cf6,tumors,0.310408
uuid-99731c1549734924a06777edd3e08d50,N Engl J Med,0.892438
uuid-99731c1549734924a06777edd3e08d50,Lancet Oncol,0.369114
uuid-99731c1549734924a06777edd3e08d50,provided in the Detailed Information,0.302862
uuid-99731c1549734924a06777edd3e08d50,protocol,0.755063
uuid-99731c1549734924a06777edd3e08d50,McDermott DF,0.82995
uuid-99731c1549734924a06777edd3e08d50,Motzer RJ,0.803103
uuid-99731c1549734924a06777edd3e08d50,ESMO,0.341635
uuid-99731c1549734924a06777edd3e08d50,phase 3 study,0.507488
uuid-99731c1549734924a06777edd3e08d50,Escudier B,0.832421
uuid-99731c1549734924a06777edd3e08d50,NEJM,0.452995
uuid-99731c1549734924a06777edd3e08d50,et al.,0.8085
uuid-99731c1549734924a06777edd3e08d50,J Clin Oncol,0.737251
uuid-99731c1549734924a06777edd3e08d50,Topalian,0.42081
uuid-99731c1549734924a06777edd3e08d50,Rizvi NA,0.588152
uuid-99731c1549734924a06777edd3e08d50,Brahmer J,0.577339
uuid-99731c1549734924a06777edd3e08d50,Weber JS,0.403598
uuid-99731c1549734924a06777edd3e08d50,phase 2 study,0.770524
uuid-94ad173c22e0405d9713c115002e1ac6,Opdivo,0.817134
uuid-94ad173c22e0405d9713c115002e1ac6,trial,0.438091
uuid-362fcc2a6c06483fb0138d85f54576ab,Opdivo,0.973714
uuid-362fcc2a6c06483fb0138d85f54576ab,using the following search terms,0.334255
uuid-362fcc2a6c06483fb0138d85f54576ab,trial,0.472338
uuid-362fcc2a6c06483fb0138d85f54576ab,reported,0.362287
uuid-3dab08db1c3848d1b87c82e5ea2f5023,N Engl J Med,0.519824
uuid-3dab08db1c3848d1b87c82e5ea2f5023,provided in the Detailed Information,0.354705
uuid-3dab08db1c3848d1b87c82e5ea2f5023,protocol,0.683206
uuid-3dab08db1c3848d1b87c82e5ea2f5023,McDermott DF,0.76147
uuid-3dab08db1c3848d1b87c82e5ea2f5023,Motzer RJ,0.747101
uuid-3dab08db1c3848d1b87c82e5ea2f5023,clinical,0.422894
uuid-3dab08db1c3848d1b87c82e5ea2f5023,phase 3 study,0.450363
uuid-3dab08db1c3848d1b87c82e5ea2f5023,Escudier B,0.751569
uuid-3dab08db1c3848d1b87c82e5ea2f5023,NEJM,0.375985
uuid-3dab08db1c3848d1b87c82e5ea2f5023,et al.,0.71679
uuid-3dab08db1c3848d1b87c82e5ea2f5023,J Clin Oncol,0.741184
uuid-3dab08db1c3848d1b87c82e5ea2f5023,Topalian,0.35096
uuid-3dab08db1c3848d1b87c82e5ea2f5023,Rizvi NA,0.353776
uuid-3dab08db1c3848d1b87c82e5ea2f5023,phase 2 study,0.6853
uuid-9090953b97a54299857065b7c1314dbe,RCC,0.898134
uuid-d22077b8e6d24c2cb070d703fd666f21,RCC,0.706185
uuid-5ff12217e7134d189c2361afdcfca8c6,nivolumab,0.608981
uuid-5ff12217e7134d189c2361afdcfca8c6,Bristol-Myers Squibb,0.349587
uuid-5ff12217e7134d189c2361afdcfca8c6,evaluating,0.484327
uuid-5ff12217e7134d189c2361afdcfca8c6,not conducted any controlled clinical trials/studies,0.539699
uuid-5ff12217e7134d189c2361afdcfca8c6,Pubmed literature search,0.797265
uuid-5ff12217e7134d189c2361afdcfca8c6,purposes other than its labeled indication must be considered investigational,0.846397
uuid-5ff12217e7134d189c2361afdcfca8c6,not identify any citations relevant to your inquiry,0.772609
uuid-5ff12217e7134d189c2361afdcfca8c6,using the following search terms,0.758973
uuid-5ff12217e7134d189c2361afdcfca8c6,efficacy and safety of nivolumab,0.369162
uuid-8c5685a0162f4ca6b429366cddeda910,efficacy,0.333315
uuid-8c5685a0162f4ca6b429366cddeda910,mg,0.89699
uuid-8c5685a0162f4ca6b429366cddeda910,safety,0.31706
uuid-8c5685a0162f4ca6b429366cddeda910,kg,0.880884
uuid-8c5685a0162f4ca6b429366cddeda910,cohort,0.303431
uuid-8d5742c9c4ed4f98ba02615377b9b305,95% CI,0.524855
uuid-8d5742c9c4ed4f98ba02615377b9b305,respectively,0.383655
uuid-8d5742c9c4ed4f98ba02615377b9b305,ASCO,0.303153
uuid-8d5742c9c4ed4f98ba02615377b9b305,Lancet Oncol,0.368041
uuid-8d5742c9c4ed4f98ba02615377b9b305,Objective response rate,0.504846
uuid-8d5742c9c4ed4f98ba02615377b9b305,ORR,0.465366
uuid-8d5742c9c4ed4f98ba02615377b9b305,Median overall survival,0.346516
uuid-8d5742c9c4ed4f98ba02615377b9b305,Median OS,0.33538
uuid-8d5742c9c4ed4f98ba02615377b9b305,ASCO 2015,0.336983
uuid-8d5742c9c4ed4f98ba02615377b9b305,small cell lung cancer,0.336892
uuid-8d5742c9c4ed4f98ba02615377b9b305,SCLC,0.344367
uuid-8d5742c9c4ed4f98ba02615377b9b305,Antonia SJ,0.55269
uuid-8d5742c9c4ed4f98ba02615377b9b305,Median duration of response,0.649605
uuid-8b764b69908b4befa096c520cceb8b31,evaluating,0.482856
uuid-8b764b69908b4befa096c520cceb8b31,not conducted any controlled clinical trials/studies,0.400982
uuid-8b764b69908b4befa096c520cceb8b31,efficacy,0.317787
uuid-8b764b69908b4befa096c520cceb8b31,NSCLC,0.733476
uuid-8b764b69908b4befa096c520cceb8b31,non-small cell lung cancer,0.71811
uuid-8b764b69908b4befa096c520cceb8b31,considered investigational,0.316189
uuid-8b764b69908b4befa096c520cceb8b31,phase 3 study,0.412719
uuid-8b764b69908b4befa096c520cceb8b31,phase 1 study,0.464853
uuid-8b764b69908b4befa096c520cceb8b31,efficacy and safety of nivolumab,0.437681
uuid-8b764b69908b4befa096c520cceb8b31,CA209-003,0.309797
uuid-8b764b69908b4befa096c520cceb8b31,safety of nivolumab monotherapy,0.454007
uuid-8b764b69908b4befa096c520cceb8b31,platinum-based doublet chemotherapy,0.369368
uuid-877219cf20c84eb090a901f985f80810,RCC,0.906223
uuid-f05ba8e01ae7493c81e597b1e22b6eea,requested,0.594234
uuid-caf0a05d812a4e0da499e7eaf2d23a70,Bristol-Myers Squibb,0.341822
uuid-caf0a05d812a4e0da499e7eaf2d23a70,not conducted any controlled clinical trials/studies,0.304507
uuid-caf0a05d812a4e0da499e7eaf2d23a70,Opdivo,0.461382
uuid-caf0a05d812a4e0da499e7eaf2d23a70,Pubmed literature search,0.614325
uuid-caf0a05d812a4e0da499e7eaf2d23a70,purposes other than its labeled indication must be considered investigational,0.586645
uuid-caf0a05d812a4e0da499e7eaf2d23a70,not identify any citations relevant to your inquiry,0.606087
uuid-caf0a05d812a4e0da499e7eaf2d23a70,adverse,0.304183
uuid-caf0a05d812a4e0da499e7eaf2d23a70,using the following search terms,0.642331
uuid-caf0a05d812a4e0da499e7eaf2d23a70,databases,0.315039
uuid-caf0a05d812a4e0da499e7eaf2d23a70,reported,0.556704
uuid-c9e711f86c9c4d42a91f67501442772b,nivolumab,0.493389
uuid-c9e711f86c9c4d42a91f67501442772b,Bristol-Myers Squibb,0.598477
uuid-c9e711f86c9c4d42a91f67501442772b,evaluating,0.837805
uuid-c9e711f86c9c4d42a91f67501442772b,not conducted any controlled clinical trials/studies,0.848713
uuid-c9e711f86c9c4d42a91f67501442772b,Pubmed literature search,0.314091
uuid-c9e711f86c9c4d42a91f67501442772b,purposes other than its labeled indication must be considered investigational,0.4415
uuid-c9e711f86c9c4d42a91f67501442772b,search of published literature,0.772891
uuid-c9e711f86c9c4d42a91f67501442772b,PubMed and EMBASE,0.743175
uuid-c9e711f86c9c4d42a91f67501442772b,efficacy and safety of nivolumab,0.905749
uuid-c9e711f86c9c4d42a91f67501442772b,not identify any citations relevant to your request,0.417576
uuid-c9e711f86c9c4d42a91f67501442772b,present using the following search terms,0.748132
uuid-a7a18209ac6047f8a4f78037649141f5,RCC,0.906223
uuid-d5ea51649c064aad9fc9d1c60f0f07e2,patients,0.416806
uuid-d5ea51649c064aad9fc9d1c60f0f07e2,trial,0.417588
uuid-86a189b64a534a799f9173bd08d8e107,RCC,0.906223
uuid-0dcaf406568c4d1099be555840b1502c,Opdivo,0.985634
uuid-0dcaf406568c4d1099be555840b1502c,using the following search terms,0.339107
uuid-0dcaf406568c4d1099be555840b1502c,trial,0.466085
uuid-0dcaf406568c4d1099be555840b1502c,reported,0.361874
uuid-db340d6e433342e3af51c3c7a4ebf3f9,Bristol-Myers Squibb,0.36472
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,N Engl J Med,0.433518
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,Lancet Oncol,0.355527
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,protocol,0.406977
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,RCC,0.53017
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,McDermott DF,0.408009
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,Motzer RJ,0.402488
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,phase 3 study,0.395225
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,Escudier B,0.423292
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,et al.,0.396603
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,J Clin Oncol,0.330421
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,Rizvi NA,0.496189
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,Weber JS,0.341747
uuid-9cbe5ca9232e4169a1e38fccc4514aa5,phase 2 study,0.508725
uuid-d89c8a6bece04d58b8747d12cbe1fbbb,mg,0.876659
uuid-d89c8a6bece04d58b8747d12cbe1fbbb,kg,0.814125
uuid-15f3906ad15a4931927f378d140fbc51,RCC,0.870014
uuid-d0b9b503cb3a4c63844288114101f8ea,95% CI,0.524855
uuid-d0b9b503cb3a4c63844288114101f8ea,respectively,0.383655
uuid-d0b9b503cb3a4c63844288114101f8ea,ASCO,0.303153
uuid-d0b9b503cb3a4c63844288114101f8ea,Lancet Oncol,0.368041
uuid-d0b9b503cb3a4c63844288114101f8ea,Objective response rate,0.504846
uuid-d0b9b503cb3a4c63844288114101f8ea,ORR,0.465366
uuid-d0b9b503cb3a4c63844288114101f8ea,Median overall survival,0.346516
uuid-d0b9b503cb3a4c63844288114101f8ea,Median OS,0.33538
uuid-d0b9b503cb3a4c63844288114101f8ea,ASCO 2015,0.336983
uuid-d0b9b503cb3a4c63844288114101f8ea,small cell lung cancer,0.336892
uuid-d0b9b503cb3a4c63844288114101f8ea,SCLC,0.344367
uuid-d0b9b503cb3a4c63844288114101f8ea,Antonia SJ,0.55269
uuid-d0b9b503cb3a4c63844288114101f8ea,Median duration of response,0.649605
uuid-359843c9e3234e23861d8b7cd1fc77d5,RCC,0.906223
uuid-948e92ecabc34c11bb409b31ed85f9df,RCC,0.906223
uuid-b7eb87da5b8144f2a2814e6feb1e0ab8,RCC,0.906223
uuid-0705a472cfc649d0888a071ba18b045f,OS,0.344846
uuid-0705a472cfc649d0888a071ba18b045f,95% CI,0.629468
uuid-0705a472cfc649d0888a071ba18b045f,NSCLC,0.336139
uuid-0705a472cfc649d0888a071ba18b045f,respectively,0.407674
uuid-0705a472cfc649d0888a071ba18b045f,Objective response rate,0.54429
uuid-0705a472cfc649d0888a071ba18b045f,ORR,0.630459
uuid-0705a472cfc649d0888a071ba18b045f,Median overall survival,0.590912
uuid-0705a472cfc649d0888a071ba18b045f,monotherapy,0.467134
uuid-0705a472cfc649d0888a071ba18b045f,Median OS,0.552454
uuid-0705a472cfc649d0888a071ba18b045f,docetaxel,0.349054
uuid-0705a472cfc649d0888a071ba18b045f,hazard ratio,0.607507
uuid-d8955a8ecb45481bb14f2623b328317e,RCC,0.906223
uuid-01ebae72a3984fe9ab4d2e43f93f7818,open-label,0.539462
uuid-01ebae72a3984fe9ab4d2e43f93f7818,phase,0.350616
uuid-cbc44c8ccd2546aa942814959e626f54,patients,0.324499
uuid-d6e95b822c0a40868e640f9911ebd597,considered investigational,0.402849
uuid-d6e95b822c0a40868e640f9911ebd597,small cell lung cancer,0.651985
uuid-d6e95b822c0a40868e640f9911ebd597,partial response,0.50367
uuid-d6e95b822c0a40868e640f9911ebd597,SCLC,0.736863
uuid-d6e95b822c0a40868e640f9911ebd597,therapy,0.843488
uuid-d6e95b822c0a40868e640f9911ebd597,relapsed,0.613852
uuid-d6e95b822c0a40868e640f9911ebd597,phase 1/2 study CA209-032,0.40439
uuid-d6e95b822c0a40868e640f9911ebd597,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-38bf3afdac384b568a0aa1dbe4d8c38c,open-label,0.539462
uuid-38bf3afdac384b568a0aa1dbe4d8c38c,phase,0.350616
uuid-c75ae67847ee403c9673bc850d165c58,RCC,0.909054
uuid-aea521208f7b429bb8cc7ac293475317,95% CI,0.539167
uuid-aea521208f7b429bb8cc7ac293475317,Median overall survival,0.479815
uuid-aea521208f7b429bb8cc7ac293475317,protocol,0.426554
uuid-aea521208f7b429bb8cc7ac293475317,McDermott DF,0.500131
uuid-aea521208f7b429bb8cc7ac293475317,Motzer RJ,0.477178
uuid-aea521208f7b429bb8cc7ac293475317,Median OS,0.603398
uuid-aea521208f7b429bb8cc7ac293475317,Escudier B,0.469696
uuid-aea521208f7b429bb8cc7ac293475317,NEJM,0.387615
uuid-aea521208f7b429bb8cc7ac293475317,et al.,0.46851
uuid-aea521208f7b429bb8cc7ac293475317,J Clin Oncol,0.51661
uuid-aea521208f7b429bb8cc7ac293475317,Topalian,0.337057
uuid-aea521208f7b429bb8cc7ac293475317,phase 2 study,0.399402
uuid-aea521208f7b429bb8cc7ac293475317,hazard ratio,0.538097
uuid-dad273f449834fc6a3f91bd014e62e05,Opdivo,0.324753
uuid-dad273f449834fc6a3f91bd014e62e05,adverse,0.411781
uuid-dad273f449834fc6a3f91bd014e62e05,safety,0.559528
uuid-dad273f449834fc6a3f91bd014e62e05,databases,0.495758
uuid-dad273f449834fc6a3f91bd014e62e05,reported,0.659158
uuid-885a1d6174f7451fa1b3f109be0b56b5,open-label,0.539462
uuid-885a1d6174f7451fa1b3f109be0b56b5,phase,0.350616
uuid-51d74044e3954d05936246aec686b9c5,RCC,0.906223
uuid-cb096b5ef19e4314bdb3796748266ffd,phase 1 study,0.552717
uuid-cb096b5ef19e4314bdb3796748266ffd,CA209-003,0.677459
uuid-cb096b5ef19e4314bdb3796748266ffd,investigating,0.912433
uuid-c3d19a0a3e49428cb82bcef25f5a4de9,RCC,0.906223
uuid-ddd5cc44043447dbab1b1ed22706e46d,nivolumab,0.308696
uuid-ddd5cc44043447dbab1b1ed22706e46d,respectively,0.474596
uuid-ddd5cc44043447dbab1b1ed22706e46d,Objective response rate,0.398542
uuid-ddd5cc44043447dbab1b1ed22706e46d,ORR,0.387529
uuid-ddd5cc44043447dbab1b1ed22706e46d,monotherapy,0.618934
uuid-ddd5cc44043447dbab1b1ed22706e46d,clinical,0.310702
uuid-ddd5cc44043447dbab1b1ed22706e46d,Antonia SJ,0.303123
uuid-8bb0e038201f47baa3b2a2ae614a4f7c,Objective response rate,0.451139
uuid-8bb0e038201f47baa3b2a2ae614a4f7c,clinicaltrials.gov,0.503706
uuid-ab3cc4f97751408f807de5cf44f6b0d4,nivolumab,0.493389
uuid-ab3cc4f97751408f807de5cf44f6b0d4,Bristol-Myers Squibb,0.598477
uuid-ab3cc4f97751408f807de5cf44f6b0d4,evaluating,0.837805
uuid-ab3cc4f97751408f807de5cf44f6b0d4,not conducted any controlled clinical trials/studies,0.848713
uuid-ab3cc4f97751408f807de5cf44f6b0d4,Pubmed literature search,0.314091
uuid-ab3cc4f97751408f807de5cf44f6b0d4,purposes other than its labeled indication must be considered investigational,0.4415
uuid-ab3cc4f97751408f807de5cf44f6b0d4,search of published literature,0.772891
uuid-ab3cc4f97751408f807de5cf44f6b0d4,PubMed and EMBASE,0.743175
uuid-ab3cc4f97751408f807de5cf44f6b0d4,efficacy and safety of nivolumab,0.905749
uuid-ab3cc4f97751408f807de5cf44f6b0d4,not identify any citations relevant to your request,0.417576
uuid-ab3cc4f97751408f807de5cf44f6b0d4,present using the following search terms,0.748132
uuid-12b50a161e074afea1268bb952aea85f,N Engl J Med,0.442834
uuid-12b50a161e074afea1268bb952aea85f,protocol,0.763252
uuid-12b50a161e074afea1268bb952aea85f,McDermott DF,0.733103
uuid-12b50a161e074afea1268bb952aea85f,Motzer RJ,0.811057
uuid-12b50a161e074afea1268bb952aea85f,phase 3 study,0.420895
uuid-12b50a161e074afea1268bb952aea85f,Escudier B,0.741048
uuid-12b50a161e074afea1268bb952aea85f,NEJM,0.402544
uuid-12b50a161e074afea1268bb952aea85f,et al.,0.660398
uuid-12b50a161e074afea1268bb952aea85f,J Clin Oncol,0.786367
uuid-12b50a161e074afea1268bb952aea85f,Topalian,0.392395
uuid-12b50a161e074afea1268bb952aea85f,phase 1 study,0.513779
uuid-12b50a161e074afea1268bb952aea85f,CA209-003,0.583337
uuid-12b50a161e074afea1268bb952aea85f,phase 2 study,0.675447
uuid-12b50a161e074afea1268bb952aea85f,present using the following search terms,0.304589
uuid-12b50a161e074afea1268bb952aea85f,investigating,0.633101
uuid-2e9ea410178d47fdad3c3fa66fb60939,N Engl J Med,0.643107
uuid-2e9ea410178d47fdad3c3fa66fb60939,respectively,0.398989
uuid-2e9ea410178d47fdad3c3fa66fb60939,Median overall survival,0.30615
uuid-2e9ea410178d47fdad3c3fa66fb60939,ESMO,0.534703
uuid-2e9ea410178d47fdad3c3fa66fb60939,Median OS,0.319939
uuid-2e9ea410178d47fdad3c3fa66fb60939,Brahmer J,0.658171
uuid-2e9ea410178d47fdad3c3fa66fb60939,Horn L,0.594193
uuid-708c49511550425f84bd793a5b52a849,N Engl J Med,0.612275
uuid-708c49511550425f84bd793a5b52a849,respectively,0.397304
uuid-708c49511550425f84bd793a5b52a849,ASCO,0.362351
uuid-708c49511550425f84bd793a5b52a849,ESMO,0.373435
uuid-708c49511550425f84bd793a5b52a849,Brahmer J,0.718391
uuid-708c49511550425f84bd793a5b52a849,docetaxel,0.334878
uuid-708c49511550425f84bd793a5b52a849,Horn L,0.500688
uuid-9c314cf7f59a4608856a4e2702401c34,95% CI,0.384282
uuid-9c314cf7f59a4608856a4e2702401c34,ASCO,0.40687
uuid-9c314cf7f59a4608856a4e2702401c34,Objective response rate,0.409634
uuid-9c314cf7f59a4608856a4e2702401c34,Median overall survival,0.319094
uuid-9c314cf7f59a4608856a4e2702401c34,Median OS,0.403026
uuid-9c314cf7f59a4608856a4e2702401c34,ASCO 2015,0.386899
uuid-9c314cf7f59a4608856a4e2702401c34,hazard ratio,0.403406
uuid-49031ff384884d32b2b2b84da952c611,adverse,0.677734
uuid-49031ff384884d32b2b2b84da952c611,phase 3 study,0.48003
uuid-49031ff384884d32b2b2b84da952c611,melanoma,0.411352
uuid-49031ff384884d32b2b2b84da952c611,Weber JS,0.31904
uuid-49031ff384884d32b2b2b84da952c611,phase 2 study,0.319618
uuid-49031ff384884d32b2b2b84da952c611,reported,0.343242
uuid-deb25a0e7c0d4ac49cf8743681493d04,nivolumab,0.493389
uuid-deb25a0e7c0d4ac49cf8743681493d04,Bristol-Myers Squibb,0.598477
uuid-deb25a0e7c0d4ac49cf8743681493d04,evaluating,0.837805
uuid-deb25a0e7c0d4ac49cf8743681493d04,not conducted any controlled clinical trials/studies,0.848713
uuid-deb25a0e7c0d4ac49cf8743681493d04,Pubmed literature search,0.314091
uuid-deb25a0e7c0d4ac49cf8743681493d04,purposes other than its labeled indication must be considered investigational,0.4415
uuid-deb25a0e7c0d4ac49cf8743681493d04,search of published literature,0.772891
uuid-deb25a0e7c0d4ac49cf8743681493d04,PubMed and EMBASE,0.743175
uuid-deb25a0e7c0d4ac49cf8743681493d04,efficacy and safety of nivolumab,0.905749
uuid-deb25a0e7c0d4ac49cf8743681493d04,not identify any citations relevant to your request,0.417576
uuid-deb25a0e7c0d4ac49cf8743681493d04,present using the following search terms,0.748132
uuid-9899747b756144288b538f8e0a264e16,RCC,0.906223
uuid-2ffd192067824506b549f4b4693acc8c,clinical,0.314197
uuid-b7cccf0b35c145f0b326463d261c71b4,RCC,0.906223
uuid-79468e695c714e848251be29f48f518d,nivolumab,0.340131
uuid-79468e695c714e848251be29f48f518d,requested,0.338413
uuid-e0cfcd858bf444daa9074d2646106178,N Engl J Med,0.347178
uuid-e0cfcd858bf444daa9074d2646106178,Lancet Oncol,0.359155
uuid-e0cfcd858bf444daa9074d2646106178,protocol,0.371457
uuid-e0cfcd858bf444daa9074d2646106178,McDermott DF,0.414017
uuid-e0cfcd858bf444daa9074d2646106178,Motzer RJ,0.384536
uuid-e0cfcd858bf444daa9074d2646106178,phase 3 study,0.443559
uuid-e0cfcd858bf444daa9074d2646106178,Escudier B,0.411866
uuid-e0cfcd858bf444daa9074d2646106178,et al.,0.39703
uuid-e0cfcd858bf444daa9074d2646106178,J Clin Oncol,0.378141
uuid-e0cfcd858bf444daa9074d2646106178,phase 1 study,0.326203
uuid-e0cfcd858bf444daa9074d2646106178,Rizvi NA,0.563772
uuid-e0cfcd858bf444daa9074d2646106178,mg,0.40261
uuid-e0cfcd858bf444daa9074d2646106178,Weber JS,0.418348
uuid-e0cfcd858bf444daa9074d2646106178,phase 2 study,0.587446
uuid-e0cfcd858bf444daa9074d2646106178,kg,0.361586
uuid-494a0cb912a2486f96b2e4ce73a0fce2,RCC,0.817392
uuid-d061b5451f2d4dda9be5e1774dce1df9,95% CI,0.539167
uuid-d061b5451f2d4dda9be5e1774dce1df9,Median overall survival,0.479815
uuid-d061b5451f2d4dda9be5e1774dce1df9,protocol,0.426554
uuid-d061b5451f2d4dda9be5e1774dce1df9,McDermott DF,0.500131
uuid-d061b5451f2d4dda9be5e1774dce1df9,Motzer RJ,0.477178
uuid-d061b5451f2d4dda9be5e1774dce1df9,Median OS,0.603398
uuid-d061b5451f2d4dda9be5e1774dce1df9,Escudier B,0.469696
uuid-d061b5451f2d4dda9be5e1774dce1df9,NEJM,0.387615
uuid-d061b5451f2d4dda9be5e1774dce1df9,et al.,0.46851
uuid-d061b5451f2d4dda9be5e1774dce1df9,J Clin Oncol,0.51661
uuid-d061b5451f2d4dda9be5e1774dce1df9,Topalian,0.337057
uuid-d061b5451f2d4dda9be5e1774dce1df9,phase 2 study,0.399402
uuid-d061b5451f2d4dda9be5e1774dce1df9,hazard ratio,0.538097
uuid-ac8b2bb24b094832a0e0cbade62d744d,N Engl J Med,0.491758
uuid-ac8b2bb24b094832a0e0cbade62d744d,Lancet Oncol,0.30041
uuid-ac8b2bb24b094832a0e0cbade62d744d,protocol,0.48309
uuid-ac8b2bb24b094832a0e0cbade62d744d,McDermott DF,0.508099
uuid-ac8b2bb24b094832a0e0cbade62d744d,Motzer RJ,0.485661
uuid-ac8b2bb24b094832a0e0cbade62d744d,phase 3 study,0.360581
uuid-ac8b2bb24b094832a0e0cbade62d744d,Escudier B,0.509679
uuid-ac8b2bb24b094832a0e0cbade62d744d,et al.,0.501339
uuid-ac8b2bb24b094832a0e0cbade62d744d,J Clin Oncol,0.433356
uuid-ac8b2bb24b094832a0e0cbade62d744d,Rizvi NA,0.389513
uuid-ac8b2bb24b094832a0e0cbade62d744d,Brahmer J,0.302347
uuid-ac8b2bb24b094832a0e0cbade62d744d,phase 2 study,0.474232
uuid-003be884835e4334a5df8b11e7d062fa,RCC,0.906223
uuid-441592f91b5148498449dbeed040b46c,nivolumab,0.437115
uuid-441592f91b5148498449dbeed040b46c,Opdivo,0.361743
uuid-ca2ae91e31504d55a230809816301ef7,95% CI,0.524855
uuid-ca2ae91e31504d55a230809816301ef7,respectively,0.383655
uuid-ca2ae91e31504d55a230809816301ef7,ASCO,0.303153
uuid-ca2ae91e31504d55a230809816301ef7,Lancet Oncol,0.368041
uuid-ca2ae91e31504d55a230809816301ef7,Objective response rate,0.504846
uuid-ca2ae91e31504d55a230809816301ef7,ORR,0.465366
uuid-ca2ae91e31504d55a230809816301ef7,Median overall survival,0.346516
uuid-ca2ae91e31504d55a230809816301ef7,Median OS,0.33538
uuid-ca2ae91e31504d55a230809816301ef7,ASCO 2015,0.336983
uuid-ca2ae91e31504d55a230809816301ef7,small cell lung cancer,0.336892
uuid-ca2ae91e31504d55a230809816301ef7,SCLC,0.344367
uuid-ca2ae91e31504d55a230809816301ef7,Antonia SJ,0.55269
uuid-ca2ae91e31504d55a230809816301ef7,Median duration of response,0.649605
uuid-23ac266c00584b6a93a5f3ab39a1e849,Bristol-Myers Squibb,0.345756
uuid-23ac266c00584b6a93a5f3ab39a1e849,not conducted any controlled clinical trials/studies,0.301395
uuid-23ac266c00584b6a93a5f3ab39a1e849,Opdivo,0.465203
uuid-23ac266c00584b6a93a5f3ab39a1e849,Pubmed literature search,0.606488
uuid-23ac266c00584b6a93a5f3ab39a1e849,purposes other than its labeled indication must be considered investigational,0.578811
uuid-23ac266c00584b6a93a5f3ab39a1e849,not identify any citations relevant to your inquiry,0.601325
uuid-23ac266c00584b6a93a5f3ab39a1e849,adverse,0.307287
uuid-23ac266c00584b6a93a5f3ab39a1e849,using the following search terms,0.63467
uuid-23ac266c00584b6a93a5f3ab39a1e849,databases,0.307083
uuid-23ac266c00584b6a93a5f3ab39a1e849,reported,0.559726
uuid-f4033e7da3ab4a10a8ca87a62cab13bb,RCC,0.906223
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,Bristol-Myers Squibb,0.341822
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,not conducted any controlled clinical trials/studies,0.304507
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,Opdivo,0.461382
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,Pubmed literature search,0.614325
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,not identify any citations relevant to your inquiry,0.606087
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,adverse,0.304183
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,using the following search terms,0.642331
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,databases,0.315039
uuid-b924dd3fe40c4aeaaa0dda04f7d7bbbd,reported,0.556704
uuid-8e671f6511fd4d618827d6767c5a6b50,Pubmed literature search,0.317911
uuid-8e671f6511fd4d618827d6767c5a6b50,purposes other than its labeled indication must be considered investigational,0.348112
uuid-8e671f6511fd4d618827d6767c5a6b50,not identify any citations relevant to your inquiry,0.310703
uuid-bbf18c2991314a5089272c78a824f368,RCC,0.450467
uuid-bbf18c2991314a5089272c78a824f368,mg,0.712879
uuid-bbf18c2991314a5089272c78a824f368,kg,0.636997
uuid-cc573594d5b6449bb8a5ee988da74a6b,RCC,0.909054
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,95% CI,0.524855
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,respectively,0.383655
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,ASCO,0.303153
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Lancet Oncol,0.368041
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Objective response rate,0.504846
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,ORR,0.465366
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Median overall survival,0.346516
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Median OS,0.33538
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,ASCO 2015,0.336983
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,small cell lung cancer,0.336892
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,SCLC,0.344367
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Antonia SJ,0.55269
uuid-921bd74c0cfd40ee90d2ad28b3d37c68,Median duration of response,0.649605
uuid-fbbf2885c0a94ab5a64e7366404ba470,RCC,0.909054
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,N Engl J Med,0.442834
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,protocol,0.763252
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,McDermott DF,0.733103
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,Motzer RJ,0.811057
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,phase 3 study,0.420895
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,Escudier B,0.741048
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,NEJM,0.402544
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,et al.,0.660398
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,J Clin Oncol,0.786367
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,Topalian,0.392395
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,phase 1 study,0.513779
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,CA209-003,0.583337
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,phase 2 study,0.675447
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,present using the following search terms,0.304589
uuid-8e5fb09aede14ad0ae4f400b2d2ee524,investigating,0.633101
uuid-3234cb72d70c4fe48588e5078f067ed6,RCC,0.909054
uuid-525ec06ec5c94569ba8c45c7155cf1a5,95% CI,0.524855
uuid-525ec06ec5c94569ba8c45c7155cf1a5,respectively,0.383655
uuid-525ec06ec5c94569ba8c45c7155cf1a5,ASCO,0.303153
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Lancet Oncol,0.368041
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Objective response rate,0.504846
uuid-525ec06ec5c94569ba8c45c7155cf1a5,ORR,0.465366
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Median overall survival,0.346516
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Median OS,0.33538
uuid-525ec06ec5c94569ba8c45c7155cf1a5,ASCO 2015,0.336983
uuid-525ec06ec5c94569ba8c45c7155cf1a5,small cell lung cancer,0.336892
uuid-525ec06ec5c94569ba8c45c7155cf1a5,SCLC,0.344367
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Antonia SJ,0.55269
uuid-525ec06ec5c94569ba8c45c7155cf1a5,Median duration of response,0.649605
uuid-e16a80e9ea784c548ef696bd9d18e23e,nivolumab,0.567409
uuid-e16a80e9ea784c548ef696bd9d18e23e,Bristol-Myers Squibb,0.438565
uuid-e16a80e9ea784c548ef696bd9d18e23e,evaluating,0.594286
uuid-e16a80e9ea784c548ef696bd9d18e23e,not conducted any controlled clinical trials/studies,0.655858
uuid-e16a80e9ea784c548ef696bd9d18e23e,Pubmed literature search,0.879255
uuid-e16a80e9ea784c548ef696bd9d18e23e,purposes other than its labeled indication must be considered investigational,0.941881
uuid-e16a80e9ea784c548ef696bd9d18e23e,not identify any citations relevant to your inquiry,0.838346
uuid-e16a80e9ea784c548ef696bd9d18e23e,using the following search terms,0.825992
uuid-e16a80e9ea784c548ef696bd9d18e23e,efficacy and safety of nivolumab,0.432448
uuid-1eeaceba1c9f46b8b5aecd1be6167201,phase 3 study,0.438282
uuid-1eeaceba1c9f46b8b5aecd1be6167201,open-label,0.458405
uuid-1eeaceba1c9f46b8b5aecd1be6167201,phase 1 study,0.470036
uuid-1eeaceba1c9f46b8b5aecd1be6167201,CA209-003,0.489831
uuid-1eeaceba1c9f46b8b5aecd1be6167201,phase 2 study,0.413633
uuid-1eeaceba1c9f46b8b5aecd1be6167201,phase,0.44867
uuid-1eeaceba1c9f46b8b5aecd1be6167201,investigating,0.410319
uuid-f54799a66e5348e1bcbb6cd07a205c0c,AEs,0.333645
uuid-f54799a66e5348e1bcbb6cd07a205c0c,fatigue,0.322776
uuid-f54799a66e5348e1bcbb6cd07a205c0c,grade,0.508804
uuid-193b5e53e02f4367a0d02174afd3453e,N Engl J Med,0.410025
uuid-193b5e53e02f4367a0d02174afd3453e,protocol,0.663749
uuid-193b5e53e02f4367a0d02174afd3453e,RCC,0.370429
uuid-193b5e53e02f4367a0d02174afd3453e,McDermott DF,0.577168
uuid-193b5e53e02f4367a0d02174afd3453e,search of published literature,0.443686
uuid-193b5e53e02f4367a0d02174afd3453e,Additionally,0.395847
uuid-193b5e53e02f4367a0d02174afd3453e,ongoing,0.335873
uuid-193b5e53e02f4367a0d02174afd3453e,Motzer RJ,0.609458
uuid-193b5e53e02f4367a0d02174afd3453e,phase 3 study,0.312748
uuid-193b5e53e02f4367a0d02174afd3453e,PubMed and EMBASE,0.438896
uuid-193b5e53e02f4367a0d02174afd3453e,Escudier B,0.595328
uuid-193b5e53e02f4367a0d02174afd3453e,et al.,0.521538
uuid-193b5e53e02f4367a0d02174afd3453e,J Clin Oncol,0.545137
uuid-193b5e53e02f4367a0d02174afd3453e,detailed search of www.clinicaltrials.gov,0.358127
uuid-193b5e53e02f4367a0d02174afd3453e,efficacy and safety of nivolumab,0.429052
uuid-193b5e53e02f4367a0d02174afd3453e,not identify any planned,0.344155
uuid-193b5e53e02f4367a0d02174afd3453e,phase 2 study,0.513121
uuid-193b5e53e02f4367a0d02174afd3453e,not identify any citations relevant to your request,0.414617
uuid-193b5e53e02f4367a0d02174afd3453e,present using the following search terms,0.417875
uuid-f733afd1f6ce40cebb40e080814253d8,N Engl J Med,0.675468
uuid-f733afd1f6ce40cebb40e080814253d8,respectively,0.321248
uuid-f733afd1f6ce40cebb40e080814253d8,ESMO,0.514821
uuid-f733afd1f6ce40cebb40e080814253d8,Rizvi NA,0.328315
uuid-f733afd1f6ce40cebb40e080814253d8,Brahmer J,0.71711
uuid-f733afd1f6ce40cebb40e080814253d8,Horn L,0.599933
uuid-f733afd1f6ce40cebb40e080814253d8,platinum-based doublet chemotherapy,0.304914
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,95% CI,0.410247
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,Lancet Oncol,0.338804
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,considered investigational,0.31999
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,Objective response rate,0.460397
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,ORR,0.42609
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,ASCO 2015,0.334207
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,small cell lung cancer,0.572318
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,SCLC,0.616142
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,Antonia SJ,0.54068
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,therapy,0.386133
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,Median duration of response,0.529786
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,phase 1/2 study CA209-032,0.403467
uuid-cef8f3e2bcfc4ef68517d13faeefe9ee,evaluates the efficacy of nivolumab monotherapy,0.353136
uuid-d16afface0aa4fa28a70d196d75311a0,95% CI,0.524855
uuid-d16afface0aa4fa28a70d196d75311a0,respectively,0.383655
uuid-d16afface0aa4fa28a70d196d75311a0,ASCO,0.303153
uuid-d16afface0aa4fa28a70d196d75311a0,Lancet Oncol,0.368041
uuid-d16afface0aa4fa28a70d196d75311a0,Objective response rate,0.504846
uuid-d16afface0aa4fa28a70d196d75311a0,ORR,0.465366
uuid-d16afface0aa4fa28a70d196d75311a0,Median overall survival,0.346516
uuid-d16afface0aa4fa28a70d196d75311a0,Median OS,0.33538
uuid-d16afface0aa4fa28a70d196d75311a0,ASCO 2015,0.336983
uuid-d16afface0aa4fa28a70d196d75311a0,small cell lung cancer,0.336892
uuid-d16afface0aa4fa28a70d196d75311a0,SCLC,0.344367
uuid-d16afface0aa4fa28a70d196d75311a0,Antonia SJ,0.55269
uuid-d16afface0aa4fa28a70d196d75311a0,Median duration of response,0.649605
uuid-fe124b4e5b024455a1f34d54e968720b,RCC,0.906223
uuid-90422dc8ee65404ab75b352e1927625d,N Engl J Med,0.324903
uuid-90422dc8ee65404ab75b352e1927625d,protocol,0.392378
uuid-90422dc8ee65404ab75b352e1927625d,McDermott DF,0.479227
uuid-90422dc8ee65404ab75b352e1927625d,Motzer RJ,0.451694
uuid-90422dc8ee65404ab75b352e1927625d,phase 3 study,0.426354
uuid-90422dc8ee65404ab75b352e1927625d,Escudier B,0.457855
uuid-90422dc8ee65404ab75b352e1927625d,et al.,0.445275
uuid-90422dc8ee65404ab75b352e1927625d,J Clin Oncol,0.459314
uuid-90422dc8ee65404ab75b352e1927625d,phase 1 study,0.344018
uuid-90422dc8ee65404ab75b352e1927625d,Rizvi NA,0.314444
uuid-90422dc8ee65404ab75b352e1927625d,CA209-003,0.318547
uuid-90422dc8ee65404ab75b352e1927625d,phase 2 study,0.509495
uuid-90422dc8ee65404ab75b352e1927625d,grade,0.383831
uuid-b9211a2f084a42b4acd1e2a865c4f360,95% CI,0.524855
uuid-b9211a2f084a42b4acd1e2a865c4f360,respectively,0.383654
uuid-b9211a2f084a42b4acd1e2a865c4f360,ASCO,0.303154
uuid-b9211a2f084a42b4acd1e2a865c4f360,Lancet Oncol,0.368042
uuid-b9211a2f084a42b4acd1e2a865c4f360,Objective response rate,0.504847
uuid-b9211a2f084a42b4acd1e2a865c4f360,ORR,0.465366
uuid-b9211a2f084a42b4acd1e2a865c4f360,Median overall survival,0.346517
uuid-b9211a2f084a42b4acd1e2a865c4f360,Median OS,0.335381
uuid-b9211a2f084a42b4acd1e2a865c4f360,ASCO 2015,0.336984
uuid-b9211a2f084a42b4acd1e2a865c4f360,small cell lung cancer,0.336893
uuid-b9211a2f084a42b4acd1e2a865c4f360,SCLC,0.344368
uuid-b9211a2f084a42b4acd1e2a865c4f360,Antonia SJ,0.552691
uuid-b9211a2f084a42b4acd1e2a865c4f360,Median duration of response,0.649604
uuid-495389431c6d458688b4603c991a85a2,95% CI,0.524855
uuid-495389431c6d458688b4603c991a85a2,respectively,0.383655
uuid-495389431c6d458688b4603c991a85a2,ASCO,0.303153
uuid-495389431c6d458688b4603c991a85a2,Lancet Oncol,0.368041
uuid-495389431c6d458688b4603c991a85a2,Objective response rate,0.504846
uuid-495389431c6d458688b4603c991a85a2,ORR,0.465366
uuid-495389431c6d458688b4603c991a85a2,Median overall survival,0.346516
uuid-495389431c6d458688b4603c991a85a2,Median OS,0.33538
uuid-495389431c6d458688b4603c991a85a2,ASCO 2015,0.336983
uuid-495389431c6d458688b4603c991a85a2,small cell lung cancer,0.336892
uuid-495389431c6d458688b4603c991a85a2,SCLC,0.344367
uuid-495389431c6d458688b4603c991a85a2,Antonia SJ,0.55269
uuid-495389431c6d458688b4603c991a85a2,Median duration of response,0.649605
uuid-3aa531db21544c499b851d59c80f6c13,RCC,0.906223
uuid-ff5464dc45a448aeaba5bc44261dfb2f,patients,0.524136
uuid-ff5464dc45a448aeaba5bc44261dfb2f,RCC,0.506737
uuid-fbf8d09398294143b69ddf9577f9d218,RCC,0.909054
uuid-5dcf817ca13e4335b15e242a6181ade5,Bristol-Myers Squibb,0.314317
uuid-5dcf817ca13e4335b15e242a6181ade5,not conducted any controlled clinical trials/studies,0.304932
uuid-5dcf817ca13e4335b15e242a6181ade5,Opdivo,0.394447
uuid-5dcf817ca13e4335b15e242a6181ade5,Pubmed literature search,0.570139
uuid-5dcf817ca13e4335b15e242a6181ade5,purposes other than its labeled indication must be considered investigational,0.548925
uuid-5dcf817ca13e4335b15e242a6181ade5,not identify any citations relevant to your inquiry,0.556463
uuid-5dcf817ca13e4335b15e242a6181ade5,using the following search terms,0.591865
uuid-5dcf817ca13e4335b15e242a6181ade5,safety,0.307302
uuid-5dcf817ca13e4335b15e242a6181ade5,databases,0.331117
uuid-5dcf817ca13e4335b15e242a6181ade5,reported,0.523091
uuid-2aa01b5d165c46dca9d454940e84f27d,mg,0.790057
uuid-2aa01b5d165c46dca9d454940e84f27d,kg,0.713234
uuid-278931057ace4add89970c877c3c94a5,melanoma,0.359495
uuid-278931057ace4add89970c877c3c94a5,mg,0.553286
uuid-278931057ace4add89970c877c3c94a5,kg,0.472679
uuid-9ebbc0a0864844da902e788f8a7e8ddf,mg,0.756375
uuid-9ebbc0a0864844da902e788f8a7e8ddf,kg,0.693625
uuid-1b4b2ff37a6d42c6add91bfe1fca5432,RCC,0.906223
uuid-8b79e1b84a1c490a86ec485bea59ece3,provided in the Detailed Information,0.356703
uuid-8b79e1b84a1c490a86ec485bea59ece3,search of published literature,0.388112
uuid-8b79e1b84a1c490a86ec485bea59ece3,Additionally,0.394589
uuid-8b79e1b84a1c490a86ec485bea59ece3,PubMed and EMBASE,0.393776
uuid-8b79e1b84a1c490a86ec485bea59ece3,detailed search of www.clinicaltrials.gov,0.317146
uuid-8b79e1b84a1c490a86ec485bea59ece3,not identify any citations relevant to your request,0.411603
uuid-8b79e1b84a1c490a86ec485bea59ece3,present using the following search terms,0.398911
uuid-b31a51735baa43bd83c7940a9bf83200,provided in the Detailed Information,0.330989
uuid-b31a51735baa43bd83c7940a9bf83200,clinical,0.694593
uuid-b31a51735baa43bd83c7940a9bf83200,trial,0.32272
uuid-c4393357a36840d9abb8b765c5b8cf2a,Bristol-Myers Squibb,0.341822
uuid-c4393357a36840d9abb8b765c5b8cf2a,not conducted any controlled clinical trials/studies,0.304507
uuid-c4393357a36840d9abb8b765c5b8cf2a,Opdivo,0.461382
uuid-c4393357a36840d9abb8b765c5b8cf2a,Pubmed literature search,0.614325
uuid-c4393357a36840d9abb8b765c5b8cf2a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c4393357a36840d9abb8b765c5b8cf2a,not identify any citations relevant to your inquiry,0.606087
uuid-c4393357a36840d9abb8b765c5b8cf2a,adverse,0.304183
uuid-c4393357a36840d9abb8b765c5b8cf2a,using the following search terms,0.642331
uuid-c4393357a36840d9abb8b765c5b8cf2a,databases,0.315039
uuid-c4393357a36840d9abb8b765c5b8cf2a,reported,0.556704
uuid-be44296229284ccd8431f032f0db88cc,nivolumab,0.395065
uuid-98c3639c49c34a3ba02a74c3d64e60eb,95% CI,0.539167
uuid-98c3639c49c34a3ba02a74c3d64e60eb,Median overall survival,0.479815
uuid-98c3639c49c34a3ba02a74c3d64e60eb,protocol,0.426554
uuid-98c3639c49c34a3ba02a74c3d64e60eb,McDermott DF,0.500131
uuid-98c3639c49c34a3ba02a74c3d64e60eb,Motzer RJ,0.477178
uuid-98c3639c49c34a3ba02a74c3d64e60eb,Median OS,0.603398
uuid-98c3639c49c34a3ba02a74c3d64e60eb,Escudier B,0.469696
uuid-98c3639c49c34a3ba02a74c3d64e60eb,NEJM,0.387615
uuid-98c3639c49c34a3ba02a74c3d64e60eb,et al.,0.46851
uuid-98c3639c49c34a3ba02a74c3d64e60eb,J Clin Oncol,0.51661
uuid-98c3639c49c34a3ba02a74c3d64e60eb,Topalian,0.337057
uuid-98c3639c49c34a3ba02a74c3d64e60eb,phase 2 study,0.399402
uuid-98c3639c49c34a3ba02a74c3d64e60eb,hazard ratio,0.538097
uuid-6fdf9658fd424dd2b4ea77b7e190fa62,provided in the Detailed Information,0.349112
uuid-6fdf9658fd424dd2b4ea77b7e190fa62,Weber JS,0.321343
uuid-9e95a784e43b4f288a5a30bec2116a0f,use of nivolumab for the treatment,0.324252
uuid-9e95a784e43b4f288a5a30bec2116a0f,mg,0.755676
uuid-9e95a784e43b4f288a5a30bec2116a0f,kg,0.690074
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,nivolumab,0.324658
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,use of nivolumab for the treatment,0.543355
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,evaluating,0.348676
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,efficacy,0.388907
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,patients,0.419915
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,search of published literature,0.449959
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,PubMed and EMBASE,0.444573
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,not approved,0.582429
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,clinical trials investigating the safety,0.64854
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,efficacy and safety of nivolumab,0.399101
uuid-e5e5b5ee29da43bda9adbd0c8dcbbb68,present using the following search terms,0.465296
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,95% CI,0.524855
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,respectively,0.383655
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,ASCO,0.303153
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Lancet Oncol,0.368041
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Objective response rate,0.504846
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,ORR,0.465366
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Median overall survival,0.346516
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Median OS,0.33538
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,ASCO 2015,0.336983
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,small cell lung cancer,0.336892
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,SCLC,0.344367
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Antonia SJ,0.55269
uuid-aa3d0b2608714c3998ea0eb66a00b9e8,Median duration of response,0.649605
uuid-d4f5dd05348b4ec7b5ce497d86ab057b,patients,0.324499
uuid-6f56a8ec3d60430388fffafd7aa4f537,RCC,0.878747
uuid-3ff573709bb84a2f96f79f28cef173f1,patients,0.387216
uuid-3ff573709bb84a2f96f79f28cef173f1,considered investigational,0.572483
uuid-3ff573709bb84a2f96f79f28cef173f1,patients with advanced or metastatic,0.390918
uuid-3ff573709bb84a2f96f79f28cef173f1,nivolumab combined with ipilimumab,0.381545
uuid-3ff573709bb84a2f96f79f28cef173f1,ipilimumab,0.418119
uuid-3ff573709bb84a2f96f79f28cef173f1,tumors,0.487867
uuid-3ff573709bb84a2f96f79f28cef173f1,ASCO 2015,0.485832
uuid-3ff573709bb84a2f96f79f28cef173f1,small cell lung cancer,0.673131
uuid-3ff573709bb84a2f96f79f28cef173f1,PD-L1,0.317304
uuid-3ff573709bb84a2f96f79f28cef173f1,combination,0.374435
uuid-3ff573709bb84a2f96f79f28cef173f1,SCLC,0.676534
uuid-3ff573709bb84a2f96f79f28cef173f1,Antonia SJ,0.423577
uuid-3ff573709bb84a2f96f79f28cef173f1,therapy,0.309098
uuid-3ff573709bb84a2f96f79f28cef173f1,phase 1/2 study CA209-032,0.582404
uuid-3ff573709bb84a2f96f79f28cef173f1,evaluates the efficacy of nivolumab monotherapy,0.546434
uuid-1467d5985ae2433fb3c89ec83aad5bf6,grade,0.35689
uuid-39b156c575b9471294e880cc45b5e5bb,RCC,0.901065
uuid-3d674fae6717432b8b0fd16c6b3ecfd4,patients,0.324499
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,N Engl J Med,0.30124
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,provided in the Detailed Information,0.336444
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,adverse,0.316014
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,phase 3 study,0.340604
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,Rizvi NA,0.348656
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,Brahmer J,0.448526
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,BMS,0.733519
uuid-b8bf0e658bfa42198a0c40ef5f57ec17,reported,0.410557
uuid-9afee0524ac44f818e5194bcca44b620,patients,0.331211
uuid-9afee0524ac44f818e5194bcca44b620,adverse,0.376253
uuid-ab5d3efc24b0494fbdc05f2e72b51a08,Bristol-Myers Squibb,0.398191
uuid-ab5d3efc24b0494fbdc05f2e72b51a08,requested,0.827269
uuid-deee18849f004db4bac06e547f157180,Bristol-Myers Squibb,0.341822
uuid-deee18849f004db4bac06e547f157180,not conducted any controlled clinical trials/studies,0.304507
uuid-deee18849f004db4bac06e547f157180,Opdivo,0.461382
uuid-deee18849f004db4bac06e547f157180,Pubmed literature search,0.614325
uuid-deee18849f004db4bac06e547f157180,purposes other than its labeled indication must be considered investigational,0.586645
uuid-deee18849f004db4bac06e547f157180,not identify any citations relevant to your inquiry,0.606087
uuid-deee18849f004db4bac06e547f157180,adverse,0.304183
uuid-deee18849f004db4bac06e547f157180,using the following search terms,0.642331
uuid-deee18849f004db4bac06e547f157180,databases,0.315039
uuid-deee18849f004db4bac06e547f157180,reported,0.556704
uuid-867c4e3c24e644b2b914ce8e2758deb2,ASCO,0.807066
uuid-1e18dbe445134df6a637b1a6a88a18e7,OS,0.44149
uuid-1e18dbe445134df6a637b1a6a88a18e7,95% CI,0.833403
uuid-1e18dbe445134df6a637b1a6a88a18e7,ASCO,0.32927
uuid-1e18dbe445134df6a637b1a6a88a18e7,Objective response rate,0.545269
uuid-1e18dbe445134df6a637b1a6a88a18e7,ORR,0.618524
uuid-1e18dbe445134df6a637b1a6a88a18e7,PFS,0.396858
uuid-1e18dbe445134df6a637b1a6a88a18e7,Median overall survival,0.72593
uuid-1e18dbe445134df6a637b1a6a88a18e7,monotherapy,0.33356
uuid-1e18dbe445134df6a637b1a6a88a18e7,Median OS,0.763854
uuid-1e18dbe445134df6a637b1a6a88a18e7,hazard ratio,0.766648
uuid-1e18dbe445134df6a637b1a6a88a18e7,Median duration of response,0.442682
uuid-6362042759824f3081706ae78a485102,N Engl J Med,0.367869
uuid-6362042759824f3081706ae78a485102,protocol,0.658742
uuid-6362042759824f3081706ae78a485102,RCC,0.375387
uuid-6362042759824f3081706ae78a485102,McDermott DF,0.560924
uuid-6362042759824f3081706ae78a485102,search of published literature,0.428619
uuid-6362042759824f3081706ae78a485102,Additionally,0.405724
uuid-6362042759824f3081706ae78a485102,ongoing,0.365225
uuid-6362042759824f3081706ae78a485102,Motzer RJ,0.596203
uuid-6362042759824f3081706ae78a485102,PubMed and EMBASE,0.423862
uuid-6362042759824f3081706ae78a485102,Escudier B,0.579918
uuid-6362042759824f3081706ae78a485102,et al.,0.511511
uuid-6362042759824f3081706ae78a485102,J Clin Oncol,0.536232
uuid-6362042759824f3081706ae78a485102,detailed search of www.clinicaltrials.gov,0.379318
uuid-6362042759824f3081706ae78a485102,efficacy and safety of nivolumab,0.423052
uuid-6362042759824f3081706ae78a485102,not identify any planned,0.3696
uuid-6362042759824f3081706ae78a485102,phase 2 study,0.471813
uuid-6362042759824f3081706ae78a485102,not identify any citations relevant to your request,0.423463
uuid-6362042759824f3081706ae78a485102,present using the following search terms,0.406049
uuid-334fb392b93048dc841e1906e6daddef,N Engl J Med,0.604857
uuid-334fb392b93048dc841e1906e6daddef,non-small cell lung cancer,0.34354
uuid-334fb392b93048dc841e1906e6daddef,ESMO,0.393944
uuid-334fb392b93048dc841e1906e6daddef,Rizvi NA,0.452745
uuid-334fb392b93048dc841e1906e6daddef,Brahmer J,0.679154
uuid-334fb392b93048dc841e1906e6daddef,PD-L1,0.347566
uuid-334fb392b93048dc841e1906e6daddef,Horn L,0.50259
uuid-334fb392b93048dc841e1906e6daddef,platinum-based doublet chemotherapy,0.304136
uuid-99fe825f86f1478888073f4ffca7ba60,patients,0.324499
uuid-954e5f7fd84444829d3e8b1352a235b9,patients with advanced or metastatic,0.478326
uuid-954e5f7fd84444829d3e8b1352a235b9,nivolumab combined with ipilimumab,0.498766
uuid-954e5f7fd84444829d3e8b1352a235b9,not approved,0.34724
uuid-954e5f7fd84444829d3e8b1352a235b9,clinical trials investigating the safety,0.426729
uuid-954e5f7fd84444829d3e8b1352a235b9,bladder cancer,0.6548
uuid-1f9b8bd81c004fdabb95e058c0589c64,patients,0.474548
uuid-1f9b8bd81c004fdabb95e058c0589c64,clinical,0.443448
uuid-1f9b8bd81c004fdabb95e058c0589c64,trial,0.367161
uuid-1f9b8bd81c004fdabb95e058c0589c64,therapy,0.339869
uuid-5ce1b01b1ec346f1a501bd03c385a81b,Bristol-Myers Squibb,0.36472
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,nivolumab,0.493198
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,Bristol-Myers Squibb,0.463694
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,evaluating,0.623996
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,not conducted any controlled clinical trials/studies,0.684951
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,Pubmed literature search,0.867442
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,purposes other than its labeled indication must be considered investigational,0.932268
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,not identify any citations relevant to your inquiry,0.825607
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,using the following search terms,0.811289
uuid-b9b555bfc1cf4fcdb46ef9eeafaef902,efficacy and safety of nivolumab,0.457066
uuid-2e427ba0b79a404e8ddf4c2c2b011f4c,RCC,0.543552
uuid-2e427ba0b79a404e8ddf4c2c2b011f4c,clinical,0.376425
uuid-2e427ba0b79a404e8ddf4c2c2b011f4c,trial,0.503448
uuid-c1a195bb1d194cbba1bd34aca76dc1ec,RCC,0.906223
uuid-a0d4f5eaa6da459797b7d09ca64ba290,RCC,0.906223
uuid-50a23eb2bd154b3a86f44181a05f8a9c,RCC,0.850819
uuid-5641f28d53d447faa50429f347ee61d4,monotherapy,0.303129
uuid-5641f28d53d447faa50429f347ee61d4,mg,0.945382
uuid-5641f28d53d447faa50429f347ee61d4,kg,0.909974
uuid-5641f28d53d447faa50429f347ee61d4,cohort,0.374882
uuid-9271114b8aca4d49b2e74143e2b5173a,nivolumab,0.359772
uuid-dd0f4ae6c12c49169b5d331c4b780d6b,RCC,0.909054
uuid-49525a823ffc47eca1bdd922a3dd45ff,requested,0.594234
uuid-dcc49d5f59ec4844a22894e21539296a,provided in the Detailed Information,0.349112
uuid-dcc49d5f59ec4844a22894e21539296a,Weber JS,0.321343
uuid-89e2632f1de24636bfade1a8c3658722,N Engl J Med,0.373796
uuid-89e2632f1de24636bfade1a8c3658722,protocol,0.420361
uuid-89e2632f1de24636bfade1a8c3658722,McDermott DF,0.513284
uuid-89e2632f1de24636bfade1a8c3658722,Motzer RJ,0.482105
uuid-89e2632f1de24636bfade1a8c3658722,phase 3 study,0.448204
uuid-89e2632f1de24636bfade1a8c3658722,Escudier B,0.482741
uuid-89e2632f1de24636bfade1a8c3658722,NEJM,0.342527
uuid-89e2632f1de24636bfade1a8c3658722,et al.,0.466863
uuid-89e2632f1de24636bfade1a8c3658722,J Clin Oncol,0.523543
uuid-89e2632f1de24636bfade1a8c3658722,Topalian,0.340171
uuid-89e2632f1de24636bfade1a8c3658722,phase 1 study,0.421699
uuid-89e2632f1de24636bfade1a8c3658722,mg,0.324901
uuid-89e2632f1de24636bfade1a8c3658722,CA209-003,0.451562
uuid-89e2632f1de24636bfade1a8c3658722,phase 2 study,0.595096
uuid-89e2632f1de24636bfade1a8c3658722,grade,0.324161
uuid-89e2632f1de24636bfade1a8c3658722,kg,0.310462
uuid-39679ec2daa3445294b3cef7da5afa2c,RCC,0.843791
uuid-35520a61c81b42de9bff59c9725c7492,Bristol-Myers Squibb,0.494637
uuid-24e65bf3eab546469278ed437526df87,ipilimumab,0.385692
uuid-24e65bf3eab546469278ed437526df87,ASCO 2015,0.417944
uuid-24e65bf3eab546469278ed437526df87,partial response,0.382425
uuid-24e65bf3eab546469278ed437526df87,Stable disease,0.586335
uuid-24e65bf3eab546469278ed437526df87,cohort,0.307748
uuid-0ea656ac47784c308f4831ff19811628,RCC,0.906223
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,adverse,0.677734
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,phase 3 study,0.48003
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,melanoma,0.411352
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,Weber JS,0.31904
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,phase 2 study,0.319618
uuid-01f37bbb1a0b45ba93d2e5bc0e2f982d,reported,0.343242
uuid-9c36b115641042edb54a8ac1e091f19d,95% CI,0.524855
uuid-9c36b115641042edb54a8ac1e091f19d,respectively,0.383655
uuid-9c36b115641042edb54a8ac1e091f19d,ASCO,0.303153
uuid-9c36b115641042edb54a8ac1e091f19d,Lancet Oncol,0.368041
uuid-9c36b115641042edb54a8ac1e091f19d,Objective response rate,0.504846
uuid-9c36b115641042edb54a8ac1e091f19d,ORR,0.465366
uuid-9c36b115641042edb54a8ac1e091f19d,Median overall survival,0.346516
uuid-9c36b115641042edb54a8ac1e091f19d,Median OS,0.33538
uuid-9c36b115641042edb54a8ac1e091f19d,ASCO 2015,0.336983
uuid-9c36b115641042edb54a8ac1e091f19d,small cell lung cancer,0.336892
uuid-9c36b115641042edb54a8ac1e091f19d,SCLC,0.344367
uuid-9c36b115641042edb54a8ac1e091f19d,Antonia SJ,0.55269
uuid-9c36b115641042edb54a8ac1e091f19d,Median duration of response,0.649605
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,search of published literature,0.394524
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,Additionally,0.413583
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,ongoing,0.322117
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,PubMed and EMBASE,0.391671
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,detailed search of www.clinicaltrials.gov,0.375936
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,efficacy and safety of nivolumab,0.370699
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,not identify any planned,0.34283
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,Weber JS,0.319229
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,not identify any citations relevant to your request,0.447813
uuid-f2fd8d2ee0174f7ea4f5cb8fe37527cf,present using the following search terms,0.408199
uuid-d994d11d4ba242cc97198cd1341063f9,clinical,0.381958
uuid-d994d11d4ba242cc97198cd1341063f9,trial,0.41071
uuid-93e459ed308840c6b9f8fe8f65c46d05,RCC,0.906223
uuid-2e1fbe4c5fb34517a031522d38137c33,RCC,0.906223
uuid-c8654d04247248a6be33fa1f97ac042a,nivolumab,0.354939
uuid-6395a4fd4ede40129452008848e8c911,ASCO,0.797516
uuid-6395a4fd4ede40129452008848e8c911,Antonia SJ,0.403825
uuid-6cb9d5fa0dfa412795654b32e9c2a266,RCC,0.909054
uuid-fc50e9b3d65040aca336168cf645b239,RCC,0.878747
uuid-29cc3496c85e4b129cb6e0f7fe088b48,RCC,0.906223
uuid-6f841ea5bdf54a909cd5fd7eb04ecaf7,monotherapy,0.325892
uuid-6f841ea5bdf54a909cd5fd7eb04ecaf7,mg,0.965292
uuid-6f841ea5bdf54a909cd5fd7eb04ecaf7,kg,0.933734
uuid-6f841ea5bdf54a909cd5fd7eb04ecaf7,cohort,0.39818
uuid-7b967a5873b049b1a4a80a7998699ccf,clinical,0.59891
uuid-94d21d5edb3d45ca94216a2a5dcfae34,nivolumab,0.953027
uuid-94d21d5edb3d45ca94216a2a5dcfae34,evaluating,0.313016
uuid-94d21d5edb3d45ca94216a2a5dcfae34,Pubmed literature search,0.373585
uuid-94d21d5edb3d45ca94216a2a5dcfae34,purposes other than its labeled indication must be considered investigational,0.444003
uuid-94d21d5edb3d45ca94216a2a5dcfae34,not identify any citations relevant to your inquiry,0.352643
uuid-94d21d5edb3d45ca94216a2a5dcfae34,search of published literature,0.385536
uuid-94d21d5edb3d45ca94216a2a5dcfae34,PubMed and EMBASE,0.384401
uuid-94d21d5edb3d45ca94216a2a5dcfae34,using the following search terms,0.343613
uuid-94d21d5edb3d45ca94216a2a5dcfae34,efficacy and safety of nivolumab,0.325498
uuid-94d21d5edb3d45ca94216a2a5dcfae34,present using the following search terms,0.435434
uuid-9e88ea234fd244d59365e4df8d767207,grade,0.422133
uuid-52c8de2c54c04b4d8f0762e53d59beec,use of nivolumab for the treatment,0.658514
uuid-52c8de2c54c04b4d8f0762e53d59beec,efficacy,0.5179
uuid-52c8de2c54c04b4d8f0762e53d59beec,patients,0.713293
uuid-52c8de2c54c04b4d8f0762e53d59beec,not approved,0.597052
uuid-52c8de2c54c04b4d8f0762e53d59beec,clinical trials investigating the safety,0.560022
uuid-52c8de2c54c04b4d8f0762e53d59beec,mg,0.642169
uuid-52c8de2c54c04b4d8f0762e53d59beec,kg,0.618427
uuid-52c8de2c54c04b4d8f0762e53d59beec,safety of nivolumab monotherapy,0.364073
uuid-88995ae7c0184c6b8c8df55edb4d2f75,95% CI,0.524855
uuid-88995ae7c0184c6b8c8df55edb4d2f75,respectively,0.383655
uuid-88995ae7c0184c6b8c8df55edb4d2f75,ASCO,0.303153
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Lancet Oncol,0.368041
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Objective response rate,0.504846
uuid-88995ae7c0184c6b8c8df55edb4d2f75,ORR,0.465366
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Median overall survival,0.346516
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Median OS,0.33538
uuid-88995ae7c0184c6b8c8df55edb4d2f75,ASCO 2015,0.336983
uuid-88995ae7c0184c6b8c8df55edb4d2f75,small cell lung cancer,0.336892
uuid-88995ae7c0184c6b8c8df55edb4d2f75,SCLC,0.344367
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Antonia SJ,0.55269
uuid-88995ae7c0184c6b8c8df55edb4d2f75,Median duration of response,0.649605
uuid-208c7464bb324924bbe5f7b959002051,OS,0.387982
uuid-208c7464bb324924bbe5f7b959002051,95% CI,0.745043
uuid-208c7464bb324924bbe5f7b959002051,respectively,0.729294
uuid-208c7464bb324924bbe5f7b959002051,Objective response rate,0.590876
uuid-208c7464bb324924bbe5f7b959002051,ORR,0.722442
uuid-208c7464bb324924bbe5f7b959002051,Median overall survival,0.659043
uuid-208c7464bb324924bbe5f7b959002051,monotherapy,0.514468
uuid-208c7464bb324924bbe5f7b959002051,Median OS,0.696688
uuid-208c7464bb324924bbe5f7b959002051,PD-L1,0.300997
uuid-208c7464bb324924bbe5f7b959002051,docetaxel,0.635065
uuid-208c7464bb324924bbe5f7b959002051,hazard ratio,0.729977
uuid-f6c42566669a44fe9e429453d89a396b,95% CI,0.524855
uuid-f6c42566669a44fe9e429453d89a396b,respectively,0.383655
uuid-f6c42566669a44fe9e429453d89a396b,ASCO,0.303153
uuid-f6c42566669a44fe9e429453d89a396b,Lancet Oncol,0.368041
uuid-f6c42566669a44fe9e429453d89a396b,Objective response rate,0.504846
uuid-f6c42566669a44fe9e429453d89a396b,ORR,0.465366
uuid-f6c42566669a44fe9e429453d89a396b,Median overall survival,0.346516
uuid-f6c42566669a44fe9e429453d89a396b,Median OS,0.33538
uuid-f6c42566669a44fe9e429453d89a396b,ASCO 2015,0.336983
uuid-f6c42566669a44fe9e429453d89a396b,small cell lung cancer,0.336892
uuid-f6c42566669a44fe9e429453d89a396b,SCLC,0.344367
uuid-f6c42566669a44fe9e429453d89a396b,Antonia SJ,0.55269
uuid-f6c42566669a44fe9e429453d89a396b,Median duration of response,0.649605
uuid-a36b8c9c0f0a4fd68a0181dd768928db,patients,0.483511
uuid-a36b8c9c0f0a4fd68a0181dd768928db,Opdivo,0.382962
uuid-a36b8c9c0f0a4fd68a0181dd768928db,adverse,0.389931
uuid-a36b8c9c0f0a4fd68a0181dd768928db,grade,0.346825
uuid-a36b8c9c0f0a4fd68a0181dd768928db,therapy,0.333851
uuid-a36b8c9c0f0a4fd68a0181dd768928db,grade 3 to 4 AEs,0.309968
uuid-a36b8c9c0f0a4fd68a0181dd768928db,reported,0.340241
uuid-736e23b9ab914ad6af7ae80881a9a19b,nivolumab,0.359772
uuid-c058381cba784840829c23b21ea3932d,95% CI,0.410247
uuid-c058381cba784840829c23b21ea3932d,Lancet Oncol,0.338804
uuid-c058381cba784840829c23b21ea3932d,considered investigational,0.31999
uuid-c058381cba784840829c23b21ea3932d,Objective response rate,0.460397
uuid-c058381cba784840829c23b21ea3932d,ORR,0.42609
uuid-c058381cba784840829c23b21ea3932d,ASCO 2015,0.334207
uuid-c058381cba784840829c23b21ea3932d,small cell lung cancer,0.572318
uuid-c058381cba784840829c23b21ea3932d,SCLC,0.616142
uuid-c058381cba784840829c23b21ea3932d,Antonia SJ,0.54068
uuid-c058381cba784840829c23b21ea3932d,therapy,0.386133
uuid-c058381cba784840829c23b21ea3932d,Median duration of response,0.529786
uuid-c058381cba784840829c23b21ea3932d,phase 1/2 study CA209-032,0.403467
uuid-c058381cba784840829c23b21ea3932d,evaluates the efficacy of nivolumab monotherapy,0.353136
uuid-4bc411494dad443e86b90c0a0db6897c,95% CI,0.539167
uuid-4bc411494dad443e86b90c0a0db6897c,Median overall survival,0.479815
uuid-4bc411494dad443e86b90c0a0db6897c,protocol,0.426554
uuid-4bc411494dad443e86b90c0a0db6897c,McDermott DF,0.500131
uuid-4bc411494dad443e86b90c0a0db6897c,Motzer RJ,0.477178
uuid-4bc411494dad443e86b90c0a0db6897c,Median OS,0.603398
uuid-4bc411494dad443e86b90c0a0db6897c,Escudier B,0.469696
uuid-4bc411494dad443e86b90c0a0db6897c,NEJM,0.387615
uuid-4bc411494dad443e86b90c0a0db6897c,et al.,0.46851
uuid-4bc411494dad443e86b90c0a0db6897c,J Clin Oncol,0.51661
uuid-4bc411494dad443e86b90c0a0db6897c,Topalian,0.337057
uuid-4bc411494dad443e86b90c0a0db6897c,phase 2 study,0.399402
uuid-4bc411494dad443e86b90c0a0db6897c,hazard ratio,0.538097
uuid-58a270b1cbcc45a4b2483a49dbc44541,use of nivolumab for the treatment,0.444892
uuid-58a270b1cbcc45a4b2483a49dbc44541,evaluating,0.30558
uuid-58a270b1cbcc45a4b2483a49dbc44541,patients,0.440855
uuid-58a270b1cbcc45a4b2483a49dbc44541,not approved,0.378002
uuid-58a270b1cbcc45a4b2483a49dbc44541,clinical trials investigating the safety,0.352423
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,N Engl J Med,0.442457
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,protocol,0.76352
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,McDermott DF,0.732828
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,Motzer RJ,0.810818
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,phase 3 study,0.420353
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,Escudier B,0.740783
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,NEJM,0.402558
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,et al.,0.660137
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,J Clin Oncol,0.78619
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,Topalian,0.392662
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,phase 1 study,0.513789
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,CA209-003,0.583235
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,phase 2 study,0.674895
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,present using the following search terms,0.303737
uuid-cdfaaa26d5f4438e9ba637e9c6e32d77,investigating,0.633492
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,Lancet Oncol,0.693877
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,patients,0.405972
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,ipilimumab,0.370825
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,phase 3 study,0.623784
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,ASCO 2015,0.343144
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,melanoma,0.311721
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,phase 1 study,0.381973
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,Rizvi NA,0.651494
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,CA209-003,0.307938
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,Weber JS,0.728839
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,phase 2 study,0.401293
uuid-4f106c96d01e49f38d27ffe1c9c3d74a,Antonia SJ,0.482552
uuid-72a3021ff2c84200a396970d151dfc7e,RCC,0.906223
uuid-219b47ec9137480d9df4459a6cf1f89d,mg,0.844087
uuid-219b47ec9137480d9df4459a6cf1f89d,kg,0.780059
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,search of published literature,0.394524
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,Additionally,0.413583
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,ongoing,0.322117
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,PubMed and EMBASE,0.391671
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,detailed search of www.clinicaltrials.gov,0.375936
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,efficacy and safety of nivolumab,0.370699
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,not identify any planned,0.34283
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,Weber JS,0.319229
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,not identify any citations relevant to your request,0.447813
uuid-1b7b2ebeaac54672ae14fab40edcf1c7,present using the following search terms,0.408199
uuid-2f18d5526b824107b1b5ea317a8013c2,nivolumab,0.564545
uuid-42d92e47a778454f84bfb94265d62548,respectively,0.308923
uuid-42d92e47a778454f84bfb94265d62548,fatigue,0.313289
uuid-ffd16844fb22491f81337d6efa4b77ef,Bristol-Myers Squibb,0.36744
uuid-ffd16844fb22491f81337d6efa4b77ef,requested,0.733493
uuid-ffd16844fb22491f81337d6efa4b77ef,Opdivo,0.328227
uuid-10a991bbeae14c00bcd1836d32edb340,N Engl J Med,0.340789
uuid-10a991bbeae14c00bcd1836d32edb340,Lancet Oncol,0.370237
uuid-10a991bbeae14c00bcd1836d32edb340,phase 3 study,0.518072
uuid-10a991bbeae14c00bcd1836d32edb340,NEJM,0.308962
uuid-10a991bbeae14c00bcd1836d32edb340,melanoma,0.385325
uuid-10a991bbeae14c00bcd1836d32edb340,phase 1 study,0.357353
uuid-10a991bbeae14c00bcd1836d32edb340,Rizvi NA,0.480708
uuid-10a991bbeae14c00bcd1836d32edb340,CA209-003,0.361396
uuid-10a991bbeae14c00bcd1836d32edb340,Weber JS,0.479511
uuid-10a991bbeae14c00bcd1836d32edb340,phase 2 study,0.521794
uuid-dc24ee363cfb478792f71ce7afc385b0,RCC,0.909054
uuid-413ead042f5c4ec8920a274ed24ac19e,OS,0.387982
uuid-413ead042f5c4ec8920a274ed24ac19e,95% CI,0.745043
uuid-413ead042f5c4ec8920a274ed24ac19e,respectively,0.729294
uuid-413ead042f5c4ec8920a274ed24ac19e,Objective response rate,0.590876
uuid-413ead042f5c4ec8920a274ed24ac19e,ORR,0.722442
uuid-413ead042f5c4ec8920a274ed24ac19e,Median overall survival,0.659043
uuid-413ead042f5c4ec8920a274ed24ac19e,monotherapy,0.514468
uuid-413ead042f5c4ec8920a274ed24ac19e,Median OS,0.696688
uuid-413ead042f5c4ec8920a274ed24ac19e,PD-L1,0.300997
uuid-413ead042f5c4ec8920a274ed24ac19e,docetaxel,0.635065
uuid-413ead042f5c4ec8920a274ed24ac19e,hazard ratio,0.729977
uuid-1147099f46034085ba4b11327a95ca36,respectively,0.589071
uuid-1147099f46034085ba4b11327a95ca36,Objective response rate,0.407286
uuid-1147099f46034085ba4b11327a95ca36,ORR,0.526086
uuid-1147099f46034085ba4b11327a95ca36,monotherapy,0.319413
uuid-1147099f46034085ba4b11327a95ca36,docetaxel,0.334344
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,Bristol-Myers Squibb,0.424079
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,evaluating,0.368713
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,not conducted any controlled clinical trials/studies,0.415449
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,NSCLC,0.464217
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,non-small cell lung cancer,0.438685
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,phase 3 study,0.481334
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,phase 1 study,0.32107
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,Rizvi NA,0.375889
uuid-56d9a3bb478b4402aa6a13497c1c7b0a,efficacy and safety of nivolumab,0.4319
uuid-388f95f480bb4a199b03dd2083e29242,McDermott DF,0.356522
uuid-388f95f480bb4a199b03dd2083e29242,Motzer RJ,0.321394
uuid-388f95f480bb4a199b03dd2083e29242,phase 3 study,0.38044
uuid-388f95f480bb4a199b03dd2083e29242,Escudier B,0.340877
uuid-388f95f480bb4a199b03dd2083e29242,et al.,0.323959
uuid-388f95f480bb4a199b03dd2083e29242,J Clin Oncol,0.31877
uuid-388f95f480bb4a199b03dd2083e29242,phase 2 study,0.410437
uuid-52f0b26384fb4facb9d1767add520df3,ASCO,0.64795
uuid-52f0b26384fb4facb9d1767add520df3,Antonia SJ,0.334859
uuid-2bf29516e949437a90f5908ebe09db58,RCC,0.843791
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,considered investigational,0.30457
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,melanoma,0.387656
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,small cell lung cancer,0.517146
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,partial response,0.323082
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,SCLC,0.592551
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,therapy,0.86274
uuid-f4397b3e5e1d4cbda1b6065890a3b6bb,relapsed,0.390331
uuid-ee2d2c5bb37a48e78ae503d4340060d3,nivolumab,0.493389
uuid-ee2d2c5bb37a48e78ae503d4340060d3,Bristol-Myers Squibb,0.598477
uuid-ee2d2c5bb37a48e78ae503d4340060d3,evaluating,0.837805
uuid-ee2d2c5bb37a48e78ae503d4340060d3,not conducted any controlled clinical trials/studies,0.848713
uuid-ee2d2c5bb37a48e78ae503d4340060d3,Pubmed literature search,0.314091
uuid-ee2d2c5bb37a48e78ae503d4340060d3,purposes other than its labeled indication must be considered investigational,0.4415
uuid-ee2d2c5bb37a48e78ae503d4340060d3,search of published literature,0.772891
uuid-ee2d2c5bb37a48e78ae503d4340060d3,PubMed and EMBASE,0.743175
uuid-ee2d2c5bb37a48e78ae503d4340060d3,efficacy and safety of nivolumab,0.905749
uuid-ee2d2c5bb37a48e78ae503d4340060d3,not identify any citations relevant to your request,0.417576
uuid-ee2d2c5bb37a48e78ae503d4340060d3,present using the following search terms,0.748132
uuid-288b7390e6504515b857503711594ef8,95% CI,0.524855
uuid-288b7390e6504515b857503711594ef8,respectively,0.383655
uuid-288b7390e6504515b857503711594ef8,ASCO,0.303153
uuid-288b7390e6504515b857503711594ef8,Lancet Oncol,0.368041
uuid-288b7390e6504515b857503711594ef8,Objective response rate,0.504846
uuid-288b7390e6504515b857503711594ef8,ORR,0.465366
uuid-288b7390e6504515b857503711594ef8,Median overall survival,0.346516
uuid-288b7390e6504515b857503711594ef8,Median OS,0.33538
uuid-288b7390e6504515b857503711594ef8,ASCO 2015,0.336983
uuid-288b7390e6504515b857503711594ef8,small cell lung cancer,0.336892
uuid-288b7390e6504515b857503711594ef8,SCLC,0.344367
uuid-288b7390e6504515b857503711594ef8,Antonia SJ,0.55269
uuid-288b7390e6504515b857503711594ef8,Median duration of response,0.649605
uuid-c2e56752b4e743f0833453e41076e619,RCC,0.906223
uuid-3daf544377854a5484ba0a808e9093b1,OS,0.387982
uuid-3daf544377854a5484ba0a808e9093b1,95% CI,0.745043
uuid-3daf544377854a5484ba0a808e9093b1,respectively,0.729294
uuid-3daf544377854a5484ba0a808e9093b1,Objective response rate,0.590876
uuid-3daf544377854a5484ba0a808e9093b1,ORR,0.722442
uuid-3daf544377854a5484ba0a808e9093b1,Median overall survival,0.659043
uuid-3daf544377854a5484ba0a808e9093b1,monotherapy,0.514468
uuid-3daf544377854a5484ba0a808e9093b1,Median OS,0.696688
uuid-3daf544377854a5484ba0a808e9093b1,PD-L1,0.300997
uuid-3daf544377854a5484ba0a808e9093b1,docetaxel,0.635065
uuid-3daf544377854a5484ba0a808e9093b1,hazard ratio,0.729977
uuid-8079fd256f3a4f52af56c3b03826af5a,search of published literature,0.311372
uuid-8079fd256f3a4f52af56c3b03826af5a,PubMed and EMBASE,0.311496
uuid-8079fd256f3a4f52af56c3b03826af5a,present using the following search terms,0.317161
uuid-4c147c69b8164101a591f395b86bb607,95% CI,0.384282
uuid-4c147c69b8164101a591f395b86bb607,ASCO,0.40687
uuid-4c147c69b8164101a591f395b86bb607,Objective response rate,0.409634
uuid-4c147c69b8164101a591f395b86bb607,Median overall survival,0.319094
uuid-4c147c69b8164101a591f395b86bb607,Median OS,0.403026
uuid-4c147c69b8164101a591f395b86bb607,ASCO 2015,0.386899
uuid-4c147c69b8164101a591f395b86bb607,hazard ratio,0.403406
uuid-1b5aa6b245df490685ac63771da6ab89,RCC,0.843791
uuid-5eb2e8bda33649b2bdb0c775607ef2b4,ipilimumab,0.385692
uuid-5eb2e8bda33649b2bdb0c775607ef2b4,ASCO 2015,0.417944
uuid-5eb2e8bda33649b2bdb0c775607ef2b4,partial response,0.382425
uuid-5eb2e8bda33649b2bdb0c775607ef2b4,Stable disease,0.586335
uuid-5eb2e8bda33649b2bdb0c775607ef2b4,cohort,0.307748
uuid-ccae86656b264915af4bb1f4c5a8fd56,Bristol-Myers Squibb,0.494637
uuid-6dbf02cda55f4df1b47aff257e3c4923,RCC,0.909054
uuid-7b746b01e776431d81cf0d09394c061e,Bristol-Myers Squibb,0.643958
uuid-7b746b01e776431d81cf0d09394c061e,evaluating,0.505739
uuid-7b746b01e776431d81cf0d09394c061e,not conducted any controlled clinical trials/studies,0.576271
uuid-7b746b01e776431d81cf0d09394c061e,efficacy and safety of nivolumab,0.431356
uuid-d00271193fab485b90a5e771fbadf881,nivolumab,0.493389
uuid-d00271193fab485b90a5e771fbadf881,Bristol-Myers Squibb,0.598477
uuid-d00271193fab485b90a5e771fbadf881,evaluating,0.837805
uuid-d00271193fab485b90a5e771fbadf881,not conducted any controlled clinical trials/studies,0.848713
uuid-d00271193fab485b90a5e771fbadf881,Pubmed literature search,0.314091
uuid-d00271193fab485b90a5e771fbadf881,purposes other than its labeled indication must be considered investigational,0.4415
uuid-d00271193fab485b90a5e771fbadf881,search of published literature,0.772891
uuid-d00271193fab485b90a5e771fbadf881,PubMed and EMBASE,0.743175
uuid-d00271193fab485b90a5e771fbadf881,efficacy and safety of nivolumab,0.905749
uuid-d00271193fab485b90a5e771fbadf881,not identify any citations relevant to your request,0.417576
uuid-d00271193fab485b90a5e771fbadf881,present using the following search terms,0.748132
uuid-02ec2cc843dd44428dcf2881b81eecd1,Bristol-Myers Squibb,0.341822
uuid-02ec2cc843dd44428dcf2881b81eecd1,not conducted any controlled clinical trials/studies,0.304507
uuid-02ec2cc843dd44428dcf2881b81eecd1,Opdivo,0.461382
uuid-02ec2cc843dd44428dcf2881b81eecd1,Pubmed literature search,0.614325
uuid-02ec2cc843dd44428dcf2881b81eecd1,purposes other than its labeled indication must be considered investigational,0.586645
uuid-02ec2cc843dd44428dcf2881b81eecd1,not identify any citations relevant to your inquiry,0.606087
uuid-02ec2cc843dd44428dcf2881b81eecd1,adverse,0.304183
uuid-02ec2cc843dd44428dcf2881b81eecd1,using the following search terms,0.642331
uuid-02ec2cc843dd44428dcf2881b81eecd1,databases,0.315039
uuid-02ec2cc843dd44428dcf2881b81eecd1,reported,0.556704
uuid-4195f723d0964cebade5ab9541ffb9c9,Opdivo,0.477778
uuid-4195f723d0964cebade5ab9541ffb9c9,clinical,0.441824
uuid-4195f723d0964cebade5ab9541ffb9c9,trial,0.418634
uuid-d9bd8bf29a794427a68ffac04b300643,melanoma,0.319123
uuid-8e598e5475d14b1b85f7557ce66c0f55,RCC,0.909054
uuid-2ab571c240bb4808b973670df0fe931e,RCC,0.906223
uuid-90dfb101932243ce8031f46810a3ac4d,95% CI,0.524855
uuid-90dfb101932243ce8031f46810a3ac4d,respectively,0.383655
uuid-90dfb101932243ce8031f46810a3ac4d,ASCO,0.303153
uuid-90dfb101932243ce8031f46810a3ac4d,Lancet Oncol,0.368041
uuid-90dfb101932243ce8031f46810a3ac4d,Objective response rate,0.504846
uuid-90dfb101932243ce8031f46810a3ac4d,ORR,0.465366
uuid-90dfb101932243ce8031f46810a3ac4d,Median overall survival,0.346516
uuid-90dfb101932243ce8031f46810a3ac4d,Median OS,0.33538
uuid-90dfb101932243ce8031f46810a3ac4d,ASCO 2015,0.336983
uuid-90dfb101932243ce8031f46810a3ac4d,small cell lung cancer,0.336892
uuid-90dfb101932243ce8031f46810a3ac4d,SCLC,0.344367
uuid-90dfb101932243ce8031f46810a3ac4d,Antonia SJ,0.55269
uuid-90dfb101932243ce8031f46810a3ac4d,Median duration of response,0.649605
uuid-babfa536c6d44a06b36ec584521e6d01,respectively,0.589071
uuid-babfa536c6d44a06b36ec584521e6d01,Objective response rate,0.407286
uuid-babfa536c6d44a06b36ec584521e6d01,ORR,0.526086
uuid-babfa536c6d44a06b36ec584521e6d01,monotherapy,0.319413
uuid-babfa536c6d44a06b36ec584521e6d01,docetaxel,0.334344
uuid-b457d2ac86d44fadabe5860b7bb0e307,RCC,0.899792
uuid-0b5ff923fca2496d8221be833ee0e7b7,95% CI,0.449664
uuid-0b5ff923fca2496d8221be833ee0e7b7,Objective response rate,0.401882
uuid-0b5ff923fca2496d8221be833ee0e7b7,ORR,0.37001
uuid-0b5ff923fca2496d8221be833ee0e7b7,patients with advanced or metastatic,0.359683
uuid-0b5ff923fca2496d8221be833ee0e7b7,nivolumab combined with ipilimumab,0.368974
uuid-0b5ff923fca2496d8221be833ee0e7b7,small cell lung cancer,0.351901
uuid-0b5ff923fca2496d8221be833ee0e7b7,SCLC,0.334829
uuid-0b5ff923fca2496d8221be833ee0e7b7,Antonia SJ,0.467279
uuid-0b5ff923fca2496d8221be833ee0e7b7,Median duration of response,0.570678
uuid-0b5ff923fca2496d8221be833ee0e7b7,phase 1/2 study CA209-032,0.332334
uuid-0b5ff923fca2496d8221be833ee0e7b7,bladder cancer,0.303581
uuid-0b5ff923fca2496d8221be833ee0e7b7,evaluates the efficacy of nivolumab monotherapy,0.330013
uuid-61c63e2ddf024364811dd5ddf7787d52,mg,0.738579
uuid-61c63e2ddf024364811dd5ddf7787d52,kg,0.670747
uuid-c0f89265e4bc4ed9bbf494e10139570c,95% CI,0.524855
uuid-c0f89265e4bc4ed9bbf494e10139570c,respectively,0.383655
uuid-c0f89265e4bc4ed9bbf494e10139570c,ASCO,0.303153
uuid-c0f89265e4bc4ed9bbf494e10139570c,Lancet Oncol,0.368041
uuid-c0f89265e4bc4ed9bbf494e10139570c,Objective response rate,0.504846
uuid-c0f89265e4bc4ed9bbf494e10139570c,ORR,0.465366
uuid-c0f89265e4bc4ed9bbf494e10139570c,Median overall survival,0.346516
uuid-c0f89265e4bc4ed9bbf494e10139570c,Median OS,0.33538
uuid-c0f89265e4bc4ed9bbf494e10139570c,ASCO 2015,0.336983
uuid-c0f89265e4bc4ed9bbf494e10139570c,small cell lung cancer,0.336892
uuid-c0f89265e4bc4ed9bbf494e10139570c,SCLC,0.344367
uuid-c0f89265e4bc4ed9bbf494e10139570c,Antonia SJ,0.55269
uuid-c0f89265e4bc4ed9bbf494e10139570c,Median duration of response,0.649605
uuid-34f133ab876e44c4a3b341eec9e04cce,Bristol-Myers Squibb,0.341822
uuid-34f133ab876e44c4a3b341eec9e04cce,not conducted any controlled clinical trials/studies,0.304507
uuid-34f133ab876e44c4a3b341eec9e04cce,Opdivo,0.461382
uuid-34f133ab876e44c4a3b341eec9e04cce,Pubmed literature search,0.614325
uuid-34f133ab876e44c4a3b341eec9e04cce,purposes other than its labeled indication must be considered investigational,0.586645
uuid-34f133ab876e44c4a3b341eec9e04cce,not identify any citations relevant to your inquiry,0.606087
uuid-34f133ab876e44c4a3b341eec9e04cce,adverse,0.304183
uuid-34f133ab876e44c4a3b341eec9e04cce,using the following search terms,0.642331
uuid-34f133ab876e44c4a3b341eec9e04cce,databases,0.315039
uuid-34f133ab876e44c4a3b341eec9e04cce,reported,0.556704
uuid-f82c23df4526474fbad7d23145a48dd0,RCC,0.906223
uuid-09e4daab2f244fbe8e8ef56282e89f36,N Engl J Med,0.643107
uuid-09e4daab2f244fbe8e8ef56282e89f36,respectively,0.398989
uuid-09e4daab2f244fbe8e8ef56282e89f36,Median overall survival,0.30615
uuid-09e4daab2f244fbe8e8ef56282e89f36,ESMO,0.534703
uuid-09e4daab2f244fbe8e8ef56282e89f36,Median OS,0.319939
uuid-09e4daab2f244fbe8e8ef56282e89f36,Brahmer J,0.658171
uuid-09e4daab2f244fbe8e8ef56282e89f36,Horn L,0.594193
uuid-dc1fc6e693f949dab66a6faf3ecdb2f3,RCC,0.906223
uuid-83723f920712448aad5aa8dafbfe51cc,RCC,0.909054
uuid-2e2934f70bee489ba267f8469e6ce6e2,N Engl J Med,0.347178
uuid-2e2934f70bee489ba267f8469e6ce6e2,Lancet Oncol,0.359155
uuid-2e2934f70bee489ba267f8469e6ce6e2,protocol,0.371457
uuid-2e2934f70bee489ba267f8469e6ce6e2,McDermott DF,0.414017
uuid-2e2934f70bee489ba267f8469e6ce6e2,Motzer RJ,0.384536
uuid-2e2934f70bee489ba267f8469e6ce6e2,phase 3 study,0.443559
uuid-2e2934f70bee489ba267f8469e6ce6e2,Escudier B,0.411866
uuid-2e2934f70bee489ba267f8469e6ce6e2,et al.,0.39703
uuid-2e2934f70bee489ba267f8469e6ce6e2,J Clin Oncol,0.378141
uuid-2e2934f70bee489ba267f8469e6ce6e2,phase 1 study,0.326203
uuid-2e2934f70bee489ba267f8469e6ce6e2,Rizvi NA,0.563772
uuid-2e2934f70bee489ba267f8469e6ce6e2,mg,0.40261
uuid-2e2934f70bee489ba267f8469e6ce6e2,Weber JS,0.418348
uuid-2e2934f70bee489ba267f8469e6ce6e2,phase 2 study,0.587446
uuid-2e2934f70bee489ba267f8469e6ce6e2,kg,0.361586
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,nivolumab,0.667202
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,Opdivo,0.680702
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,Pubmed literature search,0.389429
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,purposes other than its labeled indication must be considered investigational,0.3548
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,not identify any citations relevant to your inquiry,0.397999
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,using the following search terms,0.449212
uuid-0dbb76ec40ac498fb8b89e1147b0dba7,trial,0.311697
uuid-fb552cd100604fcdb5f3a94bbea7aeb4,Opdivo,0.390186
uuid-fb552cd100604fcdb5f3a94bbea7aeb4,clinical,0.685799
uuid-fb552cd100604fcdb5f3a94bbea7aeb4,trial,0.670334
uuid-6768ab4799ee4cfbba1f7ee557740d11,RCC,0.909054
uuid-b464b1a8dd344626a040e3849e0ce8d7,OS,0.387982
uuid-b464b1a8dd344626a040e3849e0ce8d7,95% CI,0.745043
uuid-b464b1a8dd344626a040e3849e0ce8d7,respectively,0.729294
uuid-b464b1a8dd344626a040e3849e0ce8d7,Objective response rate,0.590876
uuid-b464b1a8dd344626a040e3849e0ce8d7,ORR,0.722442
uuid-b464b1a8dd344626a040e3849e0ce8d7,Median overall survival,0.659043
uuid-b464b1a8dd344626a040e3849e0ce8d7,monotherapy,0.514468
uuid-b464b1a8dd344626a040e3849e0ce8d7,Median OS,0.696688
uuid-b464b1a8dd344626a040e3849e0ce8d7,PD-L1,0.300997
uuid-b464b1a8dd344626a040e3849e0ce8d7,docetaxel,0.635065
uuid-b464b1a8dd344626a040e3849e0ce8d7,hazard ratio,0.729977
uuid-2ef51c5554de45d1bb1c2636ef5e9247,evaluating,0.439461
uuid-2ef51c5554de45d1bb1c2636ef5e9247,not conducted any controlled clinical trials/studies,0.431506
uuid-2ef51c5554de45d1bb1c2636ef5e9247,search of published literature,0.657775
uuid-2ef51c5554de45d1bb1c2636ef5e9247,Additionally,0.629271
uuid-2ef51c5554de45d1bb1c2636ef5e9247,ongoing,0.490203
uuid-2ef51c5554de45d1bb1c2636ef5e9247,PubMed and EMBASE,0.654377
uuid-2ef51c5554de45d1bb1c2636ef5e9247,detailed search of www.clinicaltrials.gov,0.581655
uuid-2ef51c5554de45d1bb1c2636ef5e9247,efficacy and safety of nivolumab,0.604991
uuid-2ef51c5554de45d1bb1c2636ef5e9247,not identify any planned,0.523312
uuid-2ef51c5554de45d1bb1c2636ef5e9247,not identify any citations relevant to your request,0.702799
uuid-2ef51c5554de45d1bb1c2636ef5e9247,present using the following search terms,0.670227
uuid-61c1d00c299340ceb584f092d999db7f,Bristol-Myers Squibb,0.341822
uuid-61c1d00c299340ceb584f092d999db7f,not conducted any controlled clinical trials/studies,0.304507
uuid-61c1d00c299340ceb584f092d999db7f,Opdivo,0.461382
uuid-61c1d00c299340ceb584f092d999db7f,Pubmed literature search,0.614325
uuid-61c1d00c299340ceb584f092d999db7f,purposes other than its labeled indication must be considered investigational,0.586645
uuid-61c1d00c299340ceb584f092d999db7f,not identify any citations relevant to your inquiry,0.606087
uuid-61c1d00c299340ceb584f092d999db7f,adverse,0.304183
uuid-61c1d00c299340ceb584f092d999db7f,using the following search terms,0.642331
uuid-61c1d00c299340ceb584f092d999db7f,databases,0.315039
uuid-61c1d00c299340ceb584f092d999db7f,reported,0.556704
uuid-62b7db495fe74937bea2ee763b17c822,N Engl J Med,0.351111
uuid-62b7db495fe74937bea2ee763b17c822,protocol,0.35804
uuid-62b7db495fe74937bea2ee763b17c822,McDermott DF,0.384209
uuid-62b7db495fe74937bea2ee763b17c822,Motzer RJ,0.363703
uuid-62b7db495fe74937bea2ee763b17c822,Escudier B,0.384663
uuid-62b7db495fe74937bea2ee763b17c822,et al.,0.391576
uuid-62b7db495fe74937bea2ee763b17c822,J Clin Oncol,0.325264
uuid-d5cfd6b8032f440cb69c84345137442b,Bristol-Myers Squibb,0.341822
uuid-d5cfd6b8032f440cb69c84345137442b,not conducted any controlled clinical trials/studies,0.304507
uuid-d5cfd6b8032f440cb69c84345137442b,Opdivo,0.461382
uuid-d5cfd6b8032f440cb69c84345137442b,Pubmed literature search,0.614325
uuid-d5cfd6b8032f440cb69c84345137442b,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d5cfd6b8032f440cb69c84345137442b,not identify any citations relevant to your inquiry,0.606087
uuid-d5cfd6b8032f440cb69c84345137442b,adverse,0.304183
uuid-d5cfd6b8032f440cb69c84345137442b,using the following search terms,0.642331
uuid-d5cfd6b8032f440cb69c84345137442b,databases,0.315039
uuid-d5cfd6b8032f440cb69c84345137442b,reported,0.556704
uuid-501a68ef59224f1c9bc4b7be042c3207,OS,0.366994
uuid-501a68ef59224f1c9bc4b7be042c3207,PFS,0.413707
uuid-501a68ef59224f1c9bc4b7be042c3207,Overall survival,0.423718
uuid-501a68ef59224f1c9bc4b7be042c3207,Stable disease,0.374375
uuid-8ba38c10da7e4e33bc44de1b9c2cf10b,mg,0.821211
uuid-8ba38c10da7e4e33bc44de1b9c2cf10b,kg,0.749492
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,95% CI,0.524855
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,respectively,0.383655
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,ASCO,0.303153
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Lancet Oncol,0.368041
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Objective response rate,0.504846
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,ORR,0.465366
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Median overall survival,0.346516
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Median OS,0.33538
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,ASCO 2015,0.336983
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,small cell lung cancer,0.336892
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,SCLC,0.344367
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Antonia SJ,0.55269
uuid-7116b3cda6fd4a8eb85ea84e66e76a07,Median duration of response,0.649605
uuid-78bad403cf2d4bf0a598d51c3681c6bd,patients,0.324499
uuid-9c1116e6b80c43f2b0a02a666e5998fe,95% CI,0.539167
uuid-9c1116e6b80c43f2b0a02a666e5998fe,Median overall survival,0.479815
uuid-9c1116e6b80c43f2b0a02a666e5998fe,protocol,0.426554
uuid-9c1116e6b80c43f2b0a02a666e5998fe,McDermott DF,0.500131
uuid-9c1116e6b80c43f2b0a02a666e5998fe,Motzer RJ,0.477178
uuid-9c1116e6b80c43f2b0a02a666e5998fe,Median OS,0.603398
uuid-9c1116e6b80c43f2b0a02a666e5998fe,Escudier B,0.469696
uuid-9c1116e6b80c43f2b0a02a666e5998fe,NEJM,0.387615
uuid-9c1116e6b80c43f2b0a02a666e5998fe,et al.,0.46851
uuid-9c1116e6b80c43f2b0a02a666e5998fe,J Clin Oncol,0.51661
uuid-9c1116e6b80c43f2b0a02a666e5998fe,Topalian,0.337057
uuid-9c1116e6b80c43f2b0a02a666e5998fe,phase 2 study,0.399402
uuid-9c1116e6b80c43f2b0a02a666e5998fe,hazard ratio,0.538097
uuid-87106dce4f1d4b1a93a4b9785ddade56,N Engl J Med,0.347178
uuid-87106dce4f1d4b1a93a4b9785ddade56,Lancet Oncol,0.359155
uuid-87106dce4f1d4b1a93a4b9785ddade56,protocol,0.371457
uuid-87106dce4f1d4b1a93a4b9785ddade56,McDermott DF,0.414017
uuid-87106dce4f1d4b1a93a4b9785ddade56,Motzer RJ,0.384536
uuid-87106dce4f1d4b1a93a4b9785ddade56,phase 3 study,0.443559
uuid-87106dce4f1d4b1a93a4b9785ddade56,Escudier B,0.411866
uuid-87106dce4f1d4b1a93a4b9785ddade56,et al.,0.39703
uuid-87106dce4f1d4b1a93a4b9785ddade56,J Clin Oncol,0.378141
uuid-87106dce4f1d4b1a93a4b9785ddade56,phase 1 study,0.326203
uuid-87106dce4f1d4b1a93a4b9785ddade56,Rizvi NA,0.563772
uuid-87106dce4f1d4b1a93a4b9785ddade56,mg,0.40261
uuid-87106dce4f1d4b1a93a4b9785ddade56,Weber JS,0.418348
uuid-87106dce4f1d4b1a93a4b9785ddade56,phase 2 study,0.587446
uuid-87106dce4f1d4b1a93a4b9785ddade56,kg,0.361586
uuid-6caac52ac950471a92b736fe60c7147f,ASCO,0.822835
uuid-6caac52ac950471a92b736fe60c7147f,Antonia SJ,0.351104
uuid-56a6f5db37eb48a293cc29d54122de1a,NSCLC,0.361614
uuid-56a6f5db37eb48a293cc29d54122de1a,non-small cell lung cancer,0.3001
uuid-56a6f5db37eb48a293cc29d54122de1a,RCC,0.879698
uuid-95e042a7f3f84c50b09b1ff2b30e1316,RCC,0.906223
uuid-165eb46faf33498e83483bd0566bfda8,OS,0.387982
uuid-165eb46faf33498e83483bd0566bfda8,95% CI,0.745043
uuid-165eb46faf33498e83483bd0566bfda8,respectively,0.729294
uuid-165eb46faf33498e83483bd0566bfda8,Objective response rate,0.590876
uuid-165eb46faf33498e83483bd0566bfda8,ORR,0.722442
uuid-165eb46faf33498e83483bd0566bfda8,Median overall survival,0.659043
uuid-165eb46faf33498e83483bd0566bfda8,monotherapy,0.514468
uuid-165eb46faf33498e83483bd0566bfda8,Median OS,0.696688
uuid-165eb46faf33498e83483bd0566bfda8,PD-L1,0.300997
uuid-165eb46faf33498e83483bd0566bfda8,docetaxel,0.635065
uuid-165eb46faf33498e83483bd0566bfda8,hazard ratio,0.729977
uuid-8c91b91f69f748e99ad891acd44d81c3,Bristol-Myers Squibb,0.494637
uuid-85ca28a0838d43199aa7e02911dd767b,RCC,0.906223
uuid-039ed30bdbe04cfe8e6d18f4dcf76fba,NSCLC,0.361614
uuid-039ed30bdbe04cfe8e6d18f4dcf76fba,non-small cell lung cancer,0.3001
uuid-039ed30bdbe04cfe8e6d18f4dcf76fba,RCC,0.879698
uuid-a279becd89fe463d80baf031d616bdd1,RCC,0.906223
uuid-e8573e9bc2a6411ea5770420a9f5d43d,N Engl J Med,0.54825
uuid-e8573e9bc2a6411ea5770420a9f5d43d,NSCLC,0.358785
uuid-e8573e9bc2a6411ea5770420a9f5d43d,non-small cell lung cancer,0.308706
uuid-e8573e9bc2a6411ea5770420a9f5d43d,ESMO,0.396697
uuid-e8573e9bc2a6411ea5770420a9f5d43d,phase 3 study,0.368632
uuid-e8573e9bc2a6411ea5770420a9f5d43d,phase 1 study,0.306384
uuid-e8573e9bc2a6411ea5770420a9f5d43d,Rizvi NA,0.47921
uuid-e8573e9bc2a6411ea5770420a9f5d43d,Brahmer J,0.605319
uuid-e8573e9bc2a6411ea5770420a9f5d43d,phase 2 study,0.362302
uuid-e8573e9bc2a6411ea5770420a9f5d43d,Horn L,0.443225
uuid-94d70eaaefde4524a9564b983ab7c9dc,provided in the Detailed Information,0.349112
uuid-94d70eaaefde4524a9564b983ab7c9dc,Weber JS,0.321343
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,OS,0.387982
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,95% CI,0.745043
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,respectively,0.729294
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,Objective response rate,0.590876
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,ORR,0.722442
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,Median overall survival,0.659043
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,monotherapy,0.514468
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,Median OS,0.696688
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,PD-L1,0.300997
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,docetaxel,0.635065
uuid-d1cf6b7f56214b7a98e2682eee1c07f6,hazard ratio,0.729977
uuid-67a6026fee8c418a95c4080e37a14088,Opdivo,0.383436
uuid-73e8868fdf0a4a7b9766b00a33729ef1,patients,0.335911
uuid-73e8868fdf0a4a7b9766b00a33729ef1,clinical,0.383896
uuid-73e8868fdf0a4a7b9766b00a33729ef1,trial,0.32469
uuid-e7e243c34be34db18eae3a292b119ccf,RCC,0.906223
uuid-365bd87231b340dbb2337b5fa19cf26e,Bristol-Myers Squibb,0.494637
uuid-6d891fc089d54173a885d42966094f48,RCC,0.906223
uuid-571a2fbdff054053bbd329b0735123b1,nivolumab,0.343415
uuid-571a2fbdff054053bbd329b0735123b1,evaluating,0.319068
uuid-571a2fbdff054053bbd329b0735123b1,patients,0.333936
uuid-571a2fbdff054053bbd329b0735123b1,clinicaltrials.gov,0.443804
uuid-828e33496aac403ab8e3b74935a8cf79,RCC,0.909054
uuid-b750286f48a24e85a7efa8a08e33a93a,nivolumab,0.324658
uuid-b750286f48a24e85a7efa8a08e33a93a,use of nivolumab for the treatment,0.543355
uuid-b750286f48a24e85a7efa8a08e33a93a,evaluating,0.348676
uuid-b750286f48a24e85a7efa8a08e33a93a,efficacy,0.388907
uuid-b750286f48a24e85a7efa8a08e33a93a,patients,0.419915
uuid-b750286f48a24e85a7efa8a08e33a93a,search of published literature,0.449959
uuid-b750286f48a24e85a7efa8a08e33a93a,PubMed and EMBASE,0.444573
uuid-b750286f48a24e85a7efa8a08e33a93a,not approved,0.582429
uuid-b750286f48a24e85a7efa8a08e33a93a,clinical trials investigating the safety,0.64854
uuid-b750286f48a24e85a7efa8a08e33a93a,efficacy and safety of nivolumab,0.399101
uuid-b750286f48a24e85a7efa8a08e33a93a,present using the following search terms,0.465296
uuid-99299630f4ba49a7a97e481ea9c60799,N Engl J Med,0.753839
uuid-99299630f4ba49a7a97e481ea9c60799,ASCO,0.342612
uuid-99299630f4ba49a7a97e481ea9c60799,protocol,0.302013
uuid-99299630f4ba49a7a97e481ea9c60799,McDermott DF,0.355753
uuid-99299630f4ba49a7a97e481ea9c60799,Motzer RJ,0.324656
uuid-99299630f4ba49a7a97e481ea9c60799,ESMO,0.538975
uuid-99299630f4ba49a7a97e481ea9c60799,Escudier B,0.352616
uuid-99299630f4ba49a7a97e481ea9c60799,et al.,0.384505
uuid-99299630f4ba49a7a97e481ea9c60799,Rizvi NA,0.458633
uuid-99299630f4ba49a7a97e481ea9c60799,Brahmer J,0.636857
uuid-99299630f4ba49a7a97e481ea9c60799,phase 2 study,0.380554
uuid-99299630f4ba49a7a97e481ea9c60799,Horn L,0.507063
uuid-4bc13f77da1348969577827550764fa4,95% CI,0.524855
uuid-4bc13f77da1348969577827550764fa4,respectively,0.383655
uuid-4bc13f77da1348969577827550764fa4,ASCO,0.303153
uuid-4bc13f77da1348969577827550764fa4,Lancet Oncol,0.368041
uuid-4bc13f77da1348969577827550764fa4,Objective response rate,0.504846
uuid-4bc13f77da1348969577827550764fa4,ORR,0.465366
uuid-4bc13f77da1348969577827550764fa4,Median overall survival,0.346516
uuid-4bc13f77da1348969577827550764fa4,Median OS,0.33538
uuid-4bc13f77da1348969577827550764fa4,ASCO 2015,0.336983
uuid-4bc13f77da1348969577827550764fa4,small cell lung cancer,0.336892
uuid-4bc13f77da1348969577827550764fa4,SCLC,0.344367
uuid-4bc13f77da1348969577827550764fa4,Antonia SJ,0.55269
uuid-4bc13f77da1348969577827550764fa4,Median duration of response,0.649605
uuid-ea72bb0a7008486aa8c4ad829082dd39,nivolumab,0.557337
uuid-ea72bb0a7008486aa8c4ad829082dd39,Bristol-Myers Squibb,0.375449
uuid-ea72bb0a7008486aa8c4ad829082dd39,evaluating,0.515301
uuid-ea72bb0a7008486aa8c4ad829082dd39,not conducted any controlled clinical trials/studies,0.500162
uuid-ea72bb0a7008486aa8c4ad829082dd39,search of published literature,0.574507
uuid-ea72bb0a7008486aa8c4ad829082dd39,PubMed and EMBASE,0.56158
uuid-ea72bb0a7008486aa8c4ad829082dd39,efficacy and safety of nivolumab,0.58851
uuid-ea72bb0a7008486aa8c4ad829082dd39,clinicaltrials.gov,0.397658
uuid-ea72bb0a7008486aa8c4ad829082dd39,not identify any citations relevant to your request,0.393897
uuid-ea72bb0a7008486aa8c4ad829082dd39,present using the following search terms,0.582815
uuid-d10bb41812fd45518f4f2f687e550d3a,95% CI,0.539167
uuid-d10bb41812fd45518f4f2f687e550d3a,Median overall survival,0.479815
uuid-d10bb41812fd45518f4f2f687e550d3a,protocol,0.426554
uuid-d10bb41812fd45518f4f2f687e550d3a,McDermott DF,0.500131
uuid-d10bb41812fd45518f4f2f687e550d3a,Motzer RJ,0.477178
uuid-d10bb41812fd45518f4f2f687e550d3a,Median OS,0.603398
uuid-d10bb41812fd45518f4f2f687e550d3a,Escudier B,0.469696
uuid-d10bb41812fd45518f4f2f687e550d3a,NEJM,0.387615
uuid-d10bb41812fd45518f4f2f687e550d3a,et al.,0.46851
uuid-d10bb41812fd45518f4f2f687e550d3a,J Clin Oncol,0.51661
uuid-d10bb41812fd45518f4f2f687e550d3a,Topalian,0.337057
uuid-d10bb41812fd45518f4f2f687e550d3a,phase 2 study,0.399402
uuid-d10bb41812fd45518f4f2f687e550d3a,hazard ratio,0.538097
uuid-01d52f33c64c4b99ab13b8567d484e66,nivolumab,0.398492
uuid-01d52f33c64c4b99ab13b8567d484e66,Bristol-Myers Squibb,0.414709
uuid-01d52f33c64c4b99ab13b8567d484e66,evaluating,0.565164
uuid-01d52f33c64c4b99ab13b8567d484e66,not conducted any controlled clinical trials/studies,0.624762
uuid-01d52f33c64c4b99ab13b8567d484e66,Pubmed literature search,0.915314
uuid-01d52f33c64c4b99ab13b8567d484e66,purposes other than its labeled indication must be considered investigational,0.956956
uuid-01d52f33c64c4b99ab13b8567d484e66,not identify any citations relevant to your inquiry,0.880251
uuid-01d52f33c64c4b99ab13b8567d484e66,using the following search terms,0.871319
uuid-01d52f33c64c4b99ab13b8567d484e66,efficacy and safety of nivolumab,0.382283
uuid-56dc6f7e1cf7420fa5fe5320e04b9018,mg,0.75724
uuid-56dc6f7e1cf7420fa5fe5320e04b9018,kg,0.695575
uuid-cde797a7cd0e47ba8174e5457966e475,RCC,0.909054
uuid-db969f19079c4ccc88aabce81b0e557c,95% CI,0.524855
uuid-db969f19079c4ccc88aabce81b0e557c,respectively,0.383655
uuid-db969f19079c4ccc88aabce81b0e557c,ASCO,0.303153
uuid-db969f19079c4ccc88aabce81b0e557c,Lancet Oncol,0.368041
uuid-db969f19079c4ccc88aabce81b0e557c,Objective response rate,0.504846
uuid-db969f19079c4ccc88aabce81b0e557c,ORR,0.465366
uuid-db969f19079c4ccc88aabce81b0e557c,Median overall survival,0.346516
uuid-db969f19079c4ccc88aabce81b0e557c,Median OS,0.33538
uuid-db969f19079c4ccc88aabce81b0e557c,ASCO 2015,0.336983
uuid-db969f19079c4ccc88aabce81b0e557c,small cell lung cancer,0.336892
uuid-db969f19079c4ccc88aabce81b0e557c,SCLC,0.344367
uuid-db969f19079c4ccc88aabce81b0e557c,Antonia SJ,0.55269
uuid-db969f19079c4ccc88aabce81b0e557c,Median duration of response,0.649605
uuid-b4f68f96362f415ebe88aecdfed6566d,BMS,0.311458
uuid-4650b11bdf8d4ae4897f03a34a5d2779,OS,0.44149
uuid-4650b11bdf8d4ae4897f03a34a5d2779,95% CI,0.833403
uuid-4650b11bdf8d4ae4897f03a34a5d2779,ASCO,0.32927
uuid-4650b11bdf8d4ae4897f03a34a5d2779,Objective response rate,0.545269
uuid-4650b11bdf8d4ae4897f03a34a5d2779,ORR,0.618524
uuid-4650b11bdf8d4ae4897f03a34a5d2779,PFS,0.396858
uuid-4650b11bdf8d4ae4897f03a34a5d2779,Median overall survival,0.72593
uuid-4650b11bdf8d4ae4897f03a34a5d2779,monotherapy,0.33356
uuid-4650b11bdf8d4ae4897f03a34a5d2779,Median OS,0.763854
uuid-4650b11bdf8d4ae4897f03a34a5d2779,hazard ratio,0.766648
uuid-4650b11bdf8d4ae4897f03a34a5d2779,Median duration of response,0.442682
uuid-21943686de2043f4b7d03c523d859e2e,N Engl J Med,0.373796
uuid-21943686de2043f4b7d03c523d859e2e,protocol,0.420361
uuid-21943686de2043f4b7d03c523d859e2e,McDermott DF,0.513284
uuid-21943686de2043f4b7d03c523d859e2e,Motzer RJ,0.482105
uuid-21943686de2043f4b7d03c523d859e2e,phase 3 study,0.448204
uuid-21943686de2043f4b7d03c523d859e2e,Escudier B,0.482741
uuid-21943686de2043f4b7d03c523d859e2e,NEJM,0.342527
uuid-21943686de2043f4b7d03c523d859e2e,et al.,0.466863
uuid-21943686de2043f4b7d03c523d859e2e,J Clin Oncol,0.523543
uuid-21943686de2043f4b7d03c523d859e2e,Topalian,0.340171
uuid-21943686de2043f4b7d03c523d859e2e,phase 1 study,0.421699
uuid-21943686de2043f4b7d03c523d859e2e,mg,0.324901
uuid-21943686de2043f4b7d03c523d859e2e,CA209-003,0.451562
uuid-21943686de2043f4b7d03c523d859e2e,phase 2 study,0.595096
uuid-21943686de2043f4b7d03c523d859e2e,grade,0.324161
uuid-21943686de2043f4b7d03c523d859e2e,kg,0.310462
uuid-325f9508427744c8a90b9940e7f812ba,95% CI,0.524855
uuid-325f9508427744c8a90b9940e7f812ba,respectively,0.383655
uuid-325f9508427744c8a90b9940e7f812ba,ASCO,0.303153
uuid-325f9508427744c8a90b9940e7f812ba,Lancet Oncol,0.368041
uuid-325f9508427744c8a90b9940e7f812ba,Objective response rate,0.504846
uuid-325f9508427744c8a90b9940e7f812ba,ORR,0.465366
uuid-325f9508427744c8a90b9940e7f812ba,Median overall survival,0.346516
uuid-325f9508427744c8a90b9940e7f812ba,Median OS,0.33538
uuid-325f9508427744c8a90b9940e7f812ba,ASCO 2015,0.336983
uuid-325f9508427744c8a90b9940e7f812ba,small cell lung cancer,0.336892
uuid-325f9508427744c8a90b9940e7f812ba,SCLC,0.344367
uuid-325f9508427744c8a90b9940e7f812ba,Antonia SJ,0.55269
uuid-325f9508427744c8a90b9940e7f812ba,Median duration of response,0.649605
uuid-f2bb86be5733460a8bd6b069e67361a6,RCC,0.909054
uuid-ac475b4657d343eb8d8a89094b113069,RCC,0.906223
uuid-b78f162dd65a4809ae3288a82e277195,mg,0.517684
uuid-b78f162dd65a4809ae3288a82e277195,kg,0.442448
uuid-ef2eae2995cf461687df8177504ed890,requested,0.473661
uuid-00cd2a63d94849958d5e99fd885e1afc,RCC,0.909054
uuid-99a86b0fde3746578380a26dcda0e500,N Engl J Med,0.779693
uuid-99a86b0fde3746578380a26dcda0e500,Lancet Oncol,0.591516
uuid-99a86b0fde3746578380a26dcda0e500,protocol,0.810019
uuid-99a86b0fde3746578380a26dcda0e500,McDermott DF,0.872514
uuid-99a86b0fde3746578380a26dcda0e500,Motzer RJ,0.839207
uuid-99a86b0fde3746578380a26dcda0e500,phase 3 study,0.56417
uuid-99a86b0fde3746578380a26dcda0e500,Escudier B,0.874914
uuid-99a86b0fde3746578380a26dcda0e500,NEJM,0.489149
uuid-99a86b0fde3746578380a26dcda0e500,et al.,0.853321
uuid-99a86b0fde3746578380a26dcda0e500,J Clin Oncol,0.788192
uuid-99a86b0fde3746578380a26dcda0e500,Topalian,0.446082
uuid-99a86b0fde3746578380a26dcda0e500,Rizvi NA,0.742658
uuid-99a86b0fde3746578380a26dcda0e500,Brahmer J,0.455779
uuid-99a86b0fde3746578380a26dcda0e500,Weber JS,0.623231
uuid-99a86b0fde3746578380a26dcda0e500,phase 2 study,0.830393
uuid-3e09bb996c5e4f6da8defb3e8004a3aa,provided in the Detailed Information,0.502568
uuid-c7bf767eeb1c4885b8e51d2f83275b7d,RCC,0.906223
uuid-d9435ec14cd0468499932f080ca1f8c1,N Engl J Med,0.583503
uuid-d9435ec14cd0468499932f080ca1f8c1,Lancet Oncol,0.357709
uuid-d9435ec14cd0468499932f080ca1f8c1,protocol,0.528789
uuid-d9435ec14cd0468499932f080ca1f8c1,McDermott DF,0.581068
uuid-d9435ec14cd0468499932f080ca1f8c1,Motzer RJ,0.551855
uuid-d9435ec14cd0468499932f080ca1f8c1,phase 3 study,0.65941
uuid-d9435ec14cd0468499932f080ca1f8c1,Escudier B,0.569019
uuid-d9435ec14cd0468499932f080ca1f8c1,et al.,0.545935
uuid-d9435ec14cd0468499932f080ca1f8c1,J Clin Oncol,0.526611
uuid-d9435ec14cd0468499932f080ca1f8c1,phase 1 study,0.390216
uuid-d9435ec14cd0468499932f080ca1f8c1,Rizvi NA,0.57895
uuid-d9435ec14cd0468499932f080ca1f8c1,Brahmer J,0.447442
uuid-d9435ec14cd0468499932f080ca1f8c1,CA209-003,0.358407
uuid-d9435ec14cd0468499932f080ca1f8c1,Weber JS,0.44152
uuid-d9435ec14cd0468499932f080ca1f8c1,BMS,0.397097
uuid-d9435ec14cd0468499932f080ca1f8c1,phase 2 study,0.710742
uuid-3e37821b66ee453ba626a9e1d078528f,nivolumab,0.470862
uuid-3e37821b66ee453ba626a9e1d078528f,use of nivolumab for the treatment,0.653633
uuid-3e37821b66ee453ba626a9e1d078528f,evaluating,0.38728
uuid-3e37821b66ee453ba626a9e1d078528f,efficacy,0.575458
uuid-3e37821b66ee453ba626a9e1d078528f,patients,0.590103
uuid-3e37821b66ee453ba626a9e1d078528f,not approved,0.649749
uuid-3e37821b66ee453ba626a9e1d078528f,clinical trials investigating the safety,0.617109
uuid-3e37821b66ee453ba626a9e1d078528f,safety of nivolumab monotherapy,0.431722
uuid-a472b1314fe24c2ab475f87d83ddeb9f,N Engl J Med,0.442834
uuid-a472b1314fe24c2ab475f87d83ddeb9f,protocol,0.763252
uuid-a472b1314fe24c2ab475f87d83ddeb9f,McDermott DF,0.733103
uuid-a472b1314fe24c2ab475f87d83ddeb9f,Motzer RJ,0.811057
uuid-a472b1314fe24c2ab475f87d83ddeb9f,phase 3 study,0.420895
uuid-a472b1314fe24c2ab475f87d83ddeb9f,Escudier B,0.741048
uuid-a472b1314fe24c2ab475f87d83ddeb9f,NEJM,0.402544
uuid-a472b1314fe24c2ab475f87d83ddeb9f,et al.,0.660398
uuid-a472b1314fe24c2ab475f87d83ddeb9f,J Clin Oncol,0.786367
uuid-a472b1314fe24c2ab475f87d83ddeb9f,Topalian,0.392395
uuid-a472b1314fe24c2ab475f87d83ddeb9f,phase 1 study,0.513779
uuid-a472b1314fe24c2ab475f87d83ddeb9f,CA209-003,0.583337
uuid-a472b1314fe24c2ab475f87d83ddeb9f,phase 2 study,0.675447
uuid-a472b1314fe24c2ab475f87d83ddeb9f,present using the following search terms,0.304589
uuid-a472b1314fe24c2ab475f87d83ddeb9f,investigating,0.633101
uuid-036caec878594b299dca8ddb08a36b1b,NSCLC,0.361614
uuid-036caec878594b299dca8ddb08a36b1b,non-small cell lung cancer,0.3001
uuid-036caec878594b299dca8ddb08a36b1b,RCC,0.879698
uuid-20ab6e86874240708bb088a2f85379a7,N Engl J Med,0.67846
uuid-20ab6e86874240708bb088a2f85379a7,Lancet Oncol,0.374423
uuid-20ab6e86874240708bb088a2f85379a7,protocol,0.452652
uuid-20ab6e86874240708bb088a2f85379a7,McDermott DF,0.475257
uuid-20ab6e86874240708bb088a2f85379a7,Motzer RJ,0.43205
uuid-20ab6e86874240708bb088a2f85379a7,phase 3 study,0.541235
uuid-20ab6e86874240708bb088a2f85379a7,Escudier B,0.466773
uuid-20ab6e86874240708bb088a2f85379a7,et al.,0.451345
uuid-20ab6e86874240708bb088a2f85379a7,J Clin Oncol,0.399535
uuid-20ab6e86874240708bb088a2f85379a7,Rizvi NA,0.652415
uuid-20ab6e86874240708bb088a2f85379a7,Brahmer J,0.636235
uuid-20ab6e86874240708bb088a2f85379a7,Weber JS,0.396523
uuid-20ab6e86874240708bb088a2f85379a7,BMS,0.498491
uuid-20ab6e86874240708bb088a2f85379a7,phase 2 study,0.620448
uuid-a1244886aedf4b65bb22b82c3f843a27,clinical,0.719205
uuid-a1244886aedf4b65bb22b82c3f843a27,trial,0.330955
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,nivolumab,0.466963
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,evaluating,0.369548
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,not conducted any controlled clinical trials/studies,0.349054
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,search of published literature,0.360692
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,PubMed and EMBASE,0.349256
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,efficacy and safety of nivolumab,0.404689
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,clinicaltrials.gov,0.375346
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,therapy,0.381618
uuid-0dbd5ed13c254df98ec7a0a0055a86d1,present using the following search terms,0.37056
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,Bristol-Myers Squibb,0.341822
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,not conducted any controlled clinical trials/studies,0.304507
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,Opdivo,0.461382
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,Pubmed literature search,0.614325
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,purposes other than its labeled indication must be considered investigational,0.586645
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,not identify any citations relevant to your inquiry,0.606087
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,adverse,0.304183
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,using the following search terms,0.642331
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,databases,0.315039
uuid-ac5bb1b78c2c48eebde4b850b2cc5c08,reported,0.556704
uuid-63229a23172f4dd38a51f5dbe612189d,evaluating,0.350845
uuid-63229a23172f4dd38a51f5dbe612189d,not conducted any controlled clinical trials/studies,0.345107
uuid-63229a23172f4dd38a51f5dbe612189d,search of published literature,0.385331
uuid-63229a23172f4dd38a51f5dbe612189d,Additionally,0.40981
uuid-63229a23172f4dd38a51f5dbe612189d,ongoing,0.457998
uuid-63229a23172f4dd38a51f5dbe612189d,PubMed and EMBASE,0.378285
uuid-63229a23172f4dd38a51f5dbe612189d,detailed search of www.clinicaltrials.gov,0.428522
uuid-63229a23172f4dd38a51f5dbe612189d,efficacy and safety of nivolumab,0.407868
uuid-63229a23172f4dd38a51f5dbe612189d,not identify any planned,0.444729
uuid-63229a23172f4dd38a51f5dbe612189d,combination,0.388252
uuid-63229a23172f4dd38a51f5dbe612189d,BMS,0.316104
uuid-63229a23172f4dd38a51f5dbe612189d,not identify any citations relevant to your request,0.438151
uuid-63229a23172f4dd38a51f5dbe612189d,present using the following search terms,0.377101
uuid-cdae2ae3417f4319a7f16b63deaff028,use of nivolumab for the treatment,0.440423
uuid-cdae2ae3417f4319a7f16b63deaff028,search of published literature,0.311531
uuid-cdae2ae3417f4319a7f16b63deaff028,PubMed and EMBASE,0.312811
uuid-cdae2ae3417f4319a7f16b63deaff028,not approved,0.404782
uuid-cdae2ae3417f4319a7f16b63deaff028,open-label,0.578291
uuid-cdae2ae3417f4319a7f16b63deaff028,clinical trials investigating the safety,0.440014
uuid-cdae2ae3417f4319a7f16b63deaff028,present using the following search terms,0.328669
uuid-cdae2ae3417f4319a7f16b63deaff028,phase,0.41185
uuid-6fdf479e0e7a40e4a912939930e5d920,requested,0.594234
uuid-efced05d8c4c438491e5d88c5ccdcdc6,OS,0.352174
uuid-efced05d8c4c438491e5d88c5ccdcdc6,95% CI,0.568517
uuid-efced05d8c4c438491e5d88c5ccdcdc6,respectively,0.554366
uuid-efced05d8c4c438491e5d88c5ccdcdc6,Objective response rate,0.391042
uuid-efced05d8c4c438491e5d88c5ccdcdc6,ORR,0.486928
uuid-efced05d8c4c438491e5d88c5ccdcdc6,Median overall survival,0.510368
uuid-efced05d8c4c438491e5d88c5ccdcdc6,monotherapy,0.335869
uuid-efced05d8c4c438491e5d88c5ccdcdc6,Median OS,0.573777
uuid-efced05d8c4c438491e5d88c5ccdcdc6,docetaxel,0.719674
uuid-efced05d8c4c438491e5d88c5ccdcdc6,hazard ratio,0.563822
uuid-ac14d78e09c64f3b92aab9b141644716,RCC,0.906223
uuid-01a4d46f960544578bba7939f2c0cc0f,RCC,0.906223
uuid-ac1083e6bc564f18a8410d434c4f7a9e,RCC,0.906223
uuid-24eac125bdf34f6ea6ecbd7843a920bc,patients with advanced or metastatic,0.478326
uuid-24eac125bdf34f6ea6ecbd7843a920bc,nivolumab combined with ipilimumab,0.498766
uuid-24eac125bdf34f6ea6ecbd7843a920bc,not approved,0.34724
uuid-24eac125bdf34f6ea6ecbd7843a920bc,clinical trials investigating the safety,0.426729
uuid-24eac125bdf34f6ea6ecbd7843a920bc,bladder cancer,0.6548
uuid-4f3fb5b01dc2454e97e439c3d356992c,OS,0.387982
uuid-4f3fb5b01dc2454e97e439c3d356992c,95% CI,0.745043
uuid-4f3fb5b01dc2454e97e439c3d356992c,respectively,0.729294
uuid-4f3fb5b01dc2454e97e439c3d356992c,Objective response rate,0.590876
uuid-4f3fb5b01dc2454e97e439c3d356992c,ORR,0.722442
uuid-4f3fb5b01dc2454e97e439c3d356992c,Median overall survival,0.659043
uuid-4f3fb5b01dc2454e97e439c3d356992c,monotherapy,0.514468
uuid-4f3fb5b01dc2454e97e439c3d356992c,Median OS,0.696688
uuid-4f3fb5b01dc2454e97e439c3d356992c,PD-L1,0.300997
uuid-4f3fb5b01dc2454e97e439c3d356992c,docetaxel,0.635065
uuid-4f3fb5b01dc2454e97e439c3d356992c,hazard ratio,0.729977
uuid-064177e0e28b4b0eb67379987164179f,OS,0.387982
uuid-064177e0e28b4b0eb67379987164179f,95% CI,0.745043
uuid-064177e0e28b4b0eb67379987164179f,respectively,0.729294
uuid-064177e0e28b4b0eb67379987164179f,Objective response rate,0.590876
uuid-064177e0e28b4b0eb67379987164179f,ORR,0.722442
uuid-064177e0e28b4b0eb67379987164179f,Median overall survival,0.659043
uuid-064177e0e28b4b0eb67379987164179f,monotherapy,0.514468
uuid-064177e0e28b4b0eb67379987164179f,Median OS,0.696688
uuid-064177e0e28b4b0eb67379987164179f,PD-L1,0.300997
uuid-064177e0e28b4b0eb67379987164179f,docetaxel,0.635065
uuid-064177e0e28b4b0eb67379987164179f,hazard ratio,0.729977
uuid-fc6ac4221281434fa00e869d0205e2d5,RCC,0.909054
uuid-96e7896f9e024a269af969cd4ea0ff86,Bristol-Myers Squibb,0.341822
uuid-96e7896f9e024a269af969cd4ea0ff86,not conducted any controlled clinical trials/studies,0.304507
uuid-96e7896f9e024a269af969cd4ea0ff86,Opdivo,0.461382
uuid-96e7896f9e024a269af969cd4ea0ff86,Pubmed literature search,0.614325
uuid-96e7896f9e024a269af969cd4ea0ff86,purposes other than its labeled indication must be considered investigational,0.586645
uuid-96e7896f9e024a269af969cd4ea0ff86,not identify any citations relevant to your inquiry,0.606087
uuid-96e7896f9e024a269af969cd4ea0ff86,adverse,0.304183
uuid-96e7896f9e024a269af969cd4ea0ff86,using the following search terms,0.642331
uuid-96e7896f9e024a269af969cd4ea0ff86,databases,0.315039
uuid-96e7896f9e024a269af969cd4ea0ff86,reported,0.556704
uuid-2c038d77888f442b9425c7099e5ba0f2,nivolumab,0.493389
uuid-2c038d77888f442b9425c7099e5ba0f2,Bristol-Myers Squibb,0.598477
uuid-2c038d77888f442b9425c7099e5ba0f2,evaluating,0.837805
uuid-2c038d77888f442b9425c7099e5ba0f2,not conducted any controlled clinical trials/studies,0.848713
uuid-2c038d77888f442b9425c7099e5ba0f2,Pubmed literature search,0.314091
uuid-2c038d77888f442b9425c7099e5ba0f2,purposes other than its labeled indication must be considered investigational,0.4415
uuid-2c038d77888f442b9425c7099e5ba0f2,search of published literature,0.772891
uuid-2c038d77888f442b9425c7099e5ba0f2,PubMed and EMBASE,0.743175
uuid-2c038d77888f442b9425c7099e5ba0f2,efficacy and safety of nivolumab,0.905749
uuid-2c038d77888f442b9425c7099e5ba0f2,not identify any citations relevant to your request,0.417576
uuid-2c038d77888f442b9425c7099e5ba0f2,present using the following search terms,0.748132
uuid-8a8c5ab6e66a4dafb36c4abb083bf559,RCC,0.909054
uuid-d4c39b49d3e04eb684d903f10691857b,RCC,0.906223
uuid-101937c660be486c8f8532c6a0c69a0d,N Engl J Med,0.410025
uuid-101937c660be486c8f8532c6a0c69a0d,protocol,0.663749
uuid-101937c660be486c8f8532c6a0c69a0d,RCC,0.370429
uuid-101937c660be486c8f8532c6a0c69a0d,McDermott DF,0.577168
uuid-101937c660be486c8f8532c6a0c69a0d,search of published literature,0.443686
uuid-101937c660be486c8f8532c6a0c69a0d,Additionally,0.395847
uuid-101937c660be486c8f8532c6a0c69a0d,ongoing,0.335873
uuid-101937c660be486c8f8532c6a0c69a0d,Motzer RJ,0.609458
uuid-101937c660be486c8f8532c6a0c69a0d,phase 3 study,0.312748
uuid-101937c660be486c8f8532c6a0c69a0d,PubMed and EMBASE,0.438896
uuid-101937c660be486c8f8532c6a0c69a0d,Escudier B,0.595328
uuid-101937c660be486c8f8532c6a0c69a0d,et al.,0.521538
uuid-101937c660be486c8f8532c6a0c69a0d,J Clin Oncol,0.545137
uuid-101937c660be486c8f8532c6a0c69a0d,detailed search of www.clinicaltrials.gov,0.358127
uuid-101937c660be486c8f8532c6a0c69a0d,efficacy and safety of nivolumab,0.429052
uuid-101937c660be486c8f8532c6a0c69a0d,not identify any planned,0.344155
uuid-101937c660be486c8f8532c6a0c69a0d,phase 2 study,0.513121
uuid-101937c660be486c8f8532c6a0c69a0d,not identify any citations relevant to your request,0.414617
uuid-101937c660be486c8f8532c6a0c69a0d,present using the following search terms,0.417875
uuid-2b55a0337581422f904ba0d09475c271,OS,0.44149
uuid-2b55a0337581422f904ba0d09475c271,95% CI,0.833403
uuid-2b55a0337581422f904ba0d09475c271,ASCO,0.32927
uuid-2b55a0337581422f904ba0d09475c271,Objective response rate,0.545269
uuid-2b55a0337581422f904ba0d09475c271,ORR,0.618524
uuid-2b55a0337581422f904ba0d09475c271,PFS,0.396858
uuid-2b55a0337581422f904ba0d09475c271,Median overall survival,0.72593
uuid-2b55a0337581422f904ba0d09475c271,monotherapy,0.33356
uuid-2b55a0337581422f904ba0d09475c271,Median OS,0.763854
uuid-2b55a0337581422f904ba0d09475c271,hazard ratio,0.766648
uuid-2b55a0337581422f904ba0d09475c271,Median duration of response,0.442682
uuid-af9b369125164324a9e6d5377cbdf62a,RCC,0.906223
uuid-0ee5045ae0854965bbfe4cc78d21e692,RCC,0.906223
uuid-b0c591c237d74abe933c4da3010f9d3c,RCC,0.906223
uuid-a66b3f2242244094b1ca98e7f49b3b42,N Engl J Med,0.311871
uuid-a66b3f2242244094b1ca98e7f49b3b42,respectively,0.573992
uuid-a66b3f2242244094b1ca98e7f49b3b42,Lancet Oncol,0.34739
uuid-a66b3f2242244094b1ca98e7f49b3b42,patients,0.462366
uuid-a66b3f2242244094b1ca98e7f49b3b42,Objective response rate,0.336044
uuid-a66b3f2242244094b1ca98e7f49b3b42,ORR,0.416417
uuid-a66b3f2242244094b1ca98e7f49b3b42,ESMO,0.3085
uuid-a66b3f2242244094b1ca98e7f49b3b42,Rizvi NA,0.334049
uuid-a66b3f2242244094b1ca98e7f49b3b42,Brahmer J,0.359624
uuid-a66b3f2242244094b1ca98e7f49b3b42,docetaxel,0.49967
uuid-a66b3f2242244094b1ca98e7f49b3b42,Antonia SJ,0.348967
uuid-a66b3f2242244094b1ca98e7f49b3b42,grade 3 to 4 AEs,0.427894
uuid-8dc90dafe2c74460b7372b354f3cc1cb,RCC,0.906223
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,search of published literature,0.394524
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,Additionally,0.413583
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,ongoing,0.322117
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,PubMed and EMBASE,0.391671
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,detailed search of www.clinicaltrials.gov,0.375936
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,efficacy and safety of nivolumab,0.370699
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,not identify any planned,0.34283
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,Weber JS,0.319229
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,not identify any citations relevant to your request,0.447813
uuid-eef8a5bab86e40f5bb81fa5abf0fd48e,present using the following search terms,0.408199
uuid-713f3523dab64610bfb2b93bf452a557,Bristol-Myers Squibb,0.341822
uuid-713f3523dab64610bfb2b93bf452a557,not conducted any controlled clinical trials/studies,0.304507
uuid-713f3523dab64610bfb2b93bf452a557,Opdivo,0.461382
uuid-713f3523dab64610bfb2b93bf452a557,Pubmed literature search,0.614325
uuid-713f3523dab64610bfb2b93bf452a557,purposes other than its labeled indication must be considered investigational,0.586645
uuid-713f3523dab64610bfb2b93bf452a557,not identify any citations relevant to your inquiry,0.606087
uuid-713f3523dab64610bfb2b93bf452a557,adverse,0.304183
uuid-713f3523dab64610bfb2b93bf452a557,using the following search terms,0.642331
uuid-713f3523dab64610bfb2b93bf452a557,databases,0.315039
uuid-713f3523dab64610bfb2b93bf452a557,reported,0.556704
uuid-b2d51752b1c54caaa54ddbcef32d76fe,phase 3 study,0.304937
uuid-b2d51752b1c54caaa54ddbcef32d76fe,trial,0.511194
uuid-b2d51752b1c54caaa54ddbcef32d76fe,phase 2 study,0.326732
uuid-a47c280014064e99aadefb4509939424,95% CI,0.384282
uuid-a47c280014064e99aadefb4509939424,ASCO,0.40687
uuid-a47c280014064e99aadefb4509939424,Objective response rate,0.409634
uuid-a47c280014064e99aadefb4509939424,Median overall survival,0.319094
uuid-a47c280014064e99aadefb4509939424,Median OS,0.403026
uuid-a47c280014064e99aadefb4509939424,ASCO 2015,0.386899
uuid-a47c280014064e99aadefb4509939424,hazard ratio,0.403406
uuid-ad5188db78f44cd4abce1c43a6b4002a,patients,0.365501
uuid-f6ce985c3e774ee18eafcb232b43c28d,N Engl J Med,0.424152
uuid-f6ce985c3e774ee18eafcb232b43c28d,protocol,0.430423
uuid-f6ce985c3e774ee18eafcb232b43c28d,McDermott DF,0.455942
uuid-f6ce985c3e774ee18eafcb232b43c28d,Motzer RJ,0.433196
uuid-f6ce985c3e774ee18eafcb232b43c28d,phase 3 study,0.339068
uuid-f6ce985c3e774ee18eafcb232b43c28d,Escudier B,0.456527
uuid-f6ce985c3e774ee18eafcb232b43c28d,et al.,0.463141
uuid-f6ce985c3e774ee18eafcb232b43c28d,J Clin Oncol,0.395883
uuid-f6ce985c3e774ee18eafcb232b43c28d,Rizvi NA,0.348621
uuid-f6ce985c3e774ee18eafcb232b43c28d,Weber JS,0.302016
uuid-f6ce985c3e774ee18eafcb232b43c28d,phase 2 study,0.419907
uuid-8c67d4cb87054fa4aa9dee4809ca0139,Opdivo,0.414061
uuid-8c67d4cb87054fa4aa9dee4809ca0139,trial,0.396965
uuid-34cd5dc29ea04eedadb358234d8ecde2,N Engl J Med,0.427636
uuid-34cd5dc29ea04eedadb358234d8ecde2,protocol,0.429136
uuid-34cd5dc29ea04eedadb358234d8ecde2,McDermott DF,0.44782
uuid-34cd5dc29ea04eedadb358234d8ecde2,Motzer RJ,0.430476
uuid-34cd5dc29ea04eedadb358234d8ecde2,Escudier B,0.450887
uuid-34cd5dc29ea04eedadb358234d8ecde2,et al.,0.456026
uuid-34cd5dc29ea04eedadb358234d8ecde2,J Clin Oncol,0.384624
uuid-34cd5dc29ea04eedadb358234d8ecde2,Rizvi NA,0.305616
uuid-34cd5dc29ea04eedadb358234d8ecde2,phase 2 study,0.351446
uuid-609d6198f69c4b7b97db86fa2af2f67a,Bristol-Myers Squibb,0.341822
uuid-609d6198f69c4b7b97db86fa2af2f67a,not conducted any controlled clinical trials/studies,0.304507
uuid-609d6198f69c4b7b97db86fa2af2f67a,Opdivo,0.461382
uuid-609d6198f69c4b7b97db86fa2af2f67a,Pubmed literature search,0.614325
uuid-609d6198f69c4b7b97db86fa2af2f67a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-609d6198f69c4b7b97db86fa2af2f67a,not identify any citations relevant to your inquiry,0.606087
uuid-609d6198f69c4b7b97db86fa2af2f67a,adverse,0.304183
uuid-609d6198f69c4b7b97db86fa2af2f67a,using the following search terms,0.642331
uuid-609d6198f69c4b7b97db86fa2af2f67a,databases,0.315039
uuid-609d6198f69c4b7b97db86fa2af2f67a,reported,0.556704
uuid-3f611cf133e64003b20e3b71983d2952,RCC,0.906223
uuid-9169230606e54aa0802504ef53e6b6df,RCC,0.906223
uuid-1c933048b14c40d899ae38be91ccd9ea,RCC,0.906223
uuid-11db4046571040bc962fc2b8b08850fc,Bristol-Myers Squibb,0.341822
uuid-11db4046571040bc962fc2b8b08850fc,not conducted any controlled clinical trials/studies,0.304507
uuid-11db4046571040bc962fc2b8b08850fc,Opdivo,0.461382
uuid-11db4046571040bc962fc2b8b08850fc,Pubmed literature search,0.614325
uuid-11db4046571040bc962fc2b8b08850fc,purposes other than its labeled indication must be considered investigational,0.586645
uuid-11db4046571040bc962fc2b8b08850fc,not identify any citations relevant to your inquiry,0.606087
uuid-11db4046571040bc962fc2b8b08850fc,adverse,0.304183
uuid-11db4046571040bc962fc2b8b08850fc,using the following search terms,0.642331
uuid-11db4046571040bc962fc2b8b08850fc,databases,0.315039
uuid-11db4046571040bc962fc2b8b08850fc,reported,0.556704
uuid-17a5217d7bc04e8dbad5fda9201d5d8a,trial,0.413463
uuid-0b13208951e54c4fb9135b32db5bd970,adverse,0.419275
uuid-1f5cfb927a4647b1a8b45ccaa06c851c,RCC,0.906223
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,phase 3 study,0.319955
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,phase 1 study,0.446598
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,Rizvi NA,0.340455
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,mg,0.54474
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,CA209-003,0.386745
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,phase 2 study,0.37122
uuid-f6f54fc76ad94f1e99ed45238e2fd2df,kg,0.481395
uuid-4357f20360a043eaa32a8c90e0c1d645,Bristol-Myers Squibb,0.494637
uuid-bd6bc34e67c84136a0d51275a79b60ee,melanoma,0.410364
uuid-e5ace723798248948b13929ea4e7e919,requested,0.943735
uuid-e5ace723798248948b13929ea4e7e919,Horn L,0.375005
uuid-e5ace723798248948b13929ea4e7e919,platinum-based doublet chemotherapy,0.334062
uuid-d2fa7af41edc437ea57eba14f598f759,95% CI,0.524855
uuid-d2fa7af41edc437ea57eba14f598f759,respectively,0.383655
uuid-d2fa7af41edc437ea57eba14f598f759,ASCO,0.303153
uuid-d2fa7af41edc437ea57eba14f598f759,Lancet Oncol,0.368041
uuid-d2fa7af41edc437ea57eba14f598f759,Objective response rate,0.504846
uuid-d2fa7af41edc437ea57eba14f598f759,ORR,0.465366
uuid-d2fa7af41edc437ea57eba14f598f759,Median overall survival,0.346516
uuid-d2fa7af41edc437ea57eba14f598f759,Median OS,0.33538
uuid-d2fa7af41edc437ea57eba14f598f759,ASCO 2015,0.336983
uuid-d2fa7af41edc437ea57eba14f598f759,small cell lung cancer,0.336892
uuid-d2fa7af41edc437ea57eba14f598f759,SCLC,0.344367
uuid-d2fa7af41edc437ea57eba14f598f759,Antonia SJ,0.55269
uuid-d2fa7af41edc437ea57eba14f598f759,Median duration of response,0.649605
uuid-e40c3a39a1d64b3bbd9cf5771ad421f4,adverse,0.428765
uuid-e40c3a39a1d64b3bbd9cf5771ad421f4,melanoma,0.377578
uuid-e40c3a39a1d64b3bbd9cf5771ad421f4,grade,0.448451
uuid-fdeed169fd40409db9e5d88eb04166bf,Bristol-Myers Squibb,0.423788
uuid-fdeed169fd40409db9e5d88eb04166bf,evaluating,0.426952
uuid-fdeed169fd40409db9e5d88eb04166bf,not conducted any controlled clinical trials/studies,0.42513
uuid-fdeed169fd40409db9e5d88eb04166bf,NSCLC,0.378499
uuid-fdeed169fd40409db9e5d88eb04166bf,non-small cell lung cancer,0.388521
uuid-fdeed169fd40409db9e5d88eb04166bf,patients,0.318327
uuid-fdeed169fd40409db9e5d88eb04166bf,melanoma,0.310407
uuid-fdeed169fd40409db9e5d88eb04166bf,efficacy and safety of nivolumab,0.355295
uuid-fdeed169fd40409db9e5d88eb04166bf,safety of nivolumab monotherapy,0.333248
uuid-91533b7d51f64727b73911876eed6774,OS,0.300809
uuid-91533b7d51f64727b73911876eed6774,95% CI,0.487161
uuid-91533b7d51f64727b73911876eed6774,respectively,0.581809
uuid-91533b7d51f64727b73911876eed6774,ASCO,0.337958
uuid-91533b7d51f64727b73911876eed6774,Objective response rate,0.579467
uuid-91533b7d51f64727b73911876eed6774,ORR,0.605666
uuid-91533b7d51f64727b73911876eed6774,Median overall survival,0.423347
uuid-91533b7d51f64727b73911876eed6774,monotherapy,0.389069
uuid-91533b7d51f64727b73911876eed6774,Median OS,0.480031
uuid-91533b7d51f64727b73911876eed6774,docetaxel,0.341316
uuid-91533b7d51f64727b73911876eed6774,hazard ratio,0.45179
uuid-f77548106fb5441ab4f808df6e48791a,use of nivolumab for the treatment,0.403042
uuid-f77548106fb5441ab4f808df6e48791a,efficacy,0.342914
uuid-f77548106fb5441ab4f808df6e48791a,patients,0.445676
uuid-f77548106fb5441ab4f808df6e48791a,not approved,0.440616
uuid-f77548106fb5441ab4f808df6e48791a,clinical trials investigating the safety,0.475325
uuid-4e68c33260e24860a9e712cf6875b62a,fatigue,0.84862
uuid-96a9edd4bfc2488ab72f26de25b365dd,RCC,0.906223
uuid-10e9360f1b834ba79874cda4133bac5b,safety,0.599913
uuid-10e9360f1b834ba79874cda4133bac5b,databases,0.522956
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,use of nivolumab for the treatment,0.572282
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,efficacy,0.603668
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,patients,0.586146
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,not approved,0.507372
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,NEJM,0.415674
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,Topalian,0.455631
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,clinical trials investigating the safety,0.423584
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,safety,0.369333
uuid-f6d6676ad3e94d7c8fa5c895fc73cb11,safety of nivolumab monotherapy,0.433281
uuid-42a4299859474b4fa8a32e50c625a88f,AEs,0.550522
uuid-42a4299859474b4fa8a32e50c625a88f,patients,0.481202
uuid-42a4299859474b4fa8a32e50c625a88f,phase 3 study,0.300645
uuid-42a4299859474b4fa8a32e50c625a88f,NEJM,0.335322
uuid-42a4299859474b4fa8a32e50c625a88f,Topalian,0.340275
uuid-42a4299859474b4fa8a32e50c625a88f,phase 1 study,0.429463
uuid-42a4299859474b4fa8a32e50c625a88f,CA209-003,0.394481
uuid-42a4299859474b4fa8a32e50c625a88f,grade,0.349565
uuid-42a4299859474b4fa8a32e50c625a88f,grade 3 to 4 AEs,0.555884
uuid-ea50f9f71f72482dac49f096cd79e077,PD-L1,0.687713
uuid-33293c46f553445a83b2b20bc44eea7e,95% CI,0.482283
uuid-33293c46f553445a83b2b20bc44eea7e,respectively,0.319895
uuid-33293c46f553445a83b2b20bc44eea7e,ASCO,0.389676
uuid-33293c46f553445a83b2b20bc44eea7e,Objective response rate,0.357341
uuid-33293c46f553445a83b2b20bc44eea7e,ORR,0.358789
uuid-33293c46f553445a83b2b20bc44eea7e,Median overall survival,0.421434
uuid-33293c46f553445a83b2b20bc44eea7e,Median OS,0.603017
uuid-33293c46f553445a83b2b20bc44eea7e,docetaxel,0.351836
uuid-33293c46f553445a83b2b20bc44eea7e,hazard ratio,0.51871
uuid-658ce5abdba34f44a37c2a2aa9460746,PD-L1,0.687713
uuid-9dd7b3fdf41945d1a276e6db90167e06,NSCLC,0.361614
uuid-9dd7b3fdf41945d1a276e6db90167e06,non-small cell lung cancer,0.3001
uuid-9dd7b3fdf41945d1a276e6db90167e06,RCC,0.879698
uuid-cb5a3cea44bb47c9873762b9cb4f7176,Bristol-Myers Squibb,0.341822
uuid-cb5a3cea44bb47c9873762b9cb4f7176,not conducted any controlled clinical trials/studies,0.304507
uuid-cb5a3cea44bb47c9873762b9cb4f7176,Opdivo,0.461382
uuid-cb5a3cea44bb47c9873762b9cb4f7176,Pubmed literature search,0.614325
uuid-cb5a3cea44bb47c9873762b9cb4f7176,purposes other than its labeled indication must be considered investigational,0.586645
uuid-cb5a3cea44bb47c9873762b9cb4f7176,not identify any citations relevant to your inquiry,0.606087
uuid-cb5a3cea44bb47c9873762b9cb4f7176,adverse,0.304183
uuid-cb5a3cea44bb47c9873762b9cb4f7176,using the following search terms,0.642331
uuid-cb5a3cea44bb47c9873762b9cb4f7176,databases,0.315039
uuid-cb5a3cea44bb47c9873762b9cb4f7176,reported,0.556704
uuid-2cc4aa4397e74fe0b4b2fcf97119d8bb,adverse,0.583768
uuid-2cc4aa4397e74fe0b4b2fcf97119d8bb,melanoma,0.432737
uuid-2cc4aa4397e74fe0b4b2fcf97119d8bb,therapy,0.424881
uuid-120cfb505f2547d3b2cadf77dba89274,95% CI,0.524855
uuid-120cfb505f2547d3b2cadf77dba89274,respectively,0.383655
uuid-120cfb505f2547d3b2cadf77dba89274,ASCO,0.303153
uuid-120cfb505f2547d3b2cadf77dba89274,Lancet Oncol,0.368041
uuid-120cfb505f2547d3b2cadf77dba89274,Objective response rate,0.504846
uuid-120cfb505f2547d3b2cadf77dba89274,ORR,0.465366
uuid-120cfb505f2547d3b2cadf77dba89274,Median overall survival,0.346516
uuid-120cfb505f2547d3b2cadf77dba89274,Median OS,0.33538
uuid-120cfb505f2547d3b2cadf77dba89274,ASCO 2015,0.336983
uuid-120cfb505f2547d3b2cadf77dba89274,small cell lung cancer,0.336892
uuid-120cfb505f2547d3b2cadf77dba89274,SCLC,0.344367
uuid-120cfb505f2547d3b2cadf77dba89274,Antonia SJ,0.55269
uuid-120cfb505f2547d3b2cadf77dba89274,Median duration of response,0.649605
uuid-4f99754f01a14a0cb727d7d3fe11a882,95% CI,0.539167
uuid-4f99754f01a14a0cb727d7d3fe11a882,Median overall survival,0.479815
uuid-4f99754f01a14a0cb727d7d3fe11a882,protocol,0.426554
uuid-4f99754f01a14a0cb727d7d3fe11a882,McDermott DF,0.500131
uuid-4f99754f01a14a0cb727d7d3fe11a882,Motzer RJ,0.477178
uuid-4f99754f01a14a0cb727d7d3fe11a882,Median OS,0.603398
uuid-4f99754f01a14a0cb727d7d3fe11a882,Escudier B,0.469696
uuid-4f99754f01a14a0cb727d7d3fe11a882,NEJM,0.387615
uuid-4f99754f01a14a0cb727d7d3fe11a882,et al.,0.46851
uuid-4f99754f01a14a0cb727d7d3fe11a882,J Clin Oncol,0.51661
uuid-4f99754f01a14a0cb727d7d3fe11a882,Topalian,0.337057
uuid-4f99754f01a14a0cb727d7d3fe11a882,phase 2 study,0.399402
uuid-4f99754f01a14a0cb727d7d3fe11a882,hazard ratio,0.538097
uuid-b6ebc9d37a494059a2cad24eab2078d8,AEs,0.319012
uuid-b6ebc9d37a494059a2cad24eab2078d8,patients,0.368368
uuid-b6ebc9d37a494059a2cad24eab2078d8,provided in the Detailed Information,0.328662
uuid-b6ebc9d37a494059a2cad24eab2078d8,adverse,0.310932
uuid-b6ebc9d37a494059a2cad24eab2078d8,phase 3 study,0.301881
uuid-b6ebc9d37a494059a2cad24eab2078d8,grade,0.420942
uuid-b6ebc9d37a494059a2cad24eab2078d8,grade 3 to 4 AEs,0.357852
uuid-b4fbf4ea08474e8e8f075c1248aca355,RCC,0.906223
uuid-4cabf9cf659c42579949708d879f5ffe,RCC,0.906223
uuid-a5f7d55f5740442288bbc8f26bab9a96,RCC,0.906223
uuid-9a8e0d361d434a5089c01e0af0fd443b,Bristol-Myers Squibb,0.341822
uuid-9a8e0d361d434a5089c01e0af0fd443b,not conducted any controlled clinical trials/studies,0.304507
uuid-9a8e0d361d434a5089c01e0af0fd443b,Opdivo,0.461382
uuid-9a8e0d361d434a5089c01e0af0fd443b,Pubmed literature search,0.614325
uuid-9a8e0d361d434a5089c01e0af0fd443b,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9a8e0d361d434a5089c01e0af0fd443b,not identify any citations relevant to your inquiry,0.606087
uuid-9a8e0d361d434a5089c01e0af0fd443b,adverse,0.304183
uuid-9a8e0d361d434a5089c01e0af0fd443b,using the following search terms,0.642331
uuid-9a8e0d361d434a5089c01e0af0fd443b,databases,0.315039
uuid-9a8e0d361d434a5089c01e0af0fd443b,reported,0.556704
uuid-6b67016c137c44faad4358444864236b,requested,0.44769
uuid-6b67016c137c44faad4358444864236b,trial,0.309472
uuid-afc9862fd4634c3da3c3634db3a9c468,N Engl J Med,0.442834
uuid-afc9862fd4634c3da3c3634db3a9c468,protocol,0.763252
uuid-afc9862fd4634c3da3c3634db3a9c468,McDermott DF,0.733103
uuid-afc9862fd4634c3da3c3634db3a9c468,Motzer RJ,0.811057
uuid-afc9862fd4634c3da3c3634db3a9c468,phase 3 study,0.420895
uuid-afc9862fd4634c3da3c3634db3a9c468,Escudier B,0.741048
uuid-afc9862fd4634c3da3c3634db3a9c468,NEJM,0.402544
uuid-afc9862fd4634c3da3c3634db3a9c468,et al.,0.660398
uuid-afc9862fd4634c3da3c3634db3a9c468,J Clin Oncol,0.786367
uuid-afc9862fd4634c3da3c3634db3a9c468,Topalian,0.392395
uuid-afc9862fd4634c3da3c3634db3a9c468,phase 1 study,0.513779
uuid-afc9862fd4634c3da3c3634db3a9c468,CA209-003,0.583337
uuid-afc9862fd4634c3da3c3634db3a9c468,phase 2 study,0.675447
uuid-afc9862fd4634c3da3c3634db3a9c468,present using the following search terms,0.304589
uuid-afc9862fd4634c3da3c3634db3a9c468,investigating,0.633101
uuid-ff5bd00d376244319ba60c96e7da9d48,RCC,0.906223
uuid-d2f581d4f23847cfa8a2765bbba4b43a,OS,0.618068
uuid-d2f581d4f23847cfa8a2765bbba4b43a,PFS,0.654464
uuid-d2f581d4f23847cfa8a2765bbba4b43a,Overall survival,0.639937
uuid-5769b66d53e24912b2fc8e6e3bf160aa,N Engl J Med,0.766032
uuid-5769b66d53e24912b2fc8e6e3bf160aa,protocol,0.874182
uuid-5769b66d53e24912b2fc8e6e3bf160aa,McDermott DF,0.960227
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Motzer RJ,0.937306
uuid-5769b66d53e24912b2fc8e6e3bf160aa,phase 3 study,0.460393
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Escudier B,0.963515
uuid-5769b66d53e24912b2fc8e6e3bf160aa,NEJM,0.474086
uuid-5769b66d53e24912b2fc8e6e3bf160aa,et al.,0.949387
uuid-5769b66d53e24912b2fc8e6e3bf160aa,J Clin Oncol,0.883564
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Topalian,0.418815
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Rizvi NA,0.471055
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Brahmer J,0.406289
uuid-5769b66d53e24912b2fc8e6e3bf160aa,Weber JS,0.328759
uuid-5769b66d53e24912b2fc8e6e3bf160aa,phase 2 study,0.812219
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,nivolumab,0.55192
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,evaluating,0.337922
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,not conducted any controlled clinical trials/studies,0.329748
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,Pubmed literature search,0.675005
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,purposes other than its labeled indication must be considered investigational,0.700147
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,not identify any citations relevant to your inquiry,0.690766
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,Additionally,0.437954
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,ongoing,0.463383
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,using the following search terms,0.657245
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,detailed search of www.clinicaltrials.gov,0.467324
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,not identify any planned,0.463985
uuid-1bdb9c165bcd4213827e53f71f2f6f6d,not identify any citations relevant to your request,0.439724
uuid-f83b15992c7745c2ae47ca11f8d769b7,OS,0.306979
uuid-f83b15992c7745c2ae47ca11f8d769b7,95% CI,0.378929
uuid-f83b15992c7745c2ae47ca11f8d769b7,ORR,0.325152
uuid-f83b15992c7745c2ae47ca11f8d769b7,Median overall survival,0.416865
uuid-f83b15992c7745c2ae47ca11f8d769b7,Median OS,0.343981
uuid-f83b15992c7745c2ae47ca11f8d769b7,hazard ratio,0.35636
uuid-524f0a6fe8624b1688bfa0d439f9fb38,N Engl J Med,0.772728
uuid-524f0a6fe8624b1688bfa0d439f9fb38,protocol,0.330852
uuid-524f0a6fe8624b1688bfa0d439f9fb38,McDermott DF,0.347313
uuid-524f0a6fe8624b1688bfa0d439f9fb38,Motzer RJ,0.326548
uuid-524f0a6fe8624b1688bfa0d439f9fb38,phase 3 study,0.373224
uuid-524f0a6fe8624b1688bfa0d439f9fb38,Escudier B,0.353262
uuid-524f0a6fe8624b1688bfa0d439f9fb38,et al.,0.350852
uuid-524f0a6fe8624b1688bfa0d439f9fb38,Rizvi NA,0.495124
uuid-524f0a6fe8624b1688bfa0d439f9fb38,Brahmer J,0.772439
uuid-524f0a6fe8624b1688bfa0d439f9fb38,phase 2 study,0.464349
uuid-524f0a6fe8624b1688bfa0d439f9fb38,Horn L,0.38216
uuid-5b2ce4d97a3140d88c760234268ea348,95% CI,0.524855
uuid-5b2ce4d97a3140d88c760234268ea348,respectively,0.383655
uuid-5b2ce4d97a3140d88c760234268ea348,ASCO,0.303153
uuid-5b2ce4d97a3140d88c760234268ea348,Lancet Oncol,0.368041
uuid-5b2ce4d97a3140d88c760234268ea348,Objective response rate,0.504846
uuid-5b2ce4d97a3140d88c760234268ea348,ORR,0.465366
uuid-5b2ce4d97a3140d88c760234268ea348,Median overall survival,0.346516
uuid-5b2ce4d97a3140d88c760234268ea348,Median OS,0.33538
uuid-5b2ce4d97a3140d88c760234268ea348,ASCO 2015,0.336983
uuid-5b2ce4d97a3140d88c760234268ea348,small cell lung cancer,0.336892
uuid-5b2ce4d97a3140d88c760234268ea348,SCLC,0.344367
uuid-5b2ce4d97a3140d88c760234268ea348,Antonia SJ,0.55269
uuid-5b2ce4d97a3140d88c760234268ea348,Median duration of response,0.649605
uuid-16c788c66ec642439e87cd47a9d63e77,RCC,0.909054
uuid-7f1b17ac276a4b7d9cbbd39bccbdf0ee,RCC,0.909054
uuid-35c7f39c21544f489d701e91093e6751,OS,0.387982
uuid-35c7f39c21544f489d701e91093e6751,95% CI,0.745043
uuid-35c7f39c21544f489d701e91093e6751,respectively,0.729294
uuid-35c7f39c21544f489d701e91093e6751,Objective response rate,0.590876
uuid-35c7f39c21544f489d701e91093e6751,ORR,0.722442
uuid-35c7f39c21544f489d701e91093e6751,Median overall survival,0.659043
uuid-35c7f39c21544f489d701e91093e6751,monotherapy,0.514468
uuid-35c7f39c21544f489d701e91093e6751,Median OS,0.696688
uuid-35c7f39c21544f489d701e91093e6751,PD-L1,0.300997
uuid-35c7f39c21544f489d701e91093e6751,docetaxel,0.635065
uuid-35c7f39c21544f489d701e91093e6751,hazard ratio,0.729977
uuid-d592b139f7c1412797f0b77a449a6745,95% CI,0.520262
uuid-d592b139f7c1412797f0b77a449a6745,respectively,0.504068
uuid-d592b139f7c1412797f0b77a449a6745,Objective response rate,0.458568
uuid-d592b139f7c1412797f0b77a449a6745,ORR,0.525868
uuid-d592b139f7c1412797f0b77a449a6745,Median overall survival,0.455633
uuid-d592b139f7c1412797f0b77a449a6745,Median OS,0.507448
uuid-d592b139f7c1412797f0b77a449a6745,docetaxel,0.383115
uuid-d592b139f7c1412797f0b77a449a6745,hazard ratio,0.462119
uuid-7dca461ec3bb40a587a1f9bfcf7471ab,trial,0.405524
uuid-1e1f1f2c44694651b1e85cd24154e5bb,N Engl J Med,0.423835
uuid-1e1f1f2c44694651b1e85cd24154e5bb,Lancet Oncol,0.315559
uuid-1e1f1f2c44694651b1e85cd24154e5bb,protocol,0.323745
uuid-1e1f1f2c44694651b1e85cd24154e5bb,McDermott DF,0.353453
uuid-1e1f1f2c44694651b1e85cd24154e5bb,Motzer RJ,0.330312
uuid-1e1f1f2c44694651b1e85cd24154e5bb,Escudier B,0.349727
uuid-1e1f1f2c44694651b1e85cd24154e5bb,NEJM,0.309997
uuid-1e1f1f2c44694651b1e85cd24154e5bb,et al.,0.383356
uuid-1e1f1f2c44694651b1e85cd24154e5bb,J Clin Oncol,0.316125
uuid-1e1f1f2c44694651b1e85cd24154e5bb,Rizvi NA,0.372372
uuid-1e1f1f2c44694651b1e85cd24154e5bb,Brahmer J,0.309355
uuid-1e1f1f2c44694651b1e85cd24154e5bb,PD-L1,0.561715
uuid-1e1f1f2c44694651b1e85cd24154e5bb,phase 2 study,0.312929
uuid-5b1a5b264ed74bee91520204daf59e0f,N Engl J Med,0.423835
uuid-5b1a5b264ed74bee91520204daf59e0f,Lancet Oncol,0.315559
uuid-5b1a5b264ed74bee91520204daf59e0f,protocol,0.323745
uuid-5b1a5b264ed74bee91520204daf59e0f,McDermott DF,0.353453
uuid-5b1a5b264ed74bee91520204daf59e0f,Motzer RJ,0.330312
uuid-5b1a5b264ed74bee91520204daf59e0f,Escudier B,0.349727
uuid-5b1a5b264ed74bee91520204daf59e0f,NEJM,0.309997
uuid-5b1a5b264ed74bee91520204daf59e0f,et al.,0.383356
uuid-5b1a5b264ed74bee91520204daf59e0f,J Clin Oncol,0.316125
uuid-5b1a5b264ed74bee91520204daf59e0f,Rizvi NA,0.372372
uuid-5b1a5b264ed74bee91520204daf59e0f,Brahmer J,0.309355
uuid-5b1a5b264ed74bee91520204daf59e0f,PD-L1,0.561715
uuid-5b1a5b264ed74bee91520204daf59e0f,phase 2 study,0.312929
uuid-2389e36af8a94811b3cac386fe883a86,considered investigational,0.402849
uuid-2389e36af8a94811b3cac386fe883a86,small cell lung cancer,0.651985
uuid-2389e36af8a94811b3cac386fe883a86,partial response,0.50367
uuid-2389e36af8a94811b3cac386fe883a86,SCLC,0.736863
uuid-2389e36af8a94811b3cac386fe883a86,therapy,0.843488
uuid-2389e36af8a94811b3cac386fe883a86,relapsed,0.613852
uuid-2389e36af8a94811b3cac386fe883a86,phase 1/2 study CA209-032,0.40439
uuid-2389e36af8a94811b3cac386fe883a86,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,nivolumab,0.574074
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,Bristol-Myers Squibb,0.429238
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,evaluating,0.587732
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,not conducted any controlled clinical trials/studies,0.645965
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,Pubmed literature search,0.877103
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,purposes other than its labeled indication must be considered investigational,0.93987
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,not identify any citations relevant to your inquiry,0.838127
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,using the following search terms,0.82441
uuid-acfb1e6d0bdc475e81d95598b53f7a1c,efficacy and safety of nivolumab,0.42376
uuid-706eb1e96bf746af8d9eb79a7e7bca23,RCC,0.906223
uuid-df6ee509c9f947cdbfd4793be0cd4d89,RCC,0.906223
uuid-5e235f08164c43ed8421f18fb8709672,RCC,0.909054
uuid-fe1c4d91b584427db0696a090d10845c,respectively,0.589071
uuid-fe1c4d91b584427db0696a090d10845c,Objective response rate,0.407286
uuid-fe1c4d91b584427db0696a090d10845c,ORR,0.526086
uuid-fe1c4d91b584427db0696a090d10845c,monotherapy,0.319413
uuid-fe1c4d91b584427db0696a090d10845c,docetaxel,0.334344
uuid-5c2cda4121b445978da43421230a89ae,Bristol-Myers Squibb,0.341822
uuid-5c2cda4121b445978da43421230a89ae,not conducted any controlled clinical trials/studies,0.304507
uuid-5c2cda4121b445978da43421230a89ae,Opdivo,0.461382
uuid-5c2cda4121b445978da43421230a89ae,Pubmed literature search,0.614325
uuid-5c2cda4121b445978da43421230a89ae,purposes other than its labeled indication must be considered investigational,0.586645
uuid-5c2cda4121b445978da43421230a89ae,not identify any citations relevant to your inquiry,0.606087
uuid-5c2cda4121b445978da43421230a89ae,adverse,0.304183
uuid-5c2cda4121b445978da43421230a89ae,using the following search terms,0.642331
uuid-5c2cda4121b445978da43421230a89ae,databases,0.315039
uuid-5c2cda4121b445978da43421230a89ae,reported,0.556704
uuid-c6ffa3c7654841ef860faf93d85cdb84,RCC,0.909054
uuid-1c9e34b01ea84782aabf66ced16cb3e8,N Engl J Med,0.442834
uuid-1c9e34b01ea84782aabf66ced16cb3e8,protocol,0.763252
uuid-1c9e34b01ea84782aabf66ced16cb3e8,McDermott DF,0.733103
uuid-1c9e34b01ea84782aabf66ced16cb3e8,Motzer RJ,0.811057
uuid-1c9e34b01ea84782aabf66ced16cb3e8,phase 3 study,0.420895
uuid-1c9e34b01ea84782aabf66ced16cb3e8,Escudier B,0.741048
uuid-1c9e34b01ea84782aabf66ced16cb3e8,NEJM,0.402544
uuid-1c9e34b01ea84782aabf66ced16cb3e8,et al.,0.660398
uuid-1c9e34b01ea84782aabf66ced16cb3e8,J Clin Oncol,0.786367
uuid-1c9e34b01ea84782aabf66ced16cb3e8,Topalian,0.392395
uuid-1c9e34b01ea84782aabf66ced16cb3e8,phase 1 study,0.513779
uuid-1c9e34b01ea84782aabf66ced16cb3e8,CA209-003,0.583337
uuid-1c9e34b01ea84782aabf66ced16cb3e8,phase 2 study,0.675447
uuid-1c9e34b01ea84782aabf66ced16cb3e8,present using the following search terms,0.304589
uuid-1c9e34b01ea84782aabf66ced16cb3e8,investigating,0.633101
uuid-edb1ae77d9b34ec2b4dd43bb3637abb4,grade,0.441804
uuid-3de0c4729c7848b6bfd2ee78d70f7629,RCC,0.906223
uuid-f5c93772556242fd93d117eddeb0110e,95% CI,0.520262
uuid-f5c93772556242fd93d117eddeb0110e,respectively,0.504068
uuid-f5c93772556242fd93d117eddeb0110e,Objective response rate,0.458568
uuid-f5c93772556242fd93d117eddeb0110e,ORR,0.525868
uuid-f5c93772556242fd93d117eddeb0110e,Median overall survival,0.455633
uuid-f5c93772556242fd93d117eddeb0110e,Median OS,0.507448
uuid-f5c93772556242fd93d117eddeb0110e,docetaxel,0.383115
uuid-f5c93772556242fd93d117eddeb0110e,hazard ratio,0.462119
uuid-fbed62a88b4941debedd656cd7fb900e,RCC,0.906223
uuid-c4b1162850f74513ad9f555524287e1b,95% CI,0.524855
uuid-c4b1162850f74513ad9f555524287e1b,respectively,0.383655
uuid-c4b1162850f74513ad9f555524287e1b,ASCO,0.303153
uuid-c4b1162850f74513ad9f555524287e1b,Lancet Oncol,0.368041
uuid-c4b1162850f74513ad9f555524287e1b,Objective response rate,0.504846
uuid-c4b1162850f74513ad9f555524287e1b,ORR,0.465366
uuid-c4b1162850f74513ad9f555524287e1b,Median overall survival,0.346516
uuid-c4b1162850f74513ad9f555524287e1b,Median OS,0.33538
uuid-c4b1162850f74513ad9f555524287e1b,ASCO 2015,0.336983
uuid-c4b1162850f74513ad9f555524287e1b,small cell lung cancer,0.336892
uuid-c4b1162850f74513ad9f555524287e1b,SCLC,0.344367
uuid-c4b1162850f74513ad9f555524287e1b,Antonia SJ,0.55269
uuid-c4b1162850f74513ad9f555524287e1b,Median duration of response,0.649605
uuid-13cd27cfeb054d44b53790b4c69753e1,RCC,0.909054
uuid-b928077afd94412597d8cfb404169968,N Engl J Med,0.322518
uuid-b928077afd94412597d8cfb404169968,ASCO,0.74261
uuid-b928077afd94412597d8cfb404169968,protocol,0.342459
uuid-b928077afd94412597d8cfb404169968,McDermott DF,0.457307
uuid-b928077afd94412597d8cfb404169968,Motzer RJ,0.396666
uuid-b928077afd94412597d8cfb404169968,Escudier B,0.430596
uuid-b928077afd94412597d8cfb404169968,et al.,0.537544
uuid-b928077afd94412597d8cfb404169968,J Clin Oncol,0.427693
uuid-b928077afd94412597d8cfb404169968,phase 2 study,0.402538
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,95% CI,0.524855
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,respectively,0.383655
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,ASCO,0.303153
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Lancet Oncol,0.368041
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Objective response rate,0.504846
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,ORR,0.465366
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Median overall survival,0.346516
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Median OS,0.33538
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,ASCO 2015,0.336983
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,small cell lung cancer,0.336892
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,SCLC,0.344367
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Antonia SJ,0.55269
uuid-9f5f270ae4cb4d12aec993f3401ef9e2,Median duration of response,0.649605
uuid-6d2e83e6fe9d4429b502990cbccb29ef,provided in the Detailed Information,0.615999
uuid-6d2e83e6fe9d4429b502990cbccb29ef,clinical,0.61883
uuid-421068c664a747dfaedfbce49074e975,ipilimumab,0.385692
uuid-421068c664a747dfaedfbce49074e975,ASCO 2015,0.417944
uuid-421068c664a747dfaedfbce49074e975,partial response,0.382425
uuid-421068c664a747dfaedfbce49074e975,Stable disease,0.586335
uuid-421068c664a747dfaedfbce49074e975,cohort,0.307748
uuid-7f6c7be3ff38404682395d4c9c99a136,requested,0.478068
uuid-7f6c7be3ff38404682395d4c9c99a136,not approved,0.310441
uuid-7f6c7be3ff38404682395d4c9c99a136,clinical trials investigating the safety,0.316355
uuid-7f6c7be3ff38404682395d4c9c99a136,trial,0.567379
uuid-8a846f081a9f48cd8985698d162c7806,nivolumab,0.543605
uuid-8a846f081a9f48cd8985698d162c7806,Bristol-Myers Squibb,0.391121
uuid-8a846f081a9f48cd8985698d162c7806,evaluating,0.329925
uuid-8a846f081a9f48cd8985698d162c7806,not conducted any controlled clinical trials/studies,0.380629
uuid-8a846f081a9f48cd8985698d162c7806,Pubmed literature search,0.35138
uuid-8a846f081a9f48cd8985698d162c7806,purposes other than its labeled indication must be considered investigational,0.401068
uuid-8a846f081a9f48cd8985698d162c7806,not identify any citations relevant to your inquiry,0.321299
uuid-8a846f081a9f48cd8985698d162c7806,using the following search terms,0.318708
uuid-7f30cc6c4c744d9a8b4a88a9590741b7,Opdivo,0.328005
uuid-7f30cc6c4c744d9a8b4a88a9590741b7,adverse,0.417037
uuid-7f30cc6c4c744d9a8b4a88a9590741b7,safety,0.534387
uuid-7f30cc6c4c744d9a8b4a88a9590741b7,databases,0.473672
uuid-7f30cc6c4c744d9a8b4a88a9590741b7,reported,0.671841
uuid-8f4640a444374186b055fd7077f8568c,nivolumab,0.563406
uuid-8f4640a444374186b055fd7077f8568c,Bristol-Myers Squibb,0.415769
uuid-8f4640a444374186b055fd7077f8568c,evaluating,0.627848
uuid-8f4640a444374186b055fd7077f8568c,not conducted any controlled clinical trials/studies,0.6431
uuid-8f4640a444374186b055fd7077f8568c,Pubmed literature search,0.694479
uuid-8f4640a444374186b055fd7077f8568c,purposes other than its labeled indication must be considered investigational,0.774597
uuid-8f4640a444374186b055fd7077f8568c,not identify any citations relevant to your inquiry,0.658198
uuid-8f4640a444374186b055fd7077f8568c,using the following search terms,0.634144
uuid-8f4640a444374186b055fd7077f8568c,efficacy and safety of nivolumab,0.479786
uuid-edb3c3fdda0846ce958610d51b845236,requested,0.370696
uuid-6f481802b3074f8db00b7e1aeb3edc80,95% CI,0.524855
uuid-6f481802b3074f8db00b7e1aeb3edc80,respectively,0.383655
uuid-6f481802b3074f8db00b7e1aeb3edc80,ASCO,0.303153
uuid-6f481802b3074f8db00b7e1aeb3edc80,Lancet Oncol,0.368041
uuid-6f481802b3074f8db00b7e1aeb3edc80,Objective response rate,0.504846
uuid-6f481802b3074f8db00b7e1aeb3edc80,ORR,0.465366
uuid-6f481802b3074f8db00b7e1aeb3edc80,Median overall survival,0.346516
uuid-6f481802b3074f8db00b7e1aeb3edc80,Median OS,0.33538
uuid-6f481802b3074f8db00b7e1aeb3edc80,ASCO 2015,0.336983
uuid-6f481802b3074f8db00b7e1aeb3edc80,small cell lung cancer,0.336892
uuid-6f481802b3074f8db00b7e1aeb3edc80,SCLC,0.344367
uuid-6f481802b3074f8db00b7e1aeb3edc80,Antonia SJ,0.55269
uuid-6f481802b3074f8db00b7e1aeb3edc80,Median duration of response,0.649605
uuid-a12755754b334eda89908e6eadd418a6,adverse,0.305498
uuid-a12755754b334eda89908e6eadd418a6,grade,0.378535
uuid-db0bbf3264f44d4fb1148a69ac388642,95% CI,0.539167
uuid-db0bbf3264f44d4fb1148a69ac388642,Median overall survival,0.479815
uuid-db0bbf3264f44d4fb1148a69ac388642,protocol,0.426554
uuid-db0bbf3264f44d4fb1148a69ac388642,McDermott DF,0.500131
uuid-db0bbf3264f44d4fb1148a69ac388642,Motzer RJ,0.477178
uuid-db0bbf3264f44d4fb1148a69ac388642,Median OS,0.603398
uuid-db0bbf3264f44d4fb1148a69ac388642,Escudier B,0.469696
uuid-db0bbf3264f44d4fb1148a69ac388642,NEJM,0.387615
uuid-db0bbf3264f44d4fb1148a69ac388642,et al.,0.46851
uuid-db0bbf3264f44d4fb1148a69ac388642,J Clin Oncol,0.51661
uuid-db0bbf3264f44d4fb1148a69ac388642,Topalian,0.337057
uuid-db0bbf3264f44d4fb1148a69ac388642,phase 2 study,0.399402
uuid-db0bbf3264f44d4fb1148a69ac388642,hazard ratio,0.538097
uuid-a54c6c24075f4f738fe9e62e29c0373b,patients,0.402741
uuid-a54c6c24075f4f738fe9e62e29c0373b,Median duration of response,0.326962
uuid-2ac36c7013184fb794f98e8a5b930def,Opdivo,0.358043
uuid-2ac36c7013184fb794f98e8a5b930def,adverse,0.397582
uuid-2ac36c7013184fb794f98e8a5b930def,safety,0.548019
uuid-2ac36c7013184fb794f98e8a5b930def,databases,0.490699
uuid-2ac36c7013184fb794f98e8a5b930def,reported,0.658867
uuid-0b73829c3ecc4076a9137aced2e5321e,OS,0.322966
uuid-0b73829c3ecc4076a9137aced2e5321e,AEs,0.37907
uuid-0b73829c3ecc4076a9137aced2e5321e,95% CI,0.519249
uuid-0b73829c3ecc4076a9137aced2e5321e,respectively,0.375636
uuid-0b73829c3ecc4076a9137aced2e5321e,ORR,0.400073
uuid-0b73829c3ecc4076a9137aced2e5321e,Median overall survival,0.498228
uuid-0b73829c3ecc4076a9137aced2e5321e,Median OS,0.489151
uuid-0b73829c3ecc4076a9137aced2e5321e,grade,0.535657
uuid-0b73829c3ecc4076a9137aced2e5321e,hazard ratio,0.464502
uuid-0b73829c3ecc4076a9137aced2e5321e,Median duration of response,0.315988
uuid-7e24e92e78d24c06be92d91fef2053a8,95% CI,0.539167
uuid-7e24e92e78d24c06be92d91fef2053a8,Median overall survival,0.479815
uuid-7e24e92e78d24c06be92d91fef2053a8,protocol,0.426554
uuid-7e24e92e78d24c06be92d91fef2053a8,McDermott DF,0.500131
uuid-7e24e92e78d24c06be92d91fef2053a8,Motzer RJ,0.477178
uuid-7e24e92e78d24c06be92d91fef2053a8,Median OS,0.603398
uuid-7e24e92e78d24c06be92d91fef2053a8,Escudier B,0.469696
uuid-7e24e92e78d24c06be92d91fef2053a8,NEJM,0.387615
uuid-7e24e92e78d24c06be92d91fef2053a8,et al.,0.46851
uuid-7e24e92e78d24c06be92d91fef2053a8,J Clin Oncol,0.51661
uuid-7e24e92e78d24c06be92d91fef2053a8,Topalian,0.337057
uuid-7e24e92e78d24c06be92d91fef2053a8,phase 2 study,0.399402
uuid-7e24e92e78d24c06be92d91fef2053a8,hazard ratio,0.538097
uuid-547a7998afb0497b8278cfa41d1dceb6,N Engl J Med,0.410025
uuid-547a7998afb0497b8278cfa41d1dceb6,protocol,0.663749
uuid-547a7998afb0497b8278cfa41d1dceb6,RCC,0.370429
uuid-547a7998afb0497b8278cfa41d1dceb6,McDermott DF,0.577168
uuid-547a7998afb0497b8278cfa41d1dceb6,search of published literature,0.443686
uuid-547a7998afb0497b8278cfa41d1dceb6,Additionally,0.395847
uuid-547a7998afb0497b8278cfa41d1dceb6,ongoing,0.335873
uuid-547a7998afb0497b8278cfa41d1dceb6,Motzer RJ,0.609458
uuid-547a7998afb0497b8278cfa41d1dceb6,phase 3 study,0.312748
uuid-547a7998afb0497b8278cfa41d1dceb6,PubMed and EMBASE,0.438896
uuid-547a7998afb0497b8278cfa41d1dceb6,Escudier B,0.595328
uuid-547a7998afb0497b8278cfa41d1dceb6,et al.,0.521538
uuid-547a7998afb0497b8278cfa41d1dceb6,J Clin Oncol,0.545137
uuid-547a7998afb0497b8278cfa41d1dceb6,detailed search of www.clinicaltrials.gov,0.358127
uuid-547a7998afb0497b8278cfa41d1dceb6,efficacy and safety of nivolumab,0.429052
uuid-547a7998afb0497b8278cfa41d1dceb6,not identify any planned,0.344155
uuid-547a7998afb0497b8278cfa41d1dceb6,phase 2 study,0.513121
uuid-547a7998afb0497b8278cfa41d1dceb6,not identify any citations relevant to your request,0.414617
uuid-547a7998afb0497b8278cfa41d1dceb6,present using the following search terms,0.417875
uuid-61538c83ed6f48c091389590cbdc7350,RCC,0.906223
uuid-213666075b2747479a3c359a2332cddd,95% CI,0.524855
uuid-213666075b2747479a3c359a2332cddd,respectively,0.383655
uuid-213666075b2747479a3c359a2332cddd,ASCO,0.303153
uuid-213666075b2747479a3c359a2332cddd,Lancet Oncol,0.368041
uuid-213666075b2747479a3c359a2332cddd,Objective response rate,0.504846
uuid-213666075b2747479a3c359a2332cddd,ORR,0.465366
uuid-213666075b2747479a3c359a2332cddd,Median overall survival,0.346516
uuid-213666075b2747479a3c359a2332cddd,Median OS,0.33538
uuid-213666075b2747479a3c359a2332cddd,ASCO 2015,0.336983
uuid-213666075b2747479a3c359a2332cddd,small cell lung cancer,0.336892
uuid-213666075b2747479a3c359a2332cddd,SCLC,0.344367
uuid-213666075b2747479a3c359a2332cddd,Antonia SJ,0.55269
uuid-213666075b2747479a3c359a2332cddd,Median duration of response,0.649605
uuid-bd33eeb611354c75b8c5ec299c6b4731,95% CI,0.410247
uuid-bd33eeb611354c75b8c5ec299c6b4731,Lancet Oncol,0.338804
uuid-bd33eeb611354c75b8c5ec299c6b4731,considered investigational,0.31999
uuid-bd33eeb611354c75b8c5ec299c6b4731,Objective response rate,0.460397
uuid-bd33eeb611354c75b8c5ec299c6b4731,ORR,0.42609
uuid-bd33eeb611354c75b8c5ec299c6b4731,ASCO 2015,0.334207
uuid-bd33eeb611354c75b8c5ec299c6b4731,small cell lung cancer,0.572318
uuid-bd33eeb611354c75b8c5ec299c6b4731,SCLC,0.616142
uuid-bd33eeb611354c75b8c5ec299c6b4731,Antonia SJ,0.54068
uuid-bd33eeb611354c75b8c5ec299c6b4731,therapy,0.386133
uuid-bd33eeb611354c75b8c5ec299c6b4731,Median duration of response,0.529786
uuid-bd33eeb611354c75b8c5ec299c6b4731,phase 1/2 study CA209-032,0.403467
uuid-bd33eeb611354c75b8c5ec299c6b4731,evaluates the efficacy of nivolumab monotherapy,0.353136
uuid-38e676bed5be4b44b1442e85cd39a521,requested,0.734918
uuid-38e676bed5be4b44b1442e85cd39a521,protocol,0.452417
uuid-38e676bed5be4b44b1442e85cd39a521,McDermott DF,0.435835
uuid-38e676bed5be4b44b1442e85cd39a521,Motzer RJ,0.432727
uuid-38e676bed5be4b44b1442e85cd39a521,Escudier B,0.445406
uuid-38e676bed5be4b44b1442e85cd39a521,et al.,0.461877
uuid-38e676bed5be4b44b1442e85cd39a521,J Clin Oncol,0.388755
uuid-69b2a1f91e3747a3b52c582344192ca0,nivolumab,0.558222
uuid-69b2a1f91e3747a3b52c582344192ca0,Bristol-Myers Squibb,0.443938
uuid-69b2a1f91e3747a3b52c582344192ca0,evaluating,0.608737
uuid-69b2a1f91e3747a3b52c582344192ca0,not conducted any controlled clinical trials/studies,0.663765
uuid-69b2a1f91e3747a3b52c582344192ca0,Pubmed literature search,0.862861
uuid-69b2a1f91e3747a3b52c582344192ca0,purposes other than its labeled indication must be considered investigational,0.92801
uuid-69b2a1f91e3747a3b52c582344192ca0,not identify any citations relevant to your inquiry,0.823177
uuid-69b2a1f91e3747a3b52c582344192ca0,using the following search terms,0.808565
uuid-69b2a1f91e3747a3b52c582344192ca0,efficacy and safety of nivolumab,0.444405
uuid-8c8e3f3445d749a9a259fddd9bf5eb4a,AEs,0.348257
uuid-8c8e3f3445d749a9a259fddd9bf5eb4a,respectively,0.458862
uuid-8c8e3f3445d749a9a259fddd9bf5eb4a,ORR,0.349444
uuid-8c8e3f3445d749a9a259fddd9bf5eb4a,grade 3 to 4 AEs,0.351513
uuid-2d405aa241264e69b4be9342c942506d,N Engl J Med,0.442834
uuid-2d405aa241264e69b4be9342c942506d,protocol,0.763252
uuid-2d405aa241264e69b4be9342c942506d,McDermott DF,0.733103
uuid-2d405aa241264e69b4be9342c942506d,Motzer RJ,0.811057
uuid-2d405aa241264e69b4be9342c942506d,phase 3 study,0.420895
uuid-2d405aa241264e69b4be9342c942506d,Escudier B,0.741048
uuid-2d405aa241264e69b4be9342c942506d,NEJM,0.402544
uuid-2d405aa241264e69b4be9342c942506d,et al.,0.660398
uuid-2d405aa241264e69b4be9342c942506d,J Clin Oncol,0.786367
uuid-2d405aa241264e69b4be9342c942506d,Topalian,0.392395
uuid-2d405aa241264e69b4be9342c942506d,phase 1 study,0.513779
uuid-2d405aa241264e69b4be9342c942506d,CA209-003,0.583337
uuid-2d405aa241264e69b4be9342c942506d,phase 2 study,0.675447
uuid-2d405aa241264e69b4be9342c942506d,present using the following search terms,0.304589
uuid-2d405aa241264e69b4be9342c942506d,investigating,0.633101
uuid-0075c2941aa04fb5ac4457b52b313634,fatigue,0.531122
uuid-c91fe0dfe1794fdfb958ef0d8e65b69c,RCC,0.906223
uuid-8b5cec4eb6a845489ec2349361ee3751,requested,0.547876
uuid-650e9c3400d2459cb72c26c5de9db57f,N Engl J Med,0.465729
uuid-650e9c3400d2459cb72c26c5de9db57f,Lancet Oncol,0.366808
uuid-650e9c3400d2459cb72c26c5de9db57f,protocol,0.493142
uuid-650e9c3400d2459cb72c26c5de9db57f,McDermott DF,0.525348
uuid-650e9c3400d2459cb72c26c5de9db57f,Motzer RJ,0.525679
uuid-650e9c3400d2459cb72c26c5de9db57f,phase 3 study,0.762949
uuid-650e9c3400d2459cb72c26c5de9db57f,Escudier B,0.540426
uuid-650e9c3400d2459cb72c26c5de9db57f,et al.,0.50483
uuid-650e9c3400d2459cb72c26c5de9db57f,J Clin Oncol,0.439954
uuid-650e9c3400d2459cb72c26c5de9db57f,Rizvi NA,0.483052
uuid-650e9c3400d2459cb72c26c5de9db57f,Weber JS,0.594048
uuid-650e9c3400d2459cb72c26c5de9db57f,phase 2 study,0.620738
uuid-66b8587ecb114d27a67673209bbe6bb1,requested,0.751024
uuid-66b8587ecb114d27a67673209bbe6bb1,Opdivo,0.4093
uuid-7091d68e84c24d7e8709ba5d30e2468c,patients,0.556054
uuid-7091d68e84c24d7e8709ba5d30e2468c,provided in the Detailed Information,0.329929
uuid-7091d68e84c24d7e8709ba5d30e2468c,adverse,0.32982
uuid-7091d68e84c24d7e8709ba5d30e2468c,phase 3 study,0.523726
uuid-7091d68e84c24d7e8709ba5d30e2468c,melanoma,0.382071
uuid-7091d68e84c24d7e8709ba5d30e2468c,Weber JS,0.428777
uuid-7091d68e84c24d7e8709ba5d30e2468c,phase 2 study,0.307314
uuid-7091d68e84c24d7e8709ba5d30e2468c,grade 3 to 4 AEs,0.466022
uuid-b6e394ee72ff406ba53c8384d29c08f9,respectively,0.629961
uuid-b6e394ee72ff406ba53c8384d29c08f9,Objective response rate,0.439951
uuid-b6e394ee72ff406ba53c8384d29c08f9,ORR,0.462322
uuid-b6e394ee72ff406ba53c8384d29c08f9,monotherapy,0.352421
uuid-b6e394ee72ff406ba53c8384d29c08f9,docetaxel,0.410479
uuid-0f4198872751467bafcfee619b997309,adverse,0.317275
uuid-da3387103971434e974bcab031ca9b44,95% CI,0.384282
uuid-da3387103971434e974bcab031ca9b44,ASCO,0.40687
uuid-da3387103971434e974bcab031ca9b44,Objective response rate,0.409634
uuid-da3387103971434e974bcab031ca9b44,Median overall survival,0.319094
uuid-da3387103971434e974bcab031ca9b44,Median OS,0.403026
uuid-da3387103971434e974bcab031ca9b44,ASCO 2015,0.386899
uuid-da3387103971434e974bcab031ca9b44,hazard ratio,0.403406
uuid-2db8419c95ce443cb944e000a6496220,Bristol-Myers Squibb,0.66866
uuid-2db8419c95ce443cb944e000a6496220,evaluating,0.43244
uuid-2db8419c95ce443cb944e000a6496220,not conducted any controlled clinical trials/studies,0.507323
uuid-2db8419c95ce443cb944e000a6496220,efficacy and safety of nivolumab,0.383013
uuid-4dd4632c00674a38b7959f15c948f0ce,N Engl J Med,0.347178
uuid-4dd4632c00674a38b7959f15c948f0ce,Lancet Oncol,0.359155
uuid-4dd4632c00674a38b7959f15c948f0ce,protocol,0.371457
uuid-4dd4632c00674a38b7959f15c948f0ce,McDermott DF,0.414017
uuid-4dd4632c00674a38b7959f15c948f0ce,Motzer RJ,0.384536
uuid-4dd4632c00674a38b7959f15c948f0ce,phase 3 study,0.443559
uuid-4dd4632c00674a38b7959f15c948f0ce,Escudier B,0.411866
uuid-4dd4632c00674a38b7959f15c948f0ce,et al.,0.39703
uuid-4dd4632c00674a38b7959f15c948f0ce,J Clin Oncol,0.378141
uuid-4dd4632c00674a38b7959f15c948f0ce,phase 1 study,0.326203
uuid-4dd4632c00674a38b7959f15c948f0ce,Rizvi NA,0.563772
uuid-4dd4632c00674a38b7959f15c948f0ce,mg,0.40261
uuid-4dd4632c00674a38b7959f15c948f0ce,Weber JS,0.418348
uuid-4dd4632c00674a38b7959f15c948f0ce,phase 2 study,0.587446
uuid-4dd4632c00674a38b7959f15c948f0ce,kg,0.361586
uuid-c82b0b814ac84dcd9d3f44a8927f2c4f,nivolumab,0.488452
uuid-c82b0b814ac84dcd9d3f44a8927f2c4f,provided in the Detailed Information,0.457158
uuid-d0fad04d55574689966816f6e678f140,RCC,0.909054
uuid-87a1da2ee4144acf815e76766a979123,RCC,0.906223
uuid-2a2dddf27eef4effa2388d2d9917693a,requested,0.405961
uuid-2a2dddf27eef4effa2388d2d9917693a,trial,0.317169
uuid-283aea37560e426cb79555a832325d47,nivolumab,0.329344
uuid-283aea37560e426cb79555a832325d47,use of nivolumab for the treatment,0.347999
uuid-283aea37560e426cb79555a832325d47,evaluating,0.344109
uuid-283aea37560e426cb79555a832325d47,not conducted any controlled clinical trials/studies,0.321398
uuid-283aea37560e426cb79555a832325d47,efficacy,0.322634
uuid-283aea37560e426cb79555a832325d47,patients with advanced or metastatic,0.45254
uuid-283aea37560e426cb79555a832325d47,Pubmed literature search,0.368435
uuid-283aea37560e426cb79555a832325d47,purposes other than its labeled indication must be considered investigational,0.415672
uuid-283aea37560e426cb79555a832325d47,not identify any citations relevant to your inquiry,0.346657
uuid-283aea37560e426cb79555a832325d47,nivolumab combined with ipilimumab,0.449042
uuid-283aea37560e426cb79555a832325d47,not approved,0.421442
uuid-283aea37560e426cb79555a832325d47,using the following search terms,0.336514
uuid-283aea37560e426cb79555a832325d47,clinical trials investigating the safety,0.48679
uuid-283aea37560e426cb79555a832325d47,bladder cancer,0.786608
uuid-5a774347b6e74569a24ebb282da8a77e,respectively,0.397695
uuid-784cb0b47bd14343bb73184a275119af,95% CI,0.524855
uuid-784cb0b47bd14343bb73184a275119af,respectively,0.383655
uuid-784cb0b47bd14343bb73184a275119af,ASCO,0.303153
uuid-784cb0b47bd14343bb73184a275119af,Lancet Oncol,0.368041
uuid-784cb0b47bd14343bb73184a275119af,Objective response rate,0.504846
uuid-784cb0b47bd14343bb73184a275119af,ORR,0.465366
uuid-784cb0b47bd14343bb73184a275119af,Median overall survival,0.346516
uuid-784cb0b47bd14343bb73184a275119af,Median OS,0.33538
uuid-784cb0b47bd14343bb73184a275119af,ASCO 2015,0.336983
uuid-784cb0b47bd14343bb73184a275119af,small cell lung cancer,0.336892
uuid-784cb0b47bd14343bb73184a275119af,SCLC,0.344367
uuid-784cb0b47bd14343bb73184a275119af,Antonia SJ,0.55269
uuid-784cb0b47bd14343bb73184a275119af,Median duration of response,0.649605
uuid-95bd8c0665634633a17ba180a76beede,Bristol-Myers Squibb,0.333095
uuid-95bd8c0665634633a17ba180a76beede,adverse,0.435751
uuid-95bd8c0665634633a17ba180a76beede,safety,0.538229
uuid-95bd8c0665634633a17ba180a76beede,databases,0.478718
uuid-95bd8c0665634633a17ba180a76beede,reported,0.669776
uuid-3d2539e14cf342c594b91bf8013ac911,requested,0.662269
uuid-b6144ce4a2084e5386ce74a47b7eed83,OS,0.44149
uuid-b6144ce4a2084e5386ce74a47b7eed83,95% CI,0.833403
uuid-b6144ce4a2084e5386ce74a47b7eed83,ASCO,0.32927
uuid-b6144ce4a2084e5386ce74a47b7eed83,Objective response rate,0.545269
uuid-b6144ce4a2084e5386ce74a47b7eed83,ORR,0.618524
uuid-b6144ce4a2084e5386ce74a47b7eed83,PFS,0.396858
uuid-b6144ce4a2084e5386ce74a47b7eed83,Median overall survival,0.72593
uuid-b6144ce4a2084e5386ce74a47b7eed83,monotherapy,0.33356
uuid-b6144ce4a2084e5386ce74a47b7eed83,Median OS,0.763854
uuid-b6144ce4a2084e5386ce74a47b7eed83,hazard ratio,0.766648
uuid-b6144ce4a2084e5386ce74a47b7eed83,Median duration of response,0.442682
uuid-70f092e630404b03a1714aa4e5578e85,patients with advanced or metastatic,0.468858
uuid-70f092e630404b03a1714aa4e5578e85,nivolumab combined with ipilimumab,0.446918
uuid-70f092e630404b03a1714aa4e5578e85,not approved,0.352562
uuid-70f092e630404b03a1714aa4e5578e85,clinical trials investigating the safety,0.429501
uuid-70f092e630404b03a1714aa4e5578e85,bladder cancer,0.950698
uuid-982c2072307a441ab27af908f31740e9,patients with advanced or metastatic,0.468858
uuid-982c2072307a441ab27af908f31740e9,nivolumab combined with ipilimumab,0.446918
uuid-982c2072307a441ab27af908f31740e9,not approved,0.352562
uuid-982c2072307a441ab27af908f31740e9,clinical trials investigating the safety,0.429501
uuid-982c2072307a441ab27af908f31740e9,bladder cancer,0.950698
uuid-358d4e47ee20478982b7a75218b86766,patients with advanced or metastatic,0.468858
uuid-358d4e47ee20478982b7a75218b86766,nivolumab combined with ipilimumab,0.446918
uuid-358d4e47ee20478982b7a75218b86766,not approved,0.352562
uuid-358d4e47ee20478982b7a75218b86766,clinical trials investigating the safety,0.429501
uuid-358d4e47ee20478982b7a75218b86766,bladder cancer,0.950698
uuid-072cf12032454f4fb019c813a4752ee5,95% CI,0.539167
uuid-072cf12032454f4fb019c813a4752ee5,Median overall survival,0.479815
uuid-072cf12032454f4fb019c813a4752ee5,protocol,0.426554
uuid-072cf12032454f4fb019c813a4752ee5,McDermott DF,0.500131
uuid-072cf12032454f4fb019c813a4752ee5,Motzer RJ,0.477178
uuid-072cf12032454f4fb019c813a4752ee5,Median OS,0.603398
uuid-072cf12032454f4fb019c813a4752ee5,Escudier B,0.469696
uuid-072cf12032454f4fb019c813a4752ee5,NEJM,0.387615
uuid-072cf12032454f4fb019c813a4752ee5,et al.,0.46851
uuid-072cf12032454f4fb019c813a4752ee5,J Clin Oncol,0.51661
uuid-072cf12032454f4fb019c813a4752ee5,Topalian,0.337057
uuid-072cf12032454f4fb019c813a4752ee5,phase 2 study,0.399402
uuid-072cf12032454f4fb019c813a4752ee5,hazard ratio,0.538097
uuid-20a608f358c44a1f90f3cd5beb36cabd,nivolumab,0.57142
uuid-20a608f358c44a1f90f3cd5beb36cabd,Bristol-Myers Squibb,0.440266
uuid-20a608f358c44a1f90f3cd5beb36cabd,evaluating,0.595923
uuid-20a608f358c44a1f90f3cd5beb36cabd,not conducted any controlled clinical trials/studies,0.657592
uuid-20a608f358c44a1f90f3cd5beb36cabd,Pubmed literature search,0.877013
uuid-20a608f358c44a1f90f3cd5beb36cabd,purposes other than its labeled indication must be considered investigational,0.940214
uuid-20a608f358c44a1f90f3cd5beb36cabd,not identify any citations relevant to your inquiry,0.835939
uuid-20a608f358c44a1f90f3cd5beb36cabd,using the following search terms,0.823689
uuid-20a608f358c44a1f90f3cd5beb36cabd,efficacy and safety of nivolumab,0.436691
uuid-0d1c25acc6e7474c85626f1bcefe6956,requested,0.423063
uuid-0d1c25acc6e7474c85626f1bcefe6956,trial,0.355961
uuid-0639faf6a39142c3a5c97b98fba0e4d5,95% CI,0.524855
uuid-0639faf6a39142c3a5c97b98fba0e4d5,respectively,0.383655
uuid-0639faf6a39142c3a5c97b98fba0e4d5,ASCO,0.303153
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Lancet Oncol,0.368041
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Objective response rate,0.504846
uuid-0639faf6a39142c3a5c97b98fba0e4d5,ORR,0.465366
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Median overall survival,0.346516
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Median OS,0.33538
uuid-0639faf6a39142c3a5c97b98fba0e4d5,ASCO 2015,0.336983
uuid-0639faf6a39142c3a5c97b98fba0e4d5,small cell lung cancer,0.336892
uuid-0639faf6a39142c3a5c97b98fba0e4d5,SCLC,0.344367
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Antonia SJ,0.55269
uuid-0639faf6a39142c3a5c97b98fba0e4d5,Median duration of response,0.649605
uuid-fc08cec591b041e896c8b4a7c8ce8233,nivolumab,0.583757
uuid-fc08cec591b041e896c8b4a7c8ce8233,Bristol-Myers Squibb,0.47763
uuid-fc08cec591b041e896c8b4a7c8ce8233,evaluating,0.688414
uuid-fc08cec591b041e896c8b4a7c8ce8233,not conducted any controlled clinical trials/studies,0.728355
uuid-fc08cec591b041e896c8b4a7c8ce8233,Pubmed literature search,0.809169
uuid-fc08cec591b041e896c8b4a7c8ce8233,purposes other than its labeled indication must be considered investigational,0.885088
uuid-fc08cec591b041e896c8b4a7c8ce8233,not identify any citations relevant to your inquiry,0.768164
uuid-fc08cec591b041e896c8b4a7c8ce8233,search of published literature,0.358165
uuid-fc08cec591b041e896c8b4a7c8ce8233,PubMed and EMBASE,0.33031
uuid-fc08cec591b041e896c8b4a7c8ce8233,using the following search terms,0.753379
uuid-fc08cec591b041e896c8b4a7c8ce8233,efficacy and safety of nivolumab,0.575043
uuid-fc08cec591b041e896c8b4a7c8ce8233,present using the following search terms,0.344729
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,nivolumab,0.425142
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,Bristol-Myers Squibb,0.324789
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,evaluating,0.485153
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,not conducted any controlled clinical trials/studies,0.486475
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,Pubmed literature search,0.496517
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,purposes other than its labeled indication must be considered investigational,0.554902
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,not identify any citations relevant to your inquiry,0.489441
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,using the following search terms,0.455664
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,melanoma,0.341448
uuid-5d92c71ef20b48ae9c65f3b4f9a781e4,efficacy and safety of nivolumab,0.379413
uuid-554a2b55c47043d5af2abcd17c0c793a,OS,0.318845
uuid-554a2b55c47043d5af2abcd17c0c793a,AEs,0.391226
uuid-554a2b55c47043d5af2abcd17c0c793a,95% CI,0.338672
uuid-554a2b55c47043d5af2abcd17c0c793a,respectively,0.417956
uuid-554a2b55c47043d5af2abcd17c0c793a,ORR,0.397619
uuid-554a2b55c47043d5af2abcd17c0c793a,Median overall survival,0.370706
uuid-554a2b55c47043d5af2abcd17c0c793a,Median OS,0.348996
uuid-554a2b55c47043d5af2abcd17c0c793a,grade,0.477956
uuid-554a2b55c47043d5af2abcd17c0c793a,hazard ratio,0.338871
uuid-c3023c41690a4c11a10d307f964f08f9,ipilimumab,0.385692
uuid-c3023c41690a4c11a10d307f964f08f9,ASCO 2015,0.417944
uuid-c3023c41690a4c11a10d307f964f08f9,partial response,0.382425
uuid-c3023c41690a4c11a10d307f964f08f9,Stable disease,0.586335
uuid-c3023c41690a4c11a10d307f964f08f9,cohort,0.307748
uuid-5b3a0c1ed8dc472ea04a09de0d56c2e9,ESMO,0.603759
uuid-5b3a0c1ed8dc472ea04a09de0d56c2e9,Horn L,0.484674
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,Bristol-Myers Squibb,0.61693
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,evaluating,0.55118
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,not conducted any controlled clinical trials/studies,0.585844
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,NSCLC,0.495537
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,non-small cell lung cancer,0.522044
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,provided in the Detailed Information,0.331974
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,efficacy and safety of nivolumab,0.462643
uuid-9c5d276ef8cb4052a9bae6d7baabfcc6,safety of nivolumab monotherapy,0.355992
uuid-8baf8e60126e416bbf92c0c7f2658f89,adverse,0.677734
uuid-8baf8e60126e416bbf92c0c7f2658f89,phase 3 study,0.48003
uuid-8baf8e60126e416bbf92c0c7f2658f89,melanoma,0.411352
uuid-8baf8e60126e416bbf92c0c7f2658f89,Weber JS,0.31904
uuid-8baf8e60126e416bbf92c0c7f2658f89,phase 2 study,0.319618
uuid-8baf8e60126e416bbf92c0c7f2658f89,reported,0.343242
uuid-5ce0e79849334e9d97a6b1059a19490d,requested,0.331755
uuid-5ce0e79849334e9d97a6b1059a19490d,ESMO,0.575268
uuid-5ce0e79849334e9d97a6b1059a19490d,Horn L,0.594256
uuid-5ce0e79849334e9d97a6b1059a19490d,platinum-based doublet chemotherapy,0.362148
uuid-b081308b1b574d03991c562d32545f8b,requested,0.531305
uuid-b081308b1b574d03991c562d32545f8b,ESMO,0.358531
uuid-b081308b1b574d03991c562d32545f8b,Horn L,0.66756
uuid-b081308b1b574d03991c562d32545f8b,platinum-based doublet chemotherapy,0.579011
uuid-8ce4edad514542a8860e0ec2c3d04476,requested,0.331755
uuid-8ce4edad514542a8860e0ec2c3d04476,ESMO,0.575268
uuid-8ce4edad514542a8860e0ec2c3d04476,Horn L,0.594256
uuid-8ce4edad514542a8860e0ec2c3d04476,platinum-based doublet chemotherapy,0.362148
uuid-2496527e53e04c90a58296647ad2cb03,NSCLC,0.361614
uuid-2496527e53e04c90a58296647ad2cb03,non-small cell lung cancer,0.3001
uuid-2496527e53e04c90a58296647ad2cb03,RCC,0.879698
uuid-576c4063789a44bcae6ed55a5c35063e,patients with advanced or metastatic,0.468858
uuid-576c4063789a44bcae6ed55a5c35063e,nivolumab combined with ipilimumab,0.446918
uuid-576c4063789a44bcae6ed55a5c35063e,not approved,0.352562
uuid-576c4063789a44bcae6ed55a5c35063e,clinical trials investigating the safety,0.429501
uuid-576c4063789a44bcae6ed55a5c35063e,bladder cancer,0.950698
uuid-3d43e3809f994357b7fdded7dfe3aca8,requested,0.531305
uuid-3d43e3809f994357b7fdded7dfe3aca8,ESMO,0.358531
uuid-3d43e3809f994357b7fdded7dfe3aca8,Horn L,0.66756
uuid-3d43e3809f994357b7fdded7dfe3aca8,platinum-based doublet chemotherapy,0.579011
uuid-702ad1a92c0b4045bd12d07e34c5369a,OS,0.62262
uuid-702ad1a92c0b4045bd12d07e34c5369a,PFS,0.65903
uuid-702ad1a92c0b4045bd12d07e34c5369a,Overall survival,0.644151
uuid-eecb1ae782e644bab6b7d697dba4da6c,95% CI,0.524855
uuid-eecb1ae782e644bab6b7d697dba4da6c,respectively,0.383655
uuid-eecb1ae782e644bab6b7d697dba4da6c,ASCO,0.303153
uuid-eecb1ae782e644bab6b7d697dba4da6c,Lancet Oncol,0.368041
uuid-eecb1ae782e644bab6b7d697dba4da6c,Objective response rate,0.504846
uuid-eecb1ae782e644bab6b7d697dba4da6c,ORR,0.465366
uuid-eecb1ae782e644bab6b7d697dba4da6c,Median overall survival,0.346516
uuid-eecb1ae782e644bab6b7d697dba4da6c,Median OS,0.33538
uuid-eecb1ae782e644bab6b7d697dba4da6c,ASCO 2015,0.336983
uuid-eecb1ae782e644bab6b7d697dba4da6c,small cell lung cancer,0.336892
uuid-eecb1ae782e644bab6b7d697dba4da6c,SCLC,0.344367
uuid-eecb1ae782e644bab6b7d697dba4da6c,Antonia SJ,0.55269
uuid-eecb1ae782e644bab6b7d697dba4da6c,Median duration of response,0.649605
uuid-c196dcdf024c4155b484e85d5927ea11,patients with advanced or metastatic,0.478326
uuid-c196dcdf024c4155b484e85d5927ea11,nivolumab combined with ipilimumab,0.498766
uuid-c196dcdf024c4155b484e85d5927ea11,not approved,0.34724
uuid-c196dcdf024c4155b484e85d5927ea11,clinical trials investigating the safety,0.426729
uuid-c196dcdf024c4155b484e85d5927ea11,bladder cancer,0.6548
uuid-ed3c2983f05d4640afae776557c9a11a,respectively,0.589071
uuid-ed3c2983f05d4640afae776557c9a11a,Objective response rate,0.407286
uuid-ed3c2983f05d4640afae776557c9a11a,ORR,0.526086
uuid-ed3c2983f05d4640afae776557c9a11a,monotherapy,0.319413
uuid-ed3c2983f05d4640afae776557c9a11a,docetaxel,0.334344
uuid-83bca47e18204109be9c916720687259,nivolumab,0.359772
uuid-74d58b326f40473384fbd3bde1d64f49,RCC,0.906223
uuid-67aa9ceaaf594c389bb9169b14e6d32d,requested,0.531305
uuid-67aa9ceaaf594c389bb9169b14e6d32d,ESMO,0.358531
uuid-67aa9ceaaf594c389bb9169b14e6d32d,Horn L,0.66756
uuid-67aa9ceaaf594c389bb9169b14e6d32d,platinum-based doublet chemotherapy,0.579011
uuid-2fad9737b7c54849aead7915efa93376,95% CI,0.398616
uuid-2fad9737b7c54849aead7915efa93376,Median overall survival,0.347376
uuid-2fad9737b7c54849aead7915efa93376,Median OS,0.405284
uuid-2fad9737b7c54849aead7915efa93376,hazard ratio,0.374116
uuid-cca285f3a80041109e03b1c1da215abf,requested,0.531305
uuid-cca285f3a80041109e03b1c1da215abf,ESMO,0.358531
uuid-cca285f3a80041109e03b1c1da215abf,Horn L,0.66756
uuid-cca285f3a80041109e03b1c1da215abf,platinum-based doublet chemotherapy,0.579011
uuid-27d905ed99204bbdb912b0445e6d91e4,requested,0.531305
uuid-27d905ed99204bbdb912b0445e6d91e4,ESMO,0.358531
uuid-27d905ed99204bbdb912b0445e6d91e4,Horn L,0.66756
uuid-27d905ed99204bbdb912b0445e6d91e4,platinum-based doublet chemotherapy,0.579011
uuid-d1ac3a48290740228cce4cc5bb8c3bed,RCC,0.906223
uuid-40bb34aa7ba7428cb02d36941b4ea9ca,PD-L1,0.552353
uuid-5c9ccce20d35406e97def64c478881b8,Bristol-Myers Squibb,0.371954
uuid-5c9ccce20d35406e97def64c478881b8,requested,0.315186
uuid-638393feab304c048ec2ab2bb656ead3,Bristol-Myers Squibb,0.331048
uuid-638393feab304c048ec2ab2bb656ead3,not conducted any controlled clinical trials/studies,0.313091
uuid-638393feab304c048ec2ab2bb656ead3,RCC,0.811311
uuid-a0df4a798a514b9eaae8b6db5cd90905,ipilimumab,0.385692
uuid-a0df4a798a514b9eaae8b6db5cd90905,ASCO 2015,0.417944
uuid-a0df4a798a514b9eaae8b6db5cd90905,partial response,0.382425
uuid-a0df4a798a514b9eaae8b6db5cd90905,Stable disease,0.586335
uuid-a0df4a798a514b9eaae8b6db5cd90905,cohort,0.307748
uuid-95f47b6cc59a45d8a64a887ceff43480,ipilimumab,0.385094
uuid-95f47b6cc59a45d8a64a887ceff43480,ASCO 2015,0.415911
uuid-95f47b6cc59a45d8a64a887ceff43480,partial response,0.381389
uuid-95f47b6cc59a45d8a64a887ceff43480,Stable disease,0.584834
uuid-95f47b6cc59a45d8a64a887ceff43480,cohort,0.307034
uuid-d444f328bcc54ce59df5ecd8d4f1ec28,open-label,0.379679
uuid-d444f328bcc54ce59df5ecd8d4f1ec28,cohort,0.493865
uuid-64193c07c61449e58047f1a7dd860de4,RCC,0.909054
uuid-790d770ef2654609b4df643d0d89a282,requested,0.531305
uuid-790d770ef2654609b4df643d0d89a282,ESMO,0.358531
uuid-790d770ef2654609b4df643d0d89a282,Horn L,0.66756
uuid-790d770ef2654609b4df643d0d89a282,platinum-based doublet chemotherapy,0.579011
uuid-3e2adc9313b04d0ca3bee74b960abfd3,requested,0.531305
uuid-3e2adc9313b04d0ca3bee74b960abfd3,ESMO,0.358531
uuid-3e2adc9313b04d0ca3bee74b960abfd3,Horn L,0.66756
uuid-3e2adc9313b04d0ca3bee74b960abfd3,platinum-based doublet chemotherapy,0.579011
uuid-6729e467a14a47ad8209b9e497ddaaca,requested,0.531305
uuid-6729e467a14a47ad8209b9e497ddaaca,ESMO,0.358531
uuid-6729e467a14a47ad8209b9e497ddaaca,Horn L,0.66756
uuid-6729e467a14a47ad8209b9e497ddaaca,platinum-based doublet chemotherapy,0.579011
uuid-db18a0f29433447ca4f9b672fb2c5cc8,RCC,0.898547
uuid-4e8e5f22767e413c93056cef48fbf9e0,N Engl J Med,0.442834
uuid-4e8e5f22767e413c93056cef48fbf9e0,protocol,0.763252
uuid-4e8e5f22767e413c93056cef48fbf9e0,McDermott DF,0.733103
uuid-4e8e5f22767e413c93056cef48fbf9e0,Motzer RJ,0.811057
uuid-4e8e5f22767e413c93056cef48fbf9e0,phase 3 study,0.420895
uuid-4e8e5f22767e413c93056cef48fbf9e0,Escudier B,0.741048
uuid-4e8e5f22767e413c93056cef48fbf9e0,NEJM,0.402544
uuid-4e8e5f22767e413c93056cef48fbf9e0,et al.,0.660398
uuid-4e8e5f22767e413c93056cef48fbf9e0,J Clin Oncol,0.786367
uuid-4e8e5f22767e413c93056cef48fbf9e0,Topalian,0.392395
uuid-4e8e5f22767e413c93056cef48fbf9e0,phase 1 study,0.513779
uuid-4e8e5f22767e413c93056cef48fbf9e0,CA209-003,0.583337
uuid-4e8e5f22767e413c93056cef48fbf9e0,phase 2 study,0.675447
uuid-4e8e5f22767e413c93056cef48fbf9e0,present using the following search terms,0.304589
uuid-4e8e5f22767e413c93056cef48fbf9e0,investigating,0.633101
uuid-1380ed6430a54ea1a3828522bdb62ab6,Bristol-Myers Squibb,0.325587
uuid-1380ed6430a54ea1a3828522bdb62ab6,evaluating,0.385275
uuid-1380ed6430a54ea1a3828522bdb62ab6,not conducted any controlled clinical trials/studies,0.414959
uuid-1380ed6430a54ea1a3828522bdb62ab6,purposes other than its labeled indication must be considered investigational,0.301922
uuid-5ee30ccc95a949db80fb4b49f2c3387c,95% CI,0.524855
uuid-5ee30ccc95a949db80fb4b49f2c3387c,respectively,0.383655
uuid-5ee30ccc95a949db80fb4b49f2c3387c,ASCO,0.303153
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Lancet Oncol,0.368041
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Objective response rate,0.504846
uuid-5ee30ccc95a949db80fb4b49f2c3387c,ORR,0.465366
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Median overall survival,0.346516
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Median OS,0.33538
uuid-5ee30ccc95a949db80fb4b49f2c3387c,ASCO 2015,0.336983
uuid-5ee30ccc95a949db80fb4b49f2c3387c,small cell lung cancer,0.336892
uuid-5ee30ccc95a949db80fb4b49f2c3387c,SCLC,0.344367
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Antonia SJ,0.55269
uuid-5ee30ccc95a949db80fb4b49f2c3387c,Median duration of response,0.649605
uuid-101a40b6067f4abead2d37a3c17ec35d,requested,0.531305
uuid-101a40b6067f4abead2d37a3c17ec35d,ESMO,0.358531
uuid-101a40b6067f4abead2d37a3c17ec35d,Horn L,0.66756
uuid-101a40b6067f4abead2d37a3c17ec35d,platinum-based doublet chemotherapy,0.579011
uuid-812c213f1f084f19a3cd936e8b01e2bb,OS,0.506839
uuid-812c213f1f084f19a3cd936e8b01e2bb,95% CI,0.914259
uuid-812c213f1f084f19a3cd936e8b01e2bb,respectively,0.57945
uuid-812c213f1f084f19a3cd936e8b01e2bb,Objective response rate,0.616133
uuid-812c213f1f084f19a3cd936e8b01e2bb,ORR,0.78386
uuid-812c213f1f084f19a3cd936e8b01e2bb,PFS,0.374029
uuid-812c213f1f084f19a3cd936e8b01e2bb,Median overall survival,0.850584
uuid-812c213f1f084f19a3cd936e8b01e2bb,monotherapy,0.435128
uuid-812c213f1f084f19a3cd936e8b01e2bb,Median OS,0.829523
uuid-812c213f1f084f19a3cd936e8b01e2bb,docetaxel,0.347663
uuid-812c213f1f084f19a3cd936e8b01e2bb,hazard ratio,0.887303
uuid-812c213f1f084f19a3cd936e8b01e2bb,Median duration of response,0.367027
uuid-f22be116e75142ddb9285f062ed89a04,requested,0.534545
uuid-f22be116e75142ddb9285f062ed89a04,ESMO,0.354897
uuid-f22be116e75142ddb9285f062ed89a04,Horn L,0.650378
uuid-f22be116e75142ddb9285f062ed89a04,platinum-based doublet chemotherapy,0.560171
uuid-4bc74a800bf642feb6b5cb2321e9e69b,patients,0.315933
uuid-f9671e954d69427a8e2eb778550645c6,requested,0.531305
uuid-f9671e954d69427a8e2eb778550645c6,ESMO,0.358531
uuid-f9671e954d69427a8e2eb778550645c6,Horn L,0.66756
uuid-f9671e954d69427a8e2eb778550645c6,platinum-based doublet chemotherapy,0.579011
uuid-432592ff051146258bb389bb39b095b5,OS,0.506839
uuid-432592ff051146258bb389bb39b095b5,95% CI,0.914259
uuid-432592ff051146258bb389bb39b095b5,respectively,0.57945
uuid-432592ff051146258bb389bb39b095b5,Objective response rate,0.616133
uuid-432592ff051146258bb389bb39b095b5,ORR,0.78386
uuid-432592ff051146258bb389bb39b095b5,PFS,0.374029
uuid-432592ff051146258bb389bb39b095b5,Median overall survival,0.850584
uuid-432592ff051146258bb389bb39b095b5,monotherapy,0.435128
uuid-432592ff051146258bb389bb39b095b5,Median OS,0.829523
uuid-432592ff051146258bb389bb39b095b5,docetaxel,0.347663
uuid-432592ff051146258bb389bb39b095b5,hazard ratio,0.887303
uuid-432592ff051146258bb389bb39b095b5,Median duration of response,0.367027
uuid-dabda95f7c944b65b1b8c0b39bc26d6a,therapy,0.381909
uuid-2412a4d5c7e04a4aa7216e5fed76e990,ESMO,0.603759
uuid-2412a4d5c7e04a4aa7216e5fed76e990,Horn L,0.484674
uuid-b976711e37364fdba543156285dc36a9,clinical,0.328094
uuid-b976711e37364fdba543156285dc36a9,trial,0.355416
uuid-a85ac7f2112849ef91ac539a20068cfd,ASCO,0.807066
uuid-be6e90f5293a49c2ab12e4ae73f05b01,melanoma,0.515009
uuid-9ec02aa68f0248fca72c5917b769d361,OS,0.306979
uuid-9ec02aa68f0248fca72c5917b769d361,95% CI,0.378929
uuid-9ec02aa68f0248fca72c5917b769d361,ORR,0.325152
uuid-9ec02aa68f0248fca72c5917b769d361,Median overall survival,0.416865
uuid-9ec02aa68f0248fca72c5917b769d361,Median OS,0.343981
uuid-9ec02aa68f0248fca72c5917b769d361,hazard ratio,0.35636
uuid-be633b11e1b54bdcaf1a8e4855481169,nivolumab,0.403988
uuid-be633b11e1b54bdcaf1a8e4855481169,use of nivolumab for the treatment,0.324571
uuid-be633b11e1b54bdcaf1a8e4855481169,patients with advanced or metastatic,0.474367
uuid-be633b11e1b54bdcaf1a8e4855481169,Pubmed literature search,0.340092
uuid-be633b11e1b54bdcaf1a8e4855481169,purposes other than its labeled indication must be considered investigational,0.377772
uuid-be633b11e1b54bdcaf1a8e4855481169,not identify any citations relevant to your inquiry,0.320935
uuid-be633b11e1b54bdcaf1a8e4855481169,nivolumab combined with ipilimumab,0.503635
uuid-be633b11e1b54bdcaf1a8e4855481169,not approved,0.384355
uuid-be633b11e1b54bdcaf1a8e4855481169,using the following search terms,0.317674
uuid-be633b11e1b54bdcaf1a8e4855481169,clinical trials investigating the safety,0.458455
uuid-be633b11e1b54bdcaf1a8e4855481169,bladder cancer,0.590312
uuid-f3b879e0b90e4477b897327fc805cacc,requested,0.315914
uuid-3428eae7cb744416bce041e5145daa31,RCC,0.906223
uuid-7c9693c6a27e49f19c91f80c8f4973ef,95% CI,0.520262
uuid-7c9693c6a27e49f19c91f80c8f4973ef,respectively,0.504068
uuid-7c9693c6a27e49f19c91f80c8f4973ef,Objective response rate,0.458568
uuid-7c9693c6a27e49f19c91f80c8f4973ef,ORR,0.525868
uuid-7c9693c6a27e49f19c91f80c8f4973ef,Median overall survival,0.455633
uuid-7c9693c6a27e49f19c91f80c8f4973ef,Median OS,0.507448
uuid-7c9693c6a27e49f19c91f80c8f4973ef,docetaxel,0.383115
uuid-7c9693c6a27e49f19c91f80c8f4973ef,hazard ratio,0.462119
uuid-c8800b8a0dcc4deab598f93bcf11ce91,patients,0.315933
uuid-563775b4aa2747bca72fe8e310113ae8,nivolumab,0.493389
uuid-563775b4aa2747bca72fe8e310113ae8,Bristol-Myers Squibb,0.598477
uuid-563775b4aa2747bca72fe8e310113ae8,evaluating,0.837805
uuid-563775b4aa2747bca72fe8e310113ae8,not conducted any controlled clinical trials/studies,0.848713
uuid-563775b4aa2747bca72fe8e310113ae8,Pubmed literature search,0.314091
uuid-563775b4aa2747bca72fe8e310113ae8,purposes other than its labeled indication must be considered investigational,0.4415
uuid-563775b4aa2747bca72fe8e310113ae8,search of published literature,0.772891
uuid-563775b4aa2747bca72fe8e310113ae8,PubMed and EMBASE,0.743175
uuid-563775b4aa2747bca72fe8e310113ae8,efficacy and safety of nivolumab,0.905749
uuid-563775b4aa2747bca72fe8e310113ae8,not identify any citations relevant to your request,0.417576
uuid-563775b4aa2747bca72fe8e310113ae8,present using the following search terms,0.748132
uuid-4cddac2af7e44e18986b26f0fd9615cc,patients,0.594627
uuid-4cddac2af7e44e18986b26f0fd9615cc,considered investigational,0.579972
uuid-4cddac2af7e44e18986b26f0fd9615cc,provided in the Detailed Information,0.313193
uuid-4cddac2af7e44e18986b26f0fd9615cc,patients with advanced or metastatic,0.384591
uuid-4cddac2af7e44e18986b26f0fd9615cc,nivolumab combined with ipilimumab,0.361012
uuid-4cddac2af7e44e18986b26f0fd9615cc,clinical,0.456325
uuid-4cddac2af7e44e18986b26f0fd9615cc,tumors,0.483539
uuid-4cddac2af7e44e18986b26f0fd9615cc,small cell lung cancer,0.714667
uuid-4cddac2af7e44e18986b26f0fd9615cc,SCLC,0.687973
uuid-4cddac2af7e44e18986b26f0fd9615cc,therapy,0.439635
uuid-4cddac2af7e44e18986b26f0fd9615cc,phase 1/2 study CA209-032,0.602548
uuid-4cddac2af7e44e18986b26f0fd9615cc,evaluates the efficacy of nivolumab monotherapy,0.553666
uuid-c9a42f1246044dc9bf6f3a1e7c9f2400,nivolumab,0.359772
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,OS,0.506839
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,95% CI,0.914259
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,respectively,0.57945
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,Objective response rate,0.616133
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,ORR,0.78386
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,PFS,0.374029
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,Median overall survival,0.850584
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,monotherapy,0.435128
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,Median OS,0.829523
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,docetaxel,0.347663
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,hazard ratio,0.887303
uuid-e9fefc774f6d48d591bcb262f1b4b9c5,Median duration of response,0.367027
uuid-5be7ac33a832404dbe482794f659eb81,requested,0.531305
uuid-5be7ac33a832404dbe482794f659eb81,ESMO,0.358531
uuid-5be7ac33a832404dbe482794f659eb81,Horn L,0.66756
uuid-5be7ac33a832404dbe482794f659eb81,platinum-based doublet chemotherapy,0.579011
uuid-fe6717c0682a46a08032894a0442a019,OS,0.506839
uuid-fe6717c0682a46a08032894a0442a019,95% CI,0.914259
uuid-fe6717c0682a46a08032894a0442a019,respectively,0.57945
uuid-fe6717c0682a46a08032894a0442a019,Objective response rate,0.616133
uuid-fe6717c0682a46a08032894a0442a019,ORR,0.78386
uuid-fe6717c0682a46a08032894a0442a019,PFS,0.374029
uuid-fe6717c0682a46a08032894a0442a019,Median overall survival,0.850584
uuid-fe6717c0682a46a08032894a0442a019,monotherapy,0.435128
uuid-fe6717c0682a46a08032894a0442a019,Median OS,0.829523
uuid-fe6717c0682a46a08032894a0442a019,docetaxel,0.347663
uuid-fe6717c0682a46a08032894a0442a019,hazard ratio,0.887303
uuid-fe6717c0682a46a08032894a0442a019,Median duration of response,0.367027
uuid-8e10f8cf4826491bae18d41de1bf2b4b,Bristol-Myers Squibb,0.848069
uuid-8e10f8cf4826491bae18d41de1bf2b4b,evaluating,0.65215
uuid-8e10f8cf4826491bae18d41de1bf2b4b,not conducted any controlled clinical trials/studies,0.738428
uuid-8e10f8cf4826491bae18d41de1bf2b4b,efficacy and safety of nivolumab,0.55404
uuid-fe23079800a44da58448a366ba79d0c5,RCC,0.906223
uuid-383b698edee44a9d87a9d3c3fa14c0ef,use of nivolumab for the treatment,0.658514
uuid-383b698edee44a9d87a9d3c3fa14c0ef,efficacy,0.5179
uuid-383b698edee44a9d87a9d3c3fa14c0ef,patients,0.713293
uuid-383b698edee44a9d87a9d3c3fa14c0ef,not approved,0.597052
uuid-383b698edee44a9d87a9d3c3fa14c0ef,clinical trials investigating the safety,0.560022
uuid-383b698edee44a9d87a9d3c3fa14c0ef,mg,0.642169
uuid-383b698edee44a9d87a9d3c3fa14c0ef,kg,0.618427
uuid-383b698edee44a9d87a9d3c3fa14c0ef,safety of nivolumab monotherapy,0.364073
uuid-7bf2766df7bf47bd800a4407ddc11cd4,use of nivolumab for the treatment,0.658514
uuid-7bf2766df7bf47bd800a4407ddc11cd4,efficacy,0.5179
uuid-7bf2766df7bf47bd800a4407ddc11cd4,patients,0.713293
uuid-7bf2766df7bf47bd800a4407ddc11cd4,not approved,0.597052
uuid-7bf2766df7bf47bd800a4407ddc11cd4,clinical trials investigating the safety,0.560022
uuid-7bf2766df7bf47bd800a4407ddc11cd4,mg,0.642169
uuid-7bf2766df7bf47bd800a4407ddc11cd4,kg,0.618427
uuid-7bf2766df7bf47bd800a4407ddc11cd4,safety of nivolumab monotherapy,0.364073
uuid-1212e581ff7241dab354decf6c029270,Bristol-Myers Squibb,0.341451
uuid-1212e581ff7241dab354decf6c029270,ASCO,0.431681
uuid-90e9e20710df4410b295b435fdcfb80e,respectively,0.585622
uuid-90e9e20710df4410b295b435fdcfb80e,Objective response rate,0.36976
uuid-90e9e20710df4410b295b435fdcfb80e,ORR,0.514781
uuid-90e9e20710df4410b295b435fdcfb80e,docetaxel,0.31274
uuid-3b12f989023940b0b632b8ca6d0bf2c3,N Engl J Med,0.367869
uuid-3b12f989023940b0b632b8ca6d0bf2c3,protocol,0.658742
uuid-3b12f989023940b0b632b8ca6d0bf2c3,RCC,0.375387
uuid-3b12f989023940b0b632b8ca6d0bf2c3,McDermott DF,0.560924
uuid-3b12f989023940b0b632b8ca6d0bf2c3,search of published literature,0.428619
uuid-3b12f989023940b0b632b8ca6d0bf2c3,Additionally,0.405724
uuid-3b12f989023940b0b632b8ca6d0bf2c3,ongoing,0.365225
uuid-3b12f989023940b0b632b8ca6d0bf2c3,Motzer RJ,0.596203
uuid-3b12f989023940b0b632b8ca6d0bf2c3,PubMed and EMBASE,0.423862
uuid-3b12f989023940b0b632b8ca6d0bf2c3,Escudier B,0.579918
uuid-3b12f989023940b0b632b8ca6d0bf2c3,et al.,0.511511
uuid-3b12f989023940b0b632b8ca6d0bf2c3,J Clin Oncol,0.536232
uuid-3b12f989023940b0b632b8ca6d0bf2c3,detailed search of www.clinicaltrials.gov,0.379318
uuid-3b12f989023940b0b632b8ca6d0bf2c3,efficacy and safety of nivolumab,0.423052
uuid-3b12f989023940b0b632b8ca6d0bf2c3,not identify any planned,0.3696
uuid-3b12f989023940b0b632b8ca6d0bf2c3,phase 2 study,0.471813
uuid-3b12f989023940b0b632b8ca6d0bf2c3,not identify any citations relevant to your request,0.423463
uuid-3b12f989023940b0b632b8ca6d0bf2c3,present using the following search terms,0.406049
uuid-4e8b1f70af5c4ec7837d01e195e86900,nivolumab,0.37207
uuid-4e8b1f70af5c4ec7837d01e195e86900,evaluating,0.416882
uuid-4e8b1f70af5c4ec7837d01e195e86900,not conducted any controlled clinical trials/studies,0.374083
uuid-4e8b1f70af5c4ec7837d01e195e86900,search of published literature,0.460249
uuid-4e8b1f70af5c4ec7837d01e195e86900,Additionally,0.36442
uuid-4e8b1f70af5c4ec7837d01e195e86900,ongoing,0.374079
uuid-4e8b1f70af5c4ec7837d01e195e86900,PubMed and EMBASE,0.452444
uuid-4e8b1f70af5c4ec7837d01e195e86900,not approved,0.311347
uuid-4e8b1f70af5c4ec7837d01e195e86900,detailed search of www.clinicaltrials.gov,0.361658
uuid-4e8b1f70af5c4ec7837d01e195e86900,clinical trials investigating the safety,0.332232
uuid-4e8b1f70af5c4ec7837d01e195e86900,efficacy and safety of nivolumab,0.470594
uuid-4e8b1f70af5c4ec7837d01e195e86900,not identify any planned,0.362489
uuid-4e8b1f70af5c4ec7837d01e195e86900,combination,0.316988
uuid-4e8b1f70af5c4ec7837d01e195e86900,not identify any citations relevant to your request,0.439163
uuid-4e8b1f70af5c4ec7837d01e195e86900,present using the following search terms,0.466805
uuid-00cb1b95b5db406ea121ac104c045e32,OS,0.306979
uuid-00cb1b95b5db406ea121ac104c045e32,95% CI,0.378929
uuid-00cb1b95b5db406ea121ac104c045e32,ORR,0.325152
uuid-00cb1b95b5db406ea121ac104c045e32,Median overall survival,0.416865
uuid-00cb1b95b5db406ea121ac104c045e32,Median OS,0.343981
uuid-00cb1b95b5db406ea121ac104c045e32,hazard ratio,0.35636
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,adverse,0.677734
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,phase 3 study,0.48003
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,melanoma,0.411352
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,Weber JS,0.31904
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,phase 2 study,0.319618
uuid-7b6183df494f4d1b8f9ef6b5fddb76fd,reported,0.343242
uuid-08d95b591f4d4fabafbce422db2c3143,requested,0.531305
uuid-08d95b591f4d4fabafbce422db2c3143,ESMO,0.358531
uuid-08d95b591f4d4fabafbce422db2c3143,Horn L,0.66756
uuid-08d95b591f4d4fabafbce422db2c3143,platinum-based doublet chemotherapy,0.579011
uuid-7ad21d74dd81469b954884c4e93d05d0,considered investigational,0.402849
uuid-7ad21d74dd81469b954884c4e93d05d0,small cell lung cancer,0.651985
uuid-7ad21d74dd81469b954884c4e93d05d0,partial response,0.50367
uuid-7ad21d74dd81469b954884c4e93d05d0,SCLC,0.736863
uuid-7ad21d74dd81469b954884c4e93d05d0,therapy,0.843488
uuid-7ad21d74dd81469b954884c4e93d05d0,relapsed,0.613852
uuid-7ad21d74dd81469b954884c4e93d05d0,phase 1/2 study CA209-032,0.40439
uuid-7ad21d74dd81469b954884c4e93d05d0,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-836e41db72ec43f2977068bd9640d0aa,N Engl J Med,0.410025
uuid-836e41db72ec43f2977068bd9640d0aa,protocol,0.663749
uuid-836e41db72ec43f2977068bd9640d0aa,RCC,0.370429
uuid-836e41db72ec43f2977068bd9640d0aa,McDermott DF,0.577168
uuid-836e41db72ec43f2977068bd9640d0aa,search of published literature,0.443686
uuid-836e41db72ec43f2977068bd9640d0aa,Additionally,0.395847
uuid-836e41db72ec43f2977068bd9640d0aa,ongoing,0.335873
uuid-836e41db72ec43f2977068bd9640d0aa,Motzer RJ,0.609458
uuid-836e41db72ec43f2977068bd9640d0aa,phase 3 study,0.312748
uuid-836e41db72ec43f2977068bd9640d0aa,PubMed and EMBASE,0.438896
uuid-836e41db72ec43f2977068bd9640d0aa,Escudier B,0.595328
uuid-836e41db72ec43f2977068bd9640d0aa,et al.,0.521538
uuid-836e41db72ec43f2977068bd9640d0aa,J Clin Oncol,0.545137
uuid-836e41db72ec43f2977068bd9640d0aa,detailed search of www.clinicaltrials.gov,0.358127
uuid-836e41db72ec43f2977068bd9640d0aa,efficacy and safety of nivolumab,0.429052
uuid-836e41db72ec43f2977068bd9640d0aa,not identify any planned,0.344155
uuid-836e41db72ec43f2977068bd9640d0aa,phase 2 study,0.513121
uuid-836e41db72ec43f2977068bd9640d0aa,not identify any citations relevant to your request,0.414617
uuid-836e41db72ec43f2977068bd9640d0aa,present using the following search terms,0.417875
uuid-d8bde2ccb4ca4431a65d7d2337dc2ad6,nivolumab,0.300757
uuid-d8bde2ccb4ca4431a65d7d2337dc2ad6,Bristol-Myers Squibb,0.715811
uuid-d8bde2ccb4ca4431a65d7d2337dc2ad6,evaluating,0.62458
uuid-d8bde2ccb4ca4431a65d7d2337dc2ad6,not conducted any controlled clinical trials/studies,0.691748
uuid-d8bde2ccb4ca4431a65d7d2337dc2ad6,efficacy and safety of nivolumab,0.530734
uuid-401ba38e51064034864708d52f317629,patients,0.315933
uuid-ea36b7af781f413491f81b8d8de66a72,respectively,0.397695
uuid-183056c8fe274ea88709b8434acda6c2,N Engl J Med,0.427636
uuid-183056c8fe274ea88709b8434acda6c2,protocol,0.429136
uuid-183056c8fe274ea88709b8434acda6c2,McDermott DF,0.44782
uuid-183056c8fe274ea88709b8434acda6c2,Motzer RJ,0.430476
uuid-183056c8fe274ea88709b8434acda6c2,Escudier B,0.450887
uuid-183056c8fe274ea88709b8434acda6c2,et al.,0.456026
uuid-183056c8fe274ea88709b8434acda6c2,J Clin Oncol,0.384624
uuid-183056c8fe274ea88709b8434acda6c2,Rizvi NA,0.305616
uuid-183056c8fe274ea88709b8434acda6c2,phase 2 study,0.351446
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,considered investigational,0.30457
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,melanoma,0.387656
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,small cell lung cancer,0.517146
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,partial response,0.323082
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,SCLC,0.592551
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,therapy,0.86274
uuid-b33dfc228a76459f8dc9b01da2e8bb7e,relapsed,0.390331
uuid-89508aa597554b429ff1182487588752,OS,0.506839
uuid-89508aa597554b429ff1182487588752,95% CI,0.914259
uuid-89508aa597554b429ff1182487588752,respectively,0.57945
uuid-89508aa597554b429ff1182487588752,Objective response rate,0.616133
uuid-89508aa597554b429ff1182487588752,ORR,0.78386
uuid-89508aa597554b429ff1182487588752,PFS,0.374029
uuid-89508aa597554b429ff1182487588752,Median overall survival,0.850584
uuid-89508aa597554b429ff1182487588752,monotherapy,0.435128
uuid-89508aa597554b429ff1182487588752,Median OS,0.829523
uuid-89508aa597554b429ff1182487588752,docetaxel,0.347663
uuid-89508aa597554b429ff1182487588752,hazard ratio,0.887303
uuid-89508aa597554b429ff1182487588752,Median duration of response,0.367027
uuid-34963a6ec8654b6ba7e45660ca313196,95% CI,0.482283
uuid-34963a6ec8654b6ba7e45660ca313196,respectively,0.319895
uuid-34963a6ec8654b6ba7e45660ca313196,ASCO,0.389676
uuid-34963a6ec8654b6ba7e45660ca313196,Objective response rate,0.357341
uuid-34963a6ec8654b6ba7e45660ca313196,ORR,0.358789
uuid-34963a6ec8654b6ba7e45660ca313196,Median overall survival,0.421434
uuid-34963a6ec8654b6ba7e45660ca313196,Median OS,0.603017
uuid-34963a6ec8654b6ba7e45660ca313196,docetaxel,0.351836
uuid-34963a6ec8654b6ba7e45660ca313196,hazard ratio,0.51871
uuid-ef74d6dd0fad4d28942eb80c57e1a2f3,requested,0.531305
uuid-ef74d6dd0fad4d28942eb80c57e1a2f3,ESMO,0.358531
uuid-ef74d6dd0fad4d28942eb80c57e1a2f3,Horn L,0.66756
uuid-ef74d6dd0fad4d28942eb80c57e1a2f3,platinum-based doublet chemotherapy,0.579011
uuid-6e76766e40b249f4962bb17dc4415567,nivolumab,0.403102
uuid-6e76766e40b249f4962bb17dc4415567,Objective response rate,0.395013
uuid-6e76766e40b249f4962bb17dc4415567,clinicaltrials.gov,0.505675
uuid-eee6d696d5d544a19cc802a2ba7ce521,95% CI,0.524855
uuid-eee6d696d5d544a19cc802a2ba7ce521,respectively,0.383655
uuid-eee6d696d5d544a19cc802a2ba7ce521,ASCO,0.303153
uuid-eee6d696d5d544a19cc802a2ba7ce521,Lancet Oncol,0.368041
uuid-eee6d696d5d544a19cc802a2ba7ce521,Objective response rate,0.504846
uuid-eee6d696d5d544a19cc802a2ba7ce521,ORR,0.465366
uuid-eee6d696d5d544a19cc802a2ba7ce521,Median overall survival,0.346516
uuid-eee6d696d5d544a19cc802a2ba7ce521,Median OS,0.33538
uuid-eee6d696d5d544a19cc802a2ba7ce521,ASCO 2015,0.336983
uuid-eee6d696d5d544a19cc802a2ba7ce521,small cell lung cancer,0.336892
uuid-eee6d696d5d544a19cc802a2ba7ce521,SCLC,0.344367
uuid-eee6d696d5d544a19cc802a2ba7ce521,Antonia SJ,0.55269
uuid-eee6d696d5d544a19cc802a2ba7ce521,Median duration of response,0.649605
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,N Engl J Med,0.409425
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,phase 3 study,0.344105
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,phase 1 study,0.42025
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,Rizvi NA,0.372987
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,Brahmer J,0.32571
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,mg,0.34664
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,CA209-003,0.428482
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,phase 2 study,0.427642
uuid-6fe8f383f4004a4f9d4b67f9f33b9570,kg,0.335258
uuid-9e2651ab8bb841ccb75e986977420623,provided in the Detailed Information,0.613203
uuid-9e2651ab8bb841ccb75e986977420623,clinical,0.609338
uuid-6511f3b7738e476f88f2fe30939ae882,OS,0.344846
uuid-6511f3b7738e476f88f2fe30939ae882,95% CI,0.629468
uuid-6511f3b7738e476f88f2fe30939ae882,NSCLC,0.336139
uuid-6511f3b7738e476f88f2fe30939ae882,respectively,0.407674
uuid-6511f3b7738e476f88f2fe30939ae882,Objective response rate,0.54429
uuid-6511f3b7738e476f88f2fe30939ae882,ORR,0.630459
uuid-6511f3b7738e476f88f2fe30939ae882,Median overall survival,0.590912
uuid-6511f3b7738e476f88f2fe30939ae882,monotherapy,0.467134
uuid-6511f3b7738e476f88f2fe30939ae882,Median OS,0.552454
uuid-6511f3b7738e476f88f2fe30939ae882,docetaxel,0.349054
uuid-6511f3b7738e476f88f2fe30939ae882,hazard ratio,0.607507
uuid-2d76b397fb2d4f8b8946a0d1406594c7,NSCLC,0.334422
uuid-2d76b397fb2d4f8b8946a0d1406594c7,non-small cell lung cancer,0.364633
uuid-2d76b397fb2d4f8b8946a0d1406594c7,safety of nivolumab monotherapy,0.474385
uuid-2d76b397fb2d4f8b8946a0d1406594c7,phase,0.445607
uuid-a27986c3df8e4db2820effc1c42d9025,OS,0.506839
uuid-a27986c3df8e4db2820effc1c42d9025,95% CI,0.914259
uuid-a27986c3df8e4db2820effc1c42d9025,respectively,0.57945
uuid-a27986c3df8e4db2820effc1c42d9025,Objective response rate,0.616133
uuid-a27986c3df8e4db2820effc1c42d9025,ORR,0.78386
uuid-a27986c3df8e4db2820effc1c42d9025,PFS,0.374029
uuid-a27986c3df8e4db2820effc1c42d9025,Median overall survival,0.850584
uuid-a27986c3df8e4db2820effc1c42d9025,monotherapy,0.435128
uuid-a27986c3df8e4db2820effc1c42d9025,Median OS,0.829523
uuid-a27986c3df8e4db2820effc1c42d9025,docetaxel,0.347663
uuid-a27986c3df8e4db2820effc1c42d9025,hazard ratio,0.887303
uuid-a27986c3df8e4db2820effc1c42d9025,Median duration of response,0.367027
uuid-25fff3989abd4455ad31edde3db31a58,Opdivo,0.35004
uuid-25fff3989abd4455ad31edde3db31a58,adverse,0.399709
uuid-25fff3989abd4455ad31edde3db31a58,safety,0.549948
uuid-25fff3989abd4455ad31edde3db31a58,databases,0.491602
uuid-25fff3989abd4455ad31edde3db31a58,reported,0.65785
uuid-c57c33eaaab64146bbc5e68adee69873,RCC,0.876997
uuid-63a740c9a0d1442296c4166f2dbbb2df,OS,0.506839
uuid-63a740c9a0d1442296c4166f2dbbb2df,95% CI,0.914259
uuid-63a740c9a0d1442296c4166f2dbbb2df,respectively,0.57945
uuid-63a740c9a0d1442296c4166f2dbbb2df,Objective response rate,0.616133
uuid-63a740c9a0d1442296c4166f2dbbb2df,ORR,0.78386
uuid-63a740c9a0d1442296c4166f2dbbb2df,PFS,0.374029
uuid-63a740c9a0d1442296c4166f2dbbb2df,Median overall survival,0.850584
uuid-63a740c9a0d1442296c4166f2dbbb2df,monotherapy,0.435128
uuid-63a740c9a0d1442296c4166f2dbbb2df,Median OS,0.829523
uuid-63a740c9a0d1442296c4166f2dbbb2df,docetaxel,0.347663
uuid-63a740c9a0d1442296c4166f2dbbb2df,hazard ratio,0.887303
uuid-63a740c9a0d1442296c4166f2dbbb2df,Median duration of response,0.367027
uuid-da5390ffde914282bbddf0d8b7f7c546,N Engl J Med,0.775913
uuid-da5390ffde914282bbddf0d8b7f7c546,Lancet Oncol,0.394515
uuid-da5390ffde914282bbddf0d8b7f7c546,protocol,0.831494
uuid-da5390ffde914282bbddf0d8b7f7c546,McDermott DF,0.846573
uuid-da5390ffde914282bbddf0d8b7f7c546,Motzer RJ,0.84765
uuid-da5390ffde914282bbddf0d8b7f7c546,phase 3 study,0.543442
uuid-da5390ffde914282bbddf0d8b7f7c546,Escudier B,0.856834
uuid-da5390ffde914282bbddf0d8b7f7c546,NEJM,0.463538
uuid-da5390ffde914282bbddf0d8b7f7c546,et al.,0.804146
uuid-da5390ffde914282bbddf0d8b7f7c546,J Clin Oncol,0.783647
uuid-da5390ffde914282bbddf0d8b7f7c546,Topalian,0.430057
uuid-da5390ffde914282bbddf0d8b7f7c546,phase 1 study,0.32725
uuid-da5390ffde914282bbddf0d8b7f7c546,Rizvi NA,0.582327
uuid-da5390ffde914282bbddf0d8b7f7c546,Brahmer J,0.485583
uuid-da5390ffde914282bbddf0d8b7f7c546,Weber JS,0.384759
uuid-da5390ffde914282bbddf0d8b7f7c546,phase 2 study,0.779584
uuid-b936c7251d054aadb01206ef6aa2a068,use of nivolumab for the treatment,0.511079
uuid-b936c7251d054aadb01206ef6aa2a068,evaluating,0.498617
uuid-b936c7251d054aadb01206ef6aa2a068,not conducted any controlled clinical trials/studies,0.385554
uuid-b936c7251d054aadb01206ef6aa2a068,efficacy,0.579857
uuid-b936c7251d054aadb01206ef6aa2a068,patients,0.488122
uuid-b936c7251d054aadb01206ef6aa2a068,not approved,0.544271
uuid-b936c7251d054aadb01206ef6aa2a068,clinical trials investigating the safety,0.467656
uuid-b936c7251d054aadb01206ef6aa2a068,efficacy and safety of nivolumab,0.330091
uuid-b936c7251d054aadb01206ef6aa2a068,docetaxel,0.587347
uuid-b936c7251d054aadb01206ef6aa2a068,safety of nivolumab monotherapy,0.722484
uuid-a42e40e405244bbba96340103383fc6f,NSCLC,0.470112
uuid-a42e40e405244bbba96340103383fc6f,non-small cell lung cancer,0.465456
uuid-a42e40e405244bbba96340103383fc6f,patients,0.469331
uuid-a42e40e405244bbba96340103383fc6f,considered investigational,0.382071
uuid-a42e40e405244bbba96340103383fc6f,phase 1 study,0.366535
uuid-a42e40e405244bbba96340103383fc6f,small cell lung cancer,0.33658
uuid-a42e40e405244bbba96340103383fc6f,trial,0.349386
uuid-a42e40e405244bbba96340103383fc6f,SCLC,0.325558
uuid-a42e40e405244bbba96340103383fc6f,therapy,0.305305
uuid-a42e40e405244bbba96340103383fc6f,safety of nivolumab monotherapy,0.310457
uuid-a42e40e405244bbba96340103383fc6f,phase,0.347853
uuid-0216e4947f964d918203315b5fbcdcce,provided in the Detailed Information,0.523967
uuid-0216e4947f964d918203315b5fbcdcce,adverse,0.334376
uuid-0216e4947f964d918203315b5fbcdcce,clinical,0.549777
uuid-3075ab4894b04e549fa04ac58cfc1ed9,nivolumab,0.347078
uuid-3075ab4894b04e549fa04ac58cfc1ed9,patients with advanced or metastatic,0.323546
uuid-3075ab4894b04e549fa04ac58cfc1ed9,nivolumab combined with ipilimumab,0.321106
uuid-3075ab4894b04e549fa04ac58cfc1ed9,ESMO,0.690869
uuid-3075ab4894b04e549fa04ac58cfc1ed9,Horn L,0.364617
uuid-3075ab4894b04e549fa04ac58cfc1ed9,grade 3 to 4 AEs,0.308322
uuid-3075ab4894b04e549fa04ac58cfc1ed9,bladder cancer,0.496096
uuid-74865fdf778e458b98bac53bb87aa9b0,provided in the Detailed Information,0.578509
uuid-74865fdf778e458b98bac53bb87aa9b0,clinical,0.470357
uuid-9918ecf47fce460ca4837f74a2ee4063,RCC,0.906223
uuid-90fd075486a940b5b1a3023273de5431,RCC,0.906223
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,OS,0.387596
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,95% CI,0.483002
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,respectively,0.74191
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,Objective response rate,0.458401
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,ORR,0.581115
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,Median overall survival,0.451156
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,monotherapy,0.413088
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,Median OS,0.468649
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,Brahmer J,0.316336
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,docetaxel,0.630897
uuid-4c34c4c9d7614ffbadcfa1c693c258a6,hazard ratio,0.444799
uuid-7e5a52ea817442d1bfddd2f29a94b078,BMS,0.501362
uuid-0931e461f92e4d1fb7bf270b94ee0d38,patients with advanced or metastatic,0.455649
uuid-0931e461f92e4d1fb7bf270b94ee0d38,nivolumab combined with ipilimumab,0.421936
uuid-0931e461f92e4d1fb7bf270b94ee0d38,bladder cancer,0.837143
uuid-2dab5ebdc2d04871af24b10b3e665e90,search of published literature,0.394524
uuid-2dab5ebdc2d04871af24b10b3e665e90,Additionally,0.413583
uuid-2dab5ebdc2d04871af24b10b3e665e90,ongoing,0.322117
uuid-2dab5ebdc2d04871af24b10b3e665e90,PubMed and EMBASE,0.391671
uuid-2dab5ebdc2d04871af24b10b3e665e90,detailed search of www.clinicaltrials.gov,0.375936
uuid-2dab5ebdc2d04871af24b10b3e665e90,efficacy and safety of nivolumab,0.370699
uuid-2dab5ebdc2d04871af24b10b3e665e90,not identify any planned,0.34283
uuid-2dab5ebdc2d04871af24b10b3e665e90,Weber JS,0.319229
uuid-2dab5ebdc2d04871af24b10b3e665e90,not identify any citations relevant to your request,0.447813
uuid-2dab5ebdc2d04871af24b10b3e665e90,present using the following search terms,0.408199
uuid-97bc56a4cba340f4864028f561b7bf3b,fatigue,0.704358
uuid-f6a8e223922046a1ac642bac4a3c149a,ipilimumab,0.385692
uuid-f6a8e223922046a1ac642bac4a3c149a,ASCO 2015,0.417944
uuid-f6a8e223922046a1ac642bac4a3c149a,partial response,0.382425
uuid-f6a8e223922046a1ac642bac4a3c149a,Stable disease,0.586335
uuid-f6a8e223922046a1ac642bac4a3c149a,cohort,0.307748
uuid-062c3f4f545445f1ae0f25db337848e8,N Engl J Med,0.417573
uuid-062c3f4f545445f1ae0f25db337848e8,protocol,0.732107
uuid-062c3f4f545445f1ae0f25db337848e8,McDermott DF,0.700617
uuid-062c3f4f545445f1ae0f25db337848e8,search of published literature,0.306629
uuid-062c3f4f545445f1ae0f25db337848e8,Motzer RJ,0.780448
uuid-062c3f4f545445f1ae0f25db337848e8,phase 3 study,0.501546
uuid-062c3f4f545445f1ae0f25db337848e8,Escudier B,0.71017
uuid-062c3f4f545445f1ae0f25db337848e8,NEJM,0.35029
uuid-062c3f4f545445f1ae0f25db337848e8,et al.,0.627863
uuid-062c3f4f545445f1ae0f25db337848e8,J Clin Oncol,0.742879
uuid-062c3f4f545445f1ae0f25db337848e8,Topalian,0.343605
uuid-062c3f4f545445f1ae0f25db337848e8,phase 1 study,0.569065
uuid-062c3f4f545445f1ae0f25db337848e8,efficacy and safety of nivolumab,0.370954
uuid-062c3f4f545445f1ae0f25db337848e8,CA209-003,0.61519
uuid-062c3f4f545445f1ae0f25db337848e8,phase 2 study,0.70417
uuid-062c3f4f545445f1ae0f25db337848e8,present using the following search terms,0.310095
uuid-062c3f4f545445f1ae0f25db337848e8,investigating,0.650801
uuid-14b660e83ae64c8d8b81e1aeacb53c0f,patients with advanced or metastatic,0.468858
uuid-14b660e83ae64c8d8b81e1aeacb53c0f,nivolumab combined with ipilimumab,0.446918
uuid-14b660e83ae64c8d8b81e1aeacb53c0f,not approved,0.352562
uuid-14b660e83ae64c8d8b81e1aeacb53c0f,clinical trials investigating the safety,0.429501
uuid-14b660e83ae64c8d8b81e1aeacb53c0f,bladder cancer,0.950698
uuid-5fea7abecb114ffab30dc4b43285a99a,nivolumab,0.579953
uuid-5fea7abecb114ffab30dc4b43285a99a,Bristol-Myers Squibb,0.432723
uuid-5fea7abecb114ffab30dc4b43285a99a,evaluating,0.595301
uuid-5fea7abecb114ffab30dc4b43285a99a,not conducted any controlled clinical trials/studies,0.650546
uuid-5fea7abecb114ffab30dc4b43285a99a,Pubmed literature search,0.866609
uuid-5fea7abecb114ffab30dc4b43285a99a,purposes other than its labeled indication must be considered investigational,0.931953
uuid-5fea7abecb114ffab30dc4b43285a99a,not identify any citations relevant to your inquiry,0.827242
uuid-5fea7abecb114ffab30dc4b43285a99a,using the following search terms,0.812765
uuid-5fea7abecb114ffab30dc4b43285a99a,efficacy and safety of nivolumab,0.428841
uuid-5986088926044d76a0271258334b9272,OS,0.62262
uuid-5986088926044d76a0271258334b9272,PFS,0.65903
uuid-5986088926044d76a0271258334b9272,Overall survival,0.644151
uuid-308f30187d7945b69406341ee11ea87f,efficacy,0.395977
uuid-308f30187d7945b69406341ee11ea87f,respectively,0.579406
uuid-308f30187d7945b69406341ee11ea87f,ORR,0.351372
uuid-308f30187d7945b69406341ee11ea87f,Opdivo,0.412705
uuid-308f30187d7945b69406341ee11ea87f,monotherapy,0.402856
uuid-308f30187d7945b69406341ee11ea87f,not approved,0.386635
uuid-308f30187d7945b69406341ee11ea87f,clinical trials investigating the safety,0.386887
uuid-308f30187d7945b69406341ee11ea87f,docetaxel,0.539799
uuid-308f30187d7945b69406341ee11ea87f,safety of nivolumab monotherapy,0.339293
uuid-3e5d8cb3db1e4a09aca0e6cd6bce47bb,requested,0.558087
uuid-b760f2f4c23e4777ab02eafb1204d13b,RCC,0.906223
uuid-99d15c09d8c64d9381e33b590214c8db,nivolumab,0.347078
uuid-99d15c09d8c64d9381e33b590214c8db,patients with advanced or metastatic,0.323546
uuid-99d15c09d8c64d9381e33b590214c8db,nivolumab combined with ipilimumab,0.321106
uuid-99d15c09d8c64d9381e33b590214c8db,ESMO,0.690869
uuid-99d15c09d8c64d9381e33b590214c8db,Horn L,0.364617
uuid-99d15c09d8c64d9381e33b590214c8db,grade 3 to 4 AEs,0.308322
uuid-99d15c09d8c64d9381e33b590214c8db,bladder cancer,0.496096
uuid-6ff135e72ed94535852b1aaf159bb61a,provided in the Detailed Information,0.611407
uuid-6ff135e72ed94535852b1aaf159bb61a,clinical,0.62317
uuid-75fb513daceb45eeb814405659f301ba,search of published literature,0.394524
uuid-75fb513daceb45eeb814405659f301ba,Additionally,0.413583
uuid-75fb513daceb45eeb814405659f301ba,ongoing,0.322117
uuid-75fb513daceb45eeb814405659f301ba,PubMed and EMBASE,0.391671
uuid-75fb513daceb45eeb814405659f301ba,detailed search of www.clinicaltrials.gov,0.375936
uuid-75fb513daceb45eeb814405659f301ba,efficacy and safety of nivolumab,0.370699
uuid-75fb513daceb45eeb814405659f301ba,not identify any planned,0.34283
uuid-75fb513daceb45eeb814405659f301ba,Weber JS,0.319229
uuid-75fb513daceb45eeb814405659f301ba,not identify any citations relevant to your request,0.447813
uuid-75fb513daceb45eeb814405659f301ba,present using the following search terms,0.408199
uuid-9c57ce9dfb0746569aa27daff12432ea,95% CI,0.539167
uuid-9c57ce9dfb0746569aa27daff12432ea,Median overall survival,0.479815
uuid-9c57ce9dfb0746569aa27daff12432ea,protocol,0.426554
uuid-9c57ce9dfb0746569aa27daff12432ea,McDermott DF,0.500131
uuid-9c57ce9dfb0746569aa27daff12432ea,Motzer RJ,0.477178
uuid-9c57ce9dfb0746569aa27daff12432ea,Median OS,0.603398
uuid-9c57ce9dfb0746569aa27daff12432ea,Escudier B,0.469696
uuid-9c57ce9dfb0746569aa27daff12432ea,NEJM,0.387615
uuid-9c57ce9dfb0746569aa27daff12432ea,et al.,0.46851
uuid-9c57ce9dfb0746569aa27daff12432ea,J Clin Oncol,0.51661
uuid-9c57ce9dfb0746569aa27daff12432ea,Topalian,0.337057
uuid-9c57ce9dfb0746569aa27daff12432ea,phase 2 study,0.399402
uuid-9c57ce9dfb0746569aa27daff12432ea,hazard ratio,0.538097
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,OS,0.387982
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,95% CI,0.745043
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,respectively,0.729294
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,Objective response rate,0.590876
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,ORR,0.722442
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,Median overall survival,0.659043
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,monotherapy,0.514468
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,Median OS,0.696688
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,PD-L1,0.300997
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,docetaxel,0.635065
uuid-7ac23ca75b5c4b72b8ba0f90667345fe,hazard ratio,0.729977
uuid-8bb522403a3640729b8733ca3c3fbe4a,nivolumab,0.308696
uuid-8bb522403a3640729b8733ca3c3fbe4a,respectively,0.474596
uuid-8bb522403a3640729b8733ca3c3fbe4a,Objective response rate,0.398542
uuid-8bb522403a3640729b8733ca3c3fbe4a,ORR,0.387529
uuid-8bb522403a3640729b8733ca3c3fbe4a,monotherapy,0.618934
uuid-8bb522403a3640729b8733ca3c3fbe4a,clinical,0.310702
uuid-8bb522403a3640729b8733ca3c3fbe4a,Antonia SJ,0.303123
uuid-1d355222e3a348a0b21d275f0faec6e4,nivolumab,0.451257
uuid-1d355222e3a348a0b21d275f0faec6e4,Opdivo,0.334258
uuid-3fc1dc2c9e7d4daab9966e06a3343422,OS,0.62262
uuid-3fc1dc2c9e7d4daab9966e06a3343422,PFS,0.65903
uuid-3fc1dc2c9e7d4daab9966e06a3343422,Overall survival,0.644151
uuid-7751efd2470f4307b29dae005651d482,nivolumab,0.344939
uuid-7751efd2470f4307b29dae005651d482,Bristol-Myers Squibb,0.363004
uuid-7751efd2470f4307b29dae005651d482,evaluating,0.564404
uuid-7751efd2470f4307b29dae005651d482,not conducted any controlled clinical trials/studies,0.538169
uuid-7751efd2470f4307b29dae005651d482,RCC,0.336118
uuid-7751efd2470f4307b29dae005651d482,search of published literature,0.750115
uuid-7751efd2470f4307b29dae005651d482,Additionally,0.766378
uuid-7751efd2470f4307b29dae005651d482,ongoing,0.629393
uuid-7751efd2470f4307b29dae005651d482,PubMed and EMBASE,0.745288
uuid-7751efd2470f4307b29dae005651d482,detailed search of www.clinicaltrials.gov,0.729251
uuid-7751efd2470f4307b29dae005651d482,efficacy and safety of nivolumab,0.716075
uuid-7751efd2470f4307b29dae005651d482,not identify any planned,0.665705
uuid-7751efd2470f4307b29dae005651d482,not identify any citations relevant to your request,0.849476
uuid-7751efd2470f4307b29dae005651d482,present using the following search terms,0.773092
uuid-e0c873bdff274e33af4ec3c46a25ec4b,RCC,0.906223
uuid-68dfb58bb2b44c358442b0e9b9b6b235,95% CI,0.381452
uuid-68dfb58bb2b44c358442b0e9b9b6b235,respectively,0.644005
uuid-68dfb58bb2b44c358442b0e9b9b6b235,Objective response rate,0.591878
uuid-68dfb58bb2b44c358442b0e9b9b6b235,ORR,0.649362
uuid-68dfb58bb2b44c358442b0e9b9b6b235,Median overall survival,0.363267
uuid-68dfb58bb2b44c358442b0e9b9b6b235,monotherapy,0.555484
uuid-68dfb58bb2b44c358442b0e9b9b6b235,Median OS,0.356439
uuid-68dfb58bb2b44c358442b0e9b9b6b235,docetaxel,0.506362
uuid-68dfb58bb2b44c358442b0e9b9b6b235,Antonia SJ,0.301598
uuid-68dfb58bb2b44c358442b0e9b9b6b235,hazard ratio,0.348477
uuid-a8bdaceb827247fc8475878a74a59eb9,nivolumab,0.389306
uuid-a8bdaceb827247fc8475878a74a59eb9,evaluating,0.442412
uuid-a8bdaceb827247fc8475878a74a59eb9,not conducted any controlled clinical trials/studies,0.424904
uuid-a8bdaceb827247fc8475878a74a59eb9,efficacy,0.304684
uuid-a8bdaceb827247fc8475878a74a59eb9,Pubmed literature search,0.496082
uuid-a8bdaceb827247fc8475878a74a59eb9,purposes other than its labeled indication must be considered investigational,0.559795
uuid-a8bdaceb827247fc8475878a74a59eb9,not identify any citations relevant to your inquiry,0.473038
uuid-a8bdaceb827247fc8475878a74a59eb9,not approved,0.396479
uuid-a8bdaceb827247fc8475878a74a59eb9,using the following search terms,0.446064
uuid-a8bdaceb827247fc8475878a74a59eb9,clinical trials investigating the safety,0.429026
uuid-85357450355f4d01b03404a4ca719f06,RCC,0.906223
uuid-dfe117024bb0471d8117fb00a5145c6a,patients,0.315933
uuid-061bcc47ba904044990a386e4fac75a3,N Engl J Med,0.458509
uuid-061bcc47ba904044990a386e4fac75a3,Lancet Oncol,0.359849
uuid-061bcc47ba904044990a386e4fac75a3,protocol,0.48359
uuid-061bcc47ba904044990a386e4fac75a3,McDermott DF,0.519341
uuid-061bcc47ba904044990a386e4fac75a3,search of published literature,0.335512
uuid-061bcc47ba904044990a386e4fac75a3,Motzer RJ,0.518924
uuid-061bcc47ba904044990a386e4fac75a3,phase 3 study,0.756211
uuid-061bcc47ba904044990a386e4fac75a3,PubMed and EMBASE,0.333205
uuid-061bcc47ba904044990a386e4fac75a3,Escudier B,0.534389
uuid-061bcc47ba904044990a386e4fac75a3,et al.,0.498584
uuid-061bcc47ba904044990a386e4fac75a3,J Clin Oncol,0.43299
uuid-061bcc47ba904044990a386e4fac75a3,Rizvi NA,0.475626
uuid-061bcc47ba904044990a386e4fac75a3,Weber JS,0.583843
uuid-061bcc47ba904044990a386e4fac75a3,phase 2 study,0.615713
uuid-e433046089d74f00a30147c90368f41b,requested,0.531305
uuid-e433046089d74f00a30147c90368f41b,ESMO,0.358531
uuid-e433046089d74f00a30147c90368f41b,Horn L,0.66756
uuid-e433046089d74f00a30147c90368f41b,platinum-based doublet chemotherapy,0.579011
uuid-3992271bc31c480ba649238ad920f6d2,requested,0.475395
uuid-3992271bc31c480ba649238ad920f6d2,safety,0.390525
uuid-3992271bc31c480ba649238ad920f6d2,databases,0.456771
uuid-c1191d1f55be4d5abbe69ffe11b0279c,mg,0.843501
uuid-c1191d1f55be4d5abbe69ffe11b0279c,kg,0.772001
uuid-6ac28030ed8243359f50e6314c24f0de,patients,0.323701
uuid-5bdf927b8c044b58a4ce5fb224452244,requested,0.536061
uuid-5bdf927b8c044b58a4ce5fb224452244,ESMO,0.355357
uuid-5bdf927b8c044b58a4ce5fb224452244,Horn L,0.663952
uuid-5bdf927b8c044b58a4ce5fb224452244,platinum-based doublet chemotherapy,0.574466
uuid-79f186da3de948ce826ad1be2514e78a,N Engl J Med,0.367869
uuid-79f186da3de948ce826ad1be2514e78a,protocol,0.658742
uuid-79f186da3de948ce826ad1be2514e78a,RCC,0.375387
uuid-79f186da3de948ce826ad1be2514e78a,McDermott DF,0.560924
uuid-79f186da3de948ce826ad1be2514e78a,search of published literature,0.428619
uuid-79f186da3de948ce826ad1be2514e78a,Additionally,0.405724
uuid-79f186da3de948ce826ad1be2514e78a,ongoing,0.365225
uuid-79f186da3de948ce826ad1be2514e78a,Motzer RJ,0.596203
uuid-79f186da3de948ce826ad1be2514e78a,PubMed and EMBASE,0.423862
uuid-79f186da3de948ce826ad1be2514e78a,Escudier B,0.579918
uuid-79f186da3de948ce826ad1be2514e78a,et al.,0.511511
uuid-79f186da3de948ce826ad1be2514e78a,J Clin Oncol,0.536232
uuid-79f186da3de948ce826ad1be2514e78a,detailed search of www.clinicaltrials.gov,0.379318
uuid-79f186da3de948ce826ad1be2514e78a,efficacy and safety of nivolumab,0.423052
uuid-79f186da3de948ce826ad1be2514e78a,not identify any planned,0.3696
uuid-79f186da3de948ce826ad1be2514e78a,phase 2 study,0.471813
uuid-79f186da3de948ce826ad1be2514e78a,not identify any citations relevant to your request,0.423463
uuid-79f186da3de948ce826ad1be2514e78a,present using the following search terms,0.406049
uuid-1f19e21d23a249449fd25ddd3290e73b,requested,0.521845
uuid-1f19e21d23a249449fd25ddd3290e73b,RCC,0.495802
uuid-1f19e21d23a249449fd25ddd3290e73b,search of published literature,0.430549
uuid-1f19e21d23a249449fd25ddd3290e73b,Additionally,0.395714
uuid-1f19e21d23a249449fd25ddd3290e73b,PubMed and EMBASE,0.441044
uuid-1f19e21d23a249449fd25ddd3290e73b,detailed search of www.clinicaltrials.gov,0.336439
uuid-1f19e21d23a249449fd25ddd3290e73b,not identify any citations relevant to your request,0.43569
uuid-1f19e21d23a249449fd25ddd3290e73b,present using the following search terms,0.423265
uuid-211836ccf96044e98cd642fda60ce1f5,RCC,0.906223
uuid-7636e5e9caf4499789e3f5ea43c7fdba,ipilimumab,0.385692
uuid-7636e5e9caf4499789e3f5ea43c7fdba,ASCO 2015,0.417944
uuid-7636e5e9caf4499789e3f5ea43c7fdba,partial response,0.382425
uuid-7636e5e9caf4499789e3f5ea43c7fdba,Stable disease,0.586335
uuid-7636e5e9caf4499789e3f5ea43c7fdba,cohort,0.307748
uuid-a6ab64ddffd7423180ad32822a67cc8a,RCC,0.906223
uuid-d72b4a397981470ba746af4727c4b1e9,N Engl J Med,0.427636
uuid-d72b4a397981470ba746af4727c4b1e9,protocol,0.429136
uuid-d72b4a397981470ba746af4727c4b1e9,McDermott DF,0.44782
uuid-d72b4a397981470ba746af4727c4b1e9,Motzer RJ,0.430476
uuid-d72b4a397981470ba746af4727c4b1e9,Escudier B,0.450887
uuid-d72b4a397981470ba746af4727c4b1e9,et al.,0.456026
uuid-d72b4a397981470ba746af4727c4b1e9,J Clin Oncol,0.384624
uuid-d72b4a397981470ba746af4727c4b1e9,Rizvi NA,0.305616
uuid-d72b4a397981470ba746af4727c4b1e9,phase 2 study,0.351446
uuid-3361e57027fd4a17b611f8cac7c69b29,requested,0.448066
uuid-3361e57027fd4a17b611f8cac7c69b29,ESMO,0.393518
uuid-3361e57027fd4a17b611f8cac7c69b29,Horn L,0.514969
uuid-3361e57027fd4a17b611f8cac7c69b29,platinum-based doublet chemotherapy,0.368022
uuid-1ebabd363525433d861f4fc6d430aa2f,requested,0.531305
uuid-1ebabd363525433d861f4fc6d430aa2f,ESMO,0.358531
uuid-1ebabd363525433d861f4fc6d430aa2f,Horn L,0.66756
uuid-1ebabd363525433d861f4fc6d430aa2f,platinum-based doublet chemotherapy,0.579011
uuid-59569ea784344946bb0c379491b79329,provided in the Detailed Information,0.571507
uuid-59569ea784344946bb0c379491b79329,clinical,0.462007
uuid-59ac72d5cc234fd2923e76d6303b3723,patients with advanced or metastatic,0.468858
uuid-59ac72d5cc234fd2923e76d6303b3723,nivolumab combined with ipilimumab,0.446918
uuid-59ac72d5cc234fd2923e76d6303b3723,not approved,0.352562
uuid-59ac72d5cc234fd2923e76d6303b3723,clinical trials investigating the safety,0.429501
uuid-59ac72d5cc234fd2923e76d6303b3723,bladder cancer,0.950698
uuid-a115b0011bba4dae951ccdbffc7fccaf,RCC,0.906223
uuid-c30e92fd9e7f41909d035a5f849ca8a9,requested,0.531305
uuid-c30e92fd9e7f41909d035a5f849ca8a9,ESMO,0.358531
uuid-c30e92fd9e7f41909d035a5f849ca8a9,Horn L,0.66756
uuid-c30e92fd9e7f41909d035a5f849ca8a9,platinum-based doublet chemotherapy,0.579011
uuid-5ab1ea063b9f409dabb6eec5f6c38024,N Engl J Med,0.442834
uuid-5ab1ea063b9f409dabb6eec5f6c38024,protocol,0.763252
uuid-5ab1ea063b9f409dabb6eec5f6c38024,McDermott DF,0.733103
uuid-5ab1ea063b9f409dabb6eec5f6c38024,Motzer RJ,0.811057
uuid-5ab1ea063b9f409dabb6eec5f6c38024,phase 3 study,0.420895
uuid-5ab1ea063b9f409dabb6eec5f6c38024,Escudier B,0.741048
uuid-5ab1ea063b9f409dabb6eec5f6c38024,NEJM,0.402544
uuid-5ab1ea063b9f409dabb6eec5f6c38024,et al.,0.660398
uuid-5ab1ea063b9f409dabb6eec5f6c38024,J Clin Oncol,0.786367
uuid-5ab1ea063b9f409dabb6eec5f6c38024,Topalian,0.392395
uuid-5ab1ea063b9f409dabb6eec5f6c38024,phase 1 study,0.513779
uuid-5ab1ea063b9f409dabb6eec5f6c38024,CA209-003,0.583337
uuid-5ab1ea063b9f409dabb6eec5f6c38024,phase 2 study,0.675447
uuid-5ab1ea063b9f409dabb6eec5f6c38024,present using the following search terms,0.304589
uuid-5ab1ea063b9f409dabb6eec5f6c38024,investigating,0.633101
uuid-59615dd2102c422bb5118de80e56d5ce,nivolumab,0.567445
uuid-59615dd2102c422bb5118de80e56d5ce,Bristol-Myers Squibb,0.439784
uuid-59615dd2102c422bb5118de80e56d5ce,evaluating,0.594796
uuid-59615dd2102c422bb5118de80e56d5ce,not conducted any controlled clinical trials/studies,0.656647
uuid-59615dd2102c422bb5118de80e56d5ce,Pubmed literature search,0.878652
uuid-59615dd2102c422bb5118de80e56d5ce,purposes other than its labeled indication must be considered investigational,0.941484
uuid-59615dd2102c422bb5118de80e56d5ce,not identify any citations relevant to your inquiry,0.837621
uuid-59615dd2102c422bb5118de80e56d5ce,using the following search terms,0.825277
uuid-59615dd2102c422bb5118de80e56d5ce,efficacy and safety of nivolumab,0.433238
uuid-a519f61c863b48ed9c69f4017adb70da,ESMO,0.603759
uuid-a519f61c863b48ed9c69f4017adb70da,Horn L,0.484674
uuid-2123758f732044f5ac51b286b802675b,provided in the Detailed Information,0.609529
uuid-2123758f732044f5ac51b286b802675b,clinical,0.623246
uuid-3083370a52274634a29de917e63ad122,OS,0.304645
uuid-3083370a52274634a29de917e63ad122,95% CI,0.408622
uuid-3083370a52274634a29de917e63ad122,NSCLC,0.33588
uuid-3083370a52274634a29de917e63ad122,respectively,0.499027
uuid-3083370a52274634a29de917e63ad122,Objective response rate,0.688609
uuid-3083370a52274634a29de917e63ad122,ORR,0.678791
uuid-3083370a52274634a29de917e63ad122,Median overall survival,0.445394
uuid-3083370a52274634a29de917e63ad122,monotherapy,0.519987
uuid-3083370a52274634a29de917e63ad122,Median OS,0.375881
uuid-3083370a52274634a29de917e63ad122,docetaxel,0.378462
uuid-3083370a52274634a29de917e63ad122,Antonia SJ,0.333337
uuid-3083370a52274634a29de917e63ad122,hazard ratio,0.41425
uuid-e42e9e2a6ced4cfcbd68331d5508b139,patients,0.315933
uuid-b95be610796349d4988b9add8c6430b7,RCC,0.909054
uuid-9182b95b884549e49d59887e2d59f084,respectively,0.604911
uuid-9182b95b884549e49d59887e2d59f084,ASCO,0.370609
uuid-9182b95b884549e49d59887e2d59f084,Objective response rate,0.472418
uuid-9182b95b884549e49d59887e2d59f084,ORR,0.487844
uuid-9182b95b884549e49d59887e2d59f084,monotherapy,0.476726
uuid-9182b95b884549e49d59887e2d59f084,docetaxel,0.478668
uuid-9182b95b884549e49d59887e2d59f084,Antonia SJ,0.346494
uuid-600dda96e2eb43fe93f83f87b85b5fbb,requested,0.604501
uuid-ea4796a911b44d428807753e2751207c,ipilimumab,0.385692
uuid-ea4796a911b44d428807753e2751207c,ASCO 2015,0.417944
uuid-ea4796a911b44d428807753e2751207c,partial response,0.382425
uuid-ea4796a911b44d428807753e2751207c,Stable disease,0.586335
uuid-ea4796a911b44d428807753e2751207c,cohort,0.307748
uuid-ec3ab035426b4044913cd3d0d2aa20dd,fatigue,0.564058
uuid-69183c041fc344309c29f519cf8d397e,requested,0.44769
uuid-69183c041fc344309c29f519cf8d397e,trial,0.309472
uuid-91d29767b5ae4ef1829853d1e12a43c1,95% CI,0.524613
uuid-91d29767b5ae4ef1829853d1e12a43c1,respectively,0.38188
uuid-91d29767b5ae4ef1829853d1e12a43c1,ASCO,0.302042
uuid-91d29767b5ae4ef1829853d1e12a43c1,Lancet Oncol,0.366381
uuid-91d29767b5ae4ef1829853d1e12a43c1,Objective response rate,0.504016
uuid-91d29767b5ae4ef1829853d1e12a43c1,ORR,0.463956
uuid-91d29767b5ae4ef1829853d1e12a43c1,Median overall survival,0.345066
uuid-91d29767b5ae4ef1829853d1e12a43c1,Median OS,0.334782
uuid-91d29767b5ae4ef1829853d1e12a43c1,ASCO 2015,0.335889
uuid-91d29767b5ae4ef1829853d1e12a43c1,small cell lung cancer,0.33675
uuid-91d29767b5ae4ef1829853d1e12a43c1,SCLC,0.344102
uuid-91d29767b5ae4ef1829853d1e12a43c1,Antonia SJ,0.550971
uuid-91d29767b5ae4ef1829853d1e12a43c1,Median duration of response,0.649882
uuid-66e18a92330d41b096764ca8da440110,requested,0.531305
uuid-66e18a92330d41b096764ca8da440110,ESMO,0.358531
uuid-66e18a92330d41b096764ca8da440110,Horn L,0.66756
uuid-66e18a92330d41b096764ca8da440110,platinum-based doublet chemotherapy,0.579011
uuid-aa7a428fbdb340bc807f0446c600bfae,nivolumab,0.324658
uuid-aa7a428fbdb340bc807f0446c600bfae,use of nivolumab for the treatment,0.543355
uuid-aa7a428fbdb340bc807f0446c600bfae,evaluating,0.348676
uuid-aa7a428fbdb340bc807f0446c600bfae,efficacy,0.388907
uuid-aa7a428fbdb340bc807f0446c600bfae,patients,0.419915
uuid-aa7a428fbdb340bc807f0446c600bfae,search of published literature,0.449959
uuid-aa7a428fbdb340bc807f0446c600bfae,PubMed and EMBASE,0.444573
uuid-aa7a428fbdb340bc807f0446c600bfae,not approved,0.582429
uuid-aa7a428fbdb340bc807f0446c600bfae,clinical trials investigating the safety,0.64854
uuid-aa7a428fbdb340bc807f0446c600bfae,efficacy and safety of nivolumab,0.399101
uuid-aa7a428fbdb340bc807f0446c600bfae,present using the following search terms,0.465296
uuid-76c531b358884f4c969f304deb1d23e8,N Engl J Med,0.367869
uuid-76c531b358884f4c969f304deb1d23e8,protocol,0.658742
uuid-76c531b358884f4c969f304deb1d23e8,RCC,0.375387
uuid-76c531b358884f4c969f304deb1d23e8,McDermott DF,0.560924
uuid-76c531b358884f4c969f304deb1d23e8,search of published literature,0.428619
uuid-76c531b358884f4c969f304deb1d23e8,Additionally,0.405724
uuid-76c531b358884f4c969f304deb1d23e8,ongoing,0.365225
uuid-76c531b358884f4c969f304deb1d23e8,Motzer RJ,0.596203
uuid-76c531b358884f4c969f304deb1d23e8,PubMed and EMBASE,0.423862
uuid-76c531b358884f4c969f304deb1d23e8,Escudier B,0.579918
uuid-76c531b358884f4c969f304deb1d23e8,et al.,0.511511
uuid-76c531b358884f4c969f304deb1d23e8,J Clin Oncol,0.536232
uuid-76c531b358884f4c969f304deb1d23e8,detailed search of www.clinicaltrials.gov,0.379318
uuid-76c531b358884f4c969f304deb1d23e8,efficacy and safety of nivolumab,0.423052
uuid-76c531b358884f4c969f304deb1d23e8,not identify any planned,0.3696
uuid-76c531b358884f4c969f304deb1d23e8,phase 2 study,0.471813
uuid-76c531b358884f4c969f304deb1d23e8,not identify any citations relevant to your request,0.423463
uuid-76c531b358884f4c969f304deb1d23e8,present using the following search terms,0.406049
uuid-a524a0a5eeb04d22998777e4660dc33e,95% CI,0.524855
uuid-a524a0a5eeb04d22998777e4660dc33e,respectively,0.383655
uuid-a524a0a5eeb04d22998777e4660dc33e,ASCO,0.303153
uuid-a524a0a5eeb04d22998777e4660dc33e,Lancet Oncol,0.368041
uuid-a524a0a5eeb04d22998777e4660dc33e,Objective response rate,0.504846
uuid-a524a0a5eeb04d22998777e4660dc33e,ORR,0.465366
uuid-a524a0a5eeb04d22998777e4660dc33e,Median overall survival,0.346516
uuid-a524a0a5eeb04d22998777e4660dc33e,Median OS,0.33538
uuid-a524a0a5eeb04d22998777e4660dc33e,ASCO 2015,0.336983
uuid-a524a0a5eeb04d22998777e4660dc33e,small cell lung cancer,0.336892
uuid-a524a0a5eeb04d22998777e4660dc33e,SCLC,0.344367
uuid-a524a0a5eeb04d22998777e4660dc33e,Antonia SJ,0.55269
uuid-a524a0a5eeb04d22998777e4660dc33e,Median duration of response,0.649605
uuid-0e0f3469c7d5467188673ccd52ab867e,respectively,0.585622
uuid-0e0f3469c7d5467188673ccd52ab867e,Objective response rate,0.36976
uuid-0e0f3469c7d5467188673ccd52ab867e,ORR,0.514781
uuid-0e0f3469c7d5467188673ccd52ab867e,docetaxel,0.31274
uuid-f94d92ffb6c94154ac4aa02380433284,Opdivo,0.468885
uuid-f94d92ffb6c94154ac4aa02380433284,BMS,0.306876
uuid-f94d92ffb6c94154ac4aa02380433284,reported,0.404643
uuid-1b2d304abc0f482a960f1a63c696098e,NSCLC,0.358424
uuid-1b2d304abc0f482a960f1a63c696098e,non-small cell lung cancer,0.300319
uuid-1b2d304abc0f482a960f1a63c696098e,efficacy and safety of nivolumab,0.351238
uuid-9117ffbd411440d988c25afae17e65f6,RCC,0.906223
uuid-00947304ae114500a64fd293a9e11f63,patients,0.343043
uuid-00947304ae114500a64fd293a9e11f63,trial,0.338351
uuid-00947304ae114500a64fd293a9e11f63,therapy,0.448275
uuid-7a33caddc0c743eda96311880bad6d25,nivolumab,0.359772
uuid-ee0dc5c468dc46d59e05c7625d657f58,N Engl J Med,0.30412
uuid-ee0dc5c468dc46d59e05c7625d657f58,provided in the Detailed Information,0.429872
uuid-ee0dc5c468dc46d59e05c7625d657f58,protocol,0.446835
uuid-ee0dc5c468dc46d59e05c7625d657f58,McDermott DF,0.475109
uuid-ee0dc5c468dc46d59e05c7625d657f58,Motzer RJ,0.46429
uuid-ee0dc5c468dc46d59e05c7625d657f58,clinical,0.564268
uuid-ee0dc5c468dc46d59e05c7625d657f58,phase 3 study,0.49164
uuid-ee0dc5c468dc46d59e05c7625d657f58,Escudier B,0.468599
uuid-ee0dc5c468dc46d59e05c7625d657f58,et al.,0.443363
uuid-ee0dc5c468dc46d59e05c7625d657f58,J Clin Oncol,0.435038
uuid-ee0dc5c468dc46d59e05c7625d657f58,Rizvi NA,0.316659
uuid-ee0dc5c468dc46d59e05c7625d657f58,trial,0.364804
uuid-ee0dc5c468dc46d59e05c7625d657f58,phase 2 study,0.511622
uuid-b768388236bc461f8548e89a56d3e222,considered investigational,0.430939
uuid-b768388236bc461f8548e89a56d3e222,small cell lung cancer,0.642139
uuid-b768388236bc461f8548e89a56d3e222,partial response,0.482429
uuid-b768388236bc461f8548e89a56d3e222,SCLC,0.725444
uuid-b768388236bc461f8548e89a56d3e222,therapy,0.850784
uuid-b768388236bc461f8548e89a56d3e222,relapsed,0.588135
uuid-b768388236bc461f8548e89a56d3e222,phase 1/2 study CA209-032,0.396811
uuid-b768388236bc461f8548e89a56d3e222,evaluates the efficacy of nivolumab monotherapy,0.320151
uuid-4fc562ebf1b34114860c9e270a8e3507,RCC,0.909054
uuid-c70cba1bb7b84acaaab5af6584379cfa,patients,0.451578
uuid-c70cba1bb7b84acaaab5af6584379cfa,clinical,0.42034
uuid-c70cba1bb7b84acaaab5af6584379cfa,trial,0.5259
uuid-c70cba1bb7b84acaaab5af6584379cfa,fatigue,0.356152
uuid-2bc8f46648444310953cf1b2b70b924b,95% CI,0.524855
uuid-2bc8f46648444310953cf1b2b70b924b,respectively,0.383655
uuid-2bc8f46648444310953cf1b2b70b924b,ASCO,0.303153
uuid-2bc8f46648444310953cf1b2b70b924b,Lancet Oncol,0.368041
uuid-2bc8f46648444310953cf1b2b70b924b,Objective response rate,0.504846
uuid-2bc8f46648444310953cf1b2b70b924b,ORR,0.465366
uuid-2bc8f46648444310953cf1b2b70b924b,Median overall survival,0.346516
uuid-2bc8f46648444310953cf1b2b70b924b,Median OS,0.33538
uuid-2bc8f46648444310953cf1b2b70b924b,ASCO 2015,0.336983
uuid-2bc8f46648444310953cf1b2b70b924b,small cell lung cancer,0.336892
uuid-2bc8f46648444310953cf1b2b70b924b,SCLC,0.344367
uuid-2bc8f46648444310953cf1b2b70b924b,Antonia SJ,0.55269
uuid-2bc8f46648444310953cf1b2b70b924b,Median duration of response,0.649605
uuid-85e3b8342b8a4c229037b76ed9c3c919,95% CI,0.524855
uuid-85e3b8342b8a4c229037b76ed9c3c919,respectively,0.383655
uuid-85e3b8342b8a4c229037b76ed9c3c919,ASCO,0.303153
uuid-85e3b8342b8a4c229037b76ed9c3c919,Lancet Oncol,0.368041
uuid-85e3b8342b8a4c229037b76ed9c3c919,Objective response rate,0.504846
uuid-85e3b8342b8a4c229037b76ed9c3c919,ORR,0.465366
uuid-85e3b8342b8a4c229037b76ed9c3c919,Median overall survival,0.346516
uuid-85e3b8342b8a4c229037b76ed9c3c919,Median OS,0.33538
uuid-85e3b8342b8a4c229037b76ed9c3c919,ASCO 2015,0.336983
uuid-85e3b8342b8a4c229037b76ed9c3c919,small cell lung cancer,0.336892
uuid-85e3b8342b8a4c229037b76ed9c3c919,SCLC,0.344367
uuid-85e3b8342b8a4c229037b76ed9c3c919,Antonia SJ,0.55269
uuid-85e3b8342b8a4c229037b76ed9c3c919,Median duration of response,0.649605
uuid-83c6a52d49f14173be1ddee6ac8e9157,Bristol-Myers Squibb,0.786662
uuid-83c6a52d49f14173be1ddee6ac8e9157,evaluating,0.622357
uuid-83c6a52d49f14173be1ddee6ac8e9157,not conducted any controlled clinical trials/studies,0.69853
uuid-83c6a52d49f14173be1ddee6ac8e9157,efficacy and safety of nivolumab,0.531119
uuid-0ce28ef56e1747d89489cecf7aeef848,RCC,0.906223
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,95% CI,0.524855
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,respectively,0.383655
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,ASCO,0.303153
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Lancet Oncol,0.368041
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Objective response rate,0.504846
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,ORR,0.465366
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Median overall survival,0.346516
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Median OS,0.33538
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,ASCO 2015,0.336983
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,small cell lung cancer,0.336892
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,SCLC,0.344367
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Antonia SJ,0.55269
uuid-376a4ee47f7d43fc854b12f9d3c24eb2,Median duration of response,0.649605
uuid-095b11b148a8490d9eaf336218bfb538,RCC,0.909054
uuid-417bef57d1314e6ea081aaad95420b13,requested,0.594234
uuid-a72ce1d8da4d4f308421da600817f43a,search of published literature,0.394524
uuid-a72ce1d8da4d4f308421da600817f43a,Additionally,0.413583
uuid-a72ce1d8da4d4f308421da600817f43a,ongoing,0.322117
uuid-a72ce1d8da4d4f308421da600817f43a,PubMed and EMBASE,0.391671
uuid-a72ce1d8da4d4f308421da600817f43a,detailed search of www.clinicaltrials.gov,0.375936
uuid-a72ce1d8da4d4f308421da600817f43a,efficacy and safety of nivolumab,0.370699
uuid-a72ce1d8da4d4f308421da600817f43a,not identify any planned,0.34283
uuid-a72ce1d8da4d4f308421da600817f43a,Weber JS,0.319229
uuid-a72ce1d8da4d4f308421da600817f43a,not identify any citations relevant to your request,0.447813
uuid-a72ce1d8da4d4f308421da600817f43a,present using the following search terms,0.408199
uuid-460f5d022ed345f3b1506f62f8329545,95% CI,0.419001
uuid-460f5d022ed345f3b1506f62f8329545,Median overall survival,0.339993
uuid-460f5d022ed345f3b1506f62f8329545,Additionally,0.540831
uuid-460f5d022ed345f3b1506f62f8329545,ongoing,0.612172
uuid-460f5d022ed345f3b1506f62f8329545,Median OS,0.383613
uuid-460f5d022ed345f3b1506f62f8329545,detailed search of www.clinicaltrials.gov,0.57672
uuid-460f5d022ed345f3b1506f62f8329545,trial,0.396902
uuid-460f5d022ed345f3b1506f62f8329545,not identify any planned,0.593696
uuid-460f5d022ed345f3b1506f62f8329545,not identify any citations relevant to your request,0.473931
uuid-460f5d022ed345f3b1506f62f8329545,hazard ratio,0.380608
uuid-460f5d022ed345f3b1506f62f8329545,Median duration of response,0.376068
uuid-859723612d4043e48d2f13147b8c59c8,nivolumab,0.493389
uuid-859723612d4043e48d2f13147b8c59c8,Bristol-Myers Squibb,0.598477
uuid-859723612d4043e48d2f13147b8c59c8,evaluating,0.837805
uuid-859723612d4043e48d2f13147b8c59c8,not conducted any controlled clinical trials/studies,0.848713
uuid-859723612d4043e48d2f13147b8c59c8,Pubmed literature search,0.314091
uuid-859723612d4043e48d2f13147b8c59c8,purposes other than its labeled indication must be considered investigational,0.4415
uuid-859723612d4043e48d2f13147b8c59c8,search of published literature,0.772891
uuid-859723612d4043e48d2f13147b8c59c8,PubMed and EMBASE,0.743175
uuid-859723612d4043e48d2f13147b8c59c8,efficacy and safety of nivolumab,0.905749
uuid-859723612d4043e48d2f13147b8c59c8,not identify any citations relevant to your request,0.417576
uuid-859723612d4043e48d2f13147b8c59c8,present using the following search terms,0.748132
uuid-11619ad93ed64295be5d23394f182ccd,N Engl J Med,0.458509
uuid-11619ad93ed64295be5d23394f182ccd,Lancet Oncol,0.359849
uuid-11619ad93ed64295be5d23394f182ccd,protocol,0.48359
uuid-11619ad93ed64295be5d23394f182ccd,McDermott DF,0.519341
uuid-11619ad93ed64295be5d23394f182ccd,search of published literature,0.335512
uuid-11619ad93ed64295be5d23394f182ccd,Motzer RJ,0.518924
uuid-11619ad93ed64295be5d23394f182ccd,phase 3 study,0.756211
uuid-11619ad93ed64295be5d23394f182ccd,PubMed and EMBASE,0.333205
uuid-11619ad93ed64295be5d23394f182ccd,Escudier B,0.534389
uuid-11619ad93ed64295be5d23394f182ccd,et al.,0.498584
uuid-11619ad93ed64295be5d23394f182ccd,J Clin Oncol,0.43299
uuid-11619ad93ed64295be5d23394f182ccd,Rizvi NA,0.475626
uuid-11619ad93ed64295be5d23394f182ccd,Weber JS,0.583843
uuid-11619ad93ed64295be5d23394f182ccd,phase 2 study,0.615713
uuid-08f2128e89744f80aa23e099477c27a5,trial,0.424394
uuid-bb2aae5797ed4dd4aae1fb961a7da8dc,RCC,0.909054
uuid-fd0ac2e6b1d94b93aaa13491cafe8218,RCC,0.906223
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,95% CI,0.368332
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,NSCLC,0.498467
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,non-small cell lung cancer,0.430459
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,Objective response rate,0.480097
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,ORR,0.476446
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,Median overall survival,0.366656
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,monotherapy,0.355726
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,Median OS,0.348153
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,phase 1 study,0.35881
uuid-d224e2d8c0b847f0bc48a4d592fde4ae,hazard ratio,0.370178
uuid-ac81275b3265472890b53f939d64abe5,RCC,0.906223
uuid-8d45b76240764090b9339229834b2560,mg,0.731769
uuid-8d45b76240764090b9339229834b2560,kg,0.655806
uuid-b827399dd8134fa2aafd934e88682014,ESMO,0.603759
uuid-b827399dd8134fa2aafd934e88682014,Horn L,0.484674
uuid-3cb7448e72ac4720adf267581d5f0dcc,evaluating,0.328214
uuid-3cb7448e72ac4720adf267581d5f0dcc,not conducted any controlled clinical trials/studies,0.327483
uuid-3cb7448e72ac4720adf267581d5f0dcc,search of published literature,0.432005
uuid-3cb7448e72ac4720adf267581d5f0dcc,Additionally,0.407184
uuid-3cb7448e72ac4720adf267581d5f0dcc,ongoing,0.409526
uuid-3cb7448e72ac4720adf267581d5f0dcc,PubMed and EMBASE,0.425426
uuid-3cb7448e72ac4720adf267581d5f0dcc,detailed search of www.clinicaltrials.gov,0.399933
uuid-3cb7448e72ac4720adf267581d5f0dcc,efficacy and safety of nivolumab,0.429725
uuid-3cb7448e72ac4720adf267581d5f0dcc,not identify any planned,0.405514
uuid-3cb7448e72ac4720adf267581d5f0dcc,combination,0.328923
uuid-3cb7448e72ac4720adf267581d5f0dcc,BMS,0.302439
uuid-3cb7448e72ac4720adf267581d5f0dcc,not identify any citations relevant to your request,0.437165
uuid-3cb7448e72ac4720adf267581d5f0dcc,present using the following search terms,0.416231
uuid-b707b458787041c88be703f51e276088,NSCLC,0.725757
uuid-b707b458787041c88be703f51e276088,non-small cell lung cancer,0.699921
uuid-b707b458787041c88be703f51e276088,clinical,0.531059
uuid-b707b458787041c88be703f51e276088,phase 1 study,0.340539
uuid-b707b458787041c88be703f51e276088,trial,0.45696
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,nivolumab,0.344939
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,Bristol-Myers Squibb,0.363004
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,evaluating,0.564404
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,not conducted any controlled clinical trials/studies,0.538169
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,RCC,0.336118
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,search of published literature,0.750115
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,Additionally,0.766378
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,ongoing,0.629393
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,PubMed and EMBASE,0.745288
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,detailed search of www.clinicaltrials.gov,0.729251
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,efficacy and safety of nivolumab,0.716075
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,not identify any planned,0.665705
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,not identify any citations relevant to your request,0.849476
uuid-8151f3e1920141e4bc62ed9e8f13dcdc,present using the following search terms,0.773092
uuid-63a60341e0994f82bcf1f80e31b45ce1,nivolumab,0.36858
uuid-63a60341e0994f82bcf1f80e31b45ce1,Bristol-Myers Squibb,0.712171
uuid-63a60341e0994f82bcf1f80e31b45ce1,evaluating,0.785235
uuid-63a60341e0994f82bcf1f80e31b45ce1,not conducted any controlled clinical trials/studies,0.811249
uuid-63a60341e0994f82bcf1f80e31b45ce1,search of published literature,0.496564
uuid-63a60341e0994f82bcf1f80e31b45ce1,Additionally,0.410587
uuid-63a60341e0994f82bcf1f80e31b45ce1,ongoing,0.36169
uuid-63a60341e0994f82bcf1f80e31b45ce1,PubMed and EMBASE,0.462977
uuid-63a60341e0994f82bcf1f80e31b45ce1,detailed search of www.clinicaltrials.gov,0.391682
uuid-63a60341e0994f82bcf1f80e31b45ce1,efficacy and safety of nivolumab,0.789806
uuid-63a60341e0994f82bcf1f80e31b45ce1,not identify any planned,0.365923
uuid-63a60341e0994f82bcf1f80e31b45ce1,not identify any citations relevant to your request,0.462321
uuid-63a60341e0994f82bcf1f80e31b45ce1,present using the following search terms,0.48652
uuid-3138fde6d4b046668880ebcab77bd840,RCC,0.906223
uuid-bfbb99a9ad9542d98cda45de817bd72b,N Engl J Med,0.604857
uuid-bfbb99a9ad9542d98cda45de817bd72b,non-small cell lung cancer,0.34354
uuid-bfbb99a9ad9542d98cda45de817bd72b,ESMO,0.393944
uuid-bfbb99a9ad9542d98cda45de817bd72b,Rizvi NA,0.452745
uuid-bfbb99a9ad9542d98cda45de817bd72b,Brahmer J,0.679154
uuid-bfbb99a9ad9542d98cda45de817bd72b,PD-L1,0.347566
uuid-bfbb99a9ad9542d98cda45de817bd72b,Horn L,0.50259
uuid-bfbb99a9ad9542d98cda45de817bd72b,platinum-based doublet chemotherapy,0.304136
uuid-f2bb0f15248e45c2905146d3c606431f,AEs,0.459988
uuid-f2bb0f15248e45c2905146d3c606431f,adverse,0.315768
uuid-f2bb0f15248e45c2905146d3c606431f,grade,0.531419
uuid-503774795ed9407cbcbd3f8550de26db,use of nivolumab for the treatment,0.440423
uuid-503774795ed9407cbcbd3f8550de26db,search of published literature,0.311531
uuid-503774795ed9407cbcbd3f8550de26db,PubMed and EMBASE,0.312811
uuid-503774795ed9407cbcbd3f8550de26db,not approved,0.404782
uuid-503774795ed9407cbcbd3f8550de26db,open-label,0.578291
uuid-503774795ed9407cbcbd3f8550de26db,clinical trials investigating the safety,0.440014
uuid-503774795ed9407cbcbd3f8550de26db,present using the following search terms,0.328669
uuid-503774795ed9407cbcbd3f8550de26db,phase,0.41185
uuid-b0934f745e5d476ebd3020227652a965,trial,0.405524
uuid-c229933dff29471096ce46d32b7b197e,Opdivo,0.688493
uuid-c229933dff29471096ce46d32b7b197e,trial,0.366501
uuid-012b2f39010f499781db4d218e5bad14,requested,0.531305
uuid-012b2f39010f499781db4d218e5bad14,ESMO,0.358531
uuid-012b2f39010f499781db4d218e5bad14,Horn L,0.66756
uuid-012b2f39010f499781db4d218e5bad14,platinum-based doublet chemotherapy,0.579011
uuid-3bbc5fbd55ce43ee879367a5b4a38875,nivolumab,0.495956
uuid-15fe92a2489d45b48982f035954e5b11,mg,0.350635
uuid-524dd1730ef2433682e7dde46150ba1e,OS,0.387982
uuid-524dd1730ef2433682e7dde46150ba1e,95% CI,0.745043
uuid-524dd1730ef2433682e7dde46150ba1e,respectively,0.729294
uuid-524dd1730ef2433682e7dde46150ba1e,Objective response rate,0.590876
uuid-524dd1730ef2433682e7dde46150ba1e,ORR,0.722442
uuid-524dd1730ef2433682e7dde46150ba1e,Median overall survival,0.659043
uuid-524dd1730ef2433682e7dde46150ba1e,monotherapy,0.514468
uuid-524dd1730ef2433682e7dde46150ba1e,Median OS,0.696688
uuid-524dd1730ef2433682e7dde46150ba1e,PD-L1,0.300997
uuid-524dd1730ef2433682e7dde46150ba1e,docetaxel,0.635065
uuid-524dd1730ef2433682e7dde46150ba1e,hazard ratio,0.729977
uuid-b6fed74c74774ec0af18b602d0dd7bac,reported,0.308095
uuid-df14dfde90b4430b911ca0870bc94241,requested,0.44769
uuid-df14dfde90b4430b911ca0870bc94241,trial,0.309472
uuid-0403dbd3e6a947ed968dbaf047acf9e0,requested,0.594234
uuid-203b9167448140499e0ac942a4ddf94f,BMS,0.667943
uuid-fe416ef059ae4a1494df7ea182fde78a,melanoma,0.403419
uuid-c211dbad7d4b48749f40311f31475b17,ipilimumab,0.385692
uuid-c211dbad7d4b48749f40311f31475b17,ASCO 2015,0.417944
uuid-c211dbad7d4b48749f40311f31475b17,partial response,0.382425
uuid-c211dbad7d4b48749f40311f31475b17,Stable disease,0.586335
uuid-c211dbad7d4b48749f40311f31475b17,cohort,0.307748
uuid-086d3331dbb84d33af607ccc4853f46f,RCC,0.906223
uuid-1546418e36ef4cc5aa8c0057d4bc841a,requested,0.531305
uuid-1546418e36ef4cc5aa8c0057d4bc841a,ESMO,0.358531
uuid-1546418e36ef4cc5aa8c0057d4bc841a,Horn L,0.66756
uuid-1546418e36ef4cc5aa8c0057d4bc841a,platinum-based doublet chemotherapy,0.579011
uuid-607ea6ca58d84b3ca303ac042ca73e84,requested,0.311036
uuid-7bb00fa7521e4f8ab20749db170b72a3,patients with advanced or metastatic,0.468858
uuid-7bb00fa7521e4f8ab20749db170b72a3,nivolumab combined with ipilimumab,0.446918
uuid-7bb00fa7521e4f8ab20749db170b72a3,not approved,0.352562
uuid-7bb00fa7521e4f8ab20749db170b72a3,clinical trials investigating the safety,0.429501
uuid-7bb00fa7521e4f8ab20749db170b72a3,bladder cancer,0.950698
uuid-63f964b1abf1498f9b2151676a3c8c6f,reported,0.333178
uuid-27a414696d6f42ef90439ac848edbee0,requested,0.531305
uuid-27a414696d6f42ef90439ac848edbee0,ESMO,0.358531
uuid-27a414696d6f42ef90439ac848edbee0,Horn L,0.66756
uuid-27a414696d6f42ef90439ac848edbee0,platinum-based doublet chemotherapy,0.579011
uuid-1a95164040eb4d08bfc422e02202f9e1,ASCO,0.637904
uuid-1a95164040eb4d08bfc422e02202f9e1,Objective response rate,0.354111
uuid-1a95164040eb4d08bfc422e02202f9e1,phase 1 study,0.317805
uuid-4472fe0a303146ad91dc73e16b20db8c,respectively,0.585622
uuid-4472fe0a303146ad91dc73e16b20db8c,Objective response rate,0.36976
uuid-4472fe0a303146ad91dc73e16b20db8c,ORR,0.514781
uuid-4472fe0a303146ad91dc73e16b20db8c,docetaxel,0.31274
uuid-8cc0987e82434bcb89d9fa37d5379b72,patients,0.315933
uuid-35a876a78fe547f8b5fb93abb0484d88,nivolumab,0.561783
uuid-35a876a78fe547f8b5fb93abb0484d88,Bristol-Myers Squibb,0.479756
uuid-35a876a78fe547f8b5fb93abb0484d88,evaluating,0.658882
uuid-35a876a78fe547f8b5fb93abb0484d88,not conducted any controlled clinical trials/studies,0.710128
uuid-35a876a78fe547f8b5fb93abb0484d88,Pubmed literature search,0.845676
uuid-35a876a78fe547f8b5fb93abb0484d88,purposes other than its labeled indication must be considered investigational,0.919316
uuid-35a876a78fe547f8b5fb93abb0484d88,not identify any citations relevant to your inquiry,0.800451
uuid-35a876a78fe547f8b5fb93abb0484d88,using the following search terms,0.78683
uuid-35a876a78fe547f8b5fb93abb0484d88,efficacy and safety of nivolumab,0.499908
uuid-3d2d75d7a46a4e2ba5216e84f38a477a,ipilimumab,0.385692
uuid-3d2d75d7a46a4e2ba5216e84f38a477a,ASCO 2015,0.417944
uuid-3d2d75d7a46a4e2ba5216e84f38a477a,partial response,0.382425
uuid-3d2d75d7a46a4e2ba5216e84f38a477a,Stable disease,0.586335
uuid-3d2d75d7a46a4e2ba5216e84f38a477a,cohort,0.307748
uuid-ddf7202c581f40078d117b2727684430,nivolumab,0.827529
uuid-ddf7202c581f40078d117b2727684430,evaluating,0.348734
uuid-ddf7202c581f40078d117b2727684430,not conducted any controlled clinical trials/studies,0.337683
uuid-ddf7202c581f40078d117b2727684430,Pubmed literature search,0.341437
uuid-ddf7202c581f40078d117b2727684430,purposes other than its labeled indication must be considered investigational,0.422581
uuid-ddf7202c581f40078d117b2727684430,not identify any citations relevant to your inquiry,0.319537
uuid-ddf7202c581f40078d117b2727684430,clinicaltrials.gov,0.400187
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,nivolumab,0.633327
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,Bristol-Myers Squibb,0.362708
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,evaluating,0.499793
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,not conducted any controlled clinical trials/studies,0.547249
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,Pubmed literature search,0.763311
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,purposes other than its labeled indication must be considered investigational,0.823197
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,not identify any citations relevant to your inquiry,0.736904
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,using the following search terms,0.717019
uuid-584f7b1bf5544e9ca3c7dfb27e1cda41,efficacy and safety of nivolumab,0.360845
uuid-c1049bb3344946fb927ae15c797f722e,RCC,0.906223
uuid-38c012e841fb49f296ea82f34b7c8748,NSCLC,0.329758
uuid-38c012e841fb49f296ea82f34b7c8748,non-small cell lung cancer,0.30792
uuid-38c012e841fb49f296ea82f34b7c8748,RCC,0.414652
uuid-38c012e841fb49f296ea82f34b7c8748,trial,0.444793
uuid-e11f6952708046be98d9d63e6f45ede6,OS,0.506839
uuid-e11f6952708046be98d9d63e6f45ede6,95% CI,0.914259
uuid-e11f6952708046be98d9d63e6f45ede6,respectively,0.57945
uuid-e11f6952708046be98d9d63e6f45ede6,Objective response rate,0.616133
uuid-e11f6952708046be98d9d63e6f45ede6,ORR,0.78386
uuid-e11f6952708046be98d9d63e6f45ede6,PFS,0.374029
uuid-e11f6952708046be98d9d63e6f45ede6,Median overall survival,0.850584
uuid-e11f6952708046be98d9d63e6f45ede6,monotherapy,0.435128
uuid-e11f6952708046be98d9d63e6f45ede6,Median OS,0.829523
uuid-e11f6952708046be98d9d63e6f45ede6,docetaxel,0.347663
uuid-e11f6952708046be98d9d63e6f45ede6,hazard ratio,0.887303
uuid-e11f6952708046be98d9d63e6f45ede6,Median duration of response,0.367027
uuid-4595bd87b7d74d098c0cc7d3d63a0605,requested,0.531305
uuid-4595bd87b7d74d098c0cc7d3d63a0605,ESMO,0.358531
uuid-4595bd87b7d74d098c0cc7d3d63a0605,Horn L,0.66756
uuid-4595bd87b7d74d098c0cc7d3d63a0605,platinum-based doublet chemotherapy,0.579011
uuid-d942241a096c4571b85a7516420ff274,evaluating,0.358278
uuid-d942241a096c4571b85a7516420ff274,efficacy,0.339181
uuid-d942241a096c4571b85a7516420ff274,NSCLC,0.732196
uuid-d942241a096c4571b85a7516420ff274,non-small cell lung cancer,0.724946
uuid-d942241a096c4571b85a7516420ff274,safety of nivolumab monotherapy,0.385111
uuid-d942241a096c4571b85a7516420ff274,platinum-based doublet chemotherapy,0.338032
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,OS,0.300809
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,95% CI,0.487161
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,respectively,0.581809
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,ASCO,0.337958
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,Objective response rate,0.579467
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,ORR,0.605666
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,Median overall survival,0.423347
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,monotherapy,0.389069
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,Median OS,0.480031
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,docetaxel,0.341316
uuid-8a02db0d555a40a4a0f0907ac5b1a7fc,hazard ratio,0.45179
uuid-d3e3c9a03f334a18af92f91c83c4154f,nivolumab,0.51258
uuid-d3e3c9a03f334a18af92f91c83c4154f,Bristol-Myers Squibb,0.42524
uuid-d3e3c9a03f334a18af92f91c83c4154f,evaluating,0.577414
uuid-d3e3c9a03f334a18af92f91c83c4154f,not conducted any controlled clinical trials/studies,0.634872
uuid-d3e3c9a03f334a18af92f91c83c4154f,Pubmed literature search,0.859086
uuid-d3e3c9a03f334a18af92f91c83c4154f,purposes other than its labeled indication must be considered investigational,0.919963
uuid-d3e3c9a03f334a18af92f91c83c4154f,not identify any citations relevant to your inquiry,0.822522
uuid-d3e3c9a03f334a18af92f91c83c4154f,using the following search terms,0.806342
uuid-d3e3c9a03f334a18af92f91c83c4154f,efficacy and safety of nivolumab,0.404715
uuid-6e69368ce3ad4c87aa509d0415a9d1b6,Bristol-Myers Squibb,0.494637
uuid-5d4a0832668e4c1781e71ceeae8adda1,95% CI,0.524855
uuid-5d4a0832668e4c1781e71ceeae8adda1,respectively,0.383655
uuid-5d4a0832668e4c1781e71ceeae8adda1,ASCO,0.303153
uuid-5d4a0832668e4c1781e71ceeae8adda1,Lancet Oncol,0.368041
uuid-5d4a0832668e4c1781e71ceeae8adda1,Objective response rate,0.504846
uuid-5d4a0832668e4c1781e71ceeae8adda1,ORR,0.465366
uuid-5d4a0832668e4c1781e71ceeae8adda1,Median overall survival,0.346516
uuid-5d4a0832668e4c1781e71ceeae8adda1,Median OS,0.33538
uuid-5d4a0832668e4c1781e71ceeae8adda1,ASCO 2015,0.336983
uuid-5d4a0832668e4c1781e71ceeae8adda1,small cell lung cancer,0.336892
uuid-5d4a0832668e4c1781e71ceeae8adda1,SCLC,0.344367
uuid-5d4a0832668e4c1781e71ceeae8adda1,Antonia SJ,0.55269
uuid-5d4a0832668e4c1781e71ceeae8adda1,Median duration of response,0.649605
uuid-063d140bd2bb4324bda4e14e412787b0,patients,0.315933
uuid-32451f8d41724596901e4b92088785aa,N Engl J Med,0.427636
uuid-32451f8d41724596901e4b92088785aa,protocol,0.429136
uuid-32451f8d41724596901e4b92088785aa,McDermott DF,0.44782
uuid-32451f8d41724596901e4b92088785aa,Motzer RJ,0.430476
uuid-32451f8d41724596901e4b92088785aa,Escudier B,0.450887
uuid-32451f8d41724596901e4b92088785aa,et al.,0.456026
uuid-32451f8d41724596901e4b92088785aa,J Clin Oncol,0.384624
uuid-32451f8d41724596901e4b92088785aa,Rizvi NA,0.305616
uuid-32451f8d41724596901e4b92088785aa,phase 2 study,0.351446
uuid-8372cd9f067b4505988c2a04302c8cd4,respectively,0.629961
uuid-8372cd9f067b4505988c2a04302c8cd4,Objective response rate,0.439951
uuid-8372cd9f067b4505988c2a04302c8cd4,ORR,0.462322
uuid-8372cd9f067b4505988c2a04302c8cd4,monotherapy,0.352422
uuid-8372cd9f067b4505988c2a04302c8cd4,docetaxel,0.410479
uuid-ff1c8ce33ca447f28931b07484b661a4,nivolumab,0.502856
uuid-ff1c8ce33ca447f28931b07484b661a4,trial,0.511196
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,OS,0.311384
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,N Engl J Med,0.466981
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,95% CI,0.352538
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,respectively,0.427844
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,ASCO,0.399996
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,ORR,0.35692
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,Median overall survival,0.334683
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,Median OS,0.424025
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,Brahmer J,0.641393
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,docetaxel,0.351724
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,Horn L,0.330397
uuid-ce4e38a9abf74bd5a64819e9e1fd4db2,hazard ratio,0.305992
uuid-d0386b7225a44e7d8066ef78a38d8dac,ipilimumab,0.366385
uuid-d0386b7225a44e7d8066ef78a38d8dac,ongoing,0.307761
uuid-d0386b7225a44e7d8066ef78a38d8dac,combination,0.58331
uuid-f4e8db4b4a8449599987b911270a381e,evaluating,0.350845
uuid-f4e8db4b4a8449599987b911270a381e,not conducted any controlled clinical trials/studies,0.345107
uuid-f4e8db4b4a8449599987b911270a381e,search of published literature,0.385331
uuid-f4e8db4b4a8449599987b911270a381e,Additionally,0.40981
uuid-f4e8db4b4a8449599987b911270a381e,ongoing,0.457998
uuid-f4e8db4b4a8449599987b911270a381e,PubMed and EMBASE,0.378285
uuid-f4e8db4b4a8449599987b911270a381e,detailed search of www.clinicaltrials.gov,0.428522
uuid-f4e8db4b4a8449599987b911270a381e,efficacy and safety of nivolumab,0.407868
uuid-f4e8db4b4a8449599987b911270a381e,not identify any planned,0.444729
uuid-f4e8db4b4a8449599987b911270a381e,combination,0.388252
uuid-f4e8db4b4a8449599987b911270a381e,BMS,0.316104
uuid-f4e8db4b4a8449599987b911270a381e,not identify any citations relevant to your request,0.438151
uuid-f4e8db4b4a8449599987b911270a381e,present using the following search terms,0.377101
uuid-8466995d9c114e1db4d07778031f06f1,Bristol-Myers Squibb,0.814432
uuid-8466995d9c114e1db4d07778031f06f1,evaluating,0.699598
uuid-8466995d9c114e1db4d07778031f06f1,not conducted any controlled clinical trials/studies,0.768325
uuid-8466995d9c114e1db4d07778031f06f1,patients,0.455549
uuid-8466995d9c114e1db4d07778031f06f1,considered investigational,0.300467
uuid-8466995d9c114e1db4d07778031f06f1,efficacy and safety of nivolumab,0.609254
uuid-3947d86440c845758f49fa42165ad1fa,nivolumab,0.337982
uuid-3947d86440c845758f49fa42165ad1fa,efficacy,0.309445
uuid-3947d86440c845758f49fa42165ad1fa,clinical,0.444098
uuid-3947d86440c845758f49fa42165ad1fa,PD-L1,0.580941
uuid-3947d86440c845758f49fa42165ad1fa,trial,0.342575
uuid-874f465dd4734a929a268b90b1108fdd,nivolumab,0.61314
uuid-874f465dd4734a929a268b90b1108fdd,Bristol-Myers Squibb,0.45986
uuid-874f465dd4734a929a268b90b1108fdd,evaluating,0.647209
uuid-874f465dd4734a929a268b90b1108fdd,not conducted any controlled clinical trials/studies,0.693355
uuid-874f465dd4734a929a268b90b1108fdd,Pubmed literature search,0.837524
uuid-874f465dd4734a929a268b90b1108fdd,purposes other than its labeled indication must be considered investigational,0.912812
uuid-874f465dd4734a929a268b90b1108fdd,not identify any citations relevant to your inquiry,0.791758
uuid-874f465dd4734a929a268b90b1108fdd,using the following search terms,0.778965
uuid-874f465dd4734a929a268b90b1108fdd,efficacy and safety of nivolumab,0.488607
uuid-4dc03550b8b34a868cd8d5b8a3910789,use of nivolumab for the treatment,0.355443
uuid-4dc03550b8b34a868cd8d5b8a3910789,efficacy,0.608367
uuid-4dc03550b8b34a868cd8d5b8a3910789,NSCLC,0.302226
uuid-4dc03550b8b34a868cd8d5b8a3910789,non-small cell lung cancer,0.311065
uuid-4dc03550b8b34a868cd8d5b8a3910789,not approved,0.491235
uuid-4dc03550b8b34a868cd8d5b8a3910789,clinical trials investigating the safety,0.443646
uuid-4dc03550b8b34a868cd8d5b8a3910789,Brahmer J,0.45848
uuid-4dc03550b8b34a868cd8d5b8a3910789,docetaxel,0.431597
uuid-4dc03550b8b34a868cd8d5b8a3910789,safety of nivolumab monotherapy,0.560791
uuid-4dc03550b8b34a868cd8d5b8a3910789,platinum-based doublet chemotherapy,0.353445
uuid-8fcd18420e004990b07db0317170d7bd,OS,0.381415
uuid-8fcd18420e004990b07db0317170d7bd,95% CI,0.662445
uuid-8fcd18420e004990b07db0317170d7bd,respectively,0.539912
uuid-8fcd18420e004990b07db0317170d7bd,Objective response rate,0.443449
uuid-8fcd18420e004990b07db0317170d7bd,ORR,0.612019
uuid-8fcd18420e004990b07db0317170d7bd,Median overall survival,0.610257
uuid-8fcd18420e004990b07db0317170d7bd,monotherapy,0.372789
uuid-8fcd18420e004990b07db0317170d7bd,Median OS,0.644032
uuid-8fcd18420e004990b07db0317170d7bd,Brahmer J,0.359492
uuid-8fcd18420e004990b07db0317170d7bd,PD-L1,0.436881
uuid-8fcd18420e004990b07db0317170d7bd,docetaxel,0.32596
uuid-8fcd18420e004990b07db0317170d7bd,hazard ratio,0.63818
uuid-2d76786288454dfeb6ddd29897e082c2,N Engl J Med,0.347178
uuid-2d76786288454dfeb6ddd29897e082c2,Lancet Oncol,0.359155
uuid-2d76786288454dfeb6ddd29897e082c2,protocol,0.371457
uuid-2d76786288454dfeb6ddd29897e082c2,McDermott DF,0.414017
uuid-2d76786288454dfeb6ddd29897e082c2,Motzer RJ,0.384536
uuid-2d76786288454dfeb6ddd29897e082c2,phase 3 study,0.443559
uuid-2d76786288454dfeb6ddd29897e082c2,Escudier B,0.411866
uuid-2d76786288454dfeb6ddd29897e082c2,et al.,0.39703
uuid-2d76786288454dfeb6ddd29897e082c2,J Clin Oncol,0.378141
uuid-2d76786288454dfeb6ddd29897e082c2,phase 1 study,0.326203
uuid-2d76786288454dfeb6ddd29897e082c2,Rizvi NA,0.563772
uuid-2d76786288454dfeb6ddd29897e082c2,mg,0.40261
uuid-2d76786288454dfeb6ddd29897e082c2,Weber JS,0.418348
uuid-2d76786288454dfeb6ddd29897e082c2,phase 2 study,0.587446
uuid-2d76786288454dfeb6ddd29897e082c2,kg,0.361586
uuid-ad0c7beb7f0846f587e61850ab897899,PD-L1,0.769584
uuid-26f41a9095fe4d079a71ec8eac335822,RCC,0.890865
uuid-d8c443f974424d67b3f5ed96f16abd5a,use of nivolumab for the treatment,0.440423
uuid-d8c443f974424d67b3f5ed96f16abd5a,search of published literature,0.311531
uuid-d8c443f974424d67b3f5ed96f16abd5a,PubMed and EMBASE,0.312811
uuid-d8c443f974424d67b3f5ed96f16abd5a,not approved,0.404782
uuid-d8c443f974424d67b3f5ed96f16abd5a,open-label,0.578291
uuid-d8c443f974424d67b3f5ed96f16abd5a,clinical trials investigating the safety,0.440014
uuid-d8c443f974424d67b3f5ed96f16abd5a,present using the following search terms,0.328669
uuid-d8c443f974424d67b3f5ed96f16abd5a,phase,0.41185
uuid-ac5de9b0f1394eb897ee042fc179857e,open-label,0.539462
uuid-ac5de9b0f1394eb897ee042fc179857e,phase,0.350616
uuid-ad26b552ec3b44708d56d276804322dc,nivolumab,0.537378
uuid-ad26b552ec3b44708d56d276804322dc,Bristol-Myers Squibb,0.466843
uuid-ad26b552ec3b44708d56d276804322dc,evaluating,0.697736
uuid-ad26b552ec3b44708d56d276804322dc,not conducted any controlled clinical trials/studies,0.725986
uuid-ad26b552ec3b44708d56d276804322dc,Pubmed literature search,0.761883
uuid-ad26b552ec3b44708d56d276804322dc,purposes other than its labeled indication must be considered investigational,0.840956
uuid-ad26b552ec3b44708d56d276804322dc,not identify any citations relevant to your inquiry,0.724649
uuid-ad26b552ec3b44708d56d276804322dc,search of published literature,0.336793
uuid-ad26b552ec3b44708d56d276804322dc,PubMed and EMBASE,0.30681
uuid-ad26b552ec3b44708d56d276804322dc,using the following search terms,0.704937
uuid-ad26b552ec3b44708d56d276804322dc,efficacy and safety of nivolumab,0.57736
uuid-ad26b552ec3b44708d56d276804322dc,present using the following search terms,0.319392
uuid-313afdd4f0d34c7688d32bc9c10072a2,nivolumab,0.505112
uuid-313afdd4f0d34c7688d32bc9c10072a2,Bristol-Myers Squibb,0.542541
uuid-313afdd4f0d34c7688d32bc9c10072a2,evaluating,0.684826
uuid-313afdd4f0d34c7688d32bc9c10072a2,not conducted any controlled clinical trials/studies,0.721231
uuid-313afdd4f0d34c7688d32bc9c10072a2,patients,0.334859
uuid-313afdd4f0d34c7688d32bc9c10072a2,Pubmed literature search,0.588905
uuid-313afdd4f0d34c7688d32bc9c10072a2,purposes other than its labeled indication must be considered investigational,0.685369
uuid-313afdd4f0d34c7688d32bc9c10072a2,not identify any citations relevant to your inquiry,0.547702
uuid-313afdd4f0d34c7688d32bc9c10072a2,using the following search terms,0.520061
uuid-313afdd4f0d34c7688d32bc9c10072a2,efficacy and safety of nivolumab,0.544979
uuid-e320864d79fa4e2d905d51cc639be282,Objective response rate,0.451139
uuid-e320864d79fa4e2d905d51cc639be282,clinicaltrials.gov,0.503706
uuid-003bd0dd96cb46d5a4e96f25e3681872,adverse,0.326427
uuid-003bd0dd96cb46d5a4e96f25e3681872,clinical,0.437777
uuid-fede58b958584e17bea916905cc97d1c,OS,0.342556
uuid-fede58b958584e17bea916905cc97d1c,N Engl J Med,0.519444
uuid-fede58b958584e17bea916905cc97d1c,95% CI,0.45362
uuid-fede58b958584e17bea916905cc97d1c,respectively,0.526287
uuid-fede58b958584e17bea916905cc97d1c,ASCO,0.307747
uuid-fede58b958584e17bea916905cc97d1c,ORR,0.470759
uuid-fede58b958584e17bea916905cc97d1c,Median overall survival,0.459852
uuid-fede58b958584e17bea916905cc97d1c,ESMO,0.436117
uuid-fede58b958584e17bea916905cc97d1c,Median OS,0.499866
uuid-fede58b958584e17bea916905cc97d1c,Brahmer J,0.593372
uuid-fede58b958584e17bea916905cc97d1c,docetaxel,0.363588
uuid-fede58b958584e17bea916905cc97d1c,Horn L,0.47649
uuid-fede58b958584e17bea916905cc97d1c,hazard ratio,0.411231
uuid-faa60dfd382e45b8be4a00fd9517a9fd,respectively,0.397695
uuid-5224c1e965284995817471d8e15c7be1,considered investigational,0.402849
uuid-5224c1e965284995817471d8e15c7be1,small cell lung cancer,0.651985
uuid-5224c1e965284995817471d8e15c7be1,partial response,0.50367
uuid-5224c1e965284995817471d8e15c7be1,SCLC,0.736863
uuid-5224c1e965284995817471d8e15c7be1,therapy,0.843488
uuid-5224c1e965284995817471d8e15c7be1,relapsed,0.613852
uuid-5224c1e965284995817471d8e15c7be1,phase 1/2 study CA209-032,0.40439
uuid-5224c1e965284995817471d8e15c7be1,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-6ccc625f002d4f9383687fb8923d54e8,RCC,0.906223
uuid-ff4dbdd3956245f985f1e8dd88aceb22,Opdivo,0.44351
uuid-ff4dbdd3956245f985f1e8dd88aceb22,trial,0.399273
uuid-ff4dbdd3956245f985f1e8dd88aceb22,BMS,0.559618
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,nivolumab,0.344939
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,Bristol-Myers Squibb,0.363004
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,evaluating,0.564404
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,not conducted any controlled clinical trials/studies,0.538169
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,RCC,0.336118
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,search of published literature,0.750115
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,Additionally,0.766378
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,ongoing,0.629393
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,PubMed and EMBASE,0.745288
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,detailed search of www.clinicaltrials.gov,0.729251
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,efficacy and safety of nivolumab,0.716075
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,not identify any planned,0.665705
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,not identify any citations relevant to your request,0.849476
uuid-7bb8ca35d2994ac3b83a8ab4b9accc1a,present using the following search terms,0.773092
uuid-0f9af7cc4adf4e39b67753aa54294217,nivolumab,0.33639
uuid-0f9af7cc4adf4e39b67753aa54294217,Objective response rate,0.459398
uuid-0f9af7cc4adf4e39b67753aa54294217,clinicaltrials.gov,0.632338
uuid-10d1fcb1d15f44c3ba3f8dc3705e5bf5,provided in the Detailed Information,0.301872
uuid-10d1fcb1d15f44c3ba3f8dc3705e5bf5,adverse,0.376668
uuid-d8b1998cec3a48ce9f524738467ae073,N Engl J Med,0.36787
uuid-d8b1998cec3a48ce9f524738467ae073,protocol,0.658743
uuid-d8b1998cec3a48ce9f524738467ae073,RCC,0.375387
uuid-d8b1998cec3a48ce9f524738467ae073,McDermott DF,0.560925
uuid-d8b1998cec3a48ce9f524738467ae073,search of published literature,0.428619
uuid-d8b1998cec3a48ce9f524738467ae073,Additionally,0.405725
uuid-d8b1998cec3a48ce9f524738467ae073,ongoing,0.365225
uuid-d8b1998cec3a48ce9f524738467ae073,Motzer RJ,0.596204
uuid-d8b1998cec3a48ce9f524738467ae073,PubMed and EMBASE,0.423862
uuid-d8b1998cec3a48ce9f524738467ae073,Escudier B,0.579919
uuid-d8b1998cec3a48ce9f524738467ae073,et al.,0.511512
uuid-d8b1998cec3a48ce9f524738467ae073,J Clin Oncol,0.536233
uuid-d8b1998cec3a48ce9f524738467ae073,detailed search of www.clinicaltrials.gov,0.379318
uuid-d8b1998cec3a48ce9f524738467ae073,efficacy and safety of nivolumab,0.423052
uuid-d8b1998cec3a48ce9f524738467ae073,not identify any planned,0.369601
uuid-d8b1998cec3a48ce9f524738467ae073,phase 2 study,0.471814
uuid-d8b1998cec3a48ce9f524738467ae073,not identify any citations relevant to your request,0.423463
uuid-d8b1998cec3a48ce9f524738467ae073,present using the following search terms,0.406049
uuid-60ece3d425944a91b44a68a9b4b083d0,RCC,0.906223
uuid-e9f9f9af27294f1694b7579992b7af71,ESMO,0.603759
uuid-e9f9f9af27294f1694b7579992b7af71,Horn L,0.484674
uuid-27eb3fc2a0764f69a697b9f466dd0de6,ipilimumab,0.385692
uuid-27eb3fc2a0764f69a697b9f466dd0de6,ASCO 2015,0.417944
uuid-27eb3fc2a0764f69a697b9f466dd0de6,partial response,0.382425
uuid-27eb3fc2a0764f69a697b9f466dd0de6,Stable disease,0.586335
uuid-27eb3fc2a0764f69a697b9f466dd0de6,cohort,0.307748
uuid-ab3cf0cdce3e4ac780f83a9bb3bf69dd,ipilimumab,0.385692
uuid-ab3cf0cdce3e4ac780f83a9bb3bf69dd,ASCO 2015,0.417944
uuid-ab3cf0cdce3e4ac780f83a9bb3bf69dd,partial response,0.382425
uuid-ab3cf0cdce3e4ac780f83a9bb3bf69dd,Stable disease,0.586335
uuid-ab3cf0cdce3e4ac780f83a9bb3bf69dd,cohort,0.307748
uuid-fdb818dea1d54f16bceb335b4f273b94,N Engl J Med,0.437461
uuid-fdb818dea1d54f16bceb335b4f273b94,protocol,0.757512
uuid-fdb818dea1d54f16bceb335b4f273b94,McDermott DF,0.72882
uuid-fdb818dea1d54f16bceb335b4f273b94,Motzer RJ,0.806387
uuid-fdb818dea1d54f16bceb335b4f273b94,phase 3 study,0.418879
uuid-fdb818dea1d54f16bceb335b4f273b94,Escudier B,0.736516
uuid-fdb818dea1d54f16bceb335b4f273b94,NEJM,0.398115
uuid-fdb818dea1d54f16bceb335b4f273b94,et al.,0.656335
uuid-fdb818dea1d54f16bceb335b4f273b94,J Clin Oncol,0.781944
uuid-fdb818dea1d54f16bceb335b4f273b94,Topalian,0.38919
uuid-fdb818dea1d54f16bceb335b4f273b94,phase 1 study,0.513944
uuid-fdb818dea1d54f16bceb335b4f273b94,CA209-003,0.582318
uuid-fdb818dea1d54f16bceb335b4f273b94,phase 2 study,0.671563
uuid-fdb818dea1d54f16bceb335b4f273b94,present using the following search terms,0.313083
uuid-fdb818dea1d54f16bceb335b4f273b94,investigating,0.631114
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,OS,0.44149
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,95% CI,0.833403
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,ASCO,0.32927
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,Objective response rate,0.545269
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,ORR,0.618524
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,PFS,0.396858
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,Median overall survival,0.72593
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,monotherapy,0.33356
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,Median OS,0.763854
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,hazard ratio,0.766648
uuid-cb52348612bd4bbcac4fb6d584b7c4ab,Median duration of response,0.442682
uuid-8087655cc03b4bdd833613d4a5d14452,95% CI,0.524855
uuid-8087655cc03b4bdd833613d4a5d14452,respectively,0.383655
uuid-8087655cc03b4bdd833613d4a5d14452,ASCO,0.303153
uuid-8087655cc03b4bdd833613d4a5d14452,Lancet Oncol,0.368041
uuid-8087655cc03b4bdd833613d4a5d14452,Objective response rate,0.504846
uuid-8087655cc03b4bdd833613d4a5d14452,ORR,0.465366
uuid-8087655cc03b4bdd833613d4a5d14452,Median overall survival,0.346516
uuid-8087655cc03b4bdd833613d4a5d14452,Median OS,0.33538
uuid-8087655cc03b4bdd833613d4a5d14452,ASCO 2015,0.336983
uuid-8087655cc03b4bdd833613d4a5d14452,small cell lung cancer,0.336892
uuid-8087655cc03b4bdd833613d4a5d14452,SCLC,0.344367
uuid-8087655cc03b4bdd833613d4a5d14452,Antonia SJ,0.55269
uuid-8087655cc03b4bdd833613d4a5d14452,Median duration of response,0.649605
uuid-8def420d87aa4432981d3ffad0b9b916,nivolumab,0.567409
uuid-8def420d87aa4432981d3ffad0b9b916,Bristol-Myers Squibb,0.438565
uuid-8def420d87aa4432981d3ffad0b9b916,evaluating,0.594286
uuid-8def420d87aa4432981d3ffad0b9b916,not conducted any controlled clinical trials/studies,0.655858
uuid-8def420d87aa4432981d3ffad0b9b916,Pubmed literature search,0.879255
uuid-8def420d87aa4432981d3ffad0b9b916,purposes other than its labeled indication must be considered investigational,0.941881
uuid-8def420d87aa4432981d3ffad0b9b916,not identify any citations relevant to your inquiry,0.838346
uuid-8def420d87aa4432981d3ffad0b9b916,using the following search terms,0.825992
uuid-8def420d87aa4432981d3ffad0b9b916,efficacy and safety of nivolumab,0.432448
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,95% CI,0.524855
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,respectively,0.383655
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,ASCO,0.303153
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Lancet Oncol,0.368041
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Objective response rate,0.504846
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,ORR,0.465366
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Median overall survival,0.346516
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Median OS,0.33538
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,ASCO 2015,0.336983
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,small cell lung cancer,0.336892
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,SCLC,0.344367
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Antonia SJ,0.55269
uuid-8ab36f2882ff403c8da5ad340a3d5d0c,Median duration of response,0.649605
uuid-ad1f1a6729944972a9be7eebc8c6dd14,N Engl J Med,0.302601
uuid-ad1f1a6729944972a9be7eebc8c6dd14,AEs,0.348167
uuid-ad1f1a6729944972a9be7eebc8c6dd14,patients,0.536884
uuid-ad1f1a6729944972a9be7eebc8c6dd14,provided in the Detailed Information,0.387544
uuid-ad1f1a6729944972a9be7eebc8c6dd14,ESMO,0.462801
uuid-ad1f1a6729944972a9be7eebc8c6dd14,NEJM,0.66427
uuid-ad1f1a6729944972a9be7eebc8c6dd14,Topalian,0.692873
uuid-ad1f1a6729944972a9be7eebc8c6dd14,grade 3 to 4 AEs,0.626596
uuid-7f1b13091b2947eaabef9c5f881fa6af,requested,0.662269
uuid-f9ddf2cabb644259b6f8bb0e9e8eaecc,RCC,0.906223
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,nivolumab,0.438416
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,use of nivolumab for the treatment,0.317928
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,patients,0.681271
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,considered investigational,0.571476
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,patients with advanced or metastatic,0.436263
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,nivolumab combined with ipilimumab,0.414875
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,tumors,0.726655
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,small cell lung cancer,0.62662
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,SCLC,0.573895
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,therapy,0.302303
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,grade 3 to 4 AEs,0.317867
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,phase 1/2 study CA209-032,0.579859
uuid-e4cef4a5b1ac4b05a700c6ab37a1055b,evaluates the efficacy of nivolumab monotherapy,0.566793
uuid-2b78951078ed4744af28f1c1ceeaebbd,RCC,0.90361
uuid-c9557f02429846d3b895b56046ca20ba,nivolumab,0.35284
uuid-c9557f02429846d3b895b56046ca20ba,evaluating,0.496742
uuid-c9557f02429846d3b895b56046ca20ba,not conducted any controlled clinical trials/studies,0.463767
uuid-c9557f02429846d3b895b56046ca20ba,RCC,0.304327
uuid-c9557f02429846d3b895b56046ca20ba,search of published literature,0.689059
uuid-c9557f02429846d3b895b56046ca20ba,Additionally,0.645852
uuid-c9557f02429846d3b895b56046ca20ba,ongoing,0.505403
uuid-c9557f02429846d3b895b56046ca20ba,PubMed and EMBASE,0.685601
uuid-c9557f02429846d3b895b56046ca20ba,detailed search of www.clinicaltrials.gov,0.607209
uuid-c9557f02429846d3b895b56046ca20ba,phase 1 study,0.377818
uuid-c9557f02429846d3b895b56046ca20ba,efficacy and safety of nivolumab,0.658435
uuid-c9557f02429846d3b895b56046ca20ba,not identify any planned,0.541842
uuid-c9557f02429846d3b895b56046ca20ba,CA209-003,0.40691
uuid-c9557f02429846d3b895b56046ca20ba,not identify any citations relevant to your request,0.747569
uuid-c9557f02429846d3b895b56046ca20ba,present using the following search terms,0.729916
uuid-c9557f02429846d3b895b56046ca20ba,investigating,0.459269
uuid-70258f1021aa45fca3cf3f53876a8795,requested,0.538539
uuid-effd85a7421643b9bc5014ad68695007,BMS,0.425482
uuid-faf3af01d16248a68d0894c6552e8024,N Engl J Med,0.54825
uuid-faf3af01d16248a68d0894c6552e8024,NSCLC,0.358785
uuid-faf3af01d16248a68d0894c6552e8024,non-small cell lung cancer,0.308706
uuid-faf3af01d16248a68d0894c6552e8024,ESMO,0.396697
uuid-faf3af01d16248a68d0894c6552e8024,phase 3 study,0.368632
uuid-faf3af01d16248a68d0894c6552e8024,phase 1 study,0.306384
uuid-faf3af01d16248a68d0894c6552e8024,Rizvi NA,0.47921
uuid-faf3af01d16248a68d0894c6552e8024,Brahmer J,0.605319
uuid-faf3af01d16248a68d0894c6552e8024,phase 2 study,0.362302
uuid-faf3af01d16248a68d0894c6552e8024,Horn L,0.443225
uuid-269a908a004546c3bfc2e8a1527366ef,N Engl J Med,0.643107
uuid-269a908a004546c3bfc2e8a1527366ef,respectively,0.398989
uuid-269a908a004546c3bfc2e8a1527366ef,Median overall survival,0.30615
uuid-269a908a004546c3bfc2e8a1527366ef,ESMO,0.534703
uuid-269a908a004546c3bfc2e8a1527366ef,Median OS,0.319939
uuid-269a908a004546c3bfc2e8a1527366ef,Brahmer J,0.658171
uuid-269a908a004546c3bfc2e8a1527366ef,Horn L,0.594193
uuid-4adcb2a9e5b7486aaa3a422040db6c60,patients with advanced or metastatic,0.478326
uuid-4adcb2a9e5b7486aaa3a422040db6c60,nivolumab combined with ipilimumab,0.498766
uuid-4adcb2a9e5b7486aaa3a422040db6c60,not approved,0.34724
uuid-4adcb2a9e5b7486aaa3a422040db6c60,clinical trials investigating the safety,0.426729
uuid-4adcb2a9e5b7486aaa3a422040db6c60,bladder cancer,0.6548
uuid-4d634a75cbf1424c99a6a34cc76b9039,requested,0.525918
uuid-60db896cad6747baa24be158805a6ae6,nivolumab,0.33639
uuid-60db896cad6747baa24be158805a6ae6,Objective response rate,0.459398
uuid-60db896cad6747baa24be158805a6ae6,clinicaltrials.gov,0.632338
uuid-84e143eabc3945fea83b7aae88da4678,N Engl J Med,0.302601
uuid-84e143eabc3945fea83b7aae88da4678,AEs,0.348167
uuid-84e143eabc3945fea83b7aae88da4678,patients,0.536884
uuid-84e143eabc3945fea83b7aae88da4678,provided in the Detailed Information,0.387544
uuid-84e143eabc3945fea83b7aae88da4678,ESMO,0.462801
uuid-84e143eabc3945fea83b7aae88da4678,NEJM,0.66427
uuid-84e143eabc3945fea83b7aae88da4678,Topalian,0.692873
uuid-84e143eabc3945fea83b7aae88da4678,grade 3 to 4 AEs,0.626596
uuid-24a07be229a94624ab6e30f88db3713e,N Engl J Med,0.302601
uuid-24a07be229a94624ab6e30f88db3713e,AEs,0.348167
uuid-24a07be229a94624ab6e30f88db3713e,patients,0.536884
uuid-24a07be229a94624ab6e30f88db3713e,provided in the Detailed Information,0.387544
uuid-24a07be229a94624ab6e30f88db3713e,ESMO,0.462801
uuid-24a07be229a94624ab6e30f88db3713e,NEJM,0.66427
uuid-24a07be229a94624ab6e30f88db3713e,Topalian,0.692873
uuid-24a07be229a94624ab6e30f88db3713e,grade 3 to 4 AEs,0.626596
uuid-b0a5b791e70b4a7aa22f72f9002d1711,clinical,0.347744
uuid-b0a5b791e70b4a7aa22f72f9002d1711,trial,0.437133
uuid-a1b50bf0d45f4fafaa956baa41a71a7e,Bristol-Myers Squibb,0.575056
uuid-a1b50bf0d45f4fafaa956baa41a71a7e,evaluating,0.346775
uuid-a1b50bf0d45f4fafaa956baa41a71a7e,not conducted any controlled clinical trials/studies,0.387151
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,95% CI,0.524855
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,respectively,0.383655
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,ASCO,0.303153
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Lancet Oncol,0.368041
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Objective response rate,0.504846
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,ORR,0.465366
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Median overall survival,0.346516
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Median OS,0.33538
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,ASCO 2015,0.336983
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,small cell lung cancer,0.336892
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,SCLC,0.344367
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Antonia SJ,0.55269
uuid-7e22cc5c5cbd4be3b62408a9f6cbd303,Median duration of response,0.649605
uuid-d5d79c5b136c41d3af8504c5f71b7149,OS,0.44149
uuid-d5d79c5b136c41d3af8504c5f71b7149,95% CI,0.833403
uuid-d5d79c5b136c41d3af8504c5f71b7149,ASCO,0.32927
uuid-d5d79c5b136c41d3af8504c5f71b7149,Objective response rate,0.545269
uuid-d5d79c5b136c41d3af8504c5f71b7149,ORR,0.618524
uuid-d5d79c5b136c41d3af8504c5f71b7149,PFS,0.396858
uuid-d5d79c5b136c41d3af8504c5f71b7149,Median overall survival,0.72593
uuid-d5d79c5b136c41d3af8504c5f71b7149,monotherapy,0.33356
uuid-d5d79c5b136c41d3af8504c5f71b7149,Median OS,0.763854
uuid-d5d79c5b136c41d3af8504c5f71b7149,hazard ratio,0.766648
uuid-d5d79c5b136c41d3af8504c5f71b7149,Median duration of response,0.442682
uuid-177ac35e2aa54826931d412922f2fbcb,PD-L1,0.371891
uuid-f10ffea5a37f459499595e79fe95207d,N Engl J Med,0.442834
uuid-f10ffea5a37f459499595e79fe95207d,protocol,0.763252
uuid-f10ffea5a37f459499595e79fe95207d,McDermott DF,0.733103
uuid-f10ffea5a37f459499595e79fe95207d,Motzer RJ,0.811057
uuid-f10ffea5a37f459499595e79fe95207d,phase 3 study,0.420895
uuid-f10ffea5a37f459499595e79fe95207d,Escudier B,0.741048
uuid-f10ffea5a37f459499595e79fe95207d,NEJM,0.402544
uuid-f10ffea5a37f459499595e79fe95207d,et al.,0.660398
uuid-f10ffea5a37f459499595e79fe95207d,J Clin Oncol,0.786367
uuid-f10ffea5a37f459499595e79fe95207d,Topalian,0.392395
uuid-f10ffea5a37f459499595e79fe95207d,phase 1 study,0.513779
uuid-f10ffea5a37f459499595e79fe95207d,CA209-003,0.583337
uuid-f10ffea5a37f459499595e79fe95207d,phase 2 study,0.675447
uuid-f10ffea5a37f459499595e79fe95207d,present using the following search terms,0.304589
uuid-f10ffea5a37f459499595e79fe95207d,investigating,0.633101
uuid-254992e7acf44565b1802b0e0cbe4b84,RCC,0.316519
uuid-e7ee23fc857146d291f0b66c16401a8f,N Engl J Med,0.427636
uuid-e7ee23fc857146d291f0b66c16401a8f,protocol,0.429136
uuid-e7ee23fc857146d291f0b66c16401a8f,McDermott DF,0.44782
uuid-e7ee23fc857146d291f0b66c16401a8f,Motzer RJ,0.430476
uuid-e7ee23fc857146d291f0b66c16401a8f,Escudier B,0.450887
uuid-e7ee23fc857146d291f0b66c16401a8f,et al.,0.456026
uuid-e7ee23fc857146d291f0b66c16401a8f,J Clin Oncol,0.384624
uuid-e7ee23fc857146d291f0b66c16401a8f,Rizvi NA,0.305616
uuid-e7ee23fc857146d291f0b66c16401a8f,phase 2 study,0.351446
uuid-c89da6005f3e45949558caad7537b4ee,requested,0.531305
uuid-c89da6005f3e45949558caad7537b4ee,ESMO,0.358531
uuid-c89da6005f3e45949558caad7537b4ee,Horn L,0.66756
uuid-c89da6005f3e45949558caad7537b4ee,platinum-based doublet chemotherapy,0.579011
uuid-ab4cc6c9486a47389d4bfdc2bfe09da2,RCC,0.906223
uuid-9d44ebd495124497bc8fdb7969ac18fe,RCC,0.906223
uuid-47927699056c4b84bbac52a5573de8da,OS,0.306979
uuid-47927699056c4b84bbac52a5573de8da,95% CI,0.378929
uuid-47927699056c4b84bbac52a5573de8da,ORR,0.325152
uuid-47927699056c4b84bbac52a5573de8da,Median overall survival,0.416865
uuid-47927699056c4b84bbac52a5573de8da,Median OS,0.343981
uuid-47927699056c4b84bbac52a5573de8da,hazard ratio,0.35636
uuid-04a055337bd649dfb5fd2adb7a3e09ac,95% CI,0.520262
uuid-04a055337bd649dfb5fd2adb7a3e09ac,respectively,0.504068
uuid-04a055337bd649dfb5fd2adb7a3e09ac,Objective response rate,0.458568
uuid-04a055337bd649dfb5fd2adb7a3e09ac,ORR,0.525868
uuid-04a055337bd649dfb5fd2adb7a3e09ac,Median overall survival,0.455633
uuid-04a055337bd649dfb5fd2adb7a3e09ac,Median OS,0.507448
uuid-04a055337bd649dfb5fd2adb7a3e09ac,docetaxel,0.383115
uuid-04a055337bd649dfb5fd2adb7a3e09ac,hazard ratio,0.462119
uuid-21a5c9c294cc4b4d919c60be662c7d5c,Opdivo,0.371487
uuid-21a5c9c294cc4b4d919c60be662c7d5c,Pubmed literature search,0.507431
uuid-21a5c9c294cc4b4d919c60be662c7d5c,purposes other than its labeled indication must be considered investigational,0.480798
uuid-21a5c9c294cc4b4d919c60be662c7d5c,not identify any citations relevant to your inquiry,0.507885
uuid-21a5c9c294cc4b4d919c60be662c7d5c,adverse,0.379867
uuid-21a5c9c294cc4b4d919c60be662c7d5c,using the following search terms,0.53067
uuid-21a5c9c294cc4b4d919c60be662c7d5c,reported,0.508533
uuid-75d2babef4984ddc8c06722838cd3f87,ESMO,0.603759
uuid-75d2babef4984ddc8c06722838cd3f87,Horn L,0.484674
uuid-8d0bd14a2a004b31b6751fa7eacb6aec,patients with advanced or metastatic,0.468858
uuid-8d0bd14a2a004b31b6751fa7eacb6aec,nivolumab combined with ipilimumab,0.446918
uuid-8d0bd14a2a004b31b6751fa7eacb6aec,not approved,0.352562
uuid-8d0bd14a2a004b31b6751fa7eacb6aec,clinical trials investigating the safety,0.429501
uuid-8d0bd14a2a004b31b6751fa7eacb6aec,bladder cancer,0.950698
uuid-1f13a8cb5f514ffa9ee74a91b9fd46d3,RCC,0.906223
uuid-32eb9c5735a840d38b51b87a413977e2,search of published literature,0.394524
uuid-32eb9c5735a840d38b51b87a413977e2,Additionally,0.413583
uuid-32eb9c5735a840d38b51b87a413977e2,ongoing,0.322117
uuid-32eb9c5735a840d38b51b87a413977e2,PubMed and EMBASE,0.391671
uuid-32eb9c5735a840d38b51b87a413977e2,detailed search of www.clinicaltrials.gov,0.375936
uuid-32eb9c5735a840d38b51b87a413977e2,efficacy and safety of nivolumab,0.370699
uuid-32eb9c5735a840d38b51b87a413977e2,not identify any planned,0.34283
uuid-32eb9c5735a840d38b51b87a413977e2,Weber JS,0.319229
uuid-32eb9c5735a840d38b51b87a413977e2,not identify any citations relevant to your request,0.447813
uuid-32eb9c5735a840d38b51b87a413977e2,present using the following search terms,0.408199
uuid-2e1c7e5bd4154644a8529cc815a1df4b,Bristol-Myers Squibb,0.339475
uuid-7e6de90f9bb3468e9a65661847175ba0,RCC,0.906223
uuid-b2be11dfcda9497a8b67e251c5621e65,95% CI,0.524855
uuid-b2be11dfcda9497a8b67e251c5621e65,respectively,0.383655
uuid-b2be11dfcda9497a8b67e251c5621e65,ASCO,0.303153
uuid-b2be11dfcda9497a8b67e251c5621e65,Lancet Oncol,0.368041
uuid-b2be11dfcda9497a8b67e251c5621e65,Objective response rate,0.504846
uuid-b2be11dfcda9497a8b67e251c5621e65,ORR,0.465366
uuid-b2be11dfcda9497a8b67e251c5621e65,Median overall survival,0.346516
uuid-b2be11dfcda9497a8b67e251c5621e65,Median OS,0.33538
uuid-b2be11dfcda9497a8b67e251c5621e65,ASCO 2015,0.336983
uuid-b2be11dfcda9497a8b67e251c5621e65,small cell lung cancer,0.336892
uuid-b2be11dfcda9497a8b67e251c5621e65,SCLC,0.344367
uuid-b2be11dfcda9497a8b67e251c5621e65,Antonia SJ,0.55269
uuid-b2be11dfcda9497a8b67e251c5621e65,Median duration of response,0.649605
uuid-1c77f3fcf3aa436a8c9210610022678d,95% CI,0.368332
uuid-1c77f3fcf3aa436a8c9210610022678d,NSCLC,0.498467
uuid-1c77f3fcf3aa436a8c9210610022678d,non-small cell lung cancer,0.430459
uuid-1c77f3fcf3aa436a8c9210610022678d,Objective response rate,0.480097
uuid-1c77f3fcf3aa436a8c9210610022678d,ORR,0.476446
uuid-1c77f3fcf3aa436a8c9210610022678d,Median overall survival,0.366656
uuid-1c77f3fcf3aa436a8c9210610022678d,monotherapy,0.355726
uuid-1c77f3fcf3aa436a8c9210610022678d,Median OS,0.348153
uuid-1c77f3fcf3aa436a8c9210610022678d,phase 1 study,0.35881
uuid-1c77f3fcf3aa436a8c9210610022678d,hazard ratio,0.370178
uuid-c249e752e6d2470a977d0496f6343134,OS,0.517683
uuid-c249e752e6d2470a977d0496f6343134,95% CI,0.887029
uuid-c249e752e6d2470a977d0496f6343134,respectively,0.541932
uuid-c249e752e6d2470a977d0496f6343134,Objective response rate,0.732884
uuid-c249e752e6d2470a977d0496f6343134,ORR,0.826341
uuid-c249e752e6d2470a977d0496f6343134,PFS,0.416378
uuid-c249e752e6d2470a977d0496f6343134,Median overall survival,0.810566
uuid-c249e752e6d2470a977d0496f6343134,monotherapy,0.504664
uuid-c249e752e6d2470a977d0496f6343134,Median OS,0.783041
uuid-c249e752e6d2470a977d0496f6343134,hazard ratio,0.851803
uuid-c249e752e6d2470a977d0496f6343134,Median duration of response,0.350254
uuid-9113b39bb97b4610b0f72816d732ad4c,requested,0.662269
uuid-52e9f94285a94b75a23545611ac011ab,N Engl J Med,0.72464
uuid-52e9f94285a94b75a23545611ac011ab,ESMO,0.549476
uuid-52e9f94285a94b75a23545611ac011ab,Rizvi NA,0.453745
uuid-52e9f94285a94b75a23545611ac011ab,Brahmer J,0.708006
uuid-52e9f94285a94b75a23545611ac011ab,phase 2 study,0.310257
uuid-52e9f94285a94b75a23545611ac011ab,Horn L,0.57487
uuid-f597b5b239ad4109afc1a536aef7034e,Lancet Oncol,0.367354
uuid-f597b5b239ad4109afc1a536aef7034e,patients with advanced or metastatic,0.321916
uuid-f597b5b239ad4109afc1a536aef7034e,requested,0.672491
uuid-f597b5b239ad4109afc1a536aef7034e,nivolumab combined with ipilimumab,0.362639
uuid-f597b5b239ad4109afc1a536aef7034e,small cell lung cancer,0.323017
uuid-f597b5b239ad4109afc1a536aef7034e,Antonia SJ,0.366373
uuid-026cf6afd4be497f9df055625e981b1e,N Engl J Med,0.342504
uuid-026cf6afd4be497f9df055625e981b1e,protocol,0.342938
uuid-026cf6afd4be497f9df055625e981b1e,McDermott DF,0.371451
uuid-026cf6afd4be497f9df055625e981b1e,Motzer RJ,0.34781
uuid-026cf6afd4be497f9df055625e981b1e,Escudier B,0.370781
uuid-026cf6afd4be497f9df055625e981b1e,et al.,0.377999
uuid-026cf6afd4be497f9df055625e981b1e,J Clin Oncol,0.314889
uuid-cf30791d25b54666a6ea5850c993ca7f,trial,0.465942
uuid-cf30791d25b54666a6ea5850c993ca7f,phase,0.358455
uuid-74e4beb5284f4e978f2f00d38ee764da,RCC,0.906223
uuid-79393566852246458a0258dd151eceb5,requested,0.594234
uuid-3837a9cba6ef4ba0ac961512b351704f,Bristol-Myers Squibb,0.338904
uuid-3837a9cba6ef4ba0ac961512b351704f,not conducted any controlled clinical trials/studies,0.30585
uuid-3837a9cba6ef4ba0ac961512b351704f,Opdivo,0.453388
uuid-3837a9cba6ef4ba0ac961512b351704f,Pubmed literature search,0.607772
uuid-3837a9cba6ef4ba0ac961512b351704f,purposes other than its labeled indication must be considered investigational,0.582906
uuid-3837a9cba6ef4ba0ac961512b351704f,not identify any citations relevant to your inquiry,0.600428
uuid-3837a9cba6ef4ba0ac961512b351704f,adverse,0.304053
uuid-3837a9cba6ef4ba0ac961512b351704f,using the following search terms,0.63427
uuid-3837a9cba6ef4ba0ac961512b351704f,databases,0.305267
uuid-3837a9cba6ef4ba0ac961512b351704f,reported,0.555793
uuid-dbae09da1be84760b1cff91add86b5be,Bristol-Myers Squibb,0.341822
uuid-dbae09da1be84760b1cff91add86b5be,not conducted any controlled clinical trials/studies,0.304507
uuid-dbae09da1be84760b1cff91add86b5be,Opdivo,0.461382
uuid-dbae09da1be84760b1cff91add86b5be,Pubmed literature search,0.614325
uuid-dbae09da1be84760b1cff91add86b5be,purposes other than its labeled indication must be considered investigational,0.586645
uuid-dbae09da1be84760b1cff91add86b5be,not identify any citations relevant to your inquiry,0.606087
uuid-dbae09da1be84760b1cff91add86b5be,adverse,0.304183
uuid-dbae09da1be84760b1cff91add86b5be,using the following search terms,0.642331
uuid-dbae09da1be84760b1cff91add86b5be,databases,0.315039
uuid-dbae09da1be84760b1cff91add86b5be,reported,0.556704
uuid-f8b99ace060f4340aa85ab9c47300a92,requested,0.595565
uuid-562e1cb220c446c99756aaccf788a201,provided in the Detailed Information,0.523967
uuid-562e1cb220c446c99756aaccf788a201,adverse,0.334376
uuid-562e1cb220c446c99756aaccf788a201,clinical,0.549777
uuid-7e96870c6a904a818ca070cce3581af3,N Engl J Med,0.643107
uuid-7e96870c6a904a818ca070cce3581af3,respectively,0.398989
uuid-7e96870c6a904a818ca070cce3581af3,Median overall survival,0.30615
uuid-7e96870c6a904a818ca070cce3581af3,ESMO,0.534703
uuid-7e96870c6a904a818ca070cce3581af3,Median OS,0.319939
uuid-7e96870c6a904a818ca070cce3581af3,Brahmer J,0.658171
uuid-7e96870c6a904a818ca070cce3581af3,Horn L,0.594193
uuid-197c749eaa444f95b59664137d363bea,N Engl J Med,0.616236
uuid-197c749eaa444f95b59664137d363bea,respectively,0.409266
uuid-197c749eaa444f95b59664137d363bea,ASCO,0.373445
uuid-197c749eaa444f95b59664137d363bea,ESMO,0.378373
uuid-197c749eaa444f95b59664137d363bea,Brahmer J,0.712806
uuid-197c749eaa444f95b59664137d363bea,docetaxel,0.327482
uuid-197c749eaa444f95b59664137d363bea,Horn L,0.502372
uuid-14413433adec4e4abd7a40fbe9da0e1c,ASCO,0.40502
uuid-14413433adec4e4abd7a40fbe9da0e1c,requested,0.356567
uuid-8930b6cae1424466b0d766c85052d2f7,OS,0.62262
uuid-8930b6cae1424466b0d766c85052d2f7,PFS,0.65903
uuid-8930b6cae1424466b0d766c85052d2f7,Overall survival,0.644151
uuid-c214f115f49b41a69c57097e1bca4ebe,requested,0.531305
uuid-c214f115f49b41a69c57097e1bca4ebe,ESMO,0.358531
uuid-c214f115f49b41a69c57097e1bca4ebe,Horn L,0.66756
uuid-c214f115f49b41a69c57097e1bca4ebe,platinum-based doublet chemotherapy,0.579011
uuid-4441d29d4afd4a6688ac809efe452477,N Engl J Med,0.616236
uuid-4441d29d4afd4a6688ac809efe452477,respectively,0.409266
uuid-4441d29d4afd4a6688ac809efe452477,ASCO,0.373445
uuid-4441d29d4afd4a6688ac809efe452477,ESMO,0.378373
uuid-4441d29d4afd4a6688ac809efe452477,Brahmer J,0.712806
uuid-4441d29d4afd4a6688ac809efe452477,docetaxel,0.327482
uuid-4441d29d4afd4a6688ac809efe452477,Horn L,0.502372
uuid-6b1e7bea9a5049f087e3d67b723d0537,requested,0.531305
uuid-6b1e7bea9a5049f087e3d67b723d0537,ESMO,0.358531
uuid-6b1e7bea9a5049f087e3d67b723d0537,Horn L,0.66756
uuid-6b1e7bea9a5049f087e3d67b723d0537,platinum-based doublet chemotherapy,0.579011
uuid-48e09825097e4f988558eed66f79a6f7,ipilimumab,0.385692
uuid-48e09825097e4f988558eed66f79a6f7,ASCO 2015,0.417944
uuid-48e09825097e4f988558eed66f79a6f7,partial response,0.382425
uuid-48e09825097e4f988558eed66f79a6f7,Stable disease,0.586335
uuid-48e09825097e4f988558eed66f79a6f7,cohort,0.307748
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,N Engl J Med,0.642542
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,respectively,0.354234
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,ASCO,0.421515
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,ESMO,0.396666
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,Rizvi NA,0.330189
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,Brahmer J,0.728262
uuid-a0709eb1ee4f42fd9774bda6fefa72c0,Horn L,0.514137
uuid-052495595be04ce09469ffe9a5bf1d2b,respectively,0.585622
uuid-052495595be04ce09469ffe9a5bf1d2b,Objective response rate,0.36976
uuid-052495595be04ce09469ffe9a5bf1d2b,ORR,0.514781
uuid-052495595be04ce09469ffe9a5bf1d2b,docetaxel,0.31274
uuid-e58f88d6489642aead4e85d0e344184a,search of published literature,0.394524
uuid-e58f88d6489642aead4e85d0e344184a,Additionally,0.413583
uuid-e58f88d6489642aead4e85d0e344184a,ongoing,0.322117
uuid-e58f88d6489642aead4e85d0e344184a,PubMed and EMBASE,0.391671
uuid-e58f88d6489642aead4e85d0e344184a,detailed search of www.clinicaltrials.gov,0.375936
uuid-e58f88d6489642aead4e85d0e344184a,efficacy and safety of nivolumab,0.370699
uuid-e58f88d6489642aead4e85d0e344184a,not identify any planned,0.34283
uuid-e58f88d6489642aead4e85d0e344184a,Weber JS,0.319229
uuid-e58f88d6489642aead4e85d0e344184a,not identify any citations relevant to your request,0.447813
uuid-e58f88d6489642aead4e85d0e344184a,present using the following search terms,0.408199
uuid-39031355710f4eb28c76b4807a86da9e,requested,0.531305
uuid-39031355710f4eb28c76b4807a86da9e,ESMO,0.358531
uuid-39031355710f4eb28c76b4807a86da9e,Horn L,0.66756
uuid-39031355710f4eb28c76b4807a86da9e,platinum-based doublet chemotherapy,0.579011
uuid-cddc5f3b1aed498abc35cd7389f21a5a,requested,0.318029
uuid-cddc5f3b1aed498abc35cd7389f21a5a,BMS,0.678522
uuid-f3713f85da87486694a4153b109f8676,nivolumab,0.490402
uuid-f3713f85da87486694a4153b109f8676,Bristol-Myers Squibb,0.552346
uuid-f3713f85da87486694a4153b109f8676,evaluating,0.704471
uuid-f3713f85da87486694a4153b109f8676,not conducted any controlled clinical trials/studies,0.757017
uuid-f3713f85da87486694a4153b109f8676,Pubmed literature search,0.785251
uuid-f3713f85da87486694a4153b109f8676,purposes other than its labeled indication must be considered investigational,0.862956
uuid-f3713f85da87486694a4153b109f8676,not identify any citations relevant to your inquiry,0.739668
uuid-f3713f85da87486694a4153b109f8676,using the following search terms,0.725511
uuid-f3713f85da87486694a4153b109f8676,efficacy and safety of nivolumab,0.556304
uuid-27a7274b1a4b4380a60361ba41098df7,Bristol-Myers Squibb,0.346922
uuid-27a7274b1a4b4380a60361ba41098df7,not conducted any controlled clinical trials/studies,0.304473
uuid-27a7274b1a4b4380a60361ba41098df7,Opdivo,0.463406
uuid-27a7274b1a4b4380a60361ba41098df7,Pubmed literature search,0.613339
uuid-27a7274b1a4b4380a60361ba41098df7,purposes other than its labeled indication must be considered investigational,0.585443
uuid-27a7274b1a4b4380a60361ba41098df7,not identify any citations relevant to your inquiry,0.606108
uuid-27a7274b1a4b4380a60361ba41098df7,adverse,0.303737
uuid-27a7274b1a4b4380a60361ba41098df7,using the following search terms,0.641544
uuid-27a7274b1a4b4380a60361ba41098df7,databases,0.31454
uuid-27a7274b1a4b4380a60361ba41098df7,reported,0.55557
uuid-1133f63d83b14e0cb71854d6c12c9c48,OS,0.387982
uuid-1133f63d83b14e0cb71854d6c12c9c48,95% CI,0.745043
uuid-1133f63d83b14e0cb71854d6c12c9c48,respectively,0.729294
uuid-1133f63d83b14e0cb71854d6c12c9c48,Objective response rate,0.590876
uuid-1133f63d83b14e0cb71854d6c12c9c48,ORR,0.722442
uuid-1133f63d83b14e0cb71854d6c12c9c48,Median overall survival,0.659043
uuid-1133f63d83b14e0cb71854d6c12c9c48,monotherapy,0.514468
uuid-1133f63d83b14e0cb71854d6c12c9c48,Median OS,0.696688
uuid-1133f63d83b14e0cb71854d6c12c9c48,PD-L1,0.300997
uuid-1133f63d83b14e0cb71854d6c12c9c48,docetaxel,0.635065
uuid-1133f63d83b14e0cb71854d6c12c9c48,hazard ratio,0.729977
uuid-34d798001f3e4c49857b4175d7e2867b,Bristol-Myers Squibb,0.339196
uuid-34d798001f3e4c49857b4175d7e2867b,Opdivo,0.459918
uuid-34d798001f3e4c49857b4175d7e2867b,Pubmed literature search,0.581367
uuid-34d798001f3e4c49857b4175d7e2867b,purposes other than its labeled indication must be considered investigational,0.554666
uuid-34d798001f3e4c49857b4175d7e2867b,not identify any citations relevant to your inquiry,0.576075
uuid-34d798001f3e4c49857b4175d7e2867b,adverse,0.312147
uuid-34d798001f3e4c49857b4175d7e2867b,using the following search terms,0.611216
uuid-34d798001f3e4c49857b4175d7e2867b,safety,0.321458
uuid-34d798001f3e4c49857b4175d7e2867b,databases,0.330138
uuid-34d798001f3e4c49857b4175d7e2867b,reported,0.57323
uuid-606181c81d0d406292110fe7746fa8c5,requested,0.595565
uuid-fc73ee014208440092346c7b2239b49d,OS,0.62262
uuid-fc73ee014208440092346c7b2239b49d,PFS,0.65903
uuid-fc73ee014208440092346c7b2239b49d,Overall survival,0.644151
uuid-54e1b95ca6a8471885f26dc4e3a429c3,Bristol-Myers Squibb,0.619772
uuid-54e1b95ca6a8471885f26dc4e3a429c3,evaluating,0.522831
uuid-54e1b95ca6a8471885f26dc4e3a429c3,not conducted any controlled clinical trials/studies,0.593618
uuid-54e1b95ca6a8471885f26dc4e3a429c3,efficacy and safety of nivolumab,0.447663
uuid-da7ac8f56bb14d24961fa7bb642a549f,NSCLC,0.482008
uuid-da7ac8f56bb14d24961fa7bb642a549f,non-small cell lung cancer,0.465305
uuid-da7ac8f56bb14d24961fa7bb642a549f,mg,0.30182
uuid-c4a9d91fbe0e4e95beecf2716622a1e8,requested,0.594234
uuid-0ad42613212f434ba3161473eab35ad4,nivolumab,0.33639
uuid-0ad42613212f434ba3161473eab35ad4,Objective response rate,0.459398
uuid-0ad42613212f434ba3161473eab35ad4,clinicaltrials.gov,0.632338
uuid-b9b34011ca18444cb32914f5898411a9,ESMO,0.603759
uuid-b9b34011ca18444cb32914f5898411a9,Horn L,0.484674
uuid-6d851ee6226640c385ba3e48e3af0ff9,search of published literature,0.394524
uuid-6d851ee6226640c385ba3e48e3af0ff9,Additionally,0.413583
uuid-6d851ee6226640c385ba3e48e3af0ff9,ongoing,0.322117
uuid-6d851ee6226640c385ba3e48e3af0ff9,PubMed and EMBASE,0.391671
uuid-6d851ee6226640c385ba3e48e3af0ff9,detailed search of www.clinicaltrials.gov,0.375936
uuid-6d851ee6226640c385ba3e48e3af0ff9,efficacy and safety of nivolumab,0.370699
uuid-6d851ee6226640c385ba3e48e3af0ff9,not identify any planned,0.34283
uuid-6d851ee6226640c385ba3e48e3af0ff9,Weber JS,0.319229
uuid-6d851ee6226640c385ba3e48e3af0ff9,not identify any citations relevant to your request,0.447813
uuid-6d851ee6226640c385ba3e48e3af0ff9,present using the following search terms,0.408199
uuid-0ac793a4da854e42b40b8e74e5cc4e65,95% CI,0.46953
uuid-0ac793a4da854e42b40b8e74e5cc4e65,respectively,0.364009
uuid-0ac793a4da854e42b40b8e74e5cc4e65,ASCO,0.302332
uuid-0ac793a4da854e42b40b8e74e5cc4e65,Lancet Oncol,0.393468
uuid-0ac793a4da854e42b40b8e74e5cc4e65,Objective response rate,0.507196
uuid-0ac793a4da854e42b40b8e74e5cc4e65,ORR,0.453956
uuid-0ac793a4da854e42b40b8e74e5cc4e65,Median overall survival,0.306734
uuid-0ac793a4da854e42b40b8e74e5cc4e65,ipilimumab,0.332651
uuid-0ac793a4da854e42b40b8e74e5cc4e65,ASCO 2015,0.406669
uuid-0ac793a4da854e42b40b8e74e5cc4e65,small cell lung cancer,0.44207
uuid-0ac793a4da854e42b40b8e74e5cc4e65,SCLC,0.449695
uuid-0ac793a4da854e42b40b8e74e5cc4e65,Antonia SJ,0.59628
uuid-0ac793a4da854e42b40b8e74e5cc4e65,Median duration of response,0.585176
uuid-0ac793a4da854e42b40b8e74e5cc4e65,phase 1/2 study CA209-032,0.359114
uuid-0ac793a4da854e42b40b8e74e5cc4e65,evaluates the efficacy of nivolumab monotherapy,0.332511
uuid-30fc73cb696843e380b8d047698e7e13,95% CI,0.524855
uuid-30fc73cb696843e380b8d047698e7e13,respectively,0.383655
uuid-30fc73cb696843e380b8d047698e7e13,ASCO,0.303153
uuid-30fc73cb696843e380b8d047698e7e13,Lancet Oncol,0.368041
uuid-30fc73cb696843e380b8d047698e7e13,Objective response rate,0.504846
uuid-30fc73cb696843e380b8d047698e7e13,ORR,0.465366
uuid-30fc73cb696843e380b8d047698e7e13,Median overall survival,0.346516
uuid-30fc73cb696843e380b8d047698e7e13,Median OS,0.33538
uuid-30fc73cb696843e380b8d047698e7e13,ASCO 2015,0.336983
uuid-30fc73cb696843e380b8d047698e7e13,small cell lung cancer,0.336892
uuid-30fc73cb696843e380b8d047698e7e13,SCLC,0.344367
uuid-30fc73cb696843e380b8d047698e7e13,Antonia SJ,0.55269
uuid-30fc73cb696843e380b8d047698e7e13,Median duration of response,0.649605
uuid-d4456c32d8de4c60a94ca79176af0121,N Engl J Med,0.604857
uuid-d4456c32d8de4c60a94ca79176af0121,non-small cell lung cancer,0.34354
uuid-d4456c32d8de4c60a94ca79176af0121,ESMO,0.393944
uuid-d4456c32d8de4c60a94ca79176af0121,Rizvi NA,0.452745
uuid-d4456c32d8de4c60a94ca79176af0121,Brahmer J,0.679154
uuid-d4456c32d8de4c60a94ca79176af0121,PD-L1,0.347566
uuid-d4456c32d8de4c60a94ca79176af0121,Horn L,0.50259
uuid-d4456c32d8de4c60a94ca79176af0121,platinum-based doublet chemotherapy,0.304136
uuid-c3d499e12af64e66b6656fe64a516f90,95% CI,0.524855
uuid-c3d499e12af64e66b6656fe64a516f90,respectively,0.383655
uuid-c3d499e12af64e66b6656fe64a516f90,ASCO,0.303153
uuid-c3d499e12af64e66b6656fe64a516f90,Lancet Oncol,0.368041
uuid-c3d499e12af64e66b6656fe64a516f90,Objective response rate,0.504846
uuid-c3d499e12af64e66b6656fe64a516f90,ORR,0.465366
uuid-c3d499e12af64e66b6656fe64a516f90,Median overall survival,0.346516
uuid-c3d499e12af64e66b6656fe64a516f90,Median OS,0.33538
uuid-c3d499e12af64e66b6656fe64a516f90,ASCO 2015,0.336983
uuid-c3d499e12af64e66b6656fe64a516f90,small cell lung cancer,0.336892
uuid-c3d499e12af64e66b6656fe64a516f90,SCLC,0.344367
uuid-c3d499e12af64e66b6656fe64a516f90,Antonia SJ,0.55269
uuid-c3d499e12af64e66b6656fe64a516f90,Median duration of response,0.649605
uuid-76bd37e72a284df892b79c84251dd547,respectively,0.629961
uuid-76bd37e72a284df892b79c84251dd547,Objective response rate,0.439951
uuid-76bd37e72a284df892b79c84251dd547,ORR,0.462322
uuid-76bd37e72a284df892b79c84251dd547,monotherapy,0.352421
uuid-76bd37e72a284df892b79c84251dd547,docetaxel,0.410479
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,N Engl J Med,0.616236
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,respectively,0.409266
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,ASCO,0.373445
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,ESMO,0.378373
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,Brahmer J,0.712806
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,docetaxel,0.327482
uuid-a96b3eeb8c444d3fa4eceb5fde3b4d16,Horn L,0.502372
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,N Engl J Med,0.616236
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,respectively,0.409266
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,ASCO,0.373445
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,ESMO,0.378373
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,Brahmer J,0.712806
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,docetaxel,0.327482
uuid-e851368a2ebf4ff7a1c1fd8c360bc55d,Horn L,0.502372
uuid-7baf7bd9404a4dc6b65be394d6b5297a,N Engl J Med,0.409425
uuid-7baf7bd9404a4dc6b65be394d6b5297a,phase 3 study,0.344105
uuid-7baf7bd9404a4dc6b65be394d6b5297a,phase 1 study,0.42025
uuid-7baf7bd9404a4dc6b65be394d6b5297a,Rizvi NA,0.372987
uuid-7baf7bd9404a4dc6b65be394d6b5297a,Brahmer J,0.32571
uuid-7baf7bd9404a4dc6b65be394d6b5297a,mg,0.34664
uuid-7baf7bd9404a4dc6b65be394d6b5297a,CA209-003,0.428482
uuid-7baf7bd9404a4dc6b65be394d6b5297a,phase 2 study,0.427642
uuid-7baf7bd9404a4dc6b65be394d6b5297a,kg,0.335258
uuid-35bebccfbfd34d919541f7318b982765,search of published literature,0.394524
uuid-35bebccfbfd34d919541f7318b982765,Additionally,0.413583
uuid-35bebccfbfd34d919541f7318b982765,ongoing,0.322117
uuid-35bebccfbfd34d919541f7318b982765,PubMed and EMBASE,0.391671
uuid-35bebccfbfd34d919541f7318b982765,detailed search of www.clinicaltrials.gov,0.375936
uuid-35bebccfbfd34d919541f7318b982765,efficacy and safety of nivolumab,0.370699
uuid-35bebccfbfd34d919541f7318b982765,not identify any planned,0.34283
uuid-35bebccfbfd34d919541f7318b982765,Weber JS,0.319229
uuid-35bebccfbfd34d919541f7318b982765,not identify any citations relevant to your request,0.447813
uuid-35bebccfbfd34d919541f7318b982765,present using the following search terms,0.408199
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,95% CI,0.524855
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,respectively,0.383655
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,ASCO,0.303153
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Lancet Oncol,0.368041
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Objective response rate,0.504846
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,ORR,0.465366
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Median overall survival,0.346516
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Median OS,0.33538
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,ASCO 2015,0.336983
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,small cell lung cancer,0.336892
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,SCLC,0.344367
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Antonia SJ,0.55269
uuid-ffbfbdda934b4fb4a2e8c00f5a41c8e3,Median duration of response,0.649605
uuid-5954714493f846eca54bffc7c67cdc27,provided in the Detailed Information,0.446666
uuid-5954714493f846eca54bffc7c67cdc27,Overall survival,0.3244
uuid-237badc5550b4d50ad297f62a938352f,patients with advanced or metastatic,0.468858
uuid-237badc5550b4d50ad297f62a938352f,nivolumab combined with ipilimumab,0.446918
uuid-237badc5550b4d50ad297f62a938352f,not approved,0.352562
uuid-237badc5550b4d50ad297f62a938352f,clinical trials investigating the safety,0.429501
uuid-237badc5550b4d50ad297f62a938352f,bladder cancer,0.950698
uuid-12915f89b3e949fa8bb45f0156f62ff3,N Engl J Med,0.302601
uuid-12915f89b3e949fa8bb45f0156f62ff3,AEs,0.348167
uuid-12915f89b3e949fa8bb45f0156f62ff3,patients,0.536884
uuid-12915f89b3e949fa8bb45f0156f62ff3,provided in the Detailed Information,0.387544
uuid-12915f89b3e949fa8bb45f0156f62ff3,ESMO,0.462801
uuid-12915f89b3e949fa8bb45f0156f62ff3,NEJM,0.66427
uuid-12915f89b3e949fa8bb45f0156f62ff3,Topalian,0.692873
uuid-12915f89b3e949fa8bb45f0156f62ff3,grade 3 to 4 AEs,0.626596
uuid-ffbbed582c0547938b2d8fa54258d6d6,OS,0.44149
uuid-ffbbed582c0547938b2d8fa54258d6d6,95% CI,0.833403
uuid-ffbbed582c0547938b2d8fa54258d6d6,ASCO,0.32927
uuid-ffbbed582c0547938b2d8fa54258d6d6,Objective response rate,0.545269
uuid-ffbbed582c0547938b2d8fa54258d6d6,ORR,0.618524
uuid-ffbbed582c0547938b2d8fa54258d6d6,PFS,0.396858
uuid-ffbbed582c0547938b2d8fa54258d6d6,Median overall survival,0.72593
uuid-ffbbed582c0547938b2d8fa54258d6d6,monotherapy,0.33356
uuid-ffbbed582c0547938b2d8fa54258d6d6,Median OS,0.763854
uuid-ffbbed582c0547938b2d8fa54258d6d6,hazard ratio,0.766648
uuid-ffbbed582c0547938b2d8fa54258d6d6,Median duration of response,0.442682
uuid-6c3043580d644fb283097c8a4e22e1f6,requested,0.594234
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,N Engl J Med,0.616236
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,respectively,0.409266
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,ASCO,0.373445
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,ESMO,0.378373
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,Brahmer J,0.712806
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,docetaxel,0.327482
uuid-a84c1f0c72a34e4a9fb961521cd7b97c,Horn L,0.502372
uuid-0289ab36c7d349019a6cc89e096cce66,N Engl J Med,0.616236
uuid-0289ab36c7d349019a6cc89e096cce66,respectively,0.409266
uuid-0289ab36c7d349019a6cc89e096cce66,ASCO,0.373445
uuid-0289ab36c7d349019a6cc89e096cce66,ESMO,0.378373
uuid-0289ab36c7d349019a6cc89e096cce66,Brahmer J,0.712806
uuid-0289ab36c7d349019a6cc89e096cce66,docetaxel,0.327482
uuid-0289ab36c7d349019a6cc89e096cce66,Horn L,0.502372
uuid-483836e9291f4e7eb97bb800a19f6be8,search of published literature,0.394524
uuid-483836e9291f4e7eb97bb800a19f6be8,Additionally,0.413583
uuid-483836e9291f4e7eb97bb800a19f6be8,ongoing,0.322117
uuid-483836e9291f4e7eb97bb800a19f6be8,PubMed and EMBASE,0.391671
uuid-483836e9291f4e7eb97bb800a19f6be8,detailed search of www.clinicaltrials.gov,0.375936
uuid-483836e9291f4e7eb97bb800a19f6be8,efficacy and safety of nivolumab,0.370699
uuid-483836e9291f4e7eb97bb800a19f6be8,not identify any planned,0.34283
uuid-483836e9291f4e7eb97bb800a19f6be8,Weber JS,0.319229
uuid-483836e9291f4e7eb97bb800a19f6be8,not identify any citations relevant to your request,0.447813
uuid-483836e9291f4e7eb97bb800a19f6be8,present using the following search terms,0.408199
uuid-41bd99887fcf472eb2df47300d0ecaab,respectively,0.585622
uuid-41bd99887fcf472eb2df47300d0ecaab,Objective response rate,0.36976
uuid-41bd99887fcf472eb2df47300d0ecaab,ORR,0.514781
uuid-41bd99887fcf472eb2df47300d0ecaab,docetaxel,0.31274
uuid-94fdcb5b2869445e8b44499f2db2b96d,nivolumab,0.347078
uuid-94fdcb5b2869445e8b44499f2db2b96d,patients with advanced or metastatic,0.323546
uuid-94fdcb5b2869445e8b44499f2db2b96d,nivolumab combined with ipilimumab,0.321106
uuid-94fdcb5b2869445e8b44499f2db2b96d,ESMO,0.690869
uuid-94fdcb5b2869445e8b44499f2db2b96d,Horn L,0.364617
uuid-94fdcb5b2869445e8b44499f2db2b96d,grade 3 to 4 AEs,0.308322
uuid-94fdcb5b2869445e8b44499f2db2b96d,bladder cancer,0.496096
uuid-93acd5da34d84b26944e95a556235b1b,patients with advanced or metastatic,0.468858
uuid-93acd5da34d84b26944e95a556235b1b,nivolumab combined with ipilimumab,0.446918
uuid-93acd5da34d84b26944e95a556235b1b,not approved,0.352562
uuid-93acd5da34d84b26944e95a556235b1b,clinical trials investigating the safety,0.429501
uuid-93acd5da34d84b26944e95a556235b1b,bladder cancer,0.950698
uuid-6b6ef06d36054a5b98d0a699a9064f13,nivolumab,0.543496
uuid-6b6ef06d36054a5b98d0a699a9064f13,Bristol-Myers Squibb,0.42687
uuid-6b6ef06d36054a5b98d0a699a9064f13,evaluating,0.625173
uuid-6b6ef06d36054a5b98d0a699a9064f13,not conducted any controlled clinical trials/studies,0.667022
uuid-6b6ef06d36054a5b98d0a699a9064f13,considered investigational,0.395094
uuid-6b6ef06d36054a5b98d0a699a9064f13,Pubmed literature search,0.758037
uuid-6b6ef06d36054a5b98d0a699a9064f13,purposes other than its labeled indication must be considered investigational,0.831264
uuid-6b6ef06d36054a5b98d0a699a9064f13,not identify any citations relevant to your inquiry,0.715269
uuid-6b6ef06d36054a5b98d0a699a9064f13,using the following search terms,0.702926
uuid-6b6ef06d36054a5b98d0a699a9064f13,efficacy and safety of nivolumab,0.490339
uuid-86062674bf1c40bfbd528b91389ff64a,Lancet Oncol,0.383731
uuid-86062674bf1c40bfbd528b91389ff64a,Rizvi NA,0.487254
uuid-86062674bf1c40bfbd528b91389ff64a,Weber JS,0.437421
uuid-86062674bf1c40bfbd528b91389ff64a,phase 2 study,0.312055
uuid-f5b14240854f49499675ec16678dbbbf,nivolumab,0.437115
uuid-f5b14240854f49499675ec16678dbbbf,Opdivo,0.361743
uuid-20436f29090f4c2f824334173453f6fd,nivolumab,0.493389
uuid-20436f29090f4c2f824334173453f6fd,Bristol-Myers Squibb,0.598477
uuid-20436f29090f4c2f824334173453f6fd,evaluating,0.837805
uuid-20436f29090f4c2f824334173453f6fd,not conducted any controlled clinical trials/studies,0.848713
uuid-20436f29090f4c2f824334173453f6fd,Pubmed literature search,0.314091
uuid-20436f29090f4c2f824334173453f6fd,purposes other than its labeled indication must be considered investigational,0.4415
uuid-20436f29090f4c2f824334173453f6fd,search of published literature,0.772891
uuid-20436f29090f4c2f824334173453f6fd,PubMed and EMBASE,0.743175
uuid-20436f29090f4c2f824334173453f6fd,efficacy and safety of nivolumab,0.905749
uuid-20436f29090f4c2f824334173453f6fd,not identify any citations relevant to your request,0.417576
uuid-20436f29090f4c2f824334173453f6fd,present using the following search terms,0.748132
uuid-72868cf76cf24a819e300f6e98b54284,OS,0.506839
uuid-72868cf76cf24a819e300f6e98b54284,95% CI,0.914259
uuid-72868cf76cf24a819e300f6e98b54284,respectively,0.57945
uuid-72868cf76cf24a819e300f6e98b54284,Objective response rate,0.616133
uuid-72868cf76cf24a819e300f6e98b54284,ORR,0.78386
uuid-72868cf76cf24a819e300f6e98b54284,PFS,0.374029
uuid-72868cf76cf24a819e300f6e98b54284,Median overall survival,0.850584
uuid-72868cf76cf24a819e300f6e98b54284,monotherapy,0.435128
uuid-72868cf76cf24a819e300f6e98b54284,Median OS,0.829523
uuid-72868cf76cf24a819e300f6e98b54284,docetaxel,0.347663
uuid-72868cf76cf24a819e300f6e98b54284,hazard ratio,0.887303
uuid-72868cf76cf24a819e300f6e98b54284,Median duration of response,0.367027
uuid-794678dc0d5e476a85152b8fe1fe90ad,Opdivo,0.53266
uuid-794678dc0d5e476a85152b8fe1fe90ad,clinical,0.526032
uuid-794678dc0d5e476a85152b8fe1fe90ad,trial,0.594431
uuid-794678dc0d5e476a85152b8fe1fe90ad,reported,0.40024
uuid-0d631037f3a541bfa983806dc55c7f2a,N Engl J Med,0.616236
uuid-0d631037f3a541bfa983806dc55c7f2a,respectively,0.409266
uuid-0d631037f3a541bfa983806dc55c7f2a,ASCO,0.373445
uuid-0d631037f3a541bfa983806dc55c7f2a,ESMO,0.378373
uuid-0d631037f3a541bfa983806dc55c7f2a,Brahmer J,0.712806
uuid-0d631037f3a541bfa983806dc55c7f2a,docetaxel,0.327482
uuid-0d631037f3a541bfa983806dc55c7f2a,Horn L,0.502372
uuid-7709e1ca9b2f40819035303c759b2b04,Bristol-Myers Squibb,0.346922
uuid-7709e1ca9b2f40819035303c759b2b04,not conducted any controlled clinical trials/studies,0.304473
uuid-7709e1ca9b2f40819035303c759b2b04,Opdivo,0.463406
uuid-7709e1ca9b2f40819035303c759b2b04,Pubmed literature search,0.613339
uuid-7709e1ca9b2f40819035303c759b2b04,purposes other than its labeled indication must be considered investigational,0.585443
uuid-7709e1ca9b2f40819035303c759b2b04,not identify any citations relevant to your inquiry,0.606108
uuid-7709e1ca9b2f40819035303c759b2b04,adverse,0.303737
uuid-7709e1ca9b2f40819035303c759b2b04,using the following search terms,0.641544
uuid-7709e1ca9b2f40819035303c759b2b04,databases,0.31454
uuid-7709e1ca9b2f40819035303c759b2b04,reported,0.55557
uuid-724cab48043f4ffaa56eaa1399e03a06,requested,0.331761
uuid-7cc46b43ba624d0b8ce939412963fe82,95% CI,0.539167
uuid-7cc46b43ba624d0b8ce939412963fe82,Median overall survival,0.479815
uuid-7cc46b43ba624d0b8ce939412963fe82,protocol,0.426554
uuid-7cc46b43ba624d0b8ce939412963fe82,McDermott DF,0.500131
uuid-7cc46b43ba624d0b8ce939412963fe82,Motzer RJ,0.477178
uuid-7cc46b43ba624d0b8ce939412963fe82,Median OS,0.603398
uuid-7cc46b43ba624d0b8ce939412963fe82,Escudier B,0.469696
uuid-7cc46b43ba624d0b8ce939412963fe82,NEJM,0.387615
uuid-7cc46b43ba624d0b8ce939412963fe82,et al.,0.46851
uuid-7cc46b43ba624d0b8ce939412963fe82,J Clin Oncol,0.51661
uuid-7cc46b43ba624d0b8ce939412963fe82,Topalian,0.337057
uuid-7cc46b43ba624d0b8ce939412963fe82,phase 2 study,0.399402
uuid-7cc46b43ba624d0b8ce939412963fe82,hazard ratio,0.538097
uuid-e6ccd4e4c14a4235b07cff6b6e367631,provided in the Detailed Information,0.31474
uuid-e6ccd4e4c14a4235b07cff6b6e367631,clinical,0.536479
uuid-c2888c7c5c244d5a9352d396302f7b4e,nivolumab,0.892652
uuid-c2888c7c5c244d5a9352d396302f7b4e,Pubmed literature search,0.332727
uuid-c2888c7c5c244d5a9352d396302f7b4e,purposes other than its labeled indication must be considered investigational,0.398107
uuid-c2888c7c5c244d5a9352d396302f7b4e,not identify any citations relevant to your inquiry,0.315611
uuid-c2888c7c5c244d5a9352d396302f7b4e,using the following search terms,0.304559
uuid-eb6e13b37a9a43d98f3aa7d3673e8136,nivolumab,0.361138
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,nivolumab,0.35813
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,Bristol-Myers Squibb,0.40595
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,evaluating,0.420248
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,not conducted any controlled clinical trials/studies,0.416718
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,patients,0.542199
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,efficacy and safety of nivolumab,0.354783
uuid-fecec1f4f2474b1c8e727f04d37ccbe8,therapy,0.310291
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,N Engl J Med,0.616236
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,respectively,0.409266
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,ASCO,0.373445
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,ESMO,0.378373
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,Brahmer J,0.712806
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,docetaxel,0.327482
uuid-2d0e8e0a87574064a2ef1cc9ab9b1a75,Horn L,0.502372
uuid-20061dbf80c743f290f5c542e6af8377,N Engl J Med,0.616236
uuid-20061dbf80c743f290f5c542e6af8377,respectively,0.409266
uuid-20061dbf80c743f290f5c542e6af8377,ASCO,0.373445
uuid-20061dbf80c743f290f5c542e6af8377,ESMO,0.378373
uuid-20061dbf80c743f290f5c542e6af8377,Brahmer J,0.712806
uuid-20061dbf80c743f290f5c542e6af8377,docetaxel,0.327482
uuid-20061dbf80c743f290f5c542e6af8377,Horn L,0.502372
uuid-28e83eec84a84d9e8fd63185608213cc,trial,0.305907
uuid-23945088a3ea4ae0bb4247da8e41faf5,N Engl J Med,0.458509
uuid-23945088a3ea4ae0bb4247da8e41faf5,Lancet Oncol,0.359849
uuid-23945088a3ea4ae0bb4247da8e41faf5,protocol,0.48359
uuid-23945088a3ea4ae0bb4247da8e41faf5,McDermott DF,0.519341
uuid-23945088a3ea4ae0bb4247da8e41faf5,search of published literature,0.335512
uuid-23945088a3ea4ae0bb4247da8e41faf5,Motzer RJ,0.518924
uuid-23945088a3ea4ae0bb4247da8e41faf5,phase 3 study,0.756211
uuid-23945088a3ea4ae0bb4247da8e41faf5,PubMed and EMBASE,0.333205
uuid-23945088a3ea4ae0bb4247da8e41faf5,Escudier B,0.534389
uuid-23945088a3ea4ae0bb4247da8e41faf5,et al.,0.498584
uuid-23945088a3ea4ae0bb4247da8e41faf5,J Clin Oncol,0.43299
uuid-23945088a3ea4ae0bb4247da8e41faf5,Rizvi NA,0.475626
uuid-23945088a3ea4ae0bb4247da8e41faf5,Weber JS,0.583843
uuid-23945088a3ea4ae0bb4247da8e41faf5,phase 2 study,0.615713
uuid-fc9921d56ab3415f96fe1f159b648ff6,nivolumab,0.324658
uuid-fc9921d56ab3415f96fe1f159b648ff6,use of nivolumab for the treatment,0.543355
uuid-fc9921d56ab3415f96fe1f159b648ff6,evaluating,0.348676
uuid-fc9921d56ab3415f96fe1f159b648ff6,efficacy,0.388907
uuid-fc9921d56ab3415f96fe1f159b648ff6,patients,0.419915
uuid-fc9921d56ab3415f96fe1f159b648ff6,search of published literature,0.449959
uuid-fc9921d56ab3415f96fe1f159b648ff6,PubMed and EMBASE,0.444573
uuid-fc9921d56ab3415f96fe1f159b648ff6,not approved,0.582429
uuid-fc9921d56ab3415f96fe1f159b648ff6,clinical trials investigating the safety,0.64854
uuid-fc9921d56ab3415f96fe1f159b648ff6,efficacy and safety of nivolumab,0.399101
uuid-fc9921d56ab3415f96fe1f159b648ff6,present using the following search terms,0.465296
uuid-e5431b5fb9484cc3b8ef614e4e2d0607,Bristol-Myers Squibb,0.36472
uuid-97e96fe23bba4ba9977e8a49a5fca775,Bristol-Myers Squibb,0.431543
uuid-97e96fe23bba4ba9977e8a49a5fca775,not conducted any controlled clinical trials/studies,0.330106
uuid-97e96fe23bba4ba9977e8a49a5fca775,reported,0.336174
uuid-4081873183fa419eb157ae57466222ab,Bristol-Myers Squibb,0.429045
uuid-4081873183fa419eb157ae57466222ab,requested,0.809817
uuid-eaab87d141454ba8852743b524164cd9,N Engl J Med,0.604857
uuid-eaab87d141454ba8852743b524164cd9,non-small cell lung cancer,0.34354
uuid-eaab87d141454ba8852743b524164cd9,ESMO,0.393944
uuid-eaab87d141454ba8852743b524164cd9,Rizvi NA,0.452745
uuid-eaab87d141454ba8852743b524164cd9,Brahmer J,0.679154
uuid-eaab87d141454ba8852743b524164cd9,PD-L1,0.347566
uuid-eaab87d141454ba8852743b524164cd9,Horn L,0.50259
uuid-eaab87d141454ba8852743b524164cd9,platinum-based doublet chemotherapy,0.304136
uuid-254353a171ba44eb97b206609591918f,considered investigational,0.314249
uuid-254353a171ba44eb97b206609591918f,tumors,0.306446
uuid-254353a171ba44eb97b206609591918f,small cell lung cancer,0.375687
uuid-254353a171ba44eb97b206609591918f,trial,0.480517
uuid-254353a171ba44eb97b206609591918f,SCLC,0.371648
uuid-254353a171ba44eb97b206609591918f,phase 1/2 study CA209-032,0.358243
uuid-254353a171ba44eb97b206609591918f,evaluates the efficacy of nivolumab monotherapy,0.345629
uuid-f435a268e25c4d27862170764946d177,requested,0.531305
uuid-f435a268e25c4d27862170764946d177,ESMO,0.358531
uuid-f435a268e25c4d27862170764946d177,Horn L,0.66756
uuid-f435a268e25c4d27862170764946d177,platinum-based doublet chemotherapy,0.579011
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,N Engl J Med,0.751584
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Lancet Oncol,0.473486
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,protocol,0.389524
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,McDermott DF,0.464499
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Motzer RJ,0.429791
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,ESMO,0.394362
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,phase 3 study,0.498455
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Escudier B,0.464846
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,NEJM,0.362533
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,et al.,0.481176
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,J Clin Oncol,0.356969
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Topalian,0.318431
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Rizvi NA,0.637367
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Brahmer J,0.584521
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,PD-L1,0.34848
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Weber JS,0.453116
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,phase 2 study,0.570384
uuid-7ee23d3e994240aeb4ca1bc91e006ac8,Horn L,0.354795
uuid-de0ea699715f40a9802505b64aab0a2a,requested,0.594234
uuid-f03974ce56444c5eb26c904806839e69,patients with advanced or metastatic,0.468858
uuid-f03974ce56444c5eb26c904806839e69,nivolumab combined with ipilimumab,0.446918
uuid-f03974ce56444c5eb26c904806839e69,not approved,0.352562
uuid-f03974ce56444c5eb26c904806839e69,clinical trials investigating the safety,0.429501
uuid-f03974ce56444c5eb26c904806839e69,bladder cancer,0.950698
uuid-749c2462b7f843e593d2f183b0163dd6,N Engl J Med,0.426453
uuid-749c2462b7f843e593d2f183b0163dd6,protocol,0.42829
uuid-749c2462b7f843e593d2f183b0163dd6,McDermott DF,0.446636
uuid-749c2462b7f843e593d2f183b0163dd6,Motzer RJ,0.429452
uuid-749c2462b7f843e593d2f183b0163dd6,Escudier B,0.449755
uuid-749c2462b7f843e593d2f183b0163dd6,et al.,0.454861
uuid-749c2462b7f843e593d2f183b0163dd6,J Clin Oncol,0.383532
uuid-749c2462b7f843e593d2f183b0163dd6,Rizvi NA,0.304714
uuid-749c2462b7f843e593d2f183b0163dd6,phase 2 study,0.350338
uuid-cf8bfa91e06c4fd98f938a3a33fc88d1,Opdivo,0.365411
uuid-cf8bfa91e06c4fd98f938a3a33fc88d1,adverse,0.628764
uuid-cf8bfa91e06c4fd98f938a3a33fc88d1,reported,0.836555
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,95% CI,0.524855
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,respectively,0.383655
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,ASCO,0.303153
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Lancet Oncol,0.368041
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Objective response rate,0.504846
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,ORR,0.465366
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Median overall survival,0.346516
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Median OS,0.33538
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,ASCO 2015,0.336983
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,small cell lung cancer,0.336892
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,SCLC,0.344367
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Antonia SJ,0.55269
uuid-e2798e65d71f4dc8bb9e41fb1f9cce7f,Median duration of response,0.649605
uuid-e68497dcc62443cdb445695deb617697,adverse,0.677734
uuid-e68497dcc62443cdb445695deb617697,phase 3 study,0.48003
uuid-e68497dcc62443cdb445695deb617697,melanoma,0.411352
uuid-e68497dcc62443cdb445695deb617697,Weber JS,0.31904
uuid-e68497dcc62443cdb445695deb617697,phase 2 study,0.319618
uuid-e68497dcc62443cdb445695deb617697,reported,0.343242
uuid-dcc97eacbe2f451aa933c0401fe93138,N Engl J Med,0.616236
uuid-dcc97eacbe2f451aa933c0401fe93138,respectively,0.409266
uuid-dcc97eacbe2f451aa933c0401fe93138,ASCO,0.373445
uuid-dcc97eacbe2f451aa933c0401fe93138,ESMO,0.378373
uuid-dcc97eacbe2f451aa933c0401fe93138,Brahmer J,0.712806
uuid-dcc97eacbe2f451aa933c0401fe93138,docetaxel,0.327482
uuid-dcc97eacbe2f451aa933c0401fe93138,Horn L,0.502372
uuid-e339835eecf64abaa285ee1704839103,OS,0.62262
uuid-e339835eecf64abaa285ee1704839103,PFS,0.65903
uuid-e339835eecf64abaa285ee1704839103,Overall survival,0.644151
uuid-742ef8eb79134307b5cbecb0370a590a,ESMO,0.500333
uuid-742ef8eb79134307b5cbecb0370a590a,Horn L,0.306308
uuid-de138ac5126546d9a56c03dc3e2e8036,N Engl J Med,0.442834
uuid-de138ac5126546d9a56c03dc3e2e8036,protocol,0.763252
uuid-de138ac5126546d9a56c03dc3e2e8036,McDermott DF,0.733103
uuid-de138ac5126546d9a56c03dc3e2e8036,Motzer RJ,0.811057
uuid-de138ac5126546d9a56c03dc3e2e8036,phase 3 study,0.420895
uuid-de138ac5126546d9a56c03dc3e2e8036,Escudier B,0.741048
uuid-de138ac5126546d9a56c03dc3e2e8036,NEJM,0.402544
uuid-de138ac5126546d9a56c03dc3e2e8036,et al.,0.660398
uuid-de138ac5126546d9a56c03dc3e2e8036,J Clin Oncol,0.786367
uuid-de138ac5126546d9a56c03dc3e2e8036,Topalian,0.392395
uuid-de138ac5126546d9a56c03dc3e2e8036,phase 1 study,0.513779
uuid-de138ac5126546d9a56c03dc3e2e8036,CA209-003,0.583337
uuid-de138ac5126546d9a56c03dc3e2e8036,phase 2 study,0.675447
uuid-de138ac5126546d9a56c03dc3e2e8036,present using the following search terms,0.304589
uuid-de138ac5126546d9a56c03dc3e2e8036,investigating,0.633101
uuid-89872861e743455dab6ab7856d373541,N Engl J Med,0.872636
uuid-89872861e743455dab6ab7856d373541,Lancet Oncol,0.471221
uuid-89872861e743455dab6ab7856d373541,protocol,0.770081
uuid-89872861e743455dab6ab7856d373541,McDermott DF,0.794814
uuid-89872861e743455dab6ab7856d373541,Motzer RJ,0.777272
uuid-89872861e743455dab6ab7856d373541,phase 3 study,0.528633
uuid-89872861e743455dab6ab7856d373541,Escudier B,0.803501
uuid-89872861e743455dab6ab7856d373541,NEJM,0.474501
uuid-89872861e743455dab6ab7856d373541,et al.,0.764597
uuid-89872861e743455dab6ab7856d373541,J Clin Oncol,0.710391
uuid-89872861e743455dab6ab7856d373541,Topalian,0.445781
uuid-89872861e743455dab6ab7856d373541,Rizvi NA,0.665148
uuid-89872861e743455dab6ab7856d373541,Brahmer J,0.616699
uuid-89872861e743455dab6ab7856d373541,Weber JS,0.462062
uuid-89872861e743455dab6ab7856d373541,phase 2 study,0.747924
uuid-68a481ee0ce44e0fb13736614d17ab90,ipilimumab,0.385692
uuid-68a481ee0ce44e0fb13736614d17ab90,ASCO 2015,0.417944
uuid-68a481ee0ce44e0fb13736614d17ab90,partial response,0.382425
uuid-68a481ee0ce44e0fb13736614d17ab90,Stable disease,0.586335
uuid-68a481ee0ce44e0fb13736614d17ab90,cohort,0.307748
uuid-542a6db420fc46fdac6838ae634dcca4,95% CI,0.524855
uuid-542a6db420fc46fdac6838ae634dcca4,respectively,0.383655
uuid-542a6db420fc46fdac6838ae634dcca4,ASCO,0.303153
uuid-542a6db420fc46fdac6838ae634dcca4,Lancet Oncol,0.368041
uuid-542a6db420fc46fdac6838ae634dcca4,Objective response rate,0.504846
uuid-542a6db420fc46fdac6838ae634dcca4,ORR,0.465366
uuid-542a6db420fc46fdac6838ae634dcca4,Median overall survival,0.346516
uuid-542a6db420fc46fdac6838ae634dcca4,Median OS,0.33538
uuid-542a6db420fc46fdac6838ae634dcca4,ASCO 2015,0.336983
uuid-542a6db420fc46fdac6838ae634dcca4,small cell lung cancer,0.336892
uuid-542a6db420fc46fdac6838ae634dcca4,SCLC,0.344367
uuid-542a6db420fc46fdac6838ae634dcca4,Antonia SJ,0.55269
uuid-542a6db420fc46fdac6838ae634dcca4,Median duration of response,0.649605
uuid-ab1958f6ba48431aaa03d4fbb233633a,ASCO,0.807066
uuid-4ad9e48a09d84715ad16e096e98df63f,N Engl J Med,0.616236
uuid-4ad9e48a09d84715ad16e096e98df63f,respectively,0.409266
uuid-4ad9e48a09d84715ad16e096e98df63f,ASCO,0.373445
uuid-4ad9e48a09d84715ad16e096e98df63f,ESMO,0.378373
uuid-4ad9e48a09d84715ad16e096e98df63f,Brahmer J,0.712806
uuid-4ad9e48a09d84715ad16e096e98df63f,docetaxel,0.327482
uuid-4ad9e48a09d84715ad16e096e98df63f,Horn L,0.502372
uuid-56b8c8825a8746fea6b70893aed2d4bb,N Engl J Med,0.302601
uuid-56b8c8825a8746fea6b70893aed2d4bb,AEs,0.348167
uuid-56b8c8825a8746fea6b70893aed2d4bb,patients,0.536884
uuid-56b8c8825a8746fea6b70893aed2d4bb,provided in the Detailed Information,0.387544
uuid-56b8c8825a8746fea6b70893aed2d4bb,ESMO,0.462801
uuid-56b8c8825a8746fea6b70893aed2d4bb,NEJM,0.66427
uuid-56b8c8825a8746fea6b70893aed2d4bb,Topalian,0.692873
uuid-56b8c8825a8746fea6b70893aed2d4bb,grade 3 to 4 AEs,0.626596
uuid-3ca67ea1eb20442ba76394dfc5f064ab,trial,0.405524
uuid-e4d08ac5567d468aab6c348e57cc4880,N Engl J Med,0.302601
uuid-e4d08ac5567d468aab6c348e57cc4880,AEs,0.348167
uuid-e4d08ac5567d468aab6c348e57cc4880,patients,0.536884
uuid-e4d08ac5567d468aab6c348e57cc4880,provided in the Detailed Information,0.387544
uuid-e4d08ac5567d468aab6c348e57cc4880,ESMO,0.462801
uuid-e4d08ac5567d468aab6c348e57cc4880,NEJM,0.66427
uuid-e4d08ac5567d468aab6c348e57cc4880,Topalian,0.692873
uuid-e4d08ac5567d468aab6c348e57cc4880,grade 3 to 4 AEs,0.626596
uuid-f38c39f6b95e414cae40168590564607,adverse,0.851932
uuid-f38c39f6b95e414cae40168590564607,melanoma,0.419973
uuid-f38c39f6b95e414cae40168590564607,reported,0.336263
uuid-80f515167123436db56686c03b5d6bd7,provided in the Detailed Information,0.578509
uuid-80f515167123436db56686c03b5d6bd7,clinical,0.470357
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,N Engl J Med,0.442834
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,protocol,0.763252
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,McDermott DF,0.733103
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,Motzer RJ,0.811057
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,phase 3 study,0.420895
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,Escudier B,0.741048
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,NEJM,0.402544
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,et al.,0.660398
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,J Clin Oncol,0.786367
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,Topalian,0.392395
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,phase 1 study,0.513779
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,CA209-003,0.583337
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,phase 2 study,0.675447
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,present using the following search terms,0.304589
uuid-34a82a0f20de40e59d5a2f3d42f8ad52,investigating,0.633101
uuid-91800bcf52fb415cbba1af83a7f386ec,requested,0.359505
uuid-0389d4ec3696417698a214a0a8fd7234,use of nivolumab for the treatment,0.440423
uuid-0389d4ec3696417698a214a0a8fd7234,search of published literature,0.311531
uuid-0389d4ec3696417698a214a0a8fd7234,PubMed and EMBASE,0.312811
uuid-0389d4ec3696417698a214a0a8fd7234,not approved,0.404782
uuid-0389d4ec3696417698a214a0a8fd7234,open-label,0.578291
uuid-0389d4ec3696417698a214a0a8fd7234,clinical trials investigating the safety,0.440014
uuid-0389d4ec3696417698a214a0a8fd7234,present using the following search terms,0.328669
uuid-0389d4ec3696417698a214a0a8fd7234,phase,0.41185
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,Bristol-Myers Squibb,0.341822
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,not conducted any controlled clinical trials/studies,0.304507
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,Opdivo,0.461382
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,Pubmed literature search,0.614325
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,purposes other than its labeled indication must be considered investigational,0.586645
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,not identify any citations relevant to your inquiry,0.606087
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,adverse,0.304183
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,using the following search terms,0.642331
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,databases,0.315039
uuid-fe5a8b77ea42417ba3b58cb83a2bbb74,reported,0.556704
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,N Engl J Med,0.604857
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,non-small cell lung cancer,0.34354
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,ESMO,0.393944
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,Rizvi NA,0.452745
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,Brahmer J,0.679154
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,PD-L1,0.347566
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,Horn L,0.50259
uuid-a224a87bd24e4cb5993b2fc4d4ae6be2,platinum-based doublet chemotherapy,0.304136
uuid-d4adcb90feb449238630a86b70342fd6,PD-L1,0.423912
uuid-d4adcb90feb449238630a86b70342fd6,trial,0.418567
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,OS,0.506839
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,95% CI,0.914259
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,respectively,0.57945
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,Objective response rate,0.616133
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,ORR,0.78386
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,PFS,0.374029
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,Median overall survival,0.850584
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,monotherapy,0.435128
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,Median OS,0.829523
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,docetaxel,0.347663
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,hazard ratio,0.887303
uuid-9b9cf932f1b043ad87beaeb035c3dcb2,Median duration of response,0.367027
uuid-4e5dda2fcea14cc5974b24acf496a157,RCC,0.843791
uuid-c1fd2b11c6564cd5bc0209ca42ff903c,requested,0.594234
uuid-f92e50c429ce4e7d8b6e0db30a4f9344,RCC,0.909054
uuid-cfcaae4d41af4b529887c92cabf2729a,ESMO,0.603759
uuid-cfcaae4d41af4b529887c92cabf2729a,Horn L,0.484674
uuid-ba2a25de95cc4ee1b885edb7c22cc50e,requested,0.531305
uuid-ba2a25de95cc4ee1b885edb7c22cc50e,ESMO,0.358531
uuid-ba2a25de95cc4ee1b885edb7c22cc50e,Horn L,0.66756
uuid-ba2a25de95cc4ee1b885edb7c22cc50e,platinum-based doublet chemotherapy,0.579011
uuid-6afc022f8b334d7e9e3cdce5789fdf79,requested,0.77383
uuid-6afc022f8b334d7e9e3cdce5789fdf79,Horn L,0.526245
uuid-6afc022f8b334d7e9e3cdce5789fdf79,platinum-based doublet chemotherapy,0.439752
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,OS,0.44149
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,95% CI,0.833403
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,ASCO,0.32927
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,Objective response rate,0.545269
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,ORR,0.618524
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,PFS,0.396858
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,Median overall survival,0.72593
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,monotherapy,0.33356
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,Median OS,0.763854
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,hazard ratio,0.766648
uuid-cd251bc46abd4bd995f7f50f2e9a5f51,Median duration of response,0.442682
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,OS,0.387982
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,95% CI,0.745043
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,respectively,0.729294
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,Objective response rate,0.590876
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,ORR,0.722442
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,Median overall survival,0.659043
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,monotherapy,0.514468
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,Median OS,0.696688
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,PD-L1,0.300997
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,docetaxel,0.635065
uuid-4ab0f7aac9f64c6fbcdac364484c31f3,hazard ratio,0.729977
uuid-b4d4ad86431747949807e7ff61c963bc,Objective response rate,0.451139
uuid-b4d4ad86431747949807e7ff61c963bc,clinicaltrials.gov,0.503706
uuid-326c463947fd4b97a1998cb3e60f3b9a,adverse,0.308226
uuid-326c463947fd4b97a1998cb3e60f3b9a,RCC,0.764389
uuid-b183358a3bf44722bb12d653e8d351a8,ASCO,0.807066
uuid-a7822bf885734df3bafa56ff9c5b09de,N Engl J Med,0.616236
uuid-a7822bf885734df3bafa56ff9c5b09de,respectively,0.409266
uuid-a7822bf885734df3bafa56ff9c5b09de,ASCO,0.373445
uuid-a7822bf885734df3bafa56ff9c5b09de,ESMO,0.378373
uuid-a7822bf885734df3bafa56ff9c5b09de,Brahmer J,0.712806
uuid-a7822bf885734df3bafa56ff9c5b09de,docetaxel,0.327482
uuid-a7822bf885734df3bafa56ff9c5b09de,Horn L,0.502372
uuid-104ed13b0e4345d69cf93cc4825c506e,OS,0.62262
uuid-104ed13b0e4345d69cf93cc4825c506e,PFS,0.65903
uuid-104ed13b0e4345d69cf93cc4825c506e,Overall survival,0.644151
uuid-91fcb05f22694d9f9fd91772f4c51f93,95% CI,0.520262
uuid-91fcb05f22694d9f9fd91772f4c51f93,respectively,0.504068
uuid-91fcb05f22694d9f9fd91772f4c51f93,Objective response rate,0.458568
uuid-91fcb05f22694d9f9fd91772f4c51f93,ORR,0.525868
uuid-91fcb05f22694d9f9fd91772f4c51f93,Median overall survival,0.455633
uuid-91fcb05f22694d9f9fd91772f4c51f93,Median OS,0.507448
uuid-91fcb05f22694d9f9fd91772f4c51f93,docetaxel,0.383115
uuid-91fcb05f22694d9f9fd91772f4c51f93,hazard ratio,0.462119
uuid-057345aca7da415a87fcb92c41a9b0b9,use of nivolumab for the treatment,0.410333
uuid-057345aca7da415a87fcb92c41a9b0b9,efficacy,0.465563
uuid-057345aca7da415a87fcb92c41a9b0b9,not approved,0.609517
uuid-057345aca7da415a87fcb92c41a9b0b9,clinical trials investigating the safety,0.735441
uuid-1cfd2911c2644e5a94c7f14fd78e500e,ESMO,0.603759
uuid-1cfd2911c2644e5a94c7f14fd78e500e,Horn L,0.484674
uuid-7bb0d064e6b749e48d7f21f6e1d5afcb,tumors,0.351986
uuid-7bb0d064e6b749e48d7f21f6e1d5afcb,trial,0.560402
uuid-7bb0d064e6b749e48d7f21f6e1d5afcb,therapy,0.325815
uuid-6cb8876a9f514aac88dbbb227861140e,Bristol-Myers Squibb,0.632259
uuid-6cb8876a9f514aac88dbbb227861140e,evaluating,0.436195
uuid-6cb8876a9f514aac88dbbb227861140e,not conducted any controlled clinical trials/studies,0.48116
uuid-6cb8876a9f514aac88dbbb227861140e,efficacy and safety of nivolumab,0.372656
uuid-6cb8876a9f514aac88dbbb227861140e,reported,0.310403
uuid-23136d45974b4a89a9e44d04ec2e075e,Bristol-Myers Squibb,0.682514
uuid-23136d45974b4a89a9e44d04ec2e075e,evaluating,0.760722
uuid-23136d45974b4a89a9e44d04ec2e075e,not conducted any controlled clinical trials/studies,0.821539
uuid-23136d45974b4a89a9e44d04ec2e075e,Pubmed literature search,0.550877
uuid-23136d45974b4a89a9e44d04ec2e075e,purposes other than its labeled indication must be considered investigational,0.646284
uuid-23136d45974b4a89a9e44d04ec2e075e,not identify any citations relevant to your inquiry,0.499022
uuid-23136d45974b4a89a9e44d04ec2e075e,using the following search terms,0.474206
uuid-23136d45974b4a89a9e44d04ec2e075e,efficacy and safety of nivolumab,0.586666
uuid-ebb31306b43441269ed16a37d03dff39,patients with advanced or metastatic,0.468858
uuid-ebb31306b43441269ed16a37d03dff39,nivolumab combined with ipilimumab,0.446918
uuid-ebb31306b43441269ed16a37d03dff39,not approved,0.352562
uuid-ebb31306b43441269ed16a37d03dff39,clinical trials investigating the safety,0.429501
uuid-ebb31306b43441269ed16a37d03dff39,bladder cancer,0.950698
uuid-7f517279def24e6ba9eae244550a2748,Bristol-Myers Squibb,0.724246
uuid-7f517279def24e6ba9eae244550a2748,evaluating,0.664067
uuid-7f517279def24e6ba9eae244550a2748,not conducted any controlled clinical trials/studies,0.711784
uuid-7f517279def24e6ba9eae244550a2748,patients,0.389919
uuid-7f517279def24e6ba9eae244550a2748,efficacy and safety of nivolumab,0.630153
uuid-f314ab11f7084935b3f0a2ef86867714,requested,0.594234
uuid-dd181ad1c9344ff59646170adbef3f1d,requested,0.594234
uuid-a58f3e4ffe3d4fb9a579a918e4fd47a3,requested,0.531305
uuid-a58f3e4ffe3d4fb9a579a918e4fd47a3,ESMO,0.358531
uuid-a58f3e4ffe3d4fb9a579a918e4fd47a3,Horn L,0.66756
uuid-a58f3e4ffe3d4fb9a579a918e4fd47a3,platinum-based doublet chemotherapy,0.579011
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,OS,0.44149
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,95% CI,0.833403
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,ASCO,0.32927
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,Objective response rate,0.545269
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,ORR,0.618524
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,PFS,0.396858
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,Median overall survival,0.72593
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,monotherapy,0.33356
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,Median OS,0.763854
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,hazard ratio,0.766648
uuid-cb7be7e99a6a4fde86b2ec9e77a220a5,Median duration of response,0.442682
uuid-980ba55ed9904e70947df514c2e83fd9,small cell lung cancer,0.481596
uuid-980ba55ed9904e70947df514c2e83fd9,partial response,0.302847
uuid-980ba55ed9904e70947df514c2e83fd9,SCLC,0.547524
uuid-980ba55ed9904e70947df514c2e83fd9,therapy,0.861135
uuid-980ba55ed9904e70947df514c2e83fd9,relapsed,0.398505
uuid-afe836c0d1d84273bc92f4511aef8ade,provided in the Detailed Information,0.616397
uuid-afe836c0d1d84273bc92f4511aef8ade,clinical,0.585028
uuid-31dfd76de54347b5a9108dbf21915d98,ASCO,0.807066
uuid-2dd99ec0931a4d4d8050922e5b031080,mg,0.319008
uuid-90054bae66ea4e5f9555e69b8bd6be19,N Engl J Med,0.347178
uuid-90054bae66ea4e5f9555e69b8bd6be19,Lancet Oncol,0.359155
uuid-90054bae66ea4e5f9555e69b8bd6be19,protocol,0.371457
uuid-90054bae66ea4e5f9555e69b8bd6be19,McDermott DF,0.414017
uuid-90054bae66ea4e5f9555e69b8bd6be19,Motzer RJ,0.384536
uuid-90054bae66ea4e5f9555e69b8bd6be19,phase 3 study,0.443559
uuid-90054bae66ea4e5f9555e69b8bd6be19,Escudier B,0.411866
uuid-90054bae66ea4e5f9555e69b8bd6be19,et al.,0.39703
uuid-90054bae66ea4e5f9555e69b8bd6be19,J Clin Oncol,0.378141
uuid-90054bae66ea4e5f9555e69b8bd6be19,phase 1 study,0.326203
uuid-90054bae66ea4e5f9555e69b8bd6be19,Rizvi NA,0.563772
uuid-90054bae66ea4e5f9555e69b8bd6be19,mg,0.40261
uuid-90054bae66ea4e5f9555e69b8bd6be19,Weber JS,0.418348
uuid-90054bae66ea4e5f9555e69b8bd6be19,phase 2 study,0.587446
uuid-90054bae66ea4e5f9555e69b8bd6be19,kg,0.361586
uuid-5e0a9c5168154ab2bad8c9ef6056d062,requested,0.595565
uuid-7c0a1fadc16747a6bb94fe89f3d783a5,nivolumab,0.359772
uuid-0fba56254a81457cbd1838829b6f7953,ESMO,0.603759
uuid-0fba56254a81457cbd1838829b6f7953,Horn L,0.484674
uuid-790febad97c641b1aa2d957fc87cae30,RCC,0.840732
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,nivolumab,0.575226
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,Bristol-Myers Squibb,0.436942
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,evaluating,0.597197
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,not conducted any controlled clinical trials/studies,0.656299
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,Pubmed literature search,0.875849
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,purposes other than its labeled indication must be considered investigational,0.939806
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,not identify any citations relevant to your inquiry,0.835157
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,using the following search terms,0.822363
uuid-d0a5f8ccdbbc4625a7d5fca40abe88b4,efficacy and safety of nivolumab,0.434898
uuid-43211aabb93c4254889feac49b5ad488,Bristol-Myers Squibb,0.494637
uuid-3047bbb27c974ac1a6ad3c5af47df9de,N Engl J Med,0.616236
uuid-3047bbb27c974ac1a6ad3c5af47df9de,respectively,0.409266
uuid-3047bbb27c974ac1a6ad3c5af47df9de,ASCO,0.373445
uuid-3047bbb27c974ac1a6ad3c5af47df9de,ESMO,0.378373
uuid-3047bbb27c974ac1a6ad3c5af47df9de,Brahmer J,0.712806
uuid-3047bbb27c974ac1a6ad3c5af47df9de,docetaxel,0.327482
uuid-3047bbb27c974ac1a6ad3c5af47df9de,Horn L,0.502372
uuid-255cb62a78804ae18e70d29b2ec47494,patients with advanced or metastatic,0.478326
uuid-255cb62a78804ae18e70d29b2ec47494,nivolumab combined with ipilimumab,0.498766
uuid-255cb62a78804ae18e70d29b2ec47494,not approved,0.34724
uuid-255cb62a78804ae18e70d29b2ec47494,clinical trials investigating the safety,0.426729
uuid-255cb62a78804ae18e70d29b2ec47494,bladder cancer,0.6548
uuid-f745af6a903d4dda98be77a90157f1b6,N Engl J Med,0.442834
uuid-f745af6a903d4dda98be77a90157f1b6,protocol,0.763252
uuid-f745af6a903d4dda98be77a90157f1b6,McDermott DF,0.733103
uuid-f745af6a903d4dda98be77a90157f1b6,Motzer RJ,0.811057
uuid-f745af6a903d4dda98be77a90157f1b6,phase 3 study,0.420895
uuid-f745af6a903d4dda98be77a90157f1b6,Escudier B,0.741048
uuid-f745af6a903d4dda98be77a90157f1b6,NEJM,0.402544
uuid-f745af6a903d4dda98be77a90157f1b6,et al.,0.660398
uuid-f745af6a903d4dda98be77a90157f1b6,J Clin Oncol,0.786367
uuid-f745af6a903d4dda98be77a90157f1b6,Topalian,0.392395
uuid-f745af6a903d4dda98be77a90157f1b6,phase 1 study,0.513779
uuid-f745af6a903d4dda98be77a90157f1b6,CA209-003,0.583337
uuid-f745af6a903d4dda98be77a90157f1b6,phase 2 study,0.675447
uuid-f745af6a903d4dda98be77a90157f1b6,present using the following search terms,0.304589
uuid-f745af6a903d4dda98be77a90157f1b6,investigating,0.633101
uuid-1102dd646fab411eb37b173b31507144,N Engl J Med,0.373321
uuid-1102dd646fab411eb37b173b31507144,provided in the Detailed Information,0.610623
uuid-1102dd646fab411eb37b173b31507144,protocol,0.348707
uuid-1102dd646fab411eb37b173b31507144,McDermott DF,0.380783
uuid-1102dd646fab411eb37b173b31507144,Motzer RJ,0.359708
uuid-1102dd646fab411eb37b173b31507144,clinical,0.410641
uuid-1102dd646fab411eb37b173b31507144,Escudier B,0.381028
uuid-1102dd646fab411eb37b173b31507144,et al.,0.369532
uuid-1102dd646fab411eb37b173b31507144,J Clin Oncol,0.339155
uuid-1102dd646fab411eb37b173b31507144,Rizvi NA,0.315138
uuid-1102dd646fab411eb37b173b31507144,Weber JS,0.441328
uuid-1102dd646fab411eb37b173b31507144,phase 2 study,0.316899
uuid-ce198475c04f4509a7d6469e59eb707b,open-label,0.539462
uuid-ce198475c04f4509a7d6469e59eb707b,phase,0.350616
uuid-e8ba25a0d5a149798b92767084415bc1,requested,0.31148
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,search of published literature,0.794752
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,clinical,0.300316
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,phase 3 study,0.380444
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,PubMed and EMBASE,0.790759
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,trial,0.364612
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,efficacy and safety of nivolumab,0.555053
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,not identify any citations relevant to your request,0.315471
uuid-1b75cd4ebec24780ae5eb4c2bde5da70,present using the following search terms,0.745003
uuid-d75e43f688a348f3acf4ceec03f916a9,monotherapy,0.506819
uuid-d75e43f688a348f3acf4ceec03f916a9,mg,0.648288
uuid-d75e43f688a348f3acf4ceec03f916a9,kg,0.63068
uuid-d75e43f688a348f3acf4ceec03f916a9,phase,0.309642
uuid-d75e43f688a348f3acf4ceec03f916a9,cohort,0.682617
uuid-6a0185c87cd646eb9465c1ae04ab9db8,adverse,0.309398
uuid-6a0185c87cd646eb9465c1ae04ab9db8,reported,0.327133
uuid-260ce8f1c0e54910989621c527371d05,RCC,0.888397
uuid-78be54908f5145d29f3d48065cf1aaae,RCC,0.865354
uuid-80f84fca09184d36884c738f4a84706e,use of nivolumab for the treatment,0.440423
uuid-80f84fca09184d36884c738f4a84706e,search of published literature,0.311531
uuid-80f84fca09184d36884c738f4a84706e,PubMed and EMBASE,0.312811
uuid-80f84fca09184d36884c738f4a84706e,not approved,0.404782
uuid-80f84fca09184d36884c738f4a84706e,open-label,0.578291
uuid-80f84fca09184d36884c738f4a84706e,clinical trials investigating the safety,0.440014
uuid-80f84fca09184d36884c738f4a84706e,present using the following search terms,0.328669
uuid-80f84fca09184d36884c738f4a84706e,phase,0.41185
uuid-4d369992966f4377b68070657ac23cf1,ipilimumab,0.385692
uuid-4d369992966f4377b68070657ac23cf1,ASCO 2015,0.417944
uuid-4d369992966f4377b68070657ac23cf1,partial response,0.382425
uuid-4d369992966f4377b68070657ac23cf1,Stable disease,0.586335
uuid-4d369992966f4377b68070657ac23cf1,cohort,0.307748
uuid-f54f7e1a39064f47b966757b85f7e2c9,provided in the Detailed Information,0.578509
uuid-f54f7e1a39064f47b966757b85f7e2c9,clinical,0.470357
uuid-3f929410a22c4af7a278aca532590218,OS,0.300809
uuid-3f929410a22c4af7a278aca532590218,95% CI,0.487161
uuid-3f929410a22c4af7a278aca532590218,respectively,0.581809
uuid-3f929410a22c4af7a278aca532590218,ASCO,0.337958
uuid-3f929410a22c4af7a278aca532590218,Objective response rate,0.579467
uuid-3f929410a22c4af7a278aca532590218,ORR,0.605666
uuid-3f929410a22c4af7a278aca532590218,Median overall survival,0.423347
uuid-3f929410a22c4af7a278aca532590218,monotherapy,0.389069
uuid-3f929410a22c4af7a278aca532590218,Median OS,0.480031
uuid-3f929410a22c4af7a278aca532590218,docetaxel,0.341316
uuid-3f929410a22c4af7a278aca532590218,hazard ratio,0.45179
uuid-bb6965bc82054214a0788538de9f205d,RCC,0.909054
uuid-cf6645b162e640e0a2059a0fbf575b0d,patients,0.315933
uuid-e8d84cadec9c424ebf149a791da85a11,fatigue,0.531122
uuid-8d1f618d63a94e02bd8f25c4692433b1,PD-L1,0.729546
uuid-a86d6486733f42edb76db487b838812a,requested,0.594234
uuid-81f0f0805cf04851b18b656ff9352881,N Engl J Med,0.616236
uuid-81f0f0805cf04851b18b656ff9352881,respectively,0.409266
uuid-81f0f0805cf04851b18b656ff9352881,ASCO,0.373445
uuid-81f0f0805cf04851b18b656ff9352881,ESMO,0.378373
uuid-81f0f0805cf04851b18b656ff9352881,Brahmer J,0.712806
uuid-81f0f0805cf04851b18b656ff9352881,docetaxel,0.327482
uuid-81f0f0805cf04851b18b656ff9352881,Horn L,0.502372
uuid-f04d247f17724014a4ffac904b819523,ESMO,0.603759
uuid-f04d247f17724014a4ffac904b819523,Horn L,0.484674
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,N Engl J Med,0.616236
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,respectively,0.409266
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,ASCO,0.373445
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,ESMO,0.378373
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,Brahmer J,0.712806
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,docetaxel,0.327482
uuid-c2b03d7f05b846ffa3ad105377f2f4f3,Horn L,0.502372
uuid-042fa578d1f043dfaebe4fd288a64b24,OS,0.44149
uuid-042fa578d1f043dfaebe4fd288a64b24,95% CI,0.833403
uuid-042fa578d1f043dfaebe4fd288a64b24,ASCO,0.32927
uuid-042fa578d1f043dfaebe4fd288a64b24,Objective response rate,0.545269
uuid-042fa578d1f043dfaebe4fd288a64b24,ORR,0.618524
uuid-042fa578d1f043dfaebe4fd288a64b24,PFS,0.396858
uuid-042fa578d1f043dfaebe4fd288a64b24,Median overall survival,0.72593
uuid-042fa578d1f043dfaebe4fd288a64b24,monotherapy,0.33356
uuid-042fa578d1f043dfaebe4fd288a64b24,Median OS,0.763854
uuid-042fa578d1f043dfaebe4fd288a64b24,hazard ratio,0.766648
uuid-042fa578d1f043dfaebe4fd288a64b24,Median duration of response,0.442682
uuid-50e63e6b0e9a4131a11ccf9ee1515a40,ASCO,0.807066
uuid-00bfd8b5209743c48b7fb840a0ac9cae,PD-L1,0.743561
uuid-2f30579ce5124ab1ade599964a067b22,N Engl J Med,0.442834
uuid-2f30579ce5124ab1ade599964a067b22,protocol,0.763252
uuid-2f30579ce5124ab1ade599964a067b22,McDermott DF,0.733103
uuid-2f30579ce5124ab1ade599964a067b22,Motzer RJ,0.811057
uuid-2f30579ce5124ab1ade599964a067b22,phase 3 study,0.420895
uuid-2f30579ce5124ab1ade599964a067b22,Escudier B,0.741048
uuid-2f30579ce5124ab1ade599964a067b22,NEJM,0.402544
uuid-2f30579ce5124ab1ade599964a067b22,et al.,0.660398
uuid-2f30579ce5124ab1ade599964a067b22,J Clin Oncol,0.786367
uuid-2f30579ce5124ab1ade599964a067b22,Topalian,0.392395
uuid-2f30579ce5124ab1ade599964a067b22,phase 1 study,0.513779
uuid-2f30579ce5124ab1ade599964a067b22,CA209-003,0.583337
uuid-2f30579ce5124ab1ade599964a067b22,phase 2 study,0.675447
uuid-2f30579ce5124ab1ade599964a067b22,present using the following search terms,0.304589
uuid-2f30579ce5124ab1ade599964a067b22,investigating,0.633101
uuid-e771f6af3a3a489f8de163b229475b73,N Engl J Med,0.342504
uuid-e771f6af3a3a489f8de163b229475b73,protocol,0.342938
uuid-e771f6af3a3a489f8de163b229475b73,McDermott DF,0.371451
uuid-e771f6af3a3a489f8de163b229475b73,Motzer RJ,0.34781
uuid-e771f6af3a3a489f8de163b229475b73,Escudier B,0.370781
uuid-e771f6af3a3a489f8de163b229475b73,et al.,0.377999
uuid-e771f6af3a3a489f8de163b229475b73,J Clin Oncol,0.314889
uuid-a09fa6513e804729979377c320493deb,requested,0.594234
uuid-90522ca927084453ac229b7e1a373e3b,RCC,0.906223
uuid-7c92e03b919d460c9af731a273446990,N Engl J Med,0.643107
uuid-7c92e03b919d460c9af731a273446990,respectively,0.398989
uuid-7c92e03b919d460c9af731a273446990,Median overall survival,0.30615
uuid-7c92e03b919d460c9af731a273446990,ESMO,0.534703
uuid-7c92e03b919d460c9af731a273446990,Median OS,0.319939
uuid-7c92e03b919d460c9af731a273446990,Brahmer J,0.658171
uuid-7c92e03b919d460c9af731a273446990,Horn L,0.594193
uuid-38f3b2d71adb40189ba1c6ec0e095c17,Bristol-Myers Squibb,0.341822
uuid-38f3b2d71adb40189ba1c6ec0e095c17,not conducted any controlled clinical trials/studies,0.304507
uuid-38f3b2d71adb40189ba1c6ec0e095c17,Opdivo,0.461382
uuid-38f3b2d71adb40189ba1c6ec0e095c17,Pubmed literature search,0.614325
uuid-38f3b2d71adb40189ba1c6ec0e095c17,purposes other than its labeled indication must be considered investigational,0.586645
uuid-38f3b2d71adb40189ba1c6ec0e095c17,not identify any citations relevant to your inquiry,0.606087
uuid-38f3b2d71adb40189ba1c6ec0e095c17,adverse,0.304183
uuid-38f3b2d71adb40189ba1c6ec0e095c17,using the following search terms,0.642331
uuid-38f3b2d71adb40189ba1c6ec0e095c17,databases,0.315039
uuid-38f3b2d71adb40189ba1c6ec0e095c17,reported,0.556704
uuid-4f67424b590744468acf24a4f80e9cbe,ipilimumab,0.385692
uuid-4f67424b590744468acf24a4f80e9cbe,ASCO 2015,0.417944
uuid-4f67424b590744468acf24a4f80e9cbe,partial response,0.382425
uuid-4f67424b590744468acf24a4f80e9cbe,Stable disease,0.586335
uuid-4f67424b590744468acf24a4f80e9cbe,cohort,0.307748
uuid-8a5ce1cf58564fceaf97c1161a4707eb,patients with advanced or metastatic,0.468858
uuid-8a5ce1cf58564fceaf97c1161a4707eb,nivolumab combined with ipilimumab,0.446918
uuid-8a5ce1cf58564fceaf97c1161a4707eb,not approved,0.352562
uuid-8a5ce1cf58564fceaf97c1161a4707eb,clinical trials investigating the safety,0.429501
uuid-8a5ce1cf58564fceaf97c1161a4707eb,bladder cancer,0.950698
uuid-8f0e282e955a431dbbf01735eef18f6c,patients with advanced or metastatic,0.468858
uuid-8f0e282e955a431dbbf01735eef18f6c,nivolumab combined with ipilimumab,0.446918
uuid-8f0e282e955a431dbbf01735eef18f6c,not approved,0.352562
uuid-8f0e282e955a431dbbf01735eef18f6c,clinical trials investigating the safety,0.429501
uuid-8f0e282e955a431dbbf01735eef18f6c,bladder cancer,0.950698
uuid-c806360151ff4f0e9acf687e488bc15d,Bristol-Myers Squibb,0.343127
uuid-c806360151ff4f0e9acf687e488bc15d,not conducted any controlled clinical trials/studies,0.301816
uuid-c806360151ff4f0e9acf687e488bc15d,Opdivo,0.46656
uuid-c806360151ff4f0e9acf687e488bc15d,Pubmed literature search,0.611288
uuid-c806360151ff4f0e9acf687e488bc15d,purposes other than its labeled indication must be considered investigational,0.58315
uuid-c806360151ff4f0e9acf687e488bc15d,not identify any citations relevant to your inquiry,0.605218
uuid-c806360151ff4f0e9acf687e488bc15d,adverse,0.308345
uuid-c806360151ff4f0e9acf687e488bc15d,using the following search terms,0.639921
uuid-c806360151ff4f0e9acf687e488bc15d,databases,0.312627
uuid-c806360151ff4f0e9acf687e488bc15d,reported,0.557683
uuid-9b7c80de62804667b4a31b020fa77a18,ESMO,0.603759
uuid-9b7c80de62804667b4a31b020fa77a18,Horn L,0.484674
uuid-99e96d3886b04b66a6e77297bad2feea,patients with advanced or metastatic,0.478326
uuid-99e96d3886b04b66a6e77297bad2feea,nivolumab combined with ipilimumab,0.498766
uuid-99e96d3886b04b66a6e77297bad2feea,not approved,0.34724
uuid-99e96d3886b04b66a6e77297bad2feea,clinical trials investigating the safety,0.426729
uuid-99e96d3886b04b66a6e77297bad2feea,bladder cancer,0.6548
uuid-c7c749affdc9464c952c36de62fb8aa0,nivolumab,0.395467
uuid-c7c749affdc9464c952c36de62fb8aa0,patients,0.308723
uuid-c7c749affdc9464c952c36de62fb8aa0,RCC,0.626679
uuid-f5fce96aa42d48e0a78e7fabe70a231d,requested,0.594234
uuid-2b4a05a717ac46f19f480331ea90280f,ASCO,0.807066
uuid-ed1db7744f8c4804804eff7f189b0344,requested,0.594234
uuid-dbbf0773f98d41aebc02eecc616c76d3,requested,0.594234
uuid-c9e7b4b004d547c7a28c707407163fdc,ASCO,0.382205
uuid-5e61d9a8afe64d928aaa2656abca77db,ESMO,0.500333
uuid-5e61d9a8afe64d928aaa2656abca77db,Horn L,0.306308
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,nivolumab,0.308696
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,respectively,0.474596
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,Objective response rate,0.398542
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,ORR,0.387529
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,monotherapy,0.618934
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,clinical,0.310702
uuid-b3fa4b08291749ec9fcd4dbc8daf1ef3,Antonia SJ,0.303123
uuid-5448d6a1508c4d309684d62733c2d3a7,patients,0.344806
uuid-5448d6a1508c4d309684d62733c2d3a7,trial,0.483832
uuid-a91f7a4f02404dd6a49ef02673afefa2,N Engl J Med,0.616236
uuid-a91f7a4f02404dd6a49ef02673afefa2,respectively,0.409266
uuid-a91f7a4f02404dd6a49ef02673afefa2,ASCO,0.373445
uuid-a91f7a4f02404dd6a49ef02673afefa2,ESMO,0.378373
uuid-a91f7a4f02404dd6a49ef02673afefa2,Brahmer J,0.712806
uuid-a91f7a4f02404dd6a49ef02673afefa2,docetaxel,0.327482
uuid-a91f7a4f02404dd6a49ef02673afefa2,Horn L,0.502372
uuid-c40a1cd90db24ce69a211fd99d4bd68a,provided in the Detailed Information,0.367378
uuid-c40a1cd90db24ce69a211fd99d4bd68a,ESMO,0.851091
uuid-c40a1cd90db24ce69a211fd99d4bd68a,melanoma,0.459564
uuid-c40a1cd90db24ce69a211fd99d4bd68a,Horn L,0.477428
uuid-c40a1cd90db24ce69a211fd99d4bd68a,grade 3 to 4 AEs,0.485389
uuid-f904d82c74534edc9949779345e281d7,respectively,0.362254
uuid-f904d82c74534edc9949779345e281d7,patients,0.454948
uuid-f904d82c74534edc9949779345e281d7,monotherapy,0.349306
uuid-f904d82c74534edc9949779345e281d7,mg,0.640442
uuid-f904d82c74534edc9949779345e281d7,combination,0.306624
uuid-f904d82c74534edc9949779345e281d7,kg,0.608547
uuid-f904d82c74534edc9949779345e281d7,grade 3 to 4 AEs,0.442544
uuid-f904d82c74534edc9949779345e281d7,cohort,0.30832
uuid-1188299921ad46668208de4b5ed8e99f,requested,0.531305
uuid-1188299921ad46668208de4b5ed8e99f,ESMO,0.358531
uuid-1188299921ad46668208de4b5ed8e99f,Horn L,0.66756
uuid-1188299921ad46668208de4b5ed8e99f,platinum-based doublet chemotherapy,0.579011
uuid-63cb723389a743ecbfa58bd2a22d9996,provided in the Detailed Information,0.578509
uuid-63cb723389a743ecbfa58bd2a22d9996,clinical,0.470357
uuid-3b1fe5d6b8904bf296021ed9c2376b29,requested,0.531305
uuid-3b1fe5d6b8904bf296021ed9c2376b29,ESMO,0.358531
uuid-3b1fe5d6b8904bf296021ed9c2376b29,Horn L,0.66756
uuid-3b1fe5d6b8904bf296021ed9c2376b29,platinum-based doublet chemotherapy,0.579011
uuid-0f00366f3cf347149ac3a5b0709f09a0,RCC,0.906223
uuid-478461708ebf4cd88e2011f59e3bcfd5,nivolumab,0.533005
uuid-d09cb8131d4c41fa8936418ac316c44e,N Engl J Med,0.616236
uuid-d09cb8131d4c41fa8936418ac316c44e,respectively,0.409266
uuid-d09cb8131d4c41fa8936418ac316c44e,ASCO,0.373445
uuid-d09cb8131d4c41fa8936418ac316c44e,ESMO,0.378373
uuid-d09cb8131d4c41fa8936418ac316c44e,Brahmer J,0.712806
uuid-d09cb8131d4c41fa8936418ac316c44e,docetaxel,0.327482
uuid-d09cb8131d4c41fa8936418ac316c44e,Horn L,0.502372
uuid-f363a696d1234241b08ed2425dbf94d7,requested,0.524818
uuid-dbb775233575478eb8875df824d176a4,ESMO,0.603759
uuid-dbb775233575478eb8875df824d176a4,Horn L,0.484674
uuid-f9896880cf574a5581434571221154b5,Bristol-Myers Squibb,0.341822
uuid-f9896880cf574a5581434571221154b5,not conducted any controlled clinical trials/studies,0.304507
uuid-f9896880cf574a5581434571221154b5,Opdivo,0.461382
uuid-f9896880cf574a5581434571221154b5,Pubmed literature search,0.614325
uuid-f9896880cf574a5581434571221154b5,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f9896880cf574a5581434571221154b5,not identify any citations relevant to your inquiry,0.606087
uuid-f9896880cf574a5581434571221154b5,adverse,0.304183
uuid-f9896880cf574a5581434571221154b5,using the following search terms,0.642331
uuid-f9896880cf574a5581434571221154b5,databases,0.315039
uuid-f9896880cf574a5581434571221154b5,reported,0.556704
uuid-56ce1313b5a94594b7ce7746a36254e3,N Engl J Med,0.442834
uuid-56ce1313b5a94594b7ce7746a36254e3,protocol,0.763252
uuid-56ce1313b5a94594b7ce7746a36254e3,McDermott DF,0.733103
uuid-56ce1313b5a94594b7ce7746a36254e3,Motzer RJ,0.811057
uuid-56ce1313b5a94594b7ce7746a36254e3,phase 3 study,0.420895
uuid-56ce1313b5a94594b7ce7746a36254e3,Escudier B,0.741048
uuid-56ce1313b5a94594b7ce7746a36254e3,NEJM,0.402544
uuid-56ce1313b5a94594b7ce7746a36254e3,et al.,0.660398
uuid-56ce1313b5a94594b7ce7746a36254e3,J Clin Oncol,0.786367
uuid-56ce1313b5a94594b7ce7746a36254e3,Topalian,0.392395
uuid-56ce1313b5a94594b7ce7746a36254e3,phase 1 study,0.513779
uuid-56ce1313b5a94594b7ce7746a36254e3,CA209-003,0.583337
uuid-56ce1313b5a94594b7ce7746a36254e3,phase 2 study,0.675447
uuid-56ce1313b5a94594b7ce7746a36254e3,present using the following search terms,0.304589
uuid-56ce1313b5a94594b7ce7746a36254e3,investigating,0.633101
uuid-d7f1e349c9544c7986409e32f8939636,requested,0.842847
uuid-8f9292403ec8467087194102755a5cbe,nivolumab,0.33361
uuid-8f9292403ec8467087194102755a5cbe,clinicaltrials.gov,0.645643
uuid-5f9d3cf5cdc145b2be5151fcf24b2d59,ipilimumab,0.385692
uuid-5f9d3cf5cdc145b2be5151fcf24b2d59,ASCO 2015,0.417944
uuid-5f9d3cf5cdc145b2be5151fcf24b2d59,partial response,0.382425
uuid-5f9d3cf5cdc145b2be5151fcf24b2d59,Stable disease,0.586335
uuid-5f9d3cf5cdc145b2be5151fcf24b2d59,cohort,0.307748
uuid-9ccb1ac701d44159bd394d2c2c1ad555,N Engl J Med,0.549738
uuid-9ccb1ac701d44159bd394d2c2c1ad555,respectively,0.391562
uuid-9ccb1ac701d44159bd394d2c2c1ad555,ASCO,0.436507
uuid-9ccb1ac701d44159bd394d2c2c1ad555,Brahmer J,0.716533
uuid-9ccb1ac701d44159bd394d2c2c1ad555,docetaxel,0.356983
uuid-9ccb1ac701d44159bd394d2c2c1ad555,Horn L,0.382378
uuid-c86a4e6b833043e39ff613b5271bd121,respectively,0.629961
uuid-c86a4e6b833043e39ff613b5271bd121,Objective response rate,0.439951
uuid-c86a4e6b833043e39ff613b5271bd121,ORR,0.462322
uuid-c86a4e6b833043e39ff613b5271bd121,monotherapy,0.352421
uuid-c86a4e6b833043e39ff613b5271bd121,docetaxel,0.410479
uuid-2c1b444119a74d998b8e8bfd81b65166,N Engl J Med,0.775913
uuid-2c1b444119a74d998b8e8bfd81b65166,Lancet Oncol,0.394515
uuid-2c1b444119a74d998b8e8bfd81b65166,protocol,0.831494
uuid-2c1b444119a74d998b8e8bfd81b65166,McDermott DF,0.846573
uuid-2c1b444119a74d998b8e8bfd81b65166,Motzer RJ,0.84765
uuid-2c1b444119a74d998b8e8bfd81b65166,phase 3 study,0.543442
uuid-2c1b444119a74d998b8e8bfd81b65166,Escudier B,0.856834
uuid-2c1b444119a74d998b8e8bfd81b65166,NEJM,0.463538
uuid-2c1b444119a74d998b8e8bfd81b65166,et al.,0.804146
uuid-2c1b444119a74d998b8e8bfd81b65166,J Clin Oncol,0.783647
uuid-2c1b444119a74d998b8e8bfd81b65166,Topalian,0.430057
uuid-2c1b444119a74d998b8e8bfd81b65166,phase 1 study,0.32725
uuid-2c1b444119a74d998b8e8bfd81b65166,Rizvi NA,0.582327
uuid-2c1b444119a74d998b8e8bfd81b65166,Brahmer J,0.485583
uuid-2c1b444119a74d998b8e8bfd81b65166,Weber JS,0.384759
uuid-2c1b444119a74d998b8e8bfd81b65166,phase 2 study,0.779584
uuid-a7d4979e77094af69e3d7fead19228e7,trial,0.498368
uuid-51137ea887b546b6be5a1574e2f602fb,use of nivolumab for the treatment,0.440423
uuid-51137ea887b546b6be5a1574e2f602fb,search of published literature,0.311531
uuid-51137ea887b546b6be5a1574e2f602fb,PubMed and EMBASE,0.312811
uuid-51137ea887b546b6be5a1574e2f602fb,not approved,0.404782
uuid-51137ea887b546b6be5a1574e2f602fb,open-label,0.578291
uuid-51137ea887b546b6be5a1574e2f602fb,clinical trials investigating the safety,0.440014
uuid-51137ea887b546b6be5a1574e2f602fb,present using the following search terms,0.328669
uuid-51137ea887b546b6be5a1574e2f602fb,phase,0.41185
uuid-4a1b05a2de7c43228858bbe81e622845,ipilimumab,0.385692
uuid-4a1b05a2de7c43228858bbe81e622845,ASCO 2015,0.417944
uuid-4a1b05a2de7c43228858bbe81e622845,partial response,0.382425
uuid-4a1b05a2de7c43228858bbe81e622845,Stable disease,0.586335
uuid-4a1b05a2de7c43228858bbe81e622845,cohort,0.307748
uuid-ef0e7ae88ede4849bcd9bac941a22bec,95% CI,0.520262
uuid-ef0e7ae88ede4849bcd9bac941a22bec,respectively,0.504068
uuid-ef0e7ae88ede4849bcd9bac941a22bec,Objective response rate,0.458568
uuid-ef0e7ae88ede4849bcd9bac941a22bec,ORR,0.525868
uuid-ef0e7ae88ede4849bcd9bac941a22bec,Median overall survival,0.455633
uuid-ef0e7ae88ede4849bcd9bac941a22bec,Median OS,0.507448
uuid-ef0e7ae88ede4849bcd9bac941a22bec,docetaxel,0.383115
uuid-ef0e7ae88ede4849bcd9bac941a22bec,hazard ratio,0.462119
uuid-f9ae18aab57045e880cd09aada85a365,nivolumab,0.370003
uuid-421bc6cf68bf4bb5bb4e87c3f6f45def,requested,0.594234
uuid-0f9b0fbffd6d4229a080844667a71b46,ipilimumab,0.385692
uuid-0f9b0fbffd6d4229a080844667a71b46,ASCO 2015,0.417944
uuid-0f9b0fbffd6d4229a080844667a71b46,partial response,0.382425
uuid-0f9b0fbffd6d4229a080844667a71b46,Stable disease,0.586335
uuid-0f9b0fbffd6d4229a080844667a71b46,cohort,0.307748
uuid-22bc8b84344d42e59d45336219727f8c,requested,0.594438
uuid-f65a9f0d1dff412c9a1fc0edb0e52e57,patients with advanced or metastatic,0.468858
uuid-f65a9f0d1dff412c9a1fc0edb0e52e57,nivolumab combined with ipilimumab,0.446918
uuid-f65a9f0d1dff412c9a1fc0edb0e52e57,not approved,0.352562
uuid-f65a9f0d1dff412c9a1fc0edb0e52e57,clinical trials investigating the safety,0.429501
uuid-f65a9f0d1dff412c9a1fc0edb0e52e57,bladder cancer,0.950698
uuid-749ba2b98f30408b85b6d2988b054ff8,Opdivo,0.33922
uuid-749ba2b98f30408b85b6d2988b054ff8,safety,0.447806
uuid-749ba2b98f30408b85b6d2988b054ff8,databases,0.487558
uuid-344d973752b64365bff23e377487f389,nivolumab,0.561653
uuid-462c229917d54a56ac9dc4851f1f7ab6,open-label,0.539462
uuid-462c229917d54a56ac9dc4851f1f7ab6,phase,0.350616
uuid-8246fc3bee41466ca862796cca093e75,requested,0.594234
uuid-89e6e7ece1ce4bada516029cf2b52371,requested,0.44769
uuid-89e6e7ece1ce4bada516029cf2b52371,trial,0.309472
uuid-19503ac4899e47788fae7ca3a22001be,RCC,0.906223
uuid-08a7be3905d34c3388d776668c2ae868,nivolumab,0.359772
uuid-2b9e2bff56d94917a5f44c0e4a663474,N Engl J Med,0.383202
uuid-2b9e2bff56d94917a5f44c0e4a663474,provided in the Detailed Information,0.443587
uuid-2b9e2bff56d94917a5f44c0e4a663474,protocol,0.51483
uuid-2b9e2bff56d94917a5f44c0e4a663474,adverse,0.327459
uuid-2b9e2bff56d94917a5f44c0e4a663474,McDermott DF,0.59783
uuid-2b9e2bff56d94917a5f44c0e4a663474,Motzer RJ,0.577461
uuid-2b9e2bff56d94917a5f44c0e4a663474,clinical,0.420995
uuid-2b9e2bff56d94917a5f44c0e4a663474,phase 3 study,0.499109
uuid-2b9e2bff56d94917a5f44c0e4a663474,Escudier B,0.587082
uuid-2b9e2bff56d94917a5f44c0e4a663474,et al.,0.55323
uuid-2b9e2bff56d94917a5f44c0e4a663474,J Clin Oncol,0.561243
uuid-2b9e2bff56d94917a5f44c0e4a663474,phase 2 study,0.593061
uuid-8910b0a0197a4329bf69a34a3cc709a0,Opdivo,0.472854
uuid-b3077236d5ec46c28a95ea6247fd6568,RCC,0.898547
uuid-9691d48da288428590cf20c8dd073fd0,nivolumab,0.308696
uuid-9691d48da288428590cf20c8dd073fd0,respectively,0.474596
uuid-9691d48da288428590cf20c8dd073fd0,Objective response rate,0.398542
uuid-9691d48da288428590cf20c8dd073fd0,ORR,0.387529
uuid-9691d48da288428590cf20c8dd073fd0,monotherapy,0.618934
uuid-9691d48da288428590cf20c8dd073fd0,clinical,0.310702
uuid-9691d48da288428590cf20c8dd073fd0,Antonia SJ,0.303123
uuid-26ac878947b24afb9e433e438475d30b,mg,0.441866
uuid-26ac878947b24afb9e433e438475d30b,kg,0.410063
uuid-dabb615abe38462c902bac30e278985d,use of nivolumab for the treatment,0.440423
uuid-dabb615abe38462c902bac30e278985d,search of published literature,0.311531
uuid-dabb615abe38462c902bac30e278985d,PubMed and EMBASE,0.312811
uuid-dabb615abe38462c902bac30e278985d,not approved,0.404782
uuid-dabb615abe38462c902bac30e278985d,open-label,0.578291
uuid-dabb615abe38462c902bac30e278985d,clinical trials investigating the safety,0.440014
uuid-dabb615abe38462c902bac30e278985d,present using the following search terms,0.328669
uuid-dabb615abe38462c902bac30e278985d,phase,0.41185
uuid-6033e2be36ac4412ac9e77312d53133e,requested,0.788355
uuid-0592b964f07241d8b88c370364e3e377,Bristol-Myers Squibb,0.365107
uuid-0592b964f07241d8b88c370364e3e377,ESMO,0.37514
uuid-eb8b61c51e6444c69242e38ec32d0d09,95% CI,0.539167
uuid-eb8b61c51e6444c69242e38ec32d0d09,Median overall survival,0.479815
uuid-eb8b61c51e6444c69242e38ec32d0d09,protocol,0.426554
uuid-eb8b61c51e6444c69242e38ec32d0d09,McDermott DF,0.500131
uuid-eb8b61c51e6444c69242e38ec32d0d09,Motzer RJ,0.477178
uuid-eb8b61c51e6444c69242e38ec32d0d09,Median OS,0.603398
uuid-eb8b61c51e6444c69242e38ec32d0d09,Escudier B,0.469696
uuid-eb8b61c51e6444c69242e38ec32d0d09,NEJM,0.387615
uuid-eb8b61c51e6444c69242e38ec32d0d09,et al.,0.46851
uuid-eb8b61c51e6444c69242e38ec32d0d09,J Clin Oncol,0.51661
uuid-eb8b61c51e6444c69242e38ec32d0d09,Topalian,0.337057
uuid-eb8b61c51e6444c69242e38ec32d0d09,phase 2 study,0.399402
uuid-eb8b61c51e6444c69242e38ec32d0d09,hazard ratio,0.538097
uuid-b8c0425f35504c75a822890eb9e88d1b,requested,0.44769
uuid-b8c0425f35504c75a822890eb9e88d1b,trial,0.309472
uuid-6bbb6e23e451450fb1815620ff35ec72,RCC,0.906223
uuid-3ba90e95be254e43b8d6f296078b0c89,ipilimumab,0.385692
uuid-3ba90e95be254e43b8d6f296078b0c89,ASCO 2015,0.417944
uuid-3ba90e95be254e43b8d6f296078b0c89,partial response,0.382425
uuid-3ba90e95be254e43b8d6f296078b0c89,Stable disease,0.586335
uuid-3ba90e95be254e43b8d6f296078b0c89,cohort,0.307748
uuid-ed5b390ea1604fc49f8e1e6a703cd0ab,RCC,0.906223
uuid-1cc8145c041c4494a79d4bea66b002b0,requested,0.331755
uuid-1cc8145c041c4494a79d4bea66b002b0,ESMO,0.575268
uuid-1cc8145c041c4494a79d4bea66b002b0,Horn L,0.594256
uuid-1cc8145c041c4494a79d4bea66b002b0,platinum-based doublet chemotherapy,0.362148
uuid-a60a838f119e43d588458c17d3e0a81d,requested,0.531305
uuid-a60a838f119e43d588458c17d3e0a81d,ESMO,0.358531
uuid-a60a838f119e43d588458c17d3e0a81d,Horn L,0.66756
uuid-a60a838f119e43d588458c17d3e0a81d,platinum-based doublet chemotherapy,0.579011
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,N Engl J Med,0.479517
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,protocol,0.586408
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,McDermott DF,0.667328
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,Motzer RJ,0.647466
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,phase 3 study,0.431696
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,Escudier B,0.658437
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,NEJM,0.355614
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,et al.,0.629696
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,J Clin Oncol,0.609475
uuid-a2a65ffc8a1a43f0bc55cc2bc8d419bf,phase 2 study,0.578026
uuid-b67bb9c80ccf43faa4e4236ed0b2758f,Bristol-Myers Squibb,0.354281
uuid-b67bb9c80ccf43faa4e4236ed0b2758f,requested,0.387235
uuid-b67bb9c80ccf43faa4e4236ed0b2758f,ESMO,0.307326
uuid-6ff2d5e92a3647f5b5070b522e53ad38,RCC,0.906223
uuid-bde3d15190064431b7b3e82ca8db5a8e,N Engl J Med,0.427636
uuid-bde3d15190064431b7b3e82ca8db5a8e,protocol,0.429136
uuid-bde3d15190064431b7b3e82ca8db5a8e,McDermott DF,0.44782
uuid-bde3d15190064431b7b3e82ca8db5a8e,Motzer RJ,0.430476
uuid-bde3d15190064431b7b3e82ca8db5a8e,Escudier B,0.450887
uuid-bde3d15190064431b7b3e82ca8db5a8e,et al.,0.456026
uuid-bde3d15190064431b7b3e82ca8db5a8e,J Clin Oncol,0.384624
uuid-bde3d15190064431b7b3e82ca8db5a8e,Rizvi NA,0.305616
uuid-bde3d15190064431b7b3e82ca8db5a8e,phase 2 study,0.351446
uuid-40b6ae062d6b4a65b45e3958d2d84690,ipilimumab,0.385692
uuid-40b6ae062d6b4a65b45e3958d2d84690,ASCO 2015,0.417944
uuid-40b6ae062d6b4a65b45e3958d2d84690,partial response,0.382425
uuid-40b6ae062d6b4a65b45e3958d2d84690,Stable disease,0.586335
uuid-40b6ae062d6b4a65b45e3958d2d84690,cohort,0.307748
uuid-0351c49e62ff4d918d55f6bb233f1fb4,OS,0.62262
uuid-0351c49e62ff4d918d55f6bb233f1fb4,PFS,0.65903
uuid-0351c49e62ff4d918d55f6bb233f1fb4,Overall survival,0.644151
uuid-b4230a7fbd9b454088fc9079896204d7,ESMO,0.603759
uuid-b4230a7fbd9b454088fc9079896204d7,Horn L,0.484674
uuid-510692d5debd49d3b5c06ffa82adffa5,ASCO,0.807066
uuid-b0b81a3599ac4ffcab52098e2c1f2341,nivolumab,0.43789
uuid-b0b81a3599ac4ffcab52098e2c1f2341,Bristol-Myers Squibb,0.32508
uuid-b0b81a3599ac4ffcab52098e2c1f2341,evaluating,0.369025
uuid-b0b81a3599ac4ffcab52098e2c1f2341,not conducted any controlled clinical trials/studies,0.357756
uuid-b0b81a3599ac4ffcab52098e2c1f2341,requested,0.470039
uuid-b0b81a3599ac4ffcab52098e2c1f2341,efficacy and safety of nivolumab,0.329567
uuid-d2898cdecf8b475abe473d69bb4d32eb,adverse,0.544979
uuid-d2898cdecf8b475abe473d69bb4d32eb,RCC,0.56108
uuid-d2898cdecf8b475abe473d69bb4d32eb,phase 3 study,0.403724
uuid-d2898cdecf8b475abe473d69bb4d32eb,melanoma,0.359055
uuid-069caf84cfc7412dbbd8c626126749e9,N Engl J Med,0.616236
uuid-069caf84cfc7412dbbd8c626126749e9,respectively,0.409266
uuid-069caf84cfc7412dbbd8c626126749e9,ASCO,0.373445
uuid-069caf84cfc7412dbbd8c626126749e9,ESMO,0.378373
uuid-069caf84cfc7412dbbd8c626126749e9,Brahmer J,0.712806
uuid-069caf84cfc7412dbbd8c626126749e9,docetaxel,0.327482
uuid-069caf84cfc7412dbbd8c626126749e9,Horn L,0.502372
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,N Engl J Med,0.604857
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,non-small cell lung cancer,0.34354
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,ESMO,0.393944
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,Rizvi NA,0.452745
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,Brahmer J,0.679154
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,PD-L1,0.347566
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,Horn L,0.50259
uuid-863922d5de3f4b4f8523a6ca3ee5e2b5,platinum-based doublet chemotherapy,0.304136
uuid-eabf63ab87424efdbf9e20cbdc9f4315,Opdivo,0.998022
uuid-eabf63ab87424efdbf9e20cbdc9f4315,using the following search terms,0.355699
uuid-eabf63ab87424efdbf9e20cbdc9f4315,trial,0.433505
uuid-eabf63ab87424efdbf9e20cbdc9f4315,reported,0.38454
uuid-b6d7bcfa90134360930b31c0bb3187f0,clinical,0.456015
uuid-deb6002c4f92479fb5c2b26b2b32d964,phase 3 study,0.319955
uuid-deb6002c4f92479fb5c2b26b2b32d964,phase 1 study,0.446598
uuid-deb6002c4f92479fb5c2b26b2b32d964,Rizvi NA,0.340455
uuid-deb6002c4f92479fb5c2b26b2b32d964,mg,0.54474
uuid-deb6002c4f92479fb5c2b26b2b32d964,CA209-003,0.386745
uuid-deb6002c4f92479fb5c2b26b2b32d964,phase 2 study,0.37122
uuid-deb6002c4f92479fb5c2b26b2b32d964,kg,0.481395
uuid-0e702072e5034418be387199f1b5bc16,nivolumab,0.344939
uuid-0e702072e5034418be387199f1b5bc16,Bristol-Myers Squibb,0.363004
uuid-0e702072e5034418be387199f1b5bc16,evaluating,0.564404
uuid-0e702072e5034418be387199f1b5bc16,not conducted any controlled clinical trials/studies,0.538169
uuid-0e702072e5034418be387199f1b5bc16,RCC,0.336118
uuid-0e702072e5034418be387199f1b5bc16,search of published literature,0.750115
uuid-0e702072e5034418be387199f1b5bc16,Additionally,0.766378
uuid-0e702072e5034418be387199f1b5bc16,ongoing,0.629393
uuid-0e702072e5034418be387199f1b5bc16,PubMed and EMBASE,0.745288
uuid-0e702072e5034418be387199f1b5bc16,detailed search of www.clinicaltrials.gov,0.729251
uuid-0e702072e5034418be387199f1b5bc16,efficacy and safety of nivolumab,0.716075
uuid-0e702072e5034418be387199f1b5bc16,not identify any planned,0.665705
uuid-0e702072e5034418be387199f1b5bc16,not identify any citations relevant to your request,0.849476
uuid-0e702072e5034418be387199f1b5bc16,present using the following search terms,0.773092
uuid-c09df35da9b747c7ac71e6185fd970d5,nivolumab,0.493389
uuid-c09df35da9b747c7ac71e6185fd970d5,Bristol-Myers Squibb,0.598477
uuid-c09df35da9b747c7ac71e6185fd970d5,evaluating,0.837805
uuid-c09df35da9b747c7ac71e6185fd970d5,not conducted any controlled clinical trials/studies,0.848713
uuid-c09df35da9b747c7ac71e6185fd970d5,Pubmed literature search,0.314091
uuid-c09df35da9b747c7ac71e6185fd970d5,purposes other than its labeled indication must be considered investigational,0.4415
uuid-c09df35da9b747c7ac71e6185fd970d5,search of published literature,0.772891
uuid-c09df35da9b747c7ac71e6185fd970d5,PubMed and EMBASE,0.743175
uuid-c09df35da9b747c7ac71e6185fd970d5,efficacy and safety of nivolumab,0.905749
uuid-c09df35da9b747c7ac71e6185fd970d5,not identify any citations relevant to your request,0.417576
uuid-c09df35da9b747c7ac71e6185fd970d5,present using the following search terms,0.748132
uuid-b69a94d57f064b27a61df6731669d7a5,Rizvi NA,0.350132
uuid-b69a94d57f064b27a61df6731669d7a5,Brahmer J,0.573609
uuid-b69a94d57f064b27a61df6731669d7a5,BMS,0.966199
uuid-adce3ebc5cdf4a669cdba4c0415554f2,OS,0.44149
uuid-adce3ebc5cdf4a669cdba4c0415554f2,95% CI,0.833403
uuid-adce3ebc5cdf4a669cdba4c0415554f2,ASCO,0.32927
uuid-adce3ebc5cdf4a669cdba4c0415554f2,Objective response rate,0.545269
uuid-adce3ebc5cdf4a669cdba4c0415554f2,ORR,0.618524
uuid-adce3ebc5cdf4a669cdba4c0415554f2,PFS,0.396858
uuid-adce3ebc5cdf4a669cdba4c0415554f2,Median overall survival,0.72593
uuid-adce3ebc5cdf4a669cdba4c0415554f2,monotherapy,0.33356
uuid-adce3ebc5cdf4a669cdba4c0415554f2,Median OS,0.763854
uuid-adce3ebc5cdf4a669cdba4c0415554f2,hazard ratio,0.766648
uuid-adce3ebc5cdf4a669cdba4c0415554f2,Median duration of response,0.442682
uuid-3836ec5c3f9442e1815d36c93f6100c2,ipilimumab,0.385692
uuid-3836ec5c3f9442e1815d36c93f6100c2,ASCO 2015,0.417944
uuid-3836ec5c3f9442e1815d36c93f6100c2,partial response,0.382425
uuid-3836ec5c3f9442e1815d36c93f6100c2,Stable disease,0.586335
uuid-3836ec5c3f9442e1815d36c93f6100c2,cohort,0.307748
uuid-388160a941ce488d964ef4ec29fae58f,95% CI,0.524855
uuid-388160a941ce488d964ef4ec29fae58f,respectively,0.383655
uuid-388160a941ce488d964ef4ec29fae58f,ASCO,0.303153
uuid-388160a941ce488d964ef4ec29fae58f,Lancet Oncol,0.368041
uuid-388160a941ce488d964ef4ec29fae58f,Objective response rate,0.504846
uuid-388160a941ce488d964ef4ec29fae58f,ORR,0.465366
uuid-388160a941ce488d964ef4ec29fae58f,Median overall survival,0.346516
uuid-388160a941ce488d964ef4ec29fae58f,Median OS,0.33538
uuid-388160a941ce488d964ef4ec29fae58f,ASCO 2015,0.336983
uuid-388160a941ce488d964ef4ec29fae58f,small cell lung cancer,0.336892
uuid-388160a941ce488d964ef4ec29fae58f,SCLC,0.344367
uuid-388160a941ce488d964ef4ec29fae58f,Antonia SJ,0.55269
uuid-388160a941ce488d964ef4ec29fae58f,Median duration of response,0.649605
uuid-12e15ab879ad4a9b99654647fc6752dc,95% CI,0.524855
uuid-12e15ab879ad4a9b99654647fc6752dc,respectively,0.383655
uuid-12e15ab879ad4a9b99654647fc6752dc,ASCO,0.303153
uuid-12e15ab879ad4a9b99654647fc6752dc,Lancet Oncol,0.368041
uuid-12e15ab879ad4a9b99654647fc6752dc,Objective response rate,0.504846
uuid-12e15ab879ad4a9b99654647fc6752dc,ORR,0.465366
uuid-12e15ab879ad4a9b99654647fc6752dc,Median overall survival,0.346516
uuid-12e15ab879ad4a9b99654647fc6752dc,Median OS,0.33538
uuid-12e15ab879ad4a9b99654647fc6752dc,ASCO 2015,0.336983
uuid-12e15ab879ad4a9b99654647fc6752dc,small cell lung cancer,0.336892
uuid-12e15ab879ad4a9b99654647fc6752dc,SCLC,0.344367
uuid-12e15ab879ad4a9b99654647fc6752dc,Antonia SJ,0.55269
uuid-12e15ab879ad4a9b99654647fc6752dc,Median duration of response,0.649605
uuid-b75d04def32f4233bfdf716a1eae3096,95% CI,0.482283
uuid-b75d04def32f4233bfdf716a1eae3096,respectively,0.319895
uuid-b75d04def32f4233bfdf716a1eae3096,ASCO,0.389676
uuid-b75d04def32f4233bfdf716a1eae3096,Objective response rate,0.357341
uuid-b75d04def32f4233bfdf716a1eae3096,ORR,0.358789
uuid-b75d04def32f4233bfdf716a1eae3096,Median overall survival,0.421434
uuid-b75d04def32f4233bfdf716a1eae3096,Median OS,0.603017
uuid-b75d04def32f4233bfdf716a1eae3096,docetaxel,0.351836
uuid-b75d04def32f4233bfdf716a1eae3096,hazard ratio,0.51871
uuid-0aef23cecec34366be95e141384130dc,use of nivolumab for the treatment,0.440423
uuid-0aef23cecec34366be95e141384130dc,search of published literature,0.311531
uuid-0aef23cecec34366be95e141384130dc,PubMed and EMBASE,0.312811
uuid-0aef23cecec34366be95e141384130dc,not approved,0.404782
uuid-0aef23cecec34366be95e141384130dc,open-label,0.578291
uuid-0aef23cecec34366be95e141384130dc,clinical trials investigating the safety,0.440014
uuid-0aef23cecec34366be95e141384130dc,present using the following search terms,0.328669
uuid-0aef23cecec34366be95e141384130dc,phase,0.41185
uuid-45b3ec101fdf415693ce3955072e41cd,OS,0.318669
uuid-45b3ec101fdf415693ce3955072e41cd,95% CI,0.717911
uuid-45b3ec101fdf415693ce3955072e41cd,PFS,0.310929
uuid-45b3ec101fdf415693ce3955072e41cd,Median overall survival,0.606307
uuid-45b3ec101fdf415693ce3955072e41cd,Median OS,0.620427
uuid-45b3ec101fdf415693ce3955072e41cd,hazard ratio,0.612779
uuid-45b3ec101fdf415693ce3955072e41cd,Median duration of response,0.721884
uuid-b155bdf446ae4cc385d93f2f549045a6,nivolumab,0.471027
uuid-b155bdf446ae4cc385d93f2f549045a6,patients,0.417297
uuid-b155bdf446ae4cc385d93f2f549045a6,mg,0.410032
uuid-b155bdf446ae4cc385d93f2f549045a6,kg,0.346491
uuid-f3f066a7351c4c2db66b6fa72424cacd,clinical,0.363949
uuid-f3f066a7351c4c2db66b6fa72424cacd,trial,0.373264
uuid-b0eb0eae806a44748f8ec5cd12c028ea,95% CI,0.524855
uuid-b0eb0eae806a44748f8ec5cd12c028ea,respectively,0.383655
uuid-b0eb0eae806a44748f8ec5cd12c028ea,ASCO,0.303153
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Lancet Oncol,0.368041
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Objective response rate,0.504846
uuid-b0eb0eae806a44748f8ec5cd12c028ea,ORR,0.465366
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Median overall survival,0.346516
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Median OS,0.33538
uuid-b0eb0eae806a44748f8ec5cd12c028ea,ASCO 2015,0.336983
uuid-b0eb0eae806a44748f8ec5cd12c028ea,small cell lung cancer,0.336892
uuid-b0eb0eae806a44748f8ec5cd12c028ea,SCLC,0.344367
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Antonia SJ,0.55269
uuid-b0eb0eae806a44748f8ec5cd12c028ea,Median duration of response,0.649605
uuid-c7bf638932d14238aa8053618bc4c6c5,N Engl J Med,0.616236
uuid-c7bf638932d14238aa8053618bc4c6c5,respectively,0.409266
uuid-c7bf638932d14238aa8053618bc4c6c5,ASCO,0.373445
uuid-c7bf638932d14238aa8053618bc4c6c5,ESMO,0.378373
uuid-c7bf638932d14238aa8053618bc4c6c5,Brahmer J,0.712806
uuid-c7bf638932d14238aa8053618bc4c6c5,docetaxel,0.327482
uuid-c7bf638932d14238aa8053618bc4c6c5,Horn L,0.502372
uuid-e304b2b19d0e4230b051e71e016412a9,N Engl J Med,0.616236
uuid-e304b2b19d0e4230b051e71e016412a9,respectively,0.409266
uuid-e304b2b19d0e4230b051e71e016412a9,ASCO,0.373445
uuid-e304b2b19d0e4230b051e71e016412a9,ESMO,0.378373
uuid-e304b2b19d0e4230b051e71e016412a9,Brahmer J,0.712806
uuid-e304b2b19d0e4230b051e71e016412a9,docetaxel,0.327482
uuid-e304b2b19d0e4230b051e71e016412a9,Horn L,0.502372
uuid-dd81305a61244d4685ce25d4d1d09b40,95% CI,0.368332
uuid-dd81305a61244d4685ce25d4d1d09b40,NSCLC,0.498467
uuid-dd81305a61244d4685ce25d4d1d09b40,non-small cell lung cancer,0.430459
uuid-dd81305a61244d4685ce25d4d1d09b40,Objective response rate,0.480097
uuid-dd81305a61244d4685ce25d4d1d09b40,ORR,0.476446
uuid-dd81305a61244d4685ce25d4d1d09b40,Median overall survival,0.366656
uuid-dd81305a61244d4685ce25d4d1d09b40,monotherapy,0.355726
uuid-dd81305a61244d4685ce25d4d1d09b40,Median OS,0.348153
uuid-dd81305a61244d4685ce25d4d1d09b40,phase 1 study,0.35881
uuid-dd81305a61244d4685ce25d4d1d09b40,hazard ratio,0.370178
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,Bristol-Myers Squibb,0.341822
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,not conducted any controlled clinical trials/studies,0.304507
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,Opdivo,0.461382
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,Pubmed literature search,0.614325
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,not identify any citations relevant to your inquiry,0.606087
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,adverse,0.304183
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,using the following search terms,0.642331
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,databases,0.315039
uuid-9c12c7e210614d53a6c29dd5f6aa3b9b,reported,0.556704
uuid-549bc740ffaa4a649bff192ee17d27b6,N Engl J Med,0.775913
uuid-549bc740ffaa4a649bff192ee17d27b6,Lancet Oncol,0.394515
uuid-549bc740ffaa4a649bff192ee17d27b6,protocol,0.831494
uuid-549bc740ffaa4a649bff192ee17d27b6,McDermott DF,0.846573
uuid-549bc740ffaa4a649bff192ee17d27b6,Motzer RJ,0.84765
uuid-549bc740ffaa4a649bff192ee17d27b6,phase 3 study,0.543442
uuid-549bc740ffaa4a649bff192ee17d27b6,Escudier B,0.856834
uuid-549bc740ffaa4a649bff192ee17d27b6,NEJM,0.463538
uuid-549bc740ffaa4a649bff192ee17d27b6,et al.,0.804146
uuid-549bc740ffaa4a649bff192ee17d27b6,J Clin Oncol,0.783647
uuid-549bc740ffaa4a649bff192ee17d27b6,Topalian,0.430057
uuid-549bc740ffaa4a649bff192ee17d27b6,phase 1 study,0.32725
uuid-549bc740ffaa4a649bff192ee17d27b6,Rizvi NA,0.582327
uuid-549bc740ffaa4a649bff192ee17d27b6,Brahmer J,0.485583
uuid-549bc740ffaa4a649bff192ee17d27b6,Weber JS,0.384759
uuid-549bc740ffaa4a649bff192ee17d27b6,phase 2 study,0.779584
uuid-e31cc6d5c86b4e71a80ac04d24a0244a,requested,0.788355
uuid-e943446e78324e989cd48302e84cbdab,respectively,0.397695
uuid-308d1e250d20400fb36b0cd37bd4d254,BMS,0.36245
uuid-5a5e40cf61e849818dbe850dda6fa39e,ipilimumab,0.385692
uuid-5a5e40cf61e849818dbe850dda6fa39e,ASCO 2015,0.417944
uuid-5a5e40cf61e849818dbe850dda6fa39e,partial response,0.382425
uuid-5a5e40cf61e849818dbe850dda6fa39e,Stable disease,0.586335
uuid-5a5e40cf61e849818dbe850dda6fa39e,cohort,0.307748
uuid-7757942a41f247958f8f463d411ecec3,N Engl J Med,0.464492
uuid-7757942a41f247958f8f463d411ecec3,protocol,0.643681
uuid-7757942a41f247958f8f463d411ecec3,McDermott DF,0.692841
uuid-7757942a41f247958f8f463d411ecec3,Motzer RJ,0.679259
uuid-7757942a41f247958f8f463d411ecec3,phase 3 study,0.590969
uuid-7757942a41f247958f8f463d411ecec3,Escudier B,0.688934
uuid-7757942a41f247958f8f463d411ecec3,et al.,0.654623
uuid-7757942a41f247958f8f463d411ecec3,J Clin Oncol,0.64533
uuid-7757942a41f247958f8f463d411ecec3,Rizvi NA,0.379464
uuid-7757942a41f247958f8f463d411ecec3,phase 2 study,0.70439
uuid-dbc838df2c6a47919751a1aaccac0d28,mg,0.853414
uuid-dbc838df2c6a47919751a1aaccac0d28,kg,0.811553
uuid-dbc838df2c6a47919751a1aaccac0d28,cohort,0.33424
uuid-f649a4b54bc8450688637c00bcc1a70d,N Engl J Med,0.464492
uuid-f649a4b54bc8450688637c00bcc1a70d,protocol,0.643681
uuid-f649a4b54bc8450688637c00bcc1a70d,McDermott DF,0.692841
uuid-f649a4b54bc8450688637c00bcc1a70d,Motzer RJ,0.679259
uuid-f649a4b54bc8450688637c00bcc1a70d,phase 3 study,0.590969
uuid-f649a4b54bc8450688637c00bcc1a70d,Escudier B,0.688934
uuid-f649a4b54bc8450688637c00bcc1a70d,et al.,0.654623
uuid-f649a4b54bc8450688637c00bcc1a70d,J Clin Oncol,0.64533
uuid-f649a4b54bc8450688637c00bcc1a70d,Rizvi NA,0.379464
uuid-f649a4b54bc8450688637c00bcc1a70d,phase 2 study,0.70439
uuid-87d7291b01744c63a0195c4dfd078752,search of published literature,0.394524
uuid-87d7291b01744c63a0195c4dfd078752,Additionally,0.413583
uuid-87d7291b01744c63a0195c4dfd078752,ongoing,0.322117
uuid-87d7291b01744c63a0195c4dfd078752,PubMed and EMBASE,0.391671
uuid-87d7291b01744c63a0195c4dfd078752,detailed search of www.clinicaltrials.gov,0.375936
uuid-87d7291b01744c63a0195c4dfd078752,efficacy and safety of nivolumab,0.370699
uuid-87d7291b01744c63a0195c4dfd078752,not identify any planned,0.34283
uuid-87d7291b01744c63a0195c4dfd078752,Weber JS,0.319229
uuid-87d7291b01744c63a0195c4dfd078752,not identify any citations relevant to your request,0.447813
uuid-87d7291b01744c63a0195c4dfd078752,present using the following search terms,0.408199
uuid-83b501c054244008b95786727d0ad098,Bristol-Myers Squibb,0.341822
uuid-83b501c054244008b95786727d0ad098,not conducted any controlled clinical trials/studies,0.304507
uuid-83b501c054244008b95786727d0ad098,Opdivo,0.461382
uuid-83b501c054244008b95786727d0ad098,Pubmed literature search,0.614325
uuid-83b501c054244008b95786727d0ad098,purposes other than its labeled indication must be considered investigational,0.586645
uuid-83b501c054244008b95786727d0ad098,not identify any citations relevant to your inquiry,0.606087
uuid-83b501c054244008b95786727d0ad098,adverse,0.304183
uuid-83b501c054244008b95786727d0ad098,using the following search terms,0.642331
uuid-83b501c054244008b95786727d0ad098,databases,0.315039
uuid-83b501c054244008b95786727d0ad098,reported,0.556704
uuid-23775b5f0289457c84af109ba1f3681d,nivolumab,0.324658
uuid-23775b5f0289457c84af109ba1f3681d,use of nivolumab for the treatment,0.543355
uuid-23775b5f0289457c84af109ba1f3681d,evaluating,0.348676
uuid-23775b5f0289457c84af109ba1f3681d,efficacy,0.388907
uuid-23775b5f0289457c84af109ba1f3681d,patients,0.419915
uuid-23775b5f0289457c84af109ba1f3681d,search of published literature,0.449959
uuid-23775b5f0289457c84af109ba1f3681d,PubMed and EMBASE,0.444573
uuid-23775b5f0289457c84af109ba1f3681d,not approved,0.582429
uuid-23775b5f0289457c84af109ba1f3681d,clinical trials investigating the safety,0.64854
uuid-23775b5f0289457c84af109ba1f3681d,efficacy and safety of nivolumab,0.399101
uuid-23775b5f0289457c84af109ba1f3681d,present using the following search terms,0.465296
uuid-33f685d6775345abb4e365980b0ff161,NSCLC,0.351198
uuid-33f685d6775345abb4e365980b0ff161,efficacy and safety of nivolumab,0.343313
uuid-8c67a5afb04b4ba5a47fc6e80d97fda2,requested,0.59774
uuid-5e571479a38f4a20a407a40ccd10390c,Opdivo,0.489625
uuid-5e571479a38f4a20a407a40ccd10390c,trial,0.46284
uuid-f31583c976c747f2aa8056d5a15571be,95% CI,0.520262
uuid-f31583c976c747f2aa8056d5a15571be,respectively,0.504068
uuid-f31583c976c747f2aa8056d5a15571be,Objective response rate,0.458568
uuid-f31583c976c747f2aa8056d5a15571be,ORR,0.525868
uuid-f31583c976c747f2aa8056d5a15571be,Median overall survival,0.455633
uuid-f31583c976c747f2aa8056d5a15571be,Median OS,0.507448
uuid-f31583c976c747f2aa8056d5a15571be,docetaxel,0.383115
uuid-f31583c976c747f2aa8056d5a15571be,hazard ratio,0.462119
uuid-146a1f52494343628f1af1b993a5cd6f,ASCO,0.382205
uuid-8a5fa8f24749425486a437f7c4bca8bd,adverse,0.677734
uuid-8a5fa8f24749425486a437f7c4bca8bd,phase 3 study,0.48003
uuid-8a5fa8f24749425486a437f7c4bca8bd,melanoma,0.411352
uuid-8a5fa8f24749425486a437f7c4bca8bd,Weber JS,0.31904
uuid-8a5fa8f24749425486a437f7c4bca8bd,phase 2 study,0.319618
uuid-8a5fa8f24749425486a437f7c4bca8bd,reported,0.343242
uuid-be694762f7224eecb684e9255ff0e48c,N Engl J Med,0.616236
uuid-be694762f7224eecb684e9255ff0e48c,respectively,0.409266
uuid-be694762f7224eecb684e9255ff0e48c,ASCO,0.373445
uuid-be694762f7224eecb684e9255ff0e48c,ESMO,0.378373
uuid-be694762f7224eecb684e9255ff0e48c,Brahmer J,0.712806
uuid-be694762f7224eecb684e9255ff0e48c,docetaxel,0.327482
uuid-be694762f7224eecb684e9255ff0e48c,Horn L,0.502372
uuid-63f13ebb23d84cdd8f4eaa042c5708ff,respectively,0.397695
uuid-c694344e92b344128d9ba6d74650869c,requested,0.531305
uuid-c694344e92b344128d9ba6d74650869c,ESMO,0.358531
uuid-c694344e92b344128d9ba6d74650869c,Horn L,0.66756
uuid-c694344e92b344128d9ba6d74650869c,platinum-based doublet chemotherapy,0.579011
uuid-09e3b51275c84b69ac2d0e899d1a24c3,Opdivo,0.804583
uuid-09e3b51275c84b69ac2d0e899d1a24c3,trial,0.802304
uuid-9f33e0d8dc5e4c8bbbe7d0fc70213f74,trial,0.405524
uuid-ccb2bae8aa2a4281a537f80b67a5413d,use of nivolumab for the treatment,0.425664
uuid-ccb2bae8aa2a4281a537f80b67a5413d,efficacy,0.376681
uuid-ccb2bae8aa2a4281a537f80b67a5413d,patients,0.423184
uuid-ccb2bae8aa2a4281a537f80b67a5413d,not approved,0.410754
uuid-ccb2bae8aa2a4281a537f80b67a5413d,clinical trials investigating the safety,0.387606
uuid-ccb2bae8aa2a4281a537f80b67a5413d,trial,0.344445
uuid-ccb2bae8aa2a4281a537f80b67a5413d,mg,0.738715
uuid-ccb2bae8aa2a4281a537f80b67a5413d,kg,0.692379
uuid-74cc96e094534ee4b524719570e0fb5f,OS,0.506839
uuid-74cc96e094534ee4b524719570e0fb5f,95% CI,0.914259
uuid-74cc96e094534ee4b524719570e0fb5f,respectively,0.57945
uuid-74cc96e094534ee4b524719570e0fb5f,Objective response rate,0.616133
uuid-74cc96e094534ee4b524719570e0fb5f,ORR,0.78386
uuid-74cc96e094534ee4b524719570e0fb5f,PFS,0.374029
uuid-74cc96e094534ee4b524719570e0fb5f,Median overall survival,0.850584
uuid-74cc96e094534ee4b524719570e0fb5f,monotherapy,0.435128
uuid-74cc96e094534ee4b524719570e0fb5f,Median OS,0.829523
uuid-74cc96e094534ee4b524719570e0fb5f,docetaxel,0.347663
uuid-74cc96e094534ee4b524719570e0fb5f,hazard ratio,0.887303
uuid-74cc96e094534ee4b524719570e0fb5f,Median duration of response,0.367027
uuid-449eaf81b4274119a804f6401286067a,95% CI,0.539167
uuid-449eaf81b4274119a804f6401286067a,Median overall survival,0.479815
uuid-449eaf81b4274119a804f6401286067a,protocol,0.426554
uuid-449eaf81b4274119a804f6401286067a,McDermott DF,0.500131
uuid-449eaf81b4274119a804f6401286067a,Motzer RJ,0.477178
uuid-449eaf81b4274119a804f6401286067a,Median OS,0.603398
uuid-449eaf81b4274119a804f6401286067a,Escudier B,0.469696
uuid-449eaf81b4274119a804f6401286067a,NEJM,0.387615
uuid-449eaf81b4274119a804f6401286067a,et al.,0.46851
uuid-449eaf81b4274119a804f6401286067a,J Clin Oncol,0.51661
uuid-449eaf81b4274119a804f6401286067a,Topalian,0.337057
uuid-449eaf81b4274119a804f6401286067a,phase 2 study,0.399402
uuid-449eaf81b4274119a804f6401286067a,hazard ratio,0.538097
uuid-69c96d327d0b493da4769b73f65e730c,N Engl J Med,0.616236
uuid-69c96d327d0b493da4769b73f65e730c,respectively,0.409266
uuid-69c96d327d0b493da4769b73f65e730c,ASCO,0.373445
uuid-69c96d327d0b493da4769b73f65e730c,ESMO,0.378373
uuid-69c96d327d0b493da4769b73f65e730c,Brahmer J,0.712806
uuid-69c96d327d0b493da4769b73f65e730c,docetaxel,0.327482
uuid-69c96d327d0b493da4769b73f65e730c,Horn L,0.502372
uuid-2b6f3428598c4bbfa32b217be3972cc0,ipilimumab,0.385692
uuid-2b6f3428598c4bbfa32b217be3972cc0,ASCO 2015,0.417944
uuid-2b6f3428598c4bbfa32b217be3972cc0,partial response,0.382425
uuid-2b6f3428598c4bbfa32b217be3972cc0,Stable disease,0.586335
uuid-2b6f3428598c4bbfa32b217be3972cc0,cohort,0.307748
uuid-67455053c7ed430c9a3b315aa51196f1,N Engl J Med,0.302601
uuid-67455053c7ed430c9a3b315aa51196f1,AEs,0.348167
uuid-67455053c7ed430c9a3b315aa51196f1,patients,0.536884
uuid-67455053c7ed430c9a3b315aa51196f1,provided in the Detailed Information,0.387544
uuid-67455053c7ed430c9a3b315aa51196f1,ESMO,0.462801
uuid-67455053c7ed430c9a3b315aa51196f1,NEJM,0.66427
uuid-67455053c7ed430c9a3b315aa51196f1,Topalian,0.692873
uuid-67455053c7ed430c9a3b315aa51196f1,grade 3 to 4 AEs,0.626596
uuid-a21942a290974e6b8b345077022b3a63,95% CI,0.539167
uuid-a21942a290974e6b8b345077022b3a63,Median overall survival,0.479815
uuid-a21942a290974e6b8b345077022b3a63,protocol,0.426554
uuid-a21942a290974e6b8b345077022b3a63,McDermott DF,0.500131
uuid-a21942a290974e6b8b345077022b3a63,Motzer RJ,0.477178
uuid-a21942a290974e6b8b345077022b3a63,Median OS,0.603398
uuid-a21942a290974e6b8b345077022b3a63,Escudier B,0.469696
uuid-a21942a290974e6b8b345077022b3a63,NEJM,0.387615
uuid-a21942a290974e6b8b345077022b3a63,et al.,0.46851
uuid-a21942a290974e6b8b345077022b3a63,J Clin Oncol,0.51661
uuid-a21942a290974e6b8b345077022b3a63,Topalian,0.337057
uuid-a21942a290974e6b8b345077022b3a63,phase 2 study,0.399402
uuid-a21942a290974e6b8b345077022b3a63,hazard ratio,0.538097
uuid-3f1d440d6aaf435e92dd74d2de8013a5,RCC,0.906223
uuid-540a0e5564ba4d88b7e3295f35cace2c,N Engl J Med,0.336571
uuid-540a0e5564ba4d88b7e3295f35cace2c,95% CI,0.38947
uuid-540a0e5564ba4d88b7e3295f35cace2c,respectively,0.499954
uuid-540a0e5564ba4d88b7e3295f35cace2c,Objective response rate,0.362373
uuid-540a0e5564ba4d88b7e3295f35cace2c,ORR,0.434806
uuid-540a0e5564ba4d88b7e3295f35cace2c,Median overall survival,0.379806
uuid-540a0e5564ba4d88b7e3295f35cace2c,monotherapy,0.337624
uuid-540a0e5564ba4d88b7e3295f35cace2c,phase 3 study,0.328394
uuid-540a0e5564ba4d88b7e3295f35cace2c,Median OS,0.429996
uuid-540a0e5564ba4d88b7e3295f35cace2c,Rizvi NA,0.335507
uuid-540a0e5564ba4d88b7e3295f35cace2c,phase 2 study,0.364437
uuid-540a0e5564ba4d88b7e3295f35cace2c,hazard ratio,0.385445
uuid-ed893ea891fe48fda162040cd7a73f7f,safety,0.523226
uuid-ed893ea891fe48fda162040cd7a73f7f,databases,0.434356
uuid-0c23440b7e26401a8cc2a6ad90123a51,Bristol-Myers Squibb,0.341822
uuid-0c23440b7e26401a8cc2a6ad90123a51,not conducted any controlled clinical trials/studies,0.304507
uuid-0c23440b7e26401a8cc2a6ad90123a51,Opdivo,0.461382
uuid-0c23440b7e26401a8cc2a6ad90123a51,Pubmed literature search,0.614325
uuid-0c23440b7e26401a8cc2a6ad90123a51,purposes other than its labeled indication must be considered investigational,0.586645
uuid-0c23440b7e26401a8cc2a6ad90123a51,not identify any citations relevant to your inquiry,0.606087
uuid-0c23440b7e26401a8cc2a6ad90123a51,adverse,0.304183
uuid-0c23440b7e26401a8cc2a6ad90123a51,using the following search terms,0.642331
uuid-0c23440b7e26401a8cc2a6ad90123a51,databases,0.315039
uuid-0c23440b7e26401a8cc2a6ad90123a51,reported,0.556704
uuid-fa3cda646e2c440f81f470590149360e,respectively,0.629961
uuid-fa3cda646e2c440f81f470590149360e,Objective response rate,0.439951
uuid-fa3cda646e2c440f81f470590149360e,ORR,0.462322
uuid-fa3cda646e2c440f81f470590149360e,monotherapy,0.352421
uuid-fa3cda646e2c440f81f470590149360e,docetaxel,0.410479
uuid-e7433848452f46d2b8ab1004b21c7334,relapsed,0.313685
uuid-e6b633b859db4aa9b0732a8fadab9ebb,patients,0.315933
uuid-aae6eb5ec177442880317a2274340f5a,requested,0.531305
uuid-aae6eb5ec177442880317a2274340f5a,ESMO,0.358531
uuid-aae6eb5ec177442880317a2274340f5a,Horn L,0.66756
uuid-aae6eb5ec177442880317a2274340f5a,platinum-based doublet chemotherapy,0.579011
uuid-188465623c0c475b8a5d43c52dbcb751,OS,0.421512
uuid-188465623c0c475b8a5d43c52dbcb751,95% CI,0.85715
uuid-188465623c0c475b8a5d43c52dbcb751,respectively,0.313219
uuid-188465623c0c475b8a5d43c52dbcb751,Objective response rate,0.424002
uuid-188465623c0c475b8a5d43c52dbcb751,ORR,0.526308
uuid-188465623c0c475b8a5d43c52dbcb751,PFS,0.309026
uuid-188465623c0c475b8a5d43c52dbcb751,Median overall survival,0.781641
uuid-188465623c0c475b8a5d43c52dbcb751,monotherapy,0.30058
uuid-188465623c0c475b8a5d43c52dbcb751,Median OS,0.789606
uuid-188465623c0c475b8a5d43c52dbcb751,hazard ratio,0.829636
uuid-188465623c0c475b8a5d43c52dbcb751,Median duration of response,0.460911
uuid-65514be1dce24312902744bbe531b6b7,nivolumab,0.361138
uuid-25a3f77fc875469fbc582cecd3bd2758,RCC,0.906223
uuid-39103c4f93f041dc8d7498a5368f7bc1,Lancet Oncol,0.370075
uuid-39103c4f93f041dc8d7498a5368f7bc1,patients,0.514464
uuid-39103c4f93f041dc8d7498a5368f7bc1,considered investigational,0.757805
uuid-39103c4f93f041dc8d7498a5368f7bc1,patients with advanced or metastatic,0.701408
uuid-39103c4f93f041dc8d7498a5368f7bc1,nivolumab combined with ipilimumab,0.686511
uuid-39103c4f93f041dc8d7498a5368f7bc1,tumors,0.690867
uuid-39103c4f93f041dc8d7498a5368f7bc1,ASCO 2015,0.427157
uuid-39103c4f93f041dc8d7498a5368f7bc1,small cell lung cancer,0.920298
uuid-39103c4f93f041dc8d7498a5368f7bc1,SCLC,0.892497
uuid-39103c4f93f041dc8d7498a5368f7bc1,Antonia SJ,0.532824
uuid-39103c4f93f041dc8d7498a5368f7bc1,therapy,0.325448
uuid-39103c4f93f041dc8d7498a5368f7bc1,phase 1/2 study CA209-032,0.875455
uuid-39103c4f93f041dc8d7498a5368f7bc1,evaluates the efficacy of nivolumab monotherapy,0.844174
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,patients,0.387216
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,considered investigational,0.572483
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,patients with advanced or metastatic,0.390918
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,nivolumab combined with ipilimumab,0.381545
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,ipilimumab,0.418119
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,tumors,0.487867
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,ASCO 2015,0.485832
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,small cell lung cancer,0.673131
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,PD-L1,0.317304
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,combination,0.374435
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,SCLC,0.676534
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,Antonia SJ,0.423577
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,therapy,0.309098
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,phase 1/2 study CA209-032,0.582404
uuid-a70b4f50ca7d4183aa7a0ababc7ccb14,evaluates the efficacy of nivolumab monotherapy,0.546434
uuid-4bdd01131e93444197f9288c3b876c13,N Engl J Med,0.355961
uuid-4bdd01131e93444197f9288c3b876c13,Lancet Oncol,0.311699
uuid-4bdd01131e93444197f9288c3b876c13,protocol,0.30218
uuid-4bdd01131e93444197f9288c3b876c13,McDermott DF,0.320954
uuid-4bdd01131e93444197f9288c3b876c13,Motzer RJ,0.300991
uuid-4bdd01131e93444197f9288c3b876c13,Escudier B,0.319662
uuid-4bdd01131e93444197f9288c3b876c13,et al.,0.323439
uuid-4bdd01131e93444197f9288c3b876c13,Rizvi NA,0.353315
uuid-4bdd01131e93444197f9288c3b876c13,phase 2 study,0.34198
uuid-eceab5cd63ef4b43a3df7094ac87f00d,95% CI,0.524855
uuid-eceab5cd63ef4b43a3df7094ac87f00d,respectively,0.383655
uuid-eceab5cd63ef4b43a3df7094ac87f00d,ASCO,0.303153
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Lancet Oncol,0.368041
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Objective response rate,0.504846
uuid-eceab5cd63ef4b43a3df7094ac87f00d,ORR,0.465366
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Median overall survival,0.346516
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Median OS,0.33538
uuid-eceab5cd63ef4b43a3df7094ac87f00d,ASCO 2015,0.336983
uuid-eceab5cd63ef4b43a3df7094ac87f00d,small cell lung cancer,0.336892
uuid-eceab5cd63ef4b43a3df7094ac87f00d,SCLC,0.344367
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Antonia SJ,0.55269
uuid-eceab5cd63ef4b43a3df7094ac87f00d,Median duration of response,0.649605
uuid-cf9084169b9e42f19ee55681c1913d88,95% CI,0.539167
uuid-cf9084169b9e42f19ee55681c1913d88,Median overall survival,0.479815
uuid-cf9084169b9e42f19ee55681c1913d88,protocol,0.426554
uuid-cf9084169b9e42f19ee55681c1913d88,McDermott DF,0.500131
uuid-cf9084169b9e42f19ee55681c1913d88,Motzer RJ,0.477178
uuid-cf9084169b9e42f19ee55681c1913d88,Median OS,0.603398
uuid-cf9084169b9e42f19ee55681c1913d88,Escudier B,0.469696
uuid-cf9084169b9e42f19ee55681c1913d88,NEJM,0.387615
uuid-cf9084169b9e42f19ee55681c1913d88,et al.,0.46851
uuid-cf9084169b9e42f19ee55681c1913d88,J Clin Oncol,0.51661
uuid-cf9084169b9e42f19ee55681c1913d88,Topalian,0.337057
uuid-cf9084169b9e42f19ee55681c1913d88,phase 2 study,0.399402
uuid-cf9084169b9e42f19ee55681c1913d88,hazard ratio,0.538097
uuid-c4aeb2e2d1a546d287f2086ce300aa5e,patients with advanced or metastatic,0.468858
uuid-c4aeb2e2d1a546d287f2086ce300aa5e,nivolumab combined with ipilimumab,0.446918
uuid-c4aeb2e2d1a546d287f2086ce300aa5e,not approved,0.352562
uuid-c4aeb2e2d1a546d287f2086ce300aa5e,clinical trials investigating the safety,0.429501
uuid-c4aeb2e2d1a546d287f2086ce300aa5e,bladder cancer,0.950698
uuid-61ab0ad138784d81bcee966059d652e7,Bristol-Myers Squibb,0.341822
uuid-61ab0ad138784d81bcee966059d652e7,not conducted any controlled clinical trials/studies,0.304507
uuid-61ab0ad138784d81bcee966059d652e7,Opdivo,0.461382
uuid-61ab0ad138784d81bcee966059d652e7,Pubmed literature search,0.614325
uuid-61ab0ad138784d81bcee966059d652e7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-61ab0ad138784d81bcee966059d652e7,not identify any citations relevant to your inquiry,0.606087
uuid-61ab0ad138784d81bcee966059d652e7,adverse,0.304183
uuid-61ab0ad138784d81bcee966059d652e7,using the following search terms,0.642331
uuid-61ab0ad138784d81bcee966059d652e7,databases,0.315039
uuid-61ab0ad138784d81bcee966059d652e7,reported,0.556704
uuid-ee2334384b874d4081b48afde101371e,respectively,0.397695
uuid-cb2eb2e9808c4a4e9f735a8bb5274f0d,provided in the Detailed Information,0.581808
uuid-cb2eb2e9808c4a4e9f735a8bb5274f0d,clinical,0.447827
uuid-6005baaf8d6247b4bee28d771eba141a,respectively,0.585622
uuid-6005baaf8d6247b4bee28d771eba141a,Objective response rate,0.36976
uuid-6005baaf8d6247b4bee28d771eba141a,ORR,0.514781
uuid-6005baaf8d6247b4bee28d771eba141a,docetaxel,0.31274
uuid-0c66b7591c224c4980c10cdf02b8c982,ASCO,0.807066
uuid-9790c13f227347dd892bc3788550a141,Bristol-Myers Squibb,0.313438
uuid-9790c13f227347dd892bc3788550a141,patients,0.631161
uuid-9790c13f227347dd892bc3788550a141,adverse,0.402578
uuid-9790c13f227347dd892bc3788550a141,grade 3 to 4 AEs,0.337877
uuid-9790c13f227347dd892bc3788550a141,reported,0.3593
uuid-95b953fa8bf04eddb3757479f78b51da,N Engl J Med,0.616236
uuid-95b953fa8bf04eddb3757479f78b51da,respectively,0.409266
uuid-95b953fa8bf04eddb3757479f78b51da,ASCO,0.373445
uuid-95b953fa8bf04eddb3757479f78b51da,ESMO,0.378373
uuid-95b953fa8bf04eddb3757479f78b51da,Brahmer J,0.712806
uuid-95b953fa8bf04eddb3757479f78b51da,docetaxel,0.327482
uuid-95b953fa8bf04eddb3757479f78b51da,Horn L,0.502372
uuid-2afe9241a61b42c3a3cd39900cba2e08,nivolumab,0.45274
uuid-2afe9241a61b42c3a3cd39900cba2e08,investigating,0.321152
uuid-acf0a1e10ba14592a13858cb429666a3,RCC,0.909054
uuid-d4bae9e6e39c424a81d1bd9f031fc5b0,provided in the Detailed Information,0.578509
uuid-d4bae9e6e39c424a81d1bd9f031fc5b0,clinical,0.470357
uuid-ed1a3a5d1dbf40329d4df09df6508077,ASCO,0.391455
uuid-ed1a3a5d1dbf40329d4df09df6508077,Lancet Oncol,0.39503
uuid-ed1a3a5d1dbf40329d4df09df6508077,requested,0.32072
uuid-ed1a3a5d1dbf40329d4df09df6508077,ASCO 2015,0.307613
uuid-ed1a3a5d1dbf40329d4df09df6508077,Antonia SJ,0.474788
uuid-2ac728b29ce242c0a298845fafd47258,nivolumab,0.302211
uuid-2ac728b29ce242c0a298845fafd47258,clinical,0.450066
uuid-2ac728b29ce242c0a298845fafd47258,not approved,0.354492
uuid-2ac728b29ce242c0a298845fafd47258,clinical trials investigating the safety,0.361969
uuid-2ac728b29ce242c0a298845fafd47258,trial,0.468537
uuid-55b54b191e0e45cba8d9fe24ec91980d,requested,0.594234
uuid-0b6684a52aa4473bb79d4af056e36428,ASCO,0.387523
uuid-382fc51986004b18af585f446afc42c8,OS,0.44149
uuid-382fc51986004b18af585f446afc42c8,95% CI,0.833403
uuid-382fc51986004b18af585f446afc42c8,ASCO,0.32927
uuid-382fc51986004b18af585f446afc42c8,Objective response rate,0.545269
uuid-382fc51986004b18af585f446afc42c8,ORR,0.618524
uuid-382fc51986004b18af585f446afc42c8,PFS,0.396858
uuid-382fc51986004b18af585f446afc42c8,Median overall survival,0.72593
uuid-382fc51986004b18af585f446afc42c8,monotherapy,0.33356
uuid-382fc51986004b18af585f446afc42c8,Median OS,0.763854
uuid-382fc51986004b18af585f446afc42c8,hazard ratio,0.766648
uuid-382fc51986004b18af585f446afc42c8,Median duration of response,0.442682
uuid-22fc5841a439406088144b174b4bfdb6,use of nivolumab for the treatment,0.36168
uuid-22fc5841a439406088144b174b4bfdb6,evaluating,0.494326
uuid-22fc5841a439406088144b174b4bfdb6,not conducted any controlled clinical trials/studies,0.41213
uuid-22fc5841a439406088144b174b4bfdb6,efficacy,0.324699
uuid-22fc5841a439406088144b174b4bfdb6,RCC,0.322347
uuid-22fc5841a439406088144b174b4bfdb6,search of published literature,0.611038
uuid-22fc5841a439406088144b174b4bfdb6,Additionally,0.448352
uuid-22fc5841a439406088144b174b4bfdb6,ongoing,0.312655
uuid-22fc5841a439406088144b174b4bfdb6,PubMed and EMBASE,0.605009
uuid-22fc5841a439406088144b174b4bfdb6,not approved,0.376764
uuid-22fc5841a439406088144b174b4bfdb6,detailed search of www.clinicaltrials.gov,0.391682
uuid-22fc5841a439406088144b174b4bfdb6,clinical trials investigating the safety,0.401559
uuid-22fc5841a439406088144b174b4bfdb6,efficacy and safety of nivolumab,0.573339
uuid-22fc5841a439406088144b174b4bfdb6,not identify any planned,0.331383
uuid-22fc5841a439406088144b174b4bfdb6,not identify any citations relevant to your request,0.549993
uuid-22fc5841a439406088144b174b4bfdb6,present using the following search terms,0.6198
uuid-22fc5841a439406088144b174b4bfdb6,safety of nivolumab monotherapy,0.318712
uuid-1acc14561aca4b34bb348d7717a8159e,respectively,0.397695
uuid-b7de099e092f451697edfceafa49cffc,Bristol-Myers Squibb,0.341822
uuid-b7de099e092f451697edfceafa49cffc,not conducted any controlled clinical trials/studies,0.304507
uuid-b7de099e092f451697edfceafa49cffc,Opdivo,0.461382
uuid-b7de099e092f451697edfceafa49cffc,Pubmed literature search,0.614325
uuid-b7de099e092f451697edfceafa49cffc,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b7de099e092f451697edfceafa49cffc,not identify any citations relevant to your inquiry,0.606087
uuid-b7de099e092f451697edfceafa49cffc,adverse,0.304183
uuid-b7de099e092f451697edfceafa49cffc,using the following search terms,0.642331
uuid-b7de099e092f451697edfceafa49cffc,databases,0.315039
uuid-b7de099e092f451697edfceafa49cffc,reported,0.556704
uuid-151dde6fed6c4be3aa5ffb10dee278b8,OS,0.493666
uuid-151dde6fed6c4be3aa5ffb10dee278b8,95% CI,0.872793
uuid-151dde6fed6c4be3aa5ffb10dee278b8,respectively,0.581917
uuid-151dde6fed6c4be3aa5ffb10dee278b8,Objective response rate,0.558489
uuid-151dde6fed6c4be3aa5ffb10dee278b8,ORR,0.705401
uuid-151dde6fed6c4be3aa5ffb10dee278b8,PFS,0.331929
uuid-151dde6fed6c4be3aa5ffb10dee278b8,Median overall survival,0.793083
uuid-151dde6fed6c4be3aa5ffb10dee278b8,monotherapy,0.422517
uuid-151dde6fed6c4be3aa5ffb10dee278b8,Median OS,0.808565
uuid-151dde6fed6c4be3aa5ffb10dee278b8,PD-L1,0.302111
uuid-151dde6fed6c4be3aa5ffb10dee278b8,docetaxel,0.481228
uuid-151dde6fed6c4be3aa5ffb10dee278b8,hazard ratio,0.844622
uuid-151dde6fed6c4be3aa5ffb10dee278b8,Median duration of response,0.34536
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,N Engl J Med,0.340789
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,Lancet Oncol,0.370237
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,phase 3 study,0.518072
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,NEJM,0.308962
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,melanoma,0.385325
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,phase 1 study,0.357353
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,Rizvi NA,0.480708
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,CA209-003,0.361396
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,Weber JS,0.479511
uuid-9f4ae3f0a4a544a696a4197e2c5fb99c,phase 2 study,0.521794
uuid-b5b2f7ac0043423885f56c81f2abf329,nivolumab,0.639032
uuid-b5b2f7ac0043423885f56c81f2abf329,clinical,0.507135
uuid-9967f4fa620a4e748207c8a6dc43c86f,BMS,0.493804
uuid-8e201572790d40e29276bca1cc9fb986,nivolumab,0.503405
uuid-8e201572790d40e29276bca1cc9fb986,Bristol-Myers Squibb,0.396767
uuid-8e201572790d40e29276bca1cc9fb986,evaluating,0.553303
uuid-8e201572790d40e29276bca1cc9fb986,not conducted any controlled clinical trials/studies,0.60266
uuid-8e201572790d40e29276bca1cc9fb986,Pubmed literature search,0.799906
uuid-8e201572790d40e29276bca1cc9fb986,purposes other than its labeled indication must be considered investigational,0.859367
uuid-8e201572790d40e29276bca1cc9fb986,not identify any citations relevant to your inquiry,0.76263
uuid-8e201572790d40e29276bca1cc9fb986,using the following search terms,0.750949
uuid-8e201572790d40e29276bca1cc9fb986,efficacy and safety of nivolumab,0.390757
uuid-2b91b43d634f4fbe966c2d368512af85,95% CI,0.539167
uuid-2b91b43d634f4fbe966c2d368512af85,Median overall survival,0.479815
uuid-2b91b43d634f4fbe966c2d368512af85,protocol,0.426554
uuid-2b91b43d634f4fbe966c2d368512af85,McDermott DF,0.500131
uuid-2b91b43d634f4fbe966c2d368512af85,Motzer RJ,0.477178
uuid-2b91b43d634f4fbe966c2d368512af85,Median OS,0.603398
uuid-2b91b43d634f4fbe966c2d368512af85,Escudier B,0.469696
uuid-2b91b43d634f4fbe966c2d368512af85,NEJM,0.387615
uuid-2b91b43d634f4fbe966c2d368512af85,et al.,0.46851
uuid-2b91b43d634f4fbe966c2d368512af85,J Clin Oncol,0.51661
uuid-2b91b43d634f4fbe966c2d368512af85,Topalian,0.337057
uuid-2b91b43d634f4fbe966c2d368512af85,phase 2 study,0.399402
uuid-2b91b43d634f4fbe966c2d368512af85,hazard ratio,0.538097
uuid-cd8f212b902b46e1bed732f59a23bf87,N Engl J Med,0.436555
uuid-cd8f212b902b46e1bed732f59a23bf87,protocol,0.736013
uuid-cd8f212b902b46e1bed732f59a23bf87,McDermott DF,0.670036
uuid-cd8f212b902b46e1bed732f59a23bf87,Motzer RJ,0.704093
uuid-cd8f212b902b46e1bed732f59a23bf87,phase 3 study,0.312164
uuid-cd8f212b902b46e1bed732f59a23bf87,Escudier B,0.686195
uuid-cd8f212b902b46e1bed732f59a23bf87,NEJM,0.368011
uuid-cd8f212b902b46e1bed732f59a23bf87,et al.,0.64858
uuid-cd8f212b902b46e1bed732f59a23bf87,J Clin Oncol,0.643889
uuid-cd8f212b902b46e1bed732f59a23bf87,Topalian,0.300994
uuid-cd8f212b902b46e1bed732f59a23bf87,phase 2 study,0.540567
uuid-a8d9855a748e4167b4c69a8fe16b33ba,requested,0.62109
uuid-1854f308c15845bba0ba02da936a9a67,ipilimumab,0.385692
uuid-1854f308c15845bba0ba02da936a9a67,ASCO 2015,0.417944
uuid-1854f308c15845bba0ba02da936a9a67,partial response,0.382425
uuid-1854f308c15845bba0ba02da936a9a67,Stable disease,0.586335
uuid-1854f308c15845bba0ba02da936a9a67,cohort,0.307748
uuid-375f6e0f0e9943f3854e8dfea664e3d6,N Engl J Med,0.616236
uuid-375f6e0f0e9943f3854e8dfea664e3d6,respectively,0.409266
uuid-375f6e0f0e9943f3854e8dfea664e3d6,ASCO,0.373445
uuid-375f6e0f0e9943f3854e8dfea664e3d6,ESMO,0.378373
uuid-375f6e0f0e9943f3854e8dfea664e3d6,Brahmer J,0.712806
uuid-375f6e0f0e9943f3854e8dfea664e3d6,docetaxel,0.327482
uuid-375f6e0f0e9943f3854e8dfea664e3d6,Horn L,0.502372
uuid-32d592b03bdb4afe87bf4c1acf84f715,95% CI,0.539167
uuid-32d592b03bdb4afe87bf4c1acf84f715,Median overall survival,0.479815
uuid-32d592b03bdb4afe87bf4c1acf84f715,protocol,0.426554
uuid-32d592b03bdb4afe87bf4c1acf84f715,McDermott DF,0.500131
uuid-32d592b03bdb4afe87bf4c1acf84f715,Motzer RJ,0.477178
uuid-32d592b03bdb4afe87bf4c1acf84f715,Median OS,0.603398
uuid-32d592b03bdb4afe87bf4c1acf84f715,Escudier B,0.469696
uuid-32d592b03bdb4afe87bf4c1acf84f715,NEJM,0.387615
uuid-32d592b03bdb4afe87bf4c1acf84f715,et al.,0.46851
uuid-32d592b03bdb4afe87bf4c1acf84f715,J Clin Oncol,0.51661
uuid-32d592b03bdb4afe87bf4c1acf84f715,Topalian,0.337057
uuid-32d592b03bdb4afe87bf4c1acf84f715,phase 2 study,0.399402
uuid-32d592b03bdb4afe87bf4c1acf84f715,hazard ratio,0.538097
uuid-0185cf747de941fa8d72f895ec41e065,mg,0.837258
uuid-0185cf747de941fa8d72f895ec41e065,kg,0.768014
uuid-c3094368cfd74d2d99f86bc0c81b4b36,N Engl J Med,0.775913
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Lancet Oncol,0.394515
uuid-c3094368cfd74d2d99f86bc0c81b4b36,protocol,0.831494
uuid-c3094368cfd74d2d99f86bc0c81b4b36,McDermott DF,0.846573
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Motzer RJ,0.84765
uuid-c3094368cfd74d2d99f86bc0c81b4b36,phase 3 study,0.543442
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Escudier B,0.856834
uuid-c3094368cfd74d2d99f86bc0c81b4b36,NEJM,0.463538
uuid-c3094368cfd74d2d99f86bc0c81b4b36,et al.,0.804146
uuid-c3094368cfd74d2d99f86bc0c81b4b36,J Clin Oncol,0.783647
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Topalian,0.430057
uuid-c3094368cfd74d2d99f86bc0c81b4b36,phase 1 study,0.32725
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Rizvi NA,0.582327
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Brahmer J,0.485583
uuid-c3094368cfd74d2d99f86bc0c81b4b36,Weber JS,0.384759
uuid-c3094368cfd74d2d99f86bc0c81b4b36,phase 2 study,0.779584
uuid-9cb09517be4445b89c895356df2ebd0d,patients with advanced or metastatic,0.468858
uuid-9cb09517be4445b89c895356df2ebd0d,nivolumab combined with ipilimumab,0.446918
uuid-9cb09517be4445b89c895356df2ebd0d,not approved,0.352562
uuid-9cb09517be4445b89c895356df2ebd0d,clinical trials investigating the safety,0.429501
uuid-9cb09517be4445b89c895356df2ebd0d,bladder cancer,0.950698
uuid-860420fc46fe4b688dfdf5870e15e6d8,AEs,0.539869
uuid-860420fc46fe4b688dfdf5870e15e6d8,adverse,0.383322
uuid-860420fc46fe4b688dfdf5870e15e6d8,grade,0.592223
uuid-860420fc46fe4b688dfdf5870e15e6d8,grade 3 to 4 AEs,0.444514
uuid-53f02a085c6643aea8c9559b329786c3,patients,0.315933
uuid-1a6e7db750fc4b068540778c93d1119d,respectively,0.585622
uuid-1a6e7db750fc4b068540778c93d1119d,Objective response rate,0.36976
uuid-1a6e7db750fc4b068540778c93d1119d,ORR,0.514781
uuid-1a6e7db750fc4b068540778c93d1119d,docetaxel,0.31274
uuid-68b4d77b9a4e496da88bea9c928031c9,nivolumab,0.64996
uuid-46521036d5604fc8892f0baa9966518a,Opdivo,0.638066
uuid-46521036d5604fc8892f0baa9966518a,trial,0.494366
uuid-ca609dfb2050485c91ac18839c605c15,Opdivo,0.835077
uuid-ca609dfb2050485c91ac18839c605c15,trial,0.446733
uuid-8e16add70cbf46b284b52546056a641f,N Engl J Med,0.616236
uuid-8e16add70cbf46b284b52546056a641f,respectively,0.409266
uuid-8e16add70cbf46b284b52546056a641f,ASCO,0.373445
uuid-8e16add70cbf46b284b52546056a641f,ESMO,0.378373
uuid-8e16add70cbf46b284b52546056a641f,Brahmer J,0.712806
uuid-8e16add70cbf46b284b52546056a641f,docetaxel,0.327482
uuid-8e16add70cbf46b284b52546056a641f,Horn L,0.502372
uuid-2e3987a245024033a4523285302bca63,95% CI,0.539167
uuid-2e3987a245024033a4523285302bca63,Median overall survival,0.479815
uuid-2e3987a245024033a4523285302bca63,protocol,0.426554
uuid-2e3987a245024033a4523285302bca63,McDermott DF,0.500131
uuid-2e3987a245024033a4523285302bca63,Motzer RJ,0.477178
uuid-2e3987a245024033a4523285302bca63,Median OS,0.603398
uuid-2e3987a245024033a4523285302bca63,Escudier B,0.469696
uuid-2e3987a245024033a4523285302bca63,NEJM,0.387615
uuid-2e3987a245024033a4523285302bca63,et al.,0.46851
uuid-2e3987a245024033a4523285302bca63,J Clin Oncol,0.51661
uuid-2e3987a245024033a4523285302bca63,Topalian,0.337057
uuid-2e3987a245024033a4523285302bca63,phase 2 study,0.399402
uuid-2e3987a245024033a4523285302bca63,hazard ratio,0.538097
uuid-c89e501511664469b99579ad0061cf9b,patients,0.30455
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,N Engl J Med,0.442834
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,protocol,0.763252
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,McDermott DF,0.733103
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,Motzer RJ,0.811057
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,phase 3 study,0.420895
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,Escudier B,0.741048
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,NEJM,0.402544
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,et al.,0.660398
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,J Clin Oncol,0.786367
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,Topalian,0.392395
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,phase 1 study,0.513779
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,CA209-003,0.583337
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,phase 2 study,0.675447
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,present using the following search terms,0.304589
uuid-1afeccfaa25a43bf88aebb0e51e29f9c,investigating,0.633101
uuid-203184c9b977460db297695e2f2ffe3e,requested,0.594234
uuid-18585b92b58d42c6a194f3cf46035e67,95% CI,0.524855
uuid-18585b92b58d42c6a194f3cf46035e67,respectively,0.383655
uuid-18585b92b58d42c6a194f3cf46035e67,ASCO,0.303153
uuid-18585b92b58d42c6a194f3cf46035e67,Lancet Oncol,0.368041
uuid-18585b92b58d42c6a194f3cf46035e67,Objective response rate,0.504846
uuid-18585b92b58d42c6a194f3cf46035e67,ORR,0.465366
uuid-18585b92b58d42c6a194f3cf46035e67,Median overall survival,0.346516
uuid-18585b92b58d42c6a194f3cf46035e67,Median OS,0.33538
uuid-18585b92b58d42c6a194f3cf46035e67,ASCO 2015,0.336983
uuid-18585b92b58d42c6a194f3cf46035e67,small cell lung cancer,0.336892
uuid-18585b92b58d42c6a194f3cf46035e67,SCLC,0.344367
uuid-18585b92b58d42c6a194f3cf46035e67,Antonia SJ,0.55269
uuid-18585b92b58d42c6a194f3cf46035e67,Median duration of response,0.649605
uuid-f68217f5dac24cc3bd3f89749edc15e0,Bristol-Myers Squibb,0.341822
uuid-f68217f5dac24cc3bd3f89749edc15e0,not conducted any controlled clinical trials/studies,0.304507
uuid-f68217f5dac24cc3bd3f89749edc15e0,Opdivo,0.461382
uuid-f68217f5dac24cc3bd3f89749edc15e0,Pubmed literature search,0.614325
uuid-f68217f5dac24cc3bd3f89749edc15e0,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f68217f5dac24cc3bd3f89749edc15e0,not identify any citations relevant to your inquiry,0.606087
uuid-f68217f5dac24cc3bd3f89749edc15e0,adverse,0.304183
uuid-f68217f5dac24cc3bd3f89749edc15e0,using the following search terms,0.642331
uuid-f68217f5dac24cc3bd3f89749edc15e0,databases,0.315039
uuid-f68217f5dac24cc3bd3f89749edc15e0,reported,0.556704
uuid-45a32a84a59b4a3aab7d80db77545d3a,mg,0.477032
uuid-45a32a84a59b4a3aab7d80db77545d3a,kg,0.401951
uuid-88532aba78784cd8b7dc532d002434a5,evaluating,0.350845
uuid-88532aba78784cd8b7dc532d002434a5,not conducted any controlled clinical trials/studies,0.345107
uuid-88532aba78784cd8b7dc532d002434a5,search of published literature,0.385331
uuid-88532aba78784cd8b7dc532d002434a5,Additionally,0.40981
uuid-88532aba78784cd8b7dc532d002434a5,ongoing,0.457998
uuid-88532aba78784cd8b7dc532d002434a5,PubMed and EMBASE,0.378285
uuid-88532aba78784cd8b7dc532d002434a5,detailed search of www.clinicaltrials.gov,0.428522
uuid-88532aba78784cd8b7dc532d002434a5,efficacy and safety of nivolumab,0.407868
uuid-88532aba78784cd8b7dc532d002434a5,not identify any planned,0.444729
uuid-88532aba78784cd8b7dc532d002434a5,combination,0.388252
uuid-88532aba78784cd8b7dc532d002434a5,BMS,0.316104
uuid-88532aba78784cd8b7dc532d002434a5,not identify any citations relevant to your request,0.438151
uuid-88532aba78784cd8b7dc532d002434a5,present using the following search terms,0.377101
uuid-698ebb517d9545078a149fed9fb50077,N Engl J Med,0.616236
uuid-698ebb517d9545078a149fed9fb50077,respectively,0.409266
uuid-698ebb517d9545078a149fed9fb50077,ASCO,0.373445
uuid-698ebb517d9545078a149fed9fb50077,ESMO,0.378373
uuid-698ebb517d9545078a149fed9fb50077,Brahmer J,0.712806
uuid-698ebb517d9545078a149fed9fb50077,docetaxel,0.327482
uuid-698ebb517d9545078a149fed9fb50077,Horn L,0.502372
uuid-3d732e494e6c4494bde78b68762b31b4,nivolumab,0.493389
uuid-3d732e494e6c4494bde78b68762b31b4,Bristol-Myers Squibb,0.598477
uuid-3d732e494e6c4494bde78b68762b31b4,evaluating,0.837805
uuid-3d732e494e6c4494bde78b68762b31b4,not conducted any controlled clinical trials/studies,0.848713
uuid-3d732e494e6c4494bde78b68762b31b4,Pubmed literature search,0.314091
uuid-3d732e494e6c4494bde78b68762b31b4,purposes other than its labeled indication must be considered investigational,0.4415
uuid-3d732e494e6c4494bde78b68762b31b4,search of published literature,0.772891
uuid-3d732e494e6c4494bde78b68762b31b4,PubMed and EMBASE,0.743175
uuid-3d732e494e6c4494bde78b68762b31b4,efficacy and safety of nivolumab,0.905749
uuid-3d732e494e6c4494bde78b68762b31b4,not identify any citations relevant to your request,0.417576
uuid-3d732e494e6c4494bde78b68762b31b4,present using the following search terms,0.748132
uuid-0d12ff248ac549debf7fb3529194979b,N Engl J Med,0.616236
uuid-0d12ff248ac549debf7fb3529194979b,respectively,0.409266
uuid-0d12ff248ac549debf7fb3529194979b,ASCO,0.373445
uuid-0d12ff248ac549debf7fb3529194979b,ESMO,0.378373
uuid-0d12ff248ac549debf7fb3529194979b,Brahmer J,0.712806
uuid-0d12ff248ac549debf7fb3529194979b,docetaxel,0.327482
uuid-0d12ff248ac549debf7fb3529194979b,Horn L,0.502372
uuid-ff53a684565e4969b92087319f080289,respectively,0.397695
uuid-480153d441b24ef689be4d69e80bd576,requested,0.828107
uuid-480153d441b24ef689be4d69e80bd576,Horn L,0.328577
uuid-480153d441b24ef689be4d69e80bd576,platinum-based doublet chemotherapy,0.303175
uuid-e8b06502cc6647fe96e389285df2a044,patients,0.471364
uuid-e8b06502cc6647fe96e389285df2a044,adverse,0.427521
uuid-e8b06502cc6647fe96e389285df2a044,grade 3 to 4 AEs,0.381424
uuid-167fa75ccc804e56a8d2b87427edff4e,Opdivo,0.395537
uuid-167fa75ccc804e56a8d2b87427edff4e,Pubmed literature search,0.505032
uuid-167fa75ccc804e56a8d2b87427edff4e,purposes other than its labeled indication must be considered investigational,0.479284
uuid-167fa75ccc804e56a8d2b87427edff4e,not identify any citations relevant to your inquiry,0.503455
uuid-167fa75ccc804e56a8d2b87427edff4e,using the following search terms,0.528681
uuid-167fa75ccc804e56a8d2b87427edff4e,reported,0.458319
uuid-8f2c49ec42ee4234bd4a15034216abc3,OS,0.388947
uuid-8f2c49ec42ee4234bd4a15034216abc3,95% CI,0.730538
uuid-8f2c49ec42ee4234bd4a15034216abc3,respectively,0.747452
uuid-8f2c49ec42ee4234bd4a15034216abc3,Objective response rate,0.60009
uuid-8f2c49ec42ee4234bd4a15034216abc3,ORR,0.727236
uuid-8f2c49ec42ee4234bd4a15034216abc3,Median overall survival,0.658897
uuid-8f2c49ec42ee4234bd4a15034216abc3,monotherapy,0.472346
uuid-8f2c49ec42ee4234bd4a15034216abc3,Median OS,0.698223
uuid-8f2c49ec42ee4234bd4a15034216abc3,docetaxel,0.578282
uuid-8f2c49ec42ee4234bd4a15034216abc3,hazard ratio,0.719713
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,95% CI,0.318804
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,respectively,0.726363
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,Objective response rate,0.436495
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,ORR,0.491244
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,monotherapy,0.405233
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,Median OS,0.363599
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,docetaxel,0.721637
uuid-ff685cce34a94404a5f60ca0ed9bfc1e,hazard ratio,0.334698
uuid-7c86ac81cf27400c9e805ec86dead4d8,fatigue,0.704358
uuid-8695f5580b554c7386864e8257fb4296,95% CI,0.524855
uuid-8695f5580b554c7386864e8257fb4296,respectively,0.383655
uuid-8695f5580b554c7386864e8257fb4296,ASCO,0.303153
uuid-8695f5580b554c7386864e8257fb4296,Lancet Oncol,0.368041
uuid-8695f5580b554c7386864e8257fb4296,Objective response rate,0.504846
uuid-8695f5580b554c7386864e8257fb4296,ORR,0.465366
uuid-8695f5580b554c7386864e8257fb4296,Median overall survival,0.346516
uuid-8695f5580b554c7386864e8257fb4296,Median OS,0.33538
uuid-8695f5580b554c7386864e8257fb4296,ASCO 2015,0.336983
uuid-8695f5580b554c7386864e8257fb4296,small cell lung cancer,0.336892
uuid-8695f5580b554c7386864e8257fb4296,SCLC,0.344367
uuid-8695f5580b554c7386864e8257fb4296,Antonia SJ,0.55269
uuid-8695f5580b554c7386864e8257fb4296,Median duration of response,0.649605
uuid-a7382b93ae9348338d38fddf22c535f9,Bristol-Myers Squibb,0.341822
uuid-a7382b93ae9348338d38fddf22c535f9,not conducted any controlled clinical trials/studies,0.304507
uuid-a7382b93ae9348338d38fddf22c535f9,Opdivo,0.461382
uuid-a7382b93ae9348338d38fddf22c535f9,Pubmed literature search,0.614325
uuid-a7382b93ae9348338d38fddf22c535f9,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a7382b93ae9348338d38fddf22c535f9,not identify any citations relevant to your inquiry,0.606087
uuid-a7382b93ae9348338d38fddf22c535f9,adverse,0.304183
uuid-a7382b93ae9348338d38fddf22c535f9,using the following search terms,0.642331
uuid-a7382b93ae9348338d38fddf22c535f9,databases,0.315039
uuid-a7382b93ae9348338d38fddf22c535f9,reported,0.556704
uuid-1aef66fda12b43d1a0d8315725983706,therapy,0.352407
uuid-6a436cd2e9c24fccaf686c65016bc4cf,95% CI,0.539167
uuid-6a436cd2e9c24fccaf686c65016bc4cf,Median overall survival,0.479815
uuid-6a436cd2e9c24fccaf686c65016bc4cf,protocol,0.426554
uuid-6a436cd2e9c24fccaf686c65016bc4cf,McDermott DF,0.500131
uuid-6a436cd2e9c24fccaf686c65016bc4cf,Motzer RJ,0.477178
uuid-6a436cd2e9c24fccaf686c65016bc4cf,Median OS,0.603398
uuid-6a436cd2e9c24fccaf686c65016bc4cf,Escudier B,0.469696
uuid-6a436cd2e9c24fccaf686c65016bc4cf,NEJM,0.387615
uuid-6a436cd2e9c24fccaf686c65016bc4cf,et al.,0.46851
uuid-6a436cd2e9c24fccaf686c65016bc4cf,J Clin Oncol,0.51661
uuid-6a436cd2e9c24fccaf686c65016bc4cf,Topalian,0.337057
uuid-6a436cd2e9c24fccaf686c65016bc4cf,phase 2 study,0.399402
uuid-6a436cd2e9c24fccaf686c65016bc4cf,hazard ratio,0.538097
uuid-0f7620cc7025472797b0428cfdc6c6c4,Bristol-Myers Squibb,0.341822
uuid-0f7620cc7025472797b0428cfdc6c6c4,not conducted any controlled clinical trials/studies,0.304507
uuid-0f7620cc7025472797b0428cfdc6c6c4,Opdivo,0.461382
uuid-0f7620cc7025472797b0428cfdc6c6c4,Pubmed literature search,0.614325
uuid-0f7620cc7025472797b0428cfdc6c6c4,purposes other than its labeled indication must be considered investigational,0.586645
uuid-0f7620cc7025472797b0428cfdc6c6c4,not identify any citations relevant to your inquiry,0.606087
uuid-0f7620cc7025472797b0428cfdc6c6c4,adverse,0.304183
uuid-0f7620cc7025472797b0428cfdc6c6c4,using the following search terms,0.642331
uuid-0f7620cc7025472797b0428cfdc6c6c4,databases,0.315039
uuid-0f7620cc7025472797b0428cfdc6c6c4,reported,0.556704
uuid-7968f89aa89d4a299ef13832f8a3e145,respectively,0.397695
uuid-76209d7cd4184359a07ca98eed1774a5,Bristol-Myers Squibb,0.341822
uuid-76209d7cd4184359a07ca98eed1774a5,not conducted any controlled clinical trials/studies,0.304507
uuid-76209d7cd4184359a07ca98eed1774a5,Opdivo,0.461382
uuid-76209d7cd4184359a07ca98eed1774a5,Pubmed literature search,0.614325
uuid-76209d7cd4184359a07ca98eed1774a5,purposes other than its labeled indication must be considered investigational,0.586645
uuid-76209d7cd4184359a07ca98eed1774a5,not identify any citations relevant to your inquiry,0.606087
uuid-76209d7cd4184359a07ca98eed1774a5,adverse,0.304183
uuid-76209d7cd4184359a07ca98eed1774a5,using the following search terms,0.642331
uuid-76209d7cd4184359a07ca98eed1774a5,databases,0.315039
uuid-76209d7cd4184359a07ca98eed1774a5,reported,0.556704
uuid-97eafe58e57b4030a4ac0832d3037f68,ipilimumab,0.385692
uuid-97eafe58e57b4030a4ac0832d3037f68,ASCO 2015,0.417944
uuid-97eafe58e57b4030a4ac0832d3037f68,partial response,0.382425
uuid-97eafe58e57b4030a4ac0832d3037f68,Stable disease,0.586335
uuid-97eafe58e57b4030a4ac0832d3037f68,cohort,0.307748
uuid-b03b669a20d8433b87273dea0f5c7699,requested,0.44769
uuid-b03b669a20d8433b87273dea0f5c7699,trial,0.309472
uuid-68a9b40bb7834c7e8d9ae5cb45329a99,requested,0.531305
uuid-68a9b40bb7834c7e8d9ae5cb45329a99,ESMO,0.358531
uuid-68a9b40bb7834c7e8d9ae5cb45329a99,Horn L,0.66756
uuid-68a9b40bb7834c7e8d9ae5cb45329a99,platinum-based doublet chemotherapy,0.579011
uuid-c8aed8817f7f4f1c997840d128f679a1,requested,0.531305
uuid-c8aed8817f7f4f1c997840d128f679a1,ESMO,0.358531
uuid-c8aed8817f7f4f1c997840d128f679a1,Horn L,0.66756
uuid-c8aed8817f7f4f1c997840d128f679a1,platinum-based doublet chemotherapy,0.579011
uuid-a0b0fcd2fdd348a9be1b062443af4aff,open-label,0.539462
uuid-a0b0fcd2fdd348a9be1b062443af4aff,phase,0.350616
uuid-ada83690193a4306beb3653cfff2005d,patients,0.420801
uuid-ada83690193a4306beb3653cfff2005d,requested,0.477162
uuid-b6cf32ee88f24a44a408d9df7805bf6a,NSCLC,0.350329
uuid-b6cf32ee88f24a44a408d9df7805bf6a,efficacy and safety of nivolumab,0.343232
uuid-3f09a9413d454f538913e105e9f1803f,Bristol-Myers Squibb,0.752239
uuid-3f09a9413d454f538913e105e9f1803f,use of nivolumab for the treatment,0.32318
uuid-3f09a9413d454f538913e105e9f1803f,evaluating,0.913226
uuid-3f09a9413d454f538913e105e9f1803f,not conducted any controlled clinical trials/studies,0.934763
uuid-3f09a9413d454f538913e105e9f1803f,NSCLC,0.546593
uuid-3f09a9413d454f538913e105e9f1803f,non-small cell lung cancer,0.574059
uuid-3f09a9413d454f538913e105e9f1803f,considered investigational,0.497404
uuid-3f09a9413d454f538913e105e9f1803f,purposes other than its labeled indication must be considered investigational,0.367962
uuid-3f09a9413d454f538913e105e9f1803f,search of published literature,0.437446
uuid-3f09a9413d454f538913e105e9f1803f,PubMed and EMBASE,0.386857
uuid-3f09a9413d454f538913e105e9f1803f,efficacy and safety of nivolumab,0.85582
uuid-3f09a9413d454f538913e105e9f1803f,present using the following search terms,0.376687
uuid-3f09a9413d454f538913e105e9f1803f,safety of nivolumab monotherapy,0.448672
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,Bristol-Myers Squibb,0.836721
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,evaluating,0.713964
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,not conducted any controlled clinical trials/studies,0.792695
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,adverse,0.315459
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,efficacy and safety of nivolumab,0.634198
uuid-aa44bb1ae75a44d4a3080af853bfc3cc,reported,0.341045
uuid-8de4915d4c4247c3bf2c152b7f3060d4,ipilimumab,0.385692
uuid-8de4915d4c4247c3bf2c152b7f3060d4,ASCO 2015,0.417944
uuid-8de4915d4c4247c3bf2c152b7f3060d4,partial response,0.382425
uuid-8de4915d4c4247c3bf2c152b7f3060d4,Stable disease,0.586335
uuid-8de4915d4c4247c3bf2c152b7f3060d4,cohort,0.307748
uuid-204dc6b7046b4c388893daaf7c7efb58,OS,0.44149
uuid-204dc6b7046b4c388893daaf7c7efb58,95% CI,0.833403
uuid-204dc6b7046b4c388893daaf7c7efb58,ASCO,0.32927
uuid-204dc6b7046b4c388893daaf7c7efb58,Objective response rate,0.545269
uuid-204dc6b7046b4c388893daaf7c7efb58,ORR,0.618524
uuid-204dc6b7046b4c388893daaf7c7efb58,PFS,0.396858
uuid-204dc6b7046b4c388893daaf7c7efb58,Median overall survival,0.72593
uuid-204dc6b7046b4c388893daaf7c7efb58,monotherapy,0.33356
uuid-204dc6b7046b4c388893daaf7c7efb58,Median OS,0.763854
uuid-204dc6b7046b4c388893daaf7c7efb58,hazard ratio,0.766648
uuid-204dc6b7046b4c388893daaf7c7efb58,Median duration of response,0.442682
uuid-9e66029f13e2463aabf99d8ddbbe0a8f,Bristol-Myers Squibb,0.348944
uuid-9e66029f13e2463aabf99d8ddbbe0a8f,not conducted any controlled clinical trials/studies,0.301858
uuid-88bbb860cb9949c9b1d35329a1e8954d,Bristol-Myers Squibb,0.494637
uuid-ae05446d9fd24fee88c0752edc3255a9,95% CI,0.524855
uuid-ae05446d9fd24fee88c0752edc3255a9,respectively,0.383655
uuid-ae05446d9fd24fee88c0752edc3255a9,ASCO,0.303153
uuid-ae05446d9fd24fee88c0752edc3255a9,Lancet Oncol,0.368041
uuid-ae05446d9fd24fee88c0752edc3255a9,Objective response rate,0.504846
uuid-ae05446d9fd24fee88c0752edc3255a9,ORR,0.465366
uuid-ae05446d9fd24fee88c0752edc3255a9,Median overall survival,0.346516
uuid-ae05446d9fd24fee88c0752edc3255a9,Median OS,0.33538
uuid-ae05446d9fd24fee88c0752edc3255a9,ASCO 2015,0.336983
uuid-ae05446d9fd24fee88c0752edc3255a9,small cell lung cancer,0.336892
uuid-ae05446d9fd24fee88c0752edc3255a9,SCLC,0.344367
uuid-ae05446d9fd24fee88c0752edc3255a9,Antonia SJ,0.55269
uuid-ae05446d9fd24fee88c0752edc3255a9,Median duration of response,0.649605
uuid-59ef1bc8ebdc48bf9e737aa7f5c879b3,requested,0.531305
uuid-59ef1bc8ebdc48bf9e737aa7f5c879b3,ESMO,0.358531
uuid-59ef1bc8ebdc48bf9e737aa7f5c879b3,Horn L,0.66756
uuid-59ef1bc8ebdc48bf9e737aa7f5c879b3,platinum-based doublet chemotherapy,0.579011
uuid-3f7367b14b2b45c09775b2109890d09f,Opdivo,0.566612
uuid-3f7367b14b2b45c09775b2109890d09f,clinical,0.463512
uuid-3f7367b14b2b45c09775b2109890d09f,trial,0.526756
uuid-3f7367b14b2b45c09775b2109890d09f,reported,0.44666
uuid-ee8e9742f3bf4f7184801313af48fd87,95% CI,0.524855
uuid-ee8e9742f3bf4f7184801313af48fd87,respectively,0.383655
uuid-ee8e9742f3bf4f7184801313af48fd87,ASCO,0.303153
uuid-ee8e9742f3bf4f7184801313af48fd87,Lancet Oncol,0.368041
uuid-ee8e9742f3bf4f7184801313af48fd87,Objective response rate,0.504846
uuid-ee8e9742f3bf4f7184801313af48fd87,ORR,0.465366
uuid-ee8e9742f3bf4f7184801313af48fd87,Median overall survival,0.346516
uuid-ee8e9742f3bf4f7184801313af48fd87,Median OS,0.33538
uuid-ee8e9742f3bf4f7184801313af48fd87,ASCO 2015,0.336983
uuid-ee8e9742f3bf4f7184801313af48fd87,small cell lung cancer,0.336892
uuid-ee8e9742f3bf4f7184801313af48fd87,SCLC,0.344367
uuid-ee8e9742f3bf4f7184801313af48fd87,Antonia SJ,0.55269
uuid-ee8e9742f3bf4f7184801313af48fd87,Median duration of response,0.649605
uuid-5c1dd438d4eb417094a4b21215df5396,N Engl J Med,0.666678
uuid-5c1dd438d4eb417094a4b21215df5396,NSCLC,0.405107
uuid-5c1dd438d4eb417094a4b21215df5396,non-small cell lung cancer,0.383684
uuid-5c1dd438d4eb417094a4b21215df5396,phase 3 study,0.495629
uuid-5c1dd438d4eb417094a4b21215df5396,Rizvi NA,0.513667
uuid-5c1dd438d4eb417094a4b21215df5396,Brahmer J,0.704218
uuid-5c1dd438d4eb417094a4b21215df5396,phase 2 study,0.483792
uuid-5c1dd438d4eb417094a4b21215df5396,Horn L,0.330324
uuid-91999432f3a64315a480909db098fd46,Bristol-Myers Squibb,0.407167
uuid-91999432f3a64315a480909db098fd46,use of nivolumab for the treatment,0.553552
uuid-91999432f3a64315a480909db098fd46,evaluating,0.380059
uuid-91999432f3a64315a480909db098fd46,not conducted any controlled clinical trials/studies,0.37862
uuid-91999432f3a64315a480909db098fd46,efficacy,0.328172
uuid-91999432f3a64315a480909db098fd46,not approved,0.44344
uuid-91999432f3a64315a480909db098fd46,clinical trials investigating the safety,0.327598
uuid-91999432f3a64315a480909db098fd46,efficacy and safety of nivolumab,0.301738
uuid-40ad96f4cff74cc9be412b2858c41a27,RCC,0.906223
uuid-bf2a4053807b426c8c9023a12da2151f,NSCLC,0.308669
uuid-bf2a4053807b426c8c9023a12da2151f,patients,0.359831
uuid-86755765064c45b999eb5f07aa7f2d07,N Engl J Med,0.442834
uuid-86755765064c45b999eb5f07aa7f2d07,protocol,0.763252
uuid-86755765064c45b999eb5f07aa7f2d07,McDermott DF,0.733103
uuid-86755765064c45b999eb5f07aa7f2d07,Motzer RJ,0.811057
uuid-86755765064c45b999eb5f07aa7f2d07,phase 3 study,0.420895
uuid-86755765064c45b999eb5f07aa7f2d07,Escudier B,0.741048
uuid-86755765064c45b999eb5f07aa7f2d07,NEJM,0.402544
uuid-86755765064c45b999eb5f07aa7f2d07,et al.,0.660398
uuid-86755765064c45b999eb5f07aa7f2d07,J Clin Oncol,0.786367
uuid-86755765064c45b999eb5f07aa7f2d07,Topalian,0.392395
uuid-86755765064c45b999eb5f07aa7f2d07,phase 1 study,0.513779
uuid-86755765064c45b999eb5f07aa7f2d07,CA209-003,0.583337
uuid-86755765064c45b999eb5f07aa7f2d07,phase 2 study,0.675447
uuid-86755765064c45b999eb5f07aa7f2d07,present using the following search terms,0.304589
uuid-86755765064c45b999eb5f07aa7f2d07,investigating,0.633101
uuid-22f5e02c553049c4b67fa13560e8f01d,requested,0.594234
uuid-17fe60958db84a46a0a3bfefef4f6fbf,95% CI,0.524855
uuid-17fe60958db84a46a0a3bfefef4f6fbf,respectively,0.383655
uuid-17fe60958db84a46a0a3bfefef4f6fbf,ASCO,0.303153
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Lancet Oncol,0.368041
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Objective response rate,0.504846
uuid-17fe60958db84a46a0a3bfefef4f6fbf,ORR,0.465366
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Median overall survival,0.346516
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Median OS,0.33538
uuid-17fe60958db84a46a0a3bfefef4f6fbf,ASCO 2015,0.336983
uuid-17fe60958db84a46a0a3bfefef4f6fbf,small cell lung cancer,0.336892
uuid-17fe60958db84a46a0a3bfefef4f6fbf,SCLC,0.344367
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Antonia SJ,0.55269
uuid-17fe60958db84a46a0a3bfefef4f6fbf,Median duration of response,0.649605
uuid-a91e0246ec974ac3a6030038c048f33a,95% CI,0.524855
uuid-a91e0246ec974ac3a6030038c048f33a,respectively,0.383655
uuid-a91e0246ec974ac3a6030038c048f33a,ASCO,0.303153
uuid-a91e0246ec974ac3a6030038c048f33a,Lancet Oncol,0.368041
uuid-a91e0246ec974ac3a6030038c048f33a,Objective response rate,0.504846
uuid-a91e0246ec974ac3a6030038c048f33a,ORR,0.465366
uuid-a91e0246ec974ac3a6030038c048f33a,Median overall survival,0.346516
uuid-a91e0246ec974ac3a6030038c048f33a,Median OS,0.33538
uuid-a91e0246ec974ac3a6030038c048f33a,ASCO 2015,0.336983
uuid-a91e0246ec974ac3a6030038c048f33a,small cell lung cancer,0.336892
uuid-a91e0246ec974ac3a6030038c048f33a,SCLC,0.344367
uuid-a91e0246ec974ac3a6030038c048f33a,Antonia SJ,0.55269
uuid-a91e0246ec974ac3a6030038c048f33a,Median duration of response,0.649605
uuid-2e1297c3513840c3aa11297d6ee0a0b8,Bristol-Myers Squibb,0.341822
uuid-2e1297c3513840c3aa11297d6ee0a0b8,not conducted any controlled clinical trials/studies,0.304507
uuid-2e1297c3513840c3aa11297d6ee0a0b8,Opdivo,0.461382
uuid-2e1297c3513840c3aa11297d6ee0a0b8,Pubmed literature search,0.614325
uuid-2e1297c3513840c3aa11297d6ee0a0b8,purposes other than its labeled indication must be considered investigational,0.586645
uuid-2e1297c3513840c3aa11297d6ee0a0b8,not identify any citations relevant to your inquiry,0.606087
uuid-2e1297c3513840c3aa11297d6ee0a0b8,adverse,0.304183
uuid-2e1297c3513840c3aa11297d6ee0a0b8,using the following search terms,0.642331
uuid-2e1297c3513840c3aa11297d6ee0a0b8,databases,0.315039
uuid-2e1297c3513840c3aa11297d6ee0a0b8,reported,0.556704
uuid-bad5c8d4a2da430e9fd50b7ea576c210,patients,0.315933
uuid-27f7cfb3077d434f802d96d7f33767f1,use of nivolumab for the treatment,0.440423
uuid-27f7cfb3077d434f802d96d7f33767f1,search of published literature,0.311531
uuid-27f7cfb3077d434f802d96d7f33767f1,PubMed and EMBASE,0.312811
uuid-27f7cfb3077d434f802d96d7f33767f1,not approved,0.404782
uuid-27f7cfb3077d434f802d96d7f33767f1,open-label,0.578291
uuid-27f7cfb3077d434f802d96d7f33767f1,clinical trials investigating the safety,0.440014
uuid-27f7cfb3077d434f802d96d7f33767f1,present using the following search terms,0.328669
uuid-27f7cfb3077d434f802d96d7f33767f1,phase,0.41185
uuid-3277ee7baf2f4a7593a260a1d577408d,ESMO,0.615829
uuid-3277ee7baf2f4a7593a260a1d577408d,NEJM,0.3327
uuid-3277ee7baf2f4a7593a260a1d577408d,Topalian,0.377523
uuid-3277ee7baf2f4a7593a260a1d577408d,Horn L,0.30106
uuid-3277ee7baf2f4a7593a260a1d577408d,grade 3 to 4 AEs,0.375848
uuid-bd9908f50c3844acbe4a92ed1e9c727d,Bristol-Myers Squibb,0.346284
uuid-bd9908f50c3844acbe4a92ed1e9c727d,requested,0.318394
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,evaluating,0.350845
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,not conducted any controlled clinical trials/studies,0.345107
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,search of published literature,0.385331
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,Additionally,0.40981
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,ongoing,0.457998
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,PubMed and EMBASE,0.378285
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,detailed search of www.clinicaltrials.gov,0.428522
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,efficacy and safety of nivolumab,0.407868
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,not identify any planned,0.444729
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,combination,0.388252
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,BMS,0.316104
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,not identify any citations relevant to your request,0.438151
uuid-e3cc81e4c9aa49c6ae90d23a29dd8b59,present using the following search terms,0.377101
uuid-92db920118f2456d9e60d55ad9ca3f94,nivolumab,0.389809
uuid-f5971cbcf1a44447931f3bc0ade50a16,clinical,0.407943
uuid-f5971cbcf1a44447931f3bc0ade50a16,trial,0.472571
uuid-f11ced5b201249878b7ade984ab7d963,respectively,0.397695
uuid-2cec019d6b834655b34c9d15ef2db1d4,nivolumab,0.600099
uuid-2cec019d6b834655b34c9d15ef2db1d4,Opdivo,0.714465
uuid-2cec019d6b834655b34c9d15ef2db1d4,Pubmed literature search,0.375019
uuid-2cec019d6b834655b34c9d15ef2db1d4,purposes other than its labeled indication must be considered investigational,0.341042
uuid-2cec019d6b834655b34c9d15ef2db1d4,not identify any citations relevant to your inquiry,0.39106
uuid-2cec019d6b834655b34c9d15ef2db1d4,using the following search terms,0.436512
uuid-2cec019d6b834655b34c9d15ef2db1d4,trial,0.385197
uuid-163bbb6925284a83ae1736a7eb46abfd,open-label,0.312827
uuid-163bbb6925284a83ae1736a7eb46abfd,trial,0.545503
uuid-a36cf734843e42d7aa9c8fee047dab47,Bristol-Myers Squibb,0.341822
uuid-a36cf734843e42d7aa9c8fee047dab47,not conducted any controlled clinical trials/studies,0.304507
uuid-a36cf734843e42d7aa9c8fee047dab47,Opdivo,0.461382
uuid-a36cf734843e42d7aa9c8fee047dab47,Pubmed literature search,0.614325
uuid-a36cf734843e42d7aa9c8fee047dab47,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a36cf734843e42d7aa9c8fee047dab47,not identify any citations relevant to your inquiry,0.606087
uuid-a36cf734843e42d7aa9c8fee047dab47,adverse,0.304183
uuid-a36cf734843e42d7aa9c8fee047dab47,using the following search terms,0.642331
uuid-a36cf734843e42d7aa9c8fee047dab47,databases,0.315039
uuid-a36cf734843e42d7aa9c8fee047dab47,reported,0.556704
uuid-35fcf58b95164f10be96bcdc48b11340,provided in the Detailed Information,0.408955
uuid-35fcf58b95164f10be96bcdc48b11340,ESMO,0.992426
uuid-35fcf58b95164f10be96bcdc48b11340,Horn L,0.554477
uuid-35fcf58b95164f10be96bcdc48b11340,grade 3 to 4 AEs,0.502956
uuid-1c53431864a14ca78aeb24925374a8fc,patients,0.556054
uuid-1c53431864a14ca78aeb24925374a8fc,provided in the Detailed Information,0.329929
uuid-1c53431864a14ca78aeb24925374a8fc,adverse,0.32982
uuid-1c53431864a14ca78aeb24925374a8fc,phase 3 study,0.523726
uuid-1c53431864a14ca78aeb24925374a8fc,melanoma,0.382071
uuid-1c53431864a14ca78aeb24925374a8fc,Weber JS,0.428777
uuid-1c53431864a14ca78aeb24925374a8fc,phase 2 study,0.307314
uuid-1c53431864a14ca78aeb24925374a8fc,grade 3 to 4 AEs,0.466022
uuid-1987d5a6a936468b8eeefd98e74821f5,trial,0.315685
uuid-5fe16459f8aa4c0e91e2163edb88e0b6,provided in the Detailed Information,0.408955
uuid-5fe16459f8aa4c0e91e2163edb88e0b6,ESMO,0.992426
uuid-5fe16459f8aa4c0e91e2163edb88e0b6,Horn L,0.554477
uuid-5fe16459f8aa4c0e91e2163edb88e0b6,grade 3 to 4 AEs,0.502956
uuid-d9613728da8c41b1ab68e347103e814b,patients,0.67757
uuid-d9613728da8c41b1ab68e347103e814b,small cell lung cancer,0.311996
uuid-d9613728da8c41b1ab68e347103e814b,grade 3 to 4 AEs,0.317339
uuid-ec65b023423648e6bfdf912d64035dd2,NSCLC,0.351198
uuid-ec65b023423648e6bfdf912d64035dd2,efficacy and safety of nivolumab,0.343313
uuid-afd5fa86139d4b6e8e3e364bab7e0be1,ESMO,0.500333
uuid-afd5fa86139d4b6e8e3e364bab7e0be1,Horn L,0.306308
uuid-a6909c8f88d44fa082f0cd4ff2ab16d7,ASCO,0.382205
uuid-50ca4a27f45f4b2cbdf6a3767d07d825,OS,0.62262
uuid-50ca4a27f45f4b2cbdf6a3767d07d825,PFS,0.65903
uuid-50ca4a27f45f4b2cbdf6a3767d07d825,Overall survival,0.644151
uuid-08edeca3ce804b64abff0fef4b12a52d,use of nivolumab for the treatment,0.534876
uuid-08edeca3ce804b64abff0fef4b12a52d,patients,0.668718
uuid-08edeca3ce804b64abff0fef4b12a52d,considered investigational,0.869917
uuid-08edeca3ce804b64abff0fef4b12a52d,patients with advanced or metastatic,0.507496
uuid-08edeca3ce804b64abff0fef4b12a52d,nivolumab combined with ipilimumab,0.486955
uuid-08edeca3ce804b64abff0fef4b12a52d,tumors,0.582613
uuid-08edeca3ce804b64abff0fef4b12a52d,small cell lung cancer,0.909436
uuid-08edeca3ce804b64abff0fef4b12a52d,SCLC,0.891623
uuid-08edeca3ce804b64abff0fef4b12a52d,therapy,0.511791
uuid-08edeca3ce804b64abff0fef4b12a52d,phase 1/2 study CA209-032,0.785119
uuid-08edeca3ce804b64abff0fef4b12a52d,evaluates the efficacy of nivolumab monotherapy,0.716721
uuid-4c9fe0b72e134a448264ee58d2cb94ce,trial,0.530985
uuid-4c9fe0b72e134a448264ee58d2cb94ce,therapy,0.387491
uuid-a83f784643874fd59fe539a51b7c4ed5,search of published literature,0.345664
uuid-a83f784643874fd59fe539a51b7c4ed5,phase 3 study,0.62147
uuid-a83f784643874fd59fe539a51b7c4ed5,PubMed and EMBASE,0.344236
uuid-a83f784643874fd59fe539a51b7c4ed5,Rizvi NA,0.333041
uuid-a83f784643874fd59fe539a51b7c4ed5,Weber JS,0.568835
uuid-a83f784643874fd59fe539a51b7c4ed5,present using the following search terms,0.32114
uuid-43e1b0154bd9458b9b73427a1ce03a61,nivolumab,0.406126
uuid-43e1b0154bd9458b9b73427a1ce03a61,search of published literature,0.507146
uuid-43e1b0154bd9458b9b73427a1ce03a61,PubMed and EMBASE,0.512383
uuid-43e1b0154bd9458b9b73427a1ce03a61,efficacy and safety of nivolumab,0.30401
uuid-43e1b0154bd9458b9b73427a1ce03a61,not identify any citations relevant to your request,0.357003
uuid-43e1b0154bd9458b9b73427a1ce03a61,present using the following search terms,0.506083
uuid-43e1b0154bd9458b9b73427a1ce03a61,cohort,0.542919
uuid-b7bafa875d1540f99c62be2c4f253cb8,Bristol-Myers Squibb,0.429237
uuid-b7bafa875d1540f99c62be2c4f253cb8,use of nivolumab for the treatment,0.448414
uuid-b7bafa875d1540f99c62be2c4f253cb8,evaluating,0.562246
uuid-b7bafa875d1540f99c62be2c4f253cb8,not conducted any controlled clinical trials/studies,0.538025
uuid-b7bafa875d1540f99c62be2c4f253cb8,patients,0.407574
uuid-b7bafa875d1540f99c62be2c4f253cb8,considered investigational,0.4929
uuid-b7bafa875d1540f99c62be2c4f253cb8,efficacy and safety of nivolumab,0.506567
uuid-b7bafa875d1540f99c62be2c4f253cb8,safety of nivolumab monotherapy,0.319819
uuid-444f51b94a96463e8716c27535fc55cf,N Engl J Med,0.322518
uuid-444f51b94a96463e8716c27535fc55cf,ASCO,0.74261
uuid-444f51b94a96463e8716c27535fc55cf,protocol,0.342459
uuid-444f51b94a96463e8716c27535fc55cf,McDermott DF,0.457307
uuid-444f51b94a96463e8716c27535fc55cf,Motzer RJ,0.396666
uuid-444f51b94a96463e8716c27535fc55cf,Escudier B,0.430596
uuid-444f51b94a96463e8716c27535fc55cf,et al.,0.537544
uuid-444f51b94a96463e8716c27535fc55cf,J Clin Oncol,0.427693
uuid-444f51b94a96463e8716c27535fc55cf,phase 2 study,0.402538
uuid-da794b70155f41ce8430ce8cd829bdee,monotherapy,0.325892
uuid-da794b70155f41ce8430ce8cd829bdee,mg,0.965292
uuid-da794b70155f41ce8430ce8cd829bdee,kg,0.933734
uuid-da794b70155f41ce8430ce8cd829bdee,cohort,0.39818
uuid-941f33ed2a0d4810918082b162e61c9e,Bristol-Myers Squibb,0.609244
uuid-941f33ed2a0d4810918082b162e61c9e,evaluating,0.610089
uuid-941f33ed2a0d4810918082b162e61c9e,not conducted any controlled clinical trials/studies,0.665418
uuid-941f33ed2a0d4810918082b162e61c9e,considered investigational,0.400989
uuid-941f33ed2a0d4810918082b162e61c9e,RCC,0.308555
uuid-941f33ed2a0d4810918082b162e61c9e,efficacy and safety of nivolumab,0.563776
uuid-941f33ed2a0d4810918082b162e61c9e,therapy,0.325008
uuid-3bc48dd1a5a146e2a918cb235c232f6f,ipilimumab,0.385692
uuid-3bc48dd1a5a146e2a918cb235c232f6f,ASCO 2015,0.417944
uuid-3bc48dd1a5a146e2a918cb235c232f6f,partial response,0.382425
uuid-3bc48dd1a5a146e2a918cb235c232f6f,Stable disease,0.586335
uuid-3bc48dd1a5a146e2a918cb235c232f6f,cohort,0.307748
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,nivolumab,0.347078
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,patients with advanced or metastatic,0.323546
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,nivolumab combined with ipilimumab,0.321106
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,ESMO,0.690869
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,Horn L,0.364617
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,grade 3 to 4 AEs,0.308322
uuid-ae372c6f3f22421e9b2cd78bd46b96a3,bladder cancer,0.496096
uuid-5a8078fe7a5643268e8f07fa4e4249ee,requested,0.594234
uuid-2274e3f601064d589dafe98260fb44e3,ASCO,0.64795
uuid-2274e3f601064d589dafe98260fb44e3,Antonia SJ,0.334859
uuid-74581c1b83a4458fadf5fda89964c1fc,N Engl J Med,0.604857
uuid-74581c1b83a4458fadf5fda89964c1fc,non-small cell lung cancer,0.34354
uuid-74581c1b83a4458fadf5fda89964c1fc,ESMO,0.393944
uuid-74581c1b83a4458fadf5fda89964c1fc,Rizvi NA,0.452745
uuid-74581c1b83a4458fadf5fda89964c1fc,Brahmer J,0.679154
uuid-74581c1b83a4458fadf5fda89964c1fc,PD-L1,0.347566
uuid-74581c1b83a4458fadf5fda89964c1fc,Horn L,0.50259
uuid-74581c1b83a4458fadf5fda89964c1fc,platinum-based doublet chemotherapy,0.304136
uuid-a9feb98c13b54f03aea7ad0706f18f08,95% CI,0.520262
uuid-a9feb98c13b54f03aea7ad0706f18f08,respectively,0.504068
uuid-a9feb98c13b54f03aea7ad0706f18f08,Objective response rate,0.458568
uuid-a9feb98c13b54f03aea7ad0706f18f08,ORR,0.525868
uuid-a9feb98c13b54f03aea7ad0706f18f08,Median overall survival,0.455633
uuid-a9feb98c13b54f03aea7ad0706f18f08,Median OS,0.507448
uuid-a9feb98c13b54f03aea7ad0706f18f08,docetaxel,0.383115
uuid-a9feb98c13b54f03aea7ad0706f18f08,hazard ratio,0.462119
uuid-ca3c828a39324665b49c88cc33ce0e68,search of published literature,0.394524
uuid-ca3c828a39324665b49c88cc33ce0e68,Additionally,0.413583
uuid-ca3c828a39324665b49c88cc33ce0e68,ongoing,0.322117
uuid-ca3c828a39324665b49c88cc33ce0e68,PubMed and EMBASE,0.391671
uuid-ca3c828a39324665b49c88cc33ce0e68,detailed search of www.clinicaltrials.gov,0.375936
uuid-ca3c828a39324665b49c88cc33ce0e68,efficacy and safety of nivolumab,0.370699
uuid-ca3c828a39324665b49c88cc33ce0e68,not identify any planned,0.34283
uuid-ca3c828a39324665b49c88cc33ce0e68,Weber JS,0.319229
uuid-ca3c828a39324665b49c88cc33ce0e68,not identify any citations relevant to your request,0.447813
uuid-ca3c828a39324665b49c88cc33ce0e68,present using the following search terms,0.408199
uuid-17c6e8cad1e6464892cd8094b71e16e5,ipilimumab,0.385692
uuid-17c6e8cad1e6464892cd8094b71e16e5,ASCO 2015,0.417944
uuid-17c6e8cad1e6464892cd8094b71e16e5,partial response,0.382425
uuid-17c6e8cad1e6464892cd8094b71e16e5,Stable disease,0.586335
uuid-17c6e8cad1e6464892cd8094b71e16e5,cohort,0.307748
uuid-294da12f35ff4768a90b8fee23a9783f,NSCLC,0.430878
uuid-294da12f35ff4768a90b8fee23a9783f,non-small cell lung cancer,0.38056
uuid-294da12f35ff4768a90b8fee23a9783f,patients,0.358129
uuid-294da12f35ff4768a90b8fee23a9783f,considered investigational,0.305333
uuid-294da12f35ff4768a90b8fee23a9783f,tumors,0.587486
uuid-294da12f35ff4768a90b8fee23a9783f,phase 3 study,0.305707
uuid-294da12f35ff4768a90b8fee23a9783f,phase 1/2 study CA209-032,0.305651
uuid-294da12f35ff4768a90b8fee23a9783f,evaluates the efficacy of nivolumab monotherapy,0.320368
uuid-03496e67d8b34385839c58e3d5165d79,requested,0.585964
uuid-a516685468c04e3c81501f4a9dd2a607,RCC,0.300536
uuid-a516685468c04e3c81501f4a9dd2a607,Additionally,0.848665
uuid-a516685468c04e3c81501f4a9dd2a607,ongoing,0.883718
uuid-a516685468c04e3c81501f4a9dd2a607,detailed search of www.clinicaltrials.gov,0.873112
uuid-a516685468c04e3c81501f4a9dd2a607,not identify any planned,0.881885
uuid-a516685468c04e3c81501f4a9dd2a607,combination,0.512846
uuid-a516685468c04e3c81501f4a9dd2a607,not identify any citations relevant to your request,0.76848
uuid-09bd7f87fe52420499fb26817645b078,nivolumab,0.347078
uuid-09bd7f87fe52420499fb26817645b078,patients with advanced or metastatic,0.323546
uuid-09bd7f87fe52420499fb26817645b078,nivolumab combined with ipilimumab,0.321106
uuid-09bd7f87fe52420499fb26817645b078,ESMO,0.690869
uuid-09bd7f87fe52420499fb26817645b078,Horn L,0.364617
uuid-09bd7f87fe52420499fb26817645b078,grade 3 to 4 AEs,0.308322
uuid-09bd7f87fe52420499fb26817645b078,bladder cancer,0.496096
uuid-e87dcf34aedb48f4ab506a2d682a5d2c,Bristol-Myers Squibb,0.417456
uuid-e87dcf34aedb48f4ab506a2d682a5d2c,requested,0.336974
uuid-22e622cb03914b45b0c3bbd57759055c,ESMO,0.615829
uuid-22e622cb03914b45b0c3bbd57759055c,NEJM,0.3327
uuid-22e622cb03914b45b0c3bbd57759055c,Topalian,0.377523
uuid-22e622cb03914b45b0c3bbd57759055c,Horn L,0.30106
uuid-22e622cb03914b45b0c3bbd57759055c,grade 3 to 4 AEs,0.375848
uuid-eb06408bb72143779946f9ac0a7031c2,respectively,0.397695
uuid-d6d371081a02418da163677db292f246,AEs,0.394251
uuid-d6d371081a02418da163677db292f246,respectively,0.411906
uuid-d6d371081a02418da163677db292f246,provided in the Detailed Information,0.448569
uuid-d6d371081a02418da163677db292f246,clinical,0.514429
uuid-d6d371081a02418da163677db292f246,docetaxel,0.448746
uuid-d6d371081a02418da163677db292f246,grade,0.32524
uuid-d6d371081a02418da163677db292f246,grade 3 to 4 AEs,0.373049
uuid-ab799f0d57fc454287f129b2b2294f8f,patients with advanced or metastatic,0.468858
uuid-ab799f0d57fc454287f129b2b2294f8f,nivolumab combined with ipilimumab,0.446918
uuid-ab799f0d57fc454287f129b2b2294f8f,not approved,0.352562
uuid-ab799f0d57fc454287f129b2b2294f8f,clinical trials investigating the safety,0.429501
uuid-ab799f0d57fc454287f129b2b2294f8f,bladder cancer,0.950698
uuid-4933e19aa0ec4f72905093f089721cc0,ipilimumab,0.381645
uuid-4933e19aa0ec4f72905093f089721cc0,ASCO 2015,0.413229
uuid-4933e19aa0ec4f72905093f089721cc0,partial response,0.378877
uuid-4933e19aa0ec4f72905093f089721cc0,Stable disease,0.583222
uuid-4933e19aa0ec4f72905093f089721cc0,cohort,0.306093
uuid-a7867cd14a644558bd5dd15b1d25f278,requested,0.44769
uuid-a7867cd14a644558bd5dd15b1d25f278,trial,0.309472
uuid-f89d4d8ed28a414f95ba9e3c40ab3d5f,ipilimumab,0.385692
uuid-f89d4d8ed28a414f95ba9e3c40ab3d5f,ASCO 2015,0.417944
uuid-f89d4d8ed28a414f95ba9e3c40ab3d5f,partial response,0.382425
uuid-f89d4d8ed28a414f95ba9e3c40ab3d5f,Stable disease,0.586335
uuid-f89d4d8ed28a414f95ba9e3c40ab3d5f,cohort,0.307748
uuid-7b4f4db0b3124c8394cea272dcf80642,ipilimumab,0.385692
uuid-7b4f4db0b3124c8394cea272dcf80642,ASCO 2015,0.417944
uuid-7b4f4db0b3124c8394cea272dcf80642,partial response,0.382425
uuid-7b4f4db0b3124c8394cea272dcf80642,Stable disease,0.586335
uuid-7b4f4db0b3124c8394cea272dcf80642,cohort,0.307748
uuid-5943f7fb4b7f4e698d2da591550bce27,95% CI,0.524855
uuid-5943f7fb4b7f4e698d2da591550bce27,respectively,0.383655
uuid-5943f7fb4b7f4e698d2da591550bce27,ASCO,0.303153
uuid-5943f7fb4b7f4e698d2da591550bce27,Lancet Oncol,0.368041
uuid-5943f7fb4b7f4e698d2da591550bce27,Objective response rate,0.504846
uuid-5943f7fb4b7f4e698d2da591550bce27,ORR,0.465366
uuid-5943f7fb4b7f4e698d2da591550bce27,Median overall survival,0.346516
uuid-5943f7fb4b7f4e698d2da591550bce27,Median OS,0.33538
uuid-5943f7fb4b7f4e698d2da591550bce27,ASCO 2015,0.336983
uuid-5943f7fb4b7f4e698d2da591550bce27,small cell lung cancer,0.336892
uuid-5943f7fb4b7f4e698d2da591550bce27,SCLC,0.344367
uuid-5943f7fb4b7f4e698d2da591550bce27,Antonia SJ,0.55269
uuid-5943f7fb4b7f4e698d2da591550bce27,Median duration of response,0.649605
uuid-76995b0893484028a645f1dfb654d805,search of published literature,0.394524
uuid-76995b0893484028a645f1dfb654d805,Additionally,0.413583
uuid-76995b0893484028a645f1dfb654d805,ongoing,0.322117
uuid-76995b0893484028a645f1dfb654d805,PubMed and EMBASE,0.391671
uuid-76995b0893484028a645f1dfb654d805,detailed search of www.clinicaltrials.gov,0.375936
uuid-76995b0893484028a645f1dfb654d805,efficacy and safety of nivolumab,0.370699
uuid-76995b0893484028a645f1dfb654d805,not identify any planned,0.34283
uuid-76995b0893484028a645f1dfb654d805,Weber JS,0.319229
uuid-76995b0893484028a645f1dfb654d805,not identify any citations relevant to your request,0.447813
uuid-76995b0893484028a645f1dfb654d805,present using the following search terms,0.408199
uuid-12e783d9e682466db8651543f6f99850,Bristol-Myers Squibb,0.341822
uuid-12e783d9e682466db8651543f6f99850,not conducted any controlled clinical trials/studies,0.304507
uuid-12e783d9e682466db8651543f6f99850,Opdivo,0.461382
uuid-12e783d9e682466db8651543f6f99850,Pubmed literature search,0.614325
uuid-12e783d9e682466db8651543f6f99850,purposes other than its labeled indication must be considered investigational,0.586645
uuid-12e783d9e682466db8651543f6f99850,not identify any citations relevant to your inquiry,0.606087
uuid-12e783d9e682466db8651543f6f99850,adverse,0.304183
uuid-12e783d9e682466db8651543f6f99850,using the following search terms,0.642331
uuid-12e783d9e682466db8651543f6f99850,databases,0.315039
uuid-12e783d9e682466db8651543f6f99850,reported,0.556704
uuid-ddbc6a3273ff4e18b73b40158c1b3851,nivolumab,0.37166
uuid-ddbc6a3273ff4e18b73b40158c1b3851,Bristol-Myers Squibb,0.584779
uuid-ddbc6a3273ff4e18b73b40158c1b3851,evaluating,0.605349
uuid-ddbc6a3273ff4e18b73b40158c1b3851,not conducted any controlled clinical trials/studies,0.653756
uuid-ddbc6a3273ff4e18b73b40158c1b3851,considered investigational,0.417837
uuid-ddbc6a3273ff4e18b73b40158c1b3851,purposes other than its labeled indication must be considered investigational,0.375108
uuid-ddbc6a3273ff4e18b73b40158c1b3851,efficacy and safety of nivolumab,0.509979
uuid-4de75377ad5e4c32be4626c566c92914,patients,0.315933
uuid-4374904f15c24c94814e15c74b21589b,ASCO,0.807066
uuid-10101677a6424985b6bf6728e40c0bb9,considered investigational,0.402849
uuid-10101677a6424985b6bf6728e40c0bb9,small cell lung cancer,0.651985
uuid-10101677a6424985b6bf6728e40c0bb9,partial response,0.50367
uuid-10101677a6424985b6bf6728e40c0bb9,SCLC,0.736863
uuid-10101677a6424985b6bf6728e40c0bb9,therapy,0.843488
uuid-10101677a6424985b6bf6728e40c0bb9,relapsed,0.613852
uuid-10101677a6424985b6bf6728e40c0bb9,phase 1/2 study CA209-032,0.40439
uuid-10101677a6424985b6bf6728e40c0bb9,evaluates the efficacy of nivolumab monotherapy,0.330963
uuid-d3132ea5bb6e4779ab858ec4800b4db5,Bristol-Myers Squibb,0.341822
uuid-d3132ea5bb6e4779ab858ec4800b4db5,not conducted any controlled clinical trials/studies,0.304507
uuid-d3132ea5bb6e4779ab858ec4800b4db5,Opdivo,0.461382
uuid-d3132ea5bb6e4779ab858ec4800b4db5,Pubmed literature search,0.614325
uuid-d3132ea5bb6e4779ab858ec4800b4db5,purposes other than its labeled indication must be considered investigational,0.586645
uuid-d3132ea5bb6e4779ab858ec4800b4db5,not identify any citations relevant to your inquiry,0.606087
uuid-d3132ea5bb6e4779ab858ec4800b4db5,adverse,0.304183
uuid-d3132ea5bb6e4779ab858ec4800b4db5,using the following search terms,0.642331
uuid-d3132ea5bb6e4779ab858ec4800b4db5,databases,0.315039
uuid-d3132ea5bb6e4779ab858ec4800b4db5,reported,0.556704
uuid-7c40e7a741fa43f5a6c9aeef63a5d66d,requested,0.44769
uuid-7c40e7a741fa43f5a6c9aeef63a5d66d,trial,0.309472
uuid-7b27b1238f154079a5af8a032974e2eb,nivolumab,0.723465
uuid-7b27b1238f154079a5af8a032974e2eb,evaluating,0.496438
uuid-7b27b1238f154079a5af8a032974e2eb,not conducted any controlled clinical trials/studies,0.531455
uuid-7b27b1238f154079a5af8a032974e2eb,Pubmed literature search,0.868097
uuid-7b27b1238f154079a5af8a032974e2eb,purposes other than its labeled indication must be considered investigational,0.932448
uuid-7b27b1238f154079a5af8a032974e2eb,not identify any citations relevant to your inquiry,0.827771
uuid-7b27b1238f154079a5af8a032974e2eb,using the following search terms,0.813924
uuid-7b27b1238f154079a5af8a032974e2eb,efficacy and safety of nivolumab,0.345389
uuid-60a757d15d2d41feab6fc753e418b6db,ipilimumab,0.385692
uuid-60a757d15d2d41feab6fc753e418b6db,ASCO 2015,0.417944
uuid-60a757d15d2d41feab6fc753e418b6db,partial response,0.382425
uuid-60a757d15d2d41feab6fc753e418b6db,Stable disease,0.586335
uuid-60a757d15d2d41feab6fc753e418b6db,cohort,0.307748
uuid-2a53e8fbf24f4fe594de40466c1508e1,N Engl J Med,0.442834
uuid-2a53e8fbf24f4fe594de40466c1508e1,protocol,0.763252
uuid-2a53e8fbf24f4fe594de40466c1508e1,McDermott DF,0.733103
uuid-2a53e8fbf24f4fe594de40466c1508e1,Motzer RJ,0.811057
uuid-2a53e8fbf24f4fe594de40466c1508e1,phase 3 study,0.420895
uuid-2a53e8fbf24f4fe594de40466c1508e1,Escudier B,0.741048
uuid-2a53e8fbf24f4fe594de40466c1508e1,NEJM,0.402544
uuid-2a53e8fbf24f4fe594de40466c1508e1,et al.,0.660398
uuid-2a53e8fbf24f4fe594de40466c1508e1,J Clin Oncol,0.786367
uuid-2a53e8fbf24f4fe594de40466c1508e1,Topalian,0.392395
uuid-2a53e8fbf24f4fe594de40466c1508e1,phase 1 study,0.513779
uuid-2a53e8fbf24f4fe594de40466c1508e1,CA209-003,0.583337
uuid-2a53e8fbf24f4fe594de40466c1508e1,phase 2 study,0.675447
uuid-2a53e8fbf24f4fe594de40466c1508e1,present using the following search terms,0.304589
uuid-2a53e8fbf24f4fe594de40466c1508e1,investigating,0.633101
uuid-6ef3fb01ce7a4e71944e776067719e10,nivolumab,0.658786
uuid-6ef3fb01ce7a4e71944e776067719e10,Bristol-Myers Squibb,0.417954
uuid-6ef3fb01ce7a4e71944e776067719e10,evaluating,0.602184
uuid-6ef3fb01ce7a4e71944e776067719e10,not conducted any controlled clinical trials/studies,0.625875
uuid-6ef3fb01ce7a4e71944e776067719e10,Pubmed literature search,0.722578
uuid-6ef3fb01ce7a4e71944e776067719e10,purposes other than its labeled indication must be considered investigational,0.793729
uuid-6ef3fb01ce7a4e71944e776067719e10,not identify any citations relevant to your inquiry,0.692229
uuid-6ef3fb01ce7a4e71944e776067719e10,using the following search terms,0.674626
uuid-6ef3fb01ce7a4e71944e776067719e10,efficacy and safety of nivolumab,0.473902
uuid-9d18db281c5b48368fc504b4d1cd8e6c,OS,0.349054
uuid-9d18db281c5b48368fc504b4d1cd8e6c,95% CI,0.696869
uuid-9d18db281c5b48368fc504b4d1cd8e6c,respectively,0.747405
uuid-9d18db281c5b48368fc504b4d1cd8e6c,Objective response rate,0.596478
uuid-9d18db281c5b48368fc504b4d1cd8e6c,ORR,0.7237
uuid-9d18db281c5b48368fc504b4d1cd8e6c,Median overall survival,0.628269
uuid-9d18db281c5b48368fc504b4d1cd8e6c,monotherapy,0.48503
uuid-9d18db281c5b48368fc504b4d1cd8e6c,Median OS,0.660506
uuid-9d18db281c5b48368fc504b4d1cd8e6c,PD-L1,0.403686
uuid-9d18db281c5b48368fc504b4d1cd8e6c,docetaxel,0.487238
uuid-9d18db281c5b48368fc504b4d1cd8e6c,hazard ratio,0.689448
uuid-abac6d51efef4c808e8bdd6fd55b490a,phase 3 study,0.319955
uuid-abac6d51efef4c808e8bdd6fd55b490a,phase 1 study,0.446598
uuid-abac6d51efef4c808e8bdd6fd55b490a,Rizvi NA,0.340455
uuid-abac6d51efef4c808e8bdd6fd55b490a,mg,0.54474
uuid-abac6d51efef4c808e8bdd6fd55b490a,CA209-003,0.386745
uuid-abac6d51efef4c808e8bdd6fd55b490a,phase 2 study,0.37122
uuid-abac6d51efef4c808e8bdd6fd55b490a,kg,0.481395
uuid-e30b64204a134c51b15657444b3cc65d,considered investigational,0.30457
uuid-e30b64204a134c51b15657444b3cc65d,melanoma,0.387656
uuid-e30b64204a134c51b15657444b3cc65d,small cell lung cancer,0.517146
uuid-e30b64204a134c51b15657444b3cc65d,partial response,0.323082
uuid-e30b64204a134c51b15657444b3cc65d,SCLC,0.592551
uuid-e30b64204a134c51b15657444b3cc65d,therapy,0.86274
uuid-e30b64204a134c51b15657444b3cc65d,relapsed,0.390331
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,OS,0.349054
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,95% CI,0.696869
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,respectively,0.747405
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,Objective response rate,0.596478
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,ORR,0.7237
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,Median overall survival,0.628269
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,monotherapy,0.48503
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,Median OS,0.660506
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,PD-L1,0.403686
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,docetaxel,0.487238
uuid-c5e14a3dd2274f58a29bf37ba73f1d6f,hazard ratio,0.689448
uuid-7765a77a98984e3bac8ac08a6dbf71c3,ipilimumab,0.385692
uuid-7765a77a98984e3bac8ac08a6dbf71c3,ASCO 2015,0.417944
uuid-7765a77a98984e3bac8ac08a6dbf71c3,partial response,0.382425
uuid-7765a77a98984e3bac8ac08a6dbf71c3,Stable disease,0.586335
uuid-7765a77a98984e3bac8ac08a6dbf71c3,cohort,0.307748
uuid-fefef3c6eef24413b3746a386193242b,requested,0.543767
uuid-a3807bd39aef482787a907038ab46cf5,N Engl J Med,0.616236
uuid-a3807bd39aef482787a907038ab46cf5,respectively,0.409266
uuid-a3807bd39aef482787a907038ab46cf5,ASCO,0.373445
uuid-a3807bd39aef482787a907038ab46cf5,ESMO,0.378373
uuid-a3807bd39aef482787a907038ab46cf5,Brahmer J,0.712806
uuid-a3807bd39aef482787a907038ab46cf5,docetaxel,0.327482
uuid-a3807bd39aef482787a907038ab46cf5,Horn L,0.502372
uuid-18a8f69291104e06babb54e76a694e71,nivolumab,0.58179
uuid-18a8f69291104e06babb54e76a694e71,Bristol-Myers Squibb,0.323753
uuid-18a8f69291104e06babb54e76a694e71,evaluating,0.480552
uuid-18a8f69291104e06babb54e76a694e71,not conducted any controlled clinical trials/studies,0.505284
uuid-18a8f69291104e06babb54e76a694e71,considered investigational,0.3808
uuid-18a8f69291104e06babb54e76a694e71,Pubmed literature search,0.384236
uuid-18a8f69291104e06babb54e76a694e71,purposes other than its labeled indication must be considered investigational,0.476325
uuid-18a8f69291104e06babb54e76a694e71,not identify any citations relevant to your inquiry,0.342344
uuid-18a8f69291104e06babb54e76a694e71,using the following search terms,0.324153
uuid-18a8f69291104e06babb54e76a694e71,efficacy and safety of nivolumab,0.388205
uuid-9fc2851bf17448d9978662da628ec998,Opdivo,0.395537
uuid-9fc2851bf17448d9978662da628ec998,Pubmed literature search,0.505032
uuid-9fc2851bf17448d9978662da628ec998,purposes other than its labeled indication must be considered investigational,0.479284
uuid-9fc2851bf17448d9978662da628ec998,not identify any citations relevant to your inquiry,0.503455
uuid-9fc2851bf17448d9978662da628ec998,using the following search terms,0.528681
uuid-9fc2851bf17448d9978662da628ec998,reported,0.458319
uuid-94db51ec47c94aa9b7f2883c3b434eea,monotherapy,0.318106
uuid-94db51ec47c94aa9b7f2883c3b434eea,mg,0.777152
uuid-94db51ec47c94aa9b7f2883c3b434eea,kg,0.831127
uuid-94db51ec47c94aa9b7f2883c3b434eea,relapsed,0.436495
uuid-94db51ec47c94aa9b7f2883c3b434eea,cohort,0.632172
uuid-5c71c3b9613746f2bf96ad5a8f53bd62,provided in the Detailed Information,0.578509
uuid-5c71c3b9613746f2bf96ad5a8f53bd62,clinical,0.470357
uuid-b2a3284504664d08816895bc688dd785,respectively,0.397695
uuid-1b13d0816d4e438b891e38fded75da0b,nivolumab,0.438416
uuid-1b13d0816d4e438b891e38fded75da0b,use of nivolumab for the treatment,0.317928
uuid-1b13d0816d4e438b891e38fded75da0b,patients,0.681271
uuid-1b13d0816d4e438b891e38fded75da0b,considered investigational,0.571476
uuid-1b13d0816d4e438b891e38fded75da0b,patients with advanced or metastatic,0.436263
uuid-1b13d0816d4e438b891e38fded75da0b,nivolumab combined with ipilimumab,0.414875
uuid-1b13d0816d4e438b891e38fded75da0b,tumors,0.726655
uuid-1b13d0816d4e438b891e38fded75da0b,small cell lung cancer,0.62662
uuid-1b13d0816d4e438b891e38fded75da0b,SCLC,0.573895
uuid-1b13d0816d4e438b891e38fded75da0b,therapy,0.302303
uuid-1b13d0816d4e438b891e38fded75da0b,grade 3 to 4 AEs,0.317867
uuid-1b13d0816d4e438b891e38fded75da0b,phase 1/2 study CA209-032,0.579859
uuid-1b13d0816d4e438b891e38fded75da0b,evaluates the efficacy of nivolumab monotherapy,0.566793
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,OS,0.493666
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,95% CI,0.872793
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,respectively,0.581917
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,Objective response rate,0.558489
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,ORR,0.705401
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,PFS,0.331929
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,Median overall survival,0.793083
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,monotherapy,0.422517
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,Median OS,0.808565
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,PD-L1,0.302111
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,docetaxel,0.481228
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,hazard ratio,0.844622
uuid-9a02ca4a6bc74ea58754ef8cda4e5628,Median duration of response,0.34536
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,evaluating,0.350845
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,not conducted any controlled clinical trials/studies,0.345107
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,search of published literature,0.385331
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,Additionally,0.40981
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,ongoing,0.457998
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,PubMed and EMBASE,0.378285
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,detailed search of www.clinicaltrials.gov,0.428522
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,efficacy and safety of nivolumab,0.407868
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,not identify any planned,0.444729
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,combination,0.388252
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,BMS,0.316104
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,not identify any citations relevant to your request,0.438151
uuid-4bfb1b2fbd9d4baea15b543d9138e03c,present using the following search terms,0.377101
uuid-3d369ecaa5cc403c97e6595446390fc9,evaluating,0.316713
uuid-3d369ecaa5cc403c97e6595446390fc9,not conducted any controlled clinical trials/studies,0.331856
uuid-70caa0bb213d4457a7fbfb4622296ac5,Bristol-Myers Squibb,0.31164
uuid-70caa0bb213d4457a7fbfb4622296ac5,use of nivolumab for the treatment,0.529461
uuid-70caa0bb213d4457a7fbfb4622296ac5,evaluating,0.579273
uuid-70caa0bb213d4457a7fbfb4622296ac5,not conducted any controlled clinical trials/studies,0.473077
uuid-70caa0bb213d4457a7fbfb4622296ac5,efficacy,0.587374
uuid-70caa0bb213d4457a7fbfb4622296ac5,NSCLC,0.602232
uuid-70caa0bb213d4457a7fbfb4622296ac5,non-small cell lung cancer,0.624982
uuid-70caa0bb213d4457a7fbfb4622296ac5,patients,0.52064
uuid-70caa0bb213d4457a7fbfb4622296ac5,considered investigational,0.385649
uuid-70caa0bb213d4457a7fbfb4622296ac5,not approved,0.520876
uuid-70caa0bb213d4457a7fbfb4622296ac5,clinical trials investigating the safety,0.461143
uuid-70caa0bb213d4457a7fbfb4622296ac5,efficacy and safety of nivolumab,0.468498
uuid-70caa0bb213d4457a7fbfb4622296ac5,safety of nivolumab monotherapy,0.599027
uuid-70caa0bb213d4457a7fbfb4622296ac5,platinum-based doublet chemotherapy,0.303376
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,patients,0.474018
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,considered investigational,0.76629
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,patients with advanced or metastatic,0.510834
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,nivolumab combined with ipilimumab,0.496577
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,tumors,0.599445
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,small cell lung cancer,0.943116
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,SCLC,0.953292
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,Antonia SJ,0.330694
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,therapy,0.620702
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,phase 1/2 study CA209-032,0.804203
uuid-84c83f4bf3b54fb1a2d6c2d2344959cd,evaluates the efficacy of nivolumab monotherapy,0.741414
uuid-b99313c485ab483192365dcfd4579783,use of nivolumab for the treatment,0.505768
uuid-b99313c485ab483192365dcfd4579783,evaluating,0.374288
uuid-b99313c485ab483192365dcfd4579783,not conducted any controlled clinical trials/studies,0.361973
uuid-b99313c485ab483192365dcfd4579783,considered investigational,0.617891
uuid-b99313c485ab483192365dcfd4579783,small cell lung cancer,0.342835
uuid-b99313c485ab483192365dcfd4579783,SCLC,0.33153
uuid-b99313c485ab483192365dcfd4579783,phase 1/2 study CA209-032,0.327121
uuid-9cfd1ea560cf487da91b8194a802a14b,use of nivolumab for the treatment,0.374706
uuid-9cfd1ea560cf487da91b8194a802a14b,efficacy,0.422275
uuid-9cfd1ea560cf487da91b8194a802a14b,not approved,0.496604
uuid-9cfd1ea560cf487da91b8194a802a14b,clinical trials investigating the safety,0.514114
uuid-9cfd1ea560cf487da91b8194a802a14b,BMS,0.420132
uuid-b489f7865c2947a1abd2fc4d954f444d,use of nivolumab for the treatment,0.374706
uuid-b489f7865c2947a1abd2fc4d954f444d,efficacy,0.422275
uuid-b489f7865c2947a1abd2fc4d954f444d,not approved,0.496604
uuid-b489f7865c2947a1abd2fc4d954f444d,clinical trials investigating the safety,0.514114
uuid-b489f7865c2947a1abd2fc4d954f444d,BMS,0.420132
uuid-002c1e459fdd46aa95fb29bd1eb812c2,requested,0.531305
uuid-002c1e459fdd46aa95fb29bd1eb812c2,ESMO,0.358531
uuid-002c1e459fdd46aa95fb29bd1eb812c2,Horn L,0.66756
uuid-002c1e459fdd46aa95fb29bd1eb812c2,platinum-based doublet chemotherapy,0.579011
uuid-e2d66920f1a64645ae12d53fbfdd4b12,requested,0.531305
uuid-e2d66920f1a64645ae12d53fbfdd4b12,ESMO,0.358531
uuid-e2d66920f1a64645ae12d53fbfdd4b12,Horn L,0.66756
uuid-e2d66920f1a64645ae12d53fbfdd4b12,platinum-based doublet chemotherapy,0.579011
uuid-a2cf28d8a0d14989a86880c42a5459f3,requested,0.531305
uuid-a2cf28d8a0d14989a86880c42a5459f3,ESMO,0.358531
uuid-a2cf28d8a0d14989a86880c42a5459f3,Horn L,0.66756
uuid-a2cf28d8a0d14989a86880c42a5459f3,platinum-based doublet chemotherapy,0.579011
uuid-5267ea45984142b1927daff0e4d5851b,N Engl J Med,0.627779
uuid-5267ea45984142b1927daff0e4d5851b,provided in the Detailed Information,0.382673
uuid-5267ea45984142b1927daff0e4d5851b,protocol,0.417293
uuid-5267ea45984142b1927daff0e4d5851b,McDermott DF,0.505989
uuid-5267ea45984142b1927daff0e4d5851b,Motzer RJ,0.474987
uuid-5267ea45984142b1927daff0e4d5851b,ESMO,0.812302
uuid-5267ea45984142b1927daff0e4d5851b,Escudier B,0.505763
uuid-5267ea45984142b1927daff0e4d5851b,NEJM,0.36655
uuid-5267ea45984142b1927daff0e4d5851b,et al.,0.541315
uuid-5267ea45984142b1927daff0e4d5851b,J Clin Oncol,0.4212
uuid-5267ea45984142b1927daff0e4d5851b,Topalian,0.360043
uuid-5267ea45984142b1927daff0e4d5851b,phase 2 study,0.362159
uuid-5267ea45984142b1927daff0e4d5851b,Horn L,0.488821
uuid-5267ea45984142b1927daff0e4d5851b,grade 3 to 4 AEs,0.356301
uuid-754501ec347f4461adc9c6cf79e18861,ASCO,0.64795
uuid-754501ec347f4461adc9c6cf79e18861,Antonia SJ,0.334859
uuid-d5a85cd3a4dc4ef3b0010db1964b43c0,Bristol-Myers Squibb,0.44531
uuid-619a8d76165944f0b9441f8fd73e6bcb,patients with advanced or metastatic,0.468858
uuid-619a8d76165944f0b9441f8fd73e6bcb,nivolumab combined with ipilimumab,0.446918
uuid-619a8d76165944f0b9441f8fd73e6bcb,not approved,0.352562
uuid-619a8d76165944f0b9441f8fd73e6bcb,clinical trials investigating the safety,0.429501
uuid-619a8d76165944f0b9441f8fd73e6bcb,bladder cancer,0.950698
uuid-ca6e3d061c2e45938e6660ae2bec80fa,requested,0.594234
uuid-7ffe349b2f25424096d2aa4068560b21,requested,0.594234
uuid-ce75dc23c376417daf2137a5621e3259,N Engl J Med,0.616236
uuid-ce75dc23c376417daf2137a5621e3259,respectively,0.409266
uuid-ce75dc23c376417daf2137a5621e3259,ASCO,0.373445
uuid-ce75dc23c376417daf2137a5621e3259,ESMO,0.378373
uuid-ce75dc23c376417daf2137a5621e3259,Brahmer J,0.712806
uuid-ce75dc23c376417daf2137a5621e3259,docetaxel,0.327482
uuid-ce75dc23c376417daf2137a5621e3259,Horn L,0.502372
uuid-c43d75fac510401f8ee637e4c232b47d,respectively,0.397695
uuid-3ec78d5aed86434693397b5db1d93682,nivolumab,0.358758
uuid-3ec78d5aed86434693397b5db1d93682,use of nivolumab for the treatment,0.470258
uuid-3ec78d5aed86434693397b5db1d93682,efficacy,0.379187
uuid-3ec78d5aed86434693397b5db1d93682,patients,0.422024
uuid-3ec78d5aed86434693397b5db1d93682,search of published literature,0.319544
uuid-3ec78d5aed86434693397b5db1d93682,PubMed and EMBASE,0.315322
uuid-3ec78d5aed86434693397b5db1d93682,not approved,0.526697
uuid-3ec78d5aed86434693397b5db1d93682,clinical trials investigating the safety,0.574269
uuid-3ec78d5aed86434693397b5db1d93682,efficacy and safety of nivolumab,0.305421
uuid-3ec78d5aed86434693397b5db1d93682,clinicaltrials.gov,0.443697
uuid-3ec78d5aed86434693397b5db1d93682,present using the following search terms,0.344246
uuid-5cf93871ee514743884601314304258b,use of nivolumab for the treatment,0.358902
uuid-5cf93871ee514743884601314304258b,efficacy,0.557122
uuid-5cf93871ee514743884601314304258b,not approved,0.439346
uuid-5cf93871ee514743884601314304258b,clinical trials investigating the safety,0.389235
uuid-5cf93871ee514743884601314304258b,relapsed,0.620088
uuid-e0e125380e1e44ff99f905c167aa22c5,nivolumab,0.429481
uuid-e0e125380e1e44ff99f905c167aa22c5,evaluating,0.319697
uuid-e0e125380e1e44ff99f905c167aa22c5,not conducted any controlled clinical trials/studies,0.307811
uuid-e0e125380e1e44ff99f905c167aa22c5,patients,0.379857
uuid-e0e125380e1e44ff99f905c167aa22c5,trial,0.36878
uuid-e0e125380e1e44ff99f905c167aa22c5,efficacy and safety of nivolumab,0.314595
uuid-2376d39d746d41979a8c0f31d110e57f,N Engl J Med,0.627779
uuid-2376d39d746d41979a8c0f31d110e57f,provided in the Detailed Information,0.382673
uuid-2376d39d746d41979a8c0f31d110e57f,protocol,0.417293
uuid-2376d39d746d41979a8c0f31d110e57f,McDermott DF,0.505989
uuid-2376d39d746d41979a8c0f31d110e57f,Motzer RJ,0.474987
uuid-2376d39d746d41979a8c0f31d110e57f,ESMO,0.812302
uuid-2376d39d746d41979a8c0f31d110e57f,Escudier B,0.505763
uuid-2376d39d746d41979a8c0f31d110e57f,NEJM,0.36655
uuid-2376d39d746d41979a8c0f31d110e57f,et al.,0.541315
uuid-2376d39d746d41979a8c0f31d110e57f,J Clin Oncol,0.4212
uuid-2376d39d746d41979a8c0f31d110e57f,Topalian,0.360043
uuid-2376d39d746d41979a8c0f31d110e57f,phase 2 study,0.362159
uuid-2376d39d746d41979a8c0f31d110e57f,Horn L,0.488821
uuid-2376d39d746d41979a8c0f31d110e57f,grade 3 to 4 AEs,0.356301
uuid-5db408bb9128465e8b0733738a181b4f,N Engl J Med,0.334797
uuid-5db408bb9128465e8b0733738a181b4f,Objective response rate,0.335305
uuid-5db408bb9128465e8b0733738a181b4f,Brahmer J,0.390019
uuid-5db408bb9128465e8b0733738a181b4f,clinicaltrials.gov,0.42872
uuid-5db408bb9128465e8b0733738a181b4f,Horn L,0.326298
uuid-2902b10538374b34b4f1ef729a1bd62b,OS,0.493666
uuid-2902b10538374b34b4f1ef729a1bd62b,95% CI,0.872793
uuid-2902b10538374b34b4f1ef729a1bd62b,respectively,0.581917
uuid-2902b10538374b34b4f1ef729a1bd62b,Objective response rate,0.558489
uuid-2902b10538374b34b4f1ef729a1bd62b,ORR,0.705401
uuid-2902b10538374b34b4f1ef729a1bd62b,PFS,0.331929
uuid-2902b10538374b34b4f1ef729a1bd62b,Median overall survival,0.793083
uuid-2902b10538374b34b4f1ef729a1bd62b,monotherapy,0.422517
uuid-2902b10538374b34b4f1ef729a1bd62b,Median OS,0.808565
uuid-2902b10538374b34b4f1ef729a1bd62b,PD-L1,0.302111
uuid-2902b10538374b34b4f1ef729a1bd62b,docetaxel,0.481228
uuid-2902b10538374b34b4f1ef729a1bd62b,hazard ratio,0.844622
uuid-2902b10538374b34b4f1ef729a1bd62b,Median duration of response,0.34536
uuid-46c55796f8c64d9e84d90c109852aa30,Bristol-Myers Squibb,0.341822
uuid-46c55796f8c64d9e84d90c109852aa30,not conducted any controlled clinical trials/studies,0.304507
uuid-46c55796f8c64d9e84d90c109852aa30,Opdivo,0.461382
uuid-46c55796f8c64d9e84d90c109852aa30,Pubmed literature search,0.614325
uuid-46c55796f8c64d9e84d90c109852aa30,purposes other than its labeled indication must be considered investigational,0.586645
uuid-46c55796f8c64d9e84d90c109852aa30,not identify any citations relevant to your inquiry,0.606087
uuid-46c55796f8c64d9e84d90c109852aa30,adverse,0.304183
uuid-46c55796f8c64d9e84d90c109852aa30,using the following search terms,0.642331
uuid-46c55796f8c64d9e84d90c109852aa30,databases,0.315039
uuid-46c55796f8c64d9e84d90c109852aa30,reported,0.556704
uuid-b438be07d7514cb28a6323fe1434858a,requested,0.594234
uuid-ebf2d8c1843949dbaaff91fb3f434e7b,requested,0.594234
uuid-170fce9f05494adbb034ff2e47be5655,requested,0.723675
uuid-170fce9f05494adbb034ff2e47be5655,melanoma,0.399882
uuid-4e20c37e59564321b8563cfbc884f4e2,ASCO,0.807066
uuid-17498c76230f423b94bb43d1b8f0fef0,PD-L1,0.730911
uuid-eb439fb30f2041939d3c4129dbbdd9c4,Opdivo,0.542901
uuid-343e1bc002594e69b7ed78eb09bf485c,nivolumab,0.531963
uuid-343e1bc002594e69b7ed78eb09bf485c,evaluating,0.347077
uuid-343e1bc002594e69b7ed78eb09bf485c,not conducted any controlled clinical trials/studies,0.385684
uuid-343e1bc002594e69b7ed78eb09bf485c,Pubmed literature search,0.961904
uuid-343e1bc002594e69b7ed78eb09bf485c,purposes other than its labeled indication must be considered investigational,0.977378
uuid-343e1bc002594e69b7ed78eb09bf485c,not identify any citations relevant to your inquiry,0.944637
uuid-343e1bc002594e69b7ed78eb09bf485c,using the following search terms,0.933091
uuid-856a8f529a8d4ce6940b199c9c018d20,Opdivo,0.585309
uuid-856a8f529a8d4ce6940b199c9c018d20,trial,0.403274
uuid-856a8f529a8d4ce6940b199c9c018d20,BMS,0.373503
uuid-398ccfe282264fb8b3fefe71472ebe5a,clinical,0.724773
uuid-398ccfe282264fb8b3fefe71472ebe5a,trial,0.330924
uuid-c5068b3077154330a16c928e830e86e0,adverse,0.400523
uuid-c5068b3077154330a16c928e830e86e0,reported,0.502031
uuid-755098d35619404498e97d942b6aeeba,provided in the Detailed Information,0.570081
uuid-755098d35619404498e97d942b6aeeba,clinical,0.487925
uuid-fd8cd3eab9974cfa90438caca724b311,N Engl J Med,0.772728
uuid-fd8cd3eab9974cfa90438caca724b311,protocol,0.330852
uuid-fd8cd3eab9974cfa90438caca724b311,McDermott DF,0.347313
uuid-fd8cd3eab9974cfa90438caca724b311,Motzer RJ,0.326548
uuid-fd8cd3eab9974cfa90438caca724b311,phase 3 study,0.373224
uuid-fd8cd3eab9974cfa90438caca724b311,Escudier B,0.353262
uuid-fd8cd3eab9974cfa90438caca724b311,et al.,0.350852
uuid-fd8cd3eab9974cfa90438caca724b311,Rizvi NA,0.495124
uuid-fd8cd3eab9974cfa90438caca724b311,Brahmer J,0.772439
uuid-fd8cd3eab9974cfa90438caca724b311,phase 2 study,0.464349
uuid-fd8cd3eab9974cfa90438caca724b311,Horn L,0.38216
uuid-4b11b875976b41f7b14716836ccd703c,OS,0.44149
uuid-4b11b875976b41f7b14716836ccd703c,95% CI,0.833403
uuid-4b11b875976b41f7b14716836ccd703c,ASCO,0.32927
uuid-4b11b875976b41f7b14716836ccd703c,Objective response rate,0.545269
uuid-4b11b875976b41f7b14716836ccd703c,ORR,0.618524
uuid-4b11b875976b41f7b14716836ccd703c,PFS,0.396858
uuid-4b11b875976b41f7b14716836ccd703c,Median overall survival,0.72593
uuid-4b11b875976b41f7b14716836ccd703c,monotherapy,0.33356
uuid-4b11b875976b41f7b14716836ccd703c,Median OS,0.763854
uuid-4b11b875976b41f7b14716836ccd703c,hazard ratio,0.766648
uuid-4b11b875976b41f7b14716836ccd703c,Median duration of response,0.442682
uuid-3223304c15134917ac47e2b83f96576a,N Engl J Med,0.342504
uuid-3223304c15134917ac47e2b83f96576a,protocol,0.342938
uuid-3223304c15134917ac47e2b83f96576a,McDermott DF,0.371451
uuid-3223304c15134917ac47e2b83f96576a,Motzer RJ,0.34781
uuid-3223304c15134917ac47e2b83f96576a,Escudier B,0.370781
uuid-3223304c15134917ac47e2b83f96576a,et al.,0.377999
uuid-3223304c15134917ac47e2b83f96576a,J Clin Oncol,0.314889
uuid-4e18b171f6824e9f8f9980f21a6ab355,95% CI,0.524855
uuid-4e18b171f6824e9f8f9980f21a6ab355,respectively,0.383655
uuid-4e18b171f6824e9f8f9980f21a6ab355,ASCO,0.303153
uuid-4e18b171f6824e9f8f9980f21a6ab355,Lancet Oncol,0.368041
uuid-4e18b171f6824e9f8f9980f21a6ab355,Objective response rate,0.504846
uuid-4e18b171f6824e9f8f9980f21a6ab355,ORR,0.465366
uuid-4e18b171f6824e9f8f9980f21a6ab355,Median overall survival,0.346516
uuid-4e18b171f6824e9f8f9980f21a6ab355,Median OS,0.33538
uuid-4e18b171f6824e9f8f9980f21a6ab355,ASCO 2015,0.336983
uuid-4e18b171f6824e9f8f9980f21a6ab355,small cell lung cancer,0.336892
uuid-4e18b171f6824e9f8f9980f21a6ab355,SCLC,0.344367
uuid-4e18b171f6824e9f8f9980f21a6ab355,Antonia SJ,0.55269
uuid-4e18b171f6824e9f8f9980f21a6ab355,Median duration of response,0.649605
uuid-416666f35b2c47b6b1fcc0ea8a37b754,ESMO,0.603759
uuid-416666f35b2c47b6b1fcc0ea8a37b754,Horn L,0.484674
uuid-1cae4b6a1ae4455a80e80a3f60865a04,patients with advanced or metastatic,0.468858
uuid-1cae4b6a1ae4455a80e80a3f60865a04,nivolumab combined with ipilimumab,0.446918
uuid-1cae4b6a1ae4455a80e80a3f60865a04,not approved,0.352562
uuid-1cae4b6a1ae4455a80e80a3f60865a04,clinical trials investigating the safety,0.429501
uuid-1cae4b6a1ae4455a80e80a3f60865a04,bladder cancer,0.950698
uuid-c7ae10dc469446a590685209f8311b5b,provided in the Detailed Information,0.367378
uuid-c7ae10dc469446a590685209f8311b5b,ESMO,0.851091
uuid-c7ae10dc469446a590685209f8311b5b,melanoma,0.459564
uuid-c7ae10dc469446a590685209f8311b5b,Horn L,0.477428
uuid-c7ae10dc469446a590685209f8311b5b,grade 3 to 4 AEs,0.485389
uuid-035100ab61374b878ea9d84b3b0ca741,Bristol-Myers Squibb,0.55087
uuid-035100ab61374b878ea9d84b3b0ca741,evaluating,0.560696
uuid-035100ab61374b878ea9d84b3b0ca741,not conducted any controlled clinical trials/studies,0.605215
uuid-035100ab61374b878ea9d84b3b0ca741,considered investigational,0.325966
uuid-035100ab61374b878ea9d84b3b0ca741,efficacy and safety of nivolumab,0.494398
uuid-3b1e46edffcb42eea7bbd3170f0e4025,N Engl J Med,0.616236
uuid-3b1e46edffcb42eea7bbd3170f0e4025,respectively,0.409266
uuid-3b1e46edffcb42eea7bbd3170f0e4025,ASCO,0.373445
uuid-3b1e46edffcb42eea7bbd3170f0e4025,ESMO,0.378373
uuid-3b1e46edffcb42eea7bbd3170f0e4025,Brahmer J,0.712806
uuid-3b1e46edffcb42eea7bbd3170f0e4025,docetaxel,0.327482
uuid-3b1e46edffcb42eea7bbd3170f0e4025,Horn L,0.502372
uuid-c0918b5c6a4c4d2a90e3685def07a20f,docetaxel,0.401276
uuid-b531d6b771404a3dbdbec5e01bd09b78,Bristol-Myers Squibb,0.341822
uuid-b531d6b771404a3dbdbec5e01bd09b78,not conducted any controlled clinical trials/studies,0.304507
uuid-b531d6b771404a3dbdbec5e01bd09b78,Opdivo,0.461382
uuid-b531d6b771404a3dbdbec5e01bd09b78,Pubmed literature search,0.614325
uuid-b531d6b771404a3dbdbec5e01bd09b78,purposes other than its labeled indication must be considered investigational,0.586645
uuid-b531d6b771404a3dbdbec5e01bd09b78,not identify any citations relevant to your inquiry,0.606087
uuid-b531d6b771404a3dbdbec5e01bd09b78,adverse,0.304183
uuid-b531d6b771404a3dbdbec5e01bd09b78,using the following search terms,0.642331
uuid-b531d6b771404a3dbdbec5e01bd09b78,databases,0.315039
uuid-b531d6b771404a3dbdbec5e01bd09b78,reported,0.556704
uuid-72756dad768f463182effbd5b3749eb7,trial,0.308146
uuid-6fc4dd67878a4eae9cdfe6d344548d49,requested,0.594234
uuid-9a0bbb151b8c47469e91252386004001,use of nivolumab for the treatment,0.309951
uuid-9a0bbb151b8c47469e91252386004001,efficacy,0.366676
uuid-9a0bbb151b8c47469e91252386004001,not approved,0.504327
uuid-9a0bbb151b8c47469e91252386004001,clinical trials investigating the safety,0.640801
uuid-9a0bbb151b8c47469e91252386004001,bladder cancer,0.347327
uuid-e18a435c9ac64026bb08139defad2548,patients with advanced or metastatic,0.529549
uuid-e18a435c9ac64026bb08139defad2548,nivolumab combined with ipilimumab,0.505158
uuid-e18a435c9ac64026bb08139defad2548,bladder cancer,0.829903
uuid-0186d053475c4663b711179554b00b1d,nivolumab,0.485444
uuid-0186d053475c4663b711179554b00b1d,Bristol-Myers Squibb,0.397327
uuid-0186d053475c4663b711179554b00b1d,use of nivolumab for the treatment,0.43688
uuid-0186d053475c4663b711179554b00b1d,evaluating,0.467949
uuid-0186d053475c4663b711179554b00b1d,not conducted any controlled clinical trials/studies,0.439709
uuid-0186d053475c4663b711179554b00b1d,efficacy,0.43138
uuid-0186d053475c4663b711179554b00b1d,patients,0.426608
uuid-0186d053475c4663b711179554b00b1d,not approved,0.442216
uuid-0186d053475c4663b711179554b00b1d,clinical trials investigating the safety,0.410212
uuid-0186d053475c4663b711179554b00b1d,efficacy and safety of nivolumab,0.374715
uuid-0186d053475c4663b711179554b00b1d,safety of nivolumab monotherapy,0.350344
uuid-d3baf3df01c94cae97b88c480b2e3a77,ASCO,0.382205
uuid-5397e54fb9e54a3495c207b17b84624b,requested,0.594234
uuid-03d9cf32af9a40cfa15911656094ebdc,patients with advanced or metastatic,0.468858
uuid-03d9cf32af9a40cfa15911656094ebdc,nivolumab combined with ipilimumab,0.446918
uuid-03d9cf32af9a40cfa15911656094ebdc,not approved,0.352562
uuid-03d9cf32af9a40cfa15911656094ebdc,clinical trials investigating the safety,0.429501
uuid-03d9cf32af9a40cfa15911656094ebdc,bladder cancer,0.950698
uuid-a3e852bdfa134de3bb95d0de11f2ad5f,Opdivo,0.402094
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,Bristol-Myers Squibb,0.341822
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,not conducted any controlled clinical trials/studies,0.304507
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,Opdivo,0.461382
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,Pubmed literature search,0.614325
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,purposes other than its labeled indication must be considered investigational,0.586645
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,not identify any citations relevant to your inquiry,0.606087
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,adverse,0.304183
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,using the following search terms,0.642331
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,databases,0.315039
uuid-a5e1c81c2cbb4d4d88870ff7c98ef045,reported,0.556704
uuid-a598bfeee0ca4863848eba2586dfec75,N Engl J Med,0.616236
uuid-a598bfeee0ca4863848eba2586dfec75,respectively,0.409266
uuid-a598bfeee0ca4863848eba2586dfec75,ASCO,0.373445
uuid-a598bfeee0ca4863848eba2586dfec75,ESMO,0.378373
uuid-a598bfeee0ca4863848eba2586dfec75,Brahmer J,0.712806
uuid-a598bfeee0ca4863848eba2586dfec75,docetaxel,0.327482
uuid-a598bfeee0ca4863848eba2586dfec75,Horn L,0.502372
uuid-3259959570134c939cc65daf103ccc85,95% CI,0.539167
uuid-3259959570134c939cc65daf103ccc85,Median overall survival,0.479815
uuid-3259959570134c939cc65daf103ccc85,protocol,0.426554
uuid-3259959570134c939cc65daf103ccc85,McDermott DF,0.500131
uuid-3259959570134c939cc65daf103ccc85,Motzer RJ,0.477178
uuid-3259959570134c939cc65daf103ccc85,Median OS,0.603398
uuid-3259959570134c939cc65daf103ccc85,Escudier B,0.469696
uuid-3259959570134c939cc65daf103ccc85,NEJM,0.387615
uuid-3259959570134c939cc65daf103ccc85,et al.,0.46851
uuid-3259959570134c939cc65daf103ccc85,J Clin Oncol,0.51661
uuid-3259959570134c939cc65daf103ccc85,Topalian,0.337057
uuid-3259959570134c939cc65daf103ccc85,phase 2 study,0.399402
uuid-3259959570134c939cc65daf103ccc85,hazard ratio,0.538097
uuid-1cb5e58a631243309700c35e080fe02e,N Engl J Med,0.604857
uuid-1cb5e58a631243309700c35e080fe02e,non-small cell lung cancer,0.34354
uuid-1cb5e58a631243309700c35e080fe02e,ESMO,0.393944
uuid-1cb5e58a631243309700c35e080fe02e,Rizvi NA,0.452745
uuid-1cb5e58a631243309700c35e080fe02e,Brahmer J,0.679154
uuid-1cb5e58a631243309700c35e080fe02e,PD-L1,0.347566
uuid-1cb5e58a631243309700c35e080fe02e,Horn L,0.50259
uuid-1cb5e58a631243309700c35e080fe02e,platinum-based doublet chemotherapy,0.304136
uuid-1ae1d246d9a848829e5738d9b8686a7c,N Engl J Med,0.337799
uuid-1ae1d246d9a848829e5738d9b8686a7c,ASCO,0.524809
uuid-1ae1d246d9a848829e5738d9b8686a7c,requested,0.415944
uuid-1ae1d246d9a848829e5738d9b8686a7c,ESMO,0.385169
uuid-1ae1d246d9a848829e5738d9b8686a7c,et al.,0.368965
uuid-1ae1d246d9a848829e5738d9b8686a7c,Horn L,0.423375
uuid-37edd06f3b754fcab724c37c2caf17be,clinical,0.378621
uuid-37edd06f3b754fcab724c37c2caf17be,therapy,0.35658
uuid-54005b4aa1ed4663a1c1117b1ed0cc80,evaluating,0.303881
uuid-54005b4aa1ed4663a1c1117b1ed0cc80,PD-L1,0.341666
uuid-54005b4aa1ed4663a1c1117b1ed0cc80,trial,0.469995
uuid-54005b4aa1ed4663a1c1117b1ed0cc80,safety of nivolumab monotherapy,0.331209
uuid-b5dbd5ef458a4466a78b171fe43e71e0,search of published literature,0.394524
uuid-b5dbd5ef458a4466a78b171fe43e71e0,Additionally,0.413583
uuid-b5dbd5ef458a4466a78b171fe43e71e0,ongoing,0.322117
uuid-b5dbd5ef458a4466a78b171fe43e71e0,PubMed and EMBASE,0.391671
uuid-b5dbd5ef458a4466a78b171fe43e71e0,detailed search of www.clinicaltrials.gov,0.375936
uuid-b5dbd5ef458a4466a78b171fe43e71e0,efficacy and safety of nivolumab,0.370699
uuid-b5dbd5ef458a4466a78b171fe43e71e0,not identify any planned,0.34283
uuid-b5dbd5ef458a4466a78b171fe43e71e0,Weber JS,0.319229
uuid-b5dbd5ef458a4466a78b171fe43e71e0,not identify any citations relevant to your request,0.447813
uuid-b5dbd5ef458a4466a78b171fe43e71e0,present using the following search terms,0.408199
uuid-7092469a54ed4fd0baab52c1f9ef0de0,patients,0.402139
uuid-7092469a54ed4fd0baab52c1f9ef0de0,monotherapy,0.548105
uuid-7092469a54ed4fd0baab52c1f9ef0de0,ipilimumab,0.580225
uuid-7092469a54ed4fd0baab52c1f9ef0de0,ASCO 2015,0.493574
uuid-7092469a54ed4fd0baab52c1f9ef0de0,mg,0.409068
uuid-7092469a54ed4fd0baab52c1f9ef0de0,combination,0.446224
uuid-7092469a54ed4fd0baab52c1f9ef0de0,kg,0.370986
uuid-7092469a54ed4fd0baab52c1f9ef0de0,Antonia SJ,0.42389
uuid-f9842a43bc6841ebb5fa792691257134,Bristol-Myers Squibb,0.341822
uuid-f9842a43bc6841ebb5fa792691257134,not conducted any controlled clinical trials/studies,0.304507
uuid-f9842a43bc6841ebb5fa792691257134,Opdivo,0.461382
uuid-f9842a43bc6841ebb5fa792691257134,Pubmed literature search,0.614325
uuid-f9842a43bc6841ebb5fa792691257134,purposes other than its labeled indication must be considered investigational,0.586645
uuid-f9842a43bc6841ebb5fa792691257134,not identify any citations relevant to your inquiry,0.606087
uuid-f9842a43bc6841ebb5fa792691257134,adverse,0.304183
uuid-f9842a43bc6841ebb5fa792691257134,using the following search terms,0.642331
uuid-f9842a43bc6841ebb5fa792691257134,databases,0.315039
uuid-f9842a43bc6841ebb5fa792691257134,reported,0.556704
uuid-6c6b8f779e9342f8910561fd7dd67722,respectively,0.585622
uuid-6c6b8f779e9342f8910561fd7dd67722,Objective response rate,0.36976
uuid-6c6b8f779e9342f8910561fd7dd67722,ORR,0.514781
uuid-6c6b8f779e9342f8910561fd7dd67722,docetaxel,0.31274
uuid-2d86fbc4d0a64236ad661302065d1f66,N Engl J Med,0.892438
uuid-2d86fbc4d0a64236ad661302065d1f66,Lancet Oncol,0.369114
uuid-2d86fbc4d0a64236ad661302065d1f66,provided in the Detailed Information,0.302862
uuid-2d86fbc4d0a64236ad661302065d1f66,protocol,0.755063
uuid-2d86fbc4d0a64236ad661302065d1f66,McDermott DF,0.82995
uuid-2d86fbc4d0a64236ad661302065d1f66,Motzer RJ,0.803103
uuid-2d86fbc4d0a64236ad661302065d1f66,ESMO,0.341635
uuid-2d86fbc4d0a64236ad661302065d1f66,phase 3 study,0.507488
uuid-2d86fbc4d0a64236ad661302065d1f66,Escudier B,0.832421
uuid-2d86fbc4d0a64236ad661302065d1f66,NEJM,0.452995
uuid-2d86fbc4d0a64236ad661302065d1f66,et al.,0.8085
uuid-2d86fbc4d0a64236ad661302065d1f66,J Clin Oncol,0.737251
uuid-2d86fbc4d0a64236ad661302065d1f66,Topalian,0.42081
uuid-2d86fbc4d0a64236ad661302065d1f66,Rizvi NA,0.588152
uuid-2d86fbc4d0a64236ad661302065d1f66,Brahmer J,0.577339
uuid-2d86fbc4d0a64236ad661302065d1f66,Weber JS,0.403598
uuid-2d86fbc4d0a64236ad661302065d1f66,phase 2 study,0.770524
uuid-93fdb6107a03400386da696a3016e0bd,respectively,0.397695
uuid-e81ac4c5122f41f3b95e107fbf3d8949,requested,0.594234
uuid-1f5ecf681a6a4a0293323fb19106d5b7,ipilimumab,0.385692
uuid-1f5ecf681a6a4a0293323fb19106d5b7,ASCO 2015,0.417944
uuid-1f5ecf681a6a4a0293323fb19106d5b7,partial response,0.382425
uuid-1f5ecf681a6a4a0293323fb19106d5b7,Stable disease,0.586335
uuid-1f5ecf681a6a4a0293323fb19106d5b7,cohort,0.307748
uuid-82ffea26acae4f2baf57c8677b2a7ab4,95% CI,0.306759
uuid-82ffea26acae4f2baf57c8677b2a7ab4,patients,0.45713
uuid-82ffea26acae4f2baf57c8677b2a7ab4,mg,0.322908
uuid-82ffea26acae4f2baf57c8677b2a7ab4,Median duration of response,0.399993
uuid-88b3d6018e7c4b2ab556ce0a5178e531,OS,0.506839
uuid-88b3d6018e7c4b2ab556ce0a5178e531,95% CI,0.914259
uuid-88b3d6018e7c4b2ab556ce0a5178e531,respectively,0.57945
uuid-88b3d6018e7c4b2ab556ce0a5178e531,Objective response rate,0.616133
uuid-88b3d6018e7c4b2ab556ce0a5178e531,ORR,0.78386
uuid-88b3d6018e7c4b2ab556ce0a5178e531,PFS,0.374029
uuid-88b3d6018e7c4b2ab556ce0a5178e531,Median overall survival,0.850584
uuid-88b3d6018e7c4b2ab556ce0a5178e531,monotherapy,0.435128
uuid-88b3d6018e7c4b2ab556ce0a5178e531,Median OS,0.829523
uuid-88b3d6018e7c4b2ab556ce0a5178e531,docetaxel,0.347663
uuid-88b3d6018e7c4b2ab556ce0a5178e531,hazard ratio,0.887303
uuid-88b3d6018e7c4b2ab556ce0a5178e531,Median duration of response,0.367027
uuid-4fe820123c454eb3b422de9941ee11dc,Bristol-Myers Squibb,0.442099
uuid-4fe820123c454eb3b422de9941ee11dc,evaluating,0.322471
uuid-4fe820123c454eb3b422de9941ee11dc,not conducted any controlled clinical trials/studies,0.356769
uuid-2850d9191ff04376b5943e2814ebcac3,nivolumab,0.57521
uuid-2850d9191ff04376b5943e2814ebcac3,use of nivolumab for the treatment,0.318754
uuid-2850d9191ff04376b5943e2814ebcac3,considered investigational,0.369102
uuid-def639f048e844f3b2dc1b2a115ec460,95% CI,0.524855
uuid-def639f048e844f3b2dc1b2a115ec460,respectively,0.383655
uuid-def639f048e844f3b2dc1b2a115ec460,ASCO,0.303153
uuid-def639f048e844f3b2dc1b2a115ec460,Lancet Oncol,0.368041
uuid-def639f048e844f3b2dc1b2a115ec460,Objective response rate,0.504846
uuid-def639f048e844f3b2dc1b2a115ec460,ORR,0.465366
uuid-def639f048e844f3b2dc1b2a115ec460,Median overall survival,0.346516
uuid-def639f048e844f3b2dc1b2a115ec460,Median OS,0.33538
uuid-def639f048e844f3b2dc1b2a115ec460,ASCO 2015,0.336983
uuid-def639f048e844f3b2dc1b2a115ec460,small cell lung cancer,0.336892
uuid-def639f048e844f3b2dc1b2a115ec460,SCLC,0.344367
uuid-def639f048e844f3b2dc1b2a115ec460,Antonia SJ,0.55269
uuid-def639f048e844f3b2dc1b2a115ec460,Median duration of response,0.649605
uuid-36b1e04416e84f478bda321104926157,Bristol-Myers Squibb,0.341822
uuid-36b1e04416e84f478bda321104926157,not conducted any controlled clinical trials/studies,0.304507
uuid-36b1e04416e84f478bda321104926157,Opdivo,0.461382
uuid-36b1e04416e84f478bda321104926157,Pubmed literature search,0.614325
uuid-36b1e04416e84f478bda321104926157,purposes other than its labeled indication must be considered investigational,0.586645
uuid-36b1e04416e84f478bda321104926157,not identify any citations relevant to your inquiry,0.606087
uuid-36b1e04416e84f478bda321104926157,adverse,0.304183
uuid-36b1e04416e84f478bda321104926157,using the following search terms,0.642331
uuid-36b1e04416e84f478bda321104926157,databases,0.315039
uuid-36b1e04416e84f478bda321104926157,reported,0.556704
uuid-716eb1dcf3e546339e387a42ce6bde5c,OS,0.506839
uuid-716eb1dcf3e546339e387a42ce6bde5c,95% CI,0.914259
uuid-716eb1dcf3e546339e387a42ce6bde5c,respectively,0.57945
uuid-716eb1dcf3e546339e387a42ce6bde5c,Objective response rate,0.616133
uuid-716eb1dcf3e546339e387a42ce6bde5c,ORR,0.78386
uuid-716eb1dcf3e546339e387a42ce6bde5c,PFS,0.374029
uuid-716eb1dcf3e546339e387a42ce6bde5c,Median overall survival,0.850584
uuid-716eb1dcf3e546339e387a42ce6bde5c,monotherapy,0.435128
uuid-716eb1dcf3e546339e387a42ce6bde5c,Median OS,0.829523
uuid-716eb1dcf3e546339e387a42ce6bde5c,docetaxel,0.347663
uuid-716eb1dcf3e546339e387a42ce6bde5c,hazard ratio,0.887303
uuid-716eb1dcf3e546339e387a42ce6bde5c,Median duration of response,0.367027
uuid-5417972950b14734bbb3b751a5edc96c,nivolumab,0.308696
uuid-5417972950b14734bbb3b751a5edc96c,respectively,0.474596
uuid-5417972950b14734bbb3b751a5edc96c,Objective response rate,0.398542
uuid-5417972950b14734bbb3b751a5edc96c,ORR,0.387529
uuid-5417972950b14734bbb3b751a5edc96c,monotherapy,0.618934
uuid-5417972950b14734bbb3b751a5edc96c,clinical,0.310702
uuid-5417972950b14734bbb3b751a5edc96c,Antonia SJ,0.303123
uuid-24f1535c077f4ca4b202beb932b155f3,adverse,0.677734
uuid-24f1535c077f4ca4b202beb932b155f3,phase 3 study,0.48003
uuid-24f1535c077f4ca4b202beb932b155f3,melanoma,0.411352
uuid-24f1535c077f4ca4b202beb932b155f3,Weber JS,0.31904
uuid-24f1535c077f4ca4b202beb932b155f3,phase 2 study,0.319618
uuid-24f1535c077f4ca4b202beb932b155f3,reported,0.343242
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,OS,0.349054
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,95% CI,0.696869
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,respectively,0.747405
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,Objective response rate,0.596478
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,ORR,0.7237
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,Median overall survival,0.628269
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,monotherapy,0.48503
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,Median OS,0.660506
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,PD-L1,0.403686
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,docetaxel,0.487238
uuid-992d1f43bf26481eb8cdb7d431f3a1e6,hazard ratio,0.689448
uuid-4a63484543c547999a2d97e44f215e19,Bristol-Myers Squibb,0.645549
uuid-4a63484543c547999a2d97e44f215e19,evaluating,0.571488
uuid-4a63484543c547999a2d97e44f215e19,not conducted any controlled clinical trials/studies,0.62498
uuid-4a63484543c547999a2d97e44f215e19,efficacy and safety of nivolumab,0.512119
uuid-af5e611a38504450878485a1ad288604,patients,0.315933
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,OS,0.324073
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,95% CI,0.660124
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,respectively,0.809559
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,Objective response rate,0.668092
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,ORR,0.764824
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,Median overall survival,0.58138
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,monotherapy,0.532169
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,Median OS,0.629224
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,PD-L1,0.379606
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,docetaxel,0.584757
uuid-f84c8e8ed7d54462955a9ea07d0fe1c5,hazard ratio,0.649699
uuid-292ed62849f442cd94c3e8880ce37d55,fatigue,0.704358
uuid-22ecb143b2ee41198a6225ee31660a46,Bristol-Myers Squibb,0.341822
uuid-22ecb143b2ee41198a6225ee31660a46,not conducted any controlled clinical trials/studies,0.304507
uuid-22ecb143b2ee41198a6225ee31660a46,Opdivo,0.461382
uuid-22ecb143b2ee41198a6225ee31660a46,Pubmed literature search,0.614325
uuid-22ecb143b2ee41198a6225ee31660a46,purposes other than its labeled indication must be considered investigational,0.586645
uuid-22ecb143b2ee41198a6225ee31660a46,not identify any citations relevant to your inquiry,0.606087
uuid-22ecb143b2ee41198a6225ee31660a46,adverse,0.304183
uuid-22ecb143b2ee41198a6225ee31660a46,using the following search terms,0.642331
uuid-22ecb143b2ee41198a6225ee31660a46,databases,0.315039
uuid-22ecb143b2ee41198a6225ee31660a46,reported,0.556704
uuid-b252470f906740f6b27f39c17d487e59,Bristol-Myers Squibb,0.66049
uuid-b252470f906740f6b27f39c17d487e59,use of nivolumab for the treatment,0.417123
uuid-b252470f906740f6b27f39c17d487e59,evaluating,0.711442
uuid-b252470f906740f6b27f39c17d487e59,not conducted any controlled clinical trials/studies,0.742059
uuid-b252470f906740f6b27f39c17d487e59,efficacy,0.305039
uuid-b252470f906740f6b27f39c17d487e59,NSCLC,0.306921
uuid-b252470f906740f6b27f39c17d487e59,non-small cell lung cancer,0.318232
uuid-b252470f906740f6b27f39c17d487e59,considered investigational,0.477261
uuid-b252470f906740f6b27f39c17d487e59,purposes other than its labeled indication must be considered investigational,0.329112
uuid-b252470f906740f6b27f39c17d487e59,not approved,0.306797
uuid-b252470f906740f6b27f39c17d487e59,efficacy and safety of nivolumab,0.589134
uuid-b252470f906740f6b27f39c17d487e59,safety of nivolumab monotherapy,0.374629
uuid-885fb5bd566747669fe8ffcbe27290ca,nivolumab,0.604621
uuid-885fb5bd566747669fe8ffcbe27290ca,use of nivolumab for the treatment,0.356923
uuid-885fb5bd566747669fe8ffcbe27290ca,efficacy,0.380873
uuid-885fb5bd566747669fe8ffcbe27290ca,RCC,0.323324
uuid-885fb5bd566747669fe8ffcbe27290ca,not approved,0.410498
uuid-885fb5bd566747669fe8ffcbe27290ca,clinical trials investigating the safety,0.412197
uuid-aeccfa1b3b2643f282ec8fdd8c4a2914,open-label,0.539462
uuid-aeccfa1b3b2643f282ec8fdd8c4a2914,phase,0.350616
uuid-c2dcc48808f243d0bfa484da90306abe,use of nivolumab for the treatment,0.440423
uuid-c2dcc48808f243d0bfa484da90306abe,search of published literature,0.311531
uuid-c2dcc48808f243d0bfa484da90306abe,PubMed and EMBASE,0.312811
uuid-c2dcc48808f243d0bfa484da90306abe,not approved,0.404782
uuid-c2dcc48808f243d0bfa484da90306abe,open-label,0.578291
uuid-c2dcc48808f243d0bfa484da90306abe,clinical trials investigating the safety,0.440014
uuid-c2dcc48808f243d0bfa484da90306abe,present using the following search terms,0.328669
uuid-c2dcc48808f243d0bfa484da90306abe,phase,0.41185
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,nivolumab,0.355212
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,use of nivolumab for the treatment,0.394686
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,efficacy,0.312963
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,search of published literature,0.305051
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,not approved,0.46217
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,clinical trials investigating the safety,0.517417
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,efficacy and safety of nivolumab,0.302155
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,clinicaltrials.gov,0.50712
uuid-525b4c9430e94f5eb0843e4b0cd2bc3a,present using the following search terms,0.325121
uuid-bbb475811c5d4c63bf035327873cc798,N Engl J Med,0.442834
uuid-bbb475811c5d4c63bf035327873cc798,protocol,0.763252
uuid-bbb475811c5d4c63bf035327873cc798,McDermott DF,0.733103
uuid-bbb475811c5d4c63bf035327873cc798,Motzer RJ,0.811057
uuid-bbb475811c5d4c63bf035327873cc798,phase 3 study,0.420895
uuid-bbb475811c5d4c63bf035327873cc798,Escudier B,0.741048
uuid-bbb475811c5d4c63bf035327873cc798,NEJM,0.402544
uuid-bbb475811c5d4c63bf035327873cc798,et al.,0.660398
uuid-bbb475811c5d4c63bf035327873cc798,J Clin Oncol,0.786367
uuid-bbb475811c5d4c63bf035327873cc798,Topalian,0.392395
uuid-bbb475811c5d4c63bf035327873cc798,phase 1 study,0.513779
uuid-bbb475811c5d4c63bf035327873cc798,CA209-003,0.583337
uuid-bbb475811c5d4c63bf035327873cc798,phase 2 study,0.675447
uuid-bbb475811c5d4c63bf035327873cc798,present using the following search terms,0.304589
uuid-bbb475811c5d4c63bf035327873cc798,investigating,0.633101
uuid-6a417ea8487542a2a2ed830c21f78071,provided in the Detailed Information,0.578509
uuid-6a417ea8487542a2a2ed830c21f78071,clinical,0.470357
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,N Engl J Med,0.442834
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,protocol,0.763252
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,McDermott DF,0.733103
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,Motzer RJ,0.811057
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,phase 3 study,0.420895
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,Escudier B,0.741048
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,NEJM,0.402544
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,et al.,0.660398
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,J Clin Oncol,0.786367
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,Topalian,0.392395
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,phase 1 study,0.513779
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,CA209-003,0.583337
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,phase 2 study,0.675447
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,present using the following search terms,0.304589
uuid-3c5b5c30d7bf4b7d9387d7daa0d6762b,investigating,0.633101
uuid-1945e93da727475085ebb8ebd6273400,provided in the Detailed Information,0.408955
uuid-1945e93da727475085ebb8ebd6273400,ESMO,0.992426
uuid-1945e93da727475085ebb8ebd6273400,Horn L,0.554477
uuid-1945e93da727475085ebb8ebd6273400,grade 3 to 4 AEs,0.502956
uuid-58193889893b4b0aa8d3914d0687757d,McDermott DF,0.324337
uuid-58193889893b4b0aa8d3914d0687757d,Motzer RJ,0.302566
uuid-58193889893b4b0aa8d3914d0687757d,phase 3 study,0.400404
uuid-58193889893b4b0aa8d3914d0687757d,Escudier B,0.323843
uuid-58193889893b4b0aa8d3914d0687757d,et al.,0.322352
uuid-58193889893b4b0aa8d3914d0687757d,Rizvi NA,0.444726
uuid-58193889893b4b0aa8d3914d0687757d,mg,0.3792
uuid-58193889893b4b0aa8d3914d0687757d,Weber JS,0.313296
uuid-58193889893b4b0aa8d3914d0687757d,phase 2 study,0.508806
uuid-58193889893b4b0aa8d3914d0687757d,kg,0.346561
uuid-58193889893b4b0aa8d3914d0687757d,phase,0.324474
uuid-0364f7c8ec7f48bb8b045649c6be6393,95% CI,0.410247
uuid-0364f7c8ec7f48bb8b045649c6be6393,Lancet Oncol,0.338804
uuid-0364f7c8ec7f48bb8b045649c6be6393,considered investigational,0.31999
uuid-0364f7c8ec7f48bb8b045649c6be6393,Objective response rate,0.460397
uuid-0364f7c8ec7f48bb8b045649c6be6393,ORR,0.42609
uuid-0364f7c8ec7f48bb8b045649c6be6393,ASCO 2015,0.334207
uuid-0364f7c8ec7f48bb8b045649c6be6393,small cell lung cancer,0.572318
uuid-0364f7c8ec7f48bb8b045649c6be6393,SCLC,0.616142
uuid-0364f7c8ec7f48bb8b045649c6be6393,Antonia SJ,0.54068
uuid-0364f7c8ec7f48bb8b045649c6be6393,therapy,0.386133
uuid-0364f7c8ec7f48bb8b045649c6be6393,Median duration of response,0.529786
uuid-0364f7c8ec7f48bb8b045649c6be6393,phase 1/2 study CA209-032,0.403467
uuid-0364f7c8ec7f48bb8b045649c6be6393,evaluates the efficacy of nivolumab monotherapy,0.353136
uuid-6b107a5182fb4773b6d62fda68005262,nivolumab,0.53912
uuid-6b107a5182fb4773b6d62fda68005262,requested,0.456737
uuid-6b107a5182fb4773b6d62fda68005262,trial,0.319437
uuid-d654bd905988414dbddba6f7d035426d,patients,0.315933
uuid-2d3022ff2e644e3e9f50732b9d918266,phase 1 study,0.587697
uuid-2d3022ff2e644e3e9f50732b9d918266,efficacy and safety of nivolumab,0.384882
uuid-2d3022ff2e644e3e9f50732b9d918266,CA209-003,0.701987
uuid-2d3022ff2e644e3e9f50732b9d918266,present using the following search terms,0.30701
uuid-2d3022ff2e644e3e9f50732b9d918266,investigating,0.882625
uuid-36fb9d1c8d0a4d948d706e218063444b,Opdivo,0.429914
uuid-36fb9d1c8d0a4d948d706e218063444b,clinical,0.330214
uuid-36fb9d1c8d0a4d948d706e218063444b,trial,0.998048
uuid-36fb9d1c8d0a4d948d706e218063444b,phase,0.309827
uuid-82160aed03c840809d45fb74f16d7a76,95% CI,0.482283
uuid-82160aed03c840809d45fb74f16d7a76,respectively,0.319895
uuid-82160aed03c840809d45fb74f16d7a76,ASCO,0.389676
uuid-82160aed03c840809d45fb74f16d7a76,Objective response rate,0.357341
uuid-82160aed03c840809d45fb74f16d7a76,ORR,0.358789
uuid-82160aed03c840809d45fb74f16d7a76,Median overall survival,0.421434
uuid-82160aed03c840809d45fb74f16d7a76,Median OS,0.603017
uuid-82160aed03c840809d45fb74f16d7a76,docetaxel,0.351836
uuid-82160aed03c840809d45fb74f16d7a76,hazard ratio,0.51871
uuid-e76b03d060a944a0817ead3788132c04,requested,0.651419
uuid-e76b03d060a944a0817ead3788132c04,ESMO,0.304366
uuid-e76b03d060a944a0817ead3788132c04,Horn L,0.668179
uuid-e76b03d060a944a0817ead3788132c04,platinum-based doublet chemotherapy,0.584432
uuid-9df2bcedacc84c598b66ae8f0e604ce1,nivolumab,0.300534
uuid-9df2bcedacc84c598b66ae8f0e604ce1,Bristol-Myers Squibb,0.342768
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,Bristol-Myers Squibb,0.341822
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,not conducted any controlled clinical trials/studies,0.304507
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,Opdivo,0.461382
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,Pubmed literature search,0.614325
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,not identify any citations relevant to your inquiry,0.606087
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,adverse,0.304183
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,using the following search terms,0.642331
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,databases,0.315039
uuid-6171e41f3f0a4e5fb6cc2012a5a3f2a6,reported,0.556704
uuid-6b6124961336417ba954fbfad76a04ed,evaluating,0.339918
uuid-6b6124961336417ba954fbfad76a04ed,N Engl J Med,0.342471
uuid-6b6124961336417ba954fbfad76a04ed,not conducted any controlled clinical trials/studies,0.330543
uuid-6b6124961336417ba954fbfad76a04ed,protocol,0.592954
uuid-6b6124961336417ba954fbfad76a04ed,RCC,0.373721
uuid-6b6124961336417ba954fbfad76a04ed,McDermott DF,0.513555
uuid-6b6124961336417ba954fbfad76a04ed,search of published literature,0.497291
uuid-6b6124961336417ba954fbfad76a04ed,Additionally,0.393702
uuid-6b6124961336417ba954fbfad76a04ed,ongoing,0.320644
uuid-6b6124961336417ba954fbfad76a04ed,Motzer RJ,0.543662
uuid-6b6124961336417ba954fbfad76a04ed,PubMed and EMBASE,0.491423
uuid-6b6124961336417ba954fbfad76a04ed,Escudier B,0.532196
uuid-6b6124961336417ba954fbfad76a04ed,et al.,0.469328
uuid-6b6124961336417ba954fbfad76a04ed,J Clin Oncol,0.481524
uuid-6b6124961336417ba954fbfad76a04ed,detailed search of www.clinicaltrials.gov,0.348607
uuid-6b6124961336417ba954fbfad76a04ed,efficacy and safety of nivolumab,0.482856
uuid-6b6124961336417ba954fbfad76a04ed,not identify any planned,0.328388
uuid-6b6124961336417ba954fbfad76a04ed,phase 2 study,0.462884
uuid-6b6124961336417ba954fbfad76a04ed,not identify any citations relevant to your request,0.438171
uuid-6b6124961336417ba954fbfad76a04ed,present using the following search terms,0.478752
uuid-4e5cdc8e65be4bd18d99b91138b863cc,ESMO,0.422584
uuid-4e5cdc8e65be4bd18d99b91138b863cc,mg,0.618224
uuid-4e5cdc8e65be4bd18d99b91138b863cc,kg,0.582836
uuid-4e5cdc8e65be4bd18d99b91138b863cc,grade 3 to 4 AEs,0.308343
uuid-8e2829b56d9c45a48f5ef75099a3c591,N Engl J Med,0.604857
uuid-8e2829b56d9c45a48f5ef75099a3c591,non-small cell lung cancer,0.34354
uuid-8e2829b56d9c45a48f5ef75099a3c591,ESMO,0.393944
uuid-8e2829b56d9c45a48f5ef75099a3c591,Rizvi NA,0.452745
uuid-8e2829b56d9c45a48f5ef75099a3c591,Brahmer J,0.679154
uuid-8e2829b56d9c45a48f5ef75099a3c591,PD-L1,0.347566
uuid-8e2829b56d9c45a48f5ef75099a3c591,Horn L,0.50259
uuid-8e2829b56d9c45a48f5ef75099a3c591,platinum-based doublet chemotherapy,0.304136
uuid-5f630c919ac74e858549abe62b8a60bf,respectively,0.585622
uuid-5f630c919ac74e858549abe62b8a60bf,Objective response rate,0.36976
uuid-5f630c919ac74e858549abe62b8a60bf,ORR,0.514781
uuid-5f630c919ac74e858549abe62b8a60bf,docetaxel,0.31274
uuid-aca2782c5a6e4db69943561c481b0bdd,OS,0.44149
uuid-aca2782c5a6e4db69943561c481b0bdd,95% CI,0.833403
uuid-aca2782c5a6e4db69943561c481b0bdd,ASCO,0.32927
uuid-aca2782c5a6e4db69943561c481b0bdd,Objective response rate,0.545269
uuid-aca2782c5a6e4db69943561c481b0bdd,ORR,0.618524
uuid-aca2782c5a6e4db69943561c481b0bdd,PFS,0.396858
uuid-aca2782c5a6e4db69943561c481b0bdd,Median overall survival,0.72593
uuid-aca2782c5a6e4db69943561c481b0bdd,monotherapy,0.33356
uuid-aca2782c5a6e4db69943561c481b0bdd,Median OS,0.763854
uuid-aca2782c5a6e4db69943561c481b0bdd,hazard ratio,0.766648
uuid-aca2782c5a6e4db69943561c481b0bdd,Median duration of response,0.442682
uuid-1cee551588874836b9576527110a6222,OS,0.506839
uuid-1cee551588874836b9576527110a6222,95% CI,0.914259
uuid-1cee551588874836b9576527110a6222,respectively,0.57945
uuid-1cee551588874836b9576527110a6222,Objective response rate,0.616133
uuid-1cee551588874836b9576527110a6222,ORR,0.78386
uuid-1cee551588874836b9576527110a6222,PFS,0.374029
uuid-1cee551588874836b9576527110a6222,Median overall survival,0.850584
uuid-1cee551588874836b9576527110a6222,monotherapy,0.435128
uuid-1cee551588874836b9576527110a6222,Median OS,0.829523
uuid-1cee551588874836b9576527110a6222,docetaxel,0.347663
uuid-1cee551588874836b9576527110a6222,hazard ratio,0.887303
uuid-1cee551588874836b9576527110a6222,Median duration of response,0.367027
uuid-c9dd3421ac514269b5e893f477b71548,Bristol-Myers Squibb,0.361443
uuid-c9dd3421ac514269b5e893f477b71548,evaluating,0.591075
uuid-c9dd3421ac514269b5e893f477b71548,not conducted any controlled clinical trials/studies,0.544189
uuid-c9dd3421ac514269b5e893f477b71548,search of published literature,0.624938
uuid-c9dd3421ac514269b5e893f477b71548,Additionally,0.45805
uuid-c9dd3421ac514269b5e893f477b71548,ipilimumab,0.377476
uuid-c9dd3421ac514269b5e893f477b71548,ongoing,0.348279
uuid-c9dd3421ac514269b5e893f477b71548,PubMed and EMBASE,0.607881
uuid-c9dd3421ac514269b5e893f477b71548,detailed search of www.clinicaltrials.gov,0.407663
uuid-c9dd3421ac514269b5e893f477b71548,efficacy and safety of nivolumab,0.6883
uuid-c9dd3421ac514269b5e893f477b71548,not identify any planned,0.365722
uuid-c9dd3421ac514269b5e893f477b71548,combination,0.339909
uuid-c9dd3421ac514269b5e893f477b71548,not identify any citations relevant to your request,0.5315
uuid-c9dd3421ac514269b5e893f477b71548,present using the following search terms,0.608749
uuid-be39dd08821f42dd82cc1707f2e746ea,OS,0.349054
uuid-be39dd08821f42dd82cc1707f2e746ea,95% CI,0.696869
uuid-be39dd08821f42dd82cc1707f2e746ea,respectively,0.747405
uuid-be39dd08821f42dd82cc1707f2e746ea,Objective response rate,0.596478
uuid-be39dd08821f42dd82cc1707f2e746ea,ORR,0.7237
uuid-be39dd08821f42dd82cc1707f2e746ea,Median overall survival,0.628269
uuid-be39dd08821f42dd82cc1707f2e746ea,monotherapy,0.48503
uuid-be39dd08821f42dd82cc1707f2e746ea,Median OS,0.660506
uuid-be39dd08821f42dd82cc1707f2e746ea,PD-L1,0.403686
uuid-be39dd08821f42dd82cc1707f2e746ea,docetaxel,0.487238
uuid-be39dd08821f42dd82cc1707f2e746ea,hazard ratio,0.689448
uuid-8cc80455dd92455ea761f3c0c966ee98,OS,0.324073
uuid-8cc80455dd92455ea761f3c0c966ee98,95% CI,0.660124
uuid-8cc80455dd92455ea761f3c0c966ee98,respectively,0.809559
uuid-8cc80455dd92455ea761f3c0c966ee98,Objective response rate,0.668092
uuid-8cc80455dd92455ea761f3c0c966ee98,ORR,0.764824
uuid-8cc80455dd92455ea761f3c0c966ee98,Median overall survival,0.58138
uuid-8cc80455dd92455ea761f3c0c966ee98,monotherapy,0.532169
uuid-8cc80455dd92455ea761f3c0c966ee98,Median OS,0.629224
uuid-8cc80455dd92455ea761f3c0c966ee98,PD-L1,0.379606
uuid-8cc80455dd92455ea761f3c0c966ee98,docetaxel,0.584757
uuid-8cc80455dd92455ea761f3c0c966ee98,hazard ratio,0.649699
uuid-bd422f8e3284486194f3da90c3691ba9,nivolumab,0.367886
uuid-bd422f8e3284486194f3da90c3691ba9,Bristol-Myers Squibb,0.634946
uuid-bd422f8e3284486194f3da90c3691ba9,evaluating,0.650676
uuid-bd422f8e3284486194f3da90c3691ba9,not conducted any controlled clinical trials/studies,0.710585
uuid-bd422f8e3284486194f3da90c3691ba9,considered investigational,0.456776
uuid-bd422f8e3284486194f3da90c3691ba9,Pubmed literature search,0.304915
uuid-bd422f8e3284486194f3da90c3691ba9,purposes other than its labeled indication must be considered investigational,0.412949
uuid-bd422f8e3284486194f3da90c3691ba9,efficacy and safety of nivolumab,0.563796
uuid-018e8b26384846f9ab1da42a8cc6715a,requested,0.594234
uuid-0a5b54620c0941c4b6a840c85fcca4d1,ASCO,0.382205
uuid-4773377a053746e8aed1fd69d26da21d,nivolumab,0.378089
uuid-4773377a053746e8aed1fd69d26da21d,Opdivo,0.666146
uuid-4773377a053746e8aed1fd69d26da21d,trial,0.357375
uuid-7d0393a2e68b46cc8302f33aa3bdb867,docetaxel,0.329386
uuid-7d0393a2e68b46cc8302f33aa3bdb867,safety of nivolumab monotherapy,0.370617
uuid-7d0393a2e68b46cc8302f33aa3bdb867,phase,0.406006
uuid-6394abafd9f243c787232e6587e014b9,OS,0.469828
uuid-6394abafd9f243c787232e6587e014b9,AEs,0.324552
uuid-6394abafd9f243c787232e6587e014b9,95% CI,0.801461
uuid-6394abafd9f243c787232e6587e014b9,respectively,0.467672
uuid-6394abafd9f243c787232e6587e014b9,Objective response rate,0.494158
uuid-6394abafd9f243c787232e6587e014b9,ORR,0.636306
uuid-6394abafd9f243c787232e6587e014b9,PFS,0.366327
uuid-6394abafd9f243c787232e6587e014b9,Median overall survival,0.769867
uuid-6394abafd9f243c787232e6587e014b9,Median OS,0.750473
uuid-6394abafd9f243c787232e6587e014b9,grade,0.335661
uuid-6394abafd9f243c787232e6587e014b9,hazard ratio,0.762103
uuid-6394abafd9f243c787232e6587e014b9,Median duration of response,0.403853
uuid-bbb1762dba254ca58a57dbc695aa87f4,evaluating,0.311825
uuid-bbb1762dba254ca58a57dbc695aa87f4,not conducted any controlled clinical trials/studies,0.305639
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,Bristol-Myers Squibb,0.341822
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,not conducted any controlled clinical trials/studies,0.304507
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,Opdivo,0.461382
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,Pubmed literature search,0.614325
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,not identify any citations relevant to your inquiry,0.606087
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,adverse,0.304183
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,using the following search terms,0.642331
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,databases,0.315039
uuid-8a1ee5f0f8984137a69c63f5ca2564a6,reported,0.556704
uuid-15d2e97c345646f2babce521fb0cc5a8,requested,0.729914
uuid-2acb59a29d2c431dba053b4082e90212,requested,0.729914
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,N Engl J Med,0.442834
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,protocol,0.763252
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,McDermott DF,0.733103
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,Motzer RJ,0.811057
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,phase 3 study,0.420895
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,Escudier B,0.741048
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,NEJM,0.402544
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,et al.,0.660398
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,J Clin Oncol,0.786367
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,Topalian,0.392395
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,phase 1 study,0.513779
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,CA209-003,0.583337
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,phase 2 study,0.675447
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,present using the following search terms,0.304589
uuid-155a4c0c92cd42f2bb064fe79e1b51f2,investigating,0.633101
uuid-1324eeffcf8c4dac84da5a83282749ff,OS,0.62262
uuid-1324eeffcf8c4dac84da5a83282749ff,PFS,0.65903
uuid-1324eeffcf8c4dac84da5a83282749ff,Overall survival,0.644151
uuid-31e68dcf46a04f9bab7996d8cac15c12,trial,0.441648
uuid-b78e94366d44467e9800f07846360278,patients with advanced or metastatic,0.468858
uuid-b78e94366d44467e9800f07846360278,nivolumab combined with ipilimumab,0.446918
uuid-b78e94366d44467e9800f07846360278,not approved,0.352562
uuid-b78e94366d44467e9800f07846360278,clinical trials investigating the safety,0.429501
uuid-b78e94366d44467e9800f07846360278,bladder cancer,0.950698
uuid-a76748774ea6426da95c10dd664ae1a5,respectively,0.585622
uuid-a76748774ea6426da95c10dd664ae1a5,Objective response rate,0.36976
uuid-a76748774ea6426da95c10dd664ae1a5,ORR,0.514781
uuid-a76748774ea6426da95c10dd664ae1a5,docetaxel,0.31274
uuid-b1e62add6b2b4717bddd75417a3333d9,requested,0.594234
uuid-d188239df0fe411fbc7244254d1f2fcc,patients,0.308222
uuid-d188239df0fe411fbc7244254d1f2fcc,small cell lung cancer,0.460024
uuid-d188239df0fe411fbc7244254d1f2fcc,SCLC,0.507494
uuid-d188239df0fe411fbc7244254d1f2fcc,therapy,0.792898
uuid-d188239df0fe411fbc7244254d1f2fcc,relapsed,0.302508
uuid-8b11800e312b4977813db3a63a553032,provided in the Detailed Information,0.523967
uuid-8b11800e312b4977813db3a63a553032,adverse,0.334376
uuid-8b11800e312b4977813db3a63a553032,clinical,0.549777
uuid-b67c41def56e4b009954c437a64065ec,requested,0.788355
uuid-37c8529d49a94b49910faff223baae0c,N Engl J Med,0.427636
uuid-37c8529d49a94b49910faff223baae0c,protocol,0.429136
uuid-37c8529d49a94b49910faff223baae0c,McDermott DF,0.44782
uuid-37c8529d49a94b49910faff223baae0c,Motzer RJ,0.430476
uuid-37c8529d49a94b49910faff223baae0c,Escudier B,0.450887
uuid-37c8529d49a94b49910faff223baae0c,et al.,0.456026
uuid-37c8529d49a94b49910faff223baae0c,J Clin Oncol,0.384624
uuid-37c8529d49a94b49910faff223baae0c,Rizvi NA,0.305616
uuid-37c8529d49a94b49910faff223baae0c,phase 2 study,0.351446
uuid-f74a0f8f200946f283797e7dc2af040a,Bristol-Myers Squibb,0.36472
uuid-1218c6171b504db392f1a0c8d9d9ff2a,NSCLC,0.351198
uuid-1218c6171b504db392f1a0c8d9d9ff2a,efficacy and safety of nivolumab,0.343313
uuid-671c66944719431485091935b7377bf6,Bristol-Myers Squibb,0.629232
uuid-671c66944719431485091935b7377bf6,use of nivolumab for the treatment,0.341334
uuid-671c66944719431485091935b7377bf6,evaluating,0.627609
uuid-671c66944719431485091935b7377bf6,not conducted any controlled clinical trials/studies,0.646739
uuid-671c66944719431485091935b7377bf6,efficacy,0.343391
uuid-671c66944719431485091935b7377bf6,considered investigational,0.357148
uuid-671c66944719431485091935b7377bf6,efficacy and safety of nivolumab,0.491204
uuid-671c66944719431485091935b7377bf6,safety of nivolumab monotherapy,0.335629
uuid-5f94cc9ca25d47478f6257d1693e118c,OS,0.467349
uuid-5f94cc9ca25d47478f6257d1693e118c,AEs,0.31233
uuid-5f94cc9ca25d47478f6257d1693e118c,95% CI,0.817183
uuid-5f94cc9ca25d47478f6257d1693e118c,respectively,0.397399
uuid-5f94cc9ca25d47478f6257d1693e118c,Objective response rate,0.430028
uuid-5f94cc9ca25d47478f6257d1693e118c,ORR,0.575383
uuid-5f94cc9ca25d47478f6257d1693e118c,PFS,0.362016
uuid-5f94cc9ca25d47478f6257d1693e118c,Median overall survival,0.772313
uuid-5f94cc9ca25d47478f6257d1693e118c,Median OS,0.775531
uuid-5f94cc9ca25d47478f6257d1693e118c,hazard ratio,0.77812
uuid-5f94cc9ca25d47478f6257d1693e118c,Median duration of response,0.449298
uuid-431e40b5803b4593bfb4748bd5ee7a04,ASCO,0.387435
uuid-431e40b5803b4593bfb4748bd5ee7a04,requested,0.505345
uuid-431e40b5803b4593bfb4748bd5ee7a04,et al.,0.410867
uuid-5b63c531a3934c2d820e7272dcac919e,Bristol-Myers Squibb,0.506116
uuid-5b63c531a3934c2d820e7272dcac919e,evaluating,0.448845
uuid-5b63c531a3934c2d820e7272dcac919e,not conducted any controlled clinical trials/studies,0.504259
uuid-5b63c531a3934c2d820e7272dcac919e,NSCLC,0.525277
uuid-5b63c531a3934c2d820e7272dcac919e,non-small cell lung cancer,0.493709
uuid-5b63c531a3934c2d820e7272dcac919e,patients,0.323106
uuid-5b63c531a3934c2d820e7272dcac919e,phase 3 study,0.458005
uuid-5b63c531a3934c2d820e7272dcac919e,phase 1 study,0.333393
uuid-5b63c531a3934c2d820e7272dcac919e,efficacy and safety of nivolumab,0.49999
uuid-50202a0697424cffbf347f63f2fdf6b6,Bristol-Myers Squibb,0.341822
uuid-50202a0697424cffbf347f63f2fdf6b6,not conducted any controlled clinical trials/studies,0.304507
uuid-50202a0697424cffbf347f63f2fdf6b6,Opdivo,0.461382
uuid-50202a0697424cffbf347f63f2fdf6b6,Pubmed literature search,0.614325
uuid-50202a0697424cffbf347f63f2fdf6b6,purposes other than its labeled indication must be considered investigational,0.586645
uuid-50202a0697424cffbf347f63f2fdf6b6,not identify any citations relevant to your inquiry,0.606087
uuid-50202a0697424cffbf347f63f2fdf6b6,adverse,0.304183
uuid-50202a0697424cffbf347f63f2fdf6b6,using the following search terms,0.642331
uuid-50202a0697424cffbf347f63f2fdf6b6,databases,0.315039
uuid-50202a0697424cffbf347f63f2fdf6b6,reported,0.556704
uuid-72f3ef9c411c4a1d8afb6c6abe1735c3,respectively,0.397695
uuid-0217b7cf857445dab7217bd47d0079b4,respectively,0.629961
uuid-0217b7cf857445dab7217bd47d0079b4,Objective response rate,0.439951
uuid-0217b7cf857445dab7217bd47d0079b4,ORR,0.462322
uuid-0217b7cf857445dab7217bd47d0079b4,monotherapy,0.352421
uuid-0217b7cf857445dab7217bd47d0079b4,docetaxel,0.410479
uuid-75f29157f2ea44f196ceca1ef12a400d,requested,0.441019
uuid-75f29157f2ea44f196ceca1ef12a400d,trial,0.311756
uuid-27cddc20df49448ab37070cdddc2d27b,requested,0.44769
uuid-27cddc20df49448ab37070cdddc2d27b,trial,0.309472
uuid-83a92708f953451c87f293cc04979496,Brahmer J,0.459736
uuid-83a92708f953451c87f293cc04979496,BMS,0.851044
uuid-15904cd57b664e998d4f773e7ad6784c,provided in the Detailed Information,0.408955
uuid-15904cd57b664e998d4f773e7ad6784c,ESMO,0.992426
uuid-15904cd57b664e998d4f773e7ad6784c,Horn L,0.554477
uuid-15904cd57b664e998d4f773e7ad6784c,grade 3 to 4 AEs,0.502956
uuid-471d4d3b535f4f438d4d869baf5c4251,patients,0.421937
uuid-471d4d3b535f4f438d4d869baf5c4251,docetaxel,0.309853
uuid-be983478b4334df789b91c0b5741a0b9,nivolumab,0.361138
uuid-9377d6a7714f4a87ad154632babfd928,N Engl J Med,0.616236
uuid-9377d6a7714f4a87ad154632babfd928,respectively,0.409266
uuid-9377d6a7714f4a87ad154632babfd928,ASCO,0.373445
uuid-9377d6a7714f4a87ad154632babfd928,ESMO,0.378373
uuid-9377d6a7714f4a87ad154632babfd928,Brahmer J,0.712806
uuid-9377d6a7714f4a87ad154632babfd928,docetaxel,0.327482
uuid-9377d6a7714f4a87ad154632babfd928,Horn L,0.502372
uuid-60aae746c57d40469f0a9a624319e08a,Bristol-Myers Squibb,0.341822
uuid-60aae746c57d40469f0a9a624319e08a,not conducted any controlled clinical trials/studies,0.304507
uuid-60aae746c57d40469f0a9a624319e08a,Opdivo,0.461382
uuid-60aae746c57d40469f0a9a624319e08a,Pubmed literature search,0.614325
uuid-60aae746c57d40469f0a9a624319e08a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-60aae746c57d40469f0a9a624319e08a,not identify any citations relevant to your inquiry,0.606087
uuid-60aae746c57d40469f0a9a624319e08a,adverse,0.304183
uuid-60aae746c57d40469f0a9a624319e08a,using the following search terms,0.642331
uuid-60aae746c57d40469f0a9a624319e08a,databases,0.315039
uuid-60aae746c57d40469f0a9a624319e08a,reported,0.556704
uuid-71ebabbace6f43b5aae3681b0fe95e84,Bristol-Myers Squibb,0.776773
uuid-71ebabbace6f43b5aae3681b0fe95e84,evaluating,0.604575
uuid-71ebabbace6f43b5aae3681b0fe95e84,not conducted any controlled clinical trials/studies,0.693204
uuid-71ebabbace6f43b5aae3681b0fe95e84,efficacy and safety of nivolumab,0.516598
uuid-240583b0d96d4c309e02e3cda17b7374,relapsed,0.313685
uuid-9946c428577b4f4b99b8cc822b88011e,use of nivolumab for the treatment,0.705311
uuid-9946c428577b4f4b99b8cc822b88011e,efficacy,0.763268
uuid-9946c428577b4f4b99b8cc822b88011e,not approved,0.726038
uuid-9946c428577b4f4b99b8cc822b88011e,clinical trials investigating the safety,0.647347
uuid-9946c428577b4f4b99b8cc822b88011e,safety,0.518712
uuid-9946c428577b4f4b99b8cc822b88011e,relapsed,0.448701
uuid-9946c428577b4f4b99b8cc822b88011e,safety of nivolumab monotherapy,0.49088
uuid-9946c428577b4f4b99b8cc822b88011e,databases,0.310625
uuid-8e956df0aeda48938f328ec0699b8359,N Engl J Med,0.442834
uuid-8e956df0aeda48938f328ec0699b8359,protocol,0.763252
uuid-8e956df0aeda48938f328ec0699b8359,McDermott DF,0.733103
uuid-8e956df0aeda48938f328ec0699b8359,Motzer RJ,0.811057
uuid-8e956df0aeda48938f328ec0699b8359,phase 3 study,0.420895
uuid-8e956df0aeda48938f328ec0699b8359,Escudier B,0.741048
uuid-8e956df0aeda48938f328ec0699b8359,NEJM,0.402544
uuid-8e956df0aeda48938f328ec0699b8359,et al.,0.660398
uuid-8e956df0aeda48938f328ec0699b8359,J Clin Oncol,0.786367
uuid-8e956df0aeda48938f328ec0699b8359,Topalian,0.392395
uuid-8e956df0aeda48938f328ec0699b8359,phase 1 study,0.513779
uuid-8e956df0aeda48938f328ec0699b8359,CA209-003,0.583337
uuid-8e956df0aeda48938f328ec0699b8359,phase 2 study,0.675447
uuid-8e956df0aeda48938f328ec0699b8359,present using the following search terms,0.304589
uuid-8e956df0aeda48938f328ec0699b8359,investigating,0.633101
uuid-9ce3ba46060c4957b32156790e44dded,patients,0.347655
uuid-9ce3ba46060c4957b32156790e44dded,open-label,0.306094
uuid-9ce3ba46060c4957b32156790e44dded,phase,0.328486
uuid-097f89ea38554daaa15ec365741a213d,N Engl J Med,0.427636
uuid-097f89ea38554daaa15ec365741a213d,protocol,0.429136
uuid-097f89ea38554daaa15ec365741a213d,McDermott DF,0.44782
uuid-097f89ea38554daaa15ec365741a213d,Motzer RJ,0.430476
uuid-097f89ea38554daaa15ec365741a213d,Escudier B,0.450887
uuid-097f89ea38554daaa15ec365741a213d,et al.,0.456026
uuid-097f89ea38554daaa15ec365741a213d,J Clin Oncol,0.384624
uuid-097f89ea38554daaa15ec365741a213d,Rizvi NA,0.305616
uuid-097f89ea38554daaa15ec365741a213d,phase 2 study,0.351446
uuid-9add8ebf3afb4354935f2c4af3f14726,Bristol-Myers Squibb,0.341822
uuid-9add8ebf3afb4354935f2c4af3f14726,not conducted any controlled clinical trials/studies,0.304507
uuid-9add8ebf3afb4354935f2c4af3f14726,Opdivo,0.461382
uuid-9add8ebf3afb4354935f2c4af3f14726,Pubmed literature search,0.614325
uuid-9add8ebf3afb4354935f2c4af3f14726,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9add8ebf3afb4354935f2c4af3f14726,not identify any citations relevant to your inquiry,0.606087
uuid-9add8ebf3afb4354935f2c4af3f14726,adverse,0.304183
uuid-9add8ebf3afb4354935f2c4af3f14726,using the following search terms,0.642331
uuid-9add8ebf3afb4354935f2c4af3f14726,databases,0.315039
uuid-9add8ebf3afb4354935f2c4af3f14726,reported,0.556704
uuid-4632a1809894487faf95c10fd88a8833,Bristol-Myers Squibb,0.660351
uuid-4632a1809894487faf95c10fd88a8833,evaluating,0.623713
uuid-4632a1809894487faf95c10fd88a8833,not conducted any controlled clinical trials/studies,0.692832
uuid-4632a1809894487faf95c10fd88a8833,considered investigational,0.476319
uuid-4632a1809894487faf95c10fd88a8833,purposes other than its labeled indication must be considered investigational,0.329406
uuid-4632a1809894487faf95c10fd88a8833,efficacy and safety of nivolumab,0.52779
uuid-97665ee79b444ac584ed67010d4ad32a,use of nivolumab for the treatment,0.440423
uuid-97665ee79b444ac584ed67010d4ad32a,search of published literature,0.311531
uuid-97665ee79b444ac584ed67010d4ad32a,PubMed and EMBASE,0.312811
uuid-97665ee79b444ac584ed67010d4ad32a,not approved,0.404782
uuid-97665ee79b444ac584ed67010d4ad32a,open-label,0.578291
uuid-97665ee79b444ac584ed67010d4ad32a,clinical trials investigating the safety,0.440014
uuid-97665ee79b444ac584ed67010d4ad32a,present using the following search terms,0.328669
uuid-97665ee79b444ac584ed67010d4ad32a,phase,0.41185
uuid-1eeef0d0101a4e0a8a7e758406c01388,OS,0.506839
uuid-1eeef0d0101a4e0a8a7e758406c01388,95% CI,0.914259
uuid-1eeef0d0101a4e0a8a7e758406c01388,respectively,0.57945
uuid-1eeef0d0101a4e0a8a7e758406c01388,Objective response rate,0.616133
uuid-1eeef0d0101a4e0a8a7e758406c01388,ORR,0.78386
uuid-1eeef0d0101a4e0a8a7e758406c01388,PFS,0.374029
uuid-1eeef0d0101a4e0a8a7e758406c01388,Median overall survival,0.850584
uuid-1eeef0d0101a4e0a8a7e758406c01388,monotherapy,0.435128
uuid-1eeef0d0101a4e0a8a7e758406c01388,Median OS,0.829523
uuid-1eeef0d0101a4e0a8a7e758406c01388,docetaxel,0.347663
uuid-1eeef0d0101a4e0a8a7e758406c01388,hazard ratio,0.887303
uuid-1eeef0d0101a4e0a8a7e758406c01388,Median duration of response,0.367027
uuid-8dfc72dd43c646d1b803d784c760d247,nivolumab,0.441653
uuid-082b53a06e37448e8a4f141a051c102e,requested,0.781657
uuid-a747f71ceac6495ebaaa8e6d670ddda9,N Engl J Med,0.616236
uuid-a747f71ceac6495ebaaa8e6d670ddda9,respectively,0.409266
uuid-a747f71ceac6495ebaaa8e6d670ddda9,ASCO,0.373445
uuid-a747f71ceac6495ebaaa8e6d670ddda9,ESMO,0.378373
uuid-a747f71ceac6495ebaaa8e6d670ddda9,Brahmer J,0.712806
uuid-a747f71ceac6495ebaaa8e6d670ddda9,docetaxel,0.327482
uuid-a747f71ceac6495ebaaa8e6d670ddda9,Horn L,0.502372
uuid-bda5be4572aa44d5b195039da42ab6f7,nivolumab,0.563564
uuid-bda5be4572aa44d5b195039da42ab6f7,Bristol-Myers Squibb,0.466945
uuid-bda5be4572aa44d5b195039da42ab6f7,evaluating,0.644634
uuid-bda5be4572aa44d5b195039da42ab6f7,not conducted any controlled clinical trials/studies,0.690095
uuid-bda5be4572aa44d5b195039da42ab6f7,Pubmed literature search,0.84755
uuid-bda5be4572aa44d5b195039da42ab6f7,purposes other than its labeled indication must be considered investigational,0.918022
uuid-bda5be4572aa44d5b195039da42ab6f7,not identify any citations relevant to your inquiry,0.805169
uuid-bda5be4572aa44d5b195039da42ab6f7,using the following search terms,0.790615
uuid-bda5be4572aa44d5b195039da42ab6f7,efficacy and safety of nivolumab,0.476429
uuid-4d9dbc2fef344ae89402bb6b512f6905,Bristol-Myers Squibb,0.342325
uuid-4d9dbc2fef344ae89402bb6b512f6905,requested,0.460083
uuid-707b2d6d98e84e30a91d0d10fe420923,NSCLC,0.351198
uuid-707b2d6d98e84e30a91d0d10fe420923,efficacy and safety of nivolumab,0.343313
uuid-be9edde3096740728f8e57807396c404,McDermott DF,0.324337
uuid-be9edde3096740728f8e57807396c404,Motzer RJ,0.302566
uuid-be9edde3096740728f8e57807396c404,phase 3 study,0.400404
uuid-be9edde3096740728f8e57807396c404,Escudier B,0.323843
uuid-be9edde3096740728f8e57807396c404,et al.,0.322352
uuid-be9edde3096740728f8e57807396c404,Rizvi NA,0.444726
uuid-be9edde3096740728f8e57807396c404,mg,0.3792
uuid-be9edde3096740728f8e57807396c404,Weber JS,0.313296
uuid-be9edde3096740728f8e57807396c404,phase 2 study,0.508806
uuid-be9edde3096740728f8e57807396c404,kg,0.346561
uuid-be9edde3096740728f8e57807396c404,phase,0.324474
uuid-2ddbc4b77a7a4e5dbcb286c123dcc48b,patients with advanced or metastatic,0.468858
uuid-2ddbc4b77a7a4e5dbcb286c123dcc48b,nivolumab combined with ipilimumab,0.446918
uuid-2ddbc4b77a7a4e5dbcb286c123dcc48b,not approved,0.352562
uuid-2ddbc4b77a7a4e5dbcb286c123dcc48b,clinical trials investigating the safety,0.429501
uuid-2ddbc4b77a7a4e5dbcb286c123dcc48b,bladder cancer,0.950698
uuid-075ac10d844847a2a3c9b56e86268ae6,Bristol-Myers Squibb,0.908842
uuid-075ac10d844847a2a3c9b56e86268ae6,evaluating,0.885023
uuid-075ac10d844847a2a3c9b56e86268ae6,not conducted any controlled clinical trials/studies,0.948237
uuid-075ac10d844847a2a3c9b56e86268ae6,search of published literature,0.376982
uuid-075ac10d844847a2a3c9b56e86268ae6,PubMed and EMBASE,0.325763
uuid-075ac10d844847a2a3c9b56e86268ae6,efficacy and safety of nivolumab,0.818788
uuid-075ac10d844847a2a3c9b56e86268ae6,present using the following search terms,0.320491
uuid-075ac10d844847a2a3c9b56e86268ae6,safety of nivolumab monotherapy,0.338949
uuid-bced15c6505d485ba2f6de7e5b421b20,open-label,0.539462
uuid-bced15c6505d485ba2f6de7e5b421b20,phase,0.350616
uuid-b5435eb8ce23409fb096e3cf1ff004cb,requested,0.540431
uuid-4ab26a73202c4fde97d0012bc08e085d,requested,0.594234
uuid-6dd00026b19540cea4d3d6ae2331e51f,requested,0.594234
uuid-498572c6e7a445769b823e0e5b8cb209,requested,0.594234
uuid-49ec7b1435a04ed3b54b8c6e426a2780,requested,0.594234
uuid-7780f7f25c33419aa00accde514900d9,nivolumab,0.351767
uuid-7780f7f25c33419aa00accde514900d9,Bristol-Myers Squibb,0.623883
uuid-7780f7f25c33419aa00accde514900d9,evaluating,0.622557
uuid-7780f7f25c33419aa00accde514900d9,not conducted any controlled clinical trials/studies,0.679825
uuid-7780f7f25c33419aa00accde514900d9,NSCLC,0.304045
uuid-7780f7f25c33419aa00accde514900d9,non-small cell lung cancer,0.315601
uuid-7780f7f25c33419aa00accde514900d9,considered investigational,0.431009
uuid-7780f7f25c33419aa00accde514900d9,purposes other than its labeled indication must be considered investigational,0.389161
uuid-7780f7f25c33419aa00accde514900d9,efficacy and safety of nivolumab,0.525296
uuid-14b657cfce224bf0b5401e883a13e18d,respectively,0.397695
uuid-2ff1257d54554594b2c5913030492a9a,OS,0.493666
uuid-2ff1257d54554594b2c5913030492a9a,95% CI,0.872793
uuid-2ff1257d54554594b2c5913030492a9a,respectively,0.581917
uuid-2ff1257d54554594b2c5913030492a9a,Objective response rate,0.558489
uuid-2ff1257d54554594b2c5913030492a9a,ORR,0.705401
uuid-2ff1257d54554594b2c5913030492a9a,PFS,0.331929
uuid-2ff1257d54554594b2c5913030492a9a,Median overall survival,0.793083
uuid-2ff1257d54554594b2c5913030492a9a,monotherapy,0.422517
uuid-2ff1257d54554594b2c5913030492a9a,Median OS,0.808565
uuid-2ff1257d54554594b2c5913030492a9a,PD-L1,0.302111
uuid-2ff1257d54554594b2c5913030492a9a,docetaxel,0.481228
uuid-2ff1257d54554594b2c5913030492a9a,hazard ratio,0.844622
uuid-2ff1257d54554594b2c5913030492a9a,Median duration of response,0.34536
uuid-7aa83d9defa04c389440cc2d57d1c39b,trial,0.314678
uuid-2fc2b60b6b0e4f49b48b77c409d266fb,OS,0.62262
uuid-2fc2b60b6b0e4f49b48b77c409d266fb,PFS,0.65903
uuid-2fc2b60b6b0e4f49b48b77c409d266fb,Overall survival,0.644151
uuid-2bd9823747214725887e3a84c2ecaa7e,open-label,0.311408
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,N Engl J Med,0.427636
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,protocol,0.429136
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,McDermott DF,0.44782
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,Motzer RJ,0.430476
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,Escudier B,0.450887
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,et al.,0.456026
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,J Clin Oncol,0.384624
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,Rizvi NA,0.305616
uuid-47dbbde4b5b14af6aa69b324d2c5ecf1,phase 2 study,0.351446
uuid-56c69f541db0460a92cce3d93df71695,OS,0.493666
uuid-56c69f541db0460a92cce3d93df71695,95% CI,0.872793
uuid-56c69f541db0460a92cce3d93df71695,respectively,0.581917
uuid-56c69f541db0460a92cce3d93df71695,Objective response rate,0.558489
uuid-56c69f541db0460a92cce3d93df71695,ORR,0.705401
uuid-56c69f541db0460a92cce3d93df71695,PFS,0.331929
uuid-56c69f541db0460a92cce3d93df71695,Median overall survival,0.793083
uuid-56c69f541db0460a92cce3d93df71695,monotherapy,0.422517
uuid-56c69f541db0460a92cce3d93df71695,Median OS,0.808565
uuid-56c69f541db0460a92cce3d93df71695,PD-L1,0.302111
uuid-56c69f541db0460a92cce3d93df71695,docetaxel,0.481228
uuid-56c69f541db0460a92cce3d93df71695,hazard ratio,0.844622
uuid-56c69f541db0460a92cce3d93df71695,Median duration of response,0.34536
uuid-c21caa6db9b64e268ccc68e0f60a9fec,requested,0.594234
uuid-aeb0250e70c1439e948b8d510fccdc14,requested,0.594234
uuid-eff7326cabd24c96a0983b38165479f7,ipilimumab,0.385692
uuid-eff7326cabd24c96a0983b38165479f7,ASCO 2015,0.417944
uuid-eff7326cabd24c96a0983b38165479f7,partial response,0.382425
uuid-eff7326cabd24c96a0983b38165479f7,Stable disease,0.586335
uuid-eff7326cabd24c96a0983b38165479f7,cohort,0.307748
uuid-79edee02cd704d9585525623812661b8,95% CI,0.524855
uuid-79edee02cd704d9585525623812661b8,respectively,0.383655
uuid-79edee02cd704d9585525623812661b8,ASCO,0.303153
uuid-79edee02cd704d9585525623812661b8,Lancet Oncol,0.368041
uuid-79edee02cd704d9585525623812661b8,Objective response rate,0.504846
uuid-79edee02cd704d9585525623812661b8,ORR,0.465366
uuid-79edee02cd704d9585525623812661b8,Median overall survival,0.346516
uuid-79edee02cd704d9585525623812661b8,Median OS,0.33538
uuid-79edee02cd704d9585525623812661b8,ASCO 2015,0.336983
uuid-79edee02cd704d9585525623812661b8,small cell lung cancer,0.336892
uuid-79edee02cd704d9585525623812661b8,SCLC,0.344367
uuid-79edee02cd704d9585525623812661b8,Antonia SJ,0.55269
uuid-79edee02cd704d9585525623812661b8,Median duration of response,0.649605
uuid-c683d565f5954ad7bcf704b5fcde0104,Bristol-Myers Squibb,0.592009
uuid-c683d565f5954ad7bcf704b5fcde0104,evaluating,0.597755
uuid-c683d565f5954ad7bcf704b5fcde0104,not conducted any controlled clinical trials/studies,0.645715
uuid-c683d565f5954ad7bcf704b5fcde0104,NSCLC,0.475824
uuid-c683d565f5954ad7bcf704b5fcde0104,non-small cell lung cancer,0.46123
uuid-c683d565f5954ad7bcf704b5fcde0104,considered investigational,0.537938
uuid-c683d565f5954ad7bcf704b5fcde0104,small cell lung cancer,0.309939
uuid-c683d565f5954ad7bcf704b5fcde0104,efficacy and safety of nivolumab,0.502132
uuid-c683d565f5954ad7bcf704b5fcde0104,SCLC,0.313725
uuid-2d4af5a9cbe04eb287fab6e49251cb18,requested,0.594234
uuid-342b8caf07474618bc810e41c996eb4a,OS,0.349054
uuid-342b8caf07474618bc810e41c996eb4a,95% CI,0.696869
uuid-342b8caf07474618bc810e41c996eb4a,respectively,0.747405
uuid-342b8caf07474618bc810e41c996eb4a,Objective response rate,0.596478
uuid-342b8caf07474618bc810e41c996eb4a,ORR,0.7237
uuid-342b8caf07474618bc810e41c996eb4a,Median overall survival,0.628269
uuid-342b8caf07474618bc810e41c996eb4a,monotherapy,0.48503
uuid-342b8caf07474618bc810e41c996eb4a,Median OS,0.660506
uuid-342b8caf07474618bc810e41c996eb4a,PD-L1,0.403686
uuid-342b8caf07474618bc810e41c996eb4a,docetaxel,0.487238
uuid-342b8caf07474618bc810e41c996eb4a,hazard ratio,0.689448
uuid-507794abe1ef40cda597525c38d1057e,nivolumab,0.538287
uuid-507794abe1ef40cda597525c38d1057e,search of published literature,0.51033
uuid-507794abe1ef40cda597525c38d1057e,Additionally,0.471231
uuid-507794abe1ef40cda597525c38d1057e,ongoing,0.321681
uuid-507794abe1ef40cda597525c38d1057e,PubMed and EMBASE,0.523161
uuid-507794abe1ef40cda597525c38d1057e,detailed search of www.clinicaltrials.gov,0.425974
uuid-507794abe1ef40cda597525c38d1057e,efficacy and safety of nivolumab,0.404686
uuid-507794abe1ef40cda597525c38d1057e,not identify any planned,0.354341
uuid-507794abe1ef40cda597525c38d1057e,not identify any citations relevant to your request,0.606997
uuid-507794abe1ef40cda597525c38d1057e,present using the following search terms,0.607839
uuid-f57fd35ff7684931882ac82700bc40a0,patients,0.315933
uuid-72adcafedbb845889f8a712dfa19a464,requested,0.729914
uuid-17bb834da9074f9e8da73ea47103dd6b,nivolumab,0.407498
uuid-17bb834da9074f9e8da73ea47103dd6b,Bristol-Myers Squibb,0.575711
uuid-17bb834da9074f9e8da73ea47103dd6b,evaluating,0.519305
uuid-17bb834da9074f9e8da73ea47103dd6b,not conducted any controlled clinical trials/studies,0.570005
uuid-17bb834da9074f9e8da73ea47103dd6b,considered investigational,0.351856
uuid-17bb834da9074f9e8da73ea47103dd6b,purposes other than its labeled indication must be considered investigational,0.349847
uuid-17bb834da9074f9e8da73ea47103dd6b,efficacy and safety of nivolumab,0.419517
uuid-17bb834da9074f9e8da73ea47103dd6b,combination,0.388428
uuid-f57e66c9f7ee476bad073c5b129dc8fa,requested,0.594234
uuid-9b3eef6da6a5422f828698d56181ac94,requested,0.594234
uuid-6a546297168d4a659fafd5d1c5292579,requested,0.44769
uuid-6a546297168d4a659fafd5d1c5292579,trial,0.309472
uuid-6f9c1df0e0ea405f9ee2138879a8b69e,requested,0.553648
uuid-acafed8dc7404375bee21653d28e554d,N Engl J Med,0.319272
uuid-acafed8dc7404375bee21653d28e554d,patients,0.325616
uuid-acafed8dc7404375bee21653d28e554d,protocol,0.382531
uuid-acafed8dc7404375bee21653d28e554d,McDermott DF,0.441084
uuid-acafed8dc7404375bee21653d28e554d,Motzer RJ,0.41441
uuid-acafed8dc7404375bee21653d28e554d,phase 3 study,0.437334
uuid-acafed8dc7404375bee21653d28e554d,Escudier B,0.421257
uuid-acafed8dc7404375bee21653d28e554d,NEJM,0.321137
uuid-acafed8dc7404375bee21653d28e554d,et al.,0.408832
uuid-acafed8dc7404375bee21653d28e554d,J Clin Oncol,0.414371
uuid-acafed8dc7404375bee21653d28e554d,phase 1 study,0.335004
uuid-acafed8dc7404375bee21653d28e554d,Weber JS,0.329799
uuid-acafed8dc7404375bee21653d28e554d,phase 2 study,0.47241
uuid-acafed8dc7404375bee21653d28e554d,grade 3 to 4 AEs,0.354735
uuid-4ca72b3793294b6a9653f84f4ffd90ff,N Engl J Med,0.319272
uuid-4ca72b3793294b6a9653f84f4ffd90ff,patients,0.325616
uuid-4ca72b3793294b6a9653f84f4ffd90ff,protocol,0.382531
uuid-4ca72b3793294b6a9653f84f4ffd90ff,McDermott DF,0.441084
uuid-4ca72b3793294b6a9653f84f4ffd90ff,Motzer RJ,0.41441
uuid-4ca72b3793294b6a9653f84f4ffd90ff,phase 3 study,0.437334
uuid-4ca72b3793294b6a9653f84f4ffd90ff,Escudier B,0.421257
uuid-4ca72b3793294b6a9653f84f4ffd90ff,NEJM,0.321137
uuid-4ca72b3793294b6a9653f84f4ffd90ff,et al.,0.408832
uuid-4ca72b3793294b6a9653f84f4ffd90ff,J Clin Oncol,0.414371
uuid-4ca72b3793294b6a9653f84f4ffd90ff,phase 1 study,0.335004
uuid-4ca72b3793294b6a9653f84f4ffd90ff,Weber JS,0.329799
uuid-4ca72b3793294b6a9653f84f4ffd90ff,phase 2 study,0.47241
uuid-4ca72b3793294b6a9653f84f4ffd90ff,grade 3 to 4 AEs,0.354735
uuid-e79052373a684845a3d72658f1d910fd,nivolumab,0.355212
uuid-e79052373a684845a3d72658f1d910fd,use of nivolumab for the treatment,0.394686
uuid-e79052373a684845a3d72658f1d910fd,efficacy,0.312963
uuid-e79052373a684845a3d72658f1d910fd,search of published literature,0.305051
uuid-e79052373a684845a3d72658f1d910fd,not approved,0.46217
uuid-e79052373a684845a3d72658f1d910fd,clinical trials investigating the safety,0.517417
uuid-e79052373a684845a3d72658f1d910fd,efficacy and safety of nivolumab,0.302155
uuid-e79052373a684845a3d72658f1d910fd,clinicaltrials.gov,0.50712
uuid-e79052373a684845a3d72658f1d910fd,present using the following search terms,0.325121
uuid-1667e68a2f104fa6bc17fe286672c6af,requested,0.594234
uuid-f4acb686d4b042ee8433e5a36e2fa315,95% CI,0.524855
uuid-f4acb686d4b042ee8433e5a36e2fa315,respectively,0.383655
uuid-f4acb686d4b042ee8433e5a36e2fa315,ASCO,0.303153
uuid-f4acb686d4b042ee8433e5a36e2fa315,Lancet Oncol,0.368041
uuid-f4acb686d4b042ee8433e5a36e2fa315,Objective response rate,0.504846
uuid-f4acb686d4b042ee8433e5a36e2fa315,ORR,0.465366
uuid-f4acb686d4b042ee8433e5a36e2fa315,Median overall survival,0.346516
uuid-f4acb686d4b042ee8433e5a36e2fa315,Median OS,0.33538
uuid-f4acb686d4b042ee8433e5a36e2fa315,ASCO 2015,0.336983
uuid-f4acb686d4b042ee8433e5a36e2fa315,small cell lung cancer,0.336892
uuid-f4acb686d4b042ee8433e5a36e2fa315,SCLC,0.344367
uuid-f4acb686d4b042ee8433e5a36e2fa315,Antonia SJ,0.55269
uuid-f4acb686d4b042ee8433e5a36e2fa315,Median duration of response,0.649605
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,nivolumab,0.510392
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,Bristol-Myers Squibb,0.464176
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,evaluating,0.683286
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,not conducted any controlled clinical trials/studies,0.682483
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,RCC,0.308694
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,search of published literature,0.839602
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,Additionally,0.446384
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,PubMed and EMBASE,0.823429
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,detailed search of www.clinicaltrials.gov,0.366719
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,efficacy and safety of nivolumab,0.841
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,not identify any citations relevant to your request,0.605656
uuid-fc0a7d6df26c4e17885b4e6df4e2e0a6,present using the following search terms,0.832619
uuid-7b753d20c42645129eb289442f5d9494,nivolumab,0.610941
uuid-7b753d20c42645129eb289442f5d9494,Bristol-Myers Squibb,0.577794
uuid-7b753d20c42645129eb289442f5d9494,evaluating,0.784475
uuid-7b753d20c42645129eb289442f5d9494,not conducted any controlled clinical trials/studies,0.803687
uuid-7b753d20c42645129eb289442f5d9494,Pubmed literature search,0.5483
uuid-7b753d20c42645129eb289442f5d9494,purposes other than its labeled indication must be considered investigational,0.663236
uuid-7b753d20c42645129eb289442f5d9494,not identify any citations relevant to your inquiry,0.504564
uuid-7b753d20c42645129eb289442f5d9494,search of published literature,0.481145
uuid-7b753d20c42645129eb289442f5d9494,PubMed and EMBASE,0.450888
uuid-7b753d20c42645129eb289442f5d9494,using the following search terms,0.477512
uuid-7b753d20c42645129eb289442f5d9494,efficacy and safety of nivolumab,0.705575
uuid-7b753d20c42645129eb289442f5d9494,present using the following search terms,0.471602
uuid-1fbc1f84e8f7444eb13046b767637603,nivolumab,0.358578
uuid-1fbc1f84e8f7444eb13046b767637603,evaluating,0.301478
uuid-1fbc1f84e8f7444eb13046b767637603,not conducted any controlled clinical trials/studies,0.302319
uuid-1fbc1f84e8f7444eb13046b767637603,RCC,0.600768
uuid-db7040f4888d43419e9b44d686f48078,Bristol-Myers Squibb,0.561209
uuid-db7040f4888d43419e9b44d686f48078,use of nivolumab for the treatment,0.374711
uuid-db7040f4888d43419e9b44d686f48078,evaluating,0.610616
uuid-db7040f4888d43419e9b44d686f48078,not conducted any controlled clinical trials/studies,0.655473
uuid-db7040f4888d43419e9b44d686f48078,patients,0.471336
uuid-db7040f4888d43419e9b44d686f48078,considered investigational,0.655657
uuid-db7040f4888d43419e9b44d686f48078,purposes other than its labeled indication must be considered investigational,0.329675
uuid-db7040f4888d43419e9b44d686f48078,tumors,0.323959
uuid-db7040f4888d43419e9b44d686f48078,small cell lung cancer,0.522469
uuid-db7040f4888d43419e9b44d686f48078,efficacy and safety of nivolumab,0.536131
uuid-db7040f4888d43419e9b44d686f48078,SCLC,0.50553
uuid-db7040f4888d43419e9b44d686f48078,therapy,0.314329
uuid-db7040f4888d43419e9b44d686f48078,phase 1/2 study CA209-032,0.473284
uuid-db7040f4888d43419e9b44d686f48078,evaluates the efficacy of nivolumab monotherapy,0.420829
uuid-19cfb2352b654fec80a0e865f8bd1ec6,95% CI,0.524855
uuid-19cfb2352b654fec80a0e865f8bd1ec6,respectively,0.383655
uuid-19cfb2352b654fec80a0e865f8bd1ec6,ASCO,0.303153
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Lancet Oncol,0.368041
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Objective response rate,0.504846
uuid-19cfb2352b654fec80a0e865f8bd1ec6,ORR,0.465366
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Median overall survival,0.346516
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Median OS,0.33538
uuid-19cfb2352b654fec80a0e865f8bd1ec6,ASCO 2015,0.336983
uuid-19cfb2352b654fec80a0e865f8bd1ec6,small cell lung cancer,0.336892
uuid-19cfb2352b654fec80a0e865f8bd1ec6,SCLC,0.344367
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Antonia SJ,0.55269
uuid-19cfb2352b654fec80a0e865f8bd1ec6,Median duration of response,0.649605
uuid-116fe623d46145e19e43cecf554bc735,N Engl J Med,0.442834
uuid-116fe623d46145e19e43cecf554bc735,protocol,0.763252
uuid-116fe623d46145e19e43cecf554bc735,McDermott DF,0.733103
uuid-116fe623d46145e19e43cecf554bc735,Motzer RJ,0.811057
uuid-116fe623d46145e19e43cecf554bc735,phase 3 study,0.420895
uuid-116fe623d46145e19e43cecf554bc735,Escudier B,0.741048
uuid-116fe623d46145e19e43cecf554bc735,NEJM,0.402544
uuid-116fe623d46145e19e43cecf554bc735,et al.,0.660398
uuid-116fe623d46145e19e43cecf554bc735,J Clin Oncol,0.786367
uuid-116fe623d46145e19e43cecf554bc735,Topalian,0.392395
uuid-116fe623d46145e19e43cecf554bc735,phase 1 study,0.513779
uuid-116fe623d46145e19e43cecf554bc735,CA209-003,0.583337
uuid-116fe623d46145e19e43cecf554bc735,phase 2 study,0.675447
uuid-116fe623d46145e19e43cecf554bc735,present using the following search terms,0.304589
uuid-116fe623d46145e19e43cecf554bc735,investigating,0.633101
uuid-4433e77a0f0d416b8717acb245aa5702,nivolumab,0.355212
uuid-4433e77a0f0d416b8717acb245aa5702,use of nivolumab for the treatment,0.394686
uuid-4433e77a0f0d416b8717acb245aa5702,efficacy,0.312963
uuid-4433e77a0f0d416b8717acb245aa5702,search of published literature,0.305051
uuid-4433e77a0f0d416b8717acb245aa5702,not approved,0.46217
uuid-4433e77a0f0d416b8717acb245aa5702,clinical trials investigating the safety,0.517417
uuid-4433e77a0f0d416b8717acb245aa5702,efficacy and safety of nivolumab,0.302155
uuid-4433e77a0f0d416b8717acb245aa5702,clinicaltrials.gov,0.50712
uuid-4433e77a0f0d416b8717acb245aa5702,present using the following search terms,0.325121
uuid-bff3204aee6a447fabcc29a4455d8aa8,Bristol-Myers Squibb,0.676092
uuid-bff3204aee6a447fabcc29a4455d8aa8,evaluating,0.619621
uuid-bff3204aee6a447fabcc29a4455d8aa8,not conducted any controlled clinical trials/studies,0.662598
uuid-bff3204aee6a447fabcc29a4455d8aa8,NSCLC,0.336121
uuid-bff3204aee6a447fabcc29a4455d8aa8,non-small cell lung cancer,0.359798
uuid-bff3204aee6a447fabcc29a4455d8aa8,efficacy and safety of nivolumab,0.56848
uuid-131395292e2245cbb60242ab72fc5352,nivolumab,0.68244
uuid-131395292e2245cbb60242ab72fc5352,Bristol-Myers Squibb,0.517429
uuid-131395292e2245cbb60242ab72fc5352,evaluating,0.706374
uuid-131395292e2245cbb60242ab72fc5352,not conducted any controlled clinical trials/studies,0.728669
uuid-131395292e2245cbb60242ab72fc5352,Pubmed literature search,0.57197
uuid-131395292e2245cbb60242ab72fc5352,purposes other than its labeled indication must be considered investigational,0.67055
uuid-131395292e2245cbb60242ab72fc5352,not identify any citations relevant to your inquiry,0.536683
uuid-131395292e2245cbb60242ab72fc5352,search of published literature,0.482116
uuid-131395292e2245cbb60242ab72fc5352,PubMed and EMBASE,0.457926
uuid-131395292e2245cbb60242ab72fc5352,using the following search terms,0.515534
uuid-131395292e2245cbb60242ab72fc5352,efficacy and safety of nivolumab,0.648163
uuid-131395292e2245cbb60242ab72fc5352,present using the following search terms,0.479533
uuid-9980821925cf400383547fd2ffb6c7af,requested,0.427791
uuid-9980821925cf400383547fd2ffb6c7af,PD-L1,0.329076
uuid-03518acd53ca431caa8fe4c623bdf3e0,95% CI,0.482283
uuid-03518acd53ca431caa8fe4c623bdf3e0,respectively,0.319895
uuid-03518acd53ca431caa8fe4c623bdf3e0,ASCO,0.389676
uuid-03518acd53ca431caa8fe4c623bdf3e0,Objective response rate,0.357341
uuid-03518acd53ca431caa8fe4c623bdf3e0,ORR,0.358789
uuid-03518acd53ca431caa8fe4c623bdf3e0,Median overall survival,0.421434
uuid-03518acd53ca431caa8fe4c623bdf3e0,Median OS,0.603017
uuid-03518acd53ca431caa8fe4c623bdf3e0,docetaxel,0.351836
uuid-03518acd53ca431caa8fe4c623bdf3e0,hazard ratio,0.51871
uuid-e3466d841a5c433b8d8aac2854981db4,respectively,0.585622
uuid-e3466d841a5c433b8d8aac2854981db4,Objective response rate,0.36976
uuid-e3466d841a5c433b8d8aac2854981db4,ORR,0.514781
uuid-e3466d841a5c433b8d8aac2854981db4,docetaxel,0.31274
uuid-cd649a1d24e8438cbea2c69ee5a90ca5,respectively,0.585622
uuid-cd649a1d24e8438cbea2c69ee5a90ca5,Objective response rate,0.36976
uuid-cd649a1d24e8438cbea2c69ee5a90ca5,ORR,0.514781
uuid-cd649a1d24e8438cbea2c69ee5a90ca5,docetaxel,0.31274
uuid-46cef931f03248ac973918e8c1ee5543,nivolumab,0.308696
uuid-46cef931f03248ac973918e8c1ee5543,respectively,0.474596
uuid-46cef931f03248ac973918e8c1ee5543,Objective response rate,0.398542
uuid-46cef931f03248ac973918e8c1ee5543,ORR,0.387529
uuid-46cef931f03248ac973918e8c1ee5543,monotherapy,0.618934
uuid-46cef931f03248ac973918e8c1ee5543,clinical,0.310702
uuid-46cef931f03248ac973918e8c1ee5543,Antonia SJ,0.303123
uuid-674b9ddc4295436b9c4d36b4264f39f4,relapsed,0.313685
uuid-76d7ba14f84f459da2b93b7855f20d67,N Engl J Med,0.604857
uuid-76d7ba14f84f459da2b93b7855f20d67,non-small cell lung cancer,0.34354
uuid-76d7ba14f84f459da2b93b7855f20d67,ESMO,0.393944
uuid-76d7ba14f84f459da2b93b7855f20d67,Rizvi NA,0.452745
uuid-76d7ba14f84f459da2b93b7855f20d67,Brahmer J,0.679154
uuid-76d7ba14f84f459da2b93b7855f20d67,PD-L1,0.347566
uuid-76d7ba14f84f459da2b93b7855f20d67,Horn L,0.50259
uuid-76d7ba14f84f459da2b93b7855f20d67,platinum-based doublet chemotherapy,0.304136
uuid-72d1681a42304bc081a3b9e71a19b390,evaluating,0.350845
uuid-72d1681a42304bc081a3b9e71a19b390,not conducted any controlled clinical trials/studies,0.345107
uuid-72d1681a42304bc081a3b9e71a19b390,search of published literature,0.385331
uuid-72d1681a42304bc081a3b9e71a19b390,Additionally,0.40981
uuid-72d1681a42304bc081a3b9e71a19b390,ongoing,0.457998
uuid-72d1681a42304bc081a3b9e71a19b390,PubMed and EMBASE,0.378285
uuid-72d1681a42304bc081a3b9e71a19b390,detailed search of www.clinicaltrials.gov,0.428522
uuid-72d1681a42304bc081a3b9e71a19b390,efficacy and safety of nivolumab,0.407868
uuid-72d1681a42304bc081a3b9e71a19b390,not identify any planned,0.444729
uuid-72d1681a42304bc081a3b9e71a19b390,combination,0.388252
uuid-72d1681a42304bc081a3b9e71a19b390,BMS,0.316104
uuid-72d1681a42304bc081a3b9e71a19b390,not identify any citations relevant to your request,0.438151
uuid-72d1681a42304bc081a3b9e71a19b390,present using the following search terms,0.377101
uuid-3f05dd90c9e74d6fb67ab6499e98a180,requested,0.594234
uuid-0062c63d6770435d90bc014b4edcd1cb,Bristol-Myers Squibb,0.32544
uuid-0062c63d6770435d90bc014b4edcd1cb,Opdivo,0.453665
uuid-0062c63d6770435d90bc014b4edcd1cb,Pubmed literature search,0.586867
uuid-0062c63d6770435d90bc014b4edcd1cb,purposes other than its labeled indication must be considered investigational,0.558798
uuid-0062c63d6770435d90bc014b4edcd1cb,not identify any citations relevant to your inquiry,0.580782
uuid-0062c63d6770435d90bc014b4edcd1cb,using the following search terms,0.616008
uuid-0062c63d6770435d90bc014b4edcd1cb,safety,0.360931
uuid-0062c63d6770435d90bc014b4edcd1cb,databases,0.383815
uuid-0062c63d6770435d90bc014b4edcd1cb,reported,0.54155
uuid-d17df3d193e8493196fd9eed96823e97,N Engl J Med,0.302601
uuid-d17df3d193e8493196fd9eed96823e97,AEs,0.348167
uuid-d17df3d193e8493196fd9eed96823e97,patients,0.536884
uuid-d17df3d193e8493196fd9eed96823e97,provided in the Detailed Information,0.387544
uuid-d17df3d193e8493196fd9eed96823e97,ESMO,0.462801
uuid-d17df3d193e8493196fd9eed96823e97,NEJM,0.66427
uuid-d17df3d193e8493196fd9eed96823e97,Topalian,0.692873
uuid-d17df3d193e8493196fd9eed96823e97,grade 3 to 4 AEs,0.626596
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,patients,0.319152
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,McDermott DF,0.374418
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,Motzer RJ,0.336603
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,Escudier B,0.335535
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,ASCO 2015,0.330848
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,NEJM,0.438584
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,et al.,0.333675
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,J Clin Oncol,0.406649
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,Topalian,0.437561
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,phase 1 study,0.436731
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,CA209-003,0.371186
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,phase 2 study,0.375862
uuid-b9c7a6e3981a4a8da75e8107a672f9ef,investigating,0.305192
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,N Engl J Med,0.616236
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,respectively,0.409266
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,ASCO,0.373445
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,ESMO,0.378373
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,Brahmer J,0.712806
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,docetaxel,0.327482
uuid-cf5a71f6c0894c5f8e698f6cb18c7a20,Horn L,0.502372
uuid-37051fec139f4eef8f6ba9242bccf9c2,N Engl J Med,0.616236
uuid-37051fec139f4eef8f6ba9242bccf9c2,respectively,0.409266
uuid-37051fec139f4eef8f6ba9242bccf9c2,ASCO,0.373445
uuid-37051fec139f4eef8f6ba9242bccf9c2,ESMO,0.378373
uuid-37051fec139f4eef8f6ba9242bccf9c2,Brahmer J,0.712806
uuid-37051fec139f4eef8f6ba9242bccf9c2,docetaxel,0.327482
uuid-37051fec139f4eef8f6ba9242bccf9c2,Horn L,0.502372
uuid-ed765d13fd184ff98539cf43081111af,OS,0.493666
uuid-ed765d13fd184ff98539cf43081111af,95% CI,0.872793
uuid-ed765d13fd184ff98539cf43081111af,respectively,0.581917
uuid-ed765d13fd184ff98539cf43081111af,Objective response rate,0.558489
uuid-ed765d13fd184ff98539cf43081111af,ORR,0.705401
uuid-ed765d13fd184ff98539cf43081111af,PFS,0.331929
uuid-ed765d13fd184ff98539cf43081111af,Median overall survival,0.793083
uuid-ed765d13fd184ff98539cf43081111af,monotherapy,0.422517
uuid-ed765d13fd184ff98539cf43081111af,Median OS,0.808565
uuid-ed765d13fd184ff98539cf43081111af,PD-L1,0.302111
uuid-ed765d13fd184ff98539cf43081111af,docetaxel,0.481228
uuid-ed765d13fd184ff98539cf43081111af,hazard ratio,0.844622
uuid-ed765d13fd184ff98539cf43081111af,Median duration of response,0.34536
uuid-bd3238eed69e4cb3982f96dcee903349,Bristol-Myers Squibb,0.341822
uuid-bd3238eed69e4cb3982f96dcee903349,not conducted any controlled clinical trials/studies,0.304507
uuid-bd3238eed69e4cb3982f96dcee903349,Opdivo,0.461382
uuid-bd3238eed69e4cb3982f96dcee903349,Pubmed literature search,0.614325
uuid-bd3238eed69e4cb3982f96dcee903349,purposes other than its labeled indication must be considered investigational,0.586645
uuid-bd3238eed69e4cb3982f96dcee903349,not identify any citations relevant to your inquiry,0.606087
uuid-bd3238eed69e4cb3982f96dcee903349,adverse,0.304183
uuid-bd3238eed69e4cb3982f96dcee903349,using the following search terms,0.642331
uuid-bd3238eed69e4cb3982f96dcee903349,databases,0.315039
uuid-bd3238eed69e4cb3982f96dcee903349,reported,0.556704
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,N Engl J Med,0.616236
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,respectively,0.409266
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,ASCO,0.373445
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,ESMO,0.378373
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,Brahmer J,0.712806
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,docetaxel,0.327482
uuid-3eb8511fc9b64d1ea5945ca66ef0341c,Horn L,0.502372
uuid-65e19c6073c9478b9145d10ce6493647,requested,0.729914
uuid-1c56a26ba26e4302bb913a008c53de9d,nivolumab,0.359772
uuid-b61e3bd7b6dc4e839836e64fe98add6c,requested,0.594234
uuid-ae55f6d504b543e5a547ea9764a6da3f,OS,0.328008
uuid-ae55f6d504b543e5a547ea9764a6da3f,N Engl J Med,0.560793
uuid-ae55f6d504b543e5a547ea9764a6da3f,95% CI,0.374482
uuid-ae55f6d504b543e5a547ea9764a6da3f,respectively,0.446091
uuid-ae55f6d504b543e5a547ea9764a6da3f,ASCO,0.344833
uuid-ae55f6d504b543e5a547ea9764a6da3f,ORR,0.387311
uuid-ae55f6d504b543e5a547ea9764a6da3f,Median overall survival,0.384473
uuid-ae55f6d504b543e5a547ea9764a6da3f,ESMO,0.360346
uuid-ae55f6d504b543e5a547ea9764a6da3f,Median OS,0.44499
uuid-ae55f6d504b543e5a547ea9764a6da3f,Brahmer J,0.656582
uuid-ae55f6d504b543e5a547ea9764a6da3f,docetaxel,0.348372
uuid-ae55f6d504b543e5a547ea9764a6da3f,Horn L,0.453326
uuid-ae55f6d504b543e5a547ea9764a6da3f,hazard ratio,0.341105
uuid-d17384e35b144241821a1027cc5996b3,OS,0.44149
uuid-d17384e35b144241821a1027cc5996b3,95% CI,0.833403
uuid-d17384e35b144241821a1027cc5996b3,ASCO,0.32927
uuid-d17384e35b144241821a1027cc5996b3,Objective response rate,0.545269
uuid-d17384e35b144241821a1027cc5996b3,ORR,0.618524
uuid-d17384e35b144241821a1027cc5996b3,PFS,0.396858
uuid-d17384e35b144241821a1027cc5996b3,Median overall survival,0.72593
uuid-d17384e35b144241821a1027cc5996b3,monotherapy,0.33356
uuid-d17384e35b144241821a1027cc5996b3,Median OS,0.763854
uuid-d17384e35b144241821a1027cc5996b3,hazard ratio,0.766648
uuid-d17384e35b144241821a1027cc5996b3,Median duration of response,0.442682
uuid-e78e738bdcef430ca44bbd25b53611c4,patients,0.319152
uuid-e78e738bdcef430ca44bbd25b53611c4,McDermott DF,0.374418
uuid-e78e738bdcef430ca44bbd25b53611c4,Motzer RJ,0.336603
uuid-e78e738bdcef430ca44bbd25b53611c4,Escudier B,0.335535
uuid-e78e738bdcef430ca44bbd25b53611c4,ASCO 2015,0.330848
uuid-e78e738bdcef430ca44bbd25b53611c4,NEJM,0.438584
uuid-e78e738bdcef430ca44bbd25b53611c4,et al.,0.333675
uuid-e78e738bdcef430ca44bbd25b53611c4,J Clin Oncol,0.406649
uuid-e78e738bdcef430ca44bbd25b53611c4,Topalian,0.437561
uuid-e78e738bdcef430ca44bbd25b53611c4,phase 1 study,0.436731
uuid-e78e738bdcef430ca44bbd25b53611c4,CA209-003,0.371186
uuid-e78e738bdcef430ca44bbd25b53611c4,phase 2 study,0.375862
uuid-e78e738bdcef430ca44bbd25b53611c4,investigating,0.305192
uuid-66891469d7464b81895e3f27bc88472d,Bristol-Myers Squibb,0.341822
uuid-66891469d7464b81895e3f27bc88472d,not conducted any controlled clinical trials/studies,0.304507
uuid-66891469d7464b81895e3f27bc88472d,Opdivo,0.461382
uuid-66891469d7464b81895e3f27bc88472d,Pubmed literature search,0.614325
uuid-66891469d7464b81895e3f27bc88472d,purposes other than its labeled indication must be considered investigational,0.586645
uuid-66891469d7464b81895e3f27bc88472d,not identify any citations relevant to your inquiry,0.606087
uuid-66891469d7464b81895e3f27bc88472d,adverse,0.304183
uuid-66891469d7464b81895e3f27bc88472d,using the following search terms,0.642331
uuid-66891469d7464b81895e3f27bc88472d,databases,0.315039
uuid-66891469d7464b81895e3f27bc88472d,reported,0.556704
uuid-78145872930e4090971912cf0eacf752,adverse,0.677734
uuid-78145872930e4090971912cf0eacf752,phase 3 study,0.48003
uuid-78145872930e4090971912cf0eacf752,melanoma,0.411352
uuid-78145872930e4090971912cf0eacf752,Weber JS,0.31904
uuid-78145872930e4090971912cf0eacf752,phase 2 study,0.319618
uuid-78145872930e4090971912cf0eacf752,reported,0.343242
uuid-bb51b2cf808a4cbb823bfdb82eaf0abb,Bristol-Myers Squibb,0.342325
uuid-bb51b2cf808a4cbb823bfdb82eaf0abb,requested,0.460083
uuid-f884364925dd4932921475dc295b4c06,nivolumab,0.311465
uuid-f884364925dd4932921475dc295b4c06,Bristol-Myers Squibb,0.557858
uuid-f884364925dd4932921475dc295b4c06,evaluating,0.719375
uuid-f884364925dd4932921475dc295b4c06,not conducted any controlled clinical trials/studies,0.718252
uuid-f884364925dd4932921475dc295b4c06,RCC,0.320789
uuid-f884364925dd4932921475dc295b4c06,search of published literature,0.73188
uuid-f884364925dd4932921475dc295b4c06,PubMed and EMBASE,0.704554
uuid-f884364925dd4932921475dc295b4c06,efficacy and safety of nivolumab,0.845311
uuid-f884364925dd4932921475dc295b4c06,not identify any citations relevant to your request,0.406415
uuid-f884364925dd4932921475dc295b4c06,present using the following search terms,0.695497
uuid-681968244105492e9e34a2c525e70281,nivolumab,0.373728
uuid-cc81203ce83f4e37965dec1d36969ae1,nivolumab,0.479003
uuid-dadb04841d764f588dbc14ac0d7a994c,Bristol-Myers Squibb,0.341822
uuid-dadb04841d764f588dbc14ac0d7a994c,not conducted any controlled clinical trials/studies,0.304507
uuid-dadb04841d764f588dbc14ac0d7a994c,Opdivo,0.461382
uuid-dadb04841d764f588dbc14ac0d7a994c,Pubmed literature search,0.614325
uuid-dadb04841d764f588dbc14ac0d7a994c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-dadb04841d764f588dbc14ac0d7a994c,not identify any citations relevant to your inquiry,0.606087
uuid-dadb04841d764f588dbc14ac0d7a994c,adverse,0.304183
uuid-dadb04841d764f588dbc14ac0d7a994c,using the following search terms,0.642331
uuid-dadb04841d764f588dbc14ac0d7a994c,databases,0.315039
uuid-dadb04841d764f588dbc14ac0d7a994c,reported,0.556704
uuid-93d7eddbea3544b385bc6747c79a507b,Bristol-Myers Squibb,0.833664
uuid-93d7eddbea3544b385bc6747c79a507b,evaluating,0.641694
uuid-93d7eddbea3544b385bc6747c79a507b,not conducted any controlled clinical trials/studies,0.743143
uuid-93d7eddbea3544b385bc6747c79a507b,patients,0.319402
uuid-93d7eddbea3544b385bc6747c79a507b,considered investigational,0.336601
uuid-93d7eddbea3544b385bc6747c79a507b,efficacy and safety of nivolumab,0.561214
uuid-9e773eaeecfd48349740b5a3f2a35eda,Bristol-Myers Squibb,0.341822
uuid-9e773eaeecfd48349740b5a3f2a35eda,not conducted any controlled clinical trials/studies,0.304507
uuid-9e773eaeecfd48349740b5a3f2a35eda,Opdivo,0.461382
uuid-9e773eaeecfd48349740b5a3f2a35eda,Pubmed literature search,0.614325
uuid-9e773eaeecfd48349740b5a3f2a35eda,purposes other than its labeled indication must be considered investigational,0.586645
uuid-9e773eaeecfd48349740b5a3f2a35eda,not identify any citations relevant to your inquiry,0.606087
uuid-9e773eaeecfd48349740b5a3f2a35eda,adverse,0.304183
uuid-9e773eaeecfd48349740b5a3f2a35eda,using the following search terms,0.642331
uuid-9e773eaeecfd48349740b5a3f2a35eda,databases,0.315039
uuid-9e773eaeecfd48349740b5a3f2a35eda,reported,0.556704
uuid-fc2ef2bb70cc464d84997674f9e8a811,OS,0.493666
uuid-fc2ef2bb70cc464d84997674f9e8a811,95% CI,0.872793
uuid-fc2ef2bb70cc464d84997674f9e8a811,respectively,0.581917
uuid-fc2ef2bb70cc464d84997674f9e8a811,Objective response rate,0.558489
uuid-fc2ef2bb70cc464d84997674f9e8a811,ORR,0.705401
uuid-fc2ef2bb70cc464d84997674f9e8a811,PFS,0.331929
uuid-fc2ef2bb70cc464d84997674f9e8a811,Median overall survival,0.793083
uuid-fc2ef2bb70cc464d84997674f9e8a811,monotherapy,0.422517
uuid-fc2ef2bb70cc464d84997674f9e8a811,Median OS,0.808565
uuid-fc2ef2bb70cc464d84997674f9e8a811,PD-L1,0.302111
uuid-fc2ef2bb70cc464d84997674f9e8a811,docetaxel,0.481228
uuid-fc2ef2bb70cc464d84997674f9e8a811,hazard ratio,0.844622
uuid-fc2ef2bb70cc464d84997674f9e8a811,Median duration of response,0.34536
uuid-c938596390864d429f15646feceebad2,mg,0.308816
uuid-22f15e720df84f9bb822212ae346141d,95% CI,0.39545
uuid-22f15e720df84f9bb822212ae346141d,respectively,0.599632
uuid-22f15e720df84f9bb822212ae346141d,ASCO,0.363631
uuid-22f15e720df84f9bb822212ae346141d,Objective response rate,0.61752
uuid-22f15e720df84f9bb822212ae346141d,ORR,0.58547
uuid-22f15e720df84f9bb822212ae346141d,Median overall survival,0.373642
uuid-22f15e720df84f9bb822212ae346141d,monotherapy,0.411011
uuid-22f15e720df84f9bb822212ae346141d,Median OS,0.3895
uuid-22f15e720df84f9bb822212ae346141d,docetaxel,0.35961
uuid-22f15e720df84f9bb822212ae346141d,Antonia SJ,0.311246
uuid-22f15e720df84f9bb822212ae346141d,hazard ratio,0.366284
uuid-70a97e311891491c9c287e18e02051ac,nivolumab,0.483711
uuid-70a97e311891491c9c287e18e02051ac,Bristol-Myers Squibb,0.523782
uuid-70a97e311891491c9c287e18e02051ac,evaluating,0.579102
uuid-70a97e311891491c9c287e18e02051ac,not conducted any controlled clinical trials/studies,0.601074
uuid-70a97e311891491c9c287e18e02051ac,search of published literature,0.514025
uuid-70a97e311891491c9c287e18e02051ac,Additionally,0.517821
uuid-70a97e311891491c9c287e18e02051ac,ongoing,0.446625
uuid-70a97e311891491c9c287e18e02051ac,PubMed and EMBASE,0.496568
uuid-70a97e311891491c9c287e18e02051ac,detailed search of www.clinicaltrials.gov,0.490665
uuid-70a97e311891491c9c287e18e02051ac,efficacy and safety of nivolumab,0.652336
uuid-70a97e311891491c9c287e18e02051ac,not identify any planned,0.458068
uuid-70a97e311891491c9c287e18e02051ac,not identify any citations relevant to your request,0.566853
uuid-70a97e311891491c9c287e18e02051ac,present using the following search terms,0.519463
uuid-ced57027ec9d44b286e2b16cb49a5d99,search of published literature,0.394524
uuid-ced57027ec9d44b286e2b16cb49a5d99,Additionally,0.413583
uuid-ced57027ec9d44b286e2b16cb49a5d99,ongoing,0.322117
uuid-ced57027ec9d44b286e2b16cb49a5d99,PubMed and EMBASE,0.391671
uuid-ced57027ec9d44b286e2b16cb49a5d99,detailed search of www.clinicaltrials.gov,0.375936
uuid-ced57027ec9d44b286e2b16cb49a5d99,efficacy and safety of nivolumab,0.370699
uuid-ced57027ec9d44b286e2b16cb49a5d99,not identify any planned,0.34283
uuid-ced57027ec9d44b286e2b16cb49a5d99,Weber JS,0.319229
uuid-ced57027ec9d44b286e2b16cb49a5d99,not identify any citations relevant to your request,0.447813
uuid-ced57027ec9d44b286e2b16cb49a5d99,present using the following search terms,0.408199
uuid-792e192d0abc4b1a85e73da7946a6210,OS,0.493666
uuid-792e192d0abc4b1a85e73da7946a6210,95% CI,0.872793
uuid-792e192d0abc4b1a85e73da7946a6210,respectively,0.581917
uuid-792e192d0abc4b1a85e73da7946a6210,Objective response rate,0.558489
uuid-792e192d0abc4b1a85e73da7946a6210,ORR,0.705401
uuid-792e192d0abc4b1a85e73da7946a6210,PFS,0.331929
uuid-792e192d0abc4b1a85e73da7946a6210,Median overall survival,0.793083
uuid-792e192d0abc4b1a85e73da7946a6210,monotherapy,0.422517
uuid-792e192d0abc4b1a85e73da7946a6210,Median OS,0.808565
uuid-792e192d0abc4b1a85e73da7946a6210,PD-L1,0.302111
uuid-792e192d0abc4b1a85e73da7946a6210,docetaxel,0.481228
uuid-792e192d0abc4b1a85e73da7946a6210,hazard ratio,0.844622
uuid-792e192d0abc4b1a85e73da7946a6210,Median duration of response,0.34536
uuid-c2c734059c7c43898fa8fa4cb6280f45,Bristol-Myers Squibb,0.385062
uuid-c2c734059c7c43898fa8fa4cb6280f45,evaluating,0.564052
uuid-c2c734059c7c43898fa8fa4cb6280f45,not conducted any controlled clinical trials/studies,0.578116
uuid-c2c734059c7c43898fa8fa4cb6280f45,patients,0.421906
uuid-c2c734059c7c43898fa8fa4cb6280f45,considered investigational,0.319169
uuid-c2c734059c7c43898fa8fa4cb6280f45,Pubmed literature search,0.318114
uuid-c2c734059c7c43898fa8fa4cb6280f45,purposes other than its labeled indication must be considered investigational,0.410893
uuid-c2c734059c7c43898fa8fa4cb6280f45,efficacy and safety of nivolumab,0.486867
uuid-c35c698cfc194422a180c3d829279d42,provided in the Detailed Information,0.578509
uuid-c35c698cfc194422a180c3d829279d42,clinical,0.470357
uuid-387a1b3f6c73464cb85a776cb2d77cc2,respectively,0.585622
uuid-387a1b3f6c73464cb85a776cb2d77cc2,Objective response rate,0.36976
uuid-387a1b3f6c73464cb85a776cb2d77cc2,ORR,0.514781
uuid-387a1b3f6c73464cb85a776cb2d77cc2,docetaxel,0.31274
uuid-8b2ed4ceda92449c93b305172b9e6a72,nivolumab,0.707292
uuid-8b2ed4ceda92449c93b305172b9e6a72,evaluating,0.302866
uuid-8b2ed4ceda92449c93b305172b9e6a72,not conducted any controlled clinical trials/studies,0.327149
uuid-8b2ed4ceda92449c93b305172b9e6a72,patients,0.31482
uuid-8b2ed4ceda92449c93b305172b9e6a72,considered investigational,0.425551
uuid-8b2ed4ceda92449c93b305172b9e6a72,purposes other than its labeled indication must be considered investigational,0.360627
uuid-8b2ed4ceda92449c93b305172b9e6a72,tumors,0.365148
uuid-8b2ed4ceda92449c93b305172b9e6a72,small cell lung cancer,0.393104
uuid-8b2ed4ceda92449c93b305172b9e6a72,SCLC,0.365028
uuid-8b2ed4ceda92449c93b305172b9e6a72,phase 1/2 study CA209-032,0.37128
uuid-8b2ed4ceda92449c93b305172b9e6a72,evaluates the efficacy of nivolumab monotherapy,0.353148
uuid-040505cb28ca4d34898fbb74f20fca7b,search of published literature,0.394524
uuid-040505cb28ca4d34898fbb74f20fca7b,Additionally,0.413583
uuid-040505cb28ca4d34898fbb74f20fca7b,ongoing,0.322117
uuid-040505cb28ca4d34898fbb74f20fca7b,PubMed and EMBASE,0.391671
uuid-040505cb28ca4d34898fbb74f20fca7b,detailed search of www.clinicaltrials.gov,0.375936
uuid-040505cb28ca4d34898fbb74f20fca7b,efficacy and safety of nivolumab,0.370699
uuid-040505cb28ca4d34898fbb74f20fca7b,not identify any planned,0.34283
uuid-040505cb28ca4d34898fbb74f20fca7b,Weber JS,0.319229
uuid-040505cb28ca4d34898fbb74f20fca7b,not identify any citations relevant to your request,0.447813
uuid-040505cb28ca4d34898fbb74f20fca7b,present using the following search terms,0.408199
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,N Engl J Med,0.495649
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,protocol,0.736971
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,McDermott DF,0.762108
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,Motzer RJ,0.773565
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,phase 3 study,0.454434
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,Escudier B,0.763658
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,NEJM,0.4325
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,et al.,0.712875
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,J Clin Oncol,0.738632
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,Topalian,0.412144
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,Rizvi NA,0.375979
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,Weber JS,0.324917
uuid-7b9ff378e4ca4d35bf04af51dcb6bcf4,phase 2 study,0.660323
uuid-f76301f1faab4149847bbdde4f6ea39d,OS,0.493666
uuid-f76301f1faab4149847bbdde4f6ea39d,95% CI,0.872793
uuid-f76301f1faab4149847bbdde4f6ea39d,respectively,0.581917
uuid-f76301f1faab4149847bbdde4f6ea39d,Objective response rate,0.558489
uuid-f76301f1faab4149847bbdde4f6ea39d,ORR,0.705401
uuid-f76301f1faab4149847bbdde4f6ea39d,PFS,0.331929
uuid-f76301f1faab4149847bbdde4f6ea39d,Median overall survival,0.793083
uuid-f76301f1faab4149847bbdde4f6ea39d,monotherapy,0.422517
uuid-f76301f1faab4149847bbdde4f6ea39d,Median OS,0.808565
uuid-f76301f1faab4149847bbdde4f6ea39d,PD-L1,0.302111
uuid-f76301f1faab4149847bbdde4f6ea39d,docetaxel,0.481228
uuid-f76301f1faab4149847bbdde4f6ea39d,hazard ratio,0.844622
uuid-f76301f1faab4149847bbdde4f6ea39d,Median duration of response,0.34536
uuid-e55a4b0b5c84414d9e3038fdeefac338,Bristol-Myers Squibb,0.342325
uuid-e55a4b0b5c84414d9e3038fdeefac338,requested,0.460083
uuid-2a68efec28234f8eb35ce2a2b6a111e2,ASCO,0.581281
uuid-2a68efec28234f8eb35ce2a2b6a111e2,requested,0.306406
uuid-343c088d987b4c22b22d26825b0123a4,provided in the Detailed Information,0.381244
uuid-343c088d987b4c22b22d26825b0123a4,adverse,0.305047
uuid-a48e301cfdaa4fa384819efa78b723a2,nivolumab,0.520171
uuid-a48e301cfdaa4fa384819efa78b723a2,RCC,0.314891
uuid-a48e301cfdaa4fa384819efa78b723a2,NEJM,0.388811
uuid-a48e301cfdaa4fa384819efa78b723a2,Topalian,0.390018
uuid-8cce366817b24cc399aba60236f91702,patients,0.41765
uuid-8cce366817b24cc399aba60236f91702,Opdivo,0.325832
uuid-8cce366817b24cc399aba60236f91702,trial,0.34029
uuid-8cce366817b24cc399aba60236f91702,docetaxel,0.414244
uuid-68e266dddf41405f8b2c380a592674e9,requested,0.729914
uuid-49e7c095b4bb498d87fc52559ab2cdfb,RCC,0.726365
uuid-49e7c095b4bb498d87fc52559ab2cdfb,phase 1 study,0.331087
uuid-49e7c095b4bb498d87fc52559ab2cdfb,CA209-003,0.392514
uuid-49e7c095b4bb498d87fc52559ab2cdfb,investigating,0.594853
uuid-0472f7f21ae2481782cdc12eaed5fea1,N Engl J Med,0.427636
uuid-0472f7f21ae2481782cdc12eaed5fea1,protocol,0.429136
uuid-0472f7f21ae2481782cdc12eaed5fea1,McDermott DF,0.44782
uuid-0472f7f21ae2481782cdc12eaed5fea1,Motzer RJ,0.430476
uuid-0472f7f21ae2481782cdc12eaed5fea1,Escudier B,0.450887
uuid-0472f7f21ae2481782cdc12eaed5fea1,et al.,0.456026
uuid-0472f7f21ae2481782cdc12eaed5fea1,J Clin Oncol,0.384624
uuid-0472f7f21ae2481782cdc12eaed5fea1,Rizvi NA,0.305616
uuid-0472f7f21ae2481782cdc12eaed5fea1,phase 2 study,0.351446
uuid-baa62f2ed3964f2d8bb5e20e6454d6cc,requested,0.594234
uuid-7fd64ec06f904a7cbb4d13af2041aea6,requested,0.594234
uuid-f1e5e4ad82df4d51a661369df086ddf9,N Engl J Med,0.616236
uuid-f1e5e4ad82df4d51a661369df086ddf9,respectively,0.409266
uuid-f1e5e4ad82df4d51a661369df086ddf9,ASCO,0.373445
uuid-f1e5e4ad82df4d51a661369df086ddf9,ESMO,0.378373
uuid-f1e5e4ad82df4d51a661369df086ddf9,Brahmer J,0.712806
uuid-f1e5e4ad82df4d51a661369df086ddf9,docetaxel,0.327482
uuid-f1e5e4ad82df4d51a661369df086ddf9,Horn L,0.502372
uuid-7c22f6121111402f8f1995c587740911,OS,0.349054
uuid-7c22f6121111402f8f1995c587740911,95% CI,0.696869
uuid-7c22f6121111402f8f1995c587740911,respectively,0.747405
uuid-7c22f6121111402f8f1995c587740911,Objective response rate,0.596478
uuid-7c22f6121111402f8f1995c587740911,ORR,0.7237
uuid-7c22f6121111402f8f1995c587740911,Median overall survival,0.628269
uuid-7c22f6121111402f8f1995c587740911,monotherapy,0.48503
uuid-7c22f6121111402f8f1995c587740911,Median OS,0.660506
uuid-7c22f6121111402f8f1995c587740911,PD-L1,0.403686
uuid-7c22f6121111402f8f1995c587740911,docetaxel,0.487238
uuid-7c22f6121111402f8f1995c587740911,hazard ratio,0.689448
uuid-ea9537a4495a418b9784bd87c15d7736,N Engl J Med,0.616236
uuid-ea9537a4495a418b9784bd87c15d7736,respectively,0.409266
uuid-ea9537a4495a418b9784bd87c15d7736,ASCO,0.373445
uuid-ea9537a4495a418b9784bd87c15d7736,ESMO,0.378373
uuid-ea9537a4495a418b9784bd87c15d7736,Brahmer J,0.712806
uuid-ea9537a4495a418b9784bd87c15d7736,docetaxel,0.327482
uuid-ea9537a4495a418b9784bd87c15d7736,Horn L,0.502372
uuid-3c96bb4fa05f4fc5bc7dda88d55e0e4f,provided in the Detailed Information,0.312183
uuid-3c96bb4fa05f4fc5bc7dda88d55e0e4f,adverse,0.461131
uuid-52c06864445a42749b8318d45c1bc8c1,N Engl J Med,0.427636
uuid-52c06864445a42749b8318d45c1bc8c1,protocol,0.429136
uuid-52c06864445a42749b8318d45c1bc8c1,McDermott DF,0.44782
uuid-52c06864445a42749b8318d45c1bc8c1,Motzer RJ,0.430476
uuid-52c06864445a42749b8318d45c1bc8c1,Escudier B,0.450887
uuid-52c06864445a42749b8318d45c1bc8c1,et al.,0.456026
uuid-52c06864445a42749b8318d45c1bc8c1,J Clin Oncol,0.384624
uuid-52c06864445a42749b8318d45c1bc8c1,Rizvi NA,0.305616
uuid-52c06864445a42749b8318d45c1bc8c1,phase 2 study,0.351446
uuid-29a4541fa6ea456aac4e5be7e243d3fc,ESMO,0.454789
uuid-523ac886c64948dfaa11b87d6a5da69a,OS,0.349054
uuid-523ac886c64948dfaa11b87d6a5da69a,95% CI,0.696869
uuid-523ac886c64948dfaa11b87d6a5da69a,respectively,0.747405
uuid-523ac886c64948dfaa11b87d6a5da69a,Objective response rate,0.596478
uuid-523ac886c64948dfaa11b87d6a5da69a,ORR,0.7237
uuid-523ac886c64948dfaa11b87d6a5da69a,Median overall survival,0.628269
uuid-523ac886c64948dfaa11b87d6a5da69a,monotherapy,0.48503
uuid-523ac886c64948dfaa11b87d6a5da69a,Median OS,0.660506
uuid-523ac886c64948dfaa11b87d6a5da69a,PD-L1,0.403686
uuid-523ac886c64948dfaa11b87d6a5da69a,docetaxel,0.487238
uuid-523ac886c64948dfaa11b87d6a5da69a,hazard ratio,0.689448
uuid-3fb5d229c31746768505cc10749c4ed1,OS,0.509836
uuid-3fb5d229c31746768505cc10749c4ed1,95% CI,0.885542
uuid-3fb5d229c31746768505cc10749c4ed1,respectively,0.545209
uuid-3fb5d229c31746768505cc10749c4ed1,Objective response rate,0.620141
uuid-3fb5d229c31746768505cc10749c4ed1,ORR,0.779562
uuid-3fb5d229c31746768505cc10749c4ed1,PFS,0.376589
uuid-3fb5d229c31746768505cc10749c4ed1,Median overall survival,0.832465
uuid-3fb5d229c31746768505cc10749c4ed1,monotherapy,0.463383
uuid-3fb5d229c31746768505cc10749c4ed1,Median OS,0.798069
uuid-3fb5d229c31746768505cc10749c4ed1,docetaxel,0.352661
uuid-3fb5d229c31746768505cc10749c4ed1,hazard ratio,0.858121
uuid-3fb5d229c31746768505cc10749c4ed1,Median duration of response,0.35267
uuid-fb34f12b1e024c78b2963c20bb0f3629,requested,0.729914
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,evaluating,0.340112
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,N Engl J Med,0.342891
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,not conducted any controlled clinical trials/studies,0.330585
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,protocol,0.593107
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,RCC,0.37328
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,McDermott DF,0.513758
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,search of published literature,0.497209
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,Additionally,0.394025
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,ongoing,0.32103
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,Motzer RJ,0.543717
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,PubMed and EMBASE,0.491332
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,Escudier B,0.532255
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,et al.,0.469374
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,J Clin Oncol,0.482
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,detailed search of www.clinicaltrials.gov,0.348817
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,efficacy and safety of nivolumab,0.482969
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,not identify any planned,0.328696
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,phase 2 study,0.463461
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,not identify any citations relevant to your request,0.438349
uuid-4310349c8f6e4f5ca978e35e4fb2e1a5,present using the following search terms,0.478705
uuid-d9d3d3be5ec54c59890b664126d50b11,requested,0.729914
uuid-82be08ff34c6487a9bc0b26de1b64042,requested,0.594234
uuid-72889d2796ae44b58e547f0f56dd12f0,requested,0.599332
uuid-5c8eec7c35a64a85b5a52498e655fec3,respectively,0.629961
uuid-5c8eec7c35a64a85b5a52498e655fec3,Objective response rate,0.439951
uuid-5c8eec7c35a64a85b5a52498e655fec3,ORR,0.462322
uuid-5c8eec7c35a64a85b5a52498e655fec3,monotherapy,0.352421
uuid-5c8eec7c35a64a85b5a52498e655fec3,docetaxel,0.410479
uuid-10f966b9eb9b44dcad4ef35ed29077f0,nivolumab,0.334557
uuid-10f966b9eb9b44dcad4ef35ed29077f0,Bristol-Myers Squibb,0.40134
uuid-10f966b9eb9b44dcad4ef35ed29077f0,evaluating,0.609226
uuid-10f966b9eb9b44dcad4ef35ed29077f0,not conducted any controlled clinical trials/studies,0.581898
uuid-10f966b9eb9b44dcad4ef35ed29077f0,RCC,0.33549
uuid-10f966b9eb9b44dcad4ef35ed29077f0,search of published literature,0.713859
uuid-10f966b9eb9b44dcad4ef35ed29077f0,Additionally,0.732049
uuid-10f966b9eb9b44dcad4ef35ed29077f0,ongoing,0.62631
uuid-10f966b9eb9b44dcad4ef35ed29077f0,PubMed and EMBASE,0.704864
uuid-10f966b9eb9b44dcad4ef35ed29077f0,detailed search of www.clinicaltrials.gov,0.705377
uuid-10f966b9eb9b44dcad4ef35ed29077f0,efficacy and safety of nivolumab,0.724176
uuid-10f966b9eb9b44dcad4ef35ed29077f0,not identify any planned,0.654881
uuid-10f966b9eb9b44dcad4ef35ed29077f0,not identify any citations relevant to your request,0.805459
uuid-10f966b9eb9b44dcad4ef35ed29077f0,present using the following search terms,0.726587
uuid-90d771148d504c218be4833b4db3e0e1,not approved,0.389731
uuid-90d771148d504c218be4833b4db3e0e1,clinical trials investigating the safety,0.464336
uuid-90d771148d504c218be4833b4db3e0e1,fatigue,0.389752
uuid-acd99c276ac544c4a972179e9e9a4153,requested,0.662269
uuid-05b3461b967544a18f22bbab3dd286cd,requested,0.595565
uuid-3cad39d541ba4006b13fe89908fce886,nivolumab,0.43643
uuid-356176d874ea441ab52ca4b71e7d8d3a,N Engl J Med,0.604857
uuid-356176d874ea441ab52ca4b71e7d8d3a,non-small cell lung cancer,0.34354
uuid-356176d874ea441ab52ca4b71e7d8d3a,ESMO,0.393944
uuid-356176d874ea441ab52ca4b71e7d8d3a,Rizvi NA,0.452745
uuid-356176d874ea441ab52ca4b71e7d8d3a,Brahmer J,0.679154
uuid-356176d874ea441ab52ca4b71e7d8d3a,PD-L1,0.347566
uuid-356176d874ea441ab52ca4b71e7d8d3a,Horn L,0.50259
uuid-356176d874ea441ab52ca4b71e7d8d3a,platinum-based doublet chemotherapy,0.304136
uuid-885c3c33c1ca4b85b4954c92aa79c02e,N Engl J Med,0.442834
uuid-885c3c33c1ca4b85b4954c92aa79c02e,protocol,0.763252
uuid-885c3c33c1ca4b85b4954c92aa79c02e,McDermott DF,0.733103
uuid-885c3c33c1ca4b85b4954c92aa79c02e,Motzer RJ,0.811057
uuid-885c3c33c1ca4b85b4954c92aa79c02e,phase 3 study,0.420895
uuid-885c3c33c1ca4b85b4954c92aa79c02e,Escudier B,0.741048
uuid-885c3c33c1ca4b85b4954c92aa79c02e,NEJM,0.402544
uuid-885c3c33c1ca4b85b4954c92aa79c02e,et al.,0.660398
uuid-885c3c33c1ca4b85b4954c92aa79c02e,J Clin Oncol,0.786367
uuid-885c3c33c1ca4b85b4954c92aa79c02e,Topalian,0.392395
uuid-885c3c33c1ca4b85b4954c92aa79c02e,phase 1 study,0.513779
uuid-885c3c33c1ca4b85b4954c92aa79c02e,CA209-003,0.583337
uuid-885c3c33c1ca4b85b4954c92aa79c02e,phase 2 study,0.675447
uuid-885c3c33c1ca4b85b4954c92aa79c02e,present using the following search terms,0.304589
uuid-885c3c33c1ca4b85b4954c92aa79c02e,investigating,0.633101
uuid-e2bebdd6bdca49f9b35ac2d184605919,respectively,0.585622
uuid-e2bebdd6bdca49f9b35ac2d184605919,Objective response rate,0.36976
uuid-e2bebdd6bdca49f9b35ac2d184605919,ORR,0.514781
uuid-e2bebdd6bdca49f9b35ac2d184605919,docetaxel,0.31274
uuid-0988f3f85e8c4f159a27f62ad379b925,95% CI,0.524855
uuid-0988f3f85e8c4f159a27f62ad379b925,respectively,0.383655
uuid-0988f3f85e8c4f159a27f62ad379b925,ASCO,0.303153
uuid-0988f3f85e8c4f159a27f62ad379b925,Lancet Oncol,0.368041
uuid-0988f3f85e8c4f159a27f62ad379b925,Objective response rate,0.504846
uuid-0988f3f85e8c4f159a27f62ad379b925,ORR,0.465366
uuid-0988f3f85e8c4f159a27f62ad379b925,Median overall survival,0.346516
uuid-0988f3f85e8c4f159a27f62ad379b925,Median OS,0.33538
uuid-0988f3f85e8c4f159a27f62ad379b925,ASCO 2015,0.336983
uuid-0988f3f85e8c4f159a27f62ad379b925,small cell lung cancer,0.336892
uuid-0988f3f85e8c4f159a27f62ad379b925,SCLC,0.344367
uuid-0988f3f85e8c4f159a27f62ad379b925,Antonia SJ,0.55269
uuid-0988f3f85e8c4f159a27f62ad379b925,Median duration of response,0.649605
uuid-1526d694dacc4d22bc33324badd96f9f,nivolumab,0.567915
uuid-1526d694dacc4d22bc33324badd96f9f,Bristol-Myers Squibb,0.440616
uuid-1526d694dacc4d22bc33324badd96f9f,evaluating,0.595756
uuid-1526d694dacc4d22bc33324badd96f9f,not conducted any controlled clinical trials/studies,0.65735
uuid-1526d694dacc4d22bc33324badd96f9f,Pubmed literature search,0.878124
uuid-1526d694dacc4d22bc33324badd96f9f,purposes other than its labeled indication must be considered investigational,0.941032
uuid-1526d694dacc4d22bc33324badd96f9f,not identify any citations relevant to your inquiry,0.837002
uuid-1526d694dacc4d22bc33324badd96f9f,using the following search terms,0.824766
uuid-1526d694dacc4d22bc33324badd96f9f,efficacy and safety of nivolumab,0.434019
uuid-5fcec47d2c1d494e9b3c84ad7e35c142,requested,0.580238
uuid-f1626da9407749658179d6699217979a,95% CI,0.539167
uuid-f1626da9407749658179d6699217979a,Median overall survival,0.479815
uuid-f1626da9407749658179d6699217979a,protocol,0.426554
uuid-f1626da9407749658179d6699217979a,McDermott DF,0.500131
uuid-f1626da9407749658179d6699217979a,Motzer RJ,0.477178
uuid-f1626da9407749658179d6699217979a,Median OS,0.603398
uuid-f1626da9407749658179d6699217979a,Escudier B,0.469696
uuid-f1626da9407749658179d6699217979a,NEJM,0.387615
uuid-f1626da9407749658179d6699217979a,et al.,0.46851
uuid-f1626da9407749658179d6699217979a,J Clin Oncol,0.51661
uuid-f1626da9407749658179d6699217979a,Topalian,0.337057
uuid-f1626da9407749658179d6699217979a,phase 2 study,0.399402
uuid-f1626da9407749658179d6699217979a,hazard ratio,0.538097
uuid-9eb6a7a83a5c4450aa07e05eed54308e,OS,0.349054
uuid-9eb6a7a83a5c4450aa07e05eed54308e,95% CI,0.696869
uuid-9eb6a7a83a5c4450aa07e05eed54308e,respectively,0.747405
uuid-9eb6a7a83a5c4450aa07e05eed54308e,Objective response rate,0.596478
uuid-9eb6a7a83a5c4450aa07e05eed54308e,ORR,0.7237
uuid-9eb6a7a83a5c4450aa07e05eed54308e,Median overall survival,0.628269
uuid-9eb6a7a83a5c4450aa07e05eed54308e,monotherapy,0.48503
uuid-9eb6a7a83a5c4450aa07e05eed54308e,Median OS,0.660506
uuid-9eb6a7a83a5c4450aa07e05eed54308e,PD-L1,0.403686
uuid-9eb6a7a83a5c4450aa07e05eed54308e,docetaxel,0.487238
uuid-9eb6a7a83a5c4450aa07e05eed54308e,hazard ratio,0.689448
uuid-3d159fb465b34d7d9eb2bdd48af4c9a1,provided in the Detailed Information,0.578509
uuid-3d159fb465b34d7d9eb2bdd48af4c9a1,clinical,0.470357
uuid-9e7b5fdb71094b539c90647879ed4883,N Engl J Med,0.535286
uuid-9e7b5fdb71094b539c90647879ed4883,Lancet Oncol,0.364361
uuid-9e7b5fdb71094b539c90647879ed4883,protocol,0.50442
uuid-9e7b5fdb71094b539c90647879ed4883,McDermott DF,0.548182
uuid-9e7b5fdb71094b539c90647879ed4883,Motzer RJ,0.532741
uuid-9e7b5fdb71094b539c90647879ed4883,phase 3 study,0.493197
uuid-9e7b5fdb71094b539c90647879ed4883,Escudier B,0.547344
uuid-9e7b5fdb71094b539c90647879ed4883,et al.,0.519366
uuid-9e7b5fdb71094b539c90647879ed4883,J Clin Oncol,0.509597
uuid-9e7b5fdb71094b539c90647879ed4883,Rizvi NA,0.478602
uuid-9e7b5fdb71094b539c90647879ed4883,Brahmer J,0.338223
uuid-9e7b5fdb71094b539c90647879ed4883,Weber JS,0.370952
uuid-9e7b5fdb71094b539c90647879ed4883,phase 2 study,0.591434
uuid-fa76235ae0d0496cb90111b74877fbb4,N Engl J Med,0.616236
uuid-fa76235ae0d0496cb90111b74877fbb4,respectively,0.409266
uuid-fa76235ae0d0496cb90111b74877fbb4,ASCO,0.373445
uuid-fa76235ae0d0496cb90111b74877fbb4,ESMO,0.378373
uuid-fa76235ae0d0496cb90111b74877fbb4,Brahmer J,0.712806
uuid-fa76235ae0d0496cb90111b74877fbb4,docetaxel,0.327482
uuid-fa76235ae0d0496cb90111b74877fbb4,Horn L,0.502372
uuid-631b89bf8a2b4fcf96587078dc3e6c5d,evaluating,0.311085
uuid-631b89bf8a2b4fcf96587078dc3e6c5d,not conducted any controlled clinical trials/studies,0.305521
uuid-631b89bf8a2b4fcf96587078dc3e6c5d,safety,0.439253
uuid-631b89bf8a2b4fcf96587078dc3e6c5d,databases,0.451966
uuid-e11bb93a8e6542b98f438c6800934e9a,nivolumab,0.357718
uuid-61e66dc13e8244cf8ac7563d46ca95a1,requested,0.729914
uuid-c745f262bb4f4ba09bc55bbe7d372322,provided in the Detailed Information,0.565596
uuid-c745f262bb4f4ba09bc55bbe7d372322,clinical,0.466506
uuid-441bd2acdf8942b39899e6dae0575183,nivolumab,0.36204
uuid-441bd2acdf8942b39899e6dae0575183,evaluating,0.310829
uuid-441bd2acdf8942b39899e6dae0575183,not conducted any controlled clinical trials/studies,0.308383
uuid-441bd2acdf8942b39899e6dae0575183,RCC,0.634242
uuid-46d45d887118422c893d25d3dd6f3003,NSCLC,0.331263
uuid-46d45d887118422c893d25d3dd6f3003,efficacy and safety of nivolumab,0.338349
uuid-40dcd9bb314542f6ac17c533cdefae36,nivolumab,0.355212
uuid-40dcd9bb314542f6ac17c533cdefae36,use of nivolumab for the treatment,0.394686
uuid-40dcd9bb314542f6ac17c533cdefae36,efficacy,0.312963
uuid-40dcd9bb314542f6ac17c533cdefae36,search of published literature,0.305051
uuid-40dcd9bb314542f6ac17c533cdefae36,not approved,0.46217
uuid-40dcd9bb314542f6ac17c533cdefae36,clinical trials investigating the safety,0.517417
uuid-40dcd9bb314542f6ac17c533cdefae36,efficacy and safety of nivolumab,0.302155
uuid-40dcd9bb314542f6ac17c533cdefae36,clinicaltrials.gov,0.50712
uuid-40dcd9bb314542f6ac17c533cdefae36,present using the following search terms,0.325121
uuid-3655cef541d643c182dbb57b7634372f,95% CI,0.539167
uuid-3655cef541d643c182dbb57b7634372f,Median overall survival,0.479815
uuid-3655cef541d643c182dbb57b7634372f,protocol,0.426554
uuid-3655cef541d643c182dbb57b7634372f,McDermott DF,0.500131
uuid-3655cef541d643c182dbb57b7634372f,Motzer RJ,0.477178
uuid-3655cef541d643c182dbb57b7634372f,Median OS,0.603398
uuid-3655cef541d643c182dbb57b7634372f,Escudier B,0.469696
uuid-3655cef541d643c182dbb57b7634372f,NEJM,0.387615
uuid-3655cef541d643c182dbb57b7634372f,et al.,0.46851
uuid-3655cef541d643c182dbb57b7634372f,J Clin Oncol,0.51661
uuid-3655cef541d643c182dbb57b7634372f,Topalian,0.337057
uuid-3655cef541d643c182dbb57b7634372f,phase 2 study,0.399402
uuid-3655cef541d643c182dbb57b7634372f,hazard ratio,0.538097
uuid-9fbed3be71a642d8b293f885e2efc28a,Opdivo,0.473293
uuid-9fbed3be71a642d8b293f885e2efc28a,trial,0.367622
uuid-0180cd6a77134cbfae8783e36965affd,requested,0.505939
uuid-bb5b07c8d6a241bdb52983981d694465,95% CI,0.524855
uuid-bb5b07c8d6a241bdb52983981d694465,respectively,0.383655
uuid-bb5b07c8d6a241bdb52983981d694465,ASCO,0.303153
uuid-bb5b07c8d6a241bdb52983981d694465,Lancet Oncol,0.368041
uuid-bb5b07c8d6a241bdb52983981d694465,Objective response rate,0.504846
uuid-bb5b07c8d6a241bdb52983981d694465,ORR,0.465366
uuid-bb5b07c8d6a241bdb52983981d694465,Median overall survival,0.346516
uuid-bb5b07c8d6a241bdb52983981d694465,Median OS,0.33538
uuid-bb5b07c8d6a241bdb52983981d694465,ASCO 2015,0.336983
uuid-bb5b07c8d6a241bdb52983981d694465,small cell lung cancer,0.336892
uuid-bb5b07c8d6a241bdb52983981d694465,SCLC,0.344367
uuid-bb5b07c8d6a241bdb52983981d694465,Antonia SJ,0.55269
uuid-bb5b07c8d6a241bdb52983981d694465,Median duration of response,0.649605
uuid-16974c9e85624689a364ca1ddcd2f1ae,OS,0.469828
uuid-16974c9e85624689a364ca1ddcd2f1ae,AEs,0.324552
uuid-16974c9e85624689a364ca1ddcd2f1ae,95% CI,0.801461
uuid-16974c9e85624689a364ca1ddcd2f1ae,respectively,0.467672
uuid-16974c9e85624689a364ca1ddcd2f1ae,Objective response rate,0.494158
uuid-16974c9e85624689a364ca1ddcd2f1ae,ORR,0.636306
uuid-16974c9e85624689a364ca1ddcd2f1ae,PFS,0.366327
uuid-16974c9e85624689a364ca1ddcd2f1ae,Median overall survival,0.769867
uuid-16974c9e85624689a364ca1ddcd2f1ae,Median OS,0.750473
uuid-16974c9e85624689a364ca1ddcd2f1ae,grade,0.335661
uuid-16974c9e85624689a364ca1ddcd2f1ae,hazard ratio,0.762103
uuid-16974c9e85624689a364ca1ddcd2f1ae,Median duration of response,0.403853
uuid-fb9323e14f214abd911a23831beee358,nivolumab,0.405495
uuid-ca5b84ef489746bf958b99ec4ca8cd71,Lancet Oncol,0.405203
uuid-ca5b84ef489746bf958b99ec4ca8cd71,requested,0.689771
uuid-ca5b84ef489746bf958b99ec4ca8cd71,Rizvi NA,0.30306
uuid-ca5b84ef489746bf958b99ec4ca8cd71,Weber JS,0.313145
uuid-ca5b84ef489746bf958b99ec4ca8cd71,Antonia SJ,0.412316
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,N Engl J Med,0.427636
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,protocol,0.429136
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,McDermott DF,0.44782
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,Motzer RJ,0.430476
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,Escudier B,0.450887
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,et al.,0.456026
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,J Clin Oncol,0.384624
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,Rizvi NA,0.305616
uuid-6c9d254e32b64e0fb5ccedaa8831b6da,phase 2 study,0.351446
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,95% CI,0.539167
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,Median overall survival,0.479815
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,protocol,0.426554
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,McDermott DF,0.500131
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,Motzer RJ,0.477178
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,Median OS,0.603398
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,Escudier B,0.469696
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,NEJM,0.387615
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,et al.,0.46851
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,J Clin Oncol,0.51661
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,Topalian,0.337057
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,phase 2 study,0.399402
uuid-da25a452e6ed471e8b0b0f5c0d2a0dd7,hazard ratio,0.538097
uuid-4d66a0e5356848cbb52de8cd7e38b98e,N Engl J Med,0.616236
uuid-4d66a0e5356848cbb52de8cd7e38b98e,respectively,0.409266
uuid-4d66a0e5356848cbb52de8cd7e38b98e,ASCO,0.373445
uuid-4d66a0e5356848cbb52de8cd7e38b98e,ESMO,0.378373
uuid-4d66a0e5356848cbb52de8cd7e38b98e,Brahmer J,0.712806
uuid-4d66a0e5356848cbb52de8cd7e38b98e,docetaxel,0.327482
uuid-4d66a0e5356848cbb52de8cd7e38b98e,Horn L,0.502372
uuid-46edce51ba514211ba97a0feb948bc2d,respectively,0.585622
uuid-46edce51ba514211ba97a0feb948bc2d,Objective response rate,0.36976
uuid-46edce51ba514211ba97a0feb948bc2d,ORR,0.514781
uuid-46edce51ba514211ba97a0feb948bc2d,docetaxel,0.31274
uuid-b6868035698844a3b4008b7822ca6f6c,requested,0.662269
uuid-7fc1660bde074e69afff5e2330cd18d8,requested,0.531305
uuid-7fc1660bde074e69afff5e2330cd18d8,ESMO,0.358531
uuid-7fc1660bde074e69afff5e2330cd18d8,Horn L,0.66756
uuid-7fc1660bde074e69afff5e2330cd18d8,platinum-based doublet chemotherapy,0.579011
uuid-12d98f655007480797d9074f6ac40527,N Engl J Med,0.427636
uuid-12d98f655007480797d9074f6ac40527,protocol,0.429136
uuid-12d98f655007480797d9074f6ac40527,McDermott DF,0.44782
uuid-12d98f655007480797d9074f6ac40527,Motzer RJ,0.430476
uuid-12d98f655007480797d9074f6ac40527,Escudier B,0.450887
uuid-12d98f655007480797d9074f6ac40527,et al.,0.456026
uuid-12d98f655007480797d9074f6ac40527,J Clin Oncol,0.384624
uuid-12d98f655007480797d9074f6ac40527,Rizvi NA,0.305616
uuid-12d98f655007480797d9074f6ac40527,phase 2 study,0.351446
uuid-e7090d4a852f40c49ee836bdb8d847a1,Bristol-Myers Squibb,0.341822
uuid-e7090d4a852f40c49ee836bdb8d847a1,not conducted any controlled clinical trials/studies,0.304507
uuid-e7090d4a852f40c49ee836bdb8d847a1,Opdivo,0.461382
uuid-e7090d4a852f40c49ee836bdb8d847a1,Pubmed literature search,0.614325
uuid-e7090d4a852f40c49ee836bdb8d847a1,purposes other than its labeled indication must be considered investigational,0.586645
uuid-e7090d4a852f40c49ee836bdb8d847a1,not identify any citations relevant to your inquiry,0.606087
uuid-e7090d4a852f40c49ee836bdb8d847a1,adverse,0.304183
uuid-e7090d4a852f40c49ee836bdb8d847a1,using the following search terms,0.642331
uuid-e7090d4a852f40c49ee836bdb8d847a1,databases,0.315039
uuid-e7090d4a852f40c49ee836bdb8d847a1,reported,0.556704
uuid-2ad8263a8733466887abaa3daf723aa4,N Engl J Med,0.616236
uuid-2ad8263a8733466887abaa3daf723aa4,respectively,0.409266
uuid-2ad8263a8733466887abaa3daf723aa4,ASCO,0.373445
uuid-2ad8263a8733466887abaa3daf723aa4,ESMO,0.378373
uuid-2ad8263a8733466887abaa3daf723aa4,Brahmer J,0.712806
uuid-2ad8263a8733466887abaa3daf723aa4,docetaxel,0.327482
uuid-2ad8263a8733466887abaa3daf723aa4,Horn L,0.502372
uuid-7a4ed96a5ebe4436a6b81f1b157bb5fd,use of nivolumab for the treatment,0.538282
uuid-7a4ed96a5ebe4436a6b81f1b157bb5fd,not approved,0.413138
uuid-65f9dfc47ae94eae909132e78ae64a64,ipilimumab,0.385692
uuid-65f9dfc47ae94eae909132e78ae64a64,ASCO 2015,0.417944
uuid-65f9dfc47ae94eae909132e78ae64a64,partial response,0.382425
uuid-65f9dfc47ae94eae909132e78ae64a64,Stable disease,0.586335
uuid-65f9dfc47ae94eae909132e78ae64a64,cohort,0.307748
uuid-779975a38cbf45bfa8f82e2dcd3a3c5e,requested,0.594234
uuid-d5e1e4614f3d43289e8274f66a451413,requested,0.594234
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,evaluating,0.350845
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,not conducted any controlled clinical trials/studies,0.345107
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,search of published literature,0.385331
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,Additionally,0.40981
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,ongoing,0.457998
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,PubMed and EMBASE,0.378285
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,detailed search of www.clinicaltrials.gov,0.428522
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,efficacy and safety of nivolumab,0.407868
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,not identify any planned,0.444729
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,combination,0.388252
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,BMS,0.316104
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,not identify any citations relevant to your request,0.438151
uuid-7e1ebc033b214aa58f951d0dd2d97ba9,present using the following search terms,0.377101
uuid-f441ac24ef744ace95e5991efae0db1d,requested,0.788355
uuid-e49b162cb8ea48f5b36da8f04ae9edce,requested,0.594234
uuid-66d1a37ccbf44d468f469664706afc61,Bristol-Myers Squibb,0.393923
uuid-66d1a37ccbf44d468f469664706afc61,requested,0.30907
uuid-f955f3d4607d4be0915550c2cf52a0f7,requested,0.531305
uuid-f955f3d4607d4be0915550c2cf52a0f7,ESMO,0.358531
uuid-f955f3d4607d4be0915550c2cf52a0f7,Horn L,0.66756
uuid-f955f3d4607d4be0915550c2cf52a0f7,platinum-based doublet chemotherapy,0.579011
uuid-29dc0705e99544d79b308e67d9b85ea2,requested,0.594234
uuid-a719ac1f1366495386c88e2b6ebb2b55,nivolumab,0.572772
uuid-a719ac1f1366495386c88e2b6ebb2b55,Bristol-Myers Squibb,0.630242
uuid-a719ac1f1366495386c88e2b6ebb2b55,evaluating,0.730278
uuid-a719ac1f1366495386c88e2b6ebb2b55,not conducted any controlled clinical trials/studies,0.784255
uuid-a719ac1f1366495386c88e2b6ebb2b55,Pubmed literature search,0.646122
uuid-a719ac1f1366495386c88e2b6ebb2b55,purposes other than its labeled indication must be considered investigational,0.745481
uuid-a719ac1f1366495386c88e2b6ebb2b55,not identify any citations relevant to your inquiry,0.598446
uuid-a719ac1f1366495386c88e2b6ebb2b55,using the following search terms,0.577971
uuid-a719ac1f1366495386c88e2b6ebb2b55,efficacy and safety of nivolumab,0.577759
uuid-f564b1a435384724b59ac9c4fec2ccd5,requested,0.531305
uuid-f564b1a435384724b59ac9c4fec2ccd5,ESMO,0.358531
uuid-f564b1a435384724b59ac9c4fec2ccd5,Horn L,0.66756
uuid-f564b1a435384724b59ac9c4fec2ccd5,platinum-based doublet chemotherapy,0.579011
uuid-80a3e91da80c4a5989df9871c757b75f,nivolumab,0.584005
uuid-80a3e91da80c4a5989df9871c757b75f,considered investigational,0.454758
uuid-80a3e91da80c4a5989df9871c757b75f,patients with advanced or metastatic,0.445684
uuid-80a3e91da80c4a5989df9871c757b75f,nivolumab combined with ipilimumab,0.436396
uuid-80a3e91da80c4a5989df9871c757b75f,tumors,0.742152
uuid-80a3e91da80c4a5989df9871c757b75f,small cell lung cancer,0.468379
uuid-80a3e91da80c4a5989df9871c757b75f,SCLC,0.429264
uuid-80a3e91da80c4a5989df9871c757b75f,phase 1/2 study CA209-032,0.521262
uuid-80a3e91da80c4a5989df9871c757b75f,evaluates the efficacy of nivolumab monotherapy,0.542861
uuid-6940a0fc9482447fac7ece60cd3a8e14,requested,0.594234
uuid-9a13d7e34637495f8eb3d2eff466f279,requested,0.594234
uuid-34a5e294c25e4f98976a039ad2f800ab,patients with advanced or metastatic,0.468858
uuid-34a5e294c25e4f98976a039ad2f800ab,nivolumab combined with ipilimumab,0.446918
uuid-34a5e294c25e4f98976a039ad2f800ab,not approved,0.352562
uuid-34a5e294c25e4f98976a039ad2f800ab,clinical trials investigating the safety,0.429501
uuid-34a5e294c25e4f98976a039ad2f800ab,bladder cancer,0.950698
uuid-a78c9c70e49e4858b7770e46863d27dd,95% CI,0.539167
uuid-a78c9c70e49e4858b7770e46863d27dd,Median overall survival,0.479815
uuid-a78c9c70e49e4858b7770e46863d27dd,protocol,0.426554
uuid-a78c9c70e49e4858b7770e46863d27dd,McDermott DF,0.500131
uuid-a78c9c70e49e4858b7770e46863d27dd,Motzer RJ,0.477178
uuid-a78c9c70e49e4858b7770e46863d27dd,Median OS,0.603398
uuid-a78c9c70e49e4858b7770e46863d27dd,Escudier B,0.469696
uuid-a78c9c70e49e4858b7770e46863d27dd,NEJM,0.387615
uuid-a78c9c70e49e4858b7770e46863d27dd,et al.,0.46851
uuid-a78c9c70e49e4858b7770e46863d27dd,J Clin Oncol,0.51661
uuid-a78c9c70e49e4858b7770e46863d27dd,Topalian,0.337057
uuid-a78c9c70e49e4858b7770e46863d27dd,phase 2 study,0.399402
uuid-a78c9c70e49e4858b7770e46863d27dd,hazard ratio,0.538097
uuid-10fe63be35bc4a3493c993d24eff98d2,N Engl J Med,0.616236
uuid-10fe63be35bc4a3493c993d24eff98d2,respectively,0.409266
uuid-10fe63be35bc4a3493c993d24eff98d2,ASCO,0.373445
uuid-10fe63be35bc4a3493c993d24eff98d2,ESMO,0.378373
uuid-10fe63be35bc4a3493c993d24eff98d2,Brahmer J,0.712806
uuid-10fe63be35bc4a3493c993d24eff98d2,docetaxel,0.327482
uuid-10fe63be35bc4a3493c993d24eff98d2,Horn L,0.502372
uuid-843847de3a09497eb961539a9cfa156d,N Engl J Med,0.616236
uuid-843847de3a09497eb961539a9cfa156d,respectively,0.409266
uuid-843847de3a09497eb961539a9cfa156d,ASCO,0.373445
uuid-843847de3a09497eb961539a9cfa156d,ESMO,0.378373
uuid-843847de3a09497eb961539a9cfa156d,Brahmer J,0.712806
uuid-843847de3a09497eb961539a9cfa156d,docetaxel,0.327482
uuid-843847de3a09497eb961539a9cfa156d,Horn L,0.502372
uuid-7584550c68b74c249c846391ba52fbd9,provided in the Detailed Information,0.408955
uuid-7584550c68b74c249c846391ba52fbd9,ESMO,0.992426
uuid-7584550c68b74c249c846391ba52fbd9,Horn L,0.554477
uuid-7584550c68b74c249c846391ba52fbd9,grade 3 to 4 AEs,0.502956
uuid-32dddfedf3ef4341ba66375b5e8c486f,RCC,0.903652
uuid-a20c01b8efe147f59cbc453700b32f2d,patients,0.425141
uuid-a20c01b8efe147f59cbc453700b32f2d,adverse,0.349061
uuid-a20c01b8efe147f59cbc453700b32f2d,phase 3 study,0.319872
uuid-229dbc48c1a04ba0842d425b10112a0a,Bristol-Myers Squibb,0.617986
uuid-229dbc48c1a04ba0842d425b10112a0a,evaluating,0.520549
uuid-229dbc48c1a04ba0842d425b10112a0a,not conducted any controlled clinical trials/studies,0.575367
uuid-229dbc48c1a04ba0842d425b10112a0a,adverse,0.436595
uuid-229dbc48c1a04ba0842d425b10112a0a,efficacy and safety of nivolumab,0.420957
uuid-92d54de7729047919bf0c8cab7127db3,respectively,0.629961
uuid-92d54de7729047919bf0c8cab7127db3,Objective response rate,0.439951
uuid-92d54de7729047919bf0c8cab7127db3,ORR,0.462322
uuid-92d54de7729047919bf0c8cab7127db3,monotherapy,0.352421
uuid-92d54de7729047919bf0c8cab7127db3,docetaxel,0.410479
uuid-f3cb2f8fbfea416aaeceada4f26a756f,nivolumab,0.538837
uuid-f3cb2f8fbfea416aaeceada4f26a756f,Bristol-Myers Squibb,0.734639
uuid-f3cb2f8fbfea416aaeceada4f26a756f,evaluating,0.676023
uuid-f3cb2f8fbfea416aaeceada4f26a756f,not conducted any controlled clinical trials/studies,0.745086
uuid-f3cb2f8fbfea416aaeceada4f26a756f,purposes other than its labeled indication must be considered investigational,0.359081
uuid-f3cb2f8fbfea416aaeceada4f26a756f,efficacy and safety of nivolumab,0.591142
uuid-7e09f33c91944555943421d25b44d790,95% CI,0.539167
uuid-7e09f33c91944555943421d25b44d790,Median overall survival,0.479815
uuid-7e09f33c91944555943421d25b44d790,protocol,0.426554
uuid-7e09f33c91944555943421d25b44d790,McDermott DF,0.500131
uuid-7e09f33c91944555943421d25b44d790,Motzer RJ,0.477178
uuid-7e09f33c91944555943421d25b44d790,Median OS,0.603398
uuid-7e09f33c91944555943421d25b44d790,Escudier B,0.469696
uuid-7e09f33c91944555943421d25b44d790,NEJM,0.387615
uuid-7e09f33c91944555943421d25b44d790,et al.,0.46851
uuid-7e09f33c91944555943421d25b44d790,J Clin Oncol,0.51661
uuid-7e09f33c91944555943421d25b44d790,Topalian,0.337057
uuid-7e09f33c91944555943421d25b44d790,phase 2 study,0.399402
uuid-7e09f33c91944555943421d25b44d790,hazard ratio,0.538097
uuid-03bac8f4fd8b411086898e55afcb69ff,phase 3 study,0.352561
uuid-03bac8f4fd8b411086898e55afcb69ff,open-label,0.685094
uuid-03bac8f4fd8b411086898e55afcb69ff,docetaxel,0.306914
uuid-03bac8f4fd8b411086898e55afcb69ff,phase,0.650976
uuid-389c033cddce46688841a2ebffc46380,95% CI,0.39545
uuid-389c033cddce46688841a2ebffc46380,respectively,0.599632
uuid-389c033cddce46688841a2ebffc46380,ASCO,0.363631
uuid-389c033cddce46688841a2ebffc46380,Objective response rate,0.61752
uuid-389c033cddce46688841a2ebffc46380,ORR,0.58547
uuid-389c033cddce46688841a2ebffc46380,Median overall survival,0.373642
uuid-389c033cddce46688841a2ebffc46380,monotherapy,0.411011
uuid-389c033cddce46688841a2ebffc46380,Median OS,0.3895
uuid-389c033cddce46688841a2ebffc46380,docetaxel,0.35961
uuid-389c033cddce46688841a2ebffc46380,Antonia SJ,0.311246
uuid-389c033cddce46688841a2ebffc46380,hazard ratio,0.366284
uuid-8b8ffa2bca2f41418bc4651e889f8c39,OS,0.506839
uuid-8b8ffa2bca2f41418bc4651e889f8c39,95% CI,0.914259
uuid-8b8ffa2bca2f41418bc4651e889f8c39,respectively,0.57945
uuid-8b8ffa2bca2f41418bc4651e889f8c39,Objective response rate,0.616133
uuid-8b8ffa2bca2f41418bc4651e889f8c39,ORR,0.78386
uuid-8b8ffa2bca2f41418bc4651e889f8c39,PFS,0.374029
uuid-8b8ffa2bca2f41418bc4651e889f8c39,Median overall survival,0.850584
uuid-8b8ffa2bca2f41418bc4651e889f8c39,monotherapy,0.435128
uuid-8b8ffa2bca2f41418bc4651e889f8c39,Median OS,0.829523
uuid-8b8ffa2bca2f41418bc4651e889f8c39,docetaxel,0.347663
uuid-8b8ffa2bca2f41418bc4651e889f8c39,hazard ratio,0.887303
uuid-8b8ffa2bca2f41418bc4651e889f8c39,Median duration of response,0.367027
uuid-6d7927625467475d8d44868153438635,Bristol-Myers Squibb,0.494637
uuid-d09103f3512d46a3955aa63c1cf1a353,OS,0.473136
uuid-d09103f3512d46a3955aa63c1cf1a353,95% CI,0.86688
uuid-d09103f3512d46a3955aa63c1cf1a353,respectively,0.340872
uuid-d09103f3512d46a3955aa63c1cf1a353,Objective response rate,0.569358
uuid-d09103f3512d46a3955aa63c1cf1a353,ORR,0.680887
uuid-d09103f3512d46a3955aa63c1cf1a353,PFS,0.400254
uuid-d09103f3512d46a3955aa63c1cf1a353,Median overall survival,0.783555
uuid-d09103f3512d46a3955aa63c1cf1a353,monotherapy,0.347194
uuid-d09103f3512d46a3955aa63c1cf1a353,Median OS,0.768047
uuid-d09103f3512d46a3955aa63c1cf1a353,hazard ratio,0.805061
uuid-d09103f3512d46a3955aa63c1cf1a353,Median duration of response,0.455873
uuid-eff2d45b7ede404c82332ba697743816,N Engl J Med,0.442834
uuid-eff2d45b7ede404c82332ba697743816,protocol,0.763252
uuid-eff2d45b7ede404c82332ba697743816,McDermott DF,0.733103
uuid-eff2d45b7ede404c82332ba697743816,Motzer RJ,0.811057
uuid-eff2d45b7ede404c82332ba697743816,phase 3 study,0.420895
uuid-eff2d45b7ede404c82332ba697743816,Escudier B,0.741048
uuid-eff2d45b7ede404c82332ba697743816,NEJM,0.402544
uuid-eff2d45b7ede404c82332ba697743816,et al.,0.660398
uuid-eff2d45b7ede404c82332ba697743816,J Clin Oncol,0.786367
uuid-eff2d45b7ede404c82332ba697743816,Topalian,0.392395
uuid-eff2d45b7ede404c82332ba697743816,phase 1 study,0.513779
uuid-eff2d45b7ede404c82332ba697743816,CA209-003,0.583337
uuid-eff2d45b7ede404c82332ba697743816,phase 2 study,0.675447
uuid-eff2d45b7ede404c82332ba697743816,present using the following search terms,0.304589
uuid-eff2d45b7ede404c82332ba697743816,investigating,0.633101
uuid-5b9b4b9131504d4ca082db064b1716a7,OS,0.506839
uuid-5b9b4b9131504d4ca082db064b1716a7,95% CI,0.914259
uuid-5b9b4b9131504d4ca082db064b1716a7,respectively,0.57945
uuid-5b9b4b9131504d4ca082db064b1716a7,Objective response rate,0.616133
uuid-5b9b4b9131504d4ca082db064b1716a7,ORR,0.78386
uuid-5b9b4b9131504d4ca082db064b1716a7,PFS,0.374029
uuid-5b9b4b9131504d4ca082db064b1716a7,Median overall survival,0.850584
uuid-5b9b4b9131504d4ca082db064b1716a7,monotherapy,0.435128
uuid-5b9b4b9131504d4ca082db064b1716a7,Median OS,0.829523
uuid-5b9b4b9131504d4ca082db064b1716a7,docetaxel,0.347663
uuid-5b9b4b9131504d4ca082db064b1716a7,hazard ratio,0.887303
uuid-5b9b4b9131504d4ca082db064b1716a7,Median duration of response,0.367027
uuid-0e490be3068b4f2b8ef7373b95a172b7,Bristol-Myers Squibb,0.883649
uuid-0e490be3068b4f2b8ef7373b95a172b7,evaluating,0.678101
uuid-0e490be3068b4f2b8ef7373b95a172b7,not conducted any controlled clinical trials/studies,0.775601
uuid-0e490be3068b4f2b8ef7373b95a172b7,efficacy and safety of nivolumab,0.582523
uuid-74e4b9e16d944500842255b9dc0068c4,Bristol-Myers Squibb,0.342325
uuid-74e4b9e16d944500842255b9dc0068c4,requested,0.460083
uuid-6d743f99ad3645019c1d1a8bb40f5b63,95% CI,0.539167
uuid-6d743f99ad3645019c1d1a8bb40f5b63,Median overall survival,0.479815
uuid-6d743f99ad3645019c1d1a8bb40f5b63,protocol,0.426554
uuid-6d743f99ad3645019c1d1a8bb40f5b63,McDermott DF,0.500131
uuid-6d743f99ad3645019c1d1a8bb40f5b63,Motzer RJ,0.477178
uuid-6d743f99ad3645019c1d1a8bb40f5b63,Median OS,0.603398
uuid-6d743f99ad3645019c1d1a8bb40f5b63,Escudier B,0.469696
uuid-6d743f99ad3645019c1d1a8bb40f5b63,NEJM,0.387615
uuid-6d743f99ad3645019c1d1a8bb40f5b63,et al.,0.46851
uuid-6d743f99ad3645019c1d1a8bb40f5b63,J Clin Oncol,0.51661
uuid-6d743f99ad3645019c1d1a8bb40f5b63,Topalian,0.337057
uuid-6d743f99ad3645019c1d1a8bb40f5b63,phase 2 study,0.399402
uuid-6d743f99ad3645019c1d1a8bb40f5b63,hazard ratio,0.538097
uuid-86d2d163dda544f9b62037ea614de0db,patients with advanced or metastatic,0.468858
uuid-86d2d163dda544f9b62037ea614de0db,nivolumab combined with ipilimumab,0.446918
uuid-86d2d163dda544f9b62037ea614de0db,not approved,0.352562
uuid-86d2d163dda544f9b62037ea614de0db,clinical trials investigating the safety,0.429501
uuid-86d2d163dda544f9b62037ea614de0db,bladder cancer,0.950698
uuid-00cbeec4baf747ad822f5e5e360ee5e7,nivolumab,0.797322
uuid-00cbeec4baf747ad822f5e5e360ee5e7,purposes other than its labeled indication must be considered investigational,0.327317
uuid-21b9d2175ec1405990450b2bffc3a2e0,95% CI,0.539167
uuid-21b9d2175ec1405990450b2bffc3a2e0,Median overall survival,0.479815
uuid-21b9d2175ec1405990450b2bffc3a2e0,protocol,0.426554
uuid-21b9d2175ec1405990450b2bffc3a2e0,McDermott DF,0.500131
uuid-21b9d2175ec1405990450b2bffc3a2e0,Motzer RJ,0.477178
uuid-21b9d2175ec1405990450b2bffc3a2e0,Median OS,0.603398
uuid-21b9d2175ec1405990450b2bffc3a2e0,Escudier B,0.469696
uuid-21b9d2175ec1405990450b2bffc3a2e0,NEJM,0.387615
uuid-21b9d2175ec1405990450b2bffc3a2e0,et al.,0.46851
uuid-21b9d2175ec1405990450b2bffc3a2e0,J Clin Oncol,0.51661
uuid-21b9d2175ec1405990450b2bffc3a2e0,Topalian,0.337057
uuid-21b9d2175ec1405990450b2bffc3a2e0,phase 2 study,0.399402
uuid-21b9d2175ec1405990450b2bffc3a2e0,hazard ratio,0.538097
uuid-1eaa08b70b3148c8b89a9c4bee2cff4d,requested,0.72547
uuid-0ded92ba9c3f4f0a9234ce1870bde266,patients with advanced or metastatic,0.468858
uuid-0ded92ba9c3f4f0a9234ce1870bde266,nivolumab combined with ipilimumab,0.446918
uuid-0ded92ba9c3f4f0a9234ce1870bde266,not approved,0.352562
uuid-0ded92ba9c3f4f0a9234ce1870bde266,clinical trials investigating the safety,0.429501
uuid-0ded92ba9c3f4f0a9234ce1870bde266,bladder cancer,0.950698
uuid-fd2376cff4b246989aa4ea402598a21c,N Engl J Med,0.616236
uuid-fd2376cff4b246989aa4ea402598a21c,respectively,0.409266
uuid-fd2376cff4b246989aa4ea402598a21c,ASCO,0.373445
uuid-fd2376cff4b246989aa4ea402598a21c,ESMO,0.378373
uuid-fd2376cff4b246989aa4ea402598a21c,Brahmer J,0.712806
uuid-fd2376cff4b246989aa4ea402598a21c,docetaxel,0.327482
uuid-fd2376cff4b246989aa4ea402598a21c,Horn L,0.502372
uuid-019333e95f9e472491a9bf32e317e7ce,patients with advanced or metastatic,0.478326
uuid-019333e95f9e472491a9bf32e317e7ce,nivolumab combined with ipilimumab,0.498766
uuid-019333e95f9e472491a9bf32e317e7ce,not approved,0.34724
uuid-019333e95f9e472491a9bf32e317e7ce,clinical trials investigating the safety,0.426729
uuid-019333e95f9e472491a9bf32e317e7ce,bladder cancer,0.6548
uuid-4a935c2678624114a8ed6cd3b39327ae,combination,0.361069
uuid-4a935c2678624114a8ed6cd3b39327ae,BMS,0.321706
uuid-f59755d64cc2430a895154691d9cb3c0,N Engl J Med,0.604857
uuid-f59755d64cc2430a895154691d9cb3c0,non-small cell lung cancer,0.34354
uuid-f59755d64cc2430a895154691d9cb3c0,ESMO,0.393944
uuid-f59755d64cc2430a895154691d9cb3c0,Rizvi NA,0.452745
uuid-f59755d64cc2430a895154691d9cb3c0,Brahmer J,0.679154
uuid-f59755d64cc2430a895154691d9cb3c0,PD-L1,0.347566
uuid-f59755d64cc2430a895154691d9cb3c0,Horn L,0.50259
uuid-f59755d64cc2430a895154691d9cb3c0,platinum-based doublet chemotherapy,0.304136
uuid-861b572edc254153bd71d76d5f8fbbbf,requested,0.788355
uuid-b5d1ddda6c9a430e9424ccb564280c2d,nivolumab,0.324304
uuid-b5d1ddda6c9a430e9424ccb564280c2d,Bristol-Myers Squibb,0.607046
uuid-b5d1ddda6c9a430e9424ccb564280c2d,evaluating,0.660769
uuid-b5d1ddda6c9a430e9424ccb564280c2d,not conducted any controlled clinical trials/studies,0.681911
uuid-b5d1ddda6c9a430e9424ccb564280c2d,considered investigational,0.398583
uuid-b5d1ddda6c9a430e9424ccb564280c2d,purposes other than its labeled indication must be considered investigational,0.386722
uuid-b5d1ddda6c9a430e9424ccb564280c2d,efficacy and safety of nivolumab,0.526738
uuid-4e0b6cc5372747adb0e471468b2c4012,search of published literature,0.394524
uuid-4e0b6cc5372747adb0e471468b2c4012,Additionally,0.413583
uuid-4e0b6cc5372747adb0e471468b2c4012,ongoing,0.322117
uuid-4e0b6cc5372747adb0e471468b2c4012,PubMed and EMBASE,0.391671
uuid-4e0b6cc5372747adb0e471468b2c4012,detailed search of www.clinicaltrials.gov,0.375936
uuid-4e0b6cc5372747adb0e471468b2c4012,efficacy and safety of nivolumab,0.370699
uuid-4e0b6cc5372747adb0e471468b2c4012,not identify any planned,0.34283
uuid-4e0b6cc5372747adb0e471468b2c4012,Weber JS,0.319229
uuid-4e0b6cc5372747adb0e471468b2c4012,not identify any citations relevant to your request,0.447813
uuid-4e0b6cc5372747adb0e471468b2c4012,present using the following search terms,0.408199
uuid-6f569001e98848edb0e8b2a972f6e708,N Engl J Med,0.604857
uuid-6f569001e98848edb0e8b2a972f6e708,non-small cell lung cancer,0.34354
uuid-6f569001e98848edb0e8b2a972f6e708,ESMO,0.393944
uuid-6f569001e98848edb0e8b2a972f6e708,Rizvi NA,0.452745
uuid-6f569001e98848edb0e8b2a972f6e708,Brahmer J,0.679154
uuid-6f569001e98848edb0e8b2a972f6e708,PD-L1,0.347566
uuid-6f569001e98848edb0e8b2a972f6e708,Horn L,0.50259
uuid-6f569001e98848edb0e8b2a972f6e708,platinum-based doublet chemotherapy,0.304136
uuid-593b2f3734f34f5ca3869a0fd709ca69,requested,0.594234
uuid-f0fac1bd59bf4891ba45ca5aafc404e5,Bristol-Myers Squibb,0.654266
uuid-f0fac1bd59bf4891ba45ca5aafc404e5,evaluating,0.589795
uuid-f0fac1bd59bf4891ba45ca5aafc404e5,not conducted any controlled clinical trials/studies,0.662504
uuid-f0fac1bd59bf4891ba45ca5aafc404e5,purposes other than its labeled indication must be considered investigational,0.351404
uuid-f0fac1bd59bf4891ba45ca5aafc404e5,efficacy and safety of nivolumab,0.484685
uuid-4b92d20232b74edd95031e1720f17780,OS,0.506839
uuid-4b92d20232b74edd95031e1720f17780,95% CI,0.914259
uuid-4b92d20232b74edd95031e1720f17780,respectively,0.57945
uuid-4b92d20232b74edd95031e1720f17780,Objective response rate,0.616133
uuid-4b92d20232b74edd95031e1720f17780,ORR,0.78386
uuid-4b92d20232b74edd95031e1720f17780,PFS,0.374029
uuid-4b92d20232b74edd95031e1720f17780,Median overall survival,0.850584
uuid-4b92d20232b74edd95031e1720f17780,monotherapy,0.435128
uuid-4b92d20232b74edd95031e1720f17780,Median OS,0.829523
uuid-4b92d20232b74edd95031e1720f17780,docetaxel,0.347663
uuid-4b92d20232b74edd95031e1720f17780,hazard ratio,0.887303
uuid-4b92d20232b74edd95031e1720f17780,Median duration of response,0.367027
uuid-caba5ff355454e9eadc18d397f4826c4,N Engl J Med,0.616236
uuid-caba5ff355454e9eadc18d397f4826c4,respectively,0.409266
uuid-caba5ff355454e9eadc18d397f4826c4,ASCO,0.373445
uuid-caba5ff355454e9eadc18d397f4826c4,ESMO,0.378373
uuid-caba5ff355454e9eadc18d397f4826c4,Brahmer J,0.712806
uuid-caba5ff355454e9eadc18d397f4826c4,docetaxel,0.327482
uuid-caba5ff355454e9eadc18d397f4826c4,Horn L,0.502372
uuid-56ac8e29d18945d38d443acf20093f4b,Bristol-Myers Squibb,0.494637
uuid-13c72c47bea3479fbc96de551a63ed70,use of nivolumab for the treatment,0.375532
uuid-13c72c47bea3479fbc96de551a63ed70,evaluating,0.375949
uuid-13c72c47bea3479fbc96de551a63ed70,efficacy,0.523368
uuid-13c72c47bea3479fbc96de551a63ed70,NSCLC,0.428571
uuid-13c72c47bea3479fbc96de551a63ed70,respectively,0.410649
uuid-13c72c47bea3479fbc96de551a63ed70,non-small cell lung cancer,0.480892
uuid-13c72c47bea3479fbc96de551a63ed70,patients,0.333123
uuid-13c72c47bea3479fbc96de551a63ed70,ORR,0.361994
uuid-13c72c47bea3479fbc96de551a63ed70,monotherapy,0.371951
uuid-13c72c47bea3479fbc96de551a63ed70,not approved,0.410432
uuid-13c72c47bea3479fbc96de551a63ed70,clinical trials investigating the safety,0.342624
uuid-13c72c47bea3479fbc96de551a63ed70,PD-L1,0.514464
uuid-13c72c47bea3479fbc96de551a63ed70,docetaxel,0.485569
uuid-13c72c47bea3479fbc96de551a63ed70,safety of nivolumab monotherapy,0.592858
uuid-13c72c47bea3479fbc96de551a63ed70,platinum-based doublet chemotherapy,0.315738
uuid-58089fd83fcd4852a49d9b5e33079eb7,N Engl J Med,0.54825
uuid-58089fd83fcd4852a49d9b5e33079eb7,NSCLC,0.358785
uuid-58089fd83fcd4852a49d9b5e33079eb7,non-small cell lung cancer,0.308706
uuid-58089fd83fcd4852a49d9b5e33079eb7,ESMO,0.396697
uuid-58089fd83fcd4852a49d9b5e33079eb7,phase 3 study,0.368632
uuid-58089fd83fcd4852a49d9b5e33079eb7,phase 1 study,0.306384
uuid-58089fd83fcd4852a49d9b5e33079eb7,Rizvi NA,0.47921
uuid-58089fd83fcd4852a49d9b5e33079eb7,Brahmer J,0.605319
uuid-58089fd83fcd4852a49d9b5e33079eb7,phase 2 study,0.362302
uuid-58089fd83fcd4852a49d9b5e33079eb7,Horn L,0.443225
uuid-35d4470979034d888429aae5cecf05b4,trial,0.405524
uuid-90b8647accf24641bd376efa431fef47,respectively,0.629961
uuid-90b8647accf24641bd376efa431fef47,Objective response rate,0.439951
uuid-90b8647accf24641bd376efa431fef47,ORR,0.462322
uuid-90b8647accf24641bd376efa431fef47,monotherapy,0.352421
uuid-90b8647accf24641bd376efa431fef47,docetaxel,0.410479
uuid-6383f37b21f14f8f84cc7bb2decd23af,OS,0.493666
uuid-6383f37b21f14f8f84cc7bb2decd23af,95% CI,0.872793
uuid-6383f37b21f14f8f84cc7bb2decd23af,respectively,0.581917
uuid-6383f37b21f14f8f84cc7bb2decd23af,Objective response rate,0.558489
uuid-6383f37b21f14f8f84cc7bb2decd23af,ORR,0.705401
uuid-6383f37b21f14f8f84cc7bb2decd23af,PFS,0.331929
uuid-6383f37b21f14f8f84cc7bb2decd23af,Median overall survival,0.793083
uuid-6383f37b21f14f8f84cc7bb2decd23af,monotherapy,0.422517
uuid-6383f37b21f14f8f84cc7bb2decd23af,Median OS,0.808565
uuid-6383f37b21f14f8f84cc7bb2decd23af,PD-L1,0.302111
uuid-6383f37b21f14f8f84cc7bb2decd23af,docetaxel,0.481228
uuid-6383f37b21f14f8f84cc7bb2decd23af,hazard ratio,0.844622
uuid-6383f37b21f14f8f84cc7bb2decd23af,Median duration of response,0.34536
uuid-207502d7490745e1a695ed5107b8c982,nivolumab,0.483553
uuid-207502d7490745e1a695ed5107b8c982,Bristol-Myers Squibb,0.523673
uuid-207502d7490745e1a695ed5107b8c982,evaluating,0.578789
uuid-207502d7490745e1a695ed5107b8c982,not conducted any controlled clinical trials/studies,0.600989
uuid-207502d7490745e1a695ed5107b8c982,search of published literature,0.514478
uuid-207502d7490745e1a695ed5107b8c982,Additionally,0.518123
uuid-207502d7490745e1a695ed5107b8c982,ongoing,0.447069
uuid-207502d7490745e1a695ed5107b8c982,PubMed and EMBASE,0.497079
uuid-207502d7490745e1a695ed5107b8c982,detailed search of www.clinicaltrials.gov,0.491159
uuid-207502d7490745e1a695ed5107b8c982,efficacy and safety of nivolumab,0.652414
uuid-207502d7490745e1a695ed5107b8c982,not identify any planned,0.458584
uuid-207502d7490745e1a695ed5107b8c982,not identify any citations relevant to your request,0.567422
uuid-207502d7490745e1a695ed5107b8c982,present using the following search terms,0.519995
uuid-746d681a3fa2422c8ed410675c25887d,Bristol-Myers Squibb,0.595474
uuid-746d681a3fa2422c8ed410675c25887d,evaluating,0.540963
uuid-746d681a3fa2422c8ed410675c25887d,not conducted any controlled clinical trials/studies,0.601018
uuid-746d681a3fa2422c8ed410675c25887d,efficacy and safety of nivolumab,0.498734
uuid-250266275f01411d8941df785f084752,95% CI,0.39545
uuid-250266275f01411d8941df785f084752,respectively,0.599632
uuid-250266275f01411d8941df785f084752,ASCO,0.363631
uuid-250266275f01411d8941df785f084752,Objective response rate,0.61752
uuid-250266275f01411d8941df785f084752,ORR,0.58547
uuid-250266275f01411d8941df785f084752,Median overall survival,0.373642
uuid-250266275f01411d8941df785f084752,monotherapy,0.411011
uuid-250266275f01411d8941df785f084752,Median OS,0.3895
uuid-250266275f01411d8941df785f084752,docetaxel,0.35961
uuid-250266275f01411d8941df785f084752,Antonia SJ,0.311246
uuid-250266275f01411d8941df785f084752,hazard ratio,0.366284
uuid-290811d15202475992e0b908f6ec80bc,protocol,0.369065
uuid-290811d15202475992e0b908f6ec80bc,McDermott DF,0.424366
uuid-290811d15202475992e0b908f6ec80bc,Motzer RJ,0.389491
uuid-290811d15202475992e0b908f6ec80bc,phase 3 study,0.415224
uuid-290811d15202475992e0b908f6ec80bc,Escudier B,0.397744
uuid-290811d15202475992e0b908f6ec80bc,NEJM,0.462424
uuid-290811d15202475992e0b908f6ec80bc,et al.,0.386335
uuid-290811d15202475992e0b908f6ec80bc,J Clin Oncol,0.442688
uuid-290811d15202475992e0b908f6ec80bc,Topalian,0.457692
uuid-290811d15202475992e0b908f6ec80bc,phase 1 study,0.485875
uuid-290811d15202475992e0b908f6ec80bc,Rizvi NA,0.410258
uuid-290811d15202475992e0b908f6ec80bc,mg,0.415215
uuid-290811d15202475992e0b908f6ec80bc,CA209-003,0.427777
uuid-290811d15202475992e0b908f6ec80bc,Weber JS,0.340825
uuid-290811d15202475992e0b908f6ec80bc,phase 2 study,0.553213
uuid-290811d15202475992e0b908f6ec80bc,kg,0.363677
uuid-35a7d66e252a457c963f41bd0282b7da,nivolumab,0.394882
uuid-35a7d66e252a457c963f41bd0282b7da,Bristol-Myers Squibb,0.615013
uuid-35a7d66e252a457c963f41bd0282b7da,evaluating,0.632297
uuid-35a7d66e252a457c963f41bd0282b7da,not conducted any controlled clinical trials/studies,0.68988
uuid-35a7d66e252a457c963f41bd0282b7da,considered investigational,0.444455
uuid-35a7d66e252a457c963f41bd0282b7da,purposes other than its labeled indication must be considered investigational,0.40746
uuid-35a7d66e252a457c963f41bd0282b7da,efficacy and safety of nivolumab,0.533855
uuid-262b3524e84b48ae978e6601de944e73,95% CI,0.524855
uuid-262b3524e84b48ae978e6601de944e73,respectively,0.383655
uuid-262b3524e84b48ae978e6601de944e73,ASCO,0.303153
uuid-262b3524e84b48ae978e6601de944e73,Lancet Oncol,0.368041
uuid-262b3524e84b48ae978e6601de944e73,Objective response rate,0.504846
uuid-262b3524e84b48ae978e6601de944e73,ORR,0.465366
uuid-262b3524e84b48ae978e6601de944e73,Median overall survival,0.346516
uuid-262b3524e84b48ae978e6601de944e73,Median OS,0.33538
uuid-262b3524e84b48ae978e6601de944e73,ASCO 2015,0.336983
uuid-262b3524e84b48ae978e6601de944e73,small cell lung cancer,0.336892
uuid-262b3524e84b48ae978e6601de944e73,SCLC,0.344367
uuid-262b3524e84b48ae978e6601de944e73,Antonia SJ,0.55269
uuid-262b3524e84b48ae978e6601de944e73,Median duration of response,0.649605
uuid-15f25e51c9e44d49b6261340557fa848,nivolumab,0.418454
uuid-64ba69a894dd4a5d9cec6a592e73042c,requested,0.31492
uuid-64ba69a894dd4a5d9cec6a592e73042c,ESMO,0.363774
uuid-64ba69a894dd4a5d9cec6a592e73042c,Horn L,0.346129
uuid-6018c4a2704741f99d1a6719c18e4949,nivolumab,0.360862
uuid-8b09313fb44f4815b19db1cdc6d4e7da,patients,0.476598
uuid-8b09313fb44f4815b19db1cdc6d4e7da,considered investigational,0.418845
uuid-8b09313fb44f4815b19db1cdc6d4e7da,patients with advanced or metastatic,0.382423
uuid-8b09313fb44f4815b19db1cdc6d4e7da,nivolumab combined with ipilimumab,0.368421
uuid-8b09313fb44f4815b19db1cdc6d4e7da,tumors,0.584977
uuid-8b09313fb44f4815b19db1cdc6d4e7da,small cell lung cancer,0.536331
uuid-8b09313fb44f4815b19db1cdc6d4e7da,grade,0.346793
uuid-8b09313fb44f4815b19db1cdc6d4e7da,SCLC,0.488797
uuid-8b09313fb44f4815b19db1cdc6d4e7da,grade 3 to 4 AEs,0.544391
uuid-8b09313fb44f4815b19db1cdc6d4e7da,phase 1/2 study CA209-032,0.520275
uuid-8b09313fb44f4815b19db1cdc6d4e7da,evaluates the efficacy of nivolumab monotherapy,0.512704
uuid-295d32024564428dbd2a1061573bb9f2,requested,0.331755
uuid-295d32024564428dbd2a1061573bb9f2,ESMO,0.575268
uuid-295d32024564428dbd2a1061573bb9f2,Horn L,0.594256
uuid-295d32024564428dbd2a1061573bb9f2,platinum-based doublet chemotherapy,0.362148
uuid-b68b6d07d246499ab0f1b40233aa7b73,search of published literature,0.394524
uuid-b68b6d07d246499ab0f1b40233aa7b73,Additionally,0.413583
uuid-b68b6d07d246499ab0f1b40233aa7b73,ongoing,0.322117
uuid-b68b6d07d246499ab0f1b40233aa7b73,PubMed and EMBASE,0.391671
uuid-b68b6d07d246499ab0f1b40233aa7b73,detailed search of www.clinicaltrials.gov,0.375936
uuid-b68b6d07d246499ab0f1b40233aa7b73,efficacy and safety of nivolumab,0.370699
uuid-b68b6d07d246499ab0f1b40233aa7b73,not identify any planned,0.34283
uuid-b68b6d07d246499ab0f1b40233aa7b73,Weber JS,0.319229
uuid-b68b6d07d246499ab0f1b40233aa7b73,not identify any citations relevant to your request,0.447813
uuid-b68b6d07d246499ab0f1b40233aa7b73,present using the following search terms,0.408199
uuid-7cc842899a814f439d81fbfa59ce4001,evaluating,0.372764
uuid-7cc842899a814f439d81fbfa59ce4001,not conducted any controlled clinical trials/studies,0.308647
uuid-7cc842899a814f439d81fbfa59ce4001,NSCLC,0.632519
uuid-7cc842899a814f439d81fbfa59ce4001,non-small cell lung cancer,0.584772
uuid-7cc842899a814f439d81fbfa59ce4001,patients,0.537052
uuid-7cc842899a814f439d81fbfa59ce4001,considered investigational,0.476573
uuid-7cc842899a814f439d81fbfa59ce4001,phase 1 study,0.381366
uuid-7cc842899a814f439d81fbfa59ce4001,small cell lung cancer,0.400264
uuid-7cc842899a814f439d81fbfa59ce4001,SCLC,0.407783
uuid-7cc842899a814f439d81fbfa59ce4001,therapy,0.343145
uuid-7cc842899a814f439d81fbfa59ce4001,safety of nivolumab monotherapy,0.405943
uuid-90e628160c294e9bae0f55ce78827299,Additionally,0.33664
uuid-90e628160c294e9bae0f55ce78827299,ongoing,0.320419
uuid-90e628160c294e9bae0f55ce78827299,detailed search of www.clinicaltrials.gov,0.321063
uuid-90e628160c294e9bae0f55ce78827299,not identify any planned,0.32191
uuid-90e628160c294e9bae0f55ce78827299,safety,0.358284
uuid-cfb6d56b855b47fd95b80f1a438b4b6d,requested,0.728486
uuid-68d2f0ca1cae44128d69757311d08c60,OS,0.493666
uuid-68d2f0ca1cae44128d69757311d08c60,95% CI,0.872793
uuid-68d2f0ca1cae44128d69757311d08c60,respectively,0.581917
uuid-68d2f0ca1cae44128d69757311d08c60,Objective response rate,0.558489
uuid-68d2f0ca1cae44128d69757311d08c60,ORR,0.705401
uuid-68d2f0ca1cae44128d69757311d08c60,PFS,0.331929
uuid-68d2f0ca1cae44128d69757311d08c60,Median overall survival,0.793083
uuid-68d2f0ca1cae44128d69757311d08c60,monotherapy,0.422517
uuid-68d2f0ca1cae44128d69757311d08c60,Median OS,0.808565
uuid-68d2f0ca1cae44128d69757311d08c60,PD-L1,0.302111
uuid-68d2f0ca1cae44128d69757311d08c60,docetaxel,0.481228
uuid-68d2f0ca1cae44128d69757311d08c60,hazard ratio,0.844622
uuid-68d2f0ca1cae44128d69757311d08c60,Median duration of response,0.34536
uuid-14ce1ac2af5941b391e90672fb1bd575,nivolumab,0.43643
uuid-3c31aa2e42b04b87b51a3c67224d0b69,requested,0.470406
uuid-3c31aa2e42b04b87b51a3c67224d0b69,Opdivo,0.305711
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,OS,0.493666
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,95% CI,0.872793
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,respectively,0.581917
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,Objective response rate,0.558489
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,ORR,0.705401
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,PFS,0.331929
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,Median overall survival,0.793083
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,monotherapy,0.422517
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,Median OS,0.808565
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,PD-L1,0.302111
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,docetaxel,0.481228
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,hazard ratio,0.844622
uuid-7bf47f7a1d8b4e72aba9bd8d47472679,Median duration of response,0.34536
uuid-ee1f734341f34590944a7bd725853f2d,respectively,0.397695
uuid-ba5904b0e2984c90bd5f7a5d21f2404e,fatigue,0.704358
uuid-bf4c93d2cf1b49329ba4f697edea07b5,nivolumab,0.503241
uuid-bf4c93d2cf1b49329ba4f697edea07b5,Bristol-Myers Squibb,0.552034
uuid-bf4c93d2cf1b49329ba4f697edea07b5,evaluating,0.492767
uuid-bf4c93d2cf1b49329ba4f697edea07b5,not conducted any controlled clinical trials/studies,0.539125
uuid-bf4c93d2cf1b49329ba4f697edea07b5,efficacy and safety of nivolumab,0.415046
uuid-02120f18839a4afb81c140a28ad1bac8,open-label,0.539462
uuid-02120f18839a4afb81c140a28ad1bac8,phase,0.350616
uuid-9f1866fe10ec495b8866ca0a110e5662,nivolumab,0.359772
uuid-4dd27d05836d4e43afc9d62790462270,OS,0.493666
uuid-4dd27d05836d4e43afc9d62790462270,95% CI,0.872793
uuid-4dd27d05836d4e43afc9d62790462270,respectively,0.581917
uuid-4dd27d05836d4e43afc9d62790462270,Objective response rate,0.558489
uuid-4dd27d05836d4e43afc9d62790462270,ORR,0.705401
uuid-4dd27d05836d4e43afc9d62790462270,PFS,0.331929
uuid-4dd27d05836d4e43afc9d62790462270,Median overall survival,0.793083
uuid-4dd27d05836d4e43afc9d62790462270,monotherapy,0.422517
uuid-4dd27d05836d4e43afc9d62790462270,Median OS,0.808565
uuid-4dd27d05836d4e43afc9d62790462270,PD-L1,0.302111
uuid-4dd27d05836d4e43afc9d62790462270,docetaxel,0.481228
uuid-4dd27d05836d4e43afc9d62790462270,hazard ratio,0.844622
uuid-4dd27d05836d4e43afc9d62790462270,Median duration of response,0.34536
uuid-82dec4db1bef446bb760cf3626ff1357,nivolumab,0.666921
uuid-82dec4db1bef446bb760cf3626ff1357,clinicaltrials.gov,0.539611
uuid-e37e1efc7e0748af933eb54a3e7cfd5d,monotherapy,0.444089
uuid-e37e1efc7e0748af933eb54a3e7cfd5d,mg,0.853025
uuid-e37e1efc7e0748af933eb54a3e7cfd5d,kg,0.853742
uuid-e37e1efc7e0748af933eb54a3e7cfd5d,phase,0.318256
uuid-e37e1efc7e0748af933eb54a3e7cfd5d,cohort,0.461371
uuid-6f7878dfc69a48b69e0c710ead116760,95% CI,0.577238
uuid-6f7878dfc69a48b69e0c710ead116760,respectively,0.383291
uuid-6f7878dfc69a48b69e0c710ead116760,ASCO,0.398764
uuid-6f7878dfc69a48b69e0c710ead116760,Lancet Oncol,0.43514
uuid-6f7878dfc69a48b69e0c710ead116760,Objective response rate,0.677708
uuid-6f7878dfc69a48b69e0c710ead116760,ORR,0.619163
uuid-6f7878dfc69a48b69e0c710ead116760,Median overall survival,0.49247
uuid-6f7878dfc69a48b69e0c710ead116760,monotherapy,0.347152
uuid-6f7878dfc69a48b69e0c710ead116760,ipilimumab,0.415888
uuid-6f7878dfc69a48b69e0c710ead116760,Median OS,0.478621
uuid-6f7878dfc69a48b69e0c710ead116760,ASCO 2015,0.526272
uuid-6f7878dfc69a48b69e0c710ead116760,small cell lung cancer,0.464466
uuid-6f7878dfc69a48b69e0c710ead116760,combination,0.359073
uuid-6f7878dfc69a48b69e0c710ead116760,SCLC,0.464865
uuid-6f7878dfc69a48b69e0c710ead116760,Antonia SJ,0.658484
uuid-6f7878dfc69a48b69e0c710ead116760,hazard ratio,0.464726
uuid-6f7878dfc69a48b69e0c710ead116760,Median duration of response,0.415673
uuid-6f7878dfc69a48b69e0c710ead116760,phase 1/2 study CA209-032,0.369954
uuid-6f7878dfc69a48b69e0c710ead116760,evaluates the efficacy of nivolumab monotherapy,0.343527
uuid-107a428cf98140f3853499c1984d30ed,nivolumab,0.355212
uuid-107a428cf98140f3853499c1984d30ed,use of nivolumab for the treatment,0.394686
uuid-107a428cf98140f3853499c1984d30ed,efficacy,0.312963
uuid-107a428cf98140f3853499c1984d30ed,search of published literature,0.305051
uuid-107a428cf98140f3853499c1984d30ed,not approved,0.46217
uuid-107a428cf98140f3853499c1984d30ed,clinical trials investigating the safety,0.517417
uuid-107a428cf98140f3853499c1984d30ed,efficacy and safety of nivolumab,0.302155
uuid-107a428cf98140f3853499c1984d30ed,clinicaltrials.gov,0.50712
uuid-107a428cf98140f3853499c1984d30ed,present using the following search terms,0.325121
uuid-96db16bfa7e54555bf1cb1377a16dfa6,95% CI,0.520262
uuid-96db16bfa7e54555bf1cb1377a16dfa6,respectively,0.504068
uuid-96db16bfa7e54555bf1cb1377a16dfa6,Objective response rate,0.458568
uuid-96db16bfa7e54555bf1cb1377a16dfa6,ORR,0.525868
uuid-96db16bfa7e54555bf1cb1377a16dfa6,Median overall survival,0.455633
uuid-96db16bfa7e54555bf1cb1377a16dfa6,Median OS,0.507448
uuid-96db16bfa7e54555bf1cb1377a16dfa6,docetaxel,0.383115
uuid-96db16bfa7e54555bf1cb1377a16dfa6,hazard ratio,0.462119
uuid-50b5bf55bd00444eaaa06c16a5ccb58b,Opdivo,0.430718
uuid-2955b5cc9bcb4efa8dabed32db62f836,adverse,0.33226
uuid-c9fedc79a1d64bbeaa19458f0f55b196,Opdivo,0.505685
uuid-c9fedc79a1d64bbeaa19458f0f55b196,trial,0.412746
uuid-0b5274cf06414d3c902463adbe2a2239,nivolumab,0.332395
uuid-5c3a78a9b29a466a9243787dd5f2011e,OS,0.488499
uuid-5c3a78a9b29a466a9243787dd5f2011e,95% CI,0.8497
uuid-5c3a78a9b29a466a9243787dd5f2011e,respectively,0.506337
uuid-5c3a78a9b29a466a9243787dd5f2011e,Objective response rate,0.736035
uuid-5c3a78a9b29a466a9243787dd5f2011e,ORR,0.817349
uuid-5c3a78a9b29a466a9243787dd5f2011e,PFS,0.389573
uuid-5c3a78a9b29a466a9243787dd5f2011e,Median overall survival,0.782272
uuid-5c3a78a9b29a466a9243787dd5f2011e,monotherapy,0.511694
uuid-5c3a78a9b29a466a9243787dd5f2011e,Median OS,0.754536
uuid-5c3a78a9b29a466a9243787dd5f2011e,hazard ratio,0.819143
uuid-5c3a78a9b29a466a9243787dd5f2011e,Median duration of response,0.336554
uuid-975ec85304984b5cb8175b8f355316e0,N Engl J Med,0.427636
uuid-975ec85304984b5cb8175b8f355316e0,protocol,0.429136
uuid-975ec85304984b5cb8175b8f355316e0,McDermott DF,0.44782
uuid-975ec85304984b5cb8175b8f355316e0,Motzer RJ,0.430476
uuid-975ec85304984b5cb8175b8f355316e0,Escudier B,0.450887
uuid-975ec85304984b5cb8175b8f355316e0,et al.,0.456026
uuid-975ec85304984b5cb8175b8f355316e0,J Clin Oncol,0.384624
uuid-975ec85304984b5cb8175b8f355316e0,Rizvi NA,0.305616
uuid-975ec85304984b5cb8175b8f355316e0,phase 2 study,0.351446
uuid-ec6a01e00b264fa085a62a3d7f7d4840,requested,0.321026
uuid-26950bb346a84c3b9aaeae6b9b532d34,respectively,0.585622
uuid-26950bb346a84c3b9aaeae6b9b532d34,Objective response rate,0.36976
uuid-26950bb346a84c3b9aaeae6b9b532d34,ORR,0.514781
uuid-26950bb346a84c3b9aaeae6b9b532d34,docetaxel,0.31274
uuid-4500e34bbf6e4ad883ed9d183147280d,Bristol-Myers Squibb,0.591898
uuid-4500e34bbf6e4ad883ed9d183147280d,use of nivolumab for the treatment,0.39247
uuid-4500e34bbf6e4ad883ed9d183147280d,evaluating,0.558561
uuid-4500e34bbf6e4ad883ed9d183147280d,not conducted any controlled clinical trials/studies,0.564128
uuid-4500e34bbf6e4ad883ed9d183147280d,not approved,0.302876
uuid-4500e34bbf6e4ad883ed9d183147280d,efficacy and safety of nivolumab,0.451576
uuid-fd9f791e628c4634be102f29e78ee397,nivolumab,0.383606
uuid-c5229a28304c4b948918e05d1bbabb02,OS,0.506839
uuid-c5229a28304c4b948918e05d1bbabb02,95% CI,0.914259
uuid-c5229a28304c4b948918e05d1bbabb02,respectively,0.57945
uuid-c5229a28304c4b948918e05d1bbabb02,Objective response rate,0.616133
uuid-c5229a28304c4b948918e05d1bbabb02,ORR,0.78386
uuid-c5229a28304c4b948918e05d1bbabb02,PFS,0.374029
uuid-c5229a28304c4b948918e05d1bbabb02,Median overall survival,0.850584
uuid-c5229a28304c4b948918e05d1bbabb02,monotherapy,0.435128
uuid-c5229a28304c4b948918e05d1bbabb02,Median OS,0.829523
uuid-c5229a28304c4b948918e05d1bbabb02,docetaxel,0.347663
uuid-c5229a28304c4b948918e05d1bbabb02,hazard ratio,0.887303
uuid-c5229a28304c4b948918e05d1bbabb02,Median duration of response,0.367027
uuid-9808c376247442419b274825b53cccb3,Bristol-Myers Squibb,0.308908
uuid-9808c376247442419b274825b53cccb3,ESMO,0.449504
uuid-d051d406844b44888287c09217268488,Bristol-Myers Squibb,0.342186
uuid-d051d406844b44888287c09217268488,not conducted any controlled clinical trials/studies,0.304855
uuid-d051d406844b44888287c09217268488,Opdivo,0.461131
uuid-d051d406844b44888287c09217268488,Pubmed literature search,0.614377
uuid-d051d406844b44888287c09217268488,purposes other than its labeled indication must be considered investigational,0.586768
uuid-d051d406844b44888287c09217268488,not identify any citations relevant to your inquiry,0.606133
uuid-d051d406844b44888287c09217268488,adverse,0.305023
uuid-d051d406844b44888287c09217268488,using the following search terms,0.64232
uuid-d051d406844b44888287c09217268488,databases,0.314954
uuid-d051d406844b44888287c09217268488,reported,0.556804
uuid-d1f6472bacfc4ac49d8758b516beba39,patients,0.315933
uuid-57c7635dae874a258573c391df82e5f1,RCC,0.726365
uuid-57c7635dae874a258573c391df82e5f1,phase 1 study,0.331087
uuid-57c7635dae874a258573c391df82e5f1,CA209-003,0.392514
uuid-57c7635dae874a258573c391df82e5f1,investigating,0.594853
uuid-44dd137820df4f358c0cfa15174c233e,Bristol-Myers Squibb,0.506116
uuid-44dd137820df4f358c0cfa15174c233e,evaluating,0.448845
uuid-44dd137820df4f358c0cfa15174c233e,not conducted any controlled clinical trials/studies,0.504259
uuid-44dd137820df4f358c0cfa15174c233e,NSCLC,0.525277
uuid-44dd137820df4f358c0cfa15174c233e,non-small cell lung cancer,0.493709
uuid-44dd137820df4f358c0cfa15174c233e,patients,0.323106
uuid-44dd137820df4f358c0cfa15174c233e,phase 3 study,0.458005
uuid-44dd137820df4f358c0cfa15174c233e,phase 1 study,0.333393
uuid-44dd137820df4f358c0cfa15174c233e,efficacy and safety of nivolumab,0.49999
uuid-52f56410e063472789e917030ea31bbf,Lancet Oncol,0.405203
uuid-52f56410e063472789e917030ea31bbf,requested,0.689771
uuid-52f56410e063472789e917030ea31bbf,Rizvi NA,0.30306
uuid-52f56410e063472789e917030ea31bbf,Weber JS,0.313145
uuid-52f56410e063472789e917030ea31bbf,Antonia SJ,0.412316
uuid-264907a5a0794da88738bbaccb1460a7,ipilimumab,0.385692
uuid-264907a5a0794da88738bbaccb1460a7,ASCO 2015,0.417944
uuid-264907a5a0794da88738bbaccb1460a7,partial response,0.382425
uuid-264907a5a0794da88738bbaccb1460a7,Stable disease,0.586335
uuid-264907a5a0794da88738bbaccb1460a7,cohort,0.307748
uuid-bad726f75b764e5b868bce7b9076b483,95% CI,0.539167
uuid-bad726f75b764e5b868bce7b9076b483,Median overall survival,0.479815
uuid-bad726f75b764e5b868bce7b9076b483,protocol,0.426554
uuid-bad726f75b764e5b868bce7b9076b483,McDermott DF,0.500131
uuid-bad726f75b764e5b868bce7b9076b483,Motzer RJ,0.477178
uuid-bad726f75b764e5b868bce7b9076b483,Median OS,0.603398
uuid-bad726f75b764e5b868bce7b9076b483,Escudier B,0.469696
uuid-bad726f75b764e5b868bce7b9076b483,NEJM,0.387615
uuid-bad726f75b764e5b868bce7b9076b483,et al.,0.46851
uuid-bad726f75b764e5b868bce7b9076b483,J Clin Oncol,0.51661
uuid-bad726f75b764e5b868bce7b9076b483,Topalian,0.337057
uuid-bad726f75b764e5b868bce7b9076b483,phase 2 study,0.399402
uuid-bad726f75b764e5b868bce7b9076b483,hazard ratio,0.538097
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,Bristol-Myers Squibb,0.341822
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,not conducted any controlled clinical trials/studies,0.304507
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,Opdivo,0.461382
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,Pubmed literature search,0.614325
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,not identify any citations relevant to your inquiry,0.606087
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,adverse,0.304183
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,using the following search terms,0.642331
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,databases,0.315039
uuid-6051b7d4f4f04c3f9fe974c4a1d5e0c7,reported,0.556704
uuid-e9c8de9017014361a22d310533252285,requested,0.391186
uuid-e9c8de9017014361a22d310533252285,therapy,0.373744
uuid-a7114d64603a4313924b7393dbc89f5f,use of nivolumab for the treatment,0.441706
uuid-a7114d64603a4313924b7393dbc89f5f,efficacy,0.389985
uuid-a7114d64603a4313924b7393dbc89f5f,patients with advanced or metastatic,0.619544
uuid-a7114d64603a4313924b7393dbc89f5f,nivolumab combined with ipilimumab,0.664503
uuid-a7114d64603a4313924b7393dbc89f5f,not approved,0.524181
uuid-a7114d64603a4313924b7393dbc89f5f,clinical trials investigating the safety,0.62618
uuid-a7114d64603a4313924b7393dbc89f5f,bladder cancer,0.711499
uuid-a7114d64603a4313924b7393dbc89f5f,evaluates the efficacy of nivolumab monotherapy,0.340517
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,Bristol-Myers Squibb,0.611725
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,use of nivolumab for the treatment,0.420145
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,evaluating,0.583719
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,not conducted any controlled clinical trials/studies,0.5976
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,efficacy,0.310171
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,considered investigational,0.302729
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,not approved,0.340848
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,efficacy and safety of nivolumab,0.523802
uuid-e5edd7a1a2c0411aad45bc4d27bcb8cb,safety of nivolumab monotherapy,0.303526
uuid-f102b3783a3b4bd0bebc6c43f77b4360,respectively,0.585622
uuid-f102b3783a3b4bd0bebc6c43f77b4360,Objective response rate,0.36976
uuid-f102b3783a3b4bd0bebc6c43f77b4360,ORR,0.514781
uuid-f102b3783a3b4bd0bebc6c43f77b4360,docetaxel,0.31274
uuid-2c68f28c47d54d6793ed6a9a053307c5,OS,0.560509
uuid-2c68f28c47d54d6793ed6a9a053307c5,95% CI,0.836712
uuid-2c68f28c47d54d6793ed6a9a053307c5,Objective response rate,0.408748
uuid-2c68f28c47d54d6793ed6a9a053307c5,ORR,0.543199
uuid-2c68f28c47d54d6793ed6a9a053307c5,PFS,0.401926
uuid-2c68f28c47d54d6793ed6a9a053307c5,Median overall survival,0.84934
uuid-2c68f28c47d54d6793ed6a9a053307c5,Median OS,0.809358
uuid-2c68f28c47d54d6793ed6a9a053307c5,hazard ratio,0.815409
uuid-2c68f28c47d54d6793ed6a9a053307c5,Overall survival,0.354709
uuid-2c68f28c47d54d6793ed6a9a053307c5,Median duration of response,0.451073
uuid-b243353696924ada9905c06fba2f9a26,requested,0.729914
uuid-452a3e16cc024fae9f5a32f8ef26341c,nivolumab,0.360061
uuid-452a3e16cc024fae9f5a32f8ef26341c,evaluating,0.305802
uuid-452a3e16cc024fae9f5a32f8ef26341c,not conducted any controlled clinical trials/studies,0.302413
uuid-452a3e16cc024fae9f5a32f8ef26341c,RCC,0.631458
uuid-d0c347bce64e4b01aaf417abcbcffd3e,RCC,0.892889
uuid-c57768ce99f74588be1524bc9ce3c022,N Engl J Med,0.753839
uuid-c57768ce99f74588be1524bc9ce3c022,ASCO,0.342612
uuid-c57768ce99f74588be1524bc9ce3c022,protocol,0.302013
uuid-c57768ce99f74588be1524bc9ce3c022,McDermott DF,0.355753
uuid-c57768ce99f74588be1524bc9ce3c022,Motzer RJ,0.324656
uuid-c57768ce99f74588be1524bc9ce3c022,ESMO,0.538975
uuid-c57768ce99f74588be1524bc9ce3c022,Escudier B,0.352616
uuid-c57768ce99f74588be1524bc9ce3c022,et al.,0.384505
uuid-c57768ce99f74588be1524bc9ce3c022,Rizvi NA,0.458633
uuid-c57768ce99f74588be1524bc9ce3c022,Brahmer J,0.636857
uuid-c57768ce99f74588be1524bc9ce3c022,phase 2 study,0.380554
uuid-c57768ce99f74588be1524bc9ce3c022,Horn L,0.507063
uuid-465195cd195b4844aa5219ab1a20b32d,OS,0.571913
uuid-465195cd195b4844aa5219ab1a20b32d,N Engl J Med,0.369953
uuid-465195cd195b4844aa5219ab1a20b32d,95% CI,0.775208
uuid-465195cd195b4844aa5219ab1a20b32d,respectively,0.413035
uuid-465195cd195b4844aa5219ab1a20b32d,Objective response rate,0.439804
uuid-465195cd195b4844aa5219ab1a20b32d,ORR,0.614911
uuid-465195cd195b4844aa5219ab1a20b32d,PFS,0.460926
uuid-465195cd195b4844aa5219ab1a20b32d,Median overall survival,0.77346
uuid-465195cd195b4844aa5219ab1a20b32d,Median OS,0.729549
uuid-465195cd195b4844aa5219ab1a20b32d,Brahmer J,0.393929
uuid-465195cd195b4844aa5219ab1a20b32d,hazard ratio,0.739375
uuid-465195cd195b4844aa5219ab1a20b32d,Median duration of response,0.331927
uuid-e1f4bfc80f624894a970e68cf2d96486,requested,0.305995
uuid-e1f4bfc80f624894a970e68cf2d96486,RCC,0.3243
uuid-3d4aef244311402794cc6ba28cc4bfc7,Bristol-Myers Squibb,0.341822
uuid-3d4aef244311402794cc6ba28cc4bfc7,not conducted any controlled clinical trials/studies,0.304507
uuid-3d4aef244311402794cc6ba28cc4bfc7,Opdivo,0.461382
uuid-3d4aef244311402794cc6ba28cc4bfc7,Pubmed literature search,0.614325
uuid-3d4aef244311402794cc6ba28cc4bfc7,purposes other than its labeled indication must be considered investigational,0.586645
uuid-3d4aef244311402794cc6ba28cc4bfc7,not identify any citations relevant to your inquiry,0.606087
uuid-3d4aef244311402794cc6ba28cc4bfc7,adverse,0.304183
uuid-3d4aef244311402794cc6ba28cc4bfc7,using the following search terms,0.642331
uuid-3d4aef244311402794cc6ba28cc4bfc7,databases,0.315039
uuid-3d4aef244311402794cc6ba28cc4bfc7,reported,0.556704
uuid-555411e5a8754352bee21e03f6a19b56,Pubmed literature search,0.329382
uuid-555411e5a8754352bee21e03f6a19b56,purposes other than its labeled indication must be considered investigational,0.319198
uuid-555411e5a8754352bee21e03f6a19b56,not identify any citations relevant to your inquiry,0.31971
uuid-555411e5a8754352bee21e03f6a19b56,using the following search terms,0.342792
uuid-555411e5a8754352bee21e03f6a19b56,reported,0.384814
uuid-7b953cff44c84570b68cc4ad27b31877,OS,0.506633
uuid-7b953cff44c84570b68cc4ad27b31877,95% CI,0.967378
uuid-7b953cff44c84570b68cc4ad27b31877,Objective response rate,0.476428
uuid-7b953cff44c84570b68cc4ad27b31877,ORR,0.588948
uuid-7b953cff44c84570b68cc4ad27b31877,PFS,0.434723
uuid-7b953cff44c84570b68cc4ad27b31877,Median overall survival,0.872661
uuid-7b953cff44c84570b68cc4ad27b31877,Median OS,0.863233
uuid-7b953cff44c84570b68cc4ad27b31877,hazard ratio,0.904251
uuid-7b953cff44c84570b68cc4ad27b31877,Median duration of response,0.59958
uuid-777cd822c2ba433b91a27ec7c10f3d13,respectively,0.629961
uuid-777cd822c2ba433b91a27ec7c10f3d13,Objective response rate,0.439951
uuid-777cd822c2ba433b91a27ec7c10f3d13,ORR,0.462322
uuid-777cd822c2ba433b91a27ec7c10f3d13,monotherapy,0.352421
uuid-777cd822c2ba433b91a27ec7c10f3d13,docetaxel,0.410479
uuid-803d0f35a470456d859994e03875af78,ASCO,0.637904
uuid-803d0f35a470456d859994e03875af78,Objective response rate,0.354111
uuid-803d0f35a470456d859994e03875af78,phase 1 study,0.317805
uuid-c461ce2a31724945bebab54e548840e4,Bristol-Myers Squibb,0.341822
uuid-c461ce2a31724945bebab54e548840e4,not conducted any controlled clinical trials/studies,0.304507
uuid-c461ce2a31724945bebab54e548840e4,Opdivo,0.461382
uuid-c461ce2a31724945bebab54e548840e4,Pubmed literature search,0.614325
uuid-c461ce2a31724945bebab54e548840e4,purposes other than its labeled indication must be considered investigational,0.586645
uuid-c461ce2a31724945bebab54e548840e4,not identify any citations relevant to your inquiry,0.606087
uuid-c461ce2a31724945bebab54e548840e4,adverse,0.304183
uuid-c461ce2a31724945bebab54e548840e4,using the following search terms,0.642331
uuid-c461ce2a31724945bebab54e548840e4,databases,0.315039
uuid-c461ce2a31724945bebab54e548840e4,reported,0.556704
uuid-87a1d87a9f594cb1a37ece6903ffdea5,95% CI,0.521504
uuid-87a1d87a9f594cb1a37ece6903ffdea5,respectively,0.767897
uuid-87a1d87a9f594cb1a37ece6903ffdea5,Objective response rate,0.538659
uuid-87a1d87a9f594cb1a37ece6903ffdea5,ORR,0.654645
uuid-87a1d87a9f594cb1a37ece6903ffdea5,Median overall survival,0.452038
uuid-87a1d87a9f594cb1a37ece6903ffdea5,monotherapy,0.483738
uuid-87a1d87a9f594cb1a37ece6903ffdea5,Median OS,0.53642
uuid-87a1d87a9f594cb1a37ece6903ffdea5,Brahmer J,0.32469
uuid-87a1d87a9f594cb1a37ece6903ffdea5,PD-L1,0.51017
uuid-87a1d87a9f594cb1a37ece6903ffdea5,docetaxel,0.546704
uuid-87a1d87a9f594cb1a37ece6903ffdea5,hazard ratio,0.509682
uuid-6cf450a7ae9d427ba83e60806db57b2c,nivolumab,0.46506
uuid-6cf450a7ae9d427ba83e60806db57b2c,efficacy,0.346037
uuid-6cf450a7ae9d427ba83e60806db57b2c,phase 1 study,0.308149
uuid-6cf450a7ae9d427ba83e60806db57b2c,clinicaltrials.gov,0.417942
uuid-6cf450a7ae9d427ba83e60806db57b2c,safety,0.42909
uuid-6cf450a7ae9d427ba83e60806db57b2c,phase,0.442444
uuid-6cf450a7ae9d427ba83e60806db57b2c,databases,0.311239
uuid-f1e922bdbc46438da444decf4bdb5144,use of nivolumab for the treatment,0.416242
uuid-f1e922bdbc46438da444decf4bdb5144,patients,0.864267
uuid-f1e922bdbc46438da444decf4bdb5144,considered investigational,0.357632
uuid-f1e922bdbc46438da444decf4bdb5144,tumors,0.344347
uuid-f1e922bdbc46438da444decf4bdb5144,small cell lung cancer,0.457408
uuid-f1e922bdbc46438da444decf4bdb5144,SCLC,0.422647
uuid-f1e922bdbc46438da444decf4bdb5144,therapy,0.394868
uuid-f1e922bdbc46438da444decf4bdb5144,grade 3 to 4 AEs,0.392822
uuid-18648e1e573141e0913712902a68bae8,N Engl J Med,0.427636
uuid-18648e1e573141e0913712902a68bae8,protocol,0.429136
uuid-18648e1e573141e0913712902a68bae8,McDermott DF,0.44782
uuid-18648e1e573141e0913712902a68bae8,Motzer RJ,0.430476
uuid-18648e1e573141e0913712902a68bae8,Escudier B,0.450887
uuid-18648e1e573141e0913712902a68bae8,et al.,0.456026
uuid-18648e1e573141e0913712902a68bae8,J Clin Oncol,0.384624
uuid-18648e1e573141e0913712902a68bae8,Rizvi NA,0.305616
uuid-18648e1e573141e0913712902a68bae8,phase 2 study,0.351446
uuid-62de304b2a734d06bec38dc8d2d252c3,OS,0.62262
uuid-62de304b2a734d06bec38dc8d2d252c3,PFS,0.65903
uuid-62de304b2a734d06bec38dc8d2d252c3,Overall survival,0.644151
uuid-801d7615610a40eea4b3f068fb8adff6,95% CI,0.539167
uuid-801d7615610a40eea4b3f068fb8adff6,Median overall survival,0.479815
uuid-801d7615610a40eea4b3f068fb8adff6,protocol,0.426554
uuid-801d7615610a40eea4b3f068fb8adff6,McDermott DF,0.500131
uuid-801d7615610a40eea4b3f068fb8adff6,Motzer RJ,0.477178
uuid-801d7615610a40eea4b3f068fb8adff6,Median OS,0.603398
uuid-801d7615610a40eea4b3f068fb8adff6,Escudier B,0.469696
uuid-801d7615610a40eea4b3f068fb8adff6,NEJM,0.387615
uuid-801d7615610a40eea4b3f068fb8adff6,et al.,0.46851
uuid-801d7615610a40eea4b3f068fb8adff6,J Clin Oncol,0.51661
uuid-801d7615610a40eea4b3f068fb8adff6,Topalian,0.337057
uuid-801d7615610a40eea4b3f068fb8adff6,phase 2 study,0.399402
uuid-801d7615610a40eea4b3f068fb8adff6,hazard ratio,0.538097
uuid-ed7d29ea8b6c452a8d33eb3f4e9c4c50,requested,0.729914
uuid-663a29303ad44154bef92b2f85ed1e82,Bristol-Myers Squibb,0.341822
uuid-663a29303ad44154bef92b2f85ed1e82,not conducted any controlled clinical trials/studies,0.304507
uuid-663a29303ad44154bef92b2f85ed1e82,Opdivo,0.461382
uuid-663a29303ad44154bef92b2f85ed1e82,Pubmed literature search,0.614325
uuid-663a29303ad44154bef92b2f85ed1e82,purposes other than its labeled indication must be considered investigational,0.586645
uuid-663a29303ad44154bef92b2f85ed1e82,not identify any citations relevant to your inquiry,0.606087
uuid-663a29303ad44154bef92b2f85ed1e82,adverse,0.304183
uuid-663a29303ad44154bef92b2f85ed1e82,using the following search terms,0.642331
uuid-663a29303ad44154bef92b2f85ed1e82,databases,0.315039
uuid-663a29303ad44154bef92b2f85ed1e82,reported,0.556704
uuid-77d9db22edf94e0eb6f879a3be06d65c,Bristol-Myers Squibb,0.341822
uuid-77d9db22edf94e0eb6f879a3be06d65c,not conducted any controlled clinical trials/studies,0.304507
uuid-77d9db22edf94e0eb6f879a3be06d65c,Opdivo,0.461382
uuid-77d9db22edf94e0eb6f879a3be06d65c,Pubmed literature search,0.614325
uuid-77d9db22edf94e0eb6f879a3be06d65c,purposes other than its labeled indication must be considered investigational,0.586645
uuid-77d9db22edf94e0eb6f879a3be06d65c,not identify any citations relevant to your inquiry,0.606087
uuid-77d9db22edf94e0eb6f879a3be06d65c,adverse,0.304183
uuid-77d9db22edf94e0eb6f879a3be06d65c,using the following search terms,0.642331
uuid-77d9db22edf94e0eb6f879a3be06d65c,databases,0.315039
uuid-77d9db22edf94e0eb6f879a3be06d65c,reported,0.556704
uuid-95cf5580148d44b4b527dce5d43280e5,nivolumab,0.308696
uuid-95cf5580148d44b4b527dce5d43280e5,respectively,0.474596
uuid-95cf5580148d44b4b527dce5d43280e5,Objective response rate,0.398542
uuid-95cf5580148d44b4b527dce5d43280e5,ORR,0.387529
uuid-95cf5580148d44b4b527dce5d43280e5,monotherapy,0.618934
uuid-95cf5580148d44b4b527dce5d43280e5,clinical,0.310702
uuid-95cf5580148d44b4b527dce5d43280e5,Antonia SJ,0.303123
uuid-002205d53f8640909d79403c7994c1fd,nivolumab,0.311131
uuid-002205d53f8640909d79403c7994c1fd,Bristol-Myers Squibb,0.593556
uuid-002205d53f8640909d79403c7994c1fd,evaluating,0.577148
uuid-002205d53f8640909d79403c7994c1fd,not conducted any controlled clinical trials/studies,0.639265
uuid-002205d53f8640909d79403c7994c1fd,considered investigational,0.49272
uuid-002205d53f8640909d79403c7994c1fd,purposes other than its labeled indication must be considered investigational,0.347143
uuid-002205d53f8640909d79403c7994c1fd,efficacy and safety of nivolumab,0.484039
uuid-002205d53f8640909d79403c7994c1fd,phase 1/2 study CA209-032,0.30682
uuid-ac355f81957b4ac4adb251d01038255b,nivolumab,0.37309
uuid-f8a454841e7f42e5b271c1766412f099,nivolumab,0.568608
uuid-f8a454841e7f42e5b271c1766412f099,Bristol-Myers Squibb,0.649625
uuid-f8a454841e7f42e5b271c1766412f099,evaluating,0.776743
uuid-f8a454841e7f42e5b271c1766412f099,not conducted any controlled clinical trials/studies,0.808342
uuid-f8a454841e7f42e5b271c1766412f099,Pubmed literature search,0.409567
uuid-f8a454841e7f42e5b271c1766412f099,purposes other than its labeled indication must be considered investigational,0.5323
uuid-f8a454841e7f42e5b271c1766412f099,not identify any citations relevant to your inquiry,0.367153
uuid-f8a454841e7f42e5b271c1766412f099,search of published literature,0.429361
uuid-f8a454841e7f42e5b271c1766412f099,PubMed and EMBASE,0.397626
uuid-f8a454841e7f42e5b271c1766412f099,using the following search terms,0.335399
uuid-f8a454841e7f42e5b271c1766412f099,efficacy and safety of nivolumab,0.702945
uuid-f8a454841e7f42e5b271c1766412f099,present using the following search terms,0.422906
uuid-e0c1bf91ba4448f1bb552954706bc02c,Bristol-Myers Squibb,0.582592
uuid-e0c1bf91ba4448f1bb552954706bc02c,evaluating,0.570233
uuid-e0c1bf91ba4448f1bb552954706bc02c,not conducted any controlled clinical trials/studies,0.622745
uuid-e0c1bf91ba4448f1bb552954706bc02c,considered investigational,0.414397
uuid-e0c1bf91ba4448f1bb552954706bc02c,purposes other than its labeled indication must be considered investigational,0.330115
uuid-e0c1bf91ba4448f1bb552954706bc02c,efficacy and safety of nivolumab,0.459805
uuid-19d339b8226b4cbf939ddcf33d6d8dda,patients,0.450841
uuid-19d339b8226b4cbf939ddcf33d6d8dda,provided in the Detailed Information,0.357756
uuid-19d339b8226b4cbf939ddcf33d6d8dda,trial,0.499087
uuid-6b491c252a3c4070a858ac40a6b42c59,docetaxel,0.410401
uuid-8c5b4cc43a6c4c628a74648e017a11d6,nivolumab,0.33639
uuid-8c5b4cc43a6c4c628a74648e017a11d6,Objective response rate,0.459398
uuid-8c5b4cc43a6c4c628a74648e017a11d6,clinicaltrials.gov,0.632338
uuid-cb505b57669f45f5af0b50141762a7fd,patients with advanced or metastatic,0.478326
uuid-cb505b57669f45f5af0b50141762a7fd,nivolumab combined with ipilimumab,0.498766
uuid-cb505b57669f45f5af0b50141762a7fd,not approved,0.34724
uuid-cb505b57669f45f5af0b50141762a7fd,clinical trials investigating the safety,0.426729
uuid-cb505b57669f45f5af0b50141762a7fd,bladder cancer,0.6548
uuid-8e2ee94e49cd4e958f04dbdb244fce38,95% CI,0.384282
uuid-8e2ee94e49cd4e958f04dbdb244fce38,ASCO,0.40687
uuid-8e2ee94e49cd4e958f04dbdb244fce38,Objective response rate,0.409634
uuid-8e2ee94e49cd4e958f04dbdb244fce38,Median overall survival,0.319094
uuid-8e2ee94e49cd4e958f04dbdb244fce38,Median OS,0.403026
uuid-8e2ee94e49cd4e958f04dbdb244fce38,ASCO 2015,0.386899
uuid-8e2ee94e49cd4e958f04dbdb244fce38,hazard ratio,0.403406
uuid-a48db85c64f449ca89bd5e35ad8438dc,OS,0.306979
uuid-a48db85c64f449ca89bd5e35ad8438dc,95% CI,0.378929
uuid-a48db85c64f449ca89bd5e35ad8438dc,ORR,0.325152
uuid-a48db85c64f449ca89bd5e35ad8438dc,Median overall survival,0.416865
uuid-a48db85c64f449ca89bd5e35ad8438dc,Median OS,0.343981
uuid-a48db85c64f449ca89bd5e35ad8438dc,hazard ratio,0.35636
uuid-386946f6342745d79236103a3c09c7e5,N Engl J Med,0.616236
uuid-386946f6342745d79236103a3c09c7e5,respectively,0.409266
uuid-386946f6342745d79236103a3c09c7e5,ASCO,0.373445
uuid-386946f6342745d79236103a3c09c7e5,ESMO,0.378373
uuid-386946f6342745d79236103a3c09c7e5,Brahmer J,0.712806
uuid-386946f6342745d79236103a3c09c7e5,docetaxel,0.327482
uuid-386946f6342745d79236103a3c09c7e5,Horn L,0.502372
uuid-98a04320b625440e866928582e3670d6,95% CI,0.384282
uuid-98a04320b625440e866928582e3670d6,ASCO,0.40687
uuid-98a04320b625440e866928582e3670d6,Objective response rate,0.409634
uuid-98a04320b625440e866928582e3670d6,Median overall survival,0.319094
uuid-98a04320b625440e866928582e3670d6,Median OS,0.403026
uuid-98a04320b625440e866928582e3670d6,ASCO 2015,0.386899
uuid-98a04320b625440e866928582e3670d6,hazard ratio,0.403406
uuid-9595fb957998433588ef753c3dc4e4ce,nivolumab,0.370784
uuid-9595fb957998433588ef753c3dc4e4ce,Bristol-Myers Squibb,0.623808
uuid-9595fb957998433588ef753c3dc4e4ce,use of nivolumab for the treatment,0.379401
uuid-9595fb957998433588ef753c3dc4e4ce,evaluating,0.698643
uuid-9595fb957998433588ef753c3dc4e4ce,not conducted any controlled clinical trials/studies,0.724408
uuid-9595fb957998433588ef753c3dc4e4ce,considered investigational,0.443617
uuid-9595fb957998433588ef753c3dc4e4ce,purposes other than its labeled indication must be considered investigational,0.387373
uuid-9595fb957998433588ef753c3dc4e4ce,efficacy and safety of nivolumab,0.583716
uuid-9595fb957998433588ef753c3dc4e4ce,safety of nivolumab monotherapy,0.336788
uuid-164fd742386c4cad97a9a41a54c38836,N Engl J Med,0.616236
uuid-164fd742386c4cad97a9a41a54c38836,respectively,0.409266
uuid-164fd742386c4cad97a9a41a54c38836,ASCO,0.373445
uuid-164fd742386c4cad97a9a41a54c38836,ESMO,0.378373
uuid-164fd742386c4cad97a9a41a54c38836,Brahmer J,0.712806
uuid-164fd742386c4cad97a9a41a54c38836,docetaxel,0.327482
uuid-164fd742386c4cad97a9a41a54c38836,Horn L,0.502372
uuid-7a77983f511749329567cabd3ea15415,OS,0.324073
uuid-7a77983f511749329567cabd3ea15415,95% CI,0.660124
uuid-7a77983f511749329567cabd3ea15415,respectively,0.809559
uuid-7a77983f511749329567cabd3ea15415,Objective response rate,0.668092
uuid-7a77983f511749329567cabd3ea15415,ORR,0.764824
uuid-7a77983f511749329567cabd3ea15415,Median overall survival,0.58138
uuid-7a77983f511749329567cabd3ea15415,monotherapy,0.532169
uuid-7a77983f511749329567cabd3ea15415,Median OS,0.629224
uuid-7a77983f511749329567cabd3ea15415,PD-L1,0.379606
uuid-7a77983f511749329567cabd3ea15415,docetaxel,0.584757
uuid-7a77983f511749329567cabd3ea15415,hazard ratio,0.649699
uuid-2097e8f1fe344767a4522b2266fe00e8,trial,0.405524
uuid-01002256d1a647bc92ad10c236c46122,trial,0.405524
uuid-ac530f86c3e14dc2a3b8148df91c2421,trial,0.405524
uuid-3607b4b39a70436c877d4c81e8563103,patients with advanced or metastatic,0.468858
uuid-3607b4b39a70436c877d4c81e8563103,nivolumab combined with ipilimumab,0.446918
uuid-3607b4b39a70436c877d4c81e8563103,not approved,0.352562
uuid-3607b4b39a70436c877d4c81e8563103,clinical trials investigating the safety,0.429501
uuid-3607b4b39a70436c877d4c81e8563103,bladder cancer,0.950698
uuid-ad95fb27b99e46d4a68a5540c091f117,nivolumab,0.324658
uuid-ad95fb27b99e46d4a68a5540c091f117,use of nivolumab for the treatment,0.543355
uuid-ad95fb27b99e46d4a68a5540c091f117,evaluating,0.348676
uuid-ad95fb27b99e46d4a68a5540c091f117,efficacy,0.388907
uuid-ad95fb27b99e46d4a68a5540c091f117,patients,0.419915
uuid-ad95fb27b99e46d4a68a5540c091f117,search of published literature,0.449959
uuid-ad95fb27b99e46d4a68a5540c091f117,PubMed and EMBASE,0.444573
uuid-ad95fb27b99e46d4a68a5540c091f117,not approved,0.582429
uuid-ad95fb27b99e46d4a68a5540c091f117,clinical trials investigating the safety,0.64854
uuid-ad95fb27b99e46d4a68a5540c091f117,efficacy and safety of nivolumab,0.399101
uuid-ad95fb27b99e46d4a68a5540c091f117,present using the following search terms,0.465296
uuid-74ec7b2eb05048ffbc01137a70e7bd66,OS,0.62262
uuid-74ec7b2eb05048ffbc01137a70e7bd66,PFS,0.65903
uuid-74ec7b2eb05048ffbc01137a70e7bd66,Overall survival,0.644151
uuid-d806bf30b2d44ee7924dfb7eeb693c51,use of nivolumab for the treatment,0.440423
uuid-d806bf30b2d44ee7924dfb7eeb693c51,search of published literature,0.311531
uuid-d806bf30b2d44ee7924dfb7eeb693c51,PubMed and EMBASE,0.312811
uuid-d806bf30b2d44ee7924dfb7eeb693c51,not approved,0.404782
uuid-d806bf30b2d44ee7924dfb7eeb693c51,open-label,0.578291
uuid-d806bf30b2d44ee7924dfb7eeb693c51,clinical trials investigating the safety,0.440014
uuid-d806bf30b2d44ee7924dfb7eeb693c51,present using the following search terms,0.328669
uuid-d806bf30b2d44ee7924dfb7eeb693c51,phase,0.41185
uuid-b1479376723c4d4fbe8245346407cfda,patients,0.347878
uuid-b1479376723c4d4fbe8245346407cfda,trial,0.315929
uuid-b1479376723c4d4fbe8245346407cfda,mg,0.672766
uuid-b1479376723c4d4fbe8245346407cfda,kg,0.689662
uuid-b1479376723c4d4fbe8245346407cfda,cohort,0.381841
uuid-b1479376723c4d4fbe8245346407cfda,reported,0.313595
uuid-b71ebda32145479fb9695443219cac88,nivolumab,0.455347
uuid-1e6a86def7f0482eacdbd0c303d72828,nivolumab,0.429882
uuid-1e6a86def7f0482eacdbd0c303d72828,Opdivo,0.516365
uuid-1e6a86def7f0482eacdbd0c303d72828,ipilimumab,0.547272
uuid-1e6a86def7f0482eacdbd0c303d72828,ASCO 2015,0.33214
uuid-1e6a86def7f0482eacdbd0c303d72828,using the following search terms,0.329579
uuid-1e6a86def7f0482eacdbd0c303d72828,combination,0.392107
uuid-ba08a91fa9674925a58ea0b8813a3df8,nivolumab,0.373056
uuid-2347af71ae76421f9d46d2e4c1cf5fc1,provided in the Detailed Information,0.648754
uuid-2347af71ae76421f9d46d2e4c1cf5fc1,clinical,0.619366
uuid-b067ef5d9ae94aa99effb511cd209a33,nivolumab,0.359772
uuid-47bae17f1f1e480e9ae507b781ca53d8,nivolumab,0.43643
uuid-ca9d09989c244286bdafc704b49d67e5,nivolumab,0.359772
uuid-ca201ea5818f46bea38df6fa469b5ddf,requested,0.366309
uuid-3690fc287ac24a9683ad0035dd7f110f,nivolumab,0.564691
uuid-3690fc287ac24a9683ad0035dd7f110f,evaluating,0.300205
uuid-3690fc287ac24a9683ad0035dd7f110f,NSCLC,0.320438
uuid-3690fc287ac24a9683ad0035dd7f110f,patients,0.313016
uuid-3690fc287ac24a9683ad0035dd7f110f,considered investigational,0.589931
uuid-3690fc287ac24a9683ad0035dd7f110f,RCC,0.305348
uuid-3690fc287ac24a9683ad0035dd7f110f,search of published literature,0.386605
uuid-3690fc287ac24a9683ad0035dd7f110f,tumors,0.339821
uuid-3690fc287ac24a9683ad0035dd7f110f,PubMed and EMBASE,0.377802
uuid-3690fc287ac24a9683ad0035dd7f110f,small cell lung cancer,0.574156
uuid-3690fc287ac24a9683ad0035dd7f110f,efficacy and safety of nivolumab,0.355949
uuid-3690fc287ac24a9683ad0035dd7f110f,SCLC,0.589914
uuid-3690fc287ac24a9683ad0035dd7f110f,therapy,0.569846
uuid-3690fc287ac24a9683ad0035dd7f110f,present using the following search terms,0.373846
uuid-3690fc287ac24a9683ad0035dd7f110f,phase 1/2 study CA209-032,0.476085
uuid-3690fc287ac24a9683ad0035dd7f110f,evaluates the efficacy of nivolumab monotherapy,0.424659
uuid-1a62fc7f3590496282dfe9ace149cca2,considered investigational,0.458008
uuid-1a62fc7f3590496282dfe9ace149cca2,small cell lung cancer,0.704806
uuid-1a62fc7f3590496282dfe9ace149cca2,partial response,0.47705
uuid-1a62fc7f3590496282dfe9ace149cca2,SCLC,0.783138
uuid-1a62fc7f3590496282dfe9ace149cca2,therapy,0.843881
uuid-1a62fc7f3590496282dfe9ace149cca2,relapsed,0.581002
uuid-1a62fc7f3590496282dfe9ace149cca2,phase 1/2 study CA209-032,0.462661
uuid-1a62fc7f3590496282dfe9ace149cca2,evaluates the efficacy of nivolumab monotherapy,0.388238
uuid-e5170b95428d41b0b4bcc946d232eb40,docetaxel,0.410401
uuid-9a8a82db632c4dd895f658c68cdacbae,95% CI,0.577238
uuid-9a8a82db632c4dd895f658c68cdacbae,respectively,0.383291
uuid-9a8a82db632c4dd895f658c68cdacbae,ASCO,0.398764
uuid-9a8a82db632c4dd895f658c68cdacbae,Lancet Oncol,0.43514
uuid-9a8a82db632c4dd895f658c68cdacbae,Objective response rate,0.677708
uuid-9a8a82db632c4dd895f658c68cdacbae,ORR,0.619163
uuid-9a8a82db632c4dd895f658c68cdacbae,Median overall survival,0.49247
uuid-9a8a82db632c4dd895f658c68cdacbae,monotherapy,0.347152
uuid-9a8a82db632c4dd895f658c68cdacbae,ipilimumab,0.415888
uuid-9a8a82db632c4dd895f658c68cdacbae,Median OS,0.478621
uuid-9a8a82db632c4dd895f658c68cdacbae,ASCO 2015,0.526272
uuid-9a8a82db632c4dd895f658c68cdacbae,small cell lung cancer,0.464466
uuid-9a8a82db632c4dd895f658c68cdacbae,combination,0.359073
uuid-9a8a82db632c4dd895f658c68cdacbae,SCLC,0.464865
uuid-9a8a82db632c4dd895f658c68cdacbae,Antonia SJ,0.658484
uuid-9a8a82db632c4dd895f658c68cdacbae,hazard ratio,0.464726
uuid-9a8a82db632c4dd895f658c68cdacbae,Median duration of response,0.415673
uuid-9a8a82db632c4dd895f658c68cdacbae,phase 1/2 study CA209-032,0.369954
uuid-9a8a82db632c4dd895f658c68cdacbae,evaluates the efficacy of nivolumab monotherapy,0.343527
uuid-01740a87d7f54c338b2c5c561aac2c23,patients,0.601203
uuid-01740a87d7f54c338b2c5c561aac2c23,grade 3 to 4 AEs,0.306462
uuid-e24ce822e2ad4047aff00300a62998f4,nivolumab,0.322633
uuid-e24ce822e2ad4047aff00300a62998f4,Bristol-Myers Squibb,0.331267
uuid-e24ce822e2ad4047aff00300a62998f4,evaluating,0.484494
uuid-e24ce822e2ad4047aff00300a62998f4,not conducted any controlled clinical trials/studies,0.474639
uuid-e24ce822e2ad4047aff00300a62998f4,search of published literature,0.667693
uuid-e24ce822e2ad4047aff00300a62998f4,Additionally,0.675635
uuid-e24ce822e2ad4047aff00300a62998f4,ongoing,0.541245
uuid-e24ce822e2ad4047aff00300a62998f4,PubMed and EMBASE,0.663156
uuid-e24ce822e2ad4047aff00300a62998f4,detailed search of www.clinicaltrials.gov,0.63401
uuid-e24ce822e2ad4047aff00300a62998f4,efficacy and safety of nivolumab,0.628725
uuid-e24ce822e2ad4047aff00300a62998f4,not identify any planned,0.573361
uuid-e24ce822e2ad4047aff00300a62998f4,not identify any citations relevant to your request,0.75121
uuid-e24ce822e2ad4047aff00300a62998f4,present using the following search terms,0.687332
uuid-11fe24bd7c2b48e093a77dd4a206e37a,protocol,0.451855
uuid-11fe24bd7c2b48e093a77dd4a206e37a,McDermott DF,0.374896
uuid-11fe24bd7c2b48e093a77dd4a206e37a,Motzer RJ,0.398813
uuid-11fe24bd7c2b48e093a77dd4a206e37a,Escudier B,0.381202
uuid-11fe24bd7c2b48e093a77dd4a206e37a,NEJM,0.416259
uuid-11fe24bd7c2b48e093a77dd4a206e37a,et al.,0.338778
uuid-11fe24bd7c2b48e093a77dd4a206e37a,J Clin Oncol,0.378248
uuid-11fe24bd7c2b48e093a77dd4a206e37a,Topalian,0.446974
uuid-11fe24bd7c2b48e093a77dd4a206e37a,Weber JS,0.315915
uuid-11fe24bd7c2b48e093a77dd4a206e37a,phase 2 study,0.300429
uuid-66be308f881b4204b2c7fbe91192e463,trial,0.446819
uuid-f05338785f5642cfaf367b15ebcafd3d,patients,0.41524
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,nivolumab,0.364385
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,Bristol-Myers Squibb,0.560666
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,evaluating,0.530001
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,not conducted any controlled clinical trials/studies,0.593642
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,purposes other than its labeled indication must be considered investigational,0.385609
uuid-3e1a8c88ec0f49d8a78c22d1f23320a3,efficacy and safety of nivolumab,0.461089
uuid-32a618dbe6fc42faa94556b3fd63fd1a,nivolumab,0.324658
uuid-32a618dbe6fc42faa94556b3fd63fd1a,use of nivolumab for the treatment,0.543355
uuid-32a618dbe6fc42faa94556b3fd63fd1a,evaluating,0.348676
uuid-32a618dbe6fc42faa94556b3fd63fd1a,efficacy,0.388907
uuid-32a618dbe6fc42faa94556b3fd63fd1a,patients,0.419915
uuid-32a618dbe6fc42faa94556b3fd63fd1a,search of published literature,0.449959
uuid-32a618dbe6fc42faa94556b3fd63fd1a,PubMed and EMBASE,0.444573
uuid-32a618dbe6fc42faa94556b3fd63fd1a,not approved,0.582429
uuid-32a618dbe6fc42faa94556b3fd63fd1a,clinical trials investigating the safety,0.64854
uuid-32a618dbe6fc42faa94556b3fd63fd1a,efficacy and safety of nivolumab,0.399101
uuid-32a618dbe6fc42faa94556b3fd63fd1a,present using the following search terms,0.465296
uuid-60d543501c034c61ac698ce6c5d76769,patients,0.313422
uuid-60d543501c034c61ac698ce6c5d76769,mg,0.797913
uuid-60d543501c034c61ac698ce6c5d76769,kg,0.732714
uuid-c2e0671f2db847ed8ed6561db62d14c7,nivolumab,0.555166
uuid-c2e0671f2db847ed8ed6561db62d14c7,Bristol-Myers Squibb,0.654773
uuid-c2e0671f2db847ed8ed6561db62d14c7,evaluating,0.829728
uuid-c2e0671f2db847ed8ed6561db62d14c7,not conducted any controlled clinical trials/studies,0.872305
uuid-c2e0671f2db847ed8ed6561db62d14c7,Pubmed literature search,0.56469
uuid-c2e0671f2db847ed8ed6561db62d14c7,purposes other than its labeled indication must be considered investigational,0.681966
uuid-c2e0671f2db847ed8ed6561db62d14c7,not identify any citations relevant to your inquiry,0.509739
uuid-c2e0671f2db847ed8ed6561db62d14c7,search of published literature,0.477064
uuid-c2e0671f2db847ed8ed6561db62d14c7,PubMed and EMBASE,0.438779
uuid-c2e0671f2db847ed8ed6561db62d14c7,using the following search terms,0.489392
uuid-c2e0671f2db847ed8ed6561db62d14c7,efficacy and safety of nivolumab,0.759891
uuid-c2e0671f2db847ed8ed6561db62d14c7,present using the following search terms,0.44329
uuid-389574e4129b44f181cfceb42b65fb21,Bristol-Myers Squibb,0.347451
uuid-389574e4129b44f181cfceb42b65fb21,not conducted any controlled clinical trials/studies,0.309998
uuid-389574e4129b44f181cfceb42b65fb21,Opdivo,0.466158
uuid-389574e4129b44f181cfceb42b65fb21,Pubmed literature search,0.608843
uuid-389574e4129b44f181cfceb42b65fb21,purposes other than its labeled indication must be considered investigational,0.583133
uuid-389574e4129b44f181cfceb42b65fb21,not identify any citations relevant to your inquiry,0.601189
uuid-389574e4129b44f181cfceb42b65fb21,adverse,0.310461
uuid-389574e4129b44f181cfceb42b65fb21,using the following search terms,0.636351
uuid-389574e4129b44f181cfceb42b65fb21,databases,0.312052
uuid-389574e4129b44f181cfceb42b65fb21,reported,0.561127
uuid-69261a5c6a184893ada6ed18e57ff1b1,Median OS,0.366388
uuid-69261a5c6a184893ada6ed18e57ff1b1,open-label,0.353556
uuid-69261a5c6a184893ada6ed18e57ff1b1,hazard ratio,0.300103
uuid-69261a5c6a184893ada6ed18e57ff1b1,cohort,0.418199
uuid-60541fedb6df49b5b3f32538033c64c2,Bristol-Myers Squibb,0.341822
uuid-60541fedb6df49b5b3f32538033c64c2,not conducted any controlled clinical trials/studies,0.304507
uuid-60541fedb6df49b5b3f32538033c64c2,Opdivo,0.461382
uuid-60541fedb6df49b5b3f32538033c64c2,Pubmed literature search,0.614325
uuid-60541fedb6df49b5b3f32538033c64c2,purposes other than its labeled indication must be considered investigational,0.586645
uuid-60541fedb6df49b5b3f32538033c64c2,not identify any citations relevant to your inquiry,0.606087
uuid-60541fedb6df49b5b3f32538033c64c2,adverse,0.304183
uuid-60541fedb6df49b5b3f32538033c64c2,using the following search terms,0.642331
uuid-60541fedb6df49b5b3f32538033c64c2,databases,0.315039
uuid-60541fedb6df49b5b3f32538033c64c2,reported,0.556704
uuid-54578c0046d047fa8a69a7bb9dcf8eea,evaluating,0.350845
uuid-54578c0046d047fa8a69a7bb9dcf8eea,not conducted any controlled clinical trials/studies,0.345107
uuid-54578c0046d047fa8a69a7bb9dcf8eea,search of published literature,0.385331
uuid-54578c0046d047fa8a69a7bb9dcf8eea,Additionally,0.40981
uuid-54578c0046d047fa8a69a7bb9dcf8eea,ongoing,0.457998
uuid-54578c0046d047fa8a69a7bb9dcf8eea,PubMed and EMBASE,0.378285
uuid-54578c0046d047fa8a69a7bb9dcf8eea,detailed search of www.clinicaltrials.gov,0.428522
uuid-54578c0046d047fa8a69a7bb9dcf8eea,efficacy and safety of nivolumab,0.407868
uuid-54578c0046d047fa8a69a7bb9dcf8eea,not identify any planned,0.444729
uuid-54578c0046d047fa8a69a7bb9dcf8eea,combination,0.388252
uuid-54578c0046d047fa8a69a7bb9dcf8eea,BMS,0.316104
uuid-54578c0046d047fa8a69a7bb9dcf8eea,not identify any citations relevant to your request,0.438151
uuid-54578c0046d047fa8a69a7bb9dcf8eea,present using the following search terms,0.377101
uuid-0b09846e60e2436782a86936390de7cd,ipilimumab,0.385692
uuid-0b09846e60e2436782a86936390de7cd,ASCO 2015,0.417944
uuid-0b09846e60e2436782a86936390de7cd,partial response,0.382425
uuid-0b09846e60e2436782a86936390de7cd,Stable disease,0.586335
uuid-0b09846e60e2436782a86936390de7cd,cohort,0.307748
uuid-53d23865d5434cecad5becac44e0e29a,Bristol-Myers Squibb,0.341822
uuid-53d23865d5434cecad5becac44e0e29a,not conducted any controlled clinical trials/studies,0.304507
uuid-53d23865d5434cecad5becac44e0e29a,Opdivo,0.461382
uuid-53d23865d5434cecad5becac44e0e29a,Pubmed literature search,0.614325
uuid-53d23865d5434cecad5becac44e0e29a,purposes other than its labeled indication must be considered investigational,0.586645
uuid-53d23865d5434cecad5becac44e0e29a,not identify any citations relevant to your inquiry,0.606087
uuid-53d23865d5434cecad5becac44e0e29a,adverse,0.304183
uuid-53d23865d5434cecad5becac44e0e29a,using the following search terms,0.642331
uuid-53d23865d5434cecad5becac44e0e29a,databases,0.315039
uuid-53d23865d5434cecad5becac44e0e29a,reported,0.556704
uuid-d12b00f52c7a4382bdf8d44b98dec46b,N Engl J Med,0.398318
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Lancet Oncol,0.625306
uuid-d12b00f52c7a4382bdf8d44b98dec46b,patients,0.316943
uuid-d12b00f52c7a4382bdf8d44b98dec46b,protocol,0.367524
uuid-d12b00f52c7a4382bdf8d44b98dec46b,McDermott DF,0.397563
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Motzer RJ,0.387004
uuid-d12b00f52c7a4382bdf8d44b98dec46b,phase 3 study,0.676576
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Escudier B,0.399478
uuid-d12b00f52c7a4382bdf8d44b98dec46b,et al.,0.380199
uuid-d12b00f52c7a4382bdf8d44b98dec46b,J Clin Oncol,0.334518
uuid-d12b00f52c7a4382bdf8d44b98dec46b,melanoma,0.343575
uuid-d12b00f52c7a4382bdf8d44b98dec46b,phase 1 study,0.394835
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Rizvi NA,0.675421
uuid-d12b00f52c7a4382bdf8d44b98dec46b,CA209-003,0.304686
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Weber JS,0.652485
uuid-d12b00f52c7a4382bdf8d44b98dec46b,phase 2 study,0.592096
uuid-d12b00f52c7a4382bdf8d44b98dec46b,Antonia SJ,0.347602
uuid-4005d18a98544dd2a4065bf4c755f43b,patients with advanced or metastatic,0.468858
uuid-4005d18a98544dd2a4065bf4c755f43b,nivolumab combined with ipilimumab,0.446918
uuid-4005d18a98544dd2a4065bf4c755f43b,not approved,0.352562
uuid-4005d18a98544dd2a4065bf4c755f43b,clinical trials investigating the safety,0.429501
uuid-4005d18a98544dd2a4065bf4c755f43b,bladder cancer,0.950698
uuid-47e789419a794b6a8d94b90492dd5715,patients with advanced or metastatic,0.468858
uuid-47e789419a794b6a8d94b90492dd5715,nivolumab combined with ipilimumab,0.446918
uuid-47e789419a794b6a8d94b90492dd5715,not approved,0.352562
uuid-47e789419a794b6a8d94b90492dd5715,clinical trials investigating the safety,0.429501
uuid-47e789419a794b6a8d94b90492dd5715,bladder cancer,0.950698
uuid-40f145f69d0842bcaca073c2e4cfb33a,respectively,0.585622
uuid-40f145f69d0842bcaca073c2e4cfb33a,Objective response rate,0.36976
uuid-40f145f69d0842bcaca073c2e4cfb33a,ORR,0.514781
uuid-40f145f69d0842bcaca073c2e4cfb33a,docetaxel,0.31274
uuid-fbc475ccbccc4759bf7fd54310e3477f,N Engl J Med,0.430637
uuid-fbc475ccbccc4759bf7fd54310e3477f,protocol,0.751471
uuid-fbc475ccbccc4759bf7fd54310e3477f,McDermott DF,0.722143
uuid-fbc475ccbccc4759bf7fd54310e3477f,search of published literature,0.307627
uuid-fbc475ccbccc4759bf7fd54310e3477f,Motzer RJ,0.799456
uuid-fbc475ccbccc4759bf7fd54310e3477f,phase 3 study,0.417069
uuid-fbc475ccbccc4759bf7fd54310e3477f,PubMed and EMBASE,0.307407
uuid-fbc475ccbccc4759bf7fd54310e3477f,Escudier B,0.729865
uuid-fbc475ccbccc4759bf7fd54310e3477f,NEJM,0.394646
uuid-fbc475ccbccc4759bf7fd54310e3477f,et al.,0.649569
uuid-fbc475ccbccc4759bf7fd54310e3477f,J Clin Oncol,0.776082
uuid-fbc475ccbccc4759bf7fd54310e3477f,Topalian,0.38615
uuid-fbc475ccbccc4759bf7fd54310e3477f,phase 1 study,0.518149
uuid-fbc475ccbccc4759bf7fd54310e3477f,CA209-003,0.585217
uuid-fbc475ccbccc4759bf7fd54310e3477f,phase 2 study,0.668464
uuid-fbc475ccbccc4759bf7fd54310e3477f,present using the following search terms,0.325589
uuid-fbc475ccbccc4759bf7fd54310e3477f,investigating,0.631986
uuid-1da8081bedd44f398b5c16861a2e5369,therapy,0.377932
uuid-579db29e7d624aa6b6be55c1fe2f88d7,N Engl J Med,0.427636
uuid-579db29e7d624aa6b6be55c1fe2f88d7,protocol,0.429136
uuid-579db29e7d624aa6b6be55c1fe2f88d7,McDermott DF,0.44782
uuid-579db29e7d624aa6b6be55c1fe2f88d7,Motzer RJ,0.430476
uuid-579db29e7d624aa6b6be55c1fe2f88d7,Escudier B,0.450887
uuid-579db29e7d624aa6b6be55c1fe2f88d7,et al.,0.456026
uuid-579db29e7d624aa6b6be55c1fe2f88d7,J Clin Oncol,0.384624
uuid-579db29e7d624aa6b6be55c1fe2f88d7,Rizvi NA,0.305616
uuid-579db29e7d624aa6b6be55c1fe2f88d7,phase 2 study,0.351446
